STEP-UP to MEDICINE
5TH EDITION

Steven Agabegi
Elizabeth Agabegi
Mark D. Duncan
Kelley Chuang

GOLD STANDARD for clerkship, shelf exam, and USMLE Step 2 review

More than 1,000 QUICK HITS and CLINICAL PEARLS

BOARD-STYLE QUESTIONS with accurate and insightful explanations (available in print and online—more than 400 questions!)
package insert) accompanying each drug to verify, among other things, conditions of use, warnings and side effects and identify any changes in dosage schedule or contraindications, particularly if the medication to be administered is new, infrequently used or has a narrow therapeutic range. To the maximum extent permitted under applicable law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property, as a matter of products liability, negligence law or otherwise, or from any reference to or use by any person of this work.
ADVISORY BOARD

KARISSA BRITTEN, MD
Resident Physician
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

DHANANJAY CHATTERJEE, MD
Resident Physician
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

KELLEY CHUANG, MD
Clinical Instructor
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Hospitalist, VA Greater Los Angeles Healthcare System
Los Angeles, California

MARK DUNCAN, MD
Clinical Instructor
Department of Medicine
University of Colorado Anschutz Medical Campus
Denver, Colorado

SARAH JENSEN, MD
Resident Physician
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

EMILY LIANG, BA
Medical Student
David Geffen School of Medicine at UCLA
Los Angeles, California

NICHOLAS VILLANO, MD
Resident Physician
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

STANLEY YUAN, BA
Medical Student
David Geffen School of Medicine at UCLA
Los Angeles, California
REVIEWERS

The authors and publisher would like to thank the following student reviewers who provided valuable input in revising the new edition, as well as the many student readers who have provided ongoing feedback since the book’s original publication.

SALVATORE AIELLO
EDWARD BURKHARDT
SMIT DELIWALA
FLORENCE DOO
WALEED KHAN
YOON KOOK KIM
MATT MOY
ANTHONIA OJO
KAILA POMERANZ
MICHAEL REZAEE
SHANNON SANCHEZ
LAUREN SARTOR
RACHEL SLUDER
FAROOQ USMANI
It is hard to believe that it has been 14 years since the first edition of *Step-Up to Medicine* was published. Now in its fifth edition, the success of this book has always been linked to its in-depth, yet concise coverage of every medical topic that a student will encounter during the clinical years of medical school and corresponding NBME shelf examinations.

This fifth edition of *Step-Up to Medicine* has been extensively revised and edited based on constructive feedback from students, residents, and faculty. To this end, we recruited a stellar team of medical professionals, led by Dr. Mark Duncan and Dr. Kelley Chuang, to update every topic and enrich the content of each chapter. We would like to acknowledge and sincerely thank these physicians for offering their expertise and valuable time in this endeavor. The quality of this edition of *Step-Up to Medicine* is the result of their tireless efforts.

We hope you find this new edition of *Step-Up to Medicine* a valuable study tool during your clinical years of medical school. We welcome any feedback or suggestions you may have for future editions. Please email us at agabegs@ucmail.uc.edu.

*Steve and Liz Agabegi*
1 DISEASES OF THE CARDIOVASCULAR SYSTEM
   Ischemic Heart Disease
   Congestive Heart Failure
   Arrhythmias
   Tachyarrhythmias
   Bradyarrhythmias
   Diseases of the Heart Muscle
   Pericardial Diseases
   Valvular Heart Disease
   Congenital Heart Diseases
   Diseases of the Vasculature
   Cardiac Neoplasms
   Shock

2 DISEASES OF THE PULMONARY SYSTEM
   Obstructive Lung Diseases
   Lung Neoplasms
   Diseases of the Pleura
   Interstitial Lung Disease
   Respiratory Failure
   Diseases of the Pulmonary Vasculature
   Miscellaneous Topics

3 DISEASES OF THE GASTROINTESTINAL SYSTEM
   Diseases of the Colon
   Diseases of the Liver
   Diseases of the Gallbladder and Biliary Tract
   Diseases of the Appendix
Diseases of the Pancreas
Gastrointestinal Bleeding
Diseases of the Esophagus
Diseases of the Stomach
Diseases of the Small Intestine
Inflammatory Bowel Disease

4 **ENDOCRINE AND METABOLIC DISEASES**
Diseases of the Pancreas
Diseases of the Thyroid Gland
Diseases of the Pituitary Gland
Diseases of the Parathyroid Glands
Diseases of the Adrenal Glands

5 **DISEASES OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS**
Cerebrovascular Disease (Stroke)
Movement Disorders
Dementia
Altered Mental Status
Demyelinating Disease
Neuromuscular Diseases
Neurocutaneous Syndromes
Spinal Cord Diseases
Miscellaneous Conditions

6 **CONNECTIVE TISSUE AND JOINT DISEASES**
Connective Tissue Diseases
Crystal-Induced Arthritides
Myopathies and Pain Syndromes
Seronegative Spondyloarthropathies
Vasculitis

7 **DISEASES OF THE RENAL AND GENITOURINARY SYSTEM**
Renal Failure
Proteinuria and Hematuria
Glomerular Disease (Glomerulonephropathies)
Tubulointerstitial Diseases
Renal Cystic Diseases
Renal Vascular Disease
Stones and Obstructions
Neoplasms
Miscellaneous Conditions

8  FLUIDS, ELECTROLYTES, AND ACID–BASE DISORDERS
   Volume Disorders
   Sodium
   Calcium
   Potassium
   Magnesium
   Phosphate
   Acid–Base Disorders

9  HEMATOLOGIC DISEASES AND NEOPLASMS
   Anemias
   Microcytic Anemias
   Normocytic Anemias
   Macrocytic Anemias
   Hemolytic Anemias
   Platelet Disorders
   Disorders of Coagulation
   Anticoagulation
   Plasma Cell Disorders
   Lymphomas
   Leukemias
   Myeloproliferative Disorders

10 INFECTION DISASES
    Infections of the Upper and Lower Respiratory Tracts
    Infections of the Central Nervous System
    Infections of the Gastrointestinal Tract
    Infections of the Genitourinary Tract
    Sexually Transmitted Diseases
Wound and Soft Tissue Infections
Infections of the Bones and Joints
Zoonoses and Arthropod-Borne Diseases
Common Fungal Infections
Other Fungal Infections
Common Parasitic Infections
Fever and Sepsis
Miscellaneous Infections

11 DISEASES OF THE SKIN AND HYPERSENSITIVITY DISORDERS

Key Definitions
Common Skin Disorders
Acneiform Eruptions
Atopic and Contact Dermatitis
Papulosquamous Eruptions
Allergic Reactions
Other Inflammatory and Autoimmune Disorders

Skin Conditions Related to Infections and Infestations
Bacterial Infections
Viral Infections
Fungal Infections
Infestations

Benign and Malignant Skin Lesions
Benign Skin Lesions
Malignant Skin Lesions

12 AMBULATORY MEDICINE

Cardiovascular Diseases
Headache
Upper Respiratory Diseases
Gastrointestinal Diseases

Musculoskeletal Problems
Overview of Musculoskeletal Examination Maneuvers
Diseases of the Eye
Sleep Disorders
Miscellaneous Topics
**APPENDIX**

Radiographic Interpretation  
Electrocardiogram Interpretation  
Physical Examination Pearls  
Workup and Management of Common Problems  
Basic Statistics and Evidence-Based Medicine  
End-of-Life Issues and Informed Consent

*Questions*  
*Answers*  
*Index*
Diseases of the Cardiovascular System

Dhananjay Chatterjee
Ischemic Heart Disease

Stable Angina Pectoris

A. General Characteristics

1. Stable angina pectoris is due to fixed atherosclerotic lesions that narrow the major coronary arteries. Coronary ischemia is due to an imbalance between blood supply and oxygen demand, leading to inadequate perfusion. Stable angina occurs when oxygen demand exceeds available blood supply.

2. Major risk factors
   a. Diabetes mellitus (DM)—worst risk factor
   b. Hyperlipidemia—elevated low-density lipoprotein (LDL)
   c. Hypertension (HTN)—most common risk factor
   d. Cigarette smoking
   e. Age (men >45 years; women >55 years)
   f. Family history of premature coronary artery disease (CAD) or myocardial infarction (MI) in first-degree relative: Men <55 years; women <65 years
   g. Low levels of high-density lipoprotein (HDL)

3. Less common risk factors include end-stage renal disease (ESRD) on hemodialysis, human immunodeficiency virus (HIV) infection, history of mediastinal radiation. Minor risk factors (less clear significance) include obesity, sedentary lifestyle (lack of physical activity), stress, excess alcohol use.

4. Prognostic indicators of CAD
   a. Left ventricular function (ejection fraction [EF])
      • Normal >50%
      • If <50%, associated with increased mortality
   b. Vessel(s) involved (severity/extent of ischemia)
      • Left main coronary artery—poor prognosis because it supplies approximately two-thirds of the heart
      • Two- or three-vessel CAD—worse prognosis

Quick HIT

CAD can have the following clinical presentations:
• Asymptomatic
• Stable angina pectoris
• Unstable angina
• Myocardial infarction (MI)—either NSTEMI or STEMI
• Sudden cardiac death
**Typical Anginal Chest Pain**
- Substernal
- Worse with exertion
- Better with rest or nitroglycerin

**B. Clinical Features**
1. Chest pain or substernal pressure sensation
   a. Lasts less than 10 to 15 minutes (usually 1 to 5 minutes)
   b. Frightening chest discomfort, usually described as heaviness, pressure, squeezing, tightness; rarely described as sharp or stabbing pain
   c. Pain is often gradual in onset
2. Brought on by factors that increase myocardial oxygen demand, such as exertion, stress, or drugs (i.e., cocaine or methamphetamines)
3. Relieved with rest or nitroglycerin
4. Note that ischemic pain does NOT change with breathing nor with body position. Also, patients with ischemic pain do not have chest wall tenderness. If any of these are present, the pain is less likely to be due to ischemia.

**C. Diagnosis (of CAD)**
1. Note that physical examination in most patients with CAD is normal (see Clinical Pearl 1-1).
2. Resting ECG
   a. Usually normal in patients with stable angina
   b. Q waves are consistent with a prior MI
   c. If ST-segment or T-wave abnormalities are present during an episode of chest pain, then treat as unstable angina.
3. Stress test—useful for patients with an intermediate pretest probability of CAD based upon age, gender, and symptoms.

**Quick HIT**

Stress testing is used in the following situations:
- To confirm diagnosis of angina
- To evaluate response to therapy in patients with documented CAD
- To identify patients with CAD who may have a high risk of acute coronary events

a. Stress ECG
   - Highest sensitivity if patients have normal resting ECG, such that changes can be noted. Patients with baseline ECG abnormalities such as left bundle branch
block (LBBB), pre-existing ST-segment changes, or left ventricular hypertrophy (LVH), should NOT undergo stress ECG testing.

- Test involves recording ECG before, during, and after exercise on a treadmill.
- 75% sensitive if patients are able to exercise sufficiently to increase heart rate to 85% of maximum predicted value for age. A person’s maximum heart rate is calculated by subtracting age from 220 (220 – age).
- Exercise-induced ischemia results in subendocardial ischemia, producing ST-segment depression. So the detection of ischemia on a stress ECG test is based on the presence of ST-segment depression.
- Other positive findings include onset of heart failure or ventricular arrhythmia during exercise or hypotension.
- *Patients with a positive stress test result should undergo cardiac catheterization.*

**Quick HIT**

Exercise stress ECG is an ideal initial test if able to exercise and have a normal resting ECG (readily available and relatively inexpensive).

b. Stress echocardiography

- Performed before and immediately after exercise. Exercise-induced ischemia is evidenced by wall motion abnormalities (e.g., akinesis or hypokinesis) not present at rest. This study is less reliable in patients with existing wall motion abnormalities or lowered EF.
- Favored by many cardiologists over stress ECG. It is more sensitive in detecting ischemia, can assess LV size and function, can diagnose valvular disease, and can be used to identify CAD in the presence of pre-existing ECG abnormalities (see Clinical Pearl 1-2).
- *Again, patients with a positive test result should undergo cardiac catheterization.*

c. Information gained from a stress test can be enhanced by stress myocardial perfusion imaging after IV administration of a radioisotope such as thallium 201 during exercise.

**Quick HIT**

A stress test is generally considered positive if the patient develops any of the following during exercise: ST-segment depression, chest pain, hypotension, or significant arrhythmias.

- Viable myocardial cells extract the radioisotope from the blood. No radioisotope uptake means no blood flow to an area of the myocardium.
It is important to determine whether the ischemia is reversible, that is, whether areas of hypoperfusion are perfused over time as blood flow eventually equalizes. Areas of reversible ischemia may be rescued with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). Irreversible ischemia, however, indicates infarcted tissue that cannot be salvaged.

- Perfusion imaging increases the sensitivity and specificity of exercise stress tests, but is also more expensive, subjects the patient to radiation, and is often not helpful in the presence of an LBBB.

**CLINICAL PEARL 1-1**

There Are Two Conditions Termed Syndrome X

1. Metabolic Syndrome X
   - Any combination of hypercholesterolemia, hypertriglyceridemia, impaired glucose tolerance, diabetes, hyperuricemia, HTN.
   - Key underlying factor is insulin resistance (due to obesity).

2. Syndrome X
   - Exertional angina with normal coronary arteriogram: Patients present with chest pain after exertion but have no coronary stenoses at cardiac catheterization.
   - Exercise testing and nuclear imaging show evidence of myocardial ischemia.
   - Prognosis is excellent.

**CLINICAL PEARL 1-2**

Types of Stress Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Method of Detecting Ischemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise ECG</td>
<td>ST-segment depression</td>
</tr>
<tr>
<td>Exercise or dobutamine echocardiogram</td>
<td>Wall motion abnormalities</td>
</tr>
<tr>
<td>Exercise or dipyridamole perfusion study</td>
<td>Decreased uptake of the nuclear isotope during exercise</td>
</tr>
<tr>
<td>(thallium/technetium)</td>
<td></td>
</tr>
</tbody>
</table>

4. If the patient cannot exercise, perform a pharmacologic stress test.
   a. IV adenosine, dipyridamole, or dobutamine can be used. The cardiac stress induced by these agents takes the place of exercise. This can be combined with an ECG, an echocardiogram, or nuclear perfusion imaging.
b. IV adenosine and dipyridamole cause generalized coronary vasodilation. Since diseased coronary arteries are already maximally dilated at rest to increase blood flow, they receive relatively less blood flow when the entire coronary system is pharmacologically vasodilated. These agents are used for perfusion imaging.

c. Dobutamine increases myocardial oxygen demand by increasing heart rate, blood pressure, and cardiac contractility. This is typically used in stress echo studies.

5. Cardiac catheterization with coronary angiography (see Clinical Pearl 1-3; Figure 1-1).

a. Coronary angiography—definitive test for CAD. Often performed with concurrent PCI or for patients being considered for revascularization with CABG.

b. This is the test of choice for patients with very high pre-test probability of CAD.

c. Contrast is injected into coronary vessels to visualize any stenotic lesions. This defines the location and extent of coronary disease.

d. If CAD is severe (e.g., left main or three-vessel disease, or two-vessel disease with concurrent DM), refer patient for surgical revascularization (CABG). 

---

**CLINICAL PEARL 1-3**

**Cardiac Catheterization**

1. Most accurate method of determining a specific cardiac diagnosis.
2. Provides information on hemodynamics, intracardiac pressure measurements, cardiac output, oxygen saturation, etc.
3. Coronary angiography (see below) is almost always performed as well for visualization of coronary arteries.
4. There are many indications for cardiac catheterization (generally performed when revascularization or other surgical intervention is being considered):
   - After a positive stress test.
   - Acute MI with intent of performing angiogram and PCI.
   - In a patient with angina in any of the following situations: When noninvasive tests are nondiagnostic, angina that occurs despite medical therapy, angina that occurs soon after MI, and any angina that is a diagnostic dilemma.
   - If a patient is severely symptomatic and urgent diagnosis and management are necessary.
   - For evaluation of valvular disease, and to determine the need for surgical intervention.

**Coronary Arteriography (Angiography)**

1. Most accurate method of identifying the presence and severity of CAD; the standard test for delineating coronary anatomy.
2. Main purpose is to identify patients with severe coronary disease to determine whether revascularization is needed. Revascularization with PCI involving a balloon and/or a stent can be performed at the same time as the diagnostic procedure.
3. Coronary stenosis >70% may be significant (i.e., it can produce angina).
FIGURE 1.1 Coronary angiogram. Injection of the right coronary artery shows a stenosis in the midportion of the vessel, indicated by the arrow.

(Courtesy of Pinak B. Shah, MD, Brigham and Women’s Hospital, Boston, MA.)

D. Treatment
1. Risk factor modification
   a. Smoking cessation cuts CAD risk in half by 1 year after quitting.
   b. HTN—vigorous BP control reduces the risk of CAD, especially in diabetic patients.
   c. Hyperlipidemia—reduction in serum cholesterol with lifestyle modifications and HMG-CoA reductase inhibitors (statins) reduce CAD risk. Again, goal LDL is <70 mg/dL in patients with known CAD.
   d. DM—type II diabetes is considered to be a cardiovascular heart disease
equivalent, and strict glycemic control should be strongly emphasized.

e. Obesity—weight loss modifies other risk factors (diabetes, HTN, and hyperlipidemia) and provides other health benefits.

f. Exercise is critical; it minimizes emotional stress, promotes weight loss, and helps reduce other risk factors.

g. Diet: Reduce intake of saturated fat (<7% total calories) and cholesterol (<200 mg/day).

Quick HIT

Standard of care for stable angina includes:
- Drugs that improve mortality: aspirin, high-intensity statins (or in some cases a PCSK9 inhibitor to lower LDL even further)
- Drugs that relieve angina: β-blockers, nitrates, calcium channel blockers, and ranolazine

Quick HIT

Side effects of β-blockers:
- Erectile dysfunction in males
- Inability to increase HR in response to exercise

Side effects of nitrates:
- Headache
- Orthostatic hypotension
- Tolerance
- Syncope

2. Medical therapy

a. Aspirin
   - Indicated in all patients with CAD
   - *Decreases morbidity—reduces risk of MI*

b. Lipid-lowering therapy
   - HMG-CoA reductase inhibitors (statins) lower LDL and reduce risk of CV death
   - PCSK9 inhibitors lower LDL even further than statins and have been found to reduce CV events in patients on statin therapy with LDL levels above 70

c. β-Blockers—block sympathetic stimulation of the heart
   - Reduce HR, BP, and contractility, thereby decreasing cardiac work (i.e., β-blockers lower myocardial oxygen consumption)
   - *Have been shown to reduce the frequency of coronary events*

d. Nitrates—cause coronary vasodilation and systemic venodilation
   - Relieve angina; reduce preload myocardial oxygen demand
May prevent angina when taken before exertion
- Effect on prognosis is unknown; main benefit is symptomatic relief
- Can be administered orally, sublingually, transdermally, intravenously, or in paste form. For chronic angina, oral or transdermal patches are used. For acute coronary syndromes (see below), either sublingual, paste, or IV forms are used.

**Calcium channel blockers (CCBs)**
- Cause coronary vasodilation and afterload reduction, reduce contractility
- Add to antianginal therapy when β-blockers and nitrates are not fully effective

3. **Revascularization**
   a. Controversial for patients with stable CAD, as studies suggest no improvement in mortality and MI (when compared to medical therapy alone). Per guidelines, revascularization is indicated for stable angina refractory to medical therapy for symptom control.
   b. Two methods—PCI and CABG—see **Clinical Pearl 1-4**.

4. **Management decisions (general guidelines)**—risk factor modification and aspirin are indicated in all patients. Manage patients according to overall risk
   a. **Mild disease** (normal EF, mild angina, single-vessel disease)
      - Nitrates (for symptoms and as prophylaxis) and a β-blocker are appropriate
      - Consider CCBs if symptoms continue despite nitrates and β-blockers
   b. **Moderate disease** (normal EF, moderate angina, two-vessel disease)
      - If the above regimen does not control symptoms, consider coronary angiography to assess suitability for revascularization (either PCI or CABG)
   c. **Severe disease** (reduced EF, severe angina, and three-vessel/left main or left anterior descending [LAD] disease)
      - Coronary angiography and consider for CABG
      - Avoid CCBs with reduced EF

---

**Quick HIT**

The COURAGE trial showed essentially no difference in all-cause mortality and nonfatal MIs between patients with stable angina treated with maximal medical therapy alone versus medical therapy with PCI and bare metal stenting. Of note, most PCI is now done with drug-eluting stents which are superior to bare metal stents with regard to risk of stent thrombosis and recurrent MI.
Unstable Angina Pectoris

A. General Characteristics

1. Pathophysiology
   a. With unstable angina, oxygen demand is unchanged. Supply is decreased secondary to reduced resting coronary flow. This is in contrast to stable angina, which is due to increased demand.
   b. Unstable angina is significant because it indicates stenosis that has enlarged via thrombosis, hemorrhage, or plaque rupture. It may lead to total occlusion of a coronary vessel.

2. The following patients may be said to have unstable angina:
   a. Patients with chronic angina with increasing frequency, duration, or intensity of chest pain
   b. Patients with new-onset angina that is severe and worsening
   c. Patients with angina at rest

3. The distinction between unstable angina and NSTEMI is based entirely on cardiac enzymes. The latter has elevation of troponin or creatine kinase-MB (CK-MB). Both unstable angina and NSTEMI lack ST-segment elevations and pathologic Q waves.
4. Unstable angina has a higher risk of MI and death than stable angina, and patients with this diagnosis should be hospitalized. Its management is encompassed in Acute Coronary Syndrome.

Quick HIT

**Acute Coronary Syndrome (ACS)**
- The clinical manifestations of atherosclerotic plaque rupture and coronary occlusion
- Term generally refers to unstable angina, NSTEMI, or STEMI

Quick HIT

Stress testing only detects flow-limiting high-grade lesions. Thus, can still have MI despite negative stress test because mechanism of MI is acute plaque rupture onto a moderate lesion.

B. Diagnosis (see Stable Angina)

1. Perform a diagnostic workup to exclude MI in all patients.
2. Patients with unstable angina have a higher risk of adverse events during stress testing. These patients should be stabilized with medical management before stress testing or should undergo cardiac catheterization initially.

C. Treatment

1. Hospital admission on a floor with continuous cardiac monitoring. Establish IV access and give supplemental oxygen if patients are hypoxic. Provide pain control with nitrates (below) and opioids if pain refractory to nitrate therapy alone.
2. Aggressive medical management is indicated—treat as in MI except for fibrinolysis. Mortality-lowering therapy includes dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor, heparin, and β-blockers.
   a. Aspirin (325-mg dose)
   b. P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel). The most commonly used agent is clopidogrel—shown to reduce the incidence of MI in patients with unstable angina compared with aspirin alone in the CURE trial. This benefit persists whether the patient undergoes revascularization with PCI or not. Patients presenting with unstable angina should generally be treated with aspirin and clopidogrel for 9 to 12 months, in accordance with the CURE trial. This may be altered however, according to the bleeding risk of each patient. The PLATO trial showed that ticagrelor had a reduced risk of death, MI, or stroke compared to clopidogrel when used for ACS, without an elevated risk of bleeding. Prasugrel has the highest risk of bleeding and is the least commonly used.
   c. β-Blockers—first-line therapy if there are no contraindications
d. Low–molecular-weight heparin (LMWH) is superior to unfractionated heparin. Goal is to prevent progression or development of a clot
   • Should be continued for at least 48 hours
   • Enoxaparin is the drug of choice based on clinical trials (see Quick Hit on ESSENCE trial)
e. Nitrates are first-line therapy for chest pain
f. Glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban, eptifibatide) can be helpful adjuncts, if patient is undergoing PCI
g. High-intensity statin (atorvastatin 40 or 80 mg) started within 4 days of ACS can reduce risk of recurrent MI or stroke
h. Oxygen if patient is hypoxic
i. Morphine is controversial—provides good pain relief but may mask worsening symptoms
j. Replacement of deficient electrolytes, especially K\(^+\) and Mg\(^{2+}\), to lower arrhythmia risk

**Quick HIT**

The **ESSENCE** trial showed that in unstable angina and non–ST-segment elevation MI, risk of death, MI, or recurrent angina was lower in the enoxaparin group than in the heparin group at 14 days, 30 days, and 1 year. The need for revascularization was also lower in the enoxaparin group.

**Quick HIT**

Thrombolytic therapy (fibrinolysis) has NOT been proven to be beneficial in unstable angina. This is only indicated in STEMI when no access to urgent catheterization for PCI.

3. Cardiac catheterization/revascularization
   a. More than 90% of patients improve with the above medical regimen within 1 to 2 days.
   b. The choice of invasive management (early catheterization/revascularization within 48 hours) versus conservative management (catheterization/revascularization only if medical therapy fails) is controversial.
      • If patient responds to medical therapy, perform a stress test to assess need for catheterization/revascularization. Many patients with UA that is controlled with medical therapy eventually require revascularization.
      • If medical therapy fails to improve symptoms and/or ECG changes indicative of ischemia persist after 48 hours, then proceed directly to catheterization/revascularization. Additional indications for PCI include hemodynamic instability, ventricular arrhythmias, and new mitral regurgitation (MR) or new septal defect.
• The TIMI risk score can be used to guide the decision on conservative versus more aggressive treatment.

4. After the acute treatment
   a. Continue aspirin (or other antiplatelet therapy), β-blockers (metoprolol), nitrates, and statin therapy
   b. Reduce risk factors
      • Smoking cessation, weight loss
      • Treat diabetes, HTN
      • Treat hyperlipidemia—patients with any form of CAD should be started on an HMG-CoA reductase inhibitor regardless of LDL level. Clinical trials of statins have shown the efficacy of such therapy for secondary prevention in CAD (see Quick Hit on CARE trial)

Quick HIT

The CARE trial: Patients with prior history of MI were randomized to treatment with statins or placebo. The statin group had a reduced risk of death (by 24%), a reduced risk of stroke (by 31%), and a reduction in need for CABG or coronary angioplasty (by 27%).
Variant (Prinzmetal) Angina

Involves transient coronary vasospasm that usually is accompanied by a fixed atherosclerotic lesion but can also occur in normal coronary arteries. Episodes of angina occur at rest and are associated with ventricular arrhythmias, some of which may be life threatening. The angina classically occurs at night. Hallmark is transient ST-segment elevation (not depression) on ECG during chest pain, which represents transmural ischemia. Coronary angiography is a definitive test—displays coronary vasospasm when the patient is given IV ergonovine or acetylcholine (to provoke vasoconstriction). Vasodilators—CCBs and nitrates have been proven to be helpful. Risk factor modification including smoking cessation and lipid lowering is also indicated where appropriate.
Myocardial Infarction

A. General Characteristics
1. MI is due to necrosis of myocardium as a result of an interruption of blood supply (after a thrombotic occlusion of a coronary artery previously narrowed by atherosclerosis).
   a. Most cases are due to acute coronary thrombosis: Atheromatous plaque ruptures into the vessel lumen, and thrombus forms on top of this lesion, which causes occlusion of the vessel.
   b. MI is associated with a 30% mortality rate; half of the deaths are prehospital.
   c. Most patients with MI have history of angina, risk factors for CAD, or history of arrhythmias.

B. Clinical Features
1. Chest pain
   a. Intense substernal pressure sensation; often described as “crushing” and “an elephant standing on my chest.”
   b. Radiation to neck, jaw, arms, or back, commonly to the left side.
   c. Similar to angina pectoris in character and distribution but much more severe and lasts longer. Unlike in angina, pain may not respond to nitroglycerin.
   d. Some patients may have epigastric discomfort.
2. Can be asymptomatic in up to one-third of patients; painless infarcts or atypical presentations more likely in postoperative patients, the elderly, diabetic patients, and women.
3. Other symptoms
   a. Dyspnea
   b. Diaphoresis
   c. Weakness, fatigue
   d. Nausea and vomiting
   e. Sense of impending doom
   f. Syncope
4. Sudden cardiac death—usually due to ventricular fibrillation (VFib)

Quick HIT

The combination of substernal chest pain persisting for longer than 30 minutes and diaphoresis strongly suggests acute MI.
Right ventricular infarct will present with inferior ECG changes, hypotension, elevated jugular venous pressure, hepatomegaly, and clear lungs. Preload dependent—do NOT administer nitrates or diuretics as these can cause cardiovascular collapse.

Quick HIT

ST-segment elevation indicates an infarction 75% of the time. ST-segment depression indicates an infarction only 25% of the time.

C. Diagnosis

1. ECG (Figure 1-2; see also Table 1-1 and Clinical Pearl 1-5)
   a. Markers for ischemia/infarction include:
      - **Peaked T waves:** Occur very early and may be missed
      - **ST-segment elevation** indicates transmural injury and can be diagnostic of an acute infarct
      - **Q waves:** Evidence for necrosis (specific)—Q waves are usually seen late; typically not seen acutely
      - **T-wave** inversion is sensitive but not specific
      - **ST-segment depression:** Subendocardial injury
   b. Categories of infarcts
      - **ST-segment elevation infarct:** Transmural (involves entire thickness of wall); tends to be larger
      - **Non–ST-segment elevation infarct:** Subendocardial (involves inner one-third to one-half of the wall); tends to be smaller, and presentation is similar to UA—cardiac enzymes differentiate the two
FIGURE 1.2  ECG showing anterior wall myocardial infarction—all 12
leads.  
(From Davis D. Quick and Accurate 12-Lead ECG Interpretation. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:203.)

<table>
<thead>
<tr>
<th>Location of Infarct</th>
<th>ECG Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior</td>
<td>ST-segment elevation in V1–V4 (acute/active)</td>
</tr>
<tr>
<td></td>
<td>Q waves in leads V1–V4 (late change)</td>
</tr>
<tr>
<td>Posterior</td>
<td>Large R wave in V1 and V2</td>
</tr>
<tr>
<td></td>
<td>ST-segment depression in V1 and V2</td>
</tr>
<tr>
<td></td>
<td>Upright and prominent T waves in V1 and V2</td>
</tr>
<tr>
<td>Lateral</td>
<td>Q waves in leads I and aVL (late change)</td>
</tr>
<tr>
<td>Inferior</td>
<td>Q waves in leads II, III, aVF (late change)</td>
</tr>
</tbody>
</table>

Note: Augmented ECG leads from aVL indicate the left arm, and from aVF indicate the left foot.

2. Cardiac enzymes—currently the diagnostic gold standard for myocardial injury (Figure 1-3)
   a. Troponins (Troponin I and T)—most important enzyme test to order
      • Increases within 3 to 5 hours and returns to normal in 5 to 14 days; reaches a peak in 24 to 48 hours.
      • Greater sensitivity and specificity than CK-MB for myocardial injury.
      • Obtain serum levels of either troponin T or troponin I on admission, and again every 6 hours for 18 to 24 hours.
      • Troponin I can be falsely elevated in patients with renal failure; thus following trend of levels is important.
   b. CK-MB—less commonly used
      • Increases within 4 to 8 hours and returns to normal in 48 to 72 hours; reaches a peak in 24 hours.
      • When measured within 24 to 36 hours of onset of chest pain, has greater than 95% sensitivity and specificity.
      • Levels of total CK and CK-MB should be measured on admission and every 8 hours thereafter for 24 hours.
      • Most helpful in detecting recurrent infarction given quicker return to baseline than troponin.
Cardiac enzymes are drawn serially—once on admission and every 6 hours until three samples are obtained. The higher the peak and the longer enzyme levels remain elevated, the more severe the myocardial injury and the worse the prognosis.

Quick Hit

In MI, aspirin, ticagrelor, β-blockers, and ACE inhibitors are the only agents shown to reduce mortality.

**CLINICAL PEARL 1-5**

**Cardiac Monitoring for a Patient With an Acute MI**

- BP and HR: HTN increases afterload and thus oxygen demand, whereas hypotension reduces coronary and tissue perfusion. Both nitrates and morphine can cause hypotension.
- Rhythm strip with continuous cardiac monitor: Watch for dysrhythmias. Note that PVCs can lower stroke volume and coronary artery filling time. A high frequency of PVCs may predict VFib or VT.
- Auscultate the heart (third and fourth heart sounds, friction rub, and so on) and lungs (crackles may indicate LV failure, pulmonary edema).
- Hemodynamic monitoring (CVP, PCWP, SVR, cardiac index [CI]) with a pulmonary artery catheter is indicated if the patient is hemodynamically unstable. Monitoring is helpful in assessing the need for IV fluids and/or vasopressors.

**FIGURE 1.3**

Evolution of serum biomarkers in acute MI. Curve M
indicates the detection of myoglobin in the serum before other biomarkers. Serum CK (or CK-MB isoenzyme) begins to increase 3 to 8 hours after the onset of the acute infarct and peaks at 24 hours. Cardiac troponins are highly sensitive for myocardial injury and remain detectable in the serum for many days after the acute infarct.

(From Lilly LS. *Pathophysiology of Heart Disease*. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:175, Figure 7.9.)

D. Treatment

1. Admit patient to a cardiac monitored floor (CCU) and establish IV access. Give supplemental oxygen for hypoxia and analgesics (nitrates, morphine—see below).

2. Medical therapy
   a. Aspirin
      • Antiplatelet agent reduces coronary reocclusion by inhibiting platelet aggregation on top of the thrombus
      • *Has been shown to reduce mortality and should be part of long-term maintenance therapy*
   b. P2Y12 inhibitors (clopidogrel, ticagrelor)
      • Used in conjunction with aspirin; have been shown to reduce recurrent MI
      • Ticagrelor has improved mortality compared to clopidogrel in the PLATO trial (its use is limited by cost, frequent dosing, and common side effect of dyspnea)
      • Duration of therapy depends on decision to perform PCI versus CABG, risk factors of patient
   c. β-Blockers
      • Block stimulation of HR and contractility to reduce oxygen demand and decrease the incidence of arrhythmias
      • Reduce remodeling of the myocardium post-MI
      • *Have been shown to reduce mortality and should be part of maintenance therapy*
   d. ACE inhibitors
      • Initiate within hours of hospitalization if there are no contraindications
      • *Have been shown to reduce mortality and should be part of long-term maintenance therapy*
   e. Statins
      • *Reduce risk of further coronary events*
      • Stabilize plaques and lower cholesterol
      • The PROVE IT-TIMI 22 trial showed the superiority of starting atorvastatin 80
mg over other statins before discharging a STEMI patient

- Should be part of maintenance therapy

f. Oxygen


g. Nitrates

- Dilate coronary arteries (increase supply) and reduce chest pain
- Venodilation (decrease preload and thus demand)

h. Morphine

- Analgesia
- Causes venodilation, which decreases preload and thus oxygen requirements
- May mask severity of symptoms, may affect levels of antiplatelet drugs

i. Heparin

- Initiate in all patients with MI; prevents progression of thrombus; however, has not been shown to decrease mortality
- LMWH, specifically enoxaparin, is preferred over unfractionated heparin, as shown in the ExTRACT-TIMI 25 trial as well as a recent meta-analysis. Enoxaparin was shown to decrease the risk of recurrent MI versus unfractionated heparin.

Quick HIT

The CAPRICORN trial showed that the β-blocker carvedilol reduces the risk of death in patients with post-MI LV dysfunction.

Quick HIT

The following are indicated in patients with MI:

- Aspirin
- P2Y12 inhibitor
- Nitroglycerin for chest pain
- β-Blocker
- ACE inhibitor
- Heparin
- Oxygen if hypoxic
- Morphine if chest pain unrelieved with nitrates

3. Revascularization

a. Benefit highest when performed early (within 90 minutes of hospital arrival for patients with STEMI or new LBBB)

b. Should be considered in all patients.
c. Revascularization options include thrombolysis, PCI, or CABG—see Clinical Pearl 1-6.

- Several studies have shown enhanced survival and lower rates of recurrent MI and intracranial bleeding when PCI performed by skilled personnel is chosen over thrombolysis. For patients with a delayed presentation, fibrinolysis alone may be a better option.
- Urgent/emergent CABG is typically performed only in the setting of mechanical complications of an acute MI, cardiogenic shock, life-threatening ventricular arrhythmias, or after failure of PCI. It is almost never performed in the acute setting on a stable patient.

Quick HIT

Remember that patients can have a recurrent infarction on same hospital admission. CK-MB is the most helpful laboratory test to detect this if patient develops recurrent chest pain.

Quick HIT

Heparin is used for unstable angina and MI (both NSTEMI and STEMI). It is NOT used for stable angina.

d. P2Y12 inhibitors—evidence suggests that the benefit of clopidogrel or ticagrelor is additive to the effects of aspirin. Clopidogrel or ticagrelor therapy should be initiated in all patients who undergo PCI and receive a stent. Dual antiplatelet treatment with aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) should continue for at least 30 days in patients who receive a bare metal stent, and at least 12 months in patients who receive a drug-eluting stent.

CLINICAL PEARL 1-6

Methods of Revascularization

Percutaneous Coronary Intervention

- This is the preferred treatment for STEMI as long as it can be performed expeditiously (door to balloon time less than 90 minutes) and by skilled personnel.
- Also preferred in patients with contraindications for thrombolytic therapy; no risk of intracranial hemorrhage.
- PRAMI trial showed that PTCA reduces mortality more than tPA.

Thrombolytic Therapy

- Thrombolytic therapy remains an important treatment modality since PCI is still available only at specialized centers. It is useful for patients who present later, and for those in whom PCI is contraindicated.
- Early treatment is crucial to salvage as much of the myocardium as possible. Administer as soon as possible up to 24 hours after the onset of chest pain. Outcome is best if given within the first 6 hours.
- **Indications:** **ST-segment elevation** in two contiguous ECG leads in patients with pain onset within 6 hours who have been refractory to nitroglycerin.
- Alteplase has been shown to have the best outcomes among thrombolytic medications, and is the first choice in many centers, despite its high costs. Alternatives include streptokinase, tenecteplase, reteplase, lanoteplase, and urokinase.
- In ED setting, the main reason to initiate therapy with thrombolytics/angioplasty is whether there is ST-segment elevation on ECG.

**Absolute Contraindications to Thrombolytic Therapy**
- Trauma: Recent head trauma or traumatic CPR
- Previous stroke
- Recent invasive procedure or surgery
- Dissecting aortic aneurysm
- Active bleeding or bleeding diathesis

**Coronary Artery Bypass Grafting**
- Less often used than the other two in the acute setting.
- Benefits of CABG include low rates of event-free and reintervention-free survival.
- It remains the procedure of choice in patients with severe multivessel disease and complex coronary anatomy.

### Quick HIT

All patients initially treated conservatively (i.e., without revascularization) for UA/NSTEMI should have a stress test before leaving the hospital to determine the need for angiography (which in turn determines the need for angioplasty or CABG).

4. **Rehabilitation**
   - **Cardiac rehabilitation** is a physician-supervised regimen of exercise and risk factor reduction after MI.
   - **Shown to reduce symptoms and prolong survival.**

### E. Complications of Acute MI

1. Pump failure (congestive heart failure [CHF]) *(Figure 1-4)*
   - Most common cause of in-hospital mortality
   - If mild, treat medically (ACE inhibitor, diuretic)
   - If severe, may lead to cardiogenic shock; invasive hemodynamic monitoring or support with inotropes or devices may be indicated (see Cardiogenic Shock on page 64)

### Quick HIT

Patients who suffer an acute MI have a high risk of stroke during the next 5 years. The lower the EF and the older the patient, the higher the risk of stroke.
Most common cause of death in the first few days after MI is ventricular arrhythmia (either VT or VFib).

2. Arrhythmias
   a. Premature ventricular contractions (PVCs)—conservative treatment (observation) indicated; no need for antiarrhythmic agents
   b. Atrial fibrillation (AFib)
   c. Ventricular tachycardia (VT)—sustained VT requires treatment: If patient is hemodynamically unstable, electrical cardioversion is indicated. If patient is hemodynamically stable, start antiarrhythmic therapy—see treatment of VT

   d. VFib—immediate unsynchronized defibrillation and CPR are indicated (see Arrhythmias on page 21)
   e. Accelerated idioventricular rhythm does not affect prognosis; no treatment needed in most cases
   f. Paroxysmal supraventricular tachycardia (PSVT)—for treatment, see Arrhythmias

**FIGURE 1.4 Complications of MI.**
(Adapted from Lilly LS. *Pathophysiology of Heart Disease*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:183, Figure 7.12.)
g. Sinus tachycardia
- May be caused by pain, anxiety, fever, pericarditis, medications, etc.
- Worsens ischemia (increases myocardial oxygen consumption)
- Treat underlying cause (analgesics for pain, acetaminophen for fever, etc.)

h. Sinus bradycardia
- A common occurrence in early stages of acute MI, especially right-sided/inferior MI.
- May be a protective mechanism (reduces myocardial oxygen demand).
- No treatment is required other than observation. If bradycardia is severe or symptomatic (hemodynamic compromise), atropine may be helpful in increasing HR.

i. Asystole
- Very high mortality.
- Treatment should begin with electrical defibrillation for VFib, which is more common in cardiac arrest and may be difficult to clearly differentiate from asystole.
- If asystole is clearly the cause of arrest, transcutaneous pacing is the appropriate treatment.

j. AV block
- Associated with ischemia involving conduction tracts.
- First- and second-degree (type I) blocks do not require therapy.
- Second- (type II) and third-degree blocks: Prognosis is dire in the setting of an anterior MI—emergent placement of a temporary pacemaker is indicated (with later placement of a permanent pacemaker). In inferior MI, prognosis is better, and IV atropine may be used initially. If conduction is not restored, a temporary pacemaker is appropriate. Can use positive chronotropic medications to maintain HR and blood pressures (i.e., isoproterenol or dopamine) while awaiting placement of temporary pacemaker.

Quick HIT
After an MI, all patients should be discharged home with aspirin, β-blocker, statins, and an ACE inhibitor, and a P2Y12 inhibitor if indicated.

3. Recurrent infarction (extension of existing infarction or reinfarction of a new area)
   a. Both short- and long-term mortality are increased.
   b. Diagnosis is often difficult.
      - Cardiac enzymes are already elevated from the initial infarction. Troponin
levels remain elevated for a week or more, so are not useful here. CK-MB returns to normal faster, and so a reelevation of CK-MB after 36 to 48 hours may be due to recurrent infarction.

- If there is repeat ST-segment elevation on ECG within the first 24 hours after infarction, suspect recurrent infarction or LV aneurysm.

c. Treatment: Repeat thrombolysis or urgent cardiac catheterization and PCI. Continue standard medical therapy for MI.

4. Mechanical complications

a. Free wall rupture
   - A catastrophic, usually fatal event that occurs during the first 2 weeks after MI (90% within 2 weeks, most commonly 1 to 4 days after MI)
   - 90% mortality rate
   - Usually leads to hemopericardium and cardiac tamponade
   - Treatment: Hemodynamic stabilization, immediate pericardiocentesis, and surgical repair

b. Rupture of interventricular septum
   - Greater potential for successful therapy than with a free wall rupture, although this is also a critical event; emergent surgery is indicated
   - Occurs within 10 days after MI
   - Likelihood of survival correlates with size of the defect

c. Papillary muscle rupture
   - *Produces acute MR* (presents with new murmur)
   - If suspected, obtain an echocardiogram immediately
   - Emergent surgery is needed (mitral valve replacement is usually necessary), as well as afterload reduction with sodium nitroprusside or intra-aortic balloon pump (IABP)

d. Ventricular pseudoaneurysm
   - *Incomplete* free wall rupture (myocardial rupture is contained by pericardium)
   - Bedside echocardiogram may show the pseudoaneurysm
   - Surgical emergency because ventricular pseudoaneurysms tend to become a free wall rupture

e. Ventricular aneurysm
   - Rarely rupture (in contrast to pseudoaneurysms)
   - Associated with a high incidence of ventricular tachyarrhythmias
   - Medical management may be protective
   - Surgery to remove aneurysm may be appropriate in selected patients

5. Acute pericarditis

a. The incidence has decreased sharply since the introduction of revascularization
techniques.
b. Treatment consists of aspirin (which is already standard in treatment of MI).
c. NSAIDs and corticosteroids are contraindicated (may hinder myocardial scar formation).

6. Dressler syndrome (“postmyocardial infarction syndrome”)
a. Immunologically based syndrome consisting of fever, malaise, pericarditis, leukocytosis, and pleuritis, occurring weeks to months after an MI
b. Aspirin is the most effective therapy. Ibuprofen is a second option.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
</table>

If you suspect a cardiac cause of the pain, sublingual nitroglycerin is appropriate. Also give aspirin if the patient does not have a bleeding disorder.
Chest Pain

A. Differential Diagnosis

1. Heart, pericardium, vascular causes
   a. Stable angina, variant angina
   b. ACS
   c. Pericarditis
   d. Aortic dissection
2. Pulmonary: Pulmonary embolism (can have pain with pulmonary infarction), pneumothorax, pleuritis (pleural pain), pneumonia, status asthmaticus
3. GI: Gastroesophageal reflux disease (GERD), diffuse esophageal spasm, peptic ulcer disease, esophageal rupture
4. Chest wall: Costochondritis, muscle strain, rib fracture, herpes zoster
5. Psychiatric: Panic attacks, anxiety, somatization
6. Cocaine/methamphetamine use can cause angina or MI

Quick HIT

If nitroglycerin relieves the pain, a cardiac cause is more likely (although nitrates also relieve pain from diffuse esophageal spasm).

Quick HIT

If chest pain is pleuritic, positional, or reproduced with chest wall palpation, a cardiac cause may be less likely.

B. Approach to Treating a Patient With Chest Pain

1. Rule out any life-threatening causes. These include ACS, aortic dissection, pericarditis with cardiac tamponade, pulmonary embolus, tension pneumothorax, and esophageal rupture
2. Assess vital signs
3. Develop a focused history
   a. Character of the pain (pressure, squeezing, tearing, sharp, stabbing, etc.)
   b. Location of pain
   c. Severity of pain
   d. Duration of pain
   e. Setting in which pain occurred (during exertion, at rest, after meal)
   f. Radiation of pain
   g. Aggravating or alleviating factors (e.g., meal, exertion, rest, respiration)
   h. Does the patient have a cardiac history? Ask about results of previous stress tests, echocardiograms, cardiac catheterization, or of any procedures (PCI or
i. If the patient has a history of angina, ask how this episode differs from previous ones (more severe? longer duration?)

4. Perform a focused physical examination, with attention to cardiopulmonary, abdominal, and musculoskeletal examination

5. Order ancillary tests
   a. Obtain ECG in almost all cases
   b. Cardiac enzymes (CK, CK-MB, troponin) depending on clinical suspicion
   c. Obtain chest radiograph (CXR) in almost all cases
   d. Under appropriate clinical setting, work up the patient for pulmonary embolism (PE) (see Pulmonary section)

6. Develop a diagnosis
   a. It can be difficult to distinguish between GI causes of chest pain and angina. The decision of whether to initiate a cardiac workup is dependent on a patient’s overall risk of CAD and the clinical presentation. If patient is young and without risk factors, treat for GERD and follow up if pain recurs. (Anxiety may be a cause but is difficult to diagnose and usually only considered after ruling out cardiac causes first.) An older patient with risk factors should undergo a cardiac workup.
   b. There is no fail-proof algorithm for approaching chest pain. In general, have a greater index of suspicion for ischemic causes in the elderly, diabetic populations, and those with a history of CAD (see MI section).

---

**Quick HIT**

A common presentation is a patient with chronic stable angina who presents with symptoms suggestive of unstable angina. The following are the initial steps:

- Obtain ECG and cardiac enzymes
- Give aspirin
- Begin IV heparin if no contraindications (i.e., active bleeding, recent life-threatening bleed)
- Admission to hospital for workup as described above
Congestive Heart Failure

A. General Characteristics

1. CHF is a clinical syndrome resulting from the heart’s inability to meet the body’s circulatory demands under normal physiologic conditions. It is the final common pathway for a wide variety of cardiac diseases (see also Clinical Pearl 1-7).

2. Pathophysiology (Figure 1-5)
   a. Frank–Starling relationship
      • In a normal heart, increasing preload results in greater contractility.
      • When preload is low (at rest), there is little difference in performance between a normal and a failing heart. However, with exertion a failing heart produces relatively less contractility and symptoms occur (Figure 1-6).

   Quick HIT
   Often, both systolic and diastolic dysfunctions are present simultaneously.

3. Heart Failure with reduced Ejection Fraction (HFrEF) or systolic dysfunction
   a. Owing to impaired contractility (reduced EF <40%)
   b. Causes include:
      • Ischemic heart disease or after a recent MI—infarcted cardiac muscle does not pump blood (decreased EF)
      • idiopathic
      • HTN

CLINICAL PEARL 1-7

High-Output Heart Failure

• In high-output heart failure, an increase in cardiac output is needed for the requirements of peripheral tissues for oxygen.
• Causes include:
  • Chronic anemia
  • Pregnancy
  • Hyperthyroidism
  • AV fistulas
  • Wet beriberi (caused by thiamine [vitamin B₁] deficiency)
  • Paget disease of bone
  • MR
  • Aortic insufficiency
• The conditions listed above rarely cause heart failure by themselves. However, if these conditions develop
in the presence of underlying heart disease, heart failure can result quickly.

**FIGURE 1.5** Pathophysiology of CHF.

- Myocarditis (postviral, giant cell, autoimmune)
- Drugs: Alcohol, cocaine, methamphetamines, chemotherapy (anthracyclines and trastuzumab)
- Infiltrative disease (amyloidosis, sarcoidosis, hemochromatosis, Wilson disease)
- Radiation therapy
- Thyroid disease
- Peripartum cardiomyopathy
- Infectious disease (Chagas disease, HIV, endocarditis causing valvular disease)
- Valvular heart disease (usually MR, aortic stenosis or regurgitation)
- High-output heart failure (severe anemia, due to AV fistulas, pregnancy, severe thiamine deficiency)
- Congenital/hereditary

**FIGURE 1.6** Frank–Starling relationship.

4. Heart Failure with preserved Ejection Fraction (HFpEF) or diastolic dysfunction
   a. Owing to impaired ventricular filling during diastole (either impaired relaxation or increased stiffness of ventricle or both).
   b. Echocardiogram shows impaired relaxation of left ventricle.
   c. Causes include:
      - HTN leading to myocardial hypertrophy—most common cause of diastolic dysfunction
      - Valvular diseases such as aortic stenosis (AS), mitral stenosis, and aortic regurgitation
      - Restrictive cardiomyopathy (e.g., amyloidosis, sarcoidosis, hemochromatosis in their early phases)

**B. Clinical Features**
1. Symptoms of left-sided heart failure (see also Clinical Pearl 1-8)
a. Dyspnea—difficulty breathing secondary to pulmonary congestion/edema  
b. Orthopnea—difficulty breathing in the recumbent position; relieved by elevation of the head with pillows  
c. Paroxysmal nocturnal dyspnea (PNP)—awakening after 1 to 2 hours of sleep due to acute shortness of breath (SOB)  
d. Nocturnal cough (nonproductive)—worse in recumbent position (same pathophysiology as orthopnea)  
e. Confusion and memory impairment occur in advanced CHF as a result of inadequate brain perfusion  
f. Diaphoresis and cool extremities at rest—occur in desperately ill patients (NYHA class IV)  

2. Signs of left-sided heart failure  
a. Displaced PMI (usually to the left) due to cardiomegaly  
b. Pathologic S3 (ventricular gallop)  
   • Rapid filling phase “into” a noncompliant left ventricular chamber  
   • May be normal finding in children; in adults, usually associated with CHF  
   • May be difficult to hear, but is among the most specific signs of CHF  
   • Heard best at apex with bell of stethoscope  
   • The sequence in the cardiac cycle for S3: S3 follows S2 (ken-tuck-Y)  
c. S4 gallop  
   • Sound of atrial systole as blood is ejected into a noncompliant, or stiff, left ventricular chamber  
   • Heard best at left sternal border with bell of stethoscope  
   • The sequence in the cardiac cycle for S4: S4 precedes S1 (TEN-nes-see)  
d. Crackles/rales at lung bases  
   • Caused by fluid spilling into alveoli; indicates pulmonary edema  
   • Rales heard over lung bases suggest at least moderate severity of left ventricular heart failure  
e. Dullness to percussion and decreased tactile fremitus of lower lung fields caused by pleural effusion  
f. Increased intensity of pulmonic component of second heart sound suggests pulmonary HTN (heard over left upper sternal border)  

**CLINICAL PEARL 1-8**

**New York Heart Association (NYHA) Classification**  
- NYHA class I: Symptoms only occur with vigorous activities, such as playing a sport. Patients are nearly asymptomatic.
NYHA class II: Symptoms occur with prolonged or moderate exertion, such as climbing a flight of stairs or carrying heavy packages. Slight limitation of activities.

NYHA class III: Symptoms occur with usual activities of daily living, such as walking across the room or getting dressed. Markedly limiting.

NYHA class IV: Symptoms occur at rest. Incapacitating.

Quick HIT

Tests to order for a new patient with CHF:
- CBC (anemia)
- BMP (assess for renal injury due to volume overload, or cardiorenal syndrome)
- Cardiac enzymes to rule out MI
- BNP
- Chest x-ray (pulmonary edema, cardiomegaly, rule out COPD)
- ECG
- Echocardiogram (estimate EF, rule out pericardial effusion)

3. Symptoms/signs of right-sided heart failure
   a. Peripheral pitting edema—pedal edema lacks specificity as an isolated finding. In the elderly, it is more likely to be secondary to venous insufficiency
   b. Nocturia—due to increased venous return with elevation of legs
   c. Jugular venous distention (JVD)
   d. Hepatomegaly/hepatojugular reflux
   e. Ascites
   f. Right ventricular heave (found with pulmonary HTN)

4. Given enough time, left-sided heart failure can lead to right-sided heart failure (most common cause right-sided heart failure)
   a. Patients may present with sign/symptoms of both right- and left-sided HF

C. Diagnosis

1. Chest x-ray (CXR) (Figure 1-7)
   a. Cardiomegaly
   b. Kerley B lines are short horizontal lines near periphery of the lung near the costophrenic angles, and indicate pulmonary congestion secondary to dilation of pulmonary lymphatic vessels
   c. Prominent interstitial markings
   d. Pleural effusion

2. Echocardiogram (transthoracic)
   a. Initial test of choice—should be performed whenever CHF is suspected based on history, examination, or CXR.
   b. Useful in determining whether systolic or diastolic dysfunction predominates, and determines whether the cause of CHF is due to a myocardial, valvular, or
pericardial process.

c. Estimates EF (very important): Patients with systolic dysfunction (EF <40%) should be distinguished from patients with preserved left ventricular function (EF >40%).

d. Shows chamber dilation and/or hypertrophy.

FIGURE 1.7
A: Chest radiograph showing cardiogenic pulmonary edema. B: Another example of cardiogenic pulmonary edema; note cardiomegaly (patient had CHF).

(A from Mergo PJ. Imaging of the Chest—A Teaching File. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:50, Figure 24A.) (B from Stern EJ, White CS. Chest Radiology Companion. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:38, Figure 5-4.)

3. B-type natriuretic peptide (BNP) is released from the ventricles in response to ventricular volume expansion and pressure overload.
   a. BNP levels >100 pg/mL correlate strongly with the presence of decompensated CHF. (Unit of measurement varies.)
   b. BNP may be useful in differentiating between dyspnea caused by CHF and COPD.
   c. N-terminal pro-BNP (NT-proBNP) is a newer assay with similar predictive value as BNP. The normal range for this value depends on the age of the patient, but an NT-proBNP <300 virtually excludes the diagnosis of HF.
   d. BNP may be falsely low in obese patients.

4. ECG is usually nonspecific but can be useful for detecting chamber enlargement and presence of ischemic heart disease or prior MI.
5. Radionuclide ventriculography using technetium-99m (“nuclear ventriculography”). Also called multigated acquisition (MUGA) scan.

6. Cardiac catheterization can provide valuable quantitative information regarding diastolic and systolic dysfunction, and can clarify the cause of CHF if noninvasive test results are equivocal. Consider coronary angiography to exclude CAD as an underlying cause of CHF.

7. Stress testing
   a. Identifies ischemia and/or infarction
   b. Quantifies level of conditioning
   c. Can differentiate cardiac versus pulmonary etiology of dyspnea
   d. Assesses dynamic responses of HR, heart rhythm, and BP

Quick HIT

HTN is a common cause of CHF and should be treated. Goal is to reduce preload and afterload.

Quick HIT

Monitoring a patient with CHF:
- Weight—unexplained weight gain can be an early sign of worsening CHF
- Clinical manifestations (exercise tolerance is key); peripheral edema
- Laboratory values (electrolytes, K, BUN, creatinine levels; serum digoxin level, if applicable)

D. Treatment

1. Systolic dysfunction
   a. General lifestyle modification
      - Sodium restriction (less than 4 g/day)
      - Fluid restriction (1.5 to 2.0 L daily)
      - Weight loss
      - Smoking cessation
      - Restrict alcohol use
      - Exercise program
      - All patients should monitor weight daily to detect fluid accumulation
      - Annual influenza vaccine and pneumococcal vaccine recommended
   b. Diuretics
      - Most effective means of providing symptomatic relief to patients with moderate to severe CHF
      - Recommended for patients with systolic failure and volume overload
      - Have not been shown to reduce mortality or improve prognosis, just for symptom control. Goal is relief of signs and symptoms of volume overload
(dyspnea, peripheral edema)

- Loop diuretics: Furosemide (Lasix)—usually used. Other options include bumetanide (Bumex) and torsemide
- Thiazide-like diuretics: Metolazone and chlorothiazide. Used to augment diuresis with loop diuretics

Quick HIT

The RALES trial showed that spironolactone reduces morbidity and mortality in patients with class III or IV heart failure with EF <35%. It is contraindicated in renal failure (creatinine >2).

c. Therapies to improve outcomes: Standard therapy includes the following (medications in parentheses have been shown to improve mortality in HFrEF):

- ACE inhibitor (enalapril, lisinopril, captopril) or ARB (valsartan, losartan, candesartan)
- β-Blockers (metoprolol succinate, carvedilol, bisoprolol)
- Aldosterone antagonists (spironolactone, eplerenone), if EF <35%
- Primary prevention of sudden cardiac death with ICD implantation if EF <35% on optimal medical therapy
- Hydralazine and nitrates (isosorbide dinitrate) are an effective combination therapy for African American patients with HFrEF. These are also often used for patients who cannot take ACEi/ARB or aldosterone antagonists due to renal dysfunction
- Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor (ARNI) that can be used in patients with EF <35% with maximally tolerated ACEi or ARB, and has been shown to improve mortality (PARADIGM-HF trial)
- Ivabradine is a funny channel inhibitor that has been shown to reduce hospitalizations in patients with reduced EF and HR >70 on maximally tolerated β-blocker therapy
- Digoxin was once regularly used for HFrEF, but has not been shown to improve mortality

2. HFpEF: Few therapeutic options available; patients are treated symptomatically (NO medications have proven mortality benefit)

- Diuretics are used for symptom control (volume overload)
- Patients should continue salt and fluid restriction, take daily weights
- No other drug classes have been shown to produce significant mortality benefit in randomized controlled trials

3. General principles in treatment of HF (see Clinical Pearls 1-9 and 1-10)
Most common cause of death from HF is sudden death from ventricular arrhythmias. Ischemia provokes ventricular arrhythmias.
Acute Decompensated Heart Failure

Findings:
A. Acute dyspnea associated with elevated left-sided filling pressures, with or without pulmonary edema.
3. Most commonly due to LV systolic or diastolic dysfunction.
C. Flash pulmonary edema refers to a severe form of heart failure with rapid accumulation of fluid in the lungs.

Diagnosis
A. Differential includes pulmonary embolism, asthma, and pneumonia, all of which can cause rapid respiratory distress.
3. Diagnostic tests include ECG, CXR, ABG, B-type natriuretic peptide (BNP), echocardiogram, and possible coronary angiogram if indicated.

CLINICAL PEARL 1-9

General Principles in the Treatment of CHF
No one simple treatment regimen is suitable for all patients.

The following is a general guideline, but the order of therapy may differ among patients and/or with physician preferences.

Mild CHF (NYHA Classes I to II)
- Mild restriction of sodium intake (no-added-salt diet of 4-g sodium) and physical activity.
- Start a loop diuretic if volume overload or pulmonary congestion is present.
- Use an ACE inhibitor as a first-line agent.

Mild to Moderate CHF (NYHA Classes II to III)
- Start a diuretic (loop diuretic) and an ACE inhibitor.
- Add a β-blocker if moderate disease (class II or III) is present and the response to standard treatment is suboptimal.

Moderate to Severe CHF (NYHA Classes III to IV)
- Can add digoxin (to loop diuretic and ACE inhibitor) for the relief of symptoms in patients with systolic dysfunction. (It does not improve mortality.)
- Add spironolactone or eplerenone if EF <35%

CLINICAL PEARL 1-10

- Ventricular assist device (VAD). Work on these devices has been occurring for the past five decades, and most of the products on the market now represent research that was done 30 years ago. There is great potential for these devices as more research is conducted and clinicians become more experienced in their advantages and drawbacks.
- VADs may be used to support the left ventricle (LVAD), right ventricle (RVAD), or both ventricles (BiVAD).
- The pump is implanted in the abdominal cavity with cannulation to the heart. The system controller and battery are worn externally.
- These devices may allow for a patient requiring continuous hospitalization to eventually be discharged with
relatively straightforward outpatient follow-up. Patients may live with these devices for a year or more.

- Lifelong anticoagulation with heparin or warfarin is essential without exceptions as these devices are very thrombogenic.
- VADs may also be used for hemodynamic support related to the acute treatment of a STEMI or other cardiac pathology (i.e., while recovering from a severe case of myocarditis).

**Quick HIT**

ACE inhibitors

- Cause venous and arterial dilation, decreasing preload and afterload and thus blood pressure.
- *ACE inhibitors reduce mortality* (Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] and Studies of Left Ventricular Dysfunction [SOLVD] trials), *prolong survival, and alleviate symptoms in mild, moderate, and severe HFrEF*.
- Monitor BP, potassium, and creatinine.

**Treatment**

A. Oxygenation and ventilatory assistance with nonrebreather face mask, noninvasive positive pressure ventilation, or even intubation as indicated.

B. Diuretics to treat volume overload and congestive symptoms—this is the most important intervention. Decreases preload.

C. Nitrates—IV nitroglycerin (venodilator) in patients without hypotension. Decreases preload.

D. Patients who have pulmonary edema despite use of oxygen, diuretics, and nitrates may benefit from use of inotropic agents (dobutamine). Digoxin takes several weeks to work and is not indicated in an acute setting.

E. Dietary sodium and fluid restriction.

**Quick HIT**

**Angiotensin II receptor blockers (ARBs):**

- Can be used in patients unable to take ACE inhibitors due to side effect of cough

**β-Blockers (specifically metoprolol succinate, carvedilol, and bisoprolol have been shown to reduce mortality):**

- Proven to decrease mortality in patients with HFrEF.
- Reported to improve symptoms of HF; may slow progression of heart failure by slowing down tissue remodeling. The decrease in heart rate leads to decreased oxygen consumption.
- β-Blockers have antiarrhythmic, anti-ischemic, and antianginal effect.
Arrhythmias

Premature Complexes

A. Premature Atrial Complexes
1. This early beat arises within the atria, firing on its own.
2. Causes include adrenergic excess, drugs, alcohol, tobacco, electrolyte imbalances, ischemia, hypoxia, and infection.
3. On ECG, look for early P waves that differ in morphology from the normal sinus P wave (because these P waves originate within the atria and not the sinus node).
4. QRS complex is normal because conduction below the atria is normal. There is usually a pause before the next sinus P wave.
5. Premature atrial complexes (PACs) are found in more than 50% of normal adults who undergo Holter monitoring and are of no significance in a normal heart, but may be a precursor of ischemia in a diseased heart.
6. May cause palpitations or give rise to PSVTs.
7. Usually asymptomatic and do not require treatment. Monitor for increased frequency. If symptomatic (e.g., palpitations), β-blockers may be helpful.

B. Premature Ventricular Complexes
1. This early beat fires on its own from a focus in the ventricle and then spreads to the other ventricle (Figure 1-8).
2. PVCs can occur in patients with or without structural heart disease. Causes include hypoxia, electrolyte abnormalities, stimulants, caffeine, medications, and structural heart disease.
3. Since conduction is not through normal conduction pathways, but rather through ventricular muscle, it is slower than normal, causing a wide QRS.
4. Wide, bizarre QRS complexes followed by a compensatory pause are seen; a P wave is not usually seen because it is “buried” within the wide QRS complex.
5. PVCs appear in more than 50% of men who undergo 24-hour Holter monitoring.
6. Most patients are asymptomatic. Some patients may have palpitations and dizziness related to PVCs. If symptomatic, β-blockers may be used.
7. Presence of PVCs in patients with normal hearts is associated with increased mortality.
8. If a patient is found to have frequent PVCs, workup for underlying structural heart disease should be initiated which may require specific treatment.
9. Patients with frequent, repetitive PVCs and underlying heart disease are at increased risk for sudden death due to cardiac arrhythmia (especially VFib). Order an electrophysiologic study because patients may benefit from an ICD or ablation.
Normal sinus rhythm with premature ventricular contraction.

(From Nettina SM. The Lippincott Manual of Nursing Practice. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:433, Figure 13-14.)

Quick HIT

Aldosterone antagonists (spironolactone, eplerenone)

- Indicated for HFrEF with EF <35%
- Improve all-cause mortality, CV mortality, and hospitalizations
- Can cause hyperkalemia, hence BMP should be monitored (do not start if creatinine >2.5 in men or 2 in women)
Tachyarrhythmias

Atrial Fibrillation

A. General Characteristics

1. Multiple foci in the atria fire continuously in a chaotic pattern, causing a totally *irregular, rapid ventricular rate*. Instead of intermittently contracting, the atria quiver continuously.

2. Atrial rate is over 400 bpm, but most impulses are blocked at the AV node so ventricular rate ranges between 75 and 175.

3. Patients with AFib and underlying heart disease are at a markedly increased risk for adverse events, such as thromboembolism and hemodynamic compromise.

**Quick HIT**

Digoxin

- Positive inotropic agent.
- Provides short-term symptomatic relief (used to control dyspnea and will decrease frequency of hospitalizations) but has not been shown to improve mortality, thus is not a first line treatment.
- Serum digoxin level should be checked periodically.

Signs of digoxin toxicity:

- GI: Nausea/vomiting, anorexia
- Cardiac: Ectopic (ventricular) beats, AV block, AFib
- CNS: Visual disturbances, disorientation

B. Causes

1. Heart disease: CAD, MI, HTN, mitral valve disease
2. History of cardiac surgery (scar can predispose to ectopic foci of activity)
3. Pulmonary disease, including PE, COPD, any cause of hypoxia
4. Hyperthyroidism
5. Systemic illness (e.g., sepsis, malignancy)
6. Stress (e.g., postoperative, pain)
7. Excessive alcohol intake (“holiday heart syndrome”)
8. Pericarditis
9. Hyperadrenergic states: Pheochromocytoma, cocaine or methamphetamine use
10. Extremes of activity (sedentary lifestyle, excess exercise such as marathon running)

C. Clinical Features

1. Fatigue and exertional dyspnea
2. Palpitations, dizziness, angina, or syncope may be seen
3. An *irregularly irregular* pulse
4. Blood stasis (secondary to ineffective contraction) leads to formation of intramural thrombi (often in the left atrial appendage), which can embolize to the brain, causing ischemic stroke

**D. Diagnosis**

1. ECG findings: Irregularly irregular rhythm (irregular RR intervals and excessively rapid series of tiny, erratic spikes on ECG with a wavy baseline and no identifiable P waves)

**E. Treatment**

1. Acute AFib in a hemodynamically *unstable* patient: Immediate electrical cardioversion to sinus rhythm *(Figure 1-9; see Clinical Pearl 1-11)*
2. Acute AFib in a hemodynamically *stable* patient
   a. Rate control
      • Target heart rate is <110 bpm (lenient rate control was found to be noninferior to strict rate control in the RACE II trial).
      • β-Blockers are preferred agent. CCBs (such as diltiazem) are an alternative if patient does not have HFrEF.
      • If left ventricular systolic dysfunction is present, ideal choice is metoprolol succinate as it will treat both HFrEF and AFib rate control. Can also consider digoxin or amiodarone (useful for rhythm control).
Calcium channel blockers (CCBs) play no role in treatment of CHF and some may actually raise mortality.
The following medications are contraindicated in patients with CHF:

- Metformin—may cause potentially lethal lactic acidosis with renal dysfunction
- Thiazolidinediones—causes fluid retention
- NSAIDs may increase risk of CHF exacerbation
- Some antiarrhythmic agents that have negative inotropic effects

The following devices have been shown to reduce mortality in select patients:

- An ICD lowers mortality by helping prevent sudden cardiac death (which is the most common cause of death in CHF). It is indicated for patients at least 40 days post-MI, EF <35%, and class II or III symptoms despite optimal medical treatment.
- Cardiac resynchronization therapy (CRT): This is biventricular pacemaker—indications are similar to ICD except these patients also have prolonged QRS duration >130 ms. Most patients who meet criteria for CRT are also candidates for ICD and receive a combined device.

Cardiac transplantation is the last alternative if the above do not control symptoms.

Quick HIT

The overall 5-year mortality for all patients with CHF is about 50%.

Quick HIT

The Cardiac Arrhythmia Suppression Trial (CAST) I and CAST II studies showed that the use of antiarrhythmic drugs to suppress PVCs after MI increases the risk of death.

Quick HIT

PVCs

- Couplet: Two successive PVCs
- Bigeminy: Sinus beat followed by a PVC
- Trigeminy: Two sinus beats followed by a PVC

CLINICAL PEARL 1-11

Cardioversion Versus Defibrillation

Cardioversion

- Delivery of a shock that is in synchrony with the QRS complex: Purpose is to terminate certain dysrhythmias such as PSVT or VT; an electric shock during T wave can cause Vfib, so the shock is timed not to hit the T wave.
- Indications: AFib, atrial flutter, VT with a pulse, SVT

Defibrillation

- Delivery of a shock that is not in synchrony with the QRS complex: Purpose is to convert a dysrhythmia to normal sinus rhythm.
- Indications: VFib, VT without a pulse.

Automatic Implantable Defibrillator
- Device that is surgically placed: When it detects a lethal dysrhythmia, it delivers an electric shock to defibrillate. It delivers a set number of shocks until the dysrhythmia is terminated.
- Indications: VFib and/or VT that is not controlled by medical therapy.

**Quick HIT**

Patients with AFib in the presence of underlying heart disease have an especially high risk of embolization and hemodynamic compromise.

**Quick HIT**

The treatment of AFib and atrial flutter are similar. There are three main goals:
- Rate control: Goal ventricular rate <110
- Assess need for anticoagulation
- Rhythm control: Restore normal sinus rhythm if first presentation or symptomatic

b. Anticoagulation to prevent cardioembolic cerebrovascular accident (CVA)
   - Risk stratify patients for bleeding complications with the CHA\(_2\)DS\(_2\)-VASc score.
   - This is a scoring calculator used to estimate annual stroke risk in a patient with AFib or atrial flutter. It assigns 1 point each to presence of heart failure, HTN, age 65 to 74, diabetes, female sex, vascular disease, and 2 points each to age >75, and history of CVA. The higher the score, the higher the annual stroke risk.
   - For patients with CHADSVASC score >1, anticoagulation is generally indicated unless high bleeding risk.
   - Choice of anticoagulant depends on etiology of AFib or atrial flutter. For patients with mechanical valves, mitral valvular disease, or ventricular assist devices, warfarin is the only oral anticoagulant available. For other patients, direct oral anticoagulants (DOACs) can be used.
   - DOACs approved for AFib include factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitors (dabigatran). These agents do not require lab monitoring. Dabigatran is the only DOAC with an FDA-approved reversal agent.
   - An INR of 2 to 3 is the anticoagulation goal range for warfarin.
   - Acute warfarin-associated bleeding can be reversed with fresh frozen plasma (FFP), prothrombin complex concentrate (PCC).

c. Rhythm control (cardioversion)
   - Candidates for cardioversion include those who are hemodynamically unstable, those who are symptomatic, and those who are having their first ever case of AFib.
That being said, no randomized control trial has ever found the rhythm control strategy to improve mortality compared to rate control.

If rhythm control is selected as a treatment strategy, electrical cardioversion is preferred over pharmacologic cardioversion. Attempts should be made to control ventricular rate before attempting DC cardioversion.

If AFib present for >48 hours (or unknown period of time), risk of embolization during cardioversion is significant (2% to 5%). Anticoagulate patients for 3 weeks before and at least 4 weeks after cardioversion.

To avoid waiting 3 weeks for anticoagulation, obtain a transesophageal echocardiogram (TEE) to image the left atrium (LA). If no thrombus is present, start IV heparin and perform cardioversion within 24 hours. Patients still require 4 weeks of anticoagulation after cardioversion.

Use pharmacologic cardioversion only if electrical cardioversion fails or is not feasible: Parenteral ibutilide, procainamide, flecainide, sotalol, and amiodarone are choices.

AFib ablation is a newer therapy for rhythm control, which is usually reserved for symptomatic patients refractory to electrical and pharmacologic cardioversion, or those with HFrEF and high AFib burden.

**Quick HIT**

The AFFIRM trial showed that rate control is noninferior to rhythm control in treatment of AFib.

**Quick HIT**

Risk of CVA in patients with AFib. See Table 1-2.

3. Chronic AFib
   a. Rate control with a β-blocker or CCB
   b. Anticoagulation
      • Patients with “lone” AFib (i.e., AFib in the absence of underlying heart disease or other cardiovascular risk factors) under age 65 do not require anticoagulation because they are at low risk for embolization (aspirin may be appropriate).
      • Treat all other patients with chronic anticoagulation.
Atrial Flutter

A. General Characteristics

1. Pathophysiology
   a. One irritable automaticity focus in the atria fires at about 250 to 350 bpm (typically very close to 300 bpm), giving rise to regular atrial contractions.
   b. Atrial rate between 250 and 350, around 300 bpm. The long refractory period in the AV node allows only one out of every two or three flutter waves to conduct to the ventricles.

2. Causes
   a. Heart disease: Heart failure (most common association), rheumatic heart disease, CAD
   b. COPD, other hypoxic pulmonary disease
   c. Atrial septal defect (ASD)
   d. Very similar risk factors to AFib

<table>
<thead>
<tr>
<th>CHA\textsubscript{2}DS\textsubscript{2}-VASc Score</th>
<th>Annual Stroke Risk (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Same as general population</td>
</tr>
<tr>
<td>1</td>
<td>1.3</td>
</tr>
<tr>
<td>2</td>
<td>2.2</td>
</tr>
<tr>
<td>3</td>
<td>3.2</td>
</tr>
<tr>
<td>4</td>
<td>4.0</td>
</tr>
<tr>
<td>5</td>
<td>6.7</td>
</tr>
<tr>
<td>6</td>
<td>9.8</td>
</tr>
<tr>
<td>7</td>
<td>9.6</td>
</tr>
<tr>
<td>8</td>
<td>12.5</td>
</tr>
<tr>
<td>9</td>
<td>15.2</td>
</tr>
</tbody>
</table>
B. Diagnosis

1. ECG provides a **saw-tooth** baseline, with a QRS complex appearing after every second or third “tooth” (P wave). Saw-tooth flutter waves are best seen in the inferior leads (II, III, aVF) (**Figure 1-10**).

C. Treatment

1. Same general treatment strategies as AFib
2. However, atrial flutter ablation is highly successful and can be used to avoid long-term anticoagulation if risk factors present.
Multifocal Atrial Tachycardia

Usually occurs in patients with severe pulmonary disease (e.g., COPD).
ECG findings: Variable P-wave morphology and variable PR and RR intervals. At least three different P-wave morphologies are required to make an accurate diagnosis (Figure 1-11).
The diagnosis of wandering atrial pacemaker is identical except that the heart rate is between 60 and 100 bpm (i.e., not tachycardic).
Can also be diagnosed by use of vagal maneuvers or adenosine to show AV block without disrupting the atrial tachycardia.
Treatment directed at the underlying disease, improving oxygenation and ventilation (strong association between MAT and lung disease). If left ventricular function is preserved, acceptable treatments include CCBs, β-blockers, digoxin, amiodarone, IV flecainide, and IV propafenone. If LV function is not preserved, use digoxin, diltiazem, or amiodarone. Electrical cardioversion is ineffective and should not be used.
Paroxysmal Supraventricular Tachycardia

A. General Characteristics
1. Pathophysiology (most often due to reentry) (Figure 1-12)
   a. AV nodal reentrant tachycardia
      • Two pathways (one fast and the other slow) within the AV node, so the reentrant circuit is within the AV node
      • Most common cause of supraventricular tachyarrhythmia (SVT)
      • Initiated or terminated by PACs
      • ECG: Narrow QRS complexes with no discernible P waves (P waves are buried within the QRS complex). This is because the circuit is short and conduction is rapid, so impulses exit to activate atria and ventricles simultaneously. Can sometimes have retrograde P waves, or P waves which occur after QRS complex
   b. Orthodromic AV reentrant tachycardia
      • An accessory pathway between the atria and ventricles that conducts retrogradely
      • Called a “concealed bypass tract,” and is a common cause of SVTs
      • Initiated or terminated by PACs or PVCs
      • ECG: Narrow QRS complexes with P waves which may or may not be discernible, depending on the rate. This is because the accessory pathway is at some distance from the AV node (reentrant circuit is longer), and there is a difference in the timing of activation of the atria and ventricles
FIGURE

1.11 ECG of multifocal atrial tachycardia with different P-wave configurations, varying PR intervals, and an irregular rate. Visible ectopic P waves are indicated by arrows.

(From Davis D. Quick and Accurate 12-Lead ECG Interpretation. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:414.)

2. Causes
   a. Ischemic heart disease
   b. Digoxin toxicity—paroxysmal atrial tachycardia with 2:1 block is the most common arrhythmia associated with digoxin toxicity
   c. AV nodal reentrant tachycardia (AVNRT)
   d. Atrial flutter with rapid ventricular response
   e. AV reentrant tachycardia (accessory pathway)
   f. Excessive caffeine or alcohol consumption
Quick HIT

In accordance with the electrical conducting system of the heart (SA node, atria, AV node, bundle of His, bundle branches, Purkinje fibers), tachycardias can be quickly separated into two categories based on the width of the QRS complex.

- Narrow QRS complexes suggest that the arrhythmia originates at or above the level of the AV node.
- Wide QRS complexes suggest that the arrhythmia originates outside of the normal conducting system or there is a supraventricular arrhythmia with coexisting abnormality in the His–Purkinje system.

B. Treatment

1. Maneuvers that stimulate the vagus nerve delay AV conduction and thus block the reentry mechanism: The Valsalva maneuver, carotid sinus massage, breath holding, and head immersion in cold water (or placing an ice bag to the face)

2. Acute treatment
   - Pharmacologic therapy
   - *IV adenosine—agent of choice* due to short duration of action; works by inhibiting AV nodal activity. Is used both as diagnostic (to see underlying atrial rhythm) and therapeutic agent (to terminate certain SVTs like AVNRT and AVRT).
   - IV diltiazem (CCB) and IV metoprolol (β-blocker) or digoxin are alternatives in patients with preserved left ventricular function.
   - DC cardioversion if drugs are not effective or if unstable; almost always successful.

3. Prevention
   a. Pharmacologic therapy: CCBs or β-blockers.
   b. Radiofrequency catheter ablation of either the AV node or the accessory tract (depending on which is the accessory pathway) is preferred if episodes are recurrent and symptomatic.
Wolff–Parkinson–White (WPW) Syndrome

A. General Characteristics
1. An accessory conduction pathway from atria to ventricles through the bundle of Kent causes premature ventricular excitation because it lacks the delay seen in the AV node.
2. May lead to a paroxysmal tachycardia, which can be produced by two possible mechanisms:
   a. Orthodromic reciprocating tachycardia (orthodromic AVRT)
      • The impulse travels through the AV node (anterograde limb) and depolarizes the ventricles. Then it travels back through the accessory pathway (the retrograde limb) and depolarizes the atria again, creating a reentry loop.
      • No delta waves because conduction occurs retrograde over the accessory pathway.
   b. Supraventricular tachycardias (AFib or atrial flutter)
      • Usually, AV node only allows certain impulses to get to ventricles. With an accessory pathway, all or most of the impulses may pass to the ventricles. A fast ventricular rate may occur and cause hemodynamic compromise.

Quick HIT

Side Effects of Adenosine
- Headache
- Flushing
- SOB
- Chest pressure
- Nausea

B. Diagnosis
1. ECG: Narrow complex tachycardia, a short PR interval (usually <100 ms), and a delta wave (upward deflection seen before the QRS complex)

C. Treatment
1. Radiofrequency catheter ablation of one arm of the reentrant loop (i.e., of the accessory pathway) is an effective treatment. Medical options include procainamide or quinidine.
2. Avoid drugs active on the AV node (e.g., digoxin, CCBs, β-blockers, adenosine) because they may accelerate conduction through the accessory pathway, resulting in VFib. Type IA antiarrhythmics (i.e., procainamide) are better choices, as they will suppress conduction through the accessory pathway instead.
Ventricular Tachycardia

A. General Characteristics
1. Defined as rapid and repetitive firing of three or more PVCs in a row, at a rate of between 100 and 250 bpm
2. AV dissociation is present, that is, sinus P waves continue with their cycle, unaffected by the tachycardia
3. Originates below the bundle of His
4. Causes
   a. CAD with prior MI is the most common cause
   b. Active ischemia, hypotension
   c. Cardiomyopathies, especially those with infiltration into myocardium such as sarcoidosis
   d. Ventricular scar tissue
   e. Congenital defects
   f. Long QT syndrome (results in torsades de pointes)
   g. Drug toxicity
5. Sustained versus nonsustained VT
   a. Sustained VT (persists in the absence of intervention)
      • Lasts longer than 30 seconds and is often symptomatic
      • Can be associated with marked hemodynamic compromise (i.e., hypotension) and/or development of myocardial ischemia
      • A life-threatening arrhythmia
      • Can progress to VFib if untreated
   b. Nonsustained VT
      • Brief, self-limited runs of VT
      • Usually asymptomatic
      • When CAD and LV dysfunction are present, it is an independent risk factor for sudden death. Therefore, patients with nonsustained VT should be thoroughly evaluated for underlying CAD and LV dysfunction.
6. Prognosis depends on the presence of CAD and on whether VT is sustained or nonsustained. VT after an MI usually has a poor prognosis, especially if it is sustained. In patients with no underlying heart condition, the prognosis is good.

Quick HIT

VT or VFib causes 75% of episodes of cardiac arrest.
Torsades de pointes is a rapid polymorphic VT. It is a dangerous arrhythmia that often can lead to VFib.

- It is associated with many factors that prolong the QT interval.
- Risk factors for long QT include: hypokalemia, hypomagnesemia, hypocalcemia, drugs (antiemetics, antipsychotics, SSRIs, TCAs, macrolide and fluoroquinolone antibiotics, among others), and congenital long QT syndrome.
- IV magnesium provides cardiac stabilization.
- Electrical cardioversion for unstable patients. May require drugs to increase heart rate such as isoproterenol to shorten QT interval while underlying cause is addressed.
- Address the underlying cause.

**B. Clinical Features of VT**

1. Palpitations, dyspnea, lightheadedness, angina, impaired consciousness (syncope or near-syncope)
2. May present with sudden cardiac death
3. Signs of cardiogenic shock may be present
4. May be asymptomatic if rate is slow
5. Physical findings include cannon A waves in the neck (secondary to AV dissociation, which results in atrial contraction during ventricular contraction) and an S1 that varies in intensity

**C. Diagnosis**

1. **ECG:** Wide and bizarre QRS complexes (Figure 1-13).
2. QRS complexes may be mono- or polymorphic.
   a. In monomorphic VT, all QRS complexes are identical.
   b. In polymorphic VT, the QRS complexes are different.
3. Unlike PSVT, VT does not respond to vagal maneuvers or adenosine.

**D. Treatment**

1. Identify and treat reversible causes

![Figure 1.13: Ventricular tachycardia.](image-url)
Quick HIT
Always suspect VT in a patient with a wide (>0.12 second) QRS tachycardia.

2. Sustained VT
   a. Hemodynamically stable patients with mild symptoms and systolic BP >90—pharmacologic therapy
      • Advanced cardiac life support (ACLS) guidelines recommend IV amiodarone
   b. Hemodynamically unstable patients or patients with severe symptoms
      • Immediate synchronous DC cardioversion
      • Follow with IV amiodarone to maintain sinus rhythm
   c. Ideally, all patients with sustained VT should undergo placement of an ICD, unless EF is normal (then consider amiodarone)

Quick HIT
- It is important to distinguish monomorphic VT from SVT with aberrant conduction.
- Wide complex tachycardia in adults with a history of structural heart disease is much more likely to be due to VT than SVT with aberrancy.

3. Nonsustained VT
   a. If no underlying heart disease and asymptomatic, do not treat. These patients are not at increased risk of sudden death.
   b. If the patient has underlying heart disease, a recent MI, evidence of left ventricular dysfunction, or is symptomatic, order an electrophysiologic study: If it shows inducible, sustained VT, ICD placement is appropriate.
   c. Pharmacologic therapy is second-line treatment. However, amiodarone has the best results of all of the antiarrhythmic agents.
Ventricular Fibrillation

A. General Characteristics
1. Multiple foci in the ventricles fire rapidly, leading to a chaotic quivering of the ventricles and no cardiac output.
2. Most episodes of VFib begin with VT (except in the setting of acute ischemia/infarction).
3. Recurrence
   a. If VFib is not associated with acute MI, recurrence rate is high (up to 30% within the first year). These patients require chronic therapy: Either prophylactic antiarrhythmic therapy (amiodarone) or implantation of an ICD.
   b. If VFib develops within 48 hours of an acute MI, long-term prognosis is favorable and the recurrence rate is low (2% at 1 year). Chronic therapy is not required in these patients.
4. Fatal if untreated

Quick HIT
If a patient with underlying heart disease is found to have nonsustained VT, an implantable defibrillator has been shown to be the most effective treatment.

Cardiac arrest and sudden cardiac death are not synonymous:
**Cardiac arrest:** Sudden loss of cardiac output; potentially reversible if circulation and oxygen delivery are promptly restored.
**Sudden cardiac death:** Unexpected death within 1 hour of symptom onset secondary to a cardiac cause.

B. Causes
1. Ischemic heart disease is the most common cause
2. Antiarrhythmic drugs, especially those that cause torsades de pointes (prolonged QT intervals)
3. AFib with a very rapid ventricular rate in patients with Wolff–Parkinson–White (WPW) syndrome

Quick HIT
Narrow complex tachycardias originate above ventricles. Wide complex tachycardias originate within ventricles and are more ominous because they are more likely to progress to VFib.

C. Clinical Features
1. Cannot measure BP; absent heart sounds and pulse
2. Patient is unconscious
3. If untreated, leads to eventual sudden cardiac death


**D. Diagnosis**
1. ECG: No atrial P waves can be identified (**Figure 1-14**)
2. No QRS complexes can be identified
3. In sum, no waves can be identified; there is a very irregular rhythm

**E. Treatment**
1. **This is a medical emergency! Immediate defibrillation and CPR are indicated.**
   a. Initiate unsynchronized DC cardioversion (defibrillation) immediately. If the equipment is not ready, start CPR until it is.
   b. Give up to three sequential shocks to establish another rhythm; assess the rhythm between each.
2. If VF persists:
   a. Continue CPR.
   b. Intubation may be indicated.
   c. Epinephrine (1-mg IV bolus initially, and then every 3 to 5 minutes)—this increases myocardial and cerebral blood flow and decreases the defibrillation threshold.
3. Other options if the above procedures fail (refractory VFib):
   a. IV amiodarone followed by shock—ACLS guidelines recommend the use of amiodarone over other antiarrhythmic agents in refractory VFib.
   b. Lidocaine, magnesium, and procainamide are alternative second-line treatments.
4. If cardioversion is successful:
   a. Maintain continuous IV infusion of the effective antiarrhythmic agent. IV
amiodarone has been shown to be effective. 

b. Implantable defibrillators have become the mainstay of chronic therapy in patients at continued risk for VF. Long-term amiodarone therapy is an alternative.

Quick HIT

- Drugs cannot convert VFib by themselves. Defibrillation is key, along with CPR and epinephrine.
- Defibrillation does not work for asystole. Perform CPR and administer epinephrine.

Quick HIT

**Pulseless Electrical Activity (PEA)**

- Occurs when electrical activity is on the monitor but there are no pulses (even with Doppler), and carries a grim prognosis.
- Treat possible causes (hypoxia, hypovolemia, hypotension, hyperkalemia, acidosis, tamponade, tension pneumothorax, toxins, PE, MI) and medicate according to ACLS guidelines.
Bradyarrhythmias

Sinus Bradycardia

Sinus rate <60 bpm: Clinically significant when rate is persistently <45 bpm
Causes include ischemia, increased vagal tone, antiarrhythmic drugs; may be a
normal finding in trained athletes
Can be asymptomatic; patients may complain of fatigue, inability to exercise,
angina, or syncope
Atropine can elevate the sinus rate by blocking vagal stimulation to the sinoatrial
node. A cardiac pacemaker may be required if bradycardia persists with symptoms
or syncope
Sick Sinus Syndrome

Sinus node dysfunction characterized by a persistent spontaneous sinus bradycardia. Patients usually elderly. Symptoms include dizziness, confusion, syncope, fatigue, and CHF. Pacemaker implantation may be required (see Clinical Pearl 1-12).

**CLINICAL PEARL 1-12**

Cardiac Pacemakers

1. Device that delivers direct electrical stimulation to the heart when the heart’s natural pacemaker is unable to do so
2. There are three types:
   - Permanent implantable system for long-term treatment
   - Temporary systems—either transcutaneous (with electrode pads over chest) or transvenous—both use an external pulse generator that patient can secure to the waist with straps
3. On ECG, cardiac pacing is noted by the presence of a “spike.”
4. Indications
   - Sinus node dysfunction is the most common indication
   - Symptomatic heart block—Mobitz II second-degree block and complete heart block (even if asymptomatic)
   - Symptomatic bradyarrhythmias
   - Tachyarrhythmias to interrupt rapid rhythm disturbances
FIGURE 1.15


### AV Block

**A. First-Degree AV Block**
1. PR interval is prolonged (>0.20 second) *(Figure 1-15).*
2. A QRS complex follows each P wave.
3. Delay is usually in the AV node.
4. Benign condition that does not require treatment.

---

### Quick HIT

Second-degree Mobitz type II and third-degree AV blocks require pacemaker implantation.

---

**B. Second-Degree AV Block (Includes Mobitz Types I and II)**
1. Mobitz type I (Wenckebach)
   a. Characterized by progressive prolongation of PR interval until a P wave fails to conduct
   b. Site of block is usually within the AV node
   c. Benign condition that does not require treatment
2. Mobitz type II
   a. P wave fails to conduct suddenly, without a preceding PR interval prolongation; therefore, the QRS drops suddenly
   b. Often progresses to third-degree AV block
   c. Site of block is within the His–Purkinje system
   d. **Pacemaker** implantation is necessary

---

**C. Third-Degree (Complete) AV Block**
1. Absence of conduction of atrial impulses to the ventricles; no correspondence between P waves and QRS complexes
2. A ventricular pacemaker (escape rhythm) maintains a ventricular rate of 25 to 40 bpm
   a. Characterized by **AV dissociation**
   b. **Pacemaker** implantation is necessary.
Diseases of the Heart Muscle

**Dilated Cardiomyopathy**

For causes, clinical features, diagnosis, and management of dilated cardiomyopathy, see HFrEF section of this chapter.
Hypertrophic Cardiomyopathy

A. General Characteristics
1. Most cases are inherited as an **autosomal-dominant** trait. However, spontaneous mutations may account for some cases.
2. Pathophysiology
   a. The main problem is diastolic dysfunction due to a stiff, hypertrophied ventricle with elevated diastolic filling pressures.
   b. These pressures increase further with factors that increase HR and contractility (such as exercise) or decrease left ventricular filling (e.g., the Valsalva maneuver).
   c. Patients may also have a dynamic outflow obstruction due to asymmetric hypertrophy of the interventricular septum.

B. Clinical Features
1. Symptoms
   a. Dyspnea on exertion
   b. Chest pain (angina)
   c. Syncope (or dizziness) after exertion or the Valsalva maneuver
   d. Palpitations
   e. Arrhythmias (AFib, ventricular arrhythmias)—due to persistently elevated atrial pressures
   f. Cardiac failure due to increased diastolic stiffness
   g. Sudden death—sometimes seen in a young athlete; may be the first manifestation of disease
   h. Some patients may remain asymptomatic for many years
2. Signs
   a. Sustained PMI
   b. Loud S₄
   c. Systolic ejection murmur
      • Decreases with squatting, lying down, or straight leg raise (due to decreased outflow obstruction)
      • Intensity increases with Valsalva and standing (decreases LV size and thus increases the outflow obstruction)
      • Decreases with sustained handgrip (increased systemic resistance leads to decreased gradient across aortic valve)
      • Best heard at left lower sternal border (LLSB)
   d. Rapidly increasing carotid pulse with two upstrokes (bisferious pulse)
Standing, the Valsalva, and leg raise maneuvers diminish the intensity of all murmurs except MVP and hypertrophic cardiomyopathy (HCM). These maneuvers decrease left ventricular volume.

Squatting increases the intensity of all murmurs except MVP and HCM.

Sustained handgrip diminishes the intensity of HCM murmur. Sustained handgrip increases systemic resistance.

C. Diagnosis
1. Echocardiogram establishes the diagnosis
2. Clinical diagnosis and family history

D. Treatment
1. Asymptomatic patients generally do not need treatment, but this is controversial. No studies have shown any alteration in the prognosis with therapy, so treatment generally focuses on reducing symptoms.
2. All patients should avoid strenuous exercise, including competitive athletics.
3. Symptomatic patients should use negatively inotropic drugs.
   a. β-Blockers should be the initial drug used in symptomatic patients; they reduce symptoms by improving diastolic filling (as HR decreases, duration in diastole increases), and also reduce myocardial contractility and thus oxygen consumption.
   b. CCBs (verapamil or another non-DHP CCB).
      • Can be used if patient is not responding to β-blocker.
      • Reduce symptoms by similar mechanism as β-blockers.
   c. Disopyramide can be added to either β-blocker or CCB to improve symptoms.
   d. Diuretics: Use with caution, as they can cause volume depletion, leading to LV outflow tract obstruction.
   e. If AFib is present, treat accordingly (see Atrial Fibrillation).
   f. Surgery
      • Alcohol septal ablation is a less invasive procedure than myomectomy that can lower the bulk of the interventricular septum and relieve obstructive symptoms.
      • Myomectomy has a high success rate for relieving symptoms. It involves the excision of part of the myocardial septum. It is reserved for patients with severe disease.
      • Mitral valve replacement is now rarely performed. Repair sometimes performed at the time of surgical myomectomy.
Restrictive Cardiomyopathy

A. General Characteristics
1. Infiltration of the myocardium results in impaired diastolic ventricular filling due to decreased ventricular compliance.
2. Systolic dysfunction is variable and usually occurs in advanced disease.
3. Less common than dilated and hypertrophic cardiomyopathies.

B. Causes of Restrictive Cardiomyopathy
1. Amyloidosis
2. Sarcoidosis
3. Hemochromatosis
4. Scleroderma
5. Carcinoid syndrome
6. Chemotherapy or radiation induced
7. Idiopathic

C. Clinical Features
1. Elevated filling pressures cause dyspnea and exercise intolerance.
2. Right-sided signs and symptoms are present for the same reason.

D. Diagnosis
1. Echocardiogram
   a. Thickened myocardium and possible systolic ventricular dysfunction
   b. Increased right atrium (RA) and LA size with normal LV and RV size
   c. In amyloidosis, myocardium appears brighter or may have a speckled appearance
2. ECG: Low voltages or conduction abnormalities, arrhythmias, AFib
3. Endomyocardial biopsy may be diagnostic

E. Treatment
1. Treat underlying disorder
   a. Hemochromatosis: Phlebotomy or deferoxamine
   b. Sarcoidosis: Glucocorticoids for acute flares
   c. Amyloidosis: Treat underlying cause of amyloidosis, consider organ transplantation if severe end-organ disease (i.e., heart, kidney, liver if transthyretin amyloidosis)
   d. Treat according to EF (HFrEF therapy or HFpEF therapy)
2. Use diuretics and vasodilators (for pulmonary and peripheral edema) cautiously, because a decrease in preload may compromise cardiac output
Myocarditis

Inflammation of the myocardium, with many possible causes, including viruses (e.g., Coxsackie, parvovirus B19, human herpes virus 6), bacteria (e.g., group A streptococcus in rheumatic fever, Lyme disease, mycoplasma, etc.), SLE, medications (e.g., sulfonamides); can also be idiopathic. May be asymptomatic, or may present with fatigue, fever, chest pain, pericarditis, CHF, arrhythmia, or even death. The classic patient is a young male. Look for elevations in cardiac enzyme levels and erythrocyte sedimentation rate. Treatment is supportive. Treat underlying causes if possible, and treat any complications.
Pericardial Diseases

Acute Pericarditis

A. General Characteristics

1. Inflammation of the pericardial sac—may be an isolated finding or part of an underlying disorder or generalized disease

2. Causes

   a. Idiopathic (probably postviral): Most cases of idiopathic pericarditis are presumed to be postviral, usually preceded by a recent flu-like illness or by upper respiratory or GI symptoms

   b. Infectious: Viral (e.g., Coxsackievirus, echovirus, adenovirus, EBV, influenza, HIV, hepatitis A or B), bacterial (tuberculosis), fungal, toxoplasmosis

   c. Acute MI (first 24 hours after MI)

   d. Uremia

   e. Collagen vascular diseases (e.g., SLE, scleroderma, rheumatoid arthritis, sarcoidosis)

   f. Neoplasm—especially Hodgkin lymphoma, breast, and lung cancers

   g. Drug-induced lupus syndrome (procainamide, hydralazine)

   h. After MI: (Dressler syndrome)—usually weeks to months after MI

   i. After surgery—postpericardiotomy syndrome

   j. Amyloidosis

   k. Radiation

   l. Trauma

3. The majority of patients recover within 1 to 3 weeks. A minority of patients have a prolonged course or recurrent symptoms

4. Complications

   a. Pericardial effusion

   b. Cardiac tamponade—can occur in up to 15% of patients; close observation is important

B. Clinical Features

1. Chest pain (most common finding)

   a. Often severe and pleuritic (can differentiate from pain of MI because of association with breathing).

   b. Often localized to the retrosternal and left precordial regions and radiates to the trapezius ridge and neck.

   c. Pain is positional: It is aggravated by lying supine, coughing, swallowing, and
deep inspiration. *Pain is relieved by sitting up and leaning forward.*

d. Pain is not always present, depending on the cause (e.g., usually absent in rheumatoid pericarditis).

2. Fever and leukocytosis may be present
3. Patient may give symptoms of preceding viral illness such as a nonproductive cough or diarrhea
4. **Pericardial friction rub**
   a. Not always present, but it is very specific for pericarditis
   b. Caused by friction between visceral and parietal pericardial surfaces
   c. Scratching, high-pitched sound with up to three components. Patients may have any or all of the three components:
      - Atrial systole (presystolic)
      - Ventricular systole (loudest and most frequently heard)
      - Early diastole
d. Heard best during expiration with patient sitting up and with stethoscope placed firmly against the chest
e. Friction rub may come and go over a period of several hours, and can vary greatly in intensity

Quick HIT

Diagnostic criteria of acute pericarditis (need at least 2/4):
- Classic pleuritic chest pain with positional component
- Pericardial friction rub
- ECG changes—diffuse ST elevations; PR depression, PR elevation in aVR
- Pericardial effusion (seen on chest x-ray or echocardiogram)

C. Diagnosis
1. **ECG** shows four changes in sequence
   a. *Diffuse ST elevation and PR depression, with PR elevation in lead aVR*
   b. ST segment returns to normal—typically around 1 week
   c. T-wave inverts—does not occur in all patients
   d. T wave returns to normal
2. Echocardiogram if pericarditis with effusion is suspected

D. Treatment
1. Most cases are self-limited and resolve in 2 to 6 weeks.
2. Treat the underlying cause if known.
3. First-line therapy is high-dose NSAIDs (aspirin, ibuprofen, naproxen, or indomethacin). Colchicine is recommended as adjunctive therapy in addition to
NSAIDs.

4. Glucocorticoids may be tried if pain does not respond to NSAIDs, but should be avoided if at all possible, as they are associated with a high rate of recurrent pericarditis.

5. Relatively uncomplicated cases can be treated as an outpatient. However, patients with more worrisome symptoms such as fever and leukocytosis and patients with worrisome features such as pericardial effusion should be hospitalized.
Constrictive Pericarditis

A. General Characteristics
1. *Fibrous scarring of the pericardium* leads to rigidity and thickening of the pericardium, with obliteration of the pericardial cavity.
2. Pathophysiology
   a. A fibrotic, rigid pericardium restricts the diastolic filling of the heart.
   b. Ventricular filling is unimpeded during early diastole because intracardiac volume has not yet reached the limit defined by the stiff pericardium.
   c. When intracardiac volume reaches the limit set by the noncompliant pericardium, ventricular filling is halted abruptly. (In contrast, ventricular filling is impeded *throughout* diastole in cardiac tamponade.)
3. Causes
   a. In most patients, the cause is never identified and is idiopathic or related to a previous viral infection.
   b. Other causes include recurrent pericarditis, uremia, radiation therapy, tuberculosis, chronic pericardial effusion, tumor invasion, connective tissue disorders, and prior surgery involving the pericardium.

Quick HIT

Diastolic Dysfunction in Constrictive Pericarditis
- Early diastole: Rapid filling
- Late diastole: Halted filling

B. Clinical Features
1. Patients appear very ill
2. Patients with constrictive pericarditis typically present in one of the two ways:
   a. With symptoms characteristic of fluid overload such as edema, ascites, and pleural effusions
   b. With symptoms related to the diminished cardiac output such as dyspnea on exertion, fatigue, decreased exercise tolerance, and cachexia
   c. Patient can present with a combination of both of these findings
3. Signs include:
   a. JVD—most prominent physical finding; central venous pressure (CVP) is elevated and displays prominent x and y descents
   b. *Kussmaul sign*—JVP (venous pressure) paradoxically increases during inspiration
   c. Pericardial knock—corresponding to the abrupt cessation of ventricular filling
d. Ascites

e. Dependent edema

4. May be difficult to distinguish from restrictive cardiomyopathy—may require echo or cardiac catheterization to distinguish these entities

Quick HIT

If a patient has clinical signs of cirrhosis (ascites, hepatomegaly) and distended neck veins, perform tests to rule out constrictive pericarditis.

Quick HIT

Often, constrictive pericarditis progresses to worsening cardiac output and to hepatic and/or renal failure. Surgical treatment (pericardiectomy) is indicated in many cases, but has high risk of morbidity and mortality.

C. Diagnosis

1. ECG

   a. Nonspecific changes such as low QRS voltages, generalized T-wave flattening or inversion, left atrial abnormalities.

   b. AFib is more often seen in advanced disease but overall occurs in fewer than half of all patients.

2. Echocardiogram

   a. Increased pericardial thickness is seen in about half of all patients.

   b. A sharp halt in ventricular diastolic filling and atrial enlargement can also be seen.

3. CT scan and MRI may also show pericardial thickening and calcifications, and can aid greatly in the diagnosis.

4. Cardiac catheterization

   a. Elevated and equal diastolic pressures in all chambers.

   b. Ventricular pressure tracing shows a rapid y descent, which has been described as a dip and plateau or a “square root sign.”

Quick HIT

Echocardiogram is the imaging study of choice for diagnosis of pericardial effusion and cardiac tamponade physiology (has a high sensitivity).

Quick HIT

Pericardial effusion is important clinically when it develops rapidly because it may lead to cardiac tamponade.
D. Treatment
1. *Treat the underlying condition*
2. Diuretics may be extremely helpful in treating fluid overload symptoms
3. Surgical pericardiectomy
Pericardial Effusion

A. General Characteristics
1. Defined as any cause of acute pericarditis (see above) that can lead to exudation of fluid into the pericardial space
2. Can occur in association with ascites and pleural effusion in salt and water retention states such as CHF, cirrhosis, and nephrotic syndrome
3. Is often asymptomatic and suspected based on the symptoms of the underlying condition
4. May be acute or chronic. Acute effusions have higher risk of progressing to tamponade

B. Clinical Features
1. All physical examination signs are extremely nonspecific and often do not aid in the diagnosis but may include:
   a. Muffled heart sounds
   b. Soft PMI
   c. Dullness at left lung base (because it may be compressed by pericardial fluid)
   d. Pericardial friction rub may or may not be present

C. Diagnosis
1. Echocardiogram
   a. Imaging procedure of choice: Confirms the presence or absence of a significant effusion
   b. Most sensitive and specific method of determining whether pericardial fluid is present; can show as little as 20 mL of fluid
   c. Should be performed in all patients with acute pericarditis to rule out an effusion
2. CXR
   a. CXR shows enlargement of cardiac silhouette when >250 mL of fluid has accumulated
   b. Cardiac silhouette may have prototypical “water bottle” appearance
   c. An enlarged heart without pulmonary vascular congestion suggests pericardial effusion
3. ECG
   a. May show low QRS voltages and T-wave flattening but should not be used to diagnose pericardial effusion
   b. Electrical alternans (see definition below under Cardiac Tamponade) suggests a massive pericardial effusion and tamponade
4. CT scan or MRI—very accurate, but often unnecessary given the accuracy of an
echocardiogram
5. Pericardial fluid analysis—may clarify the cause of the effusion
   a. Order protein and glucose content, cell count and differential, cytology, specific gravity, hematocrit, Gram stain, acid-fast stains, mycobacterial PCR, fungal smear, cultures, LDH content

D. Treatment
1. Depends on patient’s hemodynamic stability.
2. Pericardiocentesis is not indicated unless there is evidence of cardiac tamponade. Analysis of pericardial fluid can be useful if the cause of the effusion is unknown.
3. If the effusion is small and clinically insignificant, a repeat echocardiogram in 1 to 2 weeks is appropriate.
Cardiac Tamponade

A. General Characteristics
1. Defined as accumulation of pericardial fluid. It is the rate of fluid accumulation that is important, not the amount.
   a. Two hundred milliliters of fluid that develops rapidly (i.e., blood secondary to trauma) can cause cardiac tamponade.
   b. Two liters of fluid may accumulate slowly before cardiac tamponade occurs. When fluid accumulates slowly, the pericardium has the opportunity to stretch and adapt to the increased volume (i.e., related to a malignancy).
2. Pathophysiology
   a. Pericardial effusion that mechanically impairs diastolic filling of the heart.
   b. Characterized by the elevation and equalization of intracardiac and intrapericardial pressures.
      • Pressures in the RV, LV, RA, LA, pulmonary artery, and pericardium equalize during diastole.
      • Ventricular filling is impaired during diastole.
      • Decreased diastolic filling leads to decreased stroke volume and decreased cardiac output.
3. Causes
   a. Penetrating (less commonly blunt) trauma to the thorax, such as gunshot and stab wounds
   b. Iatrogenic: Central-line placement, pacemaker insertion, pericardiocentesis, etc.
   c. Pericarditis, progressive pericardial effusion
   d. Post-MI with free wall rupture
   e. Aortic dissection

B. Clinical Features
1. Cardiac tamponade is a clinical diagnosis. Echocardiography can be helpful in confirming tamponade physiology, but the diagnosis can be made without it. The key findings are Beck triad and pulsus paradoxus
2. Beck triad: Hypotension, muffled heart sounds, elevated JVP (distended neck veins, whose venous waveforms show prominent x descent and absent y descent)
3. Pulsus paradoxus (tamponade physiology)
a. Exaggerated decrease in arterial pressure during inspiration (>10 mm Hg drop).
b. This happens because during inspiration and diastole, blood flows into the RV, and with the effusion compressing the free wall of the RV, it will expand into the interventricular septum and limit the filling of the LV, resulting in diminished stroke volume and therefore blood pressure.
c. Can be detected by a decrease in the amplitude of the femoral or carotid pulse during inspiration.
   • Pulse gets strong during expiration and weak during inspiration.
4. *Narrowed* pulse pressure (due to decreased stroke volume).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beck Triad (Cardiac Tamponade)</td>
</tr>
<tr>
<td>• Hypotension</td>
</tr>
<tr>
<td>• Muffled heart sounds</td>
</tr>
<tr>
<td>• Elevated JVP</td>
</tr>
</tbody>
</table>

C. Diagnosis
1. Echocardiogram
   a. Must be performed if suspicion of tamponade exists based on history/examination
   b. Usually diagnostic; the most sensitive and specific noninvasive test for determining tamponade physiology
2. CXR
   a. Enlargement of cardiac silhouette when >250 mL has accumulated
   b. Clear lung fields
3. ECG
   a. *Electrical alternans* (alternate beat variation in the direction of the ECG waveforms)—due to pendular swinging of the heart within the pericardial space, causing a motion artifact
   b. *Findings* are neither 100% sensitive nor specific. ECG should not be used to diagnose tamponade
4. Cardiac catheterization
   a. Shows equalization of pressures in all chambers of the heart
   b. Shows elevated right atrial pressure with loss of the y descent

D. Treatment
1. Nonhemorrhagic tamponade
   a. If patient is hemodynamically stable
- Monitor closely with echocardiogram, CXR, ECG
- If patient has known renal failure, dialysis is more helpful than pericardiocentesis

b. If patient is not hemodynamically stable
   - Pericardiocentesis is indicated
   - If no improvement is noted, fluid challenge may improve symptoms

2. Hemorrhagic tamponade secondary to trauma
   a. If the bleeding is unlikely to stop on its own, emergent surgery is indicated to repair the injury
   b. Pericardiocentesis is only a temporizing measure and is not definitive treatment. Surgery should not be delayed to perform pericardiocentesis
Valvular Heart Disease

**Mitral Stenosis**

**A. General Characteristics**

1. Almost all cases are due to rheumatic heart disease. (Patient may not recall a history of rheumatic fever.)
2. Pathophysiology
   a. Immune-mediated damage to the mitral valve (due to rheumatic fever) caused by cross-reactivity between the streptococcal antigen and the valve tissue leads to scarring and narrowing of the mitral valve orifice.
   b. Mitral stenosis results in elevated left atrial and pulmonary venous pressure leading to pulmonary congestion.
   c. Anything that increases flow across the mitral valve (exercise, tachycardia, and so on) exacerbates the pulmonary venous HTN and associated symptoms.
   d. Long-standing mitral stenosis can result in pulmonary HTN and ultimately can result in right ventricular failure (RVF).
   e. Long-standing mitral stenosis can also lead to AFib due to increased left atrial pressure and size.
   f. Patients are usually asymptomatic until the mitral valve area is reduced to approximately 1.5 cm$^2$ (normal valve area is 4 to 5 cm$^2$).

**B. Clinical Features**

1. Symptoms
   a. Exertional dyspnea, orthopnea, PND
   b. Palpitations, chest pain
   c. Hemoptysis—as the elevated LA pressure ruptures anastomoses of small bronchial veins
   d. Thromboembolism—often associated with AFib
   e. If RV failure occurs, ascites and edema may develop
2. Signs
   a. Mitral stenosis murmur.
      - The *opening snap* is followed by a *low-pitched diastolic rumble* and presystolic accentuation. This murmur increases in length as the disease worsens.
      - Heard best with bell of stethoscope in left lateral decubitus position.
   b. $S_2$ is followed by an opening snap. The distance between $S_2$ and the opening snap can give an indication as to the severity of the stenosis. The closer the
opening snap follows $S_2$, the worse is the stenosis.

c. Murmur is followed by a loud $S_1$. A loud $S_1$ may be the most prominent physical finding.

d. With long-standing disease, will find signs of RVF (e.g., right ventricular heave, JVD, hepatomegaly, ascites) and/or pulmonary HTN (loud $P_2$).

e. All signs and symptoms will increase with exercise and during pregnancy.

C. Diagnosis

1. CXR: Left atrial enlargement (early)
2. Echocardiogram—most important test in confirming diagnosis
   a. Left atrial enlargement
   b. Thick, calcified mitral valve
   c. Narrow, “fish mouth”–shaped orifice
   d. Signs of RVF, if advanced disease

D. Treatment

1. Medical
   a. Diuretics—for pulmonary congestion and edema.
   b. β-Blockers—to decrease heart rate (increase diastolic time to improve LV filling and LA emptying) and cardiac output.
2. Surgical (for severe disease)
   a. Percutaneous balloon valvuloplasty usually produces excellent results.
   b. Open commissurotomy and mitral valve replacement are other options if valvotomy is contraindicated.
3. Management
   a. No therapy is required in asymptomatic patients.
   b. Diuretics can be used if the patient has mild symptoms.
   c. If symptoms are more severe, surgical treatment is recommended.
   d. If AFib develops at any time, treat accordingly (see discussion on AFib).
Aortic Stenosis

A. General Characteristics

1. Pathophysiology
   a. Causes obstruction to LV outflow, which results in LVH.
   b. When the aortic valve area falls below 1 cm², cardiac output fails to increase with exertion, causing angina (but may be normal at rest).
   c. With long-standing AS, the LV dilates, causing progressive LV dysfunction.
   d. With severe AS, LV dilation pulls the mitral valve annulus apart, causing MR.

2. Causes
   a. Calcification of a congenitally abnormal bicuspid aortic valve.
   b. Calcification of tricuspid aortic valve in elderly.
   c. Rheumatic fever.

3. Course
   a. Patients are often asymptomatic for years (until middle or old age) despite severe obstruction.
   b. Development of angina, syncope, or heart failure is a sign of poor prognosis.
      Survival is similar to that of the normal population before the development of these three classic symptoms. Without surgical intervention, the survival is poor:
      - Angina (35%)—average survival, 3 years
      - Syncope (15%)—average survival, 2 years
      - Heart failure (50%)—average survival, 1.5 years

Quick HIT

Altogether, only one-fourth of patients with symptomatic AS survives 3 years in the absence of aortic valve replacement (i.e., the 3-year mortality rate is 75% without surgery).

B. Clinical Features

1. Symptoms
   a. Angina
   b. Syncope—usually exertional
   c. Heart failure symptoms, such as dyspnea on exertion, orthopnea, or PND

2. Signs
   a. Murmur
      - Harsh crescendo–decrescendo systolic murmur
      - Heard in second right intercostal space
      - Radiates to carotid arteries
b. *Soft S2*. S2 may also be single since the aortic component may be delayed and merge into P2. The softer the murmur, the more severe the AS
c. *S₄* with progressive disease
d. *Parvus et tardus*—diminished and delayed carotid upstrokes
e. Sustained PMI
f. Precordial thrill

**C. Diagnosis**

1. CXR findings: Calcific aortic valve, enlarged LV/LA (late)
2. ECG findings: LVH, LA abnormality
3. Echocardiography: Has replaced cardiac catheterization as *standard test* for hemodynamic and valve measurements for diagnosis of AS. Shows thickened, calcified aortic valve leaflets with limited mobility. Key measurements for diagnosis and severity are diminished valve area and increased ventricular-aortic pressure gradient
4. Exercise stress testing is indicated for asymptomatic patients with severe AS to confirm asymptomatic status. These patients, despite having severe AS, do not require intervention. Should *not* be performed in symptomatic patients
5. Cardiac catheterization
   a. Now used primarily in patients in whom echocardiography is nondiagnostic (i.e., poor visualization of valve, difficulty obtaining pressure gradients with Doppler)
   b. Useful in symptomatic patients before surgery because it can also reveal coronary anatomy, allowing the surgeon to do both CABG and aortic valve replacement in patients with both CAD and severe AS

**Quick HIT**

Management of AS is straightforward:
- If asymptomatic: No treatment
- If symptomatic: Surgical aortic valve replacement or transcatheter aortic valve replacement (TAVR) depending on patient risk

**D. Treatment**

1. Medical therapy has a limited role.
   Surgical therapy: *Aortic valve replacement is the treatment of choice*. It is indicated in all symptomatic patients. There is evidence (PARTNER A, PARTNER II trials) that TAVR is noninferior (mortality, stroke risk) to surgical AVR in patients with high and intermediate surgical risk.
Aortic Regurgitation

A. General Characteristics

1. Pathophysiology
   a. Also called aortic insufficiency; this condition is due to inadequate closure of the aortic valve leaflets. Regurgitant blood flow increases left ventricular end-diastolic volume.
   b. LV dilation and hypertrophy occur in response in order to maintain stroke volume and prevent diastolic pressure from increasing excessively.
   c. Over time, these compensatory mechanisms fail, leading to increased left-sided and pulmonary pressures.
   d. The resting left ventricular EF is usually normal until advanced disease.

2. Course
   a. For chronic aortic regurgitation, survival is 75% at 5 years.
      - After the development of angina, death usually occurs within 4 years.
      - After the development of heart failure, death usually occurs within 2 years.
   b. For acute aortic regurgitation, mortality is particularly high without surgical repair.

B. Causes

1. Acute
   a. Infective endocarditis
   b. Trauma
   c. Aortic dissection
   d. Iatrogenic as during a failed replacement surgery

2. Chronic
   a. Primary valvular: Rheumatic fever, bicuspid aortic valve, Marfan syndrome, Ehlers–Danlos syndrome, ankylosing spondylitis, SLE
   b. Aortic root disease: Syphilitic aortitis, osteogenesis imperfecta, aortic dissection, Behçet syndrome, Reiter syndrome, systemic HTN

Quick HIT

Other Physical Findings in Aortic Insufficiency
- De Musset sign: Head bobbing (rhythmic jerking of head)
- Müller sign: Uvula bobs
- Duroziez sign: Pistol-shot sound heard over the femoral arteries

C. Clinical Features
1. Symptoms
   a. May be symptomatic for many years
   b. Dyspnea on exertion, PND, orthopnea
   c. Palpitations—worse when lying down
   d. Angina
   e. Cyanosis and shock in acute aortic regurgitation (medical emergency)
2. Physical examination
   a. Widened pulse pressure—markedly increased systolic BP, with decreased diastolic BP.
   b. Diastolic decrescendo murmur best heard at left sternal border.
   c. Corrigan pulse (water-hammer pulse)—rapidly increasing pulse that collapses suddenly as arterial pressure decreases rapidly in late systole and diastole; can be palpated at wrist or femoral arteries.
   d. Austin Flint murmur—low-pitched diastolic rumble due to competing flow anterograde from the LA and retrograde from the aorta. It is similar to the murmur appreciated in mitral stenosis.
   e. Displaced PMI (down and to the left) and S₃ may also be present.
   f. Murmur intensity increases with sustained handgrip. Handgrip increases systemic vascular resistance (SVR), which causes an increased “backflow” through the incompetent aortic valve.

D. Diagnosis
1. CXR findings: Enlarged cardiac silhouette, dilated aorta
2. ECG findings: LVH
3. Echocardiogram—Perform serially in chronic, stable patients to assess need for surgery
   a. Assess LV size and function
   b. Look for dilated aortic root and reversal of blood flow in aorta
   c. In acute aortic regurgitation, look for early closure of mitral valve
4. Cardiac catheterization: To assess severity of aortic regurgitation and degree of LV dysfunction

E. Treatment
1. If asymptomatic with normal LV function, no therapy indicated
2. If asymptomatic with severe AR and LV dysfunction, ACE inhibitor or ARB indicated for afterload reduction
3. If symptomatic: Salt restriction, diuretics, afterload reduction (i.e., ACE inhibitors or ARBs), HFrEF therapy if heart failure (i.e., β-blocker, aldosterone antagonist, digoxin in selected cases), and restriction on strenuous activity
4. Definitive treatment is surgery (aortic valve replacement). This should be
considered in symptomatic patients, or in those with significant LV dysfunction on echocardiogram.

5. Acute AR (e.g., post-MI): *Medical emergency—emergent aortic valve replacement!*
Mitral Regurgitation

A. General Characteristics

1. Pathophysiology
   a. Acute
      • Abrupt elevation of left atrial pressure in the setting of normal LA size and compliance, causing backflow into pulmonary circulation with resultant pulmonary edema
      • Cardiac output decreases because of decreased forward flow, so hypotension and shock can occur
   b. Chronic
      • Gradual elevation of left atrial pressure in the setting of dilated LA and LV (with increased left atrial compliance)
      • LV dysfunction occurs due to dilation
      • Pulmonary HTN can result from chronic backflow into pulmonary vasculature

2. Causes
   a. Acute
      • Endocarditis (most often Staphylococcus aureus)
      • Papillary muscle rupture (from infarction) or dysfunction (from ischemia)
      • Chordae tendineae rupture
   b. Chronic
      • Mitral valve prolapse (MVP)
      • Rheumatic fever
      • Marfan syndrome
      • Cardiomyopathy causing dilation of mitral annulus

3. Prognosis
   a. Acute form is associated with much higher mortality
   b. Survival is related to extent of LV cavity dilation

B. Clinical Features

1. Symptoms
   a. Dyspnea on exertion, PND, orthopnea
   b. Palpitations
   c. Pulmonary edema

2. Signs
   a. Holosystolic murmur (starts with S₁ and continues on through S₂) at the apex, which radiates to the back or clavicular area, depending on which leaflet is involved
b. AFib is a common finding  
c. Other findings: Diminished S₁, widening of S₂, S₃ gallop; laterally displaced PMI; loud, palpable P₂

C. Diagnosis  
1. CXR findings: Cardiomegaly, dilated LV, pulmonary edema.  
2. Echocardiogram: MR; dilated LA and LV; decreased LV function. Should be performed serially in patients with known MR.

D. Treatment  
1. Medical  
   a. Afterload reduction with vasodilators is recommended for symptomatic patients only; they are not recommended in most asymptomatic patients as they may mask progression of the disease  
   b. Chronic anticoagulation if patient has AFib  
   c. IABP can be used as a bridge to surgery for acute MR (decreases afterload and favors normal flow, not regurgitant flow)  
2. Surgical  
   a. Mitral valve repair or replacement  
   b. Must be performed before left ventricular function is too severely compromised  
   c. Patients with very high surgical risk, severe symptoms, and favorable anatomy may be candidates for transcatheter mitral valve repair
Tricuspid Regurgitation

A. General Characteristics

1. Tricuspid regurgitation (TR) results from a failure of the tricuspid valve to close completely during systole, causing regurgitation of blood into the RA. It is estimated that up to 70% of normal adults have mild, physiologic TR as seen on high-resolution echocardiography. A much smaller percentage of people are actually symptomatic.

2. Causes—up to 90% of cases occur in people with anatomically normal valve leaflets and chords.

   a. TR is usually secondary to RV dilation. Any cause of RV dilation can result in enlargement of the tricuspid orifice.
      • Left ventricular failure is the most common cause.
      • Right ventricular infarction.
      • Inferior wall MI.
      • Cor pulmonale, secondary to pulmonary HTN.
   
   b. Tricuspid endocarditis—seen in IV drug users.
   
   c. May be secondary to rheumatic heart disease; usually accompanied by mitral and aortic valve disease.
   
   d. Ebstein anomaly—congenital malformation of tricuspid valve in which there is downward displacement of the valve into the RV.
   
   e. Other causes include carcinoid syndrome, SLE, and myxomatous valve degeneration.

B. Clinical Features

1. Usually asymptomatic unless the patient develops symptoms of RHF/pulmonary HTN

2. Signs and symptoms of RVF (ascites, hepatomegaly, edema, JVD)

3. Pulsatile liver

4. Prominent V waves in jugular venous pulse with rapid y descent

5. Inspiratory S₃ along LLSB may be present

6. Blowing holosystolic murmur

   a. At LLSB
   
   b. Intensified with inspiration; reduced during expiration or the Valsalva maneuver

7. Right ventricular pulsation along LLSB

8. AFib can be present with severe atrial dilation

C. Diagnosis

1. Echocardiogram
a. Quantifies amount of TR  
   b. Identifies prolapse/flail of tricuspid valve leaflets  
   c. Estimates pulmonary pressures based on severity of TR velocity  
   d. ECG: RV and RA enlargement  

D. Treatment  

1. Treat any underlying etiology of symptomatic TR  
2. Diuretics for volume overload and venous congestion/edema  
3. Treat left-sided heart failure, endocarditis, or pulmonary HTN  
4. Severe regurgitation may be surgically corrected if pulmonary HTN is not present  
   a. Native valve repair surgery  
   b. Valvuloplasty of tricuspid ring  
   c. Valve replacement surgery: Rarely performed
Mitral Valve Prolapse

A. General Characteristics
1. MVP is defined as the presence of excessive or redundant mitral leaflet tissue due to myxomatous degeneration of mitral valve leaflets and/or chordae tendineae. The redundant leaflet(s) prolapse toward the LA in systole, which results in the auscultated click and murmur.
2. MVP is common in patients with genetic connective tissue disorders, such as Marfan syndrome, osteogenesis imperfecta, and Ehlers–Danlos syndrome.
3. MVP is a common cause of MR in developed countries.
4. Arrhythmias and sudden death are very rare.

Quick HIT

Key Signs of MVP
- Systolic clicks
- Midsystolic rumbling murmur that increases with standing and the Valsalva maneuver and decreases with squatting

B. Clinical Features
1. Symptoms
   a. Most patients are asymptomatic for their entire lives.
   b. Palpitations and atypical chest pain may occur.
   c. TIA’s due to emboli from mitral valve have been reported, but are very rare.
2. Signs
   a. Midsystolic or late systolic click(s).
   b. Mid-to-late systolic murmur.
   c. Some patients have midsystolic click without the murmur; others may have the murmur without the click.
   d. Standing and the Valsalva maneuver increase murmur and click because these maneuvers reduce LV chamber size, allowing the click and murmur to occur earlier in systole.
   e. Squatting decreases murmur and click because it increases LV chamber size, thus delaying the onset of the click and murmur.

C. Diagnosis
1. Echocardiogram is the most useful.
2. Most patients are asymptomatic, so diagnosis is typically made on the basis of the murmur and echocardiogram alone.

D. Treatment
1. If patient is asymptomatic, reassurance. There is some association between MVP and anxiety, so all patients should be reassured about the benign nature of this condition.
2. For chest pain, β-blockers have been useful, but they are unlikely to be required.
3. Surgery is rarely required. The condition is generally benign.
Rheumatic Heart Disease

A. General Characteristics
1. Rheumatic heart disease occurs as a complication of streptococcal pharyngitis (group A streptococcus).
2. Acute rheumatic fever is an immunologically mediated systemic process that may progress to rheumatic heart disease.
3. Rheumatic heart disease describes the chronic valvular abnormalities secondary to acute rheumatic fever.
4. The most common valvular abnormality is mitral stenosis, but patients may have aortic or tricuspid involvement as well.
5. The incidence of rheumatic heart disease has fallen drastically in industrialized countries and with widespread antibiotic usage, but remains a significant cause of morbidity and mortality in developing countries.

B. Diagnosis of Acute Rheumatic Fever (requires two major criteria or one major and two minor criteria)
1. Major criteria
   a. Migratory polyarthritis
   b. Erythema marginatum
   c. Cardiac involvement (e.g., pericarditis, CHF, valve disease)
   d. Chorea
   e. Subcutaneous nodules
2. Minor criteria
   a. Fever
   b. Elevated erythrocyte sedimentation rate
   c. Polyarthralgias
   d. Prior history of rheumatic fever
   e. Prolonged PR interval
   f. Evidence of preceding streptococcal infection

C. Treatment
1. Treat streptococcal pharyngitis with a penicillin (penicillin or amoxicillin), cephalosporin, or macrolide (azithromycin or clarithromycin) antibiotic if penicillin allergy to prevent rheumatic fever.
2. Acute rheumatic fever is treated with NSAIDs. C-reactive protein is used to monitor treatment.
3. Treat the valvular pathology of rheumatic heart disease.
**Infective Endocarditis**

**A. General Characteristics**

1. Infective endocarditis is defined as an infection of the endocardial surface of the heart (usually involves the cusps of the valves)
2. Classifications (can be classified as acute or subacute)

   - **Acute endocarditis**
     - Most commonly caused by *Staphylococcus aureus* (highly virulent)
     - Occurs on a normal heart valve
     - If untreated, fatal in less than 6 weeks

   - **Subacute endocarditis**
     - Caused by less virulent organisms, such as *Streptococcus viridans* and *Enterococcus*
     - Occurs on damaged heart valves
     - If untreated, takes much longer than 6 weeks to cause death

3. **Organisms**

   - **Native valve endocarditis**
     - *Streptococcus viridans* is the most common organism in native valve endocarditis.
     - Other common organisms include *Staphylococcus* species (*Staphylococcus aureus* more commonly than *Staphylococcus epidermidis*) and *Enterococci*.
     - *Streptococcus bovis* is associated with increased risk of active colonic malignancy
     - **HACEK** group of organisms: *Haemophilus, Actinobacillus, Cardiobacterium, Eikenella,* and *Kingella.*

   - **Prosthetic valve endocarditis**
     - Staphylococci are the most common causes of early-onset endocarditis; symptoms appear within 60 days of surgery (*Staphylococcus epidermidis* more commonly than *Staphylococcus aureus*).
     - Streptococci are the most common cause of late-onset endocarditis; symptoms appear 60 days after surgery.

   - **Endocarditis in IV drug users**
     - Frequently presents with right-sided endocarditis.
     - *Staphylococcus aureus* is the most common cause.
• Other organisms include *Enterococci* and *Streptococci*. Fungi (mostly *Candida*) and gram-negative rods (mostly *Pseudomonas*) are less common causes.

4. Complications
   a. Heart failure due to valvular damage
   b. Paravalvular abscess (can result in conduction abnormalities such as AV block)
   c. Various solid organ damage from showered emboli: Septic pulmonary emboli, intramuscular abscesses, Roth spots (retinal), Janeway lesions (microabscesses in extremities), septic arthritis, epidural spinal abscess, renal abscesses, cerebral emboli causing CVA or brain abscess
   d. Glomerulonephritis
   e. Osler nodes (immunologic depositions in extremities, painful), splinter hemorrhages in nail beds

---

**Quick HIT**

TEE is better than transthoracic echocardiography (TTE) in the diagnosis of endocarditis for especially mitral valve pathology and small aortic vegetations. Most patients should get TTE as an initial screening test.

---

**Quick HIT**

Infective endocarditis is almost always fatal if left untreated.

---

**B. Diagnosis**

1. Duke clinical criteria (*Table 1-3*): Two major criteria, one major and three minor criteria, or five minor criteria are required to diagnose infective endocarditis.
2. Of note, echocardiographic evidence of vegetations is not necessary to make the diagnosis as long as sufficient Duke criteria have been met. Treatment should be initiated if clinical suspicion is high.

---

**C. Treatment**

1. Three sets of blood cultures should be drawn prior to initiating antibiotic therapy
2. Parenteral antibiotics based on culture results for extended periods (4 to 6 weeks)
3. If cultures are negative but there is high clinical suspicion, treat empirically with vancomycin plus an aminoglycoside (usually gentamicin) until the organism can be isolated
4. If patient has intracardiac devices such as pacemaker or ICD, these must be removed
5. Early surgical intervention is warranted for patients with:
   • acute heart failure due to valvular damage
- left-sided infective endocarditis with highly resistant organisms (including MRSA)
- infective endocarditis complicated by heart block or intracardiac abscess
- persistent bacteremia or fevers lasting 5 to 7 days after antibiotic initiation
- recurrent infection in those with prosthetic valves

<table>
<thead>
<tr>
<th>TABLE 1-3</th>
<th>Duke Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>Minor</td>
</tr>
<tr>
<td>• Sustained bacteremia by an organism known to cause endocarditis</td>
<td>• Predisposing condition (abnormal valve or abnormal risk of bacteremia)</td>
</tr>
<tr>
<td>• Endocardial involvement documented by either echocardiogram (vegetation, abscess, valve perforation, prosthetic dehiscence) or clearly established new valvular regurgitation</td>
<td>• Fever</td>
</tr>
<tr>
<td></td>
<td>• Vascular phenomena: Septic arterial or pulmonary emboli, mycotic aneurysms, intracranial hemorrhage, Janeway lesions(^a)</td>
</tr>
<tr>
<td></td>
<td>• Immune phenomena: Glomerulonephritis, Osler nodes,(^b) Roth spots,(^c) rheumatoid factor</td>
</tr>
<tr>
<td></td>
<td>• Positive blood cultures not meeting major criteria</td>
</tr>
<tr>
<td></td>
<td>• Positive echocardiogram not meeting major criteria</td>
</tr>
</tbody>
</table>

Note: Definitive (i.e., highly probable) diagnosis if two major, or one major plus three minor, or five minor criteria are present.

\(^a\)Janeway lesions are painless erythematous lesions on palms and soles.

\(^b\)Osler nodes are painful, raised lesions of fingers, toes, or feet.

\(^c\)Roth spots are oval, retinal hemorrhages with a clear, pale center.


D. Prophylaxis

Scope of patients who qualify for prophylaxis is much narrower than in the past. Must have both a qualifying cardiac indication AND procedure to warrant antibiotic prophylaxis.

1. Qualifying cardiac indications
   a. Prosthetic heart valves (including mechanical, bioprosthetic, and transcatheter valves)
   b. History of infective endocarditis
   c. Congenital heart disease
      • Unrepaired cyanotic congenital heart disease
      • Repaired congenital heart disease, with prosthetic material, during first 6 months after procedure
d. Cardiac transplant with valvulopathy
2. Qualifying procedures
   a. Dental procedures involving manipulation of gingival mucosa or periapical region of teeth (extractions, implants, periodontal surgery, cleaning when bleeding expected)
   b. Procedures involving biopsy or incision of respiratory mucosa
   c. Procedures involving infected skin or musculoskeletal tissue

Quick HIT

Do NOT give antibiotics for endocarditis prophylaxis for:
- Native mitral valve prolapse/stenosis
- Routine GI (endoscopy) or GU (cystoscopy) procedures
Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis)

Associated with debilitating illnesses such as metastatic cancer (found in up to 20% of cancer patients).
Sterile deposits of fibrin and platelets form along the closure line of cardiac valve leaflets.
Vegetations can embolize to the brain or periphery.
Although the use of heparin may be appropriate, no studies have confirmed its efficacy.
Nonbacterial Verrucous Endocarditis (Libman–Sacks Endocarditis)

Typically involves the aortic valves in individuals with SLE
Characterized by the formation of small warty vegetations on both sides of valve leaflets and may present with regurgitant murmurs
Rarely gives rise to infective endocarditis, but can be a source of systematic embolization
Treat underlying SLE and anticoagulate
Congenital Heart Diseases

Atrial Septal Defect

A. General Characteristics (Types)
1. Ostium secundum (most common—80% of cases)—occurs in central portion of interatrial septum
2. Ostium primum—occurs low in the septum
3. Sinus venosus defects—occurs high in the septum

Quick HIT
Congenital heart disease accounts for only 2% of heart disease in adults.

B. Pathophysiology
1. Oxygenated blood from the LA passes into the RA, increasing right heart output and thus pulmonary blood flow.
2. Leads to increased work of the right side of the heart: As shunt size increases, RA and RV dilation occurs with pulmonary-to-systemic flow ratios greater than 1.5:1.0.
3. Pulmonary HTN is a serious sequela, but is rare in ASD.

C. Clinical Course
1. Patients are usually asymptomatic until middle age (around 40).
2. Thereafter, symptoms may begin and include exercise intolerance, dyspnea on exertion, and fatigue.
3. If mild, patients can live a normal lifespan.

D. Clinical Features
1. Mild systolic ejection murmur at pulmonary area secondary to increased pulmonary blood flow
2. Fixed split $S_2$
3. Diastolic flow “rumble” murmur across tricuspid valve area secondary to increased blood flow
4. In advanced disease, signs of RV failure may be seen

E. Diagnosis
1. TEE is diagnostic (better than TTE). Contrast echocardiography can improve resolution. A so-called “bubble study” is a type of contrast echo which involves
injecting microbubbles and watching them cross the defect via a right-to-left shunt. This is often used to aid in diagnosis of ASDs.

2. CXR: Large pulmonary arteries; increased pulmonary markings.
3. ECG: Right bundle branch block and right axis deviation; atrial abnormalities can also be seen (e.g., fibrillation, flutter).

**F. Complications**

1. Pulmonary HTN—does not occur before 20 years of age, but is a common finding in patients over 40
2. **Eisenmenger disease** is a late complication seen in a minority of patients, in which irreversible pulmonary HTN leads to reversal of shunt, heart failure, and cyanosis
3. Right heart failure
4. Atrial arrhythmias, especially AFib
5. Stroke can result from paradoxical emboli or AFib

**G. Treatment**

1. Unless they are very large, most defects do not require closure.
2. Surgical repair when pulmonary-to-systemic blood flow ratio is greater than 1.5:1.0 or 2:1 or if patient is symptomatic.
Ventricular Septal Defect

A. General Characteristics
1. Ventricular septal defect is the most common congenital cardiac malformation
2. Pathophysiology
   a. Blood flows from the LV (high pressure) into the RV (low pressure) through a hole, resulting in increased pulmonary blood flow. As long as the pulmonary vascular resistance (PVR) is lower than the SVR, the shunt is left to right. If the PVR increases above the SVR, the shunt reverses.
   b. Large defects eventually lead to pulmonary HTN, whereas small defects do not change pulmonary vascular hemodynamics.

B. Clinical Features
1. Symptoms
   a. A small shunt produces no symptoms. Many of these close spontaneously.
   b. A large shunt without elevated PVR (and thus left-to-right shunt) gives rise to CHF, growth failure, and recurrent lower respiratory infections.
   c. A large shunt with very high PVR (Eisenmenger reaction) gives rise to SOB, dyspnea on exertion, chest pain, syncope, and cyanosis.
2. Signs
   a. Harsh, blowing holosystolic murmur with thrill
      - At fourth left intercostal space
      - Murmur increases with handgrip maneuver and decreases with standing
      - The smaller the defect, the louder the holosystolic murmur
   b. Sternal lift (RV enlargement, RV heave)
   c. As PVR increases, the pulmonary component of $S_2$ increases in intensity
   d. Aortic regurgitation may be seen in some patients

C. Diagnosis
1. ECG: Biventricular hypertrophy predominates when PVR is high.
2. CXR
   a. Enlargement of the pulmonary artery.
   b. Enlargement of cardiac silhouette: As PVR increases (and left-to-right shunt decreases), heart size decreases, but pulmonary artery size increases.
3. Echocardiogram shows the septal defect.

D. Complications
1. Endocarditis
2. Progressive aortic regurgitation
3. Heart failure
4. Pulmonary HTN and shunt reversal (Eisenmenger)

E. Treatment
1. Endocarditis prophylaxis is important but is NOT currently recommended for patients with uncomplicated VSD and no history of endocarditis.
2. Surgical repair is indicated if the pulmonary flow to systemic flow ratio is greater than 1.5:1.0 or 2:1, as well as for patients with infective endocarditis.
3. For the asymptomatic patient with a small defect, surgery is not indicated.
Coarctation of the Aorta

A. General Characteristics
1. Narrowing/constriction of aorta, usually at origin of left subclavian artery near ligamentum arteriosum, which leads to obstruction between the proximal and distal aorta, and thus to increased left ventricular afterload.

Quick HIT
In women, coarctation of the aorta may be associated with Turner syndrome.

B. Clinical Features
1. HTN in upper extremities with hypotension in lower extremities
2. Well-developed upper body with underdeveloped lower half
3. Midsystolic murmur heard best over the back
4. Symptoms include headache, cold extremities, claudication with exercise, and leg fatigue
5. Delayed femoral pulses when compared to radial pulses
6. Prevalence of coarctation of the aorta is increased in patients with Turner syndrome

C. Diagnosis
1. CT angiogram of the chest is diagnostic
2. ECG shows LVH
3. CXR
   a. Notching of the ribs
   b. “Figure 3” appearance due to indentation of the aorta at the site of coarctation, with dilation before and after the stenosis

D. Complications
1. Severe HTN
2. Rupture of cerebral aneurysms
3. Infective endocarditis
4. Aortic dissection

E. Treatment
1. Standard treatment involves surgical decompression.
2. Percutaneous balloon aortoplasty or stenting is also an option in selected cases.
Patent Ductus Arteriosus

A. General Characteristics
1. Communication between aorta and pulmonary artery that persists after birth.
2. During fetal life, prostaglandins and low oxygen tension maintain the ductus arteriosus. Blood is shunted away from nonfunctioning lungs; normally closes within days after birth.
3. Becomes a left-to-right shunt in life outside the womb if it remains patent (blood flows from aorta into pulmonary artery).
4. Associated with congenital rubella syndrome, high altitude, and premature births.
5. Pathophysiology
   a. Large left-to-right shunting results in volume overload, pulmonary HTN, and right-sided heart failure.
   b. Cyanosis occurs late.
   c. May eventually see reversal of blood flow.

Quick HIT

The leading causes of death in adults with PDA are heart failure and infective endocarditis.

B. Clinical Features
1. May be asymptomatic
2. Signs of heart failure
3. Loud P₂ (sign of pulmonary HTN)
4. LVH: Secondary to left-to-right shunt
5. Right ventricular hypertrophy: Secondary to pulmonary HTN
6. Continuous “machinery murmur” at left second intercostal space (both systolic and diastolic components)
7. Wide pulse pressure and bounding peripheral pulses
8. Lower extremity clubbing: Toes more likely than fingers to be cyanotic (differential cyanosis)

Quick HIT

Adults with PDA usually have normal pulmonary pressures.

C. Diagnosis
1. CXR
   a. Increased pulmonary vascular markings
   b. Dilated pulmonary artery
c. Enlarged cardiac silhouette

d. Sometimes calcifications of ductus arteriosus

2. Echocardiography reveals the patent ductus and/or turbulent blood flow

D. Treatment

1. If pulmonary vascular disease is absent: Surgical ligation.

2. If severe pulmonary HTN or right-to-left shunt is present, do not correct patent ductus arteriosus (PDA). Surgery is contraindicated.

3. Indomethacin indicated for closure. Prostaglandin E₁ can be used to keep the PDA open (may be needed in the face of other cardiac abnormalities such as transposition of the great vessels).
Tetralogy of Fallot

A. General Characteristics
1. Characterized by four cardiac abnormalities: Ventricular septal defect, right ventricular hypertrophy, pulmonary artery stenosis or atresia, and overriding aorta.
2. The exact embryologic variant is unknown, but the four abnormalities likely arise secondary to defects in the development of the infundibular septum.
3. Tetralogy of Fallot (TOF) typically occurs sporadically, but may also be part of a syndrome.

B. Clinical Features
1. Cyanosis is the most common symptom.
2. Degree of clinical symptoms depends largely on the degree of right ventricular outflow obstruction.
3. Patients experience Tet spells—they will squat after exertion such as exercise or crying spell in an infant. This maneuver increases SVR, which helps shunt blood from the RV to the lungs instead of the aorta. Oxygen, morphine, and β-blockers may also be needed if the patient continues to be cyanotic.
4. Murmur is typically crescendo–decrescendo in nature and heard best at the left upper sternal border.

C. Diagnosis
1. Echocardiography is the diagnostic modality of choice. This test can clearly define the four abnormalities as well as provide important information about aortic arch anatomy.
2. EKG may show enlarged RA and RV.
3. CXR classically shows *boot-shaped heart*.
4. Cardiac catheterization may be required in some patients to fully define the anatomy.

D. Treatment
1. Treatment is surgical. Most patients have surgery within the first year of life. Twenty-year survival rates after surgery are above 80%. The most common causes of death are sudden cardiac death and heart failure.
2. Complications after surgery include arrhythmias, pulmonary regurgitation, residual outflow obstruction, and heart failure.
Diseases of the Vasculature

Hypertensive Emergency

A. General Characteristics

1. Hypertensive emergency: Systolic BP ≥180 and/or diastolic BP ≥120 in addition to end-organ damage—immediate treatment is indicated (see Clinical Pearl 1-13).
2. Elevated BP levels alone without end-organ damage—referred to as hypertensive urgency. Hypertensive urgencies rarely require emergency therapy and can be managed with attempts to lower BP over a period of 24 hours.
3. Whenever a patient presents with markedly elevated BP, it is critical to assess the following systems for end-organ damage.
   a. Eyes: Papilledema
   b. CNS
      - Altered mental status or intracranial hemorrhage
      - Hypertensive encephalopathy may develop (suspect when BP is markedly elevated: 240/140 or higher, along with neurologic findings such as confusion)
   c. Kidneys: Renal failure or oliguria
   d. Heart: Unstable angina, MI, HF with pulmonary edema, aortic dissection
   e. Lungs: Pulmonary edema

4. Hypertensive emergency may lead to posterior reversible encephalopathy syndrome (PRES)—a radiographic condition which is postulated to be caused by autoregulatory failure of cerebral vessels as well as endothelial dysfunction.
   a. Despite the name, the syndrome may not always be reversible and can affect regions other than the posterior region of the brain.
   b. Symptoms include insidious onset of headache, altered level of consciousness, visual changes, and seizures. The classic radiographic finding is posterior cerebral white matter edema.
   c. Most patients are hypertensive, but may be normotensive. Elevated blood pressures overwhelm the autoregulatory mechanisms of the cerebral vessels, leading to arteriolar dilation and extravasation of fluid into the brain.
   d. Diagnose with clinical findings and brain MRI. First treatment step is to lower BP, usually with IV medications. Other treatment steps include correcting electrolyte abnormalities and stopping seizures if they occur.

B. Causes

1. Noncompliance with antihypertensive therapy
2. Cushing syndrome

**CLINICAL PEARL 1-13**

If a patient presents with severe headache and markedly elevated BP:
- The first step is to lower the BP with an antihypertensive agent.
- The second step is to order a CT scan of the head to rule out intracranial bleeding (subarachnoid hemorrhage is in the differential diagnosis for severe headache).
- If the CT scan is negative, one may proceed to a lumbar puncture.

3. Drugs such as cocaine, LSD, methamphetamines
4. Hyperaldosteronism
5. Eclampsia
6. Vasculitis
7. Alcohol withdrawal
8. Pheochromocytoma
9. Noncompliance with dialysis
10. Renal artery stenosis (atherosclerosis or fibromuscular dysplasia)
11. Polycystic kidney disease

**Quick HIT**

Lower BP with IV infusions of medications such as CCBs (nicardipine), β-blockers (labetalol, esmolol), and nitrates (nitroglycerin, nitroprusside).

C. Clinical Features
1. Severe headache
2. Visual disturbances
3. Altered mentation

D. Treatment
1. Hypertensive emergencies
   a. Reduce mean arterial pressure by 25% in 1 to 2 hours. The goal is not to immediately achieve normal BP, but to get the patient out of danger, then reduce BP gradually to allow cerebral autoregulation to maintain cerebral perfusion with changing systemic blood pressures.
   b. If severe (diastolic pressure >130) or if hypertensive encephalopathy is present, **IV agents**, such as esmolol, nitroprusside, labetalol, or nitroglycerin, are appropriate. Hydralazine can be given as an IV push as well.
   c. In patients who are in less immediate danger, oral agents are appropriate. Options include captopril, clonidine, labetalol, nifedipine, and diazoxide.
2. Hypertensive urgencies: BP should be lowered within 24 hours using oral agents.

Quick HIT

Hypertensive emergency—evidence of end-organ damage; use IV medications
Hypertensive urgency—no evidence of end-organ damage; use PO medications
Aortic Dissection

A. General Characteristics

1. Predisposing factors
   a. Long-standing systemic HTN (present in 70% of patients)
   b. Cocaine use (may be remote)
   c. Trauma
   d. Connective tissue diseases, such as Marfan and Ehlers–Danlos syndrome
   e. Bicuspid aortic valve
   f. Coarctation of the aorta
   g. Third trimester of pregnancy
   h. Pre-existing aortic aneurysm
   i. Intimal ulcer due to atherosclerosis

2. Stanford classification (Figure 1-16)
   a. *Type A (proximal)* involves the ascending aorta (includes retrograde extension from descending aorta).
   b. *Type B (distal)* is limited to the descending aorta (distal to the take-off of the subclavian artery).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic dissection</td>
</tr>
<tr>
<td>- Type A = ascending; treatment is surgical</td>
</tr>
<tr>
<td>- Type B = descending; treatment is medical</td>
</tr>
</tbody>
</table>

B. Clinical Features

1. Severe, tearing/ripping/stabbing pain, typically abrupt in onset, either in the anterior or back of the chest (often the interscapular region)
   a. Anterior chest pain is more common with proximal dissection (type A).
   b. Interscapular back pain is more common with distal dissection (type B).

2. Diaphoresis
3. Most are hypertensive, but some may be hypotensive
4. Pulse or BP asymmetry between limbs
5. Aortic regurgitation (especially proximal dissections)
6. Neurologic manifestations (hemiplegia, hemianesthesia) due to obstruction of carotid artery
7. Type A dissection can progress to coronaries (causing MI) or pericardium (causing cardiac tamponade)
The diagnosis of aortic dissection can be difficult to make because the classic clinical findings often are not apparent. The use of thrombolytic therapy in patients with aortic dissection who have been incorrectly diagnosed as having an acute MI can have fatal consequences.


C. Diagnosis
1. CXR shows widened mediastinum (>8 mm on AP view).
2. CT angiogram (CTA) and MRI are both highly accurate; MRI takes longer to perform, making it less ideal in the acute setting. The false lumen of the dissection plane appears larger on CT and MRI.
3. TEE has a very high sensitivity and specificity; it is noninvasive and can be performed at the bedside.
4. Aortic angiography was once the gold standard, and has largely been replaced by CTA. It can be used for patients in whom noninvasive imaging is nondiagnostic, or during endovascular intervention for dissection.

Quick HIT

CTA and TEE are the preferred tests in the diagnosis of acute aortic dissection. CTA is much more readily available in emergency rooms. TEE is very accurate and is ideal in the unstable patient because it can be performed at the bedside.

D. Treatment
1. Initiate medical therapy immediately
   a. IV β-blockers (labetalol, esmolol) to lower heart rate and diminish the force of left ventricular ejection, thus reducing shear stress on intima
   b. Goal systolic BP 100 to 120 mm Hg, to be achieved as soon as possible to minimize shear stress. Can be accomplished with β-blockers, or can add sodium nitroprusside
2. For type A dissections—surgical management
   a. Most cases of type A dissections should be treated as surgical emergencies to prevent complications such as MI, aortic regurgitation, or cardiac tamponade
   b. Open surgery is still the standard of care
   c. High risk of mortality, 1% to 2% per hour after symptom onset without intervention
3. For type B dissections—medical management
   a. Lower blood pressure as quickly as possible. First-line drugs include IV β-blockers such as labetalol, esmolol
   b. Pain control with morphine or hydromorphone
   c. Unrelenting symptoms may require surgical treatment—both open and endovascular surgical options exist
Abdominal Aortic Aneurysm

A. General Characteristics
1. Abdominal aortic aneurysm (AAA) is an abnormal localized dilation of the aorta. Most AAAs occur between the renal arteries and iliac bifurcation.
2. The incidence increases with age. AAAs are rare before the age of 50. The average age at time of diagnosis is 65 to 70 years.
3. AAAs are much more common in men, though more likely to rupture in women at a given size.

B. Causes
1. Multifactorial—in most cases, there is atherosclerotic weakening of the aortic wall.
2. Other predisposing factors include trauma, HTN, vasculitis, smoking, and positive family history.
3. Syphilis and connective tissue abnormalities (e.g., Marfan disease) are associated with thoracic aneurysms, but they may involve the lower aorta as well.

C. Clinical Features
1. Usually asymptomatic and discovered on either abdominal examination or a radiologic study done for another reason
2. Sense of “fullness”
3. Pain may or may not be present—if present, located in the hypogastrium and lower back and usually throbbing in character.
4. Pulsatile mass on abdominal examination
5. Symptoms suggesting expansion and impending rupture include the following:
   a. Sudden onset of severe pain in the back or lower abdomen, radiating to the groin, buttocks, or legs
   b. Grey Turner sign (ecchymoses on back and flanks) and Cullen sign (ecchymoses around umbilicus) are signs of retroperitoneal bleeding. Neither is very sensitive for ruptured AAA
6. Rupture of an AAA
   a. The triad of abdominal pain, hypotension, and a palpable pulsatile abdominal mass indicates a ruptured AAA and emergent laparotomy is indicated. No further diagnostic testing is needed with this constellation of symptoms; however, patients may present with only one or two components of this triad
   b. Cardiovascular collapse
   c. Syncope or near-syncope, secondary to sudden hemorrhage
   d. Nausea and vomiting
D. Diagnosis

1. Ultrasound
   a. Test of choice to evaluate both the location and size of the aneurysm
   b. 100% sensitive in detecting AAAs

2. CT scan
   a. 100% sensitive in detecting AAAs
   b. Takes longer to perform than plain radiographs or ultrasound; should only be used in hemodynamically stable patients
   c. CT is the scan of choice for preoperative planning

E. Treatment

1. Unruptured aneurysms.
   a. Management largely depends on size of the aneurysm.
      • **Data from the ADAM trial and UK-SAT have shown that if the aneurysm is >5 cm in diameter or symptomatic, surgical resection with synthetic graft placement is recommended. (The infrarenal aorta is replaced with a fabric tube.) This can often be done endovascularly by accessing the femoral artery.** The diameter of the normal adult infrarenal aorta is about 2 cm.
      • The management of asymptomatic aneurysms <5 cm is controversial. Periodic imaging is recommended to follow up growth. Growth of more than 1 cm in a year suggests elevated risk. No “safe” size exists however, and small AAAs can rupture.
   b. Other factors to consider are the patient’s life expectancy (patient may be more likely to die of other medical illnesses), and the risk of surgery.

2. Ruptured AAAs: Emergency surgical repair is indicated. All of these patients are unstable.
   a. While open repair remains the gold standard, some ruptured AAAs may be repaired endovascularly as well with stents.

---

**Quick HIT**

*Leriche syndrome:* Atheromatous occlusion of distal aorta just above bifurcation causing bilateral claudication, impotence, and absent/diminished femoral pulses.

---

**CLINICAL PEARL 1-14**

**Evaluation of a Patient With PAD**
• Evaluate the cardiovascular system (HTN, carotid bruits, murmurs, AAA).
• Assess arterial pulses.
• Inspect lower extremities for color change, ulcers, muscle atrophy, hair loss, thickened toenails, etc.
• Consider the following tests: ECG, CBC, renal function tests, and coagulation profile (factor V Leiden, antithrombin III, proteins C and S).
Peripheral Arterial Disease (Chronic Arterial Insufficiency)

A. General Characteristics
1. Peripheral arterial disease (PAD) is an occlusive atherosclerotic disease of the lower extremities (see also Clinical Pearl 1-14)
2. Patients with PAD usually have coexisting CAD (with CHF, history of MI, and so on) and other chronic medical problems (e.g., diabetes, lung disease)
3. Sites of occlusion/stenosis
   a. Superficial femoral artery (in Hunter canal) is the most common site
   b. Popliteal artery
   c. Aortoiliac occlusive disease
4. Risk factors
   a. Smoking is by far the most important risk factor
   b. CAD, hyperlipidemia, HTN
   c. Diabetes—prevalence is markedly increased in these patients
5. Prognosis
   a. If the patient has intermittent claudication, the prognosis is generally good
   b. Patients with rest pain or ischemic ulcers have the worst prognosis (especially in diabetics or smokers)

B. Clinical Features
1. Symptoms (see also Clinical Pearl 1-14)
   a. Intermittent claudication
      • Cramping leg pain that is reliably reproduced by same walking distance (distance is very constant and reproducible)
      • Pain is completely relieved by rest
   b. Rest pain (continuous)
      • Usually felt over the distal metatarsals, where the arteries are the smallest
      • Often prominent at night—awakens patient from sleep
      • Hanging the foot over side of the bed or standing relieves pain—extra perfusion to ischemic areas due to gravity
      • Rest pain is always worrisome—suggests severe ischemia such that frank gangrene of involved limb may occur in the absence of intervention
2. Signs
   a. Diminished or absent pulses, muscular atrophy, decreased hair growth, thick toenails, and decreased skin temperature
   b. Ischemic ulceration (usually on the toes)
      • Localized skin necrosis
- Secondary to local trauma that does not heal (due to ischemic limb)
- Tissue infarction/gangrene in end-stage disease
- Pallor of elevation and rubor of dependency (in advanced disease)

**Quick HIT**
- Femoral or popliteal disease causes calf claudication.
- Aortoiliac occlusive disease causes buttock and hip claudication (in addition to the calves).

**C. Diagnosis**
1. Ankle-to-brachial index (ABI): Ratio of the systolic BP at the ankle to the systolic BP at the arm
   a. Normal ABI is between 0.9 and 1.3
   b. ABI >1.3 is due to noncompressible vessels and indicates severe disease
   c. Claudication usually when ABI <0.7
   d. Rest pain usually when ABI <0.4
2. Pulse volume recordings
   a. Excellent assessment of segmental limb perfusion
   b. Pulse wave forms represent the volume of blood per heart beat at sequential sites down the leg
   c. A large wave form indicates good collateral blood flow
   d. Noninvasive using pressure cuffs
3. Arteriography (contrast in vessels and radiographs)
   a. Gold standard for diagnosing and locating PAD

**Quick HIT**
Patients with calcified arteries (especially those with DM) have false ABI readings (vessels are not compressible).

**D. Treatment**
1. Conservative management for intermittent claudication.
   a. **Smoking cessation (the importance of this cannot be overemphasized).**
      Smoking is linked to progression of atherosclerosis and causes vasoconstriction (further decreasing blood flow).
   b. Graduated exercise program: Walk to point of claudication, rest, and then continue walking for another cycle.
   c. Foot care (especially important in diabetic patients).
   d. Atherosclerotic risk factor reduction (control of hyperlipidemia, HTN, weight, diabetes, and so on).
e. Avoid extremes of temperature (especially extreme cold).
f. Aspirin along with clopidogrel has shown slight improvements in symptom relief. They are often used in these patients for stroke/MI prevention.
g. Cilostazol is a PDE inhibitor which acts both by suppressing platelet aggregation and by directly dilating arterioles.

Quick HIT

Diabetic patients have an amputation rate four times greater than that of nondiabetic patients.

2. Surgical treatment
   a. Indications: Rest pain, ischemic ulcerations (tissue necrosis), severe symptoms refractory to conservative treatment that affect quality of life or work.
   b. Options
      • Angioplasty—balloon dilation with or without stenting. Given the minimal risks and good chance of symptomatic relief for patients, this may be performed one or more times before a bypass is done. Not useful when performed on below-the-knee lesions
      • Surgical bypass grafting—has a 5-year patency rate of 70% (immediate success rate is 80% to 90%).
Acute Arterial Occlusion

A. General Characteristics
1. Acute occlusion of an artery, usually caused by embolization. The common femoral artery is the most common site of occlusion. Less commonly, in situ thrombosis is the cause.
2. Sources of emboli
   a. Heart (85%)
      - AFib is the most common cause of embolus from the heart
      - Post-MI
      - Post arterial procedure (i.e., coronary angiogram, peripheral angiogram)
      - Endocarditis
      - Myxoma
   b. Aneurysms
   c. Atheromatous plaque

B. Clinical Features of Acute Limb Ischemia (Remember the Six Ps)
1. Pain—acute onset. The patient can tell you precisely when and where it happened. The pain is very severe, and the patient may have to sit down or may fall to the ground (Table 1-4).
2. Pallor
3. Polar (cold)
4. Paralysis
5. Paresthesias
6. Pulselessness (use Doppler to assess pulses)

<table>
<thead>
<tr>
<th>TABLE 1-4 PAD Versus Acute Arterial Occlusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Features</strong></td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
</tr>
<tr>
<td>Acute arterial occlusion</td>
</tr>
</tbody>
</table>

C. Diagnosis
1. Angiogram (CTA vs. invasive angiogram) to define site of occlusion
2. ECG to look for MI, AFib
3. Echocardiogram for evaluation of cardiac source of emboli—valves, thrombus, shunts
D. Treatment
1. Main goal: Assess viability of tissues to salvage the limb.
2. Skeletal muscle can tolerate 6 hours of ischemia; perfusion should be reestablished within this time frame.
3. Immediately anticoagulate with IV heparin.
4. Emergent surgical embolectomy is indicated via cutdown and Fogarty balloon. Bypass is reserved for embolectomy failure.
5. Thrombolytics can also be infused intra-arterially. Double blind trials comparing intra-arterial thrombolytics such as recombinant urokinase to surgery showed mixed results.
6. Treat any complications such as compartment syndrome that may occur.

Quick HIT
The Fogarty balloon catheter is used for embolectomy—the catheter is inserted, the balloon is inflated, and the catheter is pulled out—the balloon brings the embolus with it.
Cholesterol Embolization Syndrome

This syndrome is due to “showers” of cholesterol crystals originating from a proximal source (e.g., atherosclerotic plaque), most commonly the abdominal aorta, iliacs, and femoral arteries. It is often triggered by a surgical or radiographic intervention (e.g., arteriogram), or by thrombolytic therapy.

It presents with small, discrete areas of tissue ischemia, resulting in blue/black toes, renal insufficiency, and/or abdominal pain or bleeding (the latter is due to intestinal hypoperfusion).

Treatment is supportive. Anticoagulation not suggested unless other indication exists (most of the occlusion is atheroembolic debris, not thrombus). Control BP. Amputation or surgical resection is only needed in extreme cases.
Mycotic Aneurysm
An aneurysm resulting from damage to the aortic wall secondary to infection
Blood cultures are positive in most cases
Treatment: IV antibiotics and surgical excision
Luetic Heart

Luetic heart is a complication of syphilitic aortitis, usually affecting men in their fourth to fifth decade of life. Aneurysm of the aortic arch with retrograde extension extends backward to cause aortic regurgitation and stenosis of aortic branches, most commonly the coronary arteries.

Treatment: IV penicillin and surgical repair.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical Features</th>
<th>Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superficial thrombophlebitis</td>
<td>Local tenderness, erythema along the course of a superficial vein</td>
<td>Clinical diagnosis</td>
<td>Analgesics, monitor for spread or cellulitis</td>
</tr>
<tr>
<td>Chronic venous insufficiency</td>
<td>Aching of lower extremities, worse at end of day; relieved by elevation of legs and worsened by recumbency; edema, pigmentation, ulcers</td>
<td>Clinical diagnosis</td>
<td>Leg elevation, avoid long periods of standing, elastic stockings; if ulcers develop, Unna boots, wet-to-dry dressings</td>
</tr>
<tr>
<td>Deep venous thrombosis</td>
<td>Usually asymptomatic; calf pain may be present</td>
<td>Duplex, D-dimer</td>
<td>Anticoagulation</td>
</tr>
</tbody>
</table>
Deep Venous Thrombosis

A. General Characteristics

1. Cause: Virchow triad (endothelial injury, venous stasis, hypercoagulability) gives rise to venous thrombosis (see also Table 1-5)

2. Risk factors
   a. Age >60
   b. Malignancy
   c. Prior history of deep venous thrombosis (DVT), PE, or varicose veins
   d. Hereditary hypercoagulable states (factor V Leiden, proteins C and S deficiency, antithrombin III deficiency)
   e. Prolonged immobilization or bed rest
   f. Cardiac disease, especially CHF
   g. Obesity
   h. Major surgery, especially surgery of the pelvis (orthopedic procedures)
   i. Major trauma
   j. Pregnancy, oral contraceptives/estrogen use

Quick HIT

If a superficial venous system is patent, the classic findings of DVT (erythema, pain, cords) will not occur because blood drains from these patent veins. This is why only half of all patients with DVT have the classic findings.

B. Clinical Features

1. Clinical presentation may be subtle

2. Classic findings (all have very low sensitivity and specificity):
   a. Lower extremity pain and swelling (worse with dependency/walking, better with elevation/rest)
   b. Homans sign (calf pain on ankle dorsiflexion)
   c. Palpable cord
   d. Fever

Quick HIT

Only 50% of patients with the classic DVT findings have a DVT, and only 50% of patients with documented DVT have the classic findings.

C. Diagnosis

1. Available studies
a. Doppler analysis and Duplex ultrasound
   - Initial test for DVT; noninvasive, but highly operator dependent
   - High sensitivity and specificity for detecting proximal thrombi (popliteal and femoral), not so for distal (calf vein) thrombi

b. Venography
   - Most accurate test for diagnosis of DVT of calf veins
   - Invasive and infrequently used
   - Allows visualization of the deep and superficial venous systems, and allows assessment of patency and valvular competence

c. Impedance plethysmography
   - A noninvasive alternative to Doppler ultrasound
   - Blood conducts electricity better than soft tissue, so electrical impedance decreases as blood volume increases
   - High sensitivity for proximal DVT, but not for distal DVT (calf veins)
   - Poor specificity because there is a high rate of false positives
   - As accurate as Doppler, but less operator dependent

d. D-dimer testing
   - Has a very high sensitivity (95%), but low specificity (50%); can be used to rule out DVT when combined with Doppler and clinical suspicion

2. Interpretation of diagnostic tests
   a. Intermediate-to-high pretest probability of DVT
      - If Doppler ultrasound is positive, begin anticoagulation
      - If Doppler ultrasound is nondiagnostic, repeat ultrasound every 2 to 3 days for up to 2 weeks

   b. Low-to-intermediate probability of DVT
      - If Doppler ultrasound is negative, there is no need for anticoagulation; observation is sufficient
      - Repeat ultrasound in 2 days

D. Complications
1. Pulmonary embolus (PE) can originate from the iliofemoral, pelvic, calf, ovarian, axillary, subclavian, and internal jugular veins, as well as the inferior vena cava and cavernous sinuses of the skull—see Chapter 3 for discussion on PE

2. Postthrombotic syndrome (chronic venous insufficiency)
   a. Occurs in approximately half of all patients with acute DVT
   b. Residual venous obstruction and valvular incompetence lead to ambulatory HTN (see section Chronic Venous Insufficiency)

3. Phlegmasia cerulea dolens (painful, blue, swollen leg)
a. Occurs in extreme cases of DVT—indicates that major venous obstruction has occurred. Often associated with malignancy causing hypercoagulable state.
b. Severe leg edema compromises arterial supply to the limb, resulting in impaired sensory and motor function.
c. Venous thrombectomy is indicated.

E. Treatment

1. Anticoagulation
   a. Prevents further propagation of the thrombus
   b. Multiple options: Injectable LMWH (e.g., enoxaparin, dalteparin) (best choice for DVT/PE associated with malignancy), DOACs (e.g., apixaban, rivaroxaban, edoxaban, dabigatran), and warfarin (requires IV heparin bridge as below).
      LMWH was the preferred choice for DVT/PE treatment in patients with malignancy, however a recent study showed that edoxaban was non-inferior to dalteparin, and also significantly reduced VTE recurrence compared to dalteparin (though with a higher bleeding risk).
   c. If warfarin chosen: Heparin bolus followed by a constant infusion and titrated to maintain the PTT at 1.5 to 2 times aPTT
   d. Start warfarin once the aPTT is therapeutic and continue for 3 to 6 months.
      Anticoagulate to INR at 2 to 3
   e. Continue heparin until the INR has been therapeutic for 48 hours

2. Thrombolytic therapy (streptokinase, urokinase, tissue plasminogen activator [tPA])
   a. Speeds up the resolution of clots
   b. Indicated mainly for patients with massive PE who are hemodynamically unstable (hypotension with SBP <90 mm Hg), and with no contraindications for thrombolytics
   c. High risk of intracranial hemorrhage with tPA (1% to 2%)

3. Inferior vena cava filter placement (Greenfield filter)
   a. Indications for treatment of VTE
      • If absolute contraindication to anticoagulation (bleeding)
      • If failure of appropriate anticoagulation
   b. Effective only in preventing PE, not DVT

4. Methods of prophylaxis after surgery
   a. Mechanical
      • Leg elevation, graduated compression stockings, early ambulation
      • Pneumatic compression boots—intermittently inflate and deflate, causing compression of the limb, usually the calves; very effective
      • IVC filter for patients at high risk for DVT/PE who have an absolute
contraindication to other forms of prophylaxis; for example, after trauma or spinal/orthopedic surgery and have evidence of bleeding.

b. Pharmacologic

- Heparin or LMWH: Unfractionated heparin or LMWH postoperatively until the patient is ambulatory.
- Combination of pneumatic compression devices and pharmacologic prophylaxis may provide the greatest protection.

**Quick HIT**

Low–Molecular-Weight Heparin
- Has longer half-life than unfractionated heparin and can be dosed once daily or BID
- Can be given on outpatient basis
- No need to follow aPTT levels
- Is much more expensive than unfractionated heparin
Chronic Venous Insufficiency (Venous Stasis Disease)

A. General Characteristics
1. Also referred to as postphlebitic syndrome
2. CVI may involve the superficial, deep, or both venous systems
3. Anatomy
   a. The lower extremity venous system consists of three systems: Deep, superficial, and perforating systems. Valves exist in all three systems, preventing retrograde blood flow.
   b. The perforating veins connect the superficial and deep systems. Valves allow flow from superficial to deep, but not vice versa.

Quick HIT

Many patients with a history of DVT eventually develop CVI (80%).

4. Pathophysiology
   a. History of DVT is the underlying cause in many cases (such a history might not be documented). This has two major effects:
      • It causes destruction of venous valves in the deep venous system. Valvular incompetence results in gravitational pressure of the blood column to be transmitted to ankles.
      • Valves in the perforator veins are also damaged secondary to the chronically elevated deep venous pressure, inhibiting transmission of blood from superficial to deep, as normally occurs.
   b. Leads to ambulatory venous HTN, which has two undesirable effects:
      • Interstitial fluid accumulation, resulting in edema.
      • Extravasation of plasma proteins and RBCs into subcutaneous tissues, resulting in brawny induration and pigmentation (a brown-black color) of skin.
   c. Eventually leads to reduced local capillary blood flow and hypoxia of tissues.
      • Even mild trauma may precipitate tissue death and ulcer formation.
      • Venous ulcers usually develop medially from the instep to above the ankle, overlying an incompetent perforator vein.

B. Clinical Features
1. Swelling of the lower leg
   a. When chronic, causes an aching or tightness feeling of the involved leg; often worse at the end of the day
   b. Symptoms are worsened by periods of sitting or inactive standing
c. Leg elevation provides relief of symptoms (the opposite is true in arterial insufficiency)

2. Chronic changes include:
   a. Skin changes
      • Skin becomes thin, atrophic, shiny, and cyanotic
      • Brawny induration develops with chronicity
   b. Venous ulcers
      • Less painful than ulcers associated with arterial insufficiency
      • Usually located just above the medial malleolus
      • Often rapidly recur

Quick HIT
Ulcer formation is directly proportional to the amount of swelling present.

C. Treatment
1. Before the development of ulcers, strict adherence to the following controls stasis sequelae in most patients.
   a. Leg elevation: Periods of leg elevation during the day and throughout the night to a level above the heart.
   b. Avoiding long periods of sitting or standing.
   c. Heavy-weight elastic stockings (knee-length) are worn during waking hours.

2. If ulcers develop, management also entails:
   a. Wet-to-dry saline dressings (three times daily).
   b. Unna venous boot (external compression stocking)—best changed every week to 10 days.
      • Healing occurs in 80% of ulcers. Compliance reduces the rate of recurrence.
      • For ulcers that do not heal with the Unna boot: Apply split-thickness skin grafts with or without ligation of adjacent perforator veins.

Quick HIT
When superficial thrombophlebitis occurs in different locations over a short period of time, think of migratory superficial thrombophlebitis (secondary to occult malignancy, often of the pancreas—Trouseau syndrome).
Superficial Thrombophlebitis

A. General Characteristics
1. Virchow triad is again implicated (but pathophysiology is not entirely clear)
2. In upper extremities, usually occurs at the site of an IV infusion
3. In lower extremities, usually associated with varicose veins (in the greater saphenous system)—secondary to static blood flow in these veins

Quick HIT

Two conditions that should not be confused with superficial thrombophlebitis are cellulitis and lymphangitis. In these conditions, swelling and erythema are more widespread, and there is no palpable, indurated vein.

B. Clinical Features
1. Pain, tenderness, induration, and erythema along the course of the vein
2. A tender cord may be palpated

c. Treatment
1. No anticoagulation is required—rarely causes PE. Only if thrombus extends into the deep system.
2. Localized thrombophlebitis—a mild analgesic (aspirin or NSAIDs) elevation, and hot compresses; continue activity.
3. Suppurative thrombophlebitis—septic phlebitis is usually due to infection of an IV cannula. Redness extends beyond the area of the vein and purulent drainage may be present. Remove the cannula and administer systemic antibiotics.
Cardiac Neoplasms

Primary tumors of the heart are rare (typically less than 0.1% of the general population). Metastases from other primary tumors are more common (75% of cardiac neoplasms). Sites of these primary tumors include the lung, breast, skin, kidney, lymphomas, and Kaposi sarcoma in patients with AIDS.
Atrial Myxoma

An atrial myxoma is a benign gelatinous growth, usually pedunculated and arising from the interatrial septum of the heart in the region of the fossa ovalis. It is the most common primary cardiac neoplasm. Although benign, atrial myxomas can embolize, leading to metastatic disease, or can cause relative valvular dysfunction. The majority of myxomas are sporadic, but autosomal-dominant transmission has been noted. Prototypically present with fatigue, fever, syncope, palpitations, malaise, and a low-pitched diastolic murmur that changes character with changing body positions (diastolic plop). Treatment: Surgical excision.
Shock Basics of Shock

A. General Characteristics

1. Shock is hypotension causing end-organ hypoperfusion. It is a medical emergency that needs to be corrected right away, before the condition becomes irreversible.

<table>
<thead>
<tr>
<th>Shock</th>
<th>Cardiac Output</th>
<th>SVR</th>
<th>PCWP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiogenic</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Hypovolemic</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Distributive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurogenic</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Septic</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Obstructive</td>
<td>↓</td>
<td>↑</td>
<td>Variable</td>
</tr>
</tbody>
</table>

2. Presents with tachycardia, a decrease in BP, and malfunction of underperfused organ systems, most notably:
   a. Lactic acidosis
   b. Renal (anuria/oliguria)
   c. CNS dysfunction (altered mentation)

3. Shock is characterized by its effect on cardiac output, SVR, and volume status (volume status is assessed via jugular venous pressure or pulmonary capillary wedge pressure [PCWP]). The hemodynamic changes associated with different types of shock are set forth in Table 1-6.

4. There are four main categories of shock:
   - Hypovolemic (poor intake or excessive loss of fluids)
   - Cardiogenic (poor pumping function or circulatory overload)
   - Distributive (low SVR and high cardiac output states which include septic, anaphylactic, neurogenic shock, and severe hepatic failure)
   - Obstructive (i.e., massive PE, cardiac tamponade, tension pneumothorax)

Quick HIT

The following signs and symptoms are common to all forms of shock:
- Hypotension
B. Initial Approach to a Patient in Shock

1. A focused history and physical examination to determine possible cause of shock.
   a. Fever, warm extremities, and a possible site of infection suggest septic shock.
   b. Trauma, GI bleeding, vomiting, or diarrhea suggests hypovolemic shock.
   c. If signs of volume overload and cool, clammy extremities are present, this suggests cardiogenic shock.
   d. If spinal cord injury or neurologic deficits are present, neurogenic shock is likely.
   e. If the patient has been exposed to a new medication or allergen, consider anaphylactic shock.

2. Initial steps: Simultaneously stabilize the patient hemodynamically and determine the cause of shock.
   a. Initiate workup: CBC, BMP, infectious workup (blood and urine cultures, chest imaging), ECG, consider bedside echocardiography if concern for cardiogenic shock.
   b. Establish two large-bore IVs if fluid resuscitation indicated, and consider a central line, and an arterial line if vasopressors indicated.
   c. A fluid bolus (multiple liters of normal saline or lactated Ringer solution) should be given in most cases (except cardiogenic shock, as more volume will worsen it).
   d. Continuous pulse oximetry.
   e. Vasopressors (such as norepinephrine) may be given if the patient remains hypotensive despite fluids.
   f. If the diagnosis is still in question after the above tests, a pulmonary artery catheter (Swan–Ganz catheter) may help in diagnosis.

C. Treatment

1. **ABCs (airway, breathing, and circulation) should be addressed for all patients in shock.**
2. Specific treatment is described below for each type of shock. With the exception of cardiogenic (and sometimes neurogenic) shock, a generous amount of IV fluid is usually required to resuscitate the patient. The more advanced the stage of shock, the greater the fluid (and blood) requirement.
Cardiogenic Shock

A. General Characteristics
1. Occurs when heart is unable to generate a cardiac output sufficient to maintain tissue perfusion
2. Can be defined as a systolic BP <90 with urine output <20 mL/hr and adequate left ventricular filling pressure (LV filling pressure usually elevated in cardiogenic shock)

B. Causes
1. After acute MI—most common cause
2. Decompensated heart failure
3. After cardiac arrest
4. Arrhythmias
5. Mechanical abnormalities (valvular defects, ventricular septal defect)

C. Clinical Features
1. Ill-appearing patients with low cardiac output, markedly increased SVR (with cool extremities due to vasoconstriction)
2. Engorged neck veins—JVP elevated
3. Pulmonary congestion

Quick HIT
Note that jugular venous pulse is only elevated in cardiogenic and obstructive shock.

D. Diagnosis
1. ECG—look for signs of ischemia (i.e., ST-segment changes) or arrhythmia (ventricular or atrial tachyarrhythmia).
2. Echocardiogram—can diagnose a variety of mechanical complications of MI, identify valve disease, estimate EF, look for pericardial effusion, etc.
3. Hemodynamic monitoring with a Swan–Ganz catheter may be indicated: PCWP, pulmonary artery pressure, cardiac output, cardiac index, SVR—keep cardiac output >4 L/min, cardiac index >2.2, PCWP <18 mm Hg.

E. Treatment
1. ABCs
2. Identify and treat underlying cause
   a. Acute MI
      • Standard treatment (see MI section)
• Emergent revascularization with PCI (or CABG) has been shown to improve survival
b. If cardiac tamponade, pericardiocentesis/surgery
c. Surgical correction of valvular abnormalities
d. Treatment of arrhythmias
3. Preload reduction for patients with volume overload: Loop diuretics, dialysis if renal failure, nitroglycerin (though this can worsen hypotension)
4. Inotropy
a. Dobutamine (inotrope) can be used to increase inotropy and simultaneously decrease afterload (SVR), enhancing cardiac output
b. Dopamine or norepinephrine can be used. The SOAP II trial found that for patients with cardiogenic shock, dopamine had higher 28-day mortality compared to norepinephrine.
c. Milrinone is a phosphodiesterase inhibitor which increases inotropy and decreases SVR. It is often used in conjunction with other inotropes.
5. Afterload reduction
a. IV agents like sodium nitroprusside can be used to quickly reduce afterload. There is a risk of hypotension with rapidly increasing the dose.
b. Oral agents like hydralazine and captopril can reduce afterload, are short acting.
6. **IV fluids are likely to be harmful if left ventricular pressures are elevated. Patients usually need diuretics.**
7. While controversial, IABPs can be used for hemodynamic support (see Clinical Pearl 1-15). Effects include:
   a. Decreased afterload
   b. Increased cardiac output
   c. Decreased myocardial oxygen demand
8. More advanced mechanical support devices such as extracorporeal membrane oxygenation and left ventricular assist devices (percutaneously or surgically implanted) can be used for patients with more severe shock, and are outside the scope of this text.

**CLINICAL PEARL 1-15**

**Intra-Aortic Balloon Pump**
- A device that gives “mechanical support” to a failing heart—it works opposite to the normal pumping action of the heart, that is, it serves to “pump” during diastole and “relax” during systole.
- A balloon catheter is positioned in the descending thoracic aorta just distal to the subclavian artery. **It facilitates ventricular emptying by deflating just before the onset of systole (reducing afterload) and increases coronary perfusion by inflating at the onset of diastole (increasing diastolic pressure).**
- **The net effect is enhanced myocardial oxygenation and increased cardiac output.**
- Indications are angina refractory to medical therapy, mechanical complications of MI, cardiogenic shock, low cardiac output states, and as a bridge to surgery in severe AS.

**Quick HIT**

- Compensatory mechanisms begin to fail when more than 20% to 25% of blood volume is lost.
- If CVP is low, hypovolemic shock is most likely present.
**Hypovolemic Shock**

A. General Characteristics

1. Primary pathophysiologic events: Decreased circulatory blood volume leads to decreased preload and cardiac output. Compensatory increase in SVR.
2. The rate of volume loss is very important. The slower the loss, the greater the effectiveness of compensatory mechanisms. Acute loss is associated with higher morbidity and mortality.
3. Patients with significant medical comorbidities (especially cardiac) may be unable to compensate physiologically in the early stages of hypovolemic shock.
4. There are four “classes” of hypovolemic shock, based on the severity of volume loss (Table 1-7).
5. Causes
   a. Hemorrhage
      - Trauma
      - GI bleeding
      - Retroperitoneal
   b. Nonhemorrhagic
      - Voluminous vomiting
      - Severe diarrhea
      - Severe dehydration for any reason
      - Burns
      - Third-space losses in bowel obstruction

<table>
<thead>
<tr>
<th>Class</th>
<th>Blood Volume Lost (%)</th>
<th>Pulse (↑)</th>
<th>Systolic BP (↓)</th>
<th>Pulse Pressure (↓)</th>
<th>Capillary Refill (↓)</th>
<th>Respiratory Rate (↑)</th>
<th>CNS</th>
<th>Urine Output (↓)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>10–15</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>II</td>
<td>20–30</td>
<td>&gt;100</td>
<td>Normal</td>
<td>Decreased</td>
<td>Delayed</td>
<td>Mild tachypnea</td>
<td>Anxious</td>
<td>20–30 mL/hr</td>
</tr>
<tr>
<td>III</td>
<td>30–40</td>
<td>&gt;120 weak</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Delayed</td>
<td>Marked tachypnea</td>
<td>Confused</td>
<td>20 mL/hr</td>
</tr>
<tr>
<td>IV</td>
<td>&gt;40</td>
<td>&gt;140 nonpal-pable</td>
<td>Marked decrease</td>
<td>Marked decrease</td>
<td>Absent</td>
<td>Marked tachypnea</td>
<td>Lethargic, coma</td>
<td>Negligible</td>
</tr>
</tbody>
</table>

B. Diagnosis

If the diagnosis is unclear from the patient’s vital signs and clinical picture, a central venous line or a pulmonary artery catheter can give invaluable information for hemodynamic monitoring: Decreased CVP/PCWP, decreased cardiac output, increased SVR (see Table 1-5).
C. Treatment

1. Airway and breathing—patients in **severe** shock and circulatory collapse generally require intubation and mechanical ventilation.

2. Circulation
   
a. If hemorrhage is the cause, apply direct pressure.
   
b. IV hydration
      
      - Patients with class I shock usually do not require fluid resuscitation. Patients with class II shock benefit from fluids, and patients with classes III and IV require fluid resuscitation.
      
      - Give fluid bolus followed by continuous infusion and reassess.
      
      - The hemodynamic response to this treatment guides further resuscitative effort.

   c. For nonhemorrhagic shock, blood is not necessary. Crystalloid solution with appropriate electrolyte replacement is adequate.

---

**Quick HIT**

Monitoring urine output is the most useful indicator of the effectiveness of treatment. A pulmonary artery catheter and/or central venous line, if available, are very helpful in monitoring as well.
Septic Shock

A. General Characteristics
1. Septic shock is defined as hypotension induced by sepsis that persists despite adequate fluid resuscitation. This results in hypoperfusion and can ultimately lead to multiple organ system failure and death.
2. Common causes include (but are not limited to) pneumonia, urinary tract infection, meningitis, abscess formation, cholangitis, cellulitis, and peritonitis.
3. Clinically, there is a progression from systemic inflammatory response syndrome (SIRS) to sepsis, to septic shock, to multiorgan dysfunction syndrome—see Clinical Pearl 1-15.
4. Pathophysiology
   a. There is a severe decrease in SVR secondary to peripheral vasodilation. Extremities are often warm due to vasodilation.
   b. Cardiac output is normal or increased (due to maintenance of stroke volume and tachycardia).
   c. EF is decreased secondary to a reduction in contractility.
5. Can be complicated by adult respiratory distress syndrome, ATN, DIC, multiple organ failure, or death.

Quick HIT

Septic (and other types of distributive shock) are associated with severe peripheral vasodilatation (flushing, warm skin).
Hypovolemic, cardiogenic, and obstructive shock are associated with peripheral vasoconstriction (cool skin).

B. Clinical Features
1. Manifestations related to cause of sepsis (e.g., pneumonia, urinary tract infection, peritonitis)
2. Signs of SIRS (see Clinical Pearl 1-16)
3. Signs of shock (hypotension, oliguria, lactic acidosis)
4. Patient may have a fever or may be hypothermic (hypothermia is more common in the very young, elderly, debilitated, and immunocompromised)

C. Diagnosis
1. Septic shock is essentially a clinical diagnosis.
2. A source of infection can aid in diagnosis, but there may be no confirmed source in some cases.

D. Treatment
1. Fluid administration to increase mean BP (initial bolus is usually 30 cc/kg of body weight).
2. Obtain cultures prior to starting antibiotics. Start IV antibiotics (broad spectrum) at maximum dosages. Antibiotics for more rare organisms or antifungal medications may be required if there is no clinical response or if suspicion for an atypical organism (i.e., immunocompromised). If cultures are positive, antibiotics can be narrowed based on sensitivity testing.
3. Surgical drainage if necessary.
4. Vasopressors (norepinephrine, vasopressin, phenylephrine) may be used if hypotension persists despite aggressive IV fluid resuscitation.

**CLINICAL PEARL 1-16**

**Systemic Inflammatory Response Syndrome (SIRS)**

**SIRS**
SIRS is characterized by two or more of the following:
- Fever (>38°C) or hypothermia (<36°C)
- Hyperventilation (rate >20 bpm) or PaCO₂ <32 mm Hg
- Tachycardia (>90 bpm)
- Increased WBC count (>12,000 cell/hpf, <4,000 cells/hpf, or >10% band forms)

**Sepsis**
- When have a suspected source of infection and SIRS is present

**Septic Shock**
- Hypotension induced by sepsis persisting despite adequate fluid resuscitation

**Multiple Organ Dysfunction Syndrome (MODS)**
- Altered organ function in an acutely ill patient, usually leading to death

**Quick HIT**

Septic shock is the most common cause of death in the ICU.
Neurogenic Shock

A. General Characteristics
1. Neurogenic shock results from a failure of the sympathetic nervous system to maintain adequate vascular tone (sympathetic denervation)
2. Causes include spinal cord injury, severe head injury, spinal anesthesia, pharmacologic sympathetic blockade
3. Characterized by peripheral vasodilation with decreased SVR

B. Clinical Features
1. Warm, well-perfused skin
2. Urine output low or normal
3. Bradycardia and hypotension (but tachycardia can occur)
4. Cardiac output is decreased, SVR low, PCWP low to normal

C. Treatment
1. Judicious use of IV fluids as the mainstay of treatment
2. Vasoconstrictors to restore venous tone, but cautiously
3. Supine or Trendelenburg position
4. Maintain body temperature
Obstructive Shock

A. General Characteristics

1. Caused by an obstruction of circulation. Most commonly due to massive pulmonary embolism (PE) or limited filling of the heart due to extrinsic pressure from pericardium (cardiac tamponade) or thoracic cavity (tension pneumothorax).
2. Cardiac output limited by obstruction, SVR makes a compensatory increase to maintain systemic blood pressure.
3. Usually manifests with elevated JVP due to limited filling of right ventricle or obstruction of pulmonary circulation by PE.
4. Treatment requires diagnosis of underlying disease. Cardiac tamponade and tension pneumothorax are clinical diagnoses that can be made at bedside.
5. Supportive treatment usually involves giving fluid and/or vasopressors to maintain blood pressures until definitive therapy can be given.
6. Cardiac tamponade: Requires pericardiocentesis or pericardial window.
7. Tension pneumothorax: Requires needle thoracostomy followed by chest tube placement.
8. Massive PE: Requires thrombolysis (systemic or catheter-directed tPA) or thrombectomy.
References


Diseases of the Pulmonary System
Kelley Chuang
Obstructive Lung Diseases

Chronic Obstructive Pulmonary Disease

A. General Characteristics
1. There are two classic types of chronic obstructive pulmonary disease (COPD): chronic bronchitis and emphysema (see Table 2-1 and Clinical Pearl 2-1)
   a. Chronic bronchitis is a clinical diagnosis: chronic cough productive of sputum for at least 3 months per year for at least 2 consecutive years.
   b. Emphysema is a pathologic diagnosis: permanent enlargement of air spaces distal to terminal bronchioles due to destruction of alveolar walls.
   c. The two often coexist. Pure emphysema or pure chronic bronchitis is rare.
   d. COPD is the third leading cause of death in the United States.
2. Risk factors and causes
   a. Tobacco smoke (indicated in almost 90% of COPD cases)
   b. α₁-Antitrypsin deficiency—risk is even worse in combination with smoking
   c. Environmental factors (e.g., second-hand smoke)
   d. Chronic asthma—which may be attributed to asthma–COPD overlap syndrome
3. Pathogenesis
   a. Chronic bronchitis
      • Excess mucus production narrows the airways; patients often have a productive cough.
      • Inflammation and scarring in airways, enlargement in mucous glands, and smooth muscle hyperplasia lead to obstruction.
   b. Emphysema
      • Destruction of alveolar walls is due to relative excess in protease (elastase) activity, or relative deficiency of antiprotease (α₁-antitrypsin) activity in the lung. Elastase is released from polymorphonuclear neutrophils (PMNs) and macrophages and digests human lung. This is inhibited by α₁-antitrypsin.
      • Tobacco smoke increases the number of activated PMNs and macrophages, inhibits α₁-antitrypsin, and increases oxidative stress on the lung by free-radical production.

Quick HIT

Pathology
Centrilobular emphysema:
Most common type, seen in smokers (rarely in nonsmokers)
- Destruction limited to respiratory bronchioles (proximal acini) with little change in distal acini
- Predilection for upper lung zones

Panlobular emphysema:
- Seen in patients with $\alpha_1$-antitrypsin deficiency
- Destruction involves both proximal and distal acini
- Predilection for lung bases

**B. Clinical Features**

1. **Symptoms**
   a. Any combination of cough, sputum production, and dyspnea (on exertion or at rest, depending on severity) may be present.
   b. Earliest symptom is exertional dyspnea, which may be difficult to detect in patients with sedentary lifestyles who avoid exertion.

2. **Signs**—the following may be present:
   a. **Prolonged expiratory time with pursed lip breathing**
   b. During auscultation, end-expiratory wheezes on forced expiration, decreased breath sounds, and/or inspiratory crackles
   c. Tachypnea, tachycardia
   d. Cyanosis
   e. Use of accessory respiratory muscles
   f. Hyperresonance on percussion and distant heart sounds
   g. Signs of cor pulmonale

**Quick HIT**

In COPD:
- The FEV$_1$/FVC ratio is <0.70.
- FEV$_1$ is decreased.
- TLC is increased.
- Residual volume is increased.

**TABLE 2-1 COPD—Emphysema and Chronic Bronchitis**

<table>
<thead>
<tr>
<th>Predominant Emphysema (&quot;Pink Puffers&quot;)</th>
<th>Predominant Chronic Bronchitis (&quot;Blue Bloaters&quot;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Patients tend to be thin due to increased energy expenditure during breathing.</td>
<td></td>
</tr>
<tr>
<td>- When sitting, patients tend to lean forward.</td>
<td></td>
</tr>
<tr>
<td>- Patients have a barrel chest (increased AP diameter of chest).</td>
<td></td>
</tr>
<tr>
<td>- Tachypnea with prolonged expiration through pursed lips is present.</td>
<td></td>
</tr>
<tr>
<td>- Patients tend to be overweight and cyanotic (secondary to chronic hypercapnia and hypoxemia).</td>
<td></td>
</tr>
<tr>
<td>- Chronic cough and sputum production are characteristic.</td>
<td></td>
</tr>
<tr>
<td>- Signs of cor pulmonale may be present in severe or long-standing disease.</td>
<td></td>
</tr>
<tr>
<td>- Respiratory rate is normal or slightly increased.</td>
<td></td>
</tr>
</tbody>
</table>
Patient is distressed and uses accessory muscles (especially strap muscles in neck). Patient is in no apparent distress, and there is no apparent use of accessory muscles.

Quick HIT

FEV₁ is the amount of air that can be forced out of the lungs in 1 second. The lower the FEV₁, the more difficulty one has breathing.

C. Diagnosis

1. PFT (spirometry)—see Table 2-2 and Figure 2-1
   a. This is the definitive diagnostic test.
   b. Obstruction is evident based on the following:
      - Decreased FEV₁ and decreased FEV₁/FVC ratio—GOLD staging is based on FEV₁. FEV₁ ≥80% of predicted value is mild disease, 50% to 80% is moderate disease, 30% to 50% is severe disease, and <30% is very severe disease.
      - Increased total lung capacity (TLC), residual volume, and functional reserve capacity (FRC) (indicating air trapping) (see Figure 2-2). Although COPD increases TLC, the excess volume in the lung is not useful because it all becomes residual volume and does not participate in gas exchange.
      - Decreased vital capacity.

Quick HIT

To diagnose airway obstruction, one must have a normal or increased TLC with a decreased FEV₁.

CLINICAL PEARL 2-1

Key Points in Taking History of COPD Patients

**General**
- History of cardiopulmonary diseases
- Smoking history (duration, intensity, current smoker)
- Family history—COPD, heart disease, asthma
- Occupation—industrial dusts, fumes
- Overall health
- History of respiratory infections—frequency, severity
- History of hospitalizations for COPD or exacerbations
- Pulmonary medications

**Pulmonary Symptoms**
- Dyspnea—quantitate severity
- Cough
- Sputum production—quantity, quality, duration, hemoptysis
- Wheezing
TABLE 2-2 Obstructive Versus Restrictive Lung Disease

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Obstructive</th>
<th>Restrictive</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁</td>
<td>Low</td>
<td>Normal or slightly low</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>Low</td>
<td>Normal or high</td>
</tr>
<tr>
<td>Peak expiratory flow rate</td>
<td>Low</td>
<td>Normal</td>
</tr>
<tr>
<td>Residual volume</td>
<td>High</td>
<td>Low, normal, or high</td>
</tr>
<tr>
<td>Total lung capacity</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Vital capacity</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>

2. Chest radiograph (CXR)
   a. Low sensitivity for diagnosing COPD; only severe, advanced emphysema will show the typical changes, which include:
      • Hyperinflation, flattened diaphragm, enlarged retrosternal space (see Figure 2-3).
      • Diminished vascular markings.
   b. Useful in an acute exacerbation to rule out complications such as pneumonia or pneumothorax.

3. Measure α₁-antitrypsin levels in patients with a personal or family history of premature emphysema (≤45 years old) or emphysema in nonsmokers

4. Arterial blood gas (ABG)—chronic PCO₂ retention, decreased PO₂

Quick HIT
COPD leads to chronic respiratory acidosis with metabolic alkalosis as compensation.

D. Treatment
1. Modalities
   a. Smoking cessation—the most important intervention.
      • Disease progression is accelerated by continued smoking and can be greatly slowed by its cessation.
      • At around age 35, FEV₁ decreases approximately 25 to 30 mL/yr. In smokers, the rate of decline is faster (three- to fourfold). If a smoker quits, the rate of decline of FEV₁ slows to that of someone of the same age who has never smoked. However, quitting does not result in complete reversal.
• Smoking cessation prolongs the survival rate but does not reduce it to the level of someone who has never smoked (see Figure 2-4).
• Respiratory symptoms improve within 1 year of quitting.

b. Inhaled anticholinergic drugs (e.g., ipratropium bromide): bronchodilators.
• Slower onset of action than the β-agonists, but last longer. Use long-acting anticholinergics (e.g., tiotropium) for patients with more severe symptoms.

![Lung volumes diagram](image)

**FIGURE 2.1** Lung volumes. IC, inspiratory capacity; ERV, expiratory reserve volume.

**Quick HIT**
Clinical monitoring of COPD patients entails the following:
- Serial FEV₁ measurements—this has the highest predictive value
- Pulse oximetry
- Severity of symptoms: exercise tolerance, cough, sputum, breathlessness

**Quick HIT**
Smoking cessation and home oxygen therapy are the only interventions shown to lower mortality.
FIGURE 2.2 Flow volume loops. Examples of flow volume curves in a patient with obstructive disease and a patient with restriction (diffuse interstitial fibrosis), as compared with a healthy person. Volumes on the axis are absolute volumes to better show the relation of flows (e.g., FEF$_{50\%}$) to hyperinflation and restriction. (Redrawn from Humes DH, DuPont HL, Gardner LB, et al. Kelley’s Textbook of Internal Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:2580, Figure 387.2.)

c. Inhaled β$_2$-agonists (e.g., albuterol): bronchodilators.
   - Provide symptomatic relief. Use long-acting agents (e.g., salmeterol) for patients requiring frequent use.

d. Combination of β-agonist albuterol with ipratropium bromide.
   - More efficacious than either agent alone in bronchodilation.
   - Also helps with adherence to therapy (both medications in one inhaler).

e. Inhaled corticosteroids (e.g., budesonide, fluticasone): anti-inflammatory.
   - May minimally slow down the decrease in FEV$_1$ over time; however, many studies have failed to show any benefit in pulmonary function.
   - Typically used in combination with a long-acting bronchodilator for patients with significant symptoms or repeated exacerbations.
Quick HIT

- Treat COPD with bronchodilators (anticholinergics, β₂-agonists, or both).
- Give steroids and antibiotics for acute exacerbations.

Quick HIT

β-Blockers are generally contraindicated in acute COPD or asthma exacerbations.

f. Theophylline (oral)—role is controversial.
   • May improve mucociliary clearance and central respiratory drive.
   • Narrow therapeutic index, so serum levels must be monitored.
   • Only modestly effective and has more side effects than other bronchodilators. Occasionally used for patients with refractory COPD.

**FIGURE 2.3** Chest radiographs showing a patient with COPD.

FIGURE 2.4 Smoking and COPD. Age-related rate of decline in lung function (FEV$_{1.0}$) in a nonsmoker (top) and susceptible smoker (bottom). The dashed lines indicate the beneficial effects of smoking cessation with moderate and severe disease. The accelerated decline in lung function approaches the normal rate, significantly delaying the onset of disability and death.


g. Phosphodiesterase-4 inhibitors (e.g., roflumilast).
   - Promote smooth muscle relaxation and decrease inflammation.
   - May reduce risk of frequent exacerbations.

Quick HIT

Systemic glucocorticoids are only used for acute exacerbations and should not be used for long-term treatment, even for patients with severe COPD.

h. Oxygen therapy.
   - Shown to improve survival and quality of life in patients with COPD and chronic hypoxemia.
Some patients need continuous oxygen, whereas others only require it during exertion or sleep. Get an ABG to determine need for oxygen (see Quick Hit).
Long-standing hypoxemia may lead to pulmonary HTN and ultimately cor pulmonale. Continuous oxygen therapy for ≥18 hr/day has been shown to reduce mortality in patients with these complications by controlling pulmonary HTN.

i. Pulmonary rehabilitation—education, exercise, physiotherapy: A major goal is to improve exercise tolerance. Pulmonary rehabilitation improves functional status and quality of life, and may reduce mortality.

### Quick HIT

**Criteria for continuous or intermittent long-term oxygen therapy in COPD:**
- \( \text{PaO}_2 \) 55 mm Hg OR
- \( \text{O}_2 \text{ saturation} \leq 88\% \) (pulse oximetry), either at rest or during exercise OR
- \( \text{PaO}_2 \) 55 to 59 mm Hg plus polycythemia or evidence of cor pulmonale
- Note that the above must be consistent findings despite optimal medical therapy

j. Vaccination.
- Influenza vaccination annually for all patients.
- Vaccination against *Streptococcus pneumoniae*—should be offered to all adult patients with COPD, regardless of age. Offer once before age 65, then once over age 65, and again every 5 to 10 years.

k. Antibiotics are given for acute exacerbations (see below)—increased sputum production in volume or change in character or worsening shortness of breath.

l. Surgery—may be beneficial in selected patients; carefully weigh potential benefits with risks. Options include:
- Lung resection
- Lung transplantation

2. Treatment guidelines—stepwise therapy based on severity of symptoms and prior number of exacerbations or COPD-related hospitalizations

a. Low risk of exacerbation (0 to 1 exacerbations in past year)
- Begin with a short-acting bronchodilator (anticholinergic and/or \( \beta \)-agonist) as needed in a metered-dose inhaler (MDI) formulation (with spacer to improve delivery).
- Add daily long-acting bronchodilator, if more symptomatic.
- Inhaled glucocorticoids may be used as well (see above). Use the lowest dose possible.

b. High risk of exacerbation (2 or more exacerbations per year)
- Regular use of long-acting bronchodilator (anticholinergic and/or \( \beta \)-agonist).
• Add inhaled corticosteroid, if more symptomatic.
• Consider additional agents (roflumilast or theophylline).
• Continuous oxygen therapy (if patient is hypoxemic).
• Pulmonary rehabilitation.

3. Acute COPD exacerbation. Definition: Increased dyspnea, sputum production, and/or cough. Acute COPD exacerbation can lead to acute respiratory failure requiring hospitalization, and possibly mechanical ventilation; potentially fatal.
   a. Bronchodilators (β₂-agonist) alone or in combination with anticholinergics are first-line therapy.
   b. Systemic corticosteroids are used for patients requiring hospitalization. A short course of oral prednisone is common practice. Do not use inhaled corticosteroids in acute exacerbations.
   c. Antibiotics (azithromycin, doxycycline, or fluoroquinolones): Reserved for those with moderate or severe exacerbations requiring hospitalization.
   d. Supplemental oxygen is used to keep O₂ saturation 88% to 92%. Start with a nasal cannula; a face mask may need to be used.
      • If SaO₂ is >92%, the patient is at risk of CO₂ retention from worsening V/Q mismatch, loss of hypoxemic respiratory drive, and the Haldane effect.
   e. Noninvasive positive pressure ventilation (NPPV) (bilevel positive airway pressure [BiPAP] or continuous positive airway pressure [CPAP]): Studies have shown a benefit in acute exacerbations. It may decrease the likelihood of respiratory failure requiring invasive mechanical ventilation.
   f. Intubation and mechanical ventilation may be required if the above do not stabilize the patient. Intubate, if increasing RR, increasing PaCO₂, and worsening acidosis.

Quick HIT

• One of the main treatment goals for COPD patients is to reduce the number and severity of exacerbations they experience each year.
• Pulmonary infection (most commonly viruses, followed by bacteria such as S. pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Moraxella catarrhalis) is one of the main precipitants of a COPD exacerbation.

E. Complications

1. Acute exacerbations—most common causes are infection, nonadherence with therapy, and cardiac disease
2. Secondary polycythemia (Hct >55% in men or >47% in women)—compensatory response to chronic hypoxemia
3. Pulmonary HTN and cor pulmonale—may occur in patients with severe, long-
If a patient presents with COPD exacerbation, the following steps are appropriate:

- CXR
- β₂-Agonist and anticholinergic inhalers
- Systemic corticosteroids
- Antibiotics
- Supplemental oxygen
- NPPV, if needed (see Clinical Pearl 2-9)
Asthma

A. General Characteristics

1. Characteristically defined by the following triad:
   a. Airway inflammation
   b. Airway hyperresponsiveness
   c. Reversible airflow obstruction
2. **Asthma can begin at any age**
3. Extrinsic versus intrinsic asthma
   a. Extrinsic asthma (most cases)
      - Patients are atopic, that is, produce immunoglobulin E (IgE) to environmental antigens. May be associated with eczema and hay fever.
      - Patients become asthmatic at a young age.
   b. Intrinsic asthma—not related to atopy or environmental triggers
4. Triggers include pollens, house dust, molds, cockroaches, cats, dogs, cold air, viral infections, tobacco smoke, medications (β-blockers, aspirin), and exercise

**Quick HIT**

Signs of acute severe asthma attacks:
- Tachypnea, diaphoresis, wheezing, speaking in incomplete sentences, and use of accessory muscles of respiration.
- Paradoxic movement of the abdomen and diaphragm on inspiration is sign of impending respiratory failure.

**B. Clinical Features**

1. Characterized by intermittent symptoms that include **SOB, wheezing, chest tightness**, and **cough**. Symptoms have variable severity and may not be present simultaneously. Usually occur within 30 minutes of exposure to triggers.
2. Symptoms are typically worse at night.
3. Wheezing (commonly during expiration, but can occur during inspiration) is the most common finding on physical examination (see **Clinical Pearl 2-2**).

**CLINICAL PEARL 2-2**

“All That Wheezes Is Not Asthma”

The most common cause of wheezing is asthma. However, any condition that mimics large airway bronchospasm can cause wheezing.
- CHF—due to edema of airways and congestion of bronchial mucosa
- COPD—inflamed airways may be narrowed, or bronchospasm may be present
- Cardiomyopathies, pericardial diseases can lead to edema around the bronchi
C. Diagnosis

1. Pulmonary function tests (PFTs) are required for diagnosis. They show an obstructive pattern: decrease in expiratory flow rates, decreased FEV₁, and decreased FEV₁/FVC ratio (<0.70).

2. Spirometry before and after bronchodilators can confirm diagnosis by proving reversible airway obstruction. If inhalation of a bronchodilator (β₂-agonist) results in an increase in FEV₁ or FVC by at least 12%, airflow obstruction is considered reversible.

3. Peak flow (peak expiratory flow rate)—useful measure of airflow obstruction. Patients should self-monitor their peak flow:
   a. Mild persistent asthma: Periodic monitoring is sufficient. Increase the dose of inhaled steroid, if the peak flow decreases.
   b. Moderate persistent asthma: Daily monitoring is required. Increase the dose of inhaled steroid, if the peak flow decreases.
   c. Severe persistent asthma: Daily monitoring is required. Initiate prednisone, if the peak flow decreases.

   a. May be useful when asthma is suspected but PFTs are nondiagnostic.
   b. Measures ease with which airways narrow in response to stimuli (hyperresponsiveness).
   c. Measures lung function before and after inhalation of increasing doses of methacholine (muscarinic agonist); hyperresponsive airways develop obstruction at lower doses.

Quick HIT

PFTs in asthma:
1. Decreased FEV₁, decreased FVC, decreased FEV₁/FVC ratio
2. Increase in FEV₁ >12% with albuterol
3. Decrease in FEV₁ >20% with methacholine or histamine

Although asthma can be diagnosed with PFTs and spirometry, in an acute setting (ED) when patient is SOB, peak flow measurement is quickest method of diagnosis.
During asthma exacerbations, the patient hyperventilates, leading to low PaCO$_2$ levels. If the patient is no longer hyperventilating (CO$_2$ level is normal or high), this could be a sign that the patient is decompensating (due to fatigue) and that intubation may be required.

5. Chest x-ray
   a. Normal in mild to moderate cases; severe asthma reveals hyperinflation.
   b. Only necessary in severe asthma to exclude other conditions (e.g., pneumonia, pneumothorax, pneumomediastinum, foreign body).

6. ABGs
   a. ABGs should be considered if the patient is in significant respiratory distress. **Hypocarbia** is common. Hypoxemia may be present.
   b. If the PaCO$_2$ is normal or increased, respiratory failure may ensue.
      • Remember that patients with an asthma attack have an increased respiratory rate, which should cause the PaCO$_2$ to decrease. Increased PaCO$_2$ is a sign of respiratory muscle fatigue or severe airway obstruction.
      • The patient should be hospitalized and mechanical ventilation considered.

**D. Treatment**

1. Available modalities (see Table 2-3).
   a. Inhaled β$_2$-agonists.
      • Short-acting β$_2$-agonists (e.g., albuterol) are used for acute attacks (rescue). Onset is 2 to 5 minutes, duration is 4 to 6 hours.
      • Long-acting versions (e.g., salmeterol) are often used in combination with inhaled corticosteroids for severe symptoms.

   **Quick HIT**

   Avoid β-blockers in asthmatics!

   b. Inhaled corticosteroids for moderate to severe asthma.
      • Preferred over oral steroids due to fewer systemic side effects. (Oral steroids are reserved for severe, persistent asthma.)
      • If used on a regular basis, airway hyperresponsiveness decreases, and the frequency of asthma exacerbations decreases.

   c. Montelukast—leukotriene modifiers—limited evidence but may be useful for prophylaxis of mild exercise-induced asthma and for control of moderate persistent disease. They may allow reductions in steroid and bronchodilator requirements.

   d. Theophylline
• Can be useful in addition to inhaled corticosteroids for persistent symptoms

<table>
<thead>
<tr>
<th>Severity</th>
<th>Long-Term Control Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild intermittent (symptoms two or fewer times per wk)</td>
<td>None</td>
</tr>
<tr>
<td>Mild persistent (symptoms two or more times per wk but not every day)</td>
<td>Low-dose inhaled corticosteroid</td>
</tr>
<tr>
<td>Moderate persistent (daily symptoms; frequent exacerbations)</td>
<td>Daily inhaled corticosteroid (low dose) with long-acting inhaled β-agonist, or daily inhaled corticosteroid (medium dose). Alternatives include adding a leukotriene modifier or theophylline to the daily inhaled corticosteroid (low dose)</td>
</tr>
<tr>
<td>Severe persistent (continual symptoms, frequent exacerbations, limited physical activity)</td>
<td>Daily inhaled corticosteroid (medium or high dose) and long-acting inhaled β2-agonists. Omalizumab (anti-IgE) may be considered additionally. If poor control, systemic corticosteroids should be considered.</td>
</tr>
</tbody>
</table>

Note: All patients should have intermittent short-acting inhaled β2-agonists as needed plus long-term control medications based on the severity of their asthma.


**Quick HIT**

- Side effects of inhaled corticosteroids are due to oropharyngeal deposition and include sore throat, oral candidiasis (thrush), and hoarseness.
- Using a spacer with MDIs and rinsing the mouth after use help minimize these side effects.

For acute asthma exacerbation, test to order:

1. Peak expiratory flow—decreased
2. ABG—increased A–a gradient
3. Chest x-ray—rule out pneumonia, pneumothorax

2. Treatment of acute severe asthma exacerbation (hospital admission).
   a. Inhaled β2-agonist (first-line therapy).
      • Via nebulizer or MDI (see Clinical Pearl 2-3).
      • Mainstays of emergency treatment—have an onset of action of minutes.
      • Assess patient response to bronchodilators (clinically and with peak flows).
   b. Corticosteroids
      • Traditionally given intravenously initially, but may also be given orally if
given in equivalent doses.

- Taper IV or oral corticosteroids, but only when clinical improvement is seen.
- Initiate inhaled corticosteroids at the beginning of the tapering schedule.

c. Third-line agent includes IV magnesium—not as effective as β-agonists; magnesium helps with bronchospasm but only used in acute severe exacerbation that has not responded to above medications (albuterol, steroids, oxygen).

d. Supplemental oxygen (keep oxygen saturation >90%).

e. Antibiotics, only if suspicion of bacterial pneumonia (as most triggers are viral).

f. Intubation for patients in respiratory failure or impending respiratory failure.

g. Guidelines for treatment are based on severity.

---

**Quick HIT**

Complications of asthma:
1. Status asthmaticus—does not respond to standard medications
2. Acute respiratory failure (due to respiratory muscle fatigue)
3. Pneumothorax, atelectasis, pneumomediastinum

---

**Quick HIT**

- Aspirin-sensitive asthma should be considered in patients with asthma and nasal polyps.

- Avoid aspirin or any nonsteroidal anti-inflammatory drugs in these patients because they may cause a severe systemic reaction.

---

**CLINICAL PEARL 2-3**

**MDIs and Nebulizers**

- An MDI with a spacer is just as effective as a nebulizer. A spacer is a holding chamber that obviates the need to coordinate inhalation and depression of the canister, and thus makes the use of an MDI easier. Its use leads to a greater bronchodilator effect because more of the drug is deposited in smaller airways and less accumulates in the oropharynx.

- A nebulizer is no more effective than an MDI, but patients may report greater relief of symptoms simply because it provides more medication. It may be preferred by patients with very severe asthma unresponsive to MDIs.
**Bronchiectasis**

**A. General Characteristics**
1. There is permanent, abnormal dilation and destruction of bronchial walls with chronic inflammation, airway collapse, and ciliary loss/dysfunction leading to impaired clearance of secretions.
2. Less common today because modern antibiotics are used for respiratory infections.

**B. Causes**
1. Recurrent infections (airway obstruction, immunodeficiency, allergic bronchopulmonary aspergillosis, mycobacterium)
2. Cystic fibrosis (CF) is the most common cause of bronchiectasis (accounts for half of all cases)
3. Primary ciliary dyskinesia (e.g., Kartagener syndrome)
4. Autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn disease, etc.)
5. Humoral immunodeficiency (abnormal lung defense), airway obstruction

**Quick HIT**
A variety of infections can cause bronchiectasis by destroying and damaging the bronchial walls and interfering with ciliary action.

**C. Clinical Features**
1. Chronic cough with large amounts of mucopurulent, foul-smelling sputum
2. Dyspnea
3. Hemoptysis—due to rupture of blood vessels near bronchial wall surfaces; usually mild and self-limited, but sometimes can be brisk and presents as an emergency
4. Recurrent or persistent pneumonia

**D. Diagnosis**
1. High-resolution CT scan is the diagnostic study of choice.
2. PFTs reveal an obstructive pattern.
3. CXR is abnormal in most cases, but findings are nonspecific.
4. Bronchoscopy may be helpful for infectious workup.

**E. Treatment**
1. Antibiotics for acute exacerbations—superimposed infections are signaled by change in quality/quantity of sputum, fever, chest pain, etc.
2. Bronchial hygiene is very important.
a. Hydration
b. Chest physiotherapy (postural drainage, chest percussion) to help remove the mucus
c. Inhaled bronchodilators

**Quick HIT**

The main goal in treating bronchiectasis is to prevent the complications of pneumonia and hemoptysis.
Cystic Fibrosis

Autosomal recessive condition predominantly affecting Caucasians
Defect in chloride channel protein causes impaired chloride and water transport,
which leads to excessively thick, viscous secretions in the respiratory tract, exocrine pancreas, sweat glands, intestines, and genitourinary tract
Typically results in obstructive lung disease pattern with chronic pulmonary infections (frequently *Pseudomonas*), pancreatic insufficiency, and other GI complications
Treatment is pancreatic enzyme replacement, fat-soluble vitamin supplements, chest physical therapy, vaccinations (influenza and pneumococcal), treatment of infections with antibiotics, inhaled recombinant human deoxyribonuclease (DNase), which breaks down the DNA in respiratory mucus that clogs the airways
Traditionally considered a pediatric topic; however, the prognosis has improved significantly, with the median age of death now over 30 years of age
Lung Neoplasms

Lung Cancer

A. General Characteristics

1. Pathologic types are divided into two subgroups:
   a. Small cell lung cancer (SCLC)—25% of lung cancers
   b. Non–small cell lung cancer (NSCLC)—75% of lung cancers; includes squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and bronchoalveolar cell carcinoma

2. Risk factors
   a. Cigarette smoking—accounts for >85% of cases
      • There is a linear relationship between pack-years of smoking and risk of lung cancer.
      • Adenocarcinoma has the lowest association with smoking of all lung cancers.
   b. Second-hand smoke
   c. Asbestos
      • Common in shipbuilding and construction industry, car mechanics, painting
      • Smoking and asbestos in combination synergistically increase the risk of lung cancer
   d. Radon—high levels found in basements
   e. COPD—an independent risk factor after smoking is taken into account

3. Staging
   a. NSCLC is staged via the primary TNM system.
   b. SCLC is staged differently (though some recommend TNM staging still be used):
      • Limited—confined to chest plus supraclavicular nodes, but not cervical or axillary nodes
      • Extensive—outside of chest and supraclavicular nodes

Quick HIT

In the diagnosis of lung cancer, it is crucial to differentiate between small cell (25%) and non–small cell (75%) types because the treatment approach is completely different (see below). A tissue diagnosis is necessary to make this differentiation.

B. Clinical Features

1. Local manifestations (squamous cell carcinoma is most commonly associated
with these symptoms)

a. Airway involvement can lead to cough, hemoptysis, obstruction, wheezing, dyspnea
b. Recurrent pneumonia (postobstructive pneumonia)

Quick HIT

Unfortunately, signs and symptoms are generally nonspecific for lung cancer, and by the time they are present, disease is usually widespread.

2. Constitutional symptoms
   a. Anorexia, weight loss, weakness
   b. Usually indicative of advanced disease

3. Local invasion
   a. **Superior vena cava (SVC) syndrome**—occurs in 5% of patients
      - Caused by obstruction of SVC by a mediastinal tumor
      - More commonly occurs with SCLC
      - Findings: facial fullness; facial and arm edema; dilated veins over anterior chest, arms, and face; jugular venous distention (JVD)
   b. Phrenic nerve palsy—occurs in 1% of patients
      - Destruction of phrenic nerve by tumor; phrenic nerve courses through the mediastinum to innervate the diaphragm
      - Results in hemidiaphragmatic paralysis
   c. Recurrent laryngeal nerve palsy (3% of patients)—causes hoarseness
   d. **Horner syndrome**—due to invasion of cervical sympathetic chain by an apical tumor. Symptoms: unilateral facial anhidrosis (no sweating), ptosis, and miosis
   e. **Pancoast tumor**
      - Superior sulcus tumor—an apical tumor involving C8 and T1–T2 nerve roots, causing shoulder pain radiating down the arm
      - Usually squamous cell cancers
      - Symptoms: pain; upper extremity weakness due to brachial plexus invasion; associated with Horner syndrome 60% of the time
   f. Malignant pleural effusion—occurs in 10% to 15% of patients
      - Prognosis is very poor—equivalent to distant metastases

4. Metastatic disease—most common sites are brain, bone, adrenal glands, and liver

5. Paraneoplastic syndromes
   a. Syndrome of inappropriate ADH: usually associated with small cell carcinoma (10% of SCLC patients)
   b. Cushing syndrome: due to ectopic ACTH secretion, typically associated with
small cell carcinoma

c. Hypercalcemia: commonly due to PTH-like hormone secretion, most commonly squamous cell carcinoma
d. Hypertrophic pulmonary osteoarthropathy: associated with both adenocarcinoma and squamous cell carcinoma; severe long-bone pain may be present, and leads to digital clubbing.
e. **Eaton–Lambert syndrome**: most common in SCLC; clinical picture is similar to that of myasthenia gravis, with proximal muscle weakness/fatigability, diminished deep tendon reflexes, paresthesias (more common in lower extremities)

**Quick HIT**

| Prognosis of SCLC: For limited disease, 5-year survival is 10% to 13% (median survival ranges from 15 to 20 months). For extensive disease, 5-year survival rate is 1% to 2% (median survival is 8 to 13 months). |

| Quick HIT |

For lung cancer, obtain a CXR, a CT scan, and a tissue biopsy to confirm diagnosis and determine histologic type (SCLC or NSCLC).

C. Diagnosis

1. **CXR**
   a. Most important radiologic study for diagnosis, but **not** used as a screening test
   b. Demonstrates abnormal findings in nearly all patients with lung cancer
   c. Stability of an abnormality over a 2-year period is almost always associated with a benign lesion

2. **CT scan of the chest with IV contrast**
   a. Very useful for staging
   b. Can demonstrate extent of local and distant metastasis
   c. Very accurate in revealing lymphadenopathy in mediastinum
   d. Consider CT of abdomen to screen for metastases to adrenal glands and liver

3. **Cytologic examination of sputum**
   a. Diagnoses central tumors (in 80%) but not peripheral lesions
   b. Provides highly variable results with low yield; if negative and clinical suspicion is high, further tests are indicated

4. **Fiberoptic bronchoscopy with endobronchial ultrasound**
   a. Can only be inserted as far as secondary branches of bronchial tree; first choice for diagnosing central visualized tumors but not peripheral lesions
   b. The larger and more central the lesion, the higher the diagnostic yield; for
visible lesions, bronchoscopy is diagnostic in >90% of cases

5. Whole-body positron emission tomography (PET)—provides additional information that primary tumor is malignant, detects lymph node and intrathoracic and distant metastases

6. Transthoracic needle biopsy (under fluoroscopic or CT guidance)
   a. Needle biopsy of suspicious pulmonary masses is highly accurate, and is useful for diagnosing peripheral lesions as well
   b. Needle biopsy is invasive and must be used only in selected patients. This is a better biopsy method for peripheral lesions, whereas central, peribronchial lesions should be biopsied using bronchoscopy

7. Mediastinoscopy
   a. Allows direct visualization of the superior mediastinum
   b. Identifies patients with advanced disease who would not benefit from surgical resection

**Quick HIT**

- CXR may show pleural effusion, which should be tapped; the fluid should be examined for malignant cells.
- Regardless of the findings on CXR or CT scan, pathologic confirmation is required for definitive diagnosis of lung cancer.

**Quick HIT**

Always perform a biopsy for intrathoracic lymphadenopathy (specificity for metastasis is 60%).

**D. Treatment**

1. NSCLC
   a. Surgery is the best option for limited disease.
      - A definitive pathologic diagnosis must be made prior to surgery.
      - Patients with metastatic disease outside the chest are not candidates for surgery.
      - Recurrence may occur even after complete resection.
   b. Radiation therapy is an important adjunct to surgery.
   c. Chemotherapy is of uncertain benefit. Some studies show a modest increase in survival especially with novel immunotherapy agents. More trials are underway.

2. SCLC
   a. For limited disease, combination of chemotherapy and radiation therapy is used initially.
   b. For extensive disease, chemotherapy is used alone as initial treatment. If patient
responds to initial chemotherapy treatment, prophylactic whole-brain irradiation decreases incidence of brain metastases and prolongs survival.

c. Surgery has a limited role because these tumors are usually nonresectable.

Quick HIT

The prognosis for lung cancer is grim. **Overall 5-year survival for lung cancer patients is 14%**; 85% of patients with SCLC have extensive disease at the time of presentation, and of these almost all die within 2 years.

Quick HIT

Most asymptomatic masses are benign.
Solitary Pulmonary Nodule

A. A single, well-circumscribed nodule usually discovered incidentally with no associated mediastinal or hilar lymph node involvement. The main question is whether the lesion is malignant and requires biopsy or resection (see Figure 2-5).

B. Has a wide differential diagnosis (e.g., infectious granuloma, bronchogenic carcinoma, hamartoma, bronchial adenoma), but one must investigate the possibility of malignancy because resection can lead to a cure with early detection.

C. Several features favor benign versus malignant nodules:
   1. Age—the older the patient, the more likely it is malignant—over 50% chance of malignancy if patient age is over 60.
   2. Smoking—if history of smoking, more likely to be malignant.
   3. Size of nodule—the larger the nodule, the more likely it is malignant. Small is <1 cm, large >2 cm (>50% chance of malignancy).
   4. Borders—Malignant nodules have more irregular borders. Benign lesions have smooth/discrete borders.
   5. Calcification—Eccentric asymmetric calcification suggests malignancy. Dense, central calcification suggests benign lesion.
   6. Change in size—enlarging nodule suggests malignancy.
FIGURE 2.5 Evaluation of a solitary pulmonary nodule.
(Adapted from Humes DH, DuPont HL, Gardner LB, et al. Kelley’s Textbook of Internal Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:2574, Figure 386.6.)

TABLE 2-4 Types of Lung Cancer
D. Considering the above factors, one designates the nodule as low, intermediate, or high probability of being malignant.

1. Low-probability nodules—serial CT scan
2. Intermediate-probability nodule, 1 cm or larger—PET scan. If PET positive, biopsy
3. High-probability nodule—biopsy (transbronchial, transthoracic, or video-assisted thoracoscopic surgery) followed by lobectomy, if appropriate.

E. Previous CXR is very helpful: Every effort should be made to find a previous CXR for comparison. If the lesion is stable for more than 2 years, it is likely benign. Malignant lesions grow relatively rapidly (growth is usually evident within months) (see Table 2-4). However, growth over a period of days is usually nonmalignant (often infectious/inflammatory) (see Table 2-5).
Mediastinal Masses

A. Causes
1. Metastatic cancer (especially from lung cancer)—most common cause of mediastinal mass in older patients
2. Most common cause according to location:
   a. Anterior mediastinum: “Four Ts”—thyroid, teratogenic tumors, thymoma, terrible lymphoma
   b. Middle mediastinum: lung cancer, lymphoma, aneurysms, cysts, Morgagni hernia
   c. Posterior mediastinum: neurogenic tumors, esophageal masses, enteric cysts, aneurysms, Bochdalek hernia

<table>
<thead>
<tr>
<th>TABLE 2-5 Benign Versus Malignant Solitary Pulmonary Nodules</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Factors That Favor a Benign Diagnosis</strong></td>
</tr>
<tr>
<td>Age &lt; 50 yrs</td>
</tr>
<tr>
<td>Nonsmoker</td>
</tr>
<tr>
<td>Size of nodule &lt; 2 cm</td>
</tr>
<tr>
<td>No growth over 2-yr period</td>
</tr>
<tr>
<td>Nodule circular and regular shaped</td>
</tr>
<tr>
<td>Central, laminated calcification</td>
</tr>
</tbody>
</table>

B. Clinical Features
1. Usually asymptomatic
   a. When symptoms are present, they are due to compression or invasion of adjacent structures
   b. Cough (compression of trachea or bronchi), sometimes hemoptysis
   c. Chest pain, dyspnea
   d. Postobstructive pneumonia
   e. Dysphagia (compression of esophagus)
   f. SVC syndrome
   g. Compression of nerves
      • Hoarseness (recurrent laryngeal nerve)
      • Horner syndrome (sympathetic ganglia)
      • Diaphragm paralysis (phrenic nerve)
If CT scan suggests a benign mass and the patient is asymptomatic, observation is appropriate.

C. Diagnosis
1. Chest CT with IV contrast is test of choice
2. Usually discovered incidentally on a CXR performed for another reason
Diseases of the Pleura

Pleural Effusion

A. General Characteristics

1. Caused by one of the following mechanisms: increased drainage of fluid into pleural space, increased production of fluid by cells in the pleural space, or decreased drainage of fluid from the pleural space (see Figure 2-6)

2. Transudative effusions—pathophysiology is due to either elevated capillary pressure in visceral or parenteral pleura (e.g., CHF), or decreased plasma oncotic pressure (e.g., hypoalbuminemia)

3. Exudative effusions

   a. Pathophysiology: caused by increased permeability of pleural surfaces or decreased lymphatic flow from pleural surface because of damage to pleural membranes or vasculature (see Clinical Pearl 2-4).

   b. If an exudative effusion is suspected, perform the following tests on the pleural fluid: differential cell count, total protein, LDH, glucose, pH, amylase, triglycerides, microbiology, and cytology.

   c. Exudative effusions meet at least one of the following of Light’s criteria (transudates have none of these):

      - Protein (pleural)/protein (serum) >0.5
      - LDH (pleural)/LDH (serum) >0.6
      - LDH >two-thirds the upper limit of normal serum LDH

Quick HIT

If the patient has minimal lung compromise, pleural effusions are well tolerated, whereas pleural effusion in the presence of lung disease may lead to respiratory failure.
FIGURE 2.6 A: Upright chest radiograph showing blunting of the right costophrenic angle, typical of a small right pleural effusion (this patient had chronic liver disease). B: Chest radiograph showing left pleural effusion.

(From Stern EJ, White CS. Chest Radiology Companion. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:375, Figure 22-1A; 376, Figure 22-2A.)

CLINICAL PEARL 2-4

Causes of Transudative and Exudative Pleural Effusions

**Transudative**
- CHF
- Cirrhosis
- PE
- Nephrotic syndrome
- Peritoneal dialysis
- Hypoalbuminemia
- Atelectasis

**Exudative**
- Bacterial pneumonia, TB
- Malignancy, metastatic disease
- Viral infection
- PE
- Collagen vascular diseases

**B. Causes**
1. CHF is the most common cause
2. Pneumonia (bacterial)
3. Malignancies: lung (36%), breast (25%), lymphoma (10%)
4. Pulmonary embolism (PE)
5. Viral diseases
6. Cirrhosis with ascites (also known as hepatic hydrothorax)

**Quick HIT**

**Pleural Fluid Pearls**
- Elevated pleural fluid amylase: esophageal rupture, pancreatitis, malignancy
- Milky, opalescent fluid: **chylothorax** (lymph in the pleural space)
- Frankly purulent fluid: **empyema** (pus in the pleural space)
- Bloody effusion: malignancy
- Exudative effusions that are primarily lymphocytic: TB
- pH < 7.2: **parapneumonic effusion** or empyema

**Quick HIT**

If pleural fluid glucose level is < 60, consider rheumatoid arthritis. However, glucose in pleural fluid can be low with other causes of pleural effusion: empyema, TB, esophageal rupture, malignancy, lupus.

**C. Clinical Features**

1. Symptoms
   a. Often asymptomatic
   b. Dyspnea on exertion
   c. Peripheral edema
   d. Orthopnea, paroxysmal nocturnal dyspnea
2. Signs
   a. Dullness to percussion
   b. Decreased breath sounds over the effusion
   c. Decreased tactile fremitus

**D. Diagnosis**

Can confirm presence/evaluate size of effusion by the following:

1. **CXR (PA and lateral)**—look for the following:
   a. Blunting of costophrenic angle
   b. About 250 mL of pleural fluid must accumulate before an effusion can be detected.
   c. Lateral decubitus films: more reliable than PA and lateral CXRs for detecting small pleural effusions; can also determine whether fluid is free flowing or loculated
2. CT chest—more reliable than CXR for detecting effusions
3. Thoracentesis
   a. Thoracentesis is indicated for evaluation of all new pleural effusions. It provides a diagnosis in 75% of patients, and even when it is not diagnostic it provides important clinical information.
   b. Therapeutic—drainage provides relief for large effusions.
   c. Pneumothorax is a complication seen in 10% to 15% of thoracenteses, but it requires treatment with a chest tube in <5% of cases. Do not perform thoracentesis if effusion is <10 mm thick on lateral decubitus CXR.

E. Treatment
1. Transudative effusions
   a. Diuretics and sodium restriction
   b. Therapeutic thoracentesis—only if massive effusion is causing dyspnea
2. Exudative effusions: treat underlying disease
3. Parapneumonic effusions (pleural effusion in presence of pneumonia)
   a. Uncomplicated effusions: antibiotics alone (in most cases)
   b. Complicated effusions or empyema
      • Chest tube drainage
      • Intrapleural injection of fibrinolytic agents (streptokinase, urokinase, or tissue plasminogen activator [tPA]); may accelerate the drainage
      • Surgical lysis of adhesions may be required
Empyema

A. Causes
1. Exudative pleural effusions, if left untreated, can lead to empyema (pus within the pleural space).
2. Most cases occur as a complication of bacterial pneumonia, but other foci of infection can also spread to the pleural space (e.g., mediastinitis, abscess).

B. Clinical Features
The clinical features are those of the underlying disease (pneumonia most common).

C. Diagnosis
CXR and CT scan of the chest are the recommended tests.

D. Treatment
1. Treat empyema with aggressive drainage of the pleura (via thoracentesis) and antibiotic therapy.
2. The infection is very difficult to eradicate, and recurrence is common, requiring repeated drainage.
3. If empyema is severe and persistent, rib resection and open drainage may be necessary.

Quick HIT
- An uncomplicated parapneumonic effusion is a noninfected pleural effusion secondary to bacterial pneumonia.
- An empyema is a complicated parapneumonic effusion, which means the pleural effusion is infected.
Pneumothorax

A. General Characteristics
1. Defined as air in the normally airless pleural space.
2. There are two major categories: spontaneous and traumatic pneumothoraces.
3. Traumatic pneumothoraces are often iatrogenic.
4. Spontaneous pneumothorax occurs without any trauma.
   a. Primary (simple) pneumothorax
      • Occurs without any underlying lung disease—that is, in “healthy” individuals
      • Caused by spontaneous rupture of subpleural blebs (air-filled sacs on the lung) at the apex of lungs—escape of air from the lung into pleural space causes lung to collapse
      • More common in tall, lean young men
      • These patients have sufficient pulmonary reserve, so severe respiratory distress does not occur in most cases.
      • Recurrence rate is 50% in 2 years
   b. Secondary (complicated) pneumothorax
      • Occurs as a complication of underlying lung disease, most commonly COPD; other underlying conditions include asthma, interstitial lung disease (ILD), neoplasms, CF, and tuberculosis (TB)
      • Is more life threatening because of lack of pulmonary reserve in these patients

Quick HIT
Spontaneous pneumothorax has a high recurrence rate—50% in 2 years.

B. Clinical Features
1. Symptoms
   a. Ipsilateral chest pain, usually sudden in onset
   b. Dyspnea
   c. Cough
2. Physical signs
   a. Decreased breath sounds over the affected side
   b. Hyperresonance over the chest
   c. Decreased or absent tactile fremitus on the affected side
   d. Mediastinal shift toward the side of the pneumothorax

C. Diagnosis
CXR confirms the diagnosis—shows the visceral pleural line (see Figure 2-7)
D. Treatment

1. Primary spontaneous pneumothorax
   a. If small and patient is asymptomatic:
      • Observation—should resolve spontaneously in approximately 10 days
      • Small chest tube (with one-way valve) may benefit some patients.
   b. If pneumothorax is larger and/or patient is symptomatic:
      • Administration of supplemental oxygen, which helps with resorption of pleural air
      • Needle aspiration or chest tube insertion to allow air to be released and lung to reexpand

2. Secondary spontaneous pneumothorax—chest tube drainage
Tension Pneumothorax

A. General Characteristics
1. Accumulation of air within the pleural space such that tissues surrounding the opening into the pleural cavity act as valves, allowing air to enter but not to escape.
2. The accumulation of air under (positive) pressure in the pleural space collapses the ipsilateral lung and shifts the mediastinum away from the side of the pneumothorax.

B. Causes
1. Mechanical ventilation with associated barotrauma
2. Cardiopulmonary resuscitation
3. Trauma

C. Clinical Features
1. Hypotension—cardiac filling is impaired due to compression of the great veins
2. Distended neck veins
3. Shift of trachea away from the side of the pneumothorax on CXR (see Figure 2-8)
4. Decreased breath sounds on the affected side
5. Hyperresonance to percussion on the side of the pneumothorax

D. Treatment
1. Must be treated as a medical emergency—If the tension in the pleural space is not relieved, the patient is likely to die of hemodynamic compromise (inadequate cardiac output or hypoxemia).
2. Immediately perform chest decompression with a large-bore needle (in the second or third intercostal space in the midclavicular line), followed immediately by chest tube placement.

Quick HIT
Do not obtain CXR if a tension pneumothorax is suspected. Immediately decompress the pleural space via large-bore needle or chest tube!
**FIGURE 2.7**

A: Right pneumothorax seen in a patient on a ventilator, with *black arrows* indicating mediastinal shift. B: Chest radiograph showing a right pneumothorax (*black arrows*) that occurred as a complication of placement of a central line. These small pneumothoraces are often difficult to detect. C: Large left pneumothorax (*white arrows*).

Not all mesotheliomas are malignant. Benign mesotheliomas have an excellent prognosis (and are unrelated to asbestos exposure).
FIGURE 2.8  
A: Example of a right tension pneumothorax. Note that the mediastinum is displaced to the left. B: Left tension pneumothorax. C: Left tension pneumothorax (white arrows) with mediastinal shift (black arrows).

(A from Erkonen WE, Smith WL. Radiology 101: The Basics and Fundamentals of Imaging. Philadelphia, PA: Lippincott Williams & Wilkins; 1998:100, Figure 6-41C.) (B from Mergo PJ.)
Imaging of the Chest—A Teaching File. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:258, Figure 145.) (C from Topol EJ. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1050, Figure 47.2.)
### Malignant Mesothelioma

Most cases are secondary to asbestos exposure. Dyspnea, weight loss, and cough are common findings. Bloody effusion is common. Prognosis is dismal (few months’ survival).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>If ILD is suspected, ask about the following:</td>
</tr>
<tr>
<td>- Medication history, because some drugs are known to be toxic to lungs (chemotherapeutic agents, gold, amiodarone, penicillamine, and nitrofurantoin)</td>
</tr>
<tr>
<td>- Previous jobs, because occupational exposure is a cause of ILD (asbestos, silicone, beryllium, coal)</td>
</tr>
<tr>
<td>- Past medical history, as many conditions are associated with ILD (connective tissue disease, inflammatory bowel disease, allergic rhinitis/asthma, or malignancy)</td>
</tr>
</tbody>
</table>
Interstitial Lung Disease

Overview

A. General Characteristics
1. ILD is defined as an inflammatory process involving the alveolar wall (resulting in widespread fibroelastic proliferation and collagen deposition) that can lead to irreversible fibrosis, distortion of lung architecture, and impaired gas exchange.
2. The prognosis is highly variable and depends on the diagnosis.
3. Patients with environmental or occupational lung disease, especially those with asbestosis, are frequently involved in lawsuits against their employers.

B. Classification
1. Classified based on pathologic and clinical characteristics
2. Environmental lung disease
   a. Coal worker’s pneumoconiosis
   b. Silicosis
   c. Asbestosis
   d. Berylliosis
3. ILD associated with granulomas
   a. Sarcoidosis—other organs in addition to the lungs are involved
   b. Langerhans cell histiocytosis
   c. Granulomatosis with polyangiitis (GPA, previously known as Wegener granulomatosis)
   d. Eosinophilic granulomatosis with polyangiitis (EGPA, previously known as Churg–Strauss syndrome)
4. Alveolar filling disease
   a. Goodpasture disease (anti-GBM antibody disease)
   b. Idiopathic pulmonary hemosiderosis
   c. Alveolar proteinosis
5. Hypersensitivity lung disease
   a. Hypersensitivity pneumonitis
   b. Eosinophilic pneumonia
6. Drug-induced—amiodarone, nitrofurantoin, bleomycin, phenytoin, illicit drugs
7. Miscellaneous
   a. Idiopathic pulmonary fibrosis
   b. Cryptogenic organizing pneumonia (COP)
c. ILD associated with connective tissue disorders: rheumatoid arthritis, scleroderma, systemic lupus erythematosus, mixed connective tissue disease

d. Radiation pneumonitis

Quick HIT

Over 100 causes of ILD have been identified.
- In general, the clinical findings and imaging study results are nonspecific and do not point to a definitive diagnosis. Often one is confronted with the question of whether to obtain a tissue biopsy.

C. Clinical Features

1. Symptoms
   a. Dyspnea (at first with exertion; later at rest)
   b. Cough (nonproductive)
   c. Fatigue
   d. Other symptoms may be present secondary to another condition (such as a connective tissue disorder)

2. Signs
   a. Dry “velcro-like” rales at the bases are common
   b. Digital clubbing is common (especially with idiopathic pulmonary fibrosis) (see Figure 2-9 and Clinical Pearl 2-5)
   c. Signs of pulmonary HTN and cyanosis in advanced disease

D. Diagnosis

1. CXR (see Figure 2-10)
   a. Findings are usually nonspecific.
   b. Typical diffuse changes are noted (reticular, reticulonodular, ground glass, honeycombing).
2. High-resolution CT scan shows the extent of fibrosis better than other imaging modalities.
3. PFTs
   a. A restrictive pattern is noted: FEV$_1$/FVC ratio is normal or increased. All lung volumes are low. Both FEV$_1$ and FVC are reduced, but the ratio is often preserved.
   b. Low diffusing capacity (DL$_{CO}$).
4. Oxygen desaturation during exercise.
5. Bronchoalveolar lavage (fluid for culture and cytology)—use is controversial because results are quite variable.
6. Tissue biopsy.
   a. This is often required in patients with ILD, though high-resolution CT can often be used to make the diagnosis without the need for biopsy.
   b. This can be done via fiberoptic bronchoscopy with transbronchial biopsy (a limited amount of tissue can be obtained, which limits its utility), open lung
biopsy, or video-assisted thoracoscopic lung biopsy.

7. Urinalysis, if there are signs of glomerular injury (for Goodpasture syndrome and GPA)

Quick HIT

“Honeycomb lung” refers to a scarred shrunken lung and is an end-stage finding with poor prognosis. Air spaces are dilated, and there are fibrous scars in the interstitium. It can arise from many different types of ILD.
Interstitial Lung Diseases Associated With Granulomas

A. Sarcoidosis

1. General characteristics
   a. A chronic systemic granulomatous disease characterized by noncaseating granulomas, often involving multiple organ systems. Lungs are almost always involved. Etiology unknown.
   b. Occurs most often in the African American population, especially women.
   c. Seventy-five percentage of cases occur when the individual is <40 years of age.
   d. Sarcoidosis carries a good prognosis in majority of patients.

CLINICAL PEARL 2-5

Clubbing of the Fingers
- Increased convexity of the nail—the distal phalanx is enlarged due to an increase in soft tissue.
- If a patient has clubbing, get a CXR because lung disease may be present.
- Chronic hypoxia is the underlying cause in most cases.
- Differential diagnoses vary and include pulmonary diseases (lung cancer, CF, ILD, empyema, sarcoidosis, and mesothelioma), congenital heart disease, bacterial endocarditis, biliary cirrhosis, inflammatory bowel disease, and primary biliary cirrhosis.
- Digital clubbing may be an idiopathic or primary finding, such as in familial clubbing or hypertrophic osteoarthropathy.
2. Clinical features
   a. Constitutional symptoms
      - Malaise, fever, anorexia, weight loss
      - Symptoms vary in severity and may be absent in many patients.
   b. Lungs: dry cough, dyspnea (especially with exercise), chest pain
   c. Skin (25% of cases)
      - Erythema nodosum
      - Plaques, subcutaneous nodules, maculopapular eruptions
   d. Eyes (25% of cases)—may result in significant visual impairment
Anterior uveitis (75%)
Posterior uveitis (25%)
Conjunctivitis
e. Heart (5% of cases)
   • Arrhythmias
   • Conduction disturbances, such as heart block
   • Sudden death
f. Musculoskeletal system (25% to 50%)
   • Arthralgias and arthritis
   • Bone lesions
g. Nervous system (5%)
   • Cranial nerve VII involvement (Bell palsy)
   • Optic nerve dysfunction
   • Papilledema
   • Peripheral neuropathy

Quick HIT
- Up to two-thirds of patients with sarcoidosis experience resolution/improvement of symptoms over several years.
- Approximately 20% of patients develop chronic disease.
- From 10% to 20% of patients are asymptomatic but have CXR findings.

Quick HIT
Cardiac disease is the most common cause of death, although it is not a common finding.

3. Diagnosis
   a. Diagnosis is based on clinical, radiographic, and histologic findings.
   b. CXR—Bilateral hilar adenopathy is the hallmark of this disease but is not specific; it is seen in 50% of cases (see Figure 2-11). Four stages have been described based on CXR findings (see below).
   c. Skin anergy with tuberculin skin test—typical finding but not diagnostic
d. **Angiotensin-converting enzyme (ACE)** is elevated in serum in about 50% to 80% of patients. This test helps support the diagnosis. However, other pulmonary diseases may cause an elevation in this enzyme (lacks sensitivity and specificity).

e. Hypercalciuria and hypercalcemia are common.

f. Definitive diagnosis requires transbronchial biopsy:
   - Must see **noncaseating granulomas**
   - By itself is not diagnostic because noncaseating granulomas are found in other diseases
   - Must be used in the context of clinical presentation
g. PFTs: decreased lung volumes (VC and TLC), decreased DLCO (diffusing capacity for carbon monoxide), decreased or normal FEV₁/FVC ratio

Quick HIT

Typical presentation of sarcoidosis: young patient with constitutional symptoms, respiratory complaints, erythema nodosum, blurred vision, and bilateral hilar adenopathy.

4. Staging of sarcoidosis (on CXR)
   a. Stage I: bilateral hilar adenopathy without parenchymal infiltrates (highest rate of remission)
   b. Stage II: hilar adenopathy with parenchymal infiltrates
   c. Stage III: diffuse parenchymal infiltrates without hilar adenopathy (least favorable prognosis)
   d. Stage IV: pulmonary fibrosis with honeycombing and fibrocystic parenchymal changes

5. Treatment
   a. Most cases resolve or significantly improve spontaneously in 2 years and do not require treatment.
   b. **Systemic corticosteroids are the treatment of choice.** The indications for treatment are unclear. However, patients who are symptomatic or have active lung disease, pulmonary function deterioration, conduction disturbances, or severe skin or eye involvement should be treated.
   c. Methotrexate or other immunosuppressive agents can be used in patients with progressive disease refractory to corticosteroids.

B. Pulmonary Langerhans Cell Histiocytosis
   1. Chronic interstitial pneumonia caused by abnormal proliferation of histiocytes (related to Langerhans cells of the skin).
   2. Most patients (90%) are cigarette smokers.
   3. Variants of disease include eosinophilic granuloma (localized to bone or lung), and two systemic forms—Letterer–Siwe disease and Hand–Schüller–Christian syndrome.
   4. Common findings include dyspnea and nonproductive cough.
   5. Other possible manifestations are spontaneous pneumothorax, lytic bone lesions, and diabetes insipidus.
   6. CXR has a honeycomb appearance, and CT scan shows cystic lesions.
   7. The prognosis and course are highly variable. Corticosteroids are sometimes effective. Lung transplantation may be necessary.

C. Granulomatosis With Polyangiitis (Previously Wegener Granulomatosis)
1. Rare disease with unknown etiology.
2. Characterized by necrotizing granulomatous vasculitis.
3. Affects vessels of lungs, kidneys, upper airway, skin, and sometimes other organs.
4. Manifestations of the disease include upper and lower respiratory infections, glomerulonephritis, and pulmonary nodules.
5. The gold standard for diagnosis is tissue biopsy, but if the patient tests positive for c-antineutrophil cytoplasmic antibodies, the likelihood of having this condition is high.
6. Treatment usually includes immunosuppressive agents and glucocorticoids.

D. Eosinophilic Granulomatosis With Polyangiitis (Previously Churg–Strauss Syndrome)
1. Granulomatous vasculitis is seen in patients with asthma.
2. Typically presents with pulmonary infiltrates, rash, and eosinophilia.
3. Systemic vasculitis may result in skin, muscle, and nerve lesions.
4. Diagnosis: Based on clinical findings in association with significant eosinophilia.
5. Associated with perinuclear antineutrophil cytoplasmic antibody.
6. Treat with systemic glucocorticoids.

**Quick HIT**

Antineutrophil cytoplasmic antibodies (ANCA) and associated ILD: c-ANCA: GPA or Wegener granulomatosis; p-ANCA EGPA or Churg–Strauss syndrome; may also be positive in anti-GBM antibody or Goodpasture disease
Environmental Lung Disease/Pneumoconiosis

A. Coal Worker’s Pneumoconiosis
1. Most have simple coal worker’s pneumoconiosis, which usually causes no significant respiratory disability.
2. Some patients may develop complicated pneumoconiosis, which is characterized by fibrosis (restrictive lung disease).
3. Causes: inhalation of coal dust, which contains carbon and silica.

Quick HIT
- Pneumoconiosis is defined as the accumulation of dust in the lungs, and the tissue reaction to its presence.
- Dusts that have been implicated: silica, beryllium, asbestos, coal dust, graphite, carbon black, aluminum, talc.

B. Asbestosis
1. Characterized by diffuse interstitial fibrosis of the lung caused by inhalation of asbestos fibers; predilection for lower lobes.
2. Develops insidiously many years (>15 to 20 years) after exposure.
3. Increased risk of bronchogenic carcinoma (smoking is synergistic) and malignant mesothelioma.
4. Symptoms and physical findings are nonspecific (see above under ILD).
5. Diagnosis made based on clinical findings and history of exposure to asbestos.
6. CXR shows hazy infiltrates with bilateral linear opacities and may show pleural plaques (especially in lower lung regions).
7. No specific treatment is available.

Quick HIT
- Classic CXR findings in environmental lung disease:
  - Asbestosis: pleural plaques
  - Silicosis: “eggshell” calcifications

C. Silicosis
1. Localized and nodular peribronchial fibrosis (upper lobes more common).
2. Can be acute (massive exposure leading to rapid onset and death), or chronic (symptoms years after exposure—up to 15 years or longer).
3. Associated with an increased risk of TB.
4. Sources include mining, stone cutting, and glass manufacturing.
5. Exertional dyspnea is the main symptom; cough with sputum is also seen.
6. There are restrictive pulmonary function abnormalities.
7. Treatment is supportive and involves removal from exposure to silica.
D. Berylliosis

1. Like silicosis, berylliosis has acute and chronic forms.
2. Acute disease is a diffuse pneumonitis caused by massive exposure to beryllium.
3. Chronic disease is very similar to sarcoidosis: granulomas, skin lesions, and hypercalcemia may be present.
4. The beryllium lymphocyte proliferation test is a useful diagnostic blood test.
5. Give glucocorticoid therapy for both acute and chronic berylliosis.
Interstitial Lung Disease Associated With Hypersensitivity

A. Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis)
1. Inhalation of an antigenic agent to the alveolar level induces an immune-mediated pneumonitis. Chronic exposure may lead to restrictive lung disease.
2. A variety of organic dusts and chemicals have been implicated.
3. The presence of serum IgG and IgA in the inhaled antigen is a hallmark finding, although many may have these antibodies without developing disease.
4. The acute form has flu-like features (e.g., fever, chills, cough, dyspnea). CXR during the acute phase shows pulmonary infiltrates.
5. The chronic form is more insidious and more difficult to diagnose.
6. Treatment involves removal of the offending agent and sometimes glucocorticoids.

Quick HIT

Some causes of hypersensitivity pneumonitis:
- Farmer's lung (moldy hay)
- Bird-breeder’s lung (avian droppings)
- Air-conditioner lung
- Bagassosis (moldy sugar cane)
- Mushroom worker’s lung (compost)

B. Eosinophilic Pneumonia
1. Fever and peripheral eosinophilia are features.
2. Eosinophilic pneumonia may be acute or chronic.
3. CXR shows peripheral pulmonary infiltrates.
4. Treatment with glucocorticoids is usually very effective, but relapses may occur.
C. Note that there is significant overlap between this category and the ILD associated with granuloma (e.g., EGPA or Churg–Strauss syndrome).
**Alveolar Filling Disease**

A. Anti-GBM Antibody or Goodpasture Disease  
1. Autoimmune disease caused by IgG antibodies directed against glomerular and alveolar basement membranes (type II hypersensitivity reaction).  
2. Results in hemorrhagic pneumonitis and glomerulonephritis.  
3. Ultimately, renal failure is a complication of proliferative glomerulonephritis.  
4. Usually presents with hemoptysis and dyspnea.  
5. Diagnosis made by tissue biopsy, serologic evidence of antiglomerular basement membrane antibodies.  
6. Prognosis is poor; treat with plasmapheresis, cyclophosphamide, and corticosteroids.

B. Pulmonary Alveolar Proteinosis  
1. Rare condition caused by accumulation of surfactant-like protein and phospholipids in the alveoli.  
2. Usually presents with dry cough, dyspnea, hypoxia, and rales.  
3. **CXR typically has a ground-glass appearance with bilateral alveolar infiltrates that resemble a bat wing shape.**  
4. Lung biopsy is required for definitive diagnosis.  
5. Treatment is with lung lavage and granulocyte colony-stimulating factor.  
6. Patients are at increased risk of infection, and corticosteroids should not be given.
Miscellaneous Interstitial Lung Diseases

A. Idiopathic Pulmonary Fibrosis
1. **General characteristics**
   a. Etiology unknown; more common in men and smokers.
   b. Presents with gradual onset of progressive dyspnea, nonproductive cough.
   c. This is a devastating and unrelenting disease. Although the prognosis is variable, the mean survival is only 3 to 7 years after first diagnosis.

2. **Diagnosis**
   a. CXR: ground-glass or a honeycombed appearance; may be normal.
   b. High-resolution CT of chest: bibasilar reticular opacities, honeycombing, and traction bronchiectasis.
   c. Definitive diagnosis requires open lung biopsy consistent with usual interstitial pneumonia.
   d. Other causes of ILD must be excluded.

3. **Treatment.** Options are limited. The majority of patients (>70%) do not improve with therapy and experience progressive and gradual respiratory failure. The following can benefit some patients:
   a. Supplemental oxygen.
   b. New anti-fibrotic agents such as nintedanib or pirfenidone have been shown in trials to slow progression of mild and moderate disease.
   c. Corticosteroids have been used historically but with little or no benefit and have significant side effects.
   d. Lung transplantation.

B. Cryptogenic Organizing Pneumonitis (COP)
1. An inflammatory lung disease with similar clinical and radiographic features to infectious pneumonia.
2. Associated with many entities (viral infections, medications, connective tissue disease). Most cases are idiopathic.
3. Features: cough, dyspnea, and flu-like symptoms; bilateral patchy infiltrates on CXR.
4. Antibiotics have not been found to be effective.
5. Spontaneous recovery may occur, but corticosteroids are used most commonly (>60% of patients recover).
6. Relapse may occur after cessation of steroids (requiring resumption of steroids).

C. Radiation Pneumonitis
1. Interstitial pulmonary inflammation—occurs in 5% to 15% of patients who
undergo thoracic irradiation for lung cancer, breast cancer, lymphoma, or thymoma. Mortality and morbidity are related to the irradiated lung volume, dose, patient status, and concurrent chemotherapy.

2. Acute form occurs 1 to 6 months after irradiation; chronic form develops 1 to 2 years later—characterized by alveolar thickening and pulmonary fibrosis.

3. Features: low-grade fever, cough, chest fullness, dyspnea, pleuritic chest pain, hemoptysis, acute respiratory distress.

4. CXR is usually normal.

5. CT scan is the best study: diffuse infiltrates (hallmark) with straight-line effect conforming to area of radiation, ground-glass density, patchy/homogeneous consolidation, pleural/pericardial pleural effusions. It is excellent for detecting recurrent cancer in irradiated area.

6. The treatment of choice is corticosteroids for symptomatic patients. Prophylactic treatment is not useful in humans (useful only in mice).

Quick HIT

- Severe hypoxemia can result in irreversible damage to organs (CNS and cardiovascular systems most affected) and must be corrected rapidly.
- Severe hypercapnia (and respiratory acidosis) can lead to dyspnea and vasodilation of cerebral vessels (with increased intracranial pressure and subsequent papilledema, headache, impaired consciousness, and finally coma).
Respiratory Failure

Acute Respiratory Failure

A. General Characteristics

1. Acute respiratory failure results when there is inadequate oxygenation of blood or inadequate ventilation (elimination of CO\textsubscript{2}) or both (see Clinical Pearls 2-6 and 2-7). The following are general criteria used to define acute respiratory failure:
   a. Hypoxia (PaO\textsubscript{2} <60 mm Hg)
   b. Hypercapnia (partial pressure of CO\textsubscript{2} [PCO\textsubscript{2}] >50 mm Hg)

2. The following structures or systems are essential components for maintaining normal respiration. Dysfunction or interruption of any component (causes are listed) can potentially lead to respiratory failure.
   a. CNS (brain and spinal cord) depression or insult—drug overdose, stroke, trauma
   b. Neuromuscular disease—myasthenia gravis, polio, Guillain–Barré syndrome, amyotrophic lateral sclerosis

CLINICAL PEARL 2-6

Hypoxemia Pearls

a. To determine the underlying mechanism of hypoxemia, three pieces of information are needed:
   - PaCO\textsubscript{2} level
   - A–a gradient
   - Response to supplemental oxygen

b. A–a gradient is normal, if hypoventilation or low inspired PO\textsubscript{2} is the only mechanism.

c. If V/Q mismatch or shunting is present, then both PaCO\textsubscript{2} and A–a gradient are elevated; response to supplemental O\textsubscript{2} differentiates between the two mechanisms.

c. Upper airway—obstruction due to a number of causes, including stenoses, spasms, or paralysis

d. Thorax and pleura—mechanical restriction due to kyphoscoliosis, flail chest, hemothorax

e. Cardiovascular system and blood—CHF, valvular diseases, PE, anemia

f. Lower airways and alveoli—asthma, COPD, pneumonia, acute respiratory distress syndrome (ARDS)

3. Classification—acute respiratory failure can be divided into two major types (overlap often exists)
   a. Hypoxemic respiratory failure.
• Low PaO₂ with a PaCO₂ that is either low or normal—present when O₂ saturation is <90% despite FiO₂ >0.6.
• Causes include disease processes that involve the lung itself (e.g., ARDS, severe pneumonia, pulmonary edema).
• Ventilation/perfusion (V/Q) mismatch and intrapulmonary shunting are the major pathophysiologic mechanisms.

b. Hypercapnic (hypercarbic) respiratory failure—a failure of alveolar ventilation.
• Either a decrease in minute ventilation or an increase in physiologic dead space leads to CO₂ retention and eventually results in hypoxemia.
• May be caused by an underlying lung disease (COPD, asthma, CF, severe bronchitis)
• May also occur in patients with no underlying lung disease who have impaired ventilation due to neuromuscular diseases, CNS depression, mechanical restriction of lung inflation, or any cause of respiratory fatigue (e.g., prolonged hyperventilation in diabetic ketoacidosis [DKA])

4. Pathophysiology
a. V/Q mismatch
• Caused by a defect in either alveolar ventilation (e.g., pulmonary edema) or perfusion (e.g., PE)
• Typically leads to hypoxia without hypercapnia (in fact, PaCO₂ levels are often low or normal)
• Most common mechanism of hypoxemia (especially in chronic lung disorders)
• Responsive to supplemental oxygen

**CLINICAL PEARL 2-7**

**Ventilation Versus Oxygenation**
- Ventilation is monitored by PaCO₂: To ↓ PaCO₂, one must either ↑ respiratory rate (RR) or ↑ tidal volume (Vₜ). Note that minute ventilation = RR × Vₜ.
- Oxygenation is monitored by O₂ saturation and PaO₂: To ↓ PaO₂ in the ventilated patient, one must either ↓ FiO₂ or ↓ PEEP.

Note that ventilation and oxygenation are unrelated. O₂ saturation may be 100% with a very high PaCO₂, and the patient can be in ventilatory failure!

b. Shunting
• Little or no ventilation in perfused areas (due to collapsed or fluid-filled alveoli); venous blood is shunted into the arterial circulation without being oxygenated; represents one end of the spectrum in V/Q mismatch.
• Causes of shunts: atelectasis or fluid buildup in alveoli (pneumonia or
pulmonary edema), direct right-to-left intracardiac blood flow in congenital heart diseases.

- **Hypoxia due to a shunt is not responsive to supplemental oxygen.**

  c. Hypoventilation—leads to hypercapnia, with secondary hypoxemia.
  
  d. Increased CO₂ production (e.g., sepsis, DKA, hyperthermia) results in hypercapnic respiratory failure.
  
  e. Diffusion impairment (e.g., ILD) causes hypoxemia without hypercapnia.

**B. Clinical Features**

1. Symptoms
   
   a. Dyspnea—first symptom
   
   b. Cough may or may not be present, depending on the underlying cause.

2. Signs—the following might be present:
   
   a. Inability to speak in complete sentences, use of accessory muscles of respiration
   
   b. Tachypnea, tachycardia
   
   c. Cyanosis
   
   d. Impaired mentation (due to fatigue or hypercapnia, or if cause of respiratory failure is CNS depression)

**C. Diagnosis**

1. ABG analysis—may confirm diagnosis and help severity of condition; should be obtained in most cases of respiratory failure (see Figure 2-12)
   
   a. Hypoxemia: Mechanisms include V/Q mismatch, intrapulmonary shunting, or hypoventilation.
   
   b. Hypercapnia: caused by hypoventilation (secondary to a variety of causes).
   
   c. Arterial pH: Respiratory acidosis occurs when hypercapnia is present. However, if the respiratory failure is chronic, renal compensation occurs and the acidosis is less severe.

2. CXR or CT scan of the chest.

3. CBC and metabolic panel.

4. If cardiogenic pulmonary edema is suspected, consider cardiac enzymes.

**Quick HIT**

The alveolar–arterial oxygen difference (A–a gradient) is normal when hypoventilation is the cause of hypoxemia. It is increased in most other causes.

**D. Treatment**

1. Treat underlying disorder (e.g., with bronchodilators, corticosteroids, antibiotics, depending on the cause).
2. Provide supplemental oxygen if patient is hypoxemic (see Table 2-6 and Clinical Pearl 2-8).

   a. Hypoxemic respiratory failure: Use the **lowest concentration of oxygen** that provides sufficient oxygenation to avoid oxygen toxicity, which is due to free-
radical production.

b. Hypercapnic respiratory failure: Results from hypoventilation. In COPD patients, excessive administration of oxygen results in V/Q mismatch, the Haldane effect, and loss of the hypoxemic respiratory drive.

3. Apply NPPV (e.g., CPAP, BiPAP) only for conscious patients with possible impending respiratory failure (see Clinical Pearl 2-9). **If the patient cannot breathe on his or her own, intubate!**

4. Intubation and mechanical ventilation may be needed in both types of respiratory failure.

**Quick HIT**

Do not ignore hypoxia in a patient with hypercarbic respiratory failure!
Acute Respiratory Distress Syndrome

A. General Characteristics

1. ARDS is a diffuse inflammatory process (not necessarily infectious) involving both lungs—neutrophil activation (due to a variety of causes) in the systemic or pulmonary circulations is the primary mechanism (see Clinical Pearl 2-10).

2. ARDS is not a primary disease, but rather a disorder that arises due to other conditions that cause a widespread inflammatory process.

CLINICAL PEARL 2-8

Techniques to Improve Tissue Oxygenation

- Increase FiO₂
- Increase PEEP
- Extend inspiratory time fraction
- Decubitus, upright, or prone positioning bronchodilation
- Improve oxygen delivery: increase cardiac output or increase hemoglobin
- Decrease oxygen requirements: decrease work of breathing, fever, agitation
- Remove pulmonary vasodilators (e.g., nitroprusside)


CLINICAL PEARL 2-9

Noninvasive Positive Pressure Ventilation

- NPPV is delivered as either BiPAP or CPAP. BiPAP can be set at separate inspiratory and expiratory pressures (the inspiratory pressure is higher than the expiratory).
- Both can be given via nasal mask or full-face mask.
- NPPV is indicated in patients with impending respiratory failure in an attempt to avoid intubation and mechanical ventilation.
- Success rates are highest in patients with hypercapnic respiratory failure (especially COPD patients).
- Note that NPPV should not be used for life support ventilation, only to temporarily support the patient’s own spontaneous breathing.
- To use NPPV, the patient must be neurologically intact, awake and cooperative, and able to protect the airway. If no improvement is seen, BiPAP should be discontinued and conventional endotracheal intubation and mechanical ventilation initiated.

3. 2012 Berlin definition:
   a. Acute onset (<1 week of known clinical insult).
   b. Bilateral infiltrates on chest imaging.
   c. Pulmonary edema not explained by fluid overload or CHF (e.g., no clinical evidence of CHF or pulmonary–capillary wedge pressure [PCWP] <18 mm Hg).
d. Abnormal PaO$_2$/FiO$_2$ ratio.
   - 200 to 300: mild ARDS
   - 100 to 200: moderate ARDS
   - <100: severe ARDS

4. Pathophysiology
   a. Massive intrapulmonary shunting of blood is a key pathophysiologic event in ARDS—severe hypoxemia with **no significant improvement on 100% oxygen (requires high PEEP to prop open airways)**. Shunting is secondary to widespread atelectasis, collapse of alveoli, and surfactant dysfunction.
   - Interstitial edema and alveolar collapse are due to an increase in lung fluid, which leads to stiff lungs, an increase in alveolar–arterial oxygen difference (A–a gradient), and ineffective gas exchange.
   - Note that the effects of the increase in pulmonary fluid are identical to those seen in cardiogenic pulmonary edema, but the cause is different: An increase in alveolar–capillary permeability causes ARDS, whereas congestive hydrostatic forces cause cardiogenic pulmonary edema.

b. Decreased pulmonary compliance—leads to increased work of breathing.

c. Increased dead space—secondary to obstruction and destruction of pulmonary–capillary bed.

d. Low vital capacity, low FRC.

---

**Quick HIT**

Patients with sepsis or septic shock have the highest risk of developing ARDS.

---

**Quick HIT**

ARDS can progress rapidly over several hours. Initially, the dyspnea may be exertional, but it can rapidly advance in severity.

B. Causes

1. Sepsis is the most common risk factor—can be secondary to a variety of infections (e.g., pneumonia, urosepsis, wound infections)
2. Aspiration of gastric contents
3. Severe trauma, fractures (e.g., femur, pelvis), acute pancreatitis, multiple or massive transfusions, near drowning
4. Drug overdose, toxic inhalations
5. Intracranial HTN
6. Cardiopulmonary bypass
Remember the Following When Examining a Patient With ARDS

- Physical findings are usually nonspecific.
- Because the patient is usually intubated and on a ventilator, decreased unilateral breath sounds may be due to the ET being in the right main bronchus or possibly a pneumothorax.
- Look for potential sources of sepsis and check for any signs of infection: acute abdomen, IV lines, wounds, decubitus ulcers, etc.
- Keep in mind that cardiogenic pulmonary edema has to be distinguished from ARDS—look for signs of volume overload, CHF, JVD, edema, and hepatomegaly.

C. Clinical Features

1. Dyspnea, tachypnea, and tachycardia due to increased work of breathing.
2. Progressive hypoxemia—not responsive to supplemental oxygen.
3. Patients are difficult to ventilate because of high peak airway pressures due to stiff, noncompliant lungs.

D. Diagnosis

1. CXR—shows diffuse bilateral pulmonary infiltrates (see Figure 2-13)
   a. There is a variable correlation between findings on CXR and severity of hypoxemia or clinical response. Diuresis improves and volume overload worsens the infiltrates—regardless of CXR findings, the underlying ARDS may or may not be improved.
   b. CXR improvement follows clinical improvement after 1 to 2 weeks or more.
2.13 A: Chest radiograph showing typical findings in ARDS. B: Another example of ARDS. Also note presence of an ET and Swan–Ganz central venous catheter.

(A from Miller WT, Miller WT Jr. *Field Guide to the Chest X-Ray*. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:4, Figure 1.2B.) (B from Daffner RH. *Clinical Radiology: The Essentials*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:175, Figure 4.117A.)

2. ABG
   a. Hypoxemia (PaO$_2$ <60)
   b. Initially, respiratory alkalosis (PaCO$_2$ <40) is present, which gives way to respiratory acidosis as the work of breathing increases and PaCO$_2$ increases.
   c. If the patient is septic, metabolic acidosis may be present, with or without respiratory compensation.

3. Pulmonary artery catheter—enables a determination of PCWP. PCWP reflects left heart filling pressures and is an indirect marker of intravascular volume status.
   a. PCWP is the most useful parameter in differentiating ARDS from cardiogenic pulmonary edema.
   b. If PCWP is low (<18 mm Hg), ARDS is more likely, whereas if PCWP is high (>18 mm Hg), cardiogenic pulmonary edema is more likely.
   c. **However, routine placement of pulmonary artery catheters has not been shown to be beneficial in ARDS or sepsis.**

4. Bronchoscopy with bronchoalveolar lavage
   a. This may be considered if patient is acutely ill and infection is suspected.
   b. Fluid collected can be cultured and analyzed for cell differential, cytology, Gram stain, and silver stain.

**Quick HIT**

2012 Berlin definition for diagnosing ARDS:
- Hypoxemia that is refractory to oxygen therapy: ratio of PaO$_2$/FiO$_2$ 200 to 300 is mild, 100 to 200 is moderate, and <100 is severe
- Bilateral diffuse pulmonary infiltrates on CXR
- No evidence of CHF clinically or PCWP ≤18 mm Hg
- Respiratory symptoms that develop within 1 week of known insult

**E. Treatment**

1. Oxygenation—try to keep O$_2$ saturation >90%.
2. Mechanical ventilation is based on the ARDSNet studies. The most important principles include using a high PEEP with low tidal volumes. Sedation and short-term paralysis may be needed to improve compliance with mechanical ventilation.

3. Fluid management
   a. Volume overload should be avoided. A low–normal intravascular volume is preferred; the goal should be a CVP 4 to 6 cm H₂O. Vasopressors may be needed to maintain BP.
   b. On the other hand, patients with sepsis have high fluid requirements, so determining the appropriate fluid management may be difficult.

4. Treat the underlying cause, for example, infection.

5. Do not forget to address the patient’s nutritional needs. Tube feedings are preferred over parenteral nutrition (see Appendix).

F. Complications
   1. Permanent lung injury—resulting in lung scarring or honeycomb lung
   2. Complications associated with mechanical ventilation
      a. Barotrauma secondary to high-pressure mechanical ventilation, possibly causing a pneumothorax or pneumomediastinum
      b. Nosocomial pneumonia
   3. Line-associated infections: central lines and pulmonary artery catheters (line infection sepsis), urinary catheters (UTI), and nasal tubes (sinus infection)
   4. Renal failure—may be due to nephrotoxic medication, sepsis with hypotension, or underlying disease
   5. Ileus, stress ulcers
   6. Multiorgan failure
   7. Critical illness myopathy and polyneuropathy
**Mechanical Ventilation**

**A. General Characteristics**

1. In treating respiratory failure, mechanical ventilation has two major goals: to maintain alveolar ventilation and to correct hypoxemia.
2. The decision to initiate mechanical ventilation should be a clinical one. Generally, patients with the following require mechanical ventilation:
   a. Significant respiratory distress (e.g., high RR) or respiratory arrest
   b. Impaired or reduced level of consciousness with inability to protect the airway (look for absent gag or cough reflex)
   c. Metabolic acidosis (if the patient is unable to compensate with adequate hyperventilation)
   d. Respiratory muscle fatigue
   e. Significant hypoxemia (PaO₂ < 70 mm Hg) or hypercapnia (PaCO₂ > 50 mm Hg); respiratory acidosis (pH < 7.2) with hypercapnia

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>In general, err on the side of caution when deciding whether to initiate mechanical ventilation. Intubation does not mean the patient will have to remain on the ventilator indefinitely!</td>
</tr>
</tbody>
</table>

3. ABGs are used to assess response to initiation of mechanical ventilation. Acceptable ranges of gas values include a PaO₂ of 50 to 60 with PaCO₂ of 40 to 50, and pH between 7.35 and 7.50.

4. General principles
   a. Initial settings should rest the respiratory muscles.
   b. The goal is to reduce the likelihood of barotraumas (high static airway pressures, overinflation) and atelectasis (low static airway pressures, underinflation).
   c. A volume-cycled ventilator is most commonly used.

**B. Ventilator Settings**

1. Assist control (AC) ventilation
   a. This is the initial mode used in most patients with respiratory failure.
   b. Guarantees a “backup” minute ventilation that has been preset, but the patient can still initiate breaths at a faster rate than the backup rate.
   c. AC and other ventilator modes can be volume targeted or pressure targeted. If volume targeted is selected, the ventilator will give a preset tidal volume for each breath regardless of the pressure required to give that breath (ensures ventilation but could lead to high pressures and barotrauma); if pressure targeted is selected, the ventilator will deliver a fixed inspiratory pressure regardless of
the tidal volume (avoids barotraumas but adequate ventilation may not be achieved).

d. All breaths initiated by the patient are supported by the ventilator (in contrast to intermittent mandatory ventilation).

**Quick HIT**

- Always confirm correct ET placement by listening for bilateral breath sounds **and** checking a post-intubation CXR.
- On CXR, the tip of the ET tube should be approximately 2 to 5 cm above the carina.

2. Synchronous intermittent mandatory ventilation (SIMV)
   a. Patients can breathe on their own above the mandatory rate **without** help from the ventilator (i.e., the tidal volume of these extra breaths is **not** determined by the ventilator, as it is in the assist-control mode).
   b. If no spontaneous breath is initiated by the patient, the predetermined mandatory breath is delivered by the ventilator.
   c. May increase respiratory fatigue and prolonged mechanical ventilation.

3. CPAP
   a. Positive pressure (0 to 20 cm H$_2$O) is delivered continuously (during expiration and inspiration) by the ventilator, but no breaths are delivered (patient breathes on his or her own).

4. Pressure support ventilation (PSV)
   a. Inspiratory pressure is set to support each patient-triggered breath, with a constant PEEP. This is mostly used during weaning trials (**Clinical Pearl 2-11**).

5. Noninvasive mechanical ventilation
   a. CPAP: Positive pressure (0 to 20 cm H$_2$O) is delivered continuously (during expiration and inspiration) by the ventilator, but no breaths are delivered (patient breathes on his or her own).
   b. BiPAP: Similar to PSV but done with a face or nasal mask rather than intubation. Delivers a set inspiratory pressure with a constant PEEP.

**CLINICAL PEARL 2-11**

**Parameters to Consider in Extubation or Weaning From the Ventilator: The More Criteria That Are Met, the More Likely That Extubation Will Be Tolerated**

- Whether patient has an adequate respiratory drive and is hemodynamically stable
- Intact cough (when suctioning secretions)
• PaO₂/FiO₂ >200, PaCO₂ <45
• O₂ saturation of >90%, PEEP of ≤5 cm H₂O, FiO₂ <40%, RR <35 breaths/min, minute ventilation ≤12 L/min, vital capacity >10 mL/kg
• Rapid shallow breathing index (RSBI, RR divided by tidal volume) <105
• Negative inspiratory pressure ≤−20 cm H₂O or more negative

C. Key Parameters

1. Settings that affect PaCO₂: Minute ventilation (RR × VT)
   a. This should be adjusted to achieve the patient’s baseline PaCO₂.
   b. An initial tidal volume (VT) of 4 to 8 mL/kg is appropriate in most cases (lower tidal volumes are recommended in patients with ARDS and COPD).
   c. A rate of 10 to 12 breaths/min is appropriate.

2. Settings that affect PaO₂: FiO₂ and PEEP
   a. FiO₂: The initial FiO₂ should be 100%. Quickly titrate down and use the lowest possible FiO₂ to maintain a PaO₂ of 50 to 60 or higher (or saturation >90%) to avoid oxygen toxicity (theoretically, FiO₂ <60% is usually safe).
   b. PEEP is positive pressure maintained at the end of a passive exhalation to keep alveoli open. 5 cm H₂O is an appropriate initial setting. High levels of PEEP increase the risk of barotrauma (injury to airway = pneumothorax) and decrease cardiac output (decreased venous return from increased intrathoracic pressure).

The presence of an ET tube does not prevent aspiration from occurring.

Quick HIT

When a patient is ventilator dependent for 2 or more weeks, a tracheostomy is usually performed to prevent tracheomalacia.

D. Complications

1. Anxiety, agitation, discomfort
   a. Both sedation and analgesia are important; paralytics should be used during intubation and can be used after intubation if the patient continues to be agitated and fights the ventilator.

2. Difficulty with tracheal secretions—suction on a regular basis.
3. Ventilator-associated pneumonia (risk is ~1% per day).
4. Barotrauma—caused by high airway pressures.
5. Tracheomalacia (softening of the tracheal cartilage)—due to the prolonged
presence of an endotracheal tube (ETT).

6. Laryngeal damage during intubation.

7. Gastrointestinal effects (stress ulcers and cholestasis)—increased risk in mechanically ventilated patients. All patients should be on a proton pump inhibitor (PPI) or H₂ blocker.
Diseases of the Pulmonary Vasculature

Pulmonary Hypertension

A. General Characteristics

1. Defined as a mean pulmonary arterial pressure greater than 25 mm Hg at rest
2. There are multiple pathophysiologic processes that can cause pulmonary hypertension (Clinical Pearl 2-12):
   a. Passive due to resistance in the pulmonary venous system (e.g., left heart failure, mitral stenosis, atrial myxoma)
   b. Hyperkinetic (left-to-right cardiac shunts such as atrial septal defect or patent ductus arteriosus)
   c. Obstruction (e.g., PE, pulmonary artery stenosis)
   d. Pulmonary vascular obliteration (e.g., collagen vascular diseases)
   e. Pulmonary vasoconstriction (e.g., chronic hypoxemia, COPD, obstructive sleep apnea [OSA])

CLINICAL PEARL 2-12

How to Determine the Cause of Pulmonary HTN

- Perform a series of tests (CXR, PFTs, ABGs, serology, echocardiogram, cardiac catheterization). These tests will give you enough information to recognize heart disease or lung disease as the cause of pulmonary HTN.
- If the cause is not revealed (neither heart nor lung), then obtain a V/Q scan: this indicates either PE or primary pulmonary hypertension (pulmonary arterial hypertension, PAH). Note that PAH is a diagnosis of exclusion.

3. Classification of pulmonary hypertension is based on the revised WHO classification system:
   a. Group 1: Pulmonary arterial hypertension (PAH)
      - Idiopathic, familial, veno-occlusive disease, and PAH with associated conditions (connective tissue disorders, congenital shunting, HIV, drugs and toxins)
      - An abnormal increase in pulmonary arteriolar resistance leads to thickening of pulmonary arteriolar walls. This worsens the pulmonary HTN, which in turn causes further wall thickening, thus leading to a vicious cycle.
      - The cause is unknown; it usually affects young or middle-aged women.
      - The prognosis is poor. Mean survival is 2 to 3 years from the time of diagnosis.
   b. Group 2: Left heart disease
      - Secondary to any cause of left heart failure, including mitral stenosis and
mitral regurgitation
c. Group 3: Lung disease and/or chronic hypoxemia  
   • Causes include ILD, COPD, OSA, and any other cause of chronic hypoxemia
d. Group 4: Chronic thromboembolic disease  
   • Recurrent PE (many patients do not have symptoms of PE), including nonthrombotic etiologies (e.g., tumor emboli)
e. Group 5: Miscellaneous  
   • Pulmonary vascular compression (e.g., tumors or lymphadenopathy), sarcoidosis, Langerhans cell histiocytosis, etc.

B. Clinical Features
1. Symptoms  
   a. Dyspnea on exertion  
   b. Fatigue  
   c. Chest pain—exertional  
   d. Syncope—exertional (with severe disease)
2. Signs  
   a. Loud pulmonic component of the second heart sound (P₂) and subtle lift of sternum (sign of RV dilatation)—These may be the only findings, and yet the patient may still have a devastating disease!  
   b. When right ventricular failure occurs, the corresponding signs and symptoms appear (JVD, hepatomegaly, ascites, peripheral edema).

C. Diagnosis
1. ECG: Often suggests right ventricular hypertrophy—specifically, right-axis deviation and right atrial abnormality are frequently present
2. CXR: Enlarged pulmonary arteries with or without clear lung fields based on the cause of pulmonary hypertension
3. Echocardiogram  
   a. Dilated pulmonary artery  
   b. Dilatation/hypertrophy of RA and RV  
   c. Abnormal movement of IV septum (due to increased right ventricular volume)
4. Right heart catheterization: required for confirmatory diagnosis of pulmonary HTN. Reveals increased mean pulmonary artery pressure >25 mm Hg

D. Treatment
1. One specific treatment plan cannot be recommended due to the variety of causes of pulmonary HTN. If the pulmonary HTN is secondary to another disease process (e.g., recurrent PE), then the underlying disease should be treated and
2. Vasoactive agents are typically used in PAH (Group 1), since trials have been done in this group.
   a. Right heart catheterization with a trial of vasodilators should precede the use of these agents.
   b. Vasoactive agents may lower pulmonary vascular resistance in some patients. Available options include inhaled nitric oxide, phosphodiesterase inhibitors (e.g., sildenafil), oral CCBs, prostacyclins (e.g., epoprostenol), and endothelin receptor antagonists (e.g., bosentan).
3. Many patients require home oxygen, diuretics, and occasionally inotropes (e.g., digoxin).
4. Lung transplantation in qualified patients.

Quick HIT

Cor pulmonale is best thought of as the right-sided counterpart to left ventricular heart disease due to systemic HTN.
Cor Pulmonale

A. General Characteristics
1. Cor pulmonale is defined as right ventricular hypertrophy with eventual RV failure resulting from pulmonary HTN, secondary to pulmonary disease.
2. The definition does not encompass any of the causes of pulmonary HTN due to left-sided heart disease (such as mitral stenosis or left-to-right shunts).

Quick HIT
Death due to cor pulmonale: Many COPD patients die of right ventricular failure secondary to chronic pulmonary HTN. Many deaths due to PE result from acute pulmonary HTN and right ventricular failure.

B. Causes
1. It is most commonly secondary to COPD.
2. Other causes include recurrent PE, ILD, asthma, CF, sleep apnea, and pneumoconioses.

C. Clinical Features
1. Decrease in exercise tolerance
2. Cyanosis and digital clubbing
3. Signs of right ventricular failure: hepatomegaly, edema, JVD
4. Parasternal lift

Quick HIT
Other sources of emboli to the lungs:
- Fat embolism (long-bone fractures)
- Amniotic fluid embolism (during or after delivery)
- Air embolism (trauma to thorax, indwelling venous/arterial lines)
- Septic embolism (IV drug use)
- Schistosomiasis

D. Diagnosis
1. CXR: enlargement of the RA, RV, and pulmonary arteries
2. ECG: right-axis deviation, P pulmonale (peaked P waves), right ventricular hypertrophy
3. Echocardiogram: right ventricular dilatation, but normal LV size and function; useful in excluding LV dysfunction

E. Treatment
1. Treat the underlying pulmonary disorder.
2. Use diuretic therapy cautiously because patients may be preload dependent.
3. Apply continuous long-term oxygen therapy if the patient is hypoxic.
4. Administer digoxin only if there is coexistent LV failure.
5. A variety of vasodilators have been studied; no definite improvement has been shown with their use.

Quick HIT

If a patient with long-bone fracture develops dyspnea, mental status change, and petechiae, think fat embolism. Respiratory failure and death can ensue rapidly.
Pulmonary Embolism

A. General Characteristics

1. A PE occurs when a thrombus in another region of the body embolizes to the pulmonary vascular tree via the RV and pulmonary artery. Blood flow distal to the embolus is obstructed.

Quick HIT

Complications in patients with PE who survive the initial event include:
- Recurrent PE
- Pulmonary HTN (up to 5% of patients)

2. Consider PE and deep venous thrombosis (DVT) as a continuum of one clinical entity (venous thromboembolism)—diagnosing either PE or DVT is an indication for treatment.

3. Sources of emboli
   a. Lower extremity DVT—PE is the major complication of DVT.
      - Most pulmonary emboli arise from thromboses in the deep veins of lower extremities above the knee (iliofemoral DVT).
      - Pulmonary emboli can also arise from the deep veins of the pelvis.
      - Although calf vein thrombi have a low incidence of embolizing to the lungs, in many patients these thrombi progress into the proximal veins, increasing the incidence of PE.
   b. Upper extremity DVT is a rare source of emboli (it may be seen in IV drug abusers).

Quick HIT

Two important studies to know:
- The Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) is a landmark study (JAMA 1990;263:2753). Guides treatment, if V/Q is performed.
- The Christopher Study (JAMA 2006;295:72–179). Guides treatment, if spiral CT is performed.

CLINICAL PEARL 2-13

Risk Factors for DVT/PE
- Age >60 years
- Malignancy
- Prior history of DVT, PE
4. Risk factors are those for DVT (see Clinical Pearl 2-13).
5. Pathophysiology
   a. Emboli block a portion of pulmonary vasculature, leading to increased pulmonary vascular resistance, pulmonary artery pressure, and right ventricular pressure. If it is severe (large blockage), acute cor pulmonale may result.
   b. Blood flow decreases in some areas of the lung. Dead space is created in areas of the lung in which there is ventilation but no perfusion. The resulting hypoxemia and hypercarbia drive respiratory effort, which leads to tachypnea.
   c. If the size of the dead space is large (large PE), clinical signs are more overt (SOB, tachypnea).
6. Course and prognosis
   a. Most often, PE is clinically silent. Recurrences are common, which can lead to development of chronic pulmonary HTN and chronic cor pulmonale.
   b. When PE is undiagnosed, mortality approaches 30%. A significant number of cases are undiagnosed (as many as 50%).
   c. When PE is diagnosed, mortality is 10% in the first 60 minutes. Of those who survive the initial event, approximately 30% of patients will die of a recurrent PE, if left untreated. Most deaths are due to recurrent PE within the first few hours of the initial PE. Treatment with anticoagulants decreases the mortality to 2% to 8%.

B. Clinical Features
1. Symptoms (frequency per the PIOPED study)
   a. Dyspnea (73%)
   b. Pleuritic chest pain (66%)
   c. Cough (37%)
   d. Hemoptysis (13%)
   e. Note that only one-third of patients with PE will have signs and symptoms of a DVT
   f. Syncope seen in large PE
2. Signs (frequency per the PIOPED study)
   a. Tachypnea (70%)
   b. Rales (51%)
c. Tachycardia (30%)
d. S4 (24%)
e. Increased P2 (23%)
f. Shock with rapid circulatory collapse in massive PE
g. Other signs: low-grade fever, decreased breath sounds, dullness on percussion

Quick HIT

Signs and symptoms are not a reliable indicators of the presence of PE. This often leads to confusion and delay in diagnosis and treatment. If, however, a patient has symptoms of PE and a DVT is found, one can make the diagnosis of PE without further testing.

C. Diagnosis

1. ABG levels are not diagnostic for PE (see Clinical Pearl 2-14).
   a. PaO₂ and PaCO₂ are low (the latter due to hyperventilation) and pH is high; thus, there is typically a respiratory alkalosis.
   b. The A–a gradient is usually elevated. A normal A–a gradient makes PE less likely, but cannot be relied on to exclude the diagnosis.

CLINICAL PEARL 2-14

Workup of PE

It is often difficult to definitively diagnose or rule out PE. The following tests provide an adequate basis for treating PE with anticoagulation:
- Intraluminal filling defects in central, segmental, or lobular pulmonary arteries on CTA
- DVT diagnosed with ultrasound and clinical suspicion
- Positive pulmonary angiogram (definitely proves PE)

The following can essentially rule out PE:
- Low-probability V/Q scan (or normal helical scan) and low clinical suspicion
- Negative pulmonary angiogram (definite)
- Negative D-dimer assay plus low clinical suspicion

Adapted from PIOPED data. JAMA 1990;263:2753.

2. CXR—usually normal.
   a. Atelectasis or pleural effusion may be present.
   b. The main usefulness is in excluding alternative diagnoses.
   c. Classic radiographic signs, such as Hampton hump or Westermark sign, are rarely present.

3. Venous duplex ultrasound of the lower extremities.
   a. If there is a positive result, treat with IV anticoagulation (heparin); treatment of DVT is the same as for PE. Keep in mind that with this approach, a false-
positive ultrasound will result in anticoagulation of some patients who do not have DVT or PE. Also, a negative result is not helpful, as the patient may still have a PE despite no DVT on ultrasound.

b. This test is very helpful when positive, but of little value when negative (negative results occur in 50% of patients with proven PE).

4. V/Q (ventilation–perfusion lung) scan
   a. Traditionally, this was the most common test used when PE is suspected, but has been replaced by CT angiography (CTA) as the initial study of choice in many medical centers.
   b. Plays an important role in diagnosis when there is a contraindication to CTA.
      - May be useful when the chest x-ray is clear and when there is no underlying cardiopulmonary disease.
   c. Interpretation of results: can be either normal, low probability, intermediate probability, or high probability (treatment guidelines based on PIOPED study).
      - A normal scan virtually rules out PE—no further testing is needed—but a scan is almost never “normal” in anyone.
      - A high-probability V/Q scan has a very high sensitivity for PE; treat with heparin.
      - **If there is low or intermediate probability, clinical suspicion determines the next step.** If clinical suspicion is high, pulmonary angiography is indicated. Alternatively, perform a lower extremity duplex ultrasound to avoid pulmonary angiography. If the duplex is positive, treatment for DVT is the same as for PE. If the duplex is negative/uncertain, then pulmonary angiography is indicated to exclude PE.

5. CTA
   a. Has been found to have good sensitivity (>90%) and specificity.
   b. Can visualize very small clots (as small as 2 mm); may miss clots in small subsegmental vessels (far periphery).
   c. The test of choice in most medical centers.
   d. In combination with clinical suspicion, guides treatment (see Figure 2-14).
   e. CTA cannot be performed in patients with significant renal insufficiency because of the IV contrast that is required.
6. Pulmonary angiography is the gold standard.
   a. **Definitively diagnoses or excludes PE, but is invasive.** Contrast injected into the pulmonary artery branch after percutaneous catheterization of the femoral vein.
   b. **Consider when noninvasive testing is equivocal and risk of anticoagulation is high, or if the patient is hemodynamically unstable and embolectomy may be required.** Angiography is rarely performed because it carries a 0.5% mortality.
7. D-dimer assay
   a. D-dimer is a specific fibrin degradation product; levels can be elevated in patients with PE and DVT.
   b. D-dimer assay is a fairly sensitive test (90% to 98%). **If results are normal and clinical suspicion is low,** PE is very unlikely.
   c. Specificity is low—D-dimer results may also be elevated in MI, CHF, pneumonia, and the postoperative state (or in any state of acute inflammation). Any cause of clot or increased bleeding can elevate the D-dimer level.

8. Overall, the workup of suspected PE is based on pretest probability. The Wells criteria (**Clinical Pearl 2-15**) is a scoring system that takes this into account and helps guide the workup.
   a. If PE is unlikely based on the scoring system, then the pretest probability for PE is low and D-dimer can be ordered to exclude PE. If PE is likely, CTA should be performed given its high sensitivity and specificity.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>If pretest probability of PE is low, D-dimer test is a good noninvasive test to rule out PE. So if D-dimer is negative, you can rule out a clot. But if it is positive, this does not help you.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start therapeutic heparin as initial treatment. Also start warfarin at the same time. Goal is therapeutic INR of 2 to 3.</td>
</tr>
</tbody>
</table>

**D. Treatment**

1. Supplemental oxygen to correct hypoxemia. Severe hypoxemia or respiratory failure requires intubation and mechanical ventilation.

**Clinical Pearl 2-15**

**Dichotomized Clinical Decision Rule for Suspected Acute Pulmonary Embolism (Modified Wells Criteria)**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms and signs of DVT</td>
<td>3.0</td>
</tr>
<tr>
<td>Alternative diagnosis less likely than PE</td>
<td>3.0</td>
</tr>
<tr>
<td>Heart rate &gt;100 beats/min</td>
<td>1.5</td>
</tr>
<tr>
<td>Immobilization (&gt;3 days) or surgery in previous 4 wks</td>
<td>1.5</td>
</tr>
</tbody>
</table>
Previous DVT or PE  
Hemoptysis  
Malignancy (current therapy, or in previous 6 months, or palliative)  

Score ≤4 indicates that PE is unlikely, score >4 indicates that PE is likely. 


2. Acute anticoagulation therapy with either unfractionated or low–molecular-weight heparin to prevent another PE. Anticoagulation prevents further clot formation, but does not lyse existing emboli or diminish thrombus size.
   a. Start immediately on the basis of clinical suspicion. **Do not wait for studies to confirm PE if clinical suspicion is high.**
   b. For unfractionated heparin, give one bolus, followed by a continuous infusion for 5 to 10 days. The goal is an aPTT of 1.5 to 2.5 times control.
      • Heparin acts by promoting the action of antithrombin III.
      • Contraindications to heparin include active bleeding, uncontrolled HTN, recent stroke, and heparin-induced thrombocytopenia (HIT).
      • Low–molecular-weight heparin has better bioavailability and lower complication rates than unfractionated heparin. It has been shown to be at least as effective or more effective than unfractionated heparin.

3. Oral anticoagulation with warfarin or one of the novel oral anticoagulants (e.g., rivaroxaban) for long-term treatment.
   a. Can start warfarin with heparin on day 1.
   b. Target INR with warfarin for PE treatment is 2 to 3.
   c. If using a novel oral anticoagulant (e.g., rivaroxaban or apixaban), concurrent treatment with heparin during initiation is not necessary as these medications are effective immediately.
   d. Continue for 3 to 6 months or more, depending on risk factors. Some patients at significant risk for recurrent PE (e.g., malignancy, hypercoagulable state) may be considered for lifelong anticoagulation.
4. Thrombolytic therapy—for example, streptokinase, tPA.
   a. Speeds up the lysis of clots.
   b. There is no evidence that thrombolysis improves mortality rates in patients with PE. Therefore, its use is not well defined at this point.
   c. Situations in which thrombolysis should be considered:
      - Patients with massive PE who are hemodynamically unstable (persistent hypotension).
      - Patients with evidence of right heart failure (thrombolysis can reverse this).
   d. Catheter-directed thrombolysis has lower systemic side effects and should be considered in patients at high risk for systemic fibrinolysis or surgery.

5. Inferior vena cava interruption (IVC filter placement).
   a. Use has become more common but reduction in mortality has not been conclusively demonstrated.
   b. Patients who have IVC filter placed are at higher risk of recurrent DVT (but lower risk of recurrent PE).
   c. Complications of IVC filter placement (rare): filter migration or misplacement, filter erosion and perforation of IVC wall, and IVC obstruction due to filter thrombosis.
   d. Indications include:
      - Contraindication to anticoagulation in a patient with documented DVT or PE.
      - A complication of current anticoagulation.
      - Failure of adequate anticoagulation as reflected by recurrent DVT or PE.
      - A patient with low pulmonary reserve who is at high risk for death from PE.

6. Surgical thrombectomy
   a. Consider in patients with hemodynamic compromise, a large, proximal thrombus, and who are poor candidates for fibrinolytics.
Miscellaneous Topics

Pulmonary Aspiration

A. General Characteristics
1. Pulmonary aspiration syndromes can be due to different types of aspirates.
   a. Acidic gastric contents, which are especially damaging to the lungs.
   b. Aspiration of oropharyngeal flora, which can lead to infection.
   c. Foreign body/fluids (e.g., chemicals).
2. The right lung is most often involved due to anatomy (right main bronchus follows a straighter path downward), particularly the lower segments of the right upper lobe and the upper segments of the right lower lobe.
3. Predisposing factors
   a. Reduced level of consciousness (e.g., seizures, stroke, sedating drugs)
   b. Alcoholism
   c. Extubation (impaired pharyngeal or laryngeal function)
   d. Excessive vomiting, ileus
   e. Tube feeding, tracheostomy tubes
   f. Anesthesia/surgery
   g. Neuromuscular diseases
   h. Esophageal disorders (e.g., achalasia, GERD, cancer)

Quick HIT
Aspiration pneumonia develops in 40% of patients who aspirate, usually 2 to 4 days after aspiration. Organisms are often mixed (aerobic–anaerobic).

B. Clinical Features
1. Presentation is variable. Some patients develop acute onset of respiratory distress. However, most often, the patient appears well, but later develops respiratory dysfunction (cough, shortness of breath, fever, tachypnea, hypoxemia, or frothy sputum).
2. It may be initially silent, with development of acute respiratory failure with no obvious cause.
3. Fever may or may not be present.
4. May lead to obstruction of the airways with localized wheezing.

C. Diagnosis
1. Findings on CXR are variable and resemble infiltrates that mimic bacterial
pneumonia. Atelectasis and local areas of collapse may also be present.

2. Differentiating between aspiration pneumonitis and aspiration pneumonia can be difficult. Aspiration pneumonitis will show infiltrates acutely on CXR, whereas aspiration pneumonia takes a few days to develop. However, many physicians treat empirically with antibiotics since it is often difficult to predict which patients will also develop pneumonia when aspiration pneumonitis is present (controversial).

Quick HIT

Aspiration can lead to lung abscess if untreated. Poor oral hygiene predisposes to such infections. Foul-smelling sputum often indicates anaerobic infection.

D. Treatment

1. If aspiration was witnessed: ABCs (airway, breathing, and circulation), supplemental oxygen, and supportive measures.
2. If aspiration pneumonia is suspected, give antibiotics that have anaerobic activity (e.g., clindamycin).
3. If obstruction is present, early bronchoscopy is indicated.
4. Prevention is critical in patients at high risk for aspiration: Keep the head of the bed elevated. Nasogastric tubes can be considered to decompress the stomach, but have not been shown to decrease the risk of aspiration.
Dyspnea

A. General Characteristics
1. Distinguish acute from chronic dyspnea.
2. Patients with chronic dyspnea usually have either heart or lung disease or both. It may be difficult to distinguish between the two.
3. The most common causes of acute dyspnea include CHF exacerbation, pneumonia, bronchospasm, PE, and anxiety.
4. Assess the patient’s baseline level of activity, whether the dyspnea is new in onset, and its association with exertion.
5. If the patient has a history of smoking, cough, sputum, repeated infections, or occupational exposure, lung disease is likely to be the reason for chronic dyspnea.

Quick HIT

Depending on patient presentation, any of the following tests may be helpful in distinguishing between lung and heart diseases:
- CXR
- Sputum Gram stain and culture (if patient has sputum)
- PFTs
- ABGs
- ECG, echocardiogram

B. Causes
1. Cardiovascular causes
   a. CHF
   b. Ischemic heart disease, acute myocardial infarction
   c. Pericarditis, cardiac tamponade
   d. Arrhythmias
   e. Valvular disease
   f. Congenital heart disease
2. Pulmonary causes
   a. Obstructive lung diseases—COPD, asthma, bronchiectasis
   b. PE
   c. ARDS
   d. Pneumonia, TB, bronchitis
   e. Pleural effusion, pulmonary edema
   f. Pneumothorax
   g. Upper airway obstruction, foreign body aspiration
   h. ILD
   i. Chest wall abnormalities (kyphoscoliosis), rib fracture
3. Psychiatric disease—generalized anxiety disorder, panic attacks, hyperventilation
4. Systemic causes—severe chronic anemia, sepsis, DKA, GERD, medication (narcotic overdose)
5. Chest wall abnormalities—kyphoscoliosis, rib fracture, ankylosing spondylitis
6. Neuromuscular diseases that weaken respiratory muscles—myasthenia gravis, muscular dystrophy

Quick HIT

Patients with chronic COPD can also experience paroxysmal nocturnal dyspnea. Their excessive airway secretions accumulate at night causing airway obstruction, resulting in dyspnea that awakens the patient and forces him or her to clear the airway. Therefore, paroxysmal nocturnal dyspnea is not specific to heart disease.

C. Diagnosis
1. Thorough history and physical examination, vital signs.
2. Pulse oximetry—normal is 96% to 100% on room air. Be aware that the baseline oxygen saturation of many COPD patients is chronically low.
3. ABG—may be indicated if oxygen saturation is low on pulse oximetry, if hypercarbia is suspected, or to evaluate for acid–base abnormalities.
4. CXR—can reveal pneumothorax, pleural effusion, pulmonary vascular congestion secondary to CHF, infiltrates due to pneumonia, ILD, and so on.
5. CBC—to evaluate for anemia, infection.
6. ECG—may show ventricular hypertrophy or evidence of ischemic heart disease.
7. Echocardiogram—for further evaluation of CHF, valvular heart disease.
8. PFTs—perform if all of the above are normal or if obstructive lung disease is suspected. See Table 2-7.
9. V/Q scan or spiral CT scan—perform if PE is suspected.
10. Bronchoscopy—indicated if foreign body aspiration is suspected.

Quick HIT

A chronic CO₂ retainer (common in COPD patients) usually has normal pH and increased HCO₃ levels. If CO₂ retention is acute, pH will be decreased and HCO₃ will be closer to normal levels.

**TABLE 2-7** Important Pulmonary Studies
<table>
<thead>
<tr>
<th>Test</th>
<th>Explanation of Test</th>
<th>Use</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse oximetry</td>
<td>• Measures percentage of oxygenated hemoglobin&lt;br&gt;• Follows a sigmoid curve in relationship to partial pressure of oxygen ((\text{PaO}_2)) in the arterial blood&lt;br&gt;• Oxygen saturation of ≤98% is the established criterion for receiving home oxygen</td>
<td>• Useful in most categories of patients in whom pulmonary disease is suspected&lt;br&gt;• Also helpful in assessing a patient with dyspnea, whether acute or chronic</td>
<td>• Useful as a screening test because it is very sensitive for detecting gas exchange abnormalities&lt;br&gt;• Not very specific&lt;br&gt;• Sensitivity is increased during exercise</td>
</tr>
<tr>
<td>Arterial blood gas (ABG)</td>
<td>Measures the partial pressures of oxygen and carbon dioxide as well as the pH of the arterial blood.&lt;br&gt;• Normal pH: 7.35–7.45&lt;br&gt;• Normal (\text{PaO}_2): decreases with age (90 is normal in a 20-yr-old person)&lt;br&gt;• Normal (\text{PaCO}_2): 35–45 mm Hg</td>
<td>For every 10 mm Hg increase or decrease in (\text{PaCO}_2), there should be a corresponding increase or decrease in pH by 0.08. In general, if the change in pH is in the same direction as change in (\text{PaCO}_2), then the primary disorder is metabolic. When there is an inverse relationship, the primary disorder is respiratory.&lt;br&gt;• ABG is not necessary in all patients with pulmonary dysfunction. Ask yourself whether the results of the ABG are going to influence what you do for the patient before performing it.&lt;br&gt;• ABG is painful, and radial artery spasm can result in ischemia of the hand in patients with radial-dominant circulation.</td>
<td></td>
</tr>
<tr>
<td>Spirometry</td>
<td>• From maximum inspiration, the patient exhales as rapidly and forcibly as possible to maximum expiration.&lt;br&gt;• Spirometer plots the change in lung volume against time (see lung volumes below).</td>
<td>• Helps to distinguish obstructive from restrictive lung disease.&lt;br&gt;• Useful in assessing degree of functional impairment as well as monitoring effectiveness of treatment (e.g., during asthma exacerbation).&lt;br&gt;• May detect respiratory impairment in asymptomatic patients (e.g., smokers).</td>
<td>• Volumes are measured as percentages of predicted values based on age, height, and sex.&lt;br&gt;• Incorrect measurement or technique may lead to false positives.</td>
</tr>
<tr>
<td>(\text{DL}_{\text{CO}})</td>
<td>• The patient breathes in a small, specific amount of CO, and the amount transferred from alveolar air to pulmonary–capillary blood is measured.&lt;br&gt;• CO is a diffusion-limited gas, so other variables are eliminated.&lt;br&gt;• Essentially measures the surface area of the alveolar–capillary membrane.</td>
<td>• Can often distinguish between asthma, emphysema, and COPD.&lt;br&gt;• Useful in monitoring various conditions, such as sarcoidosis and emphysema.</td>
<td>1. Causes for low (\text{DL}<em>{\text{CO}}) include:&lt;br&gt;• Emphysema&lt;br&gt;• Sarcoidosis&lt;br&gt;• Interstitial fibrosis&lt;br&gt;• Pulmonary vascular disease&lt;br&gt;• Also, lower with anemia due to reduced binding of CO to hemoglobin&lt;br&gt;2. Causes for high (\text{DL}</em>{\text{CO}}):&lt;br&gt;• Asthma (increased pulmonary–capillary blood volume)&lt;br&gt;• Obesity&lt;br&gt;• Intracardiac left-to-right shunt&lt;br&gt;• Exercise&lt;br&gt;• Pulmonary hemorrhage (alveolar (\text{RBCs}) bind with CO)</td>
</tr>
<tr>
<td>Ventilation–perfusion (V/Q) scan</td>
<td>• Compares the degree of ventilation to perfusion of the lungs; an exact match would correspond to a V/Q ratio of 1.&lt;br&gt;• A high V/Q ratio occurs when there is inadequate perfusion of an adequately ventilated lung. Thus, dead space is increased.&lt;br&gt;• The normal ratio of ventilation to perfusion is 0.8; so there is normally some degree of V/Q mismatch, with some degree of shunting.</td>
<td>Diagnosis of PE&lt;br&gt;• It is very rare to have a “normal” or “negative” V/Q scan. When V/Q scans are ordered for evaluation of suspected PE, the result is usually “low,” “indeterminate,” or “high probability.”</td>
<td></td>
</tr>
<tr>
<td>Methacholine challenge</td>
<td>Assesses degree of airway hyperreactivity</td>
<td>Patients in whom asthma or COPD is suspected</td>
<td>Sensitive in detecting airway hyperresponsiveness in mild asthma</td>
</tr>
</tbody>
</table>
Quick HIT

**Massive Hemoptysis**
- Defined as more than 500 mL of blood in 24 hours.
- The most common causes are bronchiectasis and bleeding diathesis.
- Airway protection is key. Intubate if necessary.
- Bronchoscopy can help identify the bleeding source.
- Use bronchial artery embolization or balloon tamponade of the airway if indicated.

**D. Treatment**
1. Treat the underlying cause.
2. Use intubation and mechanical ventilation in the following situations:
   a. If impending respiratory failure is suspected
   b. If patient is unable to protect airway (e.g., decreased mental status, stroke, drug overdose)
   c. Severe hypoxia despite supplemental oxygen (PO$_2$ <50 to 60)
   d. Severe hypercarbia (PCO$_2$ >50)
3. Exercise and conditioning may improve perception of dyspnea.
Hemoptysis

A. General Characteristics
1. Defined as expectoration of blood; hemoptysis varies widely in severity and medical significance. The amount of blood does not necessarily correspond with the gravity of the underlying cause.
2. Differential diagnosis
   a. Most common causes include:
      - Bronchitis (50% of cases)
      - Lung cancer (bronchogenic carcinoma)
      - TB
      - Bronchiectasis
      - Pneumonia
      - Many times the etiology remains idiopathic after thorough evaluation (up to 30% of cases)
   b. Other causes include:
      - Goodpasture syndrome (anti-GBM antibody disease)
      - PE with pulmonary infarction
      - Aspergilloma within cavities
      - Mitral stenosis (elevated pulmonary venous pressure)
      - Hemophilia

B. Diagnosis
1. Verify that hemoptysis has truly occurred. For example, superficial mouth lacerations, epistaxis, or hematemesis may be confused with hemoptysis.
2. History and physical
   a. Fever, night sweats, and weight loss suggest TB.
   b. Fevers and chills or a history of HIV suggests either pneumonia or TB.
   c. Look for risk factors for PE.
   d. In the presence of acute renal failure or hematuria, Goodpasture syndrome should be considered.

Quick HIT

Evaluation of hemoptysis:
- CXR
- Fiberoptic bronchoscopy
- CT scan of the chest

3. Diagnostic studies
a. CXR
   - May be a clear indicator of a pathogenic process or even diagnostic—for example, if fungus ball, irregular mass, granuloma, or opacity consistent with pulmonary infarction is present.
   - A normal CXR does not exclude a serious condition, especially PE and even lung cancer.

b. Fiberoptic bronchoscopy
   - Should be performed even if CXR is normal and if there is a significant clinical suspicion for lung carcinoma.
   - Look for a small tumor that may not be evident on a radiograph.
   - May localize the site of bleeding.

4. CT of chest—performed as a complement to bronchoscopy or as a substitute if there are contraindications to bronchoscopy.

C. Treatment
   1. Treat the underlying cause.
   2. Suppress the cough if it is aggravating the hemoptysis.
   3. Correct bleeding diathesis (although anticoagulation is the treatment for PE).
3

Diseases of the Gastrointestinal System

Sarah Jensen
Diseases of the Colon

**Colorectal Cancer**

A. General Characteristics

1. Third most common cancer in the United States in men and women.
2. **Virtually, all colorectal tumors arise from adenomas. Majority are endoluminal adenocarcinomas arising from the mucosa. Rarely, carcinoid tumors, lymphomas, and Kaposi sarcoma may be present.**

3. Screening—refer to Chapter 12, Ambulatory Medicine
   a. Stool-based screening tests
   b. Fecal occult blood testing (FOBT) has poor sensitivity and specificity. Positive predictive value is only about 20%, but all patients with positive FOBT need a colonoscopy regardless.
   c. Fecal immunochemical tests (FIT) detect human hemoglobin and are more specific for colorectal cancer (CRC) than FOBT. Screening with this test can be done yearly but also require colonoscopy if positive.
   d. Digital rectal examination: Only about 10% of tumors are palpable by rectal examination.
   e. Colonoscopy
      - **Most sensitive and specific test;** the diagnostic study of choice for patients with a positive FOBT
      - Diagnostic and therapeutic (e.g., biopsy, polypectomy)
   f. Flexible sigmoidoscopy
      - Can be used to reach the area where approximately 50% to 70% of polyps and cancers occur (with a 60-cm scope)
      - Diagnostic in about two-thirds of all CRCs
   g. Barium enema
      - No longer recommended for screening.
      - Evaluates entire colon; complementary to flexible sigmoidoscopy.
      - Any abnormal finding needs to be evaluated by colonoscopy.
   h. Carcinoembryonic antigen (CEA)—not useful for screening; useful for establishing baseline, monitoring treatment efficacy, and recurrence surveillance.
CEA does have prognostic significance: Patients with preoperative CEA >5 ng/mL have a worse prognosis.

**Quick HIT**

Colon cancer screening begins at age 50. If one family member has colon cancer, begin at age 40, or 10 years before age of onset of family member.

4. Clinical staging is done with CT scan of chest, abdomen, and pelvis and by physical examination (ascites, hepatomegaly, lymphadenopathy).

5. Pattern of spread
   a. Direct extension—circumferentially and then through the bowel wall to later invade other abdominoperineal organs
   b. Hematogenous
      - Portal circulation to liver—**liver is most common site of distant spread**
      - Lumbar/vertebral veins to lungs
   c. Lymphatic—regionally
   d. Transperitoneal and intraluminal

**Quick HIT**

About 20% of patients have distant metastatic disease at presentation.

**B. Risk Factors**

1. Age—everyone over the age of 50 years is at increased risk
2. Adenomatous polyps
   a. These are premalignant lesions, but most do not develop into cancer.
   b. Villous adenomas have higher malignant potential than tubular adenomas.
   c. The larger the size, and the greater the number of polyps, the higher the risk of cancer.
3. Personal history of prior CRC or adenomatous polyps
4. Inflammatory bowel disease (IBD)
   a. Both ulcerative colitis (UC) and Crohn disease pose an increased risk for CRC, but UC poses a greater risk than Crohn disease.
   b. Incidence of CRC is 5% to 10% at 20 years and 12% to 20% at 30 years with UC. Begin surveillance colonoscopy for CRC 8 years following the diagnosis of IBD.
5. Family history
   a. Multiple first-degree relatives with CRC.
   b. Any first-degree relative diagnosed with CRC or adenoma under age 60.
6. Dietary factors
   a. High-fat, low-fiber diets associated with a higher risk of CRC

7. Major polyposis syndromes
   a. **Familial adenomatous polyposis (FAP)**
      • Autosomal dominant disease caused by hereditary mutations in the adenomatous polyposis coli (APC) tumor suppressor gene.
      • Characterized by hundreds of adenomatous polyps in the colon. The colon is always involved, and the duodenum is involved in 90% of cases. Polyps may also form in the stomach, jejunum, and ileum.
      • In all FAP cases, the risk of CRC is 100% by the third or fourth decade of life.
      • Prophylactic colectomy is usually recommended.
   b. **Gardner syndrome**
      • Variant of FAP, autosomal dominant.
      • Polyps plus osteomas, dental abnormalities, benign soft tissue tumors, desmoid tumors, sebaceous cysts.
      • Risk of CRC is 100% by approximately age 40.
   c. **Turcot syndrome**
      • Can be inherited as autosomal dominant or recessive.
      • Polyps plus cerebellar medulloblastoma or glioblastoma multiforme.
   d. **Peutz–Jeghers**
      • Autosomal dominant.
      • Single or multiple hamartomas that may be scattered through the entire GI tract: in small bowel (78%), colon (60%), stomach (30%).
      • **Pigmented spots around lips, oral mucosa, face, genitalia, and palmar surfaces.**
      • Unlike adenomas, hamartomas have a very-low malignant potential.
      • Slightly increased incidence of various carcinomas (e.g., stomach, ovary, breast, cervix, testicle, lung).
      • Intussusception or GI bleeding may occur.
   e. **Familial juvenile polyposis coli**
      • Rare; presents in childhood.
      • Only small risk of CRC.
      • Between 10 and hundreds of juvenile colon polyps.
   f. **Hereditary nonpolyposis CRC**—without adenomatous polyposis
      • **Lynch syndrome I** (site-specific CRC)—early-onset CRC; absence of antecedent multiple polyposis.
      • **Lynch syndrome II** (cancer family syndrome)—all features of Lynch I plus increased number and early occurrence of other cancers (e.g., female genital
tract, skin, stomach, pancreas, brain, breast, biliary tract).

C. Clinical Features
1. The presence of symptoms is typically a manifestation of relatively advanced disease. Symptoms include melena or hematochezia, abdominal pain, change in bowel habits, or unexplained iron deficiency anemia.
2. Signs and symptoms potentially common to all locations
   a. Abdominal pain is the most common presenting symptom. Can be caused by partial obstruction or peritoneal dissemination. Remember that CRC is the most common cause of large bowel obstruction in adults. Colonic perforation can lead to peritonitis and is the most life-threatening complication.

   Quick HIT
   The sensitivity of individual symptoms for diagnosing CRC is poor.

   b. Weight loss
   c. Blood in stool
   d. May be asymptomatic
3. Signs and symptoms based on specific location of tumor
   a. Right-sided tumors
      • Obstruction is unusual because of the larger luminal diameter allowing for large tumor growth to go undetected. The cecum has the largest luminal diameter of any part of the colon.
      • Common findings: occult blood in stool, iron deficiency anemia, and melena.
      • Change in bowel habits is uncommon.
      • Triad of anemia, weakness, right lower quadrant (RLQ) mass (occasionally) is present.

   Quick HIT
   Right side: Melena is more common. Left side: Hematochezia is more common.

   b. Left-sided tumors
      • Smaller luminal diameter—signs of obstruction more common
      • Change in bowel habits more common—alternating constipation/diarrhea; narrowing of stools (“pencil stools”)
      • Hematochezia more common
      • Rectal cancer (20% to 30% of all CRCs)
      • Symptoms include hematochezia (most common), tenesmus, rectal mass, and
feeling of incomplete evacuation of stool due to mass.

Quick HIT

Rectal cancer has a higher recurrence rate and a lower 5-year survival rate than colon cancer.

D. Treatment

1. Surgery is the only curative treatment of CRC. Surgical resection of tumor-containing bowel as well as resection of regional lymphatics
2. CEA level should be obtained before surgery (see below)
3. Utility of adjuvant therapy (chemotherapy or radiation therapy) depends on the stage of tumor and is beyond the scope of this book
4. Follow-up is important, and varies among physicians
   a. Stool guaiac test
   b. Annual CT scan of abdomen/pelvis and CXR for up to 5 years
   c. Colonoscopy at 1 year and then every 3 years
   d. CEA levels are checked periodically (every 3 to 6 months)
      • A subsequent increase in CEA is a sensitive marker of recurrence
      • Often, second-look operations are based on high CEA levels postresection
      • Very high elevations of CEA suggest liver involvement
5. About 90% of recurrences occur within 3 years after surgery

Quick HIT

Radiation therapy is not indicated in the treatment of colon cancer, although it is used in treating rectal cancer.
Colonic Polyps

A. Nonneoplastic Polyps—benign lesions with no malignant potential
1. Hyperplastic (metaplastic) polyps are the most common (90%) nonneoplastic polyps; generally remain small and asymptomatic.
2. No specific therapy required, but they can be difficult to distinguish from neoplastic polyps and so are commonly removed.
3. Juvenile polyps (typically in children younger than 10 years) are highly vascular and common, so they should be removed.
4. Inflammatory polyps (pseudopolyps) are associated with UC.

Quick HIT

Polyps may be isolated or may occur as part of inherited polyposis syndromes, which have a very-high malignant potential.

B. Adenomatous Polyps—benign lesions, but have significant malignant potential; precursors of adenocarcinoma.
1. Can be one of three types of adenoma
   a. Tubular (most common; up to 60% to 80% of cases)—smallest risk of malignancy
   b. Tubulovillous—intermediate risk of malignancy
   c. Villous—greatest risk of malignancy
2. Can determine malignant potential by the following:
   a. Size—the larger the polyp, the greater the malignant potential
   b. Histologic type
   c. Atypia of cells
   d. Shape—sessile (flat, more likely to be malignant) versus pedunculated (on a stalk)

Quick HIT

- Most polyps are found in the rectosigmoid region.
- Most patients are asymptomatic.
- In symptomatic patients, rectal bleeding is the most common symptom.

C. Treatment—complete removal of polyp
Diverticulosis

A. General Characteristics
1. Caused by increased intraluminal pressure—in inner layer of colon bulges through the focal area of weakness in the colon wall (usually an area of blood vessel penetration).
2. Risk factors
   - Low-fiber diets: Constipation causes intraluminal pressures to increase.
   - Positive family history.
3. Prevalence increases with age.
4. The most common location is the sigmoid colon. However, diverticula may occur anywhere in the colon.

Quick HIT
Diverticulosis (pouches in the colon wall) should be distinguished from diverticulitis (inflammation or infection of diverticula). Diverticulitis is a complication of diverticulosis.

B. Clinical Features
1. Usually asymptomatic and discovered incidentally on imaging (e.g., CT abdomen/pelvis) or when a complication occurs (diverticular bleed or diverticulitis)
2. Vague left lower quadrant (LLQ) discomfort, bloating, constipation/diarrhea may be present.
3. Only 10% to 20% become symptomatic (i.e., develop complications—see below).

Quick HIT
- Complications of diverticulosis include painless rectal bleeding and diverticulitis.
- Complications of diverticulitis include bowel obstruction, abscess, and fistulas.

C. Diagnosis
1. Barium enema is the test of choice.
2. Abdominal x-rays are usually normal and are not diagnostic for diverticulosis.

D. Treatment
1. High-fiber foods (such as bran) to increase stool bulk
2. Psyllium (if the patient cannot tolerate bran)

E. Complications
1. Painless rectal bleeding (up to 40% of patients)
   a. Bleeding is usually clinically insignificant and stops spontaneously. No further treatment is necessary in these patients.
   b. Bleeding can be severe in about 5% of patients. In many cases, the bleeding stops spontaneously. Colonoscopy may be performed to locate the site of bleeding (mesenteric angiography in certain cases). If bleeding is persistent and/or recurrent, surgery (segmental colectomy) may be needed.

2. Diverticulitis (15% to 25% of patients)
   a. Occurs when feces become impacted in the diverticulum, leading to erosion and microperforation.
   b. Can be complicated (see also Clinical Pearl 3-1) or uncomplicated. Uncomplicated diverticulitis accounts for most cases and refers to diverticulitis without the complications listed in Clinical Pearl 3-1.

   **CLINICAL PEARL 3-1**

   **Complications of Diverticulitis**
   - Abscess formation (can be drained either percutaneously under CT guidance or surgically)
   - Colovesical fistula—accounts for 50% of fistulas secondary to diverticulitis; 50% close spontaneously
   - Obstruction—due to chronic inflammation and thickening of bowel wall
   - Free colonic perforation—uncommon but catastrophic (leads to peritonitis)

   c. Clinical features: fever, LLQ pain, leukocytosis.
      - Other possible features: alteration in bowel habits (constipation or diarrhea), vomiting, and sometimes a painful mass on rectal examination if inflammation is near the rectum.

   **Quick HIT**
   - Diverticulitis recurs in about 30% of patients treated medically, usually within the first 5 years.

   d. Diagnostic tests
      - **CT scan (abdomen and pelvis) with oral and IV contrast is the test of choice**; it may reveal a swollen, edematous bowel wall or an abscess.
      - Abdominal radiographs help in excluding other potential causes of LLQ pain, and can rule out ileus or obstruction (indicated by air–fluid levels, distention), and perforation (indicated by free air).
      - **Barium enema and colonoscopy are contraindicated in acute diverticulitis due to the risk of perforation.**
e. Treatment

- Uncomplicated diverticulitis is managed with IV antibiotics, bowel rest (NPO), IV fluids. Mild episodes can be treated on outpatient basis if patient is reliable and has few or no comorbid conditions. If symptoms persist after 3 to 4 days, surgery, resection of the involved segment, may be necessary. Antibiotics continued for 7 to 10 days. After successful treatment, about one-third has recurrence. Surgery recommended for recurrent episodes.
- Complicated diverticulitis—surgery indicated.

As many as 25% of patients with bleeding arteriovenous malformations have aortic stenosis. However, no cause-and-effect relationship has been proven.
Angiodysplasia of the Colon (Arteriovenous Malformations, Vascular Ectasia)

Tortuous, dilated veins in submucosa of the colon (usually proximal) wall.
A common cause of **lower GI bleeding in patients over age 60**.
Bleeding is usually low grade, but 15% of patients may have massive hemorrhage if veins rupture.
Diagnosed by colonoscopy (preferred over angiography).
In about 90% of patients, **bleeding stops spontaneously**.
It can frequently be treated by colonoscopic coagulation of the lesion. If bleeding persists, a right hemicolecotomy should be considered.

Quick HIT

- Acute mesenteric ischemia is much more common than chronic mesenteric ischemia.
- Patients with acute mesenteric ischemia often have pre-existing heart disease (e.g., congestive heart failure, CAD).
Acute Mesenteric Ischemia

A. Introduction
1. Results from a compromised blood supply, usually to the superior mesenteric vessels.
2. There are four types (three are due to arterial disease, one due to venous disease):
   a. Arterial embolism (50% of cases): Almost all emboli are of a cardiac origin (e.g., atrial fibrillation, MI, valvular disease).
   b. Arterial thrombosis (25% of cases):
      - Most of these patients have atherosclerotic disease (e.g., coronary artery disease [CAD], PVD, stroke) at other sites.
      - Acute occlusion occurs over pre-existing atherosclerotic disease. The acute event may be due to a decrease in cardiac output (e.g., resulting from MI, CHF) or plaque rupture.
      - Collateral circulation has usually developed.
   c. Nonocclusive mesenteric ischemia (20% of cases):
      - Splanchnic vasoconstriction secondary to low cardiac output.
      - Typically seen in critically ill elderly patients.
   d. Venous thrombosis (<10% of cases). Many predisposing factors—infection, hypercoagulable states, oral contraceptives, portal HTN, malignancy, pancreatitis.
3. The overall mortality rate for all types of acute mesenteric ischemia is about 60% to 70%. If bowel infarction has occurred, the mortality rate can exceed 90%.

Quick HIT

Differences in Presentation of Types of Acute Mesenteric Ischemia:
- Embolic—symptoms are more sudden and painful than other causes
- Arterial thrombosis—symptoms are more gradual and less severe than embolic causes
- Nonocclusive ischemia—typically occurs in critically ill patients
- Venous thrombosis—symptoms may be present for several days or even weeks, with gradual worsening

B. Clinical Features
1. Classic presentation is acute onset of severe abdominal pain disproportionate to physical findings. Pain is due to ischemia and possibly infarction of intestines, analogous to MI in CAD.
   a. The abdominal examination may appear benign even when there is severe ischemia. This can lead to a delay in diagnosis.
   b. The acuteness and the severity of pain vary depending on the type of acute mesenteric ischemia (see Quick Hit).
2. Anorexia, vomiting.
3. GI bleeding (mild).
4. Peritonitis, sepsis, and shock may be present in advanced disease.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Signs of intestinal infarction include hypotension, tachypnea, lactic acidosis, fever, and altered mental status (eventually leading to shock).</td>
</tr>
<tr>
<td>• Check the lactate level if acute mesenteric ischemia is suspected.</td>
</tr>
</tbody>
</table>

C. Diagnosis

1. **Mesenteric angiography** is the definitive diagnostic test.
2. Obtain a plain film of the abdomen to exclude other causes of abdominal pain.
3. “Thumbprinting” can be seen on barium enema due to thickened edematous mucosal folds.

D. Treatment

1. Supportive measures: IV fluids and broad-spectrum antibiotics
2. Direct intra-arterial infusion of papaverine (vasodilator) into the superior mesenteric system during arteriography is the therapy of choice for all arterial causes of acute mesenteric ischemia. This relieves the occlusion and vasospasm.
3. Direct intra-arterial infusion of thrombolytics or embolectomy may be indicated in some patients with embolic acute mesenteric ischemia.
4. Heparin anticoagulation is the treatment of choice for venous thrombosis.
5. Surgery (resection of nonviable bowel) may be needed in all types of acute mesenteric ischemia if signs of peritonitis develop.
Chronic Mesenteric Ischemia

Caused by atherosclerotic occlusive disease of main mesenteric vessels (celiac artery, superior and inferior mesenteric arteries).

Abdominal angina—dull pain, typically postprandial (when there is increased demand for splanchnic blood flow); analogous to anginal pain of CAD.

Significant weight loss may occur due to abdominal angina.

Mesenteric arteriography confirms the diagnosis.

Surgical revascularization is definitive treatment and leads to pain relief in 90% of cases.

Quick HIT

Patients with Ogilvie syndrome are usually ill and commonly have a history of recent surgery or medical illness.
Ogilvie Syndrome

An unusual problem in which signs, symptoms, and radiographic evidence of large bowel obstruction are present, but there is no mechanical obstruction. Common causes include recent surgery or trauma, serious medical illnesses (e.g., sepsis, malignancy), and medications (e.g., narcotics, psychotropic drugs, anticholinergics). The diagnosis cannot be confirmed until mechanical obstruction of the colon is excluded. Treatment consists of stopping any offending agent and supportive measures (IV fluids, electrolyte repletion). Decompression with gentle enemas or nasogastric suction may be helpful. Colonoscopic decompression is usually successful if the above measures fail. Surgical decompression with cecostomy or colostomy is a last resort.

Quick HIT

Whenever there is colonic distention and the colon diameter exceeds 10 cm, bowel is at risk of impending rupture leading to peritonitis and even death; decompress immediately.
Colonic Volvulus

A. General Characteristics
1. Defined as twisting of a loop of intestine about its mesenteric attachment site.
2. May result in obstruction or vascular compromise with the potential for necrosis and/or perforation if untreated.
3. The most common site is the sigmoid colon (75% of all cases).
4. Cecal volvulus accounts for 25% of all cases.
5. Risk factors
   a. Chronic illness, age, institutionalization, and CNS disease increase risk of sigmoid volvulus.
   b. Cecal volvulus is due to congenital lack of fixation of the right colon and tends to occur in younger patients.
   c. Chronic constipation, laxative abuse, antimitotility drugs.
   d. Prior abdominal surgery.

B. Clinical Features
1. Acute onset of colicky abdominal pain
2. Obstipation, abdominal distention
3. Anorexia, nausea, vomiting

C. Diagnosis
1. Plain abdominal films.
   a. Sigmoid volvulus—Omega loop sign (or bent inner-tube shape) indicates a dilated sigmoid colon.
   b. Cecal volvulus (distention of cecum and small bowel)—Coffee bean sign indicates a large air–fluid level in RLQ.
2. Sigmoidoscopy—preferred diagnostic and therapeutic test for sigmoid volvulus (not for cecal volvulus); leads to successful treatment (untwisting and decompression) in many cases.
3. Barium enema—reveals the narrowing of the colon at the point where it is twisted (“bird’s beak”).

D. Treatment
1. Sigmoid volvulus: Nonoperative reduction (decompression via sigmoidoscopy) is successful in >70% of cases. The recurrence rate is high, so elective sigmoid colon resection is recommended.
2. Cecal volvulus: Emergent surgery is indicated.
Quick HIT

Do not perform a barium enema if strangulation is suspected!
Diseases of the Liver

Acute Liver Failure

A. General Characteristics
1. Acute liver failure refers to an acute, severe liver injury with concurrent encephalopathy and impaired synthetic liver function.
2. In order to diagnose, patients must not have underlying liver disease or cirrhosis prior to insult.
3. Typically, time course of illness is less than 26 weeks.

B. Causes
1. A large number of insults can cause acute liver failure. Most notably are as follows:
   a. Acetaminophen
   b. Hepatitis A, B, C, D, E
   c. Autoimmune hepatitis
   d. Wilson disease
   e. Ischemic hepatopathy
   f. Budd–Chiari disease
   g. Acute fatty liver of pregnancy/HELLP syndrome
   h. Metastasis
   i. Sepsis
   j. Toxins

C. Diagnosis
1. Diagnosis requires three components: encephalopathy, INR >1.5 (impaired synthetic liver function) and elevated liver enzymes.
2. Patients may also present with jaundice, hepatomegaly, abdominal tenderness, and thrombocytopenia.
3. Etiology of disease can determined though history, physical exam, laboratory tests, and imaging studies (CT abdomen/pelvis, MRI, abdominal US). A liver biopsy may be necessary.

Quick HIT

Signs of Acute Liver Failure (any of the following may be present):
- Coagulopathy
- Jaundice
- Hypoglycemia (liver stores glycogen)
D. Management

1. Patients should be watched closely as they can quickly decompensate. Eligibility for liver transplant should be considered early, although 40% of patients will recover with supportive care (nutritional support and treating complications).
2. Treat underlying cause if applicable.
3. Encephalopathy—monitor with neurologic checks every 2 hours. Consider lactulose therapy, although not shown to improve overall outcomes.
4. Cerebral edema risk of elevated intracranial pressure (ICP) and brainstem herniation (a major cause of morbidity and mortality). Consider monitoring ICP in patients with advancing encephalopathy. Treat elevated ICP with mannitol.
5. Liver transplantation. Eighty percent 1-year survival posttransplant
Cirrhosis

A. General Characteristics

1. Cirrhosis is a chronic liver disease characterized by fibrosis, disruption of the liver architecture, and widespread nodules in the liver. The fibrous tissue replaces damaged or dead hepatocytes.

2. Cirrhosis is generally irreversible when advanced. In early stages, specific treatment of the cause of cirrhosis may improve or reverse the condition. The point at which the disease becomes irreversible is not clear.

3. The distortion of liver anatomy causes two major events.
   a. Decreased blood flow through the liver with subsequent hypertension in portal circulation (portal hypertension)—this has widespread manifestations, including ascites, peripheral edema, splenomegaly, and varicosity of veins “back stream” in the circulation (e.g., gastric/esophageal varices, hemorrhoids).
   b. Hepatocellular failure that leads to impairment of biochemical functions, such as decreased albumin synthesis and decreased clotting factor synthesis.

   a. Child–Pugh score (see Table 3-1) estimates hepatic reserve in liver failure. It is used to measure disease severity and is a predictor of morbidity and mortality.
   b. Child’s class C indicates most severe disease, and Child’s class A indicates milder disease.
   c. Model for End-Stage Liver Disease (MELD) score is a severity scale to predict 3-month survival. Scoring is also used to prioritize patients awaiting liver transplant. Calculation depends on patient’s serum bilirubin, serum creatinine, and INR. An increased MELD score in cirrhotic patients is associated with an increased 3-month mortality risk.

---

**TABLE 3-1** Child–Pugh Classification to Assess Severity of Liver Disease

<table>
<thead>
<tr>
<th>Child–Pugh Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Mild disease</td>
</tr>
<tr>
<td>B</td>
<td>Moderate disease</td>
</tr>
<tr>
<td>C</td>
<td>Severe disease</td>
</tr>
</tbody>
</table>

---
## B. Causes

1. **Alcoholic liver disease—most common cause**
   a. Refers to a range of conditions from fatty liver (reversible, due to acute ingestion) to cirrhosis (irreversible)
   b. Fifteen percent to 20% of heavy drinkers develop alcoholic cirrhosis

2. **Chronic hepatitis B and C infections—next most common causes**
3. Nonalcoholic steatohepatitis (NASH)
4. Drugs (e.g., acetaminophen toxicity, methotrexate)
5. Autoimmune hepatitis
6. Primary biliary cirrhosis (PBC), secondary biliary cirrhosis
7. Inherited metabolic diseases (e.g., hemochromatosis, Wilson disease)
8. Hepatic congestion secondary to right-sided heart failure, constrictive pericarditis
9. α1-Antitrypsin (AAT) deficiency
10. Hepatic veno-occlusive disease—can occur after bone marrow transplantation

## C. Clinical Features

1. Some patients have no overt clinical findings, especially early in the disease.
2. Patients may have signs or symptoms suggestive of one or more of the complications of cirrhosis (see below).

### Quick HIT

Classic signs of chronic liver disease:
- Ascites
- Varices
- Gynecomastia, testicular atrophy
- Palmar erythema, spider angiomas on skin
D. Complications

1. Portal HTN
   a. Clinical features are listed above. **Bleeding** (hematemesis, melena, hematochezia) secondary to esophagogastric varices is the most life-threatening complication of portal HTN.
   b. Diagnose based on above features. Paracentesis can help in diagnosis.
   c. Treat the specific complication. **Use transjugular intrahepatic portosystemic shunt (TIPS)** to lower portal pressure.

2. Varices
   a. Esophageal/gastric
      - Variceal hemorrhage has a high mortality rate. Patients with cirrhosis should be evaluated for the presence of varices and risk of hemorrhage. **If varices are present, prophylactic measures are indicated (such as nonselective β-blocker).**
      - Clinical features include massive hematemesis, melena, and exacerbation of hepatic encephalopathy.
      - Esophageal varices account for 90% of varices, and gastric varices for 10%.
      - Initial treatment is hemodynamic stabilization (give fluids to maintain BP). See **Clinical Pearl 3-2** for methods aimed at stopping bleeding.
      - IV antibiotics are given prophylactically.
      - IV octreotide is initiated and continued for 3 to 5 days.
      - Perform **emergent upper GI endoscopy** (once patient is stabilized) for diagnosis and to treat the hemorrhage either with variceal ligation or sclerotherapy.
      - Give nonselective β-blockers (propranolol, timolol, nadolol) as long-term therapy to prevent rebleeding.

**Quick HIT**

Once a patient develops complications of cirrhosis, they have “decompensated” disease, with high morbidity and mortality.

**Quick HIT**

Treatment of bleeding esophageal varices involves pharmacologic treatment with IV octreotide in addition to endoscopic treatment (sclerotherapy or variceal ligation).

b. Rectal hemorrhoids
c. *Caput medusae* (distention of abdominal wall veins)

3. Ascites (see also Clinical Pearl 3-3)
   a. Accumulation of fluid in the peritoneal cavity due to portal HTN (increased hydrostatic pressure) and hypalbuminemia (reduced oncotic pressure). Ascites is the most common complication of cirrhosis. Patients without portal hypertension do not develop ascites.
   b. Clinical features: abdominal distention, shifting dullness, and fluid wave.
   c. Abdominal ultrasound can detect as little as 30 mL of fluid.

**CLINICAL PEARL 3-2**

**Treatment of Bleeding Esophageal Varices**

- Variceal ligation/banding
  - Initial endoscopic treatment of choice.
  - Effective control of active bleeding.
  - Lower rate of rebleeding than sclerotherapy.
- Endoscopic sclerotherapy
  - Sclerosing substance is injected into varices during endoscopy.
  - This controls acute bleeding in 80% to 90% of cases.
  - Up to 50% of patients may have rebleeding.
- IV vasopressin
  - This is an alternative to octreotide, but is rarely used due to the risk of complications.
  - Vasoconstriction of mesenteric vessels reduces portal pressure.
- IV octreotide infusion
  - Has replaced vasopressin as first-line therapy; causes splanchnic vasoconstriction and reduces portal pressure.
  - Fewer side effects than vasopressin.
- Other options include esophageal balloon tamponade (Sengstaken–Blakemore tube is a temporary measure), repeat sclerotherapy, TIPS, surgical shunts, and liver transplantation.

d. Diagnostic paracentesis determines whether ascites is due to portal HTN or another process.
   - Indications include new-onset ascites, worsening ascites, and suspected spontaneous bacterial peritonitis (SBP) (see below).
   - Examine cell count, ascites albumin, Gram stain, and culture to rule out infection (e.g., SBP).
   - Measure the *serum ascites albumin gradient*. If it is >1.1 g/dL, portal HTN is very likely. If <1.1 g/dL, portal HTN is unlikely, and other causes must be considered.

**Quick HIT**

Ascites can be managed by salt restriction and diuretics in most cases.
e. Treatment
- A low-sodium diet and diuretics: spironolactone (used to reduce accumulation of fluid) and furosemide (used to prevent hyperkalemia caused by spironolactone).
- Perform therapeutic paracentesis if tense ascites, shortness of breath, or early satiety is present.
- Peritoneovenous shunt or TIPS to reduce portal HTN

Quick HIT

Complications of Liver Failure (note the mnemonic AC, 9H)
- Ascites
- Coagulopathy
- Hypoalbuminemia
- Portal hypertension
- Hyperammonemia
- Hepatic encephalopathy
- Hepatorenal syndrome
- Hypoglycemia
- Hyperbilirubinemia/jaundice
- Hyperestrinism
- HCC

4. Hepatic encephalopathy
   a. Toxic metabolites (there are many, but ammonia is believed to be most important) that are normally detoxified or removed by the liver accumulate and reach the brain.
   b. Occurs in 50% of all cases of cirrhosis, with varying severity.

CLINICAL PEARL 3-3

Differential Diagnosis of Ascites
- Cirrhosis, portal HTN
- CHF
- Chronic renal disease
- Massive fluid overload
- Tuberculous peritonitis
- Malignancy
- Hypoalbuminemia
- Peripheral vasodilation secondary to endotoxin-induced release of nitrous oxide, which leads to increased renin secretion (and thus secondary hyperaldosteronism)
- Impaired liver inactivation of aldosterone

c. Precipitants include alkalosis, hypokalemia (e.g., due to diuretics), sedating drugs (narcotics, sleeping medications), GI bleeding, systemic infection, and
hypovolemia.

d. Clinical features
   - Decreased mental function, confusion, poor concentration, even stupor or coma
   - Asterixis ("flapping tremor")—have the patient extend the arms and dorsiflex the hands. (However, this is not a specific sign.)
   - Rigidity, hyperreflexia
   - Fetor hepaticus—musty odor of breath

e. Treatment
   - Lactulose prevents absorption of ammonia. Metabolism of lactulose by bacteria in the colon favors formation of NH$_4^+$, which is poorly absorbed from GI tract, thereby promoting excretion of ammonia.
   - Rifaximin (antibiotic): kills bowel flora; so decreases ammonia production by intestinal bacteria. Historically, neomycin was used, but rifaximin has less side effects with same efficacy.
   - Diet—limit protein to 30 to 40 g/day.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring Patients With Cirrhosis</td>
</tr>
<tr>
<td>- Order periodic laboratory values every 3 to 4 months (CBC, renal function tests, electrolytes, LFTs, and coagulation tests).</td>
</tr>
<tr>
<td>- Perform an endoscopy to determine the presence of esophageal varices.</td>
</tr>
<tr>
<td>- If HCC is suspected, perform a CT-guided biopsy for diagnosis.</td>
</tr>
</tbody>
</table>

5. **Hepatorenal syndrome**—indicates end-stage liver disease
   - Progressive renal failure in advanced liver disease, secondary to renal hypoperfusion resulting from vasoconstriction of renal vessels.
   - Often precipitated by infection or diuretics.
   - This is a functional renal failure—kidneys are normal in terms of morphology, and no specific causes of renal dysfunction are evident. This condition does not respond to volume expansion.
   - Clinical features: azotemia, oliguria, hyponatremia, hypotension, low urine sodium (<10 mEq/L).
   - Treatment: Liver transplantation is the only cure. In general, the prognosis is very poor, and the condition is usually fatal without liver transplantation.

6. **SBP**—infected ascitic fluid; occurs in up to 20% of patients hospitalized for ascites.
   - Usually occurs in patients with ascites caused by end-stage liver disease; associated with high mortality rate (20% to 30%).
b. Has a high recurrence rate (up to 70% in first year).

c. Etiologic agents.
   - *Escherichia coli* (most common)
   - *Klebsiella*
   - *Streptococcus pneumoniae*

d. Clinical features: abdominal pain, fever, vomiting, rebound tenderness. SBP may lead to sepsis.

Quick HIT
**SBP**:
Look for fever and/or change in mental status in a patient with known ascites.

e. Diagnosis is established by paracentesis and examination of ascitic fluid for WBCs (especially PMNs), Gram stain with culture, and sensitivities.
   - WBC >500, PMN >250.
   - Positive ascites culture; culture-negative SBP is common as well.

Quick HIT
If SBP is not treated early, mortality is high. Therefore, index of suspicion should be high and diagnostic paracentesis be done early.

f. Treatment
   - Broad-spectrum antibiotic therapy: give specific antibiotic once organism is identified.
   - Clinical improvement should be seen in 24 to 48 hours. Repeat paracentesis in 2 to 3 days to document a decrease in ascitic fluid PMN (<250).

7. Hyperestrinism—due to reduced hepatic catabolism of estrogens
   a. *Spider angiomas*—dilated cutaneous arterioles with central red spot and reddish extensions that radiate outward like a spider’s web
   b. Palmar erythema
   c. Gynecomastia
   d. Testicular atrophy

8. Coagulopathy—secondary to decreased synthesis of clotting factors.
   a. Prolonged prothrombin time (PT); PTT may be prolonged with severe disease.
   b. Vitamin K supplementation ineffective because it cannot be used by diseased liver.
   c. Treat coagulopathy with fresh frozen plasma.

   Hepatocellular carcinoma (HCC)—present in 10% to 25% of patients with cirrhosis. All patients with cirrhosis should be screened for HCC, most commonly
with serum AFP measurement and liver ultrasound every 6 months.

E. Treatment
1. Treat underlying cause—for example, abstinence from alcohol, interferons for hepatitis B and C.
2. Avoid agents that may cause injury to liver, such as acetaminophen and alcohol.
3. Once cirrhosis develops, aim treatment at managing any complications that arise, as described above. The most serious complications are variceal bleeding, ascites, and hepatic encephalopathy.
4. Liver transplantation is the only hope for a cure. Abstinence from alcohol for more than 6 months is required before a patient is eligible for transplantation. Decision to proceed to liver transplantation depends on quality of life, severity of disease, and absence of contraindications.
Wilson Disease

A. General Characteristics
1. An autosomal recessive disease of copper metabolism.
2. Mutations in the ATP7B gene lead to impairment of copper excretion into bile, and incorporation of copper into ceruloplasmin, a copper-binding protein that is necessary for copper excretion.
3. Therefore, copper accumulates in liver cells. As hepatocytes die, copper leaks into plasma and accumulates in various organs, including kidney, cornea, and brain.
4. The disease is most often apparent during childhood/adolescence (after age 5), and the majority of cases present between ages 5 and 35.

B. Clinical Features
1. Clinical features are due to copper deposition in various organs.
2. Liver disease (most common initial manifestation): Manifestations vary and may include acute hepatitis, cirrhosis, and fulminant hepatic failure.
3. Kayser–Fleischer rings (yellowish rings in cornea) are caused by copper deposition in cornea; they do not interfere with vision (Figure 3-1).
4. CNS findings are due to copper deposition in the CNS.
   a. Extrapyramidal signs—parkinsonian symptoms (resting tremor, rigidity, bradykinesia), chorea, drooling, incoordination due to copper deposition in basal ganglia.
   b. Psychiatric disturbances—depression, neuroses, personality changes, psychosis.
5. Renal involvement—aminoaciduria, nephrocalcinosis.

Quick HIT
Alkaline phosphatase is normal or low in Wilson disease as copper interferes with its synthesis.
C. Diagnosis

1. Diagnosis is made by determining the following (patients may have many or only a few of these findings):
   a. Hepatic disease—elevated aminotransferases; impaired synthesis of coagulation factors and albumin.
   b. Decreased serum ceruloplasmin levels (seen in 90% of patients), although ranges within normal do not exclude the diagnosis.
   c. Liver biopsy—significantly elevated copper concentration.
2. If diagnosed, first-degree relatives must be screened as well.

D. Treatment

1. Chelating agents—for example, D-penicillamine, which removes and detoxifies the excess copper deposits
2. Zinc
   a. Prevents uptake of dietary copper
   b. Given alone (to presymptomatic or pregnant patients) or in conjunction with chelating agents (to symptomatic patients)
3. Liver transplantation (if unresponsive to therapy or fulminant liver failure)
4. Monitor patient’s copper levels, urinary copper excretion, ceruloplasmin, and liver
function; physical examination for signs of liver or neurologic disease; psychological health

Quick HIT

Secondary hemochromatosis (iron overload) can occur with multiple transfusions or in chronic hemolytic anemias.
**Hemochromatosis**

**A. General Characteristics**
1. An autosomal recessive disease of iron absorption
2. Excessive iron absorption in the intestine leads to increased accumulation of iron (as ferritin and hemosiderin) in various organs. Over many years, fibrosis in involved organs occurs secondary to hydroxyl free radicals that are generated by the excess iron.
3. Affected organs
   a. Liver (primary organ)
   b. Pancreas
   c. Heart
   d. Joints
   e. Skin
   f. Thyroid, gonads, hypothalamus
4. This is an inherited disease, so screen the patient’s siblings. Early diagnosis and treatment before development of complications (primarily cirrhosis, but also heart disease and diabetes) improve survival.

**Quick HIT**

Hemochromatosis: Early in the disease course, mild elevation of ALT and AST levels may be the only abnormalities that are noted because the patient is usually asymptomatic. Obtain iron studies. If the iron level is elevated, order a liver biopsy to confirm the diagnosis.

**B. Clinical Features**
1. Most patients are asymptomatic initially.
2. Findings may include signs of liver disease, fatigue, arthritis, impotence/amenorrhea, abdominal pain, and cardiac arrhythmias.

**C. Complications**
1. Cirrhosis
   a. Cirrhosis increases the risk of HCC by 200-fold.
   b. The presence of liver disease is a primary factor in determining the prognosis.
2. Cardiomyopathy—CHF, arrhythmias
3. Diabetes mellitus—due to iron deposition in the pancreas
4. Arthritis—most common sites are the second and third metacarpophalangeal joints, hips, and knees.
5. Hypogonadism—impotence, amenorrhea, loss of libido
6. Hypothyroidism
7. Hyperpigmentation of skin (resembles suntan, “bronzelike”)

D. Diagnosis
1. Markedly elevated serum iron and serum ferritin
2. Elevated iron saturation (transferrin saturation)
3. Decreased total iron–binding capacity (TIBC)
4. Genetic testing for etiologic mutations (gold standard for diagnosis)

E. Treatment
1. **Perform repeated phlebotomies**—this is the treatment of choice and improves survival dramatically if initiated early in the course of the disease.
2. Treat any complications (e.g., CHF, diabetes, hypothyroidism, arthritis).
3. Consider liver transplantation in advanced cases.
Hepatocellular Adenoma

Benign liver tumor, most often seen in young women (15 to 40 years of age). Oral contraceptive use, female sex, and anabolic steroid use are the main risk factors. Patient may be asymptomatic; hepatocellular adenoma may be discovered incidentally on abdominal imaging studies. RUQ pain or fullness may be present. Malignant potential is very low (<1%). However, the adenoma may rupture, leading to hemoperitoneum and hemorrhage. Diagnosis made by CT scan, ultrasound, or hepatic arteriography (most accurate but invasive). Treatment: Discontinue oral contraceptives; surgically resect tumors >5 cm that do not regress after stopping oral contraceptives (otherwise there is a risk of rupture).
Cavernous Hemangiomas

Vascular tumors that are usually small and asymptomatic. They are the most common type of benign liver tumor.

As the size of the tumor increases (e.g., due to pregnancy or use of oral contraceptives), the symptoms increase and include RUQ pain or mass. Complications (uncommon unless tumor is very large) include rupture with hemorrhage, obstructive jaundice, coagulopathy, CHF secondary to a large AV shunt, and gastric outlet obstruction.

Diagnose with ultrasound or CT scan with IV contrast. Biopsy contraindicated because of risk of rupture and hemorrhage.

Most cases do not require treatment. Consider resection if the patient is symptomatic or if there is a high risk of rupture (as with large tumors).
Focal Nodular Hyperplasia

This benign liver tumor without malignant potential occurs in women of reproductive age. **There is no association with oral contraceptives.** It is usually asymptomatic. Hepatomegaly may be present. Treatment not necessary in most cases.
Hepatocellular Carcinoma (Malignant Hepatoma)

A. General Characteristics
1. HCC accounts for more than 80% of primary liver cancers and, although rare in the United States, accounts for most deaths due to cancers worldwide. High-risk areas include Africa and Asia.
2. There are two pathologic types
   a. Nonfibrolamellar (most common)
      - Usually associated with hepatitis B or C and cirrhosis
      - Usually unresectable with very short survival time (months)
   b. Fibrolamellar
      - Usually not associated with hepatitis B or C or cirrhosis
      - More often resectable; relatively longer survival time
      - Seen most commonly in adolescents and young adults

Quick HIT
The most common malignant liver tumors are HCCs and cholangiocarcinomas. The most common benign liver tumor is the hemangioma.

B. Risk Factors
1. Cirrhosis, especially in association with alcohol or hepatitis B or C; HCC develops in 10% of cirrhotic patients.
2. Chemical carcinogens: for example, aflatoxin, vinyl chloride, Thorotrast
3. AAT deficiency
4. Hemochromatosis, Wilson disease
5. Schistosomiasis
6. Hepatic adenoma (10% risk of malignant transformation)
7. Cigarette smoking
8. Glycogen storage disease (type 1)

C. Clinical Features
1. Abdominal pain (painful hepatomegaly)
2. Weight loss, anorexia, fatigue
3. Signs and symptoms of chronic liver disease—portal HTN, ascites, jaundice, splenomegaly
4. Paraneoplastic syndromes—erythrocytosis, thrombocytosis, hypercalcemia, carcinoid syndrome, hypertrophic pulmonary osteodystrophy, hypoglycemia, high cholesterol
Prognosis of HCC
- If unresectable: less than 1 year
- If resectable: 25% of patients are alive at 5 years

D. Diagnosis
1. Liver biopsy—required for definitive diagnosis
2. Laboratory tests—hepatitis B and C serology, liver function tests (LFTs), coagulation tests
3. Imaging studies—ultrasound, CT scan (chest, abdomen, pelvis); MRI or MRA if surgery is an option (provides more detail about the anatomy of the tumor)
4. Tumor marker elevation (AFP) is useful as a screening tool. AFP level may be elevated in 40% to 70% of patients with HCC, and is also helpful in monitoring response to therapy.

E. Treatment
1. Liver resection (in the 10% of patients who have resectable tumors)
2. Liver transplantation if diagnosis is made early
3. If unresectable, consider transcatheter arterial chemoembolization (TACE), radiofrequency ablation, or selective internal radiation therapy
Nonalcoholic Steatohepatitis

Histology of the liver is identical to that in patients with alcoholic liver disease, but these patients do not have a history of alcohol use!
Associated with obesity, hyperlipidemia, diabetes mellitus (some patients have none of these).
Usually asymptomatic and has a benign course (but cirrhosis develops in 10% to 15%)
Typically discovered on routine laboratory tests (mild elevation in alanine aminotransferase [ALT] and aspartate aminotransferase [AST])
Treatment is not clearly established.
Hemobilia

Refers to blood draining into the duodenum via the common bile duct (CBD). The source of bleeding can be anywhere along the biliary tract, the liver, or the ampullary region.

Causes—trauma (most common), papillary thyroid carcinoma, surgery (e.g., cholecystectomy, CBD exploration), tumors, and infection.

Clinical features—GI bleeding (melena, hematemesis), jaundice, and RUQ pain.

Arteriogram is diagnostic. Upper GI endoscopy shows blood coming out of the ampulla of Vater.

Treatment—resuscitation (may require transfusion). If bleeding is severe, surgery is necessary (options include ligation of hepatic arteries or arteriogram with embolization of vessel).
Liver Cysts

A. Polycystic Liver Cysts
Autosomal dominant, usually associated with polycystic kidney disease. Polycystic kidney disease often results in renal failure and is the main determinant of prognosis, whereas liver cysts rarely lead to hepatic fibrosis and liver failure.
Usually asymptomatic; some patients have abdominal pain and upper abdominal mass.
Treatment is unnecessary in most cases.

B. Hydatid Liver Cysts
Caused by infection from the tapeworm *Echinococcus granulosus* or, less commonly, *Echinococcus multilocularis*. Cysts most commonly occur in the right lobe of the liver.
Small cysts are asymptomatic; larger cysts may cause RUQ pain and rupture into the peritoneal cavity, causing fatal anaphylactic shock.
Treatment is surgical resection (caution to avoid spilling contents of the cyst into the peritoneal cavity). Mebendazole is given after surgery.

Quick HIT

The most common location for liver abscess (both pyogenic and amebic) is the right lobe.
**Liver Abscess**

A. Pyogenic Liver Abscess

Most common cause is biliary tract obstruction—obstruction of bile flow allows bacterial proliferation. Other causes include GI infection (e.g., diverticulitis, appendicitis), with spread via portal venous system, and penetrating liver trauma (e.g., gunshot wound, surgery). Causative organisms include *Escherichia coli, Klebsiella, Proteus, Enterococcus,* and anaerobes. Clinical features include fever, malaise, anorexia, weight loss, nausea, vomiting, RUQ pain, and jaundice. Patients appear quite ill. Diagnosed by ultrasound or CT scan; elevated LFTs. Fatal if untreated. Treatment (IV antibiotics and percutaneous drainage of abscess) reduces mortality to about 5% to 20%. Surgical drainage is sometimes necessary.

B. Amebic Liver Abscess

Most common in men (9:1), particularly men who have sex with men. Transmitted through fecal–oral contact. Caused by intestinal amebiasis (*Entamoeba histolytica*)—the amebae reach the liver via the hepatic portal vein. Clinical features—fever, RUQ pain, nausea/vomiting, hepatomegaly, diarrhea. Serologic testing (immunoglobulin G enzyme immunoassay) establishes diagnosis. LFTs are often elevated. The *Entamoeba histolytica* stool antigen test (detects protozoa in stool) is not sensitive. Imaging studies (ultrasound, CT) identify the abscess, but it is difficult to distinguish from a pyogenic abscess. IV metronidazole is effective treatment in most cases. Therapeutic aspiration of the abscess (image-guided percutaneous aspiration) may be necessary if the abscess is large (high risk of rupture), or if there is no response to medical therapy.

*Quick HIT*

Pyogenic and amebic abscesses are potentially life threatening, if not detected early.
Budd–Chiari Syndrome

A. General Characteristics
1. Liver disease caused by occlusion of hepatic venous outflow, which leads to hepatic congestion and subsequent microvascular ischemia.
2. The course is variable, but most cases are indolent, with gradual development of portal HTN and progressive deterioration of liver function.
3. Rarely the disease is severe and leads to acute liver failure, which may be fatal without immediate therapy.

B. Causes—hypercoagulable states, myeloproliferative disorders (e.g., polycythemia vera), pregnancy, chronic inflammatory diseases, infection, various cancers, trauma. Condition is idiopathic in up to 40% of cases.

C. Clinical Features (resemble those of cirrhosis)—hepatomegaly, ascites, abdominal pain (RUQ), jaundice, variceal bleeding.

D. Diagnosis—hepatic venography; serum ascites albumin gradient >1.1 g/dL.

E. Treatment
1. Medical therapy (e.g., anticoagulation, thrombolytics, diuretics) is usually unsatisfactory.
2. Surgery is eventually necessary in most cases (balloon angioplasty with stent placement in inferior vena cava, portacaval shunts).
3. Liver transplantation if cirrhosis is present.

CLINICAL PEARL 3-4

Bilirubin Metabolism
- Eighty percent of bilirubin is derived from hemoglobin (RBC breakdown). The rest comes from myoglobin breakdown and liver enzymes.
- Hemoglobin is converted to bilirubin in the spleen. This unconjugated bilirubin circulates in plasma, bound to albumin. This bilirubin–albumin complex is not water soluble; therefore, it is not excreted in urine. In the liver, it dissociates from albumin, and the bilirubin is conjugated and excreted into the intestine, where bacteria act on it to produce urobilinogen and urobilin.
- Therefore, unconjugated hyperbilirubinemia results when there is a defect before hepatic uptake. Conjugated hyperbilirubinemia results when there is a defect after hepatic uptake.

Quick HIT
Three Major Causes of Jaundice
- Hemolysis
- Liver disease
- Biliary obstruction
Jaundice

A. General Characteristics
1. Yellow coloration of skin, mucous membranes, and sclerae due to overproduction or underclearance of bilirubin (see also Clinical Pearl 3-4)
2. Clinical jaundice usually becomes evident when total bilirubin is >2 mg/dL
3. Conjugated versus unconjugated bilirubin
   a. Conjugated (direct)
      • Loosely bound to albumin and therefore water soluble.
      • When present in excess, it is excreted in urine. Therefore, dark urine is only seen with conjugated bilirubinemia!
      • Nontoxic.
   b. Unconjugated (indirect)
      • Tightly bound to albumin and therefore not water soluble.
      • Cannot be excreted in urine even if blood levels are high.
      • Toxic—unbound form can cross blood–brain barrier and cause neurologic deficits.

Quick HIT

Dark urine and pale stools signal a diagnosis of conjugated hyperbilirubinemia.

B. Causes
1. Conjugated hyperbilirubinemia—urine positive for bilirubin (see also Clinical Pearl 3-5)
   a. Decreased intrahepatic excretion of bilirubin
      • Hepatocellular disease (viral or alcoholic hepatitis, cirrhosis)
      • Inherited disorders (Dubin–Johnson syndrome, Rotor syndrome)
      • Drug induced (oral contraceptives)
      • PBC
      • Primary sclerosing cholangitis (PSC)

CLINICAL PEARL 3-5

Cholestasis
- This refers to blockage of bile flow (whether intra- or extrahepatic) with a resultant increase in conjugated bilirubin levels.
- Clinical findings
- Jaundice, gray stools, dark urine
- Pruritus (bile salt deposition in skin)
b. Extrahepatic biliary obstruction
   - Gallstones
   - Carcinoma of head of the pancreas
   - Cholangiocarcinoma
   - Periampullary tumors
   - Extrahepatic biliary atresia

2. **Unconjugated hyperbilirubinemia—urine negative for bilirubin**
   a. Excess production of bilirubin—hemolytic anemias
   b. Reduced hepatic uptake of bilirubin or impaired conjugation
      - **Gilbert syndrome**
        - Occurs in up to 7% of the population—autosomal dominant condition in which there is decreased hepatic uridine diphosphate (UDP) glucuronyl transferase activity.
        - Common cause of isolated elevation of unconjugated bilirubin.
        - Exacerbated by fasting (crash diets), fever, alcohol, and infection.
        - Asymptomatic in most cases, but occasionally mild jaundice may be present.
        - Liver biopsy results are normal, and usually no treatment is necessary.
      - Drugs (e.g., sulfonamides, penicillin, rifampin, radiocontrast agents)
      - **Crigler–Najjar syndrome**
        - Type 1—Complete absence of UDP-glucuronosyltransferase in hepatic tissue. Severe unconjugated bilirubinemia, often resulting in brain damage at birth.
        - Type 2—Reduced UDP-glucuronosyltransferase activity, but can be detected in hepatic tissue. Not as severe as type 1.
      - Physiologic jaundice of the newborn (immaturity of conjugating system)
      - Diffuse liver disease (hepatitis, cirrhosis)

**Quick HIT**
If there is no hemolysis, isolated unconjugated hyperbilirubinemia may indicate Gilbert syndrome, which is usually asymptomatic.

**C. Diagnosis**
1. Serum levels of total conjugated and unconjugated bilirubin (Figure 3-2).
2. If unconjugated hyperbilirubinemia: CBC, reticulocyte count, haptoglobin, LDH, and peripheral smear may aid in diagnosis of hemolysis as the cause of jaundice.
3. If conjugated hyperbilirubinemia, LFTs may point to the cause.
4. Ultrasound (or CT scan) to assess biliary tract for obstruction or anatomic changes.
5. Additional tests (e.g., endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiography [PTC])—depending on the findings of the above tests.
6. Liver biopsy may be indicated in some cases to determine cause of hepatocellular injury.

**Quick HIT**
- ALT is primarily found in the liver.
- AST is found in many tissues (e.g., skeletal muscle, heart, kidney, brain).

**D. Treatment**
1. Treat the underlying cause.
Liver Function Tests

A. Aminotransferases (ALT and AST)

1. ALT is more sensitive and specific than AST for liver damage.
2. ALT and AST usually have a similar increase. The exception is in alcoholic hepatitis, in which the AST–ALT ratio may be >2:1.
3. If ALT and AST levels are mildly elevated (low hundreds), think of chronic viral hepatitis or acute alcoholic hepatitis.
4. If ALT and AST levels are moderately elevated (high hundreds to thousands), think of acute viral hepatitis.
5. If ALT and AST levels are severely elevated (>10,000), extensive hepatic necrosis has occurred. Typical cases are:
   a. Ischemia, shock liver (prolonged hypotension or circulatory collapse)
   b. Acetaminophen toxicity
   c. Severe viral hepatitis
6. Note that liver transaminases are often normal or even low in patients with cirrhosis (without any active cell necrosis) or metastatic liver disease, because the number of healthy functioning hepatocytes is markedly reduced.
FIGURE 3.2 Evaluation of jaundice.
7. The following can cause an elevation in ALT or AST levels in asymptomatic patients (note the mnemonic):
   a. Autoimmune hepatitis  
   b. Hepatitis B  
   c. Hepatitis C  
   d. Drugs or toxins  
   e. Ethanol  
   f. Fatty liver (triglyceridemia)  
   g. Growths (tumors)  
   h. Hemodynamic disorders (e.g., CHF)  
   i. Iron (hemochromatosis), copper (Wilson disease), or AAT deficiency

B. Alkaline Phosphatase (ALK-P): Not specific to liver—also found in bone, gut, and placenta.
1. ALK-P is elevated when there is obstruction to bile flow (e.g., cholestasis) in any part of the biliary tree. Normal levels make cholestasis unlikely.
2. If levels are very high (10-fold increase), think of extrahepatic biliary tract obstruction or intrahepatic cholestasis (e.g., PBC or drug-induced cirrhosis).
3. If levels are elevated, measure the gamma-glutamyl-transferase (GGT) level to make sure the elevation is hepatic in origin (rather than bone or intestinal). If the GGT level is also elevated, this strongly suggests a hepatic origin. If the GGT level is normal but ALK-P is elevated, consider pregnancy or bone disease.

Quick HIT

- In alcoholic hepatitis, the AST level is almost never >500, and the ALT level is almost never >300.
- The higher the AST–ALT ratio, the greater the likelihood that alcohol is contributing to the abnormal LFTs.

C. Bilirubin (see Jaundice section)

Quick HIT

LFT Pearls
- Cholestatic LFTs: markedly elevated alkaline phosphatase and GGT; ALT and AST are slightly elevated
- Hepatocellular necrosis or inflammation: normal or slightly elevated alkaline phosphatase; markedly elevated ALT and AST

D. GGT is often used to confirm that the ALK-P elevation is of hepatic origin (see above).

E. Albumin—decreased in chronic liver disease, nephrotic syndrome, malnutrition,
and inflammatory states (e.g., burns, sepsis, trauma).

F. Prothrombin Time (PT)
1. The liver synthesizes clotting factors I, II, V, VII, IX, X, XII, and XIII, the function of which is reflected by PT.
2. PT is not prolonged until most of the liver’s synthetic capacity is lost, which corresponds to advanced liver disease.
Diseases of the Gallbladder and Biliary Tract

A. Cholelithiasis

1. Cholelithiasis refers to stones in the gallbladder (i.e., gallstones).
2. Types of stones.
   a. Cholesterol stones (yellow to green)—associated with the following:
      - Obesity, diabetes, hyperlipidemia
      - Multiple pregnancies, oral contraceptive use
      - Crohn disease, ileal resection
      - Advanced age
      - Native American ancestry
      - Cirrhosis
      - Cystic fibrosis
   b. Pigment stones
      - Black stones are usually found in the gallbladder and are associated with either hemolysis (e.g., sickle cell disease, thalassemia, hereditary spherocytosis, artificial cardiac valves) or alcoholic cirrhosis.
      - Brown stones are usually found in bile ducts and are associated with biliary tract infection.
   c. Mixed stones have components of both cholesterol and pigment stones, and account for the majority of stones.

Quick HIT

Cholestasis refers to obstruction of bile flow from any cause. If LFTs reveal cholestasis, obtain an abdominal or RUQ ultrasound.

B. Clinical Features

1. Most cases are asymptomatic. Majority of patients found to have incidental gallstones will remain asymptomatic.
2. Biliary colic is the cardinal symptom of gallstones and is due to temporary obstruction of the cystic duct by a gallstone. Pain occurs as the gallbladder contracts against this obstruction.
   a. Pain is typically located in the RUQ or epigastrium and may be mild, moderate, or severe.
   b. Patients classically report pain after eating and at night.
c. *Boas sign*—referred right subscapular pain of biliary colic.

**Quick HIT**

One-third of patients with biliary colic develop acute cholecystitis within 2 years.

**C. Complications**

1. Cholecystitis (chronic or acute) with prolonged obstruction of cystic duct.
2. Choledocholithiasis with its associated complications—see below.
3. Gallstone ileus
4. Malignancy

**Quick HIT**

Pain in acute cholecystitis is secondary to gallbladder wall inflammation, whereas the pain of biliary colic is secondary to the contraction of the gallbladder against the obstructed cystic duct. Also, the pain of acute cholecystitis persists for several days, whereas the pain of biliary colic lasts only a few hours.

**D. Diagnosis**

1. RUQ ultrasound has high sensitivity and specificity (>95%) for stones >2 mm.
2. CT scan and MRI are alternatives.

**E. Treatment**

1. No treatment if the patient is asymptomatic.
2. Elective cholecystectomy for patients with recurrent bouts of biliary colic.
Acute Cholecystitis

A. General Characteristics
1. Obstruction of the cystic duct (not infection) induces acute inflammation of the gallbladder wall.
2. Chronic cholecystitis may develop with recurrent bouts of acute cholecystitis.
3. Ten percent of patients with gallstones develop acute cholecystitis.

B. Clinical Features
1. Symptoms
   a. Pain is always present and is located in RUQ or epigastrium; it may radiate to the right shoulder or scapula.
   b. Nausea and vomiting, anorexia
2. Signs
   a. RUQ tenderness, rebound tenderness in RUQ
   b. Murphy sign is pathognomonic—inspiratory arrest during deep palpation of the RUQ; not present in many cases
   c. Hypoactive bowel sounds
   d. Low-grade fever, leukocytosis

C. Diagnosis
1. RUQ ultrasound is the test of choice.
   a. High sensitivity and specificity
   b. Findings include thickened gallbladder wall, pericholecystic fluid, distended gallbladder, and presence of stone(s).
2. CT scan is as accurate as ultrasound but is more sensitive in identifying complications of acute cholecystitis (e.g., perforation, abscess, pancreatitis).
3. Radionuclide scan (hepatoiminodiacetic acid [HIDA])
   a. Used when ultrasound is inconclusive. Its sensitivity and specificity parallel that of ultrasound. If HIDA scan is normal, acute cholecystitis can be ruled out.
   b. A positive HIDA scan means the gallbladder is not visualized.
c. If gallbladder is not visualized 4 hours after injection, diagnosis of acute cholecystitis is confirmed.

**Quick HIT**

Acute cholecystitis is a syndrome of RUQ pain, fever, and leukocytosis associated with gallbladder inflammation.

**Quick HIT**

**Complications of Cholecystitis**
- Gangrenous cholecystitis
- Perforation of gallbladder
- Emphysematous cholecystitis
- Cholecystoenteric fistula with gallstone ileus
- Empyema of gallbladder

### D. Treatment

1. Patient should be admitted. Conservative measures include hydration with IV fluids, bowel rest (NPO), IV antibiotics, analgesics, correction of electrolyte abnormalities.

2. Surgery—cholecystectomy is indicated in most patients with symptomatic gallstones. Early cholecystectomy is preferred (first 24 to 48 hours). Recurrence rate with nonsurgical treatment is as high as 70%. In most patients, early cholecystectomy is preferred.

3. In critically ill patients with high surgical risk, percutaneous cholecystostomy tube placement for drainage of the gallbladder is an alternative to immediate surgery.

**Quick HIT**

**Gallstone Ileus**
- Gallstone enters bowel lumen via cholecystoenteric fistula—gets “stuck” in terminal ileum and causes obstruction.
- Accounts for 1% to 2% of bowel obstructions.

**Quick HIT**

Complications of acute cholecystitis include gangrene and gallbladder perforation, which can be life threatening.


**Acalculous Cholecystitis**

Acute cholecystitis without stones obstructing the cystic duct (up to 10% of patients with acute cholecystitis).

Usually idiopathic and seen in patients with severe underlying illness; possibly associated with dehydration, ischemia, burns, severe trauma, and a postoperative state.

Signs and symptoms are the same as for acute cholecystitis.

Diagnosis may be difficult because patients with this condition are often severely ill and have other medical problems; so clinical features are less apparent.

Emergent cholecystectomy is the treatment of choice. For patients who are too ill for surgery, perform percutaneous drainage of the gallbladder with cholecystostomy.
Choledocholithiasis

A. General Characteristics
1. Refers to gallstones in the CBD (see Table 3-2)
2. Primary versus secondary stones
   a. Primary stones originate in the CBD (usually pigmented stones).
   b. Secondary stones originate in the gallbladder and then pass into the CBD (usually cholesterol or mixed stones). These account for 95% of all cases.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
</table>

Complications of CBD Stones
- Cholangitis
- Obstructive jaundice
- Acute pancreatitis
- Biliary colic
- Biliary cirrhosis

B. Clinical Features
1. Patients may be asymptomatic for years.
2. Symptoms, when present, include RUQ or epigastric pain and jaundice.

| Quick HIT |

Patients with CBD stones may be asymptomatic for years. However, unlike patients with cholelithiasis, in which biliary colic may lead to acute cholecystitis, the onset of symptoms in choledocholithiasis can signal the development of life-threatening complications such as cholangitis and acute pancreatitis.

C. Diagnosis
1. Laboratory tests—total and direct bilirubin levels are elevated, as well as ALK-P.
2. RUQ ultrasound is usually the initial study, but is not a sensitive study for choledocholithiasis. It detects CBD in only 50% of cases, so it cannot be used to rule out this diagnosis.
3. **ERCP** is the gold standard (sensitivity and specificity of 95%) and should follow ultrasound. ERCP is diagnostic and therapeutic (see below).
4. **PTC** is an alternative to ERCP.

D. Treatment
1. ERCP with sphincterotomy and stone extraction with stent placement (successful in 90% of patients).
2. Laparoscopic choledocholithotomy (in select cases)
Do the following in patients with cholangitis:

- Blood cultures
- IV fluids
- IV antibiotics after blood cultures obtained
- Decompress CBD when patient stable.

### TABLE 3-2 Cholelithiasis Versus Choledocholithiasis

<table>
<thead>
<tr>
<th></th>
<th>Cholelithiasis</th>
<th>Choledocholithiasis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abnormality</strong></td>
<td>Stone in gallbladder</td>
<td>Stone in CBD</td>
</tr>
<tr>
<td><strong>Clinical features</strong></td>
<td>Asymptomatic; biliary colic</td>
<td>Asymptomatic, RUQ/epigastric pain, jaundice</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
<td>Cholecystitis, choledocholithiasis, gallstone ileus, malignancy</td>
<td>Cholangitis, obstructive jaundice, acute pancreatitis, biliary cirrhosis</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>RUQ ultrasound is highly sensitive</td>
<td>ERCP is the test of choice; RUQ ultrasound is not sensitive</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>No treatment in most cases; elective cholecystectomy if biliary colic is severe or recurrent</td>
<td>Removal of stone via ERCP and sphincterotomy</td>
</tr>
</tbody>
</table>
Cholangitis

A. General Characteristics
1. Infection of biliary tract secondary to obstruction, which leads to biliary stasis and bacterial overgrowth.
   a. Choledocholithiasis accounts for 60% of cases.
   b. Other causes include pancreatic and biliary neoplasm, postoperative strictures, invasive procedures such as ERCP or PTC, and choledochal cysts.
2. Cholangitis is potentially life threatening and requires emergency treatment.

B. Clinical Features
1. Charcot triad: RUQ pain, jaundice, and fever—this classic triad is present in only 50% to 70% of cases.
2. Reynolds pentad: Charcot triad plus septic shock and altered mental status (CNS depression—e.g., coma, disorientation).
3. Patient is acutely ill, and abdominal symptoms may be lacking or may go unrecognized.

Quick HIT
Reynolds pentad is a highly toxic state that requires emergency treatment. It can be rapidly fatal.

C. Diagnosis
1. RUQ ultrasound is the initial study.
2. Laboratory findings—hyperbilirubinemia, leukocytosis, mild elevation in serum transaminases.
3. Cholangiography (PTC or ERCP).
   a. This is the definitive test, but it should not be performed during the acute phase of illness. Once cholangitis resolves, proceed with PTC or ERCP to identify the underlying problem and plan treatment.
   b. Perform PTC when the duct system is dilated (per ultrasound) and ERCP when the duct system is normal.

Quick HIT
RUQ ultrasound is very accurate in detecting gallstones and biliary tract dilatation, but not very accurate in detecting CBD stones.

D. Treatment
1. IV antibiotics and IV fluids
a. Close monitoring of hemodynamics, BP, and urine output is important.
b. Most patients respond rapidly. Once the patient has been afebrile for 48 hours, cholangiography (PTC or ERCP) can be performed for evaluation of the underlying condition.

2. Decompress CBD via PTC (catheter drainage); ERCP (sphincterotomy), or laparotomy (T-tube insertion) once the patient is stabilized, or emergently if the condition does not respond to antibiotics.

**Quick HIT**

*Hepatic abscess* is the most serious and dreaded complication of acute cholangitis—*it has a high mortality rate.*
Carcinoma of the Gallbladder

Most are adenocarcinomas and typically occur in the elderly. Associated with gallstones in most cases; other risk factors include cholecystoenteric fistula and porcelain gallbladder (Figure 3-3). Clinical features are nonspecific and suggest extrahepatic bile duct obstruction: jaundice, biliary colic, weight loss, anorexia, and RUQ mass. Palpable gallbladder is a sign of advanced disease. Difficult to remove with surgery: cholecystectomy versus radical cholecystectomy (with wedge resection of liver and lymph node dissection) depending on depth of invasion. Prognosis is dismal—more than 90% of patients die of advanced disease within 1 year of diagnosis. Disease often goes undetected until it is advanced.

Quick HIT

Porcelain Gallbladder
- Definition: intramural calcification of the gallbladder wall.
- Prophylactic cholecystectomy is recommended because approximately 50% of patients with porcelain gallbladder will eventually develop cancer of the gallbladder.
Primary Sclerosing Cholangitis

A. General Characteristics

1. A chronic idiopathic progressive disease of intrahepatic and/or extrahepatic bile ducts characterized by thickening of bile duct walls and narrowing of their lumens; leads to cirrhosis, portal hypertension, and liver failure (Table 3-3).
2. There is a strong association with UC (less so with Crohn disease). UC is present in 50% to 70% of patients with PSC; often the UC may dominate the clinical picture. (Note: The course of PSC is unaffected by a colectomy done for UC.)

Quick HIT

Complications of PSC
- Cholangiocarcinoma (in up to 20% to 30% of patients).
- Recurrent bouts of cholangitis (in about 15% of patients).
- Can progress to secondary biliary cirrhosis, portal HTN, and liver failure.

FIGURE 3.3 Porcelain gallbladder. Note the thin layer of mineralization surrounding the gallbladder wall.
(Case courtesy of A.Prof Frank Gaillard, Radiopaedia.org, rID: 12409.)
B. Clinical Features
1. Signs and symptoms begin insidiously.
2. Chronic cholestasis findings, including jaundice and pruritus; all patients eventually present with chronic obstructive jaundice.
3. Other symptoms: fatigue, malaise, weight loss.

C. Diagnosis
1. ERCP and PTC are diagnostic studies of choice—see multiple areas of bead-like stricturing and bead-like dilatations of intra- and extrahepatic ducts.
2. Laboratory tests show cholestatic LFTs.

D. Treatment
1. There is no curative treatment other than liver transplantation.
2. When a dominant stricture causes cholestasis, ERCP with stent placement for biliary drainage and bile duct dilatation may relieve symptoms.
3. Use cholestyramine for symptomatic relief (to decrease pruritus).

<table>
<thead>
<tr>
<th>TABLE 3-3</th>
<th>Primary Biliary Cirrhosis Versus Primary Sclerosing Cholangitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathology</strong></td>
<td>Intrahepatic bile duct destruction</td>
</tr>
<tr>
<td><strong>Demographics</strong></td>
<td>Female &gt; male 9:1</td>
</tr>
<tr>
<td><strong>Association with inflammatory bowel disease</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>+ antimitochondrial antibodies (AMAs) in 90–95% of patients. Liver biopsy to confirm diagnosis</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Ursodeoxycholic acid slows progression, liver transplantation</td>
</tr>
</tbody>
</table>
Primary Biliary Cholangitis

A. General Characteristics
1. PBC is a chronic and progressive cholestatic liver disease characterized by destruction of intrahepatic bile ducts with portal inflammation and scarring (Table 3-3).
2. It is a slowly progressive disease with a variable course. It may progress to cirrhosis and end-stage liver failure.
3. It is an autoimmune disease that is often associated with other autoimmune disorders.
4. It is most common in middle-aged women.

Quick HIT

Etiology of Secondary Biliary Cirrhosis. This disease occurs in response to chronic biliary obstruction from the following:
- Long-standing mechanical obstruction
- Sclerosing cholangitis
- Cystic fibrosis
- Biliary atresia

B. Clinical Features
1. Fatigue
2. Pruritus (early in course of disease)
3. Jaundice (late in course of disease)
4. RUQ discomfort
5. Xanthomata and xanthelasmata
6. Osteoporosis
7. Portal HTN (with resultant sequelae)

C. Diagnosis
1. Laboratory findings
   a. Cholestatic LFTs (elevated ALK-P)
   b. Positive antimitochondrial antibodies (AMAs) found in 90% to 95% of patients. This is the hallmark of the disease (specificity of 98%). If serum is positive for AMAs, perform a liver biopsy to confirm diagnosis
   c. Elevated cholesterol, HDL
   d. Elevated immunoglobulin M
2. Liver biopsy (percutaneous or laparoscopic) to confirm the diagnosis.
3. Abdominal ultrasound or CT scan to rule out biliary obstruction.
D. Treatment

1. Treatment is symptomatic for pruritus (cholestyramine) and osteoporosis (calcium, bisphosphonates, vitamin D).
2. Ursodeoxycholic acid (a hydrophilic bile acid) has been shown to slow progression of the disease.
3. Liver transplantation is the only curative treatment available.
Cholangiocarcinoma

A. General Characteristics
1. Tumor of intra- or extrahepatic bile ducts: most are adenocarcinomas.
2. Mean age of diagnosis is in the seventh decade.
3. Located in three regions: proximal third of the CBD (most common, also called Klatskin tumor), distal extrahepatic (best chance of resectability), intrahepatic (least common).
4. Prognosis is dismal—survival is less than 1 year after diagnosis.
5. Risk factors
   a. PSC is the major risk factor in the United States.
   b. Other risk factors include UC, choledochal cysts, and Clonorchis sinensis infestation (in Hong Kong).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Klatskin Tumors</strong></td>
</tr>
<tr>
<td>• Tumors in proximal third of CBD—involve the junction of right and left hepatic ducts.</td>
</tr>
<tr>
<td>• Very poor prognosis because they are unresectable.</td>
</tr>
</tbody>
</table>

B. Clinical Features
2. Weight loss

C. Diagnosis
1. Cholangiography (PTC or ERCP) for diagnosis and assessment of resectability.
2. If the patient has an unresectable tumor (more likely the case with proximal than distal bile duct tumors), stent placement is an option during either PTC or ERCP and may relieve biliary obstruction.

D. Treatment
1. Most patients do not have resectable tumors at diagnosis.
2. The survival rate is low despite aggressive chemotherapy, stenting, or biliary drainage.
Choledochal Cysts

Cystic dilatations of biliary tree involving either the extra- or intrahepatic ducts, or both; more common in women (4:1).
Clinical features: epigastric pain, jaundice, fever, and RUQ mass.
Complications: cholangiocarcinoma (most feared complication—risk is about 20% over 20 years), hepatic abscess, recurrent cholangitis/pancreatitis, rupture, biliary obstruction, cirrhosis, and portal HTN.
Ultrasound is the best noninvasive test, and ERCP is definitive for diagnosis.
Treatment is surgery: complete resection of the cyst with a biliary-enteric anastomosis to restore continuity of biliary system with bowels.
**Bile Duct Stricture**

Most common cause is iatrogenic injury (e.g., prior biliary surgery such as cholecystectomy, liver transplantation). Other causes include recurring choledocholithiasis, chronic pancreatitis, and PSC. Clinical features are those of obstructive jaundice. Complications can be life threatening: secondary biliary cirrhosis, liver abscess, and ascending cholangitis. Treatment involves endoscopic stenting (preferred) or surgical bypass if obstruction is complete or if endoscopic therapy fails.
**Biliary Dyskinesia**

Motor dysfunction of the sphincter of Oddi which leads to recurrent episodes of biliary colic without any evidence of gallstones on diagnostic studies such as ultrasound, CT scan, and ERCP. Diagnosis is made by HIDA scan. Once the gallbladder is filled with labeled radionuclide, give cholecystokinin (CCK) intravenously; then determine the ejection fraction of the gallbladder. If the ejection fraction is low, dyskinesia is likely. Treatment options include laparoscopic cholecystectomy and endoscopic sphincterotomy.

*CCK is the hormone that relaxes the sphincter of Oddi and contracts the gallbladder.*
**Diseases of the Appendix**

***Acute Appendicitis***

**A. General Characteristics**

1. Pathogenesis
   a. The lumen of the appendix is obstructed by hyperplasia of lymphoid tissue (60% of cases), a fecalith (35% of cases), a foreign body, or other rare causes (parasite or carcinoid tumor [5% of cases]).
   b. Obstruction leads to stasis (of fluid and mucus), which promotes bacterial growth, leading to inflammation.
   c. Distention of the appendix can compromise blood supply. The resulting ischemia can lead to infarction or necrosis if untreated. Necrosis can result in appendiceal perforation, and ultimately peritonitis.

2. Peak incidence is in the teens to mid-20s. Prognosis is far worse in infants and elderly patients (higher rate of perforation).

**Quick HIT**

Perforation of Appendix
- Complicates 20% of cases.
- Risk factors: delay in treatment (>24 hours) and extremes of age.
- Signs of appendiceal rupture (high fever, tachycardia, marked leukocytosis, peritoneal signs, toxic appearance).

**B. Clinical Features**

1. Symptoms
   a. Abdominal pain—Classically starts in the epigastrium, moves toward umbilicus, and then to the RLQ. With distention of the appendix, the parietal peritoneum may become irritated, leading to sharp pain.
   b. Anorexia always present. Appendicitis is unlikely if the patient is hungry.
   c. Nausea and vomiting (typically follow pain).

2. Signs
   a. Tenderness in RLQ (maximal tenderness at *McBurney point*: two-thirds of the distance from the umbilicus to the right anterior superior iliac spine).
   b. Rebound tenderness, guarding, diminished bowel sounds.
   c. Low-grade fever (may spike if perforation occurs).
   d. *Rovsing sign*: deep palpation in LLQ causes referred pain in RLQ.
   e. *Psoas sign*: RLQ pain when right thigh is extended as the patient lies on the left
side.
f. *Obturator sign:* pain in RLQ when flexed right thigh is internally rotated when patient is supine.

### Quick HIT

Acute appendicitis is a clinical diagnosis. Laboratory findings (mild leukocytosis) are only supportive. Radiographs or other imaging studies are unnecessary unless the diagnosis is uncertain or the presentation is atypical.

### C. Diagnosis

1. Acute appendicitis is a clinical diagnosis.
2. Laboratory findings (mild leukocytosis) are only supportive.
3. Imaging studies may be helpful if diagnosis uncertain or in atypical presentations.
   - a. CT scan (sensitivity 98% to 100%)—lowers the false-positive rate significantly.
   - b. Ultrasound (sensitivity of 90%).

### D. Treatment

1. **Appendectomy** (usually laparoscopic). Up to 20% of patients who are diagnosed with acute appendicitis are found to have a normal appendix during surgery. Because the illness is potentially life threatening, this is an acceptable risk even during pregnancy.
2. Low-risk patients may be considered for medical management alone with antibiotics to avoid surgery. Close follow-up is necessary in case urgent surgery is required.

### Quick HIT

Carcinoid syndrome develops in 10% of patients with carcinoid tumors.
- Excess serotonin secretion can lead to **carcinoid syndrome**, which is manifested by cutaneous flushing, diarrhea, sweating, wheezing, abdominal pain, and heart valve dysfunction.
- Risk factors of metastasis increase with the size of the tumor. Metastases are rare with appendiceal tumors. Ileal tumors have the greatest likelihood of malignancy.
- Surgical resection is the treatment of choice.
Carcinoid Tumors and Carcinoid Syndrome

Carcinoid tumors originate from neuroendocrine cells and secrete serotonin. The most common site for these tumors is the appendix, but they can be found in a variety of locations (e.g., small bowel, rectum, bronchus, kidney, pancreas).
Diseases of the Pancreas

Acute Pancreatitis

A. General Characteristics
1. There is inflammation of the pancreas resulting from prematurely activated pancreatic digestive enzymes that invoke pancreatic tissue autodigestion.
2. Most patients with acute pancreatitis have mild to moderate disease, but up to 25% have severe disease. There are two forms of acute pancreatitis, mild and severe:
   a. Mild acute pancreatitis is most common and responds well to supportive treatment.
   b. Severe acute pancreatitis (necrotizing pancreatitis) has significant morbidity and mortality.

B. Causes
1. Gallstones (40%)—the gallstone passes into the bile duct and blocks the ampulla of Vater
2. Alcohol abuse (30%)
3. Post-ERCP—pancreatitis occurs in up to 10% of patients undergoing ERCP
4. Viral infections (e.g., mumps, Coxsackievirus B)
5. Drugs—sulfonamides, thiazide diuretics, furosemide, estrogens, HIV medications, and many other drugs have been implicated
6. Postoperative complications (high mortality rate)
7. Autoimmune pancreatitis
8. Scorpion bites
9. Pancreas divisum (controversial)
10. Pancreatic cancer
11. Hypertriglyceridemia, hypercalcemia
12. Uremia
13. Blunt abdominal trauma (most common cause of pancreatitis in children)

Quick HIT
Most cases of acute pancreatitis are due to alcohol or gallstones (70% to 80%). Recurrences are common in alcoholic pancreatitis.
Causes of acute pancreatitis—GET SMASHED
G—gallstones
E—ethanol
T—trauma
S—steroids
M—mumps
A—autoimmune
S—scorpion stings /spider bites
H—hyperlipidemia, hypercalcemia, hyperparathyroidism
E—ERCP
D—drugs

C. Clinical Features

1. Symptoms
   a. Abdominal pain, usually in the epigastric region
      • May radiate to back (50% of patients)
      • Often steady, dull, and severe; worse when supine and after meals
   b. Nausea and vomiting, anorexia

2. Signs
   a. Low-grade fever, tachycardia, hypotension, leukocytosis
   b. Epigastric tenderness, abdominal distention
   c. Decreased or absent bowel sounds indicate partial ileus
   d. The following signs are seen with hemorrhagic pancreatitis as blood tracks along fascial planes:
      • Grey Turner sign (flank ecchymoses)
      • Cullen sign (periumbilical ecchymoses)
      • Fox sign (ecchymosis of inguinal ligament)

Quick HIT

The diagnosis of acute pancreatitis is usually made based on clinical presentation. Laboratory studies are supportive, and CT scan is confirmatory.

Quick HIT

The level of either amylase or lipase does not reliably predict the severity of disease.

D. Diagnosis

1. Must fulfill two of three criteria: classical clinical presentation (epigastric pain that radiates to the back), lab findings, and imaging findings.
2. Laboratory studies
   a. Serum lipase and amylase. Lipase is more specific.
   b. LFTs—to identify cause (gallstone pancreatitis).
   c. Hyperglycemia, hypoxemia, and leukocytosis may also be present.
   d. Order the following for assessment of prognosis (see Table 3-4—Ranson criteria): glucose, calcium, hematocrit, BUN, arterial blood gas (PaO₂, base deficit), LDH, AST, WBC count.

3. Abdominal radiograph
   a. Has a limited role in the diagnosis of acute pancreatitis.
   b. More helpful in ruling out other diagnoses, such as intestinal perforation (free air). The presence of calcifications can suggest chronic pancreatitis.
   c. In some cases, one may see a sentinel loop (area of air-filled bowel usually in LUQ, which is a sign of localized ileus) or a colon cut-off sign (air-filled segment of transverse colon abruptly ending or “cutting off” at the region of pancreatic inflammation).

4. Abdominal ultrasound
   a. Can help in identifying cause of pancreatitis (e.g., gallstones).
   b. Useful for following up pseudocysts or abscesses.

---

**Quick HIT**

Hypocalcemia that results from acute pancreatitis is due to fat saponification: fat necrosis binds calcium.

---

**TABLE 3-4 Ranson Criteria**

<table>
<thead>
<tr>
<th>Admission Criteria (GALAW)</th>
<th>Initial 48-hr Criteria (C HOBBS)</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose &gt;200 mg/dL</td>
<td>Calcium &lt;8 mg/dL, Decrease in Hematocrit &gt;10%</td>
<td>&lt;3 criteria—1%</td>
</tr>
<tr>
<td>Age &gt;55 yrs</td>
<td>PaO₂ &lt;60 mm Hg</td>
<td>3–4 criteria—15%</td>
</tr>
<tr>
<td>LDH &gt;350</td>
<td>BUN increase &gt;5 mg/dL</td>
<td>5–6 criteria—40%</td>
</tr>
<tr>
<td>AST &gt;250</td>
<td>Base deficit &gt;4 mg/dL</td>
<td>&gt;7 criteria—100%</td>
</tr>
<tr>
<td>WBC &gt;16,000</td>
<td>Fluid sequestration &gt;6 L</td>
<td></td>
</tr>
</tbody>
</table>

5. CT scan of the abdomen
   a. Most accurate test for diagnosis of acute pancreatitis and for identifying complications of the disease.
   b. Indicated in patients with severe acute pancreatitis.

6. Indications for ERCP:
a. Severe gallstone pancreatitis with biliary obstruction.
b. To identify uncommon causes of acute pancreatitis if disease is recurrent.

**Quick HIT**
Pseudocysts may be present at sites distant from the pancreas.

**E. Complications**
1. Pancreatic necrosis (may be sterile or infected)
   a. Sterile pancreatic necrosis—infected may develop, but half of all cases resolve spontaneously. These patients should be monitored closely in an ICU. Prophylactic antibiotics are controversial but if necrosis involves more than 30% of pancreas, antibiotics should be strongly considered.
   b. Infected pancreatic necrosis—results in multiple organ failure in 50% of cases and has high mortality rate; surgical debridement and antibiotics are indicated.
   c. The only way to distinguish sterile from infected necrosis is via CT-guided percutaneous aspiration with Gram stain/culture of the aspirate.
2. Pancreatic pseudocyst
   a. Encapsulated fluid collection that appears 2 to 3 weeks after an acute attack—unlike a true cyst, it lacks an epithelial lining.
   b. Complications of untreated pseudocysts include rupture, infection, gastric outlet obstruction, fistula, hemorrhage into cyst, and pancreatic ascites. It may impinge on adjacent abdominal organs (e.g., duodenum, stomach, transverse colon) if large enough; or if located in the head of the pancreas, it may cause compression of the CBD.
   c. Diagnosis: CT scan is the study of choice.
   d. Treatment
      - Cysts <5 cm: observation
      - Cysts >5 cm: drain either percutaneously or surgically
3. Hemorrhagic pancreatitis
   a. Characterized by Cullen sign, Grey Turner sign, and Fox sign
   b. CT scan with IV contrast is the study of choice
5. Pancreatic ascites/pleural effusion—the most common cause is inflammation of peritoneal surfaces.
6. Ascending cholangitis—due to gallstone in the ampulla of Vater, leading to infection of biliary tract; see section on cholangitis.
7. Pancreatic abscess (rare)—develops over 4 to 6 weeks and is less life threatening
than infected pancreatic necrosis.

**Quick HIT**
Most patients with acute pancreatitis respond to supportive care of pain control, bowel rest, IV fluids, and correction of electrolyte abnormalities and do not require any further therapy.

**F. Treatment**

1. Patients with mild acute pancreatitis:
   a. Bowel rest (NPO)—goal is to rest the pancreas.
   b. IV fluids—patients may have severe intravascular volume depletion. Correct electrolyte abnormalities. Balanced crystalloids (lactated Ringer solution) are superior to normal saline, as normal saline can cause hyperchloremic metabolic acidosis. Acidosis will increase pancreatic zymogen activity which will then worsen autodigestion.
   c. Pain control, but be cautious in giving narcotics. Fentanyl and meperidine preferred over morphine which causes an increase in sphincter of Oddi pressure.
   d. Nasogastric tube, if severe nausea/vomiting or ileus present; routine use is controversial.
   e. All patients with gallstone pancreatitis should have cholecystectomy after recovery from pancreatitis. These patients may benefit from early ERCP.

2. Patients with severe pancreatitis:
   a. Admit to the ICU.
   b. Early enteral nutrition in the first 72 hours is recommended through a nasojejunal tube.
   c. If the severe acute pancreatitis has not resolved in a few days, supplemental parenteral nutrition should be started.
   d. If more than 30% of the pancreas is necrosed, prophylactic antibiotics (imipenem) should be considered to prevent infection (which has high morbidity and mortality).

**G. Prognosis**

1. Ranson criteria are used to determine prognosis and mortality rates.
2. Patients with more than three or four Ranson criteria should be monitored in an ICU setting.
Chronic Pancreatitis

A. General Characteristics
1. Persistent or continuing inflammation of the pancreas, with fibrotic tissue replacing pancreatic parenchyma, and alteration of pancreatic ducts (areas of stricture/dilation); eventually results in irreversible destruction of the pancreas.
2. The endocrine and exocrine functions of the pancreas are impaired.
3. Causes
   a. **Chronic alcoholism is the most common cause (>80% of cases).**
   b. Other causes include hereditary pancreatitis, tropical pancreatitis, and idiopathic chronic pancreatitis.

Quick HIT
The combination of chronic epigastric pain and calcifications on plain abdominal films is diagnostic for chronic pancreatitis. The classic triad of steatorrhea, diabetes mellitus, and pancreatic calcification on plain films or CT scan is also diagnostic.

B. Clinical Features
1. Severe pain in the epigastrium; recurrent or persistent abdominal pain.
   a. Often accompanied by nausea and vomiting.
   b. May be aggravated by an episode of binge drinking alcohol, or by eating.
   c. Radiates to the back in 50% of cases.
2. Weight loss, due to malabsorption, alcohol abuse, and diabetes; steatorrhea secondary to malabsorption.

Quick HIT
Chronic pancreatitis presents as chronic unrelenting pain with episodic flare-ups.

C. Diagnosis
1. CT scan (Figure 3-4) is the initial study of choice. It may show calcifications not seen on plain films. Mild to moderate cases may not be detectable, so a normal CT scan does not necessarily rule out chronic pancreatitis.
2. Abdominal radiograph—the presence of pancreatic calcifications is 95% specific, but is found in only 30% of cases.
3. ERCP is the gold standard, but is not done routinely because it is invasive.
4. Laboratory studies are not helpful in diagnosis. Serum amylase and lipase levels are not elevated in chronic pancreatitis.
D. Complications

1. Narcotic addiction—probably the most common complication.
2. Diabetes mellitus/impaired glucose tolerance
   a. Caused by progressive loss of islets of Langerhans
   b. Eventually appears in up to 70% of patients
3. Malabsorption/steatorrhea
   a. Caused by pancreatic exocrine insufficiency—occurs when pancreatic enzyme secretion decreases significantly.
   b. A late manifestation of chronic pancreatitis
4. Pseudocyst formation
5. Pancreatic ductal dilation
6. CBD obstruction (may occur secondary to fibrosis in head of gland)
7. Vitamin B₁₂ malabsorption
8. Effusions (e.g., pleural, pericardial, peritoneal)
9. Pancreatic carcinoma—patients with chronic pancreatitis have an increased risk.
E. Treatment

1. Nonoperative management
   a. Narcotic analgesics for pain
   b. Bowel rest (NPO)
   c. Pancreatic enzymes and H₂ blockers (given simultaneously)
      - Pancreatic enzymes inhibit CCK release and thus decrease pancreatic secretions after meals.
      - H₂ blockers inhibit gastric acid secretion, preventing degradation of the pancreatic enzyme supplements by gastric acid.
   d. Insulin—may be necessary due to severe pancreatic endocrine insufficiency.
   e. Alcohol abstinence
   f. Frequent, small-volume, low-fat meals—may improve abdominal pain.

2. Surgery—main goal is relief of incapacitating abdominal pain.
   a. Pancreaticojejunostomy (pancreatic duct drainage procedure to decompress the dilated pancreatic duct)—most common procedure
   b. Pancreatic resection (distal pancreatectomy, Whipple procedure)
Pancreatic Cancer

A. General Characteristics
1. Most common in elderly patients (75% of patients are >60 years old); rare before age 40; more common in African Americans.
2. Anatomic location
   a. Pancreatic head (75% of cases)
   b. Pancreatic body (20% of cases)
   c. Pancreatic tail (5% to 10% of cases)
3. Risk factors
   a. Cigarette smoking (most clearly established risk)
   b. Chronic pancreatitis
   c. Diabetes
   d. Heavy alcohol use
   e. Exposure to chemicals—benzidine and β-naphthylamine
4. The prognosis is dismal: most patients die within months of diagnosis.

B. Clinical Features
1. Abdominal pain (90% of patients)—may be a vague and dull ache.
2. Jaundice
   a. Most common with carcinoma of head of pancreas—less than 10% of patients with cancer involving body and tail of pancreas have jaundice.
   b. Indicates obstruction of intrapancreatic CBD and is a sign of advanced disease.
3. Weight loss (common due to decreased food intake and malabsorption); anorexia
4. Recent onset of glucose intolerance, but the diabetes is mild.
5. Depression, weakness, fatigue
6. Migratory thrombophlebitis—develops in 10% of cases
7. Courvoisier sign (palpable gallbladder)—present in 30% of patients with cancer involving head of pancreas; presents without pain.

Quick HIT
Painless jaundice is not common in pancreatic cancer!

The early clinical findings of pancreatic cancer are very vague and nonspecific. By the time a diagnosis is made, most patients have an incurable level of advanced disease.
C. Diagnosis
1. ERCP is the most sensitive test for diagnosing pancreatic cancer. It can also distinguish cancer of the head of the pancreas from tumors of the CBD, duodenum, ampulla, and lymphomas, which have more favorable prognosis.
2. CT scan is the preferred test for diagnosis and assessment of disease spread.
3. Tumor markers.
   a. CA 19-9 (sensitivity of 83% and specificity of 82%).
   b. CEA (sensitivity of 56% and specificity of 75%).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aortoenteric Fistula</strong> is a rare but lethal cause of GI bleeding. The classic presentation is a patient with a history (sometimes distant) of aortic graft surgery who has a small GI bleed involving the duodenum before massive, fatal hemorrhage hours to weeks later. Perform endoscopy or surgery during this small window of opportunity to prevent death.</td>
</tr>
</tbody>
</table>

D. Treatment
1. Surgical resection (Whipple procedure) is the only hope for a cure; however, only a minority of tumors are resectable (roughly 10%). The prognosis is grim even after resection, with a 5-year survival rate of 10%.
2. If the tumor is unresectable and biliary obstruction is present, perform PTC or ERCP with stent placement across the obstruction for palliation.
Gastrointestinal Bleeding

A. General Characteristics
1. Upper GI bleeding refers to a source of bleeding above the ligament of Treitz in the duodenum.
2. Lower GI bleeding is classically defined as bleeding below the ligament of Treitz.

B. Causes
1. Upper GI bleeding
   a. Peptic ulcer disease (PUD)—duodenal ulcer (25% of cases), gastric ulcer (20% of cases), gastritis (25% of cases)
   b. Reflux esophagitis
   c. Esophageal varices (10% of cases)—venous bleeding
   d. Gastric varices
   e. Gastric erosions, duodenitis
   f. Mallory–Weiss tear
   g. Hemobilia

   Quick HIT
   A lower GI bleed (or positive occult blood test of stool) in patients over 40 is colon cancer until proven otherwise.

   h. Dieulafoy vascular malformation—submucosal dilated arterial lesions that can cause massive GI bleeding
   i. Aortoenteric fistulas—after aortic surgery (ask about prior aortic aneurysm/graft)
   j. Neoplasm—bleeding is not rapid—usually not an emergency

   Quick HIT
   About 80% of episodes of upper GI bleeding stop spontaneously and only need supportive therapy.

2. Lower GI bleeding
   a. Diverticulosis (40% of cases)—most common source of GI bleeding in patients over age 60; usually painless.
   b. Angiodysplasia (40% of cases)—second most common source in patients over age 60.
   c. IBD (UC, Crohn disease)
d. Colorectal carcinoma
e. Colorectal adenomatous polyps
f. Ischemic colitis
g. Hemorrhoids, anal fissures
h. Small intestinal bleeding—diagnosed by excluding upper GI and colonic bleeding

Quick HIT
- Bleeding from the small bowel may manifest as melena or hematochezia.
- Colonic sources of bleeding present with either occult blood in the stool or hematochezia.

C. Clinical Features
1. Type of bleeding:
   a. Hematemesis—vomiting blood; suggests upper GI bleeding (bleeding proximal to ligament of Treitz). Indicates moderate to severe bleeding that may be ongoing.
   b. “Coffee grounds” emesis—suggests upper GI bleeding as well as a lower rate of bleeding (enough time for vomitus to transform into “coffee grounds”).
   c. Melena—black, tarry, liquid, foul-smelling stool.

Quick HIT
- Caused by degradation of hemoglobin by bacteria in the colon; presence of melena indicates that blood has remained in GI tract for several hours.
- The further the bleeding site is from the rectum, the more likely melena will occur.
- **Note that dark stools can also result from bismuth, iron, spinach, charcoal, and licorice.**
- Melena suggests upper GI bleeding 90% of the time. Occasionally, the jejunum or ileum is the source. It is unusual for melena to be caused by a colonic lesion, but if it is, the ascending colon is the most likely site.

Quick HIT
- Hematemesis and melena are the most common presentations of acute upper GI bleed, and patients may have both symptoms. Occasionally, a brisk upper GI bleed presents as hematochezia.

d. Hematochezia—bright red blood per rectum.
• This usually represents a lower GI source (typically left colon or rectum). Consider diverticulosis, arteriovenous malformations, hemorrhoids, and colon cancers.
• It may result from massive upper GI bleeding that is bleeding very briskly (so that blood does not remain in colon to turn into melena—see above). This often indicates heavy bleeding, and patient often has some degree of hemodynamic instability. An upper GI source is present in about 5% to 10% of patients with hematochezia.
• Occult blood in stool—source of bleeding may be anywhere along GI tract.

Quick HIT
An elevated PT may be indicative of liver dysfunction, vitamin K deficiency, a consumptive coagulopathy, or warfarin therapy.

2. Signs of volume depletion (depending on rate and severity of blood loss).
3. Symptoms and signs of anemia (e.g., fatigue, pallor, exertional dyspnea).

CLINICAL PEARL 3-6
Tests to Order in Patients With GI Bleeding
• Hematemesis—An upper GI endoscopy is the initial test.
• Hematochezia—First rule out an anorectal cause (e.g., hemorrhoids). Colonoscopy should be the initial test because colon cancer is the main concern in patients over age 50.
• Melena—Upper endoscopy is usually the initial test because the most likely bleeding site is in the upper GI tract. Order a colonoscopy if no bleeding site is identified from the endoscopy.
• Occult blood—Colonoscopy is the initial test in most cases (colon cancer is the main concern). Order an upper endoscopy if no bleeding site is identified from the colonoscopy.

Quick HIT
If you suspect lower GI bleeding, still exclude upper GI bleeding before attempting to localize the site of the lower GI bleed.

D. Diagnosis
1. Laboratory tests (see also Clinical Pearl 3-6 and Figure 3-5)
   a. Stool guaiac for occult blood.
   b. Hemoglobin/hematocrit level (may not be decreased in acute bleeds): A hemoglobin level >7 to 8 g/dL is generally acceptable in young, healthy patients without active bleeding. However, most elderly patients (especially those with cardiac disease) should have a hemoglobin level >10 g/dL.
   c. A low mean corpuscular volume (MCV) is suggestive of iron deficiency anemia
(chronic blood loss). Patients with acute bleeding have normocytic red blood cells.

d. Coagulation profile (platelet count, PT, PTT, INR).
e. LFTs, renal function.
f. The BUN–creatinine ratio is elevated with upper GI bleeding. This is suggestive of upper GI bleeding if patient has no renal insufficiency. The higher the ratio, the more likely the bleeding is from an upper GI source.

Quick HIT

**Initial Steps in any Patient With GI Bleeding**
- Vital signs: Decreased BP, tachycardia, or postural changes in BP or HR are signs of significant hemorrhage. However, vital signs may also be normal when significant hemorrhage is present.
- Resuscitation is the first step (e.g., IV fluids, transfusion).
- Perform rectal examination (hemoccult test).
2. Upper endoscopy  
   a. Most accurate diagnostic test in evaluation of upper GI bleeding.  
   b. Both diagnostic and potentially therapeutic (coagulate bleeding vessel). 
3. Nasogastric tube  
   a. Not required for diagnosis of patients with upper GI bleed. Historically has been
used to determine if GI bleed originating from an upper or lower GI source. Studies have not demonstrated benefit in clinical outcomes.

4. Anoscopy or proctosigmoidoscopy can exclude an anal/rectal source. Perform this if there is no obvious bleeding from hemorrhoids.

5. Colonoscopy identifies the site of the lower GI bleed in >70% of cases, and can also be therapeutic (see below).

6. A bleeding scan (radionuclide scanning) reveals bleeding even with a low rate of blood loss. It does not localize the lesion; it only identifies continued bleeding. Its role is controversial, but it may help determine whether arteriography is needed.

7. Arteriography definitively locates the point of bleeding.
   a. Mostly used in patients with lower GI bleeding.
   b. Should be performed during active bleeding.
   c. Potentially therapeutic (embolization or intra-arterial vasopressin infusion).

8. Exploratory laparotomy—last resort.

E. Treatment

1. If patient is hemodynamically unstable, resuscitation is always top priority. Remember the ABCs. Once the patient is stabilized, obtain a diagnosis (see also Clinical Pearl 3-7).
   a. Supplemental oxygen.
   b. Place two large-bore IV lines. Give IV fluids or blood if patient is volume depleted.
   c. Draw blood for hemoglobin and hematocrit, PT/INR, PTT, and platelet count. Monitor hemoglobin every 4 to 8 hours until the patient is hemoglobin stable for at least 24 hours.
   d. Type and cross-match adequate blood (PRBCs). Transfuse as the clinical condition demands (e.g., shock, patients with cardiopulmonary disease).

2. Treatment depends on the cause/source of the bleed.
   a. Upper GI bleeding.
      • Esophagogastroduodenoscopy (EGD) with coagulation of the bleeding vessel. If bleeding continues, repeat endoscopic therapy or proceed with surgical intervention (ligation of bleeding vessel).
      • If a bleeding ulcer is considered, start a proton pump inhibitor (PPI). Increasing gastric pH improves clotting.
      • If suspecting a variceal bleed (e.g., in patients with cirrhosis), start octreotide.
   b. Lower GI bleeding.
      • Colonoscopy—polyp excision, injection, laser, cautery
      • Arteriography with embolization
      • Surgical resection of involved area—last resort
3. Indications for surgery:
   a. Hemodynamically unstable patients who have not responded to IV fluid, transfusion, endoscopic intervention, or correction of coagulopathies.

   **CLINICAL PEARL 3-7**

   **Factors That Increase Mortality in GI Bleeding**
   - Age >65 years
   - Severity of initial bleed
   - Extensive comorbid illnesses
   - Onset or recurrence of bleeding while hospitalized for another condition
   - Need for emergency surgery
   - Significant transfusion requirements
   - Diagnosis (esophageal varices have a 30% mortality rate)
   - Endoscopic stigmata of recent hemorrhage

   b. Severe initial bleed or recurrence of bleed after endoscopic treatment.
   c. Continued bleeding for more than 24 hours.
   d. Visible vessel at base of ulcer (30% to 50% chance of rebleed).
   e. Ongoing transfusion requirement (five units within first 4 to 6 hours).
Diseases of the Esophagus

Esophageal Cancer

A. General Characteristics

1. There are two pathologic types. In the past, squamous cell carcinoma (SCC) accounted for up to 90% of cases. However, the incidence of adenocarcinoma has increased dramatically in the United States, and it now accounts for up to 50% of new cases.

   a. SCC
      • Incidence is higher in African American men than in other groups.
      • Most common locations are the upper and midthoracic esophagus. About one-third may be in distal 10 cm of esophagus.
      • Risk factors are alcohol and tobacco use, diet (nitrosamines, betel nuts, chronic ingestion of hot foods and beverages such as tea), human papillomavirus, achalasia, Plummer–Vinson syndrome, caustic ingestion, and nasopharyngeal carcinoma.

   b. Adenocarcinoma
      • More common in Caucasians and men (5:1 over women).
      • Most common in distal third of the esophagus/gastroesophageal junction (in 80% of cases).
      • Risk factors: GERD and Barrett esophagus are main risk factors; alcohol and tobacco may not be as important as in SCC.

   Quick HIT

   Barrett Esophagus is a complication of long-standing acid reflux disease in which there is columnar metaplasia of the squamous epithelium. Patients with Barrett esophagus are at increased risk of developing adenocarcinoma of the esophagus. Monitor these patients with routine endoscopic surveillance.

2. The prognosis is poor: Five-year survival rate is about 30% to 40% if locoregional disease, but only 5% if distant metastasis present at diagnosis.

3. Staging

   a. Stage I—tumor invades lamina propria or submucosa; nodes negative
   b. Stage IIa—tumor invades muscularis propria or adventitia; nodes negative
   c. Stage IIb—tumor invades up to muscularis propria; positive regional nodes
   d. Stage III—tumor invades adventitia (positive regional nodes) or tumor invades adjacent structures (positive or negative nodes)
   e. Stage IV—distant metastasis
B. Clinical Features
1. Dysphagia—most common symptom (initially solids only, then progression to liquids)
2. Weight loss—second most common symptom
3. Anorexia
4. Odynophagia (pain with swallowing)—a late finding that suggests extraesophageal involvement (mediastinal invasion)
5. Hematemesis, hoarseness of voice (recurrent laryngeal nerve involvement)
6. Aspiration pneumonia, respiratory symptoms due to involvement of tracheobronchial tree
7. Tracheoesophageal or bronchoesophageal fistula
8. Chest pain

C. Diagnosis
1. Barium swallow is useful in evaluation of dysphagia. A presumptive diagnosis can be made.
2. Upper endoscopy with biopsy and brush cytology is required for definitive diagnosis. It confirms the diagnosis in 95% of cases.
3. Transesophageal ultrasound helps determine the depth of penetration of the tumor and is the most reliable test for staging local cancer.
4. Full metastatic workup (e.g., CT scan of the chest/abdomen, CXR, bone scan).

D. Treatment
1. Palliation is the goal in most patients because the disease is usually advanced at presentation.
2. Surgery (esophagectomy) may be curative for patients with disease in stage 0, 1, or 2A.
3. Chemotherapy plus radiation before surgery has been shown to prolong survival more than surgery alone.
Achalasia

A. General Characteristics
1. Acquired motor disorder of esophageal smooth muscle in which the lower esophageal sphincter (LES) fails to completely relax with swallowing, and abnormal peristalsis of esophageal body replaces normal peristalsis.
2. Absolute criteria for diagnosis
   a. Incomplete relaxation of the LES
   b. Aperistalsis of esophagus

B. Causes
1. The majority in the United States are idiopathic.
2. In the United States, adenocarcinoma of proximal stomach is the second most common cause.
3. Worldwide, Chagas disease is an important cause.

C. Clinical Features
1. Dysphagia (odynophagia is less common)
   a. Equal difficulty swallowing solids and liquids (in contrast to esophageal cancer, in which dysphagia for solids starts first, than later for liquids).
   b. Patients tend to eat slowly and drink lots of water to wash down food. Also, they may twist their body, extend their neck, or walk about the room in an effort to force food into the stomach.
   c. It is exacerbated by fast eating and emotional stress.
2. Regurgitation
   a. Food gets “stuck” in the esophagus and then comes back up.
   b. Regurgitation may lead to aspiration.
3. Chest pain
4. Weight loss
5. Recurrent pulmonary complications secondary to aspiration, which may cause lung abscess, bronchiectasis, or hemoptyis

Quick HIT

Patients with achalasia have a sevenfold increase in the risk of esophageal cancer (usually squamous cell)—it occurs in 10% of patients 15 to 25 years after the initial achalasia diagnosis. Often tumors go unnoticed (even when large) due to a dilated esophagus and chronic dysphagia. Therefore, perform surveillance esophagoscopy to detect the tumor at an early stage.

D. Diagnosis
1. Barium swallow (Figure 3-6)—“bird’s beak”—beak-like narrowing of distal esophagus and a large, dilated esophagus proximal to the narrowing.
2. Upper GI endoscopy—to rule out secondary causes of achalasia (gastric carcinoma) and retention esophagitis or esophageal cancer.
3. Manometry—to confirm the diagnosis; reveals failure of LES relaxation and aperistalsis of esophageal body.

E. Treatment
1. Instruct patient on adaptive measures: chew food to consistency of pea soup before swallowing; sleep with trunk elevated; avoid eating before sleep.
2. Medical therapy
   a. Antimuscarinic agents (dicyclomine)—usually unsatisfactory
   b. Sublingual nitroglycerin, long-acting nitrates, and calcium channel blockers
      • May improve swallowing in early stages of achalasia (before esophageal dilatation occurs)
      • Most useful in the short-term treatment of achalasia (before more definitive therapy)
3. Injection of botulinum toxin into the LES during endoscopy
   a. Blocks cholinergic activity in the LES
b. Can be effective in up to 65% of cases; however, repeat procedures need to be performed every 2 years.

4. Forceful dilatation—mechanical, pneumatic, or hydrostatic
   a. Pneumatic balloon dilatation is most effective
   b. Lowers basal LES tone by disrupting the muscular ring
   c. Can be effective, but there is a 5% risk of perforation
There is no Cure for Achalasia. Treatment modalities (including surgery) are only palliative.

5. Surgical
   a. “Heller myotomy”—circular muscle layer of LES is incised
   b. Usually reserved for patients who do not respond to dilation therapy

6. Early results are promising (80% to 90% of patients experience good to excellent palliation of dysphagia at 1 year).

7. Long-term data are needed.

Quick HIT

It can be difficult to distinguish the chest pain of diffuse esophageal spasm (DES) from cardiac chest pain. Therefore, many patients undergo a cardiac workup, including cardiac catheterization, to rule out ischemic causes of chest pain, before an esophageal cause is investigated.
Diffuse Esophageal Spasm

A. General Characteristics
1. Nonperistaltic spontaneous contraction of the esophageal body—several segments of the esophagus contract simultaneously and prevent appropriate advancement of food bolus.
2. In contrast to achalasia, sphincter function is normal (normal LES pressure).

B. Clinical Features
1. There is noncardiac chest pain that mimics angina and may radiate to the jaw, arms, and back.
2. Dysphagia is common; however, regurgitation of food is uncommon.

C. Diagnosis
1. Esophageal manometry is diagnostic—simultaneous, multiphasic, repetitive contractions that occur after a swallow; sphincter response is normal.
2. Upper GI barium swallow ("corkscrew esophagus")—in 50%, which represents multiple simultaneous contractions.

D. Treatment
1. In general there is no completely effective therapy—treatment failure rates are high.
2. Medical treatment involves nitrates and calcium channel blockers (decreases amplitude of contractions). Tricyclic antidepressants may provide symptomatic relief.
3. Esophagomyotomy is usually not performed, and its efficacy is controversial. Some support its use, whereas others only recommend it when a patient is incapacitated by symptoms.
Esophageal Hiatal Hernias

A. General Characteristics
There are two types of hiatal hernias: sliding (type 1) and paraesophageal (type 2) (Figure 3-7)

1. Sliding hiatal hernias (type 1) account for >90% of cases. Both the gastroesophageal junction and a portion of the stomach herniate into the thorax through the esophageal hiatus (so that the gastroesophageal junction is above the diaphragm). This is a common and benign finding that is associated with GERD.

2. Paraesophageal hiatal hernia (types 2–4) accounts for <5% of cases. In type 2 hernias, the stomach herniates into the thorax through the esophageal hiatus, but the gastroesophageal junction does not; it remains below the diaphragm. Type 3 hernias have elements of type 1 and type 2 hernias, and both the fundus and the GE junction herniate through the hiatus. Type 4 hernias include organs other than the stomach in the hernia sac.

Quick HIT
- Paraesophageal hernias tend to enlarge with time, and the entire stomach may ultimately move into the thorax.
- Type 3 hernias (combination of type 1 and 2) are treated as type 2 hernias (surgically).

B. Clinical Features
1. The majority of cases is asymptomatic and is discovered incidentally.

2. Possible symptoms include heartburn, chest pain, and dysphagia.

3. Complications of sliding hiatal hernias include GERD (most common), reflux esophagitis (with risk of Barrett esophagus/cancer), and aspiration.

4. Complications of paraesophageal hernias are potentially life threatening and include obstruction, hemorrhage, incarceration, and strangulation.

Quick HIT
If a patient with GERD also has a hiatal hernia, the hernia often worsens the symptoms of GERD.

C. Diagnosis—barium upper GI series and upper endoscopy

D. Treatment
1. Type 1 hernias are treated medically (with antacids, small meals, and elevation of the head after meals); 15% of cases may require surgery (Nissen fundoplication), if there is no response to medical therapy or if there is evidence of esophagitis.

2. Type 2–4 hernias are treated with elective surgery due to the risk of the above
complications.
Mallory–Weiss Syndrome

This is a mucosal tear at (or just below) the gastroesophageal junction as a result of forceful vomiting or retching. It usually occurs after repeated episodes of vomiting, but it may also occur after just one episode. It is most commonly associated with binge drinking in alcoholics, but any disorder that causes vomiting can induce the mucosal tear. Hematemesis is always present—it varies from streaks of blood in vomitus to massive bright red blood. Upper endoscopy is diagnostic. Most cases (90%) stop bleeding without any treatment. Treatment is surgery ( oversewing the tear) or angiographic embolization if bleeding continues, but this is rarely necessary. Acid suppression is used to promote healing.

Quick HIT

During forceful vomiting, the marked increase in intra-abdominal pressure is transmitted to the esophagus. This can lead to two conditions, depending on the severity and location of the tear.

- If the tear is mucosal and at the gastroesophageal junction, it is referred to as Mallory–Weiss syndrome.
- If a tear is transmural (causing esophageal perforation), it is referred to as Boerhaave syndrome.
Plummer–Vinson Syndrome (Upper Esophageal Webs)

Key features: upper esophageal web (causes dysphagia), iron deficiency anemia, *koilonychia* (spoon-shaped fingernails), and atrophic oral mucosa.

Ten percent of patients develop SCC of the oral cavity, hypopharynx, or esophagus; therefore, this is considered a premalignant lesion.

Treatment: esophageal dilatation; correct nutritional deficiency.
FIGURE 3.7 Types of esophageal hiatal hernias.
**Schatzki Ring (Distal Esophageal Webs)**

A circumferential ring in the lower esophagus that is always accompanied by a sliding hiatal hernia.

It is usually asymptomatic, but mild to moderate dysphagia may be present. If the patient is symptomatic (but has no reflux), consider esophageal dilatation. If the patient has reflux, consider anti-reflux surgery.

Usually due to ingestion of alkali, acids, bleach, or detergents (e.g., in suicide attempts).

Ingesting alkali is more dangerous than ingesting acid because it may lead to liquefactive necrosis of the esophagus with full-thickness perforation. Acid ingestion does not cause full-thickness damage (only causes necrosis of esophageal mucosa).

Complications: stricture formation and risk of esophageal cancer.

Treatment is esophagectomy if full-thickness necrosis has occurred. Patient should avoid vomiting, gastric lavage, and all oral intake (can compound the original injury). Give the patient steroids and antibiotics as well. Perform bougienage (dilation) for esophageal stricture.
**Esophageal Diverticula**

Most esophageal diverticula are caused by an **underlying motility disorder** of the esophagus (Figure 3-8).

**Zenker diverticulum** is the most common type; found in upper third of the esophagus.

Failure of the cricopharyngeal muscle to relax during swallowing leads to increased intraluminal pressure. This causes outpouching of mucosa through an area of weakness in the pharyngeal constrictors. Clinical features include dysphagia, regurgitation, halitosis (bad breath), weight loss, and chronic cough. It is typically seen in patients >50 years old.

**Traction diverticula** are located in the midpoint of the esophagus near the tracheal bifurcation. It is due to traction from contiguous mediastinal inflammation and adenopathy (pulmonary tuberculosis). Tuberculosis causes hilar node scarring, which causes retraction of the esophagus. It is usually asymptomatic and does not require treatment.

**Epiphrenic diverticula** are found in lower third of esophagus. It is usually associated with spastic esophageal dysmotility or achalasia. Symptoms of dysphagia are more often related to the underlying motility disorder, unless the diverticulum is very large.

Barium swallow is the best diagnostic test for diverticula. Treatment of Zenker diverticula is surgery. Cricopharyngeal myotomy has excellent results. Treatment of epiphrenic diverticula is esophagomyotomy. Diverticulectomy is of secondary importance in both cases.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
</table>

An underlying motility disorder is the cause of both proximal (Zenker) and distal (epiphrenic) esophageal diverticula. Surgical treatment is aimed at correcting the motility disorder (i.e., myotomy). Diverticulectomy is of secondary importance.
Causes of dysphagia.

Quick HIT
If gastric/esophageal contents leak into the mediastinum or pleura, infection and septic sequelae may result.
Esophageal Perforation

Etiology: blunt trauma, medical tubes and instruments, forceful vomiting (Boerhaave syndrome) that is associated with alcoholic binges and bulimia. Clinical features: pain (severe retrosternal/chest/shoulder pain), tachycardia, hypotension, tachypnea, dyspnea, fever, Hamman sign (“mediastinal crunch” produced by the heart beating against air-filled tissues), pneumothorax, or pleural effusion.

Contrast esophagram is definitive diagnostic study (soluble gastrografin swallow preferred).

CXR usually shows air in the mediastinum.

If the patient is stable and the perforation is small (draining into lumen), medical management is appropriate: IV fluids, NPO, antibiotics, and H$_2$ blockers.

If patient is ill and the perforation is large (or if there is communication into pleural cavity), surgery should be performed within 24 hours of presentation (success rate is higher).

Quick HIT

The time interval between esophageal perforation and surgery is the most important factor in determining survival. If surgery is delayed beyond 24 hours, the mortality rate and the likelihood of fistulization increase.

Quick HIT

Most cases of PUD are due to H. pylori infection and NSAID use. It can be difficult to determine the cause in a patient with H. pylori infection who also uses NSAIDs. Both may be responsible. Therefore, if in doubt, test for H. pylori.
Diseases of the Stomach

Peptic Ulcer Disease

A. Causes

1. Most common causes
   a. *Helicobacter pylori* infection
   b. NSAIDs—inhibit prostaglandin production, which leads to impaired mucosal defenses
   c. Acid hypersecretory states, such as Zollinger–Ellison syndrome

2. Other risk factors associated with higher risk of PUD (have not been shown to be causative)
   a. Smoking
   b. Alcohol use
   c. Emotional stress and dietary factors (such as coffee and spice intake) have not been shown to be associated with higher risk of PUD.

B. Clinical Features

1. Epigastric pain
   a. Aching or gnawing in nature
   b. *Nocturnal symptoms and the effect of food on symptoms are variable* (see Table 3-5).

2. May be complicated by upper GI bleeding.

3. Other symptoms: nausea/vomiting, early satiety, and weight loss.

Quick HIT

Gastric ulcers require a biopsy to rule out malignancy; duodenal ulcers do not require biopsy.

C. Diagnosis

1. Endoscopy
   a. Most accurate test in diagnosing ulcers.
   b. Essential in diagnosis of gastric ulcers because biopsy is necessary to rule out malignancy.
   c. Preferred when severe or acute bleeding is present (can perform electrosurgery of bleeding ulcers).
Quick HIT

If a peptic ulcer is uncomplicated, a barium study or endoscopy is not needed initially. Initiate empiric therapy. However, if you suspect any of the complications of PUD, order confirmatory studies.

d. Can obtain endoscopic biopsy for diagnosis of *H. pylori*.

2. Barium swallow
   a. Sometimes used initially but is less reliable than endoscopy.
   b. Double-contrast techniques preferred due to improved accuracy.

3. Laboratory test—for diagnosis of *H. pylori* infection
   a. Biopsy: Histologic evaluation of endoscopic biopsy is the gold standard.

<table>
<thead>
<tr>
<th>TABLE 3-5 Duodenal Versus Gastric Ulcers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duodenal Ulcers</strong></td>
</tr>
<tr>
<td><strong>Pathogenesis</strong></td>
</tr>
<tr>
<td>Caused by an increase in offensive factors (higher rates of basal and stimulated gastric acid secretion)</td>
</tr>
<tr>
<td><strong>Helicobacter pylori infection</strong></td>
</tr>
<tr>
<td>70–90% of patients</td>
</tr>
<tr>
<td><strong>Malignant potential</strong></td>
</tr>
<tr>
<td>Low</td>
</tr>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>Majority are 1–2 cm distal to pylorus and on posterior wall</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Age distribution</strong></td>
</tr>
<tr>
<td>Occurs in younger patients (&lt;40)</td>
</tr>
<tr>
<td><strong>Associated blood type</strong></td>
</tr>
<tr>
<td>Type O</td>
</tr>
<tr>
<td><strong>Risk factors</strong></td>
</tr>
<tr>
<td>NSAIDs</td>
</tr>
<tr>
<td><strong>Other</strong></td>
</tr>
<tr>
<td>Eating usually relieves pain</td>
</tr>
<tr>
<td>Nocturnal pain is more common than in gastric ulcers</td>
</tr>
</tbody>
</table>

b. Stool antigen test—High sensitivity and ease of testing makes this ideal for screening.

c. Urease detection via urea breath test is highly sensitive and specific. It
documents active infection and helps to assess the results of antibiotic therapy.

d. Serology (lower specificity)—The presence of antibodies to *H. pylori* does not necessarily indicate current infection—antibodies to *H. pylori* can remain elevated for months or even years after eradication of infection.

- The following may lead to false-negative test results: PPIs, bismuth, many antibiotics, and upper GI bleeding.

4. Serum gastrin measurement—if considering Zollinger–Ellison syndrome as a diagnosis.

**D. Treatment**

1. Medical—Majority of patients with PUD can be successfully treated by curing *H. pylori* infection, avoidance of NSAIDs, and appropriate use of antisecretory drugs.

   a. Supportive (patient directives)
      - Discontinue aspirin/NSAIDs.
      - Restrict alcohol use but do not restrict any foods.
      - Stop smoking, decrease emotional stress.
      - Avoid eating before bedtime (eating stimulates nocturnal gastric acid levels).

   b. Acid suppression therapy
      - PPIs—omeprazole (Prilosec), lansoprazole (Prevacid), block H⁺/K⁺ ATPase pump directly in parietal cell membrane. First line of therapy, most effective antisecretory agents.
      - H₂ receptor blockers—cimetidine (Tagamet) and ranitidine (Zantac). Block histamine-based parietal cell acid secretion. Less effective than PPIs.
      - Antacids—somewhat outdated for primary therapy and more appropriately used for adjunctive therapy/symptomatic relief. Examples include aluminum hydroxide (Mylanta), calcium carbonate (Tums), bismuth subsalicylate (Pepto-Bismol).

<table>
<thead>
<tr>
<th>Quick HIT</th>
<th>Acid Suppression Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PPIs</strong></td>
<td>Omeprazole, Lansoprazole, Pantoprazole</td>
</tr>
<tr>
<td><strong>Esomeprazole</strong></td>
<td>Rabeprazole</td>
</tr>
</tbody>
</table>

**TABLE 3-6 Helicobacter pylori Eradication**
c. Eradicate *H. pylori* with triple or quadruple therapy (see Table 3-5). Once infection is cleared, the rate of recurrence is very low.
   - For initial therapy, triple therapy (PPI, amoxicillin, and clarithromycin) for 14 days.
   - Quadruple therapy (PPI, bismuth, metronidazole, and tetracycline) indicated for patients with risk factors for macrolide resistance.

d. Cytoprotection
   - Sucralfate—facilitates ulcer healing. Must be taken frequently, is costly, and can cause GI upset.
   - Misoprostol—reduces risk for ulcer formation associated with NSAID therapy. Costly, and can cause GI upset (common side effect).

e. Treatment regimens
   - If *H. pylori* test is positive, begin eradication therapy with either triple or quadruple therapy (see Table 3-6). Also begin acid suppression with antacids, an H₂ blocker, or a PPI.
   - If the patient has an active NSAID-induced ulcer, stop NSAID use (may switch to acetaminophen). Also begin with either a PPI or misoprostol. Continue for 4 to 8 weeks, depending on severity. Treat the *H. pylori* infection as above if present.
   - Antisecretory drugs can be discontinued after 4 to 6 weeks in patients with uncomplicated ulcers who are asymptomatic. Patients at increased risk of recurrence (especially if underlying cause of ulcer is not reversed) may benefit from maintenance therapy.
   - *H. pylori*–negative ulcers that are NOT caused by NSAIDs can be treated with antisecretory drugs (either H₂ blockers or PPI).

2. Surgical
   a. Rarely needed electively
   b. Required for the complications of PUD (bleeding, perforation, gastric outlet obstruction) (see Table 3-7 and Figure 3-9)
Acute Gastritis

Acute gastritis refers to inflammation of the gastric mucosa. There are multiple causes: NSAIDs/aspirin; *H. pylori* infection; alcohol, heavy cigarette smoking, or caffeine; extreme physiologic stress (e.g., shock, sepsis, burns).

It can either be asymptomatic or cause epigastric pain. The relationship between eating and pain is not consistent (i.e., food may either aggravate or relieve the pain). If epigastric pain is low or moderate and is not associated with worrisome symptoms/findings, empiric therapy with acid suppression is appropriate. Stop NSAIDs.

If there is no positive response after 4 to 8 weeks of treatment, consider a diagnostic workup. Include upper GI endoscopy and ultrasound (to rule out gallstones), and test for *H. pylori* infection.

If *H. pylori* infection is confirmed, antibiotic therapy is indicated (see Table 3-6).

---

**Quick HIT**

Upper GI endoscopy is the best test for evaluating a patient with epigastric pain. It can diagnose PUD, gastritis, and esophagitis. It can also rule out cancers of the esophagus and stomach, and *H. pylori* infection with biopsy.

---

**TABLE 3-7 Complications of Peptic Ulcer Disease**

<table>
<thead>
<tr>
<th>Clinical Findings</th>
<th>Diagnostic Studies</th>
<th>Management</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perforation</td>
<td>Acute, severe abdominal pain, signs of peritonitis, hemodynamic instability</td>
<td>Upright CXR (free air under diaphragm, CT scan is the most sensitive test for perforation (detects free abdominal air))</td>
<td>Emergency surgery to close perforation and perform definitive ulcer operation (such as highly selective vagotomy or truncal vagotomy/pyloroplasty)</td>
</tr>
<tr>
<td>Gastric Outlet Obstruction</td>
<td>Nausea/vomiting (poorly digested food), epigastric fullness/early satiety, weight loss</td>
<td>Barium swallow and upper endoscopy; saline load test (empty stomach with a nasogastric tube, add 750-mL saline, aspirate after 30 min—test is positive if aspirate &gt;400 mL)</td>
<td>Initially, nasogastric suction; replace electrolyte/volume deficits; supplement nutrition if obstruction is long standing. Surgery is eventually necessary in 75% of patients</td>
</tr>
<tr>
<td>GI Bleeding</td>
<td>Bleeding may be slow (leading to anemic symptoms) or can be rapid and severe (leading to shock)</td>
<td>Stool guaiac, upper GI endoscopy (diagnostic and therapeutic)</td>
<td>Resuscitation; diagnose site of bleed via endoscopy and treat; perform surgery for acute bleeds that require transfusion of ≥6 units of blood</td>
</tr>
</tbody>
</table>
Chronic Gastritis

The most common cause is *H. pylori* infection (over 80% of cases). Autoimmune gastritis leads to chronic atrophic gastritis with serum antiparietal and anti-intrinsic factor antibodies (and possible development of pernicious anemia). Most patients with chronic gastritis due to *H. pylori* are asymptomatic and never develop complications. The condition may manifest as epigastric pain similar to PUD. Other associated symptoms such as nausea/vomiting and anorexia are rare. Complications include PUD, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma.

Upper GI endoscopy with biopsy is the test of choice for diagnosis of chronic gastritis. Other tests should be used to find the cause (usually *H. pylori*). If the patient is symptomatic, treatment involves *H. pylori* eradication with triple or quadruple therapy (see Table 3-6).

![FIGURE 3.9](image)

A: An AP chest radiograph in a patient with a perforated duodenal ulcer and acute abdomen. The curved arrow shows free subdiaphragmatic air due to the perforated ulcer. The straight arrows show the diaphragms bilaterally. B: Chest radiograph (upright) showing bilateral subdiaphragmatic intraperitoneal air. Double arrows represent right and left hemidiaphragms. Note the bilateral subdiaphragmatic air (straight and curved arrows). There is air in the gastric fundus as well as free air surrounding the gastric fundus.

(From Erkonen WE, Smith WL. Radiology 101: The Basics and Fundamentals of Imaging. Philadelphia, PA: Lippincott Williams & Wilkins; 1998:103, Figure 6-46, and 159, Figure 8-22, respectively.)
Metastases of Gastric Carcinoma

- **Krukenberg tumor**—metastasis to the ovary
- **Blumer shelf**—metastasis to the rectum (pelvic cul-de-sac)—can palpate on rectal examination
- **Sister Mary Joseph node**—metastasis to the periumbilical lymph node
- **Virchow node**—metastasis to the supraclavicular fossa nodes
- **Irish node**—metastasis to the left axillary adenopathy
Gastric Cancer

A. General Characteristics
1. The majority are adenocarcinomas.
2. Gastric cancer is rare in the United States (more common in Japan).
3. Morphology
   a. Ulcerative carcinoma—ulcer through all layers
   b. Polypoid carcinoma—solid mass projects into stomach lumen
   c. Superficial spreading—most favorable prognosis
   d. Linitis plastica—“leather bottle”—infiltrates early through all layers, stomach wall is thick and rigid, poor prognosis

B. Risk Factors
1. Severe atrophic gastritis, intestinal metaplasia, gastric dysplasia
2. Adenomatous gastric polyps, chronic atrophic gastritis
3. H. pylori infection—three- to sixfold increase in risk
4. Postantrectomy—many cases reported after Billroth II anastomosis (15 to 20 years after surgery)
5. Pernicious anemia—threefold increase in risk
6. Ménétrier disease—10% of these patients develop cancer
7. High intake of preserved foods (high salt, nitrates, nitrites—smoked fish)
8. Blood type A

C. Clinical Features
1. Abdominal pain and unexplained weight loss are most common symptoms.
2. Reduced appetite, anorexia, dyspepsia, early satiety
3. Nausea and vomiting, anemia, melena, guaiac-positive stool

D. Diagnosis
1. Endoscopy with multiple biopsies—most accurate test
2. Barium upper GI series—less accurate, but can complement upper endoscopy/biopsy findings
3. Abdominal CT scan—for staging and to detect presence of metastases
4. FOBT

E. Treatment
1. Surgical resection with wide (>5 cm) margins (total or subtotal gastrectomy) with extended lymph node dissection.
2. Chemotherapy may be appropriate in some cases.
**Gastric Lymphoma**

A type of non-Hodgkin lymphoma that arises in the stomach. Clinical features are similar to those of adenocarcinoma of the stomach (e.g., abdominal pain, weight loss, anorexia). Complications include bleeding, obstruction, and perforation (possibly presented as an emergency). EGD with biopsy is the standard for diagnosis (same as adenocarcinoma of stomach). Treatment depends on the stage of the disease and the presence of complications. Options include surgical resection, radiation, and chemotherapy.

---

**Quick HIT**

<table>
<thead>
<tr>
<th>SBO</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proximal obstruction:</strong> frequent vomiting, severe pain, minimal abdominal distention</td>
<td></td>
</tr>
<tr>
<td><strong>Distal obstruction:</strong> less frequent vomiting and significant abdominal distention</td>
<td></td>
</tr>
</tbody>
</table>
Diseases of the Small Intestine

Small Bowel Obstruction

A. General Characteristics

1. There are three main points of differentiation to consider in small bowel obstruction (SBO).
   a. Partial versus complete obstruction
      • With partial obstruction, patients are able to pass gas or have bowel movements, as opposed to complete obstruction.
      • However, patients with complete obstruction may occasionally be able to pass gas or stool because they may have residual stool or gas in the colon.
   b. Closed loop versus open loop obstruction
      • With closed loop obstruction, the lumen is occluded at two points by an adhesive band or hernia ring. This can compromise the blood supply, requiring emergent surgery.
   c. Proximal versus distal SBO
      • Distal obstruction causes distention of proximal bowel segments, making diagnosis easier on plain radiograph.

Quick HIT
Excessively high intraluminal pressure may compromise blood supply, leading to strangulation. This can lead to shock, gangrene, peritonitis, or perforation of bowel—all devastating complications.

2. Pathophysiology
   a. Dehydration is a key event in SBO. Intestinal distention causes reflex vomiting, increased intestinal secretion proximal to the point of obstruction, and decreased absorption. This leads to hypochloremia, hypokalemia, and metabolic alkalosis.
   b. The resulting hypovolemia leads to systemic findings such as tachycardia, hypotension, tachypnea, altered mental status, and oliguria.

Quick HIT
Large Bowel Obstruction
- Causes: colon cancer (most common cause), volvulus, adhesions, hernias
- Results in less fluid and electrolyte disorder than SBO
- See Figure 3-10 for radiographic findings
B. Causes
1. Adhesions from previous abdominal surgery—most common cause in adults.
2. Incarcerated hernias—second most common cause.

C. Clinical Features
1. Cramping abdominal pain—if pain is continuous and severe, strangulation may be present.
2. Nausea, vomiting—may be feculent
3. Obstipation (absence of stool and flatus)
4. Abdominal distention
D. Diagnosis
1. Abdominal plain films—dilated loops of small bowel, air–fluid levels proximal to point of obstruction (on upright film), and minimal gas in colon (if complete SBO) (Figure 3-11)
2. Barium enema—to rule out colonic obstruction if plain films do not distinguish small from large bowel obstruction; barium enema identifies site of obstruction.
3. Upper GI series—with small bowel follow-through if above are not diagnostic.
FIGURE 3.11  A: An AP supine film of small bowel obstruction shows prominent valvulae conniventes (arrows). Air is confined to the small bowel, with no obvious air in the colon. Note surgical clips from previous surgery. B: An AP upright film in the same patient as shown in A. Note air–fluid levels in the small bowel (arrows) with little or no distal bowel gas. C: An AP supine film of postoperative ileus. Note the
presence of air throughout the entire GI tract.
(From Erkonen WE, Smith WL. Radiology 101: The Basics and Fundamentals of Imaging. Philadelphia, PA: Lippincott Williams & Wilkins, 1998:157, Figure 8-20a and c, and 156, Figure 8-19a.)

**Quick HIT**

Manifestations of strangulated bowel in SBO include fever, severe and continuous pain, hematemesis, shock, gas in the bowel wall or portal vein, abdominal free air, peritoneal signs, and acidosis (increased lactic acid).

**E. Treatment**

1. Nonoperative management—appropriate if bowel obstruction is incomplete and there is no fever, tachycardia, peritoneal signs, or leukocytosis.
   a. IV fluids to establish adequate urine output; add potassium to fluids to correct hypokalemia (which is typically present)
   b. Nasogastric tube to empty stomach (gastric decompression)
   c. Antibiotics
2. Surgery is indicated for complete obstruction, for partial obstruction that is persistent and/or associated with constant pain, or if strangulation is suspected. Perform an exploratory laparotomy with lysis of adhesions and resection of any necrotic bowel.
Paralytic Ileus

Peristalsis is decreased or absent (no mechanical obstruction is present). Causes include medications (e.g., narcotics, drugs with anticholinergic effects), postoperative state (after abdominal surgery), spinal cord injury, shock, metabolic disorders (especially hypokalemia), and peritonitis. Abdominal plain films show a uniform distribution of gas in the small bowel, colon, and rectum (in contrast to small bowel or colonic obstruction). Failure to pass contrast medium beyond a fixed point is diagnostic. Treatment involves IV fluids, NPO, correction of electrolyte imbalances (especially hypokalemia), nasogastric suction if necessary, and placement of a long tube if ileus persists postoperatively.

Quick HIT

Paralytic ileus resolves with time or when the cause is addressed medically. Surgery is usually not needed.
Celiac Sprue

Characterized by hypersensitivity to gluten (in wheat products). Prevalence of the condition in first-degree relatives is approximately 10%. Results in diarrhea (most common symptom), weight loss, abdominal distention, bloating, weakness, and fatigue. Patients may suffer from vitamin deficiency secondary to fat malabsorption, leading to osteoporosis (vitamin D deficiency), easy bleeding (vitamin K deficiency), and megaloblastic anemia (secondary to impaired folate and vitamin B₁₂ absorption).

Dermatitis herpetiformis (papulovesicular lesion seen on the extensor surfaces) is found in 10% to 20% of patients with celiac disease. Biopsy in proximal small bowel reveals flattening of villi, which causes malabsorption.

Strict adherence to a gluten-free diet is essential.
Whipple Disease

Rare disease caused by infection by the bacterium *Tropheryma whippeli*. Inflammation secondary to the infection damages villi in the small intestine. Weight loss, diarrhea, joint pain, and arthritis are common symptoms but clinical presentation is extremely variable. Diagnosis is made by visualization of periodic acid-Schiff stain (PAS)–positive macrophages in the lamina propria containing non–acid-fast gram-positive bacilli. Treatment is with antibiotic therapy for 1 to 2 years.
Tropical Sprue

Also known as “environmental enteropathy,” occurs in people who live in or visit tropical areas.
Unknown etiology, believed to be caused by overgrowth of bacteria.
Similar symptoms to celiac sprue including weight loss, diarrhea, cramps, fatigue, malabsorption.
Abnormal flattening of villi can be observed during endoscopy.
Treat with antibiotics and folic acid for 6 months or longer.

Quick HIT

Epidemiology of IBD
- More common in Caucasians than other racial groups
- Particularly common in Jewish populations
- Mean age of onset is 15 to 35 years
Inflammatory Bowel Disease

Crohn Disease (“Regional Enteritis”)

A. General Characteristics

1. Crohn disease is a chronic transmural inflammatory disease that can affect any part of the GI tract (mouth to anus) but most commonly involves the small bowel (terminal ileum).

2. Distribution: There are three major patterns of disease:
   a. Forty percent of patients have disease in the terminal ileum and cecum.
   b. Thirty percent of patients have disease confined to the small intestine.
   c. Twenty-five percent of patients have disease confined to the colon.
   d. Rarely, other parts of GI tract may be involved (stomach, mouth, esophagus).

3. Pathology
   a. **Terminal ileum is the hallmark location**, but other sites of GI tract may also be involved.
   b. Skip lesions—discontinuous involvement
   c. Fistulae
   d. Luminal strictures
   e. Noncaseating granulomas
   f. Transmural thickening and inflammation (full-thickness wall involvement)—results in narrowing of the lumen.
   g. Mesenteric “fat creeping” onto the antimesenteric border of small bowel.

Quick HIT

Crohn disease has a chronic, indolent course characterized by unpredictable flares and remissions. The effectiveness of medical treatment decreases with advancing disease, and complications eventually develop, requiring surgery. There is no cure, and recurrence is common even after surgery.

B. Clinical Features

1. Diarrhea (usually without blood)
2. Malabsorption and weight loss (common)
3. Abdominal pain (usually RLQ), nausea, and vomiting
4. Fever, malaise
5. Extraintestinal manifestations in 15% to 20% of cases (uveitis, arthritis, ankylosing spondylitis, erythema nodosum, pyoderma gangrenosum, aphthous oral ulcers, cholelithiasis, and nephrolithiasis) (see also Clinical Pearl 3-8)
C. Diagnosis

1. Endoscopy (sigmoidoscopy or colonoscopy) with biopsy—typical findings are aphthous ulcers, cobblestone appearance, pseudopolyps, patchy (skip) lesions.
2. Barium enema
3. Upper GI with small bowel follow-through

CLINICAL PEARL 3-8

Extraintestinal Manifestations of IBD
- Eye lesions
- Episcleritis—parallels bowel disease activity
- Anterior uveitis—independent course
- Skin lesions
- Erythema nodosum—especially in Crohn disease; parallels bowel disease activity
- Pyoderma gangrenosum—especially in UC; parallels bowel disease activity in 50% of cases.
- Arthritis—most common extraintestinal manifestation of IBD
- Migratory monoarticular arthritis—parallels bowel disease activity (coincides with exacerbation of colitis)
- Ankylosing spondylitis—patients with UC have a 30 times greater incidence of ankylosing spondylitis than the general population; the course is independent of the colitis.
- Sacroiliitis—does not parallel bowel disease activity
- Thromboembolic hypercoagulable state—can lead to deep venous thrombosis (DVT), pulmonary embolism (PE), or a cardiovascular accident (CVA)
- Idiopathic thrombocytopenic purpura
- Osteoporosis
- Gallstones in Crohn disease (ileal involvement)
- Sclerosing cholangitis in UC

D. Complications

1. Fistulae—between colon and other segments of intestine (enteroenteral), bladder (enterovesical), vagina (enterovaginal), and skin (enterocutaneous)
2. Anorectal disease (in 30% of patients)—fissures, abscesses, perianal fistulas
3. SBO (in 20% to 30% of patients) is the most common indication for surgery.
   a. Initially, it is due to edema and spasm of bowel with intermittent signs of obstruction; later, scarring and thickening of bowel cause chronic narrowing of lumen.
4. Malignancy—increased risk of colonic and small bowel tumors (but less common than risk of malignancy in UC).
5. Malabsorption of vitamin B₁₂ and bile acids (both occur in terminal ileum).
6. Cholelithiasis may occur secondary to decreased bile acid absorption.
7. Nephrolithiasis—increased colonic absorption of dietary oxalate can lead to calcium oxalate kidney stones.
8. Aphthous ulcers of lips, gingiva, and buccal mucosa (common)
9. Toxic megacolon—less common in Crohn disease than in UC
10. Growth retardation
11. Narcotic abuse, psychosocial issues due to chronicity, and often disabling nature of the disease

Quick HIT

Patients may have vague abdominal pain and diarrhea for years before a diagnosis of Crohn disease is considered.

E. Treatment

1. Medical
   a. Systemic corticosteroids (prednisone)—used as initial therapy for low-risk patients with diffuse disease or left-sided colon disease. Attempt taper when clinically improved. If unable to taper, consider immunosuppressant or biologic agent (below)
   b. Budesonide—used in low-risk patients with mild disease in ileum or right colon. Attempt taper when clinically improved. If unable to taper, consider immunosuppressant or biologic agent (below).
   c. Biologic agent (TNF inhibitor) can be used as monotherapy or in combination with thiopurine (azathioprine or 6-mercaptopurine) or methotrexate in patients with moderate to severe disease.

2. Surgical (eventually required in most patients)
   a. Reserved for complications of Crohn disease or for those who have persistent symptoms despite best medical management
   b. Involves segmental resection of involved bowel
   c. Disease recurrence after surgery is high. Up to 50% of patients experience disease recurrence at 10 years postoperatively.
   d. Indications for surgery include SBO, fistulae (especially between bowel and bladder or vagina), disabling disease, and perforation or abscess.

3. Nutritional supplementation and support—parenteral nutrition is sometimes necessary.
Ulcerative Colitis

A. General Characteristics

1. UC is a chronic inflammatory disease of the colon or rectal mucosa (see also Table 3-8).
2. It may occur at any age (usually begins in adolescence or young adulthood).
3. Distribution: UC involves the rectum in all cases and can involve the colon either partially or entirely, but is always continuous. There are no skip lesions as are seen in Crohn disease.
   a. Rectum alone (in 10% of cases)
   b. Rectum and left colon (in 40% of cases)
   c. Rectum, left colon, and right colon (in 30% of cases)
   d. Pancolitis (in 30% of cases)

<table>
<thead>
<tr>
<th>TABLE 3-8 Crohn Disease Versus Ulcerative Colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Involvement</strong></td>
</tr>
<tr>
<td>Crohn Disease</td>
</tr>
<tr>
<td>Discontinuous involvement (skip lesions)</td>
</tr>
<tr>
<td><strong>Location</strong></td>
</tr>
<tr>
<td>Crohn Disease</td>
</tr>
<tr>
<td>Can involve any part of the GI tract (resection is not curative—recurrences occur)</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
</tr>
<tr>
<td>Crohn Disease</td>
</tr>
</tbody>
</table>

4. The small bowel is not usually involved in UC, but it may reach the distal ileum in a small percentage of patients (“backwash ileitis” in 10% of cases)
5. The course is unpredictable and variable and is characterized by periodic exacerbations and periods of complete remission. Less than 5% of patients have an initial attack without any recurrence.
5. Pathology
   a. Uninterrupted involvement of rectum and/or colon
   b. Inflammation is not transmural (as it is in Crohn disease). It is limited to the mucosa and submucosa.
   c. PMNs accumulate in the crypts of the colon causing crypt abscesses.

B. Clinical Features (wide ranges of presentation are seen)
1. Hematochezia (bloody diarrhea)
2. **Abdominal pain**
3. Bowel movements are frequent but small
4. Fever, anorexia, and weight loss (severe cases)
5. Tenesmus (rectal dry heaves)
6. Extraintestinal symptoms (e.g., jaundice, uveitis, arthritis, skin lesions)—see Clinical Pearl 3-8

**Quick HIT**
Patients with UC may have nonbloody diarrhea at first, with eventual progression to bloody diarrhea.

**A. Diagnosis:** perform the following initial studies
1. Stool cultures for *Clostridium difficile*, ova, and parasites to rule out infectious diarrhea.
2. Fecal leukocytes
   a. WBCs can appear in UC, ischemic colitis, or infectious diarrhea.
3. Colonoscopy to assess the extent of disease and the presence of any complications.

**D. Complications**
1. Iron deficiency anemia
2. Hemorrhage
3. Electrolyte disturbances and dehydration secondary to diarrhea
4. Strictures, benign and malignant (usually malignant)
5. Colon cancer—The risk correlates with extent and duration of colitis. In distal proctitis there is no increased risk of CRC.
6. Sclerosing cholangitis (SC)—Does not correlate with bowel disease and is not prevented by colectomy.
7. Cholangiocarcinoma—Half of all bile duct cancers are associated with UC
8. Toxic megacolon is the leading cause of death in UC and affects <5% of patients. It is associated with the risk of colonic perforation.
9. Growth retardation
10. Narcotic abuse
11. Psychosocial issues (e.g., depression) due to chronicity and often disabling nature of the disease

**E. Treatment**
1. Medical (Figure 3-12)
   a. Sulfasalazine (topical application as a suppository)—the mainstay of treatment. Preferred over topical steroids and can be used as maintenance therapy.
Remission rates as high as 93% have been reported.
- It is effective in maintaining remissions. 5-ASA (mesalamine) is the active component.
- 5-ASA enemas can be used for proctitis and distal colitis.

b. Oral glucocorticoids—used when patients fail to respond to topical and oral 5-ASA therapy (above). If adequate clinical response is achieved, attempts to taper off of glucocorticoids should occur after 2 to 4 weeks. Can be used in conjunction with 5-ASA (topical and oral) for patients with severe colitis.

c. TNF inhibitors (infliximab, adalimumab) and thiopurines (6-mercaptopurine, azathioprine) can be used in patients who do not respond to corticosteroids or for severe disease.
d. Immunosuppressive agents in patients with refractory disease may prevent relapses but are not effective for acute attacks.

2. Surgical—often curative (unlike Crohn disease) and involves total colectomy. Indications for surgery include:
   a. Severe disease that is debilitating, refractory, and unresponsive to medical therapy
b. Toxic megacolon (risk of perforation), obstruction (due to stricture), severe hemorrhage, perforation
c. Fulminant exacerbation that does not respond to steroids
d. Evidence of colon cancer or increased risk of colon cancer
e. Growth failure or failure to thrive in children
f. Systemic complications

Quick HIT

Sulfasalazine is metabolized by bacteria to 5-ASA and sulfapyridine. 5-ASA is the effective moiety of the drug, and sulfapyridine causes the side effects.
4

Endocrine and Metabolic Diseases

Sarah Jensen
Diseases of the Pancreas

Diabetes Mellitus

A. General Characteristics

1. Classification (see also Table 4-1).
   a. Type I DM—approximately 5% of all diabetic patients.
      • This is characterized by a severe deficiency of insulin. **Patients require insulin to live.**
      • The onset is typically in youth (before age 20), but can occur at any age.
      • Not related to obesity.
   b. Type II DM—90% or more of all diabetic patients.
      • Insulin levels are usually normal to high but may diminish over many years of having diabetes.
      • Insulin resistance due to obesity plays a major role.
      • It often goes undiagnosed for many years.
   c. Impaired fasting glucose
      • Fasting glucose between 100 and 125 mg/dL or a 2-hour postprandial glucose between 140 and 199 mg/dL.
      • Impaired glucose tolerance is defined as a blood glucose between 140 and 199 mg/dL 2 hours after a 75-g oral glucose tolerance test.
      • One to five percent annual increase in risk of developing type II diabetes.
      • Increased risk for cardiovascular disease.

Quick HIT

Hypertriglyceridemia with HDL depletion is the characteristic lipid profile of insulin resistance and poorly controlled diabetes.

2. Pathogenesis of type I diabetes (see also Clinical Pearls 4-1 and 4-2)
   a. An autoimmune disease—The immune system mediates the destruction of β-cells.
   b. It develops in genetically susceptible individuals who are exposed to an environmental factor that triggers the autoimmune response; β-cell destruction ensues.
   c. Overt Type 1 DM does not appear until about 90% of β-cells are destroyed.

   a. Risk factors
• Obesity (greatest risk factor)
• Genetics
• Age (insulin production decreases with age)

b. Obesity plays a major role
• Obesity is associated with increased plasma levels of free fatty acids, which make muscles more insulin resistant, reducing glucose uptake. Therefore, obesity exacerbates insulin resistance.
• In the liver, free fatty acids increase the production of glucose.

c. Lack of compensation in type II diabetic patients
• In normal individuals, the pancreas secretes more insulin in response to free fatty acids, thus neutralizing the excess glucose.
• In type II diabetic patients, free fatty acids fail to stimulate pancreatic insulin secretion. Therefore, compensation does not occur and hyperglycemia develops; β-cells become desensitized to glucose, leading to decreased insulin secretion.

**Quick HIT**

Diabetes is diagnosed by one of the following:
1. Two fasting glucose measurements greater than 126 mg/dL
2. Single glucose level of 200 mg/dL with symptoms, with repeat confirmation
3. Two-hour 75-g oral glucose tolerance test greater than or equal to 200 mg/dL, with repeat confirmation
4. Hemoglobin A1c >6.5%

**TABLE 4-1** Comparison of Type I and II Diabetes Mellitus

<table>
<thead>
<tr>
<th></th>
<th>Type I</th>
<th>Type II</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Onset</strong></td>
<td>Sudden</td>
<td>Gradual</td>
</tr>
<tr>
<td><strong>Age at Onset</strong></td>
<td>Any age (typically young)</td>
<td>Mostly in adults</td>
</tr>
<tr>
<td><strong>Body Habitus</strong></td>
<td>Usually thin</td>
<td>Frequently obese</td>
</tr>
<tr>
<td><strong>Ketosis</strong></td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td><strong>Autoantibodies</strong></td>
<td>Present in most cases</td>
<td>Absent</td>
</tr>
<tr>
<td><strong>Endogenous Insulin</strong></td>
<td>Low or absent</td>
<td>Can be normal, decreased, or increased</td>
</tr>
<tr>
<td><strong>HLA Association</strong></td>
<td>Yes (HLA-DQ/DR)</td>
<td>No</td>
</tr>
<tr>
<td><strong>Genetic Factors</strong></td>
<td>Concordance rate between identical twins is 50%.</td>
<td>Concordance rate between identical twins is 90%. Therefore, type II demonstrates a much stronger genetic component than type I.</td>
</tr>
</tbody>
</table>
**CLINICAL PEARL 4-1**

**Dawn Phenomenon and Somogyi Effect**

- Both cause morning hyperglycemia.
- The dawn phenomenon is probably due to an increase in the nocturnal secretion of growth hormone. This phenomenon is independent of the Somogyi effect.
- The Somogyi effect is a rebound response to nocturnal hypoglycemia—that is, counterregulatory systems are activated in response to hypoglycemia, leading to morning hyperglycemia.
- If morning hyperglycemia is present, check the glucose level at 3:00 am. If the glucose level is elevated, the patient has the dawn phenomenon and his or her evening insulin should be increased to provide additional coverage in the overnight hours. If the glucose level is low, the patient has the Somogyi effect and his or her evening insulin should be decreased to avoid nocturnal hypoglycemia.

**CLINICAL PEARL 4-2**

**General Principles in Outpatient Management and Monitoring of All Diabetic Patients**

- Monitor HbA1c level every 3 months. Keeping HbA1c <7 is the objective (although difficult to achieve) because it is associated with a marked reduction in risk for microvascular complications.
- All diabetic patients should monitor daily glycemic levels with home blood glucose determinations. Patients on insulin therapy should check blood glucose levels before meals and at bedtime. Monitoring blood glucose 90 to 120 minutes after meals enables the patient to control postprandial hyperglycemia and should be strongly encouraged.
- Screen for microalbuminuria at least once per year in diabetic patients with no evidence of nephropathy.
- Prescribe ACE inhibitor or ARB if urine test is positive for microalbuminuria.
- Check BUN and creatinine level at least once per year.
- Order eye screening yearly by an ophthalmologist to screen for diabetic retinopathy.
- Check the feet at every visit. Refer high-risk patients to a foot care specialist (e.g., podiatrist). Patients should check their feet regularly for ulcers and neuropathy.
- Check cholesterol levels at least once per year. Give statin medication if LDL is above 100 mg/dL.
- Take BP at every visit. Give ACE inhibitor or ARB if BP is greater than 130/80 mm Hg.
- Daily aspirin in all diabetics over age 30 unless contraindicated.
- Pneumococcal vaccine.

<table>
<thead>
<tr>
<th>TABLE 4-2</th>
<th>Diagnostic Criteria for Diabetes Mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucose Test</strong></td>
<td><strong>Impaired Glucose Tolerance (mg/dL)</strong></td>
</tr>
<tr>
<td>Random plasma</td>
<td>—</td>
</tr>
<tr>
<td>Fasting</td>
<td>110–126</td>
</tr>
<tr>
<td>2-hr postprandial</td>
<td>140–200</td>
</tr>
<tr>
<td>Hemoglobin A1c (%)</td>
<td>5.7–6.4</td>
</tr>
</tbody>
</table>
B. Diagnosis

1. Testing recommendations (see also Table 4-2).
   a. Screen all adults between ages 40 and 70 every 3 years.
   b. For those with risk factors for diabetes (obesity, family history, history of gestational diabetes), start screening earlier. Some recommend early screening for African Americans and Native Americans.
   c. Test anyone with signs or symptoms of diabetes.

2. Perform any one of the following tests on two separate days (see Table 4-2).
   a. Fasting plasma glucose—criteria for DM: glucose >126 mg/dL.
      • If between 100 and 126 mg/dL, perform a 75-g oral glucose tolerance test (although this is rarely done) or recheck fasting glucose.
   b. Random plasma glucose—criteria for DM: glucose >200 mg/dL in a person with diabetic symptoms.
   c. Two-hour postprandial plasma glucose level—criteria for DM: glucose >200 mg/dL after administration of the equivalent of a 75-g glucose load (more sensitive than fasting glucose level, but less convenient).
   d. Hemoglobin A1c—criteria for DM: A1c >6.5% (repeat test should occur >3 months later as opposed to the next day). Many use this as preferred screening method.

Quick HIT

While evaluating a diabetic patient, focus on:
- The feet
- Vascular disease (CAD, PVD)
- Neurologic disease (neuropathies)
- Eyes (retinopathy)
- Renal disease
- Infectious disease

C. Clinical Presentation

1. Type I (see Table 4-3 and Figure 4-1)
   a. Symptoms develop quickly over days to weeks.
   b. Sometimes symptoms appear after an illness.
   c. Patients often present with acute diabetic ketoacidosis (DKA).

<table>
<thead>
<tr>
<th>TABLE 4-3 Symptoms of Diabetes Mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptom</strong></td>
</tr>
<tr>
<td>Polyuria</td>
</tr>
</tbody>
</table>
Polydipsia | A physiologic response to diuresis to maintain plasma volume
Fatigue | Mechanism unknown, but probably due to increased glucose in plasma
Weight loss | Due to loss of anabolic effects of insulin
Blurred vision | Swelling of lens due to osmosis (caused by increased glucose)
Fungal infections | Fungal infections of mouth and vagina common—*Candida albicans* thrives under increased glucose conditions
Numbness, tingling of hands and feet | Neuropathy

**FIGURE 4.1** Progression of type I diabetes mellitus.

2. Type II
   a. This is usually discovered on screening urinalysis or blood sugar measurement. Sometimes the diagnosis is made during evaluation for other diseases (e.g., heart, kidney, neurologic, infection).
   b. Symptomatic patients may present with polyuria, polydipsia, polyphagia, fatigue, blurred vision, weight loss, and/or candidal vaginitis. These symptoms are usually noted in retrospect, after elevated blood glucose has been documented.
   c. Patients who have not routinely sought medical attention may present with complications such as myocardial ischemia, stroke, intermittent claudication, impotence, peripheral neuropathy, proteinuria, or retinopathy.

**Quick HIT**

Optimal Treatment for Type II Diabetic Patients
- Glycemic control
- BP control—(<130/85)
- Optimization of serum lipids—goals: LDL ≤100, HDL ≥40. Check lipids annually.
- Smoking cessation
- Daily aspirin (if not contraindicated)
- Inspect feet at every visit
- Dilated eye examination yearly
- Urine albumin–creatinine ratio annually
- Measure A1c every 3 to 6 months.

D. Treatment

1. Diet and exercise should ideally be the only interventions in most type II diabetic patients.
   a. Diet and exercise are especially effective in obese and sedentary patients (who constitute the majority of type II diabetic patients).
   b. Most patients, however, do not lose enough weight to control glucose levels through diet and exercise alone, and will require pharmacologic treatment.
   c. Glycemic control minimizes risks for nephropathy, neuropathy, and retinopathy in both Type 1 and 2 DM, and decreases risk for cardiovascular disease for Type 1 DM.

2. Oral hypoglycemic drugs (see Table 4-4)
   a. Use these in type II diabetic patients when conservative therapy (diet and exercise) fails.
   b. Start with one agent; metformin is best initial drug therapy. If monotherapy fails, use two agents from different classes in combination. Each agent has advantages and disadvantages, so clinical judgment is required in selecting the agent.
   c. Metformin blocks gluconeogenesis. It is contraindicated in patients with renal failure.
   d. Other oral hypoglycemics include:
      • Sulfonylureas
      • Thiazolidinediones (glitazones)
      • GLP-1 agonist
      • α-Glucosidase inhibitors (acarbose, miglitol)
      • Pramlintide
      • DPP-4 inhibitor
      • SGLT2 inhibitor
      • Repaglinide/nateglinide

Quick HIT

Insulin Versus Noninsulin Agents in Type II Diabetes
- If the patient has severe hyperglycemia (fasting glucose >240 mg/dL), insulin typically is the agent of choice, whether type I or type II disease.
Noninsulin agents are effective in type II disease with moderate hyperglycemia (fasting glucose between 140 and 240 mg/dL).

e. There are numerous studies evaluating cardiovascular benefits of SGLT2 inhibitor therapy in high-risk CVD patients.
f. In patients with relatively mild disease, use of these drugs (alone or in combination) can bring glucose levels to normal, but patients with severe disease often do not respond adequately. Therefore, many type II diabetic patients eventually require insulin (see below).
g. Do not give to patients who cannot eat (e.g., because of illness or surgery).

**TABLE 4-4 Noninsulin Diabetes Medications**

**Quick HIT**

**Treatment of Diabetes**
- Type I diabetic patients require insulin to live.
- Type II diabetic patients require exercise and diet (initial steps) as well as oral hypoglycemic drugs. The current emphasis is to treat aggressively and move quickly to insulin if needed to optimize HbA1c.

3. Insulin (see Table 4-5).
   a. Method of administration.
      - Self-administered by SC injection in abdomen, buttocks, arm, and leg.
      - Given intravenously for emergency ketoacidosis.

**TABLE 4-5 Types of Insulin**

<table>
<thead>
<tr>
<th>Type</th>
<th>Onset</th>
<th>Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human insulin lispro</td>
<td>15 min</td>
<td>2–4 hrs</td>
<td></td>
</tr>
<tr>
<td>Regular insulin</td>
<td>30–60 min</td>
<td>4–6 hrs</td>
<td>Only type that can be given intravenously</td>
</tr>
<tr>
<td>NPH insulin/lente insulin</td>
<td>2–4 hrs</td>
<td>18–28 hrs</td>
<td>Most widely used form of insulin</td>
</tr>
<tr>
<td>Insulin detemir</td>
<td>2 hrs</td>
<td>6–24 hrs</td>
<td>Duration is dose-dependent</td>
</tr>
<tr>
<td>70/30 mixture</td>
<td>30 min</td>
<td>10–16 hrs</td>
<td>70% NPH, 30% regular</td>
</tr>
<tr>
<td>Glargine (Lantus)</td>
<td>3–4 hrs</td>
<td>24 hrs</td>
<td>Given at bedtime</td>
</tr>
</tbody>
</table>

b. Regimens
   - Most type I diabetic patients require 0.5 to 1.0 unit/kg per day to achieve
acceptable glycemic control.

- Start with a conservative dose (0.2 units/kg) and adjust the regimen according to the patient’s glucose levels.
- Many different regimens exist, and every patient has unique needs (see Table 4-5).

c. Intensive insulin therapy

- Long-acting insulin is given once daily in the evening. Regular insulin is given 30 to 45 minutes before each meal, and should be adjusted according to preprandial home glucose measurements.
- These more aggressive therapies have been shown to significantly decrease the incidence of diabetes complications such as retinopathy and microalbuminuria when compared to prior regimens. All attempts should be made to get patients on more aggressive treatment protocols.
- With intensive insulin therapy, **the risk for hypoglycemia is a serious concern.**
  - Alternatively, a continuous SC infusion of insulin can be given via an insulin pump. Preprandial boluses are given in addition to the basal infusion.

d. If the patient is unable/unwilling to carry out an intensive insulin program:

- Give 70/30 units before breakfast and before the evening meal for basal coverage.
- Give a short-acting insulin (regular) for prandial control if necessary.
- Adjust doses according to fasting and 4 PM glucose determinations.

e. Inpatient management of diabetic patients (sliding scale).

- An insulin sliding scale (SSI) of regular insulin doses given according to bedside finger-stick glucose determinations is helpful in controlling blood glucose levels in the hospital setting.
- **SSI should be used in addition to a regimen of long-acting insulin. If given alone, hyperglycemia usually results.**
  - Monitor blood glucose four times per day: before meals and at bedtime.
  - **Once insulin therapy is started, a blood glucose goal of 140 to 180 mg/dL should be targeted for most patients.**
  - If the home insulin dose is unclear, or if the patient anticipates greater requirements of insulin due to an illness, use the following approach to adjust appropriate insulin doses:
    - Take the total number of units of regular insulin that the patient required in 1 day (while on the sliding scale).
    - Add two-thirds of this to the prebreakfast dose and one-third before dinner. It should be given as 70/30 (i.e., 70% NPH/30% regular).
    - In practice, remember that often patients will be placed on a basal-bolus
dosing with long- and short-acting insulin with meals.

f. Modifying insulin doses (see also Clinical Pearl 4-3)
   
   • Physical activity—depending on the intensity of the activity, decrease insulin dosage 1 to 2 units per 20 to 30 minutes of activity.
   • During illness, administer all of the routine insulin. Many episodes of DKA occur during episodes of illness.
   • Stress and changes in diet require dosing adjustments.
   • Patients undergoing surgery should get one-third to one-half of the usual daily insulin requirement that day, with frequent monitoring and adjustments as necessary.

4. Surgical treatment—Surgical weight loss therapy (i.e., gastric bypass) is an effective treatment for some patients, including adolescents. Additionally, islet cell transplantation offers definitive treatment for selected qualified patients.

---

**CLINICAL PEARL 4-3**

**Monitoring Glucose Levels in DM**

- HbA1c gives an estimate of the degree of glucose control over 2 to 3 months.
- The American Diabetes Association recommends a treatment goal of HbA1c <7.0%. In general, HbA1c >10% is poor control, 8.5% to 10% is fair control, 7.0% to 8.5% is good control, and <7.0% is ideal as long as the patient is not experiencing hypoglycemic episodes.
- The American Diabetes Association recommends keeping fasting blood glucose level <130 mg/dL and peak postprandial blood glucose <180 mg/dL.
Chronic Complications of Diabetes Mellitus

A. Macrovascular Complications

1. The main problem is **accelerated atherosclerosis**, which puts patients at increased risk of stroke, MI, and CHF (Figure 4-2). The accelerated atherosclerosis in diabetics is the reason the target BP is lower in diabetics (130/80) than in general population (140/90), and the reason the target LDL is lower in diabetics (<100 mg/dL). The cause of accelerated atherosclerosis is not known, although glycation of lipoproteins and increased platelet adhesiveness/aggregation are thought to be two potential causes. In addition, the process of fibrinolysis may be impaired in diabetic patients.

2. The manifestations of atherosclerosis include the following:
   a. Coronary artery disease (CAD).
      - Risk of CAD is two to four times greater in diabetic than in nondiabetic persons.
      - **Most common cause of death in diabetic patients.**
      - Silent myocardial infarctions are common.
   b. Peripheral vascular disease—in up to 60% of diabetic patients.
   c. Cerebrovascular disease (strokes).

---

**Quick HIT**

The risk of coronary events is greatly reduced if the patient can eliminate or reduce other major cardiovascular risk factors (smoking, HTN, hyperlipidemia, obesity).
FIGURE 4.2 Chronic complications of diabetes mellitus.
B. Microvascular Complications

Risk can be markedly reduced by achieving tight glucose control (see also Clinical Pearl 4-4)

1. **Diabetic nephropathy**—most important cause of end-stage renal disease (ESRD)
   a. Pathologic types
      - Nodular glomerular sclerosis (Kimmelstiel–Wilson syndrome)—hyaline deposition in **one** area of glomerulus—pathognomonic for DM
      - Diffuse glomerular sclerosis—hyaline deposition is global. This also occurs in HTN.
      - Isolated glomerular basement membrane thickening.
   b. Microalbuminuria/proteinuria
      - If microalbuminuria is present, strict glycemic control is critical. Tight blood glucose has been shown to limit progression from microalbuminuria to clinical proteinuria.
      - Without effective treatment, the albuminuria gradually worsens—HTN usually develops during the transition between microalbuminuria and progressive proteinuria. Persistent HTN and proteinuria cause a decrease in glomerular filtration rate (GFR), leading to renal insufficiency and eventually ESRD.
      - **HTN increases the risk of progression of diabetic nephropathy to ESRD.** Control BP aggressively.
      - **Initiate ACE inhibitors or ARB immediately.** These agents are proven to decrease the rate of progression of nephropathy.
      - **Microalbuminuria is the screening test!** If you wait for the dipstick to be positive for protein, you have waited too long. Remember that microalbuminuria means levels of albumin are between 30 and 300 mg per 24 hours. But the dipstick for urine becomes trace positive at 300 mg of protein per 24 hours.
      - It usually takes 1 to 5 years for microalbuminuria to advance to full-blown proteinuria. However, with proper treatment (i.e., using ACE inhibitors to control BP) this can be prolonged.
c. Once diabetic nephropathy has progressed to the stage of proteinuria or early renal failure, glycemic control does not significantly influence its course. ACE inhibitors and dietary restriction of protein are recommended.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition of Microalbuminuria</strong></td>
</tr>
<tr>
<td>- 30 to 300 mg/day</td>
</tr>
<tr>
<td>- Albumin–creatinine ratio of 0.02 to 0.20</td>
</tr>
</tbody>
</table>

2. **Diabetic retinopathy**
   a. Prevalence is approximately 75% after 20 years of diabetes. **Annual screening of all diabetic patients by an ophthalmologist is recommended.**
   b. Background (nonproliferative) retinopathy accounts for the majority of cases.
      - Funduscopic examination shows hemorrhages, exudates, microaneurysms, and venous dilatation.
      - These patients are usually asymptomatic unless retinal edema or ischemia involves the central macula.
      - Edema of the macula is the leading cause of visual loss in diabetic patients.
   c. HTN and fluid retention exacerbate this condition.
   d. Proliferative retinopathy
      - Key characteristics are new vessel formation (neovascularization) and scarring.
      - Two serious complications are vitreous hemorrhage and retinal detachment.
      - **Can lead to blindness. Laser photocoagulation is the treatment.**

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ocular problems in diabetic patients include cataracts, retinopathy, and glaucoma. Diabetic retinopathy is the leading cause of blindness in the United States.</strong></td>
</tr>
</tbody>
</table>

**FIGURE 4.3** Progression in diabetic nephropathy. Strict glycemic control has been shown to slow or prevent progression from microalbuminuria to proteinuria. This is the critical stage (marked by star)—once proteinuria develops, glycemic control does little to control the course and will eventually lead to ESRD.
3. Diabetic neuropathy (Figure 4-3)
   
a. Peripheral neuropathy (distal symmetric neuropathy)
   
   • Usually affects sensory nerves in a “stocking/glove pattern”—Typically begins in feet, later involves hands (longest nerves affected first). Numbness and paresthesias are common.
   
   • Loss of sensation leads to the following: ulcer formation (patients do not shift their weight) with subsequent ischemia of pressure point areas; Charcot joints.
   
   • Painful diabetic neuropathy—hypersensitivity to light touch; severe “burning” pain, especially at night, that can be difficult to tolerate. Treatment is with gabapentin, tricyclic antidepressants, or pregabalin.

Quick HIT

The Diabetes Control and Complications Trial showed that tight glucose control reduces the risk of microvascular disease by 50% to 60%. However, whether it can reduce the risk of macrovascular disease remains to be proven. It is the macrovascular complications that cause death in the majority of type II diabetic patients.

b. CN complications—secondary to nerve infarction.
   
   • Most often involves CN III, but may also involve CN VI and IV.
   
   • Diabetic third nerve palsy: eye pain, diplopia, ptosis, inability to adduct the eye; but the pupils are spared.

c. Mononeuropathies—secondary to nerve infarction.
   
   • Median nerve neuropathy, ulnar neuropathy, common peroneal neuropathy.
   
   • Diabetic lumbosacral plexopathy—severe, deep pain in the thigh; atrophy and weakness in thigh and hip muscles; recovery takes weeks to months.
   
   • Diabetic truncal neuropathy—pain in distribution of one of the intercostal nerves.

d. Autonomic neuropathy
   
   • Impotence in men (most common presentation)
   
   • Neurogenic bladder—retention, incontinence
   
   • Gastroparesis—chronic nausea and vomiting, early satiety
   
   • Constipation and diarrhea (alternating)
   
   • Postural hypotension

4. Diabetic foot
   
   a. Caused by a combination of artery disease (ischemia) and nerve disease (neuropathy)—can lead to ulcers/infections and may require amputation.
   
   b. With neuropathy, the patient does not feel pain, so repetitive injuries go unnoticed and ultimately lead to nonhealing.
   
   c. In addition, neuropathy may mask symptoms of PVD (claudication/rest pain).
Also, calcific medial arterial disease is common and can cause erroneously high BP readings in lower extremities.

5. Increased susceptibility to infection
   a. This results from impaired WBC function, reduced blood supply, and neuropathy. Wound healing is impaired in diabetic patients, and this can be problematic postoperatively.
   b. Diabetic patients are at increased risk for the following infections: cellulitis, candidiasis, pneumonia, osteomyelitis, and polymicrobial foot ulcers.
   c. Infections of ischemic foot ulcers may lead to osteomyelitis and may require amputation.

C. Specific Treatment of Chronic Diabetic Complications
   1. Macrovascular disease—treatment involves reduction of risk factors (e.g., BP reduction, lipid-lowering agents, smoking cessation, exercise), a daily aspirin (if not contraindicated), and strict glycemic control.
   2. Nephropathy—ACE inhibitors, benefits of which include:
      a. Slow progression of microalbuminuria to proteinuria.
      b. Slow decline of GFR.
   3. Retinopathy—Treatment involves referral to an ophthalmologist and possible photocoagulation.
   4. Neuropathy—Treatment is complex. Pharmacologic agents that may be helpful include NSAIDs, tricyclic antidepressants, and gabapentin. For gastroparesis, a promotility agent such as metoclopramide can be helpful, in addition to exercise and a low-fat diet.
   5. Diabetic foot—The best treatment is prevention: regular foot care, regular podiatrist visits. Amputation is a last resort.
Acute Complications of Diabetes Mellitus

A. Diabetic Ketoacidosis

1. General characteristics
   a. DKA is an acute, life-threatening medical emergency that can occur in both type I and type II diabetic patients (more common in type I).
   b. Pathogenesis
      • This is secondary to insulin deficiency and glucagon excess, both of which contribute to accelerated severe hyperglycemia and accelerated ketogenesis.
      • Severe hyperglycemia leads to an osmotic diuresis, which causes dehydration and volume depletion.
   c. Consequences of DKA include hyperglycemia, ketonemia, metabolic acidosis, and volume depletion.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key Features of DKA</strong></td>
</tr>
<tr>
<td>• Hyperglycemia</td>
</tr>
<tr>
<td>• Positive serum or urine ketones</td>
</tr>
<tr>
<td>• Metabolic acidosis</td>
</tr>
</tbody>
</table>

2. Precipitating factors
   a. Any type of stress or illness (e.g., infectious process, trauma, myocardial infarction, stroke, recent surgery, sepsis, GI bleeding)
   b. Inadequate administration of insulin

3. Clinical features
   a. Nausea and vomiting
   b. Kussmaul respiration—rapid, deep breathing
   c. Abdominal pain (more common in children) that may mimic acute abdomen—often with guarding and rigidity
   d. “Fruity” (acetone) breath odor
   e. Marked dehydration, orthostatic hypotension, tachycardia—volume depletion is always present
   f. Polydipsia, polyuria, polyphagia, weakness
   g. Altered consciousness, drowsiness, and frank coma may occur if not treated
   h. Symptoms usually occur rapidly, typically in less than 24 hours

4. Diagnosis
   a. Hyperglycemia: serum glucose typically >450 mg/dL and <850 mg/dL (in certain conditions, e.g., alcohol ingestion, the patient may be euglycemic)
   b. Metabolic acidosis
• Blood pH <7.3 and serum HCO$_3^-$ <15 mEq/L
• Increased anion gap—due to production of ketones (acetoacetate and β-hydroxybutyrate)

(c) Ketonemia (serum positive for ketones) and ketonuria
• Serum levels of acetoacetate, acetone, and β-hydroxybutyrate are greatly increased.
• When DKA is accompanied by circulatory collapse, serum and urine may be falsely negative for ketones. This is because lactate production results in less acetoacetate and more β-hydroxybutyrate production, and acetoacetate is the only ketoacid that can be measured by nitroprusside agents.

(d) Ketonemia and acidosis are required for the diagnosis of DKA.

Quick HIT

**Differential Diagnosis of DKA**
- Alcoholic ketoacidosis
- Hyperosmolar hyperglycemic nonketotic syndrome (HHNS)
- Hypoglycemia (altered mental status, abdominal pain, and acidosis are possible)
- Sepsis
- Intoxication (e.g., methanol, ethanol, salicylates, isopropyl alcohol, paraldehyde, ethylene glycol)

5. **Other laboratory value abnormalities**
   a. Hyperosmolarity
   b. Hyponatremia—Serum sodium decreases 1.6 mEq/L for every 100 mg/dL increase in glucose level because of the osmotic shift of fluid from the ICF to the ECF space. Total body sodium level is normal. This generally does not require treatment.
   c. Other electrolyte disturbances
      • Potassium—Because of the acidosis, hyperkalemia may be present initially, although total body potassium is low. **As insulin is given, it causes a shift of potassium into cells, resulting in a hypokalemia. This can happen very rapidly.** Phosphate and magnesium levels may also be low.

6. **Treatment**
   a. Insulin
      • Give insulin immediately after the diagnosis is established.
      • Give a priming dose of 0.1 units/kg of regular insulin (IV) followed by an infusion of 0.1 units/kg/hr. This is sufficient to replace the insulin deficit in most patients. **Be certain that the patient is not hypokalemic before giving insulin.**
      • Continue the insulin until the anion gap closes and metabolic acidosis is
corrected, then begin to decrease the insulin. Give SC insulin when the patient starts eating again.

b. Fluid replacement (normal saline)
   - Give fluids immediately after the diagnosis is established.
   - Add 5% glucose once the blood glucose reaches 200 mg/dL to prevent hypoglycemia.

c. Replace potassium prophylactically with IV fluids.
   - Initiate within 1 to 2 hours of starting insulin. Ensure adequate renal function (measure urine output) before administering these.
   - Monitor potassium, magnesium, and phosphate levels very closely and replace as necessary.

d. HCO$_3^-$ replacement is controversial and is not necessary in most cases.

**Quick HIT**

If a patient presents with DKA:
- Take a history and perform a physical examination.
- Order laboratory tests: blood glucose, arterial blood gas, CBC, electrolytes, BUN, creatinine, and urinary analysis.
- Order ECG, CXR, and cultures.
- Initiate IV fluids.
- **If K is <3.3 mEq/L, hold insulin** and give 20 to 30 mEq/hr until serum K is >3.3. If K is 3.3 to 5.2, give potassium with IV fluids to maintain a goal of 4 to 5 mEq/L in serum. If K >5.2, do not give any with IVF, but continue to monitor every 2 hours.
- Give insulin (hold if K <3.3 as above).
- Admit to the ICU or a very closely monitored floor bed.

**Quick HIT**

Treatment of DKA: **insulin, fluids, potassium. Only initiate insulin once serum K >3.3 mEq/L.**

**B. Hyperosmolar Hyperglycemic Nonketotic Syndrome**

1. **General characteristics** (see also **Table 4-6**)
   a. A state of severe hyperglycemia, hyperosmolarity, and dehydration is typically seen in elderly type II diabetic patients.
   b. Pathogenesis
      - Low insulin levels lead to hyperglycemia. Severe hyperglycemia causes an osmotic diuresis, leading to dehydration.
      - Ketogenesis is minimal because a small amount of insulin is released to blunt counterregulatory hormone release (glucagon), and thus ketones are not produced in excess as they are in DKA.
• Ketosis and acidosis are typically absent or minimal.
• Severe dehydration is due to continued hyperglycemic (osmotic) diuresis. The patient’s inability to drink enough fluids (either due to lack of access in elderly/bedridden patients or to an inadequate thirst drive) to keep up with urinary fluid losses exacerbates the condition.

c. Precipitating events are similar to those of DKA.

**Quick HIT**

**Complications of Treatment of DKA**
- Cerebral edema—if glucose levels decrease too rapidly
- Hyperchloremic nongap metabolic acidosis—due to rapid infusion of a large amount of saline

**Quick HIT**

A number of names have been used for this clinical entity, including HHNS, hyperosmolar hyperglycemic nonketotic coma (HHNC), and hyperosmolar nonacidotic diabetes.

**TABLE 4-6 Diabetic Ketoacidosis Versus Hyperosmolar Hyperglycemic Nonketotic Syndrome**

<table>
<thead>
<tr>
<th></th>
<th>DKA</th>
<th>HHNS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
<td>Insulin deficiency → ketosis, acidosis, dehydration</td>
<td>Insulin deficiency → hyperosmolarity, osmotic diuresis, profound dehydration</td>
</tr>
</tbody>
</table>
| **Laboratory Findings** | • Hyperglycemia (>450)  
• Metabolic acidosis (anion gap)—serum pH <7.3  
• Ketosis | • Hyperglycemia (>900 mg/dL)  
• Hyperosmolarity (>320 mOsm/L)  
• Serum pH >7.3 (no acidosis) |
| **Treatment**     | Insulin, IV fluids, potassium | Aggressive IV fluids, low-dose insulin infusion |
| **Mortality Rate** | 5–10%                           | 10–20%                                        |

2. **Clinical features**
   a. Thirst, polyuria
   b. Signs of extreme dehydration and volume depletion—hypotension, tachycardia
   c. **CNS findings and focal neurologic signs are common** (e.g., seizures)—secondary to hyperosmolarity.
   d. Lethargy and confusion may develop, leading to convulsions and coma.

**Quick HIT**

HHNS has a higher mortality rate than DKA, but it is less common than DKA. This may be because many HHNS
patients are elderly with other comorbid conditions (e.g., heart, renal, or pulmonary disease).

3. **Diagnosis**
   a. Hyperglycemia: serum glucose typically **higher than DKA** and frequently >900 mg/dL.
   b. Hyperosmolarity: serum osmolarity >320 mOsm/L.
   c. Serum pH >7.3 (no acidosis); serum HCO$_3^-$ >15.
   d. BUN is usually elevated. Prerenal azotemia is common.

4. **Treatment**
   a. **Fluid replacement** is most important (normal saline): 1 L in the first hour, another liter in the next 2 hours. Most patients respond well. Switch to half normal saline once the patient stabilizes.
      - Glucose levels are lowered as the patient is rehydrated, but the patient still requires insulin. When glucose levels reach 300 mg/dL, add 5% glucose (D5 1/2 NS). Note difference in goal from DKA.
      - Very rapid lowering of blood glucose can lead to cerebral edema in children (just as in DKA).
      - In patients with cardiac disease or renal insufficiency, avoid volume overload (can lead to CHF), but generous fluids are still needed.
   b. Insulin: Check to ensure serum K >3.3 prior to initiating. An initial bolus of 0.1 U/kg as IV bolus, followed by a continuous low-dose infusion (0.1 U/kg/hr) is usually appropriate.

---

**Quick HIT**

**Key Features of HHNS**
- Severe hyperosmolarity (>320 mOsm/L)
- Hyperglycemia (>600 mg/dL)
- Dehydration
- Acidosis and ketosis are absent (unlike in DKA)
Obesity

A. General Characteristics
1. BMI ≥30 kg/m²
2. About one-third of US population is obese (with an increasing prevalence in adults, adolescents, and children).
3. Obesity is associated with an increased risk of hypertension, dyslipidemia, diabetes mellitus, cardiovascular disease, and osteoarthritis.

B. Causes
1. Result of chronic mismatches in energy balance (energy intake > energy expenditure)
2. Energy balance determined by several variables, including metabolic rate, appetite, diet, and physical activity.
3. These factors that determine energy balance are influenced by both genetic traits and environmental behaviors (such as excessive food intake, decreased physical activity).
4. Drug-induced (less common)—glucocorticoids, antipsychotics, antidepressants, oral hypoglycemics, and antiepileptics
5. Neuroendocrine disorders such as Cushing syndrome and polycystic ovarian syndrome (PCOS)

Quick HIT

BMI Classification:
- Underweight—BMI <18.5 kg/m²
- Normal weight—BMI ≥18.5 kg/m² and <25 kg/m²
- Overweight—BMI ≥25 kg/m² and <30 kg/m²
- Obese—BMI ≥30 kg/m²
- Severe obesity—BMI ≥40 kg/m²

C. Diagnosis
1. All adults should be screened by measuring height, weight, and calculating body mass index (BMI)
2. BMI = body weight (kg)/height² (meters)
3. Overweight and obese patient should be further screened with waist circumference to assess abdominal obesity.
4. Waist circumference of ≥40 inches in men and ≥35 inches in women is considered elevated and corresponds with an increased cardiometabolic risk.
5. Patients with abdominal obesity are at increased risk for heart disease, diabetes, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD).
D. Treatment  
1. The main treatment for obesity is **dieting** and **physical exercise**.
2. Medications if dieting and physical exercise fail. **Orlistat** (pancreatic lipase inhibitor), **lorcaserin** (selective 5-HT$_{2C}$ receptor agonist), and combination **phentermine and topiramate** (exact mechanism of action unknown), have shown some benefit.
3. **Bariatric surgery** remains the most effective treatment for obesity. It has been associated with long-term weight loss, improvement in obesity-related complications, and decreased mortality.
4. Bariatric surgery should **only** be attempted in patients with a BMI of 40 kg/m$^2$ or greater who have failed a sufficient exercise and diet regimen (regardless of use of obesity medication) **and** who present with obesity-related comorbid conditions such as hypertension, diabetes mellitus, and hyperlipidemia.
Hypoglycemia

A. General Characteristics
1. **The primary organ at risk in hypoglycemia is the brain**—The brain uses glucose as its main energy source except when using ketone bodies during fasting (see also Clinical Pearl 4-5).
2. Unlike other tissues, the brain cannot use free fatty acids as an energy source.
3. Hypoglycemia is really due to an imbalance between glucagon and insulin.
4. If there is no correlation between the symptoms and low glucose levels (e.g., patient has symptoms when glucose levels are normal), an underlying disorder of glucose metabolism is unlikely (i.e., the patient does not have true hypoglycemia).

B. Causes
1. Drug-induced—taking too much insulin is a common problem in diabetic patients attempting tight control of their disease.
2. Factitious hypoglycemia
   a. If the patient took insulin surreptitiously, there will be a high blood insulin level and a low blood C-peptide level because exogenous insulin does not contain C-peptide.
   b. Patients taking exogenous insulin will also develop anti-insulin antibodies, which can be measured.
   c. If the patient took sulfonylurea, check urine or serum for levels of this drug.
   d. Insulinoma
3. Ethanol ingestion—due to:
   a. Poor nutrition that leads to decreased glycogen (and loss of glycogenolysis).
   b. Metabolism of alcohol that lowers nicotinamide adenine dinucleotide levels and decreases gluconeogenesis.
4. Postoperative complications after gastric surgery (due to rapid gastric emptying)
5. Reactive (idiopathic) hypoglycemia—symptoms occur 2 to 4 hours after a meal; rarely indicates a serious underlying disorder
6. Adrenal insufficiency
7. Liver failure
8. Critical illness
9. Disorders of carbohydrate metabolism (e.g., glycogen storage diseases)—usually diagnosed at a much younger age.

**CLINICAL PEARL 4-5**

Physiologic Responses to Hypoglycemia
When glucose levels approach the low 80s, insulin levels decrease—This decrease is normally enough to prevent hypoglycemia.  
As glucose levels decrease further, glucagon levels increase. Glucagon is the first line of defense against more severe hypoglycemia.  
Epinephrine is the next hormone to combat hypoglycemia. Cortisol and other catecholamines also play a role.  
As glucose levels decrease into the 50s and below, symptoms begin.

Quick HIT

If a patient presents with hypoglycemia of unknown cause, measure:
1. Plasma insulin level
2. C-peptide
3. Anti-insulin antibodies
4. Plasma and urine sulfonylurea levels

Hypoglycemic Unawareness
1. In diabetic patients, if severe neuropathy is present, the autonomic response (epinephrine) to hypoglycemia is not activated. This leads to neuroglycopenic symptoms.
2. It is common for diabetic patients to become hypoglycemic with conventional therapy (insulin or oral hypoglycemics). With longstanding disease in which they lose their neurogenic symptom response to hypoglycemia, patients do not recognize the impending hypoglycemia and may even have a seizure or enter a coma.

C. Clinical Features
1. Symptoms occur at a blood glucose level of 40 to 50 mg/dL.
2. Elevated epinephrine levels cause sweating, tremors, increased BP and pulse, anxiety, and palpitations.
3. Neuroglycopenic symptoms—decreased glucose for the brain (CNS dysfunction), resulting in irritability, behavioral changes, weakness, drowsiness, headache, confusion, convulsions, coma, and even death.

D. Diagnosis
1. Blood glucose level—Symptoms generally begin when levels drop below 50. However, there is no cutoff value to define hypoglycemia.
2. Whipple triad is used to diagnose true hypoglycemia (i.e., hypoglycemia due to underlying disease). (See the Insulinoma section.)
3. Laboratory tests—for measurement of serum insulin, C-peptide, and glucose when symptoms occur. An overnight fast may be sufficient to produce symptoms.
4. 72-hour fast (24 hours is usually sufficient)—used to diagnose insulinoma if suspected.

E. Treatment
   a. If the patient can eat, give sugar-containing foods; if not, give 1/2 to 2 ampules of D50W intravenously.
   b. Repeat administration of D50W as necessary, but switch to D10W as clinical condition improves and glucose level is approximately >100 mg/dL.
2. Appropriate management of underlying cause (e.g., diabetes, insulinoma).
3. If reactive hypoglycemia is suspected, dietary interventions are appropriate.
4. If the patient is an alcoholic (or suspected alcoholic), give thiamine before administering glucose to avoid Wernicke encephalopathy.
Insulinoma

A. General Characteristics
1. Insulin-producing tumor arising from the β-cells of the pancreas
2. Associated with MEN I syndrome
3. Usually benign (in up to 90% of the cases)

B. Clinical Features
Hypoglycemia, which leads to:
1. Sympathetic activation—diaphoresis, palpitations, tremors, high blood pressure, anxiety
2. Neuroglycopenic symptoms—headache, visual disturbances, confusion, seizures, coma

C. Diagnosis
1. 72-hour fast (see also Table 4-7).
   a. The patient becomes hypoglycemic. Normally, the insulin level should decrease as hypoglycemia develops.
   b. In persons with insulinoma, insulin does not respond appropriately to hypoglycemia. It may decrease or increase, or it may not change. Nevertheless, the insulin levels are still higher than they would be in a normal individual for any given glucose concentration.
2. Whipple triad.
   a. Hypoglycemic symptoms brought on by fasting.
   b. Blood glucose <50 mg/dL during symptomatic attack.
   c. Glucose administration brings relief of symptoms.
3. Elevated fasting serum insulin level. C-peptide levels should also be elevated, which distinguishes insulinoma from exogenous insulin administration.

<table>
<thead>
<tr>
<th>TABLE 4-7 Laboratory Values in Hyperinsulinemic Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnosis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Insulinoma</td>
</tr>
<tr>
<td>Surreptitious insulin</td>
</tr>
<tr>
<td>Sulfonylurea abuse</td>
</tr>
</tbody>
</table>

D. Treatment
Surgical resection of tumor (up to 80% to 90% cure rate)
Zollinger–Ellison Syndrome (ZES, Gastrinoma)

A pancreatic islet cell tumor that secretes high gastrin, which leads to profound gastric acid hypersecretion, resulting in ulcers.

Up to 60% are malignant; 20% associated with MEN I (80% are sporadic); 90% located in the “gastrinoma triangle” (formed by the following points: cystic duct superiorly, junction of second and third portions of the duodenum inferiorly, and neck of pancreas medially).

Possible complications: GI hemorrhage, GI perforation, gastric outlet obstruction/stricture, and metastatic disease (liver is the most common site).

Clinical features: peptic ulcers, diarrhea, weight loss, abdominal pain.

Secretin injection test is diagnostic test of choice. Normally, secretin inhibits gastrin secretion. In patients with ZES, gastrin levels increase substantially after being given secretin.

Fasting gastrin level is elevated in patients with ZES.
Normal basal acid output is <10 mEq/hr; in patients with ZES, it is >15 mEq/hr.

Treatment consists of high-dose proton pump inhibitors.

All patients with ZES should undergo exploration to attempt curative resection (20% of patients are cured with complete resection). If there is widely metastatic or incurable gastrinoma, debulking surgery and chemotherapy are indicated.
Glucagonoma

A glucagon-producing tumor located in the pancreas. Clinical manifestations include necrotizing migratory erythema (usually below the waist), glossitis, stomatitis, DM (mild), and hyperglycemia (with low amino acid levels and high glucagon levels). Treatment is surgical resection.
Somatostatinoma
A rare, malignant pancreatic tumor; metastases usually are present by diagnosis.
Poor prognosis
Classic triad of gallstones, diabetes, and steatorrhea
VIPoma (Verner–Morrison or Watery Diarrhea, Hypokalemia, Achlorhydria Syndrome)

A rare pancreatic tumor (>50% are malignant). Clinical features include watery diarrhea (leading to dehydration, hypokalemia, acidosis), achlorhydria (VIP inhibits gastric acid secretion), hyperglycemia, and hypercalcemia. Treatment is surgical resection.
Diseases of the Thyroid Gland

Hyperthyroidism

A. Causes

1. **Graves disease (diffuse toxic goiter)** is the most common cause—80% of all cases.
   a. An autoimmune disorder: A thyroid-stimulating immunoglobulin (IgG) antibody binds to the TSH receptors on the surface of thyroid cells and triggers the synthesis of excess thyroid hormone.
   b. Seen most often in younger women. Commonly associated with other autoimmune disorders.
   c. A radioiodide scan shows diffuse uptake because every thyroid cell is hyperfunctioning.

2. **Plummer disease (multinodular toxic goiter)**—15% of all cases.
   a. Characterized by hyperfunctioning areas that produce high T4 and T3 levels, thereby decreasing TSH levels. As a result, the rest of the thyroid is not functioning (atrophy due to decreased TSH).
   b. Consequently, patchy uptake appears on the thyroid scan.
   c. More common in elderly patients, and more common in women than men.

3. Toxic thyroid adenoma (single nodule)—2% of all cases.

4. Hashimoto thyroiditis and subacute (granulomatous) thyroiditis (both can cause transient hyperthyroidism).

5. Other causes (rare)
   a. Postpartum thyroiditis (transient hyperthyroidism)
   b. Iodine-induced hyperthyroidism
   c. Excessive doses of levothyroxine (e.g., iatrogenic by health care provider or surreptitious self-administration)

---

Quick HIT

**Hyperthyroidism in the Elderly**
- In the elderly, classic symptoms of hyperthyroidism (e.g., nervousness, insomnia, hyperactivity) may be absent. The only manifestations may be weight loss, weakness, and/or atrial fibrillation.
- Consider hyperthyroidism before assuming that an elderly patient with unexplained weight loss has depression or occult malignancy.

---

B. Clinical Features

1. Symptoms
a. Nervousness, insomnia, irritability
b. Hand tremor, hyperactivity, tremulousness
c. Excessive sweating, heat intolerance
d. Weight loss despite increased appetite
e. Diarrhea
f. Palpitations (due to tachyarrhythmias)
g. Muscle weakness

**Quick HIT**

There are three signs of hyperthyroidism specific to Graves disease:
- Exophthalmos
- Pretibial myxedema
- Thyroid bruit

2. Signs
   a. Thyroid gland
      - Graves disease: a diffusely enlarged (symmetric), nontender thyroid gland; **a bruit may be present**.
      - Subacute thyroiditis: an exquisitely tender, diffusely enlarged gland (with a viral illness).
      - Plummer disease and Hashimoto thyroiditis (if multinodularity is present): thyroid gland is bumpy, irregular, and asymmetric.
      - Toxic adenoma: single nodule with an otherwise atrophic gland.

   b. Extrathyroidal
      - **Eyes**: Proptosis, due to edema of the extraocular muscles and retro-orbital tissue, is a hallmark of Graves disease (but not always present). Irritation and excessive tearing are common due to corneal exposure. Lid retraction may be the only sign in milder disease (**Figure 4-4**). Lid lag may be present.
      - Cardiovascular effects: arrhythmias (sinus tachycardia, atrial fibrillation, and premature ventricular contractions), elevated BP
      - Skin changes: warm and moist, pretibial myxedema (edema over tibial surface due to dermal accumulation of mucopolysaccharides)
      - Neurologic: brisk deep tendon reflexes, tremor
C. Diagnosis

1. Serum TSH level (low)—**initial test of choice**: If TSH is normal or high, hyperthyroidism is unlikely. (TSH-induced hyperthyroidism is quite uncommon.)
2. Next order thyroid hormone levels: T4 level should be elevated.
3. Testing the T3 level is usually unnecessary but may be helpful if TSH level is low and free T4 is not elevated, because excess T3 alone can cause hyperthyroidism.
4. Other tests (less commonly used but often tested).
   a. Radioactive T3 uptake.
      - Gives information regarding the status of thyroid-binding globulin (TBG).
      - The patient is given “resin” and radioactive T3. Radioactive T3 will only bind to the resin when there is no “space” left on TBG. By measuring how much radioactive T3 binds to the resin, you are measuring how much TBG is available to bind. For example, if large amounts of radioactive T3 are binding to the resin, the fewer “unoccupied” spots are available on TBG; this can be seen in hyperthyroidism when high levels of T4 “occupy” those TBG sites.
      - **The importance of this test is that it helps differentiate between elevations in thyroid hormones due to increased TBG from true hyperthyroidism (due to an actual increase in free T4).**
      - **Consider hyperthyroidism when the thyroid gland is producing excess T4.** In this case, all of the binding sites on TBG will be bound by T4, so radioactive T3 uptake will increase.
- **Consider pregnancy when there is high TBG.** There are more binding sites for radioactive T₃, so radioactive T₃ uptake decreases. Therefore, high TBG production leads to low radioactive T₃ uptake.

b. Free thyroxine index (FTI).
   - FTI is proportional to actual free T₄ concentration; it is calculated to correct for changes in thyroid binding proteins.
   - FTI = (radioactive T₃ uptake x serum total T₄)/100.
   - FTI = (patient’s radioactive T₃ uptake/normal radioactive T₃ uptake) x total T₄.
   - Normal FTI values are 4 to 11. FTI should not change (as T₄ decreases, radioactive T₃ uptake increases and vice versa).
   - Infrequently ordered due to newer methods of measuring free T₄ directly.

### Quick HIT

**Thyroid Hormones and TBG**
- T₄ is converted to T₃ by deiodination outside of the thyroid.
- T₃ is more biologically active than T₄.
- Most of T₄ (and T₃) is reversibly bound to TBG and is inactive.
- Factors that increase TBG (and therefore total T₄) include pregnancy, liver disease, oral contraceptives, and aspirin.

### D. Treatment Types

1. Pharmacologic
   a. Thionamides—Methimazole and propylthiouracil (PTU) inhibit thyroid hormone synthesis, and PTU also inhibits conversion of T₄ to T₃. Treatment with thionamides results in long-term remission in a minority of patients; a major serious side effect is agranulocytosis. Other side effects shared by both methimazole and PTU include skin rash, arthralgias, and hepatotoxicity.
   b. β-Blockers—for acute management of some symptoms such as palpitations, tremors, anxiety, tachycardia, sweating, and muscle weakness.
   c. Sodium ipodate or iopanoic acid—lowers serum T₃ and T₄ levels and causes rapid improvement of hyperthyroidism; appropriate for acute management of severe hyperthyroidism that is not responding to conventional therapy.

### Quick HIT

For all patients taking antithyroid medication, consider monitoring the leukocyte count for agranulocytosis on a regular basis.

2. Radioiodine 1³¹ (¹³¹I).
a. Causes destruction of thyroid follicular cells.
b. Most common therapy in the United States for Graves hyperthyroidism.
c. Main complication is hypothyroidism and occurs in majority of patients.
d. If the first dose does not control the hyperthyroidism within 6 to 12 months, then administer another dose.
e. Contraindicated during pregnancy and breastfeeding due to risk of cretinism (stunted physical and mental growth from severe hypothyroidism).

**Quick HIT**

Thyroid cells are the only cells in the body that absorb iodine. Therefore, giving radioactive iodine destroys only thyroid cells.

3. Surgical—subtotal thyroidectomy.
   a. Very effective, but only 1% of patients with hyperthyroidism are treated with surgery due to the following side effects: permanent hypothyroidism (30%), recurrence of hyperthyroidism (10%), recurrent laryngeal nerve palsy (1%), and permanent hypoparathyroidism (1%).
   b. Often reserved for patients with very large goiters (more common in toxic multinodular goiter), those who are allergic to antithyroid drugs, or patients who prefer surgery over medication.
   c. Watch for clinical manifestations of hypocalcemia after surgery that may not return to normal due to parathyroid inflammation or accidental removal.

E. Treatment

1. For immediate control of adrenergic symptoms of hyperthyroidism (of any cause): β-blocker (propranolol).
2. For nonpregnant patients with Graves disease.
   a. Start methimazole (in addition to the β-blocker).
   b. Taper β-blocker after 4 to 8 weeks (once methimazole starts to take effect).
   c. Continue methimazole for 1 to 2 years. Measure thyroid-stimulating IgG antibody at 12 months. If it is absent, then discontinue therapy. If relapse occurs, then resume methimazole for about 1 more year or consider radioiodine therapy.
3. For pregnant patients with Graves disease.
   a. Endocrinology consult is indicated before starting treatment.
   b. **PTU is preferred.**
4. Radioactive iodine ablation therapy.
   a. Leads to hypothyroidism over time in many patients.
   b. Consider therapy with $^{131}$I for the following patients:
      • Elderly patients with Graves disease.
- Patients with a solitary toxic nodule.
- Patients with Graves disease in whom therapy with antithyroid drugs fails (e.g., due to relapse, agranulocytosis).
**Thyroid Storm**

This is a rare, life-threatening complication of thyrotoxicosis characterized by an acute exacerbation of the manifestations of hyperthyroidism. There is usually a precipitating factor, such as infection, DKA, or stress (e.g., severe trauma, surgery, illness, childbirth).

**High mortality rate: up to 20% of patients enter a coma or die.**

Clinical manifestations include marked fever, tachycardia, agitation or psychosis, confusion, and GI symptoms (e.g., nausea, vomiting, diarrhea).

Provide supportive therapy with IV fluids, cooling blankets, and glucose. Give antithyroid agents (PTU every 2 hours). Follow with iodine to inhibit thyroid hormone release.

Administer β-blockers for control of heart rate. Give dexamethasone to impair peripheral generation of T₃ from T₄ and to provide adrenal support.

---

**Quick HIT**

The terms hyperthyroidism and thyrotoxicosis are interchangeable and refer to hyperfunctioning thyroid disease. **Thyroid storm is a medical emergency with life-threatening sequelae.**

---

**CLINICAL PEARL 4-6**

**Myxedema Coma**

- A rare condition that presents with a depressed state of consciousness, profound hypothermia, and respiratory depression.
- May develop after years of severe untreated hypothyroidism.
- Precipitating factors are trauma, infection, cold exposure, and narcotics.
- **A medical emergency, with a high mortality rate (50% to 75%) even with treatment.**
- Provide supportive therapy to maintain BP and respiration. Give IV thyroxine and hydrocortisone while carefully monitoring the hemodynamic state.
Hypothyroidism

A. General Characteristics
1. The onset of symptoms is usually insidious, and the condition may go undetected for years (see also Clinical Pearl 4-6).
2. Sometimes a diagnosis is made solely on laboratory evidence in an asymptomatic patient.

B. Causes
1. Primary hypothyroidism is the failure of the thyroid to produce sufficient thyroid hormone. This accounts for about 95% of all cases.
   a. Hashimoto disease (chronic thyroiditis)—most common cause of primary hypothyroidism.
   b. Iatrogenic—second most common cause of primary hypothyroidism; results from prior treatments of hyperthyroidism, including:
      • Radioiodine therapy
      • Thyroidectomy
      • Medications (e.g., lithium)
2. Secondary hypothyroidism (due to pituitary disease; i.e., deficiency of TSH) and tertiary hypothyroidism (due to hypothalamic disease; i.e., deficiency of TRH) account for less than 5% of cases. Both are associated with a low free T4 and a low TSH level.

Quick HIT
Hashimoto thyroiditis is associated with other autoimmune disorders (e.g., lupus, pernicious anemia). Patients with Hashimoto thyroiditis are at an increased risk of thyroid carcinoma and thyroid lymphoma.

C. Clinical Features
1. Symptoms
   a. Fatigue, weakness, lethargy
   b. Heavy menstrual periods (menorrhagia), slight weight gain (10 to 30 lb)—patients are not typically obese
   c. Cold intolerance
   d. Constipation
   e. Slow mentation, inability to concentrate (mild at first, in later stages dementia can occur), dull expression
   f. Muscle weakness, arthralgias
   g. Depression
h. Diminished hearing

2. Signs
   a. Dry skin, coarse hair; thickened, puffy features
   b. Hoarseness
   c. Nonpitting edema (edema due to glycosaminoglycan in interstitial tissues, not water and salt)
   d. Carpal tunnel syndrome
   e. Slow relaxation of deep tendon reflexes
   f. Loss of lateral portion of eyebrows
   g. Bradycardia
   h. Goiter (Hashimoto disease—goiter is rubbery, nontender, and even nodular; subacute thyroiditis—goiter is very tender and enlarged, although not always symmetrically.)
   i. History of upper respiratory infection and fever (subacute thyroiditis).

**CLINICAL PEARL 4-7**

**Subclinical Hypothyroidism**

- Thyroid function is inadequate, but increased TSH production maintains T\textsubscript{4} level within the reference range of normalcy; therefore, TSH level is elevated and T\textsubscript{4} level is normal.
- Look for nonspecific or mild symptoms of hypothyroidism, as well as elevated serum LDL levels.
- Treat with thyroxine if patients develop goiter, hypercholesterolemia, symptoms of hypothyroidism, significantly elevated TSH level (>10 μU/mL), or women attempting pregnancy.

**D. Diagnosis**

1. **High TSH level**—most sensitive indicator of hypothyroidism (see also Clinical Pearl 4-7).
2. Low TSH level in secondary hypothyroidism.
3. Low free T\textsubscript{4} level (or free T\textsubscript{4} index) in patients with clinically overt hypothyroidism. Free T\textsubscript{4} may be normal in subclinical cases.
4. **Increased antimicrosomal antibodies** (Hashimoto thyroiditis).
5. Other laboratory value abnormalities that may be present:
   a. Elevated LDL and decreased HDL levels.
   b. Anemia—mild normocytic anemia is the most common.

**Quick HIT**

TSH is the primary test in screening for thyroid dysfunction. Also order a lipid profile and a CBC.

**E. Treatment**
Levothyroxine (T₄)—treatment of choice

1. Effect is evident in 2 to 4 weeks; highly effective in achieving euthyroid state.
2. Convenient once—daily morning dose.
3. Treatment is continued indefinitely.
4. Monitor TSH level and clinical state periodically.
Thyroiditis

A. Subacute (Viral) Thyroiditis (subacute granulomatous thyroiditis)
1. Causes—usually follows a viral illness; associated with HLA-B35
2. Clinical features
   a. Prodromal phase that lasts a few weeks (fever, flu-like illness)
   b. It can cause transient hyperthyroidism due to leakage of hormone from inflamed thyroid gland. This is followed by a euthyroid state and then a hypothyroid state (as hormones are depleted).
   c. **Painful**, tender thyroid gland (may be enlarged).
3. Diagnosis
   a. **Radioiodine uptake is low** because thyroid follicular cells are damaged and cannot trap iodine.
   b. Low TSH level secondary to suppression by increased $T_4$ and $T_3$ levels; high erythrocyte sedimentation rate (ESR).
4. Treatment
   a. Use NSAIDs and aspirin for mild symptoms; corticosteroids, if the pain is more severe.
   b. Most patients have recovery of thyroid function within a few months to 1 year.

B. Subacute Lymphocytic Thyroiditis (painless thyroiditis, silent thyroiditis)
1. A transient thyrotoxic phase of 2 to 5 months may be followed by a hypothyroid phase. The hypothyroid phase is usually self-limited and may be the only manifestation of this disease if the hyperthyroid phase is brief.
2. Low radioactive iodine uptake—differentiates it from Graves disease during thyrotoxic phase.
3. Similar to subacute (viral) thyroiditis, only **without the pain or tenderness** of the thyroid gland.

**CLINICAL PEARL 4-8**

**Thyroid-Associated Ophthalmopathy (TAO)**
- TAO is an autoimmune attack on the periorbital connective tissue and extraocular muscles.
- Clinical findings include lid retraction (“thyroid stare”), proptosis, eyelid edema, lagophthalmos (inability to close eyelids completely), and diplopia.
- Patients may be hypothyroid, hyperthyroid (Graves disease), or euthyroid when TAO presents. Most euthyroid patients will go on to develop thyroid dysfunction within 2 years of developing TAO.
- Treatment of thyroid dysfunction has little effect on the course of TAO. TAO is usually self-limited, but surgery may be required if disease is severe. Oral steroids may also be helpful.
C. **Chronic Lymphocytic Thyroiditis** (Hashimoto thyroiditis, lymphocytic thyroiditis)

1. Most common cause of autoimmune thyroid disorder; more common in women.
2. Causes
   a. Genetic component—family history is common.
   b. Antithyroid antibodies are present in the majority of patients.
3. Clinical manifestations (see also Clinical Pearl 4-8)
   a. Goiter is the most common feature.
   b. Slow decline in thyroid function is common. Hypothyroidism is present in 20% of cases when first diagnosed but often occurs later in disease.
4. Diagnosis
   a. Thyroid function studies are normal (unless hypothyroidism is present).
   b. Antithyroid antibodies: antiperoxidase antibodies (present in 90% of patients), antithyroglobulin antibodies (present in 50%).
   c. Irregular distribution of $^{131}\text{I}$ on thyroid scan—not required for diagnosis.
5. Treatment—thyroid hormone (to achieve euthyroid state)

D. **Fibrous Thyroiditis** (Riedel thyroiditis)

1. Fibrous tissue replaces thyroid tissue, leading to a firm thyroid.
2. Surgery may be necessary if complications occur.
3. Patient may be hypothyroid as well, in which case thyroid hormone should be prescribed.
Thyroid Nodules

A. General Characteristics

1. Cancer is found in 4% to 10% of nodules that are investigated.
2. A solitary nodule can be either thyroid cancer or a benign adenoma. However, multinodular conditions may cause confusion because only one of these nodules may be palpable.
3. The most important function of the physical examination is the detection of the thyroid nodule, rather than the determination of its benign or malignant status.
4. To be detectable on palpation, a nodule must be at least 1 cm in diameter.
5. Malignancy is suggested by the following:
   a. If the nodule is fixed in place and no movement occurs on swallowing
   b. Unusually firm consistency or irregularity of the nodule
   c. If the nodule is solitary
   d. History of radiation therapy to the neck
   e. History of rapid development
   f. Vocal cord paralysis (recurrent laryngeal nerve paralysis)
   g. Cervical adenopathy
   h. Elevated serum calcitonin
   i. Family history of thyroid cancer

B. Diagnosis

1. Initial workup should include history, physical exam, ultrasound of neck and TSH.
2. Fine-needle aspiration (FNA) biopsy (see also Clinical Pearl 4-9)
a. FNA has a sensitivity of 95% and a specificity of 95%. Therefore, if FNA shows a benign nodule, the nodule is likely to be benign.

b. However, FNA biopsies have 5% false-negative results, so follow up with periodic FNA if thyroid nodularity persists. Benign lesions should continue to show consistently benign cytology.

c. FNA is reliable for all cancers (papillary, medullary, anaplastic) except follicular.

3. Thyroid scan (radioactive iodine) (Figure 4-5)

a. Thyroid scan plays a supplemental role. It is performed if the FNA biopsy is indeterminate. It is also performed in patients with a low TSH, as these patients are more likely to have a hyperfunctioning nodule.

b. It gives graphic representations of the distribution of radioactive iodine in the gland—useful in identifying whether thyroid nodules show decreased (“cold”) or increased (“hot”) accumulation of radioactive iodine compared with normal paranodular tissue. Nodules are classified as “cold” (hypofunctional), “warm” (normally functioning), or “hot” (hyperfunctional).

c. It should be limited to patients whose FNA biopsy results suggest neoplasm. (It is not cost effective to scan all patients with thyroid nodules.) When such lesions are “cold” on scan, thyroid lobectomy is recommended.

**FIGURE 4.5** A $^{123}$I thyroid scan showing a large “cold” nodule (arrow).
4. Thyroid ultrasound
   a. Differentiates a solid from a cystic nodule; most cancers are solid.
   b. Can identify nodules 1 to 3 mm in diameter.
   c. Cystic masses larger than 4 cm in diameter are not malignant.
   d. Cannot distinguish between benign and malignant thyroid nodules.
Thyroid Cancer

A. General Characteristics

1. Risk factors
   a. Head and neck radiation (during childhood)
   b. Gardner syndrome and Cowden syndrome for papillary cancer
   c. **MEN type II** for medullary cancer

Quick HIT

In general, most patients with thyroid cancer do not die of thyroid cancer (although this depends on the type of thyroid cancer).

2. Types (see also Clinical Pearl 4-10)
   a. Papillary carcinoma
      - Accounts for 70% to 80% of all thyroid cancers
      - Least aggressive thyroid cancer—slow growth and slow spreading with excellent prognosis.
      - Most important risk factor is a history of radiation to the head/neck.
      - Spreads via lymphatics in neck; frequently metastasizes to cervical lymph nodes (cervical lymphadenopathy); distant metastasis is rare.
      - Positive iodine uptake
   b. Follicular carcinoma
      - Accounts for 15% of all thyroid cancers; avidly absorbs iodine.
      - Prognosis is worse than for papillary cancer—it spreads early via a hematogenous route (brain, lung, bone, liver). Distant metastasis occurs in 20% of patients; lymph node involvement is uncommon.
      - May be associated with iodine deficiency.
      - Tumor extension through the tumor capsule or vascular invasion distinguishes it from a benign adenoma. A tissue sample is therefore needed for diagnosis.
      - More malignant than papillary cancer, but these are also slow growing.
      - One variant is the Hürthle cell carcinoma—characteristic cells contain abundant cytoplasm, tightly packed mitochondria, and oval nuclei with prominent nucleoli. These tumors are radioiodine resistant.
   c. Medullary carcinoma
      - Accounts for 2% to 3% of all thyroid cancers
      - One-third sporadic, one-third familial, one-third associated with MEN II (always screen for pheochromocytoma)
      - Arises from the parafollicular cells (C cells)—**produces calcitonin**
More malignant than follicular cancer but less so than anaplastic cancer—survival of approximately 10 years

**Quick HIT**

**Hürthle Cell Tumor**
- A variant of follicular cancer but more aggressive.
- Spread by lymphatics; does not take up iodine.
- Treatment: total thyroidectomy.

**Quick HIT**

Papillary carcinoma is the most common type of thyroid cancer to develop after radiation exposure (accounts for 80% to 90% of postradiation cancers of the thyroid).

**CLINICAL PEARL 4-10**

**Nodules**

**“Cold” Nodules**
- Decreased iodine uptake = hypofunctioning nodule.
- Significant risk of malignancy—approximately 20% of cold nodules are malignant.
- Of all nodules, 70% to 90% are cold and most of these are benign. Therefore, scanning may indicate a greatly reduced risk of malignancy in a nodule that is warm or hot, but it does not yield much additional information in a nodule that is cold.

**“Hot” Nodules**
- Increased iodine uptake = hyperfunctioning nodule.
- Rarely associated with malignancy.

d. Anaplastic carcinoma
- Accounts for 5% of all thyroid cancers; mostly seen in elderly patients
- Highly malignant
- May arise from a longstanding follicular or papillary thyroid carcinoma
- Prognosis (grim)—death typically occurs within a few months. Mortality is usually due to invasion of adjacent organs (trachea, neck vessels)

**B. Diagnosis**
1. Thyroid hormone level (frequently normal)
2. Calcitonin level (if medullary carcinoma)
3. Refer to the section on thyroid nodules for diagnostic approach.

**C. Treatment**
1. Papillary carcinoma
a. Lobectomy with isthmusectomy.
b. Total thyroidectomy if tumor is >3 cm, tumor is bilateral, tumor is advanced, or distant metastases are present.
c. Adjuvant treatment: TSH suppression therapy; radioiodine therapy for larger tumors.

2. Follicular carcinoma—total thyroidectomy with postoperative iodine ablation.
3. Medullary carcinoma—total thyroidectomy; radioiodine therapy usually unsuccessful. Modified radical neck dissection is also indicated when there is lymph node involvement (most cases).
4. Anaplastic carcinoma—chemotherapy and radiation may provide a modest improvement in survival. Palliative surgery for airway compromise may be needed.
Diseases of the Pituitary Gland

- Pituitary Adenomas

A. General Characteristics
1. Pituitary adenomas account for about 10% of all intracranial neoplasms.
2. Almost all pituitary tumors are benign. They may grow in any direction causing “parasellar” signs and symptoms.
3. Size: microadenoma (diameter ≤10 mm); macroadenoma (diameter >10 mm).

B. Clinical Features
1. Hormonal effects occur due to hypersecretion of one or more of the following hormones:
   a. Prolactin—see the following section on hyperprolactinemia
   b. GH—results in acromegaly (or gigantism if epiphyseal closure has not occurred; seen in the pediatric population)
   c. Adrenocorticotropic hormone (ACTH)—results in Cushing disease
   d. TSH—results in hyperthyroidism
2. Hypopituitarism—compression of hypothalamic-pituitary stalk; GH deficiency and hypogonadotrophic hypogonadism are the most common problems.
3. Mass effects
   a. Headache
   b. Visual defects—Bitemporal hemianopsia (due to compression of optic chiasm) is the most common finding, but it depends on the size and symmetry of the tumor.

C. Diagnosis
1. MRI is the imaging study of choice
2. Pituitary hormone levels

D. Treatment
1. Transsphenoidal surgery is indicated in most patients (except patients with prolactinomas, for which medical management can be tried first).
2. Radiation therapy and medical therapy are adjuncts in most patients.
Hyperprolactinemia

A. Causes
1. Prolactinoma
   a. Most common cause of hyperprolactinemia
   b. Most common type of pituitary adenoma (up to 40%)
2. Medications (e.g., psychiatric medications, H₂ blockers, metoclopramide, verapamil, estrogen)
3. Pregnancy
4. Renal failure
5. Suprasellar mass lesions (can compress hypothalamus or pituitary stalk)
6. Hypothyroidism
7. Idiopathic

Quick HIT

High levels of prolactin inhibit secretion of GnRH. This leads to decreased secretion of LH and FSH, which in turn leads to decreased production of estrogen and testosterone (see Clinical Features).

B. Clinical Features
1. Men
   a. Hypogonadism, decreased libido, infertility, impotence
   b. Galactorrhea or gynecomastia (uncommon)
   c. Parasellar signs and symptoms (visual field defects and headaches)
2. Women
   a. Premenopausal: menstrual irregularities, oligomenorrhea or amenorrhea, anovulation and infertility, decreased libido, dyspareunia, vaginal dryness, risk of osteoporosis, galactorrhea
   b. Postmenopausal: parasellar signs and symptoms (less common than in men)

Quick HIT

Parasellar signs and symptoms (mass effects of the tumor) are more prevalent in men than in women. This is largely because the early symptoms in men (e.g., impotence) are often attributed to psychological causes and medical evaluation is delayed, allowing for larger tumor growth.

C. Diagnosis
1. Elevated serum prolactin level.
2. Order a pregnancy test and TSH level, because both pregnancy and primary hypothyroidism are on the differential diagnosis for hyperprolactinemia.
3. CT scan or MRI to identify any mass lesions.

D. Treatment
1. Treat the underlying cause (e.g., stop medication, treat hypothyroidism).
2. If prolactinoma is the cause and the patient is symptomatic, treat with **bromocriptine**, a dopamine agonist that secondarily diminishes the production and release of prolactin. Continue treatment for approximately 2 years before attempting cessation. **Cabergoline** (another dopamine agonist) may be better tolerated than bromocriptine and is often chosen as first-line therapy.
3. Consider surgical intervention if symptoms progress despite appropriate medical therapy. However, the recurrence rate after surgery is high.

Quick HIT

Microadenomas (<10 mm diameter) tend to either remain the same size or regress with time. Only 10% to 20% continue to grow.
Acromegaly

A. General Characteristics
1. Acromegaly is broadening of the skeleton, which results from excess secretion of pituitary GH after epiphyseal closure (if before epiphyseal closure, gigantism [excessive height] results).
2. It is almost always caused by a GH-secreting pituitary adenoma (represents 10% of pituitary adenomas).

Quick HIT
Cardiovascular disease (cardiomyopathy) is the most common cause of death in patients with acromegaly.

B. Clinical Features
1. Growth promotion
   a. Soft tissue and skeleton overgrowth
   b. Coarsening of facial features
   c. Abnormally large hand and foot size (ask about increasing glove/ring size)
   d. Organomegaly
   e. Arthralgia due to joint tissue overgrowth
   f. Hypertrophic cardiomyopathy
   g. Enlarged jaw (macrognathia)
2. Metabolic disturbances
   a. Glucose intolerance and DM in 10% to 25% of patients
   b. Hyperhidrosis
3. Parasellar manifestations
   a. Headache
   b. Superior growth leads to compression of the optic chiasm, which results in visual loss (bitemporal hemianopsia)
   c. Lateral growth leads to cavernous sinus compression
   d. Inferior growth leads to sphenoid sinus invasion
   e. HTN, sleep apnea

Quick HIT
Other Laboratory Abnormalities in Patients With Acromegaly
- Hyperprolactinemia (tumor secretes prolactin and growth hormone)—30% of patients
- Elevations in serum glucose, triglycerides, and phosphate levels

C. Diagnosis
1. IGF-1, also known as somatomedin C, should be significantly elevated in acromegaly.
2. Oral glucose suppression test—glucose load fails to suppress GH (as it should in healthy individuals). This confirms the diagnosis if the IGF-1 level is equivocal.
3. MRI of the pituitary.
4. A random GH level is not useful because there is wide physiologic fluctuation of GH levels.

D. Treatment
1. Transsphenoidal resection of pituitary adenoma—treatment of choice
2. Radiation therapy if IGF-1 levels stay elevated after surgery.
3. Octreotide or other somatostatin analog to suppress GH secretion
Craniopharyngioma

Tumors of the suprasellar region arising from embryologic remnants of Rathke pouch.
These tumors comprise 20% to 25% of all pituitary mass lesions (pituitary adenoma is most common).
They result in visual field defects (bitemporal hemianopsia) due to compression of the optic chiasm and may also cause headaches, papilledema, and changes in mentation.
They are diagnosed by brain MRI.
They may cause hyperprolactinemia, diabetes insipidus, or panhypopituitarism.
Treatment is surgical excision (total or partial resection) with or without radiation therapy.

Quick HIT

Calcification of the suprasellar region seen on brain imaging is nearly diagnostic of craniopharyngioma.
Hypopituitarism

A. General Characteristics
1. All or some of the hormones released from the anterior pituitary may be absent.
2. Loss of hormones is unpredictable, but LH, FSH, and GH are usually lost before TSH and ACTH.
3. Clinical manifestations depend on which hormones are lost.

B. Causes
1. Hypothalamic or pituitary tumor is the most common cause.
2. Other causes: radiation therapy, Sheehan syndrome, infiltrative processes (e.g., sarcoidosis, hemochromatosis), head trauma, cavernous sinus thrombosis, surgery.

C. Clinical Features
1. Reduced GH: growth failure (decreased muscle mass in adults), increased LDL, increased risk of heart disease, increased LDL
2. Reduced prolactin: failure to lactate
3. Reduced ACTH: adrenal insufficiency
4. Reduced TSH: hypothyroidism
5. Reduced gonadotropins (LH and FSH): infertility, amenorrhea, loss of secondary sex characteristics, diminished libido
6. Reduced antidiuretic hormone (ADH) (if hypothalamic lesion): diabetes insipidus
7. Reduced melanocyte-stimulating hormone (MSH): decreased skin and hair pigmentation

D. Diagnosis
1. Low levels of target hormones with low or normal levels of trophic hormones (it is the suppression of the trophic hormone that is important, although the absolute level may be in the normal reference range)
2. MRI of the brain (may miss microadenomas)

E. Treatment
1. Replacement of appropriate hormones
2. Women who want to conceive should be referred to an endocrinologist
Diabetes Insipidus

A. General Characteristics

1. Two forms
   a. Central DI is the most common form—due to low ADH secretion by posterior pituitary.
   b. Nephrogenic DI—ADH secretion is normal but tubules cannot respond to ADH.

2. Causes
   a. Central DI
      • Idiopathic—50% of all cases
      • Trauma—surgery, head trauma
      • Other destructive processes involving the hypothalamus, including tumors, sarcoidosis, tuberculosis, syphilis, Hand–Schüller–Christian disease, eosinophilic granuloma, and encephalitis
   b. Nephrogenic DI—the most common cause in adults is chronic lithium use. Other causes include hypercalcemia, pyelonephritis, and demeclocycline use. It may also be congenital—caused by mutations in the ADH receptor gene or the aquaporin-2 gene.

   
   Quick HIT

   If a patient presents with polyuria and polydipsia, consider the following first in the differential diagnosis:
   • Diabetes mellitus
   • Diuretic use
   • Diabetes insipidus
   • Primary polydipsia

B. Clinical Features

1. Polyuria is a hallmark finding: 5 to 15 L daily; urine is colorless (because it is so dilute).
2. Thirst and polydipsia—hydration is maintained if the patient is conscious and has access to water.
3. Hypernatremia is usually mild unless the patient has an impaired thirst drive.

   Quick HIT

   • Primary polydipsia is usually seen in patients with psychiatric disturbances.
   • If the patient is deprived of water, urine osmolarity will increase appropriately.

C. Diagnosis
1. Urine—low specific gravity and low osmolality indicate DI
2. Plasma osmolality
   a. Normal: 250 to 290 mOsm/kg
   b. Primary polydipsia: 255 to 280 mOsm/kg
   c. DI: 280 to 310 mOsm/kg
3. A water deprivation test (dehydration test) is required to make the diagnosis (see Table 4-8)
   a. Procedure
      • Withhold fluids, and measure urine osmolality every hour.
      • When urine osmolality is stable (<30 mOsm/kg hourly increase for 3 hours),
        inject 2 g desmopressin subcutaneously. Measure urine osmolality 1 hour later.
   b. Response—see Table 4-8
4. ADH level (not the test of choice; takes a long time to get results)
   a. Low in central DI
   b. Normal or elevated in nephrogenic DI

### TABLE 4-8 Response to the Water Deprivation Test

<table>
<thead>
<tr>
<th></th>
<th>Increase in Urine Osmolality Above 280 mOsm/kg With Dehydration</th>
<th>Further Response to ADH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal patients</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Diabetes insipidus patients</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Nephrogenic diabetes insipidus patients</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

**D. Treatment**

1. Central DI
   a. Desmopressin (DDAVP) is the primary therapy and can be given by nasal spray, orally, or by injection.
   b. Chlorpropamide increases ADH secretion and enhances the effect of ADH.
   c. Treat the underlying cause.

2. Nephrogenic DI—treat with sodium restriction and thiazide diuretics.
   a. These deplete the body of sodium, which leads to increased reabsorption of sodium and water in the proximal tubules.
   b. The reabsorption of sodium and water in the proximal tubules means that less water reaches the distal tubules, leading to decreased urine volume and increased water retention.
 Syndrome of Inappropriate Secretion of Antidiuretic Hormone

A. General Characteristics

1. Pathophysiology
   a. Excess ADH is secreted from the posterior pituitary or an ectopic source. Elevated levels lead to water retention and excretion of concentrated urine. This has two major effects: hyponatremia and volume expansion.
   b. **Despite volume expansion, edema is not seen in syndrome of inappropriate secretion of antidiuretic hormone (SIADH).** This is because natriuresis (excretion of excessive sodium in urine) occurs despite hyponatremia.
   c. Reasons for natriuresis
      - Volume expansion causes an increase in atrial natriuretic peptide (ANP) which increases urine sodium excretion.
      - Volume expansion leads to a decrease in proximal tubular sodium absorption.
      - The renin–angiotensin–aldosterone system is inhibited, and thus sodium is excreted in the urine.

Quick HIT

In SIADH, volume expansion occurs due to water retention, but edema is prevented due to natriuresis.

Quick HIT

Hyponatremia Pearls
- Hypovolemic hyponatremia—volume contracted
- Hypervolemic hyponatremia—volume expanded with edema
- SIADH—volume expanded without edema

B. Causes

1. Neoplasms (e.g., in lung, pancreas, prostate, bladder), lymphomas, leukemia
2. CNS disorders (e.g., stroke, head trauma, infection)
3. Pulmonary disorders (e.g., pneumonia, tuberculosis)
4. Ventilators with positive pressure
5. Medication (e.g., vincristine, selective serotonin reuptake inhibitors [SSRIs], chlorpropamide, oxytocin, morphine, desmopressin)
6. Postoperative state (e.g., as a result of anesthesia, pain, or stress)

C. Clinical Features

1. Acute hyponatremia—Osmotic water shifts lead to increased intracellular fluid volume. Signs and symptoms are secondary to brain swelling and are primarily
neurologic.

a. Lethargy, somnolence, weakness
b. **Can lead to seizures, coma, or death if untreated.**

2. Chronic hyponatremia
   a. May be asymptomatic
   b. Anorexia, nausea, and vomiting
   c. CNS symptoms are less common because chronic loss of sodium and potassium from brain cells decreases brain edema (due to secondary water shifts from ICF to ECF).

D. Diagnosis
1. **SIADH is a diagnosis of exclusion** after other causes of hyponatremia have been ruled out. The following help in supporting the diagnosis:
   a. Hyponatremia with inappropriately concentrated urine; plasma osmolality <280 mOsm per kg.
   b. Low serum uric acid level
   c. Low BUN and creatinine
   d. Normal thyroid and adrenal function, as well as renal, cardiac, and liver function
   e. Measurement of plasma and urine ADH level
   f. Absence of significant hypervolemia

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
</table>

Major characteristics of SIADH
- Hyponatremia
- Volume expansion without edema
- Natriuresis
- Hypouricemia and low BUN
- Normal or reduced serum creatinine level because of dilution
- Normal thyroid and adrenal function

E. Treatment
1. Correct the underlying cause, if known.
2. For asymptomatic patients
   a. Water restriction is usually sufficient.
   b. Use normal saline in combination with a loop diuretic if faster results are desired.
   c. Lithium carbonate or demeclocycline are other options (with side effects)—both inhibit the effect of ADH in the kidney.
3. For symptomatic patients
   a. Restrict water intake.
b. Give isotonic saline. Hypertonic saline may occasionally be indicated in severe cases.

4. **Do not raise the serum sodium concentration too quickly.** Rapid flux of water into the extracellular fluid can result in *central pontine myelinolysis* (or osmotic demyelination syndrome). A general guideline is that the rate of sodium replacement should not exceed 0.5 mEq/L/hr.
Diseases of the Parathyroid Glands

Hypoparathyroidism

A. Causes
1. Removal of glands during head and neck surgery account for the majority of cases—thyroidectomy, parathyroidectomy, radical surgery for head and neck malignancies.
2. Nonsurgical hypoparathyroidism is rare.

Quick HIT

Pseudohypoparathyroidism
- End-organ resistance to the action of PTH
- Laboratory value findings: hypocalcemia, hyperphosphatemia, high PTH, low urinary cAMP

B. Clinical Features
1. Cardiac arrhythmias
2. Rickets and osteomalacia
3. Increased neuromuscular irritability due to hypocalcemia
   a. Numbness/tingling—circumoral, fingers, toes
   b. Tetany
      - Hyperactive deep tendon reflexes
      - Chvostek sign—Tapping the facial nerve elicits contraction of facial muscles.
      - Trousseau sign—Inflating the BP cuff to a pressure higher than the patient’s systolic BP for 3 minutes elicits carpal spasms.
   c. Grand mal seizures
4. Basal ganglia calcifications
5. **Prolonged QT interval** on ECG—Hypocalcemia should always be in the differential diagnosis of a prolonged QT interval
6. Cataracts

C. Diagnosis
1. Low serum calcium
2. High serum phosphate
3. Serum PTH inappropriately low
4. Low urine cAMP

D. Treatment
1. IV calcium gluconate in severe cases, oral calcium in mild to moderate cases.
2. Vitamin D supplementation (calcitriol).
3. Note that both vitamin D and calcium replacement can increase urinary calcium excretion, precipitating kidney stones. Therefore, administer with caution to avoid hypercalciuria. The goal is to keep serum calcium at 8.0 to 8.5 mg/dL.
Primary Hyperparathyroidism

A. General Characteristics
1. One or more glands produce inappropriately high amounts of PTH relative to the serum calcium level.
2. Most common cause of hypercalcemia in the outpatient setting.

B. Causes
1. Adenoma (80% of cases)—majority involve only one gland
2. Hyperplasia (15% to 20% of cases)—all four glands usually affected
3. Carcinoma (<1% of cases)

C. Clinical Features
1. “Stones”
   a. Nephrolithiasis
   b. Nephrocalcinosis
2. “Bones”
   a. Bone aches and pains
   b. Osteitis fibrosa cystica ("brown tumors")—predisposes patient to pathologic fractures (Figure 4-6)
3. “Groans”
   a. Muscle pain and weakness
   b. Pancreatitis
   c. Peptic ulcer disease
   d. Gout
   e. Constipation
4. “Psychiatric overtones”—depression, fatigue, anorexia, sleep disturbances, anxiety, lethargy
5. Other symptoms:
   a. Polydipsia, polyuria
   b. HTN, shortened QT interval
   c. Weight loss

D. Diagnosis
1. Laboratory (see also Clinical Pearl 4-11)
   a. Calcium levels (hypercalcemia)—when calculating calcium levels, be aware of albumin levels. Calculate the ionized fraction or get an ionized calcium level.
FIGURE 4.6 X-ray of the clavicle in a patient with osteitis fibrosa cystica (“brown tumors”), a disease in which cystic bone spaces are filled with brown fibrous tissue. Brown tumors predispose patients to pathologic fractures.


CLINICAL PEARL 4-11

Secondary Hyperparathyroidism

- Characterized by an elevated concentration of PTH and a low or low-normal serum calcium level.
- Caused by chronic renal failure (most common cause), as well as vitamin D deficiency and renal hypercalciuria.
- Treatment depends on the cause: if vitamin D deficiency, give vitamin D; if renal failure, give calcitriol and oral calcium supplements plus dietary phosphorus restriction.

b. PTH levels
   - Should be elevated relative to serum calcium level
   - Note that in the presence of hypercalcemia, a normal PTH level is “abnormal” (i.e., normal is still too high) because high calcium levels should suppress PTH secretion.

c. Hypophosphatemia
d. Hypercalciuria
e. Urine cAMP is elevated  
f. Chloride/phosphorus ratio of >33 is diagnostic of primary hyperparathyroidism (33-to-1 rule). Chloride is high secondary to renal bicarbonate wasting, a direct effect of PTH.

2. Radiographs  
   a. Subperiosteal bone resorption usually on radial aspect of second and third phalanges, but can appear in any location (see Figure 4-6)  
   b. Osteopenia

E. Treatment  
1. Surgical removal is the only definitive treatment, but not all patients require it. If the patient is over 50 years of age and is asymptomatic (with normal bone mass and renal function), surgery may not be needed.  
   a. Primary hyperparathyroidism due to hyperplasia—All the four glands are removed. A small amount of parathyroid tissue is placed in the forearm muscle to retain parathyroid function. If hyperplasia recurs postoperatively, surgery is then limited to the arm and will not involve the neck.  
   b. Primary hyperparathyroidism due to adenoma—Surgical removal of the adenoma is curative.  
   c. Primary hyperparathyroidism due to carcinoma—Remove the tumor, ipsilateral thyroid lobe, and all enlarged lymph nodes.  
2. Medical—Encourage fluids. Give diuretics (furosemide) to enhance calcium excretion if hypercalcemia is severe. Do not give thiazide diuretics as they induce calcium retention.

Quick HIT

Relative Indications for Surgery in Primary Hyperparathyroidism  
- Age <50 years  
- Marked decrease in bone mass  
- Nephrolithiasis, renal insufficiency  
- Markedly elevated serum calcium level or episode of severe hypercalcemia  
- Urine calcium >400 mg in 24 hours
Diseases of the Adrenal Glands

Cushing Syndrome

A. General Characteristics
1. Cushing syndrome results from excessive levels of glucocorticoids due to any cause. Cortisol is the principal glucocorticoid.
2. Cushing disease results from an ACTH-secreting pituitary adenoma, thus a pituitary cause of Cushing syndrome (see below).

Quick HIT

<table>
<thead>
<tr>
<th>Effects of Cortisol (generally catabolic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Impaired collagen production, enhanced protein catabolism</td>
</tr>
<tr>
<td>• Anti-insulin effects (leading to glucose intolerance)</td>
</tr>
<tr>
<td>• Impaired immunity (has inhibitory effects on PMNs, T cells)</td>
</tr>
<tr>
<td>• Enhances catecholamine activity (HTN)</td>
</tr>
</tbody>
</table>

B. Causes
1. Iatrogenic Cushing syndrome is the most common cause, and is due to prescribed prednisone or other steroids. Androgen excess is absent because the exogenous steroid suppresses androgen production by the adrenals.
2. Cushing disease is the second most common cause and leads to bilateral adrenal hyperplasia. Androgen excess is common.
3. Adrenal adenomas and carcinomas (10% to 15%)
4. Ectopic ACTH production (10% to 15%)
   a. ACTH-secreting tumor stimulates the cortisol release from the adrenal glands without the normal negative feedback loop because the source of the ACTH is outside the pituitary gland.
   b. More than two-thirds are small cell carcinomas of the lung. Bronchial carcinoid and thymoma may be the cause.

C. Clinical Features
1. Changes in appearance: central obesity, hirsutism, moon facies, “buffalo hump,” purple striae on abdomen, lanugo hair, acne, easy bruising
2. HTN
3. Decreased glucose tolerance (diabetes)
4. Hypogonadism—menstrual irregularity and infertility
5. Masculinization in females (androgen excess, see Figure 4-7)—only seen in ACTH-dependent forms
6. Musculoskeletal—proximal muscle wasting and weakness due to protein catabolism, osteoporosis, aseptic necrosis of femoral head especially with exogenous steroid use
7. Psychiatric disturbances—depression, mania
8. Increased likelihood of infections (due to impaired immunity)

Quick HIT

Some signs and symptoms in patients with high cortisol (e.g., obesity, HTN, osteoporosis, DM) are nonspecific and less helpful in diagnosing the patient. On the other hand, easy bruising, typical striae, myopathy, and virilizing signs are more helpful in diagnosis.

D. Diagnosis

1. Initial screening (Table 4-9). Two of three following tests need to be positive in order to give the diagnosis of Cushing syndrome:
   a. An overnight, low-dose dexamethasone suppression test is the initial screening test. Give the patient 1 mg of dexamethasone at 11 pm. Measure the serum cortisol level at 8 am.
      • If the serum cortisol is <5, Cushing syndrome can be excluded. This test is very sensitive.
      • If the serum cortisol is >5 (and often >10), the patient has Cushing syndrome. Order a high-dose dexamethasone suppression test to determine whether the cause is Cushing disease, an adrenal tumor, or an ectopic ACTH tumor.
   b. The 24-hour urinary free cortisol level is another excellent screening test; values greater than four times normal are rare except in Cushing syndrome.
   c. Late night salivary cortisol; saliva collected prior to patient’s bedtime. Upper limits of normal and concentrations for diagnosis will depend on commercial assay used. This measurement should be done twice.
2. ACTH level—Once you establish a diagnosis of Cushing syndrome, measure the ACTH level. If it is low, the cause of high cortisol levels is likely an adrenal tumor or hyperplasia, not a pituitary disease or an ectopic ACTH-producing tumor.
Androgen excess manifesting as masculinization in females, only seen in ACTH-dependent forms of Cushing syndrome.


<table>
<thead>
<tr>
<th>TABLE 4-9 Response to Diagnostic Tests in Cushing Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Healthy patient</strong></td>
</tr>
<tr>
<td>• Normal cortisol/normal ACTH</td>
</tr>
<tr>
<td>• Suppression with low-dose dexamethasone</td>
</tr>
<tr>
<td>• Suppression with high-dose dexamethasone</td>
</tr>
<tr>
<td>• Mild increase with CRH test</td>
</tr>
<tr>
<td><strong>Cushing disease</strong></td>
</tr>
<tr>
<td>• High cortisol/high ACTH</td>
</tr>
<tr>
<td>• No suppression with low-dose dexamethasone</td>
</tr>
<tr>
<td>• Suppression with high-dose dexamethasone</td>
</tr>
<tr>
<td>• Great increase in cortisol with CRH test</td>
</tr>
<tr>
<td><strong>Adrenal tumor</strong></td>
</tr>
<tr>
<td>• High cortisol/low ACTH</td>
</tr>
<tr>
<td>• No suppression with low-dose dexamethasone</td>
</tr>
<tr>
<td>• No suppression with high-dose dexamethasone</td>
</tr>
<tr>
<td>• No change after CRH test</td>
</tr>
<tr>
<td><strong>Ectopic ACTH-producing tumor</strong></td>
</tr>
<tr>
<td>• High cortisol/high ACTH</td>
</tr>
<tr>
<td>• No suppression with low-dose dexamethasone</td>
</tr>
<tr>
<td>• No suppression with high-dose dexamethasone</td>
</tr>
<tr>
<td>• No change after CRH test</td>
</tr>
</tbody>
</table>
3. High-dose dexamethasone suppression test.
   a. In Cushing disease, the result is a decrease (>50%) in cortisol levels.
   b. If cortisol suppression does not occur and plasma ACTH levels are high, an ectopic ACTH-producing tumor is likely the diagnosis.
4. CRH stimulation test—CRH is administered intravenously.
   a. If ACTH/cortisol levels increase (deemed a “response”), then Cushing disease is the diagnosis.
   b. If ACTH/cortisol levels do not increase (deemed “no response”), then the patient has either ectopic ACTH secretion or an adrenal tumor.
5. Once hormonal studies have established the site of disease, imaging is the next step (CT scan or MRI).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with Cushing disease may have hyperpigmentation due to elevated ACTH levels, whereas patients with Cushing syndrome due to other causes will not have hyperpigmentation.</td>
</tr>
</tbody>
</table>

**E. Treatment**

1. Iatrogenic Cushing syndrome: tapering of glucocorticoid
2. Pituitary Cushing syndrome: surgery (transsphenoidal ablation of pituitary adenoma)—usually safe and effective.
3. Adrenal adenoma or carcinoma: surgery (adrenalectomy)
4. When surgery is contraindicated or unsuccessful, or patient is awaiting surgical treatment, medical therapies are appropriate. Adrenal enzyme inhibitors (such as ketoconazole) inhibit the synthesis of cortisol and thus can be used as medical therapy.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any 24-hour urine collection (i.e., 24-hour urine collection of metanephrines and catecholamines for pheochromocytoma) should also test the amount of urine creatinine to determine if the patient has provided an appropriate sample.</td>
</tr>
</tbody>
</table>
Pheochromocytoma

A. General Characteristics
1. Pheochromocytomas are rare tumors that produce, store, and secrete catecholamines.
2. Ninety percent found in adrenal medulla (10% extra-adrenal).
3. Curable if diagnosed and treated, but **may be fatal if undiagnosed.**
4. Arise from the chromaffin cells of the adrenal medulla or from the sympathetic ganglia if extra-adrenal.

B. Clinical Features
1. HTN—BP is persistently high, with episodes of severe HTN (paroxysmal).
2. Severe pounding headache
3. Inappropriate severe sweating
4. Tachycardia
5. Palpitations, with sudden severe HTN
6. Anxiety
7. Feeling of impending doom
8. Laboratory findings: hyperglycemia, hyperlipidemia, hypokalemia

C. Diagnosis
1. Urine screen—test for the presence of the following breakdown products of catecholamines:
   a. Metanephrine
   b. Vanillylmandelic acid, homovanillic acid, normetanephrine
2. Plasma metanephrines have been proposed by some investigators as a superior test to urine metanephrines, especially when clinical suspicion is high. Urine/serum epinephrine and norepinephrine levels—if the epinephrine level is elevated, the tumor must be adrenal or near the adrenal gland (organ of Zuckerkandl) because nonadrenal tumors cannot methylate norepinephrine to epinephrine.
3. Tumor localization tests—CT, MRI.

---

**Quick HIT**

**Rule of 10s for Pheochromocytoma Tumors**
- 10% are familial
- 10% are bilateral (suspect MEN type II)
- 10% are malignant
- 10% are multiple
- 10% occur in children
- 10% are extra-adrenal (more often malignant)—The most common site is the organ of Zuckerkandl, which is
D. Treatment

1. Surgical tumor resection with early ligation of venous drainage is the treatment of choice. Ligation lowers the possibility of catecholamine release/crisis by tying off drainage.
   a. Patients should be treated with α-blockade (typically phenoxycbenzamine) for 10 to 14 days prior to surgery as well as β-blockade (i.e., propranolol) for 2 to 3 days prior to surgery.
   b. The α-blockade is used to control BP, and the β-blockade is used to decrease tachycardia.
   c. Laparoscopic adrenalectomy can be safely performed for most small- to medium-sized pheochromocytomas.

Quick HIT

Consider pheochromocytoma as the diagnosis if the following are present:
- Headache
- Profuse sweating
- Palpitations
- Tachycardia
- Apprehension or sense of impending doom
Primary Hyperaldosteronism

A. General Characteristics
1. Excessive production of aldosterone by the adrenal glands independent of any regulation by the renin–angiotensin system (see also Clinical Pearl 4-12)
2. Excess mineralocorticoids increase the activity of the Na⁺/K⁺ pumps in the cortical collecting tubules.
   a. Sodium retention causes ECF volume expansion and HTN.
   b. Potassium loss results in hypokalemia.
3. Excess aldosterone also increases the secretion of hydrogen ions into the lumen of the medullary collecting tubules resulting in metabolic alkalosis.

CLINICAL PEARL 4-12

Multiple Endocrine Neoplasia (MEN) Syndrome
- An inherited condition with the propensity to develop multiple endocrine tumors.
- Autosomal dominant inheritance with incomplete penetrance.
- Types
  - MEN type I (Wermer syndrome)—“3 Ps”
    - Parathyroid hyperplasia (in 90% of the patients with MEN I)
    - Pancreatic islet cell tumors (in two-thirds of the patients with MEN I)—ZES (50%), insulinoma (20%)
    - Pituitary tumors (in two-thirds of the patients with MEN I)
  - MEN type IIA (Sipple syndrome)—“MPH”
    - Medullary thyroid carcinoma (in 100% of the patients with MEN IIA)
    - Pheochromocytoma (in more than one-third of the patients with MEN IIA)
    - Hyperparathyroidism (in 50% of the patients with MEN IIA)
  - MEN type IIB—“MMMP”
    - Mucosal neuromas (in 100% of the patients with MEN IIB)—in the nasopharynx, oropharynx, larynx, and conjunctiva
    - Medullary thyroid carcinoma (in 85% of the patients with MEN IIB)—more aggressive than in MEN IIA
    - Marfanoid body habitus
    - Pheochromocytoma

B. Causes
1. Adrenal adenoma (in two-thirds of the cases)—aldosterone producing adenoma (Conn syndrome)
2. Adrenal hyperplasia (in one-third of the cases)—almost always bilateral
3. Adrenal carcinoma (in <1% of the cases)

Quick HIT
Always suspect hyperaldosteronism in a hypertensive patient with hypokalemia who is not on a diuretic.
C. Clinical Features

1. HTN (most common clinical feature); may otherwise be asymptomatic
2. Headache, fatigue, weakness
3. Polydipsia, nocturnal polyuria (due to hypokalemia)
4. Absence of peripheral edema

Quick HIT

The prevalence of adrenal incidentaloma is on the rise with the more widespread use of imaging techniques. An adrenal incidentaloma is a nonfunctioning adrenal tumor. Most are benign, but the risk of malignancy increases with increasing size. Treat by first ruling out a functioning tumor and then resect any tumor greater than 6 cm (high risk of malignant disease).

D. Diagnosis

1. Ratio of the plasma aldosterone level to plasma renin—A screening test in primary hyperaldosteronism reveals inappropriately elevated levels of plasma aldosterone with coexistent decreased plasma renin activity. Therefore, if the plasma aldosterone-to-renin ratio is >30, evaluate further.
2. For definitive diagnosis, one of the two tests is usually performed.
   a. Saline infusion test
      • Infusion of saline will decrease aldosterone levels in normal patients but not in those with primary aldosteronism.
      • If aldosterone levels are <8.5 ng/dL after saline infusion, primary aldosteronism may be ruled out.
   b. Oral sodium loading
      • The patient is given a high salt diet for 3 days. Serum and urine electrolytes, aldosterone, and creatinine are measured on the third day. High urine aldosterone in the setting of high urine sodium (to document appropriate sodium loading) confirms the diagnosis.

Quick HIT

It is important to distinguish adenoma from hyperplasia because HTN associated with hyperplasia is not benefited by bilateral adrenalectomy, whereas HTN associated with adenoma is usually improved/cured by removal of the adenoma.

3. To diagnose the cause of primary aldosteronism:
   a. Adrenal venous sampling for aldosterone levels—A high level of aldosterone on one side indicates an adenoma. High levels on both sides indicate bilateral hyperplasia.
b. Renin–aldosterone stimulation test—Recumbency or upright positions are assumed, followed by measurement of serum aldosterone.

c. Imaging tests
   • CT scan/MRI of adrenals—may demonstrate adenoma or hyperplasia anatomically.
   • Iodocholesterol scanning—a functional approach to differentiating between adenoma and hyperplasia.
   • Arteriography/venography (retrograde).

E. Treatment
1. For adenoma—Surgical resection (adrenalectomy) is often curative.
2. For bilateral hyperplasia
   a. Spironolactone inhibits the action of aldosterone.
   b. Surgery is not indicated.
Adrenal Insufficiency

A. Causes

1. Primary adrenal insufficiency (Addison disease) (see also Clinical Pearl 4-13).
   a. Idiopathic (thought to be autoimmune disease) is the most common type in the industrialized world.
   b. Infectious diseases—these include tuberculosis (most common cause worldwide) and fungal infections. Causes also include cytomegalovirus, cryptococcus, toxoplasmosis, and pneumocystis.
   c. Iatrogenic—for example, a bilateral adrenalectomy.
   d. Metastatic disease—from lung or breast cancer.

Quick HIT
The most common cause of Addison disease worldwide is tuberculosis; autoimmune disease is the most common cause in the Western world. However, the most common cause of adrenal insufficiency overall (99% of all cases) is abrupt cessation of exogenous glucocorticoids.

CLINICAL PEARL 4-13

Adrenal Crisis

- An acute and severely symptomatic stage of adrenal insufficiency that can include severe hypotension and cardiovascular collapse, abdominal pain (can mimic an acute abdomen), acute renal failure, and death.
- Any stress (e.g., trauma, infection, surgery) can precipitate an adrenal crisis.
- Can be fatal if untreated.
- Treat with IV hydrocortisone, IV fluids (several liters of normal saline with 5% dextrose), and a search for the underlying condition that precipitated the crisis.

2. Secondary adrenal insufficiency
   a. Patients on long-term steroid therapy—This is the most common cause of secondary adrenal insufficiency today. When these patients develop a serious illness or undergo trauma, they cannot release an appropriate amount of cortisol because of chronic suppression of CRH and ACTH by the exogenous steroids. Therefore, symptoms of adrenal insufficiency result.
   b. Hypopituitarism (rare)—due to a variety of insults.

3. Tertiary adrenal insufficiency—hypothalamic disease.

Quick HIT
Most Common Clinical Findings of Adrenal Insufficiency
B. Clinical Features
1. Lack of cortisol
   a. GI symptoms—anorexia, nausea and vomiting, vague abdominal pain, weight loss
   b. Mental symptoms—lethargy, confusion, psychosis.
   c. **Hypoglycemia**—Cortisol is a gluconeogenic hormone.
   d. **Hyperpigmentation**
      - This is a common finding in primary adrenal insufficiency; not seen in secondary adrenal insufficiency. In secondary adrenal insufficiency, ACTH levels are low, not high.
      - Low cortisol stimulates ACTH and MSH secretion.
   e. Intolerance to physiologic stress is a feared complication.
2. Low aldosterone (only seen in primary adrenal insufficiency because aldosterone depends on the renin-angiotensin system, not ACTH). Results in:
   a. Sodium loss, causing hyponatremia and hypovolemia, which may lead to:
      - **Hypotension**, decreased cardiac output, and decreased renal perfusion.
      - Weakness, **shock**, and syncope.
   b. Hyperkalemia (due to retention of potassium).

**Quick HIT**

Hyperpigmentation and hyperkalemia appear in **primary**, not secondary, adrenal insufficiency.

**Quick HIT**

The most common presentation of secondary adrenal insufficiency is a patient who has been on long-term steroids who stops them suddenly (i.e., for surgery) or who has an increased need (infection). Treatment is easy—give corticosteroids until the patient is stable clinically.

C. Diagnosis
1. Decreased plasma cortisol level (**Figure 4-8**).
2. Plasma ACTH level—if low, this implies a secondary adrenal insufficiency
(ACTH-dependent cause).

   a. This is a definitive test for primary adrenal insufficiency; give an IV infusion of synthetic ACTH, and measure plasma cortisol at the end of the infusion.
   b. In primary adrenal insufficiency, cortisol does not increase sufficiently.
   c. In secondary adrenal insufficiency, cortisol fails to respond to ACTH infusion, as in primary adrenal insufficiency (the adrenals are not used to being stimulated, so they do not respond right away). However, if the test is repeated for 4 or 5 days, the adrenals eventually respond normally.

4. Perform imaging tests (MRI of brain—pituitary/hypothalamus) if secondary or tertiary adrenal insufficiency is diagnosed.

D. Treatment
   1. Primary adrenal insufficiency: daily oral glucocorticoid (hydrocortisone or prednisone) and daily fludrocortisone (mineralocorticoid).
   2. Secondary adrenal insufficiency: same as in primary adrenal insufficiency, except that mineralocorticoid replacement is not necessary.
FIGURE 4.8 Algorithm for the diagnosis of adrenal insufficiency.

**Congenital Adrenal Hyperplasia**

A. General Characteristics
1. Autosomal recessive disease.
2. Ninety percent of the cases are due to 21-hydroxylase deficiency. 11-hydroxylase deficiency is the next most common cause.

![Quick HIT](image)

Congenital adrenal hyperplasia (CAH) is a very treatable condition. Affected female patients will develop normally and will be fertile if treated early.

B. Clinical Features
1. Decreased cortisol and aldosterone production are the main events. Increased ACTH secretion (due to the lack of negative feedback) causes adrenal overstimulation, and thus, hyperplasia.
2. As precursors of cortisol and aldosterone build up, they are shunted toward the synthesis of androgens (e.g., DHEA, testosterone), causing virilization.
3. Virilizing features.
   a. Female infants are born with **ambiguous external genitalia but normal female ovaries and uterus**.
   b. Male infants have no genital abnormalities.
4. Salt wasting form (more severe form of disease).
   a. Emesis, dehydration, hypotension, and shock can develop in first 2 to 4 weeks of life.
   b. **Hyponatremia and hyperkalemia** due to lack of aldosterone.
   c. Hypoglycemia due to lack of cortisol.

C. Diagnosis
1. High levels of **17-hydroxyprogesterone** in the serum. Neonatal screening for 21-hydroxylase deficiency is approved in all 50 states, leading to early diagnosis in many cases.

D. Treatment
1. Medically—Use cortisol and mineralocorticoid replacement; this shuts off the excess ACTH secretion via negative feedback. Beware of undertreatment and overtreatment.
2. Surgically—Early correction of female genital abnormalities is generally recommended.
Diseases of the Central and Peripheral Nervous Systems

Mark Duncan
Cerebrovascular Disease (Stroke)

Ischemic Stroke (Cerebral Infarction)

A. General Characteristics

1. Epidemiology
   a. Stroke, or cerebrovascular accident (CVA), is the third most common cause of death in the United States.
   b. It is the leading cause of neurologic disability.

Quick HIT

Types of Strokes
- Ischemic strokes (~85% of cases)
- Hemorrhagic strokes (~15% of cases)

2. Classes of ischemic stroke
   a. Transient ischemic attack (TIA)—see below
   b. **Reversible ischemic neurologic deficit** is the same as TIA except for the duration of symptoms. It lasts longer than 24 hours, but resolves in less than 2 weeks. This term is not commonly used.
   c. **Evolving stroke** is a stroke that is worsening.
   d. ** Completed stroke** is one in which the maximal deficit has occurred.

3. TIAs (see Clinical Pearl 5-1)
   a. A TIA is a neurologic deficit that lasts from a few minutes to no more than 24 hours (but usually lasts less than 30 minutes).
      - Stroke may be indistinguishable from a TIA at the time of presentation: **Duration of symptoms** is the distinguishing feature.
      - Symptoms are transient with a TIA because reperfusion occurs, either because of collateral circulation or because of the breaking up of an embolus.
   b. **The blockage in blood flow does not last long enough to cause permanent infarction.**
   c. A TIA is usually embolic. However, transient hypotension in the presence of severe carotid stenosis (>75% occlusion) can lead to a TIA.
   d. **Once a patient has a TIA, there is a high risk of stroke.** The risk is increased within days of the TIA; the risk of stroke at 30 days and 5 years is ~10% and 30%, respectively.
   e. Evaluation after TIA: brain and neurovascular imaging, ECG and cardiac
monitoring (inpatient telemetry if admitted, plus ambulatory monitoring for several weeks after), echocardiogram, and labs (CBC, chemistry, lipids, diabetes screening, and others depending on history and risk factors).

4. Risk factors
   a. The most important risk factors are age and HTN. Others include smoking, DM, hyperlipidemia, atrial fibrillation, coronary artery disease (CAD), family history of stroke, previous stroke/TIA, and carotid bruits.
   b. In younger patients, risk factors include oral contraceptive use, hypercoagulable states (e.g., protein C and S deficiencies, antiphospholipid antibody syndrome), vasoconstrictive drug use (e.g., cocaine, amphetamines), polycythemia vera, and sickle cell disease.

**Quick HIT**
The ABCD² score is often used as a risk stratification tool to identify patients at highest risk of early stroke (validated to predict stroke risk within 2 days) that require emergency assessment.
- Age
- Blood pressure elevation shortly after TIA
- Clinical features of stroke
- Duration of TIA symptoms
- Diabetes

**CLINICAL PEARL 5-1**

**TIAs Can Involve Either the Carotid or the Vertebrobasilar System**

**Carotid System**
- Temporary loss of speech; paralysis or paresthesias of contralateral extremity; clumsiness of one limb
- *Amaurosis fugax* (an example of a TIA): transient, curtain-like loss of sight in ipsilateral eye due to microemboli to the retina

**Vertebrobasilar System (i.e., Vertebrobasilar TIAs)**
- Decreased perfusion of the posterior fossa
- Dizziness, double vision, vertigo, numbness of ipsilateral face and contralateral limbs, dysarthria, hoarseness, dysphagia, projectile vomiting, headaches, and drop attacks

B. Causes
1. Emboli are a common cause of TIA/CVA *(Figure 5-1)*. Possible origins of an embolus include:
   a. Heart (most common): Typically due to embolization of mural thrombus in patients with atrial fibrillation.
   b. Internal carotid artery.
   c. Aorta.
d. Paradoxical: Emboli arise from blood clots in the peripheral veins, pass through septal defects (atrial septal defect, a patent foramen ovale, or a pulmonary AV fistula), and reach the brain.

Quick HIT

Remember these causes of stroke:
- Ischemia due to atherosclerosis
- Atrial fibrillation with clot emboli to brain
- Septic emboli from endocarditis

2. Thrombotic stroke—Atherosclerotic plaques may be in the large arteries of the neck (carotid artery disease, which most commonly involves the bifurcation of the common carotid artery), or in medium-sized arteries in the brain (especially the middle cerebral artery [MCA]).

Quick HIT

The source of an embolic stroke is evaluated by:
- Echocardiogram
- Vascular imaging (e.g., carotid Dopplers)
- ECG, ambulatory cardiac monitoring for 30 days

3. Lacunar stroke—small vessel thrombotic disease
   a. Causes approximately 20% of all strokes; usually affects subcortical structures (basal ganglia, thalamus, internal capsule, brainstem) and not the cerebral cortex
   b. Predisposing factor: A history of HTN is present in 80% to 90% of lacunar infarctions. Diabetes is another important risk factor.
   c. Narrowing of the arterial lumen is due to thickening of vessel wall (not by thrombosis).
   d. The arteries affected include small branches of the MCA, the arteries that make up the circle of Willis, and the basilar and vertebral arteries (see Clinical Pearl 5-2).
   e. When these small vessels occlude, small infarcts result; when they heal, they are called lacunes.
4. Nonvascular causes—Examples include low cardiac output and anoxia (may cause global ischemia and infarction).

**CLINICAL PEARL 5-2**

**Subclavian Steal Syndrome**

- Caused by stenosis of subclavian artery proximal to origin of vertebral artery—exercise of left arm causes reversal of blood flow down the ipsilateral vertebral artery to fill the subclavian artery distal to the stenosis because it cannot supply adequate blood to left arm
- Leads to decreased cerebral blood flow (blood “stolen” from basilar system)
- Causes symptoms of vertebrobasilar arterial insufficiency (see Clinical Pearl 5-1)
- BP in left arm is less than in right arm; decrease in pulse in left arm
- Upper extremity claudication
- Treatment: surgical bypass

C. Clinical Features

1. Thrombotic stroke—The onset of symptoms may be rapid or stepwise. Classically the patient awakens from sleep with the neurologic deficits (see
2. **Embolic stroke**
   
a. The onset of symptoms is **very rapid** (within seconds), and deficits are maximal initially.

b. Clinical features depend on the artery that is occluded. The MCA is most commonly affected, and neurologic deficits seen in MCA involvement include:
   
   - Contralateral hemiparesis and hemisensory loss.
   - Aphasia (if dominant hemisphere is involved)—for 90% of population this is left cerebral dominance.
   - Apraxia, contralateral body neglect, confusion (if nondominant hemisphere is involved).

3. **Lacunar stroke**—Clinical features are focal and usually contralateral pure motor or pure sensory deficits. Lacunar stroke includes four major syndromes:
   
a. Pure **motor** lacunar stroke—if lesion involves the **internal capsule**.

b. Pure **sensory** lacunar stroke—if lesion involves the **thalamus**.

c. Ataxic hemiparesis—incoordination ipsilaterally.

d. Clumsy hand dysarthria.

---

**Quick HIT**

A carotid bruit has two causes:

- Murmur referred from the heart
- Turbulence in the internal carotid artery (possible stroke risk)

---

**Quick HIT**

Most common location involves the MCA—results in contralateral weakness, sensory loss, and hyperreflexia.

---

**TABLE 5-1** **Deficits Seen in Stroke**

<table>
<thead>
<tr>
<th>Distribution</th>
<th>Location and/or Type of Deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior cerebral artery</td>
<td>Contralateral lower extremity and face</td>
</tr>
<tr>
<td>Middle cerebral artery</td>
<td>Aphasia, contralateral hemiparesis</td>
</tr>
<tr>
<td>Vertebral/basilar artery</td>
<td>Ipsilateral: ataxia, diplopia, dysphagia, dysarthria, and vertigo</td>
</tr>
<tr>
<td></td>
<td>Contralateral: homonymous hemianopsia with basilar—PCA lesions</td>
</tr>
<tr>
<td>Lacunar</td>
<td>Pure motor hemiparesis</td>
</tr>
<tr>
<td>Internal capsule</td>
<td>Dysarthria, clumsy hand</td>
</tr>
</tbody>
</table>
D. Initial Assessment

1. History and neurologic exam (including the National Institutes of Health Stroke Scale, NIHSS). The NIHSS score on admission predicts stroke outcomes.

2. Brain imaging (CT or MRI)
   a. CT scan of the head without contrast is preferred at most centers due to availability and time constraints, and it differentiates an ischemic from a hemorrhagic infarction. Ischemic strokes appear as dark areas on the CT scan (hemorrhagic strokes appear white—Figure 5-2). It may take 24 to 48 hours to visualize an infarct on CT.
   b. MRI of the brain is more sensitive than CT; it identifies all infarcts, and does so earlier than CT scan. Ninety-five percent of infarcts identified on MRI within 24 hours.
   c. The brain imaging modality can be combined with neurovascular imaging at some centers (e.g., CT with CTA, MRI with MRA).

3. ECG—acute MI or atrial fibrillation may be the cause of embolic strokes.

4. Labs: accucheck, CBC, electrolytes, creatinine, coags, cardiac enzymes and others based on patient factors.

E. Complications

1. Progression of neurologic insult.
2. Cerebral edema occurs within 1 to 2 days and can cause **mass effects** for up to 10 days. Hyperventilation and mannitol may be needed to lower intracranial pressure (ICP).

3. Hemorrhage into the infarction—rare.

4. Seizures—fewer than 5% of patients.

**F. Treatment**

1. Acute—Supportive treatment (airway protection, oxygen, IV fluids) is initiated. Early recognition of the cause of stroke is unreliable, and early treatment is critical. Therefore, choose therapies that have broad efficacy and safety.

   a. Thrombolytic therapy (t-PA)

      - If administered **within 4.5 hours** of the onset of an acute ischemic stroke, improved clinical outcome is seen at 3 months.

      - Do not give t-PA if the time of stroke is unknown, if more than 4.5 hours have passed, or if the patient has any of the following: uncontrolled HTN, bleeding disorder, is taking anticoagulants or has a history of recent trauma or surgery. These patients are at increased risk for hemorrhagic transformation.

      - If t-PA is given, there is risk of **intracranial hemorrhage**. Therefore, do not give aspirin for the first 24 hours, perform frequent neurologic checks (every hour), and carefully monitor BP. (Keep BP <185/110 mm Hg.)

---

**FIGURE 5.2**

CT scan of a patient with a stroke from a nonhemorrhagic
Infarct (arrow).
(From Fishman MC, Hoffman AR, Klausner RD, et al. Medicine. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:593, Figure 64-7.)

b. In eligible patients with large artery occlusion who present within 6 hours, endovascular thrombectomy has been studied in multiple large randomized controlled trials and is superior to thrombolytic therapy with t-PA. New studies are supporting that the window for therapy could be extended from 6 hours up to 16 or 24 hours from the time patient was last known to be well.
c. Aspirin should be given as early as possible (unless t-PA is used), and ideally within 48 hours of stroke onset.
d. Anticoagulants (e.g., heparin) have not been proven to have efficacy in acute stroke. However, DVT/VTE prophylaxis should be given during hospitalization.
e. Assess the patient’s ability to protect his or her airway, keep NPO, protect against hypo- or hyperglycemia, avoid fever, and elevate the head of the bed 30 degrees to prevent aspiration.

2. BP control—In general, do not give antihypertensive agents in the first 24 hours unless one of the following three conditions is present:
   a. The patient’s BP is very high (systolic >220, diastolic >120, or mean arterial pressure >130 mm Hg).
   b. The patient has a significant medical indication for antihypertensive therapy. Examples include:
      • Acute MI
      • Aortic dissection
      • Severe heart failure
      • Hypertensive encephalopathy
   c. The patient is receiving t-PA—aggressive blood pressure control is necessary to reduce the likelihood of bleeding.

Quick HIT
If stroke is caused by emboli from a cardiac source, anticoagulation is the treatment.

Quick HIT
Treatment of strokes is prophylactic. Once a stroke has occurred, there is nothing that can be done to salvage the dead brain tissue. The goal is to prevent ischemic events in the future.

3. Prevention of stroke recurrence
a. Lifestyle and pharmacotherapy for risk factors (HTN, DM, smoking, hyperlipidemia, obesity).
b. Long-term antiplatelet therapy (e.g., aspirin).
c. High intensity statin.
d. Anticoagulation for cardioembolic strokes.
e. Surgery for strokes due to carotid artery disease (Figure 5-3).

- **Symptomatic patients**—three major studies have established the benefit of carotid endarterectomy in symptomatic patients with carotid artery stenosis of >70%. (The NASCET trial was the most influential.)
- **Asymptomatic patients**—four major studies have investigated the benefit of carotid endarterectomy in asymptomatic patients. Three found no benefit. One study (ACAS) found that in asymptomatic patients who have a carotid artery stenosis of >60%, the benefits of surgery are very small. **Therefore, in asymptomatic patients, reduction of atherosclerotic risk factors and use of aspirin are recommended.**

---

**Quick HIT**

If carotid stenosis is >70% and patient is symptomatic, carotid endarterectomy is indicated.
5.3 Effect of carotid endarterectomy in carotid stenosis. NASCET, North American Symptomatic Carotid Endarterectomy Trial; ACAS, asymptomatic carotid atherosclerosis study. (Redrawn from Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998:590, Figure 34-4.)
Hemorrhagic Stroke

A. Intracerebral Hemorrhage

1. General characteristics
   a. ICH is associated with a high mortality rate (50% at 30 days). For those who survive, there is significant morbidity.
   b. Hematoma formation and enlargement may lead to local injury and increase in intracerebral pressure.

   **Quick HIT**
   
   Two major categories of hemorrhagic stroke:
   - ICH—bleeding into brain parenchyma
   - SAH—bleeding into the CSF; outside brain parenchyma

2. Causes
   a. HTN (particularly a sudden increase in BP) is the most common cause (50% to 60% of cases).
      - HTN causes a rupture of small vessels deep within the brain parenchyma. Chronic HTN causes degeneration of small arteries, leading to microaneurysms, which can rupture easily.
      - It is typically seen in older patients; risk increases with age.
   b. Ischemic stroke may convert to a hemorrhagic stroke.
   c. Other causes include amyloid angiopathy (10%), anticoagulant/antithrombolytic use (10%), brain tumors (5%), and AV malformations (5%).

   **Quick HIT**
   
   Cocaine is one of the main causes of stroke in young patients. ICH, ischemic stroke, and SAH are all associated with cocaine use.

3. Locations
   a. Basal ganglia (66%)
   b. Pons (10%)
   c. Cerebellum (10%)
   d. Other cortical areas

4. Clinical features
   a. Abrupt onset of a focal neurologic deficit that worsens steadily over 30 to 90 minutes
   b. Altered level of consciousness, stupor, or coma
c. Headache, vomiting
d. Signs of increased ICP

**Quick HIT**

Pupillary findings in ICH and corresponding level of involvement
- Pinpoint pupils—pons
- Poorly reactive pupils—thalamus
- Dilated pupils—putamen

5. **Diagnosis**
   a. CT scan of the head diagnoses 95% of ICH (may miss very small bleeds) ([Figure 5-4](#)).
   b. Coagulation panel and platelets—check these to evaluate for bleeding diathesis.

6. **Complications**
   a. Increased ICP
   b. Seizures
   c. Rebleeding
   d. Vasospasm
   e. Hydrocephalus
   f. SIADH

7. **Treatment**
   a. Admission to the ICU
   b. ABC’s (airway, breathing, and circulation)—airway management is important due to altered mental status and decreased respiratory drive. Patients often require intubation.
   c. BP reduction
      - Elevated BP increases ICP and can cause further bleeding. However, hypotension can lower cerebral blood flow, worsening the neurologic deficits. Therefore, **BP reduction must be gradual.**
      - Treatment is indicated if systolic BP is >180 or the MAP is >130. Common IV agents used include nicardipine, labetalol, nitroprusside, and others.
   d. Initial management of elevated ICP includes elevating the head of the bed to 30 degrees and appropriate sedation and pain control. Mannitol (osmotic agent) is often used to lower ICP; other options include hyperventilation, barbiturates, neuromuscular blockade, and CSF drainage.
   e. If the patient is on anticoagulation or an antiplatelet agent, reversal agents (e.g., vitamin K for warfarin, protamine sulfate for heparin, prothrombin complex concentrate for warfarin and the newer oral anticoagulants, etc.).
   f. Use of steroids is harmful and is not recommended.
g. Rapid surgical evacuation of cerebellar hematomas can be lifesaving. However, surgery is not helpful in most cases of ICH.

**FIGURE 5.4**

A: Spontaneous ICH hemorrhage in a hypertensive patient. B: On CT scan, ischemic stroke appears dark, whereas hemorrhagic stroke appears white.


**Quick HIT**

**Common Sites of SAH**
- Junction of anterior communicating artery with anterior cerebral artery
- Junction of posterior communicating artery with the internal carotid artery
- Bifurcation of the MCA

**B. Subarachnoid Hemorrhage**

1. **General characteristics**
   a. Mortality rate can be as high as 40% to 50% at 30 days.
   b. Locations—Saccular (berry) aneurysms occur at bifurcations of arteries of the circle of Willis.
Polycystic kidney disease is associated with berry aneurysms.

2. Causes
   a. Ruptured saccular (berry) aneurysms are the most common cause—has higher morbidity and mortality than other causes.
   b. Trauma is also a common cause.
   c. AV malformation.

Caution: Ophthalmologic examination is mandatory to rule out papilledema. If papilledema is present, do not perform an LP—you may cause a herniation. Repeat the CT scan first.

3. Clinical features
   a. Sudden, severe (often excruciating) headache in the absence of focal neurologic symptoms; classic description is “the worst headache of my life” but may also be more subtle.
   b. Sudden, transient loss of consciousness—in approximately 50% of patients.
   c. Vomiting (common).
   d. Meningeal irritation, nuchal rigidity, and photophobia—can take several hours to develop.
   e. Death—25% to 50% of patients die with the first rupture. Those who survive will recover consciousness within minutes.
   f. Retinal hemorrhages—in up to 30% of patients.

4. Diagnosis
   a. Noncontrast CT scan—identifies the majority of subarachnoid hemorrhages (SAHs). However, CT scan may be negative in up to 10% of cases.
   b. Perform lumbar puncture (LP) if the CT scan is unrevealing or negative and clinical suspicion is high. LP is diagnostic.
      - Blood in the CSF is a hallmark of SAH. (Be certain that it is not blood from a traumatic spinal tap.)
      - Xanthochromia (yellow color of the CSF) is the gold standard for diagnosis of SAH. Xanthochromia results from RBC lysis. Xanthochromia implies that blood has been in CSF for several hours and that it is not due to a traumatic tap.
   c. Once SAH is diagnosed, order a cerebral angiogram. It is the definitive study for detecting the site of bleeding (for surgical clipping).

5. Complications
a. Rerupture—occurs in up to 30% of patients.
b. Vasospasm—occurs in up to 50% of patients (more often with aneurysmal SAH); can cause ischemia/infarction and therefore stroke.
c. Hydrocephalus (communicating)—secondary to blood within the subarachnoid space hindering normal CSF flow.
d. Seizures may occur (blood acts as an irritant).
e. SIADH

6. Treatment
   a. Minimally invasive—consult interventional neuroradiology. Recent studies have shown endovascular coiling to have better outcomes than surgical clipping.
   b. Surgical—consult neurosurgery. Surgically clip the aneurysm to prevent rebleeding.
   c. Medical—therapy reduces the risks of rebleeding and cerebral vasospasm.
      - Bed rest in a quiet, dark room.
      - Stool softeners to avoid straining (increases ICP and risk of rerupture).
      - Analgesia for headache (acetaminophen).
      - IV fluids for hydration.
      - Control of HTN—lower the BP gradually because the elevation in BP may be a compensation for the decrease in cerebral perfusion pressure (secondary to increased ICP or cerebral arterial narrowing).
      - Calcium channel blocker (nimodipine) for vasospasm—lowers the incidence of cerebral infarction by one-third.

**Quick HIT**

The basal ganglia/striatal region normally operates as a balanced system comprising the dopaminergic system and the cholinergic system. In Parkinson disease, the dopaminergic pathway is compromised, and the cholinergic system operates unopposed. Therefore, the goal of treatment is either to enhance dopamine’s influence or to inhibit acetylcholine’s influence.
Movement Disorders

●●● Parkinson Disease

A. General Characteristics
1. Parkinson disease is the most common hypokinetic movement disorder.
2. Onset is usually after age 50 years.
3. Parkinson disease is essentially a clinical diagnosis. Laboratory studies play no role in diagnosis.
4. Parkinsonism refers to symptoms and signs of Parkinson disease and can result from many conditions (e.g., medications). Up to 10% of patients with Parkinsonism will have “Parkinson-plus syndromes”:
   a. Multiple system atrophy: parkinsonism plus one of the following subtypes: dysautonomia (Shy–Drager syndrome), cerebellar ataxia (MSA-C), or dystonia (MSA with predominant parkinsonism).
   b. Progressive supranuclear palsy: parkinsonism plus prominent oculomotor deficits.
   c. Corticobasal degeneration: parkinsonism (usually asymmetric) plus impaired cognition, dystonia, sensory deficits, and myoclonus.

CLINICAL PEARL 5-3

Progressive Supranuclear Palsy (PSP)
- PSP is a degenerative condition of the brainstem, basal ganglia, and cerebellum, most commonly affecting middle-aged and elderly men.
- Like Parkinson disease, PSP causes bradykinesia, limb rigidity, cognitive decline, and follows a progressive course.
- Unlike Parkinson disease, PSP
  - Does not cause tremor
  - Does cause ophthalmpoplegia

B. Clinical Features
1. Pill-rolling tremor at rest (worsens with emotional stress) (see Clinical Pearl 5-3). Tremor goes away when performing routine tasks.
2. Bradykinesia—slowness of voluntary movements.
3. Rigidity is characteristic. “Cogwheel rigidity” refers to a ratchet-like jerking, which can be elicited by testing the tone in one limb while the patient clenches the opposite fist.
4. Poor postural reflexes; difficulty initiating the first step, and walking with small
shuffling steps; stooped posture.
5. Masked (expressionless) facies; decreased blinking.
6. Dysarthria and dysphagia, micrographia (small handwriting).
7. Impairment of cognitive function (dementia) in advanced disease.
8. Autonomic dysfunction can lead to orthostatic hypotension, constipation, increased sweating, and oily skin.
9. Personality changes present in early stages. Patients become withdrawn, apathetic, and dependent on others. Depression is common and can be significant—causes worsening of parkinsonian symptoms.
10. Follows progressive course—significant disability usually presents within 5 to 10 years; indirectly leads to increased mortality.

Quick HIT

Lewy bodies (hyaline inclusion bodies) are a key neuronal finding in the brains of patients with Parkinson disease.

Quick HIT

The clinical features of Parkinson disease can be remembered with the mnemonic TRAP: Tremor, Rigidity, Akinesia, Postural instability.

C. Treatment

1. No cure—goals are to delay disease progression and relieve symptoms.
2. Carbidopa-levodopa (Sinemet)—drug of choice for treating parkinsonian symptoms.
   a. As the name implies, it is a combination of levodopa (L-Dopa) and carbidopa.
   b. It ameliorates all the symptoms of Parkinson disease. It is the most effective of all the antiparkinsonian drugs.
   c. Side effects.
      • Dyskinesias (involuntary, often choreic movements) can occur after 5 to 7 years of therapy. This is a major concern, and may warrant delay in initiating carbidopa-levodopa for as long as possible.
      • Nausea/vomiting, anorexia, HTN, hallucinations.
   d. Levodopa does show an “on–off” phenomenon (over the course of the day) during treatment, which leads to fluctuations in symptoms. This is due to dose–response relationships. It often occurs in advanced disease.

Quick HIT

Medications That Cause Parkinsonian Side Effects
- Neuroleptic drugs (chlorpromazine, haloperidol, perphenazine)
- Metoclopramide
- Reserpine

**Quick HIT**

Patients with tremor as a major symptom of Parkinson disease have a better prognosis than those who have bradykinesia as a predominant finding.

3. Dopamine-receptor agonists (bromocriptine, pramipexole).
   a. May control symptoms and delay need for levodopa for several years.
   b. Initiate one of these agents when you have established the diagnosis. You may use levodopa and one of these agents at the same time.
   c. Pramipexole is the most commonly used.
   d. These can be useful for sudden episodes of hesitancy or immobility (described as “freezing”).

4. Selegiline—it inhibits monoamine oxidase B activity (increases dopamine activity) and reduces metabolism of levodopa. It is an adjunctive agent, and is often used in early disease. It has mild symptomatic benefit.

5. Amantadine (antiviral agent)—mild benefit, mostly for early or mild disease.

6. Anticholinergic drugs.
   a. Trihexyphenidyl and benztropine.
   b. These may be particularly helpful in patients with tremor as a major finding. Do not use in older patients or demented patients.

7. Amitriptyline—useful in the treatment of Parkinson disease both as an anticholinergic agent and as an antidepressant.

8. Surgery (deep brain stimulation)—if patient does not respond to medications or in patients who develop severe disease before age 40 years.
Huntington Chorea

A. General Characteristics
1. **Autosomal dominant**, so lack of family history makes this diagnosis unlikely.
2. Onset is between 30 and 50 years of age. Symptoms worsen steadily, with 15 years being the typical duration from onset to death.
3. It is caused by a mutation on chromosome 4 (expanded triplet repeat sequence)—CAG leads to a loss of GABA-producing neurons in the striatum.

B. Clinical Features
1. Chorea—involving the face, head and neck, tongue, trunk, and extremities.
2. Altered behavior—irritability, personality changes, antisocial behavior, depression, obsessive-compulsive features, and/or psychosis.
3. Impaired mentation—progressive dementia is a key feature; 90% of patients are demented before age 50 years.
4. Gait is unsteady and irregular. Ultimately bradykinesia and rigidity prevail.
5. Incontinence.

**Quick HIT**
Always keep Wilson disease in mind in a young patient with movement disorders (see Chapter 3).

C. Diagnosis
1. MRI shows atrophy of the head of caudate nuclei.
2. DNA testing confirms the diagnosis. Genetic counseling plays an important role.

D. Treatment
Treatment is symptomatic—there is no curative treatment. Dopamine blockers may help with the psychosis and improve chorea. Anxiolytic and antidepressant therapy may be necessary.
Tremor

A. Physiologic Tremor

1. **Causes** (see Table 5-2)
   a. Fear, anxiety, fatigue
   b. Metabolic causes: hypoglycemia, hyperthyroidism, pheochromocytoma
   c. Toxic causes (e.g., alcohol withdrawal, valproic acid, lithium, methylxanthines—caffeine and theophylline)

2. **Treatment:** Treat the underlying cause, if known; otherwise, no treatment is necessary

<table>
<thead>
<tr>
<th>TABLE 5-2 Common Tremors and Associated Features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Feature</strong></td>
</tr>
<tr>
<td>Characteristic Setting</td>
</tr>
<tr>
<td>Description</td>
</tr>
<tr>
<td>Etiology</td>
</tr>
<tr>
<td>Associated Features</td>
</tr>
<tr>
<td>Improved By</td>
</tr>
</tbody>
</table>

B. Essential Tremor

1. Common; inherited (autosomal dominant) in up to one-third of patients.
2. It is induced or exacerbated by intentional activity, such as drinking from a cup or use of utensils, and is **markedly decreased by alcohol use** (useful in diagnosis).
3. Distorted handwriting is often present. Note that bradykinesia, rigidity, shuffling gait, or postural instability are all absent.
4. Treat with propranolol.

Quick HIT

There is no known association between essential tremor and Parkinson disease.

C. Neurologic Diseases (e.g., Parkinson disease, cerebellar disease, Wilson disease)
Ataxia

A. General Characteristics
1. Gait instability
2. Loss of balance
3. Impaired limb coordination

B. Causes
1. Acquired causes: alcohol intoxication, vitamin B\textsubscript{12} or thiamine deficiency, cerebellar infarction or neoplasm, demyelinating disease (multiple sclerosis [MS], AIDS), and tertiary syphilis (tabes dorsalis)
2. Inherited causes
   a. Friedreich ataxia
      • Autosomal recessive inheritance, onset by young adulthood
      • Presents with ataxia, nystagmus, impaired vibratory sense, and proprioception
   b. Ataxia telangiectasia
      • Autosomal recessive inheritance, childhood onset
      • Symptoms similar to those of Friedreich ataxia plus telangiectases
      • Increased incidence of cancer

C. Treatment
Treat underlying cause if possible.
Restless Leg Syndrome

A common disorder manifesting as an uncomfortable sensation to move the legs (sometimes the arms as well), that usually occurs during the evening and at rest. The pathophysiology is unclear, but it can be associated with iron deficiency and certain medications. Treat iron deficiency or withdraw offending medications if possible. If pharmacologic therapy is indicated, then dopamine agonists are typically used (e.g., pramipexole, ropinirole).
Tourette Syndrome

A. General Characteristics
1. Associated with obsessive-compulsive disorder.
2. Onset before age 21 years.
3. Thought to have autosomal dominant inheritance pattern.
4. Not all patients with tics have Tourette syndrome.
5. Not all patients with Tourette syndrome experience coprolalia (involuntary swearing).

B. Clinical Features (occur frequently and regularly). Must have both motor and phonic tics.
1. Motor tics (multiple)
2. Phonic tics (at least one kind)

C. Treatment (if symptoms are affecting the patient’s quality of life; patient education is important)
1. Clonidine
2. Pimozide
3. Haloperidol
Dementia

Overview

A. General Characteristics

1. Dementia is a progressive deterioration of intellectual function, typically characterized by preservation of consciousness.
2. The most important risk factor for dementia is increasing age.

Quick HIT

Forgetfulness Versus Dementia

- Some degree of memory loss is accepted as a normal part of aging. It may be difficult to distinguish this condition, sometimes referred to as benign forgetfulness of elderly patients, from true dementia.
- In general, benign forgetfulness does not adversely affect normal day-to-day living or baseline functioning, but it may be a risk factor for progressive dementias such as Alzheimer disease.

B. Differential Diagnosis of Dementia

1. Primary neurologic disorders (see Clinical Pearl 5-4)
   a. Alzheimer disease—accounts for 66% of all cases of dementia (see the section on Alzheimer disease below).
   b. Vascular dementia, or multi-infarct dementia, is a stepwise decline due to a series of cerebral infarctions.
   c. Space-occupying lesions, such as brain tumor or chronic subdural hematoma.
   d. Normal pressure hydrocephalus—triad of dementia, gait disturbance, and urinary incontinence; normal CSF pressure and dilated ventricles.
   e. Dementia with Lewy bodies (see section below).
   f. Frontotemporal dementia (Pick disease)—clinically similar to Alzheimer disease.
   g. Other neurologic conditions: MS, Parkinson disease, Huntington disease, Wilson disease.
2. Infections
   a. HIV infection (AIDS-related dementia)
   b. Neurosyphilis
   c. Cryptococcal infection of CNS
   d. Creutzfeldt–Jakob disease (spongiform encephalopathy)
   e. Progressive multifocal leukoencephalopathy
Causes of Dementia

Potentially Reversible Causes of Dementia
- Hypothyroidism
- Neurosyphilis
- Vitamin $\text{B}_{12}$/folate deficiency/thiamine deficiency
- Medications
- Normal pressure hydrocephalus
- Depression
- Subdural hematoma

Irreversible Causes of Dementia
- Alzheimer disease
- Parkinson, Huntington
- Multi-infarct dementia
- Dementia with Lewy bodies, Pick disease
- Unresectable brain mass
- HIV dementia
- Korsakoff syndrome
- Progressive multifocal leukoencephalopathy
- Creutzfeldt–Jakob disease

3. Metabolic disorders
   a. Thyroid disease (hypothyroidism or hyperthyroidism)
   b. Vitamin $\text{B}_{12}$ deficiency
   c. Thiamine deficiency—common in alcoholics; if untreated can lead to Korsakoff dementia (irreversible)
   d. Niacin deficiency

4. Drugs and toxins
   a. Drug abuse; chronic alcoholism (may cause dementia independent from thiamine malnutrition)
   b. Toxic substances: aniline dyes, metals (e.g., lead)

5. Pseudodementia (depression)—severe depression may cause a decline in cognition that is difficult to distinguish clinically from Alzheimer disease, but is responsive to antidepressant therapy

C. Clinical Approach to Dementia
1. Patient history—Ask patients and their family members about the nature of onset, specific deficits, physical symptoms, and comorbid conditions. Review all medications, as well as family and social history.
2. Physical examination.
   a. Focus on a thorough neurologic examination and mental status examination.
b. Gait analysis often sheds light on movement disorders, mass lesions, and nonpressure hydrocephalus.

3. Laboratory and imaging studies—Consider the following when investigating the cause of dementia: CBC with differential, chemistry panel, thyroid function tests (TSH), vitamin B₁₂, folate level, VDRL (syphilis), HIV screening, and CT scan or MRI of the head.

D. Treatment and Management

1. Treat reversible causes.
2. Avoid and/or monitor doses of medications with adverse cognitive side effects (glucocorticoids, opiates, sedative hypnotics, anxiolytics, anticholinergics, lithium).
3. Treat/control comorbid medical conditions; for example, diabetes, HTN, depression, visual and hearing impairment.
4. Pharmacologic therapy may be of benefit (see specific diseases below).
5. A multidisciplinary approach includes support groups for caregivers/families of patients with irreversible dementias.
Alzheimer Disease

A. General Characteristics

1. Epidemiology
   a. Alzheimer disease is a very common cause of death in the United States.
   b. Prevalence increases with age—Approximately 10% to 15% of individuals over age 65, and 15% to 30% of individuals over age 80 have Alzheimer disease. However, many will die of other causes first.

2. Risk factors
   a. Age
   b. Family history (especially for early-onset Alzheimer disease)
   c. Down syndrome

3. Etiology is unknown, but a heritable component may be present. Chromosomes 21, 14, and 19 have been linked to Alzheimer disease.

4. Pathology (noted at autopsy):
   a. Quantity of senile plaques (age-specific)—focal collections of dilated, tortuous neuritic processes surrounding a central amyloid core (amyloid β-protein).
   b. Quantity of neurofibrillary tangles containing abnormal tau proteins.
   c. Neuronal loss and prominent atrophy.

Quick HIT

Most important risk factor for Alzheimer disease is age.

Quick HIT

Patients with Alzheimer disease often have cerebral atrophy secondary to neuronal loss. Ventricles will correspondingly be enlarged.

B. Clinical Features

1. Begins insidiously but tends to progress at a steady rate.
2. The average time from onset to death is 5 to 10 years (with some variability).
3. Stages
   a. Early stages—mild forgetfulness, impaired ability to learn new material, poor performance at work, poor concentration, changes in personality, impaired judgment (e.g., inappropriate humor).
   b. Intermediate stages—memory is progressively impaired. Patients may be aware of the condition, yet denial is often present. Visuospatial disturbances are common (getting lost in a familiar place and difficulty following directions).
Patients may repeat questions over and over.

c. Later stages—assistance is needed for activities of daily living. Patients have difficulty remembering the names of relatives/friends or major aspects of their lives. Paranoid delusions (e.g., victim of theft) and hallucinations are common.
d. Advanced disease—complete debilitation and dependence on others, incontinence (bowel/bladder); patient may even forget his or her own name.
e. Death is usually secondary to infection or other complications of a debilitated state.

C. Diagnosis

1. Alzheimer disease is essentially a **clinical diagnosis**; exclude other causes first.
2. CT scan or MRI showing diffuse cortical atrophy with enlargement of the ventricles strengthens the diagnosis.

**Quick HIT**
**Alzheimer Disease: Treatment/Prevention**
- No treatment has been found to have a significant effect on cognitive effects.
- Hormone replacement therapy is associated with a lower risk of developing Alzheimer disease.

D. Treatment

1. Cholinesterase inhibitors—brains of patients with Alzheimer disease have lower levels of acetylcholine. **Avoid anticholinergic medications!** Options include donepezil, rivastigmine, and galantamine.
   a. Currently the first-line agent.
2. Certain dietary supplements (ginkgo, lecithin) have not been proven to be beneficial.
3. Vitamin E can be tried in mild to moderate dementia. In one study, mega doses of vitamin E (2,000 IU/day) slowed disease progression and preserved function in people with moderately severe Alzheimer disease.
4. Memantine can be added in moderate to severe dementia.

**Quick HIT**
Patients with AD have decreased acetylcholine synthesis and thus impaired cortical cholinergic function. Cholinesterase inhibitors increase cholinergic transmission by inhibiting cholinesterase.
Dementia With Lewy Bodies

Dementia with Lewy bodies has features of both Alzheimer disease and Parkinson disease, but progression may be more rapid than in Alzheimer disease. Initially, visual hallucinations predominate. Other symptoms include extrapyramidal features and fluctuating mental status. These patients are sensitive to the adverse effects of neuroleptic agents, which often exacerbate symptoms. Treatment is similar to that for Alzheimer disease, with neuroleptic agents (for hallucinations and psychotic features). Selegiline may slow the progression of disease.

**Quick HIT**

AChE medications (e.g., donepezil) are only indicated for Alzheimer dementia and Lewy body dementia. No specific therapy for other causes of dementia.
Altered Mental Status

Delirium
Differential diagnosis of AMS can be remembered by the mnemonic MOVE STUPID:
- Metabolic disorders (e.g., hypercalcemia)
- Oxygen
- Vascular (e.g., MI, CVA)
- Endocrine (e.g., hypoglycemia)
- Seizure
- Trauma
- Uremia
- Psychiatric
- Infectious
- Drugs

CLINICAL PEARL 5-5

Altered Mental Status
- Consciousness relies on arousal and cognition. Arousal is dependent on an intact brainstem (reticular activating system in brainstem). Cognition is dependent on an intact cerebral cortex.
- Altered mental status, diminished level of consciousness (drowsiness, stupor, coma), and confusion are caused by many of the same conditions and are often variations of the same theme.
- Depressed level of consciousness and coma can be caused by a variety of disorders. To help in classification and to organize one’s thinking, it is useful to organize these causes into two categories:
  - Diffuse injury to the brain due to any metabolic, systemic, or toxic disorder
  - Focal intracranial structural lesions—for example, hemorrhage, infarction, tumor

A. General Characteristics
1. Delirium is an acute period of cognitive dysfunction due to a medical disturbance or condition (see Clinical Pearl 5-5) (see Table 5-3).
2. Elderly patients are especially prone to delirium.

B. Causes

C. Clinical Features
1. In contrast to both dementia and psychosis, delirium is characterized by a rapid deterioration in mental status (over hours to days), a fluctuating level of awareness, disorientation, and attention.
2. Delirium may often be accompanied by acute abnormalities of perception, such as hallucinations.
3. Patients may be agitated (i.e., hyperactive delirium), or have a slow, blunted responsiveness (i.e., hypoactive delirium).
4. The strongest risk factor is preexisting cognitive impairment.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Delirium</th>
<th>Dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Causes</td>
<td>• Infections (UTI, systemic infection)</td>
<td>• Alzheimer disease</td>
</tr>
<tr>
<td></td>
<td>• Medications (narcotics, benzodiazepines)</td>
<td>• Multi-infarct dementia</td>
</tr>
<tr>
<td></td>
<td>• Postoperative delirium (in elderly patients)</td>
<td>• Pick disease (Frontotemporal dementia)</td>
</tr>
<tr>
<td></td>
<td>• Alcoholism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Electrolyte imbalances</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Medical conditions (stroke, heart disease, seizures, hepatic and renal disorders)</td>
<td></td>
</tr>
<tr>
<td>Level of Consciousness</td>
<td>Altered, fluctuating</td>
<td>Preserved</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>Frequently present (visual)</td>
<td>Rarely present</td>
</tr>
<tr>
<td>Presence of Tremor</td>
<td>Sometimes present (e.g., asterixis)</td>
<td>Usually absent unless dementia is due to Parkinson disease</td>
</tr>
<tr>
<td>Course</td>
<td>• Rapid onset, waxing and waning</td>
<td>Insidious, progressive</td>
</tr>
<tr>
<td></td>
<td>• “Sundowning” (worsening at night) may be present</td>
<td></td>
</tr>
<tr>
<td>Reversibility</td>
<td>Almost always reversible</td>
<td>Typically irreversible</td>
</tr>
</tbody>
</table>

**D. Diagnosis**

1. The most common delirium screening test is the Confusion Assessment Method (CAM), which is based on four features: acute onset with a fluctuating course, inattention, disorganized thinking, and an altered level of consciousness.
2. Workup of delirium depends on suspected contributing factors and reversible causes. It is largely based on a good history and physical exam (with a detailed neurologic exam and mental status assessment), especially with a good review of medications. Lab, imaging, and procedures (e.g., lumbar puncture) workup is patient-specific.

**E. Treatment**

1. Treat the underlying cause.
2. Delirium precautions while in the hospital: frequent reorientation, familiar objects and faces (i.e., family at the bedside), maintaining a normal sleep–wake cycle with blinds open during the day, and correcting sensory impairments (hearing aids, glasses, etc.).
3. Avoid restraints and pharmacologic management of agitation as much as possible;
if absolutely necessary, antipsychotics like haloperidol may be used.
Coma

A. General Characteristics
1. A coma is a depressed level of consciousness to the extent that the patient is completely unresponsive to any stimuli.
2. Causes
   a. Structural brain lesions that cause a coma are usually bilateral unless they produce enough mass effect to compress the brainstem or the opposite cerebral hemisphere (see Clinical Pearl 5-6).
   b. Global brain dysfunction (e.g., metabolic or systemic disorders)
   c. Psychiatric causes—conversion disorders and malingering may be difficult to differentiate from a true coma.

B. Approach
1. Initial steps
   a. Assess vital signs. ABC’s take priority.
   b. Always assume underlying trauma (stabilize cervical spine) and assess the patient for signs of underlying causes of trauma.
   c. Assess the level of consciousness using the Glasgow Coma Scale (see Table 5-4). Repeat this serially because it can change.

Quick HIT
Assessing the Cause of a Coma
- Abnormal pupillary light reflex—structural intracranial lesions (hemorrhage, mass); drugs that affect the pupil (morphine, atropine-like agents); anoxic encephalopathy; recent eye drops
- Bilateral fixed, dilated pupils—severe anoxia
- Unilateral fixed, dilated pupil—herniation with CN III compression
- Pinpoint pupils—narcotics, ICH

CLINICAL PEARL 5-6
Differential Diagnosis of AMS Can Be Remembered by the Mnemonic MOVE STUPID
- Metabolic disorders (e.g., hypercalcemia)
- Oxygen
- Vascular (e.g., MI, CVA)
- Endocrine (e.g., hypoglycemia)
- Seizure
- Trauma
- Uremia
- Psychiatric
2. Approach to diagnosing the cause of coma.
   a. Rapid motor examination—if asymmetry is noted in movements, a mass lesion is the likely cause. Metabolic or systemic causes of coma do not produce asymmetric motor abnormalities.
   b. Brainstem reflexes (see Clinical Pearl 5-7).

<table>
<thead>
<tr>
<th>TABLE 5-4</th>
<th>Glasgow Coma Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eye Opening (E)</strong></td>
<td>Does not open eyes</td>
</tr>
<tr>
<td></td>
<td>Opens to painful stimulus</td>
</tr>
<tr>
<td></td>
<td>Opens to voice (command)</td>
</tr>
<tr>
<td></td>
<td>Opens spontaneously</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td><strong>Motor Response (M)</strong></td>
<td>No movement</td>
</tr>
<tr>
<td></td>
<td>Decerebrate posture</td>
</tr>
<tr>
<td></td>
<td>Decorticate posture</td>
</tr>
<tr>
<td></td>
<td>Withdraws from pain</td>
</tr>
<tr>
<td></td>
<td>Localizes pain stimulus</td>
</tr>
<tr>
<td></td>
<td>Obeys commands</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>6</td>
</tr>
<tr>
<td><strong>Verbal Response (V)</strong></td>
<td>No sounds</td>
</tr>
<tr>
<td></td>
<td>Incomprehensible sounds</td>
</tr>
<tr>
<td></td>
<td>Inappropriate words</td>
</tr>
<tr>
<td></td>
<td>Appropriate but confused</td>
</tr>
<tr>
<td></td>
<td>Appropriate and oriented</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
</tbody>
</table>

- Pupillary light reflex—If the pupils are round and symmetrically reactive (constrict to bright light), the midbrain is intact and not the cause of coma. Anisocoria (asymmetric pupils) may be a sign of uncal herniation. Keep in mind that certain eye drops or systemic medications may alter pupil size.
- Eye movements—if the cervical spine is uninjured, perform the oculocephalic test (“doll’s eyes”). When the head is turned to one side, the eyes should move conjugately to the opposite direction if the brainstem is intact.
- If the patient is breathing on her or his own, the brainstem is functioning.

   c. Laboratory tests—CBC, electrolytes, calcium BUN, creatinine, glucose, plasma osmolality, arterial blood gas, ECG.
   d. Toxicologic analysis of blood and urine.
   e. CT or MRI of the brain.
   f. LP—if meningitis or SAH is suspected.
“Locked in” Syndrome
- Mimics coma, because patients are completely paralyzed (with sparing of muscles required for respiration, blinking, and vertical eye movement).
- Patients are fully aware of their surroundings and capable of feeling pain.
- This is usually caused by infarction or hemorrhage of the ventral pons.

C. Treatment
1. Correct reversible causes and treat the underlying problem (if identified)—control airway; give supplemental oxygen, naloxone (for narcotic overdose), dextrose (for hypoglycemia). Give thiamine before a glucose load. Correct any abnormalities in BP, electrolytes, or body temperature.
2. Identify and treat herniation—lowering the ICP is critical.

**CLINICAL PEARL 5-7**

**Brain Death Versus Persistent Vegetative State**
- Criteria for diagnosing brain death:
  - Irreversible absence of brain and brainstem function—unresponsiveness, apnea despite adequate oxygenation and ventilation, no brainstem reflexes (pupils, calorics, gag, cornea, doll’s eyes).
  - No drug intoxication or metabolic condition that can reversibly inhibit brain function.
  - Core body temperature >32°C/89.6°F. Brain death cannot be established in the presence of hypothermia.
  - Clinical evidence or imaging study that provides a causative explanation for brain death.
  - Examinations must be repeated or EEG performed. EEG shows isoelectric activity (electrical silence).
- In most US states, if a patient is proven to be brain dead, the physician has the right to disconnect life support—the patient is legally dead. (Obviously, sensitivity and consideration must be demonstrated to the family. They must be informed and given a chance to say goodbye to their loved one.)
- Patients in a “vegetative state” are completely unresponsive (comatose), but eyes are open and they appear awake. May have random head or limb movements. Patient may have no hope of meaningful recovery but do not meet brain death criteria. Ethical and legal issues surrounding supportive measures are much more complicated.
Demyelinating Disease

Multiple Sclerosis

A. General Characteristics

1. Pathology
   a. Selective demyelination of CNS—multifocal zones of demyelination (plaques) are scattered throughout the white matter. Classic location of plaques is at the angles of the lateral ventricles.
   b. Demyelination primarily involves white matter of the brain and spinal cord; tends to spare the gray matter/axons and the peripheral nervous system. However, improved imaging techniques are showing that cortical demyelination may be more prevalent than previously appreciated.
   c. Commonly involved tracts: pyramidal and cerebellar pathways, medial longitudinal fasciculus, optic nerve, posterior columns.

2. Women are two to three times more likely than men to have MS.
3. Etiology is unknown, but is probably secondary to the interplay of environmental, immunologic, and genetic factors.

B. Clinical Features

1. Transient sensory deficits
   a. Most common initial presentation.
   b. Decreased sensation or paresthesias in upper or lower limbs.
2. Fatigue—one of the most common complaints
3. Motor symptoms—mainly weakness or spasticity
   a. May appear insidiously or acutely.
   b. Caused by pyramidal tract involvement (upper motor neuron involvement).
   c. Spasticity (such as leg stiffness) can impair the patient’s ability to walk and maintain balance.
   d. Can lead to weakness with progression to paraparesis, hemiparesis, or quadriparesis.
4. Visual disturbances
   a. **Optic neuritis**
      - Monocular visual loss (in up to 20% of patients), often with pain during eye movement.
      - May have central scotoma (black spot in center of vision) or decreased pupillary reaction to light.
   b. **Internuclear ophthalmoplegia**—strongly suggests the diagnosis.
      A lesion in the medial longitudinal fasciculus results in ipsilateral medial rectus palsy on attempted lateral gaze (adduction defect) and horizontal nystagmus of abducting eye (contralateral to side of lesion). Diplopia can occur.

5. Cerebellar involvement—can cause ataxia, intention tremor, dysarthria.


7. Autonomic involvement—may present as impotence and/or constipation.

8. Cerebral involvement—may occur in advanced illness and manifests as memory loss, personality change, and emotional lability; anxiety and depression are common.

9. Neuropathic pain—a frustrating but common complaint that manifests as hyperesthesia and trigeminal neuralgia.

**C. Course**

1. Most patients at initial presentation are in their 20s to 30s and present with a localizing deficit such as optic neuritis, one-sided weakness, or numbness. Patients may or may not go on to develop MS. The initial presentation is termed a clinically isolated syndrome, since it is not sufficient to fulfill MS diagnostic criteria.

2. Relapsing-remitting MS is the pattern of flares (relapses) followed by either full recovery or partial recovery with residual deficits, creating a new baseline.

3. Secondary progressive MS often starts with a relapse-remitting pattern, then changes to a gradual worsening of disease that may or may not involve obvious flares.

4. Primary progressive MS has a progressive course of accumulating disability from the onset, and represents about 10% of patients.

**D. Diagnosis**

1. The diagnosis is essentially clinical—suspect it in young adults with relapsing and remitting neurologic signs and symptoms that are difficult to explain (due to
involvement of different areas of CNS white matter). Nevertheless, on suspicion, order the MRI and consider LP (discussed below), because it is important to diagnose MS with as much certainty as possible due to the implications surrounding the management approach.

a. The 2017 McDonald Criteria for the diagnosis of MS requires ruling out more likely neurologic diseases and demonstrating CNS lesions separated in time and space. The diagnosis can be confirmed with only one clinical attack, as long as there is supporting radiologic (MRI) or laboratory (CSF-specific oligoclonal bands) evidence.

2. MRI is the most sensitive test and is diagnostic in the majority of cases.
   a. The number of lesions on the MRI is **not** necessarily proportional to disease severity or speed of progression.

3. LP and CSF analysis—Although no laboratory tests are specific for MS, **oligoclonal bands** of immunoglobulin G are present in 90% of MS patients.

4. Evoked potentials can suggest demyelination of certain areas by measuring the speed of nerve conduction within the brain: newly remyelinated nerves will conduct sensory impulses more slowly.

---

**Quick HIT**

**Diagnostic Tests for MS (helpful hints)**
- MRI is abnormal in 90% of MS patients.
- CSF is abnormal in 90% of MS patients.
- Evoked potentials are abnormal in 90% of MS patients.

---

**E. Treatment**

1. Treatment of acute attacks.
   a. High-dose IV corticosteroids can shorten an acute attack. Oral steroids have not shown the same efficacy.
   b. Plasma exchange may be used for patients with a poor response to steroids.
   c. Studies have shown that treatment of acute exacerbations does not alter the outcome or course of MS.
   d. Most acute attacks resolve within 6 weeks with or without treatment.

2. Disease-modifying therapy.
   a. There are many newer therapies, and management options are evolving. Therapy should be started early to avoid progressive, irreversible disability.
   b. The older injection therapies are effective and include interferon-based therapies (e.g., interferon β-1a) or glatiramer.
   c. Natalizumab is a very effective infusion therapy, especially for those with active disease, though it increased the risk of progressive multifocal
leukoencephalopathy.

d. If convenience is a priority, then oral options include dimethyl fumarate, teriflunomide, and fingolimod.

3. Symptomatic therapy:
   a. Baclofen or dantrolene for muscle spasticity.
   b. Carbamazepine or gabapentin for neuropathic pain.
   c. Treat depression if indicated.

---

**Quick HIT**

There is no cure for MS. There are two primary goals:
- Prevent relapses
- Relieve symptoms of acute exacerbations

**Quick HIT**

IV steroids help hasten recovery of the acute episode in MS but do not result in any improvement in long-term outcome.
Guillain–Barré Syndrome

A. General Characteristics
1. Inflammatory demyelinating polyneuropathy that primarily affects motor nerves, but has many variants (e.g., Miller Fisher syndrome). The most common form of Guillain–Barré syndrome is acute inflammatory demyelinating polyneuropathy.
2. Usually preceded by a viral or mycoplasma infection of the upper respiratory or GI tract. Other common infections include Campylobacter jejuni, CMV, hepatitis, and HIV.
3. May also occur in Hodgkin disease, lupus, after surgery, or after HIV seroconversion.

B. Clinical Features
1. Abrupt onset with rapidly ascending weakness/paralysis of all four extremities; frequently progresses to involve respiratory, facial, and bulbar muscles.
   a. Usually symmetric (but not always).
   b. Weakness may be mild or severe.
   c. Weakness usually progresses from distal to central muscles.
   d. If generalized paralysis is present, it can lead to respiratory arrest.
2. Extremities may be painful, but sensory loss is not typical.
3. Sphincter control and mentation are typically spared.
4. Autonomic features (e.g., arrhythmias, tachycardia, postural hypotension) are dangerous complications.

Quick HIT

Prognosis for Guillain–Barré Syndrome
- Signs of recovery within 1 to 3 weeks after onset favor a good prognosis. If illness continues for a longer period (e.g., beyond 6 weeks), a chronic relapsing course is more likely and prognosis is less favorable.
- It may take months before the patient recovers. A minority of patients experience recurrent attacks, and about 5% die due to respiratory failure, pneumonia, or arrhythmias.

C. Diagnosis
1. CSF analysis—elevated protein, but normal cell count.
2. Electrodagnostic studies—decreased motor nerve conduction velocity.

D. Treatment
1. Carefully monitor pulmonary function. Mechanical ventilation may be necessary.
2. Administer IV immunoglobulin if the patient has significant weakness. If progression continues, plasmapheresis may reduce severity of disease.
3. Do not give steroids. They are not helpful in Guillain–Barré syndrome.
Diagnosis made by a combination of CSF fluid analysis, clinical findings, and nerve conduction velocities.
Neuromuscular Diseases

Myasthenia Gravis

A. General Characteristics

1. **Autoimmune disorder**—Autoantibodies are directed against the nicotinic acetylcholine receptors of the neuromuscular junction, which leads to a reduced postsynaptic response to acetylcholine and results in significant muscle fatigue.
2. Muscles that are stimulated repeatedly (e.g., extraocular muscles) are prone to fatigue.
3. The peak incidence in women is age 20 to 30; in men, 50 to 70. It is more common in women.

---

**Quick HIT**

*In Guillain–Barré syndrome, rapid progression to respiratory failure can occur within hours.* Therefore, a timely and accurate diagnosis is critical. If you suspect Guillain–Barré syndrome, immediately admit the patient to the hospital for monitoring.

---

B. Clinical Features

1. **Skeletal muscle weakness**—with preservation of sensation and reflexes.
   a. Weakness is exacerbated by continued use of muscle and improved by rest (see Clinical Pearl 5-8). Symptoms worsen toward the end of the day (due to fatigue).
   b. Involved muscles vary and may include the following:
      - Cranial muscles: extraocular muscles, eyelids (ptosis), facial muscles (facial weakness, difficulty in chewing, slurred speech).
      - Limb muscles (proximal and asymmetric).
2. Ptosis, diplopia, and blurred vision—most common initial symptoms.
4. The condition progresses slowly with periodic exacerbations. **Myasthenic crisis is a medical emergency that occurs in 15% of patients.** Diaphragm and intercostal fatigue result in respiratory failure, often requiring mechanical ventilation.

---

**Quick HIT**

Myasthenia gravis may be limited to extraocular muscles, especially in elderly patients.

---

C. Diagnosis
1. Acetylcholine receptor antibody test is the test of choice (most specific). Nevertheless, 20% of patients with clinical manifestations of myasthenia gravis may be “antibody negative.”

**CLINICAL PEARL 5-8**

**Lambert–Eaton Myasthenic Syndrome**
- Associated with small cell lung cancer
- Caused by autoantibodies directed against presynaptic calcium channels
- Clinical features include proximal muscle weakness and hyporeflexia
- Distinguished from myasthenia gravis in that symptoms improve with repeated muscle stimulation

2. EMG shows a decremental response to repetitive stimulation of motor nerves.
3. A CT scan of the thorax can rule out thymoma. Thymoma is present in only 10% to 15% of patients, but the thymus is histologically abnormal in 75% of patients.
4. Edrophonium (Tensilon) test—anticholinesterase (AChE) medications cause marked improvement of symptoms, but a high false-positive rate limits utility.

**D. Treatment**

1. AChE inhibitors—for example, pyridostigmine.
   a. Inhibiting AChE increases concentration of acetylcholine at the synapse by decreasing the breakdown of acetylcholine.
   b. This is a symptomatic benefit only.
2. Thymectomy.
   a. This provides a symptomatic benefit and complete remission in many patients, even in the absence of a thymoma.
   b. Although usually benign, thymoma is an absolute indication for thymectomy.
3. Immunosuppressive drugs.
   a. Use corticosteroids for patients with a poor response to AChE inhibitors.
   b. Azathioprine and cyclosporine are alternative third-line agents.
4. Plasmapheresis removes antibodies to acetylcholine receptors. Use it if all else fails or if the patient is in respiratory failure.
5. IV immunoglobulin therapy is now sometimes used for acute exacerbations.
6. Monitor serial forced vital capacities. A forced vital capacity of 15 mL/kg (about 1 L) is generally an indication for intubation. **Patients in myasthenic crisis have a low threshold for intubation—do not wait until the patient is hypoxic.**

**Quick HIT**

Medications that exacerbate symptoms of myasthenia gravis
• Antibiotics—aminoglycosides, fluoroquinolones, and others
• β-Blockers
• Antiarrhythmics—quinidine, procainamide, and lidocaine
Duchenne Muscular Dystrophy

A. General Characteristics
1. X-linked recessive (almost exclusively in males) disease involving a mutation on a gene that codes for the dystrophin protein (dystrophin is absent causing muscle cells to die).
2. Characteristically, there is no inflammation.

B. Clinical Features
1. Muscle weakness is progressive, symmetric, and starts in childhood. Proximal muscles primarily affected (pelvic girdle). Eventually involves the respiratory muscles.
2. Gowers maneuver—patient uses hands to get up from floor because the weakness in the proximal lower extremity muscles makes it difficult to arise without support.
3. Enlarged calf muscles—true muscle hypertrophy at first, followed by pseudohypertrophy as fat replaces muscle.
4. Ultimately results in wheelchair confinement, respiratory failure, and death in third decade.

C. Diagnosis
1. Serum creatine phosphokinase—levels are markedly elevated.
2. DNA testing has now replaced muscle biopsy for diagnosis.

D. Treatment
1. Prednisone is beneficial and is associated with a significant increase in strength, muscle function, and pulmonary function and may reduce risk of scoliosis. Chronic steroid treatment does have side effects, but it is recommended for boys 5 years of age and older whose motor skills are declining.
2. Surgery to correct progressive scoliosis is often necessary once patient becomes wheelchair dependent.

Quick HIT

Other Hereditary Causes of Muscle Weakness
- Mitochondrial disorders: associated with maternal inheritance and ragged red muscle fibers
- Glycogen storage diseases such as McArdle disease (autosomal recessive, muscle cramping after exercise due to glycogen phosphorylase deficiency)
Becker Muscular Dystrophy
Less common than Duchenne muscular dystrophy
Also X-linked recessive
Similar to Duchenne muscular dystrophy, but there is later onset and a less severe course. Some dystrophin is present.
Neurocutaneous Syndromes

***Neurofibromatosis Type I (von Recklinghausen Disease)***

**Autosomal dominant** disease characterized by café au lait spots, neurofibromas, CNS tumors (gliomas, meningiomas), axillary or inguinal freckling, iris hamartomas (*Lisch nodules*), bony lesions.

Cutaneous neurofibromas—may be disfiguring.

Complications include scoliosis, pheochromocytomas, optic nerve gliomas, renal artery stenosis, and erosive bone defects. Musculoskeletal manifestations include spinal deformity and congenital tibial dysplasia.

Complications may require treatment. Surgically excise any symptomatic neurofibromas.

---

**Quick HIT**

Other features that may be present in neurofibromatosis patients (both types)

- Seizures
- Mental retardation, learning disabilities
- Short height
- Macrocephalic
Neurofibromatosis Type II

Autosomal dominant disease; less common than type I neurofibromatosis. Clinical features include bilateral (sometimes unilateral) acoustic neuromas (classic finding), multiple meningiomas, café au lait spots, neurofibromas (much less common than type I), and cataracts.

Quick HIT

In patients with neurofibromatosis, prognosis depends on the type and number of tumors and their location. Most patients can function well.
Tuberous Sclerosis

Usually autosomal dominant.
Present with cognitive impairment, epilepsy, and skin lesions (including facial angiofibromas, adenoma sebaceum).
Retinal hamartomas, renal angiomyolipomas, and rhabdomyomas of the heart may also be present.
Treat complications.
Sturge–Weber Syndrome

Acquired disease.
Key pathologic feature is the presence of capillary angiomatoses of the pia mater.
Classic feature is facial vascular nevi (port-wine stain).
Epilepsy and mental retardation are usually present.
Treatment of epilepsy is often the mainstay of treatment.
Von Hippel–Lindau Disease
Autosomal dominant.  
Important features are cavernous hemangiomas of the brain or brainstem, renal angiomas, and cysts in multiple organs.  
Associated with renal cell carcinoma.  
Associated with pheochromocytomas.
Spinal Cord Diseases

Syringomyelia

Central cavitation of the cervical cord due to abnormal collection of fluid within the spinal cord parenchyma (Figure 5-5). Most commonly associated with Arnold–Chiari malformation. Other causes are posttraumatic, postinfectious, tethered cord, intramedullary tumors. Clinical features—most often asymptomatic and discovered incidentally on MRI obtained for other reasons. Symptoms may include bilateral loss of pain and temperature sensation over the shoulders in a “cape-like” distribution (lateral spinothalamic tract involvement), preservation of touch, thoracic scoliosis and muscle atrophy of the hands may occur. Diagnosed by MRI. Treatment depends on size of syrinx, symptoms, and associated findings (Chiari, tethered cord). Evaluation by neurosurgery recommended.

FIGURE

5.5 Classic lesions of the spinal cord. A: Syringomyelia. B: Hemisection of the spinal cord (Brown-Séquard syndrome).

(From Fix JD. High-Yield Neuroanatomy. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:46, Figure 8-2H and E, respectively.)
Brown-Séquard Syndrome

Spinal cord hemisection (i.e., lesion involving either the right or the left half of the spinal cord), usually at the cervical levels (where spinal cord enlarges) (see Figure 5-5).

Causes include trauma (e.g., fracture, stab wound) that causes hemisection of spinal cord or most commonly, a crush injury to one side of spinal cord, tumors, and abscesses (less common).

Clinical features: **contralateral loss of pain and temperature** (spinothalamic tract), **ipsilateral hemiparesis** (corticospinal tract), and **ipsilateral loss** of position/vibration (dorsal columns).

Prognosis for neurologic recovery is very good.
Transverse Myelitis

This is a rare condition that specifically affects the tracts across the horizontal aspect of the spinal cord at a given level. The thoracic spine is the most commonly involved.
The cause is usually unknown, but it can occur after viral infections. Progression is usually rapid.
Clinical features include lower extremity weakness or plegia, back pain, sensory deficits below the level of the lesion, and sphincter disturbance (especially urinary retention).
MRI with contrast is the imaging study of choice.
High-dose steroid therapy is often used, but evidence supporting its use is equivocal.
The prognosis is highly variable and unpredictable, ranging from full recovery to death.
**Horner Syndrome**

**A. General Characteristics**
1. Results from the interruption of cervical sympathetic nerves
2. Can be preganglionic (central lesions) or postganglionic (distal to superior cervical ganglion); the former is more worrisome and requires more thorough evaluation

**B. Clinical Features**
1. Ipsilateral **ptosis**—mild drooping of lid (levator palpebrae still intact)
2. Ipsilateral **miosis**—“pinpoint pupil”
3. Ipsilateral **anhidrosis** (decreased sweating on forehead)—may be difficult to detect

**C. Causes**
1. Idiopathic (most cases)
2. Pancoast tumor (pulmonary neoplasm of the superior sulcus at lung apex)
3. Internal carotid dissection
4. Brainstem stroke
5. Neck trauma (cervical spine injury)
Poliomyelitis

Poliovirus affects the anterior horn cells and motor neurons of spinal cord and brainstem. Causes lower motor neuron involvement. Characteristic features include asymmetric muscle weakness (legs more commonly involved); absent deep tendon reflexes; flaccid, atrophic muscles; and normal sensation.

Bulbar involvement (of CN IX and CN X) in 10% to 15% of cases can lead to respiratory and cardiovascular impairment.

No treatment is available, although poliomyelitis is entirely preventable by vaccination.
Miscellaneous Conditions

Vertigo

A. General Characteristics (Clinical Pearl 5-9)
1. Vertigo refers to a disturbance of the vestibular system characterized by a sensation of spinning or hallucination of movement.
2. It is important to identify the common complaint of “dizziness” as vertigo (“room spinning”) or lightheadedness (presyncopal symptoms from cerebral hypoperfusion).
3. The initial goal is to determine whether the cause of the vertigo is peripheral (inner ear) or central (e.g., tumor, CVA).
4. Peripheral vertigo is usually benign, but central vertigo can have serious consequences.
5. For patient with ongoing symptoms (continuous vertigo), perform a HINTS test to rule out brainstem or cerebellar stroke. HINTS is a three-part test and stands for Head Impulse, Nystagmus, and Test for Skew. The presence of all three of the following suggests a peripheral lesion, and is accurate in ruling out a central lesion: abnormal head impulse test, the presence of unidirectional, horizontal, or torsional nystagmus, and absent skew.

Quick HIT
In a patient with vertigo, goal is to differentiate between peripheral (benign) and central (worrisome) vertigo (see Table 5-5). The HINTS exam may help differentiate central from peripheral vertigo and may be more sensitive than MRI for acute stroke!

B. Types of Peripheral Vertigo
1. Benign positional vertigo (BPV).
   a. Vertigo is experienced only in specific positions or during change in position and lasts for a few moments. It has an abrupt onset as soon as the particular position is assumed.
   b. Usually presents in patients over 60 years old. Treat with meclizine.
   c. Recovery is usually complete (resolves within 6 months).

Quick HIT
Hearing loss and tinnitus only occur with peripheral vertigo. Focal neurologic problems only occur with central vertigo.
   a. Triad of **vertigo, tinnitus, and hearing loss**.
   b. Attacks may last for hours to days and recur several months or years later.
   c. The hearing loss eventually becomes permanent.
   d. Treat with sodium restriction and diuretics.
3. Acute labyrinthitis—due to viral infection of the cochlea and labyrinth; may last for several days.
4. Ototoxic drugs (aminoglycosides, some loop diuretics).
5. Acoustic neuroma (schwannoma) of the 8th cranial nerve—ataxia, gait unsteadiness, nystagmus, hearing loss, tinnitus.

**Quick HIT**

Meclizine is useful for vertigo and as an antiemetic. It has anticholinergic and antihistamine effects.

**CLINICAL PEARL 5-9**

**Vertigo**

**Central Vertigo**
- Gradual onset; other neurologic (brainstem) findings are present in most cases (e.g., weakness, hemiplegia, diplopia, dysphagia, dysarthria, facial numbness). Look for cardiovascular risk factors.
- Accompanying nystagmus can be bidirectional or vertical (does not occur in peripheral vertigo).

**Peripheral Vertigo**
- Lesions are cochlear or retrocochlear.
- Abrupt onset, nausea/vomiting, head position has strong effect on symptoms. Other brainstem deficits are absent, except for tinnitus/hearing loss.

**TABLE 5-5 Central Versus Peripheral Vertigo**

<table>
<thead>
<tr>
<th>Central Vertigo</th>
<th>Peripheral Vertigo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gradual onset</td>
<td>Sudden onset</td>
</tr>
<tr>
<td>Mild intensity</td>
<td>Severe intensity</td>
</tr>
<tr>
<td>Mild nausea/vomiting</td>
<td>Intense nausea/vomiting</td>
</tr>
<tr>
<td>Associated neurologic findings typically present</td>
<td>No associated neurologic findings</td>
</tr>
<tr>
<td>Mild nystagmus</td>
<td>Relatively intense nystagmus</td>
</tr>
<tr>
<td>Position change has mild effect</td>
<td>Position change has intense effect</td>
</tr>
<tr>
<td>No refractoriness—can repeat the “tilt” test and patient responds every time</td>
<td>Rapidly refractory—cannot repeat the “tilt” test; patient will not respond again</td>
</tr>
<tr>
<td>Patient falls to same side as lesion</td>
<td>Patient falls to same side as lesion</td>
</tr>
</tbody>
</table>
C. Causes of Central Vertigo

1. MS—demyelination of vestibular pathways of brainstem
2. Vertebrobasilar insufficiency
3. Migraine-associated vertigo—headache may or may not be present
Syncope

A. General Characteristics
1. Syncope refers to a transient loss of consciousness/postural tone secondary to acute decrease in cerebral blood flow. It is characterized by rapid recovery of consciousness without resuscitation.
2. Seizure is a cause of acute altered mental status, but is not technically a cause of syncope.

B. Causes
1. Cardiac
   a. Cardiac syncope is usually sudden and without prodromal symptoms—for example, the patient’s face hits the floor.
   b. A cardiac cause of syncope is the most important to consider and rule out, since syncope may be the first manifestation of a life-threatening cardiac condition.
   c. Causes
      • Arrhythmias (e.g., sick sinus syndrome, ventricular tachycardia, AV block, rapid supraventricular tachycardia).
      • Obstruction of blood flow (e.g., aortic stenosis, hypertrophic cardiomyopathy, pulmonary HTN, atrial myxoma, prolapsed mitral valve, severe asymmetric septal hypertrophy).
      • Pulmonary embolism can theoretically cause sudden obstruction of blood flow and temporary cerebral hypoperfusion, leading to syncope. The PESIT trial in 2016 found that for high risk patients admitted to the hospital for syncope, 1 in 6 patients were found to have a PE (these findings indicate that PE is more common in this patient group than previously appreciated, though this trial does not necessarily prove that the PE was the cause of syncope).

2. Vasovagal syncope (“neurocardiogenic,” or “reflex syncope”)
   a. Most **common cause of syncope**; may account for up to 50% of all cases of syncope.
   b. Most people have one episode, but for some it is a recurrent problem.
   c. Clues to diagnosis
      • Emotional stress, pain, fear, extreme fatigue, or claustrophobic situations as precipitating factors.
      • Premonitory symptoms (pallor, diaphoresis, lightheadedness, nausea, dimming
of vision, roaring in the ears).

- Can occur at any age, but if the first episode is after age 40, be reluctant to make this diagnosis.

- **Tilt-table study can reproduce the symptoms in susceptible people.**


d. **Pathophysiology**

- Normally, standing up causes blood to pool in the lower extremities (leading to a decrease in cardiac output, stroke volume, and BP). These changes are compensated for by increased sympathetic tone (leading to vasoconstriction and tachycardia), and decreased parasympathetic tone.

- In patients with vasovagal syncope, the compensatory response is interrupted in a few minutes by a paradoxical withdrawal of sympathetic stimulation and a replacement by enhanced parasympathetic (vagal) activity. This leads to an inappropriate bradycardia, vasodilation, marked decrease in BP, and cerebral perfusion.

e. **Treatment**

- Can usually be reversed by assuming the supine posture and elevating the legs.
- β-Blockers and disopyramide.
- Prognosis is excellent (there is no heart disease or arrhythmias).

f. **Prevention**—avoid circumstances that precipitate attack.

---

**Quick HIT**

Vasovagal and orthostatic syncope occur when the patient is upright (sitting up or standing). They do not occur when the patient is recumbent.

---

**3. Orthostatic hypotension**

a. Causes include intravascular volume depletion, autonomic insufficiency (e.g., primary autonomic insufficiency from Parkinson disease, or secondary from diabetes), age-related loss of vasomotor reflexes, and drugs.

b. Common in elderly people; diabetics (autonomic neuropathy); patients taking ganglionic-blocking agents, vasodilators, diuretics.

c. Sudden standing and prolonged standing are the precipitating causes.

d. It is also associated with premonitory symptoms (lightheadedness, nausea, etc.).

e. Treat with increased sodium intake and fluids. Consider fludrocortisone if recurrent. Remember to treat other underlying causes if identified (such as withdrawal of offending medication).

---

**Quick HIT**

If syncope occurs with exertion, assess for potentially life-threatening causes such as hypertrophic
cardiomyopathy or aortic stenosis.

**Quick HIT**

Syncope is uncommon in setting of a stroke, unless the vertebrobasilar system is involved.

4. Severe cerebrovascular disease  
   a. A rare cause of syncope.  
   b. A TIA involving the **vertebrobasilar** circulation may lead to syncope (“drop attacks”).  
   c. One practically never sees dizziness (or vertigo) in isolation with vertebrobasilar insufficiency—there will always be other deficits as well.

**Quick HIT**

**Evaluating syncope**
- The most important factors in decision making in syncope patients are presence/absence of structural heart disease and abnormal ECG.

**C. Diagnosis**

1. First, attempt to rule out conditions that are life threatening (e.g., MI, hemorrhage, and arrhythmias) (**Figure 5-6**).
2. The main goal is to **differentiate between cardiac and noncardiac etiologies**, because the prognosis is poorest for those with underlying heart disease.
3. History  
   a. Three key elements need to be determined: events before, during, and after the syncopal episode.  
   b. Check the patient’s medications—this is especially important in elderly patients.  
   c. Seek reports from witnesses of the syncopal event.
4. Physical examination (priority given to cardiovascular system)  
   a. BP and pulse measurements in supine, sitting, and standing positions (orthostatic vital signs).  
   b. Mental status (postictal state).  
   c. Murmurs (aortic stenosis, hypertrophic cardiomyopathy).
5. Diagnosis  
   a. **ECG** should be obtained in all patients with syncope, and may identify life-threatening causes (ventricular tachycardia, other arrhythmias, ischemia).  
   b. CBC, metabolic panel, and other labs based on the history and physical may be appropriate.  
   c. Echocardiography if structural heart disease is suspected.
d. Additional diagnostic tests may be indicated, and include ambulatory ECG monitoring, exercise testing, carotid sinus massage, neurologic studies such as EEG or neurovascular imaging, and electrophysiologic studies. Tilt-table testing was frequently used to diagnose vasovagal syncope in the past, but is now controversial.

**FIGURE 5.6 Syncope flowchart.**

(Adapted from Heaven DJ, Sutton R. Syncope. Crit Care Med 2000;28(10 Suppl):118, Fig. 1.
Copyright © 2000 Lippincott Williams & Wilkins.)
Seizures

A. General Characteristics

1. A seizure occurs when there is a sudden abnormal discharge of electrical activity in the brain (see Clinical Pearl 5-10).
2. The diagnosis of epilepsy is reserved for a syndrome of recurrent, idiopathic seizures. The ultimate cause of seizures in epilepsy is unknown.

B. Causes (four M’s, four I’s)

1. Metabolic and electrolyte disturbances—hyponatremia, water intoxication, hypoglycemia or hyperglycemia, hypocalcemia, uremia, thyroid storm, hyperthermia.
3. Missing drugs.
   a. Noncompliance with anticonvulsants in patients with epilepsy—this is the most common reason for poor seizure control in epileptics.
   b. Acute withdrawal from alcohol, benzodiazepines, barbiturates.

CLINICAL PEARL 5-10

Important Aspects of H & P in a Patient Presenting With a Seizure

- Acquire a description of the seizure from bystanders (e.g., postictal state, loss of continence).
- Determine what is the baseline state for the patient. Is the patient a known epileptic? Look into missed doses of antiepileptics, or any recent change in dosages/medications.
- Examine the patient for any injuries—head or spine, fractures, posterior shoulder dislocation, tongue lacerations, bowel/bladder incontinence.
- Look for signs of increased ICP.
- Perform a complete neurologic examination.

4. Miscellaneous

   a. Pseudoseizures—not true seizures but are psychiatric in origin; are often difficult to distinguish from true seizures without an EEG.
   b. Eclampsia—A preeclamptic pregnant woman seizing no longer has preeclampsia! The only definitive treatment for eclampsia is delivery, but a magnesium infusion is the pharmacologic treatment of choice.
   c. Hypertensive encephalopathy—severe hypertension can cause cerebral edema.
5. Intoxications—cocaine, lithium, lidocaine, theophylline, metal poisoning (e.g., mercury, lead), carbon monoxide poisoning.
6. Infections—septic shock, bacterial or viral meningitis, brain abscess.
7. Ischemia—stroke, TIA (common cause of seizure in elderly patients).
8. Increased ICP—for example, due to trauma.
C. Types of Epileptic Seizures

1. Partial seizure—accounts for 70% of patients with epilepsy older than 18 years of age (Figure 5-7). It begins in one part of the brain (typically the temporal lobe) and initially produces symptoms that are referable to the region of the cortex involved.
   
a. Simple partial seizure.
   
   - **Consciousness remains intact.** The seizure remains localized but may evolve into a complex partial seizure.
   - May involve transient unilateral clonic–tonic movement.

b. Complex partial seizure.
   
   - **Consciousness is impaired;** postictal confusion.
   - Automatisms (last 1 to 3 minutes)—purposeless, involuntary, repetitive movements (such as lip smacking or chewing); patients may become aggressive if restraint is attempted.
   - Olfactory or gustatory hallucinations.

Quick HIT

Partial seizures may evolve into generalized seizures. When this happens, it is called **secondary generalization.**

Quick HIT

It is important (although sometimes difficult) to differentiate between absence (petit mal) and complex partial seizures because their treatments are different. Also, absence seizures disappear in adulthood, whereas complex partial seizures do not.

2. Generalized seizure—characterized by **loss of consciousness.** Involves disruption of electrical activity in the entire brain.
   
a. Tonic–clonic (grand mal) seizure—bilaterally symmetric and without focal onset.
   
   - Begins with sudden loss of consciousness—a fall to the ground.
   - Tonic phase—The patient becomes rigid; trunk and limb extension occurs. The patient may become apneic during this phase.
   - Clonic phase—This is musculature jerking of the limbs and body for at least 30 seconds.
   - The patient then becomes flaccid and comatose before regaining consciousness.
   - Postictal confusion and drowsiness are characteristic and can last for hours, although 10 to 30 minutes is more typical.
   - Other features may include tongue biting, vomiting, apnea, and incontinence
b. Absence (petit mal) seizure.
   - Typically involves school-age children—usually resolves as child grows older.
   - Patient seems to disengage from current activity and “stare into space”—then returns to the activity several seconds later; patient looks “absent minded” during these episodes, which are often confused with “daydreaming.”
   - Episodes are brief (lasting a few seconds) but may be quite frequent (up to 100 times per day).
   - Impairment of consciousness but no loss of postural tone or continence, and no postictal confusion.
   - Minor clonic activity (eye blinks or head nodding) in up to 45% of cases.

D. Diagnosis
1. If the patient has a known seizure disorder (epileptic), check anticonvulsant levels
   —This is usually the only test that is needed. Because therapeutic anticonvulsant levels are variable, one dose may be toxic for one patient and therapeutic for
another. Therefore, take the range given in laboratory reports as a general guideline.

2. If the patient history is unclear or if this is the patient’s first seizure:
   a. CBC, electrolytes, blood glucose, LFTs, renal function tests, serum calcium, urinalysis.
   b. EEG
      • Although the EEG is the most helpful diagnostic test in the diagnosis of a seizure disorder, an abnormal EEG pattern alone is not adequate for the diagnosis of seizures.
      • A normal EEG in a patient with a first seizure is associated with a lower risk of recurrence.
   c. CT scan of the head—to identify a structural lesion.
   d. MRI of the brain—with and without gadolinium (first without).
      • An important part of the workup of a patient with a first seizure.
      • More sensitive than a CT scan in identifying structural changes, but not always practical (e.g., in an unstable patient).
   e. LP and blood cultures—if patient is febrile.

### Quick HIT

<table>
<thead>
<tr>
<th>Laboratory Values to Check Immediately in an Unfamiliar, Seizing Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum calcium</td>
</tr>
</tbody>
</table>

### E. Treatment

1. General principles.
   a. For all seizures, ABCs take priority: Secure airway and roll patient onto his side to prevent aspiration.
   b. Patients with a history of seizures (epilepsy).
      • Seizures in these patients are usually due to noncompliance with anticonvulsant therapy. (Even one missed dose can result in subtherapeutic levels.) Give a loading dose of the anticonvulsant medication and continue the regular regimen as before.
      • These patients should be chronically managed by a neurologist. Treatment with one of the standard antiepileptic drugs provides adequate control in 70% of adult patients. In another 15% to 20%, a combination regimen controls seizures.
      • If seizures persist, increase the dosage of the first anticonvulsant until signs of
toxicity appear. Add a second drug if the seizures cannot be controlled with the drug of first choice.

- If the seizures are controlled, have the patient continue the medication for at least 2 years. If the patient remains seizure free, taper the medication(s) cautiously. Confirm this decision with a lack of seizure activity on the EEG.

**Quick HIT**

**Status Epilepticus**
- Refers to prolonged, sustained unconsciousness with persistent convulsive activity in a seizing patient
- A medical emergency, with a mortality rate of up to 20%
- May be caused by poor compliance with medication, alcohol withdrawal, intracranial infection, neoplasm, a metabolic disorder, or a drug overdose
- Management involves establishing an airway, and giving IV diazepam, IV phenytoin, and 50-mg dextrose. Treat resistant cases with IV phenobarbital.

c. Patient with a first seizure.
   - EEG and neurology consult—first steps.
   - Anticonvulsant therapy—weigh risks and benefits of treatment and the risk of recurrence before initiating.
   - With a normal EEG, the risk of recurrence is relatively low (15% in the first year), compared to the risk with an abnormal EEG (41% in the first year).
   - Do not treat patients with a single seizure. Antiepileptic drugs are started if EEG is abnormal, brain MRI is abnormal, patient is in status epilepticus.

2. Anticonvulsant agents.
   a. For generalized tonic–clonic seizures and partial seizures:
      - **Phenytoin and carbamazepine are the drugs of choice.** They are equally effective, and side-effect profiles are similar.
      - Other options include phenobarbital, valproate, and primidone.
   b. For petit mal (absence) seizures, ethosuximide and valproic acid are the drugs of choice.

**Quick HIT**

Remember that anticonvulsants are teratogenic. (Do a pregnancy test before prescribing!)
Amyotrophic Lateral Sclerosis or “Lou Gehrig Disease”

A. General Characteristics
1. A disorder affecting the anterior horn cells and corticospinal tracts at many levels. Corticobulbar involvement is common as well. **The presence of upper and lower motor neuron signs is a hallmark of amyotrophic lateral sclerosis (ALS).** Note that only the motor system is involved.
2. Onset is usually between 50 and 70 years of age. (Lou Gehrig was unusually young [in his 30s] when the disease developed.) Occurrence of ALS before age 40 is uncommon.
3. Only 10% of cases are familial, with the remainder being sporadic.
4. Prognosis is dismal: 80% mortality rate at 5 years; 100% mortality rate at 10 years.

**Quick HIT**
Initially ALS can involve virtually any muscle, but as the disease progresses, every region of the body becomes symmetrically involved.

B. Clinical Features
1. **Progressive muscle weakness is the hallmark feature**
   a. Usually first noted in the legs or arms, but then spreads to other muscle groups
   b. No associated pain
   c. Muscle atrophy
2. Muscle cramps and spasticity
3. Fasciculations (unnoticed by patient)
4. Impaired speech and swallowing; dysphagia can lead to aspiration
5. Respiratory muscle weakness—dyspnea on exertion, and later, at rest; orthopnea; sleep apnea; end-stage ALS is characterized by respiratory failure
6. Weight loss and fatigue
7. The following are normal and unaffected, even in late stages:
   a. Bowel and bladder control
   b. Sensation
   c. Cognitive function
   d. Extraocular muscles
   e. Sexual function

C. Diagnosis
1. There is no specific diagnostic test for ALS. EMG and nerve conduction studies can confirm degeneration of lower motor neurons and can rule out neuromuscular
junction disorders.
2. Clinical or electrical evidence
   a. Involvement of two regions (probable ALS)
   b. Involvement of three to four regions (definite ALS)—affected regions include bulbar (face, larynx, tongue, jaw), cervical, thoracic, and lumbosacral

D. Treatment
1. Treatment has been very disappointing and is mainly supportive.
2. Riluzole is a glutamate-blocking agent—it may delay death by only 3 to 5 months.
Aphasia

A. General Characteristics

1. Aphasia is the **loss or defect of language** (e.g., in speaking, fluency, reading, writing, comprehension of written or spoken material).
2. Most lesions that cause aphasia involve the **dominant hemisphere**.
   a. In 95% of right-handed people, the left cerebral hemisphere is dominant for language.
   b. In 50% of left-handed people, the left hemisphere is dominant for language (however, the right hemisphere also has language functions in most left-handed people).
3. There are four types of aphasia (described below): Wernicke aphasia, Broca aphasia, conduction aphasia, and global aphasia.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMG and Nerve Conduction Studies</strong></td>
</tr>
<tr>
<td>• EMG measures the contractile properties of skeletal muscles</td>
</tr>
<tr>
<td>• Lower motor neuron lesions: fibrillations and fasciculations at rest</td>
</tr>
<tr>
<td>• Myopathy: No electrical activity at rest (as expected), but amplitude decreases with muscle contraction</td>
</tr>
<tr>
<td>• Nerve conduction studies</td>
</tr>
<tr>
<td>• Demyelination decreases nerve conduction velocity (MS, Guillain–Barré syndrome)</td>
</tr>
<tr>
<td>• Repetitive stimulation causes fatigue (myasthenia gravis)</td>
</tr>
</tbody>
</table>

B. Causes

1. Stroke (most common cause)
2. Trauma to brain
3. Brain tumor
4. Alzheimer disease

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>The most common cause of aphasia is cerebrovascular disease. In aphasia, when speech is fluent, the lesion is posterior to the central sulcus. When speech is nonfluent, the lesion is anterior to the central sulcus.</td>
</tr>
</tbody>
</table>

C. Types of Aphasia

1. Wernicke aphasia
   a. Receptive, fluent aphasia
   b. **Impaired comprehension of written or spoken language (key feature)**
   c. **Speech is grammatically correct and is fluid but does not make much sense.**
      Patients articulate well but often use the wrong words because they cannot
understand their own words.

2. Broca aphasia
   a. Expressive, nonfluent aphasia
   b. Speech is slow and requires effort
   c. The patient uses short sentences (as few words as possible) without grammatical construction. The content is appropriate and meaningful
   d. Good comprehension of language (written and spoken)
   e. Often associated with a right hemiparesis and hemisensory loss

3. Conduction aphasia
   a. Disturbance in repetition
   b. Pathology involves the connections between Wernicke and Broca areas

4. Global aphasia
   a. Disturbance in all areas of language function (e.g., comprehension, speaking, reading, fluency)
   b. Often associated with a right hemiparesis

D. Treatment of Aphasia
   1. Most patients spontaneously recover or improve within the first month.
   2. Speech therapy is helpful, but is unlikely to be of much benefit after the first few months.
Bell Palsy

A. General Characteristics
1. This refers to hemifacial weakness/paralysis of muscles innervated by CN VII due to swelling of the cranial nerve.
2. The prognosis is very good; 80% of patients recover fully within weeks to months.

B. Causes
1. Cause is often uncertain.
2. Possible viral etiology (herpes simplex)—immunologic and ischemic factors implicated as well.
3. Upper respiratory infection is a common preceding event.

C. Clinical Features
There is acute onset of unilateral facial weakness/paralysis. Both upper and lower parts of the face are affected.

D. Diagnosis
1. Diagnosis is clinical, but consider Lyme disease in endemic areas as the treatment approach is different.
2. Do not use steroids if Lyme is suspected!
3. Consider EMG testing if paresis fails to resolve within 10 days.

E. Treatment
1. Usually none is required, as most cases resolve in 1 month.
2. Short course of steroid therapy (prednisone) and acyclovir, if necessary.
3. Patient should wear eye patch at night to prevent corneal abrasion (cornea is exposed due to weakness of orbicularis oculi muscle).
4. Surgical decompression of CN VII is indicated if the paralysis progresses or if tests indicate deterioration.

Quick HIT
Differential Diagnosis for Facial Nerve Palsy
- Trauma (e.g., temporal bone, forceps delivery)
- Lyme disease
- Tumor (acoustic neuroma, cholesteatoma, neurofibroma)
- Guillain–Barré syndrome (palsy is usually bilateral)
- Herpes zoster
Trigeminal Neuralgia (Tic Douloureux)

A. General Characteristics
1. Trigeminal neuralgia is one of the most painful conditions known to mankind.
2. Usually idiopathic in origin.

B. Clinical Features
1. Brief (seconds to minutes) but frequent attacks of severe, lancinating facial pain
2. Involves the jaw, lips, gums, and maxillary area (ophthalmic division is less commonly affected)
3. Recurrent attacks may continue for weeks at a time.
4. No motor or sensory paralysis

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trigeminal Neuralgia</td>
</tr>
<tr>
<td>• Complete, spontaneous resolution in 85% of cases</td>
</tr>
<tr>
<td>• Mild residual disease in 10% of cases</td>
</tr>
<tr>
<td>• No resolution in 5% of cases</td>
</tr>
</tbody>
</table>

C. Diagnosis
1. Clinical diagnosis
2. MRI—to rule out cerebellopontine angle tumor

D. Treatment
1. Drug of choice is *carbamazepine* (usually effective in relieving pain); other choices are baclofen and phenytoin, either alone or in combination with carbamazepine.
2. Consider surgical decompression if medical therapy fails.
3. Patients typically experience a remitting/relapsing course. Over time, pain may become more refractory to treatment.
How to Localize a Neurologic Lesion

A. Introduction
1. Generally, neurologic deficits can be localized to one of the following 10 sites:
   a. Cerebral cortex
   b. Subcortical area
   c. Cerebellum
   d. Brainstem
   e. Spinal cord
   f. Plexus (plexopathy)
   g. Roots (radiculopathy)
   h. Peripheral nerve (peripheral neuropathy)
   i. Neuromuscular junction
   j. Muscle (myopathy)
2. Lesions in each of the above sites present with different neurologic findings. A good understanding of the deficits that accompany each lesion can help with localization.

B. Cerebral Cortex
1. Lesions in the cerebral cortex often cause two main deficits:
   a. **Contralateral** motor or sensory deficits (depending on which region of the cortex is involved)
   b. Aphasia
2. The hemiparesis seen with cortical lesions primarily affects the face, arms, and trunk. The legs may be affected, but typically that deficit is not as severe. This is because the neurons that control the lower extremities are in the interhemispheric fissure (see homunculus in Figure 5-8).
3. Aphasia is common when the left hemisphere is involved. Visual-spatial deficits are more common when the right hemisphere is involved.

C. Subcortical Lesions
1. These involve the internal capsule, cerebral peduncles, thalamus, and pons.
2. The hemiparesis is usually **complete** (face, arm, leg) because the neurons controlling these structures all merge together subcortically and are very close together.

D. Cerebellum
Incoordination, intention tremor, ataxia

E. Brainstem
1. Cranial nerve and spinal cord findings.
2. There is a crossed hemiplegia (deficit on ipsilateral face and contralateral body) because the corticospinal tract, dorsal columns, and spinothalamic tracts cross but the cranial nerves do not.

F. Spinal Cord
1. With acute injuries, spinal shock may be present and upper motor neuron signs may not be apparent initially.
2. The patient presents with upper motor neuron signs (spasticity, increased deep tendon reflexes, clonus, positive Babinski sign), but these signs may be present with lesions in the brainstem and cortical/subcortical regions as well.
3. There is a decrease in sensation below a sharp band in the abdomen/trunk. A pinprick is felt above this level but not below it. This is pathognomonic for spinal cord disease—the level of the lesion corresponds to the sensory level.

G. Plexus (Plexopathy)
1. Deficits (motor and sensory) involve more than one nerve. Findings are variable depending on which part of the plexus is involved.
2. Trauma is the most common cause overall, especially for the brachial plexus. A postsurgical hematoma in the pelvis is a more common cause in lumbosacral plexopathy.
3. Plexuses that are commonly involved include:
   a. Brachial plexus—Erb–Duchenne type is the more common (upper trunk—C5-6 roots). Lower trunk (C8-T1) is less common.
   b. Lumbosacral plexus (L5-S3).

H. Roots (Radiculopathy)
1. Pain is a key finding.
2. This affects a group of muscles supplied by a spinal root (myotome) and a sensory area supplied by a spinal root (dermatome). Therefore, the distribution of affected areas can help differentiate this from a peripheral neuropathy or a plexopathy.
3. Patients may present with weakness, atrophy, and sensory deficits in a dermatomal pattern; may include fasciculations and diminished deep tendon reflexes.
Postcentral gyrus
- Leg area
- Trunk area
- Arm area
- Head area
- Face area
- Thalamus

Somesthetic cortex

Medial lemniscus

Midbrain

Medial lemniscus

Pons

Medial lemniscus

Medulla

Decussation of medial lemniscus at the junction between the spinal cord and the brainstem

Cervical cord

Lumbosacral cord
A: Dorsal column–medial lemniscus pathway.

(A from Fix JD. High-Yield Neuroanatomy. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:39, Figure 7-2.)
FIGURE 5.8 B: The lateral spinothalamic tract.
(B from Fix JD. *High-Yield Neuroanatomy*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:41, Figure 7-3.)
Motor cortex (precentral gyrus)

Corticospinal tract

Midbrain

Pons

Medulla

Pyramid

Lateral corticospinal tract

Decussation occurs at the junction between the spinal cord and the brainstem

Spinal cord
I. Peripheral Nerve (Peripheral Neuropathy)

1. Weakness is more prominent distally at the outset (as opposed to muscle myopathy [see below])—**usually asymmetric**.
2. Presents with diminished deep tendon reflexes; may include sensory changes (numbness, paresthesias, tingling), muscle atrophy, and fasciculations.
3. Can be due to diabetes (nerve infarction), trauma, entrapment, or vasculitis.
4. Common neuropathies include radial/ulnar/median/musculocutaneous nerves, long thoracic nerve, axillary nerve, common peroneal nerve, and femoral nerve.

J. Neuromuscular Junction

1. Fatigability is the key finding. Muscles become weaker with use and recover with rest.
2. Normal sensation, no atrophy

K. Muscle (Myopathy)

1. Myopathy refers to acquired disease (dystrophy to inherited conditions).
2. Symmetric weakness affects proximal muscles more than distal muscles (shoulders and hip muscles).
3. Presents with normal reflexes, but these may diminish late in the disease in comparison to muscle weakness.
4. **Normal sensation**, no fasciculations.
5. Muscle atrophy may occur late due to disuse (in contrast to rapid atrophy in motor neuron disease).
Connective Tissue and Joint Diseases

Emily Liang
Connective Tissue Diseases

Systemic Lupus Erythematosus

A. General Characteristics

1. An autoimmune disorder leading to inflammation and tissue damage in multiple organ systems.
2. Systemic lupus erythematosus (SLE) is an idiopathic chronic inflammatory disease with genetic, environmental, and hormonal factors.
3. The pathophysiology involves autoantibody production, deposition of immune complexes, complement activation, and accompanying tissue destruction/vasculitis.

Quick HIT

Epidemiology of SLE
- Women of childbearing age account for 90% of cases, but men have more severe disease.
- African-American patients are more frequently affected than Caucasian patients.
- Milder in elderly patients; more severe in children.
- Usually appears in late childhood or adolescence.

4. Types
   a. Spontaneous SLE.
   b. Cutaneous lupus erythematosus (skin lesions without systemic disease)
   c. Drug-induced lupus
   d. ANA-negative lupus—associated findings
      - Arthritis, Raynaud phenomenon, subacute cutaneous lupus
      - Serology: Ro (anti-SS-A) or antiphospholipid antibody-positive, ANA negative
      - Risk of neonatal lupus in infants of affected women
      - ANA negativity can be influenced by laboratory testing methods, disease duration, and treatment

Quick HIT

Clinical Findings Associated With Neonatal Lupus
- Skin lesions
- Cardiac abnormalities (AV block, transposition of the great vessels)
- Valvular and septal defects

B. Clinical Features
1. Constitutional symptoms: Fatigue, malaise, fever, weight loss
2. Cutaneous: Butterfly rash (erythematous rash over cheeks and bridge of nose—found in one-third of patients) (Figure 6-1), photosensitivity, discoid lesions (erythematous raised patches with keratotic scaling), oral or nasopharyngeal ulcers, alopecia, Raynaud phenomenon (vasospasm of small vessels when exposed to cold, usually in fingers—found in about 20% of cases)
3. Musculoskeletal: Arthralgias (may be the first symptom of the disease—found in 90% of patients), arthritis (inflammatory and symmetric, rarely deforming as in rheumatoid arthritis [RA]), myalgia with or without myositis
4. Cardiac: Pericarditis, endocarditis (Libman–Sacks endocarditis is a serious complication), myocarditis
5. Pulmonary: Pleuritis (most common pulmonary finding), pleural effusion, pneumonitis (may lead to fibrosis), pulmonary HTN (rare)
6. Hematologic: Hemolytic anemia with anemia or reticulocytosis of chronic disease, leukopenia, lymphopenia, thrombocytopenia
7. Renal: Proteinuria >0.5 g/day (may have nephrotic syndrome), cellular casts, glomerulonephritis (may have hematuria), azotemia, pyuria, uremia, HTN
8. Immunologic: Impaired immune response due to many factors, including autoantibodies to lymphocytes, abnormal T-cell function, and immunosuppressive medications; often associated with antiphospholipid syndrome
9. GI: Nausea/vomiting, dyspepsia, dysphagia, peptic ulcer disease
10. CNS: Seizures, psychosis (may be subtle), depression, headaches, TIA, cerebrovascular accident
11. Other findings include conjunctivitis and an increased incidence of Raynaud phenomenon and Sjögren syndrome
FIGURE

6.1 SLE butterfly rash.
(From Goodheart HP. Goodheart's Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 25.24.)

Quick HIT

Clinical Course of SLE
- A chronic disease characterized by exacerbations and remissions
- Malar rash, joint pain, and fatigue are the most common initial findings. With more advanced disease, renal, pulmonary, cardiovascular, and nervous systems are affected.

C. Diagnosis

1. Diagnosis is made based on the 2012 SLICC criteria. The patient must have at least 4 criteria (at least 1 clinical criteria and 1 immunologic criteria) OR biopsy-proven lupus nephritis with a positive ANA or anti-dsDNA.

2. Autoantibodies in lupus:
   a. **ANA:** Sensitive but not specific; almost all patients with SLE have elevated serum ANA levels (see Clinical Pearl 6-1, Figure 6-2, and Table 6-1)
   b. Anti-ds DNA (in 70%): very specific (but not sensitive)
   c. Anti-Smith (in 30%): very specific (but not sensitive) (see Table 6-2)
   d. Antiphospholipid antibody positivity, as determined by positive lupus anticoagulant, false-positive RPR, medium- or high-titer anticardiolipin antibody
level, or positive anti-β-2 glycoprotein (see Clinical Pearl 6-2)
e. **Antihistone Abs** (in 70%) are present in >95% of cases of **drug-induced lupus** (see Clinical Pearl 6-3). If negative, drug-induced lupus can be excluded.
f. **Ro (SS-A) and La (SS-B)** are found in 15% to 35%. Associated with:
   - Sjögren syndrome
   - Subacute cutaneous SLE
   - Neonatal lupus (with congenital heart block)
   - Complement deficiency (C2 and C4)
   - ANA-negative lupus

---

**CLINICAL PEARL 6-1**

**Useful Criteria for Diagnosing SLE**

**2012 SLICC Criteria:**
Clinical criteria, in the absence of other causes:

1. Acute cutaneous lupus
2. Chronic cutaneous lupus
3. Oral or nasal ulcers
4. Nonscarring alopecia
5. Synovitis involving two or more joints
6. Serositis
7. Renal: urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500-mg protein over 24 hours OR red blood cell casts
8. Neurologic
9. Hemolytic anemia
10. Leukopenia or lymphopenia
11. Thrombocytopenia

Immunologic criteria:

1. ANA
2. Anti-ds DNA
3. Anti-Smith
4. Antiphospholipid antibody positivity
5. Low complement (C3, C4, CH50)
6. Coombs positivity (in absence of hemolytic anemia)
FIGURE

6.2  Diagnosis of SLE.

(Adapted from Humes DH, DuPont HL, Gardner LB, et al. Kelley’s Textbook of Internal Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:1387, Figure 178-3.)

Quick HIT

Conditions in Which ANAs Are Elevated
- SLE
- RA
D. Treatment

1. Avoid sun exposure because it can exacerbate cutaneous rashes
2. NSAIDs—for less severe symptoms
3. Either local or systemic **corticosteroids**—for **acute exacerbations**
4. Systemic steroids for severe manifestations
5. Best long-term therapy is antimalarial agents such as hydroxychloroquine—for constitutional, cutaneous, and articular manifestations. **Hydroxychloroquine** is continued as a preventative measure even after resolution of symptoms. Baseline and subsequent annual eye examinations are needed because of **retinal toxicity**.
6. Cytotoxic agents such as cyclophosphamide—for active glomerulonephritis
7. Monitor the following and treat appropriately:
   a. Renal disease, which produces the most significant morbidity
   b. HTN

<table>
<thead>
<tr>
<th>Laboratory Marker</th>
<th>Conditions</th>
<th>Comments</th>
</tr>
</thead>
</table>
| ANAs              | - SLE (almost all patients)  
- Scleroderma  
- Sjögren syndrome  
- Polymyositis | Highly sensitive for SLE but not for the others |
| RF                | - RA (70% of patients)  
- Healthy populations (up to 3%) | Neither sensitive nor specific for RA |
| C-ANCA            | GPA        | Sensitive and specific  
Can vary with disease activity |
| P-ANCA            | Polyarteritis nodosa | 70–80% sensitive for microscopic PAN  
Not specific |
| Lupus anticoagulant | Antiphospholipid syndrome | |
| ESR               | - Infection (acute or chronic)  
- Malignancy  
- Rheumatologic diseases  
- Miscellaneous (tissue necrosis, pregnancy) | Low sensitivity and specificity  
Major uses: Diagnose/rule out inflammatory process and monitor course of inflammatory conditions |
| C-reactive protein | - Inflammatory states and infection  
- Miscellaneous conditions (e.g., MI, | Primarily used for infection—much more sensitive and specific than ESR |
| vasculitis, trauma, malignancy, pancreatitis | • If levels are markedly elevated (>15), bacterial infection is likely present |

**Quick HIT**

Steroids are the best treatment for SLE patients with acute flare. Hydroxychloroquine for long-term treatment for SLE can cause retinal toxicity.
Scleroderma (Systemic Sclerosis)

A. General Characteristics
1. A chronic connective tissue disorder that can lead to widespread fibrosis.
2. Pathophysiology: Cytokines stimulate fibroblasts, causing an abnormal amount of collagen deposition. It is the high quantity of collagen that causes the problems associated with this disease (composition of the collagen is normal).
3. Scleroderma is more common in women. Average age of onset is 35 to 50 years.
4. There are two types of scleroderma: Diffuse (20%) and limited (80%) (see Table 6-3)

Quick HIT

The most common causes of death in SLE are opportunistic infections and renal failure.

B. Clinical Features
1. Raynaud phenomenon
   a. Present in almost all patients; usually appears before other findings
   b. Caused by vasospasm and thickening of vessel walls in the digits

Quick HIT

Only diffuse scleroderma form has renal, lung, and heart involvement.

<table>
<thead>
<tr>
<th>TABLE 6-2</th>
<th>HLA Associations With Rheumatic Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>Associated HLA</td>
</tr>
<tr>
<td>SLE</td>
<td>HLA-DR2 and HLA-DR3</td>
</tr>
<tr>
<td>Sjögren syndrome</td>
<td>HLA-DR3</td>
</tr>
<tr>
<td>RA</td>
<td>HLA-DR4</td>
</tr>
<tr>
<td>Ankylosing spondylitis, Reiter syndrome, psoriatic arthritis</td>
<td>HLA-B27</td>
</tr>
</tbody>
</table>

CLINICAL PEARL 6-2

**Antiphospholipid Antibody Syndrome**
- A hypercoagulable state that can be idiopathic or associated with SLE (or other collagen vascular diseases such as scleroderma)
- Typical findings
  - Recurrent venous thrombosis—pulmonary embolism is a risk
- Recurrent arterial thrombosis
- Recurrent fetal loss (abortions)
- Thrombocytopenia
- Livedo reticularis
- Laboratory findings: Presence of lupus anticoagulant, anticardiolipin antibody, or both. Prolonged PTT or PT is not corrected by adding normal plasma
- Treatment is long-term anticoagulation (INR of 2.5 to 3.5)
- APA antibodies react with cardiolipin, a reagent in VDRL and RPR tests leading to false positives

1. c. Can lead to digital ischemia, with ulceration and infarction/gangrene
d. Cold temperature and stress bring about color changes of fingers—blanching first, then cyanotic, and then red from reactive hyperemia

2. Cutaneous fibrosis
   a. Tightening of skin of the face and extremities (sclerodactyly refers to a claw-like appearance of the hand)
b. Can lead to contractures, disability, and disfigurement

3. GI involvement
   a. Occurs in most patients (both diffuse and limited)
b. Findings include dysphagia/reflux from esophageal immobility (up to 90% of patients), delayed gastric emptying, constipation/diarrhea, abdominal distention, and pseudo-obstruction. Prolonged acid reflux may eventually lead to esophageal strictures.

**Quick HIT**

**Differential Diagnosis of Raynaud Phenomenon**
- Primary—no other disorder exists
- Scleroderma
- SLE
- Mixed connective tissue disease
- Vasculitis (e.g., Buerger disease)
- Certain medications (e.g., β-blockers, nicotine, bleomycin)
- Disorders that disrupt blood flow or vessels, such as thromboangiitis obliterans

4. Pulmonary involvement
   a. Most common cause of death from scleroderma
   b. Interstitial fibrosis and/or pulmonary HTN may also be present

5. Cardiac involvement: pericardial effusions, myocardial involvement that can lead to CHF, arrhythmias

6. Renal involvement (renal crisis—rapid malignant hypertension) occurs in patients with diffuse disease (rare today)
The degree of skin involvement predicts prognosis: Diffuse scleroderma has a worse prognosis than limited scleroderma.

C. Diagnosis

1. Diagnostic tests are of limited utility. Almost all patients have elevated ANAs (high sensitivity, low specificity).
2. Anticentromere antibody is very specific for the limited form.
3. Antitopoisomerase I (antiscleroderma-70) Ab is very specific for the diffuse form.
4. Barium swallow (esophageal dysmotility) and pulmonary function test are used to detect complications.

**CLINICAL PEARL 6-3**

**Drug-Induced Lupus**

- Certain drugs may produce a lupus-like syndrome that is similar to SLE except that it does not affect the CNS or kidneys.
- If renal or CNS involvement is present, it is not drug-induced lupus. In addition, the classic butterfly rash, alopecia, and ulcers are typically not seen in drug-induced lupus.
- Most patients improve after withdrawal of the offending drug. Therefore, the prognosis is obviously more favorable.
- Commonly implicated agents include hydralazine, procainamide, isoniazid, chlorpromazine, methyldopa, and quinidine.
- Laboratory findings in drug-induced lupus: Antihistone antibodies are always present; there is an absence of anti-ds DNA and anti-Sm Ab.

**TABLE 6-3 Diffuse Versus Limited Scleroderma**

<table>
<thead>
<tr>
<th>Diffuse</th>
<th>Limited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Widespread skin involvement</td>
<td>Skin involvement limited to distal extremities (and face, neck)—sparing of the trunk</td>
</tr>
<tr>
<td>Rapid onset of symptoms (skin and other complications occur rapidly after onset of Raynaud phenomenon)</td>
<td>Delayed onset: Skin involvement occurs slowly after the onset of Raynaud phenomenon</td>
</tr>
<tr>
<td>Significant visceral involvement (i.e., fibrosis of internal organs)—lung, heart, GI tract, kidneys</td>
<td>Visceral involvement occurs late—pulmonary HTN and ischemic vascular disease; minimal constitutional symptoms</td>
</tr>
<tr>
<td>Antitopoisomerase I (antiscleroderma-70) antibody</td>
<td>Anticentromere antibody</td>
</tr>
<tr>
<td>Poorer prognosis—10-yr survival is 40–65%</td>
<td>Better prognosis than diffuse form. Normal life span is expected in most cases, unless severe pulmonary HTN develops. CREST syndrome is a variant</td>
</tr>
<tr>
<td>Peripheral edema (of hands and legs), polyarthritis, fatigue and weakness (muscle involvement), carpal tunnel syndrome</td>
<td>Calcinosi of the digits</td>
</tr>
<tr>
<td>Renal failure can occur, but now rare</td>
<td>Raynaud phenomenon</td>
</tr>
<tr>
<td>Interstitial lung disease more common</td>
<td></td>
</tr>
</tbody>
</table>
**D. Treatment**

1. No effective cure, and treatment is symptomatic depending on the organs involved
2. NSAIDs for musculoskeletal pains
3. H₂ blockers or proton pump inhibitors for esophageal reflux
4. Raynaud phenomenon—avoid cold and smoking, keep hands warm; if severe, use calcium-channel blockers
5. ACE inhibitors are used to prevent and treat renal hypertensive crisis
6. For severe diffuse skin and organ involvement, systemic immunosuppression is indicated

**Quick HIT**

- Twenty percent of patients with scleroderma have Sjögren syndrome.
- In patients with Sjögren syndrome, search for occult lymphoma (look for lymphadenopathy and hepatosplenomegaly).
Sjögren Syndrome

A. General Characteristics
1. Sjögren syndrome is an autoimmune disease most common in women. Lymphocytes infiltrate and destroy the lacrimal and salivary glands.
2. A multiorgan disease (can also involve the skin, lungs, thyroid, vessels, and liver)
3. Primary versus secondary Sjögren syndrome
   a. Primary Sjögren syndrome: Dry eyes and dry mouth, along with lymphocytic infiltration of the minor salivary glands (on histology); patients do not have another rheumatologic disease
   b. Secondary Sjögren syndrome: Dry eyes and dry mouth along with a connective tissue disease (RA, systemic sclerosis, SLE, polymyositis)
4. Patients have increased risk of non-Hodgkin lymphoma. Malignancy is the most common cause of death.

B. Clinical Features
1. Dry eyes—burning, redness, blurred vision, keratoconjunctivitis sicca
2. Dry mouth and tooth decay
3. Arthralgias, arthritis, fatigue
4. Interstitial nephritis and vasculitis

C. Diagnosis
1. ANAs are present in 95% of patients. Rheumatoid factor (RF) is present in 50% to 75% of patients with secondary disease.
2. Ro (SS-A) is present in 60% of patients, and La (SS-B) (more specific) is present in 40% of patients.
3. Schirmer test: Filter paper inserted in eye to measure lacrimal gland output (degree of wetting in a specified time period)—high sensitivity and specificity.
4. Salivary gland biopsy (lip or parotid) is the most accurate but not needed for diagnosis.

Quick HIT
Patients with antibodies to Ro (SS-A) are at increased risk of having a child with neonatal SLE (with congenital heart block).

D. Treatment
1. Pilocarpine or Cevimeline (muscarinic agonists that enhance oral and ocular secretions)
2. Artificial tears for dry eyes
3. Good oral hygiene
4. NSAIDs, steroids for arthralgias, arthritis
5. Patients with secondary Sjögren syndrome—therapy for connective tissue disease
Mixed Connective Tissue Disease

Mixed connective tissue disease is an “overlap” syndrome with clinical features similar to those of SLE, RA, systemic sclerosis, and polymyositis. Findings consistent with each of these diseases do not necessarily occur simultaneously. It usually takes some time for a pattern to be identified and a diagnosis of mixed connective tissue disease to be made. Clinical findings include pulmonary involvement, esophageal dysfunction, polyarthritis, sclerodactyly, cutaneous manifestations, myopathy, and Raynaud phenomenon.

The presence of anti-U1-RNP Abs is a key laboratory finding. High ANA and RF may be present.

Treatment varies according to which specific disease predominates.

Quick HIT

RA is unlikely if:
- Joint distribution is not symmetric OR
- DIPs are involved OR
- Morning stiffness is absent
Rheumatoid Arthritis

A. General Characteristics
1. RA is a chronic inflammatory autoimmune disease involving the synovium of joints. The inflamed synovium can cause damage to cartilage and bone.
2. It is a systemic disease that has many extra-articular manifestations (see below).
3. The usual age of onset is 20 to 40 years; it is more common in women than in men (3:1).
4. Etiology is uncertain. It may be caused by an infection or a series of infections (most likely viral), but genetic predisposition is necessary.

Quick HIT

Much of the joint damage that ultimately leads to disability occurs early in disease, so early treatment with DMARDs is critical.

B. Clinical Features
1. Inflammatory polyarthritis (joint swelling is the most common sign)—can involve every joint in the body except the DIP joints (Figure 6-3).
   a. **Morning stiffness** lasting >1 hour—improves as the day progresses.
   b. Joints commonly involved include joints of the hands (PIP, MCP) and wrists, knees, ankles, elbows, hips, and shoulders.
   c. Characteristic hand deformities.
      • Ulnar deviation of the MCP joints (Figure 6-4A).
      • *Boutonnière deformities* of the PIP joints (PIP flexed, DIP hyperextended) (Figure 6-4C).
      • *Swan-neck contractures* of the fingers (MCP flexed, PIP hyperextended, DIP flexed) (Figure 6-4B).

Quick HIT

**Poor Prognostic Indicators in RA**
- High RF titers
- Subcutaneous nodules
- Erosive arthritis

2. Constitutional symptoms can be prominent (see Table 6-4).
   a. Low-grade fever, weight loss.
   b. Fatigue can be prominent because this is a systemic disease.
3. Cervical spine involvement is common at C1-C2 (subluxation and instability),
but it is less common in the lower cervical spine.

a. Instability of the cervical spine is a potentially life-threatening complication of RA. Most patients do not have neurologic involvement, but if they do, it can be progressive and fatal if not treated surgically.

b. This is seen in 30% to 40% of patients. All patients with RA should have cervical spine radiographs before undergoing any surgery (due to risk of
neurologic injury during intubation). However, disease-modifying antirheumatic drugs (DMARDs) have dramatically reduced the need for cervical spine surgery in RA patients.

Quick HIT

In RA, changes in joints are usually more extensive than in OA because the entire synovium is involved in RA. Note that osteophytes (characteristic of OA) are not present in RA.

4. Cardiac involvement may include pericarditis, pericardial effusions, conduction abnormalities, and valvular incompetence.
5. Pulmonary involvement—usually pleural effusions; interstitial fibrosis may occur.
6. Ocular involvement—episcleritis or scleritis.
7. Soft tissue swelling (rather than bony enlargement).
9. Subcutaneous rheumatoid nodules over extensor surfaces may also occur in visceral structures—for example, lungs, pleura, pericardium (Figure 6-5).
   a. Pathognomonic for RA.
   b. Nearly always occurs in seropositive patients (i.e., those with RF).

C. Diagnosis
1. Laboratory findings (see Clinical Pearl 6-4)
   a. High titers of RF are associated with more severe disease and are generally nonspecific. RF is eventually present in 80% of patients with RA (may be absent early in the disease), but is also present in up to 3% of the healthy population.
FIGURE


- RF titers rarely change with disease activity and are not useful for following patients.
- Helpful in determining prognosis. High titers → more severe disease.

b. Anticitrullinated peptide/protein antibodies (ACPA)—sensitivity is 50% to 75%, specificity is over 90%.
c. Elevated ESR, C-reactive protein.
d. Anemia of chronic disease.

<table>
<thead>
<tr>
<th>TABLE 6-4 Extra-articular Manifestations in Rheumatoid Arthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constitutional Symptoms</td>
</tr>
<tr>
<td>Cutaneous</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Pulmonary</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Eyes</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Nervous System</td>
</tr>
<tr>
<td>Felty Syndrome</td>
</tr>
</tbody>
</table>
- Also anemia, thrombocytopenia, and lymphadenopathy
- Associated with high titers of RF and extra-articular disease
- Increased susceptibility to infection
- Usually occurs fairly late in the disease process

<table>
<thead>
<tr>
<th>Blood</th>
<th>Anemia of chronic disease: Mild, normocytic, normochromic anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thrombocytosis</td>
</tr>
</tbody>
</table>

| Vasculitis    | A microvascular vasculitis—can progress to mesenteric vasculitis, PAN, or other vascular syndromes |

**FIGURE 6.5** Rheumatoid nodules of the hand.

(From Stedman TL. Stedman’s Medical Dictionary for the Health Professions and Nursing: Illustrated. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.)

**CLINICAL PEARL 6-4**

**Diagnosis of RA**

1. Inflammatory arthritis of multiple joints (higher likelihood if 3 or more joints involved)—MCP, PIP, wrist, elbow, knee, ankle, MTP joints
2. Symptoms lasting at least 6 weeks
3. Elevated ESR and CRP
4. Positive serum RF or ACPA

Quick HIT

Patients with diagnosis of RA who have a positive RF, ACPA, or both are at a higher risk of developing erosive joint damage—early treatment with DMARDs is indicated.

2. Radiographs (Figure 6-6). Not required for a diagnosis of RA but may have the following characteristic findings.
   a. Loss of juxta-articular bone mass (periarticular osteoporosis) near the finger joints.
   b. **Narrowing of the joint space** (due to thinning of the articular cartilage) is usually seen late in the disease.
   c. **Bony erosions** at the margins of the joint.

3. Synovial fluid analysis (see Table 6-5) is nonspecific.

Quick HIT

Radiographs have become less important in diagnosis of RA, as joint abnormalities occur very late. DMARDs started well before radiographs indicate abnormality.

D. Treatment

1. Goal is to minimize pain and swelling, prevent disease progression, and help patient remain as functional as possible.
2. Exercise helps to maintain range of motion and muscle strength.
   a. NSAIDs are the drugs of choice for pain control.
   b. Corticosteroids (low dose)—use these if NSAIDs do not provide adequate relief. Short-term treatment may be appropriate but avoid long-term use.
FIGURE 6.6 Posteroanterior radiographs of the hand showing the typical pattern of involvement for (A) osteoarthritis (osteophytes, subchondral sclerosis, joint space narrowing) (arrows) and (B) rheumatoid arthritis (periarticular erosions, osteopenia) (arrows).


TABLE 6-5 Synovial Fluid Analysis
<table>
<thead>
<tr>
<th>Condition</th>
<th>Appearance of Fluid</th>
<th>WBC/mm³</th>
<th>PMNs</th>
<th>Other Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>Clear</td>
<td>&lt;200</td>
<td>&lt;25%</td>
<td></td>
</tr>
<tr>
<td>Noninflammatory arthritis (OA/trauma)</td>
<td>Clear, yellow; Possibly red if traumatic</td>
<td>&lt;2,000</td>
<td>&lt;25%</td>
<td>RBCs if traumatic</td>
</tr>
<tr>
<td>Inflammatory arthritis (RA, gout, pseudogout, Reiter syndrome)</td>
<td>Cloudy yellow</td>
<td>&gt;5,000</td>
<td>50–70%</td>
<td>Positively birefringent crystals with pseudogout; negatively birefringent crystals with gout</td>
</tr>
<tr>
<td>Septic arthritis (bacterial, tuberculosis)</td>
<td>Turbid, purulent</td>
<td>Usually &gt;50,000</td>
<td>&gt;70%</td>
<td>Synovial fluid culture positive for most cases of bacterial arthritis, except gonococcal (only 25% are positive)</td>
</tr>
</tbody>
</table>

**Quick HIT**

**Variants of RA**
- **Felty syndrome**: anemia, neutropenia, splenomegaly, and RA.
- **Juvenile RA**: begins before 18 years of age. Extra-articular manifestations may predominate (*Still disease*) or arthritis may predominate.
- **Caplan syndrome**: RA associated with pneumoconiosis.

4. **DMARDs**
   a. **General principles**
   - Can reduce morbidity and mortality (by nearly 30%)—by limiting complications, slowing progression of disease, and preserving joint function
   - **Should be initiated early** (at the time of diagnosis)
   - They have a slow onset of action (6 weeks or longer for effect to be seen), so begin treating RA while waiting for the disease-modifying therapy to take effect. Gradually taper and discontinue NSAIDs and corticosteroids once effects are evident
   b. **Methotrexate**—best initial DMARD
   - Initial improvement is seen in 4 to 6 weeks.
   - Side effects include GI upset, oral ulcers (stomatitis), mild alopecia, **bone marrow suppression** (coadminister with folinic acid), hepatocellular injury, and idiosyncratic interstitial pneumonitis, which may lead to pulmonary fibrosis. It increases liver enzymes in some patients.
   - Closely monitor liver and renal function
   - Supplement with folate.
Quick HIT

Combination therapy with first-line drugs (methotrexate, hydroxychloroquine, and sulfasalazine) produces higher remission rates.

c. Alternatives: leflunomide, sulfasalazine, hydroxychloroquine
d. Antitumor necrosis factor (anti-TNF) inhibiting agents (etanercept, infliximab, etc.)—used if methotrexate does not fully control the disease. Requires PPD screening because of risk of reactivation of TB.
e. Non-TNF biologics (abatacept, rituximab, tofacitinib) are also options if disease activity remains high despite methotrexate.

5. Surgery (in severe cases)
   a. Synovectomy (arthroscopic) decreases joint pain and swelling but does not prevent x-ray progression and does not improve joint range of motion
   b. Joint replacement surgery for severe pain unresponsive to conservative measures

Quick HIT

Methotrexate is the mainstay of therapy in RA.
Crystal-Induced Arthritides

Gout

A. General Characteristics

1. Gout is an inflammatory monoarticular arthritis caused by the crystallization of monosodium urate in joints (Figure 6-7) (see Table 6-6). Hyperuricemia is a hallmark of the disease, but it does not by itself indicate gout.

2. Ninety percent of patients are men over 30 years of age. Women are not affected until after menopause due to decreased estrogen-mediated urinary urate excretion.

3. Pathogenesis
   a. Increased production of uric acid.

FIGURE

6.7 Gout: common sites of involvement. MTP, metatarsophalangeal joint.

(From Stoller JK, Ahmad M, Longworth DL. The Cleveland Clinic Intensive Review of Internal Medicine. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:374, Figure 30.6.)
• Hypoxanthine-guanine phosphoribosyltransferase deficiency—for example, in Lesch–Nyhan syndrome
• **Phosphoribosyl pyrophosphate synthetase** overactivity
• **Increased cell turnover** associated with several conditions, including cancer chemotherapy, chronic hemolysis, and hematologic malignancies

b. Decreased excretion of uric acid (accounts for 90% of cases)
   • Renal disease
   • NSAIDs, diuretics
   • Acidosis

4. Pathophysiology of inflammation
   a. PMNs play a key role in the acute inflammation of gout.
   b. It develops when uric acid crystals collect in the synovial fluid as the extracellular fluid becomes saturated with uric acid.
   c. IgGs coat monosodium urate crystals, which are phagocytized by PMNs, leading to the release of inflammatory mediators and proteolytic enzymes from the PMNs, which then result in inflammation.

<table>
<thead>
<tr>
<th>TABLE 6-6</th>
<th>Major Arthritides</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Osteoarthritis</strong></td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>Insidious</td>
</tr>
<tr>
<td><strong>Common locations</strong></td>
<td>Weight-bearing joints (knees, hips, lumbar/cervical spine), hands</td>
</tr>
<tr>
<td><strong>Presence of inflammation</strong></td>
<td>No</td>
</tr>
<tr>
<td><strong>Radiographic changes</strong></td>
<td>Narrowed joint space, osteophytes, subchondral sclerosis, subchondral cysts</td>
</tr>
<tr>
<td><strong>Laboratory findings</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Other features</strong></td>
<td>• No systemic findings • Bouchard nodes and Heberden nodes in hands</td>
</tr>
</tbody>
</table>
B. Clinical Features (four stages)

1. Asymptomatic hyperuricemia.
   a. Increased serum uric acid level in the absence of clinical findings of gout, may be present without symptoms for 10 to 20 years or longer.
   b. Should not be treated because over 95% of patients remain asymptomatic.

2. Acute gouty arthritis.

   a. Peak age of onset is 40 to 60 years of age for men.
   b. Initial attack usually involves sudden onset of exquisite pain. Pain often wakes the patient from sleep.
      • Most often affects the big toe—the first metatarsophalangeal joint (podagra). Other common joints affected are ankles and knees.
   c. Pain and cellulitic changes—erythema, swelling, tenderness, and warmth.
   d. Fever may or may not be present.
   e. As it resolves, the patient may have desquamation of overlying skin.

3. Intercritical gout.
   a. An asymptomatic period after the initial attack. The patient may not have another attack for years.
   b. Sixty percent of patients have a recurrence within 1 year. Some patients (fewer than 10%) never have another attack of gout.
   c. There is a 75% likelihood of a second attack within the first 2 years.
   d. Attacks tend to become polyarticular with increased severity over time.

4. Chronic tophaceous gout.
   a. Occurs in people who have had poorly controlled gout for more than 10 to 20 years.
   b. Tophi

   Quick HIT
   Do a Gram stain and culture of the synovial fluid to rule out septic arthritis, which is the most worrisome diagnosis on the differential list.
• Aggregations of urate crystals surrounded by giant cells in an inflammatory reaction.
• Tophi cause deformity and destruction of hard and soft tissues. In joints, they lead to destruction of cartilage and bone, triggering secondary degeneration and development of arthritis. They may be extra-articular.

c. Common locations of tophi: Extensor surface of forearms, elbows, knees, Achilles tendons, and pinna of external ear.

Quick HIT

Complications of Gout
• Nephrolithiasis—risk is small (less than 1% per year)
• Degenerative arthritis occurs in less than 15% of patients.

C. Diagnosis
1. Joint aspiration and synovial fluid analysis (under a polarizing microscope) is the only way to make a definitive diagnosis—**needle-shaped and negatively birefringent urate crystals** appear in synovial fluid.
2. Serum uric acid is **not** helpful in diagnosis because it can be normal even during an acute gouty attack.

Quick HIT

In acute gout, avoid aspirin (can aggravate the problem), acetaminophen (has no anti-inflammatory properties), and urate-lowering drugs (initiation during flare may worsen or prolong the flare). Initiate urate-lowering pharmacotherapy once the acute flare has resolved.

D. Treatment
1. In all stages, avoid secondary causes of hyperuricemia.
   a. Medications that increase uric acid levels (thiazide and loop diuretics)
   b. Obesity
   c. Reduce alcohol intake.
   d. Reduce dietary purine intake. Limit intake of seafood/red meat.
2. Acute gout.
   a. Bed rest is important. Early ambulation may precipitate a recurrence.
   b. NSAIDs
      • Treatment of choice in acute gout (indomethacin is traditionally used, but other NSAIDs are effective).
c. Colchicine
  - An alternative for patients who cannot take NSAIDs or did not respond to NSAIDs.
  - Effective but less favored because 80% of treated patients develop significant nausea/vomiting, abdominal cramps, and severe diarrhea. Compliance tends to be low due to these side effects.
  - Dose must be reduced in renal insufficiency and can cause cytopenia.
d. Corticosteroids
  - Oral prednisone (7- to 10-day course) if patient does not respond to or cannot tolerate NSAIDs and colchicine.
  - Intra-articular corticosteroid injections (if only one joint is involved)—dramatic relief of symptoms.

3. Prophylactic therapy.
a. Wait until patient has had at least two acute gouty attacks before initiating prophylactic therapy. This is because the second attack may take years to occur (if at all), and so the risk-to-benefit ratio for prophylactic medication is not favorable after one gouty attack. The presence of tophi is also an indication for prophylactic therapy.
b. When giving prophylaxis, add either colchicine or an NSAID for 3 to 6 months to prevent an acute attack. The colchicine or NSAID can then be discontinued, and the patient can remain on the uricosuric agent or allopurinol indefinitely.
c. The choice of whether to use uricosuric drugs or allopurinol depends on how much uric acid is excreted in the urine in a 24-hour period.
  - Uricosuric drugs (probenecid, sulfinpyrazone)—if the 24-hour urine uric acid is <800 mg/day, this indicates undersecretion of urate. These drugs increase renal excretion of uric acid; use them only in patients with normal renal function. They are contraindicated if the patient has a history of renal stones.
  - Xanthine oxidase inhibitors (allopurinol, febuxostat)—if the 24-hour urine uric acid is >800 mg/day, this indicates overproduction. These drugs decrease uric acid synthesis. Unlike NSAIDs and uricosuric drugs, they are not contraindicated in kidney dysfunction. Watch out for Stevens–Johnson syndrome with allopurinol and cardiovascular events with febuxostat. Uricases (pegloticase, rasburicase)—These drugs catalyze the conversion of urate into allantoin, a more soluble purine degradation product. They may cause infusion reactions.
Pseudogout (Calcium Pyrophosphate Deposition Disease)

A. General Characteristics
1. Calcium pyrophosphate crystals deposit in joints, leading to inflammation.
2. Risk factors.
   a. Deposition increases with age and with OA of the joints. Therefore, pseudogout is common in **elderly patients with degenerative joint disease**.
   b. Other conditions that may increase crystal deposition include **hemochromatosis, hyperparathyroidism**, hypothyroidism, and Bartter syndrome.

Quick HIT
Presentation of pseudogout is similar to gout, but typically occurs in larger joints (knee).

B. Clinical Features
1. The most common joints affected are knees and wrists.
2. It is classically monoarticular, but can be polyarticular.

C. Diagnosis
1. Joint aspirate is required for definitive diagnosis—**weakly positively birefringent, rod-shaped and rhomboidal crystals** in synovial fluid (calcium pyrophosphate crystals) (**Figure 6-8**)
2. Radiographs—chondrocalcinosis (cartilage calcification)

D. Treatment
1. Treat the underlying disorder (if identified)
2. Symptomatic management is similar to that for gout
   - First-line therapy includes NSAIDs
   - Colchicine is useful for prophylaxis
   - Intra-articular steroid injections, particularly with triamcinolone
3. Total joint replacement is appropriate if symptoms are debilitating
**FIGURE 6.8** Evaluation of joint pain.
Myopathies and Pain Syndromes

Idiopathic Inflammatory Myopathies

A. General Characteristics
1. Classification
   a. **Polymyositis** (does not involve skin)
   b. **Dermatomyositis** (associated with characteristic skin rash)

B. Causes
1. Pathologic changes in muscle
   a. Dermatomyositis—**humoral** immune mechanisms
   b. Polymyositis and inclusion body myositis—cell-mediated process

C. Clinical Features
1. Features common to both polymyositis and dermatomyositis (see Clinical Pearl 6-5)

<table>
<thead>
<tr>
<th>CLINICAL PEARL 6-5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic Criteria for Polymyositis</strong></td>
</tr>
<tr>
<td>If two of first four → possible polymyositis</td>
</tr>
<tr>
<td>If three of first four → probable polymyositis</td>
</tr>
<tr>
<td>If all four → definite polymyositis</td>
</tr>
<tr>
<td>• Symmetric proximal muscle weakness</td>
</tr>
<tr>
<td>• Elevation in serum creatine phosphokinase</td>
</tr>
<tr>
<td>• EMG findings of a myopathy</td>
</tr>
<tr>
<td>• Biopsy evidence of myositis</td>
</tr>
<tr>
<td>• Characteristic rash of dermatomyositis</td>
</tr>
</tbody>
</table>

a. **Symmetrical proximal muscle weakness** that develops subacutely over weeks or several months
   • The earliest and most severely affected muscle groups are the neck flexors, shoulder girdle, and pelvic girdle muscles
   • Distal extremity weakness is less frequent and typically less severe
b. Myalgia in 33% of patients
c. Dysphagia in up to 30% of patients (involvement of striated muscle in the upper GI tract)
d. More common in female patients
e. Associated findings include CHF, conduction defects, arthralgias, and interstitial lung disease
2. Features unique to dermatomyositis
   a. **Heliotrope rash** (butterfly)—around eyes, bridge of nose, cheeks
   b. **Gottron papules**—papular, erythematous, scaly lesions over the knuckles (MCP, PIP, DIP)
   c. **V sign**—rash on the face, neck, and anterior chest
   d. **Shawl sign**—rash on shoulders and upper back, elbows, and knees
   e. Periungual erythema with telangiectases
   f. Subcutaneous calcifications in children—can be extremely painful
   g. Associated with vasculitis of the GI tract, kidneys, lungs, and eyes (more common in children)
   h. There is an **increased incidence of malignancy** in older adults (lung, breast, ovary, GI tract, and myeloproliferative disorders). Once dermatomyositis is diagnosed, make an effort to uncover an occult malignancy. Dermatomyositis associated with malignancy often remits once the tumor is removed.

D. Diagnosis
1. Laboratory
   a. CK level is significantly elevated. CK levels correspond to the degree of muscle necrosis, so one can monitor the disease severity.
   b. LDH, aldolase, AST, ALT are also elevated.
   c. ANA in over 50%
   d. Antisynthetase antibodies (**anti-Jo-1 antibodies**)—abrupt onset of fever, cracked hands, Raynaud phenomenon, interstitial lung disease and fibrosis, arthritis; does not respond well to therapy
   e. Antisignal recognition particle
      - Cardiac manifestations (common)
      - Worst prognosis of all subsets
   f. Anti-Mi-2 antibodies—better prognosis
2. **EMG**—abnormal in 90% of patients
3. **Muscle biopsy**
   a. Shows inflammation and muscle fiber fibrosis
   b. Dermatomyositis—**perivascular and perimysial**
   c. Polymyositis and inclusion body myositis—**endomysial**

**Quick HIT**

Inclusion body myositis is the “oddball of inflammatory myopathies” for the following reasons: Affects male patients more than female patients, absence of autoantibodies, distal muscle involvement, and relatively low creatine kinase (CK); prognosis is poor.
E. Treatment

1. Corticosteroids are the initial treatment
2. Steroid-sparing immunosuppressive agents (to reduce steroid-induced side effects)—methotrexate, azathioprine
3. Physical therapy
Inclusion Body Myositis

A. General Characteristics

More common in men (elderly)
Insidious onset of slowly progressive proximal and distal weakness, often leads to delay in diagnosis
There is early weakness and atrophy of quadriceps, forearm flexors, and tibialis anterior muscles. Involvement is asymmetrical. Facial weakness occurs in one-third of patients, and dysphagia in one-half of patients.
Patients can also have loss of deep tendon reflexes (nerves are not involved in polymyositis and dermatomyositis)
Extramuscular manifestations are rare
Diagnosis—slight elevation of CK levels (relatively low)
Poor response to therapy
Not associated with autoantibodies

Quick HIT

About 10% of people with polymyalgia rheumatica develop temporal arteritis; up to 40% to 50% of people with temporal arteritis have coexisting polymyalgia rheumatica.
Polymyalgia Rheumatica

A. General Characteristics
1. Usually occurs in elderly patients (rare before the age of 50). The mean age of onset is 70, and it is more common in women.
2. The cause is unknown, but an autoimmune process may be responsible. There is a possible genetic link (association with HLA-DR4 allele).
3. Self-limited disease (duration of 1 to 2 years).

B. Clinical Features
1. Hip and shoulder muscle pain (bilateral)
   a. Often begins abruptly (but may be gradual)
   b. Stiffness in shoulder and hip regions after a period of inactivity is the most prominent symptom
   c. Pain occurs on movement; muscle strength is normal
   d. Profound morning stiffness is common
2. Constitutional symptoms are usually present: Malaise, fever, depression, weight loss, and fatigue
3. Joint swelling
   a. Up to 20% of patients have synovitis in knees, wrists, or hand joints (can be confused with RA)
   b. Synovitis and tenosynovitis around the shoulder may lead to rotator cuff tendonitis or adhesive capsulitis
4. Signs and symptoms of temporal arteritis (if present)

C. Diagnosis
1. Essentially a clinical diagnosis
2. ESR is usually elevated and aids in diagnosis
   a. Almost always >50, frequently >100
   b. Correlates with disease activity

D. Treatment: corticosteroids
1. Response usually occurs within 1 to 7 days. Corticosteroids are not curative, but are effective in suppressing inflammation until the disease resolves itself.
2. After 4 to 6 weeks, begin to taper slowly.
3. Most patients (60% to 70%) can stop corticosteroids within 2 years. A few patients have symptoms for up to 10 years.
Fibromyalgia

A. General Characteristics
1. Adult women account for 80% to 90% of cases.
2. Chronic nonprogressive course with waxing and waning in severity; many patients improve with time.
3. **Key to diagnosis: multiple trigger points** (points that are tender to palpation)
   a. Symmetrical.
   b. Eighteen characteristic locations have been identified, including occiput, neck, shoulder, ribs, elbows, buttocks, and knees.
4. Etiology is unknown—somatization is not a proven cause.

B. Clinical Features
1. **Stiffness**, body aches (musculoskeletal), fatigue.
   a. Pain is constant and aching, and is aggravated by weather changes, stress, sleep deprivation, and cold temperature. It is worse in the morning.
   b. Rest, warmth, and mild exercise improve the pain.
2. Sleep patterns are disrupted, and sleep is unrefreshing.
3. Anxiety and depression are common.

C. Diagnosis
1. Diagnostic criteria
   a. Widespread pain including axial pain for at least 3 months
   b. Pain in at least 11 of the 18 possible tender point sites
2. There are no specific confirmatory tests for fibromyalgia, therefore, it is important to rule out/consider the following conditions: Myofascial syndromes, rheumatoid disease, polymyalgia rheumatica, ankylosing spondylitis, spondyloarthropathy, chronic fatigue syndrome, Lyme disease, hypothyroidism, polymyositis, depression and somatization disorder, and hypertrophic osteoarthropathy.

D. Treatment and Management
1. Advise the patient to stay active and engage in low intensity exercise.
2. First-line treatment for fibromyalgia is amitriptyline.
3. Local anesthetic at trigger points is used acutely.
4. Milnacipran (SNRI) and pregabalin are also used.
5. Cognitive behavioral therapy; consider psychiatric evaluation.
Seronegative Spondyloarthropathies

Ankylosing Spondylitis

A. General Characteristics
1. Strong association with HLA-B27 (90% of patients) (see Table 6-2), however, presence of HLA-B27 should not be considered diagnostic (see Clinical Pearl 6-6).
2. Three times more common in male than in female patients.
3. **Bilateral sacroiliitis** is a prerequisite for making the diagnosis.
4. Onset is in adolescence or young adulthood.
5. It is characterized by “fusion” of the spine in an ascending manner (from lumbar to cervical spine).
6. Course.
   a. There is a slow progression, but the course is highly variable; acute exacerbations are common.
   b. Life expectancy is usually normal.
   c. The first 10 years of the disease can give an indication of long-term severity.

B. Clinical Features
1. Low back pain and stiffness (secondary to sacroiliitis)—limited motion in lumbar spine
2. Neck pain and limited motion in cervical spine—occurs later in course of disease

---

**CLINICAL PEARL 6-6**

Seronegative Spondyloarthropathies

Diseases that belong to seronegative spondyloarthropathies include the following:

- Ankylosing spondylitis
- Reactive arthritis (and Reiter syndrome)
- Psoriatic arthritis
- Arthropathy of IBD
- Undifferentiated spondyloarthropathies

Seronegative spondyloarthropathies have the following **in common**:

- Negative RF
- Strong association with HLA-B27 antigen
- Oligoarthritis (asymmetrical)
- Enthesitis (inflammation at sites of insertion of fascia, ligament, or tendon to bone)
- Inflammatory arthritis (axial and sacroiliac joints)
- Extra-articular features (eyes, skin, genitourinary tract)
- Familial predisposition
Enthesitis—inflammation at tendinous insertions into bone (Achilles tendon and supraspinatus tendon)

Quick HIT
In ankylosing spondylitis, low back pain and stiffness are characteristically worse in the morning and better as the day progresses. They improve with activity and a hot shower and worsen with rest or inactivity.

With extensive spinal involvement, the spine becomes brittle and is prone to fractures with minimal trauma. Severe spinal cord injury can occur with such trauma.

Chest pain and diminished chest expansion—due to thoracic spine involvement
Shoulder and hip pain—most commonly the peripheral joints are affected
Constitutional symptoms—fatigue, low-grade fever, weight loss
Extra-articular manifestations
  a. Eye involvement (most common)—acute anterior uveitis or iridocyclitis
  b. Other extra-articular features are rare, but may involve the following systems:
     Cardiac (AV heart block and aortic insufficiency), renal, pulmonary, and nervous systems
Loss of lumbar lordosis can occur as disease advances, leading to inability to stand upright. When severe and symptomatic, this may require spine reconstruction.

Complications of Ankylosing Spondylitis
- Restrictive lung disease
- Cauda equina syndrome
- Spine fracture with spinal cord injury
- Osteoporosis
- Spondylodiscitis

C. Diagnosis
1. Imaging studies of lumbar spine and pelvis (plain film, MRI, or CT) reveal sacroiliitis—sclerotic changes in the sacroiliac area. Eventually, the vertebral columns fuse, producing “bamboo spine.”
2. Elevated ESR in up to 75% of patients (due to inflammation)—nonspecific
3. HLA-B27 is not necessary for diagnosis. Present in 8% of general population

D. Treatment
1. NSAIDs (indomethacin) for symptomatic relief
2. Anti-TNF medications (etanercept, infliximab)
3. Physical therapy (maintaining good posture, extension exercises)
4. Surgery may be necessary in some patients with severe spinal deformity
5. Patients with ankylosing spondylitis who sustain even minor trauma and who complain of neck or back pain should be strictly immobilized to prevent spinal cord injury until thorough imaging studies (including CT scan and possibly MRI) are obtained.
Reactive Arthritis/Reiter Syndrome

A. General Characteristics

1. Reactive arthritis is asymmetric inflammatory oligoarthritis of lower extremities (upper extremities less common) (see Table 6-7). The arthritis is preceded by an infectious process that is remote from the site of arthritis (1 to 4 weeks prior), usually after enteric or urogenital infections.
2. It occurs mostly in HLA-B27–positive individuals.
3. Reiter syndrome is an example of reactive arthritis, but most patients do not have the classic findings of Reiter syndrome (arthritis, uveitis, and urethritis), so the term reactive arthritis is now used.

<table>
<thead>
<tr>
<th>TABLE 6-7 Causes of Joint Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Polyarticular Joint Pain</strong></td>
</tr>
<tr>
<td>RA</td>
</tr>
<tr>
<td>SLE</td>
</tr>
<tr>
<td>Viral arthritis</td>
</tr>
<tr>
<td>Reiter syndrome</td>
</tr>
<tr>
<td>Rheumatic fever</td>
</tr>
<tr>
<td>Lyme disease</td>
</tr>
<tr>
<td>Gonococcal arthritis</td>
</tr>
<tr>
<td>Drug-induced arthritis</td>
</tr>
</tbody>
</table>

4. The organisms usually associated with reactive arthritis include *Salmonella*, *Shigella*, *Campylobacter*, *Chlamydia*, *Yersinia*.

Quick HIT
Reactive arthritis is a clinical diagnosis. If any patient has acute asymmetric arthritis that progresses sequentially from one joint to another, reactive arthritis should be in the differential diagnosis.

B. Clinical Features

1. Look for evidence of infection (GI or genitourinary) 1 to 4 weeks before the onset of symptoms.
2. Asymmetric arthritis—new joints may be involved sequentially over days. Joints are painful, with effusions and lack of mobility.
3. Fatigue, malaise, weight loss, and fever are common.
4. Joint pain may persist or recur over a long-term period.
The term **undifferentiated spondyloarthropathy** is used when a patient has features of reactive arthritis but there is no evidence of previous infection (in the GI or genitourinary tract) and the classic findings of Reiter syndrome are absent.

C. **Diagnosis**

Send synovial fluid for analysis (to rule out infection or crystals). There is no test specific to reactive arthritis.

D. **Treatment**

1. NSAIDs are first-line therapy.
2. If there is no response, then try sulfasalazine and immunosuppressive agents such as azathioprine.
3. Antibiotic use is controversial—usually not given.
Psoriatic Arthritis

Develops in 10% to 30% of patients with psoriasis. It is typically gradual in onset. Patients usually have skin disease for months to years before arthritis develops. Usually asymmetric and polyarticular. Characteristic dactylitis ("sausage digits") and nail pitting may also be present. Upper extremities most often involved; smaller joints more common than large joints. Initial treatment is NSAIDs, but persistent arthritis may require methotrexate or anti-TNF agents. Steroids are typically not used.
Vasculitis

Vasculitis Overview

1. Vasculitis refers to inflammation within blood vessel walls.
2. Vasculitides are classified based on the size of the vessels involved:
   a. Large-vessel: aorta and major branches
   b. Medium-vessel: medium arteries
   c. Small-vessel: small arteries and capillaries. Further subdivided into ANCA-associated vasculitides and immune complex vasculitides.
   d. Variable-vessel
Large-Vessel Vasculitides

Temporal/Giant Cell Arteritis

A. General Characteristics
1. Vasculitis of unknown cause; typical patient is >50 years of age; twice as common in women as men (see Clinical Pearl 6-7).
2. The temporal arteries are most frequently affected, but it may involve other arteries, such as the aorta or carotids. Carotid bruits, decreased pulses in the arms, and aortic regurgitation may also be observed.
3. Associated with increased risk of aortic aneurysm and aortic dissection.

B. Clinical Features
1. Constitutional symptoms of malaise, fatigue, weight loss, and low-grade fever
2. Headaches—may be severe
3. Visual impairment (in only 25% to 50%)
   a. Caused by involvement of ophthalmic artery
   b. Optic neuritis; amaurosis fugax; may lead to blindness in up to 50% if not treated early and aggressively
4. Jaw pain with chewing—intermittent claudication of jaw/tongue when chewing
5. Tenderness over temporal artery; absent temporal pulse
6. Palpable nodules
7. Forty percent of patients also have polymyalgia rheumatica

Quick HIT

<table>
<thead>
<tr>
<th>Keys to Diagnosing Temporal Arteritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Age &gt;50 years</td>
</tr>
<tr>
<td>2. New headache</td>
</tr>
<tr>
<td>3. Tender/palpable temporal artery</td>
</tr>
<tr>
<td>4. High ESR</td>
</tr>
<tr>
<td>5. Jaw claudication</td>
</tr>
</tbody>
</table>

C. Diagnosis
1. ESR elevated (but normal ESR does not exclude the diagnosis)
2. Biopsy of the temporal artery has a sensitivity of 90%. A single negative biopsy does not exclude the diagnosis.

D. Treatment
1. Use high-dose steroids (prednisone) early to prevent blindness.
   a. Start treatment immediately, even if temporal arteritis is only suspected. Do not
wait for biopsy results. If visual loss is present, admit the patient to the hospital for IV steroids; otherwise, start oral prednisone. **CLINICAL PEARL 6-7**

**Vasculitis**

- In all of the vasculitic syndromes, blood vessels are inflamed and vascular necrosis can result. Findings depend on the size of the vessel involved and the location of involvement (target organ ischemia).
- If any patient has a systemic illness that has not been explained by another process (or has ischemia involving one or more systems), entertain the diagnosis of vasculitis.
- Classified according to size of vessel
- **Large vessel:** Takayasu arteritis, temporal arteritis
- **Medium vessel:** PAN, Kawasaki disease (pediatric)
- **Small vessel:**
  - ANCA-associated: GPA, EGPA, microscopic polyangiitis
  - Immune complex: cryoglobulinemic, IgA vasculitis (pediatric)
  - Variable vessel: Behçet syndrome

b. If the diagnosis is confirmed, continue treatment for at least 4 weeks, then taper gradually, but maintain steroid therapy for up to 2 to 3 years. Relapse is likely to occur if steroids are stopped prematurely.

**Quick HIT**

If temporal arteritis is suspected, begin prednisone and order a temporal artery biopsy.

2. Follow up on ESR levels to monitor effectiveness of treatment.
3. Visual loss in one eye may be temporary or permanent. Prompt and aggressive steroid treatment is primarily given to prevent involvement of the other eye, but it may improve the visual outcome in the affected eye as well.
4. Even if untreated, the disease is usually eventually self-limiting in most patients, although vision loss may be permanent.

**Quick HIT**

Suspect Takayasu arteritis in a young woman with:
- Decreased/absent peripheral pulses
- Discrepancies of BP (arm vs. leg)
- Arterial bruits

**Takayasu Arteritis**

**A. General Characteristics**

1. Most common in young Asian women
2. Granulomatous vasculitis of aortic arch and its major branches—leading to fibrosis and potentially causing to stenosis or narrowing of vessels
3. Diagnosed via arteriogram

B. Clinical Features
1. Constitutional symptoms—fever, night sweats, malaise, arthralgias, fatigue
2. Pain and tenderness over involved vessels
3. Absent pulses in carotid, radial, or ulnar arteries; aortic regurgitation may be present
4. Signs and symptoms of ischemia eventually develop in areas supplied by involved vessels
5. Severe complications include limb ischemia, aortic aneurysms, aortic regurgitation, stroke, and secondary HTN due to renal artery stenosis. The main prognostic predictor is the presence or absence of these complications.
6. Causes visual disturbances due to ocular involvement and hemorrhage of retinal arteries

C. Treatment
1. Steroids such as prednisone may relieve the symptoms.
2. Treat HTN.
3. Surgery or angioplasty may be required to recannulate stenosed vessels. Bypass grafting is sometimes necessary.
Medium-Vessel Vasculitides

Polyarteritis Nodosa

A. General Characteristics
1. Vasculitis of medium-sized vessels involving the nervous system and GI tract
2. Can be associated with hepatitis B, HIV, and drug reactions
3. Pathophysiology: PMN invasion of all layers and fibrinoid necrosis plus resulting intimal proliferation lead to reduced luminal area, which results in ischemia, infarction, and aneurysms
4. Necrosis is segmented, leading to “rosary sign” as a result of aneurysms

Quick HIT
There is no pulmonary involvement in PAN (which distinguishes it from GPA).

B. Clinical Findings
1. Early symptoms are fever, weakness, weight loss, myalgias, arthralgias, and abdominal pain (bowel angina).
2. Other findings are HTN, mononeuritis multiplex, and livedo reticularis.

C. Diagnosis
1. Diagnosis is made by biopsy of involved tissue or mesenteric angiography.
2. ESR is usually elevated, and p-ANCA may be present.
3. Test for fecal occult blood.

D. Prognosis and Treatment
The prognosis is poor, but is improved to a limited extent with treatment. Start with corticosteroids. If severe, add cyclophosphamide.
ANCA-associated Small-Vessel Vasculitides

Granulomatosis With Polyangiitis (GPA), Formerly Called Wegener Granulomatosis

A. General Characteristics
Vasculitis predominantly involving the kidneys and upper and lower respiratory tract (sometimes other organs as well)

Quick HIT
Most patients with GPA also have sinus disease, pulmonary disease, and glomerulonephritis. Renal disease accounts for the majority of deaths.

B. Clinical Features
1. Upper respiratory symptoms (e.g., sinusitis); purulent or bloody nasal discharge
2. Oral ulcers (may be painful)
3. Pulmonary symptoms (cough, hemoptysis, dyspnea)
4. Renal involvement (glomerulonephritis—may have rapidly progressive renal failure)
5. Eye disease (conjunctivitis, scleritis)
6. Musculoskeletal (arthralgias, myalgias)
7. Tracheal stenosis
8. Constitutional findings (e.g., fever, weight loss)

C. Diagnosis
1. Chest radiograph is abnormal (nodules or infiltrates).
2. Laboratory findings: Markedly elevated ESR, anemia (normochromic normocytic), hematuria, positive c-ANCA in 90% of patients—sensitive and specific; thrombocytopenia may be present.
3. Open lung biopsy confirms diagnosis.

D. Prognosis and Treatment
1. Prognosis is poor—most patients die within 1 year after the diagnosis.
2. A combination of cyclophosphamide and corticosteroids can induce remissions in many patients, but a relapse may occur at any time.
3. Consider renal transplantation if the patient has end-stage renal disease (ESRD).

Eosinophilic Granulomatosis With Polyangiitis (EGPA), Previously Called Churg–Strauss Syndrome
Vasculitis involving many organ systems (respiratory, cardiac, GI, skin, renal,
Clinical features include constitutional findings (fever, fatigue, weight loss), prominent respiratory tract findings (asthma, dyspnea), skin lesions (subcutaneous nodules, palpable purpura), as well as eosinophilia. Diagnosis is made by biopsy of lung or skin tissue (prominence of eosinophils). It is associated with p-ANCA.

The prognosis is poor with a 5-year survival of 25% (death is usually due to cardiac or pulmonary complications). With treatment (steroids), the 5-year prognosis improves to 50%.

**Microscopic Polyangiitis**

Like GPA, commonly involves the skin (palpable purpura), lungs (cough, dyspnea, hemoptysis, pulmonary fibrosis, pulmonary hypertension), and kidneys (glomerulonephritis)

Unlike GPA, does not typically have nasopharyngeal involvement

Can also be distinguished from GPA by biopsy, which shows necrotizing vasculitis without granulomas
Immune Complex Small-Vessel Vasculitides

Cryoglobulinemic Vasculitis
Caused by deposition of cryoglobulins, which are immunoglobulins that precipitate in cold temperatures
Classified into Type I, Type II, and Type III based on the type and clonality of immunoglobulins
Most common cause is chronic HCV infection. Other causes include chronic HBV infection, HIV infection, and other causes of chronic liver disease (e.g., autoimmune hepatitis, primary biliary cirrhosis).
Proposed mechanism is deposition of antigen-antibody complexes (such as HCV antibodies) in small vessels, which leads to complement activation and inflammation. Liver disease may contribute to decreased immune complex clearance, which leads to greater tissue deposition and disease activity.
Common clinical manifestations include palpable purpura, renal disease, arthralgias/arthritis, peripheral neuropathy, and hypocomplementemia. Pulmonary and CNS involvement are rare.
Diagnosis is made clinically, by the presence of circulating cryoglobulins, and by a biopsy showing leukocytoclastic vasculitis (inflammation with polymorphonuclear leukocyte nuclear debris). Patients should be tested for underlying HCV, HBV, and HIV.
Variable-Vessel Vasculitis

Behçet Syndrome

An autoimmune, multisystem vasculitic disease; cause is unknown. Clinical features: painful, sterile oral and genital ulcerations (pathergy), arthritis (knees and ankles most common), eye involvement (uveitis, optic neuritis, iritis, conjunctivitis), CNS involvement (meningoencephalitis, intracranial HTN), fever, and weight loss. Diagnosis is made by biopsy of involved tissue (laboratory tests are not helpful). Treatment is steroids, which are helpful. Often presents in Middle Easterners.
Diseases of the Renal and Genitourinary System

Nick Villano
# Renal Failure

#### Acute Kidney Injury

## A. General Characteristics

### Quick HIT

<table>
<thead>
<tr>
<th>Types of AKI (see Figure 7-1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prerenal AKI</strong>—decrease in renal blood flow (60% to 70% of cases)</td>
</tr>
<tr>
<td><strong>Intrinsic AKI</strong>—damage to renal parenchyma (25% to 40% of cases)</td>
</tr>
<tr>
<td><strong>Postrenal AKI</strong>—urinary tract obstruction (5% to 10% of cases)</td>
</tr>
</tbody>
</table>

1. **Definition:** A rapid decline in renal function, with an increase in serum creatinine level (while the cutoff for rise in creatinine which qualifies as an “injury” is controversial, an increase of as little as 0.3 mg/dL may have clinical relevance, while traditional definitions describe a relative increase of 50% or an absolute increase of 0.5 to 1.0 mg/dL) (Figure 7-1). The creatinine may be normal despite a markedly reduced glomerular filtration rate (GFR) in the early stages of acute kidney injury (AKI) due to the time it takes for creatinine to accumulate in the body. This condition is also called acute renal failure (ARF).

2. One consensus definition of AKI is called the RIFLE criteria.
   a. **RISK:** 1.5-fold increase in the serum creatinine or GFR decrease by 25% or urine output <0.5 mL/kg/hr for 6 hours.
   b. **INJURY:** Twofold increase in the serum creatinine or GFR decrease by 50% or urine output <0.5 mL/kg/hr for 12 hours.
   c. **FAILURE:** Threefold increase in the serum creatinine or GFR decrease by 75% or urine output of <0.5 mL/kg/hr for 24 hours, or anuria for 12 hours.
   d. **LOSS:** Complete loss of kidney function (i.e., requiring dialysis) for more than 4 weeks.
   e. **ESRD:** Complete loss of kidney function (i.e., requiring dialysis) for more than 3 months.

3. AKI may be nonoliguric, oliguric, or anuric. Severe AKI may occur without a reduction in urine output (nonoliguric AKI).
   a. General goals of therapy are reversing the initial insult to the kidney and/or supportive care as GFR recovers, as well as preventing fulminant kidney failure requiring temporary or permanent hemodialysis.

4. Weight gain and edema are most common findings in patients with AKI. This is due to a positive water and sodium (Na+) balance.
5. Characterized by **azotemia** (elevated BUN and Cr).
   a. Elevated BUN is also seen with catabolic drugs (e.g., steroids), GI/soft tissue bleeding (due to RBC digestion and re-absorption of urea), and dietary protein intake.
   b. Elevated Cr is also seen with increased muscle breakdown and various drugs. The baseline Cr level varies proportionately with muscle mass.

6. Prognosis
   a. More than 80% of patients in whom AKI develops recover completely. However, prognosis varies widely depending on the severity of renal failure and other comorbidities.
   b. The older the patient and the more severe the insult, the lower is the likelihood of complete recovery.
   c. The most common cause of death is infection (75% of all deaths), followed by cardiorespiratory complications. Other nonfatal complications include chronic kidney injury and need for dialysis.

![Flowchart](image_url)

**FIGURE 7.1** Causes of AKI.

**B. Categories**

1. Prerenal failure (see also Clinical Pearl 7-1)
   a. Most common cause of AKI; potentially reversible
   b. Etiology (decrease in systemic arterial blood volume or renal perfusion leading to renal ischemia)—can complicate any disease that causes hypovolemia, low cardiac output, or systemic vasodilation
Quick HIT

Monitoring a Patient With AKI

- Daily weights, intake, and output (worsening volume status can be an indication for urgent dialysis)
- BP
- Serum electrolytes (hyperkalemia and acidosis can also be indications for urgent dialysis, also tend toward hypotension and hyperphosphatemia)
- Hb and Hct (for anemia)
- Watch for signs of infection

- Hypovolemia—dehydration, excessive diuretic use, poor fluid intake, vomiting, diarrhea, burns, hemorrhage
- CHF, cardiorenal syndrome
- Hypotension (systolic BP below 90 mm Hg), from sepsis, excessive antihypertensive medications, bleeding, dehydration
- Renal arterial obstruction (kidney is hypoperfused despite elevated blood pressure)
- Cirrhosis, hepatorenal syndrome
- In patients with decreased renal perfusion, NSAIDs (constrict afferent arteriole), ACE inhibitors (cause efferent arteriole vasodilation), and cyclosporin can precipitate prerenal failure.

CLINICAL PEARL 7-1

Diagnostic Approach in AKI

- History and physical examination.
- The first thing to do is to determine the duration of renal failure. A baseline Cr level provides this information.
- The second task is to determine whether AKI is due to prerenal, intrarenal, or postrenal causes. This is done via a combination of H&P and laboratory findings.
  - Signs of volume depletion and CHF or cirrhosis suggest a prerenal etiology.
  - Signs of an allergic reaction (rash) suggest acute interstitial nephritis (an intrinsic renal etiology).
  - A suprapubic mass, BPH, or bladder dysfunction suggests a postrenal etiology.
- Medication review
- Urinalysis
- Urine chemistry (FENa or FEUrea, osmolality, urine Na⁺, urine Cr, urine BUN).
- Renal ultrasound (to rule out obstruction)

<table>
<thead>
<tr>
<th>Table 7-1</th>
<th>Studies to Differentiate Prerenal From Intrinsic AKI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinalysis</td>
<td>Prerenal</td>
</tr>
<tr>
<td>Hyaline casts</td>
<td>Abnormal</td>
</tr>
<tr>
<td>BUN/Cr Ratio</td>
<td>&gt;20:1</td>
</tr>
<tr>
<td>FENa</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>
c. Pathophysiology
   • Renal blood flow decreases enough to lower the GFR, which leads to decreased clearance of metabolites (BUN, Cr, uremic toxins).
   • Because the renal parenchyma is undamaged, tubular function (and therefore the concentrating ability) is preserved. Therefore, the kidney responds appropriately, conserving as much sodium and water as possible.
   • This form of AKI is reversible on restoration of blood flow; but if hypoperfusion persists, ischemia results and can lead to acute tubular necrosis (ATN) (see below).

d. Clinical features—signs of volume depletion (dry mucous membranes, hypotension, tachycardia, decreased tissue turgor, oliguria/anuria)

<table>
<thead>
<tr>
<th>Prerenal Failure</th>
<th>ATN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine osmolarity</td>
<td>&gt;500 mOsm</td>
</tr>
<tr>
<td>Urine Na⁺</td>
<td>&lt;20</td>
</tr>
<tr>
<td>FENa</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Urine sediment</td>
<td>Scant</td>
</tr>
</tbody>
</table>

e. Laboratory findings
   • **Oliguria**—always found in prerenal failure (this is to preserve volume)
   • Increased BUN-to-serum Cr ratio (>20:1 is the classic ratio)—because kidney can reabsorb urea to increase sodium and water retention
   • Increased urine osmolality (>500 mOsm/kg H₂O)—because the kidney is able to appropriately reabsorb water
   • Decreased urine Na⁺ (<20 mEq/L with fractional excretion of sodium [FENa] <1%) because Na⁺ is avidly reabsorbed
   • Increased urine–plasma Cr ratio (>40:1)—because much of the filtrate is reabsorbed (but not the creatinine)
   • Bland urine sediment, indicating lack of significant cellular damage to glomeri or tubules
Note that prerenal azotemia and ischemic AKI are part of a spectrum of manifestations of renal hypoperfusion. The latter differs in that injury to renal tubular cells occurs.

2. Intrinsic renal failure (see Table 7-1 and Clinical Pearl 7-2)
   a. Kidney tissue (interstitium, glomeruli, tubules) is damaged such that glomerular filtration and tubular function are significantly impaired. Thus, kidneys are unable to concentrate urine effectively.
   b. Causes
      • Tubular disease (ATN)—can be caused by ischemia (most common cause), nephrotoxins (see Clinical Pearls 7-3 and 7-4)
      • Glomerular disease (acute glomerulonephritis [GN])—for example, Goodpasture syndrome, granulomatosis with polyangiitis, poststreptococcal GN, lupus
      • Vascular disease—for example, renal artery occlusion, TTP, HUS
      • Interstitial disease—for example, allergic interstitial nephritis, often due to a hypersensitivity reaction to medication (see Tubulointerstitial Diseases section)

---

**CLINICAL PEARL 7-2**

**Rhabdomyolysis**

1. Skeletal muscle breakdown caused by trauma, crush injuries, prolonged immobility, seizures, snake bites.
2. Release of muscle fiber contents (myoglobin) into bloodstream. Myoglobin is toxic to kidneys, which can lead to AKI via tubular damage and obstruction.
3. Presents with sequelae of cell death: markedly elevated creatine phosphokinase (CPK), hyperkalemia, hypocalcemia (due to released phosphate), hyperuricemia.
4. Treat with IV fluids, mannitol (osmotic diuretic) and bicarbonate (drives K back into cells).

---

**CLINICAL PEARL 7-3**

**Causes of Acute Tubular Necrosis (ATN)**

- **Ischemic AKI**
- Secondary to severe decline in renal blood flow, as in shock, hemorrhage, sepsis, disseminated intravascular coagulation, heart failure.
- Ischemia results in the death of tubular cells.
- **Nephrotoxic AKI**
- Injury secondary to substances that directly injure renal parenchyma and result in cell death.
- Causes include antibiotics (aminoglycosides, vancomycin), radiocontrast agents, NSAIDs (especially in the setting of CHF), poisons, myoglobinuria (from muscle damage, rhabdomyolysis, strenuous exercise), hemoglobinuria (from hemolysis), chemotherapeutic drugs (cisplatin), and kappa and gamma light chains produced in multiple myeloma.
c. Clinical features depend on the cause. Edema is usually present. Recovery may be possible but takes longer than in prerenal failure.

d. Laboratory findings
   - Decreased BUN-to-serum Cr ratio (<20:1, typically closer to 10:1 ratio) in comparison with prerenal failure. Both BUN and Cr levels are still elevated, but less urea is reabsorbed than in prerenal failure as kidney is no longer actively reabsorbing it.
   - Increased urine Na\(^+\) (>40 mEq/L with FENa > 2% to 3%)—because Na\(^+\) is poorly reabsorbed
   - Decreased urine osmolality (<350 mOsm/kg H\(_2\)O)—because renal water reabsorption is impaired
   - Decreased urine–plasma Cr ratio (<20:1)—because filtrate cannot be reabsorbed

3. Postrenal failure
   a. Least common cause of AKI
   b. Obstruction of any segment of the urinary tract (with intact kidney) causes increased tubular pressure (urine produced cannot be excreted), which leads to decreased GFR. Blood supply and renal parenchyma are intact. Note that both kidneys must be obstructed (e.g., prostatic enlargement) for creatinine to rise.

   **Quick HIT**
   **Three Basic Tests for Postrenal Failure**
   - Physical examination—palpate the bladder
   - Ultrasound—look for obstruction, hydronephrosis
   - Catheter—look for large volume of urine

   c. Renal function is restored if obstruction is relieved before the kidneys are damaged.
   d. Postrenal obstruction, if untreated, can lead to ATN.
   e. Causes
      - Urethral obstruction secondary to enlarged prostate (BPH) is the most common cause
      - Obstruction of solitary kidney

   **CLINICAL PEARL 7-4**
   **Course of ATN**
   - Onset (insult)
   - Oliguric phase
Azotemia and uremia—average length 10 to 14 days

Urine output

**Diuretic phase**
- Begins when urine output is >500 mL/day
- High urine output due to the following: fluid overload (excretion of retained salt, water, other solutes that were retained during oliguric phase); osmotic diuresis due to retained solutes during oliguric phase; tubular cell damage (delayed recovery of epithelial cell function relative to GFR)

**Recovery phase**—recovery of tubular function

---

**CLINICAL PEARL 7-5**

**Urine Osmolality**

1. Urine osmolality is a measure of urine concentration. The higher the osmolality, the more concentrated the urine.
2. Dehydration in a healthy person leads to increase in urine concentration (osmolality) as follows: Dehydration causes low intravascular volume, which triggers ADH release, which stimulates reabsorption of water from kidney to fill the vasculature. Increased water reabsorption leads to more concentrated urine.
3. In ATN, the tubule cells are damaged and cannot reabsorb water (or sodium); so the urine cannot be concentrated, which leads to low urine osmolality.

- Nephrolithiasis
- Obstructing neoplasm (bladder, cervix, prostate, and so on)
- Retroperitoneal fibrosis
- Ureteral obstruction is an uncommon cause because obstruction must be bilateral to cause renal failure.

---

**Quick HIT**

Diagnosis of AKI is usually made by finding elevated BUN and Cr levels. The patient is usually asymptomatic.

**C. Diagnosis**

1. Blood tests (see also Clinical Pearl 7-5).
   a. Elevation in BUN and Cr levels. Be aware that small changes in Cr may reflect a much more significant decrease in GFR.
   b. Electrolytes (retention of \(K^+\), \(PO_4^{3-}\), drop in \(HCO_3^-\) indicating acidosis, decrease in \(Na^+\) due to fluid retention)
   c. Albumin levels to monitor for nephrotic syndrome
   d. CBC with differential

---
Obtain the Following in Any Patient With AKI

- Urinalysis
- Urine chemistry
- Serum electrolytes (Na⁺, K⁺, BUN, Cr), CBC
- Bladder catheterization to rule out obstruction (diagnostic and therapeutic)
- Renal ultrasound to look for obstruction

2. Urinalysis (Figure 7-2 and Table 7-2).
   a. A dipstick test positive for protein (3+, 4+) suggests intrinsic renal failure due to glomerular insult.
   b. Microscopic examination of the urine sediment:
      - **Crystals** indicate presence of stones.
      - **Micro-organisms** are seen in both infection and nonpathogenic colonization (differentiation made based on symptoms).
      - **Granular casts** degeneration of cells and protein aggregates seen in ATN (“muddy brown” casts)
      - **Hyaline casts** are devoid of contents (seen in prerenal failure).
      - **RBC casts** indicate glomerular disease.
      - **WBC casts** indicate renal parenchymal inflammation.
      - **Fatty casts** indicate nephrotic syndrome.

3. Urine chemistry—to distinguish between different forms of AKI.
   a. Urine Na⁺, Cr, and osmolality: Urine Na⁺ **depends on dietary intake.**
   b. FENa: collect urine and plasma electrolytes simultaneously = 
      \[ \frac{U_{Na}}{P_{Na}} \times \frac{U_{Cr}}{P_{Cr}} \times 100 \], where U = urine and P = plasma.
      - Values below 1% suggest prerenal failure.
      - Values above 2% to 3% suggest ATN.
      - **FENa is most useful if oliguria is present.**
      - If patient is on diuretics, U_{Na} will be artificially elevated and fractional excretion of urea (FEUrea) must be used instead.
   c. Renal failure index 5 (uNa/[uCr/pCr]) × 100
      - Values below 1% suggest prerenal failure.
      - Values above 1% suggest ATN.

4. Urine culture and sensitivities—if infection is suspected.
5. Renal ultrasound.
a. Primarily useful for evaluating kidney size and for excluding urinary tract obstruction (i.e., postrenal failure)—presence of bilateral hydronephrosis or hydroureter

b. Order for most patients with AKI—unless the cause of the AKI is obvious and is not postrenal

6. CT scan (abdomen and pelvis)—may be helpful in some cases; usually done if renal ultrasound shows an abnormality such as hydronephrosis

7. Renal biopsy—useful occasionally if there is suspicion of acute GN or acute allergic interstitial nephritis

8. Renal arteriography—to evaluate for possible renal artery occlusion; should be performed only if specific therapy will make a difference
In the early phase of AKI, the most common mortal complications are hyperkalemic cardiac arrest and pulmonary edema.

D. Complications
1. ECF volume expansion and resulting pulmonary edema—treat with a diuretic (furosemid)
2. Metabolic
   a. **Hyperkalemia**—due to decreased excretion of $K^+$ and the movement of potassium from ICF to ECF due to tissue destruction and acidosis
   b. **Metabolic acidosis** (with increased anion gap)—due to decreased excretion of hydrogen ions; if severe (below 16 mEq/L), correct with sodium bicarbonate
   c. Hypocalcemia—loss of ability to form active vitamin D and rapid development of PTH resistance
   d. Hyponatremia may occur if water intake is greater than body losses, or if a volume-depleted patient consumes excessive hypotonic solutions. (Hyponatremia may also be seen in hypovolemic states.)
   e. **Hyperphosphatemia**—due to decreased clearance
   f. Hyperuricemia
3. Uremia—toxic end products of metabolism accumulate (especially from protein metabolism), leading to such complications as:
   a. Platelet dysfunction
   b. Immune dysfunction
   c. Pericarditis

---

### Urinalysis Findings in Renal Failure

<table>
<thead>
<tr>
<th>Cause</th>
<th>Urine Sediment</th>
<th>Protein</th>
<th>Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prerenal</td>
<td>Benign sediment—few hyaline casts</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Intrarenal</strong></td>
<td><strong>Acute tubular necrosis</strong></td>
<td>Trace</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>“Muddy brown” casts, renal tubular cells/casts, granular casts</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Acute glomerulonephritis</strong></td>
<td>4+</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>Dysmorphic RBCs, RBCs with casts, WBCs with casts, fatty casts</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Acute interstitial nephritis</strong></td>
<td>1+</td>
<td>2+</td>
</tr>
<tr>
<td></td>
<td>RBCs, WBCs, WBCs with casts, eosinophils</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postrenal</td>
<td>Benign; may or may not see RBCs, WBCs</td>
<td>Negative</td>
<td>Negative</td>
</tr>
</tbody>
</table>
d. Encephalopathy

4. Infection
   a. A common and serious complication of AKI (occurs in 50% to 60% of cases). The cause is probably multifactorial, but uremia itself is thought to impair immune function.
   b. Examples include pneumonia, UTI, wound infection, and sepsis.

E. Treatment
1. General measures (see also Table 7-3).
   a. Avoid medications that decrease renal blood flow (NSAIDs) and/or that are nephrotoxic (e.g., aminoglycosides, radiocontrast agents).
   b. Adjust medication dosages for level of renal function.
   c. Correct fluid imbalance.
      - If volume depleted, give IV fluids. However, many patients with AKI are volume overloaded (especially if they are oliguric or anuric), so diuresis may be necessary.

<table>
<thead>
<tr>
<th>TABLE 7-3 Prognostic Factors in AKI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity of renal failure</td>
</tr>
<tr>
<td>Presence of oliguria</td>
</tr>
<tr>
<td>Fractional excretion of sodium</td>
</tr>
<tr>
<td>Requirement for dialysis</td>
</tr>
<tr>
<td>Duration of severe renal failure</td>
</tr>
<tr>
<td>Marked abnormalities on urinalysis</td>
</tr>
<tr>
<td>Underlying health of patient</td>
</tr>
<tr>
<td>Presence, severity, and reversibility of underlying disease</td>
</tr>
<tr>
<td>Clinical circumstances</td>
</tr>
<tr>
<td>Severity and reversibility of acute process(es)</td>
</tr>
<tr>
<td>Number and type of other failed organ systems</td>
</tr>
<tr>
<td>Development of sepsis and other complications</td>
</tr>
</tbody>
</table>


- The goal is to strike a balance between correcting volume deficits and avoiding volume overload (while maintaining adequate urine output). Remember that urine output is a reflection of renal blood flow (volume status) and GFR (kidney function).
- Monitor fluid balance by daily weight measurements (most accurate estimate) and intake–output records.
- Be sure to take into account the patient’s cardiac history when considering treatment options for fluid imbalances (i.e., do not give excessive fluid to a patient with CHF).

Quick HIT
Radiographic contrast media can cause ATN (typically very rapidly) by causing spasm of the afferent arteriole. It can usually be prevented by premedicating with saline hydration.

d. Correct electrolyte disturbances if present.

e. Optimize cardiac output. BP should be approximately 120 to 140/80 to 90.

f. Order dialysis if symptomatic uremia, intractable acidemia, hyperkalemia, or volume overload develop. Indications for urgent dialysis often remembered by “AEIOU” mnemonic: Acidosis, Electrolytes, Intoxications (such as in overdoses), volume Overload, Uremia.

2. Prerenal

a. Treat the underlying disorder (such as hypovolemic or cardiogenic shock).

b. Give fluids to maintain euvolemia and restore blood pressure—do not give to patients with edema or ascites. May be necessary to stop antihypertensive medications. Remember that NS is often preferred unless acidemia is present (may worsen with hyperchloremia), in which case LR can be used.

c. Eliminate any offending agents (ACE inhibitors, NSAIDs).

d. If patient is unstable, Swan–Ganz monitoring for accurate assessment of intravascular volume.

Quick HIT
Whenever a patient has elevated Cr levels, the first thing to do is to look at previous laboratory data to determine the patient’s baseline Cr level, if possible. This helps determine whether the patient has AKI, CKD, or chronic renal insufficiency/failure with superimposed AKI. (This condition is known as “acute on chronic” renal failure.)

3. Intrinsic

a. Once ATN develops, therapy is supportive and renal function generally recovers. Eliminate the cause/offending agent.

b. If oliguric, a trial of furosemide may help to increase urine flow. This improves fluid balance.

4. Postrenal—a bladder catheter may be inserted to decompress the urinary tract. Consider urology consultation.
a. Be aware of the potential for post-obstructive diuresis and a rapid increase in urine output when obstruction is resolved, which may require IV fluid replacement.

<table>
<thead>
<tr>
<th><strong>Quick HIT</strong></th>
</tr>
</thead>
</table>
| • **Azotemia** refers to the elevation of BUN.  
• **Uremia** refers to the signs and symptoms associated with accumulation of nitrogenous wastes due to impaired renal function. It is difficult to predict when uremic symptoms will appear, but it rarely occurs unless the BUN is >60 mg/dL. |
Chronic Kidney Disease

A. General Characteristics

1. Chronic kidney disease (CKD) is defined as either decreased kidney function (GFR <60 mL/min) or kidney damage (structural or functional abnormalities) for at least 3 months, regardless of cause (see also Table 7-4).

<table>
<thead>
<tr>
<th>TABLE 7-4</th>
<th>Differentiation of AKI Versus CKD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Favors Chronic</td>
</tr>
<tr>
<td>History of kidney disease, HTN, abnormal urinalysis, edema</td>
<td>—</td>
</tr>
<tr>
<td>Small kidney size on renal ultrasound</td>
<td>—</td>
</tr>
<tr>
<td>Hyperkalemia, acidemia, hyperphosphatemia, anemia</td>
<td>Hyperkalemia, acidemia, hyperphosphatemia, anemia</td>
</tr>
<tr>
<td>Urinalysis with broad casts (i.e., more than two to three WBCs in diameter)</td>
<td>Urine output &lt;500 mL/day without uremic symptoms</td>
</tr>
</tbody>
</table>


2. Causes
   a. Diabetes is the most common cause (30% of cases).
   b. HTN is responsible for 25% of cases.
   c. Chronic GN accounts for 15% of cases.
   d. Interstitial nephritis, polycystic kidney disease, obstructive uropathy.
   e. Any of the causes of AKI may lead to CKD if prolonged and/or if treatment is delayed.

3. Pathophysiology
   a. Plasma Cr varies inversely with GFR.
   b. Cr clearance is the most common clinical measure of GFR (although remember this is an indirect estimation and can lead to miscalculations).
   c. An increase in plasma Cr indicates disease progression, whereas a decrease suggests recovery of renal function (assuming muscle mass has not changed). Most laboratories now also report an estimated GFR (eGFR) each time the creatinine is ordered.

**Quick HIT**

Diabetes and hypertension are the most common causes of ESRD.

**Quick HIT**

ESRD is not defined by BUN or creatinine levels. It is classically a loss of kidney function that leads to laboratory and clinical findings of uremia. Newer definitions use CrCl to estimate GFR (CrCl < 15 mL/min distinguished as ESRD).

**B. Clinical Features**—any of the following may be present:

1. Cardiovascular
   a. HTN
      - Secondary to salt and water retention—decreased GFR stimulates renin–angiotensin system and aldosterone secretion to increase, which leads to an increase in BP.
      - Renal failure is the most common cause of secondary HTN.
   b. CHF—due to volume overload, HTN, and anemia.
   c. Pericarditis (uremic).
2. GI (usually due to uremia).
   a. Nausea, vomiting.
   b. Loss of appetite (anorexia).
3. Neurologic
   a. Symptoms include lethargy, somnolence, confusion, peripheral neuropathy, and uremic seizures. Physical findings include weakness, asterixis, and hyperreflexia. Patients may show “restless legs”—neuropathic pain in the legs that is only relieved with movement.
   b. Hypocalcemia (from decreased vitamin D conversion) can cause lethargy, confusion, and tetany.
4. Hematologic
   a. Normocytic normochromic anemia (secondary to deficiency of erythropoietin) —may be severe.
   b. Bleeding secondary to platelet dysfunction (due to uremia). Platelets do not degranulate in uremic environment.
5. Endocrine/metabolic
   a. Calcium–phosphorus disturbances.
      - Decreased renal clearance of phosphate leads to hyperphosphatemia, which results in decreased renal production of 1,25-dihydroxy vitamin D. This leads to hypocalcemia, which causes secondary hyperparathyroidism.
So, hypocalcemia and hyperphosphatemia are usually seen, but long-standing secondary hyperparathyroidism and calcium-based phosphate binders may sometimes cause hypercalcemia. This can be due to a parathyroid gland secreting excess PTH without responsiveness to plasma calcium levels, known as tertiary hyperparathyroidism.

- Secondary hyperparathyroidism causes renal osteodystrophy, which causes weakening of bones and possibly fractures.
- Hyperphosphatemia may cause calcium and phosphate to precipitate, which causes vascular calcifications that may result in necrotic skin lesions. This is called calciphylaxis and is usually irreversible.

**Quick HIT**

Increased susceptibility to infections is a major cause of mortality in patients with CKD.

b. Sexual/reproductive symptoms due to hypothalamic–pituitary disturbances and gonadal response to sex hormones: in men, decreased testosterone; in women, amenorrhea, infertility, and hyperprolactinemia.
c. Pruritus (multifactorial etiology)—common and difficult to treat. Dialysis and ultraviolet light.

**Quick HIT**

Hypocalcemia leads to secondary hyperparathyroidism, which removes calcium from bones, making them weak and susceptible to fracture.

6. Fluid and electrolyte problems (see Chapter 8).
   a. Volume overload—watch for pulmonary edema.
   b. Hyperkalemia—due to decreased urinary secretion.
   c. Hypermagnesemia—occurs secondary to reduced urinary loss.
   d. Hyperphosphatemia—see above.
   e. Metabolic acidosis—due to loss of renal mass (and thus decreased production of ammonia, which the kidneys use to buffer excreted acid) and the kidney’s inability to excrete H⁺ itself.

7. Immunologic—uremia inhibits cellular and humoral immunity.

C. Diagnosis

1. Urinalysis—examine sediment (see AKI).
   a. Level of proteinuria is increasingly being reported alongside GFR as it is associated with more rapid progression of CKD.
2. Measure Cr clearance to estimate GFR.
3. CBC (anemia, thrombocytopenia).
4. Serum electrolytes (e.g., K⁺, Ca²⁺, PO₄³⁻, serum protein)
5. Renal ultrasound—evaluate size of kidneys/rule out obstruction.
   a. Small kidneys are suggestive of chronic renal insufficiency with little chance of recovery.
   b. Presence of normal-sized or large kidneys does not exclude CKD.
   c. Renal biopsy—in select cases to determine specific etiology.

Quick HIT

In a patient with CKD, symptomatic volume overload and severe hyperkalemia are the most common complications that require urgent intervention.

D. Treatment

1. Diet
   a. Low protein—to 0.7 to 0.8 g/kg body weight per day: data suggests this may slow progression of CKD.
   b. Use a low-salt diet if HTN, CHF, or oliguria are present.
   c. Restrict potassium, phosphate, and magnesium intake.

Quick HIT

Life-Threatening Complications in CKD
- Hyperkalemia—obtain an ECG (be aware that potassium levels can be high without ECG changes).
- Pulmonary edema secondary to volume overload—look for recent weight gain.
- Infection (e.g., pneumonia, UTI, sepsis).

2. ACE inhibitors—dilate efferent arteriole of glomerulus
   a. If used early on, they reduce the risk of progression to ESRD because they slow the progression of proteinuria.
   b. Use with great caution because they can cause hyperkalemia.

3. BP control
   a. Strict control decreases the rate of disease progression.
   b. ACE inhibitors are the preferred agents. Multiple drugs, including diuretics, may be required.

4. Glycemic control (if the patient is diabetic) prevents worsening of proteinuria.
5. Smoking cessation has been associated with slower rates of progression.
6. Correction of electrolyte abnormalities
   a. Correct hyperphosphatemia with calcium citrate (a phosphate binder).
   b. Patients with chronic renal disease are generally treated with long-term oral
calcium and vitamin D in an effort to prevent secondary hyperparathyroidism and uremic osteodystrophy.

c. Acidosis—treat the underlying cause (renal failure). Patients may require oral bicarbonate replacement.

7. Anemia—treat with erythropoietin, which kidneys normally secrete.

8. Pulmonary edema—arrange for dialysis if the condition is unresponsive to diuresis.

9. Pruritus—try capsaicin cream or cholestyramine and UV light

10. Dialysis (See indications in the Dialysis section.)

11. Transplantation is the only cure.
Dialysis

A. General Characteristics

1. Overview
   a. Dialysis is the artificial mechanism by which fluid and toxic solutes are removed from the circulation when the kidneys cannot do so sufficiently.
   b. In all forms of dialysis, the blood interfaces with an artificial solution resembling human plasma (called the dialysate), and diffusion of fluid and solutes occurs across a semipermeable membrane.
   c. The two major methods of dialyzing a patient are hemodialysis and peritoneal dialysis (discussed below).
   d. The majority of dialysis patients in the United States receive hemodialysis at hospitals or dialysis centers, but more and more patients are opting for chronic ambulatory peritoneal dialysis (CAPD).
   e. For patients with life-threatening complications of AKI, continuous renal replacement therapy (CRRT) can be used for constant renal support. This also avoids the larger fluid shifts of intermittent hemodialysis which hemodynamically unstable or heart failure patients may not be able to handle.

Quick HIT

<table>
<thead>
<tr>
<th>Absolute Indications for Dialysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Acidosis—significant, intractable metabolic acidosis</td>
</tr>
<tr>
<td>• Electrolytes—severe, persistent hyperkalemia</td>
</tr>
<tr>
<td>• Intoxications—methanol, ethylene glycol, lithium, aspirin</td>
</tr>
<tr>
<td>• Overload—hypervolemia not managed by other means</td>
</tr>
<tr>
<td>• Uremia (severe)—based on clinical presentation, not laboratory values (e.g., uremic pericarditis or encephalopathy are absolute indications for dialysis)</td>
</tr>
</tbody>
</table>

B. When to Initiate Dialysis

1. General settings in which dialysis is considered.
   a. CKD—dialysis serves as a bridge to renal transplantation or as a permanent treatment when the patient is not a transplantation candidate.
   b. AKI—dialysis is often required as a temporary measure until the patient’s renal function improves, often due to absolute indications (see Quick Hit).
   c. Overdose of medications or ingestions of substances cleared by the kidneys—some, but not all medications and toxins can be dialyzed (see Quick Hit).

2. Nonemergent indications
   a. Note: Cr and BUN levels are not absolute indications for dialysis, however some nephrologists will decide to initiate dialysis once a CKD patient’s GFR drops below a certain value.
b. Symptoms of uremia
   • Nausea and vomiting
   • Lethargy/deterioration in mental status, encephalopathy, seizures
   • Pericarditis

Quick HIT
Creatinine level is not an absolute indication for dialysis.

3. Emergent indications (usually in the setting of renal failure)
   a. Life-threatening manifestations of volume overload
      • Pulmonary edema
      • Hypertensive emergency refractory to antihypertensive agents
   b. Severe, refractory electrolyte disturbances, for example, hyperkalemia, hypermagnesemia
   c. Severe metabolic acidosis
   d. Drug toxicity/ingestions (particularly in patients with renal failure): methanol, ethylene glycol, lithium, aspirin

Quick HIT
Dialyzable Substances
- Salicylic acid
- Lithium
- Ethylene glycol
- Magnesium-containing laxatives

C. Hemodialysis
1. Process
   a. The patient’s blood is pumped by an artificial pump outside of the body through the dialyzer, which typically consists of fine capillary networks of semipermeable membranes. The dialysate flows on the outside of these networks, and fluid and solutes diffuse across the membrane.
   b. The patient’s blood must be heparinized to prevent clotting in the dialyzer.
2. Frequency: Most hemodialysis patients require 3 to 5 hours of dialysis 3 days per week.
3. Access
   a. Use the central catheter placed using the Seldinger technique most often in the subclavian or jugular vein for temporary access.
   b. Tunneled catheters are placed under the skin which leads to a lower rate of
infection. These catheters are often suitable for use up to 6 months.

c. Arteriovenous fistula.
   • Best form of permanent dialysis access.
   • It requires vascular surgery to connect the radial or brachial artery to veins in the forearm.
   • An audible bruit and palpable thrill (due to high flow) over the fistula indicates that it is patent. Absence of these findings is abnormal and is concerning for thrombosis of the vessel.

d. An alternative to an arteriovenous fistula is an implantable graft—typically made of polytetrafluoroethylene (PTFE).

4. Alternatives to traditional hemodialysis.
   a. Continuous arteriovenous hemodialysis (CAVHD) and continuous venovenous hemodialysis (CVVHD) are often used in hemodynamically unstable patients, such as ICU patients with AKI. This allows for closer control of electrolytes and fluid status.
   b. Lower flow rates of blood and dialysate enable dialysis to occur while minimizing rapid shifts in volume and osmolality which these patients may not be able to tolerate.
   c. They require highly efficient dialyzers to be effective.

5. Advantages of hemodialysis.
   a. It is more efficient than peritoneal dialysis. High flow rates and efficient dialyzers shorten the period of time required for dialysis.
   b. It can be initiated more quickly than peritoneal dialysis, using temporary vascular access in the emergent setting.

6. Disadvantages of hemodialysis.
   a. It is less similar to the physiology of natural kidney function than is peritoneal dialysis, predisposing the patient to the following:
      • Hypotension due to rapid removal of intravascular volume leading to rapid fluid shifts from the extravascular space into cells.
      • Hypo-osmolality due to solute removal.
   b. Requires vascular access.

D. Peritoneal Dialysis

1. Process
   a. The peritoneum serves as the dialysis membrane. Dialysate fluid is infused into the peritoneal cavity, then fluids and solutes from the peritoneal capillaries diffuse into the dialysate fluid, which is drained from the abdomen.
   b. A hyperosmolar (high-glucose) solution is used, and water is removed from the blood via osmosis.
2. Frequency: dialysate fluid is drained and replaced every hour in acute peritoneal dialysis, but only once every 4 to 8 hours in CAPD.

3. Access
   a. With CAPD, dialysate is infused into the peritoneal fluid via an implanted catheter.
   b. A temporary catheter is used for acute peritoneal dialysis.

4. Advantages
   a. The patient can learn to perform dialysis on his or her own.
   b. It mimics the physiology of normal kidney function more closely than hemodialysis in that it is more continuous.

5. Disadvantages
   a. High glucose load may lead to hyperglycemia and hypertriglyceridemia.
   b. Peritonitis is a significant potential complication.
   c. The patients must be highly motivated to self-administer it.
   d. Cosmetic—there is increased abdominal girth due to dialysate fluid.

E. Limitations and Complications of Dialysis

1. Limitations—dialysis does not replicate the kidney’s synthetic functions. Therefore, dialysis patients are still prone to erythropoietin and vitamin D deficiency, with their associated complications.

2. Complications associated with hemodialysis.
   a. Hypotension—may result in myocardial ischemia, fatigue, and so on.
   b. The relative hypo-osmolality of the ECF compared with the brain may result in nausea, vomiting, headache, and rarely, seizures or coma.
   c. “First-use syndrome”—chest pain, back pain, and rarely, anaphylaxis may occur immediately after a patient uses a new dialysis machine.
   d. Hemolysis: often due to issues with dialysate solution
   e. Complications associated with anticoagulation—hemorrhage, hematoma, etc.
   f. Infection of vascular access site—may lead to sepsis.
   g. Hemodialysis-associated amyloidosis of \( \beta_2 \)-microglobulin in bones and joints, can lead to bilateral carpal tunnel syndrome.

3. Complications associated with peritoneal dialysis.
   a. Peritonitis, often accompanied by fever and abdominal pain—usually can be treated with intraperitoneal antibiotics; cloudy peritoneal fluid is key sign.
   b. Abdominal/inguinal hernia—increased risk due to elevated intra-abdominal pressures.
   c. Hyperglycemia—especially with diabetic patients.
   d. Protein malnutrition.
Proteinuria and Hematuria

Proteinuria

Quick HIT

Asymptomatic Proteinuria
- Asymptomatic transient proteinuria has an excellent prognosis (no further evaluation necessary). Often due to fever or exercise.
- Asymptomatic persistent proteinuria and symptomatic proteinuria require further workup (high chance of renal disease in these patients).

A. General Characteristics
1. Defined as the urinary excretion of >150 mg protein/24 hours
2. Classification
   a. Glomerular
      - Due to increased glomerular permeability to proteins from various causes
      - Can lead to nephrotic syndrome (see below)
      - May be seen in all types of GN
      - Protein loss tends to be more severe than in nonglomerular causes
   b. Tubular
      - Small proteins normally filtered at the glomerulus then reabsorbed by the tubules appear in the urine because of abnormal tubules (i.e., due to decreased tubular reabsorption)
      - Proteinuria and kidney damage tends to be less severe due to a lower quantity and nephrotoxicity of the associated proteins
      - Causes include sickle cell disease, urinary tract obstruction, and interstitial nephritis
   c. Overflow proteinuria—increased production of small proteins overwhelms the tubules’ ability to reabsorb them (e.g., Bence Jones protein in multiple myeloma, myoglobin in rhabdomyolysis)
   d. Other causes of proteinuria (all of the following can affect renal blood flow):
      - UTI
      - Fever, heavy exertion/stress, CHF
      - Pregnancy
      - Orthostatic proteinuria—occurs when the patient is standing but not when recumbent; self-limited and benign
3. Nephrotic syndrome
a. Key features

- **Urine protein** excretion rate >3.5 g/24 hours
- **Hypoalbuminemia**—hepatic albumin synthesis cannot keep up with these urinary protein losses. The result is decreased plasma oncotic pressure, which leads to edema.
- **Edema**—this is often the initial complaint (from pedal edema to periorbital to anasarca, ascites, pleural effusion), and results from hypoalbuminemia. Increased aldosterone secretion exacerbates the problem (increases sodium reabsorption).
- **Hyperlipidemia** and lipiduria—increased hepatic synthesis of LDL and VLDL because liver is revving up albumin synthesis.
- Hypercoagulable state (due to loss of certain anticoagulants in the urine)—increased risk of thromboembolic events (deep venous thrombosis, pulmonary embolism, renal vein thrombosis).
- Increased incidence of infection—results from loss of immunoglobulins in the urine, particularly susceptible to pneumococcal infections.

---

**Quick HIT**

**Three Key Features of Nephrotic Syndrome**

- Proteinuria
- Hypoalbuminemia
- Hyperlipidemia

---

b. Nephrotic syndrome usually indicates significant glomerular disease (either primary or secondary to systemic illness) as the underlying cause is abnormal glomerular permeability.

c. Causes

- Primary glomerular disease (50% to 75% of cases of nephrotic syndrome)—membranous nephropathy is most common in adults (40% of cases), followed by focal segmental glomerulosclerosis (FSGS) (35%) and membranoproliferative GN (15%). Minimal change disease (MCD) is the most common cause in children (75% of cases).
- Secondary glomerular pathology:
  - Amyloidosis, cryoglobulinemia.
  - Drugs/toxins—captopril, heroin, heavy metals, NSAIDs, penicillamine.
  - Infection—bacterial, viral, protozoal.
  - Multiple myeloma, malignant HTN, transplant rejection.
B. Diagnosis

1. Urine dipstick test (read color changes)
   a. Specific for albumin—detects concentrations of 30 mg/dL or higher
   b. Graded 0, trace, 1+ (15 to 30 mg/dL) through 4+ (>500 mg/dL)
   c. More sensitive to albumin than to immunoglobulins, thus can lead to false-negative results when predominant urinary protein is globulin (e.g., light chains in myeloma)

2. Urinalysis (see Clinical Pearl 7-6)
   a. Initial test once proteinuria is detected by dipstick test.
   b. Examination of urine sediment is important.
      - RBC casts suggest GN.
      - WBC casts suggest pyelonephritis and interstitial nephritis.
      - Fatty casts suggest nephrotic syndrome (lipiduria).
   c. If urinalysis confirms the presence of protein, a 24-hour urine collection (for albumin and Cr) is appropriate to establish the presence of significant proteinuria.

   **CLINICAL PEARL 7-6**

   **Urinalysis**

   Collection—a clean-catch, midstream urine sample (after cleaning urethral meatus) is usually adequate for urinalysis and urine culture in adults.

   Urinalysis consists of the following three steps:
   - Visual inspection of urine—examine color, clarity
   - Dipstick reactions
     - pH—this depends on acid–base status. The average is about 6, but can range from 4.5 to 8.0.
     - Specific gravity—this is directly proportional to urine osmolality (and therefore solute concentration in urine). Normal is 1.002 to 1.035. It increases with volume depletion and decreases with volume overload. Appropriate changes in specific gravity with volume status of the patient indicate adequate tubular function (i.e., renal concentrating ability).
     - Protein—proteinuria is defined as >150 mg/day; nephrotic syndrome, >3.5 g/day. The following are rough guidelines: Trace = 50 to 150 mg/day; 1+ = 150 to 500 mg/day; 2+ = 0.5 to 1.5 g/day; 3+ = 2 to 5 g/day; 4+ = >5 g/day.
     - Glucose—excessive glucose indicates diabetes. Absence of glucosuria does not rule out diabetes, however.
     - Blood—hematuria—see text
     - Ketones—DKA, starvation
     - Nitrite—suggests presence of bacteria in urine, usually GNR
     - Leukocyte esterase—suggests presence of WBC in urine; if negative, infection is unlikely
   - Microscopic examination of urine sediment
     - Look for casts, cells, bacteria, WBCs, RBCs (number, shape), crystals.

3. Test for microalbuminuria
Corresponds to albumin excretion of 30 to 300 mg/day. This is below the range of sensitivity of standard dipsticks. Special dipsticks can detect microgram amounts of albumin. If the test result is positive, perform a radioimmunoassay (the most sensitive and specific test for microalbuminuria).

c. **Microalbuminuria can be an early sign of diabetic nephropathy and often presents before any other laboratory abnormalities or overt signs or symptoms.**

4. Other tests to determine etiology (may or may not be necessary depending on case)
   a. Cr clearance—best test of renal function/GFR estimation
   b. Serum BUN and Cr
   c. CBC, vitamin D—to detect anemia due to renal failure
   d. Serum albumin level—varies inversely with degree of proteinuria
   e. Renal ultrasound—to detect obstruction, masses, cystic disease
   f. Intravenous pyelogram (IVP)—to detect chronic pyelonephritis
   g. Immunologic tests: ANA levels (lupus), antiglomerular basement membrane (Goodpasture syndrome), hepatitis serology (causes of MN, MPGN), antistreptococcal antibody titers (PSGN), complement levels, cryoglobulin studies
   h. Serum and urine electrophoresis (myeloma)
   i. Renal biopsy—if no cause is identified by less invasive means

C. **Treatment**

1. Asymptomatic proteinuria.
   a. If it is transient, no further workup or treatment is necessary.
   b. If it is persistent, further testing is indicated. Start by checking BP and examining urine sediment. Treat the underlying condition and associated problems (e.g., hyperlipidemia).

2. Symptomatic proteinuria—further testing is always required.
   a. Treat the underlying disease (diabetes, multiple myeloma, SLE, MCD).
   b. ACE inhibitors (ARB cannot tolerate ACE)—these decrease urinary albumin loss. They are an essential part of treatment for diabetics with HTN and should be started before fixed albuminuria is present.
   c. Diuretics—if edema is present.
   d. Limit dietary protein and sodium.
   e. Treat hypercholesterolemia (using diet or a lipid-lowering agent).
   f. Anticoagulate if thrombosis occurs. Currently, there is not enough data to support routine prophylactic anticoagulation of these patients and must be considered on a case-by-case basis.
   g. Vaccinate against influenza and pneumococcus—there is an increased risk of
infection in these patients.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hematuria is a common presenting sign in patients with bladder cancer (up to 85% of cases) and patients with renal cell carcinoma (up to 40% of cases).</td>
</tr>
</tbody>
</table>
Hematuria

A. General Characteristics
1. Hematuria is defined as >3 erythrocytes/HPF on urinalysis.
2. Microscopic hematuria is more commonly glomerular in origin; gross hematuria is more commonly nonglomerular or urologic in origin.
3. Consider gross painless hematuria to be a sign of bladder or kidney cancer until proven otherwise.
4. This may lead to obstruction if large clots form in the lower GU tract (potentially requiring bladder catheterization and irrigation). Excessive blood loss can lead to iron deficiency anemia.

Quick HIT
Infection (cystitis, urethritis, prostatitis) accounts for 25% and stones for 20% of all cases of atraumatic hematuria.

B. Causes
1. Intrarenal
   a. Tumor (RCC), infection (pyelonephritis, abscess), stones, and trauma
   b. Glomerular disease, immunoglobulin A nephropathy
   c. Strenuous exercise (marathon running), fever—hematuria is generally harmless
   d. Polycystic kidney disease, simple cysts
   e. Sickle cell disease
   f. Analgesic nephropathy (renal papillary necrosis and chronic interstitial nephritis)
   g. Renal papillary necrosis

Quick HIT
Menstrual blood can contaminate a urine sample and lead to a false-positive dipstick reading for hematuria.

2. Ureter
   a. Tumor, infection (pyelonephritis), stones, and trauma
   b. Stricture
3. Lower urinary tract (Bladder, Urethra, Prostate)
   a. Tumor (bladder, prostate), infection (cystitis, prostatitis), stones, and trauma (Foley placement, invasive procedures)
   b. BPH—rarely causes isolated hematuria
   c. Chronic irritation
4. Other
   a. Systemic diseases (SLE, rheumatic fever, Henoch–Schönlein purpura, 
      granulomatosis with polyangiitis, HUS, Goodpasture syndrome, PAN)
   b. Bleeding disorders (e.g., hemophilia, thrombocytopenia)
   c. Medications (cyclophosphamide, anticoagulants, salicylates, sulfonamides)

C. Diagnosis
   1. Urine dipstick—sensitivity in identifying hematuria is >90% (Figure 7-3).
   2. Urinalysis—crucial in evaluation of hematuria.
FIGURE 7.3 Evaluation of hematuria.

Quick HIT

If the patient has no other symptoms associated with hematuria, and thorough workup fails to reveal a cause, the prognosis is excellent. (There is usually mild glomerular/interstitial disease.)

a. Examine urine sediment—this is very important in identifying possible renal disease.

b. If RBC casts and proteinuria are also present, a glomerular cause is almost always present (usually GN).
c. If pyuria is present, send for urine culture.
d. If dipstick is positive for blood, but urinalysis does not reveal microscopic hematuria (no RBCs), hemoglobinuria or myoglobinuria (as in rhabdomyolysis) is likely present.

3. Urine specimen—for cytology.
   a. To detect cancers (bladder cancer is the main concern).
   b. **If suspicion for malignancy is high, perform a cystoscopy to evaluate the bladder regardless of cytology results. This is a necessity in nearly all patients over 40 or those with risk factors for bladder cancer.**

4. Twenty-four–hour urine—test for Cr and protein to assess renal function. Collect if proteinuria is present. (If it is heavy, glomerular disease is likely.)
5. Blood tests—coagulation studies, CBC, BUN/Cr.
6. IVP, CT scan, ultrasound—if no cause is identified by the above tests; look for stones, tumors, cysts, ureteral strictures, or vascular malformations.
7. Renal biopsy—if there is suspicion of glomerular disease.

**D. Treatment:** Treat the underlying cause; maintain urine volume.
Glomerular Disease (Glomerulonephropathies)

Overview

A. General Characteristics

1. Can be primary (intrinsic renal pathology) or secondary (to a systemic disease). Two important categories of glomerular pathology are diseases that present with nephrotic syndrome and those that present with nephritic syndrome. Many conditions have features of both. See Table 7-5.

<table>
<thead>
<tr>
<th>Pathogenesis</th>
<th>Nephritic Syndrome</th>
<th>Nephrotic Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Inflammation of glomeruli due to any of the causes of glomerulonephritis</td>
<td>Abnormal glomerular permeability due to a number of conditions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Causes</th>
<th>Nephritic Syndrome</th>
<th>Nephrotic Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Poststreptococcal glomerulonephritis is the most common cause, but may be due to any of the causes of glomerulonephritis</td>
<td>Many conditions. Membranous glomerulonephritis is the most common cause in adults. Other causes include diabetes, SLE, drugs, infection, glomerulonephritis (focal segmental and others). Minimal change disease is the most common cause in children</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory Findings</th>
<th>Nephritic Syndrome</th>
<th>Nephrotic Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematuria</td>
<td>AKI—azotemia, oliguria</td>
<td>Urine protein excretion rate &gt;3.5 g/24 hr</td>
</tr>
<tr>
<td></td>
<td>Proteinuria, if present, is mild and not in nephrotic range</td>
<td>Hypoalbuminemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hyperlipidemia, fatty casts in urine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Findings</th>
<th>Nephritic Syndrome</th>
<th>Nephrotic Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN</td>
<td>Edema</td>
<td>Edema</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercoagulable state</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk of infection</td>
</tr>
</tbody>
</table>

2. There is a wide range in the rate of disease progression, varying from days to weeks in the acute glomerular diseases, to years in the chronic disorders.

Quick HIT

Rapid progressive GN is a clinical syndrome that includes any type of GN in which rapid deterioration of renal function occurs over weeks to months, leading to renal failure and ESRD.

B. Causes

1. GN is usually caused by immune-mediated mechanisms.
2. Other mechanisms include metabolic and hemodynamic disturbances.
C. Clinical Features

1. Glomerular disorders are characterized by impairment in selective filtration of blood, resulting in excretion of larger substances such as plasma proteins and blood cells. As disease advances, GFR decreases proportionately, leading to renal failure and the possible need for dialysis and/or transplantation.

2. The classic features are proteinuria, hematuria, or both. Nephrotic range proteinuria is pathognomonic for glomerular disease.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Possible Presentations of Glomerular Disease</td>
</tr>
<tr>
<td>• Isolated proteinuria</td>
</tr>
<tr>
<td>• Isolated hematuria</td>
</tr>
<tr>
<td>• Nephritic syndrome—hematuria, HTN, azotemia</td>
</tr>
<tr>
<td>• Nephrotic syndrome—proteinuria, edema, hypoalbuminemia, hyperlipidemia</td>
</tr>
</tbody>
</table>

D. Diagnosis

1. Urinalysis (hematuria, proteinuria, RBC casts)
2. Blood tests (renal function tests)
3. Needle biopsy of the kidney

E. Treatment depends on the disease, but often involves steroids and cytotoxic agents.
Primary Glomerular Disorders

A. Minimal Change Disease
1. Nephrotic syndrome—most common presentation (see also Clinical Pearl 7-7).
2. Most common in children—Hodgkin disease and non-Hodgkin lymphoma have been associated with MCD.
3. No histologic abnormalities on light microscopy; **fusion/effacement of foot processes on electron microscopy.**
4. Excellent prognosis; responsive to steroid therapy (4 to 8 weeks), although relapses may occur.
5. Current evidence points to systemic T-cell dysfunction as the most likely root cause of MCD.

B. Focal Segmental Glomerulosclerosis
1. A histopathologic lesion which is the result of a wide range of disease processes
2. This accounts for 25% of cases of nephrotic syndrome in adults and is more common in blacks. Hematuria and HTN are often present.
3. It has a fair to poor prognosis. It is generally resistant to steroid therapy—patients develop renal insufficiency within 5 to 10 years of diagnosis. The course is progressive to ESRD.
4. The treatment regimen is controversial, but remission has been achieved in 50% of patients with the use of cytotoxic agents, steroids, and immunosuppressive agents. ACE/ARBs are also commonly indicated.

C. Membranous Glomerulonephritis
1. Usually presents with nephrotic syndrome; glomerular capillary walls are thickened. Most common nephrotic syndrome in nondiabetic adults.

**CLINICAL PEARL 7-7**

**Glomerular Disease (GD) Versus Tubular Disease (TD)**
1. TD is usually acute, whereas GD is more chronic.
2. TD is often caused by toxins (NSAIDs, contrast, myoglobin, drugs); GD is typically not caused by toxins.
3. TD does not cause nephrotic syndrome, GD does.
4. TD does not need biopsy, GD often does.
5. Steroids used for GD, not TD.
6. Immunosuppressive medications used for GD, not TD.

2. Primary disease is idiopathic (this is the most common etiology). The secondary form is due to infection (hepatitis C virus, hepatitis B virus, syphilis, malaria),
drugs (gold, captopril, penicillamine), neoplasm, or lupus.
3. Prognosis is fair to good and course is variable; remission is common (in 40% of cases), but renal failure develops in 33% of patients. Steroids do not change survival rate.

D. IgA Nephropathy (Berger Disease)
1. Asymptomatic recurrent hematuria/mild proteinuria is common. **This is the most common cause of glomerular hematuria.** Gross hematuria **1 to 3 days** after an upper respiratory infection (or other viral infection or exercise) is common (as opposed to weeks after a URI in PSGN).
2. Renal function is usually normal.
3. Mesangial deposition of IgA and C3 are seen on electron microscopy.
4. The prognosis in most patients is good with preservation of renal function (renal insufficiency may develop in 25%).
5. Some advocate steroids for unstable disease, but no therapy has been proven to be effective.

E. Hereditary Nephritis (Alport syndrome)
1. X-linked or autosomal dominant inheritance with variable penetrance
2. Features include hematuria, pyuria, proteinuria, high-frequency hearing loss without deafness, progressive renal failure
3. No effective treatment
Secondary Glomerular Disorders

A. Diabetic Nephropathy—most common cause of ESRD (see Chapter 4)

B. Hypertensive Nephropathy—(see Renal Vasculature Disease section)

C. Lupus—(see Chapter 6)

D. Membranoproliferative GN
1. Can present with proteinuria/nephrotic syndrome or hematuria/nephritis
2. Usually due to hepatitis C infection; other causes include hepatitis B, syphilis, and lupus
3. Common association with cryoglobulinemia
4. The prognosis is poor. Renal failure develops in 50% of patients. Treatment is rarely effective.

E. Poststreptococcal GN—most common cause of nephritic syndrome
1. Occurs after infection with group A β-hemolytic streptococcal infection of the upper respiratory tract (or skin—impetigo). The GN develops about 10 to 14 days after infection. Primarily affects children (ages 2 to 6 years).
2. Features include hematuria, edema, HTN, low complement levels, and proteinuria.
3. Antistreptolysin-O may be elevated.
4. It is self-limited (usually resolves in weeks to months) with an excellent prognosis. Some cases develop into rapidly progressive GN (more commonly in adults).
5. Therapy is primarily supportive: antihypertensives, loop diuretics for edema; the use of antibiotics is controversial but have not been shown to prevent disease when given during acute streptococcal infection. Steroids may be helpful in severe cases.

F. Goodpasture Syndrome
1. Classic triad of proliferative GN (usually crescentic), pulmonary hemorrhage, and IgG antiglomerular basement membrane antibody.
2. Clinical features: rapidly progressive renal failure, hemoptysis, cough, and dyspnea
3. Lung disease precedes kidney disease by days to weeks.
4. Renal biopsy shows linear immunofluorescence pattern.
5. Treat with plasmapheresis to remove circulating anti-IgG antibodies. Cyclophosphamide and steroids can decrease the formation of new antibodies.
G. Dysproteinemias—amyloidosis, light chain/heavy chain diseases

H. Sickle Cell Nephropathy—(see Renal Vascular Disease section)

I. HIV Nephropathy
1. Characteristics include proteinuria, edema, and hematuria.
2. Histopathology most often resembles a collapsing form of FSGS.
3. Treat with prednisone, ACE inhibitors, and antiretroviral therapy.

J. Granulomatosis With Polyangiitis—(see Chapter 6).

K. PAN—(see Chapter 6).
Tubulointerstitial Diseases

Acute Interstitial Nephritis

A. General Characteristics
1. Inflammation involving interstitium (tissue that surrounds glomeruli and tubules)

Quick HIT
Diagnosing AIN
In the setting of recent infection and/or start of a new medication, look for allergic symptoms (rash, fever, general aches/pains) and signs/symptoms of AKI.

2. Accounts for 10% to 15% of cases of AKI
3. Causes
   a. **Acute allergic reaction to medication is the most common cause**—for example, penicillins, cephalosporins, sulfa drugs, diuretics (furosemide, thiazide), anticoagulants, phenytoin, rifampin, allopurinol, proton pump inhibitors.
   b. Infection (especially in children)—due to a variety of agents, including *Streptococcus* spp. and *Legionella pneumophila*.
   c. Collagen vascular diseases—for example, sarcoidosis.
   d. Autoimmune diseases—for example, SLE, Sjögren syndrome.

Quick HIT
The diagnosis of AIN can be made if the patient is known to have been exposed to one of the offending agents, and has the following: rash, fever, acute renal insufficiency, and eosinophilia.

B. Clinical Features
1. Acute interstitial nephritis (AIN) causes intrinsic AKI and its associated symptoms.
2. Rash, fever, and eosinophilia are the classical findings.
3. Pyuria and hematuria may be present.

C. Diagnosis
1. Renal function tests (increased BUN and Cr levels)
2. Urinalysis
   a. **Eosinophils in the urine suggest the diagnosis, given the proper history and**
findings.

b. WBC and white cell casts are often seen.
c. Mild proteinuria or microscopic hematuria may be present.

3. Note that it is often impossible to distinguish AIN from ATN based on clinical grounds alone. Renal biopsy is the only way to distinguish between the two, but is usually not performed given its invasiveness.

| Quick HIT |
|------------|------------------------------------------------|
| **Acute Versus Chronic Interstitial Nephritis** |
| • **Acute** interstitial nephritis causes a rapid deterioration in renal function and is associated with interstitial eosinophils or lymphocytes. |
| • **Chronic** interstitial nephritis has a more indolent course and is associated with tubulointerstitial fibrosis and atrophy. |

**D. Treatment**

1. Removing the offending agent is usually enough to reverse the clinical findings. If creatinine continues to increase after stopping the offending agent, steroids may help.
2. Treat infection if present.
Renal Papillary Necrosis

Most commonly associated with analgesic nephropathy, diabetic nephropathy, sickle cell disease, urinary tract obstruction, UTI, chronic alcoholism, and renal transplant rejection. (A common mnemonic is POSTCARDS—Pyelonephritis, Obstruction, Sickle cell disease, Tuberculosis, Cirrhosis, Analgesics, Renal vein thrombosis, Diabetes, Systemic vasculitis)

Diagnosis is typically made by excretory urogram—note change in papilla or medulla.

Variable course: some patients have rapid progression, and others have a more indolent, chronic course.

Sloughed, necrotic papillae can cause ureteral obstruction (presents with flank pain and hematuria).

Treat the underlying cause, and stop the offending agents (e.g., NSAIDs).

Quick HIT

Analgesic Nephropathy Pearls

- Analgesic nephropathy is a form of toxic injury to the kidney due to excessive use of over-the-counter analgesics (those that contain phenacetin, acetaminophen, NSAIDs, or aspirin).
- It can manifest as interstitial nephritis (acute or chronic) or renal papillary necrosis.
- It may lead to acute or chronic renal failure.
Renal Tubular Acidosis

A. General Characteristics
1. Renal tubular acidosis (RTA) is a disorder of the renal tubules that leads to a nonanion gap hyperchloremic metabolic acidosis (through different mechanisms detailed below). Glomerular function is normal (see Table 7-6).
2. It is characterized by a decrease in the H⁺ excreted in the urine, leading to acidemia and urine alkalosis.
3. There are three types of RTA (types 1, 2, and 4). (Type 3 RTA is a term that is no longer used.)

B. Type 1 (Distal)
1. The defect is an inability to secrete H⁺ at the distal tubule (thus bicarbonate cannot be dissociated from protons and recycled to further buffer the blood). This inability to acidify the urine and generate new bicarbonate results in metabolic acidosis. Although normally the urine pH can be as low as 4.7, in distal RTA the urine pH cannot be lowered below 6, regardless of the severity of metabolic acidosis.
2. It leads to increased excretion of ions (sodium, calcium, potassium, sulfate, phosphate), with the following effects:
   a. Decrease in ECF volume
   b. Hypokalemia (defect in H⁺/K⁺ pump in alpha-intercalated cell)
   c. Renal stones/nephrocalcinosis (due to increased calcium and phosphate excretion into alkaline urine)
   d. Rickets/osteomalacia in children
3. Leads to hypokalemic, hyperchloremic, nonanion gap metabolic acidosis
4. Symptoms are secondary to nephrolithiasis and nephrocalcinosis. Up to 70% of patients have kidney stones.
5. Causes: congenital, multiple myeloma, nephrocalcinosis, nephrotoxicity (e.g., amphotericin B toxicity), autoimmune diseases (lupus, Sjögren syndrome), medullary sponge kidney, and analgesic nephropathy.
6. Treatment
   a. Correct acidosis with sodium bicarbonate. This can also help prevent kidney stones, which is a major goal of therapy.
   b. Administer phosphate salts (promotes excretion of titratable acid).

<table>
<thead>
<tr>
<th>Type</th>
<th>Distinguishing Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (distal)</td>
<td>• Inability to secrete H⁺</td>
</tr>
</tbody>
</table>
• Urine pH >6
• Nephrolithiasis and nephrocalcinosis do occur

2 (proximal)
- Inability to reabsorb HCO$_3^-$
- Increased bicarbonate excretion
- Nephrolithiasis and nephrocalcinosis do not occur

3 (mixed)
- Rare autosomal recessive disorder: carbonic anhydrase II deficiency
- Characteristics of type I and II

4 (hyperaldosteronism)
- Decreased Na$^+$ absorption and H$^+$ and K$^+$ secretion in distal tubule
- Results in hyperkalemia and acidic urine
- Nephrolithiasis and nephrocalcinosis are rare

C. Type 2 (Proximal)
1. The defect is an inability to reabsorb HCO$_3^-$ at the proximal tubule, resulting in increased excretion of bicarbonate in the urine and metabolic acidosis. The patient also loses K$^+$ and Na$^+$ in the urine.
2. Characterized by hypokalemic, hyperchloremic nonanion gap metabolic acidosis (as in type 1 RTA)
3. Causes
   a. Fanconi syndrome (in children), defined as a generalized proximal resorption defect
   b. Cystinosis, Wilson disease, lead toxicity, multiple myeloma (monoclonal gammopathies are the major cause in adults), nephrotic syndrome, amyloidosis, acetazolamide
   c. The excretion of monoclonal light chains is a common feature, so multiple myeloma should always be ruled out in a patient with proximal RTA.
4. Nephrolithiasis and nephrocalcinosis do not occur (as they do in type 1 RTA).
5. Treatment: treat the underlying cause.
   a. Do not give bicarbonate to correct the acidosis because it will be excreted in the urine.
   b. Sodium restriction increases sodium reabsorption (and thus bicarbonate reabsorption) in the proximal tubule.

D. Type 4
1. This is the name for the normal anion gap metabolic acidosis that results from any condition that is associated with hypoaldosteronism, or increased renal resistance to aldosterone.
2. It is common in patients with interstitial renal disease and diabetic nephropathy.
3. It is characterized by decreased Na$^+$ absorption and decreased H$^+$ and K$^+$ secretion in the distal tubule.
4. Unlike other types of RTA, type 4 results in hyperkalemia and acidic urine.
(although a nonanion gap metabolic acidosis still occurs).
5. Nephrolithiasis and nephrocalcinosis are rare.
Hartnup Syndrome

Autosomal recessive inheritance of defective amino acid transporter
Results in decreased intestinal and renal reabsorption of neutral amino acids, such as tryptophan, causing nicotinamide (niacin analog) deficiency
Clinical features are similar to those of pellagra: dermatitis, diarrhea, ataxia, and psychiatric disturbances.
Give supplemental nicotinamide if the patient is symptomatic.
Fanconi Syndrome

Fanconi syndrome is a hereditary or acquired proximal tubule dysfunction that leads to defective transport of some of the following: glucose, amino acids, sodium, potassium, phosphate, uric acid, and bicarbonate. Recall that the proximal tubule is the primary site of resorption in the nephron. It is associated with glucosuria, phosphaturia (leads to skeletal problems: rickets/impaired growth in children; osteomalacia, osteoporosis, and pathologic fractures in adults), proteinuria, polyuria, dehydration, type 2 RTA, hypercalciuria, and hypokalemia.
Treat with phosphate, potassium, alkali and salt supplementation, as well as adequate hydration.
Renal Cystic Diseases

Autosomal Dominant Polycystic Kidney Disease

A. General Characteristics

1. Polycystic kidney disease may be inherited as an autosomal dominant or autosomal recessive trait. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of CKD (Figure 7-4).

2. The course is variable, but ESRD commonly develops in 50% of the patients (by late 50s or 60s); remainder have a normal lifespan. Renal failure occurs from cysts replacing renal parenchyma over time, as well as recurrent episodes of pyelonephritis and nephrolithiasis.

![Renal ultrasound demonstrating polycystic kidney disease](image)

**FIGURE 7.4** The renal ultrasound demonstrates polycystic kidney disease.

(From Kawamura DM, Nolan TD. *Diagnostic Medical Sonography: Abdomen and Superficial Structures*. 4th ed. Philadelphia, PA: Wolters Kluwer; 2018, Figure 5-23F.)
B. Clinical Features
1. Hematuria: usually visible and thought to be due to rupture of cysts into the collecting system
2. Abdominal pain: sources include pyelonephritis, stones, and hemorrhaging into cysts
3. HTN (in >50% of the cases)
4. Palpable kidneys on abdominal examination
5. Complications/associated findings
   a. **Intracerebral berry aneurysm (in 5% to 20% of cases)—most do not rupture**
   b. Infection of renal cysts; bleeding into cysts
   c. Renal failure (late in the disease)
   d. Kidney stones
   e. Heart valve abnormalities (especially mitral valve prolapse)
   f. Cysts in other organs (liver, spleen, pancreas, brain)
   g. Diverticula (colon)
   h. Hernias (abdominal/inguinal)

---

Quick HIT

ADPKD presents with:
- Pain
- Hematuria
- Infection
- Hypertension
- Kidney stones

---

C. Diagnosis
1. Ultrasound is confirmatory—multiple cysts appear on the kidney.
2. CT scan and MRI are alternatives.

D. Treatment
1. No curative therapy is available.
2. Drain cysts if symptomatic.
3. Treat infection with antibiotics.
Autosomal Recessive Polycystic Kidney Disease

A. General Characteristics
1. Autosomal recessive polycystic kidney disease (ARPKD) was previously called infantile polycystic kidney disease. It is characterized by cysts predominantly in the renal collecting ducts as well as hepatic fibrosis.
2. It is less common compared to the ADPKD, though the true incidence is unknown since many affected newborns die without proper diagnosis.
3. As with ADPKD, there is a wide variability in the level of renal impairment. However, most patients ultimately will experience progressive renal failure.

B. Clinical Features
1. Liver involvement is always present, and may be the dominant clinical feature, especially in older individuals.
   a. Hepatic complications include portal HTN and cholangitis.
2. Kidneys are increased in size which may cause severe abdominal distension.
3. HTN
4. Pulmonary insufficiency secondary to pulmonary hypoplasia and enlarged kidneys limiting diaphragmatic movement may be severe. Pulmonary complications are the leading cause of morbidity and mortality in the neonatal period.
5. Newborns with severe ARPKD may present with Potter syndrome, which is the constellation of clinical features associated with decreased amniotic fluid (oligohydramnios). Potter syndrome is characterized by hypoplasia of the lungs, limb abnormalities (e.g., club feet), and characteristic abnormal facies.

C. Diagnosis
1. Some cases are detected prenatally due to the widespread use of ultrasound during pregnancy. Less severe cases may not be detected until much later.
2. Oligohydramnios during pregnancy usually indicates severe disease.
3. Ultrasound will show characteristic renal cysts in the absence of renal cysts in either parent. Ultrasound will also show hepatomegaly and dilated bile ducts.
4. Molecular genetic testing may confirm the disease in cases where the diagnosis is unclear.

D. Treatment
1. No curative therapy is available.
2. Manage respiratory issues in newborns, and treat ESRD with renal replacement therapy.
**Medullary Sponge Kidney**

Characterized by cystic dilation of the collecting ducts (Figure 7-5)

May present with hematuria, UTIs, or nephrolithiasis, can often also be asymptomatic

Thought to be associated with hyperparathyroidism and parathyroid adenoma

Diagnosed by IVP

No treatment is necessary other than the prevention of stone formation and the treatment of recurrent UTIs

---

**FIGURE 7.5**

Excretory urogram in a patient with medullary sponge kidney, showing multiple spherical or oval dilatations of medullary collecting ducts in all papillary groups of the right kidney, giving a “bouquets of flowers” appearance.

(From Schrier RW. Diseases of the Kidney and Urinary Tract. 8th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007, Figure 17-8.)
**Simple Renal Cysts**

Very common (50% of the people over age 50); incidence increases with age
May be single or multiple; usually asymptomatic and discovered incidentally on abdominal ultrasound or other imaging study
Occasionally associated with hematuria or pain from rupture, infection, or hypertension
No treatment is necessary in most cases
Renal Vascular Disease

Renal Artery Stenosis (Renovascular Hypertension)

A. General Characteristics

1. Renal artery stenosis causes a decrease in blood flow to the juxtaglomerular apparatus. As a result, the renin–angiotensin–aldosterone system becomes activated, leading to HTN.
2. **This is the most common cause of secondary HTN.**

B. Causes

1. Atherosclerosis
   a. Accounts for two-thirds of the cases (most often in elderly men)
   b. Bilateral in up to one-third of the cases
   c. Smoking and high cholesterol levels are predisposing factors.
2. Fibromuscular dysplasia
   a. Usually seen in young females
   b. Bilateral in 50% of patients

**Quick HIT**

ACE inhibitors should be used carefully in patients with renovascular HTN.

C. Clinical Features

1. HTN—look for a sudden onset of HTN in a patient without a family history, that is severe (may cause malignant HTN), and/or that is refractory to multiple antihypertensive agents.
2. Decreased renal function
3. Abdominal bruit (RUQ, LUQ, or epigastrium) is present in 50% to 80% of patients; it is especially common in patients with fibromuscular hyperplasia.

**Quick HIT**

Suspect renovascular HTN in the following situations:
- Malignant HTN
- Sudden onset of HTN
- HTN that suddenly worsens
- HTN that does not respond to standard medical therapy
D. Diagnosis
1. Renal arteriogram is the gold standard, but contrast dye can be nephrotoxic—do not use it in patients with renal failure.
2. MRA is a new test that has high sensitivity and specificity. The magnetic dye is not nephrotoxic so it can be used in patients with renal failure.
3. Duplex Doppler ultrasonography of the renal arteries and contrast enhanced CT scan may also be helpful in some cases.

E. Treatment
1. Revascularization with percutaneous transluminal renal angioplasty (PRTA) is the initial treatment in most patients; it has a higher success rate and a lower restenosis rate with fibromuscular dysplasia than with the atherosclerotic type.
2. Surgery if PRTA is not successful (bypass).
3. Conservative medical therapy (ACE inhibitors, calcium channel blockers) may be tried alone or in combination with revascularization procedures. ACE inhibitors may inhibit kidneys’ natural mechanism to increase GFR when RBF is low from stenosis (efferent arteriole constriction) and thus should be used carefully.
Renal Vein Thrombosis

May be seen in the following clinical settings: nephrotic syndrome (due to increased risk of VTE), invasion of renal vein by renal cell carcinoma, trauma, pregnancy/oral contraceptives, extrinsic compression (retroperitoneal fibrosis, aortic aneurysm, lymphadenopathy), or severe dehydration (in infants). Clinical features depend on the acuity and severity of the process and include decreased renal perfusion (can lead to renal failure), flank pain, HTN, hematuria, and proteinuria. Chronic thromboses are largely asymptomatic but may lead to progressive renal damage or PE. Diagnostic tests include selective renal venography visualizing the occluding thrombus (definitive study) or IVP. Anticoagulate to prevent pulmonary embolism.
Atheroembolic Disease of the Renal Arteries

Refers to showers of cholesterol crystals that dislodge from plaques in large arteries and embolize to the renal vasculature.

Can occur in other organs as well, such as the retina, brain, or skin.

Refer to cholesterol embolization syndrome in Chapter 1.
Hypertensive Nephrosclerosis

A. Definition: Systemic HTN increases capillary hydrostatic pressure in the glomeruli, leading to benign or malignant sclerosis.

1. Benign nephrosclerosis—hypertrophic thickening of the glomerular afferent arterioles and glomeruli themselves (global or focal segmental) develops in patients with long-standing HTN.
   a. Results in mild to moderate increase in Cr levels, microscopic hematuria, and mild proteinuria
   b. Advanced disease can lead to ESRD.

   **Quick HIT**

   Nephrosclerosis due to HTN is the second most common cause of ESRD (diabetes is the most common cause).

2. Malignant nephrosclerosis—this accelerated variant of nephrosclerosis typically may develop in a patient with malignant hypertension or with long-standing benign HTN.
   a. Characterized by a rapid decrease in renal function and accelerated HTN due to diffuse intrarenal vascular injury. It is also known as acute hypertensive nephrosclerosis.
   b. African-American men are the most susceptible.
   c. Clinical manifestations include:
      - Markedly elevated BP (papilledema, cardiac decompensation, CNS findings).
      - Renal manifestations: a rapid increase in Cr, proteinuria, hematuria, RBC and WBC casts in urine sediment, and sometimes nephrotic syndrome
      - Microangiopathic hemolytic anemia may also be present.

B. Treatment

1. The most important treatment for both benign and malignant forms is controlling the BP (see Chapter 12). It is not clear which blood pressure agents should be used in the chronic setting, or how effective they are once frank albuminuria is present. Care must also be taken to avoid acutely dropping renal perfusion.
2. In advanced disease, treat as for CKD. Dialysis may be required.
Scleroderma

In rare cases, this may cause malignant HTN. See Chapter 6.
Sickle Cell Nephropathy

If ischemic injury to the renal tubules occurs (due to hemodynamic changes or nephrotoxins), there is increased risk of dehydration (from impaired urine concentration), precipitating sickling crises. This sickling of RBCs in the microvasculature leads to infarction. In the kidney this occurs mostly in the renal papilla. Sequelae of recurrent papillary infarction include papillary necrosis, ATN, and renal failure, as well as a high frequency of UTIs. Nephrotic syndrome can also develop (which can lead to renal failure). It progresses to ESRD in approximately 5% of the patients. ACE inhibitors may be helpful.

**Quick HIT**

### Causes of Hypercalciuria and Hyperoxaluria

**Causes of hypercalciuria**
- ↑ Intestinal absorption of calcium, not usually from diet alone
- ↓ Renal reabsorption of calcium, leading to ↑ renal excretion of calcium
- ↑ Bone reabsorption of calcium
- Primary hyperparathyroidism
- Sarcoidosis
- Malignancy
- Vitamin D excess
- Acidemia, leading to displacement of calcium from albumin

**Causes of hyperoxaluria**
- Severe steatorrhea of any cause can lead to calcium oxalate stones (due to calcium binding to fat instead of oxalate in intestine and thus ↑ absorption of free oxalate)
- Small bowel disease, Crohn disease
- Pyridoxine deficiency
- Vitamin C excess
- Ethylene glycol ingestion
Stones and Obstructions

Nephrolithiasis

A. General Characteristics

1. Nephrolithiasis is the development of stones within the urinary tract.
2. Sites of obstruction
   a. Ureterovesicular junction—most common site of impaction
   b. Calyx of the kidney
   c. Ureteropelvic junction
   d. Intersection of the ureter and the iliac vessels (near the pelvic brim)
3. Risk factors
   a. In general, precipitation is dependent on factors which affect the relative concentration of certain stone-forming substances within the urine as well as urine pH.
   b. Low fluid intake—most common and preventable risk factor which can predispose to concentration of urine and precipitation of crystals
   c. Family history
   d. Conditions known to precipitate stone formation (e.g., gout [hyperuricemia], Crohn disease [hyperoxaluria], hyperparathyroidism [hypercalciuria], type 1 RTA [increased urine pH])
   e. Medications (e.g., loop diuretics [hypercalciuria], acetazolamide [increased urine pH], antacids, chemotherapeutic drugs that cause cell breakdown [uric acid stones], medications which can themselves precipitate in the nephrons [acyclovir, sulfadiazine])
   f. Male gender (three times more likely to have urolithiasis)
   g. UTIs (especially with urease-producing bacteria leading to struvite stones)
   h. Dietary factors—low calcium and high oxalate intake, both of which lead to hyperoxaluria (high calcium intake itself is rarely associated with increased stones)
4. Types of stones
   a. Calcium stones (most common form)
      - Account for 80% to 85% of urinary stones; composed of calcium oxalate or calcium phosphate (less often) or both
      - Bipyramidal or biconcave ovals
      - Radiodense (i.e., visible on an abdominal radiograph)
      - Secondary to hypercalciuria and hyperoxaluria, which can be due to a variety of causes
- Acidic urine pH promotes calcium oxalate stone formation while a basic pH induces calcium phosphate stones

b. Uric acid stones (second most common)
- Account for 10% of stones
- Flat square plates
- **Stones are radiolucent (cannot be seen on an abdominal radiograph)—** require CT, ultrasound, or IVP for detection.
- These are associated with hyperuricemia, secondary to gout or to chemotherapeutic treatment of leukemias and lymphomas with high cell destruction. The release of purines from dying cells leads to hyperuricemia.
- A persistently acidic urine pH (<5.5) promotes uric acid stone formation.

c. Struvite stones (staghorn stones)
- Account for 5% to 10% of stones
- Radiodense (visible on an abdominal radiograph); rectangular prisms
- Occur in patients with recurrent UTIs due to urease-producing organisms (Proteus, Klebsiella, Serratia, Enterobacter spp.)
- They are facilitated by alkaline urine: urea-splitting bacteria convert urea to ammonia, thus producing the alkaline urine.
- The resultant ammonia combines with magnesium and phosphate to form struvite calculi, which may involve the entire renal collecting system.

d. Cystine stones
- Account for 1% of urinary stones
- Genetic predisposition—cystinuria (autosomal recessive), usually seen in children
- Hexagon-shaped crystals are poorly visualized.

5. Clinical course
   a. If a stone is >1 cm, it is unlikely to pass spontaneously. **Stones <0.5 cm usually do pass spontaneously.**
   b. Recurrence is common. Up to 50% of the patients have recurrences within 10 years of having the first stone.

---

**Quick HIT**

Classic Presentation of Nephrolithiasis
- Sudden onset of colicky flank pain that radiates into groin
- Urinalysis showing hematuria

B. Clinical Features
1. Renal colic—refers to the pain associated with passing a kidney stone into the
ureter, with ureteral obstruction and spasm

a. Description of pain—begins suddenly and soon may become severe (patient cannot sit still—usually writhes in excruciating pain). Pain may occur in waves or paroxysms.

b. Location of pain—begins in the flank and radiates anteriorly toward the groin (i.e., follows path of the stone)

2. Nausea and vomiting are common.

3. Hematuria (in over 90% of the cases)

4. UTI

C. Diagnosis

1. Laboratory testing
   a. Urinalysis
      • Reveals either microscopic or gross hematuria
      • Reveals an associated UTI if pyuria or bacteriuria are present
      • Examine the urinary sediment for crystals (calcium, cystine, uric acid, or struvite crystals)
      • Determine the urinary pH—alkaline urine might indicate the presence of urease-producing bacteria that cause an infection stone. Acidic urine is suggestive of uric acid stones.
   b. Urine culture—obtain if infection is suspected.
   c. Twenty-four–hour urine—collect to assess Cr, calcium, uric acid, oxalate, and citrate levels. Usually done for patients with recurrent stones to assess risk factors and etiology.
   d. Serum chemistry—obtain BUN and Cr levels (for evaluation of renal function, if kidney parenchyma are not damaged this will likely be normal) and also calcium, uric acid, and phosphate levels.
   e. Stone analysis: patient can strain urine for stones, which can then be sent for analysis of chemical composition.

Quick HIT
Hematuria plus pyuria indicates a stone with concomitant infection.

2. Imaging
   a. Plain radiograph of the kidneys, ureter, and bladder (KUB) (Figure 7-6)
      • Initial imaging test for detecting stones
      • Cystine and uric acid stones are not usually visible on plain films.
   b. CT scan (spiral CT) without contrast
• Gold standard for diagnosis. Most sensitive test for detecting stones
• All stones, even radiolucent ones such as uric acid stones and cystine stones, are visible on the CT scan.

c. IVP
• Most useful test for defining degree and extent of urinary tract obstruction
• This is usually not necessary for the diagnosis of renal calculi. IVP may be appropriate for deciding whether a patient needs procedural therapy.

d. Renal ultrasonography
• Helps in detecting hydronephrosis or hydroureter
• False-negative results are common in early obstruction. Also, there is a low yield in visualizing the stone.
• Procedure of choice in patients who cannot receive radiation (i.e., pregnant patients)

Quick HIT

Having the stone for analysis is very helpful both in treatment and in preventing recurrence. Likewise, reporting a history of stones and their composition (if determined) is very helpful. The patient should attempt to recover the stone that is passed (strain urine).
D. Treatment

1. General measures (for all types of stones)
   a. Analgesia: IV morphine, parenteral NSAIDs (ketorolac)
   b. Vigorous fluid hydration—beneficial in all forms of nephrolithiasis
   c. Alpha-1 blockers (tamsulosin) may be used to facilitate stone passage.
   d. Antibiotics—if UTI is present
   e. Outpatient management is appropriate for most patients. Indications for hospital admission include:
- Pain not controlled with oral medications
- Anuria (usually in patients with one kidney)
- Renal colic plus UTI and/or fever
- Large stone (>1 cm) that is unlikely to pass spontaneously

2. Specific measures (based on severity of pain)
   a. Mild to moderate pain: high fluid intake, oral analgesia while waiting for stone to pass spontaneously (give the patient a urine strainer)
   b. Severe pain (especially with vomiting)
      - Prescribe IV fluids and pain control.
      - Obtain a KUB and an IVP to find the site of obstruction.
      - If a stone does not pass spontaneously after 3 days, consider urology consult.
   c. Surgical intervention is necessary in cases of ongoing obstruction and persistent pain not controlled by narcotics, signs of infection/sepsis, kidney injury/failure, or failure to respond to conservative measures.
      - Extracorporeal shock wave lithotripsy (most common method) breaks the stone apart using sound waves; once the calculus is fragmented, the stone can pass spontaneously. Best for stones that are >5 mm but <2 cm in diameter.
      - If lithotripsy fails or if stone is >2 cm in diameter, percutaneous or ureteroscopic nephrolithotomy (surgical stone removal) is indicated.
      - If obstruction is complicated by infection, renal insufficiency or failure, urgent intervention via stent or nephrostomy tube is indicated.

3. Prevention of recurrences
   a. Dietary measures
      - High fluid intake is essential (keep urine volume at 2 L/day)
      - Limit animal protein intake in patients with hyperuricosuria (uric acid stones).
      - Advise patient to not to restrict calcium in their diet as lower intake is associated with hyperoxaluria and increased stones (unless in rare cases when dietary intake is identified as likely etiology of stones).
   b. Pharmacologic measures
      - Thiazide diuretics reduce urinary calcium and have been found to lower recurrence rates, especially in patients with hypercalciuria.
      - Allopurinol is effective in preventing recurrence in patients with high uric acid levels in the urine.
Urinary Tract Obstruction

A. General Characteristics

1. Can lead to renal insufficiency and hydronephrosis (dilation of urinary tract, specifically the pelvis and calyces)
2. More common in men (due to BPH and prostate cancer)
3. Urinary tract obstruction does not usually cause AKI unless the obstruction is bilateral or there is pre-existing renal damage.
4. Classification
   a. Acute versus chronic obstruction
      • Acute obstruction—clinical features are sudden in onset.
      • Chronic obstruction—this causes progressive renal failure/uremia, recurrent infections, and bladder calculi.
   b. Lower versus upper tract obstruction
      • Lower tract obstruction (below ureterovesical junction)—affects urination
      • Upper tract obstruction (above ureterovesical junction)—typically causes renal colic
   c. Complete versus partial obstruction
   d. Unilateral versus bilateral obstruction (if upper tract)
5. Degree of damage to kidneys and likelihood of return to normal renal function is dependent on the severity and duration of the obstruction.
6. Causes
   a. Lower tract obstruction
      • BPH, prostate cancer
      • Urethral stricture, stone
      • Neurogenic bladder (multiple sclerosis, diabetes)
      • Trauma (pelvic fracture or straddle injury)
      • Bladder cancer
   b. Upper tract obstruction
      • Intrinsic causes—kidney stones, blood clots, sloughed papilla (RPN), crystal deposition (e.g., uric acid), tumors, strictures, ureteropelvic or ureterovesical junction dysfunction
      • Extrinsic causes—pregnancy, tumors (gynecologic, metastatic), abdominal aortic aneurysm, retroperitoneal fibrosis, endometriosis, prolapse, hematomas, Crohn disease, diverticulitis

Quick HIT

Evaluation of urinary tract obstruction
B. Clinical Features (depend on duration, location, cause, and duration of obstruction)

1. Renal colic and pain—this is more common with acute obstruction (kidney stones, sloughed papilla, blood clot); pain may manifest only during urination. Chronic obstruction may be asymptomatic.
2. Suprapubic pain and distention—may be seen in lower urinary tract obstruction
3. Urine output may be normal, though oliguria/anuria may be seen in complete obstruction (usually in lower tract obstruction).
4. Signs/symptoms of UTI, which can be a result of urinary stasis or stones
5. Hypertension, particular in oliguric patients due to sodium/fluid retention
6. Renal failure

C. Diagnosis

1. Renal ultrasound is the initial test—it shows urinary tract dilation. It is very sensitive and specific for identifying hydronephrosis
2. Urinalysis (may reveal hematuria or proteinuria), standard laboratory tests (e.g., CBC, electrolytes, BUN, Cr)
3. KUB—can reveal stones
4. Intravenous urogram—also called IVP
   a. Gold standard for diagnosis of ureteral obstruction
   b. Contraindicated if the patient is pregnant, is allergic to contrast material, or has renal failure
5. Voiding cystourethrography—for lower tract obstruction
6. Cystoscopy—to evaluate urethra and bladder
7. CT scan—to help identify the cause of obstruction

Quick HIT

If a patient has an acute obstruction and a UTI, emergent diagnostic tests (renal ultrasound or excretory urogram) are indicated. Intervene immediately to relieve the obstruction.

D. Treatment

1. Treatment depends on duration, severity, location, and cause of the obstruction.
2. Location of obstruction
   a. Lower urinary tract obstruction
      • Urinary catheter—for acute obstruction (can be diagnostic and therapeutic), urethral catheter is first choice but if passage is difficult or contraindicated,
suprapubic catheter may be used.

- Dilatation or internal urethrotomy—if cause is urethral strictures
- Prostatectomy—if BPH is the cause

b. Upper urinary tract obstruction
   - Nephrostomy tube drainage—for acute obstruction, particularly in urgent setting when kidney function is impaired or infection is present and source control is needed
   - Ureteral stent (through cystoscope)—if ureteral obstruction

3. Duration and severity of obstruction
   a. Acute complete obstruction—pain or renal failure may be present. This requires immediate therapy.
   b. Acute partial obstruction—usually due to stones (see the Treatment section of Nephrolithiasis)
   c. Chronic partial obstruction—this requires immediate therapy only when infection, severe symptoms, renal failure, or urinary retention is present.
Neoplasms

Prostate Cancer

A. General Characteristics: Prostate cancer is the second most common form of cancer in men worldwide (see also Clinical Pearl 7-8). Ninety-five percent are adenocarcinomas which arise in the peripheral (outermost) zone of the prostate.

1. Risk factors
   a. Age (most important risk factor)
   b. African-American race

   CLINICAL PEARL 7-8

   Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography
   
   - If PSA level >10 ng/mL, TRUS with biopsy is indicated, regardless of DRE findings.
   - If DRE is abnormal, TRUS with biopsy is indicated, regardless of PSA level.
   - If PSA is <4.0 ng/mL and DRE is negative, annual follow-up is indicated.
   - If PSA is 4.1 to 10.0 and DRE is negative, biopsy is usually recommended.

   c. High-fat diet
   d. Positive family history
   e. Exposure to herbicides and pesticides—certain occupations, such as farming and work in industrial chemical industry, present a higher risk.

B. Clinical Features

1. Early stages—it is most commonly asymptomatic. Cancer begins in the periphery of the gland and moves centrally. Thus, obstructive symptoms occur late. In fact, by the time prostate cancer causes urinary obstruction, it often has metastasized to bone or lymph nodes.

2. As the cancer grows locally—symptoms due to obstruction of the urethra occur as the other zones of the prostate are affected: difficulty in voiding, dysuria, and increased urinary frequency.

3. Advanced stages/metastasis—bone pain from metastases (most commonly vertebral bodies, pelvis, and long bones in legs), weight loss.

Quick HIT

Vertebral metastasis may manifest itself as low back pain in an elderly man with prostate cancer.
C. Diagnosis

1. Digital rectal examination (DRE).
   a. Carcinoma is characteristically hard, nodular, and irregular.
   b. Normal prostate feels like a thenar eminence. Cancer feels like a knuckle. Men with induration, asymmetry, or palpable nodularity of prostate need a biopsy, especially if over age 45.
   c. If DRE is abnormal, transrectal ultrasonography (TRUS) with biopsy is indicated, regardless of the prostate-specific antigen (PSA) level.
   d. When palpable, 60% to 70% have spread beyond the prostate.

2. PSA
   a. Not used routinely as a screening test as the absolute risk reduction of death from prostate cancer is small (growth is very slow and most will die of other causes) and the harm from unnecessary biopsies and interventions may be more significant.
   b. PSA is not cancer specific. PSA levels also increase as a result of the following:
      • Prostatic massage (but DRE does not change PSA levels)
      • Needle biopsy
      • Cystoscopy
      • BPH
      • Prostatitis
      • Advanced age

Quick HIT

The combination of DRE and PSA levels can detect up to 60% of prostate cancers while they are still localized.

c. Refinements of the PSA assay—some strategies for improving the diagnostic capability of the PSA test include:
   • Age-adjusted PSA (because PSA normally increases with age).
   • PSA velocity—analysis of the rate of increase in the level with time.
   • Quantifying free and protein-bound forms of serum PSA—PSA produced by prostate cancer tends to be bound by plasma proteins, whereas PSA produced by normal cells is more likely to be free in plasma.
   • PSA density—correlation of PSA levels with prostate volume.

Quick HIT

Key points about PSA:
1. The higher the PSA, the higher the cancer risk
2. Normal PSA does not rule out prostate cancer
3. TRUS with biopsy
   a. May need to repeat biopsies for definitive diagnosis
   b. Indications
      - PSA > 10 ng/dL (or possibly lower). If PSA is >10, chance of finding cancer is over 50%.
      - PSA velocity >0.75 per year
      - Abnormal DRE

4. Other tests in the evaluation include a bone scan, plain radiographs of the pelvis and spine, and a CT scan of the pelvis to evaluate for metastatic disease.

Quick HIT

**Stages of Prostate Cancer**
- Stage A—nonpalpable, confined to prostate
- Stage B—palpable nodule, but confined to prostate
- Stage C—extends beyond capsule without metastasis
- Stage D—metastatic disease

D. Treatment

1. Localized disease (to prostate)—this is usually a curable disease. The definitive therapy is radical prostatectomy. However, watchful waiting is warranted in older men (i.e., those whose remaining natural life expectancy is <10 years) who are asymptomatic. Most common complications of prostatectomy are erectile dysfunction and urinary incontinence.

2. Locally invasive disease—**give radiation therapy plus androgen deprivation** (not curative, but decreases the local spread).

3. Metastatic disease—reduce the amount of testosterone with any of the following:
   a. Orchietomy (removes testes)—more common in patients who are noncompliant with medical therapy.
   b. Antiandrogens.
   c. GnRH agonists—cause continuous stimulation of receptor instead of normal pulsatile activation, leading to suppression of luteinizing hormone release (leuprolide).
   d. GnRH antagonists—suppress testosterone by binding to and blocking receptors in the pituitary without causing a transient surge of LH or FSH (degarelix).
Renal Cell Carcinoma

A. General Characteristics

1. It is twice as common in men as in women.
2. Renal cell carcinoma (RCC) comprises about 85% of primary renal cancers (transitional cell of the renal pelvis is the second most common).
3. Most cases are sporadic; less than 2% occur as part of autosomal dominant von Hippel–Lindau syndrome. The pathogenesis is unknown.
4. Usually discovered when localized to kidney or with regional lymph node spread
5. Areas of metastasis include the lung, liver, brain, and bone. Tumor thrombus can invade the renal vein or inferior vena cava, resulting in hematogenous dissemination.

Quick HIT

Up to 20% to 30% of cases of renal cell carcinoma are discovered incidentally on a CT scan or ultrasound performed for other reasons.

B. Risk Factors

1. Cigarette smoking
2. Analgesics (high use), particular phenacetin-containing medications but acetaminophen, NSAIDs, and aspirin have also been implicated.
3. Adult polycystic kidney disease
4. Chronic dialysis (multicystic disease develops)
5. Exposure to heavy metals (mercury, cadmium)
6. Hypertension
7. Obesity

C. Clinical Features

1. Hematuria is the most common symptom (gross or microscopic)—occurs in 70% of the patients.
2. Abdominal or flank pain—occurs in 50% of the patients
3. Abdominal (flank) mass—occurs in 40% of the patients
4. Findings seen in many neoplasms: Weight loss, fever, anemia of chronic inflammation
5. Paraneoplastic syndromes (uncommon)—these tumors can ectopically secrete erythropoietin (causing polycythemia), PTH-like hormone (causing hypercalcemia), renin (causing HTN), cortisol (causing Cushing syndrome), or gonadotropins (causing feminization or masculinization).
Quick HIT

The classic triad of hematuria, flank pain, and abdominal mass occurs in less than 10% of patients with renal cell carcinoma.

D. Diagnosis
1. Abdominal CT (with and without contrast)—optimal test for diagnosis and staging; perform if ultrasound shows a mass or cysts. Cannot distinguish benign and malignant solid masses, both are usually empirically resected.
2. Renal ultrasound—occasionally used for detection of renal mass and to distinguish from cyst

E. Treatment
1. Partial nephrectomy (open or laparoscopic) can be used for smaller tumors, particularly when bilateral or with associated genetic syndrome, to save renal parenchyma and function.
2. Radical nephrectomy (excision of kidney and adrenal gland, including Gerota fascia with excision of nodal tissue along the renal hilum) when any invasion into surrounding vasculature or adipose is noted.
3. For advanced disease, debulking surgery and adjuvant chemotherapy is often used.
Bladder Cancer

A. General Characteristics
1. Bladder carcinoma is the most common type of tumor of the genitourinary tract; 90% of bladder cancers are transitional cell carcinomas. Transitional cell carcinomas can occur anywhere from the kidney to the bladder (e.g., renal pelvis, ureter), but 90% of these carcinomas are in the bladder.
2. The most common route of spread is direct local extension to surrounding tissues (rather than hematologic/lymphatic dissemination).
3. It is likely to recur after removal.
4. Risk factors
   a. Cigarette smoking (the major identified risk factor)
   b. Industrial carcinogens (aniline dye, azo dyes)
   c. Long-term treatment with cyclophosphamide (may cause hemorrhagic cystitis and increase the risk of transitional cell carcinoma)

Quick HIT
Transitional cell carcinoma accounts for 90% of all bladder cancers. Other types are squamous cell (5%) and adenocarcinoma (2%).

B. Clinical Features
1. Initial presenting sign is hematuria in most cases (painless hematuria is the classic presentation). It is more likely to be gross, but can be microscopic as well.
2. Irritable bladder symptoms, such as dysuria, frequency, and/or urgency
3. Pain or obstructive symptoms may be seen when carcinoma becomes more invasive.
4. Physical exam is usually unremarkable.

C. Diagnosis
1. Urinalysis and urine culture—to detect RBCs and confirm hematuria as red urine may also be due to various foods or medications (e.g., beets, dyes, phenazopyridine, myoglobin, Serratia) and to rule out infection
2. Urine cytology—to detect malignant cells
3. Cystoscopy and biopsy—definitive test which should be performed in all patients >40 years old or with risk factors for bladder cancer
4. Chest radiograph and CT scan—for staging
5. IVP is superior at detecting certain small tumors of ureter or renal pelvis, it can also be used if CT unavailable.

D. Treatment (depends on the stage of the disease)
1. Stage 0 (superficial, limited to mucosa; also known as carcinoma in situ)—intravesical chemotherapy

2. Stage A (involves lamina propria)
   a. Transurethral resection of the bladder tumor
   b. **Tends to recur**, so frequent cystoscopy and removal of recurrent tumors are indicated

3. Stage B (muscle invasion)—radical cystectomy, lymph node dissection, removal of prostate/uterus/ovaries/anterior vaginal wall, and urinary diversion (e.g., ileal conduit)
   a. **Extension of the tumor into the muscular layer** is an important branching point of therapy as it indicates radical cystectomy has become necessary to prevent further spread

4. Stage C (extends to perivesicular fat)—treatment is the same as for stage B

5. Stage D (metastasis to lymph nodes, abdominal organs, or distant sites)—consider cystectomy and systemic chemotherapy
Testicular Cancer

A. General Characteristics
1. Most common in men 20 to 35 years of age, but can occur in men of any age
2. Has a relatively high cure rate compared with other cancers
3. Types
   a. Germ cell tumors (account for 95% of all testicular cancers)—most common in men 20 to 40 years of age; curable in >95% of the cases
      • Seminomas (35%)—most common; slow growth and late invasion; most radiosensitive
      • Nonseminomatous (65%)—usually contain cells from at least two of the following four types (mixed cell type): embryonal carcinoma (high malignant potential, hemorrhage and necrosis are common; metastases to the abdominal lymphatics and the lungs may occur as an early event); choriocarcinoma (most aggressive type; rare; metastases usually occur by time of diagnosis); teratoma (rarely metastasize); yolk sac carcinoma (rare in men, usually occurs in young boys)

Quick HIT
In a patient with a scrotal mass, perform a careful physical examination to determine its site of origin because testicular cancers are almost always malignant, whereas extratesticular tumors within the scrotum are almost always benign.

b. Nongerm cell tumors (account for 5% of all testicular cancers)—are usually benign
   • Leydig cell tumors are hormonally active—most are benign and are treated with surgery. Prognosis is poor if metastasis occurs. They may secrete a variety of steroid hormones, including estrogen and androgens, and are associated with precocious puberty in children and gynecomastia in adults.
   • Sertoli cell tumors are usually benign.

B. Risk Factors
1. Cryptorchidism—surgical correction reduces but does not eliminate risk
2. Klinefelter syndrome

C. Clinical Features
1. Painless mass/lump/firmness of the testicle—because of lack of pain, may go unnoticed by the patient until advanced.
2. While pain is rare, a “dull ache” in the pelvis is often described.
3. Gynecomastia may be present because some of the nonseminomatous germ cell
tumors produce gonadotropins.

**Quick HIT**

**Differential Diagnosis of Testicular Cancer**
- Varicocele—dilated, tortuous veins in testicle
- Testicular torsion
- Spermatocoele (testicular cyst)
- Hydrocele (fluid in testicle)
- Epididymitis
- Lymphoma

**D. Diagnosis**
1. Physical examination (testicular mass)
2. Testicular ultrasound—initial test for localizing the tumor
3. Tumor markers—helpful in diagnosis, staging, and monitoring response to therapy
   a. β-hCG
      - Always elevated in choriocarcinoma
      - May be elevated in other types of nonseminomatous germ cell tumors as well
   b. AFP
      - Increased in embryonal tumors (in 80% of the cases)
      - Choriocarcinoma and seminoma never have an elevated AFP
4. CT scan and chest radiograph for staging
5. Biopsy is NOT performed due to concern for seeding/metastasizing the tumor

**Quick HIT**

**Staging (Boden–Gibb) of Testicular Cancer**
- Stage A—confined to testis/cord
- Stage B—retroperitoneal lymph node spread (below diaphragm)
- Stage C—distant metastasis

**E. Treatment**
1. If testicular cancer is suspected based on physical examination or ultrasound, the testicle should be removed surgically (to confirm diagnosis). An inguinal approach is used because a scrotal incision may lead to tumor seeding of the scrotum.
2. After orchiectomy, perform a CT scan of the chest, abdomen, and pelvis for staging.
3. Perform β-hCG and AFP measurement after orchiectomy for comparison with the preoperative values.
4. Further treatment depends on the histology of the tumor.
   a. Seminoma—inguinal orchiectomy and radiation (very radiosensitive).
   b. Nonseminomatous disease—orchiectomy and retroperitoneal lymph node dissection with or without chemotherapy.

**Quick HIT**

A young man with a firm, painless testicular mass should be presumed to have testicular cancer until proven otherwise.
Penile Cancer

The peak incidence of this tumor is in men in their seventh decade. Circumcision may have a protective effect because penile cancer is very rare in those who have been circumcised. It is associated with herpes simplex virus and HPV 18 infection. It presents as an exophytic mass on the penis. Treatment of the primary disease is local excision.
Testicular Torsion

Epididymitis may be difficult to differentiate from testicular torsion.

Twisting of the spermatic cord leading to arterial occlusion and venous outflow obstruction; ischemia can lead to testicular infarction. Usually seen in adolescents following trauma or physical activity. Acute severe testicular pain, swollen and tender scrotum, and an elevated testicle (as twisting occurs, the testicle moves to a higher position in scrotum, the “bell clapper deformity”). Absence of cremasteric reflex is also seen. **Testicular ultrasound with Doppler** should be performed immediately, torsion is suggested by the absence of normal arterial pulsations. **This is a surgical emergency:** immediate surgical detorsion and orchiopexy to the scrotum (perform bilaterally to prevent torsion in the contralateral testicle). **If surgery is delayed beyond 6 hours, infarction may occur, and the testicle may not be salvageable.** Orchiectomy if a nonviable testicle is found.
Epididymitis

Infection of the epididymis. The common offending organism in children and elderly patients is *Escherichia coli*; in young men, sexually transmitted diseases are more common (gonorrhea, *Chlamydia*).

A swollen, tender testicle; dysuria; fever/chills; scrotal pain; and a scrotal mass. Intact cremasteric reflex.

Rule out testicular torsion with ultrasound, and administer antibiotics.

**Quick HIT**

Do not confuse testicular cancer with testicular torsion or epididymitis.
Chapter 8

Fluids, Electrolytes, and Acid–Base Disorders

Nick Villano
Volume Disorders

Approach to Volume Disorders

A. Normal Body Fluid Compartments

1. Men: total-body water (TBW) = 60% of body weight (Figure 8-1).
2. Women: TBW = 50% of body weight.
3. Percentage of TBW decreases with age and increasing obesity (TBW decreases because fat contains very little water).
4. Distribution of water.
   a. Intracellular fluid (ICF) is two-thirds of TBW (or 40% of body weight)—the largest proportion of TBW is in skeletal muscle mass.
   b. Extracellular fluid (ECF) is one-third of TBW (or 20% of body weight).
      • Plasma is one-third of ECF, one-twelfth of TBW, and 5% of body weight.
      • Interstitial fluid is two-thirds of ECF, one-fourth of TBW, and 15% of body weight.
5. Water exchange
   a. Normal intake: Average 1,500 mL in fluids taken PO per day; 500 mL in solids or product of oxidation.
   b. Normal output.
      • From 800 to 1,500 mL in urine per day is the normal range. Minimum urine output to excrete products of catabolism is about 500 to 600 mL/day, assuming normal renal concentrating ability.
      • Output of 250 mL/day occurs in stool.
      • From 600 to 900 mL/day in insensible losses occurs. This is highly variable but increases with fever, sweating, hyperventilation, and tracheostomies (unhumidified air)—see below.
   c. Remember the Starling equation and forces: fluid shift depends on hydrostatic and oncotic pressures.
   d. As osmolality of fluids (ECF or ICF) changes (e.g., hyponatremia, hyperglycemia), water will shift freely through the permeable cell membranes to maintain isotonicity, which will lead to a change in the distribution of TBW.

Quick HIT

For body fluid compartments, remember the 60-40-20 rule.
- TBW is 60% of body weight (50% for women).
- ICF is 40% of body weight.
- ECF is 20% of body weight (interstitial fluid 15% and plasma 5%).
Three reasons for oliguria:
- Low blood flow to kidney (either from volume depletion or cardiac/hepatic congestion)
- Kidney problem
- Post renal obstruction (place a Foley catheter)

B. Assessing Volume Status
1. This is not a simple task as physical exam and objective data is notoriously undependable. For example, a patient with lower extremity edema may be euvolemic, or may be total-body overloaded but intravascularly depleted. Skin turgor and mucous membranes are very difficult to assess and are not always reliable indicators of volume status. Patients with CHF may have either pulmonary edema or anasarca, depending on which ventricle is involved.
2. Tracking input and output is not an exact science either because there is no accurate way of calculating insensible losses. Monitoring urine output is very important in the assessment of volume status: Normal urine output in infants is more than 1.0 mL/kg/hr, while normal urine output for an adult is generally regarded as 0.5 to 1.0 mL/kg/hr. As long as the kidneys are functioning properly and in the absence of obstruction, low urine output reflects an appropriate response to low renal blood flow, either from volume depletion or low effective circulatory volume (as in CHF, cirrhosis).
3. Daily weights may give a more accurate assessment of volume trends.
4. Keep in mind the larger picture of the patient’s condition.
   a. Insensible losses: These may cause an underestimation of fluid needs. In general, patients with sepsis, fever, burns, or open wounds have high insensible losses (and higher metabolic demands). For each degree of atmospheric temperature over 37°C, the body’s water loss increases by approximately 100 mL/day.
   b. Oncotic pressure: Patients with liver failure, nephrotic syndrome, or any condition causing hypoalbuminemia tend to third-space fluid out of the vasculature and may be total-body hypervolemic but intravascularly depleted.
   c. Patients with ESRD are very prone to hypervolemia for obvious reasons.

C. Fluid Replacement Therapy
1. Normal saline (NS)
   a. Uses: most common resuscitative fluid used to increase intravascular volume if the patient is dehydrated or has lost blood
   b. Cautions:
      • Chloride load will tend to cause non-gap hyperchloremic metabolic acidosis with large boluses
• Remember only 25% of NS fluid volume given will stay intravascular
• Use with caution in patients with CHF unless the patient needs urgent resuscitation due to true volume depletion

**Quick HIT**

If a patient is receiving hypotonic solutions (1/2 NS, 1/4 NS), water is initially transferred from the ECF to intracellular space to equilibrate osmotic pressures in both compartments.

2. D51/2NS
   a. Uses: Often the standard maintenance fluid (often given with 20 mEq of KCl/L of fluid), can be used without D5 in diabetic patients
   b. Benefits: Has some glucose, which can spare muscle breakdown, and has water for insensible losses

3. D5W
   a. Uses:
      • Used to dilute powdered medicines
      • Often used to provide free water to correct hypernatremia
   b. Cautions:
      • Only one-twelfth remains intravascular because it diffuses into the TBW compartment, so not effective in maintaining intravascular volume
      • Use with caution in diabetic patients

4. Lactated Ringer solution
   a. Uses:
      • This is excellent for replacement of intravascular volume; it is not a maintenance fluid. It is the most common trauma resuscitation fluid.
   b. Benefits:
      • Does not cause hyperchloremic metabolic acidosis like NS
   c. Cautions:
      • Do not use if hyperkalemia is a concern (contains potassium)

5. Colloid solutions (e.g., albumin)
   a. The use of colloid solutions, as opposed to crystalloids, in the setting of acute resuscitation has been controversial. While they do, in theory, provide intravascular oncotic pressure which saline solutions do not, they have not shown clear benefit in large trials, are expensive, and may cause harm in critically ill and TBI patients due to shift of albumin into the interstitial space. They are currently not the fluid of choice.
Hypovolemia

A. Causes
1. Inadequate intake
2. Trauma, open wounds, sequestration of fluid into soft tissue injuries
3. GI losses due to vomiting, nasogastric suction, diarrhea, fistula drainage, etc.
4. Polyuria—for example, diabetic ketoacidosis (DKA)
5. Third-spacing due to ascites, effusions, bowel obstruction, crush injuries, burns
6. Sepsis, intra-abdominal and retroperitoneal inflammatory processes
7. Insensible losses—evaporatory losses through the skin (75%) and the respiratory tract (25%)

B. Clinical Features
1. CNS findings: mental status changes, sleepiness, apathy, coma
2. Cardiovascular findings (due to decrease in plasma volume): orthostatic hypotension, tachycardia, decreased pulse pressure, decreased central venous pressure (CVP), and pulmonary capillary wedge pressure (PCWP), can also be thought of in terms of the Classes of Hypovolemic Shock:
   a. Class I (<750 mL estimated blood loss [EBL]): Vital signs normal, minimal symptoms
   b. Class II (750 to 1,500 mL EBL): Tachycardia and tachypnea, normal BP, decreased urine output
   c. Class III (1,500 to 2,000 mL EBL): Above symptoms and hypotension at rest, very decreased urine output (<20 cc/hr)
   d. Class IV (>2,000 mL EBL): Above symptoms and little to no urine output
   e. Note that the initial signs of hypovolemia/hemorrhage may be subtle including tachycardia with a normal BP, once BP falls usually at least 30% blood volume has been lost
3. Skin: poor skin turgor, hypothermia, cool and pale extremities (due to vasoconstriction), dry tongue and axilla
4. Ileus, weakness
5. Decreased urine output, either compensatory to conserve fluid or as a manifestation of acute renal failure due to prerenal azotemia (fractional excretion of sodium <1% and/or BUN/creatinine >20)
6. Remember that once these symptoms of end-organ damage are present, patient has entered shock and typically has lost 20% to 30% of their total blood volume.

C. Diagnosis
1. Monitor urine output and daily weights. If the patient is critically ill and has cardiac or renal dysfunction, consider placing a Swan–Ganz catheter (to measure
CVP and PCWP).
2. Elevated serum sodium, low urine sodium, and a BUN/Cr ratio of >20:1 suggest hypoperfusion to the kidneys, which usually (not always) represents hypovolemia.
3. Hematocrit: 3% increase for each liter of deficit, unless otherwise lowered due to hemorrhage. However note that hematocrit may be normal in acute blood loss as fluid has not yet had time to transition from interstitial space back to vasculature.
4. The concentration of formed elements in the blood (RBCs, WBCs, platelets, plasma proteins) increases with an ECF deficit and decreases with an ECF excess.

**Quick HIT**

Do not combine bolus fluids with dextrose (which can lead to hyperglycemia) or potassium (which can lead to hyperkalemia).

**D. Treatment**

1. Correct volume deficit.
   a. Use bolus to achieve euvoolemia. Begin with isotonic solution (lactated Ringer’s or NS).
   b. Targeting euvoolemia via frequent monitoring of HR, BP, urine output, and weight is essential.
   c. **Maintain urine output at 0.5 to 1 mL/kg/hr.**
   d. Blood loss—replace blood loss with crystalloid at a 3:1 ratio. As stated above, initial hematocrit may not reflect actual quantity of blood lost. Therefore, in the acute trauma setting, replace the estimated blood lost.

   a. D51/2NS solution with 20 mEq KCl/L is the most common adult maintenance fluid. (Dextrose is added to inhibit muscle breakdown.)
   b. There are two methods of calculating the amount of maintenance fluid (see Clinical Pearl 8-1).
Hypervolemia

**Quick HIT**

Most cases of edema result from renal sodium retention.

**A. Causes**
1. Iatrogenic (parenteral overhydration)
2. Fluid-retaining states: CHF, nephrotic syndrome, cirrhosis, ESRD

**B. Clinical Features**
1. Weight gain
2. Vital signs in some cases may show hypotension and hemodynamic instability (as in decompensated heart failure) or tachypnea and hypoxia if pulmonary edema is present.
3. Physical exam signs of fluid overload:
   a. Peripheral (usually pitting) edema (pedal or sacral)
   b. Ascites: flank bulging and dullness (most sensitive), fluid wave (most specific), and shifting dullness
   c. Pulmonary edema: manifesting as rales or dullness at the lung bases
   d. Jugular venous distention: may be difficult to evaluate in obese patients or if TR is present
4. Labs may show low hematocrit and albumin concentration, hyponatremia
5. Elevated CVP and PCWP on Swan–Ganz Catheter

**Quick HIT**

**Signs of Volume Overload**
- Elevated jugular venous pressure
- Pulmonary rales—due to pulmonary edema
- Peripheral edema

**C. Treatment**
1. Fluid restriction
2. Judicious use of diuretics
3. Monitor urine output and daily weights, and consider Swan–Ganz catheter placement depending on the patient’s condition.
4. If patient is hemodynamically unstable and initial attempts are unsuccessful, urgent dialysis may rarely be indicated (recall volume overload is one of the AEIOU indications, see Chapter 7).
Sodium

Overview of Sodium Homeostasis

A. Salt and Water Regulation
1. Na\(^+\) regulation is intimately associated with water homeostasis, yet it is regulated by independent mechanisms.
2. Changes in Na\(^+\) concentration are a reflection of water homeostasis, whereas changes in Na\(^+\) content (and subsequently, fluid volume) are a reflection of Na\(^+\) homeostasis.
3. Disturbance of Na\(^+\) balance may lead to hypovolemia or hypervolemia, and disturbance of water balance may lead to hyponatremia or hypernatremia.

B. Sodium Homeostasis
1. Sodium is actively pumped out of cells and is therefore restricted to the extracellular space. It is the main osmotically active cation of the ECF.
2. An increase in sodium intake results in an increase in ECF volume, which results in an increase in GFR and sodium excretion. This occurs partially through release of ANP and BNP by the heart and decrease of renal renin release, which together promote natriuresis and inhibit norepinephrine, epinephrine, aldosterone, and ADH release.
3. A decline in the extracellular circulating volume results in a decreased GFR and a reduction in sodium excretion. This is a response to the sympathetic nervous system increasing cardiac output as well as a decrease in renal perfusion pressure resulting in activation of the renin–angiotensin–aldosterone system. Aldosterone increases sodium reabsorption and potassium secretion from the late distal tubules.
4. Diuretics inhibit Na\(^+\) reabsorption through various mechanisms in the renal tubular system. Furosemide and other loop diuretics inhibit the Na\(^+\)–K\(^+\)–Cl\(^-\) transporter in the thick ascending limb of the loop of Henle, whereas thiazide diuretics inhibit the Na\(^+\)–Cl\(^-\) cotransporter at the early distal tubule. However, the majority of Na\(^+\) reabsorption occurs in the proximal tubule.

Quick HIT
- Aldosterone increases sodium reabsorption, water then follows.
- ADH increases water reabsorption alone.

C. Water Homeostasis
1. Osmoreceptors in the hypothalamus are stimulated by plasma hypertonicity (usually >295 mOsm/kg); activation of these stimulators produces thirst.
2. Hypertonic plasma also stimulates the secretion of antidiuretic hormone (ADH) from the posterior pituitary gland. When ADH binds to V₂ receptors in the renal collecting ducts, water channels are synthesized and more water is reabsorbed.
3. ADH is suppressed as plasma tonicity decreases.
4. Ultimately, the amount of water intake and output (including renal, GI, and insensible losses from the skin and the respiratory tract) must be equivalent over time to preserve a steady state.
5. When a steady state is not achieved, hyponatremia or hypernatremia usually occurs.
Hyponatremia

Quick HIT

- Hyponatremia and hypernatremia are caused by too much or too little water.
- Hypovolemia and hypervolemia are caused by too little or too much sodium.

A. General Characteristics
1. This refers to too much water in relation to sodium in the serum.
2. It is typically defined as a plasma Na⁺ concentration <135 mmol/L.
3. Symptoms usually begin when the Na⁺ level falls to <120 mEq/L. An important exception is increased intracranial pressure (ICP) (e.g., after head injury). As ECF osmolality decreases, water shifts into brain cells, further increasing ICP. (Therefore, it is critical to keep serum sodium normal or slightly high in such patients.)

B. Causes and Classification (based on serum osmolality)
1. Hypotonic hyponatremia—“true hyponatremia”—serum osmolality <280 mOsm/kg (can be measured or calculated using sodium, BUN, and glucose)
   a. Hypovolemic
      • Low urine sodium (<10 mEq/L)—implies increased sodium retention by the kidneys to compensate for extrarenal losses (e.g., diarrhea, vomiting, nasogastric suction, diaphoresis, third-spacing, burns, pancreatitis) of sodium-containing fluid.
      • High urine sodium (>20 mEq/L)—renal salt loss is likely due to tubular dysfunction—for example, diuretic excess, decreased aldosterone (i.e., RTA type IV, causes include ACE inhibitors and ARBs), ATN.
   b. Euvolemic—no evidence of ECF expansion or contraction on clinical grounds
      • SIADH: Causes are numerous and include CNS pathologies, malignancy (most commonly small cell lung cancer), surgery (postoperative hyponatremia), drugs (e.g., SSRIs, oxytocin, carbamazepine, haloperidol, cyclophosphamide, certain antineoplastic agents), infections (HIV, pulmonary infections), and more
      • Hypothyroidism: mechanism not fully understood

Excessive water intake alone rarely leads to hyponatremia because the kidneys have a great capacity to excrete water.
• Adrenal insufficiency: cause is multifactorial
• Psychogenic polydipsia
• Administration/intake of a relative excess of free water—if a patient is given D5W (or other hypotonic solution) to replace fluids, or if water alone is consumed after intensive exertion (with profuse sweating)
• Low dietary solute intake: kidneys excrete free water by diluting urine, however all urine must contain some solute; therefore individuals with poor diets (beer drinkers, elderly persons with “tea and toast” diet) with a relative deficiency of these solutes will be limited in daily free water excretion

c. Hypervolemic (low urine sodium)—This is due to water-retaining states. The relative excess of water in relation to sodium results in hyponatremia.
• CHF
• Nephrotic syndrome (renal failure)
• Liver disease

2. Isotonic hyponatremia (pseudohyponatremia)
   a. An increase in plasma solids (e.g., proteins or lipids) artificially lowers the plasma sodium concentration measurement via laboratory artifact, but the amount of sodium in plasma is normal (hence, pseudohyponatremia).
   b. This can be caused by any condition that leads to elevated protein or lipid levels.

3. Hypertonic hyponatremia
   a. Caused by the presence of osmotic substances that cause an osmotic shift of water out of cells. These substances cannot cross the cell membrane and therefore create osmotic gradients
   b. These substances include:
      • Glucose—Hyperglycemia increases osmotic pressure, and water shifts from cells into ECF leading to a dilutional hyponatremia. For every 100 mg/dL increase in blood glucose level above normal, the serum sodium level decreases about 3 mEq/L. Note that the actual sodium content in the ECF is unchanged.
      • Mannitol, sorbitol, glycerol, maltose
      • Radiocontrast agents

Quick HIT
As opposed to acute water intoxication, when hyponatremia develops gradually (over a few days), the clinical features do not appear until a relatively lower sodium level is reached.

C. Clinical Features
1. Neurologic symptoms predominate—caused by “water intoxication”—osmotic
water shifts, which leads to increased ICF volume, specifically brain cell swelling or cerebral edema

a. Headache, delirium, irritability
b. Muscle twitching, weakness
c. Hyperactive deep tendon reflexes

2. Increased ICP, seizures, coma
3. GI—nausea, vomiting, ileus, watery diarrhea
4. Cardiovascular—hypertension due to increased ICP
5. Increased salivation and lacrimation
6. Oliguria progressing to anuria—may not be reversible if therapy is delayed and acute renal failure develops

D. Diagnosis
1. Plasma osmolality—low in a patient with true hyponatremia (Figure 8-2)
2. Urine osmolality
   a. Low if the kidneys are responding appropriately by diluting the urine—for example, primary polydipsia
   b. Elevated if there are increased levels of ADH—for example, SIADH, CHF, and hypothyroidism
3. Urine sodium concentration
   a. Urine Na⁺ should be low in the setting of hyponatremia
   b. Urine Na⁺ concentration 20 to 40 mmol/L is consistent with SIADH, salt-wasting nephropathy or hypoaldosteronism. Diuretics may produce this as well
   c. Urine Na⁺ concentration <25 mmol/L is consistent with hypovolemia
E. Treatment
1. Isotonic and hypertonic hyponatremias—diagnose and treat the underlying disorder.
2. Hypotonic hyponatremia.
a. Mild (Na⁺ 120 to 130 mmol/L)—withhold free water, and allow the patient to reequilibrate spontaneously. In SIADH, salt tablets can also be used.
b. Moderate (Na⁺ 110 to 120 mmol/L)—loop diuretics (given with saline to prevent renal concentration of urine due to high ADH).
c. Severe (Na⁺ <110 mmol/L) or if symptomatic—give hypertonic saline to increase serum sodium by 1 to 2 mEq/L/hr until symptoms improve.
   • Hypertonic saline rapidly increases the tonicity of ECF.
   • Do not increase sodium more than 8 mmol/L during the first 24 hours. An overly rapid increase in serum sodium concentration may produce central pontine demyelination.
   • Rate of correction: Maximum 8 mEq/L in 24 hours to prevent overcorrection and osmotic demyelination syndrome, however in symptomatic patients aim for correcting 4 to 6 mEq/L in first 6 hours. Make sure to check sodium levels frequently.

Quick HIT

Most cases of hypernatremia are due to the following types of free water loss:
- Nonrenal loss: insensible loss, GI tract (diarrhea)
- Renal loss: osmotic diuresis, diabetes insipidus
Excessively rapid correction of hypernatremia can lead to cerebral edema as water shifts into brain cells. Therefore, the rate of correction should not exceed 12 mEq/L/day (should be <8 mEq/L in the first 24 hours).

A. General Characteristics
1. Defined as a plasma Na+ concentration >145 mmol/L
2. Refers to excess sodium in relation to water; can result from water loss or, rarely, sodium infusion
3. Assess ECF volume clinically, as follows (Figure 8-3):
   a. Hypovolemic hypernatremia (sodium stores are depleted, but relatively more water has been lost)
      - Renal loss—from diuretics, osmotic diuresis (most commonly due to glycosuria in diabetics), renal failure
      - Extrarenal loss—from diarrhea, diaphoresis, respiratory losses
   b. Isovolemic hypernatremia (sodium stores normal, water lost)
      - Diabetes insipidus: central (usually due to CNS pathologies) or peripheral (causes include lithium toxicity, hypercalcemia, hypokalemia, renal disease, drugs)
      - Insensible respiratory (tachypnea)
   c. Hypervolemic hypernatremia (sodium excess)—occurs infrequently
      - Iatrogenic—most common cause of hypervolemic hypernatremia (e.g., large amounts of parenteral NaHCO₃, TPN)
      - Exogenous glucocorticoids
      - Cushing syndrome
      - Saltwater drowning
      - Primary hyperaldosteronism

Clinical features of hypernatremia are secondary to osmotic effects on the brain (water shifts out of brain cells, leaving them dehydrated). Symptoms are more prominent and severe when sodium levels increase rapidly.

B. Clinical Features
1. Neurologic symptoms predominate
   a. Altered mental status, restlessness, weakness, focal neurologic deficits
   b. Can lead to confusion, seizures, coma
2. Tissues and mucous membranes are dry; salivation decreases

![Diagram showing the evaluation of hypernatremia]

**FIGURE 8.3** Evaluation of hypernatremia.
(Adapted from Glasscock RJ, Massry SG. Massry and Glassock’s Textbook of Nephrology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.)

**CLINICAL PEARL 8-1**
Calculation of Maintenance Fluids

- **100/50/20 rule:**
  - 100 mL/kg for first 10 kg, 50 mL/kg for next 10 kg, 20 mL/kg for every 1 kg over 20
  - Divide total by 24 for hourly rate
  - For example, for a 70 kg man: 100 \times 10 = 1,000; 50 \times 10 = 500, 20 \times 50 \text{ kg} = 1,000. Total = 2,500. Divide by 24 hours: **104 mL/hr**

- **4/2/1 rule:**
  - 4 mL/kg for first 10 kg, 2 mL/kg for next 10 kg, 1 mL/kg for every 1 kg over 20
  - For example, for a 70 kg man: 4 \times 10 = 40; 2 \times 10 = 20; 1 \times 50 = 50. Total = **110 mL/hr**

C. Diagnosis

1. Urine volume should be low if the kidneys are responding appropriately.
2. Urine osmolality should be >800 mOsm/kg.
3. Desmopressin should be given to differentiate nephrogenic from central diabetes insipidus if diabetes insipidus is suspected (see Chapter 4).

D. Treatment

1. Hypovolemic hypernatremia—Give isotonic NaCl to achieve euvolemia and restore hemodynamics initially. Correction of hypernatremia can wait until the patient is hemodynamically stable, then replace the free water deficit (see Clinical Pearl 8-1).
2. Isovolemic hypernatremia—Patients with diabetes insipidus require vasopressin (nephrogenic DI, unless hereditary, is rarely complete), low sodium diet, and thiazide diuretics. Prescribe oral fluids, or if the patient cannot drink, give D5W.
3. Hypervolemic hypernatremia—Give diuretics (such as furosemide, to correct volume status) and D5W (to achieve normal sodium concentration) to remove excess sodium. Dialyze patients with renal failure.

Quick HIT

Calculating free water deficit

Water deficit = TBW \times (1 - \text{actual Na}^+ ÷ \text{desired Na}^+ )
Calcium

**Calcium Metabolism**

A. **Normal Serum Calcium:** The normal serum calcium (Ca\(^{2+}\)) range is 8.5 to 10.5 mg/dL. Calcium balance is regulated by hormonal control, but the levels are also affected by albumin and pH.

1. Albumin
   a. Calcium in plasma exists in two forms:
      - Protein-bound form: most calcium ions are bound to albumin, so the total calcium concentration fluctuates with the protein (albumin) concentration.
      - Free ionized form: **physiologically active** fraction; under tight hormonal control (PTH), independent of albumin levels.
   b. In hypoalbuminemia, the total calcium is low, but ionized calcium is normal, and can be estimated by the following formula: total calcium—(serum albumin × 0.8).

2. Changes in pH alter the ratio of calcium binding. An increase in pH increases the binding of calcium to albumin. Therefore, in alkalemic states (especially acute respiratory alkalosis), total calcium is normal, but ionized calcium is low and the patient frequently manifests the signs and symptoms of hypocalcemia.

B. **Hormonal Control**

1. PTH—↑ plasma Ca\(^{2+}\) and ↓ plasma PO\(_4\)\(^{3-}\) by acting on:
   a. Bone: ↑ bone resorption
   b. Kidney: ↑ Ca\(^{2+}\) reabsorption, ↓ PO\(_4\)\(^{3-}\) reabsorption
   c. Gut: activation of vitamin D

2. Calcitonin—↓ plasma Ca\(^{2+}\) and ↓ plasma PO\(_4\)\(^{3-}\) by acting on:
   a. Bone: ↓ bone resorption
   b. Kidney: ↓ Ca\(^{2+}\) reabsorption, ↑ PO\(_4\)\(^{3-}\) reabsorption
   c. Gut: ↓ postprandial Ca\(^{2+}\) absorption

3. Vitamin D—↑ plasma Ca\(^{2+}\) and ↑ plasma PO\(_4\)\(^{3-}\) by acting on:
   a. Bone: ↑ bone resorption
   b. Kidney: ↑ Ca\(^{2+}\) reabsorption, ↑ PO\(_4\)\(^{3-}\) reabsorption
   c. Gut: ↑ Ca\(^{2+}\) absorption, ↑ PO\(_4\)\(^{3-}\) reabsorption
Maintenance of calcium balance is a function of PTH, calcitonin, and vitamin D, and their target organs bone, kidney, and gut.
Hypocalcemia

A. Causes
1. Hypoparathyroidism (most common cause)—usually due to surgery on the thyroid gland (with damage to nearby parathyroids)
2. Renal insufficiency—mainly due to decreased production of 1,25-dihydroxy vitamin D.
3. Vitamin D deficiency
4. Hyperphosphatemia—PO$_4^{3-}$ precipitates with Ca$_2^+$ resulting in calcium phosphate deposition
5. Hypomagnesemia—results in decreased PTH secretion. Malabsorption—for example, short bowel syndrome, leading to low vitamin D or magnesium
6. Pseudohypoparathyroidism—autosomal recessive disease causing congenital end-organ resistance to PTH (so PTH levels are actually high); also characterized by mental retardation and short metacarpal bones
7. Hypoalbuminemia—clinically irrelevant as ionized (metabolically active) component is normal.
8. Alkalemia—as above, increase in pH causes increased calcium binding, serum levels will be normal but clinically important as ionized fraction is low
9. Acute pancreatitis—deposition of calcium deposits lowers serum Ca$_2^+$ levels
10. Blood transfusion (with citrated blood)—calcium binds to citrate
11. Osteoblastic metastases
12. DiGeorge syndrome—caused by a deletion on chromosome 22. Absence of thymic shadow on chest x-ray

Quick HIT

Ionized calcium may be low with normal serum calcium levels in acute alkalotic states.

B. Clinical Features
1. Asymptomatic
2. Rickets and osteomalacia
3. Increased neuromuscular irritability
   a. Numbness/tingling—circumoral in fingers, in toes
   b. Tetany
      • Hyperactive deep tendon reflexes
      • Chvostek sign—tapping a facial nerve leads to a contraction (twitching) of facial muscles
      • Trousseau sign—Inflate BP cuff to a pressure higher than the patient’s systolic BP for 3 minutes (occludes blood flow in forearm). This elicits carpal spasms.
c. Seizures
4. Basal ganglia calcifications
5. Cardiac manifestations
   a. Arrhythmias
   b. Prolonged QT interval on ECG—hypocalcemia should always be in the differential diagnosis for a prolonged QT interval

Quick HIT
Hospitalized patients frequently have low serum albumin concentrations. Therefore, if you see a low calcium level, look at the albumin level (it is usually low as well). A low serum ionized calcium level is much less common.

C. Diagnosis
1. To evaluate for the above-listed etiologies, obtain the following: BUN, Cr, magnesium, albumin, and ionized calcium. Amylase, lipase, and liver function tests may also be warranted.
2. Serum PO$_4^{3-}$: high in renal insufficiency and in hypoparathyroidism, low in primary vitamin D deficiency
3. PTH
   a. Low in hypoparathyroidism
   b. Elevated in vitamin D deficiency, CKD
   c. Very high in pseudohypoparathyroidism

D. Treatment
1. If symptomatic, provide emergency treatment with IV calcium gluconate.
2. For long-term management, use oral calcium supplements (calcium carbonate) and vitamin D.
3. For PTH deficiency.
   a. Replacement therapy with vitamin D (or calcitriol) plus a high oral calcium intake.
   b. Thiazide diuretics—lower urinary calcium and prevent urolithiasis.
4. It is also important to correct hypomagnesemia. It is very difficult to correct the calcium level if the magnesium is not replaced first.
Hypercalcemia

A. Causes

1. Endocrinopathies
   a. Hyperparathyroidism—increased Ca\(^{2+}\), low PO\(_{4}^{3-}\), usually due to an adenoma (most common cause in outpatients)
   b. Renal failure—usually results in hypocalcemia, but sometimes secondary hyperparathyroidism desensitizes the parathyroid to calcium levels and elevates PTH levels high enough to cause hypercalcemia (this is known as tertiary hyperparathyroidism)
   c. Paget disease of the bone—due to osteoclastic bone resorption
   d. Hyperparathyroidism, acromegaly, Addison disease

2. Malignancies (most common cause in inpatients)
   a. Metastatic cancer—bony metastases result in bone destruction due to osteoclastic activity. Most tumors that metastasize to bone cause both osteolytic and osteoblastic activities (prostate cancer, mainly osteoblastic; breast and kidney carcinoma, usually osteolytic)
   b. Multiple myeloma—secondary to two causes
      • Lysis of bone by tumor cells
      • Release of osteoclast-activating factor by myeloma cells
   c. Tumors that release PTH-like hormone (e.g., squamous cell cancers such as lung, head, and neck)
   d. Tumors that release PTH (lung, ovarian cancers)
   e. Tumors that release vitamin D (e.g., lymphomas)

3. Pharmacologic
   a. Vitamin D intoxication—increased GI absorption of calcium
   b. Milk-alkali syndrome—hypercalcemia, alkalosis, and renal impairment due to excessive intake of calcium and certain absorbable antacids (calcium carbonate, milk)
   c. Drugs—thiazide diuretics (inhibit renal excretion), lithium (increases PTH levels in some patients, e.g., squamous cell carcinoma)

4. Other
   a. Sarcoidosis—increased GI absorption of calcium
   b. Familial hypocalciuric hypercalcemia—distinguished from primary hyperparathyroidism by a low urine calcium excretion versus a normal or high urine calcium excretion in primary hyperparathyroidism

B. Clinical Features

1. “Stones” (due to chronic hypercalciuria rather than hypercalcemia alone)
a. Nephrolithiasis
b. Nephrocalcinosis

2. “Bones”
   a. Bone aches and pains
   b. Osteitis fibrosa cystica (“brown tumors”) predisposes to pathologic fractures

3. “Grunts and groans”
   a. Muscle pain and weakness
   b. Pancreatitis
   c. Peptic ulcer disease
   d. Gout
   e. Constipation

4. “Psychiatric overtones”—depression, fatigue, anorexia, sleep disturbances, anxiety, lethargy

5. Other findings
   a. Polydipsia, polyuria
   b. Nephrogenic DI
   c. Hypertension
   d. Weight loss
   e. ECG—shortened QT interval
   f. Patients may be asymptomatic

---

**Quick HIT**

- In hypercalcemia, ECG shows shortening of the QT interval.
- In hypocalcemia, ECG shows a prolongation of the QT interval.

---

**C. Diagnosis**

1. Same laboratory tests as in hypocalcemia
2. Radioimmunoassay of PTH: elevated in primary hyperparathyroidism, low in occult malignancy
3. Radioimmunoassay of PTH-related protein: elevated in malignancy
4. Bone scan or bone survey to identify lytic lesions
5. Urinary cAMP: markedly elevated in primary hyperparathyroidism

**D. Treatment**

1. Patients usually do not require management beyond correction of underlying etiology unless hypercalcemia is severe (>14 mg/dL) or significant symptoms are present.
2. Increase urinary excretion in all patients.
   a. IV fluids (NS)—**first step in management**
b. Diuretics (furosemide)—further inhibit calcium reabsorption

3. Inhibit bone resorption in patients with osteoclastic disease (e.g., malignancy).
   a. Bisphosphonates (pamidronate)
   b. Calcitonin

4. Give glucocorticoids if vitamin D-related mechanisms (intoxication, granulomatous disorders) and multiple myeloma are the cause of the hypercalcemia. However, glucocorticoids are ineffective in most other forms of hypercalcemia.

5. Use hemodialysis for renal failure patients.

6. Phosphate is effective but incurs the risk of metastatic calcification.
Potassium

Potassium Metabolism

**Normal K⁺ levels:** 3.5 to 5.0 mEq/L.

**Location in the body**—most of the body’s potassium (98%) is intracellular.

**Hypokalemia**—alkalosis and insulin administration may cause hypokalemia because they cause a shift of potassium into the cells.

**Hyperkalemia**—acidosis and anything resulting in cell lysis increase serum K⁺ (both force K⁺ out of cells into the ECF).

**Potassium secretion**—most of the excretion of potassium occurs through the kidneys (80%); the remainder occurs via the GI tract. Aldosterone plays an important role in renal potassium secretion.

---

**Quick HIT**

Serum potassium is affected by pH: alkalosis can lead to hypokalemia, whereas acidosis can lead to hyperkalemia.
Hypokalemia

A. Causes

1. GI losses
   a. Vomiting and nasogastric drainage (volume depletion and metabolic alkalosis also result)
   b. Diarrhea
   c. Laxatives and enemas
   d. Intestinal fistulas—particularly after inflammatory bowel disorders such as Crohn’s or diverticulitis
   e. Decreased potassium absorption in intestinal disorders

Quick HIT

Diarrhea is a common cause of both hypokalemia and non-AG metabolic acidosis.

Quick HIT

The presence or absence of HTN is useful in differentiating the causes of hypokalemia. If the patient is hypertensive, excessive aldosterone activity is likely. If the patient is normotensive, either GI or renal loss of K⁺ is likely.

2. Renal losses
   a. Diuretics
   b. Renal tubular or parenchymal disease
   c. Primary and secondary hyperaldosteronism
   d. Excessive glucocorticoids—due to mineralocorticoid action at high serum levels
   e. Magnesium deficiency
   f. Bartter syndrome—chronic volume depletion secondary to an autosomal-recessive defect in salt reabsorption in the thick ascending limb of the loop of Henle leads to hyperplasia of juxtaglomerular apparatus, which leads to increased renin levels and secondary aldosterone elevations.

Quick HIT

Always monitor K⁺ levels in patients taking digoxin. It is common for these patients to be taking diuretics as well (for CHF), which can cause hypokalemia. Hypokalemia predisposes the patient to digoxin toxicity.

3. Other causes
   a. Insufficient dietary intake
b. Insulin administration
c. Certain antibiotics especially amphotericin B
d. Profuse sweating
e. Epinephrine ($\beta_2$-agonists)—hypokalemia occurs in 50% to 60% of trauma patients, perhaps due to increased epinephrine levels

**Quick HIT**

Arrhythmias are the most dangerous complications of hypokalemia. ECG changes in hypokalemia appear as follows:
- T wave flattens out; if severe, T wave inverts
- U wave appears

**B. Clinical Features**

1. **Arrhythmias**—prolongs normal cardiac conduction
   a. Exacerbates digitalis toxicity
   b. Flattening of T waves on EKG. U waves appear if severe
2. Muscular weakness, fatigue, paralysis, and muscle cramps
3. Decreased deep tendon reflexes
4. Paralytic ileus
5. Polyuria and polydipsia
6. Nausea/vomiting

**Quick HIT**

Interpretation of urine potassium in hypokalemia
- Low with GI losses (<20 mEq/L)
- High with renal losses (>20 mEq/L)

**C. Treatment**

1. Identify and treat the underlying cause (**Figure 8-4**).
2. Discontinue any medications that can aggravate hypokalemia.
3. Oral KCl is the preferred (safest) method of replacement and is appropriate in most instances. Always retest the K$^+$ levels after administration.
   a. Using 10 mEq of KCl usually increases K$^+$ levels by 0.1 mEq/L, it will increase levels more in patients with renal insufficiency due to decreased clearance.
   b. It comes in slow-acting and fast-acting forms.
4. IV KCl can be given if hypokalemia is severe (<2.5), if the patient cannot take PO, or if the patient has arrhythmias secondary to hypokalemia.
   a. Give slowly to avoid hyperkalemia.
b. Monitor K\(^+\) concentration and monitor cardiac rhythm when giving IV potassium.

c. Infusion pearls.
   - Maximum infusion rate of 10 mEq/hr in peripheral IV line.
   - Maximum infusion rate of 20 mEq/hr in central line.
   - May add 1\% lidocaine to bag to decrease pain (potassium burns!)

5. As with calcium, it is difficult to correct the potassium level if any hypomagnesemia is not corrected first.
**Hyperkalemia**

**A. Causes**

1. Increased total-body potassium
   a. Renal failure (acute or chronic)
   b. Hypoaldosterone states: Addison disease, hyporeninemic hypoaldosteronism, ACE inhibitors, potassium-sparing diuretics (spironolactone)
   c. Iatrogenic—excessive doses of potassium (use caution when administering potassium in patients with renal failure) and certain medications (e.g., trimethoprim-sulfamethoxazole)
   d. Blood transfusion—usually due to lysed cells

---

**FIGURE 8.4** Diagnostic evaluation of hypokalemia.

(Adapted from Humes DH, DuPont HL, Gardner LB, et al. Kelley’s Textbook of Internal...
Quick HIT

Hyperkalemia inhibits renal ammonia synthesis and reabsorption. Thus, net acid excretion is impaired and results in metabolic acidosis. This further exacerbates hyperkalemia due to K⁺ movement out of cells.

2. Redistribution—translocation of potassium from intracellular to extracellular space
   a. Acidosis (notably not seen in lactic or ketoacidosis)
   b. Tissue/cell breakdown—rhabdomyolysis (muscle breakdown), chemotherapy, hemolysis, burns
   c. GI bleeding
   d. Insulin deficiency—insulin stimulates the Na⁺-K⁺-ATPase and causes K⁺ to shift into cells. Therefore, insulin deficiency and hypertonicity (high glucose) promote K⁺ shifts from ICF to ECF
   e. Rapid administration of β-blocker

3. Pseudohyperkalemia (spurious)
   a. This refers to an artificially elevated plasma K⁺ concentration due to K⁺ movement out of cells immediately before or after venipuncture. Contributing factors include prolonged use of a tourniquet with or without repeated fist clenching. This can cause acidosis and subsequent K⁺ loss from cells. Nevertheless, plasma (not serum) K⁺ should be normal. (Repeat the test to confirm this.)
   b. Additionally, if the sample is not processed quickly, some red blood cells will hemolyze and cause spillage of K⁺ leading to a falsely elevated result. The test should be repeated in this case.
   c. Other contributing factors include leukocytosis and thrombocytosis.
ECG changes in hyperkalemia become prominent when $K^+ >6$ and include:

- Peaked T waves (by 10 mm)
- A prolonged PR interval
- Widening of QRS and merging of QRS with T wave
- Ventricular fibrillation and cardiac arrest (with increasing levels of $K^+$)
B. Clinical Features

1. **Arrhythmias**—The most important effect of hyperkalemia is on the heart (Figure 8-5). Check an ECG immediately in a hyperkalemic patient. With increasing potassium, ECG changes progress through tall, peaked T waves, QRS widening, PR interval prolongation, loss of P waves, and finally a sine-wave pattern.

2. Muscle weakness and (rarely) flaccid paralysis

3. Decreased deep tendon reflexes

4. Respiratory failure

5. Nausea/vomiting, intestinal colic, diarrhea

6. Acidosis due to decreased ammonium formation in renal tubules

---

**Quick HIT**

Of all electrolyte disturbances, hyperkalemia is the most dangerous and can be the most rapidly fatal.

C. Treatment

1. If the hyperkalemia is severe, or if ECG changes are present, first give IV calcium.
   a. Calcium stabilizes the resting membrane potential of the myocardial membrane—that is, it decreases membrane excitability.
   b. Use caution in giving calcium to patients on digoxin. (Hypercalcemia predisposes the patient to digoxin toxicity.)

2. Shift potassium into the intracellular compartment.
   a. **Glucose and insulin**—Works via stimulation of Na⁺/K⁺ pump. Glucose alone will stimulate insulin from β-cells, but exogenous insulin is more rapid (and thus should be one of the first steps in management). Give both to prevent hypoglycemia.
   b. Beta agonists (e.g., albuterol)—Also works via stimulation of Na⁺/K⁺ pump. Transient management in those with symptoms or EKG changes.
   c. Sodium bicarbonate—Increases pH level, which shifts K⁺ into cells via H⁺/K⁺ pump. Similar to β agonists, an emergency measure in severe hyperkalemia.

3. Remove potassium from the body.
   a. **Kayexalate**—GI potassium exchange resin (Na⁺/K⁺ exchange in GI tract) absorbs K⁺ in the colon, preventing reabsorption (passed in stool, thus reliant on patient being able to defecate).
   b. Diuretics (furosemide)—Effect is variable and thus is rarely used as monotherapy.
   c. Hemodialysis.
     - Most rapid and effective way of lowering plasma K⁺.
• Reserved for intractable hyperkalemia (usually over 7) and for those with renal failure.
Magnesium

Overview

Normal Mg\(^{2+}\) levels: 1.8 to 2.5 mg/dL.

Location in the body—Most of the magnesium in the body (two-thirds) is in bones. The remainder (one-third) is intracellular. Only 1% of magnesium is extracellular.

Influences on magnesium excretion—Many hormones can alter urinary magnesium excretion (e.g., insulin/glucagons, PTH, calcitonin, ADH, and steroids).

Magnesium absorption and balance—About 30% to 40% of dietary magnesium is absorbed in the GI tract, but this percentage increases when magnesium levels are low. The kidney has a great capacity to reabsorb magnesium and is the major regulator of magnesium balance.
Hypomagnesemia

**Quick HIT**
Hypomagnesemia makes hypokalemia and hypocalcemia more difficult to treat.

**A. Causes**
1. GI causes
   a. Malabsorption, steatorrheic states (most common cause)
   b. Prolonged fasting
   c. Fistulas
   d. Patients receiving TPN without Mg$^{2+}$ supplementation
2. Alcoholism (common cause)—due to increased urinary excretion as well as frequently concomitant diarrhea, pancreatitis, and poor diet
3. Renal causes
   a. SIADH
   b. Diuretics (often seen in patients being treated for heart failure exacerbation)
   c. Gitelman and Bartter syndrome
   d. Drugs: gentamicin, amphotericin B, cisplatin
   e. Renal transplantation
4. Other causes: postparathyroidectomy, DKA, thyrotoxicosis, lactation, burns, pancreatitis, cisplatin

**B. Clinical Features**
1. Marked neuromuscular and CNS hyperirritability
   a. Muscle twitching, weakness, tremors
   b. Hyperreflexia, seizures
   c. Mental status changes
2. Effect on calcium levels: **coexisting hypocalcemia is common** because of decreased release of PTH and bone resistance to PTH when Mg$^{2+}$ is low
3. Effect on potassium levels
   a. Coexisting hypokalemia—in up to 50% of cases, usually due to etiology which leads to loss of both
   b. In muscle and myocardium, when either intracellular Mg$^{2+}$ or K$^{+}$ decreases, a corresponding decrease in the other cation takes place
4. ECG changes—prolonged QT interval, T-wave flattening, and ultimately, torsade de pointes

**C. Treatment**
1. For mild hypomagnesemia—oral Mg$^{2+}$ (e.g., magnesium oxide)
2. For severe hypomagnesemia—parenteral Mg$^{2+}$ (e.g., magnesium sulfate)
Hypermagnesemia

A. Causes
1. Renal failure (most common cause)
2. Early-stage burns, massive trauma or surgical stress, severe ECF volume deficit, severe acidosis
3. Excessive intake of magnesium-containing laxatives or antacids combined with renal insufficiency
4. Adrenal insufficiency
5. Rhabdomyolysis
6. Iatrogenic—usually in the obstetric setting in women with preeclampsia or eclampsia being treated with magnesium sulfate

B. Clinical Features
1. Nausea, weakness
2. Facial paresthesias
3. Progressive loss of deep tendon reflexes (classically the first sign)
4. ECG changes resemble those seen with hyperkalemia (increased P-R interval, widened QRS complex, and elevated T waves)
5. Somnolence leading to coma and muscular paralysis occur late
6. Death is usually caused by respiratory failure or cardiac arrest

Quick HIT
Hyperkalemia and hypermagnesemia have some similar etiologies, cause suppression of muscular function, and induce similar EKG changes, so always check magnesium when suspecting hyperkalemia!

C. Treatment
1. Withhold exogenously administered magnesium.
2. Prescribe IV calcium gluconate for emergent symptoms (cardioprotection as in hyperkalemia).
3. Administer saline and furosemide.
4. Order dialysis in renal failure patients.
5. Prepare to intubate if respiratory depression is severe.
**Phosphate**

<table>
<thead>
<tr>
<th>Quick</th>
<th>HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma Phosphate Concentration</strong></td>
<td></td>
</tr>
<tr>
<td>• Normal: 3.0 to 4.5 mg/dL</td>
<td></td>
</tr>
<tr>
<td>• Hypophosphatemia: &lt;2.5 mg/dL</td>
<td></td>
</tr>
<tr>
<td>• Hyperphosphatemia: &gt;5 mg/dL</td>
<td></td>
</tr>
</tbody>
</table>
Overview

Normal phosphate levels: 3.0 to 4.5 mg/dL.
Location in the body—Most of the phosphorus is in the bones (85%); the remainder is intracellular in soft tissues (15%) and a very small amount (0.1%) in ECF.
Influence on phosphate absorption—Vitamin D controls phosphorus absorption in the GI tract.
Phosphate excretion and balance—PTH controls phosphorus excretion in the kidney—PTH increases renal phosphorus excretion by inhibiting reabsorption. The function of the kidney in maintaining phosphate balance is very important.
Hypophosphatemia

A. Causes
1. Decreased intestinal absorption due to alcohol abuse, vitamin D deficiency, malabsorption of phosphate, excessive use of phosphate-binding antacids, hyperalimentation (TPN), and/or starvation
2. Increased renal excretion
   a. Excess PTH states (vitamin D deficiency, hyperparathyroidism)
   b. Hyperglycemia (glycosuria), oncogenic osteomalacia, ATN, renal tubular acidosis, and so on
   c. Hypokalemia or hypomagnesemia
3. Other causes: respiratory alkalosis, anabolic steroids, severe hyperthermia, DKA, hungry bone syndrome (deposition of bone material after parathyroidectomy)

Quick HIT
The most common causes of severe hypophosphatemia are alcohol abuse and DKA.

B. Clinical Features
1. None, if the hypophosphatemia is mild.
2. Any of the following, if the hypophosphatemia is severe, primarily due to a lack of available ATP and 2,3 DPG, the latter causing decreased O₂ release from RBC:
   a. Neurologic: encephalopathy, confusion, seizures, numbness, paresthesias
   b. Musculoskeletal: muscular weakness, myalgias, bone pain, rickets/osteomalacia
   c. Hematologic: hemolysis, RBC dysfunction, WBC dysfunction, platelet dysfunction
   d. Cardiac: cardiomyopathy and myocardial depression secondary to low ATP levels, may lead to cardiac arrest
   e. Rhabdomyolysis
   f. Anorexia
   g. Difficulty in ventilator weaning

C. Treatment
1. If mild (>1 mg/dL), oral supplementation: Neutra-Phos capsules, K-Phos tablets, milk (excellent source of phosphate)
2. If severe/symptomatic or if patient is NPO: parenteral supplementation
Hyperphosphatemia

A. Causes
1. Decreased renal excretion of PO$_4^{3-}$ due to renal insufficiency (most common cause), bisphosphonates, hypoparathyroidism, vitamin D intoxication, and/or tumor calcinosis
2. Increased phosphate administration (e.g., PO$_4^{3-}$ repletion or PO$_4^{3-}$ enemas)
3. Rhabdomyolysis, cell lysis, or acidosis (releases PO$_4^{3-}$ into the ECF)

B. Clinical Features
1. This results in metastatic calcification and soft tissue calcifications; a calcium–phosphorus product (serum calcium × serum phosphorus) >70 indicates that calcification is likely to occur. A calcium-phosphate product <55 is usually the goal for CKD patients to prevent calcification.
2. The associated hypocalcemia can lead to neurologic changes (tetany, neuromuscular irritability).

C. Treatment
1. Phosphate-binding antacids containing aluminum hydroxide or carbonate (bind phosphate in bowel and prevent its absorption)
2. Hemodialysis (if patient has renal failure)
Acid–Base Disorders

Metabolic Acidosis

A. General Characteristics

1. Metabolic acidosis is characterized by decreased blood pH and a decreased plasma bicarbonate concentration (see Clinical Pearl 8-2). The goal is to identify the underlying condition that is causing the metabolic acidosis.
2. Anion gap (AG)—A useful measurement for identifying the cause of acidosis, whether due to a relative excess of chloride with respect to bicarbonate (normal gap) or an abundance of other acids (high gap)
   a. AG (mEq/L) = [Na+] − ([Cl−] + [HCO3−]).
   b. Reflects ions present in serum but unmeasured (i.e., proteins, phosphates, organic acids, sulfates).
   c. Normal values are 5 to 15 mEq/L, but this varies to some extent.
   d. Always check albumin level and add 2.5 to gap for every 1 g/dL below 4.

<table>
<thead>
<tr>
<th>CLINICAL PEARL 8-2</th>
</tr>
</thead>
</table>

Effects of Acidosis and Alkalosis

- **Acidosis**
  - Right shift in oxygen–hemoglobin dissociation curve diminishes the affinity of hemoglobin for oxygen (so increases oxygen delivery to tissues)
  - Depresses CNS
  - Decreases pulmonary blood flow
  - Arrhythmias
  - Impairs myocardial function
  - Hyperkalemia

- **Alkalosis**
  - Decreases cerebral blood flow
  - Left shift in oxygen–hemoglobin dissociation curve increases the affinity of hemoglobin for oxygen (so decreases oxygen delivery to tissues)
  - Arrhythmias
  - Tetany, seizures

3. Pathophysiology (Figure 8-6).
   a. Anion gap metabolic acidosis: When a fixed acid (lactic acid, ketones, salicylic acid) is added, the H+ is buffered by the bicarbonate system. CO2 is formed and removed by lungs (respiratory compensation). H+ + HCO3− ↔ H2CO3− ↔ H2O + CO2. HCO3− levels decrease in ECF and the conjugate bases of the acid in the
serum now exist as unmeasured anions which raise the measured gap. With time, kidneys reabsorb more $\text{HCO}_3^-$ (new) to maintain pH (renal compensation).

b. Non-anion gap metabolic acidosis: Bicarbonate is lost without being used as a buffer to an added acid, usually in GI tract or urine, or chloride concentration relatively increases.

c. Three situations can arise:
   - The change in AG equals the change in $\text{HCO}_3^-$ (see Figure 8-7A): simple metabolic acidosis—the addition of acid causes the AG to increase proportionally.
   - The change in AG is less than the change in $\text{HCO}_3^-$ (see Figure 8-7B): normal AG acidosis PLUS high AG acidosis—If after the addition of acid, the $\text{HCO}_3^-$ is lower than the calculated prediction, then you started with a lower $\text{HCO}_3^-$. 
   - The change in AG is greater than the change in $\text{HCO}_3^-$ (see Figure 8-7C): metabolic alkalosis PLUS high AG acidosis—when you have a high AG, the acid has to be buffered by $\text{HCO}_3^-$, so $\text{HCO}_3^-$ decreases. If $\text{HCO}_3^-$ does not decrease, it means you started at a higher $\text{HCO}_3^-$. 

**FIGURE 8.6** An increase in lactate results in a decrease in $\text{HCO}_3^-$ (due to buffering) in ECF. The kidneys must then reabsorb more $\text{HCO}_3^-$ to maintain pH.
A: Simple metabolic acidosis. The change in AG is equal to the change in HCO$_3^-$.

As you add acid, HCO$_3^-$ decreases, and AG increases proportionately.

B: Normal anion gap acidosis PLUS high anion gap acidosis.

The change in AG is less than the change in HCO$_3^-$. If after the addition of acid, HCO$_3^-$ is lower than predicted, then you started at a lower HCO$_3^-$ level (*).

C: Metabolic alkalosis plus high anion gap acidosis.

The change in AG is greater than the change in HCO$_3^-$. If after the addition of acid, the decrease in HCO$_3^-$ is less than expected, then you started at a higher HCO$_3^-$ level (*).

Quick HIT

The bicarbonate level obtained in a serum chemistry panel (venous CO$_2$) is a measured value (more reliable), whereas the level obtained in an arterial blood gas is a calculated value (less reliable).

B. Causes

1. Increased AG acidosis (see also Clinical Pearl 8-3)
   a. Ketoacidosis
      • Diabetes mellitus
      • Prolonged starvation
      • Prolonged alcohol abuse

CLINICAL PEARL 8-3

Arterial Blood Gas Interpretation

- CO$_2$ level
  • If elevated, think of either respiratory acidosis or compensation for metabolic alkalosis.
  • If low, think of either respiratory alkalosis or compensation for metabolic acidosis.

- HCO$_3^-$ level
  • If elevated, think of either metabolic alkalosis or compensation for respiratory acidosis.
  • If low, think of either metabolic acidosis or compensation for respiratory alkalosis.
  • The base excess/base deficit values in the arterial blood gas indicate the amount of acid or base that is needed to titrate the plasma pH to 7.40 (with a PaCO$_2$ of 40).

Quick HIT

Salicylate overdose causes both primary respiratory alkalosis and primary metabolic acidosis.
b. Lactic acidosis—can occur in many different conditions
   • Low tissue perfusion (decreased oxygen delivery to tissues)
   • Shock states (septic, cardiogenic, hypovolemic)
   • Excessive expenditure of energy (e.g., seizures)
c. Renal failure—decreased NH₄⁺ excretion (thus decreasing net acid)—decreased excretion of organic anions, sulfate, and phosphate increases AG
d. Intoxication
   • Salicylate (aspirin)
   • Methanol
   • Ethylene glycol
2. Normal AG acidosis (hyperchloremic metabolic acidosis)—The low HCO₃⁻ is associated with high Cl⁻, so that the AG remains normal.
   a. Renal loss of bicarbonate
      • Proximal tubular acidosis—this is characterized by decreased HCO₃⁻ reabsorption. Causes include multiple myeloma, cystinosis, and Wilson disease.
      • Distal tubular acidosis—this is characterized by the inability to make HCO₃⁻. Causes include SLE, Sjögren syndrome, and taking amphotericin B.
      • Carbonic anhydrase inhibition (e.g., acetazolamide—a diuretic)
   b. GI loss of HCO₃⁻
      • Diarrhea—HCO₃⁻ loss in diarrhea (most common cause of non-AG acidosis)
      • Pancreatic fistulas—pancreatic secretions contain high HCO₃⁻ levels
      • Small bowel fistulas
      • Ureterosigmoidostomy—colon secretes HCO₃⁻ in urine in exchange for Cl⁻
   c. Insufficient excretion of daily acid load
      • Hypoaldosterone states: Addison’s disease, spironolactone, amiloride, triamterene
      • CKD
d. Chloride excess
   • Primarily due to iatrogenic saline infusions

C. Clinical Features
1. Hyperventilation (deep rhythmic breathing), also known as Kussmaul respiration
   a. This is a typical compensation (i.e., response) for a metabolic acidosis and is a cardinal feature of metabolic acidosis; it is usually seen in severe metabolic acidosis (pH <7.20).
   b. It is less prominent when the acidosis is chronic.
2. Decreased cardiac output and decreased tissue perfusion.
   a. Occurs with severe metabolic acidosis (blood pH <7.2).
   b. Acidosis diminishes tissue responsiveness to catecholamines. This can lead to an undesirable chain of events: poor tissue perfusion $\rightarrow$ lactic acidosis $\rightarrow$ decreased cardiac output $\rightarrow$ hypotension $\rightarrow$ further decrease in tissue perfusion.

**D. Diagnosis**

1. History is important.
2. Calculate the AG.
3. If gap is present, calculate the Delta Gap = (Measured anion gap - 12) + HCO$_3^-$
   a. Delta gap > 26 ± 2: Concurrent metabolic alkalosis
   b. Delta gap < 20 ± 2: Concurrent non-anion gap metabolic acidosis
4. If no gap is present, urine anion gap can be measured ($U_{Na}^+ + U_{K}^+ - U_{Cl^-}$)
   a. If positive, suggests low urinary NH$_4^+$ (renal etiology of acidosis due to inability of renal tubules to excrete acid, likely RTA)
   b. If negative, suggests appropriate urinary NH$_4^+$ (nonrenal cause of acidosis)
5. Calculate Winter formula: expected PaCO$_2$ = 1.5 (measured HCO$_3^-$) + 8 ± 2.
   a. Predicts the expected respiratory compensation (PaCO$_2$ level) to metabolic acidosis: If the PaCO$_2$ does not fall within an acceptable range, then the patient has a respiratory acid–base disorder as well.
   b. If the PaCO$_2$ falls within the predicted range, then the patient has a simple metabolic acidosis with an appropriate secondary hypocapnia.
   c. If the actual PaCO$_2$ is higher than the calculated PaCO$_2$, then the patient has metabolic acidosis with respiratory acidosis (i.e., they are underbreathing). **This is a serious finding because this failure of compensation can be a sign of impending respiratory failure. The classic example is an asthmatic child who has a PaCO$_2$ that goes from abnormal to normal with no treatment. This is a bad sign, and it probably means the child will need emergent intubation shortly.**
   d. If the actual PaCO$_2$ is lower than the calculated PaCO$_2$, then the patient has metabolic acidosis with respiratory alkalosis (i.e., they are overbreathing).

**Quick HIT**

With metabolic **acidosis**, PaCO$_2$ should decrease. With metabolic **alkalosis**, PaCO$_2$ should increase. This is normal respiratory compensation. **Failure of respiratory compensation indicates an additional primary respiratory acid–base disorder.**

**E. Treatment**
1. Treatment varies depending on the cause.
2. Sodium bicarbonate is sometimes needed (especially for normal AG acidosis and with renal dysfunction) in severe acidosis to maintain a pH of no lower than 7.20. In correcting metabolic acidosis, realize that this $\text{HCO}_3^-$ takes 24 hours to get to the brain. During this time, hyperventilation continues. Therefore, $\text{PaCO}_2$ remains low while $\text{HCO}_3^-$ is increasing—a dangerous combination ($[\text{H}^+] = 24 \left[\text{PaCO}_2 \div \text{HCO}_3^-\right]$).
3. Mechanical ventilation may be required if the patient is fatigued from prolonged hyperventilation, especially in DKA.
Metabolic Alkalosis

**Quick HIT**
While evaluating a patient with metabolic alkalosis, the first step is to determine whether the ECF volume has contracted or expanded, and why.

**A. General Characteristics**
1. Metabolic alkalosis is characterized by an increased blood pH and plasma HCO$_3^-$.
2. Uncomplicated metabolic alkalosis is typically transient, because kidneys can normally excrete the excess HCO$_3^-$.
3. Consider two events in metabolic alkalosis:
   a. Event that initiates the metabolic alkalosis (loss of H$^+$ via gastric drainage, vomiting, and so on), or increased HCO$_3^-$ concentration due to ECF volume contraction
   b. Mechanism that maintains the metabolic alkalosis due to the kidney’s inability to excrete the excess HCO$_3^-$

**Quick HIT**
Exogenous bicarbonate loading (administering bicarbonate) can cause metabolic alkalosis, but this usually occurs in ESRD.

**B. Causes**
1. Saline-sensitive metabolic alkalosis (urine chloride <10 mEq/L)—characterized by ECF contraction and hypokalemia, usually due to HCO$_3^-$ loss and/or RAAS system activation.
   a. Vomiting or nasogastric suction—When the patient loses HCl, gastric HCO$_3^-$ generation occurs, which causes alkalosis.
   b. Diuretics—These decrease the ECF volume. Body HCO$_3^-$ content remains normal, but plasma HCO$_3^-$ increases because of ECF contraction.
   c. Villous adenoma of colon, diarrhea with high chloride content.
2. Saline-resistant metabolic alkalosis (urine chloride >20 mEq/L)—characterized by ECF expansion and hypertension (due to increased mineralocorticoids).
   a. Most are secondary to adrenal disorders (primary hyperaldosteronism). Increased levels of mineralocorticoid secretion lead to increased tubular reabsorption of Na$^+$ and HCO$_3^-$, and an excessive loss of Cl$^-$, K$^+$, and H$^+$ in the urine. The result is metabolic alkalosis and expansion of the ECF compartment
(because of increased Na\(^+\) reabsorption).

b. Other causes include Cushing syndrome, severe K\(^+\) deficiency, Bartter syndrome, and diuretic abuse.

---

**Quick Hit**

It is useful to distinguish between the following:
- Metabolic alkalosis with volume **contraction** (usually due to fluid loss—e.g., vomiting or diuretics)
- Metabolic alkalosis with volume **expansion** (usually due to pathology of adrenal gland). An easy way to make this distinction is via the chloride concentration in the urine.

---

**C. Clinical Features**

1. There are no characteristic signs or symptoms.
2. The patient’s medical history is most helpful (look for vomiting, gastric drainage, diuretic therapy, and so on).

---

**D. Diagnosis**

1. Elevated HCO\(_3\)^\(-\) level, elevated blood pH.
2. Hypokalemia is common (due to renal loss of K\(^+\)).
3. PaCO\(_2\) is elevated as a compensatory mechanism (due to hypoventilation). It is rare for a compensatory increase in PaCO\(_2\) to exceed 50 to 55 mm Hg (the respiratory rate to achieve this is so low that PaO\(_2\) would be decreased). A higher value implies a superimposed respiratoric acidosis.
4. The urine chloride level is very important in distinguishing between saline-sensitive and saline-resistant types.

---

**E. Treatment**

1. Treat the underlying disorder that caused the metabolic alkalosis.
2. NS plus potassium will restore the ECF volume if the patient is volume contracted.
3. Address the underlying cause (or prescribe spironolactone) if the patient is volume expanded.
Respiratory Acidosis

Any disorder that reduces CO₂ clearance (i.e., inhibits adequate ventilation) can lead to respiratory acidosis.

A. General Characteristics
1. Defined as a reduced blood pH and PaCO₂ >40 mm Hg.
2. Renal compensation (increased reabsorption of HCO₃⁻) begins within 12 to 24 hours and takes 5 days or so to complete.

B. Causes—alveolar hypoventilation
1. Primary pulmonary diseases—for example, COPD, airway obstruction
2. Neuromuscular diseases—for example, myasthenia gravis
3. CNS malfunction—jury to brainstem
4. Drug-induced hypoventilation (e.g., from morphine, anesthetics, or sedatives)—narcotic overdose in postoperative patients is a possibility (look for pinpoint pupils).
5. Respiratory muscle fatigue

C. Clinical Features
1. Somnolence, confusion, and myoclonus with asterixis.
2. Headaches, confusion, and papilledema are signs of acute CO₂ retention.

D. Diagnosis
1. Elevation of HCO₃⁻, PaCO₂
2. Determine if acute or chronic acidosis. Clinical history is important, though it can also be calculated; for every 10 mm Hg increase in PaCO₂, pH will decrease roughly:
   a. 0.07 in acute acidosis
   b. 0.03 in chronic acidosis
   c. Intermediate values suggest a mixed picture
3. Calculate if renal compensation is appropriate:
   a. Acute respiratory acidosis

Increased PaCO₂ → increased cerebral blood flow, → increased CSF pressure, which results in generalized CNS depression.
• There is an immediate compensatory elevation of HCO$_3^-$.
• There is an increase of 1 mmol/L for every 10 mm Hg increase in PaCO$_2$.

b. Chronic respiratory acidosis
• Renal adaptation occurs, and HCO$_3^-$ increases by 3 to 4 mmol/L for every 10 mm Hg increase in PaCO$_2$.
• This is generally seen in patients with underlying lung disease, such as chronic obstructive pulmonary disease (COPD).

E. Treatment
1. Verify patency of the airway.
2. If PaO$_2$ is low (<60 mm Hg), initiate supplemental oxygen. Caution: In patients who are “CO$_2$ retainers” (e.g., COPD patients), oxygen can exacerbate the respiratory acidosis, so administer oxygen judiciously. (See the discussion under Acute Respiratory Failure in Chapter 2.)
3. Correct reversible causes.
4. Any measure to improve alveolar ventilation.
   a. Aggressive pulmonary toilet.
   b. Correct reversible pulmonary disease (e.g., treat pneumonia).
   c. Remove obstruction.
   d. If there is drug-induced hypoventilation, clear the agent from the body (naloxone!).
   e. Administer bronchodilators.
5. Intubation and mechanical ventilation may be necessary to relieve the acidemia and hypoxia that result from hypoventilation. The following situations require intubation:
   a. Severe acidosis.
   b. PaCO$_2$ >60 or inability to increase PaO$_2$ with supplemental oxygen.
   c. If patient is obtunded or shows deterioration in mental status.
   d. Impending respiratory fatigue (ensues with prolonged labored breathing).
Respiratory Alkalosis

A. General Characteristics
1. Characterized by an increased blood pH and decreased PaCO₂.
2. Chronicity of disease can, as in respiratory acidosis, be determined by clinical history or estimated through change in pH. For every 10 mm Hg decrease in PaCO₂, pH will increase roughly:
   a. 0.07 in acute alkalosis
   b. 0.03 in chronic alkalosis
3. In order to maintain blood pH within the normal range, HCO₃ must decrease, so renal compensation occurs (i.e., HCO₃⁻ excretion increases). However, this does not occur acutely, but rather over the course of several hours.
   a. Acutely, for each 10 mm Hg decrease in PaCO₂, plasma HCO₃⁻ decreases by 2 mEq/L and blood pH increases by 0.08 mEq/L.
   b. Chronically, for each 10 mm Hg decrease in PaCO₂, plasma HCO₃⁻ decreases by 5 to 6 mEq/L and blood pH decreases by 0.02 mEq/L.

Quick HIT

PaCO₂ is primarily determined by respiratory rate and tidal volume.

B. Causes—alveolar hyperventilation
1. Anxiety
2. Pulmonary embolism, pneumonia, asthma
3. Sepsis
4. Hypoxia—leads to increased respiratory rate
5. Mechanical ventilation
6. Pregnancy—increased serum progesterone levels cause hyperventilation
7. Liver disease (cirrhosis)
8. Medication (salicylate toxicity)
9. Hyperventilation syndrome

Quick HIT

Any disorder that increases the respiratory rate inappropriately can lead to respiratory alkalosis.

C. Clinical Features
1. Symptoms are mostly related to decreased cerebral blood flow (vasoconstriction): lightheadedness, dizziness, anxiety, paresthesias, and perioral numbness
2. Tetany (indistinguishable from hypocalcemia)
3. Arrhythmias (in severe cases)

**D. Treatment**
1. Correct the underlying cause.
2. Sometimes this does not need to be treated (e.g., in the case of pregnancy).
3. An inhaled mixture containing CO₂ or breathing into a paper bag may be useful.
Hematologic Diseases and Neoplasms
Karissa Britten
Anemias

Basics of Anemia

Quick HIT

Historical Findings to Consider in Patients With Anemia
- Family history (e.g., hemophilia, G6PD deficiency, thalassemia)
- Bleeding (e.g., recent trauma/surgery, hematemesis, melena)
- Chronic illnesses (e.g., renal failure, autoimmune diseases, malignancies)
- Ingestions (e.g., alcohol, medications)

A. General Characteristics
1. Anemia is defined as a reduction in the number of circulating red blood cells, as measured by hemoglobin (Hb) or hematocrit (Hct).
2. When red cell mass decreases, several compensatory mechanisms maintain oxygen delivery to the tissues, including:
   a. Increased cardiac output
   b. Increased oxygen extraction ratio
   c. Rightward shift of the oxyhemoglobin curve (increased 2,3-diphosphoglycerate [2,3-DPG])
   d. Expansion of plasma volume
3. Symptoms of anemia are highly variable, depending on the severity of anemia, the rate at which it developed, and the underlying oxygen demands of the patient. If anemia develops rapidly, symptoms are more likely to be present, because there is little time for physiologic compensation. If the onset is gradual, compensatory mechanisms are able to maintain adequate oxygen delivery to tissues, and symptoms may be minimal or absent.
4. As a general rule, blood transfusion is not recommended unless either of the following is true:
   a. The Hb concentration is <7 g/dL OR
   b. The patient requires increased oxygen-carrying capacity (e.g., patients with coronary artery disease or some other cardiopulmonary disease)

B. Clinical Features
1. Fatigue
2. Dyspnea
3. Headache
4. Palpitations
5. Tachycardia
6. Pallor—best noted in the conjunctiva
7. Signs/symptoms of the underlying cause: orthostatic lightheadedness, syncope, or hypotension if acute bleeding; jaundice if hemolytic anemia; blood in stool if GI bleeding

Quick HIT

Pseudoanemia or dilutional anemia refers to a decrease in Hb and Hct secondary to dilution (i.e., secondary to acute volume infusion or overload).

C. Diagnosis

1. Decreased Hb and Hct
   a. Formula for converting Hb to Hct: Hb × 3 = Hct (1 unit of packed RBCs [PRBCs] increases Hb level by 1 point and Hct by 3 points)
   b. Hb of 7 to 8 provides sufficient oxygen-carrying capacity for most patients—anemia is not tolerated as well in patients with impaired cardiac function (see Clinical Pearl 9-1)
2. Reticulocyte index
   a. Reports the number of reticulocytes present as a percentage of the total number of RBCs
   b. The reticulocyte count is an important initial test in evaluating anemia because it indicates whether effective erythropoiesis is occurring in the bone marrow.
   c. Effective erythropoiesis is dependent on adequate raw materials (iron, vitamin B₁₂, folate) in the bone marrow, absence of intrinsic bone marrow disease (e.g., aplastic anemia), adequate erythropoietin from the kidney, and survival of reticulocytes (no premature destruction before leaving the bone marrow)—see Clinical Pearl 9-2.
   d. A reticulocyte index >2% implies the bone marrow is responding to increased RBC requirements
   e. A reticulocyte index <2% implies inadequate RBC production by the bone marrow
3. RBC indices
   a. Mean corpuscular volume (MCV) is the average size of a patient’s RBCs
   b. Mean corpuscular hemoglobin (MCH) is the average Hb content of a patient’s RBCs
   c. Mean corpuscular hemoglobin concentration (MCHC) is the average Hb concentration in each RBC
   d. RDW is the variation in RBC size
4. Peripheral blood smear
Transfusion Pearls

- PRBCs (contain no platelets or clotting factors)
  - Mix with normal saline to infuse faster (not with lactated Ringer solution because calcium causes coagulation within the IV line)
  - Each unit raises the hematocrit by 3 to 4 points
  - Each unit may be given to an adult for over 90 to 120 minutes
  - Always check CBC after the transfusion is completed
- FFP
  - Contains all of the clotting factors
  - Contains no RBCs/WBCs/platelets
  - Given for high PT/PTT, coagulopathy, and deficiency of clotting factors—FFP can be given if you cannot wait for vitamin K to take effect, or if patient has liver failure (in which case vitamin K will not work)
  - Follow up PT and PTT to assess response
- Cryoprecipitate
  - Contains factor VIII and fibrinogen
  - For hemophilia A, decreased fibrinogen (DIC) and vWD
- Platelet transfusions—1 unit raises platelet count by 10,000
- Whole blood only for massive blood loss
- For any patient with massive blood loss, the ideal ratio of platelets: FFP: PRBCs which are transfused should be 1:1:1. Additionally, during massive blood transfusions, blood should be warmed to prevent a decrease in core body temperature.

Quick HIT

If Hb and Hct reveal anemia, the next tests to obtain to determine cause of anemia are reticulocyte count and MCV.

Quick HIT

Note that all causes of anemia are initially normocytic because it takes some time for the abnormal-sized RBCs to outnumber the normal-sized ones.

CLINICAL PEARL 9-2

Hemolytic Transfusion Reactions Are Divided Into Intravascular and Extravascular Hemolysis

- Intravascular hemolysis (also called acute hemolytic reactions):
  - Very serious and life-threatening—caused by ABO-mismatched blood transfused into patient (usually due to clerical error). For example, if B blood is given to a type A patient, anti-B IgM antibodies attach to all of the infused B RBCs, activate the complement pathway, and produce massive intravascular hemolysis as C9 punches holes through RBC membranes.
Symptoms include fever/chills, nausea/vomiting, pain in the flanks/back, chest pain, and dyspnea

Complications include hypovolemic shock (hypotension, tachycardia), DIC, and renal failure with hemoglobinuria

Management involves stopping the transfusion immediately and aggressively replacing the fluid to avoid shock and renal failure, epinephrine for anaphylaxis, dopamine/norepinephrine as needed to maintain blood pressure

Extravascular hemolysis (also called delayed hemolytic transfusion reaction):

- Extravascular hemolysis is less severe and in most cases is self-limited; it may occur within 3 to 4 weeks after a transfusion
- It is caused by one of the minor RBC antigens. For example, if a patient is Kell antigen-negative and has anti-Kell IgG antibodies from a previous exposure to the antigen, reexposure of her memory B cells to Kell antigen on RBCs will result in synthesis of IgG anti-Kell antibodies. These antibodies coat all of the Kell antigen-positive donor RBCs, which will be removed extravascularly by macrophages in the spleen, liver, and bone marrow.
- Symptoms are subtle and include fever, jaundice, and anemia
- No treatment required—the prognosis is good

D. Diagnosing the Cause of Anemia (General Approach)

1. If the reticulocyte index is <2%, indicating an inadequate bone marrow response, examine the peripheral blood smear and RBC indices (Figure 9-1).
   a. If microcytic anemia (MCV <80), the differential diagnosis includes the following:
      - Iron deficiency anemia—most common cause
      - Anemia of chronic disease—iron is present in the body but is not available for hemoglobin synthesis due to iron-trapping in macrophages
      - Thalassemia—defective synthesis of globin chains
      - Sideroblastic anemia (includes lead poisoning, pyridoxine deficiency, toxic effects of alcohol)—defective synthesis of protoporphyrins leading to iron accumulation in mitochondria
b. If macrocytic anemia (MCV >100), the differential diagnosis includes the following:
   - Vitamin B$_{12}$ or folate deficiency (MCV increases significantly)—defective DNA synthesis leading to nuclear defects in RBCs
   - Liver disease (MCV increases up to 115)—abnormal incorporation of plasma lipoproteins into RBC membranes alters RBC shape and increases their volume
   - Stimulated erythropoiesis (MCV increases up to 110)—reticulocytes are larger than mature RBCs, resulting in an increase in polychromatophilic RBCs
   - Alcoholism
- Hypothyroidism

3. If normocytic anemia (MCV 80 to 100), the differential diagnosis includes the following:
   - Aplastic anemia—bone marrow failure
   - Bone marrow fibrosis
   - Bone marrow infiltration
   - Anemia of chronic disease
   - Renal failure—decreased erythropoietin production results in decreased erythropoiesis

2. If the reticulocyte index is >2%, indicating an adequate bone marrow response, the differential diagnosis includes the following:
   a. Acute blood loss
   b. Hemolysis

Quick HIT

The first step in evaluation of the anemic patient is to assess volume status and hemodynamic stability, in order to identify any active bleeding. If hemodynamically unstable, transfuse PRBCs before attempting to find the source.
Microcytic Anemias

Iron Deficiency Anemia

Quick HIT

In elderly patients with iron deficiency anemia, you must rule out colon cancer.

Quick HIT

Pica (the craving for nonfood items) and pagophagia (the craving for ice) have been associated with iron-deficiency anemia.

A. Causes

1. Chronic blood loss
2. Most common cause of iron deficiency anemia in adults
3. Menstrual blood loss is the most common source—in the absence of menstrual bleeding, GI blood loss is most likely
4. Dietary deficiency/increased iron requirements, which are primarily seen in the following three age groups:
   5. Infants and toddlers—occurs especially if the diet is predominantly human milk, which is low in iron; children in this age group also have an increased requirement for iron due to accelerated growth
   6. Adolescents—increased requirement for iron due to rapid growth; adolescent women are particularly at risk due to loss of menstrual blood
   7. Pregnant women—pregnancy increases iron requirements

B. Diagnosis

1. Iron studies (see Table 9-1)
   a. Decreased serum ferritin
   b. Increased TIBC/transferrin levels
   c. Decreased transferrin saturation
   d. Decreased serum iron
2. Peripheral blood smear—reveals microcytic, hypochromic RBCs (Figure 9-2)
3. Bone marrow biopsy—reveals absence of stainable iron; this test is technically the gold standard, but typically only indicated if laboratory evidence of iron deficiency anemia is present and no source of blood loss is found
4. Guaiac stool test or colonoscopy if GI bleeding is suspected—colon cancer is a
common cause of GI bleeding in the elderly

**TABLE 9-1 Iron Studies in Microcytic Anemias**

<table>
<thead>
<tr>
<th></th>
<th>Serum Ferritin</th>
<th>Serum Iron</th>
<th>TIBC</th>
<th>RDW</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Iron Deficiency Anemia</strong></td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td><strong>Anemia of Chronic Disease</strong></td>
<td>Normal/high</td>
<td>Low</td>
<td>Normal/low</td>
<td>Normal</td>
</tr>
<tr>
<td><strong>Thalassemia</strong></td>
<td>Normal/high</td>
<td>Normal/high</td>
<td>Normal</td>
<td>Normal/high</td>
</tr>
</tbody>
</table>

**FIGURE 9.2 Blood smear: iron deficiency anemia.**


**Quick HIT**
The MCH and MCHC are of little value clinically. They are neither sensitive nor specific for any diagnosis. However, MCV is very valuable in diagnosing the cause of anemia.
The RDW measures the variation in RBC size. The RDW is usually abnormal in iron deficiency, but is generally normal in all of the other microcytic anemias.

C. Treatment

1. Oral iron replacement (ferrous sulfate)
   a. A trial of iron replacement therapy may be given to young, otherwise healthy, menstruating women without investigating for additional sources of blood loss (in men and postmenopausal women, attempt to determine the source of blood loss first)
   b. Side effects include constipation, nausea, and dyspepsia

2. Parenteral iron replacement
   a. Iron dextran can be administered IV or IM
   b. Rarely necessary because most patients respond to oral iron therapy—may be useful in patients with poor gut absorption, patients who require more iron than oral therapy can provide, patients who cannot tolerate oral ferrous sulfate, or certain heart failure patients

3. Blood transfusion is not recommended unless anemia is severe or the patient has cardiopulmonary disease
Thalassemias

A. General Characteristics
1. Inherited disorders characterized by reduced production of either the α- or β-globin chain of hemoglobin
2. β-Thalassemias
   a. β-Chain production is decreased, but the synthesis of α-chains is unaffected
   b. Excess α-chains bind to and damage the RBC membrane
   c. Severity depends on the number of alleles mutated and the severity of these mutations
   d. It is most often found in people of Mediterranean, Middle Eastern, and Indian ancestry
3. α-Thalassemias
   a. There is a decrease in α-chains, which are a component of all types of hemoglobins
   b. Excess β-globin chains form tetramers, which are abnormal hemoglobins
   c. Severity depends on the number of alleles that are deleted/mutated, ranging from an asymptomatic carrier state to fetal death

Quick HIT
If iron deficiency anemia is suspected, but the anemia does not respond to iron therapy, obtain a hemoglobin electrophoresis to rule out α- and β-thalassemia.

B. β-Thalassemias
1. β-Thalassemia major (Cooley anemia; homozygous β-chain thalassemia)
   a. Clinical features
      • Severe anemia beginning in late infancy
      • Jaundice and dark urine
      • Massive hepatosplenomegaly
      • Expansion of marrow space—can cause distortion of bones and result in “crew-cut” appearance on skull X-ray
      • Growth retardation and failure to thrive
      • If untreated, death occurs within the first few years of life secondary to progressive CHF
   b. Diagnosis
      • Hemoglobin electrophoresis—reveals elevated Hb F and HbA₂
      • Peripheral blood smear—reveals microcytic, hypochromic anemia; target cells may be seen (Figure 9-3)
c. Treatment
   • Frequent PRBC transfusions are required to sustain life
2. β-Thalassemia minor (heterozygous β-chain thalassemia)
   a. Characterized by asymptomatic carrier state or mild anemia
   b. Diagnosed with hemoglobin electrophoresis
   c. Peripheral blood smear reveals microcytic, hypochromic RBCs
   d. Treatment usually not necessary (patients are not transfusion-dependent)
3. β-Thalassemia intermedia
   a. Characterized by anemias of varying severity
   b. Diagnosed with hemoglobin electrophoresis
   c. Peripheral blood smear reveals microcytic, hypochromic RBCs
   d. Most individuals are not transfusion-dependent in childhood, but many will become transfusion-dependent in adulthood

Quick HIT
Iron overload can develop in patients with transfusion-dependent thalassemia. If untreated, this can lead to CHF and other symptoms of hemochromatosis. These individuals are often treated with deferoxamine, an iron-chelating agent.

C. α-Thalassemias
1. Silent carriers (mutation/deletion of only one α-locus)
   a. Asymptomatic
   b. Normal Hb and Hct level
   c. No treatment necessary
2. α-Thalassemia trait/minor (mutation/deletion of two α-loci)
   a. Characterized by mild anemia
   b. Peripheral blood smear reveals microcytic, hypochromic RBCs
   c. No treatment necessary
3. Hb H disease (mutation/deletion of three α-loci)
   a. Characterized by anemias of varying severity
   b. Hemoglobin electrophoresis shows Hb H
   c. Peripheral blood smear reveals microcytic, hypochromic RBCs
   d. Most individuals are not transfusion-dependent, but many require periodic transfusions during episodes of increased hemolysis (e.g., infection)
4. Mutation/deletion of all four α-loci
   a. Either fatal at birth (hydrops fetalis) or shortly after birth
FIGURE
9.3 Blood smear: thalassemia. Target cells (arrows) and circulating nucleated red blood cells (arrowhead).


Quick HIT

The most common type of thalassemia is thalassemia minor (with β-thalassemia minor being more common than α-thalassemia minor). Both of these conditions can be mistaken for iron deficiency anemia.
Sideroblastic Anemia

Caused by abnormality in RBC iron metabolism leading to pathologic iron deposits in RBC mitochondria

May be hereditary or acquired—acquired causes include drugs (e.g., chloramphenicol, INH, alcohol), exposure to lead, collagen vascular disease, and neoplastic disease (e.g., myelodysplastic syndromes)

Characterized by ringed sideroblasts in bone marrow, increased serum iron, increased serum ferritin, normal TIBC, and normal/elevated TIBC saturation (which distinguishes it from iron deficiency anemia)

Treatment involves removing offending agents and transfusing as necessary—may also consider pyridoxine
Normocytic Anemias

Anemia of Chronic Disease

Occurs in the setting of chronic infection (e.g., tuberculosis, lung abscess), malignancy (e.g., lung, breast, Hodgkin disease), inflammation (e.g., rheumatoid arthritis, systemic lupus erythematosus [SLE]), or trauma—the release of inflammatory cytokines has a suppressive effect on erythropoiesis

Generally mild and well tolerated

May be difficult to differentiate from iron deficiency anemia

Laboratory findings include low serum iron, normal-to-low TIBC-serum transferrin, and increased serum ferritin

Peripheral blood smear usually reveals normocytic and normochromic anemia, but may be microcytic and hypochromic as well

No specific treatment is necessary other than treatment of the underlying process—do not give iron
Aplastic Anemia

A. General Characteristics
1. Bone marrow failure leading to pancytopenia (i.e., anemia, neutropenia, thrombocytopenia)
2. Causes
   a. Idiopathic—majority of cases
   b. Radiation exposure
   c. Medications (e.g., chloramphenicol, sulfonamides, gold, carbamazepine)
   d. Viral infection (e.g., human parvovirus, hepatitis C, hepatitis B, Epstein–Barr virus [EBV], cytomegalovirus [CMV], herpes zoster, varicella, HIV)
   e. Chemical exposure (e.g., benzene, insecticides)

B. Clinical Features
1. Signs/symptoms of anemia: fatigue, dyspnea, headache, palpitations, pallor
2. Signs/symptoms of thrombocytopenia: petechiae, easy bruising
3. Increased incidence of infections—due to neutropenia
4. Can transform into acute leukemia

C. Diagnosis
1. Pancytopenia
2. Peripheral blood smear—reveals normocytic anemia with decreased neutrophils and platelets
3. Bone marrow biopsy (for definitive diagnosis)—reveals hypocellular marrow and the absence of progenitors of all three hematopoietic cell lines

Quick HIT
Pernicious anemia is a special case of vitamin B₁₂ deficiency. It is an autoimmune disorder resulting in inadequate production of intrinsic factor, which leads to impaired absorption of vitamin B₁₂ in the terminal ileum.

D. Treatment
1. Discontinuation of offending agents or treatment of any known underlying causes
2. Transfusion of PRBCs and platelets as necessary—use judiciously
3. Bone marrow transplantation
Macrocytic Anemias

Vitamin B12 Deficiency

A. General Characteristics

1. Vitamin B$_{12}$ serves as a cofactor in two important reactions required for normal erythropoiesis and CNS functioning:
   a. The conversion of homocysteine to methionine
   b. The conversion of methylmalonyl-CoA to succinyl-CoA
2. The main dietary sources of vitamin B$_{12}$ are meat and fish
3. After ingestion, vitamin B$_{12}$ is bound to intrinsic factor (produced by gastric parietal cells) so it can be absorbed by the terminal ileum
4. Vitamin B$_{12}$ stores in the liver are plentiful and can sustain an individual for 3 or more years
5. Causes
   a. Most commonly due to impaired absorption (either via lack of intrinsic factor or lack of absorptive ileal surface)
   b. Pernicious anemia—lack of intrinsic factor due to autoimmune destruction; most common cause in the Western hemisphere
   c. Gastrectomy—lack of intrinsic factor due to removal of parietal cells
   d. Inadequate dietary intake (e.g., strict vegetarianism, alcoholism)
   e. Crohn disease or resection of terminal ileum (approximately the last 100 cm)
   f. Other organisms competing for vitamin B$_{12}$ (i.e., Diphyllobothrium latum infestation [fish tapeworm] and blind loop syndrome [bacterial overgrowth])

Quick HIT

In a patient with megaloblastic anemia, it is important to determine whether folate or vitamin B$_{12}$ deficiency is the cause prior to initiating treatment. Folate supplements can improve the anemia of vitamin B$_{12}$ deficiency, but not the neurologic impairment. Therefore, if the vitamin B$_{12}$ deficiency remains untreated, irreversible neurologic disease can result.

Quick HIT

Note that patients with vitamin B$_{12}$ deficiency can have moderate-to-severe neurologic symptoms with little-to-no anemia (i.e., blood counts may be normal). Delay in diagnosis and treatment may lead to irreversible neurologic disease.
B. Clinical Features
1. Sore tongue (stomatitis and glossitis)
2. Neuropsychiatric changes/dementia—look for vitamin B$_{12}$ deficiency in the workup for dementia
3. Neuropathy and subacute combined degeneration of the spinal cord—distinguishes vitamin B$_{12}$ deficiency from folate deficiency
   a. Leads to a loss of position/vibratory sensation in lower extremities, ataxia, and upper motor neuron signs (increased deep tendon reflexes, spasticity, weakness, Babinski sign)
   b. Can lead to urinary and fecal incontinence, impotence

C. Diagnosis
1. Peripheral blood smear—reveals megaloblastic (macrocytic) anemia with hypersegmented neutrophils (Figure 9-4)
2. Low serum vitamin B$_{12}$ level
3. Elevated serum methylmalonic acid and homocysteine levels—most useful if the vitamin B$_{12}$ level is borderline
4. Antibodies to intrinsic factor (for the diagnosis of pernicious anemia)
5. Schilling test was historically used to determine if B$_{12}$ deficiency is due to pernicious anemia, but is no longer routinely performed:
   a. Administer IM dose of unlabeled vitamin B$_{12}$ to saturate binding sites
   b. Administer oral dose of radioactive vitamin B$_{12}$
   c. Measure the amount of radioactive vitamin B$_{12}$ in urine and plasma to determine the amount absorbed in the gut
   d. Repeat the administration of oral radioactive vitamin B$_{12}$ with the addition of intrinsic factor
   e. If malabsorption is the cause of deficiency, adding intrinsic factor will not change study results. However, if pernicious anemia is present, the addition of intrinsic factor will improve the amount of vitamin B$_{12}$ absorbed.
D. Treatment

1. Cyanocobalamin (vitamin B$_{12}$) IM—parenteral therapy is preferred
Folate Deficiency

Quick HIT

The serum homocysteine level is increased in both folate deficiency and vitamin $B_{12}$ deficiency. However, serum methylmalonic acid levels are only seen in vitamin $B_{12}$ deficiency.

A. General Characteristics
1. Folate plays an important role in DNA synthesis
2. Green vegetables and folic acid–supplemented foods are the main dietary sources of folate
3. Folic acid stores in the body are limited, and inadequate intake over a 3-month period can lead to deficiency
4. Causes
   a. Inadequate dietary intake (e.g., “tea and toast” diet, alcoholism)—most common cause
   b. Long-term use of oral antibiotics
   c. Increased folate requirements (e.g., pregnancy, chronic hemolysis)
   d. Use of folate antagonists (e.g., methotrexate)
   e. Anticonvulsant medications (e.g., phenytoin)
   f. Malabsorptive syndromes (e.g., celiac disease)
   g. Hemodialysis

B. Clinical Features
1. Similar to those of vitamin $B_{12}$ deficiency, but no neurologic symptoms
2. Signs/symptoms of anemia: fatigue, dyspnea, headache, palpitations, pallor
3. Neuropsychiatric changes/dementia—look for folate deficiency in the workup for dementia

C. Diagnosis
1. Peripheral blood smear—reveals megaloblastic (macrocytic) anemia with hypersegmented neutrophils
2. Low serum folate level
3. Elevated serum homocysteine level—methylmalonic acid levels are normal

D. Treatment
1. Daily oral folic acid replacement
Hemolytic Anemias

Overview

A. General Characteristics

1. Hemolysis refers to the premature destruction of RBCs due to a variety of causes.
2. Bone marrow is typically normal and responds appropriately by increasing erythropoiesis, leading to an elevated reticulocyte count. However, if erythropoiesis cannot keep up with the destruction of RBCs, anemia results.
3. Hemolytic anemia can be classified according to cause, site, chronicity, or mechanism of destruction.
4. Hemolytic anemias are classified based on cause as follows:
   a. Hemolysis due to abnormality extrinsic to RBC—most cases are acquired:
      - Immune hemolysis
      - Mechanical hemolysis (e.g., prosthetic heart valves, microangiopathic hemolytic anemia)
      - Medications, burns, toxins (e.g., snake bite, brown recluse spider bite), infections (e.g., malaria, clostridium)
   b. Hemolysis due to intrinsic RBC defects—most cases are inherited:
      - Hemoglobin abnormality (e.g., sickle cell anemia, hemoglobin C disease, thalassemias)
      - Membrane defects (e.g., hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria [PNH])
      - Enzyme defects (e.g., glucose-6-phosphate dehydrogenase [G6PD] deficiency, pyruvate kinase deficiency)
5. Hemolytic anemias are classified based on the predominant site of hemolysis as follows:
   a. Intravascular hemolysis—within the circulation
   b. Extravascular hemolysis—within the reticuloendothelial system, primarily the spleen

Quick HIT

Ethnic background, family history of jaundice/anemia, and medications are all relevant aspects of the history of a patient with hemolytic anemia.
Mechanical heart valves can hemolyze RBCs and lead to hemolytic anemia.

**Expected Laboratory Results in Hemolytic Anemia**
- Elevated reticulocyte count, LDH, indirect bilirubin
- Decreased haptoglobin and Hb/Hct

Physical injury to RBCs leads to the presence of fragmented RBCs called schistocytes or helmet cells on the blood smear. This can occur in TTP, DIC, and patients with prosthetic heart valves.

**B. Clinical Features**
1. Signs/symptoms of anemia: fatigue, dyspnea, headache, palpitations, pallor
2. Jaundice
3. Dark urine color if intravascular process—due to hemoglobinuria, not bilirubin
4. Hepatosplenomegaly, cholelithiasis, and lymphadenopathy if chronic
5. Signs/symptoms of underlying disease (e.g., bone crises in sickle cell disease)

**C. Diagnosis**
1. Low Hb/Hct—level depends on degree of hemolysis and reticulocytosis
2. Elevated reticulocyte count—due to increased RBC production
3. Peripheral blood smear
   a. Schistocytes suggest intravascular hemolysis (“trauma” or mechanical hemolysis) ([Figure 9-5](#))
   b. Spherocytes or helmet cells suggest extravascular hemolysis (depending on the cause)
   c. Sickled RBCs if sickle cell anemia
   d. Heinz bodies if G6PD deficiency
4. Low haptoglobin (especially with intravascular hemolysis)—haptoglobin binds to free hemoglobin, so decreased levels suggest hemoglobin release secondary to RBC destruction
5. Elevated LDH—released when RBCs are destroyed
6. Elevated indirect (unconjugated) bilirubin—due to degradation of heme as RBCs are destroyed
7. Positive direct Coombs test if autoimmune hemolytic anemia (AIHA)—detects antibody or complement on RBC membrane
8. Positive osmotic fragility test (see below)
D. Treatment

1. Treat underlying cause
2. Transfusion of PRBCs if severe anemia is present or patient is hemodynamically compromised
3. Folate supplementation—folate is depleted in hemolysis
Sickle Cell Disease

A. General Characteristics

1. Sickle Cell Anemia
   a. Autosomal recessive disorder resulting from the inheritance of two Hb S genes (homozygous), causing normal Hb A to be replaced by the mutant Hb S
   b. Hb S is distinguished from Hb A by its substitution of an uncharged valine for a negatively charged glutamic acid at the sixth position of the β-chain
   c. Under reduced oxygen conditions (e.g., acidosis, hypoxia, changes in temperature, dehydration, and infection) the Hb S molecules polymerize, causing the RBCs to sickle. Sickled RBCs obstruct small vessels, leading to ischemia (see Clinical Pearl 9-3).

2. Sickle cell trait
   a. Results from the inheritance of one Hb S gene (heterozygous)
   b. 1 in 12 people of African descent are carriers, but sickle cell trait also appears in individuals of Italian, Greek, and Saudi Arabian descent
   c. Patients with sickle cell trait are not anemic and have a normal life expectancy
   d. Sickle cell trait is associated with isosthenuria, the inability to concentrate or dilute urine—patients will have a constant osmolality on urinalysis testing
   e. Screening can identify asymptomatic individuals with sickle cell trait, for whom genetic counseling may be provided

3. Prognosis
   a. In general, sickle cell disease reduces life expectancy, with a median survival of 58 years in the United States
   b. Factors that have been associated with increased mortality rates include greater frequency of hospitalization, acute chest syndrome, and renal insufficiency
   c. The most common causes of death include acute chest syndrome and multiorgan failure

CLINICAL PEARL 9-3

Almost Every Organ Can Be Involved in Sickle Cell Disease

- Blood—chronic hemolytic anemia, aplastic crises
- Heart—high-output CHF due to anemia
- CNS—stroke
- GI tract—gallbladder disease (stones), splenic infarctions, abdominal crises
- Bones—painful crises, osteomyelitis, avascular necrosis
- Lungs—infected, acute chest syndrome
- Kidneys—hematuria, papillary necrosis, renal failure
- Eyes—proliferative retinopathy, retinal infarcts
- Genitalia—priapism
Sickle cell crises vary in severity and frequency among patients. Some have many painful events requiring multiple hospitalizations per year, while others have very few. Each episode is typically followed by a period of remission.

Vaso-occlusive crises are due to obstruction of microcirculation by sickled RBCs. This leads to ischemia in various organs, producing the characteristic “painful crises.”

B. Clinical Features

1. Manifestations of chronic, hemolytic anemia
   a. Pallor and/or jaundice
   b. Gallstone disease (pigmented gallstones)
   c. Delayed growth and maturation (especially in boys)
   d. High-output heart failure
2. Manifestations of acute vaso-occlusion
   a. Pain crises—most common clinical manifestation
   b. Vaso-occlusion results in bone infarction, causing severe pain
   c. Bone pain usually involves multiple sites (e.g., tibia, humerus, femur) and may or may not be bilateral
   d. Pain is self-limiting and usually lasts 2 to 7 days
   e. Hand-foot syndrome (dactylitis)
      • Painful swelling of dorsa of hands and feet seen in infancy and early childhood (usually 4 to 6 months)
      • Often the first manifestation of sickle cell disease
      • Caused by avascular necrosis of the metacarpal and metatarsal bones
   f. Acute chest syndrome
      • Clinical presentation similar to pneumonia
      • Characterized by chest pain, respiratory distress, pulmonary infiltrates, and hypoxia
      • Due to repeated episodes of pulmonary infarctions
   g. Splenic infarction
      • Recurrent episodes eventually lead to autosplenectomy, whereby the spleen is reduced to a small, calcified remnant
      • The spleen is large in childhood but is no longer palpable by 4 years of age
   h. Priapism
• Erection due to vaso-occlusion, usually lasting between 30 minutes and 3 hours
• Usually subsides spontaneously, after urine is passed, after light exercise, or after a cold shower
• A trial of hydralazine, nifedipine, or antiandrogens (e.g., stilbestrol) may prevent further episodes
• Sustained priapism (i.e., lasting more than 3 hours) is rare (less than 2%), but is a medical emergency
i. Renal papillary necrosis—common, affecting up to 20% of patients
   • Characterized by hematuria (usually painless)
   • Seldom requires hospitalization and may cease spontaneously
j. Stroke—primarily in children
k. Myocardial infarction
l. Avascular necrosis of joints—most common in hip and shoulder

3. Manifestations of chronic vaso-occlusion
   a. Chronic lower extremity ulcers—most common over lateral malleoli
   b. Ophthalmologic complications (e.g., retinal infarcts, vitreous hemorrhage, proliferative retinopathy, retinal detachment)
   c. Chronic pain
4. Aplastic crises
   a. Usually provoked by a viral infection such as human parvovirus B19, which reduces the ability of the bone marrow to compensate for chronic hemolysis
5. Infectious complications
   a. Functional asplenia results in increased susceptibility to infections (particularly encapsulated bacteria such as *Haemophilus influenzae, Streptococcus pneumoniae*)
   b. Predisposition to *Salmonella* osteomyelitis (encapsulated organism)
C. Diagnosis

1. Anemia—most common finding
2. Peripheral blood smear—reveals sickle-shaped RBCs (Figure 9-6)
3. Hemoglobin electrophoresis—required for diagnosis, although most patients are diagnosed on newborn screening

D. Treatment

1. Prevention of crises
   a. Avoid high altitudes—low oxygen tension can precipitate crisis
   b. Maintain fluid intake—dehydration can precipitate crisis
   c. Treat infections promptly— infection/fever can precipitate crisis and should be considered a medical emergency
2. Prevention of infections
   a. Early vaccination for *S. pneumoniae, H. influenzae*, and *Neisseria meningitidis*
   b. Prophylactic penicillin for children <5 years of age
3. Hydroxyurea
   a. Indicated for adults with severe/symptomatic sickle cell disease, frequent pain crises, severe/recurrent acute chest syndrome, or chronic pain
b. Enhances Hb F levels, which reduces sickling

c. Reduces vaso-occlusive events, including pain crises and acute chest syndrome

4. Management of anemia
   a. Folic acid supplementation
   b. Blood transfusion as necessary—base need for transfusion on the patient’s clinical condition and not on Hb levels (e.g., the presence of vaso-occlusive phenomena like acute chest syndrome, stroke, or cardiac decompensation)

5. Management of pain crises
   a. Hydration—oral hydration if mild episode, IV fluids (normal saline) for moderate/severe episodes
   b. Morphine for pain control—do not underestimate patient’s pain

6. Bone marrow transplantation—has been performed successfully to cure sickle cell anemia, but is not routinely performed due to matched donor availability and risk of complications
Hereditary Spherocytosis

Quick HIT

Causes of Spherocytosis
- Hereditary spherocytosis
- G6PD deficiency
- ABO incompatibility (but not Rh incompatibility)
- Hyperthermia
- AIHA

A. General Characteristics
1. Hereditary spherocytosis is caused by the autosomal dominant inheritance of a defect in the gene coding for spectrin and other RBC proteins
2. There is a loss of RBC membrane surface area without a reduction in RBC volume, necessitating a spherical shape. The spherical RBCs become trapped and destroyed in the spleen (by macrophages)—hence the term extravascular hemolysis.

B. Clinical Features
1. Hemolytic anemia—can be severe
2. Jaundice
3. Splenomegaly
4. Gallstones
5. Occasional hemolytic crises

C. Diagnosis
1. Microcytic anemia
2. Elevated reticulocyte count
3. Elevated MCHC
4. Peripheral blood smear—reveals spherocytes (sphere-shaped RBCs) (Figure 9-7)
5. Negative direct Coombs test—helps to distinguish hereditary spherocytosis (HS) from AIHA (also characterized by spherocytes)
6. Eosin-5-maleimide (EMA) binding testing
7. EMA is a dye that binds to several proteins present on the RBC membrane
8. Spherocytes have a reduced number of these proteins present on their membranes and will demonstrate decreased EMA binding on testing
9. Osmotic fragility testing
   a. Tests the ability of RBCs to swell in a graded series of hypotonic solutions
   b. Because of their reduced surface area to volume ratio, spherocytes are less tolerant of swelling and will rupture earlier (in more concentrated solutions) than...
normal RBCs (they are osmotically fragile)

**Quick HIT**

Following splenectomy, patients must be immunized against encapsulated organisms—*N. meningitidis, S. pneumoniae, H. influenzae.*

**D. Treatment**

1. Blood transfusion as necessary
2. Splenectomy in patients with symptomatic or moderate/severe anemia

**FIGURE 9.7** Blood smear: spherocytes (hereditary spherocytosis).

(From Strayer DS, Rubin E. *Rubin’s Pathology: Clinicopathologic Foundations of Medicine.* 7th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014:1094, Figure 26-17.)
Glucose-6-Phosphate Dehydrogenase Deficiency

A. General Characteristics
1. X-linked recessive disorder that primarily affects men
2. Most common inherited RBC enzymatic defect
3. Known precipitants include sulfonamides, nitrofurantoin, primaquine, dimercaprol, fava beans, and infection
4. Specific variants are more common in certain populations:
   a. G6PD A− variant
      • A mild form of G6PD deficiency present in 10% of African-American men
      • In this form, enzymatic activity is preserved in young RBCs, but declines as RBCs age
      • Because hemolysis is limited to the older, enzyme-deficient RBCs, hemolytic episodes are usually mild and self-limited
      • Hemolytic episodes are usually triggered by infection or by certain drugs, such as antimalarials (e.g., primaquine) and sulfur-containing antibiotics (e.g., sulfonamide or trimethoprim sulfamethoxazole)
   b. G6PD Mediterranean variant
      • More severe form of G6PD deficiency most common in individuals of Mediterranean descent
      • In this form, the majority of RBCs are enzyme-deficient (young as well as old RBCs)
      • Causes severe hemolytic anemia, especially when exposed to fava beans
      • May require transfusions until the inciting agent is eliminated from the body

Quick HIT
- Deficiency of G6PD results in the accumulation of H₂O₂ in RBCs, which denatures Hb and precipitates Heinz body formation within RBCs.
- Heinz bodies attach to RBC membranes, reducing their flexibility and making them prone to splenic sequestration.

B. Clinical Features
1. Episodic hemolytic anemia—usually induced by drugs, foods, or illness
2. Dark urine
3. Jaundice

C. Diagnosis
1. Anemia, elevated LDH, decreased haptoglobin, and elevated indirect bilirubin (during episodes of hemolysis)
2. Peripheral blood smear
   a. “Bite cells”—RBCs that appear to have “bites” taken out of them, secondary to phagocytosis of Heinz bodies by splenic macrophages (Figure 9-8)
   b. Heinz bodies—abnormal hemoglobin precipitates within RBCs
3. G6PD assay—reveals deficient NADPH formation
4. Decreased G6PD level is diagnostic—important to note that G6PD levels may be normal during acute hemolytic episodes, because RBCs most deficient in G6PD have already been destroyed; repeating the test at a later date facilitates diagnosis

**FIGURE 9.8** Blood smear: bite cells (Glucose-6-phosphate dehydrogenase deficiency).


**D. Treatment**
1. Avoid drugs or other exposures that precipitate hemolysis
2. Maintain hydration
3. Blood transfusion as necessary
Autoimmune Hemolytic Anemia

A. General Characteristics
1. Production of autoantibodies to RBC membrane antigen(s) which leads to hemolysis
2. The type of antibody produced (IgG or IgM) determines the prognosis, site of RBC destruction, and response to treatment
3. The course is variable, but tends to be more fulminant in children than in adults
4. Warm AIHA—more common than cold AIHA
   a. Autoantibody is IgG, which binds optimally to RBC membranes at 37°C (“warm” temperatures)
   b. Results in extravascular hemolysis—the primary site of RBC sequestration is the spleen, and splenomegaly is a common feature
   c. May be primary/idiopathic or secondary to lymphomas, leukemias (e.g., chronic lymphocytic leukemia), other malignancies, collagen vascular diseases (especially SLE), and drugs (e.g., α-methyldopa)
5. Cold AIHA
   a. Autoantibody is IgM, which binds optimally to the RBC membrane at 0° to 5°C (“cold” temperatures)
   b. Results in complement activation and intravascular hemolysis—primary site of RBC sequestration is the liver
   c. May be primary/idiopathic (especially in the elderly) or secondary to infection (e.g., Mycoplasma pneumoniae infection, infectious mononucleosis)

B. Clinical Features
1. Signs/symptoms of anemia: fatigue, dyspnea, headache, palpitations, pallor
2. Jaundice if significant hemolysis is present
3. Signs/symptoms of the underlying disease

C. Diagnosis
1. Anemia with elevated reticulocyte count
2. Elevated LDH
3. Decreased haptoglobin
4. Elevated indirect bilirubin
5. Peripheral blood smear—reveals spherocytes if warm AIHA, or RBC aggregates if cold AIHA
6. Direct Coombs test
   a. If positive for IgG on RBCs, suggests a diagnosis of warm AIHA
   b. If positive for complement alone on RBCs, suggests a diagnosis of cold AIHA
7. Positive cold agglutinin titer if cold AIHA

D. Treatment

1. The therapeutic approach depends on the type of autoantibody causing the hemolysis

2. Warm AIHA
   a. Glucocorticoids—mainstay of therapy
   b. Splenectomy—for patients whose condition does not respond to glucocorticoids
   c. Rituximab—for patients whose condition does not respond to splenectomy
   d. Immunosuppression (azathioprine or cyclophosphamide)—for patients whose condition does not respond to splenectomy
   e. RBC transfusions as necessary
   f. Folic acid supplementation

3. Cold AIHA
   a. Avoiding exposure to cold—prevents bouts of hemolysis
   b. Rituximab
   c. Various chemotherapy agents
   d. RBC transfusions as necessary
   e. Steroids are not beneficial
Paroxysmal Nocturnal Hemoglobinuria

A. General Characteristics
1. Acquired disorder that affects hematopoietic stem cells and cells of all blood lineages
2. Caused by a deficiency of proteins that anchor complement-inactivating proteins to blood cell membranes. This deficiency results in an unusual susceptibility to complement-mediated lysis of RBCs, WBCs, and platelets.

B. Clinical Features
1. Signs/symptoms of anemia: fatigue, dyspnea, headache, palpitations, pallor
2. Signs/symptoms of chronic intravascular hemolysis: paroxysmal hemoglobinuria (dark urine), jaundice
3. Pancytopenia
4. Thrombosis—primarily of venous systems (e.g., of the hepatic veins [Budd–Chiari syndrome])
5. May evolve into aplastic anemia, myelodysplasia, myelofibrosis, and acute leukemia
6. Abdominal, back, and musculoskeletal pain

C. Diagnosis
1. Normocytic anemia with elevated reticulocyte count
2. Elevated LDH
3. Reduced haptoglobin
4. Elevated indirect bilirubin
5. Peripheral blood smear—reveals normochromic, normocytic RBCs
6. Flow cytometry of anchored cell surface proteins (CD55, CD59)

D. Treatment
1. Eculizumab—monoclonal antibody that serves as a complement inhibitor, for patients with significant disease manifestations (e.g., transfusion dependence, renal insufficiency, or thrombosis)
2. Folic acid supplementation
3. Blood transfusion as necessary
4. Bone marrow transplantation—potentially curative
Platelet Disorders

Thrombocytopenia

A. General Characteristics

1. Defined as platelet count <150,000 (normal range is 150,000 to 400,000/mL [Figure 9-9])

2. Causes
   a. Decreased production
      - Bone marrow failure: acquired (e.g., aplastic anemia), congenital (e.g., Fanconi syndrome), congenital intrauterine rubella
      - Bone marrow invasion: tumors, leukemia, fibrosis
      - Bone marrow injury: drugs (e.g., ethanol, gold, cancer chemotherapy agents, chloramphenicol), chemicals (e.g., benzene), radiation, infection
   b. Increased destruction
      - Immune: infection, drug-induced, immune thrombocytopenic purpura (ITP), SLE, heparin-induced thrombocytopenia (HIT) type 2, HIV-associated thrombocytopenia
      - Nonimmune: disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), HIT type 1
   c. Sequestration from splenomegaly
   d. Dilutional—after transfusions or hemorrhage
   e. Pregnancy—usually an incidental finding (especially third trimester) but can also occur in setting of preeclampsia or eclampsia (remember HELLP syndrome)
FIGURE 9.9 Classification of platelet disorders.

Quick HIT

HIT
- HIT type 1: Heparin directly causes platelet aggregation, leading to a mild drop in platelets; seen <48 hours after initiating heparin; no treatment is needed.
- HIT type 2: Heparin induces antibody-mediated injury to platelets, leading to a significant drop in counts; seen 3 to 12 days after initiating heparin; heparin should be discontinued immediately.

B. Clinical Features

1. Cutaneous bleeding: petechiae (most common in dependent areas), purpura, ecchymoses at sites of minor trauma
2. Mucosal bleeding: epistaxis, menorrhagia, hemoptyse, bleeding in GI and genitourinary (GU) tracts
3. Excessive bleeding after procedures or surgery (when platelet count <50,000)
4. Intracranial hemorrhage and heavy GI bleeding (when platelet count <10,000)
can be life-threatening
5. Do not see heavy bleeding into tissues (hematomas) or joints (hemarthroses) like what is seen in coagulation disorders (e.g., hemophilia)

C. Diagnosis
1. Decreased platelet count
2. Peripheral blood smear
3. Bone marrow biopsy—may be required if primary hematologic disorder is suspected

D. Treatment
1. Remove any offending drugs (e.g., aspirin, NSAIDs) and treat the underlying cause
2. Platelet transfusion as necessary—depending on the cause and severity of thrombocytopenia

<table>
<thead>
<tr>
<th>Table 9-2</th>
<th>Severity of Thrombocytopenia and Associated Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Platelet Count</strong></td>
<td><strong>Risk</strong></td>
</tr>
<tr>
<td>&gt;100,000</td>
<td>Abnormal bleeding (even after trauma or surgery) is unusual</td>
</tr>
<tr>
<td>20,000–70,000</td>
<td>Increased bleeding hemorrhage during surgery or trauma</td>
</tr>
<tr>
<td>&lt;20,000</td>
<td>Minor spontaneous bleeding: easy bruising, petechiae, epistaxis, menorrhagia, bleeding gums</td>
</tr>
<tr>
<td>&lt;5,000</td>
<td>Major spontaneous bleeding: intracranial bleeding, heavy GI bleeding</td>
</tr>
</tbody>
</table>
Immune (Idiopathic) Thrombocytopenic Purpura

A. General Characteristics
1. IgG autoantibodies to host platelets coat and damage platelets, which are then removed by splenic macrophages (see also Table 9-2)
2. May be acute or chronic:
   a. Acute form
      • Usually seen in children
      • Preceded by a viral infection in most cases
      • Usually self-limited—80% of cases resolve spontaneously within 6 months
   b. Chronic form
      • Usually seen in adults, most commonly in women 20 to 40 years of age
      • Spontaneous remissions are rare

B. Clinical Features
1. Many patients have minimal bleeding symptoms despite extremely low platelet counts (<5,000/mL)
2. Cutaneous bleeding: petechiae, purpura, ecchymoses at sites of minor trauma
3. Mucosal bleeding: epistaxis, menorrhagia, hemoptysis, GI/GU bleeding
4. Splenomegaly is not seen

C. Diagnosis
1. Decreased platelet count (frequently less than 20,000)—remainder of the blood count is normal
2. Peripheral blood smear—reveals decreased platelets

D. Treatment
1. Glucocorticoids—mainstay of therapy
2. IV immune globulin (IVIG)—saturates the reticuloendothelial system binding sites for platelet-bound self-immunoglobulin, decreasing platelet uptake and destruction by the spleen; typically reserved for patients with active bleeding
3. Splenectomy—induces remission in 70% to 80% of the cases of chronic, steroid-resistant ITP
4. Rituximab, thrombopoietin receptor agonists (e.g., eltrombopag), and some immunosuppressive agents have been used successfully in splenectomy-resistant patients
5. Platelet transfusions as necessary—for patients with severe bleeding and platelet counts <30,000
Thrombotic Thrombocytopenic Purpura

A. General Characteristics
1. TTP is a rare disorder in which patients lack functional ADAMTS13, a protease that cleaves von Willebrand factor (vWF), resulting in the build-up of ultralarge vWF multimers in the blood.
2. This build-up of vWF multimers leads to the formation of microthrombi that consume platelets, occlude small vessels, and cause mechanical damage to RBCs (microangiopathic hemolytic anemia [MAHA]).
3. TTP is a life-threatening emergency that can involve any organ. It is highly responsive to therapy (see below), but leads to death if left untreated.

Quick HIT

TTP and HUS
- There is no consumption of clotting factors in TTP, so PT and PTT are normal.
- TTP = HUS + fever + altered mental status
- HUS = microangiopathic hemolytic anemia + thrombocytopenia + renal failure

B. Clinical Features
1. Signs/symptoms of hemolytic anemia: fatigue, dyspnea, pallor, jaundice
2. Signs/symptoms of thrombocytopenia: petechiae, purpura
3. Acute renal failure—typically mild
4. Fever
5. Fluctuating, transient neurologic signs/symptoms—can range from confusion to hemiplegia

Quick HIT

Although TTP and HUS may present similarly, renal failure is a more common clinical feature of HUS, while encephalopathy is a common feature of TTP.

C. Diagnosis
1. Anemia
2. Thrombocytopenia
3. Elevated LDH
4. Decreased haptoglobin
5. Elevated indirect bilirubin
6. Peripheral blood smear—reveals schistocytes

D. Treatment
1. Plasmapheresis (large volume)—begin as soon as diagnosis is established, can be stopped once platelet count recovers
2. Corticosteroids
Complication of exposure to heparin caused by autoantibodies to the heparin-platelet factor 4 complex

Remember the “4 T’s”: thrombocytopenia (decrease in platelet count typically >50%), timing (onset typically 5 to 10 days after first heparin exposure), thrombosis (secondary to platelet clumping), and lack of other causes for thrombocytopenia

Diagnosis is confirmed with antiplatelet factor 4 antibody testing or serotonin release assay

Treated by discontinuing heparin and initiating anticoagulation (e.g., thrombin inhibitor such as lepirudin, argatroban, and dabigatran)

Avoid heparin in the future in any patient who has developed an episode of HIT

Quick HIT

Main complication of HIT is venous thrombosis (e.g., DVT or PE).
Bernard–Soulier Syndrome

Autosomal recessive disease
Disorder of platelet adhesion (to subendothelium) due to deficiency of platelet glycoprotein GPIb-IX
On peripheral blood smear, platelets are abnormally large
Platelet count itself is only mildly reduced

Quick HIT

The ristocetin assay can be used to test for vWD.
**Glanzmann Thrombasthenia**
Autosomal recessive disease
Disorder of platelet aggregation due to deficiency in platelet glycoprotein GPIIb-IIIa
Bleeding time is prolonged
Platelet count itself is normal
Disorders of Coagulation

von Willebrand Disease

A. General Characteristics

1. Most common inherited bleeding disorder, affecting 1 to 3% of the population
2. Autosomal dominant disorder characterized by deficiency or defect of factor VIII-related antigen (vWF) (see also Table 9-3)
3. vWF enhances platelet aggregation and adhesion (the first steps in clot formation) and acts as a carrier of factor VIII in blood
4. There are three major subtypes with varying severity:
   a. Type 1 (most common)—decreased levels of vWF
   b. Type 2 (less common)—exhibits qualitative abnormalities of vWF
   c. Type 3 (least common)—absent vWF (very severe disease)

<table>
<thead>
<tr>
<th>TABLE 9-3 vWF Versus Factor VIII Coagulant Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>vWF (Also Known as Factor VIII-Related Antigenic Protein)</strong></td>
</tr>
<tr>
<td><strong>Site of Synthesis</strong></td>
</tr>
<tr>
<td><strong>Functions</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Inheritance Pattern</strong></td>
</tr>
<tr>
<td><strong>vWD</strong></td>
</tr>
<tr>
<td><strong>Hemophilia</strong></td>
</tr>
</tbody>
</table>

Quick HIT

Factor VIII has two portions: the coagulant portion (factor VIII coagulant protein) and an antigenic portion (factor VIII antigenic protein). The latter is synonymous with vWF.

Quick HIT

Other causes of impaired platelet function include uremia and the use of NSAIDs or aspirin.
In general, the bleeding seen in vWD is much milder than that of hemophilia—spontaneous hemarthroses do not occur. In many patients, diagnosis is not made until prolonged bleeding is noted after surgery or trauma.

First-line treatment for vWD is desmopressin. If no response, give factor VIII concentrate.

Suspect hemophilia if unsuspected hemorrhage occurs in a male patient with a positive family history.

B. Clinical Features
1. Cutaneous bleeding: easy bruising
2. Mucosal bleeding: epistaxis, menorrhagia (affects more than 50% of women with von Willebrand Disease [vWD]), bleeding after dental extraction
3. GI bleeding is possible

C. Diagnosis
1. Prolonged bleeding time with normal platelet count
2. PTT may be prolonged—normal PTT does not exclude the diagnosis
3. Decreased plasma vWF
4. Decreased factor VIII activity
5. Reduced ristocetin-induced platelet aggregation

D. Treatment
1. DDAVP (desmopressin)—induces release of vWF from endothelial cells
   a. Treatment of choice for type 1 vWD
   b. Less effective in patients with type 2 vWD
   c. Ineffective in those with type 3 vWD
2. Factor VIII concentrates (containing high–molecular-weight vWF)
   a. For all patients with vWD (any type) after major trauma or during surgery
   b. Recommended for type 3 vWD (and type 2 patients not responsive to DDAVP)
3. Avoid aspirin/NSAIDs and intramuscular injections—can exacerbate bleeding tendency
Hemophilia A

A. General Characteristics
1. X-linked recessive disorder affecting primarily males (approximately 1 in 10,000 male patients)
2. Caused by deficiency or defect of factor VIII coagulant protein
3. Bleeding tendency is related to degree of factor VIII activity (see Table 9-4)

B. Clinical Features
1. Hemarthrosis (bleeding into joints)—knee is the most common site, but any joint can be involved; progressive joint destruction can occur secondary to recurrent bleeding
2. Intracranial bleeding—common cause of death; any head trauma is potentially life-threatening and requires urgent evaluation
3. Intramuscular hematomas
4. Retroperitoneal hematomas
5. Hematuria or hemospermia

<table>
<thead>
<tr>
<th>TABLE 9-4</th>
<th>Classification of Severity of Hemophilia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classification</strong></td>
<td><strong>Amount (or Activity) of Factor VIII</strong></td>
</tr>
<tr>
<td>Subclinical</td>
<td>10% of normal factor VIII</td>
</tr>
<tr>
<td>Mild factor VIII deficiency</td>
<td>5–10% of normal factor VIII</td>
</tr>
<tr>
<td>Moderate factor VIII deficiency</td>
<td>1–5% of normal factor VIII</td>
</tr>
<tr>
<td>Severe factor VIII deficiency—accounts for about 60% of all cases; diagnosed in infancy or early childhood</td>
<td>&lt;1% of normal factor VIII</td>
</tr>
</tbody>
</table>

Quick HIT

Detection of Factor VIII Inhibitor
- If normal plasma is mixed with plasma from a hemophilia patient, PTT becomes normal.
- If PTT fails to normalize, this is diagnostic of the presence of a factor VIII inhibitor.

C. Diagnosis
1. Prolonged PTT (see also Table 9-4)
2. Low factor VIII coagulant level with normal levels of vWF

D. Treatment
1. Factor VIII replacement—may be administered episodically (e.g., for acute bleeding episodes, prior to planned surgery/dental work) or continuously (typically in patients with >2 episodes of hemorrhrosis or bleeding)
2. DDAVP—may be helpful in patients with mild disease
3. Acute hemorrhrosis
   a. Analgesia—codeine with or without acetaminophen (avoid aspirin and NSAIDs)
   b. Immobilization of the joint
   c. Ice packs

Quick HIT
- PT: reflects extrinsic pathway (prolonged by warfarin)
- PTT: reflects intrinsic pathway (prolonged by heparin)
- Thrombin time: measure of fibrinogen concentration
- Bleeding time: reflects platelet function
Hemophilia B
X-linked recessive disorder
Much less common than hemophilia A
Caused by deficiency of factor IX
Clinical features are identical to those of hemophilia A
Treatment involves administration of factor IX concentrates—DDAVP does not play a role in treatment
Disseminated Intravascular Coagulation

A. General Characteristics

1. Disseminated intravascular coagulation (DIC) is characterized by abnormal activation of the coagulation cascade and formation of microthrombi throughout the microcirculation, leading to the consumption of platelets, fibrin, and coagulation factors.
2. Widespread thrombi cause fibrinolytic mechanisms to be activated, which subsequently leads to hemorrhage (bleeding and thrombosis occur simultaneously).
3. Most common in critically ill patients, but can occur in healthy patients as well.
4. Causes
   a. Infection (especially gram-negative sepsis, although any infection can cause DIC)—most common cause
   b. Obstetric complications (e.g., amniotic fluid emboli, retained dead fetus, abruptio placentae)—placenta and uterus have increased tissue factor
   c. Major tissue injury (e.g., trauma, major surgery, burns, fractures)
   d. Malignancy (especially lung, pancreas, prostate, GI tract, acute promyelocytic leukemia [APL])
   e. Shock/circulatory collapse
   f. Snake venom (rattlesnakes)

Quick HIT

- Normal PT = 11 to 15 seconds
- Normal PTT = 25 to 40 seconds
- Normal bleeding time = 2 to 7 minutes

Quick HIT

Whenever a coagulopathy is present, include vitamin K deficiency and liver disease in the differential diagnosis (in addition to DIC):
- Liver disease: PT and PTT are elevated, but TT, fibrinogen, and platelets are usually normal
- Vitamin K deficiency: PT is prolonged, but PTT, TT, platelet count, and fibrinogen level S are normal

Quick HIT

Complications of DIC
- Hemorrhage—intracranial bleeding is a common cause of death
- Thromboembolism—stroke, PE, bowel infarction, acute renal failure, arterial occlusion
All critically ill patients are at risk for DIC.

**B. Clinical Features**

1. **Bleeding**—more common in acute cases
   a. Superficial hemorrhage (e.g., ecchymoses, petechiae, purpura)
   b. Bleeding from GI tract, GU tract, gingival, or oral mucosa
   c. Oozing from sites of catheters, procedures or incisions
2. **Thrombosis**—more common in chronic cases
3. End-organ infarction may occur, especially in the CNS and kidney

**C. Diagnosis**

1. Prolonged bleeding time, PT, PTT, and TT—due to consumption of coagulation factors and platelets (see Table 9-5)
2. Elevated D-dimer and fibrin split products—due to activation of fibrinolytic system
3. Decreased fibrinogen level—normal/elevated fibrinogen essentially rules out the diagnosis
4. Decreased platelet count
5. Peripheral blood smear—reveals schistocytes due to shearing of RBCs by microthrombi in the microcirculation

**D. Treatment**

1. Treat the underlying cause (e.g., sepsis, malignancy)
2. Supportive measures if severe hemorrhage is present (only temporizing measures):
   a. Blood transfusion as necessary
   b. Platelet transfusion for platelet counts <50,000
   c. Cryoprecipitate (replaces clotting factors and fibrinogen) or FFP (replaces clotting factors) for significantly prolonged PT/PTT or significantly decreased fibrinogen
   d. Anticoagulation to prevent thrombosis is controversial—typically only given in rare cases in which thrombosis dominates the clinical picture
   e. Other supportive measures include oxygen and IV fluids

**TABLE 9-5 Laboratory Findings for Bleeding Disorders**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Platelet Count</th>
<th>Bleeding Time</th>
<th>PT</th>
<th>PTT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemophilia</td>
<td>NL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NL</td>
<td>NL</td>
<td>Increased</td>
</tr>
<tr>
<td>Condition</td>
<td>Initial</td>
<td>Heparin</td>
<td>Warfarin</td>
<td>Liver disease</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>---------</td>
<td>----------</td>
<td>---------------</td>
</tr>
<tr>
<td>vWD</td>
<td>NL</td>
<td>Increased</td>
<td>NL</td>
<td>Increased</td>
</tr>
<tr>
<td>ITP</td>
<td>Decreased</td>
<td>Increased</td>
<td>NL</td>
<td>NL</td>
</tr>
<tr>
<td>TTP</td>
<td>Decreased</td>
<td>Increased</td>
<td>NL</td>
<td>NL</td>
</tr>
<tr>
<td>DIC</td>
<td>Decreased</td>
<td>Increased</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Heparin</td>
<td>NL or decreased</td>
<td>NL</td>
<td>NL</td>
<td>Increased</td>
</tr>
<tr>
<td>Warfarin</td>
<td>NL</td>
<td>NL</td>
<td>Increased</td>
<td>NL</td>
</tr>
<tr>
<td>Liver disease</td>
<td>NL</td>
<td>NL</td>
<td>Increased</td>
<td>Increased</td>
</tr>
</tbody>
</table>

*aNL, normal.*
Vitamin K Deficiency

**Quick HIT**
The fat-soluble vitamins include vitamins A, D, E, and K.

**Quick HIT**
Vitamin K deficiency is most commonly seen in critically ill patients (especially those who are NPO and/or receiving antibiotics).

A. General Characteristics
1. Several clotting factors (II, VII, IX, and X; proteins C and S) depend on vitamin K for synthesis by the liver, where it serves as a key cofactor in posttranslational modification (γ-carboxylation)
2. Vitamin K is obtained through dietary sources (e.g., leafy green vegetables) and synthesis by intestinal bacterial flora
3. Causes of vitamin K deficiency include:
   a. Broad-spectrum antibiotics—due to suppression of gut flora
   b. Inadequate dietary intake
   c. Total parenteral nutrition (TPN)—unless vitamin K is added
   d. Malabsorption of fat-soluble vitamins (e.g., small bowel disease, inflammatory bowel disease, obstructive jaundice)

**Quick HIT**
Factor VII has the shortest half-life (3 to 5 hours) of all clotting factors, so prolonged PT is the first laboratory finding.

B. Clinical Features
1. Petechiae
2. Purpura
3. Easy bruising
4. Gingival bleeding
5. Melena
6. Hematuria

C. Diagnosis
1. Prolonged PT—first laboratory finding due to the short half-life of factor VII
2. Prolonged PTT—follows as other coagulation factors diminish
D. Treatment
   1. Vitamin K replacement (oral or subcutaneous)—may take several days for PT to return to normal
   2. FFP if bleeding is severe and emergency treatment is necessary
Coagulopathy of Liver Disease

Quick HIT

Prolonged PT is a poor prognostic indicator in cirrhosis because synthesis of clotting factors is not significantly impaired until liver disease is advanced.

Quick HIT

Coagulopathy of liver disease may present similarly to DIC with prolonged PT/PTT and low fibrinogen. However, schistocytes will be present on blood smear in DIC.

Quick HIT

Patients with AT III deficiency do not respond to heparin. Heparin requires the presence of AT III.

A. General Characteristics
1. All clotting factors are produced by the liver (except vWF)
2. The overall prognosis for patients with this type of coagulopathy is very poor, since liver disease must be severe for coagulopathy to develop
3. Causes of coagulopathy in liver failure:
   a. Decreased synthesis of clotting factors
   b. Decreased vitamin K absorption due to cholestasis
   c. Thrombocytopenia caused by splenic sequestration of platelets (the result of splenomegaly due to portal hypertension)

B. Clinical Features
1. Bleeding—GI bleeding is most common and is primarily due to varices (secondary to portal hypertension), but is exacerbated by coagulopathy

C. Diagnosis
1. Prolonged PT and PTT (especially PT)
2. Thrombocytopenia

D. Treatment
1. Cryoprecipitate or FFP if bleeding is present
2. Vitamin K if cholestasis is present
3. DVT prophylaxis if hospitalized—although INR is elevated, patients are often prone to clots (not “auto-anticoagulated”)
Hypercoagulable States

Quick HIT

Patients with antiphospholipid antibody syndrome usually have a prolonged PTT during laboratory testing. This is because the antibody interferes with the test, and is a false prolongation.

A. General Characteristics
1. Factor V Leiden (activated protein C resistance)
   a. Inherited cause of hypercoagulability (autosomal dominant)
   b. Caused by mutation in factor V gene
   c. Most common hereditary hypercoagulability disorder among Caucasians
   d. Protein C unable to inactivate mutated factor V, leading to unregulated prothrombin activation and increased thrombosis
2. Antithrombin (AT) III deficiency
   a. Inherited cause of hypercoagulability (autosomal dominant)
   b. AT III inhibits thrombin, so its deficiency leads to increased thrombosis
3. Protein C deficiency
   a. Inherited cause of hypercoagulability (autosomal dominant)
   b. Protein C inhibits factors V and VIII, so its deficiency leads to unregulated fibrin synthesis and thrombosis
4. Protein S deficiency
   a. Inherited cause of hypercoagulability (autosomal dominant)
   b. Protein S is a cofactor of protein C, so its deficiency leads to decreased protein C activity and thrombosis
5. Antiphospholipid antibody syndrome
   a. Acquired cause of hypercoagulability
   b. Caused by autoantibodies to phospholipid-binding proteins, including lupus anticoagulant, anticardiolipin, and β2-microglobulin
   c. Can present with arterial or venous thrombosis, recurrent fetal loss, or thrombocytopenia
6. Prothrombin gene mutation
7. Hyperhomocysteinemia

Quick HIT

In many cases, inherited hypercoagulable diseases cause thrombotic events only when other risk factors (e.g., immobilization, pregnancy) are also present.
Check for any secondary hypercoagulable states or risk factors (see Clinical Pearl 9-4) in any patient with a DVT, PE, or any thrombotic event, especially if recurrent.

It is very important to identify the patient with an inherited hypercoagulable state because prophylactic anticoagulation should be started and genetic counseling may be appropriate.

B. Clinical Features

1. Recurrent venous thromboembolisms (e.g., DVT and PE)—hypercoagulable disorders are usually not diagnosed until the patient has had several episodes of DVT or PE (see Clinical Pearl 9-4)
2. Thrombosis in unusual sites (e.g., mesenteric veins, inferior vena cava, renal veins, cerebral veins)
3. First thrombotic event before age 40
4. Family history of DVT, PE, or recurrent thrombotic events

C. Diagnosis

1. Functional assays are available for AT, antiphospholipid antibodies, protein C, protein S, factor V Leiden, prothrombin gene mutation, and hyperhomocysteinemia

D. Treatment

1. Standard treatment for DVT or PE as in patients without primary hypercoagulable states
2. Permanent anticoagulation for patients with recurrent thromboembolic events

CLINICAL PEARL 9-4

Secondary Hypercoagulable States or Risk Factors

- Malignancy (especially pancreas, GI, lung, and ovaries)
- Antiphospholipid antibody syndrome
- Pregnancy—up to 2 months postpartum
- Immobilization
- Myeloproliferative disorders
- Oral contraceptives
- Postoperative state (especially after orthopedic procedures)
- Trauma
- Nephrotic syndrome
- HIT or DIC
- PNH
- Heart failure
Anticoagulation

Heparin

A. Mechanism of Action
1. Potentiates the action of AT III to primarily inhibit clotting factors IIa and Xa, preventing conversion of fibrinogen to fibrin
2. Prolongs PTT
3. Half-life of standard heparin is 1 hour (half-life is longer for LMWHs—3 to 24 hours, depending on the product)

B. Indications for Use
1. Venous thromboembolism (e.g., DVT, PE)
2. Atrial fibrillation in acute setting
3. Acute coronary syndromes (e.g., unstable angina, myocardial infarction)
4. DVT prophylaxis in hospitalized patients

C. Administration
1. Therapeutic dosing usually given intravenously as an initial bolus followed by continuous IV infusion
2. Prophylactic dosing usually given subcutaneously
3. Monitored using PTT or antifactor Xa levels—therapeutic PTT is usually 60 to 90 seconds, although this varies depending on the clinical situation

D. Adverse Effects
1. Bleeding
2. HIT—skin necrosis may occur as a consequence
3. Osteoporosis—with chronic use, lower incidence with LMWHs
4. Transient alopecia
5. Rebound hypercoagulability after discontinuation—due to depression of AT III

E. Contraindications
1. History of HIT
2. Active bleeding (e.g., GI bleeding, intracranial bleeding)
3. Severe thrombocytopenia
4. Use with caution in severe HTN or after recent surgery (especially of eyes, spine, brain)

**Quick HIT**

Administer FFP if severe bleeding occurs (for patients on either warfarin or heparin).

**F. Reversing the Effects of Heparin and LMWHs**

1. The half-life of standard heparin is short, so its effects will cease within 4 hours of discontinuation—LMWH has a longer half-life
2. Protamine sulfate will reverse the effects of heparin, if necessary
Low–Molecular-Weight Heparin

A. Mechanism of Action
1. LMWHs primarily inhibit factor Xa (equivalent inhibition of factor Xa as standard heparin, but less inhibition of factor IIa [thrombin])
2. Cannot be monitored by PT or PTT because they do not affect either
3. Examples include enoxaparin, dalteparin, and tinzaparin

B. Indications for Use
1. Similar to standard heparin (e.g., DVT/PE, ACS, DVT prophylaxis)
2. Used with increasing frequency as compared to standard heparin due to greater convenience (e.g., subcutaneous administration, less frequent monitoring) and decreased risk of side effects (e.g., HIT, osteoporosis)
3. More expensive than standard heparin, but often more cost-effective in the long run due to reduced testing, nursing time, and length of hospital stay
4. Preferred anticoagulant in patients with malignancy

C. Contraindications
1. Similar to standard heparin (e.g., history of HIT, active bleeding, severe thrombocytopenia)
2. Use with caution in patients with renal dysfunction—LMWH excreted via kidneys
Warfarin

A. Mechanism of Action
1. Inhibits action of vitamin K epoxide reductase, an enzyme required for the hepatic synthesis of vitamin K-dependent coagulation factors, leading to a decrease in factors II, VII, IX, X, and proteins C and S
2. Causes prolongation of PT (and increase in INR)
3. Anticoagulant effect begins after 4 to 5 days of use, requiring the use of a concurrent heparin “bridge” if immediate anticoagulation is required. Once warfarin is therapeutic (via INR monitoring), stop heparin and continue warfarin alone.

B. Indications for Use
1. Thromboembolism prophylaxis (e.g., DVT/PE, stroke secondary to atrial fibrillation)
2. Preferred anticoagulant for patients with mechanical heart valves or antiphospholipid antibody syndrome

C. Administration
1. Given orally
2. Heparin must be initiated first to avoid warfarin-induced skin necrosis (see below)
3. Once PTT is therapeutic on heparin alone, initiate warfarin
4. Continue heparin for at least 4 days after starting warfarin
5. Once INR is therapeutic on warfarin, stop the heparin
6. Monitored via INR—in most cases, INR of 2 to 3 is therapeutic (patients with mechanical heart valves have goal INR of 2.5 to 3.5)

D. Adverse Effects
1. Bleeding
2. Skin necrosis—rare but serious complication caused by rapid decrease in protein C (a vitamin K–dependent inhibitor of factors Va and VIIIa)

E. Contraindications
1. Active bleeding
2. Pregnancy—warfarin is a teratogen
3. Use with caution in alcoholics or any patient prone to frequent falls due to potential for intracranial bleeding

F. Reversing the Effects of Warfarin
1. Discontinue warfarin—takes 5 days to correct due to the long half-life of warfarin
2. Administer vitamin K—takes 12 to 24 hours to correct due to the time required
for the liver to synthesize new clotting factors
3. Transfuse FFP—may take up to 8 hours to correct due to the time required for transfusion
4. Administer unactivated prothrombin-complex concentrates (PCC)—replaces vitamin K-dependent coagulation factors and corrects within 10 minutes of administration

Quick HIT

If rapid reversal of acute bleeding from warfarin is indicated, give vitamin K, FFP, and PCC.
Direct Oral Anticoagulants (DOACs) or Target-Specific Oral Anticoagulants (TSOACs)

A. May also be referred to as novel oral anticoagulants (NOACs) or
B. Direct factor Xa inhibitors (e.g., Rivaroxaban, Apixaban, Edoxaban)
   1. Inhibit factor Xa directly (as opposed to potentiating AT III like heparin)
   2. Currently approved for treatment of DVT/PE, DVT/PE prophylaxis, and stroke prophylaxis in patients with atrial fibrillation
C. Direct thrombin (factor II) inhibitors (e.g., Lepirudin, Argatroban, Dabigatran)
   1. Inhibit thrombin directly
   2. Currently approved for treatment of HIT
Oncology

A detailed description of many cancers can be found in the appropriate anatomical chapter of this book (i.e., lung cancers in pulmonary chapter, colon cancer in GI).
Epidemiology

In order of occurrence, the most common cancers in males are prostate, lung, and colon. The cancer with the highest mortality in males is lung, followed by prostate and colon.

In order of occurrence, the most common cancers in females are breast, lung, and colon. The cancer with the highest mortality in females is lung, followed by breast and colon.

The number one avoidable risk factor for most cancers is smoking. All patients should be encouraged to stop smoking.

Other etiologic agents in cancer include viruses (e.g., hepatitis B/C for hepatocellular carcinoma, HPV in cervical cancer), chemicals (e.g., asbestos, ethanol, aflatoxin, cadmium, silica), and UV light.
Cancer Prevention and Screening

Breast cancer—mammogram every 2 years beginning at age 40 years for females
Cervical cancer—HPV vaccine (Gardasil) approved for males and females ages 9 to 26; pap smears every 3 years for females ages 21 to 30 (even if not sexually active) and every 5 years with HPV co-testing for females ages 30 to 65
Colorectal cancer (CRC)—colonoscopy every 10 years for average risk individuals starting at age 50; if first-degree relative with CRC, begin screening at age 40 or 10 years before the age of diagnosis of relative (whichever is earlier)
Prostate cancer—no consensus that screening with prostate-specific antigen (PSA) testing decreases mortality
Lung cancer—screen any previous or current smoker with minimum 30 pack year history ages 55 to 80 using low-dose CT annually (NLST trial showed 20% reduction in mortality in CT cohort vs. chest x-ray cohort)
Principles of Cancer Staging and Therapy

Cancer is usually treated using three modalities: surgery, chemotherapy, and radiation.

Clinical staging is usually performed by clinical examination and imaging techniques (PET, CT, MRI scans). TNM staging is most commonly employed: T (T1–T4) describes the size of the primary tumor and whether it has invaded any nearby tissue, N (N1–N3) describes extent of tumor spread to regional lymph nodes, and M (M0 or M1) indicates presence or absence of any distant metastatic disease. Pathologic staging is defined after surgical resection and can give more precise information with regards to local or distant spread of the tumor.

A. Surgical Oncology
1. Goal is to resect primary tumor with negative margins
2. Many times these surgeries involve excision or sampling of locoregional lymph nodes
3. Work closely with medical and radiation oncologists to determine optimal treatment plan based on accurate clinical staging and evidence-based medicine

B. Radiation Oncology
1. Basics of Radiation Therapy
   a. Therapy using ionizing radiation that is generated by either megavoltage linear accelerators, heavy ions (e.g., protons, neutrons, carbon ions), or radioisotopes (e.g., iodine-131 for thyroid cancer)
   b. Can be given via an external beam (EBRT or stereotactic radiosurgery), sealed source that is implanted in or near a tumor (brachytherapy), or as a radiation source conjugated to antibodies (radioimmunotherapy)
2. Mechanism of Action
   a. Photons interact with biologic matter and damage DNA either directly or indirectly (through generation of reactive oxygen species)
   b. DNA double-strand breaks are the critical determinant of cellular response to radiation and eventual cell death
3. Clinical Radiation Oncology
   a. Radiation is primarily used in conjunction with surgery as adjuvant therapy to prevent local tumor recurrence
   b. With the advent of new technologies that allow for dose escalation while sparing normal tissues, radiation can also be used as definitive therapy (e.g., stereotactic radiosurgery for inoperable brain tumors and early stage lung cancers) or as neoadjuvant therapy (i.e., to shrink tumors prior to surgery)
C. Medical Oncology

1. Chemotherapy
   a. Primarily used when cancer has spread regionally or systemically
   b. Also used in the adjuvant setting (to prevent tumor recurrence) and neoadjuvant setting (to decrease size of tumor prior to resection)
   c. Chemotherapy is definitive therapy for most leukemias and can be used to consolidate disease or induce a remission

2. Mechanisms of action
   a. A comprehensive list of chemotherapeutic agents is too vast to be covered in this section, but key categories include DNA alkylation agents (e.g., melphalan, cyclophosphamide, cisplatin, carboplatin), antimetabolites (e.g., methotrexate, cytarabine, gemcitabine, fluorouracil), antimicrotubule agents (e.g., vincristine, paclitaxel, docetaxel), topoisomerase inhibitors (e.g., irinotecan, topotecan), and anthracyclines (e.g., doxorubicin, daunorubicin, bleomycin)
   b. Next generation chemotherapeutic agents
      - Targeted therapies interfere with specific mutations that give rise to cancer—examples include imatinib (targets the tyrosine kinase that is aberrantly upregulated in the majority of chronic myelogenous leukemias), trastuzumab (blocks Her2/neu receptor in breast cancers with amplification of this oncogene), and cetuximab (epidermal growth factor receptor inhibitor)
      - Immunotherapy agents target various immune system checkpoints—examples include nivolumab (inhibits PD-1 receptor)

Quick HIT
Oncologic emergencies which necessitate immediate treatment include hypercalcemia (IV fluids, diuretics, bisphosphonates), spinal cord compression (steroids, MRI, surgical consult), pericardial tamponade (pericardiocentesis), and tumor lysis syndrome (IV fluids, correction of electrolyte abnormalities).
Breast Cancer

A. Risk factors include prior history of breast cancer, age, family history of breast cancer, female gender, prior thoracic radiation, smoking, alcohol consumption, and anything which increases the number of menstrual cycles (early menarche, late menopause, nulliparity)

B. Breast cancer is rare in women under 35—think of fibroadenoma if a young woman presents with a round, movable mass which changes in size over the course of the menstrual cycle

C. The differential diagnosis for a breast mass at any age includes cysts (benign if not bloody after aspiration and does not recur) and fibrocystic changes (bilateral breast pain caused by cyclic hormonal stimulation)

D. The premalignant in situ breast cancers are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)—distinguished histologically:
   1. DCIS represents a broad spectrum of disease which arises from the ductal elements of the breast. It is often found on screening mammogram, and a mass may or may not be present. As this is a marker for the possible development of invasive ductal carcinoma (typically in the same breast), treat with lumpectomy (or mastectomy if negative margins cannot be achieved). Radiation and systemic chemotherapy are used less often depending on the specific lesion in question.
   2. LCIS arises from the lobular elements of the breast. The lesion is typically found incidentally during biopsy of another breast lesion, and a mass is rarely palpable. It leads to an increased risk of breast cancer in either breast. Unfortunately, removal of the lesion does not reduce the risk of progression to invasive cancer. Treatment is variable, but may include close observation, selective estrogen receptor modulators, and prophylactic bilateral mastectomy.

E. The two most common types of breast cancer are invasive ductal carcinoma, accounting for over 70% of invasive cancers, and invasive lobular carcinoma
   1. Patients may present with a palpable mass, palpable lymph nodes, skin dimpling, nipple retraction, or no symptoms at all (found on mammogram)
   2. Diagnosis should be confirmed with tissue biopsy, which should include testing for the estrogen/progesterone receptor and Her-2/neu amplification status
   3. Treatment typically begins with surgery with adjuvant radiotherapy (if the tumor has not spread to sentinel lymph nodes) to decrease tumor recurrence
   4. Adjuvant chemotherapy is required for large lesions in premenopausal women, but is typically not necessary for all small lesions (typically <1 cm) without lymph node involvement
   5. Postmenopausal women with large lesions or lymph node involvement may receive either chemotherapy or Tamoxifen/Herceptin, depending on the status of
the estrogen receptor
Plasma Cell Disorders

Monoclonal Gammopathy of Undetermined Significance

Common in the elderly (up to 10% in patients >75 years of age)
Asymptomatic, premalignant clonal plasma cell proliferation
Diagnosis is confirmed by the presence of monoclonal protein (M-protein) spike <3.0 g and <10% plasma cells in bone marrow without evidence of multiple myeloma (i.e., lytic bone lesions, anemia, hypercalcemia, or renal insufficiency)
Fewer than 20% of patients develop multiple myeloma in 10 to 15 years, but almost all patients with multiple myeloma have a preceding monoclonal gammopathy of undetermined significance (MGUS)
No specific treatment is necessary (just close observation)

Quick HIT

The signs of multiple myeloma can be remembered using the mnemonic CRAB: Calcium (hypercalcemia), Renal failure, Anemia, and Bone lesions (lytic)

Quick HIT

Diagnostic criteria for multiple myeloma include at least 10% abnormal plasma cells in bone marrow plus one of the following:
- M-protein in the serum
- M-protein in the urine
- Lytic bone lesions (well-defined radiolucencies on radiographs)

Quick HIT

Almost all patients with multiple myeloma have an M-protein in either the serum or urine.
Multiple Myeloma

A. General Characteristics
1. Multiple myeloma is characterized by the neoplastic proliferation of a single plasma cell line that produces monoclonal immunoglobulin, leading to enormous copies of one specific immunoglobulin (usually of the IgG or IgA type)
2. Incidence is increased after age 50 and it is twice as common in African-American patients as in Caucasian patients
3. The etiology is unclear
4. As the disease process advances, bone marrow elements are replaced by malignant plasma cells, resulting in anemia, leukopenia, and thrombocytopenia

B. Clinical Features
1. Lytic bone lesions—result in significant bone pain (especially in the low back, chest, and jaw), pathologic fractures, and loss of height secondary to collapse of vertebrae
2. Anemia—present in most patients due to bone marrow infiltration and renal failure
3. Renal failure—due to myeloma nephrosis (immunoglobulin precipitation in renal tubules) and hypercalcemia
4. Recurrent infections (especially of the lung or urinary tract)—most common cause of death, due to lack of normal immunoglobulins
5. Cord compression—may occur secondary to a plasmacytoma or fractured bone fragment

C. Diagnosis
1. Serum and urine protein electrophoresis (SPEP/UPEP)—reveals monoclonal protein spike (M-spike) due to a malignant clone of plasma cells synthesizing a single Ig (usually IgG, although specific subtype can be determined via immunofixation)
2. Low-dose CT, PET/CT, or MRI—reveal lytic bone lesions
3. Bone marrow biopsy (required for diagnosis)—reveals >10% abnormal plasma cells
4. Hypercalcemia—due to bone destruction
5. Elevated serum total protein—due to paraproteins in blood (hyperglobulinemia)
6. Elevated creatinine—due to renal damage
7. Anemia, leukopenia, or thrombocytopenia (especially in advanced disease)—due to bone marrow invasion
8. Peripheral blood smear—reveals normocytic anemia with RBCs in rouleaux formation (RBCs resemble a stack of poker chips as a result of clumping caused
by hyperglobulinemia) (Figure 9-10)

9. Urinalysis—reveals large amounts of free light chains called Bence Jones protein

![Rouleaux formation (multiple myeloma).](image)

**FIGURE 9.10** Rouleaux formation (multiple myeloma).
(From Anderson SC. Anderson’s Atlas of Hematology. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.)

D. Treatment

1. In contrast to the premalignant conditions MGUS and smoldering multiple myeloma, patients with MM and end-organ damage require treatment
2. The preferred treatment is high-dose chemotherapy with autologous hematopoietic cell transplantation (HCT)
3. Bisphosphonates for patients with one or more skeletal lesions

**Quick HIT**

- Radiographs show punched-out lytic lesions, osteoporosis, or fractures in 75% of patients with multiple myeloma
- Osteolytic lesions are secondary to the release of osteoclast-activating factor by the neoplastic plasma cells
Multiple myeloma has a poor prognosis with a median survival of 2 to 4 years with treatment (and only a few months without treatment). The 5-year survival rate is about 10%.

**Quick HIT**

Hyperviscosity syndrome can lead to retinal vessel dilation with resulting hemorrhage and possible blindness.

**Quick HIT**

- Lymphomas are cancers of the lymphatic system
- There are two types: Hodgkin disease and non-Hodgkin disease (NHL)
- Lymphadenopathy is usually the first finding in lymphomas
Waldenström Macroglobulinemia

Malignant proliferation of plasmacytoid lymphocytes that produce IgM paraprotein, a very large protein that causes hyperviscosity of the blood. Diagnosis is confirmed by the presence of an IgM monoclonal gammopathy and >10% plasmacytoid lymphocytes on bone marrow biopsy. Clinical features include fatigue, weight loss, neurologic symptoms, lymphadenopathy, splenomegaly, anemia, abnormal bleeding, Bence Jones proteinuria, and hyperviscosity syndrome (due to elevated IgM). There is no definitive cure—use chemotherapy and plasmapheresis for hyperviscosity syndromes.
Lymphomas

Hodgkin Lymphoma

A. General Characteristics

1. Bimodal age distribution: $X_1 = 15$ to 30 years of age; $X_2 = >50$ years of age
2. Lymph node histology divides the disease into four subtypes:
   a. Lymphocyte predominance (5%)—few Reed–Sternberg cells and many B cells
   b. Nodular sclerosis (70%)—occurs more frequently in women; bands of collagen envelope pools of Reed–Sternberg cells
   c. Mixed cellularity (25%)—large numbers of Reed–Sternberg cells in a pleomorphic background
   d. Lymphocyte depletion (<1%)—lacking in mix of reactive cells; associated with the worst prognosis
3. Staging is based on physical examination, CT scan (chest, abdomen, pelvis), and bone marrow biopsy. Ann Arbor staging system:
   a. Stages
      - Stage I: confined to single lymph node (or one extralymphatic site)
      - Stage II: involvement of two or more lymph nodes but confined to same side of diaphragm
      - Stage III: both sides of diaphragm involved
      - Stage IV: dissemination of disease to extralymphatic sites
   b. Suffixes
      - A: No symptoms
      - B: Fever, weight loss, night sweats—presence of these constitutional symptoms worsens the prognosis

Quick HIT

The histologic subtype does not greatly influence the prognosis of Hodgkin disease (with the exception of the lymphocyte-depleted type, which has the worst prognosis). Treatment is effective in most patients with the other histologic types of Hodgkin disease.

Quick HIT

Chemotherapy and radiation therapy in combination achieve cure rates of over 70% in Hodgkin disease.
**Quick HIT**

**Key Epidemiologic Associations With NHL**
- Burkitt lymphoma in regions of Africa
- Patients with HIV and HIV-associated lymphomas
- Adult T-cell lymphoma in Japan and the Caribbean

It is beyond the scope of this chapter to give a detailed account of each specific type of NHL. Focus on the general clinical presentations as well as certain commonly tested pathologic features (see highlighted points in Table 9-6).

**B. Clinical Features**

1. Painless lymphadenopathy—most common symptom
   a. May involve supraclavicular, cervical, axillary, or mediastinal lymph nodes
   b. Spreads by continuity from one lymph node to adjacent nodes
2. B symptoms (e.g., fever, night sweats, weight loss)
3. Pruritis
4. Cough—secondary to mediastinal lymph node involvement

**C. Diagnosis**

1. Lymph node biopsy
   a. Reveals Reed–Sternberg cells—required to make the diagnosis (Figure 9-11)
      - Large, neoplastic cell with two or more nuclei—resemble owl’s eyes
      - Usually B-cell phenotype
      - May be found in other neoplasms
   b. Reveals inflammatory cell infiltrates—distinguishes Hodgkin lymphoma from NHL
      - The inflammatory cells present are reactive to the Reed–Sternberg cells
      - These include plasma cells, eosinophils, fibroblasts, and T and B lymphocytes
2. CXR and CT scan (chest, abdomen)—may reveal lymph node involvement
3. Bone marrow biopsy—may reveal bone marrow involvement
4. Leukocytosis with eosinophilia
Rituximab, a monoclonal antibody against CD20 antigen, is often used in combination with CHOP therapy to treat NHL and other cancers with better outcomes than CHOP alone.

**Quick HIT**

**Staging NHL**
- Stage I: single lymph node involved (or one extralymphatic site)
- Stage II: two or more lymph nodes on the same side of the diaphragm
- Stage III: lymph node involvement on both sides of the diaphragm
- Stage IV: disseminated involvement of one or more extralymphatic organs with or without lymph node involvement

**D. Treatment**

1. Consists mainly of chemotherapy and radiation therapy to the involved field
2. Stages I and II are usually treated with a combination of chemotherapy and radiation, although chemotherapy alone may be acceptable for some patients.
3. Stages IIIB and IV require chemotherapy.
Non-Hodgkin Lymphoma

A. General Characteristics

1. NHL is a diverse group of solid tumors which occurs with the malignant transformation and growth of B or T lymphocytes (or their precursors) in the lymphatic system
   a. The type of lymphocyte involved and its level of differentiation determine the course of the disease and its prognosis
   b. B-cell lymphomas account for 85% of all cases, while T-cell lymphomas account for 15% of all cases
   c. The disease usually starts in lymph nodes and may spread to blood and bone marrow
2. NHL is the sixth most common cause of cancer-related death in the United States
3. NHL is twice as common as Hodgkin disease, and patients with NHL tend to have more advanced disease at presentation than patients with Hodgkin disease
4. The mean age of onset varies with subtype, but there is an increased overall incidence with increasing age
5. Risk factors
   a. HIV/AIDS
   b. Immunosuppression (e.g., organ transplant recipients)
   c. History of certain viral infections (e.g., EBV, HTLV-1)
   d. History of *Helicobacter pylori* gastritis (risk of primary associated gastric lymphoma)
   e. Autoimmune disease (e.g., Hashimoto thyroiditis or Sjögren syndrome [risk of mucosa-associated lymphoid tissue])
6. Classification
   a. There are more than 20 different subtypes of NHL, arranged into several unique classification systems
   b. One such classification system stratifies subtypes according to histologic grade: low grade (or indolent), intermediate grade, and high grade (see Table 9-6)

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Low-grade lymphomas: Cure is rare. Median survival is 5 to 7 years.</td>
</tr>
<tr>
<td>- Intermediate-grade lymphomas: Fifty percent of patients can be cured with aggressive therapy. Median survival is about 2 years.</td>
</tr>
<tr>
<td>- High-grade lymphomas: Up to 70% can be cured with aggressive therapy. Median survival without treatment is a few months.</td>
</tr>
</tbody>
</table>

B. Clinical Features
1. Painless lymphadenopathy—sometimes the only manifestation of disease
   a. Lymph nodes are usually firm and mobile
   b. Most often involves supraclavicular, cervical, and axillary nodes
2. B symptoms—less common than in Hodgkin lymphoma
3. Hepatosplenomegaly
4. Anemia, leukopenia, or thrombocytopenia—due to bone marrow involvement

C. Diagnosis
1. Lymph node biopsy—any lymph node >1 cm present for more than 4 weeks that cannot be attributed to infection should be biopsied
2. CXR and CT scan (chest, abdomen, pelvis)—may reveal lymph node involvement
3. Bone marrow biopsy—may reveal bone marrow involvement
4. Elevated alkaline phosphatase if bone or liver involvement
5. Elevated liver function tests or bilirubin if liver involvement
6. Anemia, leukopenia, or thrombocytopenia if bone marrow involvement

<table>
<thead>
<tr>
<th>TABLE 9-6 Non-Hodgkin Lymphomas</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grade</strong></td>
</tr>
<tr>
<td>Indolent or Low Grade</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
</tr>
<tr>
<td>High Grade</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
abdominal organs (hepatomegaly, abdominal masses, lymphadenopathy)  
- **African variety linked with EBV infection**  
- **Associated with specific translocation:** t(8;14)  
60% of patients

| **Miscellaneous Lymphomas** | **Mycosis fungoides** | **T-cell lymphoma of the skin**  
| | | Presents with *eczematoid skin lesions* that progress to generalized erythroderma  
| | | **Cribriform shape of lymphocytes**  
| | | Disseminate to lymph nodes, blood, and other organs  
| | | Depends on degree of dissemination (<2 yrs if dissemination has occurred)  
| | | Potentially curable (with radiation, topical chemotherapy) if limited to skin

| **Sézary syndrome** | Involves skin as well as blood stream  
| **HIV-associated lymphomas** | Not a discrete entity: usually Burkitt or diffuse, large-cell lymphoma  
| | | Very poor prognosis

---

CHOP therapy consists of:  
- Cyclophosphamide  
- Hydroxydaunomycin (doxorubicin)  
- Oncovin (vincristine)  
- Prednisone

### D. Treatment

1. Varies depending on the stage and subtype of NHL  
2. Indolent forms of NHL are rarely curable, but have a 5-year survival rate of 75%. These patients are treated in a variety of ways, including observation, chemotherapy, and radiation therapy.  
3. Intermediate and high-grade NHLs may be curable with aggressive treatments, but if complete remission is not achieved, survival is usually less than 2 years. In general, aggressive forms are treated with multiple regimens of combination chemotherapy (e.g., CHOP) and radiation therapy.  
4. Some patients may benefit from high-dose chemotherapy with bone marrow transplantation.

---

Not all types for each grade are included in this table.
Acute leukemias account for 60% of all leukemias, 25% are CLL and 15% are CML.

General Evaluation in Patients With Leukemias (acute or chronic)
- Evidence of infection
- Evidence of bleeding or easy bruising
- Lymphadenopathy, hepatosplenomegaly
- Signs of anemia
- Fatigue, weight loss

For testing purposes, the age of a patient can be a simple yet important aid to confirming the correct leukemia diagnosis. Patients less than 15 most likely have ALL, while those greater than 65 typically have CLL. AML and CML both typically present from age 40 to 60.

A. General Characteristics
1. Two types
   a. Acute myelogenous leukemia (AML)
      - Neoplasm of myelogenous progenitor cells
      - AML occurs mostly in adults (accounts for 80% of adult acute leukemias)
      - Risk factors include exposure to radiation, myeloproliferative syndromes, Down syndrome, and prior chemotherapy (e.g., alkylating agents)
      - Response to therapy is not as favorable as in acute lymphoblastic leukemia
      - Poor prognostic indicators include older age, presence of other medical comorbidities, and history of exposure to cytotoxic agents and/or radiation therapy
      - One important variant of AML is acute promyelocytic leukemia (APL). This condition is characterized by t(15;17) and often presents with pancytopenia. Patients may be very sick, so treatment should be started with all-trans retinoic acid (ATRA) without delay along with concurrent chemotherapy once the diagnosis is confirmed (see Clinical Pearl 9-5).
b. Acute lymphoblastic leukemia (ALL)
   • Neoplasm of early lymphocytic progenitor cells—histology reveals a predominance of lymphoblasts
   • ALL is the most common malignancy in children under age 15 in the United States
   • It is the leukemia most responsive to therapy
   • Poor prognostic indicators include age <2 or >9, WBC >10^5/mm^3, and/or CNS involvement
   • Presence of any of the following is associated with an increased risk for CNS involvement: B-cell phenotype, increased LDH, rapid leukemic cell proliferation

2. Many patients with acute leukemias can be cured if treated aggressively. If left untreated, the most aggressive acute leukemias can be fatal within months.

B. Clinical Features
1. Anemia and its associated signs/symptoms (e.g., dyspnea, pallor)
2. Increased risk of bacterial infections—due to neutropenia
   a. Pneumonia, urinary tract infection, cellulitis, pharyngitis, esophagitis
   b. Associated with high morbidity and mortality (potentially life-threatening)
3. Thrombocytopenia and associated signs/symptoms (e.g., epistaxis, bleeding at puncture sites, petechiae/purpura, ecchymoses)
4. Splenomegaly, hepatomegaly, lymphadenopathy
5. Bone and joint pain—due to invasion of periosteum
6. Diffuse or focal neurologic dysfunction (e.g., meningitis, seizures)—due to CNS involvement
7. Testicular involvement (ALL)
8. Anterior mediastinal mass (T-cell ALL)
9. Skin nodules (AML)

CLINICAL PEARL 9-5

Leukemias
• Leukemias are characterized by neoplastic proliferation of abnormal WBCs. As these abnormal WBCs accumulate, they interfere with the production of normal WBCs, as well as the production of erythrocytes and platelets, resulting in anemia and thrombocytopenia.
• Leukemias are classified in two ways:
  • By the type of WBC affected
    • If granulocytes or monocytes are affected, myelogenous leukemia is present
    • If lymphocytes are affected, lymphocytic leukemia is present
  • By the maturity of cells affected and the rapidity of disease progression
    • Acute leukemias are characterized by rapid progression and affect immature cells (i.e., immature cells
Chronic leukemias progress slowly and affect mature cells.

**Quick HIT**

Auer rods (granules and eosinophilic rods inside malignant cells) are present in AML but not ALL.

**Tumor Lysis Syndrome**
- This is a potential complication of chemotherapy seen in acute leukemia, high-grade NHL, and solid cancers with very high tumor burden
- Rapid cell death with release of intracellular contents causes hyperkalemia, hyperphosphatemia, and hyperuricemia
- Treat as a medical emergency

**C. Diagnosis**

1. Leukopenia or leukocytosis—WBC count is variable (from 1,000/mm$^3$ to 100,000/mm$^3$), but always accompanied by significant numbers of blast cells (immature cells) in peripheral blood
2. Anemia
3. Thrombocytopenia
4. Electrolyte disturbances (e.g., hyperuricemia, hyperkalemia, hyperphosphatemia)
5. Bone marrow biopsy (required for diagnosis)
   a. In ALL, reveals proliferation of blasts of the lymphoid lineage (>20%)
   b. In AML, reveals proliferation of blasts of the myeloid lineage (>20%) and Auer rods, especially if it is the APL phenotype (Figure 9-12)

**D. Treatment**

1. Treatment of emergencies
   a. Antibiotics as necessary for infection
   b. Blood transfusion as necessary for anemia
   c. Platelet transfusion as necessary for bleeding
2. Aggressive, combination chemotherapy in high doses for several weeks is appropriate to obtain remission (i.e., absent leukemic cells in bone marrow). Once remission occurs, maintenance therapy is used for months or years to prevent recurrence.
   a. ALL: More than 75% of children with ALL achieve complete remission (compared with 30% to 40% of adults). Relapses, when they occur, usually respond to treatment. With aggressive therapy, survival rates in children can be up to 15 years or longer. Up to 50% of patients are cured.
b. AML: This is more difficult to treat and does not respond as well to chemotherapy. Survival rates are considerably lower despite intensive treatment. Bone marrow transplantation gives the best chance of remission or cure.

3. Bone marrow transplantation
Chronic Lymphocytic Leukemia

A. General Characteristics

1. CLL is the most common leukemia in the Western world, and the most common leukemia that occurs after age 50. Most patients with CLL are >60 years of age.
2. Caused by the monoclonal proliferation of lymphocytes that are morphologically mature but functionally defective (i.e., they do not differentiate into antibody-manufacturing plasma cells)
3. In general, this is the least aggressive type of leukemia, and CLL patients survive longer than those with acute leukemias or chronic myeloid leukemia (CML). The natural history is variable, but may follow a prolonged indolent course. Many patients die of other causes.
4. The most recent WHO classification describes CLL as identical to the indolent NHL B-cell neoplasm small lymphocytic leukemia (SLL). That is, they are considered the same disease at different stages.

FIGURE 9.12 Auer rods (acute myelogenous leukemia).
AIHAs can be seen in patients with CML.

Remember that the cells of the myeloid lineage include erythrocytes, granulocytes, and platelets.

Differentiating Benign Leukemoid Reaction From CML Leukemoid Reaction
- Usually no splenomegaly
- Increased leukocyte alkaline phosphatase
- History of a precipitating event (e.g., infection)

B. Clinical Features
1. Usually asymptomatic at time of diagnosis—may be discovered secondary to abnormalities on routine labs
2. Painless lymphadenopathy (usually cervical)
3. Hepatosplenomegaly
4. Frequent respiratory or skin infections—due to immune deficiency
5. In more advanced disease: fatigue, weight loss, pallor, skin rashes, easy bruising, bone tenderness, and/or abdominal pain

C. Diagnosis
1. Leukocytosis—WBC typically 50,000 to 200,000
2. Anemia
3. Thrombocytopenia
4. Neutropenia
5. Peripheral blood smear
   a. Reveals absolute lymphocytosis—almost entirely mature, small lymphocytes
   b. Reveals smudge cells—“fragile” leukemic cells that rupture when placed on glass slide
6. Flow cytometry—reveals clonal population of B cells
7. Bone marrow biopsy—reveals presence of infiltrating leukemic cells in bone marrow

D. Treatment
1. Patients with asymptomatic disease are typically observed
2. Regimens for symptomatic CLL vary with the age of the patient: younger patients often receive a combination of fludarabine and rituximab, while older patients typically receive ibrutinib (an inhibitor of Bruton tyrosine kinase)
3. Prognosis is variable depending on the number of lymphoid tissues involved and the presence or absence of anemia/thrombocytopenia
Chronic Myeloid Leukemia

A. General Characteristics
1. Neoplastic, clonal proliferation of myeloid stem cells
2. Patients are usually >40 years of age
3. CML follows an indolent (chronic) course for many years before it transforms to acute leukemia. The end-stage of the disease course is usually an acute phase (also known as a blast crisis), which is an accelerated phase of blast and promyelocyte production.
4. It is associated with translocation t(9,22) in >90% of patients. This fusion of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9 is known as the Philadelphia chromosome. The abnormal chromosome results in a constitutively active tyrosine kinase protein, which is targeted by imatinib. Note that patients without the Philadelphia chromosome have shorter survival times and respond more poorly to treatment.

Quick HIT
Treat CML with TKIs (e.g., imatinib, dasatinib, or nilotinib).

B. Clinical Features
1. Most patients (85%) present in the chronic phase and may be asymptomatic at the time of diagnosis—disease discovered on routine labs
2. Constitutional symptoms (e.g., fevers, night sweats, anorexia, weight loss)
3. Recurrent infections
4. Anemia and its associated signs/symptoms
5. Thrombocytopenia and its associated signs/symptoms
6. Hepatosplenomegaly
7. Lymphadenopathy
8. Patients may also present in more advanced stages (i.e., the accelerated phase or blast crisis)

Quick HIT
Imatinib is current standard of care for CML.

C. Diagnosis
1. Leukocytosis with eosinophilia—WBCs from 50,000 to 200,000
2. Thrombocytosis
3. Peripheral blood smear—reveals increased numbers of immature granulocytes,
anemia, thrombocytosis, and basophilia
4. Bone marrow biopsy—increased numbers of immature granulocytes

D. Treatment
1. Treatment for CML is one of the great stories of modern medicine. After the mechanism of disease was elucidated, the oral tyrosine kinase inhibitor (TKI) imatinib was developed. This drug targets the dysfunctional chimeric protein BCR-ABL formed by the t(9,22) Philadelphia chromosome. Second-generation TKIs are now available.
2. Unfortunately, patients who present in a blast crisis still have very poor outcomes. The TKIs can still be attempted in these patients. Stem cell transplantation is also an option.
Myeloproliferative Disorders

Polycythemia Vera

Quick HIT

An often-tested presentation for PV is a patient who complains of severe pruritus after a hot bath or shower.

A. General Characteristics
1. Malignant clonal proliferation of hematopoietic stem cells leading to excessive erythrocyte production
2. The increase in RBC mass occurs independent of erythropoietin
3. The median survival with treatment is about 9 to 14 years
4. Mutations in the JAK2 tyrosine kinase are found in >90% of cases

B. Clinical Features
1. Signs/symptoms of hyperviscosity: headache, dizziness, weakness, transient visual disturbances, dyspnea
2. Thrombotic phenomena (e.g., DVT, PE, CVA, MI, portal vein thrombosis)
3. Aquagenic pruritis
4. Facial plethora
5. Hepatosplenomegaly
6. HTN

Quick HIT

Diagnostic Criteria for Polycythemia Vera
Must have all three major criteria or the first two major criteria plus any two minor criteria:

Major Criteria
- Elevated Hb (men >16.5 g/dL; women >16.0 g/dL)
- Bone marrow biopsy with trilineage hypercellularity (erythroid, granulocytic, and megakaryocytic proliferation)
- JAK2 V617F or JAK2 exon 12 mutation

Minor Criteria
- Serum erythropoietin level below normal

C. Diagnosis
1. Rule out causes of secondary polycythemia (e.g., hypoxemia, carbon monoxide exposure)
2. Elevated RBC count, hemoglobin, hematocrit (usually >50%)
3. Thrombocytosis
4. Leukocytosis
5. Decreased serum erythropoietin levels
6. Elevated vitamin B₁₂ level
7. Hyperuricemia
8. Bone marrow biopsy—reveals hypercellularity with increased proliferation of erythrocyte, granulocyte, and megakaryocyte precursors

D. Treatment
1. Repeated phlebotomy—mainstay of therapy to lower hematocrit
2. Aspirin
3. Hydroxyurea for patients with history of thrombosis
Myelodysplastic Syndromes

Quick HIT

Hyperviscosity and elevated total blood volume in polycythemia vera account for most of the clinical findings.

A. General Characteristics

1. Myelodysplastic syndromes are a class of acquired malignant hematopoietic stem cell disorders characterized by ineffective hematopoiesis
2. The result is pancytopenia, despite a normal or hypercellular bone marrow
3. They occur more commonly in elderly patients and are slightly more common in men
4. They are usually idiopathic, although exposure to radiation, immunosuppressive agents, and certain toxins are known risk factors
5. They are classified into subtypes according to findings on bone marrow biopsy and peripheral blood smear
6. The prognosis, although variable, is generally poor, and the end result is often progression to acute leukemia

Quick HIT

Thrombotic and hemorrhagic complications in polycythemia vera can be life-threatening.

B. Clinical Features

1. Often asymptomatic in the early stages—pancytopenia may be an incidental finding on routine labs
2. Anemia
3. Thrombocytopenia
4. Neutropenia

Quick HIT

Clinical features in myelodysplastic syndromes are due to bone marrow failure and mimic those of aplastic anemia.

C. Diagnosis

1. Anemia with decreased reticulocyte count
2. Thrombocytopenia
3. Neutropenia
4. Peripheral blood smear—reveals normocytic anemia with Howell–Jolly bodies,
basophilic stippling of RBCs, agranular platelets, or other evidence of dysplasia
5. Bone marrow biopsy—typically reveals dysplastic marrow cells with blasts or ringed sideroblasts
6. Cytogenetic studies often reveal chromosomal abnormalities or mutated oncogenes

D. Treatment
1. Supportive treatment—mainstay of treatment
   a. RBC and platelet transfusions as necessary
   b. Erythropoietin—may help to reduce the number of blood transfusions necessary
   c. Granulocyte colony-stimulating factor—can be an effective adjunctive treatment for neutropenic patients
   d. Vitamin supplementation (particularly with vitamins B₆, B₁₂, and folate)—important given the increased turnover of marrow cells
2. Chemotherapy and immunosuppressive agents—may improve survival in some patients
3. Bone marrow transplantation
Essential Thrombocytopenia

Defined as platelet count >600,000/mm³
It is a disease with high morbidity but low mortality
A diagnosis of exclusion—reactive thrombocytosis (due to infection, inflammation, bleeding) and other myeloproliferative disorders must be excluded
It is primarily manifested by thrombosis (e.g., CVA), or paradoxically and less frequently, bleeding (due to defective platelet function)
Other findings may include splenomegaly, pseudohyperkalemia, elevated bleeding time, and erythromelalgia (burning pain and erythema of the extremities due to microvascular occlusions)
Peripheral blood smear shows hypogranular, abnormally shaped platelets
Bone marrow biopsy shows an increased number of megakaryocytes
JAK2 tyrosine kinase mutation seen in 40% to 50% of cases
Treatment usually involves antiplatelet agents such as anagrelide and low-dose aspirin. Hydroxyurea is sometimes used for severe thrombocytosis.
Infections of the Upper and Lower Respiratory Tracts

Pneumonia

Quick HIT

- “Classic” CAP presents with a sudden chill followed by fever, pleuritic pain, and productive cough.
- The “atypical pneumonia” syndrome, associated with Mycoplasma or Chlamydia infection, often begins with a sore throat and headache followed by a nonproductive cough and dyspnea.

A. General Characteristics

1. There are two types of pneumonia: community-acquired and nosocomial
   a. Community-acquired pneumonia (CAP)
      - Occurs in the community or within first 72 hours of hospitalization
      - Can be typical or atypical
      - Most common bacterial pathogen is *Streptococcus pneumoniae*
   b. Nosocomial pneumonia
      - Occurs during hospitalization after first 72 hours
      - Most common bacterial pathogens are gram-negative rods (*Escherichia coli, Pseudomonas*) and *Staphylococcus aureus*

2. There are two recommended methods of prevention
   a. Influenza vaccine—give yearly to people at increased risk for complications and to healthcare workers
   b. Pneumococcal vaccine—for patients >65 years and for younger people at high risk (e.g., those with heart disease, cochlear implants, sickle cell disease, pulmonary disease, diabetes, alcoholic cirrhosis, asplenia)

Quick HIT

Most cases of CAP result from aspiration of oropharyngeal secretions because the majority of organisms that cause CAP are normal inhabitants of the pharynx.

Quick HIT

*S. pneumoniae* accounts for up to 66% of all cases of bacteremic pneumonia, followed by *H. influenzae*, influenza virus, and *Legionella* spp.
B. Typical CAP

1. Common agents
   a. *S. pneumoniae* (60%)
   b. *Haemophilus influenzae* (15%)
   c. Aerobic gram-negative rods (6% to 10%)—*Klebsiella* (and other Enterobacteriaceae)
   d. *S. aureus* (2% to 10%)

2. Clinical features
   a. Symptoms
      - Acute onset of fever and shaking chills
      - Cough productive of thick, purulent sputum
      - Pleuritic chest pain (suggests pleural effusion)
      - Dyspnea
   b. Signs
      - Tachycardia, tachypnea
      - Late inspiratory crackles, bronchial breath sounds, increased tactile and vocal fremitus, dullness on percussion
      - Pleural friction rub (associated with pleural effusion)

3. Chest radiograph (CXR)
   a. Lobar consolidation
   b. Multilobal consolidation indicates very serious illness

Quick HIT

“Atypical” pneumonia refers to organisms not visible on Gram stain and not culturable on standard blood agar.

Quick HIT

*Sputum Culture CAP*  
- The value of routine sputum collection for Gram stain and culture is controversial. The Infectious Disease Society of America has recently advocated performing sputum Gram stain and culture in all patients hospitalized with CAP.
- A good sputum specimen has >25 PMNs and <10 epithelial cells per low-power field.

C. Atypical CAP
1. Common agents
   a. *Mycoplasma pneumoniae* (most common)
   b. *Chlamydia pneumoniae*
   c. *Chlamydia psittaci*
   d. *Coxiella burnetii* (Q fever)
   e. *Legionella* spp.
   f. Viruses: influenza virus (A and B), adenoviruses, parainfluenza virus, RSV

2. Clinical features
   a. Symptoms
      - Insidious onset—headache, sore throat, fatigue, myalgias
      - Dry cough (no sputum production)
      - Fevers (chills are uncommon)
   b. Signs
      - Pulse-temperature dissociation—normal pulse in the setting of high fever is suggestive of atypical CAP
      - Wheezing, rhonchi, crackles
   c. CXR
      - Diffuse reticulonodular infiltrates
      - Absent or minimal consolidation

D. Diagnosis
1. PA and lateral CXR required to confirm the diagnosis (*Figure 10-1*) (see also Clinical Pearls 10-1 and 10-2).
   a. Considered sensitive—if CXR findings are not suggestive of pneumonia, do not treat the patient with antibiotics.
   b. After treatment, changes evident on CXR usually lag behind the clinical response (up to 6 weeks).
   c. Changes include interstitial infiltrates, lobar consolidation, and/or cavitation.
   d. False-negative chest radiographs occur with neutropenia, dehydration, infection with PCP (*Pneumocystis carinii* pneumonia), and early disease (<24 hours).
FIGURE 10.1  Chest PA (A) and lateral (B) radiographs: Right lower lobe pneumonia (straight arrows). On the PA radiograph, the right cardiac border is clearly visible, and the right hemidiaphragm is partially silhouetted (double straight arrows). These findings indicate that the infiltrate is posterior or in the right lower lobe as confirmed on the lateral radiograph (straight arrows).

(From Erkonen WE, Smith WL. Radiology 101: The Basics and Fundamentals of Imaging. Philadelphia, PA: Lippincott Williams & Wilkins, 1998:110, Figure 6–54A and B.)

CLINICAL PEARL 10-1

General Approach to Diagnosis of CAP

The first task is to differentiate lower respiratory tract infection from the other causes of cough and from upper respiratory infection.

- If nasal discharge, sore throat, or ear pain predominates, upper respiratory infection is likely.
- Once lower tract infection is suspected, the next task is to differentiate between pneumonia and acute bronchitis. Unfortunately, clinical features (cough, sputum, fever, dyspnea) are not reliable in differentiating between the two.
- CXR is the only reasonable method of differentiating between pneumonia and acute bronchitis.
Patients admitted to the hospital with suspected pneumonia should get:
- CXR (PA and lateral)
- Laboratory tests—CBC and differential, BUN, creatinine, glucose, electrolytes
- $O_2$ saturation
- Two pretreatment blood cultures
- Gram stain and culture of sputum
- Antibiotic therapy

Radiographic changes and clinical findings do not help in identifying the causative pathogen in CAP.

Test for microbial diagnosis for outpatients is not required. Empiric treatment is often successful if CAP is suspected.

2. Pretreatment expectorated sputum for Gram stain and culture—low sensitivity and specificity, but still worthwhile tests because antimicrobial resistance is an increasing problem.
   a. Sputum Gram stain—try to obtain in all patients.
      - Commonly contaminated with oral secretions.
      - A good specimen has a sensitivity of 60% and specificity of 85% for identifying gram-positive cocci in chains (S. pneumoniae).
   b. Sputum culture—try to obtain in all patients requiring hospitalization.
      - Specificity is improved if the predominant organism growing on the culture media correlates with the Gram stain.

3. Special stains of the sputum in selected cases.
   a. Acid-fast stain (Mycobacterium spp.) if tuberculosis (TB) is suspected.
   b. Silver stain (fungi, P. carinii) for HIV/immunocompromised patients.

4. Urinary antigen assay for Legionella in selected patients.
   a. This test is very sensitive.
   b. The antigen persists in the urine for weeks (even after treatment has been started).

5. Consider two pretreatment blood cultures from different sites. Blood cultures positive in 5% to 15% of cases.
**CLINICAL PEARL 10-2**

**Pneumonia Pearls**

- In alcoholics, think of *Klebsiella pneumoniae*; in immigrants, think of TB.
- In nursing home residents, consider a nosocomial pathogen and predilection for the upper lobes (e.g., *Pseudomonas*).
- HIV-positive patients are at risk for *P. carinii* and *M. tuberculosis*, but are still more likely to have a typical infectious agent.
- *Legionella* pneumonia is common in organ transplant recipients, patients with renal failure, patients with chronic lung disease, and smokers and presents with GI symptoms and hyponatremia. *Legionella* pneumonia is rare in healthy children and young adults.

**Quick HIT**

If patient is hypoxic or hypotensive, admit to hospital.

**Quick HIT**

For uncomplicated CAP in patients without significant comorbidities, treat with azithromycin or clarithromycin. If the patient has comorbidities, give a fluoroquinolone.

**E. Treatment of CAP**

1. Decision to hospitalize.
   a. The decision to hospitalize or treat as an outpatient is probably the most important decision to be made and is based on severity of disease (see Table 10-1).
   b. Patients are stratified into five classes based on severity (see Table 10-1). The pneumonia severity index can serve as a general guideline, but clinical judgment is critical in making this decision. The decision to admit the patient is not based on a specific organism (one does not have this information when making this decision).

2. Antimicrobial therapy.
   a. Because the specific cause is usually not determined on initial evaluation, empiric therapy is often required.
   b. For outpatients.
      - In people younger than 60 years of age, the most common organisms are *S. pneumoniae, Mycoplasma, Chlamydia*, and *Legionella*. Macrolides (azithromycin or clarithromycin) or doxycycline cover all of these organisms and are the first-line treatment. Fluoroquinolones are alternative agents. Penicillins or cephalosporins do not cover the atypical organisms in this age
In older adults and patients with comorbidities (more likely to have typical CAP) or those treated with antibiotics in the last 3 months, a respiratory fluoroquinolone (levofloxacin, moxifloxacin) PLUS a macrolide or amoxicillin-clavulanate is the first-line agent.

For outpatients, treatment is continued for 5 days. Do not stop treatment until patient has been afebrile for 48 hours.

c. For hospitalized patients, a fluoroquinolone alone or a third-generation cephalosporin PLUS a macrolide (i.e., ceftriaxone plus azithromycin) is appropriate.

---

**F. Treatment of Hospital-Acquired Pneumonia**

1. Treatment is tailored toward gram-negative rods (any of the following three are appropriate):
   a. Cephalosporins with pseudomonal coverage: ceftazidime or cefepime
   b. Carbapenems: imipenem
   c. Piperacillin/tazobactam

2. Macrolides are not used as single-agent therapy (as they are in CAP)

---

**G. Complications**

1. Pleural effusion (“parapneumonic effusions”)—see Chapter 2.
   a. Can be seen in more than 50% of patients with CAP on routine CXR. Empyema is infrequent in these patients.
b. Most of these effusions have an uncomplicated course and resolve with treatment of the pneumonia with antibiotics.

c. Thoracentesis should be performed if the effusion is significant (>1 cm on lateral decubitus film). Send fluid for Gram stain, culture, pH, cell count, determination of glucose, protein, and LDH levels.

2. Pleural empyema occurs in 1% to 2% of all cases of CAP (up to 7% of hospitalized patients with CAP). See Chapter 2.

3. Acute respiratory failure may occur if the pneumonia is severe.
Ventilator-Associated Pneumonia

A. Patients on mechanical ventilation are at risk of developing pneumonia because the normal mucociliary clearance of the respiratory tract is impaired (cannot cough). Also, positive pressure impairs the ability to clear colonization.

B. Findings to help with diagnosis: new infiltrate on chest x-ray, purulent secretions from endotracheal tube, fever, rising WBC count.

C. Bronchoalveolar lavage (BAL)—bronchoscope passed into lungs to get cultures.

D. Treatment is with a combination of the following three different drugs:
   1. Cephalosporin (ceftazidime or cefepime) OR beta-lactam and beta-lactamase inhibitor (piperacillin/tazobactam) OR carbapenem (imipenem).
   2. Aminoglycoside OR fluoroquinolone.
   3. Vancomycin OR linezolid.
Lung Abscess

A. General Characteristics
1. Abscess in the lung parenchyma results when infected lung tissue becomes necrotic and forms suppurative cavitary lesions. The typical case is aspiration of a large volume of oropharyngeal contents or food, with resulting pneumonia and necrosis when adequate treatment is not administered. Most patients who have aspiration pneumonia are treated promptly, thereby avoiding abscess formation.
2. By definition, a lung abscess is formed by one or more cavities, each >2 cm in diameter.
3. Lung abscesses can be complications of the following:
   a. Aspiration of organisms.
   b. Acute necrotizing pneumonia (gram-negative rods).
   c. Hematogenous spread of infection from distant site.
   d. Direct inoculation with contiguous spread.
4. Causative organisms are mainly bacteria that colonize the oropharynx.
   b. Other bacteria: *S. aureus, S. pneumoniae*, and aerobic gram-negative bacilli
5. Epidemiology/risk factors.
   a. The main risk factor is predisposition to aspiration. This may be seen in patients with impaired consciousness (alcoholism, seizures), dysphagia, neurologic conditions (CVA), or mechanical disruption of normal defense mechanisms (nasogastric or endotracheal tube).
   b. Poor dental hygiene increases the content of oral anaerobes.
   c. Edentulous patients are less likely to aspirate oropharyngeal secretions.

B. Clinical Features
1. The majority of cases have an indolent onset; some present more acutely.
2. Common symptoms and signs.
   a. Cough—Foul-smelling sputum is consistent with anaerobic infection. It is sometimes blood tinged.
   b. Shortness of breath.
   c. Fever, chills.
   d. Constitutional symptoms: fatigue, malaise, weight loss.

C. Diagnosis
1. CXR
   a. This reveals thick-walled cavitation with air–fluid levels.
b. Look for abscess in dependent, poorly ventilated lobes.
2. CT scan may be necessary to differentiate between abscess and empyema.
3. Sputum Gram stain and culture has low sensitivity and specificity.
4. Consider obtaining cultures via bronchoscopy or transtracheal aspiration rather than simple expectoration to avoid contamination with oral flora.

D. Treatment
1. Hospitalization is often required if lung abscess is found. Postural drainage should be performed.
2. Antimicrobial therapy.
   a. Antibiotic regimens include coverage for the following:
      - Gram-positive cocci—ampicillin/sulbactam or amoxicillin/clavulanic acid, ampicillin/sulbactam, or vancomycin for *S. aureus*.
      - Anaerobes—clindamycin or metronidazole.
      - If gram-negative organisms are suspected, add a fluoroquinolone or ceftazidime.
   b. Continue antibiotics until the cavity is gone or until CXR findings have improved considerably—this may take months!
Tuberculosis

Quick HIT

TB is the most common cause of death due to infection worldwide.

A. General Characteristics

1. Microbiology
   a. Caused by *Mycobacterium tuberculosis*
   b. Mycobacteria are acid-fast bacilli (AFB)—considered slow growing but hardy organisms
   c. Inhibited by the cellular arm of the immune system

2. Transmission
   a. Transmission occurs via inhalation of aerosolized droplets containing the active organism
   b. Only those people with active TB are contagious (e.g., by coughing, sneezing)
   c. People with primary TB are not contagious

3. Pathophysiology
   a. Primary TB
      • Bacilli are inhaled and deposited into the lung, then ingested by alveolar macrophages
      • Surviving organisms multiply and disseminate via lymphatics and the bloodstream. Granulomas form and “wall off” the mycobacteria. The granulomas in oxygen-rich areas, such as the lungs, allow these organisms to remain viable (they are aerobes). After the resolution of the primary infection, the organism remains dormant within the granuloma
      • An insult to the immune system may activate the TB at any time
      • Only 5% to 10% of individuals with primary TB will develop active disease in their lifetime
   b. Secondary TB (reactivation)
      • Occurs when the host’s immunity is weakened (e.g., HIV infection, malignancy, immunosuppressants, substance abuse, poor nutrition)
      • Usually manifests in the most oxygenated portions of the lungs—the apical/posterior segments
      • Produces clinical manifestations of TB
      • Can be complicated by hematogenous or lymphatic spread, resulting in miliary TB
   c. Extrapulmonary TB
• Individuals with impaired immunity may not be able to contain the bacteria at either the primary or the secondary stage of the infection
• This may result in active disease throughout the body
• It is common in patients with HIV because their cellular immunity is impaired

4. Risk factors (almost all patients with TB have one or more of the following):
   a. HIV-positive patients
   b. Recent immigrants (within the past 5 years)
   c. Prisoners
   d. Healthcare workers
   e. Close contacts of someone with TB
   f. Alcoholics
   g. Diabetics
   h. Glucocorticoid/immunosuppressant use
   i. Hematologic malignancy
   j. Injection drug users

Quick HIT

Radiographic Findings in Primary TB
• Ghon complex—calcified primary focus with an associated lymph node
• Ranke complex—when Ghon complex undergoes fibrosis and calcification

Quick HIT

Diagnosis of TB is challenging in HIV patients because:
• PPD skin test result is negative.
• Patients have “atypical” CXR findings.
• Sputum smears are more likely to be negative.
• Granuloma formation may not be present in the late stages.

B. Clinical Features

1. Primary TB
   a. Usually asymptomatic
   b. Pleural effusion may develop
   c. If the immune response is incomplete, the pulmonary and constitutional symptoms of TB may develop. This is known as progressive primary TB

2. Secondary (active) TB
   a. Constitutional symptoms—fever, night sweats, weight loss, and malaise are common
   b. Cough progresses from dry cough to purulent sputum. Hemoptysis suggests advanced TB
c. Apical rales may be present on examination

3. Extrapulmonary TB
   a. May involve any organ. The lymph nodes, pleura, genitourinary tract, spine, intestine, and meninges are some of the common sites of infection
   b. Miliary TB refers to hematogenous dissemination of the tubercle bacilli
      • May be due to a reactivation of dormant, disseminated foci or a new infection
      • Also common in patients with HIV
      • May present with organomegaly, reticulonodular infiltrates on CXR, and choroidal tubercles in the eye

C. Diagnosis
   1. Must have a high index of suspicion, depending on patient’s risk factors and presentation
   2. CXR
      a. Classic findings are upper lobe infiltrates with cavitations
      b. Other possible findings
         • Pleural effusion(s)
         • Ghon complex and Ranke complex: evidence of healed primary TB
         • Atypical findings common in immunocompromised patients
   3. Sputum studies (sputum acid-fast testing)
      a. Definitive diagnosis is made by sputum culture—growth of *M. tuberculosis*
      b. Obtain three morning sputum specimens—culture takes 4 to 8 weeks
      c. PCR can detect specific mycobacterial DNA more rapidly
      d. Diagnosis is sometimes made by finding AFB on microscopic examination, but this is not definitive because other mycobacteria may colonize airways
   4. Tuberculin skin test (PPD test)
      a. Tuberculin skin test is a screening test to detect those who may have been exposed to TB. It is not for diagnosis of active TB, but rather of latent (primary) TB (a positive chest x-ray is used to diagnose active TB). PPD is not a screening test for everyone, only patients with one or more of the risk factors mentioned above should have this test. If patient is symptomatic or has abnormal chest x-ray, order a sputum acid-fast test, not a PPD
      b. Inject PPD into the volar aspect of forearm. Measure the amount of induration 48 to 72 hours later. Positive result is interpreted as follows:
         • Patients with no risk factors: induration ≥15 mm
         • Certain high-risk populations (e.g., those who live in high-prevalence areas, immigrants in the last 5 years, the homeless, prisoners, healthcare workers, nursing home residents, close contact of someone with TB, alcoholics, diabetics): induration ≥10 mm
Patients with HIV, steroid users, organ transplant recipients, close contacts of those with ACTIVE TB, or those with radiographic evidence of primary TB: induration ≥5 mm

**Quick HIT**

Patients previously vaccinated with BCG will have a positive PPD test but this does not affect treatment decisions.

**Quick HIT**

INH should always be started with vitamin B6 (pyridoxine) to prevent symptoms of B6 deficiency, which include stomatitis, glossitis, cheilosis, convulsions, hyperirritability, peripheral neuropathy, and sideroblastic anemia.

c. If a patient has never had a PPD test before, repeat the test in 1 to 2 weeks if the first test is negative (first test may be false negative). The results of the second test (whether positive or negative) are used for management
d. If PPD test is positive, a chest x-ray is needed to rule out active disease. Once active disease is excluded, 9 months of isoniazid treatment is initiated. A patient with a positive PPD test has a 10% lifetime risk of TB, and this risk is reduced to 1% after 9 months of isoniazid treatment
e. Many persons born outside of United States have been Bacille Calmette–Guerin (BCG)-vaccinated, which may cause a positive PPD skin test. However, this does not affect treatment decisions. If a patient has a positive PPD test, isoniazid for 9 months is indicated even if the patient had prior BCG vaccine

**D. Treatment**

1. Patients with active TB must be isolated until sputum is negative for AFB.
   a. First-line therapy is a four-drug regimen: isoniazid (INH), rifampin, pyrazinamide, and ethambutol or streptomycin.
   b. The initial treatment regimen consists of 2 months of treatment with the four-drug regimen. The initial 2-month phase is followed by a 4-month phase of INH and rifampin.

2. Prophylactic treatment for latent (primary) TB (i.e., positive PPD skin test): consists of 9 months of INH **after** active TB has been excluded (negative CXR, sputum, or both).

**Quick HIT**

- For a positive TB exposure and a positive PPD test (but no active disease), treatment is INH only.
- If the patient has active TB, multiagent therapy is indicated.
All TB medications can cause hepatotoxicity. Discontinue treatment only if liver transaminases rise to three to five times the upper limit of normal.
Influenza

An orthomyxovirus transmitted via respiratory droplets, typically occurring in winter months.
Antigenic types A and B are responsible for the clinical syndrome known as the “flu.”
Annual epidemics are due to minor genetic reassortment and usually are not life-threatening except in the very young, the very old, the immunocompromised, and hosts with significant medical comorbidities.
Rarely occurring pandemics are due to major genetic recombination and are often fatal, even in young, otherwise healthy hosts.
Clinical findings are a rapid onset of fever, chills, malaise, headache, nonproductive cough, and sore throat. Nausea may also be present.
Treatment is largely supportive. Antiviral agents are available but these are only indicated in patients with severe disease (requiring hospitalization) or at high risk of complications and must be given within the first 48 hours of illness. Give antibiotics only for secondary bacterial infections. (See Chapter 12 for vaccination recommendations.)
A neuraminidase inhibitor (zanamivir or oseltamivir) is the recommended antiviral agent.
Infections of the Central Nervous System

Meningitis

A. General Characteristics

1. This refers to inflammation of the meningeal membranes that envelop the brain and spinal cord. It is usually associated with infectious causes, but noninfectious causes (such as medications, SLE, sarcoidosis, and carcinomatosis) also exist.

2. Pathophysiology
   a. Infectious agents frequently colonize the nasopharynx and respiratory tract.
   b. These pathogens typically enter the CNS via one of the following:
      • Invasion of the bloodstream, which leads to hematogenous seeding of CNS.
      • Retrograde transport along cranial (e.g., olfactory) or peripheral nerves.
      • Contiguous spread from sinusitis, otitis media, surgery, or trauma.

3. Can be classified as acute or chronic, depending on onset of symptoms.
   a. Acute meningitis—onset within hours to days.
   b. Chronic meningitis—onset within weeks to months; commonly caused by mycobacteria, fungi, Lyme disease, or parasites.

4. Another important distinction is bacterial versus aseptic (described below).

5. Acute bacterial meningitis.
   a. Causes
      • Neonates—Group B streptococci, E. coli, Listeria monocytogenes.
      • Children >3 months—Neisseria meningitidis, S. pneumoniae, H. influenzae.
      • Adults (ages 18 to 50)—S. pneumoniae, N. meningitidis, H. influenzae.
      • Elderly (>50)—S. pneumoniae, N. meningitidis, L. monocytogenes, gram-negative bacilli.
      • Immunocompromised—L. monocytogenes, gram-negative bacilli, S. pneumoniae.
   b. Complications
      • Seizures, coma, brain abscess, subdural empyema, DIC, respiratory arrest.
      • Permanent sequelae—deafness, brain damage, hydrocephalus.

6. Aseptic meningitis
   a. Aseptic meningitis is most commonly caused by a variety of nonbacterial pathogens, frequently viruses such as enterovirus and herpes simplex virus (HSV). It can also be caused by certain bacteria, parasites, and fungi.
   b. It may be difficult to distinguish it clinically from acute bacterial meningitis. If there is uncertainty in diagnosis, treat for acute bacterial meningitis.
meningitis.
c. It is associated with a better prognosis than acute bacterial meningitis.

Quick HIT

**Acute Bacterial Meningitis (clinical features)**
**Characteristic triad includes:**
- Fever
- Nuchal rigidity
- Change in mental status

B. Clinical Features

1. Symptoms (any of the following may be present)
   a. Headache (may be more severe when lying down)
   b. Fevers
   c. Nausea and vomiting
   d. Stiff, painful neck
   e. Malaise
   f. Photophobia
   g. Alteration in mental status (confusion, lethargy, even coma)

2. Signs (any of the following may be present)
   a. Nuchal rigidity: stiff neck, with resistance to flexion of spine (may be absent)
   b. Rashes
      - Maculopapular rash with petechiae—purpura is classic for *N. meningitidis*
      - Vesicular lesions in varicella or HSV
   c. Increased ICP and its manifestations—for example, papilledema, seizures
   d. Cranial nerve palsies
   e. *Kernig sign*—inability to fully extend knees when patient is supine with hips flexed (90 degrees)
      - Caused by irritation of the meninges
      - Only present in approximately half of patients with bacterial meningitis
   f. *Brudzinski sign*—flexion of legs and thighs that is brought on by passive flexion of neck for same reason as above; also present in only half of patients with bacterial meningitis
   g. *Jolt test*—worsening headache when patient is asked to turn head back and forth
quickly at frequency of at least 3 turns per second. Most sensitive and specific for acute bacterial meningitis.

C. Diagnosis

1. CSF examination (LP)—Perform this if meningitis is a possible diagnosis unless there is evidence of a space-occupying lesion (see Table 10-2). Also note the opening pressure.
   a. Examine the CSF. Cloudy CSF is consistent with a pyogenic leukocytosis.
   b. CSF should be sent for the following: cell count, chemistry (e.g., protein, glucose), Gram stain, culture (including AFB), and cryptococcal antigen or India ink.
   c. Bacterial meningitis—pyogenic inflammatory response in CSF.
      • Elevated WBC count—PMNs predominate.
      • Low glucose.
      • High protein.
      • Gram stain—positive in 75% to 80% of patients with bacterial meningitis.

   ![TABLE 10-1 CSF Findings in Bacterial Versus Aseptic Meningitis](image)

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Bacterial Meningitis</th>
<th>Aseptic Meningitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WBC count</strong></td>
<td>&lt;5</td>
<td>&gt;1,000 (1,000-20,000)</td>
<td>&lt;1,000</td>
</tr>
<tr>
<td>(cells/mm³)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WBC differential</strong></td>
<td>All lymphocytes or monocytes; no PMNs</td>
<td>Mostly PMNs</td>
<td>Mostly lymphocytes and monocytes</td>
</tr>
<tr>
<td><strong>Glucose (mg/dL)</strong></td>
<td>50–75</td>
<td>Low</td>
<td>Normal</td>
</tr>
<tr>
<td><strong>Protein (mg/dL)</strong></td>
<td>&lt;60</td>
<td>High</td>
<td>Moderate elevation</td>
</tr>
</tbody>
</table>

d. Aseptic meningitis—nonpyogenic inflammatory response in CSF.
   • There is an increase in mononuclear cells. Typically a lymphocytic pleocytosis is present.
   • Protein is normal or slightly elevated.
   • Glucose is usually normal.
   • CSF may be completely normal.

2. CT scan of the head is recommended before performing an LP if there are focal neurologic signs or if there is evidence of a space-occupying lesion with elevations in ICP.

3. Obtain blood cultures before antibiotics are given.

D. Treatment
1. Bacterial meningitis.
   a. Empiric antibiotic therapy—Start immediately after LP is performed. If a CT scan must be performed or if there are anticipated delays in LP, give antibiotics first. Pathogen can often still be identified from CSF several hours after administration of antibiotics.
   b. Intravenous (IV) antibiotics.
      • Initiate immediately if the CSF is cloudy or if bacterial infection is suspected.
      • Begin empiric therapy according to the patient’s age (see Table 10-3).
      • Modify treatment as appropriate based on Gram stain, culture, and sensitivity findings.
   c. Steroids—if suspect *S. pneumoniae* as causative organism to prevent cerebral edema.
   d. Vaccination
      • Vaccinate all adults >65 years for *S. pneumoniae*.
      • Vaccinate asplenic patients for *S. pneumoniae, N. meningitidis*, and *H. influenzae* (encapsulated organisms).
      • Vaccinate immunocompromised patients for *N. meningitidis*.
   e. Prophylaxis (e.g., rifampin or ceftriaxone)—for all close contacts of patients with meningococcus.

2. Aseptic meningitis.
   a. No specific therapy other than supportive care is required. The disease is self-limited.
   b. Analgesics and fever reduction may be appropriate.

### TABLE 10-2 Empiric Treatment for Acute Bacterial Meningitis

<table>
<thead>
<tr>
<th>Age or Risk Factor</th>
<th>Likely Etiology</th>
<th>Empiric Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (&lt;3 mo)</td>
<td>Group B streptococci, <em>E. coli</em>, <em>Klebsiella</em> spp., <em>L. monocytogenes</em></td>
<td>Cefotaxime + ampicillin + vancomycin (aminoglycoside if &lt;4 weeks)</td>
</tr>
<tr>
<td>3 mo–50 yrs</td>
<td><em>N. meningitidis, S. pneumoniae, H. influenzae</em></td>
<td>Ceftriaxone or cefotaxime + vancomycin</td>
</tr>
<tr>
<td>&gt;50 yrs</td>
<td><em>S. pneumoniae, N. meningitidis, L. monocytogenes</em>, Gram-negative bacilli</td>
<td>Ceftriaxone or cefotaxime + vancomycin + ampicillin</td>
</tr>
<tr>
<td>Impaired cellular immunity (e.g., HIV)</td>
<td><em>S. pneumoniae, N. meningitidis, L. monocytogenes</em>, aerobic gram-negative bacilli (including <em>P. aeruginosa</em>)</td>
<td>Ceftazidime + ampicillin + vancomycin</td>
</tr>
</tbody>
</table>
Encephalitis

Differential diagnosis in patients with fever and altered mental status: infection
- Sepsis, UTI/urosepsis, pneumonia, bacterial meningitis, intracranial abscess, subdural empyema, medication/drugs
- Neuroleptic malignant syndrome (haloperidol, phenothiazines)
- Delirium tremens, metabolic derangements
- Thyroid storm

A. General Characteristics
1. Encephalitis is a diffuse inflammation of the brain parenchyma and is often seen simultaneously with meningitis
2. It is usually viral in origin. Nonviral causes, however, must also be considered
   a. Viral causes
      • Herpes (HSV-1)
      • Arbovirus—for example, Eastern equine encephalitis, West Nile virus
      • Enterovirus—for example, polio
      • Less common causes—for example, measles, mumps, EBV, CMV, VZV, rabies, and prion diseases such as Creutzfeldt–Jakob disease
   b. Nonviral infectious causes
      • Toxoplasmosis
      • Cerebral aspergillosis
   c. Noninfectious causes
      • Metabolic encephalopathies
      • T-cell lymphoma
3. Risk factors
   a. AIDS—patients with AIDS are especially at risk for toxoplasmosis when the CD4 count is <200
   b. Other forms of immunosuppression
   c. Travel in underdeveloped countries
   d. Exposure to insect (e.g., mosquito) vector in endemic areas
   e. Exposure to certain wild animals (e.g., bats) in an endemic area for rabies
4. The overall mortality associated with viral encephalitis is approximately 10%

B. Clinical Features
1. Patients often have a prodrome of headache, malaise, and myalgias.
2. Within hours to days, patients become more acutely ill.
3. Patients frequently have signs and symptoms of meningitis (e.g., headache, fever, photophobia, nuchal rigidity).

4. In addition, patients have altered sensorium, possibly including confusion, delirium, disorientation, and behavior abnormalities.

5. Focal neurologic findings (e.g., hemiparesis, aphasia, cranial nerve lesions) and seizures may also be present.

C. Diagnosis

1. Routine laboratory tests (to rule out nonviral causes) include CXR, urine and blood cultures, urine toxicology screen, and serum chemistries.

2. Perform an LP to examine CSF, unless the patient has signs of significantly increased ICP.
   a. Lymphocytosis (>5 WBC/mL) with normal glucose is consistent with viral encephalitis (similar CSF as in viral meningitis). CSF cultures are usually negative.
   b. **CSF PCR** is the most specific and sensitive test for diagnosing many various viral encephalitides, including HSV-1, CMV, EBV, and VZV.

3. MRI of the brain is the imaging study of choice.
   a. Can rule out focal neurologic causes, such as an abscess.
   b. Increased areas of T2 signal in the frontotemporal localization are consistent with HSV encephalitis.

4. EEG can be helpful in diagnosing HSV-1 encephalitis—it would show unilateral or bilateral temporal lobe discharges.

5. Brain biopsy is indicated in an acutely ill patient with a focal, enhancing lesion on MRI without a clear diagnosis.

Quick HIT

Not all brain abscesses are bacterial—especially in immunocompromised hosts!
- *Toxoplasma gondii* and fungi in patients with AIDS
- *Candida* spp., *Aspergillus* spp., or zygomycosis in neutropenic patients

D. Treatment

1. Supportive care, mechanical ventilation if necessary

2. Antiviral therapy
   a. There is no specific antiviral therapy for most causes of viral encephalitis
   b. HSV encephalitis—acyclovir for 2 to 3 weeks
   c. CMV encephalitis—ganciclovir or foscarnet

3. Management of possible complications
   a. Seizures—require anticonvulsant therapy
b. Cerebral edema—treatment may include hyperventilation, osmotic diuresis, and steroids
Infections of the Gastrointestinal Tract (see also Chapter 3)

●●● Viral Hepatitis

**Quick HIT**

- **Hepatitis B** is associated with PAN.
- **Hepatitis C** is associated with cryoglobulinemia.

### A. General Characteristics

1. Hepatitis simply means inflammation of the liver. There are many noninfectious types of hepatitis, such as alcoholic hepatitis, drug-induced hepatitis, autoimmune hepatitis, and numerous hereditary diseases that can cause hepatitis.
2. Causes of viral hepatitis.
   a. There are five well-understood, main categories of viral hepatitis: hepatitis A, B, C, D, and E. Hepatitis viruses are often abbreviated by their type (i.e., HAV is hepatitis A virus, HBV is hepatitis B virus, and so forth.)
   b. Other viruses that can cause one form or another of hepatitis are EBV, CMV, and HSV. These are not commonly associated with hepatitis in immunocompetent patients.
3. Transmission varies depending on the specific virus.
   a. Hepatitis A and E are transmitted via the fecal–oral route and are more prevalent in developing countries.
   b. Hepatitis E is particularly prevalent in India, Pakistan, southeast Asia, and parts of Africa.
   c. **Hepatitis B is transmitted parenterally or sexually.** Perinatal transmission is also possible and is a significant health issue in parts of Africa and Asia.
   d. Hepatitis D requires the outer envelope of the hepatitis B surface antigen (HB₅AG) for replication and therefore can be transmitted only as a coinfection with HBV, or as a superinfection in a chronic HBV carrier.
   e. **The main route of transmission for hepatitis C is parenteral,** and it is therefore more prevalent in IV drug users. Sexual or perinatal transmission is not common.
   f. **Hepatitis B, C, and D are the types that can progress to chronic disease.**
In general, HAV and HEV cause a milder form of hepatitis and do not become chronic.

B. Clinical Features

1. Classified as acute (<6 months of liver inflammation) or chronic (>6 months of persistent liver inflammation) (Figure 10-2)

2. Acute hepatitis has a wide spectrum of clinical presentations, ranging from virtually asymptomatic to fulminant liver failure
   a. General clinical features
      - Jaundice—look first in the sclera, because this may be the first place jaundice can be detected, especially in black patients
      - Dark-colored urine may be present (due to conjugated hyperbilirubinemia)
      - RUQ pain
      - Nausea and vomiting
      - Fever and malaise
      - Hepatomegaly may also be present
   b. In severe cases, acute hepatitis may result in liver failure and its complications. This is known as fulminant hepatitis (uncommon) and may be life-threatening. It occurs more commonly in hepatitis B, D, and E than in other types. Complications include:
      - Hepatic encephalopathy—Look for asterixis and palmar erythema
      - Hepatorenal syndrome
      - Bleeding diathesis—this occurs only when liver function is very compromised
   c. Sometimes acute hepatitis may only present with transient flu-like symptoms such as fever, myalgias, and malaise
   d. Acute HBV may also present with a serum sickness-like illness
   e. Hepatitis C typically does not cause significant acute illness
If transaminases are markedly elevated (>500), think of acute viral hepatitis, shock liver, or drug-induced hepatitis.

3. Chronic hepatitis also has a wide variety of presentations. Some patients are asymptomatic (“chronic carriers”) and may only present with late complications of hepatitis, such as cirrhosis or hepatic cell carcinoma (HCC)
   a. Chronic hepatitis occurs after acute hepatitis in 1% to 10% of patients with HBV and >80% patients with HCV
   b. It is categorized based on the grade of inflammation, the stage of fibrosis, and the etiology of disease
   c. The risk of developing cirrhosis or HCC is 25% to 40% in patients with chronic HBV and 10% to 25% in patients with chronic HCV

Look for positive HBsAg and positive IgM anti-HBc to check for hepatitis B infection.

C. Diagnosis
1. Serum serology—the presence of serum antigens and immunoglobulins is the most important factor for diagnosing viral hepatitis. These are helpful for determining the acuity or chronicity of illness as well as adequate immunity (see
Clinical Pearl 10-3).

2. PCR is used to detect viral RNA to diagnose HCV.

3. LFTs—Elevation of serum transaminases is not diagnostic, but LFTs are helpful.
   a. ALT (SGPT) is typically elevated more than AST (SGOT) for all forms of viral hepatitis (the opposite of alcoholic hepatitis).
   b. In acute hepatitis, ALT is usually >1,000. It is generally not as high as in drug-induced hepatitis.
   c. In chronic HBV, ALT can also be >1,000, but this varies. In chronic HCV, ALT is generally lower than this due to destruction of hepatocytes from longevity of disease.

---

**CLINICAL PEARL 10-3**

**Hepatitis Serology**

**Hepatitis A**
- Hepatitis A antibody (anti-HAV)
  - Anti-HAV is detectable during acute infection and persists for life, so its presence does not distinguish between active disease and immunity. IgM-specific antibody denotes acute infection.

**Hepatitis B**
- HB$_s$Ag
  - Present in acute or chronic infection
  - Detectable as early as 1 to 2 weeks after infection
  - It persists in chronic hepatitis regardless of whether symptoms are present. If virus is cleared, then HB$_s$Ag is undetectable
  - Hepatitis B e antigen (HB$_e$Ag)
    - Reflects active viral replication, and presence indicates infectivity
    - Appears shortly after HB$_s$Ag
  - Anti-HB$_s$Ag antibody (anti-HBs)
    - Present after vaccination or after clearance of HB$_s$Ag—usually detectable 1 to 3 months after infection
    - In most cases, presence of anti-HBs indicates immunity to HBV
  - Hepatitis B core antibody (anti-HBc)
    - Assay of IgM and IgG combined
    - Useful because it may be the only serologic marker of HBV infection during the “window period” in which HB$_s$Ag is disappearing and anti-HB$_s$Ag is not yet detectable
    - Does not distinguish between acute and chronic infection, and presence does not indicate immunity
  - Viral load
    - HBV DNA measured by PCR; if it persists for more than 6 weeks, patient is likely to develop chronic disease

**Hepatitis C**
- Hepatitis C antibody
  - Key marker of HCV infection
  - Sometimes not detectable until months after infection, so its absence does not rule out infection
  - Viral load: HCV RNA measured by PCR
Detectable 1 to 2 weeks after infection—more sensitive than HCV antibody

**Hepatitis D**
- Hepatitis D antibody (anti-HDV)
  - Presence indicates HDV superinfection
  - The antibody may not be present in acute illness, so repeat testing may be necessary

**D. Treatment**

1. Active (vaccine) and passive (immunoglobulin) immunization are available for both hepatitis A and B. It is the standard of care for infants and healthcare workers to be vaccinated for HBV (see Chapter 12).
2. Travelers often receive vaccinations for HAV. Passive immunization can be given for people who are exposed to the virus.
3. Treatment for hepatitis A and E is supportive.
5. Chronic HCV—treat with IFN-α and ribavirin.
   a. Interferon-free regimens: Newer direct-acting antiviral agents (e.g., ledipasvir, sofosbuvir) can cure chronic HCV. They are very expensive. Treatment regimen depends on stage of liver fibrosis, treatment history, and HCV genotype.
   b. Interferon-containing regimens: Peginterferon and ribavirin. Associated with a high frequency of side effects, such as hematologic toxicity (neutropenia, thrombocytopenia, anemia), fatigue, flu-like symptoms, and neuropsychiatric symptoms.
6. Consider liver transplantation in advanced disease, although recurrence can occur after transplantation. Hepatitis C is the most frequent indication for liver transplantation in the United States.
**Botulism**

**A. General Characteristics**
1. Results from ingestion of preformed toxins produced by spores of *Clostridium botulinum*. Improperly stored food (e.g., home-canned foods) can be contaminated with these spores. Toxins can be inactivated by cooking food at high temperatures (e.g., 100°C [212°F] for 10 minutes).
2. Wound contamination is another source.
3. Inhalation botulism has been reported in laboratory workers but is not a common occurrence. Could be a possible bioterrorism weapon.

**B. Clinical Features**
1. The severity of illness ranges widely, from mild, self-limiting symptoms to rapidly fatal disease.
2. Abdominal cramps, nausea, vomiting, and diarrhea are common.
3. The hallmark clinical manifestation is symmetric, descending flaccid paralysis. It starts with dry mouth, diplopia, and/or dysarthria. Paralysis of limb musculature occurs later.

**Quick HIT**

Differential diagnosis of food-borne botulism includes:
- Guillain–Barré syndrome—characteristically ascending paralysis, but one variety (Fischer) can be descending
- Eaton–Lambert syndrome
- Myasthenia gravis—EMG studies differentiate
- Diphtheria
- Tick paralysis

**C. Diagnosis**
1. The definitive diagnosis is identification of toxin in serum, stool, or gastric contents (bioassay).
2. Identifying *C. botulinum* alone in food is not a reliable diagnostic indicator.

**D. Treatment**
1. Admit the patient and observe respiratory status closely. Gastric lavage is helpful only within several hours after ingestion of suspected food.
2. If suspicion of botulism is high, administer antitoxin (toxoid) as soon as laboratory specimens are obtained (do not wait for the results).
3. For contaminated wounds—(in addition to the above) wound cleansing and penicillin.
Intra-Abdominal Abscess

Causes include spontaneous bacterial peritonitis, pelvic infection (e.g., tubo-ovarian abscess), pancreatitis, perforation of the GI tract, and osteomyelitis of the vertebral bodies with extension into the retroperitoneal cavity. Usually polymicrobial in origin. Diagnose using CT scan or ultrasound. Treatment typically involves drainage of the abscess. The antibiotic regimen should include broad coverage against gram-negative rods, enterococci, and anaerobes.
Pseudomembranous Colitis

A. General Characteristics
1. This is also referred to as antibiotic-associated colitis because many patients do not have grossly visible pseudomembranes.
2. Antibiotic treatment kills organisms that normally inhibit growth of Clostridium difficile, leading to overgrowth of C. difficile and toxin production.
3. Almost all antibiotics have been associated, but the most frequently implicated antibiotics are clindamycin, ampicillin, and cephalosporins.
4. Symptoms usually begin during first week of antibiotic therapy. However, up to 6 weeks may elapse after stopping antibiotics before clinical findings become apparent.
5. Disease severity can be classified as mild–moderate[a], severe, or fulminant depending on the WBC count, serum creatinine, and presence of hypotension/shock, ileus, or megacolon.

Quick HIT
Complications of severe pseudomembranous colitis that may require surgery:
- Toxic megacolon
- Colonic perforation
- Anasarca, electrolyte disturbances

B. Clinical Features
1. Profuse watery diarrhea, usually without blood or mucus
2. Crampy abdominal pain
3. Toxic megacolon (in severe cases) with risk of perforation

C. Diagnosis
1. Demonstration of C. difficile toxins in stool is diagnostic, but results take at least 24 hours (95% sensitivity).
2. Flexible sigmoidoscopy is the most rapid test and is diagnostic, but because of discomfort/expense, it is infrequently used (usually reserved for special situations).
3. Abdominal radiograph is used to rule out toxic megacolon and perforation.
4. Leukocytosis is very common.

D. Treatment
1. Discontinue the offending antibiotic, if possible.
2. Initial episode if mild–moderate or severe: vancomycin or fidaxomicin.
3. Initial episode if fulminant: vancomycin. If ileus is present, add metronidazole.
Subtotal colectomy or diverting loop ileostomy with colonic lavage may be necessary.

4. First recurrence: vancomycin or fidaxomicin
5. Second or subsequent recurrence: vancomycin, fidaxomicin, or fetal microbiota transplantation
6. Regardless of choice of antibiotic, 15% to 35% of successfully treated patients will have recurrence may occur within 2 to 8 weeks after stopping the antibiotic. This occurs in 15% to 35% of successfully treated patients.
Infections of the Genitourinary Tract

Lower Urinary Tract Infections

Quick HIT

More than 90% of uncomplicated UTIs are caused by *E. coli*, *S. saprophyticus*, and *Enterococcus* spp. A small percentage is caused by *Proteus*, *Klebsiella*, *Enterobacter*, and *Pseudomonas*.

A. General Characteristics

1. Urinary tract infections (UTIs) are much more common in women than in men. Up to 33% of all women experience a UTI in their lifetime. The most common UTI is uncomplicated acute cystitis.
2. The majority of UTIs are caused by ascension of pathogens from the urethra to the bladder. These pathogens are from fecal flora that have colonized the vaginal area.
   a. *E. coli* (most common)—causes 80% of cases.
   b. Other organisms—*Staphylococcus saprophyticus*, *Enterococcus*, *Klebsiella*, *Proteus* spp., *Pseudomonas*, *Enterobacter*, and yeast (such as *Candida* spp.)

B. Risk Factors

1. Female gender—greater risk due to shorter urethral length
2. Sexual intercourse
   a. Often the trigger of a UTI in women, thus the term “honeymoon cystitis”
   b. Use of diaphragms and spermicides further increases risk (alters vaginal colonization)
3. Pregnancy
4. Indwelling urinary catheters—risk factor for hospitalized patients
5. Personal history of recurrent UTIs
6. Host-dependent factors—increase risk for recurrent or complicated UTIs
   a. Diabetes—diabetic patients are at risk for upper UTIs
   b. Patients with spinal cord injury
   c. Immunocompromised state
   d. Any structural or functional abnormality that impedes urinary flow (e.g., incomplete voiding, neurogenic bladder, BPH, vesicoureteral reflux, calculi)
7. Male risk factors
   a. Uncircumcised males are at higher risk due to bacterial colonization of the
foreskin
b. Anal intercourse
c. Vaginal intercourse with a female colonized with uropathogens

Quick HIT

Noninfectious causes of cystitis or cystitis-like symptoms:
- Cytotoxic agents (e.g., cyclophosphamide)
- Radiation to the pelvis
- Dysfunctional voiding
- Interstitial cystitis

Quick HIT

Urine culture and sensitivity may modify antibiotic therapy, but most UTIs are treated based on urinalysis and Gram stain results. Obtain cultures under the following conditions: patient age ≥65 years, diabetes, recurrent UTIs, presence of symptoms for 7 days or more, use of a diaphragm.

Quick HIT

Asymptomatic Bacteriuria
- To diagnose asymptomatic bacteriuria, two successive positive cultures (≥10⁵ CFU/mL) must be present.
- Treat asymptomatic bacteriuria only in pregnancy or before urologic surgery.

Quick HIT

On UA, most important finding is white blood cells.

C. Clinical Features
1. Dysuria—commonly expressed as burning on urination
2. Frequency
3. Urgency
4. Suprapubic tenderness
5. Gross hematuria is sometimes present
6. In lower UTIs, fever is characteristically absent

D. Diagnosis
1. Dipstick urinalysis
   a. Positive urine leukocyte esterase test—presence of leukocyte esterase reflects pyuria
   b. Positive nitrite test for presence of bacteria (gram-negative)—nitrite test is sensitive and specific for detecting Enterobacteriaceae. But it lacks sensitivity
for other organisms, so a negative test should be interpreted with caution.

2. Urinalysis (clean-catch midstream specimen)
   a. Adequacy of collection
      - The presence of epithelial (squamous) cells indicates vulvar or urethral contamination
      - If contamination is suspected, perform a straight catheterization of the bladder
   b. Criteria for UTI
      - Bacteriuria: >1 organism per oil-immersion field. Bacteriuria without WBCs may reflect contamination and is not a reliable indicator of infection
      - Pyuria is the most valuable finding for diagnosis: Greater than or equal to 10 leukocytes/μL is abnormal
   c. Other findings—hematuria and mild proteinuria may be present. Hematuria in and of itself does not require extended therapy

3. Urine Gram stain
   a. A count of >10^5 organisms/mL represents significant bacteriuria
   b. It is 90% sensitive and 88% specific

4. Urine culture
   a. Confirms the diagnosis (high specificity). Obtaining a urine culture is warranted if symptoms are not characteristic of UTI, if a complicated infection is suspected, or if symptoms persist despite prior antibiotic treatment
   b. Traditional criteria: ≥10^5 CFU/mL of urine from a clean-catch sample; misses up to one-third of UTIs
   c. Colony counts as low as 10^2 to 10^4 CFU/mL are adequate for diagnosis if clinical symptoms are present

5. Blood cultures—only indicated if patient is ill and urosepsis is suspected

6. IVP, cystoscopy, and excretory urography are not recommended unless structural abnormalities or obstruction is suspected

---

**Quick HIT**

Complicated UTI is caused by functional or structural abnormalities of the urinary tract or underlying disease. The following groups of patients are considered to have complicated UTI:

- Men
- Diabetics, renal failure
- Pregnancy
- History of pyelonephritis in last year
- Urinary tract obstruction, indwelling catheter, stent, nephrostomy tube
- Antibiotic-resistant organism
- Immunocompromised patients (e.g., HIV patients, transplant recipients)
E. Complications

1. Complicated UTI
   a. Any UTI that spreads beyond the bladder (e.g., pyelonephritis, prostatitis, urosepsis)—risk factors for upper UTI: pregnancy, diabetes, and vesicoureteral reflux
   b. Any UTI caused by structural abnormalities, metabolic disorder, or neurologic dysfunction

2. UTI during pregnancy—increased risk of preterm labor, low birth weight, and other complications, especially in advanced pregnancy

3. Recurrent infections
   a. Usually due to infection with new organism, but sometimes is a relapse due to unsuccessful treatment of the original organism
   b. Risk factors include impaired host defenses, pregnancy, vesicoureteral reflux, and sexual intercourse in women
   c. Generally, the consequences are not significant unless the patient is at risk for upper UTI

**Quick HIT**
For uncomplicated UTI, empiric treatment is appropriate—do not wait for culture results.

**Quick HIT**
If complicated UTI, extend antibiotic treatment to 7 days.

F. Treatment

1. Acute uncomplicated cystitis—that is, nonpregnant women. Several options exist:
   a. Oral TMP/SMX (Bactrim) for 3 days.
   b. Nitrofurantoin (5 to 7 days)—do not give if early pyelonephritis is suspected.
   c. Fosfomycin (single dose)—do not give if early pyelonephritis is suspected.
   d. Amoxicillin is a less popular alternative due to increasing antimicrobial resistance.
   e. Fluoroquinolones (ciprofloxacin in 3-day regimen) is a reasonable alternative to the above-mentioned agents.
   f. Treat presumptively for pyelonephritis if the condition fails to respond to a short course of antibiotics.
   g. Phenazopyridine (Pyridium) is a urinary analgesic; it can be given for 1 to 3 days for dysuria.
2. Pregnant women with UTI.
   a. Treat with ampicillin, amoxicillin, or oral cephalosporins for 7 to 10 days.
   b. Avoid fluoroquinolones (can cause fetal arthropathy).
3. UTIs in men.
   a. Treat as with uncomplicated cystitis in women, but for 7 days.
   b. Urologic workup is required in all men presenting with UTI unless there is an obvious underlying risk factor (catheterization, etc.).
4. Recurrent infections.
   a. If relapse occurs within 2 weeks of cessation of treatment, continue treatment for 2 more weeks and obtain a urine culture.
   b. Otherwise treat as for uncomplicated cystitis. If the patient has more than two UTIs per year, give chemoprophylaxis.
      - Single dose of TMP/SMX after intercourse or at first signs of symptoms.
      - Alternative low-dose prophylactic antibiotics (e.g., low-dose TMP/SMX) for 6 months.
Pyelonephritis

A. General Characteristics
1. Pyelonephritis is an infection of the upper urinary tract.
   a. It is usually caused by ascending spread from the bladder to the kidney.
   b. Uncomplicated pyelonephritis is limited to the renal pyelocalyceal-medullary region.
   c. Vesicoureteral reflux facilitates this ascending spread. See above for other risk factors.
2. Organisms
   a. *E. coli* (most frequent cause).
   b. Other gram-negative bacteria include *Proteus, Klebsiella, Enterobacter,* and *Pseudomonas* spp.
   c. Gram-positive bacteria (less common) include *Enterococcus faecalis* and *S. aureus*.
3. Complications (unusual).
   a. Sepsis occurs in 10% to 25% of patients with pyelonephritis. May lead to shock.
   b. Emphysematous pyelonephritis—caused by gas-producing bacteria in diabetic patients.
   c. Chronic pyelonephritis and scarring of the kidneys—rare unless underlying renal disease exists.

B. Clinical Features
1. Symptoms
   a. Fever, chills
   b. Flank pain
   c. Symptoms of cystitis (may or may not be present)
   d. Nausea, vomiting, and diarrhea (sometimes present)
2. Signs
   a. Fever with tachycardia
   b. Patients generally appear more ill than patients with cystitis
   c. Costovertebral angle tenderness—unilateral or bilateral
   d. Abdominal tenderness may be present on examination

C. Diagnosis
1. Urinalysis
   a. Look for pyuria, bacteriuria, and **leukocyte casts**
   b. As in cystitis, hematuria and mild proteinuria may be present
2. Urine cultures—obtain in all patients with suspected pyelonephritis
3. Blood cultures—obtain in ill-appearing patients and all hospitalized patients
4. CBC—leukocytosis with left shift
5. Renal function—this is usually preserved. Impairment is usually reversible, especially with IV fluids
6. Imaging studies—perform these if treatment fails or in any patient with complicated pyelonephritis. Consider renal ultrasound, CT, IVP, or retrograde ureterogram

D. Treatment
1. For uncomplicated pyelonephritis.
   a. Use outpatient treatment if the patient can take oral antibiotics. Treat based on Gram stain:
      • TMP/SMX or a fluoroquinolone for 10 to 14 days is effective for most gram-negative rods.
      • Amoxicillin is appropriate for gram-positive cocci (enterococci, S. saprophyticus).
      • A single dose of ceftriaxone or gentamicin is often given initially before starting oral treatment.
   b. Repeat urine culture 2 to 4 days after cessation of therapy.
   c. If symptoms fail to resolve within 48 hours, adjust treatment based on urine culture.
   d. Failure to respond to appropriate antimicrobial therapy suggests a functional or structural abnormality; perform a urologic investigation.
2. If the patient is very ill, elderly, pregnant, unable to tolerate oral medication, or has significant comorbidities, or if urosepsis is suspected
   a. Hospitalize the patient and give IV fluids.
   b. Treat with antibiotics.
      • Start with parenteral antibiotics (broad-spectrum)—ampicillin PLUS gentamicin or ciprofloxacin are common initial choices.
      • If blood cultures are negative, treat with IV antibiotics until the patient is afebrile for 24 hours, then give oral antibiotics to complete a 14- to 21-day course.
      • If blood cultures are positive (urosepsis), treat with IV antibiotics for 2 to 3 weeks.
3. For recurrent pyelonephritis.
   a. If relapse is due to the same organism despite appropriate treatment, treat for 6 weeks.
   b. If relapse is due to a new organism, treat with appropriate therapy for 2 weeks.
A. General Characteristics
1. Acute bacterial prostatitis
   a. Less common than chronic bacterial prostatitis
   b. Occurs more commonly in younger men
   c. Pathophysiology
      • Ascending infection from the urethra and reflux of infected urine
      • May occur after urinary catheterization
      • Other causes—direct or lymphatic spread from the rectum
      • Hematogenous spread (rare)
   d. Gram-negative organisms predominate (e.g., *E. coli*, *Klebsiella*, *Proteus*, *Pseudomonas*, *Enterobacter*, and *Serratia* spp.)
2. Chronic bacterial prostatitis
   a. More common than acute bacterial prostatitis; true prevalence is difficult to determine because many cases are asymptomatic and are diagnosed incidentally
   b. It most commonly affects men 40 to 70 years of age
   c. It has the same routes of infection as acute bacterial prostatitis. It may develop from acute bacterial prostatitis
   d. Organisms are similar to those in acute prostatitis

Avoid prostatic massage in patients with acute bacterial prostatitis because it may induce bacteremia. In fact, rectal examination may be skipped if the diagnosis is straightforward.

B. Clinical Features
1. Acute prostatitis
   a. Fever, chills—patients may appear toxic.
   b. Irritative voiding symptoms—dysuria, frequency, and urgency are common.
   c. Perineal pain, low back pain, and urinary retention may be present as well.
2. Chronic prostatitis
a. Patients may be asymptomatic. Patients do not appear ill. Fever is uncommon.
b. Patients frequently have recurrent UTIs with irritative voiding and/or obstructive urinary symptoms.
c. There is dull, poorly localized pain in the lower back, perineal, scrotal, or suprapubic region.

C. Diagnosis
1. DRE—there is a boggy, exquisitely tender prostate in acute disease. In chronic disease, prostate is enlarged and usually nontender.
2. Urinalysis—numerous (sheets of) WBCs are present in acute bacterial prostatitis.
3. Urine cultures—almost always positive in acute prostatitis.
4. Chronic prostatitis—the presence of WBCs in expressed prostatic secretions suggests diagnosis. Urine cultures may be positive (chronic bacterial prostatitis) or negative (chronic nonbacterial prostatitis).
5. Obtain CBC and blood cultures if patient appears toxic or if sepsis is suspected.

D. Treatment
1. Acute prostatitis.
   a. If it is severe and the patient appears toxic, hospitalize the patient and initiate IV antibiotics.
   b. If it is mild, treat on an outpatient basis with antibiotics—TMP/SMX or a fluoroquinolone and doxycycline. Treat for 4 to 6 weeks.
   c. The patient usually responds to therapy.
2. Chronic prostatitis.
   a. Treat with a fluoroquinolone. For chronic bacterial prostatitis, a prolonged course is recommended but does not guarantee complete eradication.
   b. It is very difficult to treat. Recurrences are common.

Quick HIT
Recurrent exacerbations are common in chronic prostatitis if not treated adequately. Recurrent UTI is very common in these patients.
Sexually Transmitted Diseases

Genital Warts

Eighty percent of cases of reactive arthritis (formerly Reiter syndrome) are associated with chlamydial infection.

These are caused by HPV.

**They are the most common** sexually transmitted disease (**STD**).

See Chapter 11, Common Dermatologic Problems, Inflammatory, Allergic, and Autoimmune Skin Conditions, Warts.
Chlamydia

Quick HIT

Chlamydia infection is a risk factor for cervical cancer, especially when there is a history of multiple infections.

A. General Characteristics
1. **Chlamydia is the most common bacterial STD.** The organism is an intracellular pathogen.
2. Many patients are coinfected with gonorrhea (up to 40% of women and 20% of men).
3. The incubation period is 1 to 3 weeks.

Quick HIT

Complications of Chlamydia
- Complications in men include epididymitis and proctitis.
- Complications in women include pelvic inflammatory disease, salpingitis, tubo-ovarian abscess, ectopic pregnancy, and Fitz-Hugh–Curtis syndrome. **Chlamydia is a leading cause of infertility in women due to tubal scarring.**

B. Clinical Features
1. Many cases are asymptomatic (80% of women, 50% of men).
2. Men who are symptomatic may have any of the following: dysuria, purulent urethral discharge, scrotal pain and swelling, and fever.
3. Women who are symptomatic may have purulent urethral discharge, intermenstrual or postcoital bleeding, and dysuria.

C. Diagnosis
1. Diagnostic tests include culture, enzyme immunoassay, and molecular tests such as PCR. Serologic tests are not used for *Chlamydia*.
2. Molecular diagnostic tests are replacing culture as the screening test of choice due to higher sensitivity.
3. Sexually active women should be screened for chlamydial and gonorrheal infection even if they are asymptomatic.

D. Treatment
1. Azithromycin (oral one dose) or doxycycline (oral for 7 days).
2. Treat all sexual partners.
Gonorrhea

Quick HIT
In gonorrhea, infection of the pharynx, conjunctiva, and rectum can occur.

A. General Characteristics
1. The responsible organism is *Neisseria gonorrhoeae* (a gram-negative, intracellular diplococcal organism).
2. Gonorrhea is usually asymptomatic in women but symptomatic in men. Therefore, complications occur more often in women due to undetected disease.
3. It is almost always transmitted sexually (except with neonatal transmission).
4. Coinfection with *Chlamydia trachomatis* occurs in 30% of patients (more common in women).

Quick HIT
**Gonorrheal Complications**
- Pelvic inflammatory disease, with possible infertility and chronic pelvic pain
- Epididymitis, prostatitis (uncommon)
- Salpingitis, tubo-ovarian abscess
- Fitz-Hugh–Curtis syndrome (perihepatitis)—RUQ pain; elevated LFTs
- Disseminated gonococcal infection

B.Clinical Features
1. Men
   a. Gonorrhea is asymptomatic in up to 10% of carriers. These asymptomatic carriers can still transmit the disease
   b. Most men have symptoms involving the urethra—for example, purulent discharge, dysuria, erythema and edema of urethral meatus, and frequency of urination
2. Women
   a. **Most women are asymptomatic or have few symptoms**
   b. Women may have symptoms of cervicitis or urethritis—for example, purulent discharge, dysuria, intermenstrual bleeding, and dyspareunia
3. Disseminated gonococcal infection (occurs in 1% to 2% of cases; more common in women)—possible findings:
   a. Fever, arthralgias, tenosynovitis (of hands and feet)
   b. Migratory polyarthritis/septic arthritis, endocarditis, or even meningitis
   c. Skin rash (usually on distal extremities)
C. Diagnosis
1. Gram stain of urethral discharge showing organisms within leukocytes is highly specific for gonorrhea.
2. Obtain cultures in all cases—in men from the urethra; in women from the endocervix. May treat empirically because culture results take 1 to 2 days to return.
3. Consider testing for syphilis and HIV.
4. Obtain blood cultures if disease has disseminated.

D. Treatment
1. Ceftriaxone (IM, one dose) is preferred because it is also effective against syphilis. Other options are oral cefixime, ciprofloxacin, or ofloxacin.
2. Also give azithromycin (one dose) or doxycycline (for 7 days) to cover coexistent chlamydial infection.
3. If disseminated, hospitalize the patient and initiate ceftriaxone (IV or IM for 7 days).
A. General Characteristics

1. Pathophysiology
   a. The most common virus associated with HIV is the HIV type 1 human retrovirus
   b. The virus attaches to the surface of CD4+ T lymphocytes (targets of HIV-1); it enters the cell and uncoats, and its RNA is transcribed to DNA by reverse transcriptase
   c. Billions of viral particles are produced each day by activated CD4 cells. When the virus enters the lytic stage of infection, CD4 cells are destroyed. It is the depletion of the body’s arsenal of CD4 cells that weakens host cellular immunity

2. Transmission is usually sexual or parenteral. Other than semen and blood, fluids that transmit the disease are breast milk and vaginal fluid
   a. Risk of transmission:
      • Needlestick injury—1 in 300
      • Vaginal (male to female)—1 in 1,000
      • Vaginal (female to male)—1 in 3,000
      • Anal receptive—1 in 100
      • Mother to child—1 in 3 without medications. With medications, risk is under 2 in 100
   b. Cesarean delivery is indicated if viral load is over 1,000 copies. If CD4 count is high (over 500) and viral load is low (under 1,000), C-section is not necessary

3. Mortality is usually secondary to opportunistic infection, wasting, or cancer

4. High-risk individuals: men who have sex with men, IV drug abusers, blood transfusion recipients before 1985 (before widespread screening of donor blood), heterosexual contacts of HIV-positive individuals, unborn and newborn babies of mothers who are HIV positive

CLINICAL PEARL 10-4

HIV Serology

CD4 Cell Count
It is the best indicator of the status of the immune system and the risk for opportunistic infections and disease progression.

- It is used to determine when to initiate antiretroviral therapy and PCP prophylaxis. It is also useful in assessing the response to antiretroviral therapy.
- If untreated (no retroviral therapy), the CD4 cell count decreases at an average rate of about 50 per year.
- If >500, the immune system is essentially normal. HIV-related infection or illness is unlikely.
- If 200 to 500, there is an increased risk of HIV-related problems, such as herpes zoster, TB, lymphoma, bacterial pneumonias, and Kaposi sarcoma. However, many patients are asymptomatic at these CD4 levels.
- Most opportunistic infections occur when the CD4 count falls below 200.

**Viral Load (HIV-1 RNA Levels)**

- Used to assess response to and adequacy of antiretroviral therapy; provides complementary prognostic information to the CD4+ count.
- If the viral load is still >50 after about 4 months of treatment, modification in the regimen may be needed.
- Do not stop antiretroviral therapy even if viral loads are undetectable for years. Latently infected cells can lead to reappearance of viral RNA once therapy is stopped.
- Measure the plasma HIV RNA levels and the CD4 cell count at the time of diagnosis and every 3 to 4 months thereafter.

---

**Quick HIT**

The course of HIV varies considerably from patient to patient. However, the typical course can be divided into the following four phases: primary infection, asymptomatic infection, symptomatic infection, and full-blown AIDS.

**Quick HIT**

The combination of ELISA and Western blot yields an overall sensitivity and specificity of >99%.

### B. Clinical Features

1. Primary infection (see also Clinical Pearl 10-4).
   - a. A mononucleosis-like syndrome about 2 to 4 weeks after exposure to HIV.
      Duration of the illness is brief (3 days to 2 weeks).
   - b. Symptoms include fever, sweats, malaise, lethargy, headaches, arthralgias/myalgias, diarrhea, sore throat, lymphadenopathy, and a truncal maculopapular rash.

2. Asymptomatic infection (seropositive, but no clinical evidence of HIV infection).
   - a. CD4 counts are normal (>500/mm³).
   - b. Longest phase (lasts 4 to 7 years, but varies widely, especially with treatment).

   - a. First evidence of immune system dysfunction.
   - b. Without treatment, this phase lasts about 1 to 3 years.
   - c. The following frequently appear:
      - Persistent generalized lymphadenopathy.
• Localized fungal infections (e.g., on fingernails, toes, mouth).
• Recalcitrant vaginal yeast and trichomonal infections in women.
• Oral hairy leukoplakia on the tongue.
• Skin manifestations that include seborrheic dermatitis, psoriasis exacerbations, molluscum, and warts.
• Constitutional symptoms (night sweats, weight loss, and diarrhea).

4. AIDS
a. Marked immune suppression leads to disseminated opportunistic infections and malignancies.
b. CD4 count is <200 cells/mm³.
c. Pulmonary, GI, neurologic, cutaneous, and systemic symptoms are common (see Table 10-4).

C. Diagnosis
1. PCR RNA viral load test—patients with acute HIV infection have very high levels of viremia. This test is repeated to assess effectiveness of therapy.
2. p24 antigen assay—less costly but less sensitive alternative to viral load testing.
3. Seroconversion occurs 3 to 7 weeks after infection and confirms the diagnosis.
   a. Enzyme-linked immunosorbent assay (ELISA) method.
      • Screening test for detecting antibody to HIV; becomes positive 1 to 12 weeks after infection.
      • A negative ELISA essentially excludes HIV (99% sensitive) if the patient has not had a subsequent exposure before testing (before seroconversion).
      • If positive, Western blot test should be performed for confirmation.
   b. Western blot test is a specific test used to confirm a positive result on an ELISA test.
4. Diagnosis of AIDS.
   a. CDC definition of AIDS: A patient with HIV has AIDS if he or she has (1) a CD4+ T-cell count below 200, (2) a CD4+ T cell percentage of total lymphocytes below 14%, or (3) an AIDS-defining illness. (See Table 10-5.)

<table>
<thead>
<tr>
<th>System</th>
<th>Condition</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary</td>
<td>Community-acquired bacterial pneumonia</td>
<td>Recurrent bacterial pneumonia (two or more episodes per year) is 20 times more common in HIV-1 patients with low CD4 cell counts (&lt;200/mm³) than in those with normal counts</td>
</tr>
<tr>
<td></td>
<td>PCP</td>
<td>• Seventy percent of patients acquire PCP at some point; often the initial opportunistic infection establishes the diagnosis of AIDS</td>
</tr>
</tbody>
</table>
**Leading cause of death in patients with AIDS**
- Occurs when CD4 count is <200
- Clinical findings: fever, nonproductive cough, shortness of breath (with exertion at first, then occurring at rest)
- CXR: diffuse interstitial infiltrates; negative radiographs in 10–15% of patients with PCP
- Treatment: TMP-SMX (PO or IV) for 3 wks; steroid therapy if patient is hypoxic or has elevated A–a gradient
- Prophylaxis: Oral TMP-SMX, 1 dose daily, is recommended

| Tuberculosis (other infections) | Negative PPD test results are frequent among AIDS patients due to immunosuppression
| CMV or MAC: **increased risk when the CD4 count <50**
| C. neoformans, Histoplasma capsulatum, neoplasms (Kaposi sarcoma) |

### Nervous system
- **HIV-associated dementia**
  - Progressive process in 33% of patients
  - Occurs primarily in untreated patients with advanced HIV
  - Characterized by deficits in memory, executive functioning, attention, and concentration; apathy; and psychomotor slowing

### Toxoplasmosis
- Usually a reactivation of latent infection of *Toxoplasma gondii*
- Symptoms both of a mass lesion (discrete deficits, headache) and of encephalitis (fever, altered mental status)
- CT scan or MRI shows characteristic findings: multiple (more than three) **contrast-enhanced mass lesions in the basal ganglia and subcortical white matter** though single lesions are possible

### Cryptococcal meningitis
- Diagnosed by identifying organisms in CSF by cryptococcal antigen, culture, or staining with India ink
- Treat with amphotericin B for 10–14 days. Follow this with 8–10 wks of oral fluconazole. Lifelong maintenance therapy with fluconazole is indicated

### Other CNS infections
- Bacterial meningitis, histoplasmosis, CMV, progressive multifocal leukoencephalopathy (PML), HSV, neurosyphilis, TB

### Noninfectious CNS diseases
- CNS lymphoma, CVA, metabolic encephalopathies

### Gastrointestinal
- **Diarrhea**
  - Most common GI complaint; caused by a variety of pathogens (*E. coli, Shigella, Salmonella, Campylobacter, CMV, Giardia, Cryptosporidium, Isospora belli, Mycobacterium avium-intracellulare*). Antibiotic therapy is also a common cause

### Oral lesions
- Oral thrush (candidiasis; scrapable), HSV or CMV (ulcers), oral hairy leukoplakia (EBV infection; nonscrapable), Kaposi sarcoma

### Esophageal involvement
- Candidiasis is most common cause of dysphagia; also CMV and HSV—**seen with CD4 counts <100**

### Anorectal disease
- Proctitis—*N. gonorrhoeae, C. trachomatis*, syphilis, HSV

### Dermatologic
- **Kaposi sarcoma**
  - More common in men who have sex with men than in other groups
  - Painless, raised brown-black or purple papules (common sites: face, chest, genitals, oral cavity)
  - Widespread dissemination can occur
<table>
<thead>
<tr>
<th>Infections</th>
<th>HSV infections, molluscum contagiosum, secondary syphilis, warts, shingles, and many other skin conditions/infections occur with higher frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscellaneous</td>
<td>CMV infection</td>
</tr>
<tr>
<td></td>
<td>• Common cause of serious opportunistic viral disease</td>
</tr>
<tr>
<td></td>
<td>• Disseminated disease is common and usually involves the GI or pulmonary systems</td>
</tr>
<tr>
<td></td>
<td>• Most important manifestation is retinitis—unilateral visual loss that can become bilateral if untreated (seen in 5–10% of AIDS patients)</td>
</tr>
<tr>
<td></td>
<td>• Colitis and esophagitis are other findings</td>
</tr>
<tr>
<td></td>
<td>• Treat with ganciclovir or foscarnet</td>
</tr>
<tr>
<td>Mycobacterium avium complex (MAC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Most common opportunistic bacterial infection in AIDS patients. Wasting syndrome (weight loss, fever), lymphadenopathy, anemia</td>
</tr>
<tr>
<td></td>
<td>• MAC causes disseminated disease in 50% of AIDS patients. MAC occurs in patients with advanced AIDS and fewer than 50 CD4 cells</td>
</tr>
<tr>
<td></td>
<td>• Diarrhea and weight loss are constitutional symptoms</td>
</tr>
<tr>
<td>HIV-1 wasting syndrome</td>
<td>Profound involuntary loss of more than 10% of body weight in conjunction with either of the following:</td>
</tr>
<tr>
<td></td>
<td>• Chronic diarrhea (two or more stools per day for more than 1 mo)</td>
</tr>
<tr>
<td></td>
<td>• Fever and persistent weakness for a similar period in the absence of another cause</td>
</tr>
<tr>
<td>Malignancies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Kaposi sarcoma</td>
</tr>
<tr>
<td></td>
<td>• Non-Hodgkin lymphoma—rapidly growing mass lesion in CNS</td>
</tr>
<tr>
<td></td>
<td>• Primary CNS lymphoma</td>
</tr>
</tbody>
</table>

**D. Treatment**

1. Antiretroviral therapy (Table 10-6)
   a. Indications
      • Symptomatic patients regardless of CD4 count
      • Asymptomatic patients with CD4 count <500
   b. Triple-drug regimens known as highly active antiretroviral therapy (HAART):
      To target and prevent HIV replication at three different points along the replication process, use two nucleoside reverse transcriptase inhibitors and either of the following:
      • A nonnucleoside reverse transcriptase inhibitor
      • A protease inhibitor
   c. Monitor the response to treatment using plasma HIV RNA load—the goal is to reduce the viral load to undetectable levels
   d. It is generally recommended that HAART therapy be continued in pregnant patients with HIV
• The importance of strict (i.e., 100%) adherence to the triple-drug regimen cannot be overemphasized, because even minor deviations may result in drug resistance. This has been improved in recent years by combining the medications into a single pill for patients.
• Do not initiate triple-drug therapy in a patient who is not willing or able to fully comply with the prescribed regimen.

2. Opportunistic infection prophylaxis
   a. Pneumocystic pneumonia (PCP), formerly *P. carinii*, now named *Pneumocystis jiroveci*
      • Occurs in patients with AIDS when CD4 cell count is <200 and patient is not on prophylaxis
      • Dyspnea, dry cough, fever
      • Tests: chest x-ray (bilateral interstitial infiltrates), LDL level (always elevated), ABG (hypoxia or increased A–a gradient), sputum stain for pneumocystis (very specific but not sensitive), bronchoscopy with BAL (most accurate test)
      • TMP/SMX is the preferred agent
   b. TB
      • Screen all patients with a yearly PPD test
      • Prescribe isoniazid plus pyridoxine if the patient has positive PPD
   c. Atypical mycobacteria—Mycobacterium avium complex (MAC)
      • Start prophylaxis when CD4 cell count is <100
      • Clarithromycin and azithromycin are prophylactic agents
   d. Toxoplasmosis
      • Start prophylaxis when CD4 count is <100
      • TMP/SMX is the preferred agent

3. Vaccination (*no live-virus vaccines!*)
   a. Pneumococcal polysaccharide vaccine (Pneumovax)—every 5 to 6 years
   b. Influenza vaccine—yearly
   c. Hepatitis B vaccine (if not already antibody-positive) (See Chapter 12.)

---

**TABLE 10-4 AIDS Indicator Diseases**

<table>
<thead>
<tr>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candidiasis, invasive</td>
</tr>
<tr>
<td>Cervical cancer, invasive</td>
</tr>
<tr>
<td>Coccidioidomycosis, extrapulmonary</td>
</tr>
<tr>
<td>Cryptococcosis, extrapulmonary</td>
</tr>
<tr>
<td>Cryptosporidiosis of &gt;1-mo duration</td>
</tr>
<tr>
<td>Cytomegalovirus disease outside lymphoreticular system</td>
</tr>
<tr>
<td>Encephalopathy, HIV-related</td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Herpes simplex infection of &gt;1-mo duration or visceral herpes simplex</td>
</tr>
<tr>
<td><em>Salmonella</em> bacteremia, recurrent</td>
</tr>
<tr>
<td>Histoplasmosis, extrapulmonary</td>
</tr>
<tr>
<td>Isosporiasis of &gt;1-mo duration</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
</tr>
<tr>
<td>Lymphoma: primary central nervous system, immunoblastic, or Burkitt</td>
</tr>
<tr>
<td>Mycobacterial disease, disseminated or extrapulmonary</td>
</tr>
<tr>
<td><em>M. tuberculosis</em> infection</td>
</tr>
<tr>
<td>PCP</td>
</tr>
<tr>
<td>Pneumonia, recurrent (more than one episode in 1 yr)</td>
</tr>
<tr>
<td>Progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>Toxoplasmosis, cerebral</td>
</tr>
<tr>
<td>Wasting syndrome due to HIV</td>
</tr>
</tbody>
</table>

Herpes Simplex

A. General Characteristics

1. There are two types of HSV: HSV-1 and HSV-2. Both are very prevalent in the general population (Figure 10-3).
   a. HSV-1 is typically associated with lesions of the oropharynx.
   b. HSV-2 is associated with lesions of the genitalia (see Table 10-7).
   c. Both viruses, however, can cause either genital or oral lesions.

<table>
<thead>
<tr>
<th>TABLE 10-5 Antiretroviral Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug</strong></td>
</tr>
<tr>
<td>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</td>
</tr>
<tr>
<td>Abacavir (ABC)</td>
</tr>
<tr>
<td>Didanosine (ddI)</td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
</tr>
<tr>
<td>Stavudine (d4T)</td>
</tr>
<tr>
<td>Tenofovir (TDF) (only nucleotide)</td>
</tr>
<tr>
<td>Tenofovir (TDF) (only nucleotide)</td>
</tr>
<tr>
<td>Zalcitabine (ddC)</td>
</tr>
<tr>
<td>Zidovudine (ZDV, formerly AZT)</td>
</tr>
<tr>
<td>Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)</td>
</tr>
<tr>
<td>Efavirenz (contraindicated in pregnancy)</td>
</tr>
<tr>
<td>Nevirapine (contraindicated in pregnancy)</td>
</tr>
<tr>
<td>Delavirdine (contraindicated in pregnancy)</td>
</tr>
<tr>
<td>Protease Inhibitors</td>
</tr>
<tr>
<td>Atazanavir</td>
</tr>
<tr>
<td>Darunavir</td>
</tr>
<tr>
<td>Fosamprenavir</td>
</tr>
<tr>
<td>Indinavir (crystal-induced nephropathy)</td>
</tr>
<tr>
<td><strong>Ritonavir</strong></td>
</tr>
<tr>
<td><strong>Saquinavir</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Integrase Inhibitors</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Raltegravir</td>
<td>Inhibit integration into host cell.</td>
</tr>
<tr>
<td>Elvitegravir</td>
<td></td>
</tr>
<tr>
<td>Dolutegravir</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Fusion Inhibitors</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Enfuvirtide</td>
<td>Binds gp41, inhibits entry. Binds CCR-5, inhibits interaction with gp120.</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>Eosinophilia causing skin reaction at injection site.</td>
</tr>
</tbody>
</table>

2. Pathophysiology: After inoculation, the HSV replicates in the dermis and epidermis, then travels via sensory nerves up to the dorsal root ganglia. It resides as a latent infection in the dorsal root ganglia, where it can be reactivated at any time and reach the skin through peripheral nerves.

3. Transmission
   a. HSV is transmitted by contact with people who have active ulcerations or shedding of virus from mucous membranes. HSV-1 is typically associated with transmission through nonsexual personal contact (e.g., kissing), and HSV-2 through sexual contact.
   b. Most people acquire HSV-1 in childhood, and more than 80% of adults have been infected with HSV-1.
   c. The incidence of HSV-2 has increased in recent years.
   d. Episodes of genital herpes frequently may be asymptomatic or may produce symptoms that often go unrecognized. Virus is still shed, and the infected person is contagious.
   e. Contracting one form of herpes confers some degree of cross-immunity, rendering primary infection with the other form of herpes less severe.
   f. Infection with genital herpes is associated with an increased risk of contracting HIV.
**FIGURE 10.3** Herpes simplex virus.
(From Goodheart HP. *Goodheart’s Photoguide of Common Skin Disorders*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003, Figure 19.13).

**TABLE 10-6** Clinical Manifestations of Genital Ulcers With Regional Lymphadenopathy
B. Clinical Features

1. HSV-1
   a. Primary infection is usually asymptomatic and often goes unnoticed.
   b. When symptomatic, primary infection is associated with systemic manifestations (e.g., fevers, malaise) as well as oral lesions (described below).
   c. Oral lesions involve groups of vesicles on patches of erythematous skin. Herpes labialis (cold sores) are most common on the lips (usually painful, heal in 2 to 6 weeks).
   d. HSV-1 is also associated with Bell palsy.

2. HSV-2
   a. Primary infection results in more severe and prolonged symptoms, lasting up to
3 weeks in duration.

b. Recurrent episodes are milder and of shorter duration, usually resolving within 10 days. There is also a decrease in the frequency of episodes over time.

c. Constitutional symptoms (e.g., fever, headache, malaise) often present in primary infection.

d. HSV-2 presents with painful genital vesicles or pustules (see Figure 10-3). Other findings are tender inguinal lymphadenopathy and vaginal and/or urethral discharge.

3. Disseminated HSV

   a. Usually limited to immunocompromised patients.
   b. May result in encephalitis, meningitis, keratitis, chorioretinitis, pneumonitis, and esophagitis.
   c. Rarely, pregnant women may develop disseminated HSV, which can be fatal to the mother and fetus.

4. Neonatal HSV (vertical transmission at time of delivery) is associated with congenital malformations, intrauterine growth retardation (IUGR), chorioamnionitis, and even neonatal death.

5. Ocular disease—either form of herpes simplex can cause keratitis, blepharitis, and keratoconjunctivitis.

C. Diagnosis

1. The diagnosis can be made clinically when characteristic lesions are recognized.
2. If there is uncertainty, perform the following tests to confirm the diagnosis.
   a. Tzanck smear—quickest test.
      - Perform by swabbing the base of the ulcer and staining with Wright stain.
      - This shows multinucleated giant cells. It does not differentiate between HSV and VZV.
   b. **Culture of HSV is the gold standard of diagnosis.**
      - Perform by swabbing the base of the ulcer.
      - Results are available within 2 to 3 days.
   c. Direct fluorescent assay and ELISA.
- 80% sensitive.
- Results available within minutes to hours.

D. Treatment
1. There is no cure available for either type of herpes simplex. Antiviral treatment provides symptomatic relief and reduces the duration of symptoms (see below).
2. Mucocutaneous disease
   a. Treat with oral and/or topical acyclovir for 7 to 10 days.
   b. Valacyclovir and famciclovir have better oral bioavailability.
   c. Oral acyclovir may be given as prophylaxis for patients with frequent recurrences.
   d. Foscarnet may be given for resistant disease in immunocompromised patients.
Syphilis

A. General Characteristics

1. It is caused by *Treponema pallidum* spirochetes and transmitted by **direct sexual contact** with infectious lesions.
2. It is a systemic illness with four stages (see below). The late stages can be prevented by early treatment.

Quick HIT

Primary syphilis is characterized by a hard chancre (indurated, painless ulcer with clean base).

B. Clinical Features

1. Primary stage
   a. **Chancre**—a **painless**, crater-like lesion that appears on the genitalia 3 to 4 weeks after exposure (Figure 10-4)
   b. Heals in 14 weeks, even without therapy
   c. Highly infectious—anyone who touches the lesion can transmit the infection

2. Secondary stage
   a. This may develop 4 to 8 weeks after the chancre has healed. **A maculopapular rash is the most characteristic finding in this stage**
   b. Other possible manifestations: flu-like illness, aseptic meningitis, hepatitis
   c. Patients are contagious during this stage
   d. About one-third of untreated patients with secondary syphilis develop latent syphilis

Quick HIT

Most common presentations for syphilis include:
- Genital lesion (chancre)
- Inguinal lymphadenopathy
- Maculopapular rash of secondary syphilis
3. Latent stage
   a. Latent stage is defined as the presence of positive serologic test results in the absence of clinical signs or symptoms. Two-thirds of these patients remain asymptomatic; one-third develop tertiary syphilis
   b. It is called early latent syphilis if serology has been positive for <1 year. During this time, the patient may relapse back to the secondary phase.
   c. It is called late latent syphilis if serology has been positive for >1 year. Patients are not contagious during this time and do not have any symptoms of the disease.

4. Tertiary stage
   a. One-third of untreated syphilis patients in the latent phase enter this stage
   b. It occurs years after the development of the primary infection (up to 40 years later)
   c. Major manifestations include cardiovascular syphilis, neurosyphilis, and gummas (subcutaneous granulomas)
   d. Neurosyphilis is characterized by dementia, personality changes, and tabes dorsalis (posterior column degeneration)
   e. It is very rare nowadays due to treatment with penicillin

C. Diagnosis
1. Dark-field microscopy (definitive diagnostic test)—examines a sample of the chancre with visualization of spirochetes. May be required in patients presenting with chancre because serology might not be positive yet.
2. Serologic tests (most commonly used tests).
   a. Nontreponemal tests—RPR, VDRL (most commonly used).
      • High sensitivity—ideal for screening.
      • Specificity is only around 70%. If positive, confirmation is necessary with the specific treponemal tests.
   b. Treponemal tests—FTA-ABS, MHA-TP.
      • More specific than nontreponemal tests
      • Not for screening, just for confirmation of a positive nontreponemal test.
3. All patients should be tested for HIV infection.

**Quick HIT**

Diagnosis of syphilis: first obtain VDRL and RPR. If positive, confirm with FTA-ABS.

**Quick HIT**

RPR or VDRL may be falsely positive in patients with SLE.

**D. Treatment**

1. Antibiotics are effective in early syphilis but less so in late syphilis.
2. Benzathine penicillin g (one dose IM) is the preferred agent. If the patient is allergic to penicillin, give oral antibiotics (doxycycline, tetracycline) for 2 weeks.
3. If the patient has late latent syphilis or tertiary syphilis, give penicillin in three doses IM once per week.
4. Repeat nontreponemal tests every 3 months to ensure adequate response to treatment. Titers should decrease fourfold within 6 months. If they do not, that may signal treatment failure or reinfection.
Chancroid

Caused by *Haemophilus ducreyi*, a gram-negative rod.
Transmission through sexual contact.
Incubation period of 2 to 10 days
There are no systemic findings. Disseminated infection does not occur.
Clinical features: **painful genital ulcer(s)** that can be deep with ragged borders and with a purulent base (Figure 10-5); unilateral tender inguinal lymphadenopathy (“buboes”) that appears 1 to 2 weeks after ulcer.
Diagnosis is made clinically. Rule out syphilis and HSV and consider testing for HIV. No serologic tests are available, and culture of the organism is not practical because it requires special media that are not widely available.
Treatment options include azithromycin (oral, one dose), ceftriaxone (IM, one dose), or an oral course of azithromycin, erythromycin, or ciprofloxacin.
With treatment, most ulcers resolve in 1 or 2 weeks.

---

**Quick HIT**

**Diagnosis of Chancroid**
- Painful genital ulcer(s)
- Tender lymphadenopathy
- Syphilis ruled out (negative dark-field examination and negative serologic tests)
- HSV ruled out based on clinical presentation or negative culture for HSV
Lymphogranuloma Venereum

A sexually transmitted disease caused by *C. trachomatis*. Clinical features—painless ulcer at the site of inoculation that may go unnoticed. A few weeks later, tender inguinal lymphadenopathy (usually unilateral) and constitutional symptoms develop. If untreated, proctocolitis may develop with perianal fissures and rectal stricture; obstruction of lymphatics may lead to elephantiasis of genitals. Diagnosis is made by serologic tests (complement fixation, immunofluorescence). The treatment is doxycycline (oral for 21 days).
Pediculosis Pubis (Pubic Lice)

Pediculosis pubis (pubic lice or “crabs”) is a common STD caused by Phthirus pubis (the pubic or crab louse).

It can be transmitted through sexual contact or fomites (clothing, bedding, towels). Severe pruritus in the genital region is characteristic. Other hairy areas of the body can be involved.

Diagnosis is made by examination of hair under microscope (or possibly with the naked eye)—identification of adult lice or nits.

Treat with permethrin 1% shampoo (Elimite)—apply to all hairy regions from neck down and wash off after several hours. Sexual partner(s) should also be treated. Combs, clothes, and bed linens should be washed thoroughly.

FIGURE 10.5 Chancroid.

(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003, Figure 19.14).

Quick HIT

There are three forms of pediculosis: pediculosis capitis (head lice), pediculosis corpora (body lice), and pediculosis pubis (pubic lice or “crabs”).
Wound and Soft Tissue Infections

Cellulitis

A. General Characteristics
1. Cellulitis is an inflammatory condition of skin and subcutaneous tissue.
2. It is caused by a wide variety of bacteria, the most common being group A streptococci or S. aureus.
3. Likely bacterial pathogens are based on patient histories. Bacteria gain entry through breaks in the skin: IV catheters, incisions, immersion in water, and bites or wounds. Venous stasis diseases, lymphedema, and diabetic ulcers also are associated with cellulitis (see Table 10-8).
4. If untreated, cellulitis may lead to potentially life-threatening bacteremia.

Quick HIT
Patients with cellulitis are predisposed to recurrences in the same area because of damage that occurs to the local lymphatic vessels.

B. Clinical Features
1. Classic findings of inflammation: erythema, warmth, pain, swelling
2. Fever (may or may not be present)

Quick HIT
Spread to the face is a worrisome complication of cellulitis, and any evidence of orbital involvement is a medical emergency requiring urgent evaluation by an ophthalmologist.

C. Diagnosis
1. The diagnosis is essentially clinical.
2. Obtain blood cultures if the patient has a fever.
3. Obtain tissue cultures if there is a wound, ulcer, or site of infection.
4. Obtain imaging (plain film, MRI) if there is suspicion of deeper infection.

D. Treatment
1. Base treatment on suspected pathogens from the patient history. Most patients require parenteral antibiotic therapy.
2. Treatment should cover group A streptococci and MSSA (e.g., oxacillin, cefazolin). If suspected, MRSA should also be covered (e.g., vancomycin).
3. Continue IV antibiotics until signs of infection improve. Follow up with oral antibiotics for 2 weeks.
**Erysipelas**

Erysipelas is a cellulitis that is usually confined to the dermis and lymphatics (see also Clinical Pearl 10-5).

It is usually caused by group A streptococci (other forms of streptococci less commonly).

The classic presentation is a well-demarcated, fiery red, painful lesion, most commonly on the lower extremities and the face. High fever and chills may be present.

Predisposing factors include lymphatic obstruction (e.g., after radical mastectomy), local trauma or abscess, fungal infections, diabetes mellitus, and alcoholism.

Complications include sepsis, local spread to subcutaneous tissues, and necrotizing fasciitis.

Treatment for uncomplicated cases is oral penicillin or amoxicillin; otherwise treat as for cellulitis. Has a high rate of recurrence.

<table>
<thead>
<tr>
<th>TABLE 10-7</th>
<th>Common Pathogens in Cellulitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Means of Bacterial Invasion</strong></td>
<td><strong>Likely Pathogen</strong></td>
</tr>
<tr>
<td>Local trauma, breaks in skin</td>
<td>Group A Streptococcus (<em>S. pyogenes</em>)</td>
</tr>
<tr>
<td>Wounds, abscesses</td>
<td><em>S. aureus</em></td>
</tr>
<tr>
<td>Immersion in water</td>
<td><em>P. aeruginosa, Aeromonas hydrophila, Vibrio vulnificus</em></td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td><em>H. influenzae</em></td>
</tr>
</tbody>
</table>

**CLINICAL PEARL 10-5**

**Differentiating Deep Vein Thrombosis (DVT) From Cellulitis**

- Like cellulitis, acute DVT also presents with erythema, warmth, and tenderness in the affected extremity.
- Inflammation in DVT is usually restricted to the posterior calf.
- Because Homans sign and the palpation of venous cords are not sensitive in detecting DVT, venous Doppler must sometimes be performed to differentiate between cellulitis and acute DVT.
**Necrotizing Fasciitis**

Necrotizing fasciitis is a life-threatening infection of deep soft tissues that rapidly tracks along fascial planes. Common bacterial causes include *Streptococcus pyogenes* and *Clostridium perfringens*. Risk factors include recent surgery, diabetes, trauma, and IV drug use. Clinical features may include fever and pain out of proportion to appearance of skin in early stages, so a high index of suspicion is important. Extension of infection leads to thrombosis of microcirculation, resulting in tissue necrosis, discoloration, crepitus, and cutaneous anesthesia. It may rapidly progress to sepsis, toxic shock syndrome (TSS), and multiorgan failure. Antibacterial treatment alone is not sufficient. **Rapid surgical exploration and debridement is an absolute necessity!** Broad-spectrum parenteral antimicrobial therapy is warranted.
Lymphadenitis

This is inflammation of a lymph node (single or multiple) usually caused by local skin or soft tissue bacterial infection (often hemolytic streptococci and staphylococci). It presents with fever, tender lymphadenopathy of regional lymph nodes, and red streaking of skin from the wound or area of cellulitis. Complications include thrombosis of adjacent veins, sepsis, and even death if untreated. Helpful diagnostic studies include blood and wound cultures. It usually responds well to treatment. Treat with appropriate antibiotics (penicillin G, antistaphylococcal penicillin, or cephalosporin) and warm compresses. Wound drainage may ultimately be necessary.
Tetanus

A. General Characteristics
1. Causes
   a. It is caused by neurotoxins produced by spores of Clostridium tetani, a gram-positive anaerobic bacillus.
   b. C. tetani proliferates and produces its exotoxin in contaminated wounds. The exotoxin blocks inhibitory transmitters at the neuromuscular junction.
2. Patients at risk are those who have incomplete or no tetanus immunization (see Chapter 12).

Quick HIT
The following types of wounds are most likely to result in tetanus:
- Wounds contaminated with dirt, feces, or saliva
- Wounds with necrotic tissue
- Deep puncture wounds

B. Clinical Features
1. The classic and earliest symptom is hypertonicity and contractions of the masseter muscles, resulting in trismus, or “lockjaw.”
2. Progresses to severe, generalized muscle contractions including:
   a. Risus sardonicus—grin due to contraction of facial muscles.
   b. Opisthotonos—arched back due to contraction of back muscles.

Quick HIT
The incubation period for tetanus ranges from about 2 days to 2 weeks. The onset of symptoms is characteristically gradual (1 to 7 days).

TABLE 10-8  Guide to Tetanus Immunization in Wound Management
### C. Diagnosis

1. The diagnosis is mainly clinical.
2. Obtain wound cultures, but they are not a reliable means of diagnosis.

### D. Treatment

1. Admit the patient to the ICU and provide respiratory support if necessary (see also Table 10-9). Give diazepam for tetany.
2. Neutralize unbound toxin with passive immunization—give a single IM dose of tetanus immune globulin (TIG).
3. Provide active immunization with tetanus/diphtheria toxoid (Td).
4. Thoroughly clean and debride any wounds with tissue necrosis.
5. Give antibiotics (metronidazole or penicillin G), although efficacy is somewhat controversial.

<table>
<thead>
<tr>
<th>History of Immunization (Td Doses)</th>
<th>Clean, Minor Wounds</th>
<th>Other Wounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3 known Td doses</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>&lt;3 doses, unknown status, or &gt;10 yrs since last booster</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Td, tetanus/diphtheria toxoid; TIG, tetanus immune globulin.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Infections of the Bones and Joints

Osteomyelitis

A. General Characteristics
1. Osteomyelitis refers to inflammatory destruction of bone due to infection.
2. There are two main categories of osteomyelitis.
   a. Hematogenous osteomyelitis (most common in children)—occurs secondary to sepsis.
   b. Direct spread of bacteria from any of the following:
      • An adjacent infection (e.g., infected diabetic foot ulcer, decubitus ulcer).
      • Trauma (e.g., open fractures).
      • Vascular insufficiency (e.g., peripheral vascular disease).
3. The most common microorganisms causing osteomyelitis are S. aureus and coagulase-negative staphylococci.
4. Osteomyelitis can involve any bone. Common locations include long bones (tibia, humerus, femur), foot and ankle, and vertebral bodies.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common Bugs in Osteomyelitis</strong></td>
</tr>
<tr>
<td>Catheter septicemia: S. aureus</td>
</tr>
<tr>
<td>Prosthetic joint: coagulase-negative staphylococci</td>
</tr>
<tr>
<td>Diabetic foot ulcer: polymicrobial organisms</td>
</tr>
<tr>
<td>Nosocomial infections: Pseudomonas spp.</td>
</tr>
<tr>
<td>IV drug abuse, neutropenia: fungal species, Pseudomonas spp.</td>
</tr>
<tr>
<td>Sickle cell disease: Salmonella spp.</td>
</tr>
</tbody>
</table>

B. Risk Factors (for complications or chronic osteomyelitis)
1. Open fractures
2. Diabetes mellitus (causes predisposition to infection and peripheral vascular disease)
3. Use of illicit IV drugs
4. Sepsis

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 10% of patients with open fractures eventually develop osteomyelitis. Use of orthopedic hardware increases this risk (foreign body is the site of bacterial colonization).</td>
</tr>
</tbody>
</table>
C. Clinical Features
1. Pain over the involved area of bone is the most common finding.
2. Localized erythema, warmth, or swelling may be present.
3. Systemic symptoms (e.g., fever, headache, fatigue) may be present, but are inconsistent findings.
4. A draining sinus tract through the skin may form in chronic disease.

D. Diagnosis
1. WBC count—may or may not be elevated and is not useful for diagnosis
2. ESR and CRP
   a. These are fairly nonspecific, but if these markers of inflammation are elevated in the appropriate clinical setting, seriously consider a diagnosis of osteomyelitis. However, a normal ESR and CRP do not exclude the diagnosis
   b. Both ESR and CRP are very useful in monitoring the response to therapy

Quick HIT
Osteomyelitis of the vertebral body due to M. tuberculosis is called Pott disease.

3. Needle aspiration of infected bone or bone biopsy (obtained in operating room) —most direct and accurate means of diagnosis. Culture results can determine the specific antibiotic therapy
4. Plain radiography
   a. The earliest radiographic changes (periosteal thickening or elevation) are not evident for at least 10 days
   b. Lytic lesions are only apparent in advanced disease
5. Radionucleotide bone scans—usually positive within 2 to 3 days of infection, but are relatively nonspecific (can be positive in metastatic bone disease, trauma, or overlying soft tissue inflammation)
6. MRI is generally the most effective imaging study for diagnosing osteomyelitis and assessing the extent of disease process

E. Treatment
Give IV antibiotics for extended periods (4 to 6 weeks). Initiate antibiotic therapy only after the microbial etiology is narrowed based on data from cultures, or if the patient is hemodynamically unstable. General guidelines:
1. Empiric therapy requires antibiotics with high bone penetration including cephalosporins (cefazolin, ceftriaxone, cefuroxime), fluoroquinolones (levofloxacin, ciprofloxacin, moxifloxacin), vancomycin, linezolid, daptomycin, and clindamycin. Rifampin can also be added as adjunct to help with biofilm
penetration.
2. Add an aminoglycoside and possibly a β-lactam antibiotic if there is a possibility of infection with a gram-negative organism.
3. Surgical debridement of infected necrotic bone is an important aspect of treatment.

Quick HIT

Chronic osteomyelitis refers to bone necrosis and soft tissue compromise or to a relapse of previously treated osteomyelitis. It is very challenging to treat and almost impossible to completely eradicate.
Acute Infectious Arthritis

A. General Characteristics

1. Acute infectious arthritis occurs when microorganisms (usually bacteria) invade the joint space (not the bone itself), where they release endotoxins and trigger cytokine release and neutrophil infiltration. These inflammatory reactions ultimately lead to erosion and destruction of the joint.

2. Pathogenesis—microorganisms penetrate the joint via the following mechanisms:
   a. Hematogenous spread—most common route.
   b. Contiguous spread from another locus of infection (e.g., osteomyelitis, abscess, or cellulitis).
   c. Traumatic injury to joint.
   d. Iatrogenic (e.g., from arthrocentesis, arthroscopy).

Quick HIT

If patient has a painless range of motion of involved joint, septic arthritis is very unlikely, even in the presence of erythema. Micromotion of joint causes severe pain in septic arthritis.

3. Microbiology
   a. The most common offender is bacteria.
   b. Acute bacterial arthritis can be caused by any of the following:
      • S. aureus is the most common agent overall in adults and children. Various streptococcal species are also frequently involved.
      • An important gram-negative agent is N. gonorrhoeae. Gonococcal arthritis is the most common cause of acute infectious arthritis in young, sexually active adults (see also Clinical Pearl 10-6).
      • Consider gram-negative organisms such as Pseudomonas aeruginosa or Salmonella spp. if there is a history of sickle cell disease, immunodeficiency, or IV drug abuse.

4. Other risk factors for acute infectious arthritis.
   a. Prior joint damage (e.g., rheumatoid arthritis).
   b. Joint prosthesis
   c. Diabetes mellitus

CLINICAL PEARL 10-6

Gonococcal Arthritis

• This presents with acute monoarthritis or oligoarthritis, and often progresses within days in a migratory or
additive pattern.
- Knees, wrists, hands, and ankles are the most commonly involved.
- Tenosynovitis is often present in the hands and feet.
- Fever, chills, and rash (macules, papules, and/or pustules) are signs of disseminated gonococcal infection. If
  the patient has disseminated gonococcal infection, admit to the hospital.
- After the joint is initially aspirated, repeated aspiration is unnecessary (unlike in other causes of septic
  arthritis), and antibiotics alone usually lead to improvement. Treat presumptively for chlamydial infection
  (e.g., with doxycycline).
- Consider testing for HIV and syphilis. Educate the patient about the risks of sexual practices.

Quick HIT

Septic Arthritis
- The most common joint affected is the knee. The hip, wrist, shoulder, and ankle may also be involved.
- Patients with immunosuppression or connective tissue diseases may have polyarticular arthritis (and a worse
  prognosis).

B. Clinical Features
1. The joint is swollen, warm, and painful.
   a. The range of motion (active or passive) is very limited.
   b. An effusion can be palpated.
2. Constitutional symptoms such as fever, chills, and malaise are common.

C. Diagnosis
1. Perform a joint aspiration (“tap”) and analysis of synovial fluid in all patients
   suspected of having a septic joint. Order the following studies on aspirated
   synovial fluid.
   a. WBC count with differential—usually >50,000 WBCs/mm$^3$ with >80% PMNs
      —the most helpful test.
   b. Gram stain of fluid—positive in approximately 75% of gram-positive cases, but
      only 30% to 50% of gram-negative cases.
   c. Culture—aerobic and anaerobic.
   d. Crystal analysis—keep in mind that acute gout may present like septic arthritis.
   e. PCR of synovial fluid—this may be useful if gonococcal arthritis is suspected
      but Gram stain and cultures are negative.
2. Blood cultures are positive in >50% of all cases (frequently negative in
   gonococcal arthritis).
3. Other laboratory abnormalities.
   a. Leukocytosis—present in about half of patients with a septic joint.
   b. Elevated ESR—elevated in up to 90% of patients with septic joint.
   c. Elevated CRP—useful in monitoring clinical improvement.
4. Imaging studies.
a. Plain radiographs—generally not useful unless joint damage is severe.
b. CT or MRI—helpful if the sacroiliac or facet joints are involved.

5. Obtain cultures from appropriate mucosal surfaces (e.g., genitourinary tract) if gonococcal arthritis is suspected.

D. Treatment

   a. Do not delay in initiating antimicrobial therapy when acute infectious arthritis is suspected.
   b. If the Gram stain result is negative but acute bacterial arthritis is still suspected, treat empirically based on the clinical scenario (see Table 10-10) until culture and sensitivity results are available.

2. Drainage
   a. Daily aspiration of affected joint as long as effusion persists is one treatment option. However, surgical drainage is recommended to prevent further damage to the articular cartilage that occurs with persistent infectious process. Certain joints are amenable to arthroscopic drainage (shoulder, knee) whereas others are not (hip, wrist, elbow, ankle) and should be opened.

<table>
<thead>
<tr>
<th>TABLE 10-9 Medical Treatment of Acute Bacterial Arthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult (Relatively Healthy): Treat for <em>S. aureus</em></td>
</tr>
<tr>
<td>Parenteral, β-lactamase-resistant penicillin (e.g., oxacillin) or first-generation cephalosporin × 4 wks</td>
</tr>
<tr>
<td>Treat with vancomycin if MRSA is suspected</td>
</tr>
<tr>
<td>Patient is Immunocompromised or has Significant Risk Factors for Gram-negative Arthritis</td>
</tr>
<tr>
<td>Parenteral, broad-spectrum antibiotics (with gram-negative coverage) (e.g., a third-generation cephalosporin or aminoglycoside) for 3–4 wks</td>
</tr>
<tr>
<td>For pseudomonal infection, use aminoglycoside + extended-spectrum penicillin</td>
</tr>
<tr>
<td>Young Adult With History and Presentation Consistent with Gonococcal Arthritis</td>
</tr>
<tr>
<td>Parenteral, third-generation cephalosporin (e.g., ceftriaxone) until there is improvement</td>
</tr>
</tbody>
</table>

Quick HIT

**Complications of Septic Arthritis**
- Destruction of joint and surrounding structures (e.g., ligaments, tendons), leading to stiffness, pain, and loss of function
- Avascular necrosis (if hip is involved)
- Sepsis
Zoonoses and Arthropod-Borne Diseases

**Lyme Disease**

**A. General Characteristics**

1. Three major endemic areas in the United States
   a. Northeastern seaboard (from Maine to Maryland)
   b. Midwest (north central states—e.g., Minnesota, Wisconsin)
   c. West coast (Northern California)

2. Incubation period is 3 to 32 days
3. Transmission cycle
   a. Caused by spirochete *Borrelia burgdorferi*
   b. Transmitted by ticks—commonly the deer tick *Ixodidae scapularis*
   c. The tick is hosted by white-footed mice (immature ticks), white-tailed deer (mature ticks), and brief and unfortunate encounters with humans

**Quick HIT**

Lyme disease is the most common vector-borne illness in the United States. The peak incidence is in summer months. It is associated with outdoor activities in wooded areas (e.g., hiking, camping).

- Patients with tick bites should be followed up closely for the appearance of erythema migrans, but the majority of tick bites do not result in infection.
- A vaccine against *B. burgdorferi* has been developed but was taken off the market due to lack of use in the medical community.

**B. Clinical Features**

1. Stage 1—early, localized infection.
   a. **Erythema migrans** is the hallmark skin lesion at site of the tick bite. Characteristically it is a large, painless, well-demarcated target-shaped lesion, commonly seen on the thigh, groin, or axilla (Figure 10-6).
   b. Multiple lesions signify that hematogenous spread has occurred (see below).
2. Stage 2—early, disseminated infection.
   a. Infection spreads via lymphatics and the bloodstream within days to weeks after the onset of erythema migrans.
   b. Clinical features: intermittent flu-like symptoms, headaches, neck stiffness,
fever/chills, fatigue, malaise, musculoskeletal pain.

3. After several weeks, about 15% of patients develop one or several of the following (usually resolve within several months):
   - Meningitis (Brudzinski and Kernig signs negative).
   - Encephalitis.
   - Cranial neuritis (often bilateral facial nerve palsy).
   - Peripheral radiculoneuropathy (motor or sensory).

4. Within weeks to months of onset of symptoms, about 8% will have cardiac manifestations (e.g., AV block, pericarditis, carditis). These usually only last for several weeks, but recurrence is not uncommon.

3. Stage 3—late, persistent infection (months to years after initial infection).
   a. Arthritis—This occurs in 60% of untreated patients; it typically affects the large joints (especially knees). Chronic arthritis will develop in some patients.
   b. Chronic CNS disease—subacute, mild encephalitis, transverse myelitis, or axonal polyneuropathy.
   c. Acrodermatitis chronica atrophicans (a rare skin lesion)—reddish-purple plaques and nodules on the extensor surfaces of the legs.

![Erythema migrans (Lyme disease).](From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003, Figure 7.19).

C. Diagnosis
   1. Clinical diagnosis—In early, localized disease, documented erythema migrans in a
patient with a history of tick exposure in an endemic area obviates the need for laboratory confirmation. Treat empirically.

2. **Serologic studies—most important tests to confirm a clinical suspicion of Lyme disease (see also Clinical Pearl 10-7)**

   a. ELISA is used to detect serum IgM and IgG antibodies during the first month of illness.
   
   b. Western blot is used to confirm positive or equivocal results.

**D. Treatment**

1. Early localized disease.
   
   a. If it is confined to the skin, 10 days of antibiotic therapy is adequate.
   
   b. If there is any evidence of spread beyond the skin, extend treatment to 20 to 30 days.
   
   c. For early Lyme disease.
      
      - Oral doxycycline (for 21 days)—contraindicated in pregnant women and in children <8 years of age.
      - Amoxicillin and cefuroxime are alternative agents.
      - Erythromycin may be given to pregnant patients with penicillin allergies.

2. Treatment of complications such as facial nerve palsy, arthritis, or cardiac disease is prolonged antibiotic therapy (30 to 60 days). For meningitis or other CNS complications, treat with IV antibiotics for 4 weeks.

**Quick HIT**

Early treatment with antibiotics is extremely important because later sequelae of disease can usually be prevented. Treatment in later stages is usually effective, but recovery may be delayed.

**CLINICAL PEARL 10-7**

**Lyme Serology**

- IgM antibodies peak 3 to 6 weeks after the onset of symptoms. If a few months have passed since the onset of disease, IgM levels are basically worthless.
- IgG antibodies slowly increase and remain elevated in patients with disseminated illness. If a patient has had Lyme disease in the past and now has symptoms consistent with new illness, IgG levels will not indicate whether the infection is acute or chronic.
- Patients with a history of distant Lyme disease may have elevated IgG levels despite adequate antibiotic treatment.
- IgG antibodies cross-react with *T. pallidum*, but patients with Lyme disease will not have a positive VDRL.
Rocky Mountain Spotted Fever

A. General Characteristics
1. Caused by the intracellular bacteria *Rickettsia rickettsii*.
2. Ticks feeding on various mammals serve as vectors for disease transmission.
3. The major endemic areas include the southeastern, midwestern, and western United States. Peak incidence is in the spring and summer months due to increased outdoor activity.
4. Pathophysiology of disease.
   a. Organisms enter the host cells via tick bites, multiply in the vascular endothelium, and spread to different layers of the vasculature.
   b. Damage to the vascular endothelium results in increased vascular permeability, activation of complement, microhemorrhages, and microinfarcts.

B. Clinical Features
1. The onset of symptoms is typically 1 week after the tick bite.
2. It classically presents with a sudden onset of fever, chills, malaise, nausea, vomiting, myalgias, photophobia, and headache.
3. Papular rash usually appears after 4 to 5 days of fever. Rash starts peripherally (wrists, forearms, palms, ankles, and soles) but then spreads centrally (to the rest of the limbs, trunk, and face). It becomes maculopapular, and eventually petechial.
4. It may lead to interstitial pneumonitis.

C. Diagnosis
1. Diagnosis is primarily clinical. Laboratory abnormalities may include elevated liver enzymes and thrombocytopenia.
2. Acute and convalescent serology and immunofluorescent staining of skin biopsy are confirmatory tests.

D. Treatment
1. Doxycycline—usually given for 7 days; given intravenously if the patient is vomiting.
2. CNS manifestations or pregnant patients—give chloramphenicol.
**Malaria**

A. General Characteristics
1. A protozoal infection caused by one of four organisms
   a. *Plasmodium falciparum*
   b. *Plasmodium ovale*
   c. *Plasmodium vivax*
   d. *Plasmodium malariae*
2. Prevalent in tropical climates, parts of Africa and the Middle East
3. Transmitted via mosquito bite in endemic areas

B. Clinical Features
1. Symptoms may include fever and chills, myalgias, headache, nausea, vomiting, and diarrhea.
2. Fever pattern varies depending on cause
   a. *P. falciparum*—fever is usually constant
   b. *P. ovale* and *P. vivax*—fever usually spikes every 48 hours
   c. *P. malariae*—fever usually spikes every 72 hours

**Quick HIT**
The onset of illness in malaria usually occurs weeks to months after infection, but it is dependent on the specific cause.

C. Diagnosis
1. Identify organism on peripheral blood smear
2. Blood smear must have **Giemsa stain**

**Quick HIT**
*P. falciparum* infection is by far the most serious and life-threatening cause of malaria.

D. Treatment
1. Use chloroquine phosphate unless resistance is suspected. In many countries, chloroquine resistance is so prevalent that it should be assumed.
2. If chloroquine resistance is suspected, give quinine sulfate and tetracycline. Alternative agents are atovaquone–proguanil and mefloquine.
3. *P. falciparum* infection may require IV quinidine and doxycycline.
4. Relapses can occur in *P. vivax* and *P. ovale* infection as a result of dormant hypnozoites in the liver. Add a 2-week regimen of primaquine phosphate for these
types of malarial infection.
5. Prophylaxis is important for travelers to endemic regions. Mefloquine is the agent of choice in chloroquine-resistant areas. Chloroquine can be used in areas where chloroquine resistance has not been reported.

Quick HIT

Side effects of medications can be a factor in choosing appropriate malaria prophylaxis:
- Atovaquone–proguanil is contraindicated in patients with renal disease and pregnancy.
- Mefloquine is contraindicated in patients with seizures and psychiatric conditions.
- Chloroquine is well tolerated and can be used in pregnancy.

Primaquine is contraindicated in patients with G6PD deficiency due to precipitation of hemolytic anemia.
Rabies

A. General Characteristics
1. A devastating, deadly viral encephalitis
2. Contracted from a bite or scratch by an infected animal (dog, bat, raccoon, fox, coyote); infection from a corneal transplant has been documented as well
3. More prevalent in developing countries where rabies vaccination of animals is not widespread

B. Clinical Features
1. The incubation period typically ranges from 30 to 90 days, but varies considerably.
2. Once symptoms are present, rabies is almost invariably fatal.
   a. Pain at site of bite.
   b. Prodromal symptoms of sore throat, fatigue, headache, nausea, and/or vomiting.
   c. Encephalitis—confusion, combativeness, hyperactivity, fever, and seizures may be present.
   d. Hydrophobia—inability to drink due to laryngeal spasm, hypersalivation (“foaming at mouth”), usually progresses to coma and death.
   e. Some patients may present with ascending paralysis.

C. Diagnosis
1. Virus or viral antigen can be identified in infected tissue. Virus can be isolated in saliva as well.
2. Fourfold increase in serum antibody titers.
3. Histologic identification of Negri bodies (eosinophilic intracytoplasmic inclusion bodies).
4. PCR detection of virus RNA.

Quick HIT

Pre-exposure prophylaxis—Rabies vaccine is available for at-risk individuals (e.g., those with potential occupational exposure, such as veterinarians, wildlife officials, and laboratory workers).

D. Treatment (Postexposure Management)
1. Clean the wound thoroughly with soap.
2. For wild animal bites (e.g., bat or raccoon), the animal should be captured if possible, destroyed, and sent to a laboratory for immunofluorescence of brain tissue.
3. If a patient was bitten by a healthy dog or cat in an endemic area, the animal should be captured and observed for 10 days. If there is no change in the animal’s condition, then it most likely does not have rabies.
4. For known rabies exposure, both of the following should be performed.
   a. Passive immunization—administer the human rabies immunoglobulin to patients, into the wound as well in the gluteal region.
   b. Active immunization—administer the antirabies vaccine in three IM doses into the deltoid or thigh over a 28-day period.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Organism</th>
<th>Transmission</th>
<th>Reservoir</th>
<th>Clinical Findings</th>
<th>Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptospirosis</td>
<td><em>Leptospira</em> spp. (spirochetes)</td>
<td>Contaminated water</td>
<td>Rodents, farm animals</td>
<td>Anicteric: rash, LAN, ↑ LFTs</td>
<td>Isolation of organism in blood or urine CTX¹ Icteretic: renal and/or liver failure, vasculitis, vascular collapse</td>
<td>Oral antibiotics: doxycycline; if severe, IV penicillin G</td>
</tr>
<tr>
<td>Ehrlichiosis</td>
<td><em>Ehrlichia</em> spp. (intracellular, gram-negative bacteria)</td>
<td>Tick bite</td>
<td>Deer</td>
<td>Fever, chills, malaise ± rash</td>
<td>Clinical; confirm by serology</td>
<td>Oral doxycycline × 1 week</td>
</tr>
<tr>
<td>Tularemia</td>
<td><em>Francisella tularensis</em> (small gram-negative bacillus)</td>
<td>Tick bite, animal bites, handling carcass</td>
<td>Rabbits, other rodents</td>
<td>Fever, headache, nausea; ulcer at site of tick bite; painful LAN</td>
<td>Isolation of organism in blood or wound CTX</td>
<td>IM streptomycin or gentamicin</td>
</tr>
<tr>
<td>Q fever</td>
<td>C. burnetii (gram-negative organism)</td>
<td>Blood, ingestion of infected milk, inhalation</td>
<td>Farm animals</td>
<td>Acute: constitutional symptoms, nausea, vomiting Chronic: endocarditis</td>
<td>Serology; CXR—multiple opacities in acute illness</td>
<td>Acute: doxycycline or fluoroquinolone Chronic: rifampin</td>
</tr>
<tr>
<td>Cat scratch disease</td>
<td><em>Bartonella henselae</em> (gram-negative bacillus)</td>
<td>Scratch from a flea-infested cat</td>
<td>Cats, fleas</td>
<td>LAN or lymphadenitis; systemic symptoms rare</td>
<td>Serology, clinical</td>
<td>Usually self-limited; if severe, oral doxycycline or ciprofloxacin</td>
</tr>
</tbody>
</table>

¹LAN, lymphadenopathy; CTX, culture.
Other Zoonoses

Table 10-11 covers leptospirosis, ehrlichiosis, tularemia, Q fever, and cat scratch fever.
Common Fungal Infections

Candidiasis

A. General Characteristics
1. *Candida* species are oval, budding yeasts known for their formation of hyphae and long pseudohyphae. They normally colonize humans, and it is the overgrowth of these organisms that results in the clinical pathology of candidiasis
2. *Candida albicans* is the most common cause of candidiasis
3. Risk factors for candidiasis
   a. Antibiotic therapy
   b. Diabetes mellitus
   c. Immunocompromised hosts (increased risk for both mucocutaneous and systemic candidiasis)

B. Clinical Features
1. Typical presentation is the mucocutaneous growth. The most common affected areas are:
   a. Vagina—“yeast infection”
      • This results in a thick, white, “cottage cheese-like” vaginal discharge
      • The discharge characteristically is painless but does cause pruritus
   b. Mouth, oropharynx—“thrush”
      • This causes thick, white, scrapable plaques that adhere to the oral mucosa
      • Usually painless
      • Unexplained oral thrush should raise suspicion of HIV infection
   c. Cutaneous candidiasis
      • This causes erythematous, eroded patches with “satellite lesions” (*Figure 10-7*)
      • It is more common in obese diabetic patients; it appears in skin folds (e.g., axilla, groin, underneath breasts) and in macerated skin areas
   d. GI tract (e.g., esophagus)
      • Candida esophagitis may cause significant odynophagia
      • It may also be asymptomatic
2. Disseminated or invasive disease may occur in immunocompromised hosts. Manifestations include sepsis/septic shock, meningitis, and multiple abscesses in various organs.
C. Diagnosis
1. Mucocutaneous candidiasis diagnosis is primarily clinical; KOH preparation demonstrates yeast.
2. Invasive candidiasis is diagnosed by blood or tissue culture.

D. Treatment
1. Remove indwelling catheters or central lines.
2. Acceptable treatments for oropharyngeal candidiasis.
   a. Clotrimazole troches (dissolve in the mouth) five times per day.
   b. Nystatin mouthwash (“swish and swallow”) three to five times per day; only for oral candidiasis.
   c. Oral ketoconazole or fluconazole for esophagitis.
3. Vaginal candidiasis—miconazole or clotrimazole cream.
4. Cutaneous candidiasis—oral nystatin powder, keeping skin dry.
5. For systemic candidiasis, use amphotericin B or fluconazole. New, alternative antifungal agents include voriconazole and caspofungin.
Aspergillus

A. General Characteristics
1. *Aspergillus* spp. spores are found everywhere in the environment. Typically, disease occurs when spores are inhaled into the lung.
2. There are three main types of clinical syndromes associated with *Aspergillus* (see clinical features below).
3. Invasive aspergillosis is usually limited to severely immunocompromised patients. It should be considered in any immunocompromised patient with fever and respiratory distress despite use of broad-spectrum antibiotics.

B. Clinical Features
1. Allergic bronchopulmonary aspergillosis.
   a. A type I hypersensitivity reaction to *Aspergillus*.
   b. It presents with asthma and eosinophilia. Recurrent exacerbations are common.
2. Pulmonary aspergilloma.
   a. Pulmonary aspergilloma is caused by inhalation of spores into the lung. Patients with a history of sarcoidosis, histoplasmosis, TB, and bronchiectasis are at risk.
   b. It presents with chronic cough; hemoptysis may be present as well.
   c. It may resolve spontaneously or invade locally.
3. Invasive aspergillosis.
   a. This occurs when hyphae invade the lung vasculature, resulting in thrombosis and infarction.
   b. Hosts are typically at-risk patients with acute leukemia, transplant recipients, and patients with advanced AIDS.
   c. It usually presents with acute onset of fever, cough, respiratory distress, and diffuse, bilateral pulmonary infiltrates.
   d. It is transmitted via hematogenous dissemination, and may invade the sinuses, orbits, and brain.

C. Diagnosis
1. CXR reveals a dense pulmonary consolidation and sometimes a fungus ball.
2. Definitive diagnosis of invasive aspergillosis is by tissue biopsy, but diagnosis is presumed when *Aspergillus* is isolated from the sputum of a severely immunocompromised/neutropenic patient with clinical symptoms.
3. Blood cultures are usually not helpful because they are rarely positive.

D. Treatment
1. For allergic bronchopulmonary aspergillosis, patients should avoid exposure to *Aspergillus*; corticosteroids may be beneficial.
2. For pulmonary aspergilloma, patients with massive hemoptysis may require a lung lobectomy.
3. For invasive aspergillosis, treat with IV amphotericin B, voriconazole, or caspofungin.
4. Suspicion of head or brain involvement warrants prompt evaluation (imaging studies). Surgery may be required.
Cryptococcosis

A. General Characteristics
1. Caused by *Cryptococcus neoformans*, a budding, round yeast with a thick polysaccharide capsule
2. Associated with pigeon droppings
3. Most commonly seen in patients with advanced AIDS
4. Infection is due to inhalation of fungus into lungs. Hematogenous spread may involve the brain and meninges

B. Clinical Features
1. CNS disease—meningitis or meningoencephalitis; brain abscess is also possible
   a. CNS disease is a life-threatening condition that requires aggressive treatment (see below). It should always be on the differential diagnosis of an HIV-positive patient with a fever and headache. If untreated, it is almost invariably fatal.
   b. Symptoms include fever, headache, irritability, dizziness, confusion, and possibly seizures. The onset may be insidious.
2. Isolated pulmonary infection may also occur.

C. Diagnosis
1. LP is absolutely essential if meningitis is suspected.
   a. Latex agglutination or ELISA can detect cryptococcal antigen in the CSF.
   b. India ink smear shows encapsulated yeasts.
   c. Culture yields cryptococcal colonies in 3 to 7 days.
2. Tissue biopsy is characterized by lack of inflammatory response.
3. The organism may also be present in urine and blood.

D. Treatment
1. Use amphotericin B with flucytosine for approximately 2 weeks, followed by oral fluconazole.
2. The duration of therapy varies depending on follow-up CSF cultures.
Other Fungal Infections

Table 10-12 covers blastomycosis, histoplasmosis, coccidioidomycosis, and sporotrichosis.
Common Parasitic Infections

Table 10-13 covers cryptosporidiosis, amebiasis, giardiasis, ascariasis, hookworm, pinworm (enterobiasis), tapeworm, and schistosomiasis.
Fever and Sepsis

Fever of Unknown Origin

A. General Characteristics

1. Defining fever of unknown origin (FUO)
   a. Classically defined as having the following necessary criteria:
      • Fever >38.3°C (101°F)
      • Continuing “on several occasions” for at least 3 weeks
      • No diagnosis over this time period despite 1 week of inpatient workup
   b. Because of changes in medical practice, this definition has been altered: Three outpatient visits now substitute for 1 week in the hospital

2. Causes
   a. Infection—most common cause
      • TB and other mycobacterial infection
      • Occult abscesses (e.g., hepatic, retroperitoneal)
      • UTI/complicated UTI
      • Endocarditis
      • Sinusitis
      • HIV
      • Infectious mononucleosis and other viruses
      • Malaria and other parasitic infections
   b. Occult neoplasms are the second most common cause, particularly:
      • Lymphoma (especially Hodgkin lymphoma)
• Leukemia
c. Collagen vascular disease
  • SLE
  • Still disease
  • Polyarteritis nodosa (PAN)
  • Temporal arteritis
  • Polymyalgia rheumatica
d. Other causes (in no particular order)
  • Granulomatous disease (e.g., sarcoidosis, Crohn disease)
  • Drug fevers (e.g., sulfonamides, penicillin, quinidine, barbiturates, “diet pills” [with phenolphthalein])
  • Pulmonary embolism
  • Hemolytic anemia
  • Familial Mediterranean fever
  • Gout
  • Subacute thyroiditis
  • Factitious illnesses

B. Clinical Features
1. Manifestations that may accompany fever but are not specific to any specific entity
   a. Chills—ironic sensation of cold, often with shivering
   b. Rigors—severe form of chills with pronounced shivering and chattering of teeth
   c. Night sweats
   d. Change in mental status—especially at extremes of age
2. Look for systemic manifestations of some of the more common causes of FUO (e.g., skin changes, constitutional symptoms, anemia, weight loss).

Quick HIT
FUO is obviously a term of exclusion, and is not itself a diagnosis. In patients with persistent unexplained fevers, continue diagnostic testing until the cause is found.

C. Diagnosis
1. Careful history and physical examination—with attention to medications, travel, immune system competency, and review of systems
2. Laboratory tests
   a. CBC with differential
   b. Urinalysis
   c. Cultures of blood, sputum, CSF, urine, and stool when indicated by clinical
d. Analysis and culture of abnormal fluid collections (e.g., joint, pleural)
e. Complement assay
f. PPD when TB is on the differential
g. Other laboratory values: LFTs, ESR, ANA, rheumatoid factor, TSH

3. Imaging studies
   a. CXR, CT scan of the chest and abdomen—to detect tumors and abscesses
   b. Tagged WBC scan—sometimes helpful
c. MRI, ultrasound, and echocardiogram may be appropriate, depending on the clinical situation

4. Invasive diagnostic procedures—biopsy of lymph node, bone marrow, or other tissue when there is a high suspicion of tumor or abscess

5. Observation is sometimes necessary to make a diagnosis

D. Treatment

1. Antibiotics and corticosteroids may mask the patterns of fever response (see also Clinical Pearl 10-8). Base empiric treatment with antibiotics on the severity of illness.

2. If the patient is not acutely ill, observation alone may be all that is necessary to arrive at a specific diagnosis.

3. In some cases of FUO, fevers may resolve spontaneously without ever being diagnosed.

4. The sense of urgency in determining the cause of the fevers should be in proportion to the severity of illness and the host’s immune status.

---

**CLINICAL PEARL 10-8**

**Approach to Fever**

- There is no uniformly accepted definition, but most sources define fever as body temperature >37.5°C (99.5°F) measured by a modern oral thermometer.
- Measurement—Readings obtained using rectal thermometers are slightly higher than oral or axillary thermometer readings.
- Hyperthermia versus fever.
  - Hyperthermia is an elevation in body temperature not caused by “raising the thermostat” (i.e., no change in the hypothalamic set-point).
  - Hyperthermia is usually caused by the inability of the body to dissipate heat.
  - Causes of hyperthermia include neuroleptic malignant syndrome, malignant hyperthermia, and heat stroke.
  - Hyperthermia does not respond to antipyretics, but rather to external cooling measures (e.g., ice, fans) and medications specific to the cause (e.g., dantrolene for malignant hyperthermia).
- Fever occurs when there is an elevation in the hypothalamic set-point. It is a natural response to an inflammatory process.
- Fever usually responds to antipyretics.
Treat a fever with antipyretics when:
- The fever is really hyperthermia.
- The fever is dangerously high: >41°C (>105°F).
- The patient is pregnant.
- There is significant cardiopulmonary disease (increased oxygen demand may cause ischemia).
- The patient wants symptomatic relief (chills, myalgias).
Toxic Shock Syndrome

A. General Characteristics
1. TSS is most commonly associated with menstruating women and tampon use, but can occur in patients of all ages, male and female.
2. Other risk factors include surgical wounds, burns, nasal packing, and infected insect bites.
3. It is caused by an enterotoxin of *S. aureus*, or less frequently an exotoxin of group A Streptococcus. Note that it is the toxin rather than the bacteria that causes the pathology associated with TSS.

B. Clinical Features
1. The onset of symptoms is characteristically abrupt
2. Symptoms may include:
   a. Flu-like symptoms: high fevers, headache, myalgias
   b. Diffuse macular, erythematous rash
   c. Hyperemic mucous membranes, “strawberry tongue”
   d. Warm skin due to peripheral vasodilation (see Chapter 1, Shock)
   e. Hypotension
   f. Nausea, vomiting, and diarrhea may also be present
3. By definition, there must be involvement of at least three organ systems, which may include:
   a. GI—nausea, vomiting, and diarrhea; elevations of aminotransferases
   b. Renal—elevations of BUN and/or creatinine, pyuria
   c. Hematologic—thrombocytopenia
   d. Musculoskeletal—elevations of creatine kinase levels
   e. CNS—confusion, disorientation (must be present when fever is absent)
4. Multisystem organ dysfunction or failure may occur
5. During the convalescent phase of illness, the rash usually desquamates over the palms and soles

Quick HIT

- The mortality rate for menstrual-related TSS is now <2% but is slightly higher (8%) for non-menstrual-related TSS.
- Previous TSS does not confer immunity. In fact, patients with a history of TSS are at greater risk for recurrent TSS.

C. Diagnosis
1. A high index of clinical suspicion is important.
2. Blood cultures are often negative.
3. Cultures may be taken from the suspected source, but the diagnosis is primarily clinical.

D. Treatment
1. Hemodynamic stabilization should be the first concern and may require aggressive fluids and even vasopressors. Patient is often treated in a burn intensive care unit.
2. The source of toxin (e.g., tampon) should be removed immediately. Wounds may require drainage or debridement.
3. Give antistaphylococcal therapy, such as nafcillin, oxacillin, or vancomycin, in a very ill patient. Clindamycin is sometimes used as adjunctive therapy.
Catheter-Related Sepsis

Central venous catheters are a common cause of fever and sepsis in the hospital, especially in the ICU.

The most common organisms are *S. aureus* and *Staphylococcus epidermidis*. Risk factors for catheter-related sepsis are emergent placement, femoral lines, and prolonged indwelling of the line.

Only half of all patients with catheter-related sepsis have clinical evidence of infection at the site of insertion (i.e., erythema, purulence). Therefore, a high index of suspicion is required.

If you suspect catheter-related sepsis, promptly remove the catheter and send the tip for culture. This alone typically leads to resolution of fever and a decrease in leukocytosis. Antibiotics are usually initiated. Narrow the spectrum once the organism is identified.

**Quick HIT**

Catheter-related sepsis almost always involves central IV catheters. Peripheral venous catheters and arterial catheters are rarely involved.

**Quick HIT**

- Neutropenia is defined by absolute neutrophil count (ANC) <1,500/mm³ (ANC: combination of bands and mature neutrophils).
- ANC <500/mm³ corresponds to a severely increased risk of infection.
Neutropenic Fever

Common causes include bone marrow failure (e.g., due to toxins, drugs), bone marrow invasion (e.g., from hematologic malignancy, metastatic cancer), and peripheral causes (e.g., hypersplenism, SLE, AIDS). Isolated neutropenia (agranulocytosis) is commonly caused by drug reactions. Because neutropenia severely compromises the patient’s ability to mount an inflammatory response, fever may be the only manifestation of a raging infection. The most common infections seen in neutropenic individuals are transient bacteremia due to gut translocation of bacteria, cellulitis, and pneumonia. Obtain the following for any neutropenic patient with a fever: CXR, pan culture (blood, urine, sputum, line tips, wound), CBC, complete metabolic panel. Place the patient on reverse isolation precautions (positive-pressure room, masks, and strict handwashing for those entering the patient’s room). Give broad-spectrum antibacterial agents immediately after cultures are drawn. If fever persists beyond 4 to 5 days despite broad-spectrum antibacterial therapy, give antifungal agents, such as IV amphotericin B. Consider G-CSF.
Miscellaneous Infections

Infectious Mononucleosis

A. General Characteristics

1. Caused by EBV (rarely by CMV which causes a similar clinical picture but is milder) (see also Table 10-13).
2. It is most commonly seen in adolescents and young adults, especially college students and military recruits (but may occur at any age). Infected children often experience milder symptoms or no symptoms.
3. Differential diagnosis in patients with fever, lymphadenopathy, and pharyngitis includes acute HIV infection, streptococcal infection, CMV, or toxoplasma infection.
   a. In pregnant patients, it is important to perform diagnostic tests as HIV, CMV, and toxoplasma infection can have adverse effects on the fetus.
4. Transmission
   a. The usual mode of transmission is through infected saliva (e.g., kissing, sharing food).
   b. Most adults (90%) have been infected with EBV and are carriers but infectious mononucleosis is uncommon in adults.
   c. One infection usually confers lifelong immunity.
   d. The incubation period is typically 2 to 5 weeks.

<table>
<thead>
<tr>
<th>TABLE 10-13</th>
<th>Common Organisms in Various Infections</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pneumonia</strong></td>
<td>Community-acquired</td>
</tr>
<tr>
<td>Typical</td>
<td>S. pneumoniae, H. influenzae, Moraxella catarrhalis, Mycoplasma spp.,</td>
</tr>
<tr>
<td>Atypical</td>
<td>Chlamydia spp., Legionella spp.</td>
</tr>
<tr>
<td>Nosocomial</td>
<td>S. aureus, gram-negative rods</td>
</tr>
<tr>
<td>Aspiration pneumonia</td>
<td>Oral anaerobes, gram-negative rods, S. aureus</td>
</tr>
<tr>
<td><strong>Urinary Tract Infection</strong></td>
<td>E. coli, S. saprophyticus, Enterococcus, Klebsiella, Proteus spp., Pseudomonas, Enterobacter, yeast (Candida spp.)</td>
</tr>
<tr>
<td><strong>Osteomyelitis, Septic Arthritis</strong></td>
<td>S. aureus, S. epidermidis, Streptococcus spp., gram-negative rods</td>
</tr>
<tr>
<td>Consider N. gonorrhoeae in septic arthritis in adolescents</td>
<td></td>
</tr>
<tr>
<td><strong>Skin/soft Tissue</strong></td>
<td>Surgical wound</td>
</tr>
<tr>
<td></td>
<td>S. aureus, gram-negative rods</td>
</tr>
<tr>
<td>Diabetic ulcer</td>
<td>S. aureus, gram-negative rods, anaerobes</td>
</tr>
</tbody>
</table>
Intravenous catheter site

Cellulitis

Necrotizing fasciitis

Upper Respiratory

Pharyngitis

Acute bronchitis

Acute sinusitis

Chronic sinusitis

Endocarditis

Subacute

Acute

Gastroenteritis

Intra-abdominal

Meningitis

B. Clinical Features

1. Symptoms
   a. Fever—temperatures may be as high as 40°C (104°F); fever usually resolves within 2 weeks
   b. Sore throat
   c. Malaise, myalgias, weakness—may linger for several months

2. Signs
   a. Lymphadenopathy—this is found in >90% of patients. Tonsillar or cervical (especially posterior cervical) lymph nodes may be quite enlarged, painful, and tender
   b. Pharyngeal erythema and/or exudate—frequently present
   c. Splenomegaly—present in half of patients
   d. Maculopapular rash—present in approximately 15% of patients, but much higher if ampicillin is given
   e. Hepatomegaly—in 10% of cases
   f. Palatal petechiae and eyelid (periorbital) edema—may occur in a minority of cases

Quick HIT

Infectious mononucleosis includes fever, fatigue, tonsillar pharyngitis, and lymphadenopathy.
C. Diagnosis

1. Serology
   a. Monospot test—for detection of heterophile antibody
      - Heterophile antibodies are positive within 4 weeks of infection with EBV mononucleosis and are undetectable by 6 months. Thus, a positive monospot test indicates acute infection with EBV mononucleosis
      - Heterophile antibodies do not form in CMV mononucleosis
      - Rapid heterophile tests are highly sensitive and specific, particularly in adolescents
   b. EBV-specific antibody testing—perform in cases in which diagnosis is not straightforward (usually done by indirect immunofluorescence microscopy or by ELISA)

2. Peripheral blood smear—usually reveals lymphocytic leukocytosis with large, atypical lymphocytes

3. Throat culture—perform if pharyngitis is present to rule out a secondary infection with β-hemolytic streptococci

D. Complications

1. Hepatitis
2. Neurologic complications (rare): meningoencephalitis, Guillain–Barré syndrome, Bell palsy
3. Splenic rupture—rare
4. Thrombocytopenia, hemolytic anemia
5. Upper airway obstruction due to lymphadenopathy—rare
E. Treatment

1. Generally, no specific treatment is indicated (or available) as most people recover completely within 3 to 4 months. Supportive care includes:
   a. Rest, fluids
   b. Avoidance of strenuous activities and contact sports until splenomegaly resolves to prevent splenic rupture. This precaution applies to all patients, even those without splenomegaly on physical examination (low sensitivity for detecting splenomegaly)
   c. Analgesics to reduce temperature and pharyngeal pain—NSAIDs or acetaminophen

2. Give a short course of steroids if there is airway compromise. Steroids have also been effective in patients with thrombocytopenia or hemolytic anemia. Steroids are not recommended for routine IM without complications

3. When to return to sports—concern is splenic rupture. Patients should wait 3 to 4 weeks from symptom onset before returning to sports as splenic rupture is very rare after 4 weeks
Diseases of the Skin and Hypersensitivity Disorders

Emily Liang

KEY DEFINITIONS

Note: exact size definitions vary, but below are common definitions used

**Dermatosis:** any cutaneous lesion/group of lesions; nonspecific term used to include any type of skin disease

**Dermatitis:** inflammation of the skin

**Macule:** circumscribed *flat* alterations in skin color ≤1 cm

**Patch:** a macule >1 cm

**Papule:** solid, *elevated* lesion with **no visible fluid** ≤0.5 cm

**Nodule:** a single lesion (papule) >0.5 cm

**Plaque:** discrete elevated lesions >0.5 cm, often formed by a confluence of papules

**Vesicle:** *fluid-filled* (serous fluid) lesions that are elevated and ≤0.5 cm

**Pustule:** *fluid-filled* (cloudy/purulent material of necrotic inflammatory cells)

**Bullae:** vesicle >0.5 cm

**Wheal:** rounded/flat-topped edematous elevation in the skin; often erythematous

**Telangiectasia:** visible, dilated blood vessel in the superficial skin that blanches

**Petechiae:** small (1 to 2 mm), nonblanching erythematous macules that result from microhemorrhages

**Ecchymosis:** nonblanching and nonpalpable red/purple discoloration of the skin that results from extravasation of blood into the skin

**Palpable purpura:** palpable, nonblanching red/purple discoloration of the skin that results from extravasation of blood into the skin with an inflammatory etiology (i.e., vasculitis)

COMMON SKIN DISORDERS
Acneiform Eruptions

Acne Vulgaris

A. General Characteristics
1. Acne vulgaris is an inflammatory condition of the skin that is most prevalent during adolescence.
2. Pathogenesis is multifactorial:
   a. Follicular hyperkeratinization.
   b. Increased sebum production.
   c. Obstruction of sebaceous follicles (by sebum) leads to the proliferation of *Cutibacterium acnes* (an anaerobic bacterium, formerly known as *Propionibacterium acnes*) in the sebum.
   d. Inflammation as a result of *C. acnes* proliferation.
3. Risk factors are male sex, puberty, Cushing syndrome, oily complexion, androgens (due to any cause), and medications.
4. Classification:
   a. Obstructive acne: closed comedones (whiteheads) or open comedones (blackheads).
   b. Inflammatory acne: Lesions progress from papules/pustules to nodules, then to cysts, then scars.

Quick HIT
- There is no proven link between acne and diet (e.g., chocolate, fatty foods).
- Oral contraceptives (especially some of the newer oral contraceptive pills) help some women with acne.

B. Treatment
1. General guidelines:
   a. Instruct patient to keep affected area clean (vigorous washing is unnecessary); reduce or discontinue acne-promoting agents (certain make-up, creams, oils, steroids, androgens).
   b. It takes about 6 weeks to notice the effects of medications (skin may get worse before it gets better). Start with one drug to assess its efficacy.
2. Mild to moderate acne:
   a. Begin with topical benzoyl peroxide (2.5%)—should be applied once or twice daily. It destroys acne-causing bacteria and prevents plugging of pores by drying the skin.
b. Add topical retinoids if the above fails. They cause peeling of the skin, which prevents clogging of pores.
c. Add topical erythromycin or topical clindamycin—both act to suppress *C. acnes*.

3. Moderate to severe nodular pustular acne:
   a. Add on systemic antibiotic therapy: tetracycline, minocycline, doxycycline, erythromycin, clindamycin, azithromycin, and TMP-SMX.
   b. Add oral retinoids (e.g., isotretinoin) for severe, recalcitrant, nodular acne that is not responsive to the above treatments. Oral retinoids are extremely teratogenic. All female patients must have two negative pregnancy tests before starting oral isotretinoin. In addition, they should use two forms of birth control for 1 month before starting the medication through 1 month after stopping the medication.

Quick HIT

Do not give systemic antibiotics unless the patient is already on topical benzoyl peroxide, topical tretinoin, and topical antibiotics and the response is inadequate.
Rosacea
A chronic condition resulting in reddening of the face (mainly the forehead, nose, and cheeks). It often appears very similar to acne, but unlike acne it first starts in middle age.
Mostly affects Caucasian women between 30 and 50 years of age.
The most common skin findings include erythema, telangiectasia, papules, and pustules with redness, typically affecting the face. Unlike acne vulgaris, there are no comedones (Figure 11-1).
In severe cases, skin can become thickened and greasy—on the nose, it creates a bulbous appearance called rhinophyma (mostly seen in men).
Treatment of erythema and flushing: avoid alcohol, hot beverages, extremes of temperature, and emotional stressors. If inadequate, topical brimonidine can be used.
Treatment of papules and pustules: start with topical metronidazole gel; alternatives are azelaic acid and topical ivermectin. If inadequate, may add systemic antibiotics (e.g., tetracycline), and then oral isotretinoin as a last option.

FIGURE 11.1 Rosacea.
(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 1.14.)
Hidradenitis Suppurativa

Inflammatory skin condition affecting intertriginous areas (axilla is the most common site), causing nodules, abscesses, and draining sinus tracts that can result in scarring.

More common in women, and typical onset in second or third decade of life. Strong relationship with smoking.

Pathogenesis includes follicular occlusion and subsequent rupture, leading to acute inflammation.

Treatment is based on severity of disease. For mild disease, topical clindamycin may be used. For moderate disease, oral antibiotics, oral retinoids, or hormonal therapy may be used; if these are inadequate, adalimumab may be used. For severe extensive disease, surgical excision is often required.
Atopic and Contact Dermatitis

Atopic Dermatitis (Eczema)

The terms “dermatitis” and “eczema” are often used interchangeably. There are several common dermatoses (atopic dermatitis, contact dermatitis, stasis dermatitis, etc.) that involve dry, inflamed, and pruritic lesions. The term eczema most commonly refers to atopic dermatitis.

Eczema is more frequent in children but also occurs in adults and commonly involves flexor surfaces (e.g., antecubital and popliteal fossae, wrists). It is commonly associated with a personal or family history of atopy (seasonal allergies, asthma).

Management involves first eliminating triggers (allergens, frequent bathing without moisturizing, heat, low humidity) and adjuncts such as antihistamines for pruritus. Topical steroids should be used for affected areas, with the potency of steroids chosen based on severity. Topical calcineurin inhibitors (i.e., tacrolimus) can be used if there is an inadequate response to high potency steroids.
Contact Dermatitis

A. General Characteristics
1. There are two forms of contact dermatitis: irritant and allergic.
2. Irritant contact dermatitis is more common and results from a chemical or physical insult to the skin (e.g., contact with detergents, acids, or alkalis, or from frequent hand washing).
   a. A previous sensitizing event is not needed to produce the rash (i.e., it is not an immunologic reaction).
   b. The rash begins shortly after exposure to the irritant (in contrast to the allergic type, which begins several hours to a few days later).
3. Allergic contact dermatitis is a delayed-type hypersensitivity (type IV) reaction.
   a. No history of atopy is necessary for allergic contact dermatitis to occur. It can occur in anyone.
   b. Sensitization of the skin occurs 1 to 2 weeks after the first exposure to the allergen. Subsequent exposure leads to dermatitis hours to days after the reexposure. Therefore, dermatitis develops only in patients who have already been sensitized to the allergen. Common allergens include poison ivy, oak, and sumac; iodine; nickel; rubber; topical medications (e.g., neomycin, topical anesthetics); and cosmetics.

B. Clinical Features
1. The appearance of the rash depends on the stage.
   a. Acute stage: erythematous papules and vesicles with oozing (Figure 11-2); edema may be present.
   b. Chronic stage: crusting, thickening, and scaling; lichenification.
2. The rash is usually very pruritic and is found only in exposed areas.
3. The interval between exposure and appearance of the rash varies, but is usually from several hours to as long as 4 to 5 days.
Contact dermatitis.

(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 2.41.)

C. Diagnosis
1. Diagnosis is usually made clinically based on history and examination.
2. Patch testing (to identify the allergen that caused the allergic reaction) is indicated if the diagnosis is in doubt, the rash does not respond to treatment, or the rash recurs.

Quick HIT

Do not confuse allergic contact dermatitis with any of the following:
- Irritant contact dermatitis—rash is usually identical to that seen in allergic contact dermatitis, except the rash begins very soon after exposure
- Atopic dermatitis—onset is in infancy or childhood
- Seborrheic dermatitis
- Psoriasis

D. Treatment
1. Avoid the contact allergen!
2. Apply cool tap water compresses.
3. Apply topical corticosteroids.
4. Prescribe systemic corticosteroids (e.g., prednisone, 1 mg/kg/day) for severe cases. Continue for 10 to 14 days and then taper.
Psoriasis

A. General Characteristics
1. Psoriasis is due to abnormal (markedly accelerated) proliferation of skin cells. Because of this, the skin does not have time to mature normally. This leads to defective keratinization, which causes the scaling.
2. The cause is unknown, but genetics are believed to be important.
3. This is a chronic condition characterized by exacerbations and remissions—it improves during the summer (sun exposure) and worsens in the winter (dries skin).
4. Trauma to the skin (e.g., infection, abrasion) can cause local flares at the site of injury, which is termed the Koebner phenomenon.
5. Up to three-fourths of patients have somewhat localized disease (<20% to 25% of body surface area [BSA]).
6. Less than 10% of patients develop psoriatic arthritis (see Chapter 6).

Quick HIT
There is no cure for psoriasis, but the disease can be managed.

B. Clinical Features
1. The most common clinical subtype is chronic plaque psoriasis; other variations include pustular psoriasis, guttate psoriasis, nail psoriasis, and others.
2. Lesions are well-demarcated, erythematous papules or plaques that are covered by thick, silvery scaling; pruritus is rarely present (Figure 11-3).
3. Auspitz sign—removal of the scale causes pinpoint bleeding.
4. It can involve any part of the body, but the most common areas are the extensor surfaces of extremities (knees, elbows), scalp, intergluteal cleft, palms, and soles.
5. Pitting of the surface of nails, or onycholysis (distal separation of the nail from the nail bed).

C. Treatment
1. Topical therapy
   a. Corticosteroids and emollients are the most commonly prescribed first-line agents.
b. Calcipotriene and calcitriol are vitamin D derivatives that have become first- or second-line agents. They are very effective in most patients.
c. Tars have an unpleasant odor, so they are less desirable to use. Patients should use tars for 4 to 6 weeks before expecting to see a benefit. Tars are more effective in combination therapy and are associated with an 80% to 90% remission rate.
d. Other options include tazarotene (a vitamin A derivative), anthralin, and topical calcineurin inhibitors.
e. Combination therapy (e.g., steroids and calcipotriene) is more effective than either agent alone.
f. Phototherapy (with ultraviolet light) should be used for moderate–severe psoriasis if feasible.

2. Systemic treatment is indicated in patients with severe psoriasis. Options include immune-modulating therapy (e.g., methotrexate, infliximab, cyclosporine), oral retinoids (e.g., acitretin), and combinations of these agents with phototherapy.
Oral steroids should be avoided in psoriasis, since discontinuation can cause flaring and can precipitate erythroderma.
Seborrheic Dermatitis

A. General Characteristics
1. A chronic, idiopathic, inflammatory skin disorder that occurs in all age groups.
2. Very common problem (affects 5% of the population), especially in patients with oily skin.
4. Common locations: scalp (dandruff), hairline, behind ears, external ear canal, folds of skin around nose, eyebrows, armpits, under breasts, groin area (skin folds).
5. May be complicated by secondary bacterial infection.

Quick HIT
Seborrheic dermatitis is a chronic condition with no cure. Therapy may be needed indefinitely for control of symptoms.

B. Clinical Features
1. Mild cases manifest as dandruff.
2. Severe cases yellowish, oily, and thick flakes appear near eyelashes, in the ear canal, on the middle chest, behind the ears, and other skin folds.
3. Scaly patches with surrounding areas of mild to moderate erythema (Figure 11-4).
4. Usually asymptomatic, but pruritus, skin lesions, and hair loss can occur if left untreated.

C. Treatment
1. Sunlight exposure often helps.
2. Dandruff shampoo (over-the-counter) is usually adequate.
3. Topical ketoconazole (to decrease yeast count on skin) has been found to be effective.
4. Topical corticosteroids for severe cases.
FIGURE 11.4 Seborrheic dermatitis.
(From Goodheart HP. Goodheart’s Same-Site Differential Diagnosis: A Rapid Method of Diagnosing and Treating Common Skin Disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.)
Pityriasis Rosea

Papulosquamous eruption—initially, “herald patches” that resemble ringworm (multiple round/oval patches) appear, and then a generalized rash with multiple oval-shaped lesions appears. The rash is classically described as having a Christmas tree–type appearance (Figure 11-5).

It is not contagious and is possibly related to herpes type 7.

It is common on the trunk and upper arms and thighs, and is usually not found on the face. Pruritus is often present, and varies in severity.

It spontaneously remits within a few (6 to 8) weeks without treatment. There is no treatment other than antihistamines for pruritus. Recurrences are rare.
Lichen Planus

Chronic, inflammatory mucocutaneous lesions of unknown etiology. It may be associated with hepatitis C and certain drugs.

(4 Ps): Pruritic, polygonal, purple, flat-topped papules.
Most commonly seen on wrists, shins, oral mucosa, and genitalia.
Treat with steroids.
Urticaria (Hives)

Urticaria is caused by the release of mediators from mast cells, with a resultant increase in vascular permeability. It may be acute (<6 weeks) or chronic.

FIGURE 11.5 Pityriasis rosea.
(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 4.3.)
Urticaria can be precipitated by food, drugs, latex, animal dander, pollen, dust, plants, infections, cold/heat, and certain medical conditions (e.g., hypocomplementemnic urticarial vasculitis). Findings—migratory edematous wheals (hives) that often quickly appear and then disappear. They blanch with pressure, and may cause intense pruritus or stinging. Lesions get worse with scratching (Figure 11-6). Treatment involves removal of the offending agent. Antihistamines are effective for symptomatic relief. Systemic corticosteroids may help in more severe cases.

**Quick HIT**

Unlike erythema multiforme, urticaria has a clear or pink center and is blanchable.
Angioedema

The mechanism is similar to that in urticaria, though angioedema occurs deeper in the skin (i.e., fluid extravasation occurs in deeper layers of skin/subcutaneous tissue). Angioedema and urticaria can occur simultaneously or independently. Angioedema can be caused by any of the precipitants of urticaria. ACE inhibitors are a specific cause of angioedema (reaction usually occurs within 1 week of initiating the drug). Unlike urticaria, which can occur anywhere, angioedema usually affects the eyelids, lips and tongue, genitalia, hands, or feet.

**Quick HIT**

**Hereditary angioedema:** autosomal dominant condition caused by C1 esterase inhibitor deficiency, characterized by recurrent episodes of angioedema; can be life-threatening

Angioedema results in nonpitting, puffy skin with firm swelling that is more tender and “burning” than pruritic (because there are fewer mast cells/sensory nerve endings in deeper tissues) (Figure 11-7). Angioedema can involve the GI tract, causing nausea/vomiting and abdominal pain (can be so severe as to mimic acute abdomen).

**Severe angioedema can lead to potentially life-threatening airway obstruction.** Treatment is similar to treatment of urticaria. Give SC epinephrine for laryngeal edema or bronchospasm.

![Angioedema](image_url)
PA: Lippincott Williams & Wilkins; 2003, Figure 20.1.)
Anaphylaxis

The most severe form of allergy, anaphylaxis is a systemic, life-threatening allergic reaction caused by a massive release of mast cell mediators (usually a type I hypersensitivity reaction) that occurs within seconds to minutes. Numerous causes have been identified, including foods (most common cause), medications, radiocontrast agents, blood products, venoms (e.g., from snakes), insect stings, latex, hormones, ragweed/molds, and various chemicals. Clinical findings include skin and mucosal signs (most common and early findings; urticaria, swollen lips and tongue, periorbital edema), respiratory signs (dyspnea, wheeze, airway obstruction), GI signs (nausea/vomiting, crampy abdominal pain), and cardiovascular signs (tachycardia, hypotension, shock).

Treatment of anaphylaxis:

- ABCs—secure the airway (intubation may be necessary) and provide supplemental oxygen, treat hypotension with rapid infusion of IV fluids.
- Give IM epinephrine immediately; may require several doses of 0.3 to 0.5 mg (1 mg/mL preparation). If not responding, prepare IV epinephrine infusion.
- If still wheezing despite epinephrine, give albuterol for bronchospasm.
- Adjuncts to consider: antihistamines (both H\textsubscript{1} and H\textsubscript{2} blockers such as diphenhydramine and ranitidine) and corticosteroids. These are less important for the acute management of anaphylaxis.
Drug Reactions

Overview

An adverse drug reaction is not necessarily an allergic drug reaction (see also Clinical Pearl 11-1). Adverse drug reactions include drug side effects, drug–drug interactions, drug toxicity and associated illnesses, and drug allergy. Most cases of adverse drug reactions are not related to allergy (only 10% have a true allergic basis).

Many patients who state they are “allergic” to a medication believe themselves to be allergic because they have been incorrectly labeled without direct immunologic evidence. However, given the serious risks of a true drug allergy, one should avoid the suspected medication.

β-Lactam antibiotics (penicillins), aspirin, NSAIDs, and sulfa drugs account for more than 80% of all cases of drug allergy. Other drugs implicated include insulin, local anesthetics, ACE inhibitors, and radiocontrast agents.

Drug-induced hypersensitivity reactions most commonly manifest as type IV reactions with diffuse maculopapular eruptions; however, all four hypersensitivity mechanisms can serve as the underlying mechanism, and clinical findings can vary widely and can affect multiple organ systems (e.g., interstitial nephritis, pneumonitis, cardiovascular collapse from anaphylaxis, etc.).

Quick HIT

- Allergic reactions typically appear within 1 month of initiating the drug. It is uncommon for a drug reaction to occur within less than 1 week of initiating the drug.

Fixed Drug Eruption

Typically caused by antibiotics or NSAIDs, fixed drug eruption characteristically appears early (within hours) after reexposure to the precipitating medication in the same body location.

A purple patch will typically appear, and upon reexposure more lesions can develop. The lesions typically resolve spontaneously, leaving an area of postinflammatory hyperpigmentation.

CLINICAL PEARL 11-1

Types of Hypersensitivity Reactions

- **Type I:** IgE-mediated (e.g., anaphylaxis, asthma)
- **Type II:** IgG- (or IgM-) and cytotoxic cell-mediated (e.g., Goodpasture disease, pemphigus vulgaris)
- **Type III:** antigen–antibody complexes (e.g., SLE, Arthus reaction, serum sickness)
Acute Generalized Exanthematous Pustulosis (AGEP)

AGEP presents with fever, leukocytosis, and a skin eruption of small pustules on an erythematous background. The eruption typically occurs within hours or days after exposure to the drug, and typically begins on the face and neck and then spreads to the trunk and limbs. Antibiotics are the most common culprit, and treatment is supportive (discontinuing the medication and topical steroids).

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)

A systemic reaction that typically occurs 2 to 6 weeks after starting a medication (longer latency than other drug reactions). Initial symptoms include fever, lymphadenopathy, facial edema, and a diffuse, morbilliform skin eruption. The reaction can progress to involve multiple organ systems, most commonly the liver, kidneys, and lung. The most common precipitating medications are allopurinol, antiepileptics, sulfa drugs, vancomycin, minocycline, and dapsone. Diagnosis is made using a clinical scoring system based on history of exposure to a common medication, typical examination findings (e.g., fever, morbilliform eruption), and laboratory abnormalities (eosinophilia, abnormal liver enzymes, acute kidney injury). After withdrawal of the offending agent, treatment may involve steroids if there is significant lung or kidney involvement, and liver involvement can sometimes progress to acute liver failure requiring transplant.

Quick HIT

EM is caused by infection in 90% of cases. Viral, bacterial, and fungal infections can all cause EM, but two common (and commonly tested) associations are HSV and Mycoplasma.

Erythema Multiforme

Erythema multiforme (EM) is an inflammatory skin condition that has been described on the same spectrum of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), but newer research suggests that it is a distinct entity. EM is characterized by erythematous macules/papules that resemble target lesions (“bull’s-eye lesions”) that can become bullous (Figure 11-8). Skin lesions may be pruritic and painful, and often affect the palms, soles, and mouth. EM can be caused by medications, though the majority of cases are caused by infections (especially HSV). The most common precipitating medications are
antibiotics, sulfa drugs, antiepileptics, and NSAIDs. Other causes of EM include autoimmune disease, malignancy, vaccines, and radiation. Treatment is directed at the underlying etiology (e.g., acyclovir for HSV). Topical steroids and oral antihistamines are used for symptomatic relief; oral steroids can be used for more severe cases.

Quick HIT

The “rule of nines” is the quickest method of estimating the affected BSA—the head is 9%, each arm is 9%, each leg is 18%, and each side of the trunk (anterior and posterior) is 18% (e.g., for a rash covering both arms and half the chest, the total affected BSA is 27%). Alternatively, for smaller areas, the palm and fingers together are 1%.

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
SJS and TEN are part of a disease continuum of severe mucocutaneous eruptions. They are dermatologic emergencies. SJS involves <10% BSA, and TEN involves >30% BSA. SJS/TEN overlap describes patients with 10% to 30% BSA involvement.

FIGURE 11.8 Erythema multiforme. A: Bulla. B: Target (or iris) lesion.
(From Bickley LS, Szilagyi P. Bates’ Guide to Physical Examination and History Taking. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Table 4.8.)

The majority of cases are caused by medications (most commonly antiepileptics,
sulfa antibiotics, allopurinol, nevirapine, and NSAIDs), though up to a third of cases have no apparent trigger. Mycoplasma is a known infectious precipitant. Skin lesions are typically coalescing erythematous macules and target lesions that progress to vesicles/bullae with extensive skin necrosis and sloughing. Mucosal involvement is very common in both SJS and TEN. **Potentially life-threatening** (mortality rate is 10% for SJS and 30% for TEN). Other complications include massive fluid and electrolyte loss, secondary infections and sepsis, and multiorgan failure. Management: admit to ICU or burn unit. Withdraw the suspected medication; aggressive rehydration and symptomatic management. Urgent dermatology and ophthalmology consultation is indicated.

**Erythroderma**

A life-threatening dermatologic emergency that causes erythema and scaling that involves 90% or more of the patient’s BSA. Erythroderma may be caused by medications or a flare of an existing dermatitis (such as atopic dermatitis or psoriasis, especially after abrupt discontinuation of oral steroids). A large number of cases are idiopathic. Other less common associations include the Sezary syndrome (cutaneous T-cell lymphoma), other hematologic and solid organ malignancies, autoimmune disease (lupus), and infections. Treatment involves intensive skin care (emollients, dressings, warm and humid environment), oral antihistamines and topical steroids, and addressing the underlying condition.
Other Inflammatory and Autoimmune Disorders

- Erythema Nodosum

Erythema nodosum appears as painful, red, subcutaneous, elevated nodules, typically located over the anterior aspect of the tibia (less commonly on the trunk or arms) (Figure 11-9). It is self-limited and usually resolves within a few weeks. Low-grade fever, malaise, and joint pain may precede the rash. It is much more common in women (especially young women) than in men. Many causes: Streptococcus infection, tuberculosis, other bacterial, viral, and fungal infections, sarcoidosis, inflammatory bowel disease, Behçet disease, pregnancy, medications (e.g., oral contraceptives, sulfa drugs, amiodarone, antibiotics), syphilis, tuberculosis, malignancy, and others. Many cases are idiopathic.

FIGURE

11.9 Erythema nodosum.
(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 25.17.)

Perform the following to help determine the underlying condition: chest radiograph
(for sarcoidosis, tuberculosis, other infections), antistreptolysin-O titer, CBC, erythrocyte sedimentation rate and C-reactive protein, and tuberculin skin test or interferon-gamma release assay. Additional tests should be based on patient factors (pregnancy test in females, STI screen, etc.).

Treat the underlying condition, if known.

Prescribe bed rest, leg elevation, NSAIDs, and heat for symptoms. Potassium iodide may help.
**Pyoderma Gangrenosum**

A neutrophilic dermatosis that most commonly presents with ulcerating lesions that display pathergy (trauma makes the lesion worse, so avoid debridement). Pyoderma gangrenosum is commonly associated with IBD, hematologic disease (especially IgA monoclonal gammopathy), and rheumatologic disease (rheumatoid arthritis, seronegative spondyloarthritis, and others).

Treatment involves nontraumatic wound care and topical agents (high potency steroids or tacrolimus). If severe or fails to respond to initial measures, then alternatives include systemic dapsone or minocycline, or immunomodulating therapies such as cyclosporine.
**Bullous Pemphigoid**

Multiple subepithelial blisters on abdomen, groin, and extremities (Figure 11-10). Elderly people are most commonly affected. Blisters are less easily ruptured than in pemphigus vulgaris. Autoimmune condition; no malignant potential but may be persistent. Treat with systemic or topical glucocorticoids.
Pemphigus Vulgaris

Autoimmune blistering condition resulting in loss of normal adhesion between cells (acantholysis) (Figure 11-11). Starts in oral mucosa; may become generalized. Blisters rupture, leaving painful erosions. Most commonly affects elderly people, often fatal if untreated. Autoantibodies (usually IgG) directed against the adhesion molecule desmoglein. Treat with systemic glucocorticoids and other immunosuppressants. Pemphigus may be the presenting symptoms of malignancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Castleman disease.

FIGURE 11.10 Bullous pemphigoid.

FIGURE 11.11 Pemphigus vulgaris.
(From Elder D, Elenitsas R, Johnson B, et al. Synopsis and Atlas of Lever’s Histopathology of the Skin [Clinical Figure IVD3.b]. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.)
Vitiligo

Chronic, depigmenting condition due to unknown cause; hereditary component is suspected
Sharply demarcated areas of skin become amelanotic—most common on the face
Associated with diabetes mellitus, hypothyroidism, pernicious anemia, and Addison disease
Topical glucocorticoids and photochemotherapy are used to promote repigmentation with varying degrees of success

SKIN CONDITIONS RELATED TO INFECTIONS AND INFESTATIONS
Bacterial Infections (See Chapter 10)

Viral Infections

Warts

A. General Characteristics

1. Warts are caused by HPV and are transmitted via skin-to-skin contact. For genital warts, transmission is via intimate sexual contact.

2. Types
   a. The common wart (*Verruca vulgaris*)—most common type.
      - May occur anywhere, but the most common sites include elbows, knees, fingers, and palms.
      - Appearance: flesh-colored or whitish with a hyperkeratotic surface.
   b. The flat wart (*Verruca plana*).
      - Common sites include the chin/face, dorsum of hands, and legs.
      - Appears flesh-colored with smooth papules and a flat surface.
   c. The plantar wart (*Verruca plantaris*).
      - Solitary or multiple warts found on the plantar side of the foot; can cause foot pain if located on pressure areas (e.g., metatarsal head, heel).
      - Appearance: flesh colored with a rough, hyperkeratotic surface.
   d. Anogenital wart (*Condyloma acuminatum*).
      - Most common STD, commonly associated with HPV 6 and 11 (Figure 11-12).
      - HPV (types 16, 18) infection can lead to cervical cancer in women (Pap smear is important), and protective vaccines are available.
      - Appearance: single or multiple soft, fleshy growths on the genitalia, perineum, and anus.
Most warts disappear spontaneously within 1 to 2 years. However, if the condition is left untreated, more warts can appear.

B. Treatment
1. First line is typically salicylic acid or cryotherapy (freezing with liquid nitrogen).
2. For refractory warts, options include 5-FU, intralesional bleomycin, topical or intralesional immunotherapy (e.g., Candida antigen), surgical therapy, laser therapy, imiquimod, and many others.

Warts can be recurrent and may require multiple treatments (despite the method of therapy chosen).
Molluscum Contagiosum

A common, self-limited viral infection caused by a poxvirus; common in sexually active young adults and in children. It manifests as small papules (2 to 5 mm) with central umbilication. Lesions are asymptomatic. In HIV-positive patients, lesions can be extensive (Figure 11-13). It is transmitted via skin-to-skin contact (sexual contact can lead to genital involvement) and is highly contagious. Often regresses spontaneously, but multiple treatment modalities are effective (e.g., curettage, drops containing podophyllin and cantharidin, cryosurgery), but scarring is always a risk.

**FIGURE 11.13** Molluscum contagiosum.

(From Goodheart HP. *Goodheart’s Photoguide of Common Skin Disorders*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 6.13.)
FIGURE 11.14 Herpes zoster.
(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 6.33.)
Herpes Zoster (Shingles)

A. General Characteristics

1. Caused by reactivation of the varicella-zoster virus, which remains dormant in the dorsal root ganglia and is reactivated in times of stress, infection, or illness; only occurs in those who have previously had chickenpox.
2. It is typically seen in patients over 50 years of age. In patients less than 50 years of age, suspect an immunosuppressed state.
3. Contagious when open vesicles present and only for those who have never had chickenpox or are immunocompromised (or newborns). Zoster is not as contagious as chickenpox.

Quick HIT

<table>
<thead>
<tr>
<th>Complications of Zoster</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Postherpetic neuralgia</td>
</tr>
<tr>
<td>• Occurs most frequently in patients older than 50 years</td>
</tr>
<tr>
<td>• Manifests as excruciating pain that persists after the lesions have cleared, and does not respond to analgesics</td>
</tr>
<tr>
<td>• Can be chronic and debilitating</td>
</tr>
<tr>
<td>• Uveitis</td>
</tr>
<tr>
<td>• Dissemination</td>
</tr>
<tr>
<td>• Meningoencephalitis, deafness</td>
</tr>
</tbody>
</table>

B. Clinical Features

1. **Severe pain and rash in a dermatomal distribution.** Pain comes before the rash. Rash is characterized by grouped vesicles on an erythematous base. If severe, low-grade fever and malaise may be present.
2. The most common sites of involvement are the thorax (most cases) and trigeminal distribution (especially ophthalmic division). Affected sites can also include other cranial nerves, as well as arms and legs (Figure 11-14).
3. Rarely life-threatening, even if dissemination occurs. Herpes zoster is more severe, however, in immunocompromised patients.

C. Treatment

1. Keep the lesions clean and dry.
2. Prescribe analgesics for pain relief (aspirin or acetaminophen; codeine if needed). In severe cases, administer a local injection of triamcinolone in lidocaine.
3. Prescribe antiviral agents (acyclovir, famciclovir, valacyclovir) to reduce the pain, decrease the length of illness, and reduce the risk of postherpetic neuralgia.
4. The use of corticosteroids to decrease the incidence of postherpetic neuralgia remains controversial.
5. Live vaccine has been shown to be effective in reducing the number of cases of
shingles in patients over the age of 60 in addition to reducing the severity and duration of postherpetic neuralgia in patients who do end up with the disease. The vaccine should be recommended to all patients over 60 who do not have contraindications.
Dermatophytes

Dermatophytes are superficial fungi that infect cutaneous epithelium, nails, and hair. The three main genera of dermatophytes are *Trichophyton*, *Microsporum*, and *Epidermophyton*.

Important dermatophyte infections are covered in Table 11-1. Scrape lesions and use KOH preparation to visualize the fungus.

<table>
<thead>
<tr>
<th>Fungal Infection</th>
<th>Location</th>
<th>Age Group</th>
<th>Findings</th>
<th>Diagnosis</th>
<th>First-Line Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Tinea corporis</em></td>
<td>Body/trunk</td>
<td>All ages</td>
<td>Pinkish, annular lesions</td>
<td>Direct microscopy; visualization of hyphae from skin scrapings with KOH preparation</td>
<td>Topical antifungals (e.g., ketoconazole, miconazole)</td>
</tr>
<tr>
<td><em>Tinea capitis</em></td>
<td>Scalp</td>
<td>Children</td>
<td>Areas of scaling with hair loss ± pruritus</td>
<td>• Direct microscopy</td>
<td>Oral griseofulvin (antifungal)</td>
</tr>
<tr>
<td><em>Tinea unguium</em> (onychomycosis)</td>
<td>Nails</td>
<td>Elderly people</td>
<td>Thick, opacified nails</td>
<td>Direct microscopy (nail scrapings)</td>
<td>Oral griseofulvin (antifungal)</td>
</tr>
<tr>
<td><em>Tinea pedis</em> (&quot;athlete’s foot&quot;)</td>
<td>Feet—web spaces of toes</td>
<td>Young adults</td>
<td>Scaling, erythema, pruritus</td>
<td>Direct microscopy</td>
<td>Topical antifungals, good foot hygiene</td>
</tr>
<tr>
<td><em>Tinea cruris</em> (&quot;Jock itch&quot;)</td>
<td>Groin, inner thighs</td>
<td>Adults: males &gt; females</td>
<td>Areas of scaling, erythema: spares scrotum</td>
<td>Direct microscopy</td>
<td>Topical antifungals, good hygiene</td>
</tr>
</tbody>
</table>

Table 11-1: Important Dermatophyte Infections
**Tinea Versicolor**

A common superficial fungal infection which is likely caused by several species in the Malassezia group, which are part of the normal skin flora (Figure 11-15). Characteristic lesions are **well demarcated** and most commonly affect the trunk. As the name implies, lesions may be hyper- or hypopigmented and can range in color from brown to tan to white. Adolescents and young adults are most commonly affected, though almost any age can be affected. Hot/humid weather, excessive sweating, and skin oils may contribute to transformation from normal skin flora to pathologic condition. Diagnosis should be made with KOH prep, which will show the “spaghetti and meatballs” pattern consistent with both hyphae and yeast balls. Treatment consists of oral or topical antifungals, depending on the severity of the disease. Selenium sulfide lotion may also be helpful.

---

**Quick HIT**

Treat tinea capitis and onychomycosis with oral antifungal agents. Others are treated with topical antifungals.

---

**FIGURE 11.15** Tinea versicolor.
(Courtesy of Paul S. Matz, MD. *Visual Diagnosis and Treatment in Pediatrics*. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.)
Infestations

Scabies

A. General Characteristics
1. Caused by the human skin mite *Sarcoptes scabiei*.
2. Highly contagious—transmitted via skin-to-skin contact or through towels, bed linens, or clothes.
3. Pathogenesis—the mites tunnel into the epidermis, lay eggs, and deposit feces (called scybala). A delayed type IV hypersensitivity reaction develops toward the mites, eggs, and feces, causing intense pruritus.
4. Common locations include the fingers, interdigital areas, and wrists. In more extensive infestations, the elbows, feet, ankles, penis, scrotum, buttocks, and axillae. The head, neck, palms, and soles are typically spared.

B. Clinical Features
1. Severe pruritus—this is often the most severe during the night.
2. Burrows—linear marks (several millimeters in length) represent the tunneled path of the mite. There is typically a dark dot at one end, representing the female mite.
3. Scratching may lead to excoriations.
4. Eczematous plaques, crusted papules, or secondary bacterial infection may develop (Figure 11-16).

Quick HIT

Suspect scabies in any patient who has persistent, generalized, severe pruritus.

C. Diagnosis
1. Look for characteristic burrows on hands, wrists, and ankles, and in the genital region.
2. Confirm the diagnosis by scraping the burrow with a scalpel and examining it under a microscope to detect the presence of mites, ova, or scybala.

D. Treatment
1. Specific medications.
   a. Permethrin 5% cream is often used as first-line treatment; it causes paralysis of the parasite (acts on nerve cell membrane).
      • Should be applied to every area of the body (head to toe), even under fingernails and toenails, around the genital area, and in the cleft of the
buttocks. Patients should leave cream on overnight (>8 to 10 hours) and wash it off the next morning. Some recommend a second treatment 1 to 2 weeks later.

b. Other options include oral ivermectin, topical lindane (γ-benzene-hexachloride), and others.

FIGURE 11.16 Scabies.
(From Stedman TL. Stedman’s Medical Dictionary for the Health Professions and Nursing: Illustrated. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.)

2. General recommendations.
   a. Treat all close contacts of the patient simultaneously (even if asymptomatic) with Permethrin 5% cream.
   b. The patient is no longer contagious after one treatment, although pruritus may continue for a few weeks as dead mites are shed from the skin. Use topical corticosteroids and oral antihistamines to control pruritus during this time.
   c. Thoroughly wash all underwear and bed linens.

BENIGN AND MALIGNANT SKIN LESIONS
Benign Skin Lesions

- Actinic Keratosis (Also Called Solar Keratosis)

Small, rough, scaly lesions due to prolonged and repeated sun exposure (Figure 11-17).
Most commonly seen in fair-skinned people. Lesions are typically on the face.
Prevention: advise patients to avoid excessive sun exposure and to use sunscreen.
Although the risk of malignant transformation is low (1 in 1,000), biopsy is still recommended for hyperkeratotic actinic keratosis lesions to exclude SCC.
Additionally, lesions which become indurated, tender, or bleed spontaneously must be biopsied to exclude SCC.
Treatment options include surgical removal (scraping), freezing with liquid nitrogen, or application of topical 5-FU for multiple lesions (destroys sun-damaged skin cells).

Quick HIT

Once a patient has developed actinic keratosis with excessive sun exposure, other lesions may develop, even without further sun exposure.
**Seborrheic Keratosis**

These are very common skin lesions that begin to appear after the age of 30 years. Hereditary—they probably are autosomal dominant, and are harmless growths with no malignant potential. There is no association with sunlight. They can be located anywhere, but are common on the face and trunk. They increase in number with time, and some patients have many of them. They are slightly elevated plaques, gradually turning darker in color, and appear as if they were “stuck” on the skin (Figure 11-18). Treatment is not necessary and is only for cosmetic reasons: Liquid nitrogen cryotherapy or curettage is effective and easily performed in the office setting.

![Image of Seborrheic Keratosis](image-url)
FIGURE 11.18 Seborrheic keratosis.

(From Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 21.13.)
Keratoacanthoma

Epithelial tumors which clinically resemble squamous cell carcinoma (SCC). Current debate centers on whether this is a subtype of SCC or a separate entity altogether.
Lesions grow **VERY** quickly. The lesions progress to the typical dome with central crater containing keratinous material over the course of several weeks. This type of growth is very rare for SCC.
Treatment involves observation, as many of these will regress spontaneously over several months.
Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common skin cancer (accounts for 60% to 75% of all skin cancers). It arises from the basal layer of cells in the epidermis. The most important risk factor is sun exposure. It occurs most frequently in fair-skinned individuals who burn easily and involves sun-exposed areas, such as the head and neck (the nose is the most common site). The classic appearance is a pearly, smooth papule with rolled edges and surface telangiectases (three Ps: pearly, pink, papule) (Figure 11-19). Metastasis is extremely rare, but can be locally destructive. Surgical resection is curative.
FIGURE 11.20  Squamous cell carcinoma.
(From Stedman TL. Stedman’s Medical Dictionary for the Health Professions and Nursing: Illustrated. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.)
Squamous Cell Carcinoma

SCC is less common than BCC. (SCC accounts for less than 20% of all skin cancers.)

It arises from epidermal cells undergoing keratinization.
Sunlight exposure is the most important risk factor. Concomitant actinic keratoses, chronic skin damage, and immunosuppressive therapy are also risk factors.

It is typically described as a crusting, ulcerated nodule or erosion (Figure 11-20).

The likelihood of metastasis is higher than with BCC, but much lower than with melanoma.
The prognosis is excellent if it is completely excised (95% cure rate). Lymph node involvement, however, carries a poor prognosis.

Quick HIT

Marjolin ulcer: an SCC arising from a chronic wound such as a previous burn scar (tends to be very aggressive)

Quick HIT

Women with malignant melanoma have a better prognosis than men (with equivalent lesions).
Melanoma

A. General Characteristics

1. Most aggressive form of skin cancer and the number one cause of death due to skin cancer.
2. Increasing incidence worldwide
3. Risk factors
   a. Fair complexion; primarily affects Caucasian patients, especially those with any of the following:
      • Inability to tan
      • Easily sunburned
      • Red hair and/or freckles
      • Numerous moles
   b. Sun exposure, especially for:
      • Patients with a history of severe sunburn before the age of 14 years
      • Patients living in a sunny climate
   c. Family history of melanoma (e.g., first-degree relative)
   d. Genodermatoses (e.g., xeroderma pigmentosa)
   e. Increasing age
   f. Large numbers of nevi (moles)
      • Although most melanomas arise de novo, they may arise from pre-existing nevi in up to 50% of cases
      • Any change in a nevus is concerning because it may indicate malignancy or malignant transformation. Look for color change, bleeding, ulceration, or a papule arising from the center of an existing nevus
   g. Dysplastic nevus syndrome
      • Numerous, atypical moles—these tend to be large with indistinct borders and variations in color. The chances of a single dysplastic nevus becoming a melanoma are small
      • If dysplastic nevus syndrome and a family history of melanoma are present, the risk of developing melanoma approaches 100%
   h. Giant congenital nevi—the risk of melanoma is about 5% to 8%. Prophylactic

Quick HIT

Spitz Nevi
- Well-circumscribed, raised lesion commonly confused with melanoma; color varies.
- Complete excision is recommended.
excision is recommended

FIGURE 11.21 Malignant melanoma.
(From Goodheart HP. Goodheart's Photoguide of Common Skin Disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003, Figure 21.20.)

4. Growth phases
   a. Radial (initial) growth phase
      • Growth is predominantly lateral within the epidermis
      • There is a good prognosis with surgical resection because metastasis is unlikely
   b. Vertical (later) phase
      • Growth extends into the reticular dermis or beyond
      • Lymphatic or hematogenous metastasis may occur
      • Depth of invasion is the most important indicator of prognosis

B. Clinical Features
   1. A melanoma may present with some or all of the following features:
      a. Asymmetry
      b. Border irregularity
      c. Color variegation—ranging from pink to blue to black
      d. Diameter greater than 6 mm
      e. Evolution—changes in size, shape, or color (Figure 11-21)
C. Diagnosis

1. Excision biopsy is the standard of care for diagnosis of any suspicious lesion.
   a. Shave biopsy and punch biopsy are less accurate than excision biopsy in assessing the depth of invasion.
   b. Acceptable skin margins are 1 to 3 cm for most lesions, as determined by depth of invasion.

2. Lymph node dissection is appropriate if nodes are palpable.

D. Treatment

1. Early detection is the most important way to prevent death, because prognosis is directly related to depth of invasion.
2. Surgical options exist, and even surgical excision of metastases (termed metastasectomy) may be beneficial.
3. For advanced disease, immunotherapy or targeted therapies (e.g., BRAF inhibition) may be offered.

Quick HIT

<table>
<thead>
<tr>
<th>Sites of Metastases</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymph nodes, skin, subcutaneous (59%)</td>
<td></td>
</tr>
<tr>
<td>Lung (36%)</td>
<td></td>
</tr>
<tr>
<td>Liver (20%)</td>
<td></td>
</tr>
<tr>
<td>Brain (20%)—common cause of death</td>
<td></td>
</tr>
<tr>
<td>Bone (17%)</td>
<td></td>
</tr>
<tr>
<td>GI tract (7%)</td>
<td></td>
</tr>
</tbody>
</table>
Ambulatory Medicine
Stanley Yuan
Cardiovascular Diseases

Hypertension

A. General Characteristics

1. **Essential hypertension** (HTN) (i.e., there is no identifiable cause) **applies to more than 95% of cases of HTN.**
2. Secondary HTN has many identifiable causes.
   a. **Renal/renovascular disease**—renal artery stenosis (most common cause of secondary HTN), chronic renal failure, polycystic kidneys.
   b. Endocrine causes—hyperaldosteronism, thyroid or parathyroid disease, Cushing syndrome, pheochromocytoma, acromegaly.
   c. Medications—oral contraceptives, decongestants, estrogen, appetite suppressants, chronic steroids, tricyclic antidepressants (TCAs), nonsteroidal anti-inflammatory drugs (NSAIDs).
   d. Coarctation of the aorta.
   e. Cocaine, other stimulants.
   f. Obstructive sleep apnea (OSA).

Quick HIT

Birth control pills are the most common secondary cause of HTN in young women.

Quick HIT

Pathophysiology of the Effects of HTN on the Heart

- Increased systemic vascular resistance (afterload) → concentric left ventricle hypertrophy (LVH) → decreased LV function. As a result, the chamber dilates → symptoms and signs of heart failure.
- HTN accelerates atherosclerosis, leading to a higher incidence of CAD (as well as peripheral vascular disease and stroke).

B. Risk Factors

1. Age—both systolic and diastolic BP increase with age.
2. Gender—more common in men (gap narrows over age 60); men have higher complication rates.
3. Race—it is twice as common in African-American patients than in Caucasian patients; African-American patients have higher complication rates (stroke, renal failure, heart disease).
4. Obesity, sedentary lifestyle, dyslipidemia.
5. Family history.
6. Increased sodium intake—this correlates with increased prevalence in large populations, but not in individuals; individual susceptibility to the effects of high salt intake varies.
7. Alcohol—intake of more than 2 oz of liquor, 8 oz of wine, or 24 oz of beer per day is associated with HTN.

Quick HIT

Target Organ Damage
- Heart—LVH, MI, CHF
- Brain—stroke, TIA
- Chronic kidney disease
- Peripheral arterial disease, AAA, aortic dissection
- Retinopathy

C. Definitions

1. Classification (for adults >18 years)
   a. Normal—systolic BP <120 and diastolic BP <80
   b. Elevated—systolic BP 120 to 139 or diastolic BP 80 to 89
   c. Stage I—systolic BP 140 to 159 or diastolic BP 90 to 99
   d. Stage II—systolic BP ≥160 or diastolic BP ≥100

2. Hypertensive urgency—severe HTN (typically systolic BP >180 and/or diastolic BP >120) in an asymptomatic patient

3. Hypertensive emergency—severe HTN with end-organ damage (e.g., neurologic changes, myocardial ischemia, aortic dissection)
CNS (intracerebral hemorrhage, encephalopathy)

Eyes (hemorrhages, exudates, papilledema)

Aortic dissection

Heart (CHF, CAD, MI)

Kidneys (renal failure)
D. Complications

1. The major complications of HTN are cardiac complications (coronary artery disease [CAD], CHF with left ventricular hypertrophy [LVH]), stroke, and renal failure (Figure 12-1). These account for the majority of deaths associated with untreated HTN.

2. HTN affects the following organs (target organ damage):
   a. Cardiovascular system
      - Effects on the heart are most important. HTN is a major risk factor for CAD, with resultant angina and MI.
      - CHF is a common end-result of untreated HTN as LVH occurs.
      - Most deaths due to HTN are ultimately due to MI or CHF.
      - HTN predisposes the patient to peripheral artery disease (PAD).
      - HTN is associated with increased incidence of abdominal aortic aneurysm (AAA) and aortic dissection.

---

**Quick HIT**

HTN is an asymptomatic disease (“silent killer”)—it causes insidious damage to the following target organs: heart, eyes, CNS, and kidneys.

**Quick HIT**

Patients with a systolic BP of 120 to 129 are considered prehypertensive and require lifestyle modifications to prevent cardiovascular disease.
b. Eyes (retinal changes)
   - Early changes—arteriovenous nicking (discontinuity in the retinal vein secondary to thickened arterial walls) and cotton wool spots (infarction of the nerve fiber layer in the retina) can cause visual disturbances and scotomata (Figure 12-2).
   - More serious disease—hemorrhages and exudates.
   - Papilledema—an ominous finding seen with severely elevated BP.

c. CNS
   - Increased incidence of intracerebral hemorrhage.
- Increased incidence of other stroke subtypes as well (transient ischemic attacks [TIAs], ischemic stroke, and lacunar stroke).
- Hypertensive encephalopathy when BP is severely elevated (uncommon).

d. Kidney
- Arteriosclerosis of afferent and efferent arterioles and glomerulus—called nephrosclerosis.
- Decreased GFR and dysfunction of tubules—with eventual renal failure.

### Quick HIT Goals in Evaluating a Patient With HTN
- Look for secondary causes (may be treatable).
- Assess damage to target organs (heart, kidneys, eyes, CNS).
- Assess overall cardiovascular risk.
- Make therapeutic decisions based on the above.

### Quick HIT Definition of HTN
BP >130/80 in general population (including patients with diabetes and renal disease)

### E. Diagnosis

1. BP measurement
   a. Unless the patient has severe HTN or evidence of end-organ damage, never diagnose HTN on the basis of one BP reading. Establish the diagnosis on the basis of at least two readings over 4 or more weeks apart
   b. Observe the following to obtain an accurate BP reading
      - The arm should be at heart level, and the patient should be seated comfortably
      - Have the patient sit quietly for at least 5 minutes before measuring BP
      - Make sure the patient has not ingested caffeine or smoked cigarettes in the past 30 minutes (both elevate BP temporarily)
      - Use a cuff of adequate size (a cuff that is too small can falsely elevate BP readings). The bladder within the cuff should encircle at least 80% of the arm

2. Order the following laboratory tests to evaluate target organ damage and assess overall cardiovascular risk
   a. Urinalysis
   b. Chemistry panel: serum K\(^1\), BUN, Cr
   c. Fasting glucose (if patient is diabetic, check for microalbuminuria)
   d. Lipid panel
   e. ECG
3. If the history and physical examination (H&P) or laboratory tests suggest a secondary cause of HTN, order appropriate tests

**F. Treatment**

1. Management goals ([Table 12-1](#)).
2. Lifestyle changes, listed in order of effect on BP reduction:
   a. Weight loss lowers BP significantly. In patients with central obesity (who often have coexisting diabetes, hyperlipidemia, and other risk factors), weight loss is particularly important because multiple risk factors are reduced concomitantly.
   b. Follow a low–saturated-fat diet rich in fruits, vegetables, and low-fat dairy products (DASH diet).
   c. Exercise regularly. Regular aerobic exercise can lower BP (and reduce overall cardiovascular risk).
   d. Reduce salt intake. Reduction in dietary salt has been shown to reduce BP. Recommend either a no-added-salt diet (4 g sodium/day) or a low-sodium diet (2 g/day).
   e. Avoid excessive alcohol consumption. Alcohol has a pressor action, and excessive use can increase BP.
   f. Others—stop unnecessary medications that may contribute to HTN. Engage in appropriate stress management practices.
3. Pharmacologic treatment (seven classes of drugs) ([Table 12-2](#)).
   a. Thiazide diuretics.
      • Because “salt-sensitive” HTN is more common in African-American patients, diuretics are a good initial choice for these patients (though a calcium channel blocker is equally recommended as a first-line option).
      • A good option in patients with osteoporosis (increases calcium reabsorption in the nephron).

---

**Quick HIT**

Always obtain a pregnancy test in reproductive age women before starting an antihypertensive medication. Thiazides, ACE inhibitors, calcium channel blockers, and ARBs are contraindicated in pregnancy. β-Blockers and hydralazine are safe.

**Quick HIT**

If a patient presents with moderate-to-severe HTN, consider initiating therapy right away instead of waiting 1 to 2 months to confirm diagnosis and start treatment.

b. β-Blockers—decrease HR and cardiac output and decrease renin release.
   • A good option in patients with CHF, CAD, or atrial fibrillation; a poor option
in patients with obstructive lung disease, heart block, or depression.

c. **ACE inhibitors.**
   - Inhibit the renin–angiotensin–aldosterone system (RAAS) by inhibiting the conversion of angiotensin I to angiotensin II. Angiotensin II normally causes vasoconstriction, aldosterone release, and ventricular remodeling.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiazide diuretics</td>
<td>Hypokalemia, hyperuricemia, hyperglycemia, elevation of cholesterol and triglyceride levels, metabolic alkalosis, hyperuricemia, hypomagnesemia</td>
</tr>
<tr>
<td>β-Blockers</td>
<td>Bradycardia, bronchospasm, sleep disturbances (insomnia), fatigue, may increase TGs and decrease HDL, depression, sedation, may mask hypoglycemic symptoms in diabetic patients on insulin</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>Acute renal failure, hyperkalemia, dry cough, angioedema, skin rash, altered sense of taste</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>Dihydropyridines (e.g., amlodipine): peripheral edema</td>
</tr>
<tr>
<td></td>
<td>Nondihydropyridines (e.g., verapamil, diltiazem): heart block</td>
</tr>
</tbody>
</table>

- ACE also acts to degrade bradykinin, so inhibition results in excess levels in the lung that can cause a chronic dry cough.
- **Preferred in all diabetic patients** because of their protective effect on kidneys; also a good option for patients with CHF, CAD.

d. **Angiotensin II receptor blockers (ARBs).**
   - Also inhibit RAAS.
   - ARBs have the same beneficial effects on the kidney in diabetic patients as ACE inhibitors and do not cause a chronic cough; ACE inhibitors and ARBs should not be used in combination.

e. **Calcium channel blockers**—cause vasodilation of arteriolar vasculature.

f. **α-Blockers**—decrease arteriolar resistance.
   - May be of benefit if the patient has concurrent benign prostatic hyperplasia (BPH) but these are not considered first- or second-line agents.

g. **Vasodilators** (hydralazine and minoxidil)—not commonly used; typically given in combination with β-blockers and diuretics to patients with refractory HTN.
Quick HIT

Treatment with ACE inhibitors and ARBs is associated with decreased risk of new-onset diabetes in patients with HTN.

   a. BP should be lowered to <140/90 mm Hg for patients <60 years old, and <150/90 mm Hg for patients ≥60 years old. If patients ≥60 years old previously tolerated a BP goal <140/90 mm Hg, their treatment does not need to be changed.
   b. Each of the antihypertensive agents is roughly equally effective in lowering BP. However, there is great variability in how patients respond to each drug. The three classes of drugs that are used for initial monotherapy are thiazide diuretics, long-acting calcium channel blockers (most often a dihydropyridine), and ACE inhibitors/ARBs. β-Blockers are not commonly used as initial monotherapy in the absence of a specific indication because of adverse effects on some cardiovascular outcomes especially in elderly patients.

Quick HIT

Most patients eventually need more than one drug to attain goal BP (especially diabetics, obese patients, and those with renal failure).

c. Drug treatment is often lifelong. However, patients with very mild HTN may be able to be weaned off medication if their BP can be lowered and controlled with nonpharmacologic measures, such as lifestyle modifications. However, these patients need frequent BP checks.

Quick HIT

If “white coat hypertension” is suspected, there are two options for determining whether the increased BP persists outside the office.
- Twenty-four–hour ambulatory blood pressure monitoring is the most effective.
- Home blood pressure monitoring is an alternative.

d. ALLHAT trial compared chlorthalidone, amlodipine, lisinopril, and doxazosin in patients with essential HTN and at least one CAD risk factor. The doxazosin arm was terminated early because of an increased risk of CHF compared to chlorthalidone. The other three agents were similar in regards to rates of fatal CAD and nonfatal MI, however chlorthalidone reduced rates of CAD, stroke, CHF, and angina when compared to lisinopril.

e. ACCOMPLISH trial showed that treatment with antihypertensive combination
therapy—the ACE inhibitor benazepril plus the calcium channel blocker amlodipine—was more effective than treatment with the ACE inhibitor plus diuretic. Based on this trial, it makes sense to start monotherapy with either a calcium channel blocker or an ACE inhibitor, so that the other can be added if combination therapy is needed. Despite the findings of this trial, thiazide diuretics remain a common initial drug choice.

Quick HIT

Cardiovascular risk factors: smoking, diabetes, hypercholesterolemia, age over 60, family history, male sex (higher than for female only until menopause)
Clinical risk factors: presence of CAD, PAD, or prior MI; any manifestations of target organ disease—LVH, retinopathy, nephropathy; stroke or TIA

f. If the patient’s response to one agent is not adequate, there are two options:
   - Increase the dose of the first agent to the maximum dose.
   - Add a second medication (thiazide, calcium channel blocker, ACE inhibitor, or ARB); if target BP not achieved, increase the dose of each as necessary until the maximum dose is achieved.

g. If a patient’s response is still inadequate with two agents, consider a third agent and referral to an HTN specialist.
h. The decision of when to start pharmacologic treatment is based on the patient’s total cardiovascular risk, not just the elevation in BP.
   - For any level of BP elevation, the presence of cardiovascular risk factors and/or comorbid conditions dramatically accelerates the risk from HTN, and therefore modifies the treatment plan. Estimation of overall risk depends on cardiovascular risk factors and clinical risk factors (see Clinical Pearl 12-1).

Quick HIT

Patients at increased risk for coronary artery disease (e.g., strong family history and/or obesity) should be screened with a fasting lipid profile every 5 years starting at age 20. For patients without risk factors, screen starting at age 45 for women and age 35 for men.

CLINICAL PEARL 12-1

Risk Factors for CAD in Evaluation of Patients With Hyperlipidemia
- Current cigarette smoking (dose-dependent risk)
- HTN
- Diabetes mellitus
- Low HDL cholesterol (<35 mg/dL); high HDL (>60 mg/dL) is a negative risk factor (subtract 1 from total)
- **Age**
  - Male: >45 years of age
  - Female: >55 years of age
- **Male gender**—if you count as a risk factor, do not count age
- **Family history of premature CAD**
  - MI/sudden death in male first-degree relative <55 years of age
  - MI/sudden death in female first-degree relative <65 years of age
Hyperlipidemias

A. General Characteristics

1. Hyperlipidemia is one of the most important (and modifiable) risk factors for CAD. It causes accelerated atherosclerosis.

2. Hyperlipidemia may be a primary disorder, such as a familial dyslipidemia syndrome, or secondary to another cause.

3. Classification of dyslipidemia syndromes—types IIA, IIB, and IV account for over 80% of all familial dyslipidemias (Table 12-3)

4. Secondary causes of hyperlipidemia
   a. Endocrine disorders—hypothyroidism, DM, Cushing syndrome
   b. Renal disorders—nephrotic syndrome, uremia
   c. Chronic liver disease
   d. Medications—glucocorticoids, estrogen, thiazide diuretics, β-blockers
   e. Pregnancy

5. Risk factors
   a. Diet
      • Saturated fatty acids and cholesterol cause elevation in LDL and total cholesterol
      • High-calorie diets do not increase LDL or cholesterol levels (are “neutral”) but do increase triglyceride (TG) levels
      • Alcohol increases TG levels and HDL levels but does not affect total cholesterol levels

| TABLE 12-2 Dyslipidemia Syndromes |
b. Age—cholesterol levels increase with age until approximately age 65. The increase is greatest during early adulthood—about 2 mg/dL per year

c. Inactive lifestyle, abdominal obesity

d. Family history of hyperlipidemia

e. Gender—men generally have higher cholesterol levels than women; when women reach menopause, cholesterol levels then equalize and may even be higher in women than in men

f. Medications

- Thiazides—increase LDL, total cholesterol, TG (VLDL) levels
- β-Blockers (propranolol)—increase TGs (VLDL) and lower HDL levels
- Estrogens—TG levels may be further increased in patients with hypertriglyceridemia
- Corticosteroids and HIV protease inhibitors can elevate serum lipids

g. Genetic mutations that predispose to the most severe hyperlipidemias

h. Secondary causes of dyslipidemia (see above)

6. Role of lipids in CAD risk

a. LDL cholesterol

- Accounts for two-thirds of total cholesterol. **CAD risk is primarily due to the LDL component** because LDL is the most atherogenic of all lipoproteins
- LDL cholesterol is not directly measured. It is calculated as follows: \( \text{LDL} = \)
b. Total cholesterol
   • The risk of CAD increases sharply when total cholesterol is above 240 mg/dL

c. HDL cholesterol
   • Its protective effect (removes excess cholesterol from arterial walls) is at least as strong as the atherogenic effect of LDL
   • For every 10 mg/dL increase in HDL levels, CAD risk decreases by 50%
   • High HDL (>60 mg/dL) is a “negative” risk factor (counteracts one risk factor) for CAD

d. **The total cholesterol-to-HDL ratio**—the lower the total cholesterol-to-HDL ratio, the lower the risk of CAD
   • Ratio of 5.0 is average (standard) risk
   • Ratio of 10 is double the risk
   • Ratio of 20 is triple the risk
   • Ratio of <4.5 is desirable

e. TGs—elevated TGs are associated with coronary risk, but it is unknown whether this association is causal. It is uncertain whether lowering TG level reduces coronary risk.

---

**Quick HIT**

**Estrogen Replacement Therapy in Postmenopausal Women**

Recent HERS trial showed no benefit of hormone replacement therapy on cardiovascular outcomes in women with established CHD. However, the study did not address the issue in women without CHD. The results are somewhat controversial.

---

**B. Clinical Features**

1. Most patients are asymptomatic.
2. The following may be manifestations of severe hyperlipidemia:
   a. *Xanthelasma*—yellow plaques on eyelids.
   b. *Xanthoma*—hard, yellowish masses found on tendons (finger extensors, Achilles tendon, plantar tendons).
3. Pancreatitis can occur with severe hypertriglyceridemia.

**C. Diagnosis**

1. Lipid screening (see Health Maintenance section)—measure total cholesterol and HDL levels (nonfasting is acceptable). If either is abnormal, then order a full fasting lipid profile.
2. A full fasting lipid profile includes TG levels and calculation of LDL levels.
3. Consider checking laboratory tests to exclude secondary causes of
hyperlipidemia.
a. TSH (hypothyroidism).
b. LFTs (chronic liver disease).
c. BUN and Cr, urinary proteins (nephrotic syndrome).
d. Glucose levels (diabetes).

**Quick HIT**
Statins have been shown to significantly reduce rates of MI, stroke, and coronary and all-cause mortality in prospective placebo-controlled trials.

**D. Treatment**

1. New guidelines issued by the ACC/AHA in 2013 have dramatically changed lipid management.
   a. The long-term goal is the same: to reduce morbidity and mortality from CAD.
   b. Key differences of the new guidelines compared to the previous guidelines (Adult Treatment Panel III):
      • Targeting specific cholesterol goals is no longer recommended.
      • The use of nonstatin medications to lower LDL is generally not recommended.
      • The use of a new risk calculator to calculate a patient’s 10-year risk of atherosclerotic cardiovascular disease (ASCVD) (found online at http://my.americanheart.org/cvriskcalculator).

2. Therapy for ASCVD risk reduction.
   a. Statin therapy is recommended for four categories of patients (Table 12-4).
   b. Dietary therapy is important before and during statin therapy. Lowering fat intake (especially saturated fats) reduces serum cholesterol more than lowering cholesterol intake. Foods rich in omega-3 fatty acids (such as fish) are particularly beneficial. With an intensive diet, LDL can be reduced by an average of 10%, as follows: <30% of total calories from fat; with fewer than 10% from saturated fat; <300 mg/day of cholesterol.
   c. Exercise and weight loss—reduce risk of CAD.
- Exercise increases HDL and reduces other CAD risk factors by lowering BP and enhancing the efficiency of peripheral oxygen extraction.
- Weight loss reduces myocardial work as well as the risk of diabetes.

d. Smoking cessation.
e. Drug therapy—see Table 12-5. Available agents include HMG CoA reductase inhibitors (statins), niacin, bile-acid sequestrants, and gemfibrozil.
- Patients given drug therapy should almost always be treated with a statin. Statins can reduce relative cardiovascular risk by about 20% to 30% regardless of baseline LDL levels.
- The other classes of drugs should only be used if a patient does not tolerate statin therapy.

**Quick HIT**

Patients should have their AST and ALT measured before starting a statin, and after only if symptoms of hepatotoxicity are evident. It is no longer recommended to routinely monitor AST and ALT after starting a statin.

3. Therapy for high TG levels—the data are fairly limited regarding which patients should be treated and which medication to use.
   a. First-line therapy is weight loss, aerobic exercise, glycemic control in diabetics, and low-fat diet.
   b. Medications include fibrates, nicotinic acid (niacin), and fish oil.
   c. Statins should be considered even in patients with high TG levels because of their cardioprotective effects.

### Table 12-3: Updated Cholesterol Treatment Guidelines

<table>
<thead>
<tr>
<th>Category</th>
<th>Recommended Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical ASCVD&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>High-intensity statin</td>
</tr>
<tr>
<td>LDL cholesterol ≥190 mg/dL</td>
<td>High-intensity statin</td>
</tr>
</tbody>
</table>
| Diabetic patients aged 40–75 yrs with LDL cholesterol 70–189 mg/dL | • ASCVD risk score <7.5%, moderate-intensity statin  
• ASCVD risk score ≥7.5%, high-intensity statin |
| Nondiabetic patients aged 40–75 yrs with LDL cholesterol 70–189 mg/dL | ASCVD risk score ≥7.5%, moderate- to high-intensity statin |

<sup>a</sup>The new guidelines do not make recommendations for patients aged >75 yrs, with NYHA class II–IV heart failure, or with end-stage renal disease undergoing hemodialysis due to insufficient evidence from randomized controlled trials.

<sup>b</sup>ASCVD, atherosclerotic cardiovascular disease.
Includes patients with acute coronary syndromes or a history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease from atherosclerosis.


<table>
<thead>
<tr>
<th>Drug</th>
<th>Effects</th>
<th>Comments</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMG CoA reductase inhibitors (statins)</td>
<td>Lower LDL levels (most potent for lowering LDL)</td>
<td>Have been shown to reduce mortality from cardiovascular events and significantly reduce total mortality. Drugs of choice for ASCVD risk reduction</td>
<td>Monitor LFTs. Harmless elevation in muscle enzymes (CPK) may occur</td>
</tr>
<tr>
<td></td>
<td>Minimal effect on HDL and TG levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niacin</td>
<td>Lowers TG levels</td>
<td>Do not use in diabetic patients (may worsen glycemic control) Most potent agent for increasing HDL levels and lowering TG levels</td>
<td>Flushing effect (cutaneous flushing of face/arms; pruritus may be present) Check LFTs and CPK levels as with statin drugs</td>
</tr>
<tr>
<td></td>
<td>Lowers LDL levels Increases HDL levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bile acid-binding resins (cholestyramine, colestipol)</td>
<td>Lowers LDL Increases TG levels</td>
<td>Effective when used in combination with statins or niacin to treat severe disease in high-risk patients</td>
<td>Adverse GI side effects, poorly tolerated</td>
</tr>
<tr>
<td>Fibrates (gemfibrozil)</td>
<td>Lower VLDL and TG Increase HDL</td>
<td>Primarily for lowering TG levels</td>
<td>GI side effects (mild) Mild abnormalities in LFTs Gynecomastia, gallstones, weight gain, and myopathies are other side effects</td>
</tr>
<tr>
<td>CPK, creatine phosphokinase.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Headache

**Tension Headache**

**A. General Characteristics**

1. Cause is unknown; may be similar to that of migraines (see below) (see also Clinical Pearls 12-2 and 12-3)
2. Usually worsens throughout the day; precipitants include anxiety, depression, and stress
3. Mild migraines can easily be confused with tension headaches and vice versa

**Quick HIT**

Emergency Evaluation of Headache

- Obtain a noncontrast CT scan to first rule out any type of intracranial bleed.
- However, small bleeds (subarachnoid hemorrhage) may be missed by CT scan, so a lumbar puncture may be necessary (to potentially visualize the presence of blood breakdown products).

**B. Clinical Features**

1. Pain is steady, aching, “vise-like,” and encircles the entire head (tight band-like pain around the head).
   a. Usually generalized, but may be the most intense around the neck or back of head.
   b. Can be accompanied by tender muscles (posterior cervical, temporal, frontal).
2. Tightness in posterior neck muscles.

**CLINICAL PEARL 12-2**

**Differential Diagnosis of Headache**

- Primary headache syndromes—migraines, cluster headache, tension headache
- Secondary causes of headache (“VOMIT”)
  - Vascular—subarachnoid hemorrhage, subdural hematoma, epidural hematoma, intraparenchymal hemorrhage, temporal arteritis
  - Other causes—malignant HTN, pseudomotor cerebri, post-lumbar puncture, pheochromocytoma
  - Medication/drug related—nitrates, alcohol withdrawal, chronic analgesic use/abuse
  - Infection—meningitis, encephalitis, cerebral abscess, sinusitis, herpes zoster, fever
  - Tumor
### Headache Red Flags

- Sudden onset within seconds to minutes.
- Worst headache of the patient’s life.
- New-onset headache that the patient has never experienced before, especially over the age of 50 years.
- Headache pattern: increase in severity and frequency over time, worse after lying down.
- Mental status change or any focal neurologic symptoms/signs.
- New-onset headache associated with heavy exertion or head trauma.
- New-onset headache associated with fever, stiff neck, or rash.
- New-onset headache in a patient with HIV infection or cancer.

### C. Treatment

1. Attempt to find the causal factor(s). Evaluate the patient for possible depression or anxiety. Stress reduction is important.
2. NSAIDs (such as aspirin) and acetaminophen are the standard treatment for mild/moderate headaches.
3. If headaches are severe, medications that are used for migraines (triptans) may be appropriate, given the difficulty in distinguishing between these two entities.
Cluster Headaches

A. General Characteristics
1. Very rare—thought by some to be a variant of migraine headache
2. Usually occurs in middle-aged men
3. Subtypes
   a. Episodic cluster headaches (90% of all cases)—last 2 to 3 months, with remissions of months to years
   b. Chronic cluster headaches (10% of all cases)—last 1 to 2 years; headaches do not remit

B. Clinical Features
1. Excruciating periorbital pain (“behind the eye”)—almost always unilateral
2. Cluster headache is described as a “deep, burning, searing, or stabbing pain.” Pain may be so severe that the patient may even become suicidal
3. Accompanied by ipsilateral lacrimation, facial flushing, nasal stuffiness/discharge
4. Usually begins a few hours after the patient goes to bed and lasts for 30 to 90 minutes; awakens patient from sleep (but daytime cluster headaches can also occur)
5. Attacks occur nightly for 2 to 3 months and then disappear. Remissions may last from several months to several years
6. Worse with alcohol and sleep

C. Treatment
1. Acute attacks
   a. Sumatriptan (Imitrex) and inhaled O₂ are the first-line treatments
2. Prophylaxis
   a. Of all the headache types, cluster headaches are the most responsive to prophylactic treatment. Offer all patients prophylactic medication. Verapamil taken daily is the drug of choice
   b. Ergotamine, methysergide, lithium, and corticosteroids (prednisone) are alternative agents
   c. These agents cause resolution (or marked reduction) of the number of headaches within 1 week
Migraine

A. General Characteristics

1. An inherited disorder (probably an autosomal dominant trait with incomplete penetrance)
2. The pathogenesis is not clearly defined, but serotonin depletion plays a major role
3. More common in women than men; more common in those with a family history; typically occurs one to two times per month
4. Types
   a. Migraine with aura (15% of cases)—“classic migraine.” Aura is usually visual (flashing lights, scotomata, visual distortions), but can be neurologic (sensory disturbances, hemiparesis, dysphasia)
   b. Migraine without aura (85% of cases)—“common migraine”
   c. Menstrual migraine
      - Occurs between 2 days before menstruation and the last day of menses; linked to estrogen withdrawal
      - Treatment is similar to that of nonmenstrual migraine except that estrogen supplementation is sometimes added
   d. Status migrainosus—lasts over 72 hours and does not resolve spontaneously
5. The following can provoke a migraine:
   a. Hormonal alteration (menstruation)
   b. Stress, anxiety
   c. Sleeping disturbances (lack of sleep)
   d. Certain drugs/foods—chocolate, cheese, alcohol, smoking, oral contraceptive pills
   e. Weather changes and other environmental factors

Quick HIT

Visual Aura in Migraine
- The classic presentation is a bilateral homonymous scotoma. Bright, flashing, crescent-shaped images with jagged edges often appear on a page, obscuring the underlying print. The aura usually lasts 10 to 20 minutes.
- A patient may have isolated visual migraines (as above) without headaches.

B. Clinical Features

1. Prodromal phase (occurs in 30% of patients)
   a. Consists of symptoms of excitation or inhibition of the CNS: elation, excitability, increased appetite and craving for certain foods (especially sweets); alternatively, depression, irritability, sleepiness, and fatigue may be manifested
   b. May precede the actual migraine attack by up to 24 hours
2. Severe, throbbing, unilateral headache (not always on the same side)
   a. Lasts 4 to 72 hours
   b. At times, it may be generalized over the entire head and may last for days if not treated
   c. Pain is aggravated by coughing, physical activity, or bending down
   d. Variable pain quality—“throbbing” or “dull and achy”
3. Other symptoms include nausea and vomiting (in as many as 90% of cases), photophobia, and increased sensitivity to smell

Quick HIT
Many patients who are labeled as having migraines actually have rebound analgesic headaches. These occur more frequently (every 1 to 2 days) than migraines. These headaches do not respond to drugs used to treat migraines. Wean patient from analgesics. Do not use narcotics!

C. Treatment
1. Acute attacks of migraine
   a. If migraines are mild, analgesics such as NSAIDs or acetaminophen may be effective. If they are not effective, try either dihydroergotamine (DHE) or a triptan
   b. DHE—a serotonin (5-HT1) receptor agonist
      • This is highly effective in terminating migraine pain. It is available for SC, IM, IV, or nasal administration
      • Contraindications—CAD, pregnancy, TIAs, PAD, sepsis
   c. Sumatriptan—a more selective 5-HT1 receptor agonist than DHE or other triptans
      • Acts rapidly (within 1 hour) and is highly effective
      • Should not be used more than once or twice per week
      • Contraindications—CAD, pregnancy, uncontrolled HTN, basilar artery migraine, hemiplegic migraine, use of MAOI, SSRI, or lithium
   d. If none of the available migraine medications work, it is unlikely that the patient is suffering from a migraine headache

Quick HIT
Most patients experience a decrease in the number and intensity of headaches as they age.

2. Prophylaxis (must be taken daily)
   a. Consider prophylaxis for patients with weekly episodes that are interfering with activities. Before initiating prophylactic medications, the patient should make
attempts to avoid any known precipitants of the migraines

b. First-line agents include amitriptyline (TCAs) and propranolol (β-blocker). Propranolol is most effective of the prophylactic medications for migraines
c. Second-line agents include verapamil (calcium channel blocker), valproic acid (anticonvulsant), and methysergide
d. NSAIDs are effective for menstrual migraines
Upper Respiratory Diseases

Cough

A. General Characteristics
1. Cough can be divided into acute (less than 3 weeks duration) and chronic (more than 3 weeks duration)
2. If the cause is benign, cough usually resolves in a few weeks. If a cough lasts for longer than 1 month, further investigation is warranted
3. Causes
   a. Conditions that are usually associated with other symptoms and signs
      • Upper respiratory infections (URIs)—this is probably the most common cause of acute cough
      • Pulmonary disease—pneumonia, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, lung cancer, asthma, lung abscess, tuberculosis
      • CHF with pulmonary edema
   b. Isolated cough in patients with normal chest radiograph
      • Smoking
      • Postnasal drip—may be caused by URIs (viral infections), rhinitis (allergic or nonallergic), chronic sinusitis, or airborne irritants
      • Gastroesophageal reflux disease (GERD)—especially if nocturnal cough (when lying flat, reflux worsens due to position and decreased lower esophageal sphincter [LES] tone)
      • Asthma—cough may be the only symptom in 5% of cases
      • ACE inhibitors—may cause a dry cough (by inhibiting bradykinin breakdown, leading to increased bradykinin production)

Quick HIT

Postnasal Drip
The mucosal receptors in the pharynx and larynx are stimulated by secretions of the nose and sinuses that drain into the hypopharynx.

B. Diagnosis
1. Usually no tests are indicated in a patient with acute cough.
2. CXR is indicated only if a pulmonary cause is suspected, if the patient has hemoptysis, or if the patient has a chronic cough. It also may be appropriate in a long-term smoker in whom COPD or lung cancer is a possibility.
3. CBC if infection is suspected.
4. Pulmonary function testing if asthma is suspected or if cause is unclear in a patient with chronic cough.
5. Bronchoscopy (if there is no diagnosis after above workup) to look for tumor, foreign body, or tracheal web.

Quick HIT

<table>
<thead>
<tr>
<th>Causes of Chronic Cough in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Smoking</td>
</tr>
<tr>
<td>• Postnasal drip</td>
</tr>
<tr>
<td>• GERD</td>
</tr>
<tr>
<td>• Asthma</td>
</tr>
</tbody>
</table>

C. Treatment

1. Treat the underlying cause, if known
2. Smoking cessation, if smoking is the cause
3. Postnasal drip—treat this with a first-generation antihistamine/decongestant preparation. If sinusitis is also present, consider antibiotics. For allergic rhinitis, consider a nonsedating long-acting oral antihistamine (loratadine)
4. Nonspecific antitussive treatment
   a. Unnecessary in most cases, because cough usually resolves with specific treatment of the cause
   b. May be helpful in the following situations:
      • If cause is unknown (and thus specific therapy cannot be given)
      • If specific therapy is not effective
      • If cough serves no useful purpose, such as clearing excessive sputum production or secretions
   c. Medications
      • Codeine
      • Dextromethorphan
      • Benzonatate (Tessalon Perles) capsules
   d. Agents used to improve the effectiveness of antitussive medications include expectorants such as guaifenesin and water

Quick HIT

It is often difficult to distinguish between a viral and a bacterial infection.

<table>
<thead>
<tr>
<th>Common Features of Viral Versus Bacterial URIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feature</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>Rhinorrhea</td>
</tr>
<tr>
<td>Myalgias</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Fever</td>
</tr>
<tr>
<td>Cough</td>
</tr>
<tr>
<td>Yellow sputum</td>
</tr>
</tbody>
</table>
Acute Bronchitis

A. General Characteristics
1. Viruses account for the majority of cases.
2. Laboratory tests are not indicated. Obtain a chest radiograph only if you suspect pneumonia; there is no infiltrate or consolidation in acute bronchitis (presence of fever, tachypnea, crackles, egophony on auscultation, or dullness to percussion suggests pneumonia).

B. Clinical Features
1. Cough (with or without sputum) is the predominant symptom—it lasts 1 to 2 weeks. In a significant number of patients, the cough may last for 1 month or longer.
2. Chest discomfort and shortness of breath may be present.
3. Fever may or may not be present.

C. Treatment
1. Antibiotics are usually not necessary—most cases are viral.
2. Cough suppressants (codeine-containing cough medications) are effective for symptomatic relief.
3. Bronchodilators (albuterol) may relieve symptoms.
The Common Cold

A. General Characteristics
1. The “common cold” is the most common upper respiratory tract infection. Children are more frequently affected than adults. Susceptibility depends on pre-existing antibody levels.
2. Caused by viruses (identification of virus is not important).
   a. Rhinoviruses are the most common (at least 50% of cases)—there are more than 100 antigenic serotypes, so reinfection with another serotype can lead to symptoms (no cross-immunity among the serotypes).
   b. Other viruses include coronavirus, parainfluenza viruses (types A, B, and C), adenovirus, coxsackievirus, and RSV.
3. Hand-to-hand transmission is the most common route.
4. Complications include secondary bacterial infection (bacterial sinusitis or pneumonia). These secondary infections (especially pneumonia) are very rare.
5. Most resolve within 1 week, but symptoms may last up to 10 to 14 days.

Quick HIT
- The common cold is synonymous with acute rhinosinusitis—inflammation and congestion of mucous membranes of nasal and sinus passages.
- In most cases, it is very difficult to distinguish between the common cold (viral rhinosinusitis) and acute bacterial sinusitis on the basis of clinical features.
- Sneezing/rhinorrhea, nasal discharge (whether clear, purulent, or colored), nasal obstruction, and facial pain/headaches occur in both.

B. Clinical Features
1. Rhinorrhea, sore throat, malaise, nonproductive cough, nasal congestion.
2. Fever is uncommon in adults (suggests a bacterial complication or influenza), but is not unusual in children.

C. Treatment (Symptomatic)
1. Adequate hydration
   a. Loosens secretions and prevents airway obstruction
   b. Can be achieved by increasing fluid intake and inhaling steam
2. Rest and analgesics (aspirin, acetaminophen, ibuprofen)—for relief of malaise, headache, fever, aches
3. Cough suppressant (dextromethorphan, codeine)
4. Nasal decongestant spray (Neo-Synephrine) for less than 3 days
5. Oral first-generation antihistamines for rhinorrhea/sneezing
Many of the symptoms seen with the common cold are also seen in influenza, but are more severe in the latter. Fever, headache, myalgias, and malaise are much more pronounced with influenza.
Sinusitis

A. General Characteristics
1. There is inflammation of the lining of the paranasal sinuses, often due to infection. Mucosal edema obstructs the sinus openings (ostia), trapping sinus secretions
2. Most cases of acute sinusitis occur as a complication of the common cold or other URIs. (However, fewer than 1% of URIs lead to acute sinusitis.) May also be caused by nasal obstruction due to polyps, deviated septum, or foreign body
3. Classification
   a. Acute bacterial sinusitis—usually due to Streptococcus pneumoniae, Haemophilus influenzae, or anaerobes
   b. Other types—viral, fungal, or allergic
4. The most common sinuses involved are the maxillary sinuses

Quick HIT
Sinusitis is usually self-limited, but can be associated with high morbidity. It can be life-threatening if the infection spreads to bone or to the CNS.

B. Clinical Features
1. Acute sinusitis
   a. Nasal stuffiness, purulent nasal discharge, cough
   b. Sinus pain or pressure (location depends on which sinus is involved)—pain worsens with percussion or bending head down
      • Maxillary sinusitis (most common)—pain over the cheeks that may mimic pain of dental caries
      • Frontal sinusitis—pain in the lower forehead
      • Ethmoid sinusitis—retro-orbital pain, or pain in the upper lateral aspect of the nose
   c. Fever in 50% of cases
2. Chronic sinusitis
   a. Nasal congestion, postnasal discharge
   b. Pain and headache are usually mild or absent; fever is uncommon
   c. By definition, symptoms should be present for at least 2 to 3 months
   d. In addition to the organisms listed for acute sinusitis, patients with a history of multiple sinus infections (and courses of antibiotics) are at risk for infection with S. aureus and gram-negative rods
C. Diagnosis
1. Diagnosis is based on clinical findings. Consider acute bacterial sinusitis if a patient has a cold for more than 8 to 10 days or has prolonged nasal congestion.
2. Physical examination.
   a. Look for purulent discharge draining from one of the turbinates.
   b. Perform transillumination of maxillary sinuses (note impaired light transmission)—the room must be completely dark with a strong light source.
   c. Palpate over the sinuses for tenderness (not a reliable finding).
3. Imaging studies—usually not indicated in routine community-acquired infections.
   b. A CT scan (coronal view) is superior to a plain radiograph. It should be performed in complicated disease or if surgery is being planned.

D. Complications
1. Mucocele, polyps
2. Orbital cellulitis—usually originating from ethmoid sinusitis
3. Osteomyelitis of the frontal bones or maxilla
4. Cavernous sinus thrombosis (rare)
5. Very rare—epidural abscess, subdural empyema, meningitis, and brain abscess—due to contiguous spread through bone or via venous channels

E. Treatment
1. Acute purulent sinusitis
   a. General measures/advice for the patient
      • Saline nasal spray aids drainage
      • Avoid smoke and other environmental pollutants
   b. Decongestants (pseudoephedrine or oxymetazoline)
      • Facilitate sinus drainage and relieve congestion
Available in both topical and systemic preparations
Give for no more than 3 to 5 days

c. Antibiotics
- Amoxicillin, amoxicillin-clavulanate, TMP/SMX, levofloxacin, moxifloxacin, and cefuroxime are good choices.

d. Antihistamines
- Reserve for patients with allergies; use discriminately because of the “drying effect”
- Loratadine (Claritin), fexofenadine (Allegra), chlorpheniramine (Chlor-Trimeton)

e. Nasal steroids (fluticasone, beclomethasone)—may be worth a trial if sinusitis is secondary to allergic rhinitis or if there is concurrent allergic rhinitis

2. Chronic sinusitis
   a. Treat with a broad-spectrum penicillinase-resistant antibiotic
   b. Refer to an otolaryngologist—endoscopic drainage may be necessary

**Quick HIT**

Antihistamines have a drying effect (making secretions thicker) and can sometimes worsen congestion. If this occurs, avoid decongestants with antihistamines.
Laryngitis

Usually viral in origin; may also be caused by *Moraxella catarrhalis* and *H. influenzae*

Common cause of hoarseness; cough may be present along with other URI symptoms

Typically self-limiting

Patient should rest voice until laryngitis resolves to avoid formation of vocal nodules
Sore Throat

A. General Characteristics

1. Causes of sore throat
   a. Viruses are by far the most common cause (adenovirus, parainfluenza, rhinovirus, Epstein–Barr virus, herpes simplex)
   b. The main concern is infection with group A β-hemolytic streptococcus due to the possibility of rheumatic fever
   c. Other organisms
      • Chlamydia, Mycoplasma
      • Gonococci (oral sex)
      • Corynebacterium diphtheriae—pseudomembrane covering pharynx
      • Candida albicans (if immunosuppressed, on antibiotics, or severely ill)

2. Viral versus bacterial infection—often difficult to distinguish, but if patient has a cough and runny nose, viral is more likely

Quick HIT

Think of the following if a patient has a sore throat:
- Viral infection
- Tonsillitis (usually bacterial)
- Strep throat
- Mononucleosis

Quick HIT

Only 50% of patients with pharyngeal exudates have strep throat, and only 50% of patients with strep throat have exudates.

B. Diagnosis

1. Throat culture—takes 24 hours, but is more accurate than rapid strep test
2. Rapid strep test—results within 1 hour, but will not indicate whether sore throat is caused by a bacterium other than Streptococcus or a virus
   a. Centor criteria: helps predict the likelihood of Strep throat and the appropriate management
      • One point each for history of fever, tonsillar exudates, tender anterior cervical lymphadenopathy, absence of cough, age <15; age >44 subtracts one point
      • −1, 0, or 1 point: No antibiotic, no throat culture
      • 2 or 3 points: Throat culture, treat with antibiotic if throat culture is positive
      • 4 or 5 points: Treat empirically with an antibiotic
3. If mononucleosis is suspected, obtain the appropriate blood tests (Monospot)

**C. Treatment**

1. If strep throat—penicillin for 10 days (erythromycin if patient has penicillin allergy)
2. If viral—symptomatic treatment (see below)
3. If mononucleosis—advise rest and acetaminophen/ibuprofen for symptoms; avoid contact sports since there is splenomegaly and a risk of splenic rupture
4. Symptomatic treatment of sore throat
   a. Acetaminophen or ibuprofen
   b. Gargling with warm salt water
   c. Use of a humidifier
   d. Sucking on throat lozenges, hard candy, flavored frozen desserts (such as Popsicles)

**Quick HIT**

Most cases (up to 90%) of dyspepsia/heartburn are due to PUD, GERD, gastritis, or nonulcer dyspepsia.
Gastrointestinal Diseases

Dyspepsia

A. General Characteristics

1. “Dyspepsia” refers to a spectrum of epigastric symptoms, including heartburn, “indigestion,” bloating, and epigastric pain/discomfort.
2. Dyspepsia is extremely common, and sometimes is confused with angina.
3. Etiology
   a. GI causes—peptic ulcer disease (PUD), GERD, nonulcer dyspepsia (functional dyspepsia), gastritis, hepatobiliary disease (cholecystitis, biliary colic), malignancy (gastric, esophageal), pancreatic disease (pancreatitis, pseudocyst, cancer), esophageal spasm, hiatal hernia.
   b. Other causes include lactose intolerance, malabsorption, DM (gastroparesis), and irritable bowel syndrome (IBS).

B. Diagnosis

1. Base the decision to perform tests on clinical presentation and response to empiric therapy.
2. Endoscopy is the test of choice for evaluation of dyspepsia.
   a. It can identify an esophageal stricture or ulcer, cancer, and reflux esophagitis.
   b. It should not be routinely performed in all patients with dyspepsia. Some general indications include:
      • Patients with alarming symptoms—weight loss, anemia, dysphagia, or obstructive symptoms.
      • Patients >55 years of age with new-onset dyspepsia.
      • Patients with recurrent vomiting or any evidence of upper GI bleeding.
      • Patients who do not respond to empiric therapy (see below).
      • Patients with signs of complications of PUD.
      • Patients with recurrent symptoms.
      • Patients with evidence of systemic illness.
3. Noninvasive testing for Helicobacter pylori: an option if the patient does not
require an EGD.

a. Urea breath test: detects active infection.
b. Serology: cannot reliably determine active infection (antibodies may persist after *H. pylori* is cleared).
c. Stool antigen test: detects active infection.
d. Results
   - If positive, treat for *H. pylori*.
   - If negative, PUD is unlikely and the patient likely has either GERD or nonulcer dyspepsia (treat empirically—see below).

C. Treatment

1. Treat the cause if known
2. Advise the patient to:
   a. Avoid alcohol, caffeine, and other foods that irritate the stomach
   b. Stop smoking
   c. Raise the head of the bed when sleeping
   d. Avoid eating before sleeping
3. Use a proton pump inhibitor (PPI) trial for 8 weeks. Endoscopy is indicated if this fails to relieve symptoms
4. Eradication of *H. pylori* infection—see Chapter 3[AQ1]

Quick HIT

If GERD is associated with dysphagia, this suggests the development of *peptic stricture*. Alternatively, a motility disorder or cancer may be present.
Gastroesophageal Reflux Disease

A. General Characteristics
1. GERD is a multifactorial problem. Inappropriate relaxation of the LES (decreased LES tone) is the primary mechanism, leading to retrograde flow of stomach contents into the esophagus. Other factors that may contribute include:
   a. Decreased esophageal motility to clear refluxed fluid
   b. A gastric outlet obstruction
   c. A hiatal hernia (common finding in patients with GERD)
   d. Dietary factors (e.g., alcohol, tobacco, chocolate, high-fat foods, coffee)—may decrease LES pressure and exacerbate the condition
2. GERD is a very common condition. Its prevalence increases with age

Quick HIT
Diagnostic tests are usually not necessary for typical, uncomplicated cases of GERD, and therapy can be initiated. Tests are indicated in atypical, complicated, or persistent cases (despite treatment). Endoscopy should be performed if worrisome symptoms (anemia, weight loss, or dysphagia) are present.

B. Clinical Features
1. Heartburn, dyspepsia
   a. Retrosternal pain/burning shortly after eating (especially after large meals)
   b. Exacerbated by lying down after meals
   c. May mimic cardiac chest pain (which may lead to unnecessary workup for ischemic heart disease)
2. Regurgitation
3. Waterbrash—reflex salivary hypersecretion
4. Cough—due to either aspiration of refluxed material or a reflex triggered by acid reflux into the lower esophagus
5. Hoarseness, sore throat, feeling a lump in the throat
6. Early satiety, postprandial nausea/vomiting

Quick HIT
GERD is a chronic disorder. Regular follow-up is recommended to identify any complications (e.g., Barrett esophagus, stricture, esophagitis).

C. Diagnosis
1. Endoscopy with biopsy—the test of choice but not necessary for typical uncomplicated cases.
a. Indicated if heartburn is refractory to treatment, or is accompanied by dysphagia, odynophagia, or GI bleeding.
b. A biopsy should also be performed to assess changes in esophageal mucosa.

2. Upper GI series (barium contrast study)—this is only helpful in identifying complications of GERD (strictures/ulcerations), but cannot diagnose GERD itself.

3. Twenty-four–hour pH monitoring in the lower esophagus—this is the most sensitive and specific test for GERD. It is the gold standard, but is usually unnecessary.

4. Esophageal manometry—use if a motility disorder is suspected.

D. Complications

1. Erosive esophagitis—these patients are at high risk of developing complications such as stricture, ulcer, or Barrett esophagus. These patients are candidates for long-term PPI therapy (see below).

2. Peptic stricture
   a. Consists of fibrotic rings that narrow the lumen and obstruct the passage of food
   b. Presents with dysphagia; may mimic esophageal cancer
   c. EGD can confirm the diagnosis. Dilation should be performed

3. Esophageal ulcer—possible cause of upper GI bleeding

4. Barrett esophagus—occurs in 10% of patients with chronic reflux
   a. The normal stratified squamous epithelium of the distal esophagus is replaced by columnar epithelium. Dysplastic changes may occur, with risk of adenocarcinoma
   b. Patients who have had symptomatic GERD for at least 5 years (and can undergo surgery if cancer is found) should be screened for the possibility of Barrett esophagus
   c. Endoscopy with biopsy is required. If the patient has documented Barrett esophagus without any dysplastic changes, periodic surveillance is appropriate (every 3 years)
   d. Medical treatment—long-term PPIs

5. Recurrent pneumonia (due to recurrent pulmonary aspiration)—the cytologic aspirate finding on bronchoscopy that can diagnose aspiration of gastric contents is lipid-laden macrophages (from phagocytosis of fat)

6. Pitting of dental enamel (dental erosion); gingivitis

7. Laryngitis, pharyngitis

E. Treatment

1. Initial treatment:
   a. Behavior modification—diet (avoid fatty foods, coffee, alcohol, orange juice, chocolate; avoid large meals before bedtime); sleep with trunk of body elevated;
stop smoking
b. Antacids—after meals and at bedtime

2. Add an H₂ blocker—can be used instead of or in addition to antacids for mild and intermittent symptoms

3. If above treatment fails or patient has severe GERD (e.g., erosive esophagitis), switch to a PPI

4. Antireflux surgery for severe or resistant cases
   a. Indications for surgery
      • Intractability (failure of medical treatment)
      • Respiratory problems due to reflux and aspiration of gastric contents
      • Severe esophageal injury (ulcer, hemorrhage, stricture, Barrett esophagus)
   b. Types of surgery
      • Nissen fundoplication (may be done open or laparoscopically)—procedure of choice for a patient with normal esophageal motility
      • Partial fundoplication—when esophageal motility is poor
   c. Outcome of surgery—excellent results have been reported
**Diarrhea**

**A. General Characteristics**

1. Most cases of diarrhea are acute, benign, and self-limited (see also Clinical Pearl 12-4). Some cases are chronic and may be associated with underlying disease.
2. Acute diarrhea is diarrhea that lasts less than 2 to 3 weeks; chronic diarrhea lasts more than 4 weeks.
3. Most common cause of acute diarrhea is viral infection (rotavirus and the Norwalk virus are the most common). Most severe forms of acute diarrhea are due to bacterial infections (*Shigella*, *Escherichia coli*, *Salmonella*, *Campylobacter*, *Clostridium perfringens*, *Clostridium difficile*). Protozoa that may cause diarrhea include *Giardia lamblia*, *Entamoeba histolytica*, and *Cryptosporidium*.
4. Elderly and immunocompromised patients (e.g., with HIV, transplantation patients) are vulnerable to diarrheal illnesses due to impaired immunity. In patients with HIV, diarrhea can be caused by *Mycobacterium avium-intracellulare*, *Cryptosporidium*, *Cyclospora*, or CMV.

**CLINICAL PEARL 12-4**

**Diarrhea Pearls**
- Acute diarrhea is usually due to infection (virus, bacteria, and parasite) or medications.
- If nausea and vomiting are present, suspect viral gastroenteritis or food poisoning.
- If food poisoning is the cause, diarrhea appears within hours of the meal.
- Remember that occult blood in the stool may be present in all types of acute infectious diarrhea, but it is much less common to have gross blood.
- A finding of fever and blood together is typical of infection with *Shigella*, *Campylobacter*, *Salmonella* (may also be without blood), or enterohemorrhagic *E. coli*.
- No fever and no blood is typical of infection with viruses (rotavirus, Norwalk virus), enterotoxigenic *E. coli*, and food poisoning (*S. aureus*, *C. perfringens*).

**B. Causes**

1. Acute diarrhea
   a. **Infection**—viruses most common (viral gastroenteritis), followed by bacteria, then parasites
   b. **Medications**
      - Antibiotics (most common cause)—antibiotic-associated diarrhea is caused by *C. difficile* toxin in 25% of cases (see Chapter 3)
      - Others include laxatives, prokinetic agents (cisapride), antacids, digitalis, colchicine, alcohol, magnesium-containing antacids, and chemotherapeutic agents
c. Malabsorption (e.g., lactose intolerance)
d. Ischemic bowel in elderly patients with history of PAD and bloody diarrhea, along with abdominal pain
e. Intestinal tumors (very rare)

2. Chronic diarrhea
   a. IBS (most common cause, but is a diagnosis of exclusion)
   b. Inflammatory bowel disease (IBD)
   c. Medications—see above
d. Infection—see above, bacterial enterocolitis (Shigella, Salmonella, Campylobacter, enteroinvasive E. coli)
e. Colon cancer
f. Diverticulitis
g. Malabsorption syndromes—pancreatic insufficiency, celiac disease, short bowel syndrome, ischemic bowel, bacterial overgrowth
h. Postsurgical (e.g., gastrectomy, vagotomy)
i. Endocrine causes (hyperthyroidism, Addison disease, diabetes, gastrinoma, VIPoma)
j. Fecal impaction—because only liquid stool can pass around the impaction
k. Laxative abuse (factitious diarrhea)
l. Immunocompromised patients with acute infectious diarrhea

C. Diagnosis
1. Laboratory tests are usually unnecessary in acute diarrhea (see also Clinical Pearl 12-5 and Figure 12-3)
2. Some indications for diagnostic studies
   a. Chronic diarrhea or diarrhea that is prolonged
   b. Severe illness or high fever
   c. Presence of blood in the stool/high suspicion for IBD
d. Severe abdominal pain
e. Immunodeficiency
f. Signs of volume depletion

Quick HIT
Assess volume status (dehydration is a concern), perform an abdominal examination, and check stool for occult blood in patients with diarrhea. In mild to moderate cases of acute diarrhea, further workup is unnecessary.
Important Parts of the History in a Patient With Diarrhea

- Is the stool bloody or melanotic?
- Are there any other symptoms (e.g., fever, abdominal pain, vomiting)?
- Is there anyone in the family or group with a similar illness?
- Has there been any recent travel outside the United States, or any hiking trips (parasitic infections)?
- Are symptoms linked to ingestion of certain foods (e.g., milk)?
- Are there any medical problems (e.g., AIDS, hyperthyroidism)?
- Have there been recent changes in medications (e.g., antibiotics within the past few weeks)?
3. Laboratory tests to order
   a. CBC—look for anemia, WBC elevation
   b. Stool sample—for presence of fecal leukocytes
      - If fecal leukocytes are absent, there is no need to order stool cultures because they are unlikely to grow pathogenic organisms (unless invasive bacterial enteritis is suspected or the patient has bloody diarrhea)
      - If fecal leukocytes are present and the patient has moderate to severe diarrhea, consider sending stool for culture and/or *C. difficile* toxin assay, and consider empiric treatment with an antibiotic
      - Fecal leukocytes are present in *Campylobacter*, *Salmonella*, *Shigella*, enteroinvasive *E. coli* infection, and *C. difficile*; absent in staphylococcal or clostridial food poisoning; and absent in viral gastroenteritis
   c. Stool sample—test three samples for presence of ova and parasites. Order this if a parasite is suspected. For *Giardia*, order enzyme-linked immunosorbent assay (ELISA) test for antigen
   d. Bacterial stool culture
      - This has low sensitivity (and is an expensive test), and usually does not affect treatment or outcome
      - It should not be ordered routinely. Some indications include: if invasive bacterial enteritis is suspected, if the patient has moderate to severe illness or fever, if the patient requires hospitalization, and if the stool sample is positive for fecal leukocytes
      - Most laboratory tests examine stool culture for only three organisms: *Shigella*, *Salmonella*, and *Campylobacter*
   e. Stool sample—measure for *C. difficile* toxin if the patient has been treated with
antibiotics recently. Note that this test has a false-negative rate of 10%. Treat the patient empirically even before laboratory results are back if the suspicion is high.

f. Colonoscopy/flexible sigmoidoscopy—may be considered for patients with blood in the stool or for patients with chronic diarrhea for which a cause cannot be identified.

g. CT scan may be helpful if IBD or diverticulitis is suspected; colonoscopy should not be performed during a flare due to the risk of bowel perforation.

Quick HIT

Salmonella, Campylobacter, Shigella, and enteroinvasive E. coli cause diarrhea with fecal leukocytes and often blood.

Quick HIT

The most common electrolyte/acid–base abnormalities seen with severe diarrhea are metabolic acidosis and hypokalemia.

D. Treatment

1. Acute diarrhea is typically self-limited and does not require hospitalization. However, consider hospitalization for any of the following reasons:
   a. Dehydration (especially in elderly patients)
   b. Patients initially unable to tolerate or hold down PO fluids
   c. Bloody diarrhea (with profuse or brisk bleeding)
   d. High fever, toxic appearance

2. The identification of the specific agent responsible for acute infectious diarrhea is not critical with regard to treatment. Treat the diarrhea according to the patient’s medical history and clinical condition.

3. Specific therapy
   a. Rehydrate; monitor electrolytes and replace if necessary
   b. Treat the underlying cause (e.g., stop or change medication, advise a lactose-free diet). Consider a trial of NPO status to see if diarrhea stops
   c. Consider antibiotics. Use of antibiotics in infectious diarrhea has been shown to decrease the duration of illness by 24 hours (regardless of the etiologic agent). Therefore, consider a 5-day course of ciprofloxacin in patients who have moderate to severe disease. Antibiotics are definitely recommended in the following situations:
      • Patient has high fever, bloody stools, or severe diarrhea—quinolones are appropriate
• Stool culture grows one of the pathogenic organisms (see Table 12-6)
• Patient has traveler’s diarrhea
• C. difficile infection—use metronidazole

4. Loperamide (Imodium) is an antidiarrheal agent that should only be given if diarrhea is mild to moderate and is not recommended in patients with fever or with blood in their stool
**Constitution**

**A. Causes**

1. **Diet**—lack of fiber
2. **Medications**—anticholinergic drugs (antipsychotics), antidepressants, **narcotic analgesics**, iron, calcium channel blockers, aluminum- or calcium-containing antacids, laxative abuse, and dependence
3. **IBS**
4. **Obstruction**—colorectal cancer (CRC) (always keep this in mind!), anal stricture, hemorrhoids, anal fissure
5. **Ileus, pseudo-obstruction**
6. **Anorectal problems**—hemorrhoids, fissures
7. **Endocrine/metabolic causes**—hypothyroidism, hypercalcemia, hypokalemia, uremia, dehydration
8. **Neuromuscular disorders**—Parkinson disease, multiple sclerosis, CNS lesions, scleroderma, DM (autonomic neuropathy)
9. **Congenital disorders**—Hirschsprung disease

**TABLE 12-5 Common Pathogens Responsible for Acute Infectious Diarrhea**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Symptoms</th>
<th>Fever?</th>
<th>Fecal Leukocytes</th>
<th>Duration of Illness</th>
<th>Transmission</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute viral gastroenteritis (rotavirus, Norwalk virus)</td>
<td>Myalgias, malaise, headache, watery diarrhea, abdominal pain, nausea/vomiting</td>
<td>Possible, low grade</td>
<td>No</td>
<td>48–72 hrs, symptoms may linger for up to 1 wk</td>
<td>Fecal–oral route</td>
<td>Most common cause of acute diarrhea in the United States. Look for similar illness in family members</td>
</tr>
<tr>
<td>Salmonella</td>
<td>Abdominal pain, diarrhea, nausea, and vomiting</td>
<td>Possible, low grade</td>
<td>No</td>
<td>Resolves within 1 wk (rarely longer)</td>
<td>Fecal–oral route</td>
<td>Food (domestic fowl and their eggs—most common); fecal–oral route as well. Symptoms appear 24–48 hrs after ingesting food. No treatment is required except in immunocompromised patients or in cases of enteric fever (caused by Salmonella typhi)—rare in the United States. Ciprofloxacin (Cipro) is the preferred agent</td>
</tr>
<tr>
<td>Shigella</td>
<td>Diarrhea, abdominal pain, tenesmus; nausea, vomiting less common</td>
<td>Possible, low grade</td>
<td>Yes</td>
<td>Resolves within 1 wk (4–5 days)</td>
<td>Fecal–oral route</td>
<td>More common than food. Treat with a fluoroquinolone</td>
</tr>
<tr>
<td><em>Staphylococcus</em> food poisoning</td>
<td>Abdominal pain, nausea and vomiting, diarrhea</td>
<td>No</td>
<td>No</td>
<td>Within 24 hrs</td>
<td>Food (e.g., ham, poultry, potato salad, any food containing mayonnaise)</td>
<td>Exposed people become ill within 1–6 hrs (e.g., after a picnic). Can be quite severe and may require hospitalization</td>
</tr>
</tbody>
</table>

**B. Diagnosis**

1. Laboratory tests that **may** be necessary include TSH, serum calcium levels, CBC
(if colon cancer is suspected), and electrolytes (if obstruction is suspected).

2. Always attempt to rule out obstruction.
   a. If H&P is suggestive of obstruction, order abdominal films.
   b. Consider flexible sigmoidoscopy in select cases (if an obstructing colorectal mass is suspected).

3. A rectal examination may help identify fissures, hemorrhoids, fecal impaction, or masses.

4. If no cause is found after the above measures, and conservative treatment does not help, more specialized tests are available—for example, radiopaque marker transit study, anorectal motility study.

**Quick HIT**

<table>
<thead>
<tr>
<th>Complications of Chronic Constipation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhoids</td>
</tr>
<tr>
<td>Rectal prolapse</td>
</tr>
<tr>
<td>Anal fissures</td>
</tr>
<tr>
<td>Fecal impaction</td>
</tr>
</tbody>
</table>

**C. Treatment**

1. Diet and behavioral modification are the most important aspects of treatment. Advise the patient to:
   a. Increase physical activity.
   b. Eat high-fiber foods.
   c. Increase fluid intake.

2. Bulk laxatives are preferred over osmotic laxatives in patients that do not respond to diet and lifestyle changes.

3. Use an enema, such as a disposable Fleet enema, for temporary relief if no bowel movement occurs despite the above measures or if the patient is bedridden.

4. If obstruction is present, urgent surgery consultation is indicated.
Irritable Bowel Syndrome

A. General Characteristics
1. IBS refers to an idiopathic disorder associated with an intrinsic bowel motility dysfunction (abnormal resting activity of GI tract) that affects 10% to 15% of all adults.
2. Common associated findings include depression, anxiety, and somatization. Psychiatric symptoms often precede bowel symptoms. Symptoms are exacerbated by stress and irritants in the intestinal lumen.
3. All laboratory test results are normal, and no mucosal lesions are found on sigmoidoscopy. IBS is a benign condition and has a favorable long-term prognosis.
4. Symptoms should be present for at least 3 months to diagnose IBS.

B. Clinical Features
1. Change in frequency/consistency of stool—diarrhea, constipation (or alternating diarrhea and constipation)
2. Cramping abdominal pain (relieved by defecation)—location varies widely, but sigmoid colon is the common location of pain
3. Bloating or feeling of abdominal distention

C. Diagnosis
1. This is a clinical diagnosis, and a diagnosis of exclusion.
2. Rome III diagnostic criteria: recurrent abdominal pain/discomfort ≥3 days per month in the last 3 months, and ≥2 of the following:
   a. Pain/discomfort improves with defecation.
   b. Symptom onset is associated with a change in the frequency of the stool.
   c. Symptom onset is associated with a change in the form of the stool.
3. Initial tests that may help exclude other causes include CBC, renal panel, fecal occult blood test, stool examination for ova and parasites, erythrocyte sedimentation rate, and possibly a flexible sigmoidoscopy. Order these tests only if there is suspicion of other causes for the symptoms.

D. Treatment
1. For mild symptoms, diet and lifestyle changes (e.g., avoiding dairy products, excess caffeine). Manage the symptoms below as indicated:
   a. Diarrhea—diphenoxylate, loperamide.
   b. Constipation—colace, psyllium, cisapride.
   c. Abdominal pain—antispasmodics (e.g., pinaverium, trimebutine, peppermint oil, cimetropium/dicyclomine), antidepressants, rifaximin.

Quick HIT

The following must be frequently excluded in diagnosing IBS:
- Obstruction (plain abdominal film)
- IBD
- Lactose or sorbitol intolerance
- Malignancy (in older patients or those with family history)—colonoscopy, occult blood in stool
Nausea and Vomiting

A. General Characteristics
1. The most common causes are viral gastroenteritis and food poisoning. However, other more emergent diseases must be kept in mind.
2. Many conditions present with other prominent symptoms (e.g., abdominal pain, diarrhea, fever) in addition to nausea/vomiting.

Quick HIT

Gastroenteritis
• Typically caused by an enterovirus, and is seen in groups among family members, colleagues, and so on.
• Diarrhea is often present as well, but may appear later.

B. Approach
1. Questions to ask when taking the history: Recent food intake (Unusual foods? Time of onset of vomiting in relation to food intake? Did anyone else eat that food?) (Clinical Pearl 12-6). Are symptoms related to meals? Ask about medications and recent changes/additions. Is there a history of abdominal surgery (obstruction) or recent surgery? Are there family members with a similar illness?
2. Define the vomitus
   a. Bilious—obstruction is distal to ampulla of Vater
   b. Feculent—distal intestinal obstruction, bacterial overgrowth, gastrocolic fistula
   c. Vomiting of undigested food—esophageal problem more likely (achalasia, stricture, diverticulum)
   d. Projectile vomiting—increased intracranial pressure or pyloric stenosis
   e. Coffee-ground material or blood—GI bleeding
3. Accompanying symptoms
   a. Diarrhea and fever point to an infectious process (gastroenteritis)
   b. Abdominal pain points to obstruction, acute inflammatory conditions (e.g., peritonitis, cholecystitis)
   c. Headache, visual disturbances, and other neurologic findings point to increased intracranial or intraocular pressure (IOP).

C. Diagnosis
1. Order routine laboratory tests such as CBC, electrolytes, glucose levels, LFTs, if appropriate, based on history and examination findings.
2. Order a pregnancy test in women of child-bearing age.
3. Abdominal films—order upright and supine films in patients with acute vomiting if obstruction or perforation is suspected.
4. Order other diagnostic tests depending on clinical findings (e.g., upper GI endoscopy for ulcer disease or outlet obstruction, ultrasound for biliary disease, CT scan of head for neurologic findings).

5. In at least 50% of patients, the above tests do not reveal a cause. Special tests for GI motility may be indicated if there is suspicion of a motility disorder.

**CLINICAL PEARL 12-6**

**Causes of Acute Nausea/Vomiting**

- Pregnancy (normal pregnancy, hyperemesis gravidarum)
- Metabolic: diabetic ketoacidosis, Addison disease, uremia, electrolyte disturbance (hypercalcemia, hypokalemia), hyperthyroidism
- GI: gastroenteritis (viral, food poisoning), PUD, GERD, gastroparesis (diabetics), gastric outlet obstruction, intestinal obstruction (SBO, pseudo-obstruction), ileus, peritonitis
- Acute visceral conditions: pancreatitis, appendicitis, pyelonephritis, cholecystitis, cholangitis
- Neurologic: increased intracranial pressure, vestibular disturbance (vertigo), migraine
- Acute MI
- Drugs: chemo, digoxin, ASA/NSAIDs, narcotics, antibiotics, excessive alcohol intake
- Psychiatric: eating disorder (bulimia nervosa, anorexia nervosa), anxiety
- Miscellaneous: motion sickness, systemic illness, radiation therapy, postoperatively

**Quick HIT**

**Possible Complications of Severe or Prolonged Vomiting**

- Fluid/electrolytes—dehydration, metabolic alkalosis, hypokalemia
- Dental caries
- Aspiration pneumonitis
- GI: Mallory–Weiss tears, Boerhaave syndrome, Mallory–Weiss syndrome

**D. Treatment**

1. Most causes are self-limiting. If vomiting is severe, it may cause dehydration, requiring hospitalization.
2. Assess hydration status—fluid replacement is the first step in management, NS is used in most cases (but type of fluid and electrolyte repletion based on laboratory findings).
3. Identify and treat the underlying cause if possible.
4. Medications—choice of drug depends on the suspected cause (e.g., promethazine for hyperemesis gravidarum)
   a. Prochlorperazine, promethazine, metoclopramide, ondansetron (especially with chemotherapy), erythromycin (prokinetic).
The most common electrolyte abnormality seen after severe vomiting is **hypokalemia with metabolic alkalosis**.
Hemorrhoids

A. General Characteristics
1. Varicose veins of anus and rectum
2. Two types
   a. External hemorrhoids (painful)—dilated veins arising from inferior hemorrhoidal plexus; distal to dentate line (sensate area)
   b. Internal hemorrhoids (not painful)—dilated submucosal veins of superior rectal plexus; above dentate line (insensate area)

B. Risk Factors
1. Constipation/straining
2. Pregnancy
3. Portal HTN
4. Obesity
5. Prolonged sitting (especially truck drivers and pilots) or prolonged standing
6. Anal intercourse

C. Clinical Features
1. Bleeding and rectal prolapse (main symptoms)
   a. Bright red blood per rectum
   b. This is usually harmless, but look for iron deficiency anemia (rare[AQ3]). Occult rectal bleeding should prompt an investigation into more serious causes and should never be attributed to hemorrhoids until other conditions are ruled out
   c. Bleeding is usually painless
2. External hemorrhoids are usually asymptomatic unless thrombosed, in which case they present as sudden painful swelling (may ulcerate, bleed). Pain lasts for several days, and then gradually subsides. The response to surgery is rapid
3. Internal hemorrhoids usually do not cause pain. A mass is present when they prolapse

D. Treatment
1. General measures to ease symptoms
   a. Sitz bath
   b. Application of ice packs to anal area and bed rest
   c. Stool softeners to reduce strain
   d. High-fiber, high-fluid diet
   e. Topical steroids
2. Rubber band ligation for internal hemorrhoids—rubber bands applied to
hemorrhoidal bundle(s) leads to necrosis and sloughing of lesion
3. Surgical (hemorrhoidectomy)—perform surgery if the condition does not respond to conservative methods, or if severe prolapse, strangulation, very large anal tags, or fissure is present. Surgery can be performed in an outpatient setting

**Quick HIT**

**Most Common Causes of LBP**
- Musculoligamentous strain
- Degenerative disc disease
- Facet arthritis

**MUSCULOSKELETAL PROBLEMS**
Overview of Musculoskeletal Examination

Maneuvers

●●● Low Back Pain

A. General Characteristics

1. Second most common reason for medical office visits in the United States (Table 12-7).
2. Acute low back pain (LBP) refers to symptoms present for less than 4 weeks, subacute is 4 to 12 weeks, and chronic LBP refers to pain lasting more than 12 weeks. The natural history of acute and subacute LBP is very favorable. Management of chronic back pain is very challenging.
3. Risk factors for chronic LBP: smoking, obesity, older age, sedentary work, physically strenuous work, psychologically strenuous work, low educational attainment, worker’s compensation insurance, job dissatisfaction, psychological factors (depression, anxiety, etc.)
4. Majority of patients present with “nonspecific” or mechanical back pain, meaning there is no significant underlying cause such as neoplasm or infection or spine pathology.
5. If patient has significant radicular leg pain, nerve compression is likely. If leg symptoms are severe, or if objective weakness is present, an MRI of lumbar spine is obtained. An MRI is unnecessary in most patients who present with an acute episode of pain.

Quick HIT

Factors that Exacerbate Pain in Disc Herniation
- Maneuvers that increase intraspinal pressure, such as coughing or sneezing
- Forward flexion—sitting, driving, or lifting; worsens leg pain

Quick HIT

Majority of patients with lumbar disc herniation and sciatica improve with conservative care. Only about 10% will require surgical intervention.

B. Causes

1. There are many causes of LBP. Most patients who present with back pain do not have a specific spine pathology, which is referred to as “nonspecific” LBP.
2. The following conditions can all cause LBP. Note that many patients with these imaging findings do not have back pain. Therefore, imaging findings do not
necessarily correlate with symptoms. For example, many patients with degenerative disc disease or spondylolisthesis have no back pain.

a. Degenerative disc disease (osteoarthritis)—many people with severe degenerative disc disease do not have back pain. Surgery is controversial for this indication.

b. Spondylolisthesis—forward slippage of cephalad vertebra on the caudal vertebra. Most common at L4–L5 and L5–S1. Spinal stenosis often coexists, leading to neurogenic claudication.

c. Lumbar disc herniation—radicular leg pain (commonly referred to as sciatica) is the predominant finding, although some patients have back pain as well. Back pain without any radicular pain is uncommon but can occur. Most common at L4–L5 and L5–S1. Treatment is anti-inflammatory medication, physical therapy, and epidural steroid injections. Surgery indicated when conservative treatment fails or if patient has progressive neurologic deficits.

Quick HIT

Patients with spinal stenosis have leg pain with back extension—pain worsens with standing or walking (relief with bending or sitting).

Quick HIT

Pathology in other organ systems can cause back pain and should be ruled out:
- Vascular disease (aortic aneurysm, aortic dissection)
- Pancreatic disease
- Urologic disease (prostate infection, renal calculi)
- Gynecologic/obstetric disease (endometriosis, ectopic pregnancy, pelvic inflammatory disease)

d. Spinal stenosis—narrowing of spinal canal due to degenerative changes which causes neurogenic claudication. Back pain may coexist, but predominant finding is neurogenic claudication.

- Neurogenic claudication refers to radicular leg or buttock pain that is caused by spinal stenosis. It can manifest as pain, cramping, numbness, or paresthesias, particularly worse with walking and relieved with sitting.
  Forward flexion of spine improves symptoms (patients lean on shopping cart).
- Treat with epidural steroid injections if it is affecting patient’s quality of life. Surgery is very effective if conservative treatment fails.

### TABLE 12-6 Important Musculoskeletal Physical Examination Maneuvers

<table>
<thead>
<tr>
<th>General</th>
</tr>
</thead>
</table>
Important aspects include observation (asymmetry, atrophy, etc.), palpation of important landmarks (joint line, surrounding muscles and tendons, etc.), active and passive range of motion, assessment of muscle strength, and special testing (below) when a diagnosis is suspected.

### Neck

**Spurling maneuver**
- Technique: patient asked to extend neck, rotate and tilt to side of pain while downward pressure is applied onto head
- High specificity but low sensitivity for **cervical root compression**, which is suggested by reproduction of the pain below the shoulder joint (radicular pain)

### Shoulder

**Empty can test**
- Technique: arms held out in front of the patient parallel to the ground with thumbs pointed downward. Resistance is applied by the examiner and the patient tries to maintain the position
- Pain with resistance may indicate a **supraspinatus** defect

**External rotation**
- Technique: arm is held at patient’s side with elbow flexed at 90 degrees. Patient is asked to externally rotate the forearm against resistance.
- Pain with resistance may indicate an **infraspinatus** defect.

**Lift-off test**
- Technique: patient’s hand is placed behind their back with the dorsum of the hand against the back. They are asked to lift their hand off their back.
- An inability to bring their hand off their back indicates a defect in internal rotation, which may indicate a **subscapularis** defect.

**Neer test**
- Technique: the patient’s arm is fully pronated (thumb pointed downward) and forcibly flexed above their head.
- Pain with this maneuver may indicate **rotator cuff impingement**.

**Hawkins test**
- Technique: patient’s arm is abducted to 90 degrees with the elbow bent (as if holding the arm out to catch a hawk), and the examiner internally rotates the shoulder.
- Pain with this maneuver may indicate **rotator cuff impingement**.

**Cross-arm test**
- Technique: patient’s arm is held in front of them to 90 degrees and the patient actively adducts the arm (crosses it in front of them).
- Pain at the acromioclavicular (AC) joint indicates **AC joint dysfunction** (which can be confused with rotator cuff pathology).

### Knee

**Varus/valgus stress test**
- Technique: examiner stabilizes the knee joint with one hand and uses the other hand to grab the lower leg and apply a lateral force. A varus stress is when the force on the knee is applied toward the body (in a lateral to medial), and a valgus stress is the opposite.
- Laxity with a varus stress implies a defect in the **lateral collateral ligament** (LCL), and laxity with a valgus stress implies a defect in the **medial collateral ligament** (MCL).

**Lachman and anterior drawer**
- Technique: the Lachman test is performed with the knee flexed at 30 degrees whereas the anterior drawer is performed with the knee flexed at 90 degrees. In both examinations, the proximal tibia is pulled anteriorly, away from the femur.
- Excessive anterior translation of the tibia suggests an **anterior cruciate ligament** (ACL) tear.

**Posterior drawer**
- Technique: the patient is placed supine and the knee flexed at 90 degrees. The proximal tibia is pushed posteriorly toward the femur.
- Excessive posterior translation of the tibia suggests a **posterior cruciate ligament** (PCL) tear.

**McMurray test**
- Technique: the knee is passively flexed by the examiner, then externally rotated with a varus
stress as the knee is extended. This is repeated with internal rotation.

- A painful click or joint line tenderness suggests a **meniscal** injury.

---

**Quick HIT**

Chronic LBP: Imaging findings on MRI do not necessarily correlate with presence or severity of pain. Psychosocial variables are much stronger predictors of pain and disability.

---

e. **Musculoligamentous strain**—usually after an episode of bending/twisting, patient feels the back “give way,” often when lifting a heavy object, with immediate onset of back pain. Radiation of pain may occur to buttock/upper posterior thigh to knee level—this is called “referred pain” from muscle spasm. Pain typically does not radiate distal to the knee because no nerve root compression is present.

f. **Vertebral compression fracture**—acute back pain caused by minor stress in elderly or in patients on long-term steroid treatment. Pain is at the level of the fracture with local radiation across the back and around the trunk (rarely to legs).

- Can occur with minimal or no trauma in patients with osteoporosis.
- Multiple compression fractures can lead to severe kyphosis in the thoracic spine.
- Treatment options include bracing (if patient’s body habitus allows), analgesics, and giving the fracture time to heal. Most fractures heal in 6 to 8 weeks and symptoms gradually improve. Interventional options include kyphoplasty/vertebroplasty (injection of cement into vertebral body). Recent randomized controlled trials have brought the efficacy of these interventions into question.

h. **Neoplasms**—most common spinal tumor by far is metastatic carcinoma—common primary neoplasms that metastasize to spine include breast, lung, prostate, kidney, and thyroid.

---

**Infection—discitis or osteomyelitis.**

- Suspect in patients with history of IV drug use, dialysis, indwelling catheter; most common organism is *S. aureus*.
- Laboratory tests to order include CBC with differential, ESR, and CRP.
- If suspicion is high, MRI should be obtained.
- Epidural abscess in the cervical and thoracic spine can lead to rapid neurologic deterioration and in most cases, requires surgical decompression; epidural abscess in the lumbar spine can often be medically managed with antibiotics if there are no neurologic deficits and patient is not septic.
C. Back Examination

1. The main goal of the history and physical examination is to rule out any structural or systemic conditions that can be the source of back pain. The neurologic examination is very important, and any weakness should be documented.

2. The straight leg raise can suggest nerve root compression. The test is positive if radiculopathy is reproduced when the leg is elevated 30 to 60 degrees with the patient supine. If the patient is in severe pain and cannot tolerate even a slight elevation of the leg during this test, it is highly suggestive of nerve root compression.

D. Diagnostic Tests

1. Imaging is not necessary during the first 4 to 6 weeks in the absence of any of the following—progressive neurologic deficits or disabling symptoms, osteoporosis or prolonged steroid use, constitutional symptoms (unexplained fever or weight loss), history of malignancy, recent trauma, IV drug use (see also Clinical Pearl 12-7).

2. MRI is indicated if patient has failed a course of conservative treatment (rest, physical therapy, NSAIDs) for at least 3 months. Patients with neurologic signs or symptoms should have an MRI sooner, depending on the severity and acuteness of clinical findings.

CLINICAL PEARL 12-7

Cauda Equina Syndrome

- Caused by severe stenosis in the lumbar spine, most commonly due to an acute disc herniation.
- Patients present with severe back or leg pain (uni- or bilateral), with or without weakness in the legs. The key findings are bladder dysfunction (retention, incontinence) and saddle anesthesia (numbness in perineal or buttock region).
- Symptoms can have acute onset, or start with leg pain initially and over the ensuing days, progress to weakness and bladder dysfunction.
- This is a surgical emergency. An MRI should be obtained immediately.
In general, radiologic imaging is unnecessary in evaluation of LBP. Imaging is appropriate if symptoms do not resolve within 1 month or if there are neurologic signs/symptoms.

E. Treatment

1. Most patients with acute LBP have improvement or resolution within 3 to 6 weeks and are managed with NSAIDs, acetaminophen, activity modification, and gradual return to activities. Narcotic analgesics and muscle relaxants should be used judiciously, if at all. Patients should be advised to continue ordinary activities within the limits permitted by pain. If symptoms do not improve in 4 to 6 weeks, a course of physical therapy for core-strengthening exercises may be helpful.

2. If neurologic deficits present, particularly if these deficits are progressive, a more aggressive approach is indicated. An MRI should be obtained, and if nerve root or spinal cord compression is present, evaluation by a spine specialist is recommended.

3. The treatment of chronic nonspecific LBP is challenging. Most patients with chronic LBP with or without radiculopathy are treated conservatively (with physical therapy, NSAIDs, injections).
   
   a. Physical therapy is focused on core-strengthening exercises and aerobic conditioning.
   
   b. There is some evidence that massage therapy, chiropractics, and acupuncture may be helpful in the short term, but studies have not been able to show long-term benefits.
   
   c. If conservative measures fail and symptoms persist for at least 1 year, surgery can be considered, depending on findings on imaging studies and degree of disability. In general, outcomes from surgery are more predictable and successful when surgery is done for radiculopathy (to decompress nerve roots) than for LBP per se. Surgery (fusion) for degenerative disc disease and chronic LBP is controversial, and randomized controlled trials have NOT shown significant benefits. A very small percentage of patients may benefit from surgery but careful patient selection is critical and informed consent about expected outcomes is recommended.

Quick HIT

It is helpful to differentiate patients with predominantly LBP from those with predominantly leg pain. When conservative treatment has failed, surgery is often effective for leg pain, but results for LBP are less predictable.

Quick HIT

Management of LBP
Avoid prolonged inactivity (leads to deconditioning). In the first week, attempt a walking routine (20 minutes, three times per day, interspersed with bed rest).
Common Disorders of the Cervical Spine

A. General Characteristics
1. Spondylosis (osteoarthritis) of the cervical spine is very common and is not necessarily a source of neck pain. Patients with spondylosis of the cervical spine present with axial neck pain, cervical radiculopathy, or cervical myelopathy.
2. Chronic axial neck pain (without radiating arm pain) is common and just like chronic LBP can be difficult to treat. Many of the principles discussed above for nonspecific LBP apply to nonspecific neck pain as well. Surgery is not a good option for patients with neck pain without radicular arm symptoms.
3. The most common cause of acute neck pain is cervical strain which is usually self-limiting and resolves with time. Physical therapy can be helpful if symptoms last longer than 2 to 4 weeks.

B. Cervical Radiculopathy
1. Compression of a spinal nerve leads to arm pain, numbness, tingling, or weakness. Most common complaint is unilateral neck pain radiating to the arm in a dermatomal pattern.
2. The most common cause is cervical spondylosis (osteoarthritis) and disc herniation. Differential diagnosis includes shoulder pathology (impingement syndrome, rotator cuff disease), peripheral nerve entrapment (carpal tunnel or cubital tunnel syndrome), thoracic outlet syndrome, zoster, and Pancoast tumor (can present with brachial plexus symptoms).
3. The best test to diagnose nerve root compression is MRI of cervical spine.
4. Most patients can be treated conservatively (NSAIDs, time, physical therapy, epidural injections). Surgery is helpful in patients who do not respond to conservative management or who have significant weakness in one or more muscle groups.
5. It is very unusual for a patient with cervical radiculopathy to progress to myelopathy. It appears that these are two distinct entities.

Quick HIT
Shoulder impingement syndrome is often confused with cervical radiculopathy involving the C5 nerve root. If in doubt, inject the shoulder (subacromial space) with cortisone to see if symptoms resolve.

C. Cervical Myelopathy
1. Neurologic dysfunction secondary to spinal cord compression (cervical stenosis) in the cervical spine. Diagnosis made by MRI of cervical spine.
2. Earliest symptom is gait disturbance. Patients feel unsteady when ambulating.
Other symptoms include loss of hand dexterity (clumsiness, difficult with buttoning shirts, changes in handwriting), with bowel and bladder dysfunction being late findings.

a. Pain is not a common finding so patients may go undiagnosed until the myelopathy is severe.

3. Patients often start relying on a cane or walker (due to unsteady gait), and if untreated may eventually lose the ability to walk. Frank weakness is a late finding. In its most advanced stage, patients become nonambulatory, with loss of functional use of upper extremities, and bowel and bladder function.

4. Natural history is gradual deterioration. Treatment is surgery to decompress the spinal cord when diagnosis is made. Conservative treatment does not play a role in the treatment of cervical stenosis with myelopathy. Main goal of surgery is to prevent further neurologic worsening which is why it is important to make the diagnosis early. Once the patient loses the ability to ambulate, it is unlikely to return even with surgery.

Quick HIT

Gait unsteadiness in elderly patients is often not investigated and attributed to “old age.” Whenever an elderly patient begins to rely more on assistive devices for walking, consider cervical stenosis and order an MRI. Refer for surgical consultation if stenosis is present.
Knee Pain

A. Causes

1. Osteoarthritis—most common cause of knee pain in older patients (see below) (see Clinical Pearl 12-8).
2. Patellofemoral pain—very common cause of anterior knee pain; worse with climbing and descending stairs. Physical therapy aimed at quadriceps/hamstrings rehabilitation (stretching/strengthening) is very effective.
3. Degeneration or tear of a meniscus—meniscal tears may be due to a specific injury or secondary to a degenerative process (the latter being a common cause of knee pain in older patients). Key features include recurrent knee effusions, tenderness along medial or lateral joint lines, and a positive McMurray test. If no arthritic changes are present, surgery (arthroscopic meniscectomy or repair) is effective. Surgery is less effective when concomitant arthritic changes are present and results are less predictable.
4. Rheumatoid arthritis, psoriatic arthritis, SLE.
5. Acute monoarticular arthritis—septic arthritis, disseminated gonorrhea, gout, pseudogout, rheumatic fever, seronegative spondyloarthropathy, Lyme disease.
6. Osteochondritis dissecans (OCD)—an area of necrotic bone and degenerative changes in the overlying cartilage. The bone/cartilage piece may separate from the underlying bone and become a loose body in the joint, causing symptoms of pain, catching, and popping. Treatment options are limited but arthroscopic surgery can help. If the loose fragment is in the joint, arthroscopic removal of fragment is indicated.

Quick HIT
Patellofemoral pain is a very common cause of anterior knee pain. Send these patients to physical therapy to strengthen/stretch quadriceps and hamstrings.

CLINICAL PEARL 12-8

Causes of Arthritis

- Osteoarthritis (most common cause)
- Systemic immune disease—rheumatoid arthritis, SLE, seronegative spondyloarthropathies (e.g., reactive arthritis, ankylosing spondylitis, IBD)
- Crystal disease—gout, pseudogout
- Infectious—septic arthritis, Lyme disease
- Trauma
- Charcot joint (diabetes)
- Pediatric orthopedic conditions such as congenital hip dysplasia, Legg–Calvé–Perthes disease, slipped capital
7. Iliotibial (IT) band syndrome—pain over the lateral knee (where the IT band attaches to the proximal tibia), primarily in runners and cyclists.
9. Baker cyst—caused by intra-articular pathology (e.g., meniscus tear).
   a. Rupture can cause pain/swelling, and if it extends into the calf, may mimic thrombophlebitis or acute deep venous thrombosis.
   b. Majority resolves spontaneously.
    b. Running and jumping sports—an “overuse” injury.
    c. Treatment is activity modification and quadriceps/hamstring rehabilitation (stretching/strengthening program).
11. Plica syndrome—a diagnosis of exclusion, typically seen in athletes or with overuse injuries, sometimes after trauma. MRI and examination findings are unreliable. Patients have pain along the medial patella and a feeling of snapping of the knee with walking, with or without intermittent effusion. Treatment is conservative (physical therapy), anti-inflammatory medications, steroid injections. If conservative treatment fails, arthroscopic release of plica can be helpful.

**Quick HIT**

Recurrent knee effusion is a sign of intra-articular pathology and further investigation is warranted.

**B. Diagnosis**

1. Radiographs—if degenerative disease is suspected or if there is a history of trauma or acute injury.
2. MRI—if any ligamentous instability is apparent or a meniscal tear is suspected.
3. Knee aspiration (“tap”)—use this for analysis of synovial fluid if septic joint is suspected. In general, synovial fluid examination is recommended for monoarticular joint swelling. It may relieve symptoms.
Ankle Sprains

A. General Characteristics

1. The lateral side of the ankle consists of three ligaments: anterior talofibular ligament (ATFL), calcaneofibular ligament (CFL), and posterior talofibular ligament. The ATFL is most commonly injured.
2. The medial side ligaments (deltoid ligaments) are typically not injured in a classic inversion ankle sprain.
3. Classification into three grades is based on severity.
   a. Grade 1: partial rupture of ATFL.
   b. Grade 2: complete rupture of ATFL and partial rupture of CFL.
   c. Grade 3: complete rupture of both ATFL and CFL.

Quick HIT

By following the Ottawa ankle rules, unnecessary radiographs of the ankle are avoided and clinically significant fractures are not missed.

B. Diagnosis

1. Patients typically have tenderness directly over the injured ligament. ATFL is located just at the anterior tip of the distal fibula.
2. Ankle radiographs are not necessary if the following conditions are met (Ottawa ankle rules):
   a. Patient is able to walk four steps at the time of injury and at the time of evaluation.
   b. There is no bony tenderness over distal 6 cm of either malleolus.
   c. There is no bony tenderness at the base of 5th metatarsal or navicular bone.

Quick HIT

Treatment of all acute ankle sprains (even severe sprains) involves RICE and physical therapy. Surgery is rarely, if ever, needed acutely. Recurrent ankle sprains, however, require evaluation for possible surgery.

C. Treatment

1. Rest, ice, compression, elevation (RICE) in the acute period, then controlled pain-free range-of-motion exercises with gradual return to weight bearing.
2. Physical therapy after the acute phase of swelling has subsided to regain full range of motion, strength, and proprioception. Physical therapy involves peroneal tendon strengthening and proprioceptive training.
3. Surgery is rarely necessary acutely, even for grade 3 sprains.
4. Chronic ankle instability (recurrent ankle sprains) needs further evaluation by an orthopedic surgeon.

**Quick HIT**

**Impingement Syndrome**
- Common cause of shoulder pain
- Due to impingement of greater tuberosity on acromion
- Pain with overhead activity
- May lead to rotator cuff pathology over time
- Steroid injections offer temporary relief
- Surgery (acromioplasty) is very effective
Tendinitis and Bursitis

A. Tendinitis

1. Supraspinatus (rotator cuff) tendinitis—impingement syndrome.
   a. Most common cause of shoulder pain.
   b. Pain occurs subacromially and on the lateral aspect of the shoulder with arm abduction; pain is poorly localized (difficult for patient to pinpoint) with an insidious onset. It is generally located over the lateral deltoid.
   c. This is seen in elderly patients (degeneration of tendons) and in young patients who do a lot of overhand lifting/throwing (sports or work related).
   d. Pain may be referred to the lateral arm.
   e. If weakness is present on shoulder abduction, a rotator cuff tear should be suspected. (MRI is the best test for diagnosis of rotator cuff tear.)
   f. Treatment: physical therapy (strengthen shoulder musculature), subacromial steroid injection. Arthroscopic surgery is helpful if conservative treatment fails.

2. Lateral epicondylitis at the elbow (“tennis elbow”).
   a. Caused by inflammation/degeneration of the extensor tendons of the forearm, which originates from the lateral epicondyle; results from excessive/repetitive supination/pronation.
   b. Splinting the forearm (counterforce brace) is the initial treatment (do not splint or wrap the elbow itself).
   c. Physical therapy is often helpful—strengthening/stretching extensors of forearm. This, along with activity modification, typically leads to resolution of pain.
   d. Injections only if physical therapy fails. Surgery is effective but only used if all conservative measures have been exhausted. Surgery is rarely necessary for this condition.

3. Medial epicondylitis at the elbow (“golfer’s elbow”).
   a. Pain distal to medial epicondyle (origin of flexor muscles of the forearm).
   b. Exacerbated by wrist flexion; caused by overuse of the flexor pronator muscle group. Treatment similar to lateral epicondylitis (physical therapy, activity modification).

4. De Quervain tenosynovitis
   a. Pain at the radial aspect of the wrist (especially with pinch gripping) in region of radial styloid; common for pain to radiate to elbow or into thumb.
   b. Due to inflammation of the abductor pollicis longus and extensor pollicis brevis tendons.
   c. Positive Finkelstein test—have the patient clench the thumb under the other fingers when making a fist. Then ulnarly deviate the wrist. The test is positive if pain is reproduced.
d. Treatment is thumb spica splint and NSAIDs. Local cortisone injections can be helpful. Surgery done if conservative measures fail and is usually effective.

---

**Quick HIT**

Hip osteoarthritis presents with groin pain. Lateral hip pain (over the greater trochanter) or in the buttock region is not due to osteoarthritis. Before diagnosing osteoarthritis of the hip as source of pain, make certain patient’s symptoms are primarily in the groin.

**B. Bursitis**

1. Olecranon bursitis—swelling (and perhaps pain) at point of elbow; spongy “bag of fluid” over olecranon (due to effusion into the olecranon bursa).
   a. Treatment is conservative.
   b. If infection is suspected, drainage may be necessary.
2. Trochanteric bursitis—this is a very common cause of lateral hip pain. The greater trochanter is exquisitely painful on palpation.
   a. Causes include trauma, overuse injury, weakness of hip musculature. In many cases, no inciting event is present and the onset is insidious.
   b. Treatment is NSAIDs and activity modification. If symptoms persist, local cortisone injections into the bursa are very effective in providing relief.

---

**Quick HIT**

Differential diagnosis of hand numbness (as seen in carpal tunnel syndrome):
- Cervical radiculopathy (nerve root compression in the cervical spine)
- Peripheral neuropathy (diabetes)
- Median nerve compression in forearm
### Carpal Tunnel Syndrome

#### A. General Characteristics

1. Caused by **median nerve compression** within the tight confines of the carpal tunnel, causing numbness and pain in median nerve distribution. If long standing and severe, atrophy of thenar muscles may be seen.
2. Associated conditions include hypothyroidism, diabetes, repetitive use of hands in certain activities, pregnancy, recent trauma, or fracture of the wrist.

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>A negative Phalen test or Tinel sign does not exclude carpal tunnel syndrome.</td>
</tr>
</tbody>
</table>

#### B. Clinical Features

1. Numbness, pain, or tingling in the **median nerve distribution**—usually worse at night; sometimes patient has pain/numbness along the entire arm (as far as the shoulder).
2. Muscle weakness and thenar atrophy may develop later.

#### C. Diagnosis

1. Physical examination
   a. **Tinel sign**—tap over median nerve at wrist crease; causes paresthesias in median nerve distribution
   b. **Phalen test**—palmar flexion of the wrist for 1 minute; causes paresthesias in median nerve distribution
2. Electromyography (EMG) and nerve conduction velocity (NCV) study
   a. For definitive diagnosis
   b. Indicated if diagnosis is not clear from clinical findings or if patient develops weakness or persistent symptoms

#### D. Treatment

1. Wrist splints (volar carpal splint) should be worn at night during sleep. The purpose is to prevent wrist flexion during sleep (which compresses the nerve).
2. Anti-inflammatory medications (NSAIDs).
3. Local corticosteroid injection—relief can be long term in some patients.
4. Surgical release is very effective. Consider this option for patients who have persistent symptoms or if the symptoms are limiting the patient’s activities or quality of life.
Osteoarthritis

A. General Characteristics
1. Osteoarthritis (OA) is characterized by degeneration of cartilage (due to wear and tear) and by hypertrophy of bone at the articular margins.
2. By age 65, more than 75% of the population has radiographic evidence of osteoarthritis in weight-bearing joints (hips, knees, lumbar spine).
3. Any joint can be affected, but weight-bearing joints are most commonly involved (hips, knees, cervical, and lumbar spine).

B. Risk Factors
1. Age
2. Obesity
3. Excessive joint loading (manual labor, athletes, etc.)
4. Trauma
   a. Repeated microtrauma—in many cases, a patient’s occupation or athletic activities requires repetitive motions (such as repeated knee bending) that predispose the patient to degenerative joint disease in later years
   b. Macrotrauma (fractures, ligament injuries)—intra-articular fractures can cause OA
5. Genetic predisposition
6. Altered joint anatomy or instability (developmental hip dysplasia, dislocation due to trauma, rheumatoid arthritis, gout, pseudogout)
7. Deposition diseases cause chondrocyte injury, or make the cartilage stiffer (hemochromatosis, ochronosis, alkaptonuria, Wilson disease, Gaucher disease, gout, CPPD)
8. Hemophilia (hemarthroses)

Quick HIT

The following can contribute to or exacerbate forces to the cartilage:
- Compromised pain sensation or proprioception
- Ligamental laxity
- Falls of very short distances (because they do not provide ample opportunity for compensatory movements to decrease the impact load)

C. Clinical Features
1. Joint pain (often monoarticular)
   a. This is caused by movement of one joint surface against another (bone on bone) because of cartilage loss. There are no pain fibers in cartilage, so its insidious
destruction over time goes unnoticed. Once it is completely worn out, the bones (which do have pain fibers) start rubbing against each other, producing the pain of osteoarthritis

**Quick HIT**

If the spine is involved, nerve roots may become compressed and lead to radicular pain.

b. Deep, dull ache that is relieved with rest and worsened with activity  
c. Insidious onset, with gradual progression over many years

2. Stiffness in the morning or after a period of inactivity (Note: morning stiffness lasting >30 minutes may suggest an inflammatory arthritis such as rheumatoid arthritis)

3. Limited range of motion (late stages) due to bony enlargement of joints (osteophytes); bony crepitus may be present

4. No systemic symptoms; no erythema or warmth. Swelling may be present and suggests inflammation

**Quick HIT**

Hip osteoarthritis causes pain in the groin (not lateral hip or buttock). If patient is tender over the lateral aspect of hip, suspect greater trochanteric bursitis.

**D. Diagnosis**

1. Plain radiographs are the initial tests and should be obtained in all patients suspected of having osteoarthritis (Figure 12-4). Ideally, radiographs should be obtained in the standing position (for lower extremities). Findings include:  
   a. **Joint space narrowing** (due to loss of cartilage)—key finding on radiographs  
   b. **Osteophytes**  
   c. **Sclerosis** of subchondral bony end plates adjacent to diseased cartilage—most severe at points of maximum pressure  
   d. **Subchondral cysts**—occur as a result of increased transmission of intra-articular pressure to the subchondral bone

2. All blood tests are normal

3. MRI of the spine if indicated (neurologic findings, before surgery)

**Quick HIT**

Radiographic findings in osteoarthritis: joint space narrowing, osteophytes, subchondral sclerosis, subchondral cysts.
E. Treatment

   a. Avoid activities that involve excessive use of the joint.
   b. Weight loss is very important.
   c. Physical therapy can be beneficial. Goals are to maintain range of motion and muscle strength. Swimming is an ideal exercise (involves minimal involvement of weight-bearing joints); avoid excessive walking.
   d. Use canes or crutches to reduce weight on the joint.

   a. Acetaminophen is the first-line agent.
   b. NSAIDs are just as effective as acetaminophen (but GI bleeding is a concern with long-term use). Of selective COX-2 inhibitors, only celecoxib remains on the market but is rarely used. All the others have been removed from the market due to increased risk of cardiovascular events. Main benefit of selective COX-2 inhibitors is a decrease in gastric/duodenal ulcers and a decrease in GI symptoms, with the same (not superior) analgesic and anti-inflammatory effects of the nonselective NSAIDs.
   c. Intra-articular injections of corticosteroids are very helpful, but more than three to four injections per year is not recommended. Patients may have up to 3 months of pain relief with each injection. In elderly patients with severe OA who are not good surgical candidates for joint replacement, more frequent injections are justified if it provides good pain control.
   d. Viscosupplementation—hyaluronic acid is injected into the knee joint and augments the viscoelastic properties of normal synovial fluid. Recent studies show good pain relief, but results are variable.

Quick HIT

Common (but Useless) “Pimp” Information
- **Bouchard nodes**: Bony overgrowth and significant osteoarthritic changes (i.e., osteophytes) at the PIP joints
- **Heberden nodes**: Bony overgrowth and significant osteoarthritic changes (i.e., osteophytes) at the DIP joints

Quick HIT

With osteoarthritis of the hips, the pain is in the **groin region** and sometimes radiates to the anterior thigh.

Quick HIT

For **left** knee or hip pain, the cane should be held in the **right** hand.
   a. Total joint replacement may be performed if conservative therapy fails to control pain. It should be delayed as long as possible because a revision may be needed 15 to 20 years after surgery. Total hip and knee replacements are among the most successful procedures in orthopedics with reliable pain relief.

Quick HIT

Although x-rays are diagnostic of OA, not all patients with x-ray findings of OA have symptoms. There is no consistent correlation between symptoms and severity of x-ray findings.

   a. Over-the-counter products that many patients claim to improve arthritis symptoms, although high-quality randomized trials have not shown any meaningful benefit.
FIGURE 12.4  A: Right knee AP radiograph showing osteoarthritis. Note medial joint space narrowing, osteophyte formation (curved arrow), and irregular articular surfaces (straight arrow). B: Pelvic AP radiograph. Bilateral osteoarthritis of the hip. Note narrowing of hip joint spaces, osteophytes (curved arrows), and osteophytes in the lumbar spine (double curved arrows). Also note subchondral cysts and sclerosis of the femoral heads.

Osteoporosis

A. General Characteristics
1. Decreased bone mass/quality causes increased bone fragility and fracture risk. In osteoporosis, the bone mineral density is at least 2.5 standard deviations below that of young, normal individuals.

Quick HIT
It is often difficult to differentiate between primary and secondary osteoporosis, and the two may coexist. It is best to attempt to identify any predisposing conditions and eliminate them if possible.

2. Mechanism: failure to attain optimal (peak) bone mass before age 30, or rate of bone resorption exceeds rate of bone formation after peak bone mass is attained

3. Most osteoporotic patients are postmenopausal women and elderly men

Quick HIT
Some elderly patients have progressive kyphosis (hunchback deformity) because they have multiple vertebral compression fractures.

4. Classification
a. Primary osteoporosis (two types that are impractical clinically)
   - Type I (most often in postmenopausal women 51 to 75 years of age)—excess loss of trabecular bone; vertebral compression fractures and Colles fractures are common
   - Type II (most often in men and women over 70 years of age)—equal loss of both cortical and trabecular bone; fractures of femoral neck, proximal humerus, and pelvis most common
b. Secondary osteoporosis—an obvious cause is present, such as excess steroid therapy/Cushing syndrome, immobilization, hyperthyroidism, long-term heparin, hypogonadism in men, and vitamin D deficiency

Quick HIT
Osteoporosis is a “silent” disease. It is asymptomatic until a fracture occurs.

B. Risk Factors
1. Estrogen depletion
   a. Postmenopausal state—all women are estrogen deficient after menopause;
however, osteoporosis does not develop in all women
b. History of athletic amenorrhea, eating disorders, oligomenorrhea
c. Early menopause

Quick HIT

An exercise program along with calcium and vitamin D supplementation is the mainstay of the therapy for prevention or treatment of osteoporosis.

2. Female gender—women have a lower peak bone mass and smaller vertebral end plates
3. Calcium deficiency/vitamin D deficiency
4. Decreased peak bone mass
5. Heritable risk factors—family history, European or Asian ancestry, thin/slight build
6. Decreased physical activity (prolonged immobility)
7. Endocrine—hypogonadism in men (with low testosterone), hyperthyroidism (see Clinical Pearl 12-9)
8. Smoking and alcohol abuse
9. Medications—corticosteroids, prolonged heparin use

Quick HIT

The PROOF trial showed the following regarding calcitonin:
• No effect at hip
• Shown to decrease risk of vertebral fractures by as much as 40%
• Slight increase in bone density at lumbar vertebrae

Quick HIT

Recommend the following to all patients with osteoporosis:
• Daily calcium
• Daily vitamin D
• Weight-bearing exercise
• Smoking cessation

C. Clinical Features
1. Vertebral body compression fractures (of the middle and lower thoracic and upper lumbar spine) are the most common. Very rare in cervical spine
   a. Result in pain and deformity, including kyphosis
   b. Severe back pain after minor trauma
   c. Restricted spinal movement, loss of height
2. Colles fracture (distal radius fracture)—usually due to fall on outstretched hand; more common in postmenopausal women
3. Hip fractures—femoral neck, intertrochanteric fractures
4. Increased incidence of long bone fractures—humerus, femur, tibia

**Quick HIT**

Of all fragility fractures, hip fractures have highest morbidity and mortality.

**CLINICAL PEARL 12-9**

**Osteoporotic Fracture Risk Assessment**

Validated risk factors for osteoporotic fracture risk that are independent of bone mineral density are:

- Advanced age
- Previous osteoporotic fracture
- Long-term steroid therapy
- Cigarette smoking
- Low body weight (<58 kg)
- Family history of hip fracture
- Excess alcohol intake
- Rheumatoid arthritis
- Secondary osteoporosis

**D. Diagnosis**

1. DEXA (dual-energy x-ray absorptiometry) scan is the gold standard.
   a. Very precise for measuring bone density.
   b. Indications for bone mineral density measurement:
      - All women 65 and older.
      - Postmenopausal women <65 with one or more risk factors for fracture.
      - Men with risk factors for fracture.

**Quick HIT**

If DEXA scan is normal and no risk factors, repeat DEXA in 3 to 5 years.

   c. Sites selected are femoral neck and lumbar spine. Compare the density of bone with a standard control, which is the bone density of a healthy 30-year-old person.
   d. Can range from normal to osteopenia to osteoporosis. T-scores are used according to WHO classification (see Table 12-8).
      - WHO classification (T-scores) are used in all postmenopausal and
perimenopausal women, and in men over age 50. In all other patients (including premenopausal women), z-scores are used.

2. Rule out secondary causes—check calcium, phosphorus, alkaline phosphatase, TSH, vitamin D, free PTH, creatinine, CBC.

Quick HIT

Unfortunately, most patients with fragility fractures do not subsequently receive osteoporosis therapy, despite data showing a beneficial effect in reducing the risk of a second fracture.

E. Treatment

1. Nonpharmacologic therapy
   a. Diet—adequate calorie intake, avoid malnutrition
      - Supplemental elemental calcium (1,200 mg/day)
      - 800 international units of vitamin D daily
   b. Exercise—weight-bearing exercise for 30 minutes, at least 3 times a week, to stimulate bone formation
   c. Smoking cessation is critical—smoking accelerates bone loss
   d. Eliminate or reduce alcohol intake

2. Pharmacologic therapy
   a. Indicated in the following patients:
      - Postmenopausal women with established osteoporosis (T-score −2.5 or less) or fragility fracture (hip or vertebral)
      - High-risk postmenopausal women with osteopenia (T-score between −1.0 and −2.5)
   b. Bisphosphonates inhibit bone resorption and are first-line treatment
      - They decrease osteoclastic activity (via binding to hydroxyapatite) and decrease the risk of fractures
      - Oral bisphosphonates (alendronate, risedronate) are preferred in most patients
      - Side effects include reflux, esophageal irritation, and ulceration
      - If patient cannot tolerate oral bisphosphonates, use IV bisphosphonates (IV zoledronic acid)
   c. PTH therapy or human recombinant PTH therapy
      - PTH is an effective drug that increases bone mineral density and reduces fracture risk. Due to high cost, subcutaneous administration, and long-term safety concerns, it is not a first-line drug
      - Indicated in patients with severe osteoporosis (T-score less than −2.5) who cannot tolerate bisphosphonates, or who continue to fracture despite being on bisphosphonates for 1 year
Maximum duration of treatment is 24 months, because of concern for osteosarcomas, which have been observed in rats. After stopping PTH, can restart bisphosphonates

d. Calcitonin (can be administered by nasal spray)—long-term benefits are minimal, but it is useful as short-term therapy, especially in elderly female patients with vertebral compression fracture. It is less popular and not commonly used

e. Estrogen–progestin therapy is no longer a first-line approach for the treatment of osteoporosis in postmenopausal women because of increased risk of breast cancer, stroke, venous thromboembolism, and perhaps CAD

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>T-Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>Greater than or equal to 1.0</td>
</tr>
<tr>
<td>Osteopenia</td>
<td>Between −1.0 and −2.5</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>Less than or equal to −2.5</td>
</tr>
<tr>
<td>Severe osteoporosis</td>
<td>Less than or equal to −2.5 and fragility fracture</td>
</tr>
</tbody>
</table>

Diseases of the Eye

Age-Related Macular Degeneration

Most common cause of vision loss in people over 65 years of age in developed countries.

Age-related macular degeneration (ARMD) is characterized by loss of central vision (because the macula is affected). Blurred vision, distortion, and scotoma are common. Complete loss of vision almost never occurs. Peripheral vision is preserved.
The main risk factor is advanced age. Other risk factors are female gender, Caucasian race, smoking, HTN, and family history.

Two categories: exudative (“wet”) and nonexudative (“dry”) macular degeneration. Exudative ARMD causes sudden visual loss due to leakage of serous fluid and blood as a result of abnormal vessel formation (neovascularization) under the retina. Nonexudative ARMD is characterized by atrophy and degeneration of the central retina. Yellowish-white deposits called drusen form under the pigment epithelium and can be seen with an ophthalmoscope.

Intraocular injections of medications (anti-VEGF inhibitors) have supplanted laser photocoagulation and other therapies for wet ARMD.
Over-the-counter formulations of vitamins are recommended for dry and wet ARMD.

Quick HIT

Most common causes of visual impairment/loss in developed countries:

- Diabetic retinopathy (most common cause in adults <65 years)
- ARMD (most common cause in adults >65 years)
- Cataracts
- Glaucoma
Glaucoma

A. General Characteristics

1. Glaucoma is one of the most important causes of blindness worldwide. It is a complex disease typically characterized by increased IOP, damage to the optic nerve, and irreversible vision loss.

2. The pathogenesis of optic nerve damage in glaucoma is not fully understood. Ischemia may play a major role. Over time, there is a loss of ganglion cells, leading to atrophy of the optic disc and enlargement of the optic cup, called “cupping.”

Quick HIT

Age-Related Macular Degeneration

- The “wet” form of ARMD can develop at any time, so patients with “dry” ARMD must be monitored closely.
- Supplements of certain vitamins containing antioxidants are thought to be beneficial, but a preventative or therapeutic effect has not been proven.
- Ranibizumab (and several other related drugs), given as repeated intraocular injections, have been shown to be effective in treating “wet” ARMD.

3. There are many types of glaucoma, but they generally fall into the following two categories:

   a. Open-angle glaucoma—accounts for 90% of all cases.
      - Characterized by impaired outflow of aqueous humor from the eye.
      - Absence of symptoms early in the course can lead to delay in diagnosis and “silent” progression.

b. Closed-angle glaucoma.
   - Acute angle-closure glaucoma—characterized by very rapid increase in IOP due to occlusion of the anterior chamber angle (between the cornea and the iris where the trabecular meshwork is located) and obstruction of outflow of aqueous humor.
   - This is an ophthalmologic emergency that can lead to irreversible vision loss within hours if untreated.
   - May be precipitated by dilation of the iris in a patient with a pre-existing anatomically narrow anterior chamber angle.

Quick HIT

Glaucoma is the most common cause of irreversible blindness in African Americans.
B. Risk Factors
1. Older age (over 50 years)
2. African-American race (increased incidence of open-angle glaucoma)
3. Asian or Eskimo ancestry (increased incidence of acute angle-closure glaucoma)
4. Family history of glaucoma
5. History of significant eye trauma or intraocular inflammation
6. Steroid medications

C. Clinical Features
1. Open-angle glaucoma
   a. Painless, increased IOP (may be the only sign), characteristic changes in optic nerve
   b. Progressive and insidious visual field loss (usually sparing central vision until end-stage disease)

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with acute angle-closure glaucoma may have severe abdominal pain and nausea, and they are occasionally misdiagnosed as having an acute surgical abdomen (e.g., appendicitis).</td>
</tr>
</tbody>
</table>

2. Closed-angle glaucoma
   a. Red, painful eye
   b. Sudden decrease in visual acuity (blurred vision), seeing “halos,” markedly elevated IOP
   c. Nausea and vomiting (common), headache
   d. Involved pupil is dilated and nonreactive (in mid-dilation)

D. Diagnosis
1. Tonometry measures IOP; should be performed regularly in patients with or at risk for glaucoma.
2. Ophthalmoscopy—evaluate the optic nerve for glaucomatous damage.
3. Gonioscopy is used to visualize the anterior chamber and helps determine the cause of glaucoma. It requires skill to perform.
4. Visual field testing should be performed in all patients in whom glaucoma is suspected and regularly in everyone with glaucoma to monitor disease progression.
5. Imaging (OCT) of the optic nerve also is helpful in assessing and monitoring progression of axonal loss of the optic nerve in glaucoma patients.

E. Treatment
1. Chronic open-angle glaucoma (in escalating order).
a. Topical medications—most patients are first treated topically with a β-blocker, α-agonist, carbonic anhydrase inhibitor, and/or prostaglandin analogue by themselves or in combination to reach the target pressure.
b. Laser or surgical treatment for refractory cases.

**Quick HIT**

The goal of treatment is to control IOP, and thereby prevent further optic nerve and visual field loss.

   a. An ophthalmic emergency—refer to an ophthalmologist immediately.
      Emergently lower the IOP. Medical treatment includes timolol, brimonidine, dorzolamide, pilocarpine, and/or prednisolone drops. Can give IV acetazolamide and oral mannitol if IOP is still elevated after previous measures.
   b. Laser or surgical iridectomy is a definitive treatment.
Cataracts

Opacifications of the natural lens of the eye: half of people over age 75 have cataracts (Figure 12-5).

There is a loss of visual acuity that progresses slowly over many years. Patients may complain of glare and difficulty driving at night. Risk factors include old age, cigarette smoking, glucocorticoid use, prolonged UV radiation exposure, trauma, diabetes, Wilson disease, Down syndrome, and certain metabolic diseases.

Surgery is the definitive treatment and is very effective in restoring vision. It is indicated if visual loss is significant to the patient and interferes with daily or occupational activities. It involves extraction of the cataract with implantation of an artificial intraocular lens.

(From Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, Figure 12-2.)
Red Eye

A. General Characteristics

1. Many causes of red eye are benign, but the initial goal in evaluation should be to identify conditions that require (emergent or nonemergent) referral to an ophthalmologist.
2. Conjunctivitis is the most common cause of red eye, but always attempt to exclude other, more serious causes.
3. The following conditions require a referral to an ophthalmologist:
   a. Eye pain that does not respond to therapy.

Quick HIT

“Second Sight”
- Some patients with cataracts become increasingly near-sighted and may no longer require reading glasses. This is referred to as “second sight.”
- This phenomenon is due to the cataract increasing the refractive power of the lens of the eye.

   b. Flashers, floaters, or a sudden decrease in visual acuity.
   c. History of recent eye surgery—especially if infection is suspected.
   d. Corneal opacification, corneal ulcer, or corneal foreign body that cannot be removed.
   e. History of penetrating trauma or significant blunt trauma.
   f. History of chemical exposure (especially alkali agents).
   g. Orbital cellulitis.
   h. Presence of hypopyon or ciliary flush (suggests acute glaucoma, corneal inflammation, or iridocyclitis)
   i. Asymmetric or unreactive pupils.

4. Always check visual acuity, pupil size, and reactivity. Evert lids to look for a foreign body.

Quick HIT

In general, steroid eye drops should only be administered by an ophthalmologist.

B. Differential Diagnosis

1. Conjunctivitis—see below
2. Subconjunctival hemorrhage
   a. Caused by rupture of small conjunctival vessels; induced by Valsalva maneuver trauma or, less commonly, coagulopathies or HTN
b. Causes focal unilateral blotchy redness of the conjunctiva (looks worse than it is)
c. Usually self-limiting and resolves in a few weeks

3. Keratoconjunctivitis sicca (dry eye)
   a. Very long differential diagnosis, including medications (e.g., anticholinergics or antihistamines), autoimmune diseases (e.g., Sjögren’s), CN V or VII lesions
   b. The eye may appear normal, or may be mildly injected
   c. Patients may complain of a foreign body sensation
   d. Treat with artificial tears during the day. Consider a lubricating ointment at night. Many other treatments are available

4. Acute angle-closure glaucoma (see above)—consult an ophthalmologist immediately

5. Blepharitis
   a. Inflammation of the eyelid; often associated with infection with *Staphylococcus* spp.
   b. Usually diagnosed by careful examination of the eyelid margins, which are red and often swollen with crusting that sticks to the lashes
   c. Treat with lid scrubs and warm compresses. Give topical antibiotics for severe cases

6. Episcleritis
   a. Inflammation of vessels lining the episclera (the lining just beneath the conjunctiva)
   b. Thought to be an autoimmune process—may be seen with connective tissue diseases, but usually idiopathic
   c. Causes redness, irritation, dull ache, and possible watery discharge
   d. The sclera may appear blotchy with areas of redness over the episcleral vessels
   e. Usually self-limiting; NSAIDs may provide symptomatic relief
   f. Refer the patient for evaluation by an ophthalmologist

7. Scleritis
   a. Inflammation of the sclera is associated with systemic immunologic disease, such as rheumatoid arthritis
   b. It causes significant eye pain (severe, deep pain). On examination, there is ocular redness and pain on palpation of the eyeball. It can cause visual impairment
   c. Refer the patient for prompt evaluation by an ophthalmologist. Treatment involves topical and sometimes systemic corticosteroids

8. Acute anterior uveitis (also known as iritis or iridocyclitis)
   a. Inflammation of the iris and ciliary body; more common in the young and middle-aged
b. Associated with connective tissue diseases (e.g., sarcoidosis, ankylosing spondylitis, Reiter syndrome, and IBD)

c. Clinical findings: ciliary flush (redness most prominent around the cornea), blurred vision, pain and photophobia; constricted pupil compared with contralateral eye

d. Refer the patient for prompt evaluation by an ophthalmologist

9. Herpes simplex keratitis

a. Caused by HSV-1; may present similarly to viral conjunctivitis, except usually unilateral

b. Presents with ocular irritation and photophobia. Pain may be absent

c. Look for classic **dendritic ulcer on the cornea; can result in irreversible vision loss if untreated**

d. Warrants semiurgent ophthalmology referral

e. Treat with topical antiviral eye drops or ganciclovir gel. Consider oral acyclovir or valcylovir for those who cannot tolerate or administer topical therapy.

**Quick HIT**

**Viral conjunctivitis is highly contagious!** Patients should avoid any direct or indirect eye contact with others. Encourage strict personal hygiene and frequent handwashing. Clean all surfaces and equipment in contact with the patient as soon as the patient leaves the office.
Conjunctivitis

A. General Characteristics
1. Conjunctivitis is the most common cause of red eye.
2. Conjunctivitis generally refers to inflammation of the transparent membrane that lines the inside of the eyelids (palpebral conjunctiva) and the globe (bulbar conjunctiva).

**Quick HIT**
When a patient presents with red and itchy eyes, tearing, and nasal congestion, think allergic conjunctivitis.

B. Causes
1. Viral conjunctivitis (see also Clinical pearl 12-10).
   a. The **most common** form of conjunctivitis. Adenovirus is the most common organism.
   b. Inquire about a recent history of URI.
   c. Hyperemia of one or both eyes, usually one eye followed by spread to the other in a few days is common. Watery discharge is frequently present.
   d. A palpable preauricular lymph node may be present.

**Quick HIT**
Wearing contact lenses overnight dramatically increases a person’s risk for developing corneal infection and ulceration.

e. It is usually self-limited, but some patients develop membranous conjunctivitis that requires topical steroids and stripping of the membranes.

2. Bacterial conjunctivitis.
   a. Most commonly caused by *S. aureus* in adults, though other common organisms include *S. pneumoniae, H. influenzae*, and *M. catarrhalis*.
   b. Rapid onset of irritation, hyperemia, and tearing.
   c. Characterized by a mucopurulent exudate with crusting.

**CLINICAL PEARL 12-10**

Do Not Send a Patient Home Who Has a Rapid Onset of Copious, Purulent Exudate!
- This is consistent with **hyperacute bacterial conjunctivitis**, caused by *Neisseria gonorrhoeae*.
- The typical patient is a sexually active young adult.
Symptoms progress rapidly to severe redness, swelling, and pain. This warrants immediate attention from an ophthalmologist. If untreated, it can lead to corneal scarring and blindness.

3. Chlamydial conjunctivitis—two important forms.
   a. Trachoma (caused by *Chlamydia trachomatis* serotypes A, B, and C)
      • Most common cause of blindness worldwide due to chronic scarring.
   b. Inclusion conjunctivitis (*C. trachomatis* serotypes D to K).
      • Mainly transmitted by genital-hand-eye contact in patients with sexually transmitted infection (STI).

   a. Very common in patients with atopic disease; usually seasonal.
   b. It is typically characterized by redness, itching, tearing, and nasal conjunctivitis. Eyelid edema may also be present. It is typically bilateral.

5. Conjunctivitis secondary to irritants (e.g., contact lenses, chemicals, foreign bodies, dryness).

C. Treatment

1. Viral conjunctivitis: cold compress, strict hand washing; topical antibiotics if bacterial superinfection is suspected
2. Bacterial conjunctivitis
   a. Acute—use broad-spectrum topical antibiotics (e.g., erythromycin, ciprofloxacin, sulfacetamide). Therapy can be altered based on culture results
   b. Hyperacute—treat gonococcal conjunctivitis with a one-time dose of ceftriaxone, 1g IM, as well as topical therapy.

3. Chlamydial conjunctivitis
   a. Adults and adolescents—oral tetracycline, doxycycline, or erythromycin for 2 weeks
   b. Treat sexual partner(s) for STI

4. Allergic conjunctivitis
   a. Remove the allergen, if possible. Advise the use of cold compresses
   b. Treat with topical antihistamines or mast cell stabilizers
   c. Systemic antihistamines can be effective as well
   d. Topical NSAIDs may be a useful adjunct to treatment
Amaurosis Fugax

Some variability with how this is defined, but generally refers to sudden, transient loss of vision in one or both eyes
Causes of transient monocular vision loss include carotid artery disease (cholesterol plaque embolization), cardioembolic phenomenon, giant cell (temporal) arteritis, and others
Order carotid ultrasonography and cardiac workup (e.g., lipid profile, ECG)
Sleep Disorders

Obstructive Sleep Apnea

A. General Characteristics
1. Intermittent obstruction of the air flow (typically at the level of the oropharynx) produces periods of apnea during sleep.
2. Each apneic period is usually 20 to 30 seconds long (but may be longer) and results in hypoxia, which arouses the patient from sleep. This occurs multiple (sometimes hundreds of) times overnight.

B. Risk Factors
1. Obesity (especially around the neck)—although nonobese patients can also have OSA
2. Structural abnormalities—enlarged tonsils, uvula, soft palate; nasal polyps; hypertrophy of muscles in the pharynx; deviated septum; deep overbite with small chin
3. Family history
4. Alcohol and sedatives worsen the condition
5. Hypothyroidism (multifactorial)

C. Clinical Features
1. Snoring
2. Daytime sleepiness due to disrupted nocturnal sleep
3. Personality changes, decreased intellectual function, decreased libido
4. Repeated oxygen desaturation and hypoxemia can lead to systemic and pulmonary HTN as well as cardiac arrhythmias
5. Other features: morning headaches, polycythemia

D. Diagnosis Polysomnography (overnight sleep study in a sleep laboratory) confirms the diagnosis.

E. Treatment
1. All patients should undergo behavior modification, which includes weight loss and exercise, avoiding alcohol and sedatives, and sleeping in a nonsupine position
2. Mild to moderate OSA
   a. Should be offered positive airway pressure therapy
   b. If patient refuses or there are issues with compliance, an oral appliance can be offered
3. Severe OSA
   a. **Continuous positive airway pressure** provides positive pressure, thus preventing occlusion of the upper pharynx. This is the preferred therapy for the majority of patients because it is noninvasive and has proven efficacy. It is poorly tolerated by some due to noise and discomfort.
   b. Uvulopalatopharyngoplasty—removal of redundant tissue in oropharynx to allow for more air flow.
   c. Tracheostomy is a last resort for those in whom all other therapies have failed or who have life-threatening OSA (severe hypoxemia or arrhythmias).

Quick HIT

**Complications of OSA**
- Increased pulmonary vascular resistance (due to hypoxemia); over time, can lead to pulmonary HTN and eventually cor pulmonale (more likely if the patient is obese).
- Systemic HTN (due to increase in sympathetic tone).
Narcolepsy

- Inherited disorder (of variable penetrance) of REM sleep regulation (i.e., REM sleep involuntarily occurs at random and inappropriate times)
- Results in **excessive sleepiness** during the day
- Characterized by the following features:
  1. Involuntary “sleep attacks” at any time of day (during any activity, including driving) that last several minutes
  2. Cataplexy, which is loss of muscle tone that generally occurs with an intense emotional stimulus (e.g., laughter, anger)
  3. Sleep paralysis, in which patient cannot move when waking up
  4. Hypnagogic hallucinations that are vivid (visual or auditory)—“dreams” while awake
- The disorder can range from mild to severe
- Automobile accidents are a major problem
- Treatment: modafinil (use is supported by RCTs), methylphenidate (Ritalin), or amphetamines; planned naps during the day may prevent sleep attacks
Insomnia

A. Causes

1. Acute or transient insomnia is usually due to psychological stress or travel over time zones (“jet lag”)
2. Chronic causes
   a. Secondary insomnia accounts for over 90% of all cases
      - Psychiatric conditions—depression, anxiety disorders, posttraumatic stress disorder, manic phase of bipolar disorder, schizophrenia, obsessive-compulsive disorder
      - Medications and substance abuse—alcohol, sedatives (with prolonged use, patients develop tolerance and withdrawal rebound insomnia), caffeine, β-blockers, stimulant drugs (amphetamines), decongestants, some SSRIs, nicotine
      - Medical problems—advanced COPD, renal failure, CHF, chronic pain
      - Other—fibromyalgia, chronic fatigue syndrome (CFS)
   b. Primary insomnia is a diagnosis of exclusion. DSM-5 defines it as dissatisfaction with sleep and one of the following: difficulty initiating sleep, difficulty maintaining sleep, or early-morning awakenings and a subsequent inability to fall back asleep
      - By definition, it is nonrestorative sleep that occurs three nights per week for at least 3 months in the absence of other medical, psychiatric, or sleep disorders, and that causes clinically significant distress and social or occupational impairment
      - Patients worry excessively about not falling asleep and become preoccupied with it. The cause is unknown

Quick HIT

Questions to ask the patient with insomnia—sleep history, timing of insomnia, sleep habits

B. Treatment

1. Treat the underlying cause, if found.
2. Consider a psychiatric evaluation if psychiatric causes or primary insomnia are suspected.
3. Use sedative–hypnotic medications sparingly and with caution for symptomatic relief. Use the smallest dose possible, and avoid use for longer than 2 to 3 weeks.
Miscellaneous Topics

Obesity

A. General
1. Considered to be a global epidemic, particularly in developed nations
2. Health hazards associated with obesity: HTN, heart disease, hyperlipidemia, type 2 diabetes, stroke, osteoarthritis, liver disease, cancer, OSA, obesity hypoventilation syndrome, and depression
3. Obesity is associated with a significant increase in mortality
4. Body Mass Index (BMI) = weight divided by height squared (kg/m$^2$)
   a. Underweight: BMI less than 18.5
   b. Normal: 18.5 to 24.9
   c. Overweight: 25 to 29.9
   d. Obese: 30 and over
      • Obesity class I: 30 to 34.9
      • Obesity class II: 35 to 39.9
      • Obesity class III: 40 and over

B. Treatment
1. Diet, exercise, and lifestyle modification are mainstays of treatment.
2. Drug therapy—for patients who have not succeeded in losing weight with diet and exercise. Orlistat is a first-line agent and can be continued for up to 4 years.
   a. Bariatric surgery is effective in reducing comorbidities associated with obesity, including HTN, diabetes, OSA, and hyperlipidemia. This translates into a 29% reduction in mortality. Only indicated in patients who have earnestly tried other means of losing weight and have been unsuccessful.
   b. Best evidence is for patients with BMI over 40.
   c. Bariatric surgery is based on two mechanisms: restriction of intake (via a small stomach reservoir) and malabsorption (via decreasing small bowel length). Restrictive techniques are technically easier, have lower complication rates, but result in less weight loss than malabsorptive techniques[AQ4].
   d. Most common procedure is the laparoscopic Roux-en-Y gastric bypass. The laparoscopic adjustable gastric banding (LapBand) has fewer complications, is reversible, but is not as effective in achieving weight loss as compared with the gastric bypass.
**Hearing Loss/Impaired Hearing**

**A. General Characteristics—two types of hearing loss**

1. Conductive hearing loss
   a. **Caused by lesions in the external or middle ear**
   b. Due to interference with mechanical reception or amplification of sound, which occurs with disease of the auditory canal, tympanic membrane, or ossicles

2. Sensorineural hearing loss—due to lesions in the cochlea or CN VIII (auditory branch)

**B. Causes**

1. Conductive hearing loss
   a. External canal
      - Cerumen impaction—buildup obstructs the auditory canal (most common cause)
      - Otitis externa
      - Exostoses—bony outgrowths of external auditory canal related to repetitive exposure to cold water (e.g., scuba divers, swimmers)

   b. Tympanic membrane perforation
      - Usually due to trauma (direct or indirect)
      - May be secondary to middle ear infection

   c. Middle ear
      - Any cause of middle ear effusion (fluid in middle ear interferes with sound conduction)—otitis media, allergic rhinitis
      - Otosclerosis—bony fusion (immobilization) of the stapes to the oval window; an autosomal dominant condition (variable penetrance); corrected with surgery; rarely progresses to deafness
      - Other—neoplasms, congenital malformation of the middle ear

2. Sensorineural hearing loss
   a. Presbycusis (most common cause)
      - Gradual, symmetric hearing loss associated with aging—most common cause
of diminished hearing in elderly patients

- Pathology—degeneration of sensory cells and nerve fibers at the base of the cochlea
- Hearing loss is most noticeable at high frequencies with slow progression to lower frequencies

Quick HIT

Hearing Impairment

- History: medications; history of head trauma, infection (otitis media, otitis externa); noise exposure (occupational or recreational)
- Physical examination: inspect auditory canal (impacted cerumen, exostoses); examine tympanic membrane (inflammation, perforation, scarring); assess middle ear (fluid)

b. Noise-induced hearing loss
   - Chronic, prolonged exposure to sound levels >85 dB
   - Hair cells in the organ of Corti are damaged

c. Infection—viral or bacterial infection of cochlear structures or labyrinth

d. Drug-induced hearing loss
   - Aminoglycoside antibiotics, furosemide, ethacrynic acid; cisplatin, quinidine
   - Aspirin can cause tinnitus and reversible hearing impairment

e. Injury to inner ear or cochlear nerve (e.g., skull fracture)

g. Ménière disease
   - Fluctuating, unilateral hearing loss
   - Sensorineural hearing loss, sense of pressure/fullness in ear, tinnitus, vertigo
   - Vertigo usually responds to dietary salt restriction and meclizine, but hearing loss is progressive

h. CNS causes—acoustic neuromas, meningitis, auditory nerve neuritis (multiple sclerosis, syphilis), menigioma

C. Clinical Features

1. Conductive hearing loss
   a. Decreased perception of sound (especially for low-frequency sounds)
   b. Can hear loud noises well

2. Sensorineural hearing loss
   a. Difficulty hearing loud noises; shouting may exacerbate the problem (annoyed by loud speech)
   b. Can hear sounds, but has trouble deciphering words (poor speech discrimination)
c. More difficulty with high-frequency sounds (doorbells, phones, child’s voice, female voice)
d. Tinnitus is often present

D. Diagnosis
1. Whisper test—ask the patient to repeat words whispered into the tested ear (mask the other ear) (see Clinical Pearl 12-11)
2. An audiogram is an essential component of the evaluation
3. MRI—in selected cases (e.g., if CNS tumor or multiple sclerosis is suspected)

E. Treatment
1. Cerumen impaction is best treated by irrigation after several days of softening with carbamide peroxide (Debrox) or triethanolamine (Cerumenex)
2. Conductive hearing loss
   a. Treat underlying cause
   b. Surgical techniques such as tympanoplasty (reconstructs middle ear) for patients with chronic otitis media; stapedectomy for otosclerosis
   c. Hearing aids
3. Sensorineural hearing loss
   a. Treat underlying cause
   b. Hearing aids
   c. Cochlear implants—transduce sounds to electrical energy, stimulates CN VIII
Urinary Incontinence

A. General Characteristics
1. There are five major types of incontinence (urge, stress, overflow, functional, and mixed). Many patients have more than one type.
2. Male incontinence is usually due to BPH or neurologic disease. A urology evaluation is indicated for incontinent male patients.
3. Female incontinence is usually due to hormonal changes, pelvic floor dysfunction or laxity, or uninhibited bladder contractions (detrusor contractions) secondary to aging.

Quick HIT
The most common cause of incontinence in elderly patients is urge incontinence. In women <70 years of age, the most common cause is stress incontinence.

CLINICAL PEARL 12-11

Rinne and Weber Tests
- Conductive loss
  - Abnormal Rinne test—bone conduction is better than air conduction
  - Weber—sound lateralizes to the affected side (tuning fork is perceived more loudly in the ear with a conductive hearing loss)
- Sensorineural loss
  - Normal Rinne test—air conduction is better than bone conduction
  - Weber—sound lateralizes to the unaffected side

B. Risk Factors
1. Age—diminished size of bladder, earlier detrusor contractions, postmenopausal genitourinary atrophy
2. Recurrent urinary tract infections
3. Immobility, decreased mental status, dementia, stroke, Parkinson disease, depression
4. DM, CHF
5. Multiparity, history of prolonged labor

Quick HIT
Evaluating a Patient with Urinary Incontinence
Inquire about the history of diabetes, multiple sclerosis, Parkinson disease, stroke, spinal cord injury or disease, and pelvic surgery.
6. Pelvic floor dysfunction in women, BPH and prostate cancer in men
7. Medications
   a. Diuretics increase bladder filling, increasing the episodes of incontinence
   b. Anticholinergics and adrenergics cause urinary retention
   c. β-Blockers diminish sphincter tone
   d. Calcium channel blockers and narcotics can decrease detrusor contraction
   e. Alcohol, sedatives, hypnotics (depress mentation)

Quick HIT

- If urgency of urination is the prominent finding, suspect urge incontinence.
- If increased intra-abdominal pressure (cough, laugh) causes urine loss, suspect stress incontinence.

C. Types of Urinary Incontinence

1. Urge incontinence (also called detrusor instability)
   a. Most common type in elderly and nursing-home patients
   b. Multiple causes (often idiopathic), including dementia, stroke, severe illness, Parkinson disease
   c. Mechanism: involuntary and uninhibited detrusor contractions result in involuntary loss of urine
   d. Clinical features: sudden urge to urinate (e.g., patients are unable to make it to the bathroom), a loss of large volumes of urine with small postvoid residual, and nocturnal wetting
   e. Diagnostic study of choice is urodynamic study
   f. Management is initially with bladder-training exercises (the goal being to increase the amount of time between voiding). If this is unsuccessful, medications include anticholinergics (oxybutynin) and TCAs (imipramine).

Quick HIT

Elderly women commonly have both urge and stress incontinence.

d. Clinical features: sudden urge to urinate (e.g., patients are unable to make it to the bathroom), a loss of large volumes of urine with small postvoid residual, and nocturnal wetting

e. Diagnostic study of choice is urodynamic study

2. Stress incontinence
   a. Occurs mostly in women (after multiple deliveries of children)
   b. Mechanism: Weakness of the pelvic diaphragm (pelvic floor) leads to loss of bladder support (with resultant hypermobility of the bladder neck). This causes the proximal urethra to descend below the pelvic floor so that an increase in intra-abdominal pressure is transmitted mostly to the bladder (instead of an equal transmission to the bladder and urethra)
Clinical features: involuntary urine loss (only in spurts) during activities that increase intra-abdominal pressure (cough, laugh, sneeze, exercise); small postvoid volume

Management: Kegel exercises (multiple contractions of pelvic floor muscles as if the patient were interrupting flow of urine) to strengthen pelvic floor musculature; estrogen replacement therapy; use of a pessary; surgery (there are various options, and a popular option is the midurethral sling)

Overflow incontinence

Common in diabetic patients and patients with neurologic disorders

Mechanism: Inadequate bladder contraction (due to impaired detrusor contractility) or a bladder outlet obstruction leads to urinary retention and subsequent overdistention of the bladder. Bladder pressure increases until it exceeds urethral resistance, and then urine leakage occurs

Causes: neurogenic bladder (diabetic patients, lower motor neuron lesions), medications (anticholinergics, α-agonists, and epidural/spinal anesthetics), obstruction to urine flow (BPH, prostate cancer, urethral strictures, severe constipation with fecal impaction)

Clinical features: nocturnal wetting, frequent loss of small amount of urine; large postvoid residual (usually exceeds 100 mL)

Management (primarily medical): intermittent self-catheterization is the best management; cholinergic agents (e.g., bethanechol) to increase bladder contractions; α-blockers (e.g., terazosin, doxazosin) to decrease sphincter resistance

Functional incontinence—secondary to disabling and debilitating diseases

D. Diagnosis

1. Urinalysis (all patients)—to exclude infection and hematuria
2. Postvoid urine catheterization—record the residual volume. Normal residual volume is less than 50 mL. A urine volume greater than 50 mL may indicate urinary obstruction or a hypotonic bladder
3. Urine cultures—if dysuria and positive urinalysis (WBCs in urine)
4. Renal function studies (BUN/Cr), glucose levels
5. Voiding record is useful—time, volume of episodes, record of oral intake, medications, associated activities
6. Perform further testing in carefully selected patients in whom the cause is not identified. Tests include cystometry, uroflow measurement/urethral pressure profile, imaging studies such as intravenous pyelogram, and voiding cystourethrogram, as needed
Laboratory studies in workup of fatigue:
- CBC (anemia)
- TSH (hypothyroidism)
- Fasting glucose (diabetes mellitus)
- BMP (electrolyte abnormalities)
- Urinalysis, BUN/creatinine (renal disease)
- LFT (liver disease)
**Fatigue**

**A. General Characteristics**

1. Fatigue refers to a lack of energy or a sense of being tired—differentiate this from muscular weakness. It is not directly related to exertion.

2. Differential diagnosis
   a. Psychiatric causes—depression (most common cause); anxiety and somatization
   b. Endocrine causes—hypothyroidism, poorly controlled DM, apathetic hyperthyroidism of elderly patients, Addison disease, hypopituitarism, hyperparathyroidism, and other causes of hypercalcemia
   c. Hematologic/oncologic causes—severe anemia, occult malignancy (e.g., pancreatic carcinoma)
   d. Metabolic causes—chronic renal failure, hepatocellular failure
   e. Infectious diseases—mononucleosis, viral hepatitis, HIV, syphilis, hepatitis B and C, CMV, parasitic disease, tuberculosis and subacute bacterial endocarditis, Lyme disease
   f. Cardiopulmonary disease—OSA, CHF
   g. Medications—antihypertensive medications (clonidine, methyldopa), antidepressants (amitriptyline, doxepin, trazodone are more sedating), hypnotics, β-blockers, antihistamines, drug abuse/withdrawal
   h. Other causes: CFS, fibromyalgia, sleep disturbances (sleep apnea, narcolepsy, insomnia)

---

**Quick HIT**

**Etiology of Chronic Fatigue**

- Only 5% of cases are diagnosed as CFS.
- Most cases of chronic fatigue are due to depression, anxiety, or both (up to two-thirds of cases).
- Between 20% and 25% of cases are idiopathic, yet do not fit the criteria for CFS.
- Less than 5% are due to an unidentified medical illness.

3. Chronic fatigue syndrome (CFS)
   a. CFS is profound fatigue for longer than 6 months that is not due to a medical or psychiatric disorder. More common in women
   b. Cause is unknown. A flu-like illness may act as the triggering event, but infection has not been established as the proven cause. Other theories point to immunologic disturbance or endocrine dysfunction as possible causes
   c. CFS is a diagnosis of exclusion—rule out other causes before making a diagnosis of CFS
   d. Most patients experience partial recovery within 2 years, but relapses can occur at any time
e. There are specific criteria for diagnosis. The key features include:
   - New or definite onset of unexplained fatigue, not alleviated by rest, not due to exertion, and significantly affecting quality of life
   - Four or more of the following symptoms (for at least 6 months): diminished short-term memory or concentration, muscle pain, sore throat, tender lymph nodes, unrefreshing sleep, joint pain (without redness/swelling), headaches, postexertional malaise for longer than 24 hours
f. Depression is common in patients with CFS

B. Diagnosis
1. Basic laboratory tests to exclude other causes—consider CBC, LFTs, serum electrolytes, calcium, TSH, erythrocyte sedimentation rate, and HIV testing (if indicated).
2. Extensive testing other than the above is not indicated.

C. Treatment
1. Treat the underlying disorder, if known
2. Treat CFS and patients with idiopathic fatigue as follows:
   a. Cognitive behavioral therapy, including exercise, social, and psychological behavior modifications
   b. Antidepressants, as appropriate
   c. NSAIDs for relief of headache, arthralgias
Erectile Dysfunction

A. General Characteristics
1. Erectile dysfunction is the recurring inability to achieve and maintain an erection sufficient for satisfactory sexual performance.
2. It is thought that up to half of all men in the United States between the ages of 40 and 70 have some form of erectile dysfunction. Prevalence increases with age.
3. Pathophysiology—once thought to be psychogenic in origin, it is now known that most cases (80%) are organic. A normal erection is largely dependent on the healthy penile and systemic vasculature.
4. Some cases of erectile dysfunction are psychogenic.

B. Risk Factors
1. The most important risk factors are those that contribute to atherosclerosis (e.g., HTN, smoking, hyperlipidemia, diabetes)
2. Medications—antihypertensives (may indirectly lower intracavernosal pressure by virtue of lowering systemic BP)
3. Hematologic—sickle cell disease
4. History of pelvic surgery or perineal trauma
5. Alcohol abuse
6. Any cause of hypogonadism/low testosterone state, including hypothyroidism
7. Congenital penile curvature

C. Diagnosis
1. Detailed history and examination, including a digital rectal examination and neurologic examination. Assess for signs of PAD.
2. Laboratory tests—obtain a CBC, chemistry panel, fasting glucose, and lipid profile. If there is hypogonadism or loss of libido, order serum testosterone, prolactin levels, and thyroid profile.
3. Nocturnal penile tumescence—if normal erections occur during sleep, a psychogenic cause is likely. If not, the cause is probably organic.
4. Consider vascular testing—evaluate arterial inflow and venous trapping of blood. Tests include intracavernosal injection of vasoactive substances, duplex ultrasound, and arteriography.
5. Psychological testing may be appropriate in some cases.

D. Treatment
1. Treat the underlying cause. Address atherosclerotic risk factors.
2. First-line treatment is with phosphodiesterase inhibitors such as sildenafil citrate (Viagra), which acts by increasing cGMP levels, causing increased nitric oxide
release and penile smooth muscle relaxation. It can be taken 30 to 60 minutes before anticipated intercourse. It is contraindicated with use of nitrates because together they can cause profound hypotension.

3. Intracavernosal injections of vasoactive agents (patient learns to self-administer).

4. Vacuum constriction devices are rings placed around the base of the penis that enhance venous trapping of blood; they may interfere with ejaculation.

5. Psychological therapy may be indicated to reduce performance anxiety and address underlying factors that may be causing or contributing to erectile dysfunction.

6. Hormonal replacement (e.g., testosterone) in patients with documented hypogonadism.

7. Penile implants for patients who have not responded to the above.

### Quick HIT

**Alcohol and Lipid Levels**

Modest alcohol intake (maximum of 1 to 2 drinks per day) is associated with an increase in HDL. On the other hand, alcohol use increases TG levels.
Alcoholism

A. General Characteristics

1. Ten to fifteen percent of people have alcoholism (alcohol abuse or dependence). There is a genetic component to alcoholism—close relatives of alcoholics (especially sons) are at increased risk for alcoholism.

2. Screening for alcoholism—ask all patients about alcohol use. If alcoholism is suspected, use one of the following screening methods:
   a. CAGE (Any more than one positive answer may suggest alcohol abuse)
      • Cut down? (Have you ever felt the need to cut down on your drinking?)
      • Annoyed? (Have you ever felt annoyed by criticisms of your drinking?)
      • Guilty? (Have you ever felt guilty about drinking?)
      • Eye-opener? (Have you ever felt the need to have a drink first thing in the morning?)
   b. MAST (Michigan Alcoholism Screening Test) questionnaire—a 25-item questionnaire that also helps identify alcoholism

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
</table>

**Laboratory Findings in Alcoholics**
- Anemia
- Macrocytic (most common)—due to folate deficiency
- Microcytic—due to GI bleeding
- LFTs—increased GGT; AST–ALT ratio is 2:1
- Hypertriglyceridemia
- Hyperuricemia, hypocalcemia
- Thiamine deficiency
- Decreased testosterone level

B. Complications

1. GI—gastritis, esophagitis, PUD, alcoholic liver disease (alcoholic hepatitis, cirrhosis, portal HTN), pancreatitis (acute and chronic), Mallory–Weiss tears

2. Cardiac—alcoholic cardiomyopathy, essential HTN (more than three drinks per day significantly increases BP)

3. CNS
   a. Wernicke encephalopathy—often reversible
      • Caused by thiamine deficiency
      • Manifests as nystagmus, ataxia, ophthalmoplegia, confusion
      • Can be precipitated by administering glucose in alcoholics without first giving thiamine replacement
   b. Korsakoff psychosis—irreversible
Caused by thiamine deficiency
- Alcohol-induced amnestic disorder
- Mostly affects short-term memory; confabulation is common

4. Pulmonary—pneumonia, aspiration
5. Nutritional deficiencies (vitamins, minerals)—especially thiamine deficiency, hypomagnesemia, and folate deficiency
6. Peripheral neuropathy—due to thiamine deficiency
7. Sexual dysfunction—impotence, loss of libido
8. Psychiatric—depression, anxiety, insomnia
9. Increased risk of malignancy—esophagus, oral, liver, lung
10. Frequent falls, minor injuries, **motor vehicle accidents**

**C. Treatment**
1. Alcoholics Anonymous (AA) (see also **Clinical Pearl 12-12**)
2. Naltrexone is a good first-line drug that improves abstinence rates by reducing the craving for alcohol
3. Acamprosate is another first-line drug that is a good option in patients with liver disease (naltrexone contraindicated)
4. Other options: baclofen, disulfiram, topiramate, gabapentin, SSRIs, and ondansetron
   a. Disulfiram (Antabuse) inhibits aldehyde dehydrogenase and leads to the accumulation of acetaldehyde. A few minutes after drinking alcohol, patient experiences shortness of breath, flushing, palpitations, and tachycardia. If more alcohol is consumed, headache and nausea/vomiting ensue. Symptoms last about 90 minutes. It is appropriate for short-term use and should not be taken chronically. It is contraindicated in patients with heart disease
5. Drugs for withdrawal—benzodiazepines—best to use long-acting agents (diazepam)
6. Correction of fluid imbalance, vitamin supplementation (thiamine, folate, multivitamins)

**CLINICAL PEARL 12-12**

**Alcohol Withdrawal**
- Features include tachycardia, sweating, anxiety, hallucinations.
- Goal is to prevent progression to delirium tremens (DT), which is a medical emergency (mortality rate, 20%). DT occurs in 5% of alcoholic withdrawals.
- DT is delirium developing within a week of the last alcohol intake, usually 2 to 4 days after the last drink. DT is characterized by tactile hallucinations, visual hallucinations, confusion, sweating, increased tachycardia, and elevated BP.
- Risk factors are pancreatitis, hepatitis, or other illness. DT is rare in healthy people.
- Give benzodiazepines if withdrawal symptoms are present. Prevention of DT is the best treatment.
- Diet is important in treatment (high in calorie, high in carbohydrates, multivitamins).
Smoking

A. Health Risks Associated with Cigarette Smoking
1. Cardiovascular disease—CAD, acute MI, and stroke; there is a dose-dependent relationship between smoking and cardiovascular disease
2. COPD risk increases with smoking in a dose-dependent manner
3. Malignancy—smoking increases the risk of lung cancer, head and neck cancer, GI cancers (laryngeal/pharyngeal, esophageal, gastric, pancreatic, hepatic, colorectal), GU cancers (renal, ureter, bladder, penile, cervical), and myeloid leukemia
4. PUD
5. Osteoporosis—decreases peak bone mass and increases the rate of bone loss
6. Premature skin aging
7. PAD, Buerger disease
8. Adverse effects during pregnancy—smoking increases the risk of spontaneous abortion, fetal death, neonatal death, sudden infant death syndrome, and low birth weight
9. Infections, especially respiratory

Quick HIT
Most important causes of smoking-related mortality are lung cancer, COPD, and ASCVD.

B. Smoking Cessation
1. Varenicline—partial agonist at the α-4–β-2 subunit of the nicotinic acetylcholine receptor. Its efficacy has been demonstrated in several randomized controlled trials. Considered first-line therapy (nicotine replacement is the alternative).

Quick HIT
Behavioral modification is crucial for long-term smoking cessation. The patch or gum should be used in conjunction with a smoking withdrawal clinic (behavioral program). Quit rates are higher with this combination.

2. Nicotine replacement therapy.
   a. Both a long-acting agent (nicotine patch) and a short-acting agent (nicotine gum or lozenge) should be used together for higher quit rates.
   b. Nicotine patch.
      • Quit rates are 2.5 times higher at 6 months than with placebo.
      • Continuous nicotine delivery weans the patient from nicotine, and the dose is gradually decreased. There are no peaks or troughs as associated with smoking,
so it eliminates nicotine withdrawal symptoms.

- The patch should be worn for 16 hours per day (should not be worn during sleep at night because it can cause headaches). The strongest dose (21-mg patch) is used for 1 month or so, then is gradually tapered to a lower dose (14-mg patch) for a few weeks, and finally to the lowest dose (7-mg patch) for a few weeks. Once the habit is broken, the patch use is stopped.

- **The patient should not continue to smoke while using the patch** (there have been case reports of MIIs in these patients).

c. Nicotine chewing gum or lozenge.

- Gum is used whenever there is an urge to smoke. Use is continued for 2 to 4 months.


a. Quit rates are similar to that of nicotine replacement therapy (twice that of placebo).

b. The patient continues treatment for up to 2 months.

c. The patient can take bupropion in combination with nicotine replacement therapy—combined use may result in higher quit rates than either method alone.

d. Adverse effects may include dry mouth, insomnia, and headaches.
Health Maintenance

A. Screening for Hypertension
1. The United States Preventive Services Task Force (USPSTF) recommends screening all adults 18 years of age and older for HTN. However, other authorities do not recommend screening for HTN until middle age.
2. The recommended interval is 2 years for adults with a normal BP, and 1 year for adults with prehypertension.

B. Screening for Hyperlipidemia
1. USPSTF 2008 guidelines recommend screening all men ≥35 and women at risk for CAD ≥45 (grade A); the guidelines also recommend screening men aged 20 to 35 at increased risk for CAD and women aged 20 to 45 at increased risk for CAD (grade B).
2. ACC/AHA 2013 guidelines state that it is reasonable to assess cardiovascular disease risk in healthy patients aged 20 to 79 every 4 to 6 years.
3. **Measure a nonfasting total cholesterol and HDL cholesterol every 5 years.**
   a. If total cholesterol is <200 mg/dL and HDL is >35 mg/dL, repeat screening in 5 years.
   b. If total cholesterol is >240 mg/dL or between 200 and 240 with multiple risk factors, get a complete lipoprotein profile (TG levels and calculation of LDL).
   c. Calculating LDL level is not necessary for screening.
   d. Screen more frequently if the patient has increased risk of CAD (e.g., smokers, diabetic patients, family history of CAD, HTN).
4. Adults with CAD—obtain a complete lipoprotein profile.

C. Colorectal Cancer Screening/surveillance
1. Average-risk patients 50 to 75 years of age—any of the following (USPSTF 2008 guidelines):
   a. Colonoscopy every 10 years
   b. Flexible sigmoidoscopy every 5 years and fecal occult blood test every 3 years
   c. **Fecal occult blood test every year**
2. Moderate-risk patients
   a. Patients with single or multiple polyps, personal history of CRC—initial colonoscopy; repeat at 3 years—if normal, then colonoscopy every 5 years

**Quick HIT**

For CRC screening, a colonoscopy is equivalent to flexible sigmoidoscopy plus barium enema but is more expensive.
b. Family history of CRC or adenomatous polyps in first-degree relatives—
colonoscopy at age 40 or 10 years younger than the youngest case in family; if
normal, repeat in 3 to 5 years

Quick HIT

Colonoscopy is the best of all colon cancer screening methods. Sigmoidoscopy will miss 40% of cancers. Fecal occult blood testing will detect cancer but if positive, a colonoscopy is needed.

3. High-risk patients
   a. Families with familial adenomatous polyposis—genetic testing at age 10;
      consider colectomy if positive genetic testing or polyposis is confirmed; if not,
      colonoscopy every 1 to 2 years beginning at puberty
   b. Families with hereditary nonpolyposis CRC—genetic testing at age 21; if
      positive, colonoscopy every 2 years until age 40, and then every year thereafter
   c. Patients with ulcerative colitis—colonoscopy 8 years after disease onset, then
      every year thereafter

D. Prostate Cancer Screening
   1. This is controversial
   2. The USPSTF now recommends against prostate cancer screening with prostate-
      specific antigen (PSA)
   3. Other groups state that there is insufficient evidence for or against screening with
      PSA, and that the physician should engage the patient in the decision to screen

E. Lung Cancer Screening
   1. USPSTF 2013 guidelines—high-risk adults 55 to 80 years of age should
      receive an annual low-dose CT scan.
      • High-risk adults are those with a 30 pack-year smoking history and who are
        currently smoking or quit within the past 15 years; once the patient has
        stopped smoking for >15 years, annual screening can be discontinued.

F. Women’s Health
   1. Breast cancer
      a. USPSTF—mammogram every 2 years for women 50 to 74 years of age
         • In agreement with the American College of Physicians and American
           Academy of Family Physicians
      b. American Cancer Society, National Cancer Institute, National Comprehensive
         Cancer Network, American College of Obstetricians and Gynecologists,
         American Medical Association: recommend routine screening every year
starting at the age of 40
c. Recommendations for clinical breast examination (CBE) and breast self-examination (BSE) vary based on expert group recommendations; USPSTF states that there is insufficient evidence to recommend for or against CBE, and some groups (e.g., WHO) recommend against BSE

2. Cervical cancer
   a. **Start at age 21, irrespective of sexual history**
   b. **Ages 21 to 29, Pap smear every 3 years**
   c. **Ages 30 to 65, Pap smear every 3 years or Pap smear + HPV testing every 5 years**
   d. **Can discontinue screening at age 65 if adequate negative prior screening (3 negative Pap smears or 2 negative Pap smears with negative HPV testing within the previous 10 years, with the most recent test within the previous 5 years)**

3. Ovarian cancer
   a. **Routine screening is not recommended**

G. Sexually Transmitted Infections
1. **All men and women aged 15 to 65 years should be screened for HIV; more frequent screening should be offered for those at risk.**
2. **All sexually active women <24 years old should be screened for chlamydia and gonorrhea. Insufficient evidence to make these recommendations for men.**
3. **Asymptomatic men and women with risk factors should be screened for syphilis.**

H. Miscellaneous
1. **Screening for diabetes mellitus:**
   a. The updated 2015 USPSTF guidelines recommend screening for diabetes as part of a cardiovascular risk assessment in nonpregnant adults aged 40 to 70 who are overweight or obese.
   b. The American Diabetes Association recommends screening all adults with a BMI $\geq 25$ kg/m$^2$ and at least one risk factor for diabetes every 3 years with hemoglobin A1c, fasting plasma glucose, or a 2-hour oral glucose tolerance test (OGTT). Adults without risk factors should be screened starting at the age of 45.
2. The USPSTF recommends screening for hepatitis B virus in patients at risk— injection drug users, men who have sex with men (MSM), hemodialysis.
3. The USPSTF recommends screening for hepatitis C virus in patients at risk and a one-time screening in patients born between 1945 and 1965.
4. In elderly patients, assess risk factors for PAD, osteoporosis, stroke, and CAD.
5. Osteoporosis—DEXA scan starting at age 65 in women (see osteoporosis section for details).

6. AAA screening with a one-time ultrasound in men aged 65 to 75 who have ever smoked.

7. The USPSTF recommends screening all adults for depression and alcohol misuse (and providing appropriate treatment and follow-up). The USPSTF does not recommend for or against screening for dementia.

8. Routine screening for thyroid disease is not recommended by the USPSTF, though some expert groups recommend it.

**Quick HIT**

Remember that functionally or anatomically asplenic individuals are at risk for infection with encapsulated organisms, so they should receive the *H. influenzae* type B (HIB) vaccine, meningococcal and pneumococcal vaccines.

**I. Vaccinations**

1. Vaccination is most commonly associated with children but is very important in adults as well, especially elderly patients and those with chronic medical problems.

2. The most important vaccinations to know are influenza, pneumococcal polysaccharide, hepatitis B, and tetanus; for who should receive them and when, see Table 12-9.

**TABLE 12-8 Vaccines**

<table>
<thead>
<tr>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Meningococcal vaccine is indicated for adults with asplenia, military recruits, residents of college dormitories, terminal complement deficiency, travelers to Mecca or Medina in Saudi Arabia for the Hajj.</td>
</tr>
<tr>
<td>4. Hepatitis A and B vaccines are indicated in adults with chronic liver disease, homosexual men, injection drug users, and household contacts with hepatitis A or B.</td>
</tr>
<tr>
<td>5. There are many misconceptions about contraindications to vaccination. The following are not contraindications to vaccination.</td>
</tr>
<tr>
<td>a. Mild illness (e.g., common cold, low-grade fever, mild diarrhea).</td>
</tr>
<tr>
<td>b. Convalescent phase of an illness.</td>
</tr>
<tr>
<td>c. Recent exposure to a communicable disease.</td>
</tr>
<tr>
<td>d. Breastfeeding.</td>
</tr>
<tr>
<td>e. Current antibiotic therapy.</td>
</tr>
</tbody>
</table>
f. History of a nonspecific reaction to penicillin.

Quick HIT

Most important vaccines in adults are influenza and pneumococcus.
APPENDIX

Radiographic Interpretation

Chest Radiograph

A. **Views:** Obtain PA and lateral views for all patients who are well enough to be transported to the radiology department and maintain an upright position. Obtain an AP film (i.e., portable chest radiograph [CXR]) for all patients who are too ill to be transported and positioned for a PA film.

B. **Always Try to Compare a Patient’s CXR With a Previous Film** to note any changes in condition and to assess whether changes are new or chronic.

C. **Density:** The lower the density, the more radiolucent (or transparent) the object will appear on plain radiographs. Following are structures in the body (main composition) listed from most radiolucent to most radiopaque: Air (lungs, trachea, gastric bubble), fat (breasts), fluid (most of the structures have high fluid content [e.g., vessels, heart, soft tissues]), bone, metallic foreign bodies (e.g., bullets, orthopedic hardware).

D. **Assessment of the Film’s Quality**
   1. Assess penetration.
      a. The intervertebral spaces should be visible on a good-quality film.
      b. The outline of the vertebral bodies should be visible within (or through) the cardiac silhouette.
   2. Assess inspiratory effort.
      a. A CXR is usually taken at the end of a full, deep inspiration. You should be able to see at least nine posterior ribs on the right side above the diaphragm. In general, if the diaphragm is crossing the tenth rib posteriorly (or the eighth rib anteriorly), inspiratory effort is optimal.
      b. Patients who are ill may not be able to hold a full, deep breath for the CXR, leading to a poor inspiratory effort.
      c. The heart appears larger than it actually is when there is poor inspiratory effort, which can be misleading.
3. Assess for rotation.
   a. There should be symmetrical spacing of the clavicles on either side of the sternum, otherwise the patient is rotated.
   b. Imagine a horizontal line connecting the clavicular heads and a vertical line down the midline connecting the spinous processes of the vertebrae—these lines should be perpendicular to one another.

Quick HIT

Proper position of lines, tubes, and catheters
- Endotracheal tube—the tip should be approximately 4 to 6 cm above the tracheal carina (this is about the level of the clavicular heads) when the patient’s head is neither flexed nor extended. The endotracheal tube tip can move up to 2 cm with extension or flexion of the head.
- Central line—the tip should be just above the right atrium in the superior vena cava. If placed deeper into the right atrium, there is a higher chance of arrhythmias or cardiac perforation.
- Swan–Ganz catheter—the tip should be within the right or left main pulmonary arteries within the mediastinal shadow. If more distal to this there is higher chance of pulmonary infarction or vessel rupture.
- Nasogastric tube—the tip should be distal to the esophagogastric junction in the stomach. A good rule of thumb is to ensure the nasogastric tube tip is below the diaphragm and does not traverse the course of the carina into the lung.

E. Examination of the PA/AP CXR (Figure A-1): No one approach is standard. Be sure to observe the following points:

1. Examine bones: shoulders, clavicles, cervical and thoracic spine, and ribs—on PA films, the horizontal ribs are posterior (anterior ribs are angled downward).
2. Evaluate cardiac size: the transverse diameter of the cardiac silhouette should not be more than half the transverse diameter of the thorax; this is the cardiothoracic ratio. (A larger cardiothoracic ratio is acceptable for an AP film because the cardiac silhouette is larger on an AP film.)
FIGURE
A.1  A: PA CXR with diagrammatic overlay: 1, first rib; 2, upper portion of manubrium; 3, trachea; 4, right main bronchus; 5, left main
bronchus; 6, main pulmonary artery; 7, left pulmonary artery; 8, right interlobar pulmonary artery; 9, right pulmonary vein; 10, aortic arch.

B: CXR of the same subject without diagrammatic overlay. C: Lateral CXR of the same patient as in A: 1, trachea; 2, right upper lobe bronchus; 3, left upper lobe bronchus; 4, right pulmonary artery; 5, left pulmonary artery; 6, inferior vena cava; 7, ascending aorta; 8, descending aorta. D: Same lateral CXR without diagrammatic overlay. E: Technical adequacy of a CXR: 1, a technically adequate CXR should be labeled with the patient’s name, date, and a side marker; 2, the midportion of the right hemidiaphragm should be below the 10th rib; 3, vertebral bodies should be visualized throughout the spine; 4, pulmonary vessels should be visible to the outer third of the lung; 5, the thoracic spinous processes should be midway between the heads of the clavicle.


3. Check for mediastinal widening, which may be present in aortic dissection, trauma, and mediastinal masses such as lymphoma.
4. Evaluate the position of the trachea; it should be in the midline.
5. Compare right and left lung fields. It is best to divide the lung fields into thirds (horizontally) and compare the two sides.
   a. Look for any infiltrates or consolidation.
   b. Congestion—look for enlarged cardiac silhouette, pulmonary vessels that are more visible and extend further into the lung field than normal (“cephalization” of the pulmonary vessels).
   c. Pneumothorax—look for a line demarcating free air (hyperlucent with no pulmonary vascular markings) in the pleural space.
   d. Pleural effusion—examine the costophrenic angles; they should be sharp and clear without any blunting.
   e. Look at the diaphragms—the right diaphragm is normally slightly higher than the left due to presence of the liver.
F. Examination of the Lateral Film (see Figure A-1).

1. Look at the cardiac silhouette.
   a. Anterior border—formed by the right ventricle.
   b. Posteroinferior border—formed by the left ventricle.
   c. Posterosuperior border—formed by the left atrium.
   d. The right atrium cannot be seen.

2. Look at the trachea.

3. Examine the retrosternal and retrocardiac spaces for any abnormalities.

4. Examine the diaphragms—note that the anterior portion of the left hemidiaphragm is not visible because of the cardiac silhouette. The entire right hemidiaphragm should be visible, however.
Abdominal Radiographs

A. The Standard Abdominal Film — KUB — is a supine view, which is ideal for seeing the gas pattern.

B. Order an Obstruction Series (includes PA CXR, as well as supine and upright abdominal films) to evaluate the gas pattern and to look for the following:
   1. Free intraperitoneal air (see later) — free air is seen under the diaphragm on the CXR. If the patient is too ill to be upright, order a left lateral decubitus film instead (air rises to the nondependent area).
   2. Air–fluid levels — seen on the upright film (see later).

C. Most Important Things to Look for on Abdominal Films
   1. Air–fluid levels — sign of obstruction; if prominent and multiple, mechanical obstruction is more likely than ileus.
   2. Free air under the diaphragm (perforation of a viscous) — this is a surgical emergency.
   3. Dilated loops of bowel (obstruction, ileus) — it may be difficult to distinguish mechanical obstruction from ileus. The following may help:
      a. If air is in the small intestine, colon, and rectum, ileus is more likely because ileus distention involves the entire GI tract.
      b. In small bowel obstruction, there are distended loops of small bowel proximal to the site of obstruction and multiple air–fluid levels on upright or decubitus films. Colonic gas is usually minimal.
      c. In large bowel obstruction, look for haustral markings — they span one-half to two-thirds of the diameter of large bowel — as well as the colonic shadow on the periphery or in the pelvis.
      d. In an ileus, the dilated loops are scattered and lack organization (e.g., like a “bag of popcorn”); in mechanical obstruction, dilated loops are stacked on top of one another (e.g., like a “bag of sausages”).
      e. Too little gas in the abdomen can be due to high obstruction.
Electrocardiogram Interpretation

Electrocardiogram Pearls

A. Always Look for an Old Electrocardiogram (ECG) With Which to Compare the Current ECG. This is critical in assessing whether any significant changes have occurred.

B. Determine Rate
1. Count the number of large blocks (with five little squares) between each R wave. Divide this number by 300 (the distance between large blocks represents 1/300 minute). Therefore, if there are four blocks between each R wave, there is 4/300 or 1/75 minute between each R wave, which means that the rate is 75. (Note that this is the same as the 300-150-75-60-50 rule.)
2. If the rate is irregular, count the number of beats in 6 seconds and multiply by 10.
3. Each block is 1 mm (0.04 seconds), so five boxes equal 0.20 seconds.
4. Tachycardia is defined as a rate >100 beats/min.
5. Bradycardia is defined as a rate of <60 beats/min.

C. Determine Rhythm (look at lead II)—is the rhythm regular or irregular? Note that rhythms may be regularly irregular or irregularly irregular as well. (See Chapter 1, Arrhythmias section.)

D. Determine Axis
1. Look at the QRS complex in leads I and aVF.
2. If both are mainly positive, then the axis is normal.
3. If mainly positive in lead I and mainly negative in aVF, the axis is deviated to the left.
4. If mainly negative in lead I and mainly positive in aVF, the axis is deviated to the right.
5. If mainly negative in both I and aVF, then there is extreme right axis deviation.
6. If lead aVF is isoelectric (meaning it is neither positive nor negative), look at lead II as the “tie breaker” since lead II is also an inferior lead. The same rules apply for lead II as for lead aVF.

E. Intervals
1. P-R interval—this should be <0.2 seconds.
   a. In first-degree heart block, the P-R interval is >0.2 seconds (one large box).
   b. In second-degree AV block (Wenckebach or Mobitz type I), there is a
progressive lengthening of the P-R interval followed by a dropped QRS complex.

c. In the **Mobitz type II** form of second-degree heart block, the P-R interval is constant, but not every P wave is followed by a QRS complex. There may be two, three, or even more P waves before a QRS, but the ratio of P waves to QRS complexes (e.g., 2:1, 3:1) is constant.

d. In **third-degree heart** block, there is no relationship between atrial (P waves) and ventricular (QRS) activity.

2. QRS complex—this should be <0.12 seconds.
   
a. Prolongation of the QRS complex is seen in bundle branch block, ventricular rhythms, and paced rhythms.
   
b. In **right bundle branch block (RBBB)**, look for a widened QRS complex, an rSR wave in the chest leads, and a wide S wave in lead I.
   
c. In **left bundle branch block (LBBB)**, look for a widened QRS complex and loss of Q waves with broad, notched R waves in leads I, V5, or V6.

3. QT interval—the normal QT interval should be less than half of the R-R interval (<0.42 seconds). Prolongation of the QT interval may be seen in the following.
   
a. Medications: tricyclic antidepressants, phenothiazines, nonsedating antihistamines; class IA, IC, and III antiarrhythmics.
   
b. Electrolyte disturbances: hypocalcemia, hypokalemia.
   
c. Congenital long QT syndromes.
   
d. Other: ischemia, significant bradyarrhythmias, and certain CNS lesions.

**F. Examine Waves**

1. P waves—there should be one P wave for each QRS complex in a normal sinus rhythm.
   
a. **Left atrial enlargement**—wide P wave (>0.12 seconds) in lead II or a diphasic P wave with a deep terminal component in V1.
   
b. **Right atrial enlargement**—tall P wave (>2.5 mm) in lead II or a diphasic P wave with a large initial component in V1.
   
c. **Wandering atrial pacemaker (if HR < 100)**—at least three different P-wave morphologies are present. This is also called multifocal atrial tachycardia if HR >100.

2. Q waves—indicate myocardial necrosis (acute or old MI).
   
a. To be considered significant, they must be >0.04 seconds wide and >25% of the QRS amplitude.
   
b. Isolated Q waves in certain leads may be normal, especially in aVR.

3. QRS complex.
   
a. Should be narrow (<0.12 seconds) with a regular morphology.
b. The following are indicators of left ventricular hypertrophy (LVH). There are multiple criteria for diagnosing LVH (not all listed here), but only one needs to be met for a diagnosis of LVH.
- R wave in V₅ or V₆ >26 mm high.
- S wave in V₁ + R wave in V₅ or V₆ >35 mm high in adults (>age 30)
- R wave in aVL ≥11 mm
- Left axis deviation is often present (this does not need to be met for LVH to be present).

c. The following are indicators of right ventricular hypertrophy (RVH) (assuming QRS duration <120 ms, since RBBB can produce these changes as well)
- R wave ≥7 mm in V₁.
- R/S ratio in V₁ ≥1.
- Progressive decrease in R-wave height across the precordial leads.
- Right axis deviation is often present.

4. ST segments
a. ST segment depression can occur in the following conditions:
   - Myocardial ischemia
   - Subendocardial MI
   - Digoxin effect
   - Hypokalemia
   - LBBB or RBBB

b. ST segment elevation is a key indicator of myocardial necrosis—it is a hallmark of acute transmural MI, but may persist in an old MI.
   - ST segment elevations in I, aVL, V₅, and V₆ are consistent with a lateral wall MI (left circumflex coronary artery).
   - ST segment elevations in V₁ to V₄ are consistent with an anterior wall MI (left anterior descending coronary artery).
   - ST segment elevations in II, III, and aVF are consistent with an inferior wall MI (terminal branches of right or left coronary artery).
   - Diffuse ST segment elevations may be present in pericarditis.
   - Small, concave ST segment elevations may be a normal finding in young people (early repolarization).
   - If LBBB is present, ST segment elevations may be present and are an unreliable indicator of ischemia/infarction.

Quick HIT

Large R waves and ST segment depressions in V₁ or V₂ suggest a posterior wall MI.
5. T waves
   a. Peaked T waves may be present in the following situations:
      • Very early stages of MI (before true infarction occurs).
      • Hyperkalemia
      • Hypermagnesemia
   b. T-wave inversions may be present in the following situations:
      • Myocardial ischemia/infarction
      • Pericarditis
      • Cardiomyopathy
      • Intracranial bleeding
      • Electrolyte disturbances, acidosis
      • LBBB, LVH
      • Small T-wave inversions may be normal in the limb leads
Intravenous Therapy

A. Forms of IV Therapy
1. “Intravenous (IV) push”—this is administration of a medication directly into the IV access. It is typically used in emergency situations when a rapid response is needed or when a loading dose of a medication is to be given, followed by a continuous infusion.
2. Continuous administration—electronic devices deliver fluid or medication at a preset volume per hour.
3. Intermittent administration can be accomplished via a number of methods.
   a. Heparin lock or saline lock—this is used when the patient no longer needs IV fluids and IV medications can be given intermittently. The IV line is kept open with saline or heparin when no medication is being given.
   b. Piggyback—a medication or solution is given through another established primary infusion. The first bag that is hung is the primary infusion. Tubes from both the primary bag and the piggyback bag connect to a common tube that feeds into the patient’s vein.
   c. Nontunneled central catheter—the exit site of the catheter is at the skin. Locations include internal jugular (IJ), femoral, and subclavian veins.
   d. Tunneled central catheters (e.g., Hickman)—the catheter is inserted into the subclavian vein, but the end of the catheter is then “tunneled” in the subcutaneous tissue so that it exits the skin away from the site of vein insertion. With both nontunneled and tunneled central catheters, there is easy access but also the risk of infection at the exit site (although infection risk is lower with a tunneled central catheter).
   e. Ports—the catheter is inserted into a central vein and is tunneled subcutaneously. There is not an exit site because the catheter attaches to the port (chamber) that is placed subcutaneously as well. To administer medication, an anesthetic agent is used to numb the skin, and the needle is inserted into the chamber. Often used for chemotherapy administration. Port-a-Cath is an example. There is less risk of infection (no exit site), but access is more difficult and must be performed by a trained medical professional.
   f. Peripherally inserted central catheter (PICC) line—these are often used to administer IV antibiotics at home (or blood products, other medications, or chemotherapy). Locations include cephalic, basilic, or brachial veins. A PICC is inserted through the veins of the antecubital fossa, and the tip is advanced into the super vena cava. It can be left in place for weeks to months.

B. Complications of IV Therapy
1. Thrombophlebitis—manifested by redness, swelling, and pain at IV site; can be
prevented by changing the IV every 2 to 3 days. Treat by removing the IV and applying warm compresses.

2. Infiltration—medication/fluid leaks into the surrounding tissue. If it is significant and involves a large area, it may lead to compartment syndrome.

3. Blockage

4. Air embolus
Central Venous Line

A. Indications
1. Hemodynamic monitoring (e.g., placement of a pulmonary artery catheter)
2. Transvenous pacing
3. Emergent or short-term hemodialysis
4. Emergent delivery of IV medications (particularly in cardiac arrest)—if feasible, it is generally preferable to have a central venous catheter over a peripheral catheter for the administration of drugs in cardiac arrest because the medication is delivered to the heart and the arterial vasculature more rapidly
5. To administer TPN—the high concentration makes it difficult to administer this through peripheral veins
6. Administration of medications that can be harmful if given peripherally
   a. Irritating medications, which can cause thrombophlebitis in peripheral veins (e.g., high-concentration potassium chloride, chemotherapy)
   b. Vasopressors—cause arterial vasoconstriction and should not be given through peripheral lines, because if infiltration occurs in a peripheral line, it may cause compartment syndrome or soft tissue necrosis
7. Volume replacement (fluid or blood)—if large volumes of fluid must be given rapidly, large-diameter central catheters are needed, particularly if the patient does not have adequate peripheral access. (But in general, peripheral IVs are ideal for rapid fluid resuscitation since the flow rate of fluids is inversely proportional to the length of the catheter.)
8. Although routine or frequent blood draws are not an indication for central venous line placement, an already-existing central line can be used for this purpose

Quick HIT

- Immediately after placing a central line (IJ or subclavian), obtain a CXR to check for pneumothorax and to ensure proper position of the catheter tip. The catheter tip should be in the superior vena cava just above the right atrium.
- When removing a line, the patient should be in Trendelenburg position and should exhale or hum during removal to prevent an air embolism.

B. Sites
1. IJ vein
2. Subclavian vein
3. Femoral vein

Quick HIT
Pulmonary Artery Line

- A central catheter that is inserted through one of the large veins, threaded through the right ventricle, and into the pulmonary artery.
- Also known as a “Swan–Ganz catheter.”
- Used to measure various hemodynamic parameters, including central venous pressure, pulmonary capillary wedge pressure (PCWP), cardiac index and output, stroke volume, and systemic vascular resistance.

C. Complications

1. Pneumothorax
   a. Can occur with subclavian lines and IJ lines (but more common with subclavian lines); obviously does not occur with femoral lines
   b. Note that patients with elevated PEEP have hyperinflated lungs, and the apex of the lungs is more superior than normal, increasing the chances of an iatrogenic pneumothorax

2. Venous air embolism—if air is sucked into the vena cava, it can be pumped through the right ventricle into the lungs, leading to pulmonary embolism (PE) of air. This is a potentially life-threatening complication. If the patient has a patent foramen ovale, it can result in a paradoxical air embolism to the brain

3. Puncture of adjacent artery (carotid, subclavian, or femoral)—depending on the site, this can lead to complications including hemothorax (subclavian) and hematoma (IJ and femoral). Apply compression if this occurs. Vascular surgery consultation is needed

4. Infection—central lines can cause central line–associated blood stream infections which may lead to sepsis, which can be life-threatening

5. Deep vein thrombosis and thrombophlebitis

6. Cardiac arrhythmias—this can occur during insertion if the guidewire is too deep and irritates the myocardium. Patient should always be on cardiac monitor during central line insertion

Quick HIT

There are two means of providing nutrition for a patient who cannot eat: enteral nutrition and parenteral nutrition.
Arterial Lines

Definition—IV catheters (same ones used for peripheral lines) that are inserted into the radial artery (rarely in ulnar or brachial artery).

Uses—arterial lines have two major uses.

- BP monitoring is the most important—arterial lines give more accurate and instantaneous readings than noninvasive blood pressure cuffs. A patient on vasopressors generally should have an A-line for proper BP monitoring.
- Used for frequent blood gas draws.
Nutritional Support

A. Enteral Nutrition (administered into the GI tract)

1. Enteral nutrition is preferred over parenteral nutrition because the intestine is used in a physiologic manner.
2. There are two methods of administering enteral nutrition.
   a. Nasoenteric tubes (e.g., nasogastric or nasojejunal tubes)—best for short-term nutrition.
   b. Enterostomy tubes (e.g., PEG/G-tubes, J-tubes)—for long-term support.
3. There are many different formulas available for tube feeds—special formulas can be provided for patients with renal disease, liver disease, CHF, and so on.
4. Tube feeds can be delivered intermittently (in boluses) or continuously.
   a. Intermittent feeding (into the stomach) requires close monitoring (by nurses). There is no clear consensus on an appropriate cutoff level for a safe gastric residual volume, but in general gastric residuals should be checked every 6 to 8 hours and tube feeds should be held if the residual is >500 mL. A high residual volume should prompt a recheck in 1 hour but does not always necessitate stopping the tube feeds.
   b. Continuous feeding (into duodenum or jejunum) has a lower risk of aspiration than intermittent feeding.

Quick HIT

- PEG tube—the tube is inserted with the help of an endoscope through the mouth. Alternatively, it can also be done through an open abdominal incision, which is called open gastrostomy.
- The J-tube (jejunostomy) is placed in the intestine and can only be done through an open abdominal procedure.

5. Complications of enteral nutrition.
   a. Intolerance to tube feeds—check for diarrhea, constipation, nausea, vomiting, abdominal pain, or distention.
   b. Malpositioning of tube (in trachea/bronchus).
   c. Aspiration pneumonia (the risk of aspiration is not lessened by enteral feeding compared to oral feeding).
   d. Overload of solutes—due to high rate of hyperosmolar feedings (can cause diarrhea, electrolyte imbalance, hyperglycemia).

B. Parenteral Nutrition (administered into the vein)

1. The term TPN (total parenteral nutrition) is used for a high-concentration solution that can be given alone to meet the body’s caloric demands. TPN can also play a supplementary role when enteral feeding alone is inadequate.
2. It is used if the patient cannot eat for prolonged periods or cannot tolerate enteral feedings, and in severely malnourished patients.

3. There are two ways of administration.
   a. Central—via central venous catheter (e.g., subclavian vein)—preferred in patients who require long-term support.
   b. Peripheral—via peripheral line—one cannot administer as much protein or calories with this as with a central line. It should only be used for a short-term period. TPN cannot be administered in a peripheral line.

4. Complications of parenteral nutrition
   a. Electrolyte imbalances, volume disturbances
   b. Hyperglycemia
   c. Complications associated with placing a central line (e.g., pneumothorax)
   d. Infection of central (or peripheral) line (higher rates of infection, especially with fungal organisms, than usual due to presence of nutrients and glucose).
A. Cell Wall Inhibitors

1. Penicillins (see Table A-1)
   a. Mechanism of action
      - A ß-lactam antibiotic
      - Inhibit cross-linkage (transpeptidation step) of bacterial cell walls as they are synthesized
      - Bacterial cell walls lose structural and osmotic integrity
      - Cell lysis ultimately occurs
      - To achieve the desired effect, penicillins must first bind to proteins located inside the bacterial cell wall. These proteins are called penicillin-binding proteins
   b. Antimicrobial coverage (not exhaustive)
      - More effective against **gram-positive** than gram-negative organisms. Effective against viridans group streptococci, *Streptococcus pyogenes*, oral anaerobes, syphilis, Leptospira
      - Acts synergistically with aminoglycosides
      - Penicillin G is a long-acting intramuscular form of penicillin which is the drug of choice to treat syphilis. Because of microbial resistance, it is used less commonly to treat respiratory tract infections caused by streptococcal species, such as pharyngitis secondary to *S. pyogenes* or pneumococcal pneumonia
      - Penicillin V is the oral form of penicillin G which has some anaerobic activity, so it is more useful for dental infections
      - Penicillins are not good choices for empiric coverage for most infections due to widespread resistance
      - Ampicillin and amoxicillin have extended gram-negative activity. Ampicillin is typically given IV, while amoxicillin is an oral drug often used to treat outpatient upper respiratory tract infections caused by streptococcus. They cover the same organisms as penicillin, in addition to *Escherichia coli*, Lyme disease and few other gram-negative rods (*Haemophilus influenzae*, *Listeria*, *E. coli*, *Proteus*, *Salmonella*)
      - Penicillinase-resistant penicillins (PRPs) include oxacillin, cloxacillin, dicloxacillin, and nafcillin
      - Penicillins are generally ineffective against intracellular bacteria

---

**TABLE A-1 Important Antibiotics**

---
<table>
<thead>
<tr>
<th>Antibiotic/Antibiotic Category</th>
<th>Mechanism of Action</th>
<th>Most Common Uses</th>
<th>Adverse Reactions Commonly Seen*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillins</td>
<td>Cell wall inhibitors (interfere with transpeptidation)</td>
<td>Depends on extension of antimicrobial spectrum Oral and respiratory infections Streptococcal infections Syphilis</td>
<td>Hypersensitivity reactions</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Cell wall inhibitor (see text)</td>
<td>MRSA Enterococcal infections Endocarditis (used with aminoglycoside) Alternative if penicillin allergy present</td>
<td>“Red man” syndrome</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>Inhibit 30 S bacterial ribosomal subunit</td>
<td>Chlamydia Rickettsiae Lyme disease Topical use for acne vulgaris</td>
<td>Deposition in bones and teeth of children &gt;6 yrs old, fetuses</td>
</tr>
<tr>
<td>Macrolides</td>
<td>Inhibit 50 S bacterial ribosomal subunit</td>
<td>Atypical pneumonia Alternative to penicillin (i.e., allergy)</td>
<td>GI upset</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Inhibits 50 S bacterial ribosomal subunit</td>
<td>Anaerobes, staphylococci, streptococci</td>
<td>C. difficile colitis, Pseudomembranous colitis</td>
</tr>
<tr>
<td>Cephalexins</td>
<td>Cell wall inhibitors (similar to penicillins)</td>
<td>Depends on generation: First: Similar to penicillins, surgical prophylaxis, streptococci and staphylococci infections Second: Pneumonia in elderly patients, recurrent pneumonia Third: Gonorrhea, meningitis Fourth: Broad-spectrum, including streptococci, staphylococci, and pseudomonas</td>
<td>Possible cross-sensitivity with penicillin A few promote bleeding diathesis, correctable with vitamin K</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>Inhibit bacterial DNA-gyrase</td>
<td>UTIs Diarrhea secondary to gram-negative rods Penicillin-resistant pneumonia Some with anti-Pseudomonas activity</td>
<td>Damage to cartilage in children Tendon rupture</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Inhibit 30 S bacterial ribosomal subunit</td>
<td>Gram-negative sepsis Endocarditis (with vancomycin) Complicated UTIs</td>
<td>Nephrotoxicity Ototoxicity</td>
</tr>
<tr>
<td>TMP/SMX</td>
<td>Blocks bacterial DNA synthesis through action on folate pathway (two steps)</td>
<td>P. carinii pneumonia UTIs</td>
<td>Rash Stevens–Johnson syndrome</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Products of reduction reaction kill susceptible bacteria and protozoans</td>
<td>Anaerobes Trichomonas Nistolytica and Giardia</td>
<td>Metallic taste Disulfiram-like effect</td>
</tr>
</tbody>
</table>

*Note that these are not necessarily the most common side effects.

**Quick HIT**

Best antibiotics for gram-positive coci (Staph and Strep):
1. PRPs (oxacillin, nafcillin, etc.)
2. First-generation cephalosporins
3. Fluoroquinolones

c. Adverse reactions
   - **Hypersensitivity reactions**—type I hypersensitivity reaction may present as rash, angioedema, or even anaphylaxis
   - Diarrhea
   - Interstitial nephritis
d. Other features
   - Penicillins are used to treat otitis media, UTI in pregnant women, dental infections, enterococcal infections, Listeria monocytogenes, Lyme disease
   - Penicillin is used as prophylaxis against infection in patients with sickle cell disease
   - Bacteria gain resistance to penicillins through alterations in penicillin-binding proteins—for example, MRSA
   - Resistance is also conferred by β-lactamases, enzymes that hydrolyze the penicillin’s β-lactam ring. This can be overcome with the addition of a β-lactamase inhibitor, for example, ampicillin-sulbactam or amoxicillin-clavulanate.
e. Examples (list of examples is not exhaustive)
   - Penicillin G
   - Penicillin V
   - Ampicillin
   - Amoxicillin
   - Methicillin
   - Nafcillin
   - Oxacillin
   - Piperacillin

---

**Quick HIT**

Hypersensitivity Reactions to Penicillin

- Type I hypersensitivity reaction.
- This may present with rash, angioedema, or even anaphylaxis.
- Cross-reactions with other β-lactam antibiotics can occur.
- Nausea, vomiting, and diarrhea are not hypersensitivity reactions.
- It may develop at any time, even if past treatments with penicillin were uneventful.

2. Cephalosporins
   a. Mechanism of action
- Similar mechanism of action to penicillin
- As with penicillin, the β-lactam ring confers **bactericidal** activity

b. Antimicrobial coverage (not necessarily exhaustive—this applies to the rest of antimicrobial section)

- Cephalosporins are classified according to antimicrobial activity and β-lactamase resistance into “generations”
- First-generation cephalosporins generally serve as substitutes for penicillin, and also have coverage against *Proteus*, *Klebsiella*, and *E. coli*. Cefazolin is the only parenteral first-generation cephalosporin available in the United States
- Second-generation cephalosporins have more gram-negative activity and less gram-positive activity than first-generation cephalosporins. They are used to treat *H. influenzae*, *Neisseria gonorrhoeae*, and *Enterobacter* spp.
- Third-generation cephalosporins have even more **gram-negative activity, less gram-positive activity**, and are **able to cross the blood–brain barrier**. (First- and second-generation cephalosporins do not penetrate the CSF and should not be used to treat infections of the central nervous system)
- Fourth-generation cephalosporins are the most broad-spectrum, including activity against *Pseudomonas*, *Neisseria*, and methicillin-sensitive *Staphylococcus aureus*, as well as most of the above-mentioned organisms. It has better staphylococcal coverage than third-generation drugs
- Fifth-generation cephalosporins are a new class of drugs which show high activity against MRSA

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
</table>
| Best antibiotics for anaerobes:  
  a. Penicillin (G, VK, amoxicillin, ampicillin)  
  b. Clindamycin  
  c. Metronidazole (for abdominal/GI)  |

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cephalosporins (every generation) will cover viridans group streptococci, group A, B, and C streptococci, <em>E. coli</em>, <em>Klebsiella</em>, <em>Proteus mirabilis</em>.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Third- and fourth-generation cephalosporins are not useful for treating infections due to gram-positive cocci (except for <em>Streptococcus</em> species) or <em>Acinetobacter</em>.</td>
</tr>
</tbody>
</table>

c. Adverse reactions
• **Hypersensitivity reactions**—allergic cross-reaction with penicillin can occur in 10% of cephalosporins
• Certain cephalosporins (especially the second generation) can promote a bleeding diathesis, which is reversible with vitamin K, but this is rare
• Some second-generation cephalosporins may cause a disulfiram-like reaction to alcohol
d. Other features
• First-generation cephalosporins are used for surgical prophylaxis or mild cellulitis
• Most forms of cephalosporins must be administered intravenously
• Cefuroxime is sometimes used to treat community-acquired pneumonia
• Cefoxitin can be used for abdominal infections, such as peritonitis
• Ceftriaxone can be given as an IM injection to treat gonorrhea. Intravenously it plays an important role in empiric treatment for meningitis
• Third-generation antibiotics are one of the classes of drugs which have been shown to have the highest association with antibiotic-induced *Clostridium difficile* infection
• Because of its broad coverage (including pseudomonas), cefepime is a good choice for empiric therapy in nosocomial infections as well as febrile neutropenia
• Fifth-generation cephalosporins are currently approved to treat uncomplicated skin and soft tissue infections, though their MRSA activity offers great promise
e. Examples (list of examples is not exhaustive)
• First generation: cefazolin, cephalexin, cefadroxil
• Second generation: cefaclor, cefoxitin, cefuroxime, cefotetan, cefprozil
• Third generation: ceftriaxone, cefixime, cefotaxime, ceftazidime, cefdinir, cefpodoxime
• Fourth generation: cefepime is the only fourth-generation cephalosporin
• Fifth generation: ceftaroline, ceftobiprole

3. **Miscellaneous cell wall inhibitors**
a. **Vancomycin**
• Inhibits cell wall synthesis by interfering with cross-linkage of peptidoglycan chains (different site of action from penicillin), also damages cell membranes
• Main use is to treat staphylococcal infections resistant to other β-lactams, such as MRSA, or if penicillin allergy is present; not used for gram-negative organisms
• Oral vancomycin is effective to treat *C. difficile* infections of the bowel
• Acts synergistically with aminoglycosides to treat enterococcal infections
• Adverse reactions include fever, nephrotoxicity, ototoxicity, and “red man
syndrome” (flushing due to infusion-induced histamine release). Treat red man syndrome by slowing the infusion and giving antihistamines (i.e., diphenhydramine)

- Serum levels must be followed up in prolonged therapy, and doses must be adjusted for renal insufficiency
- Vancomycin resistance is an emerging, ominous phenomenon. Many enterococci have developed resistance to vancomycin creating vancomycin-resistant enterococci (VRE)

Quick HIT

Treat MRSA with vancomycin. Treat MSSA with a penicillin such as oxacillin or nafcillin.

b. Carbapenems
   - Synthetic β-lactams designed to be more resistant to β-lactamases and penicillinases
   - Examples include imipenem, ertapenem, doripenem, and meropenem
   - Imipenem is always combed with cilastatin to prevent renal toxicity associated with the metabolism of imipenem
   - Carbapenems have broad-spectrum antimicrobial coverage, including penicillin-resistant pneumococci, *Pseudomonas* (except ertapenem), anaerobes, and *Enterobacter* infections
   - They are used empirically for patients in whom gram-negative sepsis is suspected
   - They may cause nausea, vomiting, and sometimes neutropenia
   - They reduce the seizure threshold (especially imipenem)

c. Monobactams
   - Aztreonam is currently the only available preparation in the United States
   - Contains only one of the two structural rings found in other β-lactams, hence the name. It retains resistance to β-lactamases
   - Narrow spectrum of activity: Primarily aerobic gram-negative rods, including *Pseudomonas, Klebsiella*, and *Serratia*
   - Less cross-reactivity with penicillin than other β-lactam antibiotics makes it useful for patients with penicillin allergies

d. β-Lactamase inhibitors
   - Examples include sulbactam, tazobactam, and clavulanic acid
   - Not used by themselves, but rather combined with penicillins to enhance antimicrobial activity (e.g., amoxicillin + clavulanic acid = Augmentin)

e. Bacitracin
- Inhibits bacterial cell wall synthesis by inhibiting transport of peptidoglycans
- Effective against gram-positive organisms
- Used **topically** only (because it is so nephrotoxic)

---

### Quick HIT

Piperacillin and ticarcillin are always used in combination with a β-lactamase inhibitor (e.g., tazobactam, clavulanic acid).

---

**B. Protein Synthesis Inhibitors**

1. **Tetracycline**
   a. **Mechanism of action**
      - Inhibits protein synthesis by binding to 30 S subunit of bacterial ribosome
      - **Bacteriostatic**
   b. **Antimicrobial coverage**
      - Effective against certain intracellular bacteria: Chlamydia, rickettsial diseases (e.g., Rocky Mountain spotted fever), mycoplasma, spirochetes
      - Treats gram-negative *Vibrio cholerae*
      - Also treats spirochete causing Lyme disease (*Borrelia burgdorferi*)
      - Often used to treat uncomplicated respiratory tract infections such as sinusitis and bronchitis
      - Tigecycline is broad-spectrum (including MRSA and VRE) and is able to evade the resistance mechanisms which render the other tetracyclines less active
   c. **Adverse reactions**
      - GI—epigastric pain, nausea, vomiting
      - **Deposits occur in calcified tissues** (e.g., teeth and bones of the fetus if given during pregnancy and potentially in any child <8 years old). This can result in permanent discoloration of teeth, stunting of growth, and skeletal deformities
      - Phototoxicity
      - Hepatotoxicity—may occur in pregnant women
   d. **Cautions**
      - Do not give to pregnant women or children <8 years old
      - Do not give to patients with renal insufficiency (except doxycycline)
      - Decreased absorption occurs if taken with milk and antacids
      - Resistance is common
   e. **Examples**
      - Tetracycline
      - Doxycycline
• Minocycline
• Tigecycline is a new antibiotic in a related class of drugs called glycylcyclines.

2. **Macrolides**
   a. Mechanism of action
      • Inhibit protein synthesis by binding to 50 S subunit of bacterial ribosome
      • **Bacteriostatic** (may be bactericidal at high doses)
   b. Antimicrobial coverage
      • Good at treating intracellular pathogens, such as *Mycoplasma, Chlamydia,* and *Legionella*
      • Erythromycin and clarithromycin have activity against staphylococci and streptococci
      • Clarithromycin is the treatment of choice for *Mycoplasma pneumonia* (“walking pneumonia”) and *Legionella* spp.
      • Erythromycin is also appropriate as an alternative to penicillin G if there is a penicillin allergy (e.g., treatment of chlamydia in pregnancy, to avoid tetracycline)
      • Due to adverse events and frequent dosing, erythromycin is being used less often as an antibiotic. It is still regularly used as a GI stimulant however
      • Clarithromycin is one of the drugs used in therapy for eradication of *Helicobacter pylori*
      • Azithromycin and clarithromycin have activity against *H. influenzae*
      • Azithromycin also treats *Moraxella catarrhalis*
   c. Adverse reactions
      • GI side effects are the most common and include epigastric pain, nausea, and vomiting (particularly with erythromycin)
      • Cholestasis
      • Prolongation of QT interval, especially with erythromycin
   d. Cautions
      • Erythromycin should not be prescribed to patients with liver failure because it is metabolized in the liver
      • Erythromycin and clarithromycin interact with many drugs due to their inhibitory effect on the P-450 system
   e. Examples
      • Azithromycin
      • Clarithromycin
      • Erythromycin

3. **Aminoglycosides**
   a. Mechanism of action
• Inhibit protein synthesis by binding to 30 S subunit of bacterial ribosome
• **Bactericidal**

b. Antimicrobial coverage

• Treat gram-negative aerobes, such as *E. coli, Pseudomonas, Acinetobacter,* or *Klebsiella*. Used for empiric coverage for gram-negative sepsis when resistant organisms are suspected
• Sometimes used in combination with ampicillin or other β-lactams for complicated UTIs, meningitis, or other serious infections
• No activity against anaerobes

c. Adverse reactions

• **Otitotoxicity**—may cause irreversible hearing loss, especially if infused too quickly. Baseline and follow-up hearing tests are required for patients on aminoglycosides long term
• **Nephrotoxicity**—may cause renal insufficiency or acute tubular necrosis. Aminoglycoside toxicity is dose-related, so be sure to adjust dose for renal dysfunction

**Quick HIT**

Most common application of aminoglycosides for treating serious infections caused by aerobic gram-negative rods:
- Sepsis
- Complicated UTI
- Pneumonia
- Osteomyelitis
- Complicated intra-abdominal infections

d. Other points

• Most are given parenterally.
• Check peak and trough levels to avoid drug toxicities

e. Examples

• Gentamicin
• Streptomycin
• Tobramycin
• Amikacin
• Neomycin

4. **Miscellaneous protein synthesis inhibitors**

a. Clindamycin

• Binds to 50 S subunit of ribosome, inhibiting bacterial protein synthesis
• Key feature is activity against anaerobic bacteria. In addition to anaerobes, can
be used for streptococcal and staphylococcal infections (may be helpful to inhibit bacterial toxin production)

- It can also be used to treat many types of gram-positive cocci. If the patient is allergic to cephalexin (Keflex), clindamycin can be given instead
- The most notable adverse effect is its potential to cause antibiotic-associated diarrhea, including *C. difficile* colitis.

b. Chloramphenicol
- It binds to 50 S bacterial ribosomal subunit, but may also interfere with human ribosomal activity, and so it has the potential to be highly toxic
- Broad-spectrum antimicrobial coverage, including anaerobes and rickettsiae; readily penetrates the CSF
- Adverse effects may be severe and even fatal: **aplastic anemia** and **gray baby syndrome** (cyanosis due to respiratory depression and cardiovascular collapse)
- Inhibits the P-450 system, potentiating the effect of many important drugs

c. Linezolid
- Has great coverage of gram-positive bacteria, including streptococci, enterococci, and MRSA
- Most serious reported adverse effect is thrombocytopenia (monitor blood counts with prolonged therapy). Peripheral neuropathy has also been reported with extended treatment regimens
- Linezolid inhibits monoamine oxidase. This may lead to serotonin syndrome when given with pro-serotonin agents such as SSRIs
- Great oral bioavailability

C. **Fluoroquinolones**

1. Mechanism of action—direct inhibitors of bacterial DNA synthesis
   a. Inhibit bacterial DNA gyrase and topoisomerase IV, blocking replication of bacterial DNA
   b. **Bactericidal**

2. Antimicrobial coverage
   a. Have excellent activity against **gram-negative organisms**, including *Pseudomonas, E. coli, Proteus, Legionella*, and gonorrhea. Gram-positive coverage is variable. Certain fluoroquinolones (e.g., levofloxacin, moxifloxacin) have good gram-positive coverage and are excellent agents for community-acquired pneumonia. Only moxifloxacin has anaerobic coverage
   b. Commonly used to treat UTIs. Ciprofloxacin also treats acute diarrhea due to enteric bacteria (traveler’s diarrhea)
   c. Best therapy for community-acquired pneumonia
Fluoroquinolones are only antimicrobial agents in clinical use that are direct inhibitors of bacterial DNA synthesis.

3. Adverse reactions
   a. GI—nausea, vomiting, diarrhea
   b. CNS—dizziness, headache, lightheadedness, agitation
   c. Nephrotoxicity
   d. Hypoglycemic coma
   e. Cartilage damage in children has not been shown in humans, although animal studies suggest this
   f. Tendinitis and tendon rupture
   g. Cautions
      • Significantly reduced absorption if consumed with divalent cations, such as antacids that contain magnesium
      • Must be adjusted for renal insufficiency
      • Do not give to nursing mothers and to children (although the latter is evolving, especially in children with cystic fibrosis)
      • Absolutely contraindicated in pregnant patients because animal studies show cartilage damage
   h. Examples
      • Levoﬂoxacin
      • Ciproﬂoxacin
      • Ofloxacin
      • Moxifloxacin
      • Gemifloxacin

Best antibiotics for gram-negative rods (E. coli, Klebsiella, Proteus, Enterobacter, Pseudomonas):
- Fluoroquinolones
- Aminoglycosides
- Carbapenems
- Piperacillin
- Aztreonam
- Cephalosporins

D. Antituberculosis Antibiotics
1. Principles of therapy.
   a. Never treat tuberculosis with only one antibiotic. Use multidrug therapy
because drug resistance is such a problem with *Mycobacterium tuberculosis*.

b. Treat active tuberculosis with three to four antibiotics (isoniazid [INH], rifampin, pyrazinamide [PZA], and sometimes ethambutol) for 2 months, followed by rifampin and INH for 4 months.

c. Since *M. tuberculosis* is a slow-growing organism, the required duration of treatment is longer than it is in other bacterial infections.

2. Important first-line antituberculosis agents (many second-line agents also exist).
   a. INH
      - Attacks the enzyme that produces the mycolic acids that comprise the mycobacterial cell walls.
      - Resistance to INH develops rapidly if it is used alone.
      - INH is drug of choice for treatment of latent TB.
      - The most important adverse reaction is **drug-induced hepatitis**, which can be fatal.
      - It may cause a relative pyridoxine (vitamin B$_6$) deficiency, resulting in peripheral neuropathy. This is reversible with pyridoxine administration.

   b. Rifampin
      - Inhibits bacterial RNA synthesis by blocking RNA polymerase.
      - In addition to its role as an antituberculosis agent, rifampin is used as prophylaxis for close contacts of patients with meningococcal meningitis.
      - Rifampin is also active against *Mycobacterium leprae*, which causes leprosy.
      - May stain tears or urine an orange-red color; induces hepatic microsomal enzymes and decreases the half-life of many medications.
      - Rifampin is a powerful inducer of the cytochrome P-450 enzyme system, so drug interactions should be monitored carefully.

   c. PZA
      - Inhibits fatty acid synthesis of even slow-growing *M. tuberculosis* at a different step than INH.
      - Active against tubercle bacilli residing in macrophages.
      - May cause hyperuricemia, resulting in a gouty attack.
      - Potentially hepatotoxic

   d. Ethambutol
      - Inhibits an essential component of the mycobacterial cell wall.
      - It may cause **optic neuritis**, resulting in diminished visual ability as well as red-green color blindness. Periodic visual testing may be necessary.
      - It may also precipitate a gouty attack.
      - Also used in the treatment of *Mycobacterium avium intracellulare*.

E. Miscellaneous Antibiotics
1. Trimethoprim (TMP)
   a. TMP inhibits dihydrofolic acid reductase, blocking bacterial DNA synthesis.
   b. It works synergistically with sulfonamides.
   c. TMP was formerly used alone to treat UTIs but now is most commonly used in combination with sulfamethoxazole (SMX). SMX inhibits a second, unique step in bacterial folate synthesis, creating a synergistic effect.
   d. TMP/SMX is used both for prophylaxis and treatment of *Pneumocystis jirovecii* (formerly *carinii*).
   e. It may cause folate deficiency, resulting in megaloblastic anemia.
   f. TMP/SMX is used to treat *S. aureus* (including some MRSA), UTIs, *Pneumocystis carinii* pneumonia, *Shigella*, and *Salmonella*, among other infections.
   g. Side effects of TMP include hematologic (bone marrow suppression), renal (inhibition of creatinine secretion), and hyperkalemia.

2. Sulfonamides
   a. Structural analogs of *p*-aminobenzoic acid that inhibit the enzyme dihydropteroate synthase, which is necessary for folic acid, and thus DNA synthesis.
   b. Treat both gram-positive and gram-negative bacteria, although resistance to sulfonamides is increasingly common.
   c. Most sulfonamides that were once used alone have been replaced by the combination of TMP/SMX.
   d. Some forms of sulfonamides are still given as monotherapy, such as silver sulfadiazine (topical solution) in burn patients to prevent infection, and sodium sulfacetamide (ophthalmic ointment) for bacterial conjunctivitis.
   e. The most common adverse reactions are rash, photosensitivity, nausea, vomiting, and diarrhea.
   f. A rare but dreaded associated adverse reaction is **Stevens–Johnson syndrome**.
   g. **Do not give to patients with G6PD because they can precipitate a hemolytic response.**

3. Metronidazole
   a. Forms a cytotoxic compound through an oxidation–reduction action which damages DNA. Bactericidal.
   b. Effective against anaerobic bacteria as well as certain protozoal organisms such as *Entamoeba histolytica*, *Giardia*, and *Trichomonas*.
   c. Oral form very useful in the treatment of *C. difficile* diarrheal infections.
   d. Adverse effects—results in a **disulfiram-like reaction** if consumed with alcohol. May also cause headache and a metallic taste. Hepatitis and pancreatitis are extremely rare. Warfarin effects are enhanced with concomitant use of metronidazole due to inhibition of warfarin metabolism—warfarin levels should
be closely monitored.

4. Nitrofurantoin
   a. Works by a complex mechanism to inactivate several bacterial enzyme systems including acetyl CoA.
   b. Primary use is for **uncomplicated** lower urinary tract infections caused by *E. coli* or other common community-acquired organisms. Do not use for pyelonephritis or infections outside of the urinary system.

5. Table A-1 lists mechanisms of action, uses, and adverse reactions for important antibiotics.
Physical Examination Pearls

Heart Sounds

A. For murmur of mitral stenosis and to hear $S_3$ and $S_4$, use the bell of the stethoscope.

B. For pericardial friction rubs, aortic/mitral regurgitation murmurs, and to hear $S_1$ and $S_2$, use the diaphragm of the stethoscope.

C. Ventricular systole takes place between $S_1$ and $S_2$, and ventricular diastole between $S_2$ and $S_1$. Remember that diastole lasts longer than systole; this distinction makes it easy to identify the two sounds.

D. How to differentiate $S_3$ and $S_4$ (the lines represent duration of pause between sounds): $S_3$ comes immediately after $S_2$, and $S_4$ comes immediately before $S_1$.
   1. $S_1$—$S_2$—$S_3$
   2. $S_4$—$S_1$—$S_2$

E. Splitting of $S_2$ during inspiration and paradoxical splitting of $S_2$.
   1. The second heart sound has two parts: Aortic valve closure, then pulmonic valve closure.
   2. With inspiration, there is increased blood return to the right heart. This increased flow delays pulmonary valve closure, which results in the normal splitting of $S_2$ during inspiration.
   3. Paradoxical splitting of $S_2$ refers to the narrowing of this split during inspiration (instead of the normal widening that occurs). This can occur as a result of delayed aortic closure (as seen in LBBB, aortic stenosis, and hypertension).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>• $S_1$ = mitral valve closure</td>
</tr>
<tr>
<td>• $S_2$ = aortic valve closure (pulmonic valve closure contributes)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Aortic area = right second intercostal space close to sternum</td>
</tr>
<tr>
<td>• Pulmonic area = left second intercostal space close to sternum</td>
</tr>
<tr>
<td>• Tricuspid area = left fourth and fifth intercostal space</td>
</tr>
<tr>
<td>• Mitral area = apex</td>
</tr>
</tbody>
</table>
F. It is easier to hear $S_3$, $S_4$, and murmur of mitral stenosis if the patient is lying on his or her left side. Use the bell of the stethoscope and apply light pressure at the apical impulse. $S_3$ disappears if a lot of pressure is applied.
Murmurs

A. **Grade 1** — very faint; only a cardiologist can hear it

B. **Grade 2** — quiet

C. **Grade 3** — moderately loud

D. **Grade 4** — loud; associated with a thrill

E. **Grade 5** — very loud; can hear it with stethoscope partially off the chest

F. **Grade 6** — heard with stethoscope entirely off the chest
Breath Sounds

A. Vesicular Breath Sounds
1. Soft, low-pitched
2. Audible throughout most lung fields
3. Heard during all of inspiration and first third of expiration

B. Bronchial Breath Sounds
1. Loud, high-pitched
2. Longer expiratory than inspiratory phase (opposite of vesicular sounds)
3. Hear a gap between inspiration and expiration
4. Heard in central areas (over trachea)
5. Bronchial sounds are abnormal if heard over the peripheral lung areas (where only vesicular sounds should be heard). This suggests an area of consolidation

C. Bronchovesicular Sounds
1. Intermediate pitch
2. Equal duration of inspiratory and expiratory phases

D. Adventitious Breath Sounds
1. Rales (also called crackles)
   a. Can be heard during inspiration or expiration; intermittent (discontinuous) sounds
   b. Usually due to excessive fluid in the lungs or atelectasis
   c. Causes include pneumonia, CHF, interstitial lung disease (usually dry, “Velcro-like” crackles)
   d. Sometimes differentiated based on sound—fine crackles are high-pitched, soft, and brief in duration; coarse crackles are lower-pitched, louder, and longer in duration
2. Wheezes have a hissing or musical sound caused by air moving through narrowed airways. Asthma is the most common cause
3. Rhonchi have a snoring quality and lower pitch, and are due to high mucus production in the large airways (e.g., chronic bronchitis)
Abdominal Examination

A. Inspect — look for scars.

B. Auscultate — listen to bowel sounds; this is a nonspecific part of the abdominal examination.

C. Palpate — feel all quadrants, then palpate more deeply in all quadrants.
   1. Is the abdomen soft? A rigid abdomen may be a sign of a perforated viscus or peritoneal inflammation (acute abdomen).
   2. Check for tenderness in all quadrants.
   3. Check for rebound tenderness—does it hurt when you push down or let go? Pain on withdrawal of the hand is rebound tenderness and suggests peritoneal inflammation.
   4. Is there guarding? Guarding refers to an area of rigidity and is significant when it is involuntary (i.e., not due to voluntary muscular contraction).
Neurologic Examination

A. Evaluate the Following:
1. Level of consciousness, speech fluency
2. Pupillary size and reactivity, extraocular muscle movement—give information about function of the brainstem, especially CNs III and VI
3. Complete cranial nerve examination
4. Muscle strength testing
5. Truncal ataxia, pronator drift of arm (sensitive test of motor weakness)
6. Sensation
7. Cerebellar testing—finger to nose and heel to shin; test gait on ambulation, heel-to-toe walking is good for detecting mild ataxia
8. Deep tendon reflexes— asymmetry suggests corticospinal tract dysfunction (upper motor neuron lesion)
9. Babinski sign—toes should normally flex. If they extend, this is a positive Babinski sign

B. Upper and Lower Motor Neuron Defects (See Table A-2)
1. Deep tendon reflexes
   a. Grading of reflexes
      • 0 = No reflex
      • 1 = Diminished reflexes
      • 2 = Normal
      • 3 = Increased reflexes
      • 4 = Hyperactive reflexes
   b. Locations
      • Biceps (C5)
      • Brachioradialis (C6)
      • Triceps (C7)
      • Patellar (knee jerk) (L4)
      • Ankle (S1)
   c. Muscle strength
      • 0 = No contraction
      • 1 = Flicker of contraction (muscle is “firing”)
      • 2 = Moves limb when gravity is eliminated
      • 3 = Moves limb against gravity (but not against any resistance)
      • 4 = Moves limb against gravity and some resistance
      • 5 = Normal muscle strength; moves limb against maximal resistance
If you cannot elicit lower extremity reflexes, have the patient lock the fingers and pull his or her arms apart (to distract them) as you try again.

### TABLE A-2 Upper Versus Lower Motor Neuron Defects

<table>
<thead>
<tr>
<th>Upper Motor Neuron Signs</th>
<th>Lower Motor Neuron Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spasticity</td>
<td>Flaccid paralysis</td>
</tr>
<tr>
<td>Increased deep tendon reflexes (hyperreflexia)</td>
<td>Decreased deep tendon reflexes</td>
</tr>
<tr>
<td>Babinski reflex (plantar response extensor)—toes upward (abnormal)</td>
<td>No Babinski reflex (plantar response flexor)—toe downward (normal)</td>
</tr>
<tr>
<td>No atrophy</td>
<td>Muscle atrophy</td>
</tr>
<tr>
<td>No fasciculations</td>
<td>Fasciculations present</td>
</tr>
</tbody>
</table>
FIGURE A.2 Palpation of the lymph nodes in a physical examination.

C. Palpation of Lymph Nodes (Figure A-2)
Tumor Markers

Tumor markers and the cancers they differentiate, as well as their usefulness, are covered in Table A-3.
Workup and Management of Common Problems

On The Wards

Refer to respective sections in each chapter for a more thorough discussion.
Hypotension

A. Causes: All causes of shock (sepsis, hypovolemia, cardiogenic, anaphylactic, neurogenic), medication (β-blockers, calcium channel blockers, nitrates, morphine, sedatives, epidural infusion)

<table>
<thead>
<tr>
<th>Tumor Marker</th>
<th>Cancer</th>
<th>Limitations</th>
<th>Uses/Comments</th>
</tr>
</thead>
</table>
| CEA          | Colorectal cancer | Lacks sensitivity and specificity—this is not an effective screening test; levels may be elevated in other malignancies and in some nonmalignant diseases | • Effective for monitoring disease process—a decrease in CEA indicates a favorable response to surgery, and an increase in CEA indicates disease progression  
• Prognosis—the risk of recurrence is higher if the CEA level was elevated before surgery |
| AFP          | HCC and nonseminomatous germ cell tumors of testis (NSGCT) | Not specific; can be elevated in nonmalignant diseases such as cirrhosis and hepatitis | Highly elevated AFP levels are present almost exclusively in primary HCC and NSGCT of the testis |
| CA-125       | Ovarian cancer | Neither sensitive nor specific for ovarian cancer, therefore not useful for screening—a normal CA-125 does not exclude ovarian cancer | • Very useful for monitoring the response to therapy (after surgery or chemotherapy)—a decrease in CA-125 after treatment indicates shrinkage of the tumor, and an increase indicates disease progression or recurrence  
• Between 80% and 90% of women 50 yrs of age with a pelvic mass and an increased CA-125 will be found to have ovarian cancer |
| Prostate-specific antigen (PSA) | See prostate section | | |
| CA 19-9      | Pancreatic cancer | Low specificity—this is elevated in colorectal, pancreatic, and gastric cancer, as well as pancreatitis and ulcerative colitis | 73% of patients with pancreatic cancer have CA 19-9 levels greater than 100 U/mL |
| β-hCG        | Gestational trophoblastic disease, gonadal germ cell tumor | Elevated in pregnancy | • This has a high sensitivity for diagnosis of choriocarcinoma and trophoblastic neoplasm after evacuation of a molar pregnancy  
• Either hCG or AFP is elevated in 90% of patients with NSGCT of the testis  
• hCG may be elevated in either seminomatous germ cell tumors or NSGCTs, but AFP is only elevated in NSGCTs |

B. Management
1. Quickly assess mental status—how symptomatic is the patient?
2. Obtain a full set of vitals, including BP in both arms. Expect a compensatory tachycardia. Bradycardia may result in reduced cardiac output.
3. Determine baseline BP (may not be significantly different).
4. Consider ECG, CXR, arterial blood gas (ABG), blood culture (if febrile), and CBC (if bleeding is suspected).
5. Treatment should be directed toward the cause.
6. If patient is symptomatic, the reverse Trendelenburg position may be helpful.
7. Consider NS bolus (500 mL or 1 L)—repeat this if BP does not improve (but be careful in patients with CHF or cardiogenic shock).
8. Discontinue or hold antihypertensive medications.
9. Vasopressors may be needed if there is no response to IV fluids.
10. If hypotension is profound or persists despite fluid therapy, consider transferring the patient to the ICU.
11. Put the patient on a cardiac monitor.
Hypertension

A. Causes
1. Failure to administer, order, or take antihypertensive medications
2. Pain, agitation
3. Hypertensive emergencies (manifested by MI, aortic dissection, encephalopathy, hemorrhagic CVA, or acute CHF exacerbation)
4. Delirium tremens or alcohol/benzodiazepine withdrawal
5. Eclampsia or preeclampsia
6. Cocaine, amphetamine use

B. Management
1. Always recheck the BP with a properly fitting cuff to confirm HTN. Check other vital signs.
2. Check the patient’s medication record to ensure appropriate compliance with therapy.
3. Check for signs of end-organ damage due to HTN, which indicate that a hypertensive emergency is occurring: chest pain/ECG changes, neurologic examination findings/encephalopathy, acute renal insufficiency or failure, papilledema.

Quick HIT

With hypotension or hypertension, treat the patient, not the BP reading. Asymptomatic patients with hypotension often do not require treatment.

4. Consider the following tests as appropriate, given the presentation: ECG, renal function panel, cardiac enzymes, CXR, CT of the head.
5. Treat pain and agitation as needed.
6. If HTN is mild and the patient is asymptomatic, observation with follow-up may be appropriate.
7. Oral antihypertensive medications (e.g., α-blockers, calcium channel blockers, ACE inhibitors, or oral β-blockers) can be given for most cases of hypertension. Follow response and repeat medication as needed. Be careful not to overtreat hypertension, especially when long standing.
8. **Never ignore symptomatic HTN or hypertensive emergencies.** BP must be reduced quickly but carefully. (Reduce mean arterial pressure by no more than 25% in the first 2 hours.) This should be done in the ICU, with IV labetalol, nitroprusside, or enalaprilat, or additional doses of the patient’s current regimen.
9. Reduce or discontinue IV fluids if volume overload is suspected.
Be careful not to lower BP too quickly in a hypertensive patient.
Chest Pain

A. Causes
1. **Heart/vascular:** Angina, MI, pericarditis, aortic dissection
2. **GI:** Gastroesophageal reflux disease, diffuse esophageal spasm, peptic ulcer disease, gallbladder disease, acute cholecystitis
3. **Chest wall:** Costochondritis, rib fracture, muscle strain, herpes zoster
4. **Psychiatric:** Anxiety, somatization
5. **Pulmonary:** PE, pneumothorax, pleuritis
6. **Cocaine use:** Can cause angina or MI

B. Management
1. As always, check vital signs. In most cases, obtain a 12-lead ECG. Compare with an old ECG. Get more information about the patient’s cardiac history and current history of chest pain.
2. Order cardiac enzymes (troponin) × 3, every 8 hours, if unstable angina or MI is suspected.
3. Consider CXR (pneumothorax, widened mediastinum, pleural effusion). Consider ABG or CT scan if PE is suspected.
4. If myocardial ischemia is suspected:
   a. Oxygen if SpO₂ < 90%, 2 L by NC, titrate up as needed.
   b. Nitroglycerin (sublingual) for pain; if pain continues, can give morphine IV or nitroglycerin IV infusion until free of chest pain.
   c. Keep systolic BP > 90 mm Hg.
   d. Aspirin
   e. Heparin—give a loading dose, then start a drip. Check the PTT at baseline and in 6 hours. Ensure there are no contraindications to anticoagulation prior to starting (recent intracranial hemorrhage, active bleeding).
   f. Put the patient on a cardiac monitor, and consider transfer to a cardiac care unit.
5. Treat other suspected conditions appropriately. See discussions of PE, aortic dissection, pneumothorax, GERD, and PUD.
Tachycardia

A. Types: Determine whether the tachycardia is a narrow or wide complex. Obtain an ECG—is it regular? If wide, treat like ventricular tachycardia (VT). If narrow, determine whether the tachycardia is sinus or non-sinus.

B. Sinus Tachycardia
1. HR >100, hardly ever >200 beats/min.
2. Sinus P waves precede each QRS complex.
3. Causes include pain, exercise, anxiety, panic attacks, dehydration, PE, volume loss (bleeding), hyperthyroidism, fever, anemia, albuterol, decongestants, and substance withdrawal.
4. Treat the underlying cause. In older patients with cardiac disease, consider a β-blocker to prevent the increase in myocardial O$_2$ demand that occurs at a high HR. Never start a β-blocker to “treat the tachycardia” unless you have ruled out all serious causes above.

C. Narrow Complex Non-Sinus Tachycardia
1. Also known as supraventricular tachycardias (SVT). May be due to atrial flutter, atrial fibrillation, AV reentrant tachycardia (AVRT), or AV nodal reentrant tachycardia (AVNRT).
2. Treatments vary according to the arrhythmia.
   a. AVRT or AVNRT—treat with vagal maneuvers or IV adenosine. Prior to any treatment, ensure patient is on a cardiac monitor and the crash cart is at bedside. AV nodal blockers may also be used.
   b. Atrial fibrillation—control the rate with a β-blocker, DC cardioversion, anticoagulation.
   c. Atrial flutter—treat as with atrial fibrillation.
   d. VT—if the patient is stable, give IV amiodarone. If the patient is unstable, perform DC cardioversion.

D. Wide Complex Tachycardia
1. Either ventricular tachycardia (VT) or supraventricular tachycardia with aberration (early reentrant pathway)
2. Treat all wide complex tachycardias as VT unless proven otherwise. If patient is stable, give antiarrhythmics such as IV amiodarone. If the patient is unstable, perform cardioversion.
3. Ventricular fibrillation—perform immediate defibrillation and CPR.
**Oliguria**

**A. Typically Defined as Urine Output <400 mL/day or <0.05 mL/kg/hr**

**B. Causes**

2. Renal: glomerulonephritis, acute tubular necrosis, acute interstitial nephritis, vascular insult, and so on.
3. Postrenal: obstruction of lower or upper (bilateral) urinary tract.

**C. Management**

1. Check other vital signs.
2. Inquire about potential precipitating factors—for example, recent IV contrast administration, new medications (NSAIDs, ACE inhibitors, antibiotics), surgery, recent intake and output, other comorbid conditions (e.g., sepsis, CHF).
3. Palpate the bladder, check a post-void residual, and consider insertion of a Foley catheter if obstruction is suspected. If the patient already has a Foley catheter, flush it with 2 to 30 mL of saline to make sure it is not clogged. If urine flows after the Foley placement or flushing, obstruction was most likely the cause.
4. Order serum and urine chemistries and a renal function panel. Calculate the fractional excretion of sodium (FeNa <1% is consistent with prerenal causes). If the patient is on diuretics, calculate the fractional excretion of urea (as the FeNa is no longer reliable).
5. Consider a renal ultrasound to exclude hydronephrosis.
6. If prerenal causes are suspected, give an IV fluid challenge (250 to 500 mL of NS). Repeat boluses and maintenance fluids may be required.
7. If CHF and cardiorenal syndrome is suspected, consider diuresis (e.g., furosemide 20 to 60 mg IV).
8. Stop offending agents (nephrotoxic drugs).
9. Give IV fluids if radiocontrast-induced ATN is suspected.
10. Treat electrolyte disturbances and determine if there is an indication for dialysis.
Fever in the Hospitalized Patient

A. Causes
1. Infection: Likely sources are central lines, peripheral IV lines, pneumonia, Foley catheter, urinary tract, wounds, heart valves, GI tract (diverticulitis), joints (septic arthritis).
2. Noninfectious causes: PE/DVT, medications (especially antibiotics), neoplasms, connective tissue disorders, postoperative atelectasis.

B. Diagnosis
1. Check vital signs (tachycardia is an expected physiologic response to fever). Screen for sepsis criteria (tachycardia, fever, elevated WBC count, tachypnea) and treat accordingly.
2. Evaluate for signs and symptoms of localizing disease—for example, cough, abdominal pain, dysuria, meningeal signs, joint pain, diarrhea, cellulitis.
3. Consider CBC, urinalysis, CXR, cultures (blood × 2, urine, sputum, all ports of all lines, any fluid collections), with sensitivity panels.
4. Lumbar puncture if meningitis is a possible cause; CT of the abdomen if intra-abdominal infection is suspected.

C. Therapies
1. Acetaminophen is appropriate in most cases.
2. If the patient is ill-appearing, hemodynamically unstable or neutropenic, start broad-spectrum antimicrobial treatment empirically as soon as cultures are obtained. Transfer to an ICU if patient is in septic shock.
3. If the patient is on an antibiotic and the fever spikes again, consider adding another antibiotic or changing the antibiotic altogether. Antifungal agents may be required.
4. Remove or replace IV lines and indwelling catheters. Culture tips of central lines.
5. If no signs of infection and patient is hemodynamically stable, treat underlying etiology or continue diagnostic workup.
Hypoglycemia

Usually due to excess insulin or oral hypoglycemic administration (relative to dietary intake) in diabetic patients.
If the patient can drink and hypoglycemia is mild, give juice. Consider giving 50 mL of D50W intravenously if the patient is symptomatic.
If the patient is NPO or hypoglycemia persists, start D5W or D10W at 100 mL/hr. If there is no IV access and the patient cannot drink/eat, give glucagon (0.5 to 1.0 mg SC or IM).
Review and modify insulin and oral hypoglycemic regimens.
Change in Mental Status (Confusion)

A. Causes
1. **Medications and intoxications**: sedatives, narcotics, insulin, oral hypoglycemics, H₂ blockers, TCAs, anticholinergics, corticosteroids, hallucinogens, cocaine, alcohol, methanol, ethylene glycol
2. **Hypoxia**—very common
3. **Postoperative delirium**—compounded by pain medications
4. **Hypotension**—with reduced cerebral perfusion
5. **Substance withdrawal**—for example, alcohol, benzodiazepines
6. **Hypercapnia**
7. **Infection**—sepsis, meningitis, encephalitis, UTI, intracerebral abscess
8. **Trauma**—head trauma, burns
9. **Metabolic disturbances**—acidosis, hypoglycemia, sodium, calcium, magnesium, hypo/hypernatremia, ammonia (liver failure)
10. **Hyperthyroidism or hypothyroidism, thyroid storm**
11. **Neurologic causes**—CVA, subarachnoid hemorrhage, increased ICP, subclinical seizure
12. **Dehydration and malnutrition**—deficiencies of thiamine, vitamin B₁₂
13. **ICU psychosis**, sundowning

B. Management
1. Determine if there is a baseline history of dementia—any recent fall?
2. Check vitals; perform a focused examination (including neurologic examination and mental status).
3. Consider pulse oxygen (“pulse ox”), ABG, electrolytes, finger stick, CXR, blood cultures, LFTs, urine toxicology screen.
4. Consider a CT of the head to rule out CVA or intracranial mass or bleed.
5. Correct reversible causes and stop offending medications (if possible).
6. Consider naloxone (2 mg IV), dextrose (D50), and oxygen.
7. If patient is combative or is pulling out IVs, consider haloperidol (Haldol) or possibly restraints if necessary.
8. Consider spot EEG to evaluate for subclinical seizure.
Shortness of Breath/Acute Hypoxia

A. Causes
1. Cardiac: PE, CHF exacerbation, MI, arrhythmia
2. Pulmonary: pneumonia, bronchospasm, pleural effusion, pulmonary edema, pneumothorax, upper airway obstruction, hyperventilation
3. Oversedation: narcotics, benzodiazepines (determine exactly how much sedating medication the patient has received)
4. Systemic causes: severe chronic anemia, sepsis, diabetic ketoacidosis
5. Other causes: rib fracture, anxiety, panic attacks

Quick HIT
Case-control studies and cohort studies are often referred to as “observational studies.”

B. Management
1. Perform pulse oximetry immediately. If low, or if the patient appears ill, obtain an ABG and give supplemental oxygen (titrate according to response). Consider bilevel positive airway pressure in cases of COPD or CHF exacerbation.
2. Remember ABCs—intubate if necessary.
3. Consider nebulizer treatments, furosemide, and naloxone as appropriate.
4. Perform portable CXR immediately unless hypoxia is readily resolved (e.g., with naloxone).
5. Consider ECG, CBC (anemia, infection); scan (or CTA chest) if PE suspected.
6. Consider anxiolytics if anxiety-related hyperventilation is suspected and the patient is stable.

Quick HIT
Randomization is important because it leaves patient assignment to either experimental or control group completely to chance. When any element of human intrusion or judgment enters the process of patient assignment, bias is introduced.
Basic Statistics and Evidence-Based Medicine

A. Evidence-Based Medicine has been defined as “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients” (Sacket D. *BMJ*. 1996;312:71).

<table>
<thead>
<tr>
<th>Quick HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hierarchy of evidence (from highest to lowest)</td>
</tr>
<tr>
<td>1. Meta-analysis of randomized controlled trials</td>
</tr>
<tr>
<td>2. Randomized controlled trials</td>
</tr>
<tr>
<td>3. Cohort studies</td>
</tr>
<tr>
<td>4. Case-control studies</td>
</tr>
<tr>
<td>5. Case series</td>
</tr>
<tr>
<td>6. Expert opinion</td>
</tr>
</tbody>
</table>

B. Types of Research Studies

1. Case series—these may describe the results of a specific treatment, determine long-term outcome of a treatment or procedure, or describe the complication rates of a procedure or the natural history of a disease (see also Clinical Pearls A-1 and A-2).
   a. Size of a case series can range from two or three patients to thousands of patients. A case report is the description of a rare or interesting case.
   b. Major disadvantage is the lack of a comparison group so one cannot reach definitive conclusions about treatment efficacy. Case series are prone to many biases.
   c. Very common in surgical research.

2. Cross-sectional studies—subjects are studied at a specific point in time (“snapshot” of a population).

3. Case-control studies.
   a. Patients are selected because they have a certain outcome, and their history is retrospectively reviewed to identify exposures or risk factors that may be associated with that outcome.
   b. By definition, case-control studies can be only retrospective.
   c. Good for rare diseases and for diseases with long latent periods.
   d. Very susceptible to bias because both exposure and disease development occurred prior to initiation of the study.
The basic difference between a randomized controlled trial and a prospective cohort study is the manner in which patients are assigned to either group.
- In a randomized controlled trial, patients are assigned to either the experimental or control group randomly, without input from physician or patient.
- In a cohort study, the treatment decision is not random and is determined by the recommendations of the physician, as well as the wishes of the patient, among other factors.

4. Cohort studies.
   a. Subjects are selected according to exposure (e.g., a new medication, a procedure) and are followed over time to observe the development or progression of disease.
   b. Cohort studies can be prospective or retrospective.
   c. Prospective cohort studies follow patients over time to observe a certain outcome, but patient assignment into the two treatment groups is not randomized, so confounding variables may be unequally distributed (see later).

5. Randomized controlled trial.
   a. A type of cohort study involving a control group and an intervention group.
   b. Patient assignment into either group is left completely to chance (if properly done). Therefore, known and unknown confounders are likely to be equally distributed.
   c. Methodologically superior to other study designs because it is least susceptible to bias.

6. Meta-analyses
   a. Meta-analyses combine data from several individual studies to estimate an overall effect.
   b. The strength of a meta-analysis is only as good as the quality of the primary studies it analyzes (e.g., a meta-analysis of 14 flawed, biased studies will produce a biased estimate of effect).
   c. A meta-analysis of well-conducted randomized controlled trials is the highest level of evidence.

The null hypothesis postulates that there is no difference between two groups. This hypothesis is either rejected or not rejected by a study.
Consolidation of Standards for Reporting Trials (CONSORT) Statement
- Twenty-one–point checklist of essential items that randomized controlled trial reports should include to facilitate their appraisal and interpretation.
- Many journals have endorsed CONSORT, but the rigor of enforcement varies.

CLINICAL PEARL A-2
Cochrane Library (www.cochrane.org)
- Regularly updated evidence-based medicine database
- Includes randomized controlled trials and systematic reviews in all specialties of medicine to determine how strong the evidence is for various medical treatments
- Consists of an international network of researchers and physicians who gather and evaluate the evidence in medical research

C. Sensitivity and Specificity
1. Sensitivity = a/(a + c) (see Table A-4). Tests with high sensitivity are used for screening. They may yield false-positive results but do not miss people with the disease (low false-negative rate).
2. Specificity = d/(b + d). Tests with high specificity are used for disease confirmation.
3. Positive predictive value (PPV) = a/(a + b).
   a. If the test is positive, what is the probability that the patient has the disease?
   b. PPV depends on the prevalence (the higher the prevalence, the greater the PPV) and the sensitivity/specificity of the test (e.g., an overly sensitive test yields more false-positive results and has a lower PPV).
4. Negative predictive value (NPV) = d/(c + d).
   a. If test is negative, what is the probability that patient does not have the disease? A high NPV is very important for a screening test.
   b. NPV also depends on prevalence of disease (higher prevalence = lower NPV) and the sensitivity/specificity of the test (the more sensitive the test, the fewer the number of false-negative results, and the higher the NPV).

Quick HIT
Clinical significance is unrelated to statistical significance. A study may obtain statistical significance for differences that have no clinical significance (e.g., 41% vs. 42% infection rate for two groups). With a large enough sample size, any study will obtain statistical significance.

D. Type 1 and 2 Errors
1. Type 1 (α) error: Null hypothesis is rejected even though it is true (false-positive finding).
   a. \( P \) value is the chance of a type 1 error occurring.
   b. If the \( P \) value is \( \leq 0.05 \), it is unlikely that a type 1 error has been made (i.e., a type 1 error is made five or fewer times out of 100 attempts).

2. Type 2 (β) error: Null hypothesis is not rejected even though it is false (a false-negative finding).
   a. A type 2 error results when the \( P \) value fails to reach statistical significance even though the groups being compared are truly different. A type 2 error usually occurs when sample size is too small.
   b. The likelihood of avoiding a type 2 error is termed the statistical power of a study.

Quick HIT
If a study has a power of 80%, this means that if a difference of a particular stated magnitude exists between groups, there is an 80% chance of correctly detecting it.

Quick HIT
The lack of statistical power (i.e., sample size too small) invalidates a study because it can lead to statistical insignificance when there actually is a clinically meaningful difference.

E. Statistical Power
1. A study with “negative” result (no difference between groups) must have adequate power to detect clinically meaningful differences.
2. Conventionally, a β-error rate of 20% is chosen, which corresponds with a study power of 80%. A study power of less than 80% is believed to have an unacceptably high risk of false-negative results (i.e., a study found no difference between two groups, when there actually was a difference).

<table>
<thead>
<tr>
<th>TABLE A-4</th>
<th>Sensitivity and Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Result of Test Under Investigation</strong></td>
<td><strong>Result of Gold Standard</strong></td>
</tr>
<tr>
<td>Test positive (a 1 b)</td>
<td>True positive (a)</td>
</tr>
<tr>
<td>Test negative (c 1 d)</td>
<td>False negative (c)</td>
</tr>
</tbody>
</table>

3. Factors that affect the power of a study.
   a. Sample size—when sample size is small, a study is susceptible to type 2 error,
which is why sample size calculation is done prior to the study being initiated.

b. Level of statistical significance—conventionally, a $P$ value of 0.05 is chosen, although this is somewhat arbitrary.

c. Variability of the sample data—the lower the variability, the fewer subjects are needed to demonstrate significant differences if they do indeed exist.

d. Effect size chosen by researcher—this is based on pre-existing data and clinical judgment and is beyond the scope of this discussion.

Quick HIT

Think of the CI as a weather forecast: a vague forecast of “warm with possibility of rain” (this is a “wide” CI) is more likely to hold true but is not very precise. However, a forecast of “70 degrees with 30% chance of rain” (narrow CI) is much more precise but has a lower likelihood of holding true.

F. Confidence Interval

1. The confidence interval (CI) allows the reader to apply the results of a study to the “true” population from which the sample in the study was taken.

2. The most common CI is 95%, which means that the CI (i.e., the range) reported in the study holds true for 95 of 100 samples similar to the one in the study.

3. A “wider” CI increases the certainty of the estimate (i.e., it is more likely that the population from which the sample was selected would fall within the reported interval), but lowers its precision (see Quick Hit). A very wide CI should be interpreted with caution (a larger sample size may be needed to maintain power).

4. The larger the CI, the less power a study has to detect differences between two groups. The width of the CI depends on sample size; the larger the sample size (more likely to have power), the narrower the CI.

Quick HIT

Selection bias refers to differences in characteristics of subjects included/excluded or differences between selected comparison groups.

G. Association Versus Correlation

1. Association is used for describing relationships between categorical variables; correlation describes relationships between continuous variables.

2. Neither association nor correlation implies causation. These terms describe only the relationship and strength of this relationship.

3. Correlation is a matter of “degree.” It can range from −1.00 (inverse proportionality) to +1.00 (proportional relationship). Zero signifies no correlation.
Selection Bias
Ideally, comparison groups should be identical in all respects other than factor under investigation. In reality, this comparison group does not exist due to confounding variables. Therefore, randomized controlled trials are preferred to minimize confounding.

H. Causality. It is very difficult to prove causality. The following factors help assess causality, but none can give indisputable evidence of a cause-and-effect relationship:
1. Strength of association
2. Biologic plausibility—does the association make biologic sense?
3. Consistency of the association across different studies
4. Dose–response relationship
5. Experimental evidence to support causality—for example, if you eliminate an exposure, does this reduce the incidence of a particular disease?
6. Temporal sequence (very important)—the causative factor must precede the effect.
7. Experimental evidence—has a randomized controlled trial (highest level of evidence) been performed?

Quick HIT
The only inherent advantage of randomized controlled trials over observational studies is the reduction in confounding.

I. Bias
1. A study that is biased lacks internal validity. Bias can be introduced in the design of a study or during the statistical analysis because of the lack of statistical power (inadequate sample size). In addition, conflict of interest can introduce bias and affect the validity of a study. Critical appraisal of medical literature essentially requires the ability to identify bias.
2. There are four main types of bias: Selection bias, performance bias, detection bias, and attrition bias (see Clinical Pearl A-3).
3. A confounding variable is a factor other than the intervention under investigation that obscures the primary comparison.
   a. Common confounding variables include age, gender, comorbidities, smoking, and socioeconomic status.
   b. A true confounding variable must meet two criteria: It must be associated with the explanatory (independent) variable, and it should be a risk factor for the outcome of interest.
   c. Randomized controlled trials control for both known and unknown confounders.
Types of Bias

- **Selection bias**—occurs when there are differences in the characteristics of subjects between comparison groups of a study. Unequal distribution of confounding variables among the two groups leads to selection bias.
- **Performance bias**—occurs when subjects in comparison groups are given different care (other than the intervention that is being studied). For example, only one group may receive counseling in addition to the intervention that is being studied (the counseling may affect the outcome in some way). Blinding is important in preventing performance bias (patient and investigators are not aware of the treatment rendered).
- **Detection bias**—refers to inconsistency in outcome assessment. Use of validated outcome measures and blinding of outcome assessors help prevent detection bias.
- **Attrition bias**—refers to patient drop-outs or exclusion from a study. There is no recognized drop-out rate that is deemed “acceptable.” Drop-outs should be kept to a minimum, but if they do occur, **intent-to-treat analysis** is critical to maintain the integrity of randomization (see text).

4. Minimizing bias in randomized clinical trials hinges on the following:
   a. **Proper randomization**—each patient should have an equal chance of receiving either treatment.
   b. **Concealment of allocation**—the person enrolling patients into study should be unaware of next “assignment” into either the experimental or control group. This can be done with sealed opaque envelopes, remote allocation (call made to a separate department to determine patient allocation), or computerized allocation.
   c. **Blinding**—the higher the level of blinding, the lower the risk of bias. The following participants can potentially be blinded depending on the nature of the study: Patients, physicians, data collectors, assessors of outcome, data analysts. A study should describe precisely which participants were blinded. Terms such as “double” and “triple” blinding, if not defined, are confusing and should be avoided because textbooks and physicians often have varying interpretations of these terms.
   d. **Intent-to-treat analysis**—drop-outs are analyzed in groups to which they were initially assigned. Excluding drop-outs from analysis threatens the balance that randomization achieves. Drop-outs often do worse than patients who remain, and excluding them creates bias.

**Quick HIT**

When evaluating a randomized clinical trial, go through this checklist to assess whether a study is biased:
- Proper randomization
- Concealment of allocation
- Blinding
- Completeness of follow-up and intent-to-treat analysis
Intent-to-Treat Analysis

Patients are analyzed with the group to which they were randomly assigned, regardless of whether they actually received that treatment or completed the study.

J. Glossary of Common Statistical Terms

1. Mean—the average
2. Median—value corresponding to the middle case or middle observation (i.e., 50% of values are less than and 50% of the values are more than the median).
3. Mode—value that occurs most often
4. Standard deviation (SD)—used for normal distributions. An SD of ± 1 includes about 68% of the observations, an SD of ± 2 includes about 95% of the observations, and an SD of ± 3 includes about 99.7% of the observations.
5. Incidence—number of new cases of a disease per year.
6. Prevalence—overall proportion of the population who have the disease.
7. Relative risk—incidence in exposed group/incidence in unexposed group.
   Relative risk can be calculated only after a prospective or experimental study.
8. Odds ratio—a method of estimating the relative risk in retrospective studies. It is the probability of an event happening divided by the probability of the event not happening.
9. Reliability—ability of a test or measure to reproduce the same results under the same conditions.
10. Validity—extent to which a study correctly represents the relationships being assessed.
    a. Internal validity—a study that suffers from bias lacks internal validity.
    b. External validity—a study may have internal validity but its results may not be generalized to a larger population (lacks external validity).
End-of-Life Issues and Informed Consent

1. Advance directives are instructions given by patients that specify what actions to take for their health if they are not able to make decisions due to illness.
   a. A living will leaves instructions for treatment, outlining the patient’s wishes. A living will may specify that patient does not want to be on a ventilator, or does not want a blood transfusion. These instructions should be respected even if a family member disagrees with them.
   b. A power of attorney (healthcare proxy)—person appointed by patient to make decisions on their behalf.
   c. Ethics committee is used when patient has lost decision-making capacity and there is no advance directive. In most situations the next of kin becomes the patient’s surrogate decision maker.
   d. Court order—when patient has no capacity to understand and the family is in disagreement and there is no healthcare proxy specified.
   e. State appointed guardian—when the patient lacks decision-making capacity and is unrepresented, for example, there is no next of kin available or family declines to participate in healthcare decision making.

2. An adult who can participate in the discussion regarding the risks and benefits of treatment decisions has ultimate decision-making capacity about his or her own medical care. Note that decision-making capacity is specific to the particular decision at hand (meaning, a patient may have capacity to make one decision but lack capacity to make another decision if unable to understand the benefits of treatment or risks of foregoing treatment). If such an adult refuses a treatment, respect his or her wishes, even if that treatment is clearly indicated or the standard of care. For example, never force a Jehovah’s Witness to accept blood products. Patients can refuse medical care even if this refusal results in their death or disability.
   a. All medical interventions (including artificial nutrition and hydration) may be terminated at the patient’s request.
   b. If a patient who is mentally incapacitated is in a persistent vegetative state or comatose, family members (even if not formally appointed as proxy decision makers) can withdraw life-sustaining treatments based on prior conversations with the patient or their understanding of the patient’s values.

Quick HIT

DNR (do not resuscitate)—refers only to withholding cardiopulmonary resuscitation.
3. Definition of death: An individual who has sustained either (1) irreversible cessation of circulatory and respiratory functions, or (2) irreversible cessation of all the functions of the entire brain, including the brain stem. To declare an individual dead, either the heart and lungs OR the brain and brain stem stop functioning permanently.

4. Informed consent.
   a. Every procedure needs informed consent. Only the person performing the procedure should obtain consent.
   b. Informed consent should include the following:
      • The diagnosis or medical problem for which the physician is recommending treatment.
      • A description of the proposed treatment or procedure, including its purpose, duration, methods, and implements used, as well as the probability of success.
      • All material risks of the procedure or treatment.
      • Any reasonable alternatives to the proposed procedure
      • The risks of not being treated.
   c. Patient who does not have capacity to consent (comatose, incompetent)—healthcare power of attorney can consent or refuse. If there is uncertainty about a patient’s competence, psychiatric evaluation may be necessary. If a patient is determined to be incompetent, and if there is no POA, the wishes of family (or next of kin) should be respected. If there is disagreement among family members, consult the hospital ethics committee.
   d. If an adult regains capacity, then the duty of informed consent returns to the patient and the healthcare POA cannot make decisions.
   e. Emergencies: Consent is not needed in an emergency, it is implied. If a pediatric patient needs emergent treatment and parent is not available for consent, physician may proceed to treat patient without consent.
   f. Remember that minors (under 18) cannot make decisions or consent to or refuse medical treatments. Only parents or legal guardians can consent. Patients under 18 do not require parental consent in the following situations:
      • They are emancipated (married, living on their own and financially independent, raising children, serving in armed forces).
      • Have an STD.
      • Want contraception.
      • Are pregnant and need prenatal care.
      • Want drug tx or counseling (substance abuse treatment).
      • Have psychiatric illness.
Questions

1. A 61-year-old male presents to your office with the chief complaint of “coughing up blood and weakness” for the past 3 weeks. He reports at least five to six episodes every 2 to 3 days of coughing of bright red blood, approximately one to two tablespoons each time. The patient denies any chest pain, fevers, chills, or recent travel. He has mild dyspnea at baseline. He has recently developed lower extremity muscle cramps and he has difficulty rising from a chair. Past medical history is significant for COPD diagnosed 5 years ago and HTN. He has a 40-pack-year smoking history and currently smokes 1 pack per day. Examination is notable for end-expiratory wheezing and a prolonged expiratory phase on lung auscultation. He has 3/5 hip flexion and decreased deep tendon reflexes bilaterally in lower extremities. Laboratory tests are normal including electrolytes. CXR reveals typical changes seen in COPD (flattened diaphragms, hyperinflation) and a perihilar mass. What is the most likely diagnosis?
   A. Bronchial carcinoid
   B. Adenocarcinoma
   C. Large cell carcinoma
   D. Squamous cell carcinoma
   E. Small cell carcinoma

2. A 67-year-old male presents to the ED with LLQ pain that began a few hours ago. His PMH is significant for hypertension, CHF, and renal calculi. He reports one episode of blood in his stools a few months ago. Vital signs are as follows: Temperature = 101.1°F, BP = 130/76 mm Hg, pulse = 70. On physical examination, he has guarding and tenderness to palpation in the LLQ but no epigastric tenderness or flank tenderness. His examination is otherwise unremarkable. His stool is negative for occult blood. Urinalysis reveals no leukocytes or RBCs and Gram stain is negative. Laboratory tests reveal a leukocyte count of 16,000 cells/μL and normal electrolytes and renal function. What is the next step in managing this patient?
   A. Check a serum lactate
   B. Obtain a retroperitoneal ultrasound
   C. Prepare the patient for colonoscopy
   D. Obtain contrast-enhanced CT of the abdomen
   E. Proceed to the operating room
3. A 64-year-old female with a history of HTN, CAD, and CHF presents to the ED with a chief complaint of left-sided chest pain that began 4 to 5 hours ago. She has a history of periodic episodes of chest pain for which she takes sublingual nitroglycerin, but today’s episode has been more severe, has lasted longer, and is not relieved by nitroglycerin. She denies nausea/vomiting, any radiation of the pain, or diaphoresis. Temperature = 97.8°F, BP = 136/76 mm Hg, HR = 105, RR = 20. Physical examination includes clear lungs on auscultation, no JVP elevation, and no LE swelling. ECG shows Q waves in lateral leads and no ST elevation. Troponin is 0.50 ng/mL. Aspirin is given. What is the most important intervention indicated at this time?

A. Alteplase  
B. Heparin  
C. Hydralazine  
D. Furosemide  
E. Digoxin

4. A 64-year-old male presents to the ED with symptoms of RUE weakness and slurred speech. His symptoms started 5 hours ago and have not improved. He has a medical history significant for hypertension and diabetes. Neurologic examination confirms RUE paresis and dysarthria. Rest of examination is normal. Vitals: BP 190/100 mm Hg, HR 75. Labs are notable for glucose of 135 mg/dL, A1c 7.3%. CT head shows an area of ischemia without associated hemorrhage. Home medications include metformin and lisinopril. What is the most important intervention at this point?

A. Insulin  
B. Heparin  
C. Aspirin  
D. Alteplase  
E. Labetalol

5. A 58-year-old male presents to your office with weakness in his legs and a history of frequent falls over the past few months. He also complains of fatigue at the end of the day. He denies any back pain. He does not drink alcohol or smoke. His medical history is significant for gastric carcinoma for which he underwent total gastrectomy 2 years ago and there are no signs of recurrence. On physical examination, he is found to have conjunctival pallor, increased deep tendon reflexes, and mild weakness of his lower extremities, along with diminished vibratory sense in his toes. Cerebellar testing is normal. His examination is otherwise unremarkable. What would be the best test in confirming the cause of his symptoms?

A. Folate
6. A 37-year-old nulliparous female presents to your office complaining of weakness. Her symptoms have developed gradually over the past year and she has largely ignored them. She reports a recent weight gain of 25 lb over the past year and has been feeling melancholy for the past few months. She has also had back pain for the past several months. Her medical history is significant for mild HTN and insulin-dependent DM. Physical examination reveals mild obesity, with fat deposition mainly around the trunk and the posterior neck. You note some facial hair and scattered purple striae on the abdomen. Radiographs reveal a compressed fracture at the level of T11. Vital signs are as follows: BP = 140/85 mm Hg, pulse = 70. What would be the most appropriate next test in this patient?

A. Serum ACTH  
B. MRI brain  
C. CT abdomen  
D. 24-hour urine-free cortisol  
E. CRH stimulation test

7. A 56-year-old male with a history of cigarette smoking and hypercholesterolemia is brought to the ED with severe, crushing chest pain that has lasted for 90 minutes. He states that he felt ill all day and then started experiencing pain in his jaw, which progressed to chest pain with radiation to the left arm associated with nausea. Vital signs are as follows: Temperature = 97.4°F, HR = 50, BP = 85/45 mm Hg, RR = 22, pulse oximetry = 98% on room air. Examination reveals JVP without elevation, normal lung examination, and no peripheral edema. An ECG reveals significant ST elevations in leads II, III, and aVF. What is the next step in managing this patient?

A. Nitroglycerin  
B. Normal saline  
C. Furosemide  
D. Metoprolol  
E. Morphine

8. A 45-year-old female with history of DM, alcohol abuse, and COPD is evaluated for confusion in the ED. She lives with a roommate who states the patient was acting differently from baseline. The patient is agitated, not oriented, and not responding to questions appropriately. Vitals T 37.5°C, P 110, RR 30. Physical examination reveals lungs with minimal end-expiratory wheezing. Physical examination is otherwise normal. UA is within normal limits. Labs: Na 140
mEq/L, Cl 105 mEq/L, K 5 mEq/L, HCO₃ 15 mEq/L, BUN 20 mg/dL, Cr 1 mg/dL. ABG: pH 7.30, PCO₂ 25 mm Hg, PO₂ 85 mm Hg. What is the next appropriate medical intervention?
A. Fomepizole  
B. Acetylcysteine  
C. Albuterol  
D. Sodium bicarbonate  
E. Insulin

9. A 64-year-old male presents to your office for a physical examination. His PMH is significant for HTN, for which he takes metoprolol. He has never had screening for colorectal cancer previously. On examination, there are no palpable masses in the abdomen, no tenderness, and bowel sounds are normal. He denies any change in bowel habits. The remainder of his physical examination is unremarkable. He is given fecal occult blood testing and two of three samples are positive. What is the appropriate next step in managing this patient?
A. Flexible sigmoidoscopy  
B. Digital rectal examination  
C. Video capsule endoscopy  
D. CT colonography  
E. Colonoscopy

10. A 55-year-old male presents to the ED with epigastric abdominal pain. He denies nausea/vomiting/diarrhea. His PMH is significant for stroke HTN and osteoarthritis of his knees. Medications include enalapril and a daily aspirin tablet. Vital signs are as follows: RR = 20, BP = 155/90 mm Hg, pulse = 70. His physical examination reveals epigastric tenderness, no abdominal distention, and rectal examination is positive for dark stool that is guaiac positive. Laboratory tests reveal hemoglobin of 10.2 g/dL, hematocrit of 30.0%, platelets 190 × 10³/μL. LFT results are normal. Na 135 mEq/L, K 4.5 mEq/L, Cl 105 mEq/L, HCO₃ 22 mEq/L, BUN 30 mg/dL, Cr 1.2 mg/dL. What is the next recommended step in managing this patient?
A. IV omeprazole  
B. IV octreotide  
C. Platelet transfusion  
D. RBC transfusion  
E. Normal saline

11. A 45-year-old female is admitted to the hospital with abdominal swelling. She has not previously sought medical care and had been well until 3 months ago when swelling began. Swelling gradually began and has worsened to the point that she
is now short of breath and has difficulty mobilizing. She was born in Mexico but has been living in the United States for the past 20 years. She denies any use of medications. She admits to social drinking but denies daily use. Lung examination reveals decreased breath sounds at the bases. Cardiac examination reveals no murmurs, JVP 2 cm above sternal angle. Abdomen is moderately distended with a positive fluid wave; liver is unable to be palpated. Skin examination does not reveal telangiectasias. A diagnostic/therapeutic paracentesis is performed which reveals the following: serum albumin 2.5 g/dL, serum total protein 5.0 g/dL, ascites total protein 2.3 g/dL, ascites albumin 1.6 g/dL. What test is the most likely to reveal the cause of her ascites?

A. Echocardiogram  
B. Pelvic ultrasound  
C. Liver biopsy  
D. PPD  
E. 24-hour urine protein

12. A 65-year-old man presents to the ED with lower extremity weakness. His symptoms started 1 week prior when he noticed difficulty walking and he tripped once. He now has difficulty raising his legs off the floor and is now using a wheelchair. He denies any pain in his lower extremities but does have paresthesias in both legs. He denies weakness elsewhere. He denies dyspnea or any other associated symptoms. Prior to this he had an episode of nonbloody diarrhea a few weeks prior but that is now resolved. His only past medical history is hypertension for which he takes hydrochlorothiazide. Cardiac examination is normal. Pulmonary examination reveals nonlabored breathing, clear lung fields, and O₂ saturation 98% on room air. Neurologic examination reveals normal speech without dysarthria and cranial nerves without deficits. Strength is 5/5 in bilateral upper extremities in shoulder/elbow/wrist flexion and extension, 1/5 dorsiflexion/plantar flexion bilateral ankles, 1/5 flexion/extension knees, 2/5 hip flexion. Achilles and patellar reflexes are absent bilaterally. Sensory examination is normal. Labs including electrolytes, renal function, and blood counts are normal. CT head is negative for stroke and shows no acute findings. Lumbar puncture is performed and analysis reveals 3 WBC/mm³, protein 100 mg/dL (normal range <50 mg/dL), Gram stain negative. What is the most appropriate therapy?

A. Prednisone  
B. IVIG  
C. Ciprofloxacin  
D. Pyridostigmine  
E. Botulism antitoxin
13. A 24-year-old female presents to your office for a routine examination. She reports a history of heavy menstrual bleeding since menarche. Her mother had similar symptoms. On further questioning, she states that she has episodes of epistaxis about once every 2 weeks or so and has a tendency to bruise easily. Her physical examination is unremarkable. CBC results are as follows: Hgb = 7.9 g/dL, Hct = 23.9%, MCV = 69 fL. Platelet count is 230,000/μL. PT—12 seconds (normal). PTT—30 seconds (normal). LFTs including bilirubin are normal. What is the most appropriate test to order?
A. Fibrinogen
B. Coombs antibody
C. Factor IX level
D. Mixing study
E. Ristocetin cofactor activity

14. A 43-year-old male presents to the ED with a complaint of headache. Headache developed acutely over the past few hours and is severe in nature. Pain is located bilateral top of his head without radiation elsewhere. He denies any associated weakness. He denies double vision, dizziness, nausea, and vomiting. He denies phonophobia/photophobia. He has no prior history of headaches. Vitals: BP 144/90 mm Hg, T 37.2°C. Examination reveals a middle-aged man in distress related to pain. Neurologic examination is negative for focal weakness or sensory deficit. No nuchal rigidity. CNs are intact. CT brain without contrast is obtained and negative for ischemia or hemorrhage. What is the next most appropriate intervention?
A. Sumatriptan
B. MRI brain
C. Cerebral angiogram
D. CT brain with contrast
E. Lumbar puncture

15. A 59-year-old female presents to the office because she is “sick and tired” of this cough she has had for 5 years, and it is getting worse. The cough is often productive of watery mucus. She is also becoming more and more short of breath and cannot climb a flight of stairs without taking a rest. She denies chest pain, paroxysmal nocturnal dyspnea, fevers, chills, and weight loss. PMH is significant for HTN and a 35-pack-year history of cigarette smoking. Vital signs are as follows: Temperature = 99.0°F, HR = 75, RR = 21, BP = 158/82 mm Hg. O₂ saturation is 94% at rest and reaches a nadir of 90% with activity. Physical examination reveals an obese woman in no acute distress. On lung auscultation, there are coarse breath sounds bilaterally but no wheezes or crackles. Chest radiograph is significant for prominent lung markings at the bases. PFTs show
FEV₁/FVC ratio 0.60 and FEV₁ 65%. What is the most effective long-term intervention for this woman?
A. Smoking cessation  
B. Tiotropium inhaler  
C. Fluticasone inhaler  
D. Oxygen therapy  
E. Azithromycin

16. A 56-year-old male comes to your clinic requesting advice after recent cardiac surgery. The patient had a long-standing murmur and was diagnosed with mitral stenosis. He eventually underwent repair with a prosthetic valve and his symptoms of dyspnea have resolved. He has resumed physical activity and seeks to maintain his current health. He wants advice on future procedures and possible risk of infection. Which procedure will you advise warrants such treatment solely for endocarditis prophylaxis?
A. Colonoscopy  
B. Wisdom tooth extraction  
C. EGD  
D. Bronchoscopy without biopsy  
E. Dilatation ureteral stricture

17. A 67-year-old African-American male presents to your office with complaint of right hip pain for the last week. He denies any history of falls or injury. The pain came on suddenly as he was getting up from a chair. Prior to this episode, he denies any history of hip pain. PMH is significant for HTN, diabetes, and hypothyroidism. He started using a cane a few days ago but due to increasing pain is now in a wheelchair. On physical examination, he has severe pain with any attempted motion of the right hip joint. Pulses are palpable bilaterally, and neurologic examination is normal. Radiographs of the right hip are obtained and show normal bone density with a displaced fracture of the right femoral neck. Labs: Na⁺ 135 mEq/L, Cl 105 mEq/L, HCO₃ 25 mEq/L, Ca²⁺ 11.0 mg/dL, Cr 1.9 mg/dL, Hgb 9.5 g/dL, MCV 90 fL. Labs a year ago were completely normal. He is up-to-date on routine health screening. In addition to obtaining an orthopedic surgery referral for repair of the fracture what other testing would be indicated that would best explain the patient’s findings?
A. SPEP  
B. ⁹⁹ᵐTc bone scan  
C. PTHrP  
D. PTH  
E. DEXA
18. A 38-year-old female presents to your office with chief complaint of fatigue and weight gain for the past 5 to 6 months. Her fatigue has also affected her performance at work, where she has difficulty concentrating on tasks. She recently began losing hair. She feels more tired than usual after work and has difficulty playing with her children in the evening. She did not have any of these symptoms until 6 months ago. She denies hot/cold intolerance. Weight has been relatively stable but she has gained \( \sim 10 \) lb in the past 6 months despite attempting to eat healthy and exercise a few times weekly. She is generally happy and denies any recent mood changes. PMH is insignificant. The patient smokes five to six cigarettes a day and drinks alcohol socially. She takes birth control pills. HR 55, BP 120/80 mm Hg, RR 16, BMI 31. Physical examination reveals a pleasant female, oriented and appropriate. ENT examination reveals normal pharynx, no neck fullness, and no palpable thyroid nodules. Abdomen is soft, nontender. Skin examination reveals no lesions/rashes and there is no lower extremity edema. She donated blood last week and was told that her Hgb was normal. What is the appropriate next step in managing this patient?

A. US thyroid
B. TPO
C. Thyroid uptake scan
D. FNA
E. TSH

19. A 38-year-old female presents to the ED with a 2-day history of shortness of breath and chest pain. She states that she has felt tired for the past couple of weeks but is otherwise vague in reporting her history. She denies any history of smoking. PMH is unremarkable. On physical examination, she has diffuse wheezing but no calf tenderness or lower extremity edema. BP = 126/74 mm Hg, pulse = 80, RR = 20, temperature = 98.6°F. D-dimer is elevated. CXR reveals no infiltrate. She subsequently undergoes a CT scan which reveals an 8-mm round nodule without associated lymphadenopathy or effusions and no evidence of pulmonary embolism. There are no calcifications in the nodule. She is treated with albuterol and discharged home in stable condition. What is the appropriate recommendation to this patient upon outpatient follow-up with her primary care physician?

A. Follow-up CT chest
B. Bronchoscopy
C. Needle biopsy
D. Follow-up CXR
E. PET-CT scan

20. A 75-year-old female with a history of two MIs presents to the ED after fainting.
She reports fatigue and dyspnea for 2 months. She has mild chest pain and dyspnea. A 12-lead ECG reveals a bradycardia with a ventricular rate of 35 bpm. BP 80/55 mm Hg. Examination reveals: General—mild distress, Heart—regular, bradycardia, no murmurs, Lungs—clear without crackles/effusions, Skin—cold, clammy. Home medications include ASA, metoprolol, atorvastatin, and lisinopril. ECG is as below. Prior echocardiogram from 6 months prior showed EF of 29% with diastolic dysfunction; valves were normal without stenosis or regurgitation. Laboratory testing reveals normal electrolytes including Mg and K. Troponin is elevated. What is the most appropriate management?

A. Echocardiogram
B. Nitroglycerin
C. Metoprolol
D. Atropine
E. ICD

21. A 40-year-old male presents to your office with a complaint of “chest burning” and cough for the past 5 to 6 months. The pain is not related to meals and is intermittent. Triggers for his symptoms include drinking alcohol and lying flat in bed. He denies food getting stuck upon swallowing. He has tried over-the-counter calcium carbonate and used ranitidine as needed with minimal relief of symptoms. He denies any recent weight loss. He denies any dark or bloody stools. He is a nonsmoker. He denies any history of seasonal allergies, itchy/watery eyes, sneezing, dyspnea, or prior diagnosis of asthma. His PMH is significant for HTN, which is controlled with metoprolol. He does not take any other medications. Physical examination is unremarkable. How would you treat this patient?

A. Helicobacter pylori antigen
B. EGD
C. pH monitoring
D. Gastrin level
E. Omeprazole
22. A 32-year-old female presents to your office with a history of diarrhea and intermittent abdominal cramping/bloating with flatus. She reports having loose, watery diarrhea very frequently on and off for several years, but her symptoms have been worse recently. Prior to initial onset she had normal, formed daily bowel movements. Her weight is 75 kg and on review of her records it is 7 kg less than when her symptoms first started. She denies any blood in the stool. There is no family history of IBD or colon cancer. The patient’s only past medical history is depression for which she is undergoing counseling. Laboratory evaluation reveals AST 65 U/L, ALT 55 U/L, TSH 3.0 mU/L, and Cr 1.0 mg/dL. Blood counts show Hgb 9.8 g/dL with MCV 70 fL. Vitals: T 37°C, BP 120/85 mm Hg, RR 16. Physical examination reveals a rash on extensor surfaces of both elbows with erythematous vesicles present. A stool test for occult blood is negative. She is a college student and is studying for her midterm examination. What test should be the next intervention?

A. EGD with small bowel biopsy
B. Colonoscopy
C. Loperamide
D. Sertraline
E. Skin biopsy

23. A 65-year-old Caucasian female with a history of DM, HTN, and a large anterior wall MI 5 years ago presents to the clinic complaining of shortness of breath. At baseline the patient finds it difficult to do any household chores. She has shortness of breath at rest and is homebound because of her symptoms. Vital signs are: Temperature = 98.7°F, HR = 62, RR = 19, BP = 160/85 mm Hg, oxygen saturation = 90% on room air. There are bibasilar crackles with scattered expiratory wheezes. There is also 2+ pitting edema of the lower extremities. JVP is measured just above the clavicle. An ECG reveals left ventricular hypertrophy (LVH), with Q waves and T-wave inversions in V_1 to V_4 and diffuse nonspecific ST segment abnormalities. A CXR shows cardiomegaly and considerable congestion of the pulmonary vasculature. Prior echocardiogram obtained 1 year prior shows EF 30% with wall motion abnormalities. Labs are normal including CBC, Cr, K. The patient’s medications include losartan, carvedilol, and aspirin. What is the most important long-term intervention for this patient?

A. Isosorbide dinitrate
B. Spironolactone
C. Hydralazine
D. Digoxin
E. Furosemide

24. A 23-year-old female is in your clinic to be evaluated for wheezing and shortness
of breath. She has no history of respiratory problems prior to the past few months. She recently joined a gym and began increasing her physical activity. Every time she runs she has similar symptoms of wheezing and shortness of breath. Symptoms seem to last the duration of the activity but will resolve afterward. She has no dyspnea between episodes. She denies runny nose, sneezing, congestion. She has no fevers/chills or sputum production. She has no known allergies. She does not smoke. Physical examination reveals a young female with no respiratory distress. Cardiac examination reveals normal rate, no murmurs are appreciated, and JVP is not elevated. Lung examination reveals normal expansion, good air movement in all lung fields without rhonchi or wheezing. Peak flow in clinic is normal. PFTs are obtained and show FEV$_1$/FVC 0.8. FEV$_1$ is 93% of predicted. TLC is normal. What is the most appropriate management?

A. CXR  
B. Inhaled fluticasone  
C. Reassurance  
D. Inhaled albuterol prn  
E. Inhaled salmeterol

25. A 35-year-old female undergoes routine laboratory workup for an insurance physical. Labs reveal WBC 5.0 $10^3$/mm$^3$, Hgb 12.7 g/dL, Cr 1.0 mg/dL. Urinalysis shows 2+ bacteria and urine culture grows $10^5$ CFU *Escherichia coli*. PMH is otherwise negative. She has had occasional UTIs in the past but none for the past year. Her only medication is oral contraceptives. Urine hCG is negative. Vital signs are: Temperature = 98.6°F, BP = 115/60 mm Hg, pulse = 80, RR = 20. Lungs are clear to auscultation bilaterally. Both heart rate and rhythm are regular, without murmurs. The patient appears well and is alert and oriented. She has no tenderness at the right costovertebral angle and no suprapubic tenderness. What is the appropriate next step in managing this patient?

A. Nitrofurantoin  
B. Ciprofloxacin  
C. Trimethoprim-sulfamethoxazole  
D. No treatment  
E. Repeat urinalysis and culture

26. A 45-year-old female is brought to the ED complaining of fatigue. The patient has been feeling extremely weak over the past few days. Today she stood up and almost fainted, prompting her visit. She has had cough, rhinorrhea, and nasal congestion for the past week. Today she also began having nausea, vomiting, and severe abdominal pain. Past medical history is significant for hypertension, CKD, and SLE. Home medications are lisinopril, hydroxychloroquine, and prednisone 15 mg daily. Vitals: Temperature = 38.5°C, BP = 85/55 mm Hg, HR = 126.
General—appears weak, lethargic. Cardiac—tachycardic, regular, without murmurs. Lungs—occasional rhonchi, no wheezing. Abdomen—diffuse tenderness with normal bowel sounds. Labs: Na 124, K 5.3, Cr 3.0 (baseline 1.8). Hgb is 11.1 g/dL. The patient is diagnosed with influenza and started on IV fluids. After 2 L of normal saline her blood pressure is 90/60 mm Hg. What is the most appropriate next step?

A. Cortisol level  
B. IV hydrocortisone  
C. CT adrenal glands  
D. MRI pituitary  
E. Cosyntropin stimulation test

27. A 71-year-old female presents to the ED with a 2-day history of severe abdominal pain. Pain developed suddenly with no clear correlation to meals. Her symptoms were mild at first, becoming severe in the next 6 to 10 hours. She has nausea, but denies vomiting or dysphagia. Her past medical history is significant for GERD, CHF, poorly controlled DM, and atrial fibrillation. She is afebrile. HR 70, BP 135/85 mm Hg. Cardiac examination reveals a 3/6 systolic murmur in L axilla and irregularly irregular heart rate. Her abdominal examination reveals very mild tenderness in the midabdomen. Her stool is positive for blood. Laboratory studies show Hgb 10.0 g/dL, WBC 17.5 $10^3$/mm$^3$, Na 144 mEq/L, Cl 105 mEq/L, K 4.0 mEq/L, HCO$_3$ 20 mEq/L, Cr 1.1 mg/dL, A1c 12.6%, and INR 1.6. Medications are metoprolol, warfarin, insulin, and enalapril. What is the appropriate next step in evaluation?

A. CT angiography  
B. Gastric emptying study  
C. Colonoscopy  
D. EGD  
E. Vitamin K

28. A 43-year-old male presents to your office with a 3-day history of chest pain, which is mostly centrally located and radiates to the right side of his neck. The pain worsens with deep breathing and improves when he sits up. He denies nausea, vomiting, sweating, and SOB. He had an upper respiratory infection about 2 weeks ago which resolved without treatment. PMH is significant for hyperlipidemia. He takes lovastatin. He smokes half a pack of cigarettes a day. Vital signs are: Temperature = 99.4°F, BP = 125/80 mm Hg, pulse = 84. Physical examination is significant for a friction rub over the left sternal border heard best when he leans forward. A 12-lead ECG shows ST elevation in leads I, II, III, aVL, V$_2$, V$_3$, V$_4$, V$_5$, and V$_6$. Echocardiogram shows EF 50% with no regional wall motion abnormalities and normal valvular function. There is a small pericardial
effusion. What is the most appropriate next step?

A. Coronary angiogram
B. Drainage of pericardial effusion
C. Prednisone
D. Azathioprine
E. Ibuprofen

29. A 55-year-old male with past history of COPD presents to the emergency department with complaint of chest pain and SOB that started last evening. His chest pain is on the right side of the chest and is stabbing in quality, and the pain increases with inspiration. He is short of breath even at rest. He denies any traumatic event or overexertion. He also denies fevers, chills, and sputum. He has a 35-pack-year smoking history. He takes tiotropium and albuterol prn. Temperature = 98.2°F, BP = 130/80 mm Hg, HR = 115, RR = 24. Pulse oximetry shows 84% oxygen saturation on room air. He is 6 ft 2 in and 175 lb, and he otherwise appears healthy. Physical examination reveals absent breath sounds in R upper lung field. There is minimal end-expiratory wheezing in both lungs without crackles. No stridor is appreciated. Heart examination reveals regular tachycardia without murmurs. JVP is flat. There is no lower extremity edema. What is the appropriate next step in managing this patient?

A. Albuterol–ipratropium nebulizer
B. Prednisone
C. Chest tube insertion
D. Azithromycin
E. Pleurodesis

30. A 78-year-old male with a past history of hypertension and diabetes presents to office for evaluation. He is doing well, except for some palpitations over the past few months. He denies associated shortness of breath or syncope. He has never fallen. On physical examination, you note an irregularly irregular heart rhythm and a middiastolic murmur in the L axilla. Examination is otherwise normal. You obtain an ECG, which confirms the irregularly irregular arrhythmia. The patient has no history of bleeding and Hgb is normal. What is the recommended medication to start the patient on?
31. A 73-year-old male with HTN presents to the office with a 3-month history of chest pain and dyspnea induced by lifting weights, shoveling snow, and running on a treadmill. Vital signs are as follows: Temperature = 98.3°F, HR = 85, RR = 17, BP = 165/85 mm Hg. Physical examination reveals a 4/6 crescendo–decrescendo murmur heard at the right upper sternal border with radiation to the carotid arteries, weak and delayed carotid pulses, and an S4 gallop. ECG reveals sinus rhythm without arrhythmia. Echocardiogram reveals EF 45% and aortic valve area 0.8 cm². Prior coronary angiography 1 year prior showed 20% lesion in the mid-LAD, 30% RCA lesion, and no significant stenosis in the L circumflex artery. What is the most effective intervention strategy for this patient?

A. Nitroglycerin  
B. Aortic valve replacement  
C. Aspirin  
D. Carotid Doppler  
E. Coronary artery bypass grafting

32. A 38-year-old female presents to your office complaining of left knee pain for the past 2 to 3 months. She denies any history of injury. PMH is significant for SLE. She was recently increasing her running in an attempt to lose weight but her pain is now limiting her activity. She describes her pain as primarily “around and under my knee cap.” She points to her patella and the anterior aspect of her knee as the site of her pain. She especially has difficulty climbing and descending stairs. She has full range of motion without pain. She has no tenderness along medial or lateral joint lines. Examination reveals negative anterior and posterior drawer tests, full ROM in flexion and extension without crepitus, no effusion or erythema present. X-rays of the knee reveal normal alignment with preservation of joint space. Labs: Na 135 mEq/L, K 4.0 mEq/L, Cr 2.3 mg/dL. ANA is positive. ESR
10 mm/hr. What is appropriate next step in the management of this patient?
A. Corticosteroid injection
B. Physical therapy
C. Knee arthroscopy
D. MRI knee
E. Ibuprofen

33. A 57-year-old male had a fasting plasma glucose level of 160 mg/dL 1 month ago. Today, his fasting glucose level is 140 mg/dL. His medical history is significant for CHF and hyperlipidemia. His current medications include aspirin, lisinopril, and metoprolol. He is 5 ft 11 in and weighs 215 lb. BP 142/79. This patient is asymptomatic, and his physical examination is unremarkable. Labs: Na 142 mEq/L, K 4.0 mEq/L, Cr 1.7 mg/dL. Urine microalbumin:Cr ratio >30 mg/g. A1c 7.1%. In addition to lifestyle changes including increase in physical activity, diet changes, and weight loss, how would you manage this patient?
A. Hydrochlorothiazide
B. Insulin
C. Pioglitazone
D. Metformin
E. Lisinopril

34. A 36-year-old African-American female presents to your office with a 4-month history of dry cough, SOB, and fatigue. She has a 10-pack-year smoking history. Vital signs are: Temperature = 98.2°F, BP = 132/79 mm Hg, HR = 74, RR = 16. Pulse oximetry shows 96% O₂ saturation on room air. Examination reveals crackles bilaterally in the lower lung fields. There is no wheezing. She has two tender erythematous nodules on her left leg measuring approximately 3 × 3 cm. CXR shows bilateral hilar adenopathy. What is the next best test in order to confirm the suspected underlying diagnosis that explains the patient’s constellation of symptoms?
A. Serum calcium
B. CT chest
C. ACE level
D. Biopsy leg lesion
E. Biopsy hilar adenopathy

35. A 68-year-old male with a history of lung cancer undergoes follow-up labs after recent cycle of chemotherapy. He has mild difficulty with concentration over the past week but is otherwise able to complete all of his daily tasks. He denies any nausea, vomiting, or positional lightheadedness. He has no other significant past medical history. He takes no medications chronically. Vital signs are as follows:
Temperature = 99.8°F, RR = 18, BP = 135/88 mm Hg, pulse = 76. On examination, he is alert and oriented. Cardiac examination reveals RRR, no murmurs, JVP not elevated. Lung and abdominal examination is normal. There is no lower extremity edema. Skin turgor is normal. Neurologic examination reveals 5/5 strength in all extremities, no focal deficits and normal gait. Laboratory tests reveal the following: WBC = 8.3 × 10³/mm³, Hgb = 10.2 g/dL, glucose = 106 mg/dL, serum Na⁺ = 121 mEq/L, K⁺ = 4.3 mEq/L, BUN 7.0 mg/dL, Cr 0.4 mg/dL. TSH 2.0 mU/L. Serum osmolality 250 mOsm/kg, urine Na 45 mEq/L, urine osmolality 450 mOsm/kg. What would be the most appropriate management of this patient?

A. Administer IV normal (0.9%) saline
B. Initiate fluid restriction
C. Initiate hemodialysis
D. Administer hypertonic (3%) saline
E. Administer hydrochlorothiazide

36. A 20-year-old male presents for evaluation after an episode of dark urine. He felt well up until 2 weeks ago when he had a sore throat and mild fever for which he did not seek medical care. Urinary symptoms started the day prior to evaluation. He denies cough, dyspnea, hemoptysis, joint pains, dysuria, and flank pain. He does have two recent sexual partners but uses condoms. He has no prior medical history and denies any family history of renal diseases. BP 145/90 mm Hg, HR 65, T 37°C. Physical examination reveals a well-appearing male with normal heart sounds, clear lungs, and mild lower extremity edema. There are no skin lesions. Urinalysis that is obtained is dark red in color. Microscopic examination is positive for deformed RBCs and RBC casts. Cr is 1.6 mg/dL. What is the most likely test to help aid in the diagnosis of this patient?

A. ANCA
B. Anti-GBM
C. HIV
D. Antistreptolysin titer
E. IgA levels

37. A 31-year-old female with hypertension presents to your office complaining of painful joints for the past 4 to 5 months, affecting her wrists, ankles, and knees. She also reports several outbreaks of a rash over her face over the past few months. Her only medications are hydrochlorothiazide and acetaminophen as needed. Vital signs are as follows: Temperature = 99.2°F, RR = 20, BP = 145/83 mm Hg, pulse = 78. Physical examination reveals three ulcers in her mouth and mild swelling of the left wrist and ankle. She has 1+ pitting edema in her lower extremities bilaterally. Examination is otherwise unremarkable. CBC reveals a
WBC count of 2,300/mm$^3$, Hgb 12.2 g/dL, and platelets 82,000/mm$^3$. What is the most likely diagnosis?

A. Osteoarthritis  
B. Reactive arthritis  
C. Behçet disease  
D. Gout  
E. SLE

38. A 62-year-old male presents to your office accompanied by his wife. He complains of a tremor in his hands that disappears when he uses his hands for writing or handling utensils. His wife thinks he stares often and does not show as much emotion as before. He still participates in his usual activities and enjoys gardening with his wife. His appetite and sleep habits have remained unchanged. Weight is similar to his last clinic visit. She notices that he is slower in moving than before and walks steadily. On examination, you note a mild resting tremor and a fixed expression on his face. There is resistance on passive range of motion with upper extremities. Gait is slow, without imbalance or falling, and his arm does not swing when walking. He scored 26/30 on Mini-Mental Status Examination. What is the best intervention to improve the patient’s symptoms?

A. Fluoxetine  
B. Carbidopa–levodopa  
C. Propranolol  
D. Memantine  
E. Deep brain stimulation

39. A 24-year-old male presents to your office having with worsening RLQ cramping abdominal pain for the past 2 months. He reports having diarrhea on and off for the past 1 to 2 years. He previously had colonoscopy with a terminal ileum biopsy showing ulceration, acute inflammation, and noncaseating granulomas. Two months ago he was placed on mesalamine. He has lost 20 lb since then despite attempting to increase his dietary intake. He denies any other medical problems and takes no other medications. His physical examination reveals mild tenderness in the RLQ with normal bowel sounds. There are no anal fissures or fistulae. His stool is negative for occult blood. Vital signs are as follows: Temperature = 98.7°F, RR = 15, BP = 122/78 mm Hg, pulse = 65. BMI 21. Laboratory test results show normal liver/renal function. CBC shows Hgb 9.9 g/dL, MCV 82 fL, WBC 10.1 × 10$^3$/mm$^3$. X-ray abdomen reveals nonspecific gas pattern without free air or distended bowel loops. CT enterography reveals thickened mucosa in distal ileum with adjacent mesenteric stranding; there is no fistula, abscess, or free air present. What would be the single most effective intervention recommended to this patient?
A. Loperamide  
B. Azathioprine  
C. Infliximab  
D. Surgical resection  
E. Ciprofloxacin and metronidazole

40. A 58-year-old male presents to your office with complaint of left wrist pain for the past 3 months. He cannot recall any history of injury or trauma. He works as a car mechanic. He also has a new granddaughter who is 6 months old that he babysits every weekend. He is an amateur golfer when time allows. He denies neck pain. He has no associated paresthesias or weakness. PMH is significant for mild HTN and chronic kidney disease with a baseline Cr of 2.5 mg/dL. Examination reveals normal sensation throughout bilateral upper extremities. Neck flexion/extension/rotation does not reproduce his symptoms. Strength testing is normal in bilateral upper extremities. There is no evidence of muscle wasting on examination of the hands. With the patient making a fist surrounding the thumb, ulnar deviation of the wrist produces pain over the distal radial styloid. Prolonged wrist flexion does not elicit pain. Palpation over the flexor surface of the wrist base does not reproduce the patient’s symptoms. Pain is not elicited with resisted wrist extension or flexion. What is the most appropriate next step in management?

A. Thumb spica splint  
B. Wrist splint  
C. Counterforce forearm brace  
D. Carpal tunnel corticosteroid injection  
E. Ibuprofen

41. You are a hospitalist called to evaluate a 74-year-old female for SOB and increasing oxygen requirements. She denies any cough or sputum. The patient was admitted yesterday with multiple leg fractures after a motor vehicle accident. She has been on strict bed rest since admission while a plan is made for surgical repair. She has mild chest pain and feels short of breath. Past medical history is significant for CHF and COPD. She is compliant with her medications which include tiotropium, furosemide, metoprolol, and inhaled fluticasone. Temperature = 100.0°F, BP = 116/74 mm Hg, pulse = 120, RR = 24, oxygen saturation = 91% on 5 L of oxygen via nasal cannula. General examination reveals a patient who is alert to name and year but she does not know where she is. Mental status on admission was normal and she has no history of dementia. She is moderately tachypneic. Lung examination reveals good air movement throughout with no wheezing, crackles, or consolidation. JVP is not elevated. There are scattered petechiae on the upper chest. Bilateral lower extremities have symmetric 1+ edema without calf tenderness. CT chest shows scattered ground-glass opacities
without consolidation, no segmental or subsegmental emboli, and no effusions. What is the appropriate next step in management?

A. Albuterol  
B. Reduction of fracture  
C. Furosemide  
D. Levofloxacin  
E. IV heparin

42. A 38-year-old man is evaluated for palpitations in the ED. He has had these symptoms several times over the past year but this episode is worse. He denies any associated chest pain, lightheadedness, or syncope. He denies any history of medical problems and takes no medications. Examination reveals an adult male in no significant distress. Cardiac examination is significant for regular tachycardia with no JVP elevation. Lungs are clear without crackles or wheezing. There is no lower extremity edema. ECG shows: ________________. What is the best intervention at this point?

A. Valsalva maneuver  
B. Adenosine  
C. Metoprolol  
D. Digoxin  
E. Cardioversion

43. A 38-year-old female presents to your office with pain in her wrists, ankles, and knees bilaterally. She reports noticing numbness and morning stiffness in her hands about 1 year ago, mostly in cold weather. This stiffness gradually spread to her wrists, knees, and ankles, with lesser involvement of her shoulders. The stiffness and pain are worse in the morning but improve as the day wears on. Symptoms have gradually worsened. Some days she cannot go outside her house because of the pain. She denies a history of rash or photosensitivity. She often feels tired and “worn out.” Medical history is significant for HTN, for which she
takes hydrochlorothiazide. On examination, her metacarpal joints and wrists are swollen and tender, as are her knees and ankles bilaterally. Her examination is otherwise unremarkable. Labs reveal normal liver and renal function. CBC is unremarkable. ESR 65 mm/hr. CCP is positive. ANA is negative. X-rays of hands show erosive changes in MCP joints. What is the most important intervention for this patient to control her disease?

A. Prednisone
B. Corticosteroid injection
C. Indomethacin
D. Hydroxychloroquine
E. Physical therapy

44. A 60-year-old female presents to the ED with a complaint of RUQ abdominal pain that began several hours ago. She has had occasional RUQ pain over the past 3 months but never this severe. Her PMH is only significant for HTN and osteoarthritis. On physical examination, she appears ill. Scleral icterus is present. She has RUQ abdominal tenderness without peritoneal signs and bowel sounds are normal. There are no surgical scars on the abdomen. Initial vital signs are as follows: Temperature = 102.1°F, RR = 16, BP = 95/70 mm Hg, pulse = 120. Laboratory tests reveal ALT 136 U/L and AST 119 U/L, ALP 105 U/L, direct bilirubin 4.5 mg/dL, and WBC count 16.8 × 10^3/mm^3. Ultrasound of the abdomen shows common bile duct dilatation with gallstones obstructing. Piperacillin-tazobactam is started and the patient is resuscitated with IV fluids. Repeat BP 12 hours after antibiotics and 4 L of IV fluids is BP = 110/82 mm Hg and HR = 85. Temperature = 98.8°F. What is the next step in managing this patient?

A. Cholecystectomy
B. Liver biopsy
C. ERCP
D. MRCP
E. Percutaneous transhepatic cholangiography

45. A 42-year-old female presents to the clinic for pre-employment screening. She is starting a new job as a bus driver and needs to have a physical and TB test before being hired. She denies any fever, chills, sputum, and weight loss. She was born in America and has not traveled outside of the country. She has never received a tuberculosis vaccine. She denies any contact with anyone infected with tuberculosis. She does not use IV drugs. Recent STD testing, including HIV, was negative. Physical examination is normal including lungs. PPD testing is performed and on reevaluation in 48 hours there is 10 mm of induration. What is the best recommendation to the patient?

A. AFB sputum culture
B. Rifampin, isoniazid, pyrazinamide, ethambutol
C. Isoniazid
D. Chest x-ray
E. No further intervention

46. A 64-year-old male presents to your office with left knee pain swelling. He has occasional pain in both knees that is usually dull and resolves with acetaminophen. Over the past few days, he has had swelling which has made it difficult to move the joint. He had a similar episode of swelling a year ago that resolved on its own but this episode is much more severe. He denies any preceding trauma. He denies any morning stiffness. He has pain in his right knee as well, but it is mild and does not bother him that much. On physical examination, he has a moderate effusion in his left knee with erythema overlying (no effusion in the right knee). He has crepitus in both knees. Strength is normal, and examination does not indicate any ligamentous instability. X-ray shows mild narrowing of the joint space and calcification of the cartilage. Aspiration of the effusion reveals straw-colored fluid, 25,000 WBCs, 85% PMNs, Gram stain and culture are negative. Evaluation for crystals reveals no intracellular negatively birefringent crystals, but does reveal multiple intracellular positively birefringent rhomboid-shaped crystals. What is the most appropriate laboratory test to obtain?
A. Uric acid
B. TSH
C. ANA
D. ESR
E. HLA-B27

47. A 62-year-old female presents to your clinic with questions regarding her new diagnosis of osteoporosis. She had a hip fracture 6 months ago after a fall. Subsequently, she had a prolonged hospital course complicated by a DVT for which she completed therapy with warfarin. She has had no further falls and is back to her baseline level of activity after a 1 month rehabilitation stay. She had a DEXA scan which showed a T-score of −2.6 in the hip and −2.3 in vertebrae. Her past medical history includes achalasia for which she gets dilatations as needed. Currently she only takes omeprazole on a daily basis. Labs including renal function, calcium, and vitamin D are all normal. She is inquiring about further options to prevent her from having fractures. What is the appropriate management of this patient besides recommending continued supplementation with vitamin D and calcium?
A. Zoledronic acid
B. Alendronate
C. Raloxifene
D. Calcitonin
E. Estrogen

48. A 53-year-old female presents to the hospital with abdominal pain. She is diagnosed with cholecystitis and has a cholecystectomy performed. The following day she complains of palpitations. On questioning she has had an irregular heart beat off/on for the past few months but acutely worsened during this episode. She also notes a 15-lb weight loss over the past month. She denies dizziness, syncope, dyspnea, or chest pain. She has a known history of hyperlipidemia but has otherwise been healthy. Medications include ASA and atorvastatin. Vitals: Temperature = 102.4°F, BP = 155/88 mm Hg, pulse = 134. Oxygen saturation at room air = 96%. Physical examination: patient is agitated and appears confused, sometimes answering questions inappropriately. Skin is diaphoretic. Neck is supple without tenderness and no palpable nodules or enlargement. Cardiac examination reveals an irregular rhythm, tachycardia, and no murmurs. ECG confirms atrial fibrillation with rapid ventricular response. TSH is <0.01 mU/L. What is the most appropriate next step in the management of this patient?
A. Radioactive iodine uptake scan
B. Iodine
C. US thyroid
D. Propranolol
E. Thyroidectomy

49. A 61-year-old male who has been your patient for several years presents to your office with a complaint of two episodes of bloody urine over the past 24 hours. He denies any flank pain, dysuria, fevers, or chills. His urine stream is strong, he is able to void completely and he denies the need to start/stop or strain during urination. PMH is significant for hyperlipidemia, HTN, diabetes, glaucoma, and osteoarthritis. He has smoked one pack of cigarettes per day for the past 35 to 40 years. Physical examination reveals no CVA or suprapubic tenderness. Prostate examination reveals nontender, nonenlarged prostate. Urinalysis shows gross hematuria without proteinuria, pyuria, or RBC casts. Cr 1.1 mg/dL. Urine culture is negative. What is the appropriate next step in managing this patient?
A. CT urography
B. Ultrasound kidneys
C. Renal biopsy
D. PSA
E. Prostate biopsy

50. A 57-year-old male presents to your office with a 2-week history of cough. The cough is associated with clear sputum, occurs daily and has persisted over the past 2 weeks. He has occasional dyspnea and wheezing at times. He denies myalgias,
fevers, or chills. He has experienced chest discomfort due to excessive coughing. PMH is negative and he takes no medications and specifically denies any history of pulmonary disease. Temperature is 99.1°F. RR 18. O₂ saturation is 96% on room air. On examination, the patient is in no respiratory distress and is breathing comfortably. Auscultation of lungs reveals scattered rhonchi and wheezing but no consolidation, egophony, or crackles. CXR shows normal expansion of the lungs without infiltrates or effusions. Peak flow is 530 L/min (expected 556 L/min). What is the most appropriate management?

A. Prednisone
B. Oseltamivir
C. Azithromycin
D. Albuterol
E. Sputum culture

51. A 32-year-old African-American male, who recently moved to the area, presents to your office for the first time for a routine checkup. PMH is significant for type II DM. He is 5 ft 9 in and weighs 215 lb. The only medication he takes is metformin. He smokes half a pack of cigarettes a day; does not drink alcohol; and exercises sporadically, approximately once every 2 weeks. His mother died at the age of 62 due to an MI. His father is 73 years of age and is healthy. Physical examination is normal. Vital signs are: BP = 146/95, pulse = 73, RR = 19, temperature = 98.2°F. Which of the following lifestyle modifications has been shown to result in the greatest reduction in blood pressure?

A. Dietary Approaches to Stop Hypertension (DASH) diet
B. Weight loss
C. Decreasing alcohol consumption
D. Increasing exercise
E. Smoking cessation

52. The patient in the previous question returns to your office in 6 weeks for a repeat evaluation. He has no complaints. He states that he has been walking briskly for 30 minutes four times a week, has lost 10 lb, and has been eating a healthier diet. His laboratory results are within normal limits. Hemoglobin A1c is 7.2. CXR, ECG, and urinalysis are normal. His BP today is between 140/90 and 145/95. Physical examination is unchanged from 2 months ago. What is your recommended treatment?

A. Lisinopril
B. Amlodipine
C. Hydrochlorothiazide
D. Atenolol
E. Propranolol
53. A 17-year-old female is referred to the ED by her primary physician; she presents with a 3-day history of fevers, dysuria, and vomiting. She denies vaginal discharge, abdominal pain, or diarrhea. She is sexually active with her boyfriend. Vital signs are as follows: Temperature = 103°F, RR = 20, BP = 98/65, pulse = 100. She appears ill and is unable to tolerate liquids, but she is alert and oriented. Her examination is positive for suprapubic as well as costovertebral angle tenderness bilaterally. Urinalysis reveals numerous WBCs and bacteria, and it is positive for WBC casts and leukocyte esterase. Other laboratory study results are within normal limits, including a negative urine pregnancy test. What is the likely diagnosis?

A. Pyelonephritis  
B. Nephrolithiasis  
C. Appendicitis  
D. Ectopic pregnancy  
E. Acute interstitial nephritis

54. A 32-year-old male presents to the ED with a complaint of severe low back pain for the last 5 weeks. He reports that the pain is most severe when he first wakes up in the morning and gradually improves with exercise throughout the day. He cannot recall any trauma or insult to his back when the pain started. He denies any pain or numbness in the lower extremities. Bowel and bladder function is normal. Physical examination reveals a moderately overweight male in some distress. He has very minimal tenderness on palpation of his low back. Neurologic examination is normal. What is the appropriate next step in managing this patient?

A. Local heat  
B. Physical therapy  
C. Nonsteroidal anti-inflammatory drugs (NSAIDs)  
D. Epidural steroid injection  
E. Surgical laminectomy

55. A 29-year-old male with a history of asthma presents to the ED with severe SOB for the past 2 days. He also complains of sore throat, generalized malaise, and a nonproductive cough. He denies chest pain, fever, and chills. Temperature = 98.9°F, HR = 95, RR = 33, BP = 140/82, and O₂ saturation = 90% on room air. Breathing is labored, and he is speaking in short gasps. Lung auscultation reveals bilateral diffuse expiratory wheezing. There is no urticaria or angioedema on skin examination. ABG is drawn: 7.42/43/70/22. What is the appropriate next step in managing this patient?

A. Cautious oxygen administration, targeting an SaO₂ <94% to prevent hypercapnia  
B. IV ceftriaxone and azithromycin
C. Subcutaneous epinephrine for bronchodilation  
D. Nebulized ipratropium for bronchodilation  
E. Nebulized albuterol for bronchodilation

56. A 22-year-old female presents to the ED with abrupt onset of a rash, high fever, and vomiting. Vital signs are as follows: Temperature = 104°F, HR = 118, RR = 22, BP = 76/40, and pulse oximetry = 98% on room air. On examination, she appears confused and disoriented. Her skin is warm, and there is a diffuse macular rash over her body. She is admitted to the ICU and subsequently develops multisystem organ dysfunction. Which of the following organisms is most likely implicated in this patient’s diagnosis?

A. *Streptococcus pyogenes*  
B. *Neisseria meningitidis*  
C. *Staphylococcus aureus*  
D. *Streptococcus pneumoniae*  
E. *Rickettsia rickettsii*

57. A 33-year-old Caucasian male comes to the clinic with a 4-day history of chest pain. The pain radiates to the right side of the neck and is worsened by deep inspiration and improved by leaning forward. Several weeks ago he had a fever and cough, which have both since improved. He is afebrile, BP is 130/85, and pulse is 88. On examination, there is a scratching sound heard over the left sternal border on expiration. ECG shows ST elevation in leads I, II, III, avL, and V2 to V6. The patient is offered treatment but refuses all medications. Which of the following is the most common complication if this disease remains untreated?

A. Cardiac tamponade  
B. Recurrent pericarditis  
C. Constrictive pericarditis  
D. Ventricular free wall rupture  
E. Valvular insufficiency

58. A 52-year-old woman with a history of diabetes mellitus and hypertension presents to the emergency department with fevers, chills, and abdominal pain. The symptoms began about 1 week ago and have been getting worse. The abdominal pain is associated with nausea and vomiting, and she has not been able to eat. On examination, her temperature is 102.1, blood pressure is 104/68 mm Hg, heart rate is 94/min, and respiratory rate is 16/min. Her abdominal examination shows right-sided pain to deep palpation, and she has severe right-sided costovertebral angle tenderness. Laboratories demonstrate a leukocytosis (15,400/mm³) and urinalysis shows WBCs, WBC casts, protein, and bacteria. Despite IV ceftriaxone for 5 days, the patient remains febrile. The patient’s urine culture is positive for
*Escherichia coli* and is sensitive to ceftriaxone and ciprofloxacin. What is the appropriate next step in management?

A. Renal biopsy  
B. CT scan with contrast  
C. Continue the current antibiotic  
D. Stop ceftriaxone and start ciprofloxacin  
E. Stop ceftriaxone and reculture urine

59. You are paged to come and evaluate a 33-year-old female with SOB and tachycardia. She normally takes inhaled fluticasone and albuterol for asthma, however she is not currently responding to the albuterol. On examination, she appears anxious and is moderately short of breath. There are loud bilateral wheezes on examination, with a prolonged inspiratory and expiratory phase and use of accessory muscles of respiration. Temperature = 99.4°F, pulse = 116, BP = 116/56, RR = 36. Oxygen saturation is 91% on room air. Examination shows use of accessory muscles on inspiration. An arterial blood gas is obtained and shows a pH of 7.4, PO$_2$ of 60 mm Hg, and PCO$_2$ of 40 mm Hg. What is the appropriate next step to be taken in the management of this patient?

A. Increase supplemental oxygen flow rate  
B. IV corticosteroids  
C. Azithromycin  
D. Intubation  
E. Nebulized albuterol

50. A 61-year-old man with a history of chronic alcoholism and parathyroid adenoma presents with pain in his left knee for the last 2 days. He denies fevers, chills, night sweats, or any history of trauma to the knee, but does endorse abdominal pain and constipation. Physical examination is significant for tenderness and erythematous skin overlying the left knee. There is also marked swelling of the left knee. Laboratory findings reveal an elevated calcium level (12.1 mg/dL). If joint aspiration is performed, which of the following will be seen on synovial fluid analysis?

A. Negatively birefringent needle-shaped crystals  
B. Positively birefringent rhomboid-shaped crystals  
C. Neutrophil predominance with gram-positive cocci  
D. Negatively birefringent needle-shaped crystals AND gram-positive cocci  
E. Normal synovial fluid findings

51. A 26-year-old man presents to his primary care physician complaining of fatigue, headache, and a sore throat for the past week. There is also nausea and diarrhea, but no weight loss, productive cough, or difficulty breathing. He denies any past
medical history, does not take any medications, and has no recent sick contacts. He is sexually active and uses condoms inconsistently; he drinks alcohol heavily on the weekends and admits to previous IV drug use. On examination, his temperature is 39°C and the rest of his vital signs are normal. He has nontender cervical and axillary lymphadenopathy, tonsillar exudates, and mild splenomegaly. There are also several painful, well-demarcated ulcers within his mouth and a mild maculopapular rash over his chest and arms. A rapid strep test and a monospot (heterophile antibody) test are negative; further screening for chlamydia, gonorrhea, syphilis, and HIV is negative. What is the likely diagnosis?

A. Hodgkin lymphoma  
B. Acute retroviral syndrome  
C. Infectious mononucleosis  
D. Secondary syphilis  
E. Upper respiratory infection

52. A 30-year-old medical student is undergoing medical screening in order to start a rotation at a new hospital. She denies any current symptoms and reports no previous medical problems. She is originally from South Africa and her vaccinations are up-to-date, including a BCG vaccine she received as a child. A purified protein derivative (PPD) is placed and read 48 hours later, which shows an area of induration that is 11 mm wide. What is the most appropriate next step in management?

A. Start rifampin, isoniazid, pyrazinamide, and ethambutol  
B. Obtain a chest x-ray; if normal, reassure the patient  
C. Obtain a chest x-ray; if normal, start isoniazid and pyridoxine for 9 months  
D. Start isoniazid and pyridoxine for 9 months  
E. Reassurance

53. A 35-year-old male presents with complaint of a 6-month history of fatigue and lethargy. His medical history is unremarkable. He denies melena and recent trauma or surgery. He reports that he does not drink alcohol, smoke, or take any medications. His family history is noncontributory. He appears well nourished. Vital signs are as follows: RR = 16, BP = 130/80, pulse = 70. Laboratory test results are as follows: Hb = 7.6, Hct = 22.8%, and MCV = 68. The remainder of his laboratory test results are normal. Which of the following is the best next step in management of this patient?

A. Serum iron studies  
B. Hemoglobin electrophoresis  
C. Serum lead levels  
D. Peripheral blood smear  
E. Stool guaiac test
54. A 56-year-old female presents to the ED with a complaint of severe abdominal pain, primarily in the epigastric region. She has had two episodes of vomiting in the past 5 hours. She describes the pain as sharp, with occasional radiation to her back. PMH is significant for DM, HTN, alcoholism, asthma, and chronic low back pain. Her current medications include insulin, atenolol, albuterol inhaler, and oxycodone. She has had abdominal pain several times in the past year, but never this severe and never associated with vomiting. On examination, she has tenderness in the epigastric region. There is mild guarding but no rebound. Physical examination is otherwise unremarkable. Temperature = 101.3°F, BP = 136/88, pulse = 116. She is alert and oriented and is in obvious distress. Which of the following is the most specific finding in this condition?

A. Elevated amylase
B. Elevated ALT
C. Elevated lipase
D. Positive fecal fat test
E. Calcifications on x-ray

55. A 37-year-old female presents to your office with a history of fatigue for the past few months. She does not have any other complaints. After a thorough medical history, she admits to mild constipation that is not troublesome for her. She reports a 5-lb weight gain over the past 6 months, which she attributes to living a more sedentary life of late due to her fatigue and lethargy. Her physical examination is unremarkable; her thyroid does not seem enlarged, although her face is slightly puffy. Which of the following is the best next step in management?

A. Free T4 levels
B. Thyroid-stimulating hormone (TSH) levels
C. Thyroglobulin levels
D. Radioactive iodine uptake (RAIU) scan
E. Biopsy

56. A 21-year-old male college student is brought to the ED by his friends after developing fever, neck stiffness, confusion, and severe sensitivity to light. Vital signs on admission are as follows: Temperature = 105°F, RR = 20, BP = 120/75, pulse = 92, and pulse oximetry 99% on room air. Examination reveals a confused male patient with nuchal rigidity. A fundoscopic examination shows bilateral blurring of the optic disk margins and retinal venous engorgement. Which of the following is the next best step in management?

A. CT scan
B. MRI
C. Lumbar puncture
D. Administer empiric antibiotics
E. Administer empiric antiviral therapy

57. A 64-year-old male presents with back pain, constipation, and slight confusion for the past 5 to 6 months. Two days ago he fell while shoveling snow, and he has pain in his right arm as well. Plain films of the spine show several small lytic lesions in the vertebral bodies at the L3 to L4 level. Right humerus films reveal lytic areas in the metaphysis and diaphysis of the right humerus. There is a fracture line through the abnormal area on the humerus film. Physical examination reveals tenderness on palpation of the low back and right humerus, but is otherwise unremarkable. There is no splenomegaly or lymphadenopathy. CBC results are as follows: Hb = 9.1 g/dL, Hct = 27.6%, MCV = 90, platelet count = 150,000/μL. Serum chemistries are as follows: Sodium = 137 mmol/L, potassium = 4.1 mmol/L, chloride = 107 mmol/L, CO₂ = 24 mmol/L, glucose = 89 mg/dL, BUN = 46 mg/dL, Cr = 3.5 mg/dL. Which of the following additional findings do you expect with this patient’s condition?
   A. Mechanical obstruction
   B. Electrolyte abnormality
   C. Hormone level abnormality
   D. Arterial blood gas abnormality
   E. Venous blood gas abnormality

58. A 47-year-old male presents to your office with severe low back pain for the past 2 days. This morning he had an episode of loss of control of his urine, followed by progressive weakness in bilateral lower extremities. His low back pain is severe and sharp, and it radiates into the right lower extremity. PMH is significant for mild asthma. He has had intermittent low back pain for the past 2 years but never this severe and never associated with weakness or urinary symptoms. On physical examination, he has very limited motion of his lumbar spine secondary to pain. He has 3/5 strength in gastrocnemius muscles bilaterally and 2/5 strength with great toe dorsiflexion bilaterally. He has diminished sensation throughout his lower extremities, and reflexes are diminished. Rectal tone is absent as is sensation in the perineal area. What is the next best step in management of this patient’s condition?
   A. Steroids
   B. Surgery
   C. MRI lumbar spine
   D. Bed rest
   E. NSAIDs

59. A 67-year-old female presents to the ED after a transient episode of visual loss in her right eye. She reports that she has had right-sided headache for several
months, for which she takes ibuprofen, with some relief. On physical examination, she has tenderness over her scalp in the left temporal region and complains that her jaw “gets tired with chewing.” Neurologic examination is normal with no focal deficits. Vital signs are as follows: Temperature = 101.1°F, HR = 72, RR = 16, BP = 140/82. Which of the following is associated with this condition?

A. Aortic aneurysm  
B. Inflammatory bowel disease  
C. Hepatitis B  
D. Smoking history  
E. Alcohol history

70. A 63-year-old female is brought to the ED by the rescue squad after an episode of syncope at home. Her husband witnessed the event. He describes the patient as falling suddenly to the floor from a standing position. She lost consciousness for about 5 seconds, after which she rapidly regained consciousness and was oriented and appropriate. The patient remembers feeling lightheaded, nauseous, and developing “tunnel vision” prior to the event. No bowel or bladder incontinence was noted. PMH is significant for DM, HTN, and depression. She denies any chest pain or SOB. Vital signs are: Temperature = 100.2°F, BP = 118/68, pulse = 84, RR = 18. Oxygen saturation on room air is 96%. Physical examination is significant only for bruising of her left wrist and thigh. Heart and lung examination is normal. Which of the following is the most likely diagnosis?

A. Arrhythmia  
B. Orthostatic hypotension  
C. Seizure  
D. Vasovagal syncope  
E. Aortic stenosis

71. A 63-year-old female presents to your office with complaint of mid to low back pain for the last year, which has become worse over the past 3 months. She denies any weakness or radiating pain in her lower extremities. She currently takes oxycodone for her back pain with inadequate relief. She has difficulty sleeping at night because of the back pain. PMH is significant for HTN, for which she takes a β-blocker. Thoracic and lumbar spine radiographs show multiple compression fractures at T8, T11, L3, and L4, as well as diffuse osteopenia. Laboratory studies are as follows: WBC 8, hemoglobin 9.7, hematocrit 29%, platelets 189, Na+ 142, K− 4.1, BUN 43, creatinine 2.3, calcium 14.3. Physical examination reveals tenderness on palpation of thoracic and lumbar spine. She has limited lumbar flexion due to pain. Neurologic examination is normal. Which of the following would be abnormal in this patient’s condition?
A. CA-15-3  
B. Carcinoembryonic antigen (CEA)  
C. Alkaline phosphatase  
D. Serum immunoelectrophoresis  
E. Bone scan

72. A 62-year-old female is brought to the ED by EMS for confusion, headache, and vomiting over the past 12 hours. Vital signs are as follows: Temperature = 96.9°F, HR = 100, RR = 22, BP = 220/150. She is disoriented and uncooperative. Examination is otherwise unremarkable. What is the most likely diagnosis, and what is the most appropriate management?

A. Hypertensive urgency; gradual lowering of blood pressure with oral agents  
B. Hypertensive urgency; rapid lowering of blood pressure with IV agents  
C. Hypertensive emergency; gradual lowering of blood pressure with oral agents  
D. Hypertensive emergency; rapid lowering of blood pressure with IV agents  
E. Hypertension; gradual lowering of blood pressure with oral agents

73. A 74-year-old male is brought to your office by his daughter, who is having increasing problems caring for him at home. She reports that he has recently had urinary incontinence and has been “clumsier” than usual. She states that he behaves inappropriately at times, and on two occasions he has wandered outside the home and has gotten lost. He misplaces items frequently, and his personality has changed to being more belligerent and demanding. He seems to lack judgment in social situations, and he never had this problem in the past. She states that these problems have become worse gradually over the past 4 months. Physical examination is unremarkable. What is the likely diagnosis?

A. Pseudotumor cerebri  
B. Alzheimer disease  
C. Normal pressure hydrocephalus  
D. Multi-infarct dementia  
E. Lewy body dementia

74. A 73-year-old female is brought to the ED by EMS with a complaint of SOB and progressive dyspnea. Her medical history is significant for a previous MI 5 years ago and mild CHF. The patient has also had several episodes of ventricular tachycardia that ultimately required cardioversion. She is currently taking a prophylactic medication and has not had any recurrent arrhythmias. On physical examination, she is in moderate respiratory distress and she has dry rales throughout her lung fields. Temperature = 99.1°F, BP = 138/75, pulse = 96, RR = 28. CXR is normal, but CT scan of the chest shows diffuse ground-glass opacities. Which of the following is contributing to this patient’s symptoms and clinical findings?
A. Digoxin
B. Lisinopril
C. Amiodarone
D. Bleomycin
E. Losartan

75. A 39-year-old female presents to your office with a 3-year history of headaches. They occur once or twice per week, lasting several hours. The headaches are throbbing and are usually on her left side. During these episodes, the patient is incapacitated and must lie down in a dark room for several hours. She is sensitive to light during the episodes and cannot move because of the pain. She is often nauseated and has vomited on several occasions. Medical history is significant for hypothyroidism, for which she takes levothyroxine (Synthroid). Her physical examination is unremarkable, however the patient endorses another similar headache and begins vomiting near the end of the examination. What is the appropriate next step in managing this patient?

A. Propranolol
B. Amitriptyline
C. Chlorpromazine
D. Verapamil
E. Sumatriptan

76. A 55-year-old female presents to your office for a routine follow-up examination. Medical history is significant for poorly controlled DM (20-year history), HTN, and osteoarthritis of bilateral knees. She also has had chronic renal insufficiency for the past 5 years. Her current medications include hydrochlorothiazide, lisinopril, insulin, and metoprolol. She has been taking increasing amounts of NSAIDs for the past several weeks for her painful knees. She is obese with 2+ peripheral pitting edema. She appears weak with dry mucous membranes and is tachycardic. Laboratory tests reveal the following: Na⁺ = 138, K⁺ = 4.6, Cl⁻ = 104, HCO₃⁻ = 27, Cr = 3.6, WBC = 7.9, Hgb = 8.2, Hct = 24.6, MCV = 75. On her last visit 3 months ago, her Cr was 2.3. Which of the following would be most helpful in determining the etiology of this patient’s renal failure?

A. Urine dipstick
B. Urine sodium
C. Fractional excretion of sodium (FENa)
D. Renal ultrasound
E. No further workup is necessary

77. A 64-year-old female presents to the ED with sudden onset of severe chest pain that occasionally radiates to her back. She has a history of angina and takes
nitroglycerin, but this time the pain is much worse and is not relieved with nitroglycerin. PMH is significant for HTN. She is afebrile, and HR = 105, BP = 160/105, RR = 17. Cardiac enzymes are negative. CXR shows a widened mediastinum. What is the likely diagnosis?

A. Myocardial infarction  
B. Aortic dissection  
C. Stroke  
D. Acute aortic regurgitation  
E. Hypertensive emergency

78. A 17-year-old male presents to the ED with severe pain in his right leg and back that began suddenly a few days ago. The pain is sharp and throbbing. He has a history of sickle cell disease with frequent painful crises requiring hospitalization once or twice per year. He has no other medical problems. Vital signs are as follows: Temperature = 101.6°F, HR = 94, RR = 20, BP = 132/84. Oxygen saturation is 97% on room air. His right shin is very tender, as is his low back in the midline. His examination is otherwise unremarkable. CBC results are as follows: Hb = 7, Hct = 21%, MCV = 94. Osteomyelitis of the right tibia is ultimately diagnosed. What is the most likely cause of this patient’s osteomyelitis?

A. Listeria  
B. Salmonella  
C. Shigella  
D. Cryptosporidium  
E. Campylobacter

79. A 42-year-old male presents to your office because he noticed a “lump” in his neck 1 month ago. He endorses weight loss and palpitations, but denies pain or dysphagia. On physical examination, you note a nontender, firm nodule about 2 cm in size to the left of the midline in the region of the thyroid gland. Vital signs are as follows: BP = 125/82, pulse = 75. He does not take any medications and has no significant medical history. He denies any family history of thyroid disease or cancer. His routine serum laboratory values (CBC, electrolytes, BUN, creatinine) are normal. The physician decides to do a radioactive iodine uptake (RAIU) scan. Which of the following features is not associated with an increased risk of malignancy?

A. Hard and immobile mass  
B. Cold nodule on RAIU  
C. Cervical lymphadenopathy  
D. Hot nodule on RAIU  
E. Microcalcifications
30. A 65-year-old female presents to your office with a 1-month history of intermittent neck and shoulder pain with SOB that normally occurs when she does chores around the house or climbs stairs. She is previously healthy and denies any medical conditions. She does not smoke or drink alcohol. The patient is up-to-date on vaccinations and had a mammogram done at her previous appointment 1 year ago that was normal. BP = 148/86 and pulse = 88. She had a colonoscopy performed 6 years ago that was normal. You order an ECG, CXR, CBC, and electrolytes. What should be recommended to the patient at her visit today?

A. Mammogram  
B. Colonoscopy  
C. Calcium and phosphorus levels  
D. Dual-energy x-ray absorptiometry (DEXA)  
E. CT scan of the chest

31. A 54-year-old male with a history of parathyroid adenoma presents to the ED with severe pain in his right knee. He says that the pain is extreme and intolerable, and he is in obvious distress. On examination, there is exquisite tenderness, erythema, and swelling of the right knee joint and it feels very warm to the touch. The pain began suddenly a few hours ago. He denies any previous episodes or pain in any other joints. He denies any trauma. Medical history is significant for osteoarthritis of his left knee, for which he takes ibuprofen. He drinks 6 to 7 glasses of wine per day. He does not take any other medications. Vital signs are as follows: Temperature = 100.5°F, RR = 16, BP = 140/85, pulse = 78. Which of the following is the best next step in management for this patient?

A. Indomethacin  
B. Joint aspiration with synovial fluid analysis  
C. Uric acid levels  
D. Knee x-ray

32. A 41-year-old male presents to your office with a complaint of epigastric pain for the past several months. He takes over-the-counter antacids, but symptoms have been worse over the past month. He denies any weight loss, vomiting, hematemesis, or melena. The discomfort is worse after eating. Medical history is noncontributory. He takes no other medications. He smokes half a pack of cigarettes a day and drinks alcohol socially about once per week. Physical examination is unremarkable except for mild epigastric tenderness. What is the appropriate next step in managing this patient?

A. Continue antacids  
B. Barium swallow evaluation  
C. Empiric 1-month trial with proton pump inhibitor (PPI)  
D. Upper GI endoscopy
E. Observation

33. An 81-year-old female was in a motor vehicle accident 3 days ago and suffered a left femur fracture, for which she had surgery on the same day. She has been hospitalized since the day of surgery and has been taking part in daily physical therapy without difficulty. Her family (husband and daughter) report that she has not been “acting like herself” at times when they come to visit her. She becomes agitated and is belligerent toward them, and she sometimes wonders why she is in the hospital. She reports seeing “creatures.” At other times, the patient is doing very well, and they do not notice these inconsistencies. The patient has a history of borderline HTN. Current medications include a stool softener and morphine for pain control. On examination, the patient is alert and oriented to time/place/person and is appropriately responding to questions. She denies any hallucinations. Neurologic examination is normal. Which of the following is true of this patient’s condition?

A. Anticholinergic medications are first-line treatment
B. Pathologic findings include neurofibrillary tangles and β-amyloid plaques
C. Long-term memory is intact, but short-term memory is affected
D. This is an irreversible condition
E. Etiologies include infection and polypharmacy

34. A 49-year-old female presents to the ED with complaint of severe epigastric and RUQ abdominal pain. Her symptoms started 3 days ago but have progressively worsened over the past 12 hours. Her symptoms are worse with meals. She has had two episodes of vomiting in the past 12 hours and is nauseous currently. PMH is significant for diabetes, osteoarthritis, and HTN. Temperature = 102.3°F, BP = 146/80, pulse = 110, RR = 16. On physical examination, there is severe right upper quadrant pain on deep palpation, most pronounced on palpation after deep inspiration. Bowel sounds are diminished. The patient is lying on her side holding an emesis basin. Which of the following is causing this patient’s disorder?

A. Alcoholic liver disease
B. Gallstone obstruction in the cystic duct
C. Obstruction from carcinoma of the head of the pancreas
D. Gallstone obstruction in the common bile duct
E. Pancreatic inflammation

35. A 31-year-old female presents to your office with multiple musculoskeletal aches and pains including, but not limited to, her shoulders, elbows, knees, neck, and buttocks. She has had these symptoms for at least the past year. She does not sleep very well when the pain is severe and has no relief with NSAIDs. She has tried exercising more, but the pain is persistent. On palpation, she has marked tenderness over both lateral epicondyles, the anterior aspect of her left shoulder,
the medial aspect of her right knee, her posterior neck, and her left greater trochanter. There are no effusions at any of the above sites. Routine laboratory test results are normal. What is the appropriate next step in managing this patient?

A. Prednisone  
B. Naproxen  
C. Amitriptyline  
D. Colchicine  
E. Steroid injections

36. A 52-year-old male with a long-standing history of alcohol abuse is brought to the ED by his wife for vomiting blood. He vomited bright red blood at least twice this morning. PMH is significant for cirrhosis, HTN, and arthritis. He has never vomited blood before. On examination, the patient is awake but appears nervous and is in moderate distress. Delayed capillary refill is present. You are able to determine that he has vomited approximately 2 L of blood over the past 6 hours. Vital signs are: Temperature = 99.2°F, BP = 90/58, HR = 134, RR = 20. Pulse oximetry shows 98% oxygenation on room air. What is the appropriate next step in managing this patient?

A. Immediate upper GI endoscopy  
B. Administration of fluids  
C. Helicobacter pylori serologic testing  
D. Intravenous (IV) proton pump inhibitor  
E. Reassurance

37. A 57-year-old female presents to the ED with a complaint of abdominal pain and vomiting. The pain is diffuse and poorly localized. She has had these symptoms for the past month and has been constipated during this time. She has not had a bowel movement or passed gas in 3 days. She has no significant PMH. Vital signs are: Temperature = 99.2°F, BP = 128/78, HR = 78, RR = 16. On physical examination, there is abdominal distention and no guarding or rebound tenderness. The remainder of the examination is normal. What is the next appropriate step in the management of this patient?

A. Abdominal ultrasound  
B. Colonoscopy  
C. Abdominal x-ray  
D. Sigmoidoscopy  
E. CT scan of abdomen

38. A 43-year-old female with a history of Crohn disease presents to the ED with a 4-hour history of left flank pain radiating to her left groin. The pain was sudden in onset but was mild at first. However, it has been increasing in severity over the
past 2 to 3 hours. The pain is now constant and excruciating. It was associated with nausea and vomiting, but the patient denies fevers/chills. She denies seeing any gross blood in his urine. Medical history is insignificant. Vital signs are as follows: Temperature = 98.1°F, RR = 24, BP = 148/88, pulse = 93. On physical examination, the patient is in obvious distress, writhing in pain. She has marked tenderness along the left flank, but the examination is otherwise unremarkable. Urinalysis reveals 2+ heme. Urine sediment reveals no casts but many RBCs and few WBCs per HPF. Laboratory tests reveal the following: WBC 8.2, Hgb 11.9, Hct 36.1, BUN 14, Cr 0.9. A urine pregnancy test is negative. What is the most likely diagnosis?

A. Pyelonephritis
B. Nephrolithiasis
C. Appendicitis
D. Ectopic pregnancy
E. Pancreatitis

39. A 39-year-old female is brought to the ED by her husband with the chief complaint of acute SOB and anxiety that started suddenly 2 to 3 hours ago while she was working around the house. Last night she drank seven glasses of wine with her husband. She denies chest pain. Her PMH is unremarkable, however she uses diuretics to help “prevent bloating.” She also takes oral contraceptives. Vital signs are: Temperature = 99.1°F, RR = 34, BP = 148/90, pulse = 100. Oxygen saturation is 94% on room air. On examination, the patient appears healthy although in moderate respiratory distress. Her examination is otherwise unremarkable. Laboratory tests reveal: WBC = 7.1, Hgb = 12.2, Hct = 37.3, Na⁺ = 138, K⁺ = 4.7, Cl⁻ = 109, HCO₃⁻ = 25, BUN = 14, Cr = 0.9, glucose = 106. ABGs are obtained and reveal: pH = 7.52, HCO₃⁻ = 20, PaCO₂ = 26, PaO₂ = 70. CXR and ECG are normal. Which of the following is the etiology of her acid–base disturbance?

A. Accumulation of unmeasured anions due to hepatic metabolism of alcohol
B. Vomiting due to alcohol toxicity
C. Hyperventilation secondary to anxiety
D. Electrolyte imbalance due to diuretic use
E. Hypoventilation from respiratory depression due to alcohol intoxication

90. A 63-year-old male is brought to the ED by his wife for altered mental status. The patient regularly drinks alcohol and has a long-standing history of alcohol use. Over the past 24 hours, he has become more confused and is not “acting like himself” according to his wife. She states that he has never acted like this before. On further questioning, the patient had an episode of massive hematemesis last year that required admission to the hospital, necessitating blood transfusion and
other treatment that the wife does not recall. On physical examination, the patient is arousable and is alert to person but not to place or time. He is cachectic, with prominent veins over his abdomen. He has a significant ascites. There are several dilated superficial arterioles scattered throughout his body. When the patient extends his arms out in front of him, a jerking movement of the limbs is observed. Which of the following is the most appropriate next step in management?

A. Furosemide  
B. Thiamine  
C. Lactulose  
D. Morphine  
E. Hydromorphone

91. A 65-year-old obese female presents to your office with a chief complaint of low back pain and bilateral knee pain that is worse with activity and relieved by rest. She has had this pain for 6 or 7 months. She denies any recent trauma or any event that she recalls precipitating the pain. One year ago she suffered a distal radius fracture when she tripped in her bedroom and landed on her outstretched left arm. Medical history is significant for HTN, for which she takes hydrochlorothiazide. She smokes approximately 12 cigarettes per day and has a 25-pack-year history of smoking. She denies any alcohol use. She does not exercise. On physical examination, she has no radicular symptoms, and the straight-leg test is negative. What is the appropriate next step in managing this patient?

A. Intra-articular corticosteroid injection  
B. Acetaminophen  
C. Naproxen  
D. Allopurinol  
E. Observation

92. A 46-year-old male presents to your office with the complaint of fatigue for the past 2 months. He does not abuse alcohol. His medical history is significant for HTN, for which he takes metoprolol. He denies melena, hematochezia, or any other blood loss. His family history is noncontributory. He has no symptoms other than fatigue. He admits he does not have a good diet. Vital signs are: BP = 135/85, pulse = 70. Physical examination is unremarkable except for mild pallor. Stool is negative for occult blood. Laboratory test results are: Hb = 9.2, Hct = 27.6, MCV = 117. ECG is normal. The patient is started on folic acid and 4 weeks later presents with a hemoglobin level of 10.1 mg/dL. However, he reports a new “pins and needles” sensation in his distal toes and fingers. Which of the following is the underlying cause of the patient’s current symptoms?

A. Inadequate treatment with folic acid
B. Iron deficiency
C. Glucose intolerance
D. Vitamin B₁₂ deficiency
E. Peripheral neuropathy from diabetes mellitus

93. A 41-year-old female with history of hypertension presents to your office for a routine checkup. She is new to your office as she recently moved and presents to establish care. She takes blood pressure medications but cannot recall the names. On today’s visit, her BP is 142/96. She is asymptomatic except for leg swelling. Physical examination reveals bilateral edema of the lower extremities. She smokes one pack of cigarettes per day and has a 20-pack-year history. Family history is negative. Her total serum cholesterol concentration is 175 mg/dL and HDL is 40 mg/dL. Routine laboratory test results are within normal limits. Which medication is most likely responsible for the patient’s complaint?
A. Amlodipine
B. Metoprolol
C. Hydrochlorothiazide
D. Metformin
E. Glipizide

94. A 73-year-old male is brought to the ED in a coma. He was delivered to the ED from a nursing home and was reported by the nursing home staff to have had a seizure that lasted less than 1 minute. He was subsequently confused and soon thereafter entered a comatose state. His medical history is significant for type II DM requiring insulin, HTN, and mild CHF. In the ED, the patient is very lethargic and responds only to pain stimuli. His vital signs are stable, and CBC and electrolyte levels are normal. Serum glucose is 16 mg/dL and serum insulin is elevated. C-peptide is 0.2 ng/mL (normal range, 0.5 to 3 ng/mL). Urine sulfonylurea level is undetectable. What is the likely cause of this patient’s condition?
A. Factitious hypoglycemia from surreptitious injection of insulin
B. Insulinoma
C. Somatization disorder
D. Glucagonoma
E. Dehydration

95. A 78-year-old female presents to your office for a routine checkup. Her only complaint is burning when she urinates that she has had for several weeks. Her medical history is significant for HTN and DM. She has four children, all delivered vaginally. Medications include hydrochlorothiazide for her HTN, insulin, and a daily aspirin. She wears adult pads because she loses large volumes
of urine throughout the day and usually cannot reach the bathroom in time. Physical examination is unremarkable. Vital signs are unremarkable. Routine laboratory test results are within normal limits except for a random blood glucose level of 210. Urinalysis shows positive nitrites and bacteria. She receives oral antibiotics for a urinary tract infection. After completing the course of antibiotics, she goes on a run, and feels a “pop” above her heel that is associated with severe pain. She has pain and difficulty with plantar flexion of the affected foot. Which of the following antibiotics is most likely responsible?

A. Trimethoprim-sulfamethoxazole  
B. Metronidazole  
C. Tobramycin  
D. Ciprofloxacin  
E. Azithromycin

96. A 33-year-old female presents to your office with the complaint of insomnia and difficulty concentrating at work for several weeks. She reports a 20-lb weight loss over the past 2 to 3 months, despite eating more. When questioned, she reports that she frequently feels “hot and sweaty” at work and at home. She denies chest pain or palpitations but does have diarrhea frequently. Vital signs are: Temperature = 98.9°F, RR = 15, BP = 130/80, pulse = 98. She appears worried. On physical examination, she has warm and moist skin. She has a slight hand tremor. On palpation of her thyroid, you note a diffusely enlarged thyroid gland that is nontender. Which of the following is the best next step in management?

A. Free T4 levels  
B. Thyroid-stimulating hormone (TSH) levels  
C. Thyroglobulin levels  
D. Radioactive iodine uptake (RAIU) scan  
E. A fine-needle aspiration (FNA) biopsy

97. A 26-year-old medical student is injured via needle stick while drawing blood from a patient with chronic hepatitis B. The patient received his final hepatitis B vaccination of the series 7 years ago. The patient had his titers checked before clinical rotations 6 months ago and was found to be positive for anti-hepatitis B surface antibodies (HBsAbs). Which of the following is the best next step in the management of this patient?

A. Hepatitis B immunoglobulin (HBIG) now  
B. Serologic testing for HBsAg  
C. Hepatitis B vaccination  
D. Reassurance

98. A 71-year-old female is brought to the ED by her husband for increased confusion
over the past 3 days. The husband reports that the patient fell 4 days ago and immediately after the fall she was asymptomatic but over the ensuing days has become lethargic and more confused. PMH is significant for hyperlipidema. She underwent a right total hip replacement 5 weeks ago and was diagnosed with a DVT 2 weeks after the operation. Medications include warfarin and atorvastatin. Two weeks ago, her INR was 2.7. On examination, patient has slurred speech and appears confused. She is oriented to person but not to place or time. Neurologic examination is normal. The remainder of physical examination is normal. A head CT is ordered which confirms the diagnosis. Which of the following is the etiology of this patient’s condition?

A. Tearing of the middle meningeal artery
B. Tearing of the bridging veins
C. Ruptured aneurysm
D. Hypertensive hemorrhage
E. Alzheimer disease

99. A 66-year-old male is brought to your office by his wife with complaint of productive cough, fever, and chills for the past 2 days. The patient lives with his wife and is retired. PMH is significant for DM, for which he takes insulin; CHF, with an ejection fraction of 40%; and a history of renal insufficiency. He is alert and oriented. There is no history of smoking or alcohol use. On physical examination, the patient is lethargic. He has crackles over the left lower lung. Cardiovascular examination is normal. Vital signs are: Temperature = 103.3°F, BP = 82/54, HR = 128, RR = 24. Oxygen saturation on room air is 97%. CXR shows infiltrates and consolidation in the left lower lobe of the lung. Laboratory test results show WBC 15, hematocrit 36, Na 142, glucose 167, BUN 36, creatinine 1.5. Lactate is elevated. What is the likely diagnosis in this patient?

A. Cardiogenic shock
B. Pulmonary embolism
C. Sepsis
D. Severe sepsis
E. Septic shock

100. You are called to see a 69-year-old male with acute SOB. Vital signs are: Temperature = 100.1°F, BP = 166/88, pulse = 130, RR = 33. You rush to see the patient and on your arrival, oxygen saturation is 79% on a 100% oxygen nonrebreather face mask. The nurse informs you that his oxygen saturation was 68% on room air. He currently has heavily labored breathing and appears cyanotic. The nurse informs you that the patient was admitted 2 days ago for a severe COPD exacerbation. You decide to emergently intubate the patient. Which of the following will reduce the risk of developing pneumonia in this patient?
A. Place the patient in a supine position
B. Avoid daily attempts to wean the patient from the ventilator
C. Administer oral chlorhexidine solution twice daily
D. Administer daily omeprazole
E. Avoid any instrumentation of the airway, including endotracheal suctioning
1. **Answer: E. Small cell carcinoma.** The patient most likely has small cell carcinoma given the main risk factor of a strong smoking history, a mass located in the central/proximal airways and the weakness suggestive of paraneoplastic Lambert–Eaton syndrome. Other associated paraneoplastic syndromes with small cell include Cushing’s and SIADH.

   Bronchial carcinoid is not clearly associated with smoking or Lambert–Eaton, although usually presents as a central/proximal lesion. Large cell carcinoma is not associated with Lambert–Eaton. Squamous cell carcinoma is not associated with Lambert–Eaton but is typically a central lesion; this lung malignancy is also the most likely lung cancer associated with paraneoplastic hypercalcaemia.

2. **Answer: D. Obtain contrast-enhanced CT of the abdomen.** The patient is presenting with typical signs/symptoms of acute diverticulitis—fever, leukocytosis, LLQ location of pain. Further suggestion is made by the fact that the patient had a prior episode of rectal bleeding, likely from underlying diverticulosis. CT scan will help not only confirm the diagnosis but also to rule out other processes and assess for any complications of diverticulitis.

   Checking the serum lactate will help assess for ischemia but will not help you confirm the diagnosis of diverticulitis. Retroperitoneal ultrasound will assess for hydronephrosis and pyelonephritis but urinalysis/chemistry are normal and there is no suggestion of obstruction/infection regardless of his history of renal stones. Colonoscopy would be contraindicated in a patient with acute diverticulitis because of the risk of perforation. Proceeding to the operating room would be premature unless the patient had surgical indications such as fistula, stricture, large abscess, or perforation related to the diverticulitis.

3. **Answer: B. Heparin.** IV UFH (unfractionated heparin) and subq LMWH are shown to decrease mortality in UA/NSTEMI. In addition, statins, ASA, β-blockers are shown to do so as well. ACE inhibitors have evidence of benefit and are recommended prior to discharge.

   Alteplase is NOT indicated for UA/NSTEMI but ONLY for STEMI when PCI is not available. Hydralazine, furosemide, and digoxin offer no mortality benefit in this setting either.

4. **Answer: C. Aspirin.** Aspirin is shown to reduce recurrent stroke and to decrease mortality and should be administered within 48 hours.
Insulin is not necessary as the level of glucose elevation is not contributing to the current presentation; in fact, aggressive glycemic control is associated with worse outcomes. Heparin has not been shown to improve outcomes and is not recommended as an acute treatment for ischemic stroke. Alteplase can be considered but only for significant deficits when the patient presents within 3 hours of symptom onset and has no contraindications; this patient presented too late for this to be a treatment option. Labetalol would not be used despite the elevated BP as permissive hypertension is allowed in the setting of an acute ischemic stroke; BP up to 220/120 mm Hg is generally tolerated initially.

5. **Answer: E. Methylmalonic acid.** The other answers will help narrow down your differential but will not definitely give your diagnosis. The patient has a gastrectomy and thus loss of intrinsic factor leading to impaired absorption of \( B_{12} \). The neurologic symptoms are a result of this deficiency and the fatigue/pallor are related to macrocytic anemia. Laboratory assessment of \( B_{12} \), methylmalonic acid, or homocysteine would all be useful to confirm deficiency; however, homocysteine is also elevated in folate deficiency and thus not as specific. Folate level could help confirm a deficiency in this vitamin which does cause a macrocytic anemia but this deficiency is not associated with neurologic deficits; in addition, folic acid is absorbed in the small intestine not the stomach. CBC with mean corpuscular volume may help confirm macrocytic anemia but this is not always present with \( B_{12} \) deficiency; in addition, there are multiple causes of macrocytosis and anemia and this will not confirm his diagnosis. Intrinsic factor Ab is present in pernicious anemia; it is not a sensitive test but regardless, a positive test would not confirm the cause of his symptoms. MRI lumbar spine has nonspecific findings in \( B_{12} \) deficiency; it may help assess for central/foraminal stenosis but without back pain this is unlikely and would this test would not assess his pallor/anemia.

6. **Answer: D. 24-hour urine-free cortisol.** The patient likely has Cushing syndrome given the constellation of weight gain, striae (without prior history of pregnancy), new-onset diabetes, hypertension, and vertebral compression fracture indicative of osteoporosis. The diagnosis of Cushing syndrome requires that at least two of the three first-line tests are positive. These include a 24-hour urine-free cortisol level, a low-dose dexamethasone suppression test, or a late night salivary cortisol level.

Serum ACTH is not used for screening and is only helpful in determining the etiology once the diagnosis of Cushing syndrome has been made. It helps establish ACTH-dependent from ACTH-independent etiologies, narrowing the differential diagnosis and subsequent evaluation. MRI brain and CT abdomen may help identify pituitary adenoma and adrenal adenoma, respectively, but this
test is premature at this point as the diagnosis of Cushing syndrome has not yet been confirmed. CRH stimulation test is only used once hypercortisolism has been established and ACTH is elevated as it helps distinguish Cushing disease versus ectopic ACTH production.

7. **Answer: B. Normal saline.** The patient is presenting with an inferior MI as evidenced by the location of the ST elevations on ECG. Because the patient also has bradycardia and hypotension he also has evidence of an associated right ventricular MI, which is strongly associated with inferior wall MIs and importantly is treated much differently than a left-sided MI. The diagnosis can be confirmed with a right-sided ECG, which would show ST elevations in V3R-V6R. It is important to remember that hemodynamic instability can result from increased vagal tone and sinus node dysfunction. The patient is preload dependent and IV fluids are indicated and will increase the patient’s systemic blood pressure. Treatment with ASA, fibrinolysis versus PCI, heparin are all indicated as well.

   Nitroglycerin will decrease preload and worsen the patient’s hemodynamics. Furosemide is not indicated as the patient has no signs of fluid overload and diuresis will decrease preload. Patient is already showing signs of hemodynamic instability and metoprolol will cause further bradycardia and hypotension. Morphine may cause vasodilation and further hypotension.

8. **Answer: D. Sodium bicarbonate.** The patient has evidence of an anion gap metabolic acidosis (HCO₃⁻ is decreased and AG is 15) as well as a respiratory alkalosis (CO₂ is decreased) consistent with salicylate toxicity. This involves using Winter’s formula and the expected PCO₂ in this example is 31 ± 2; however, the actual PCO₂ is 25 confirming there is a respiratory alkalosis as well. Treatment options include alkalization of urine and hemodialysis.

   Fomepizole is indicated for methanol or ethylene glycol toxicity; however neither of these would also cause respiratory alkalosis. Albuterol will treat a COPD exacerbation although this usually leads to retention of CO₂ from inability to expire sufficiently and respiratory acidosis would be the dominant finding in that scenario. Insulin will help treat DKA if that was the underlying diagnosis but ketones are not mentioned thus assumed to be negative and not treating salicylate toxicity in a timely fashion will be detrimental.

9. **Answer: E. Colonoscopy.** The patient has not had colorectal cancer screening and this would certainly be indicated at this time given his age (>50). Initial choices for screening include FOBT, flexible sigmoidoscopy, or colonoscopy. In this example, the patient had a positive screening test and requires a colonoscopy as it will allow full visualization of the entire colon for diagnostic and therapeutic (biopsy if needed) purposes.
Flexible sigmoidoscopy will miss more than half of the colon and therefore is not the best answer. Digital rectal examination has no role as it will not be sensitive enough to check anything but the rectum. Video capsule endoscopy is not the best next step; it will allow visualization of the entire GI tract but will not allow for biopsy if needed. CT colonography will not be sensitive enough to detect small lesions and again will not allow for intervention of necessary.

10. **Answer: A. IV omeprazole.** The patient likely has an upper GI bleed as evidenced by epigastric abdominal pain, melena, and labs showing an elevated BUN:Cr ratio of 25 in the setting of ASA use. Acid suppression and upper endoscopy (EGD) are the indicated interventions.

   IV octreotide is not indicated as the patient has no signs of liver disease to suggest esophageal varices as the cause of bleeding. Platelet transfusion will not reverse the effect aspirin has had on platelets and the platelet level presented is not low enough to lead to bleeding. RBC transfusion is not necessary as the patient is hemodynamically stable and the Hgb is not low enough that the patient is symptomatic. Normal saline is not necessary as the patient is already hypertensive and does not have hypovolemia.

11. **Answer: E. 24-hour urine protein.** The patient has ascites in the setting of a low SAAG (<1.1 g/dL) indicating the etiology is not portal hypertension, and low ascitic protein (<2.5 g/dL) indicating low protein overall. The expected diagnoses would be severe malnutrition or protein-losing disorder such as nephrotic syndrome; thus, 24-hour urine protein is the most appropriate test.

   Echocardiogram would be helpful if the patient had hepatic congestion in the setting of elevated SAAG and elevated ascitic protein. Pelvic ultrasound to assess for potential ovarian malignancy would be indicated if patient had low SAAG and elevated ascitic protein. Liver biopsy would be helpful to assess for causes of cirrhosis if patient had elevated SAAG and low ascitic protein. PPD would be indicated if patient had low SAAG and elevated ascitic protein.

12. **Answer: B. IVIG.** The patient is presenting with an ascending paralysis, absent reflexes, and albuminocytologic dissociation consistent with a diagnosis of Guillain–Barré syndrome in the setting of a preceding diarrheal illness. IVIG and plasmapheresis are the recommended treatments.

   Prednisone is not recommended as steroids have not shown benefit. Ciprofloxacin is not indicated as there are no signs of infection; there are many precipitating illnesses that can trigger this disorder. Pyridostigmine would be indicated in myasthenia gravis. Botulism antitoxin would be beneficial if the patient has symptoms suggestive of botulism, a DESCENDING paralysis.

13. **Answer: E. Ristocetin cofactor activity.** The patient is presenting with
mucocutaneous bleeding suggestive of von Willebrand disease. vWD is an autosomal dominant disorder and can be associated with factor VIII deficiency, sometimes manifested by an increased PTT level. Ristocetin testing is the only test mentioned that assess platelet aggregation.

Fibrinogen levels can be low in DIC but these patients are usually acutely ill and PT/PTT would also be elevated. Coombs testing will assess for causes of anemia but not for bleeding; in addition, billirubin is normal suggesting against hemolysis. Factor IX level would be testing for hemophilia B but this is X linked recessive so unlikely to see in successive generations of females; in addition, hemarthrosis or hematomas would be more prominent. Mixing study is not indicated as the PT/PTT times are normal so unlikely to have a factor deficiency.

14. **Answer:** E. Lumbar puncture. The patient has acute headache in “thunderclap” fashion and subarachnoid hemorrhage is the worrisome consideration. CT brain showed no hemorrhage but LP would be the next step to evaluate for RBCs/xanthochromia and for increased opening pressure.

Sumatriptan would be used for migraines but symptoms are not suggestive and ruling out SAH is necessary. MRI brain may have comparable sensitivity to CT scan but regardless a negative scan demands a lumbar puncture for definitive evaluation. Cerebral angiogram will be useful once SAH is confirmed, but is invasive and will not be the next step. CT brain with contrast is unlikely to visualize a small aneurysm and is not the next step.

15. **Answer:** A. Smoking cessation. She has evidence of obstructive pulmonary disease as indicated by her FEV$_1$/FVC ratio <0.70. Not only will smoking cessation decrease the rate of decline in lung function it has also been shown to decrease mortality.

Tiotropium inhaler and fluticasone inhaler are likely to decrease her symptoms but will have no effect on mortality. Oxygen therapy has been shown to decrease mortality but is only indicated if O$_2$ saturation is 88% or below, otherwise if 89% and evidence of cor pulmonale, pulmonary hypertension, or elevated hematocrit. Azithromycin would be indicated for a COPD exacerbation if a bacterium was thought to be the cause but there is no suggestion of infection in the provided scenario.

16. **Answer:** B. Wisdom tooth extraction. Endocarditis prophylaxis requires a high-risk situation PLUS a qualifying procedure which is high risk for bacteremia and resultant endocarditis. According to the 2008 AHA guidelines, antibiotic prophylaxis is recommended for the following cardiac conditions: certain congenital heart diseases, a history of infective endocarditis, valve disease in a heart transplant patient, and a prosthetic valve. Thus, this patient should receive prophylaxis since he has a prosthetic valve and is undergoing a dental procedure.
Colonoscopy, EGD, as well as GI procedures in general do not require prophylaxis. Bronchoscopy only requires prophylaxis if mucosa will be broken, such as with biopsy. Dilatation ureteral strictures as well as GU procedures in general do not require antibiotics solely for the purpose of endocarditis prophylaxis.

17. **Answer:** A. **SPEP (serum protein electrophoresis).** The patient is presenting with a pathologic fracture indicating that there is weakening of the underlying bone prior to a low impact injury. Given the laboratory findings (hypercalcemia, normocytic anemia, renal failure, and low anion gap) it is most suggestive of the patient having multiple myeloma; thus, SPEP would be the ideal test to confirm.

Bone scans detect osteoblastic activity and can be falsely negative in myeloma. PTHrP is cancer related of which there is no suggestion of a separate primary malignancy; in addition, this would explain only the hypercalcemia. PTH elevation in hyperparathyroidism would explain only the hypercalcemia. DEXA would be useful if evaluating for osteoporosis but cortical bone was described as normal in density thus this is unlikely, and the injury was most likely related to a lytic lesion at the site of fracture.

18. **Answer:** E. **TSH.** The patient has symptoms suggestive of hypothyroidism (bradycardia, fatigue, weight gain, hair loss) and TSH is the best initial screening test.

US thyroid is not necessary when the physical examination is normal. TPO would help confirm Hashimoto’s as a potential cause of hypothyroidism but would not help confirm hypothyroidism itself as patients may have elevated antibodies but normal thyroid function. Thyroid uptake scan would be more helpful in evaluating hyperthyroidism, such as thyroiditis or Graves disease. FNA is only indicated if a patient has a nodule with size or features worrisome for malignancy and in need of tissue diagnosis.

19. **Answer:** A. **Follow-up CT chest.** The patient has an indeterminate nodule discovered incidentally and this requires further follow-up. The patient is low risk (<5%) as evidenced by her lack of smoking history and young age. CT scan would be the most appropriate follow-up (Fleischner guidelines and ACCP guidelines). Of note, if the patient clearly has benign properties such as popcorn calcification suggesting hamartoma no further follow-up is required.

Bronchoscopy and needle biopsy would be indicated if the patient had an intermediate/high malignancy risk, it was enlarging or the patient desired a tissue diagnosis. CXR would not be sensitive enough to follow changes in size. PET-CT scan would also be indicated if there is intermediate/high risk of malignancy.

20. **Answer:** D. **Atropine.** The patient has symptomatic bradycardia with
hypoperfusion leading to her symptoms; she requires increase in heart rate to maintain cardiac output and atropine is the only choice that would be able to provide this. If this medication was ineffective then epinephrine, dopamine, or transcutaneous pacing would all be alternative treatments.

Echocardiogram will not help treat the patient in the acute setting as the patient demands urgent intervention; obtaining this test will only delay treatment. Nitroglycerin can be used for chest pain in the setting of angina to cause vasodilation, but will cause worsened hypotension and is contraindicated in this patient. ICD is a consideration for this patient for long-term primary prevention of VF/VT given her sustained decreased EF; however, it is not an acute treatment for the patient’s life-threatening condition.

21. **Answer: E. Omeprazole.** His symptoms are suggestive of gastroesophageal reflux with a component of laryngeal reflux as well. Treatment failure is not considered until there have been at least several months of scheduled PPI use; he is currently only using as needed. PPIs are more effective than H₂ blockers and if a patient fails empiric treatment then one can consider workup for other causes of his symptoms.

    *H. pylori* antigen would be useful if evaluating for abdominal pain if gastritis/ulcers were the suspected diagnoses. EGD would be indicated if patient was following lifestyle changes and taking scheduled PPI but having no relief in symptoms, or if he had alarm symptoms (melena, anemia, weight loss, or dysphagia). pH monitoring can also be used for refractory symptoms after appropriate empiric therapy. Gastrin level would only be indicated if evaluating for suspected gastrinoma or with multiple gastroduodenal ulcers.

22. **Answer: A. EGD with small bowel biopsy.** The patient has chronic symptoms suggestive of celiac sprue (iron deficiency, transaminitis, anemia, and dermatitis herpetiformis). There is also an association with psychiatric issues with celiac sprue. TTG serology would be reasonable and duodenal biopsy is necessary for confirmation.

    Colonoscopy would not be able to evaluate for a diagnosis of celiac sprue. Loperamide may help diarrhea but will not address the underlying cause of her symptoms and is therefore not the best answer. Sertraline would not help in diagnosing or treating her condition; there is a link of IBS with mood disorders but IBS is a diagnosis of exclusion and only considered when labs/examination is normal. Skin biopsy may confirm dermatitis herpetiformis but small bowel biopsy would still be needed for the diagnosis of celiac sprue, as one may have this skin condition without having sprue.

23. **Answer: B. Spironolactone.** The patient has stage IV systolic heart failure and spironolactone is shown to decrease mortality in these patients as it is
cardioprotective. β-Blockers, ACE inhibitors, and ICDs are also shown to decrease mortality in patients with systolic heart failure.

Isosorbide dinitrate and hydralazine are shown to decrease mortality in class III/IV heart failure in African Americans but this patient is Caucasian and not expected to receive that same benefit. Digoxin and furosemide do not decrease mortality in any heart failure patients.

24. **Answer: D. Inhaled albuterol prn.** The patient has classic symptoms of exercise-induced bronchoconstriction and would benefit from pre-exercise inhaler usage to prevent symptoms. It is important to remember that PFTs may be normal between episodes when the patient is asymptomatic; a challenge may be needed to objectively evaluate the bronchoconstriction.

CXR is not necessary as the lung examination is clear and she has no symptoms at baseline. Inhaled fluticasone is not the best answer as the patient only has intermittent symptoms related to activity, not any symptoms between episodes to suggest chronic asthma. Reassurance is not appropriate as the patient clearly has symptoms that limit her lifestyle and are causing airway constriction. Inhaled salmeterol is not appropriate as the patient has no baseline symptoms between episodes; in addition, treatment of asthma with LABA alone, without cotreatment with corticosteroids, is associated with increased mortality.

25. **Answer: D. No treatment.** It is not recommended to screen for asymptomatic bacteriuria as treatment does not offer benefit but does include potential harm from side effects, etc. The only population in which to screen and treat asymptomatic bacteriuria is pregnancy.

Nitrofurantoin would be the drug of choice for a patient with uncomplicated cystitis. Ciprofloxacin and TMP-SMX would be considerations for cystitis or for pyelonephritis. Repeat urinalysis and culture would not be indicated as screening and treating asymptomatic patients does not offer clinical benefit.

26. **Answer: B. IV hydrocortisone.** The patient is presenting with acute adrenal insufficiency and this is a medical emergency. The patient must be adequately resuscitated with aggressive IV normal saline in addition to replacement of corticosteroids. The most likely cause for the patient’s adrenal insufficiency is her long-term use of corticosteroids and inadequate response in the setting of her acute illness.

Cortisol level can be checked but medical treatment is the most important intervention and is mandatory. CT adrenal glands and MRI pituitary are unlikely to yield further information regarding the diagnosis in the patient; in addition, they would be inappropriate as they would delay the treatment of the patient and lead to higher morbidity/mortality. Cosyntropin stimulation test can be used to confirm the diagnosis of adrenal insufficiency but should NOT delay treatment;
dexamethasone could be used if the diagnosis is in question as it will not interfere with interpretation of this test.

27. **Answer: A. CT angiography.** The patient has pain out of proportion to examination in the setting of atherosclerotic risk factors for thrombosis as well as atrial fibrillation with a subtherapeutic INR which would be risk factors for embolism; the most likely diagnosis is acute mesenteric ischemia and CT angiography would be helpful in confirming this diagnosis.

   Gastric emptying study would be helpful in evaluating for gastroparesis which the patient is at risk for with uncontrolled DM; however, this patient is presenting with acute abdominal pain and not consistent with that diagnosis. EGD and colonoscopy would help evaluate for many causes of abdominal pain but will delay the time to diagnosis of mesenteric ischemia which is needed urgently to prevent infarction/necrosis. Vitamin K will reverse warfarin in the setting of the patient’s bleeding but given the scenario suggestive of mesenteric ischemia and stable hemodynamics (INR is also therapeutic) this is not indicated and anticoagulation will be used if thrombosis/embolism is confirmed.

28. **Answer: E. Ibuprofen.** NSAIDs are the mainstay of treatment for acute pericarditis. Colchicine can be added to this regimen for added benefit.

   Coronary angiogram is not indicated as there are no focal ST elevations or wall motion abnormalities suggestive of an acute MI. Drainage of pericardial effusion is only indicated in large effusions causing hemodynamic compromise or for diagnostic purposes. Prednisone is not indicated unless the patient fails NSAIDs or has contraindications to receiving them. Azathioprine would only be used if the patient had recurrent pericarditis and was unable to wean off of steroids.

29. **Answer: C. Chest tube insertion.** It is important to recognize that the above patient is presenting with a symptomatic pneumothorax, in this setting related to his underlying COPD and likely bleb rupture. CXR can confirm the diagnosis but this can also be made clinically. Supplemental oxygen would be appropriate followed by needle aspiration or chest tube insertion to remove air from the pleural space.

   Albuterol–ipratropium nebulizer and prednisone would help treat COPD exacerbation but this is not the diagnosis presented. Azithromycin would not be the best answer as there is no suggestion of infection in this patient. Pleurodesis is only indicated if there are recurrent pneumothoraces.

30. **Answer: D. Warfarin.** The patient has valvular atrial fibrillation and a CHADS2-VASc score of 4, thus warranting systemic anticoagulation. Warfarin is indicated and the most appropriate choice.

   Aspirin is not adequate as warfarin has superior efficacy in stroke prevention in
comparison to aspirin. Dabigatran is one of the newer oral anticoagulants that could be considered as an alternative to warfarin but it is only used in the setting of nonvalvular afib; this patient has evidence of mitral stenosis on examination and this is the presumed cause of his atrial fibrillation. Clopidogrel is inferior to warfarin for stroke prevention in the setting of atrial fibrillation. Fondaparinux is used in treatment/prophylaxis for DVT, not for afib stroke prevention.

31. **Answer: B. Aortic valve replacement.** The patient has symptomatic aortic stenosis which is an indication for surgery. Nitroglycerin would be indicated if his symptoms were related solely to atherosclerotic disease; however, vasodilation may worsen his systemic blood pressure. Aspirin will prevent further atherosclerotic disease but will not fix his valvular disease. Carotid Doppler will assess for carotid stenosis; however, the murmur heard in the neck is referred from the aortic valve. Coronary artery bypass grafting is sometimes done at the same time as a valve replacement if significant atherosclerotic disease is present; however, he has very mild disease on prior angiogram and this is not indicated.

32. **Answer: B. Physical therapy.** The diagnosis here is patellofemoral pain syndrome and PT is the most appropriate intervention. Corticosteroid injection would be unlikely to be helpful as the cause of pain is not intra-articular; she does have an underlying autoimmune disease but there is no effusion and markers do not show significant inflammation to heighten suspicion of SLE as the cause. Knee arthroscopy and MRI knee are also unwarranted at this time given the normal examination and lack of trauma to suggest meniscal or ligamentous injury. Ibuprofen is contraindicated given CKD.

33. **Answer: E. Lisinopril.** The patient has a new diagnosis of type 2 diabetes and requires not only control of his glucose but also treatment for complications related to his disease. An ACE inhibitor or ARB would be indicated for hypertension, CKD, or microalbuminuria and thus lisinopril is the best answer. Hydrochlorothiazide is not the best answer as it does not have renoprotective features that ACE inhibitors do; in addition, efficacy decreases as GFR decreases. Insulin is not necessary given relatively controlled A1c and lack of a lifestyle intervention trial yet. Pioglitazone is contraindicated in setting of CHF. Metformin is contraindicated with CKD.

34. **Answer: E. Biopsy hilar adenopathy.** The patient’s clinical picture is consistent with possible sarcoidosis. Tissue biopsy showing noncaseating granulomas along with ruling out other diseases is essential for the diagnosis. One of the major risk factors of sarcoidosis is being African American.

    Serum calcium will be elevated in a subset of sarcoid patients but this is not
sensitive enough to make the diagnosis. CT chest will yield more information in regard to lung imaging but will not confirm a diagnosis. ACE level is not sensitive enough to confirm a diagnosis. Biopsy of a leg lesion which is easily accessible will reveal inflammation as the patient has findings consistent with erythema nodosum; however, this will NOT show noncaseating granulomas so this will not confirm a diagnosis of sarcoid.

35. **Answer: B. Initiate fluid restriction.** The patient is euvoletic and has lung cancer, low serum osmolality, and high urine osmolality all suggestive of SIADH as the cause. He has very mild symptoms and can be managed with fluid restriction and increased salt intake.

   Administering IV normal (0.9%) saline is not the appropriate answer as sodium will be excreted but water will be retained; thus, worsening hyponatremia. Initiating hemodialysis is not appropriate as the patient has minimal symptoms, has not failed other therapies, and because it is invasive. Administering hypertonic (3%) saline is not necessary as the patient has minimal symptoms; if the patient had more severe symptoms such as confusion, lethargy, nausea, or vomiting this would be appropriate. Administering hydrochlorothiazide is not correct as this medication itself is a cause of hyponatremia; loop diuretics such as furosemide can be used to correct sodium levels in SIADH.

36. **Answer: D. Antistreptolysin titer.** The patient is presenting with hematuria in the setting of a recent infection and the most likely diagnosis is poststreptococcal glomerulonephritis. Antistreptolysin titer can help confirm recent strep infection.

   ANCA is unlikely to be helpful as the patient does not have other symptoms suggestive of a systemic vasculitis. Anti-GBM is also unlikely to assist in the diagnosis as the patient has no other symptoms to suggest Goodpasture’s and the time course fits best with PSGN. HIV is associated with renal disease, most specifically collapsing variant of FSGS but this is nephrotic in presentation. IgA levels are unnecessary as serum IgA levels are not useful in the diagnosis of IgA nephropathy; in addition, the glomerulonephritis associated with IgA deposits happens much quicker after the infection, usually within several days.

37. **Answer: E. SLE.** This patient has multiple symptoms and examination findings consistent with a likely diagnosis of SLE—oral ulcers, malar rash, arthritis, edema suggestive of renal impairment, as well as hematologic abnormalities.

   Osteoarthritis is unlikely given the patient’s young age and would not explain the patient’s multiple other symptoms. Reactive arthritis usually follows a GI/GU infection and includes arthritis, urethritis, and uveitis. Behçet disease can include many symptoms, most notably oral/genital ulcerations but would be unlikely to include the classic malar rash and is very rare in the United States. Gout is possible given her use of HCTZ and potential for hyperuricemia but this would
not explain the other findings.

38. **Answer:** B. Carbidopa–levodopa. The patient is presenting with symptoms consistent with Parkinson’s and medical treatment would be recommended with dopamine agonist.

   Fluoxetine is not appropriate as the patient does not have a clinical diagnosis of depression; his psychomotor slowing alone should not be misinterpreted as depressive symptoms unless there are other symptoms such as sadness, appetite changes, sleep disturbance, or disinterest in activities. Propranolol would be beneficial in patients with essential tremor. Memantine would be indicated only if patient had moderate to severe dementia. Deep brain stimulation is invasive and would not be considered unless there were severe symptoms in which the patient had failed other medical therapy.

39. **Answer:** C. Infliximab. The patient has moderate to severe Crohn disease (anemia, abdominal tenderness, and weight loss) and demands appropriate therapy to prevent complications. Infliximab is an anti-TNF antibody that is indicated for moderate to severe Crohn disease.

   Loperamide should not be used in active inflammatory bowel disease. Azathioprine is less likely to offer control of the patient’s symptoms than infliximab; in addition, this medication takes up to 6 weeks to reach a therapeutic effect and needs to be given alongside steroids. Surgical resection is not indicated as the patient has no evidence of abscess, perforation, or fistula. Ciprofloxacin and metronidazole is more useful in mild disease and will not treat the underlying inflammatory process responsible for the patient’s symptoms.

40. **Answer:** A. Thumb spica splint. The patient has risk factors for several causes of pain related to overuse in the upper extremity but examination reveals a positive Finkelstein test which confirms a diagnosis of de Quervain tenosynovitis. This is related to a combination of repetitive motions a mechanic but also associated with caring for and lifting his grandchild. Immobilization of the thumb is the most appropriate intervention.

   Wrist splint would be helpful if the patient had carpal tunnel syndrome. Counterforce forearm brace would be helpful if patient had lateral/medial epicondylitis. Carpal tunnel corticosteroid injection is not helpful as this is not the source of his pain. Ibuprofen is contraindicated given his known chronic kidney disease.

41. **Answer:** B. Reduction of fracture. The patient has the classic triad diagnostic for fat embolism: hypoxia, petechial rash, and neurologic abnormalities. Treatment is supportive and given the source is the multiple long bone fractures; these should be repaired when the patient is stabilized.
Albuterol is not indicated as the patient has no evidence of obstruction (e.g., wheezing) as a cause for her acute decline. Furosemide is not indicated as the patient has no evidence of volume overload in the pulmonary vasculature. Levofloxacin is not indicated as there is no evidence of pulmonary infection. IV heparin will be ineffective in improving the patient’s symptoms as it cannot dissolve fat, only thrombi.

42. **Answer: A. Valsalva maneuver.** The patient has SVT likely related to AVNRT and he has no concerning symptoms. Initial attempt at termination should use vagal maneuvers such as Valsalva maneuver or carotid sinus massage.

Adenosine is very short acting and can be used if vagal maneuvers fail to terminate the arrhythmia. Metoprolol would also be considered if the above measures failed. Digoxin would also inhibit the AV node but has more potential side effects than the other medications and is rarely used for this purpose. Cardioversion would be reserved for hemodynamic instability including hypotension, heart failure, or angina.

43. **Answer: D. Hydroxychloroquine.** The patient is presenting with signs/symptoms fulfilling criteria for a diagnosis of rheumatoid arthritis. The most important intervention is DMARD therapy (disease-modifying antirheumatoid drugs), especially given the patient already has evidence of joint damage.

Prednisone, corticosteroid injections, and indomethacin will all help control symptoms but not control joint damage. Physical therapy will help improve function for the patient but without DMARD therapy her joint damage will continue to worsen.

44. **Answer: C. ERCP.** The patient has cholangitis secondary to obstructing common bile duct stone and is presenting with severe sepsis. The patient needs hemodynamic support, antibiotics, and control of the source of infection. ERCP is the next step in order to relieve the obstruction and allow drainage of the biliary system.

Cholecystectomy is recommended eventually to prevent recurrence but not in the acute setting given the high morbidity and mortality. Liver biopsy will not aid in diagnosis or treatment; the cause of transaminitis is evident. MRCP will not aid in management as the diagnosis is already confirmed. Percutaneous transhepatic cholangiography is second line to ERCP as it carries higher morbidity in regard to bleeding or peritonitis.

45. **Answer: E. No further intervention.** There is no further workup or treatment that is required at this point. The patient is in a low-risk category with no identifiable risk factors and a PPD would only be considered positive if 15 mm or greater.
AFB sputum culture is not necessary to rule out active pulmonary TB because the patient is asymptomatic and has a negative PPD test. Rifampin, isoniazid, pyrazinamide, ethambutol would be indicated only if the patient had active pulmonary TB. Isoniazid would be indicated for prophylaxis if the patient had a positive TB test without any pulmonary symptoms and a negative CXR. Chest x-ray would be indicated to screen for evidence of pulmonary TB if the PPD was positive.

46. **Answer:** B. TSH. The patient has calcium pyrophosphate dehydrate deposition disease (CPPD, pseudogout). This is confirmed by the inflammatory arthrocentesis with CPPD crystals and imaging findings showing deposition. Associated disorders include hemochromatosis, hypothyroidism, and hyperparathyroidism so labs including ferritin/transferrin/TSH/Ca are all reasonable to screen for as treatment of underlying disorder can improve symptoms.

Uric acid would be helpful in determining initial treatment for gout but this is not the underlying diagnosis. ANA and ESR are nonspecific and would not be helpful in guiding therapy. HLA-B27 is not indicated as the diagnosis of CPPD is confirmed and this will not screen for any associated disease.

47. **Answer:** A. Zoledronic acid. The patient has osteoporosis and a history of a fracture; thus, every attempt would be made to start the patient on a medication to reduce her risk of fractures. Zoledronic acid is a bisphosphonate which will reduce both vertebral/nonvertebral fractures; in addition, it is given intravenously and is most appropriate in this patient with achalasia.

Alendronate is a PO bisphosphonate and would be contraindicated given achalasia and the risk of pill esophagitis. Raloxifene is a SERM and has evidence only for reduction of vertebral fractures and would thus not be an ideal choice; in addition, it is contraindicated given the prior history of thromboembolic disease. Calcitonin is inferior to bisphosphonates and is not the correct choice. Estrogen is no longer used for management of osteoporosis given many risks, one of them DVT/PE, and this medication would be contraindicated in this patient.

48. **Answer:** D. Propranolol. The patient is presenting with thyroid storm, an endocrine emergency, and requires treatment without delay. This was likely triggered by her recent surgery. Adrenergic effects of thyroid hormone (e.g., tachycardia) as well as T4 → T3 conversion are blocked with this treatment.

RAIU at this point will delay treatment which is not appropriate given the morbidity/mortality associated with thyroid storm. Iodine is a treatment option used in thyroid storm; however, it should be given AFTER methimazole or PTU to avoid its use as a substrate for more thyroid hormone synthesis. US thyroid is also unnecessary and will delay treatment. Thyroidectomy should only be
performed once the hyperthyroidism is treated given the mortality rate associated with surgery in thyroid storm.

49. **Answer: A. CT urography.** The patient has hematuria and whether it be gross or microscopic demands further workup. Infection has been ruled out and by the fact that casts are not seen, a glomerular cause has been ruled out. To evaluate the rest of the GU tract one must perform urine cytology, cystoscopy, and CT urography. Ultrasound of kidneys will evaluate the kidneys relatively well but miss small tumors and will be less sensitive in evaluating the ureters. Renal biopsy is not indicated in this scenario as a glomerular source of bleeding is unlikely; RBC casts or dysmorphic RBCs on microscopy would be suggestive of glomerular cause. PSA and prostate biopsy are unlikely to yield a cause of the patient’s bleeding and would not evaluate the rest of the GU tract.

50. **Answer: D. Albuterol.** The patient has a diagnosis of acute bronchitis and this is most likely viral in nature. Symptoms are related to hyperreactive airways and should self-resolve in a few weeks; treatment is symptomatic. Because of the wheezing associated with his symptoms albuterol would be the appropriate choice.

Prednisone is not indicated as the patient has no underlying reactive lung disease, is not in distress, and his peak flow is normal. Oseltamivir is not indicated because the patient does not have symptoms suggestive of influenza; in addition, he is well outside the appropriate window of treatment given his risk factors. Azithromycin or any antibiotics is NOT indicated as most bronchitis is caused by viruses; antibiotics would be indicated if pertussis was suspected or pneumonia was confirmed. Sputum culture is not necessary as a viral cause is much more likely.

51. **Answer: B. Weight loss.** Most groups recommend the following lifestyle modifications for patients with hypertension: Reducing dietary sodium to less than 2.4 g per day; increasing exercise to at least 30 minutes per day (4 days per week); limiting alcohol consumption to 2 drinks or less per day for men and 1 drink or less per day for women; following the Dietary Approaches to Stop Hypertension (DASH) diet (high in fruits, vegetables, potassium, calcium, and magnesium; low in fat and salt); and achieving a weight loss goal of 10 lb (4.5 kg) or more. Of these, weight loss has shown to have the highest reduction in systolic blood pressure (reduction from 5 to 20 mm Hg) in overweight patients. (A, C, D) These three lifestyle modifications are also recommended and do have a substantial effect on reduction of systolic pressure, just not as much as weight loss does. (E) Smoking cessation should always be encouraged as part of any comprehensive lifestyle modification plan.
52. **Answer: C. Hydrochlorothiazide.** For most patients with hypertension, thiazide diuretics are the best proven first-line treatment in reducing morbidity and mortality. Thiazide diuretics are especially effective in preventing secondary cardiovascular events in patients with hypertension. (D, E) Current evidence does not support the use of β-blockers, particularly atenolol, as first-line treatment for hypertension. (A, B) Although there is increasing evidence that ACE inhibitors (lisinopril) and possibly calcium channel blockers (amlodipine) may be equivalent to thiazide diuretics in reducing morbidity and mortality, the relative expense of these medications makes thiazide diuretics an ideal first-line choice.

53. **Answer: A. Pyelonephritis.** Pyelonephritis produces flank pain, but is also suggested by fever, leukocytosis, and a urine dipstick showing infection (e.g., positive nitrites, positive leukocyte esterase). The presence of WBC casts is also seen in pyelonephritis, as is the physical examination finding of costovertebral angle tenderness (CVA) tenderness. (B) Nephrolithiasis (kidney stones) produces a colicky pain that shoots down into either groin region. It does not produce fever, leukocytosis, or urine dipstick findings suggestive of infection (however it often is positive for blood). Calcium stones are the most common type of kidney stones, and patients with these stones are encouraged to increase their dietary intake of calcium (in order to decrease oxalate absorption in the GI tract). (C) Appendicitis if a very important diagnosis to consider in young patients with abdominal pain, however does not produce positive urinalysis findings. (D) Ectopic pregnancy can often mimic the pain produced in nephrolithiasis, however this diagnosis is unlikely given the negative pregnancy test. (E) Acute interstitial nephritis (AIN) can indeed produce WBC casts in the urine, but also produces urine eosinophils. AIN is a type of intrinsic renal acute kidney injury (AKI) that produces fever, rash, arthralgias, and/or eosinophilia. The most common cause is an allergic reaction to medications.

54. **Answer: C. Nonsteroidal anti-inflammatory drugs (NSAIDs).** Back pain is a high-yield topic on the USMLE. Back pain that improves with exercise, but worsens with rest in an otherwise healthy patient lends credence to the diagnosis of ankylosing spondylitis (AS). AS is a seronegative spondyloarthropathy (rheumatoid factor is negative) that is a systemic rheumatic disease. Ninety percent of people express the HLA-B27 genotype. It is also three times more common in males than females. In addition to back pain, patients can also experience anterior uveitis causing eye redness and pain, in addition to cardiovascular and lung involvement. The first-line treatment for all seronegative spondyloarthropathies is NSAIDs but biologics and disease-modifying antirheumatic drugs (DMARDs) are effective in treating the progression of the disease. (A, B) Local heat and physical therapy are especially effective in back
pain caused by disc herniation. Disc herniation typically causes an electricity-like shooting lower back pain. (D, E) Epidural steroid injections and surgical laminectomy are typically reserved for advanced refractory back pain that does not respond to more conservative measures initially.

55. Answer: E. Nebulized albuterol for bronchodilation. This patient is likely suffering from an asthma exacerbation caused in part by his recent exposure to a viral illness. There were wheezes on examination with no urticaria or angioedema, making an anaphylactic reaction unlikely. (C) Management of an acute asthma exacerbation involves oxygen administration as well as intermittent or continuous nebulized albuterol, which is the first-line treatment. If the patient fails to respond to albuterol, then ipratropium and magnesium are additional options to promote bronchodilation. Oral corticosteroids should also be given to reduce airway inflammation during and after the exacerbation. Response to therapy can be monitored by following the SaO\textsubscript{2} as well as either the FEV\textsubscript{1} or the peak expiratory flow (PEF). Arterial blood gases may also be useful; be concerned about the finding of a normal PaCO\textsubscript{2}, which is often indicative of respiratory fatigue leading to the requirement of intubation (hypoxemia should cause hyperventilation and hypocapnia). (A) Oxygen should be administered to asthmatics with a target SaO\textsubscript{2} >90%. In COPD, the target is 90% to 94% due to the concern for the development of hypercapnia, however this is not seen in asthma. (B) This patient is unlikely to have pneumonia given that he is afebrile and has no suggestive findings of pneumonia on lung examination. (C) Subcutaneous epinephrine is useful in anaphylaxis, but has no benefit over inhaled \(\beta_2\)-agonists in asthma for bronchodilation. (D) Ipratropium is an anticholinergic and is the first-line treatment for COPD exacerbation (although albuterol is often used too); it may be used as an adjunctive therapy in asthma exacerbation, but albuterol is the first-line therapy.

56. Answer: C. Staphylococcus aureus. This patient’s clinical presentation and subsequent deterioration are consistent with a diagnosis of toxic shock syndrome (TSS), which is caused by preformed \textit{S. aureus} exotoxin, TSST-1. TSS is associated with prolonged tampon use. For the purposes of your Step, always suspect prolonged tampon use in young women. The toxin acts as a superantigen, which activates T cells leading to massive cytokine release. TSS typically presents with fever, vomiting, diarrhea, and the development of a diffuse macular erythematous rash. Complications of TSS include acute respiratory distress syndrome (ARDS), hypotension, disseminated intravascular coagulation (DIC), and hemorrhage. (A) \textit{Streptococcus pyogenes} is very rarely associated with TSS (only group A Strep species are associated with TSS), but when it is, it is not associated with tampon use. (B) \textit{Neisseria meningitidis} can certainly present with
fever and diffuse rash, however it is not associated with such a high fever or tampon use. (D) *Streptococcus pneumoniae* is a type of group B Strep species, and accordingly, does not cause TSS. (E) Rocky Mountain spotted fever presents with fever and a rash that is first apparent in the extremities and moves centrally.

57. Answer: B. Recurrent pericarditis. The chest pain and ECG are typical of acute pericarditis, which commonly presents with fever, pleuritic chest pain, new-onset pericardial effusion, and diffuse concave ST elevations on ECG. Most cases have an infectious etiology, including Coxsackie viruses, HIV, influenza, *Staphylococcus aureus, Streptococcus pneumoniae*, tuberculosis, and various fungi. Other important causes include cancer, autoimmune diseases, post-MI or cardiac surgery, radiation therapy, and uremia. All patients should be treated with NSAIDs and colchicine to improve symptoms and prevent complications. Patients who are not treated are much more likely to develop recurrent pericarditis, which is defined as a recurrence of symptoms after the inciting event (e.g., virus) has passed. (A) Pericardial effusions commonly accompany acute pericarditis, however cardiac tamponade is a rare complication. (C) Constrictive pericarditis is a possible outcome of any cause of acute pericarditis, however it is not the most common complication. (D) Free wall rupture is a complication of acute myocardial infarction. (E) Pericarditis affects the pericardium although the myocardium is sometimes affected as well. However, the rate of valve involvement and complications is low.

58. Answer: B. CT scan with contrast. This patient has pyelonephritis that likely progressed to a renal or perinephric abscess, which is indicated by the persistent fever. Patients with this complication will present with symptoms typical of pyelonephritis (fevers, chills, flank pain, abdominal pain, anorexia, nausea/vomiting), but will continue to be febrile despite treatment with appropriate antibiotics. Most cases of renal/perinephric abscesses are caused by urologic pathogens (e.g., *E. coli* and other enteric gram-negative bacilli), however *Staphylococcus aureus* is also common and arrives at the kidneys by hematogenous spread. The best diagnostic test is a CT scan of the abdomen with contrast, although a renal ultrasound can also identify many renal/perinephric abscesses. If the abscess is small (<5 cm), it can be observed with antibiotics alone; if the patient does not respond to antibiotics, or if the abscess is large (≥5 cm), both antibiotics and drainage are necessary. Antibiotic therapy should always be based on culture and sensitivity data when available, however empiric therapy for renal/perinephric abscesses is the same as for pyelonephritis. Options include a fluoroquinolone, ceftriaxone, ampicillin–sulbactam, an aminoglycoside, or antistaphylococcal antibiotics if *S. aureus* is suspected. (A) WBC casts do not necessarily indicate acute interstitial nephritis or glomerulonephritis; they may
also indicate an upper urinary tract infection such as pyelonephritis. Therefore, a renal biopsy is not the next step. (C) Failure to defervesce after treatment with antibiotics raises the concern for a complication of pyelonephritis, such as a renal or perinephric abscess, and therefore further diagnostic workup should be pursued. (D, E) The organism is sensitive to both antibiotics, so there is no benefit of changing antibiotics or stopping antibiotics.

59. **Answer:** D. Intubation. The patient in this vignette is experiencing an acute asthma exacerbation with worrisome symptoms/signs: loud wheezes, use of respiratory accessory muscles, tachycardia, tachypnea, and poor oxygen saturation. In addition, the arterial blood gas shows a normal PaCO₂ which is not a good sign; hypoxic patients should hyperventilate to maintain oxygenation, which causes hypocapnia and a respiratory alkalosis. When a patient has a normal PaCO₂, this is a sign that the patient is tiring and decompensating. Even though intubation should be avoided if possible, there is a low threshold for intubating patients that are showing signs of respiratory fatigue. (A) Increasing the oxygen flow rate might improve oxygenation, but the patient is likely starting to develop hypercapnic respiratory failure, which is due to inadequate ventilation. Once the patient is on a ventilator, ventilation is controlled primarily by adjusting the respiratory rate or tidal volume. Oxygenation can be maintained by adjusting the FiO₂ and positive end-expiratory pressure (PEEP). (B) IV corticosteroids are used in acute exacerbations but will not act immediately to prevent this patient from further decompensation. (C) Azithromycin and other antibiotics are used in acute COPD exacerbations, not acute asthma exacerbations. (E) This arterial blood gas shows a normal PaCO₂ which is not a good sign. Although nebulized albuterol is typically first-line treatment for acute asthma exacerbation, this patient is decompensating as evidenced by the arterial blood gas and intubation must be pursued next.

50. **Answer:** B. Positively birefringent rhomboid-shaped crystals. This patient has a history of parathyroid adenoma which is likely causing hypercalcemia secondary to hyperparathyroidism. Patients with hypercalcemia are at risk for developing pseudogout, a rheumatologic disease with diverse symptoms and signs arising from the accumulation of calcium pyrophosphate dihydrate crystals in the connective tissues. It commonly presents with acute onset, painful monoarthropathy of the knee. Joint aspiration with synovial fluid analysis confirms the diagnosis, showing rhomboid-shaped crystals that are positively birefringent. (A) Negatively birefringent needle-shaped crystals describe gout, which also presents with acute onset monoarthropathy, but usually affects the first metatarsophalangeal joint of the foot. Furthermore, gout is not triggered by hypercalcemia. (C, D) Neutrophil predominant synovial fluid with gram-positive
cocci is diagnostic of septic arthritis. This patient has no fever, making septic arthritis highly unlikely from the clinical picture alone. (E) Normal synovial fluid findings are not the norm in the setting of pseudogout.

51. **Answer: B. Acute retroviral syndrome.** Acute HIV infection can present in a variety of ways, but typical symptoms of the “acute retroviral syndrome” include a mononucleosis-like syndrome with fever, lymphadenopathy, headache, myalgias/arthritis, sore throat, and a maculopapular rash. Another less sensitive but more specific finding is painful, well-demarcated mucocutaneous ulcerations. Additional clues to the diagnosis in this case are the patient’s high-risk behaviors (unprotected sex, IV drug use) and negative test results for other conditions on the differential diagnosis (mononucleosis due to EBV, syphilis, and other STIs, etc.). During the acute phase of HIV infection, there may be a negative screening test (ELISA may take weeks to become positive) with high viral RNA levels. Typically, the diagnosis of HIV is made with a highly sensitive screening test (e.g., ELISA) followed by a more specific confirmatory test (e.g., Western blot). (A) The finding of diffuse nontender lymphadenopathy is more consistent with a systemic process such as a viral infection rather than Hodgkin lymphoma, which often presents with focal or asymmetric lymphadenopathy. (C) Though heterophile-negative mononucleosis due to CMV is a possibility, the findings of both a maculopapular rash and mucocutaneous ulcerations make HIV more likely (both may occur in CMV infection but are less common manifestations, and GI ulcerations usually occur in the setting of immunosuppression). (D) Secondary syphilis is less likely to have mucocutaneous ulcerations and the screening test was negative. Although false negatives are possible with RPR and VDRL tests, the constellation of findings makes HIV infection much more likely than a false-negative syphilis test. (E) These clinical findings are much more severe than typical upper respiratory infection symptoms.

52. **Answer: C. Obtain a chest x-ray; if normal, start isoniazid and pyridoxine for 9 months.** There are a couple important teaching points in this vignette. First, screening for TB is often performed with a PPD or an interferon gamma release assay (IGRA). In patients with close contact to a patient with active TB, a concerning chest x-ray, or who are immunosuppressed (via medications, HIV infection, etc.), a positive test is >5 mm. For those patients at high risk (healthcare workers, jail workers, the homeless, IV drug users, uncontrolled diabetes, chronic kidney disease, etc.), a positive test is >10 mm. And for all others without risk factors, a positive test is >15 mm. This patient has an induration of 11 mm and is a healthcare worker, therefore she warrants further workup to differentiate active from latent TB. (Note: prior BCG vaccination rarely produces an induration >10 mm as an adult, and the CDC recommends that BCG vaccination status should
not influence the workup and treatment of TB.) If the chest x-ray is negative, then the patient has latent TB and should be treated with 9 months of isoniazid and pyridoxine (vitamin B\textsubscript{6}, which helps to prevent isoniazid-induced neuropathy). Alternatively, other treatment options include isoniazid for 6 months, isoniazide and rifapentine for 3 months, or rifampin for 4 months. \textbf{(A)} Treatment of active TB is becoming complicated with MDR TB, however active TB is generally treated with a 4-drug regimen (rifampin, isoniazid, pyrazinamide, ethambutol) for 2 months followed up a 2-drug regimen (rifampin, isoniazid) for 4 months. \textbf{(B)} Because this patient is a healthcare worker, she should be treated for latent TB given the risk of reactivation and exposure to other patients. \textbf{(D)} A chest x-ray should be performed before starting treatment to differentiate latent from active TB. \textbf{(E)} Reassurance would only be appropriate if the PPD result was negative.

\textbf{53. Answer: A. Serum iron studies.} The patient in this question is presenting with a microcytic anemia (MCV <80 fL). The differential diagnosis of microcytic anemia can be remembered by the mnemonic \textit{"TAILS\textquotedblleft} (Thalassemia, Anemia of chronic disease, Iron-deficiency anemia, Lead poisoning, Sideroblastic anemia). The most common cause of microcytic anemia is iron deficiency and the best next step is ordering iron studies: serum iron, total iron-binding capacity (TIBC), and serum ferritin. In iron-deficiency anemia, serum iron is typically low, TIBC is increased, and serum ferritin is low. After iron-deficiency anemia is confirmed, the underlying cause should be determined. Iron deficiency is by far the most common cause of microcytic anemia, so a trial of iron supplementation is often performed instead of an extensive workup.

\textbf{(B)} Hemoglobin electrophoresis would be useful for diagnosing thalassemia. β-Thalassemia trait usually has reduced or absent HbA, elevated levels of HbA\textsubscript{2}, and increased HbF. Clinical manifestations generally arise very early in life. \textbf{(C)} Although lead poisoning is a cause of microcytic anemia, it is uncommon and should only be sought after iron-deficiency anemia has been ruled out. \textbf{(D)} Peripheral blood smear is often used to exclude sideroblastic anemia, but this is an uncommon cause of microcytic anemia. \textbf{(E)} Stool guaiac test should most likely have been performed on initial presentation, but this patient’s young age makes malignancy an unlikely diagnosis. Considering this patient’s already known microcytic anemia present on CBC, serum iron studies should be performed in order to evaluate the cause.

\textbf{54. Answer: C. Elevated lipase.} The patient in this question is presenting with signs and symptoms of acute pancreatitis (epigastric abdominal pain radiating to the back, nausea, and vomiting). The vast majority of cases (80\%) result from gallstones and alcohol. However, other causes of acute pancreatitis can be remembered with the mnemonic \textit{GET SMASHED} (Gallstones, Ethanol, Trauma,
Steroids, Mumps, Autoimmune, Scorpion bite, Hyperlipidemia, ERCP, Drugs [specifically diuretics, gliptins, azathioprine, salicylates, steroids]). Acute pancreatitis can be diagnosed through several modalities: physical examination demonstrating epigastric pain radiating to the back, elevated amylase and lipase levels (typically 3× higher than the normal limit), and abdominal imaging (CT) showing pancreatic enlargement with heterogeneous enhancement with IV contrast. Ultrasound is also helpful in diagnosing gallstone pancreatitis by visualizing gallstones in the gallbladder. Lipase has the greatest specificity of all possible tests and is usually more elevated than amylase in acute pancreatitis. (A) Amylase can sometimes be normal in acute pancreatitis (particularly if the etiology is hyperlipidemia). Furthermore, amylase is not specific to the pancreas as there is not only pancreatic amylase, but also salivary amylase. (B) Although elevated ALT is very useful in suggesting gallstone pancreatitis, it does not encompass all the causes of acute pancreatitis and therefore is not a specific test. (D) Positive fecal fat test is typically positive (>7 g/day) in chronic pancreatitis, however chronic pancreatitis presents with symptoms of malabsorption (as opposed to pain) and is typically due to alcohol use (neither of which this patient endorses). (E) Pancreatic calcifications are seen in chronic pancreatitis, not acute pancreatitis.

35. **Answer:** B. **Thyroid-stimulating hormone (TSH) levels.** The patient in this question is demonstrating clinical manifestations of hypothyroidism. In approaching the diagnosis of thyroid disorders, the first step is to order a TSH level. TSH is the most sensitive test to detect primary hypothyroidism and hyperthyroidism. Based on the TSH level, additional tests can be performed. (A) Free T4 is important in the diagnostic workup of thyroid disorders and should be the next test ordered if TSH comes back decreased. If free T4 is increased with a decreased TSH level, this is diagnostic of primary hyperthyroidism. If free T4 is decreased with a decreased TSH level, then central hypothyroidism is the diagnosis and the etiology involves the pituitary gland or the hypothalamus. Finally, if free T4 is normal with a decreased TSH, then this is subclinical hypothyroidism. (C) Thyroglobulin is often increased in goiter and hyperthyroidism and is also a tumor marker for thyroid cancer. It is not the best first test in working up thyroid disorders. (D) Radioactive iodine uptake (RAIU) scan is the next best step once primary hyperthyroidism is diagnosed (increased free T4 with decreased TSH) as it can help differentiate causes of hyperthyroidism (Graves vs. multinodular goiter vs. silent thyroiditis). (E) Thyroid biopsy is far too invasive of a test without a baseline TSH level.

36. **Answer:** A. **CT scan.** The suspected diagnosis here is meningitis, and a CT scan should be performed first to rule out mass effect before a lumbar puncture is
performed. He has a high fever, as well as other symptoms/signs of meningitis (including the most sensitive test for meningitis: the jolt accentuation sign, in which a patient’s headache intensifies after a quick head jolt). Kernig and Brudzinski signs are not sensitive, but they are fairly specific. Once a diagnosis of meningitis is suspected and a lumbar puncture needs to be performed, a CT scan should be performed in patients thought to be at high risk for cerebral herniation. Risk factors include papilledema, previous CNS disease, a seizure in that past week, immunosuppression, altered mental status, and focal neurologic signs. (C) This patient has both papilledema and immunosuppression (methotrexate), and therefore a CT scan should be performed before a lumbar puncture to assess the risk for cerebral herniation during lumbar puncture. (B) An MRI provides better visualization of the brain, however it is costly and time-consuming. Because the purpose here is to rule out mass effect, a CT scan can do this adequately and quickly. (D, E) It is most appropriate to administer empiric antibiotics (and antivirals if HSV encephalitis is suspected) shortly after blood and CSF cultures are sent, however the lumbar puncture has not been performed yet.

57. **Answer: B. Electrolyte abnormality.** The patient in this question is presenting with anemia, low back pain, increased erythrocyte sedimentation rate (ESR), and renal dysfunction, suggesting the diagnosis of multiple myeloma. A peripheral smear often shows the rouleaux formation (stacked appearance of RBCs). This patient additionally is presenting with constipation and confusion, both symptoms of hypercalcemia (>10.2 mg/dL), which is seen in about one-third of patients with multiple myeloma. The etiology of hypercalcemia in multiple myeloma is bone lysis from humoral factors released by the plasma cells. (A) Mechanical obstruction secondary to malignancy also can cause constipation, but the patient’s signs and symptoms do not lend credence to colon cancer. (C, D, E) Hormone level and blood gas abnormalities are typically not seen in multiple myeloma and are not associated with constipation.

58. **Answer: B. Surgery.** This patient is presenting with signs and symptoms consistent with a diagnosis of cauda equina syndrome, a serious neurologic condition in which damage to the cauda equina (a bundle of spinal nerves originating in the conus medullaris) causes acute loss of function of the lumbar plexus. The management of this condition is urgent surgical decompression. However, there are several physicians who advocate for steroids prior to surgical decompression. (A) Nonetheless, there is no evidence that steroids are useful in treatment of cauda equina syndrome. (C) Imaging will only delay the diagnosis of cauda equina syndrome and increase the likelihood of long-term neurologic damage. (D, E) Given the finding of absent rectal tone and saddle anesthesia, conservative management with NSAIDs and bed rest should be avoided as cauda
equina syndrome is a neurologic emergency.

59. **Answer: A. Aortic aneurysm.** The patient in this question is presenting with signs, symptoms, and laboratory values consistent with a diagnosis of giant-cell arteritis (GCA), also known as temporal arteritis. Symptoms can include headache, visual problems, jaw claudication, fever, and temporal scalp tenderness. GCA is a vasculitis most commonly involving large and medium arteries of the head, predominantly the branches of the external carotid artery. A decreased temporal artery pulse can be noted as well. ESR and C-reactive protein are commonly elevated. High-dose corticosteroids should be started as soon as the diagnosis is suspected (even before confirmation by temporal artery biopsy) to prevent irreversible blindness secondary to ophthalmic artery occlusion. GCA can involve branches of the aorta leading to aortic aneurysm, thus patients should have serial chest x-rays performed. **(B)** Inflammatory bowel disease includes ulcerative colitis and Crohn disease and is not associated with GCA. **(C)** Hepatitis B is associated with polyarteritis nodosa (30% of the time), a vasculitis of medium and small-sized arteries. **(D)** A smoking history is seen in thromboangiitis obliterans (Buerger disease), which presents with progressive inflammation and thrombosis of small and medium arteries of the hands and feet. Ulceration and gangrene are common complications. **(E)** Alcohol has never been shown to be associated with the development of temporal arteritis.

70. **Answer: D. Vasovagal syncope.** Syncope is defined as loss of consciousness that results from cerebral hypoperfusion. The most common cause of syncope is neurocardiogenic (vasovagal) syncope, which is caused by a sudden surge of sympathetic activity that transiently increases the contractility of the left ventricle. Mechanoreceptors in the left ventricle sense this increased contractility and cause an excessive vagal response, which lowers heart rate and contractility. This transiently drops the blood pressure and causes syncope. These patients typically have symptoms of lightheadedness, nausea, and narrowing vision before losing consciousness and can usually brace their fall somewhat. Diagnosis can be made with the tilt table test. **(A, E)** Cardiovascular causes of syncope include arrhythmias, mechanical heart disease (e.g., aortic stenosis and hypertrophic cardiomyopathy), pulmonary embolism, aortic dissection, and cardiac tamponade. Patients with sudden-onset syncope and trauma to the face (indicating an inability to brace the fall) should increase the reader’s suspicion for a cardiac etiology. **(B)** Orthostatic hypotension usually occurs in the presence of hypovolemia, dysautonomia, and/or certain medications (e.g., diuretics and β-blockers). Diagnosis can be made if systolic blood pressure decreases by ≥20 mm Hg or diastolic blood pressure decreases by ≥10 mm Hg when going from a sitting to a standing position, which was not seen in this patient. **(C)** Seizures technically do
not meet the definition of syncope, since they are not caused by a disruption in cerebral blood flow. History that would indicate a seizure includes a preceding aura, tonic–clonic movements during the episode, and a postictal state (confusion with gradual improvement in neurologic function).

71. Answer: **D. Serum immunoelectrophoresis.** The patient in this question is presenting with signs and symptoms consistent with a diagnosis of multiple myeloma. CRAB can be a useful mnemonic in diagnosing multiple myeloma: HyperCalcemia, Renal failure, Anemia, Bone lesions (often punched out lesions in the skull). Serum and urine electrophoresis with immunofixation may reveal a monoclonal spike and is useful for confirmation of the diagnosis. (A) CA-15-3 is a tumor marker for breast cancer. (B) CEA is a tumor marker for adenocarcinomas, particularly colon (but also lung, breast, and stomach). (C) Alkaline phosphatase would be elevated in Paget disease, however Paget disease is not characterized by hypercalcemia (as seen with this patient). Furthermore, Paget disease is characterized by a mixed osteolytic and osteoblastic phase (where multiple myeloma is purely osteolytic). As a result, rather than showing punched out skull lesions as seen in multiple myeloma, Paget disease will show a “cotton wool” appearance due to irregular areas of sclerosis. (E) An abnormal bone scan is certainly not diagnostic of multiple myeloma; rather it is useful in diagnosing cancer of the bone or cancers that have metastasized to the bone.

72. Answer: **D. Hypertensive emergency; rapid lowering of blood pressure with IV agents.** Hypertensive urgency is defined as a systolic blood pressure >180 mm Hg and/or a diastolic blood pressure >120 mm Hg with no end-organ damage. Hypertensive emergency is the same definition with the addition of end-organ damage. Many organs are acutely affected by high blood pressure, including the brain (stroke), eyes (papilledema), heart (aortic dissection), lungs (pulmonary edema), and kidneys (renal failure). Within the umbrella term of hypertensive emergency, there are additional terms for specific end-organ involvement: malignant hypertension refers to hypertensive emergency in the presence of papilledema (other ophthalmologic findings include retinal exudates and hemorrhage), and malignant nephrosclerosis refers to renal damage. This patient has a hypertensive emergency with end-organ involvement including the brain (headache) and the eyes (papilledema). (A, B, C, E) The management of hypertensive urgencies and emergencies is slightly different. In hypertensive urgency, the goal is to gradually lower the blood pressure to achieve a normal value within a couple of days. Oral antihypertensive agents are given while monitoring the reduction in blood pressure over hours. Some options for oral medications include labetalol, captopril, clonidine, furosemide, and hydralazine. In hypertensive emergency, there is ongoing end-organ damage and therefore
blood pressure needs to be lowered quickly. The goal in this setting is to immediately lower blood pressure using IV agents, targeting a decrease in mean arterial pressure by 25% within minutes to hours. Some options for IV medications include nitroprusside, nitroglycerin, calcium channel blockers (e.g., nicardipine), labetalol, hydralazine, fenoldopam, and phentolamine. Because adaptive mechanisms occur with chronically elevated blood pressure, rapid lowering of blood pressure is not always tolerated and can cause cerebral hypoperfusion. If this happens, the blood pressure must be lowered more gradually.

73. **Answer: C. Normal pressure hydrocephalus.** The patient in this question is presenting with dementia, urinary incontinence, and gait disturbance. This triad, often remembered by “wet, wacky, wobbly,” is characteristic of normal pressure hydrocephalus (NPH). NPH is diagnosed by MRI, which will show dilated ventricles. As one would expect from the name, the opening pressure measured during lumbar puncture is normal. Treatment generally consists of repeated spinal taps to improve the symptoms (by decreasing the pressure exerted on the adjacent cortical tissue by the enlarged ventricles). **(B)** Alzheimer disease is not associated with gait problems or urinary incontinence. **(A)** Pseudotumor cerebri is associated with headaches, not memory impairment or dementia. Furthermore, it is typically seen in young, obese females. **(D)** Although this patient has a history of hypertension, it is well controlled and thus her symptoms are unlikely to be a result of multi-infarct dementia. This type of dementia tends to be very abrupt in onset and show multiple areas of increased T2-weighted density on MRI in the periventricular regions. **(E)** Lewy body dementia is the second most common form of dementia (after Alzheimer) closely associated with Parkinson disease.

74. **Answer: C. Amiodarone.** Amiodarone is an antiarrhythmic medication that may be used for prophylaxis or treatment of serious arrhythmias, especially ventricular arrhythmias. This patient has a history of ventricular tachycardia, and therefore has an indication to be taking amiodarone. This drug has many toxicities, and therefore when started the patient must have baseline pulmonary function tests, thyroid function tests, and liver function tests due to the toxicity involving each of these organs. Other notable side effects include blue-gray discoloration of the skin, corneal deposits, and peripheral neuropathy. This patient developed pulmonary fibrosis as a result of chronic amiodarone use. **(A, B, E)** Digoxin, lisinopril, and losartan are not associated with pulmonary fibrosis. **(D)** Bleomycin can cause pulmonary fibrosis, but it is an antineoplastic drug and the patient has no reason to be taking this medication.

75. **Answer: C. Chlorpromazine.** The patient in this question is likely having an acute episode of a migraine headache. Migraines are characterized by unilateral,
pulsating pain that is often associated with photophobia and an aura of neurologic symptoms prior to the onset of the headache. Acute attacks can range in duration from 4 to 72 hours. Acute treatment and primary preventive treatment vary in migraine headaches. Acute attacks are best treated with intravenous antiemetic medications (chlorpromazine and prochlorperazine) and/or triptans (sumatriptan). (E) Given that this patient presents with vomiting, chlorpromazine is the best choice since it can be given in IV form, unlike sumatriptan. (A, B) Propranolol and amitriptyline are both excellent medications used for migraine prophylaxis, not for acute episodes. These would be appropriate to give to the patient after her acute migraine episode resolves to prevent further attacks. (D) Verapamil is a calcium channel blocker that is the first-line medication for cluster headache prophylaxis. However, this patient is having a migraine, not a cluster headache. Cluster headaches typically involve pain around the eye with eye watering, nasal congestion, and swelling.

76. **Answer: C. Fractional excretion of sodium (FENa).** Acute kidney injury (AKI) is defined as an abrupt rise (within 48 hours) in serum creatinine by ≥0.3 mg/dL from baseline, a ≥50% increase in serum creatinine from baseline, or oliguria of <0.5 cc/kg/hr for >6 hours. Once AKI is recognized, the next step in diagnosis is determining whether the etiology is prerenal, intrinsic renal, or postrenal. These terms reflect the perceived sight of pathology; prerenal AKI is caused by decreased blood flow to the kidneys, intrinsic renal AKI is caused by direct damage to the kidney parenchyma (i.e., to the renal vasculature, tubules/interstitium, or glomeruli), and postrenal AKI is caused by an obstruction in the urinary tract leading away from the kidneys. The patient in this question is hypovolemic (tachycardia and dry mucus membranes). In response to hypovolemia, the renal arterioles vasoconstrict, decreasing blood flow to the kidneys and decreasing the glomerular filtration rate (GFR). Prerenal AKI is a result of ischemia from poor perfusion, however it can progress to acute tubular necrosis (ATN), which is a form of intrinsic renal AKI. Besides hypovolemia, her daily NSAID may also be contributing to the AKI since NSAIDs cause renal vasoconstriction. One of the best tests for differentiating between prerenal AKI and ATN is the FENa. In prerenal AKI, sodium is reabsorbed in an attempt to maintain circulating blood volume, and therefore there will be little sodium in the urine. (B) Although this is often reflected by the urine sodium, this value is affected by renal water handling and urine output. FENA is a better test, since it only measures the fraction of sodium excretion and is not affected by urine output. In general, low FENa values indicate prerenal AKI and high values indicate intrinsic renal AKI (tubular damage leads to salt wasting). The FENa will be <1% in prerenal AKI and >2% in ATN. (Note: FENa should not be used in the setting of diuretics, but the fractional excretion of urea may be used instead.) (A)
A urine dipstick is a helpful screening tool for things like proteinuria or infection, but it will not help to differentiate between prerenal and intrinsic renal AKI. (D) A renal ultrasound would be helpful in excluding postrenal AKI, which is not suspected in this case. (E) The diagnosis of prerenal AKI versus ATN cannot be made by history alone.

77. **Answer: B. Aortic dissection.** The most important risk factor for aortic dissection in the general population is hypertension, however there is a high incidence in patients with connective tissue disease (e.g., Marfan and Ehlers–Danlos syndromes). Sharp chest pain radiating to the back is the first clue to this diagnosis. Other symptoms may occur based on which arteries are occluded by the dissected flap. Finally, a widened mediastinum is seen on chest x-ray. Other potential manifestations not seen in this patient are cardiac tamponade and Horner syndrome (from compression of the superior cervical ganglion). Dissections involving the proximal aorta require immediate surgical intervention. (A, C, D) All of these diagnoses are a result of the patient’s aortic dissection, but are not the underlying (primary) diagnosis. Acute coronary syndromes (ACS) may occur during an aortic dissection as a result of involvement of one or more coronary arteries, and stroke can occur with involvement of the carotid arteries. Aortic regurgitation is common in patients with Marfan syndrome, and this can also occur as a result of a dissection in the ascending aorta. In either situation, it is not the primary diagnosis. (E) Hypertensive emergency requires a systolic blood pressure >180 mm Hg and/or a diastolic blood pressure >120 mm Hg.

78. **Answer: B. Salmonella.** Patients with sickle cell disease have functional asplenism from infarction. This often results in impaired immunologic response to encapsulated organisms, such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*. Furthermore, they are more prone to invasive Salmonella infections which, when localized, can result in osteomyelitis. In addition to treatment with antibiotics here, this patient should immediately be treated with oxygen, aggressive hydration, and analgesics (morphine). (A, C, D, E) These organisms do not cause osteomyelitis in sickle cell patients.

79. **Answer: D. Hot nodule on RAIU.** Thyroid nodules are fairly common with a 5% to 10% prevalence. Approximately 5% of thyroid nodules are malignant. (A, B, C, E) Factors associated with malignancy include history of radiation to the neck, male sex, hard and immobile mass, age greater than 70 years, worrisome ultrasound findings such as irregular borders and microcalcifications, cervical lymphadenopathy, and cold nodule on RAIU. Cold nodules are nonfunctional and do not absorb the radioiodine. Hot nodules, on the other hand, are autonomous (toxic) and readily absorb the radioiodine. However, hot nodules are benign and not associated with malignancy.
30. **Answer: D. Dual-energy x-ray absorptiometry (DEXA).** Risk factors for osteoporosis include smoking, family history, low body weight, excessive alcohol use, and secondary organic causes such as premature menopause, among others. Regardless of symptoms, the USPSTF recommends a one-time screening for osteoporosis in all women aged 65 years or older with DEXA scan of the spine and hips. A bone density with T-score <2.5 standard deviations below the mean is associated with osteoporosis and a T-score between 1 and 2.5 standard deviations below the mean is associated with osteopenia. (A) The patient had a normal mammogram the year before. Mammograms should be performed every 2 years in her age group. (B) The patient had a colonoscopy 6 years ago that was normal. She is due for another colonoscopy in 4 years (reaching the 10-year mark after her previous one). (C) Calcium and phosphorus levels are normal in patients with osteoporosis and have no value in screening for the condition. (E) There is no history or clinical suspicion here for lung cancer, so a CT scan of the chest is not warranted.

31. **Answer: B. Joint aspiration with synovial fluid analysis.** This patient is presenting with signs and symptoms consistent with an acute gout attack. The patient’s alcohol use lends credence to the history of gouty arthritis. Furthermore, the patient is presenting with acute right knee pain, swelling, and low-grade fever, all confirming the likely diagnosis of gout. Given that septic arthritis and pseudogout can show clinical similarities to gout, it is imperative to first perform joint aspiration and synovial fluid analysis. Synovial fluid analysis of gout will demonstrate a leukocyte count of 2,000 to 50,000/mm$^3$ and negatively birefringent needle-shaped crystals with a negative Gram stain and negative culture. (A) Indomethacin (an NSAID) is very helpful in treating acute gout. Nonetheless, the diagnosis of gout must first be confirmed before administering indomethacin especially with its side-effect profile. (C) Uric acid levels will certainly be elevated in gout (elevated uric acid is the underlying cause of the clinical manifestations), however uric acid levels do not have a high degree of sensitivity or specificity for diagnosing gout. (D) An x-ray of the knee is not as specific as synovial fluid analysis for diagnosing gout.

32. **Answer: C. Empiric 1-month trial with proton pump inhibitor (PPI).** The patient in this question is presenting with dyspepsia (characterized by epigastric pain and early satiety). Dyspepsia is a common presentation, and only a minority of patients are diagnosed with an underlying etiology contributing to the dyspepsia. The most common etiologies of dyspepsia are GERD, NSAIDs, peptic ulcer disease (PUD), and malignancy. (D) Importantly, if a patient presents with any “alarm symptoms” such as unexplained weight loss, persistent vomiting, blood loss, dysphagia, or family history of gastrointestinal cancer, then he/she
should undergo an upper GI endoscopy to evaluate for malignancy. In patients without the “alarm symptoms,” current recommendations are to test for Helicobacter pylori in regions where there is a high prevalence of the bacteria and begin treatment with a PPI. In regions where there is a low prevalence of H. pylori, some physicians will treat empirically with a PPI. The most important thing to note here is that patients who fail either of these treatment options after 4 to 8 weeks should undergo endoscopy. (A) Antacids have not alleviated this patient’s symptoms and therefore are not the correct answer here. (B) Barium swallow evaluation is not helpful in diagnosing the etiology of dyspepsia. (E) This patient is symptomatic and clearly not responding to over-the-counter antacids. Observation is inappropriate.

33. **Answer:** E. Etiologies include infection and polypharmacy. This patient is presenting with signs and symptoms consistent with a diagnosis of delirium, which has several etiologies including infection, surgery, trauma, or polypharmacy side effects. Acute onset of symptoms, fluctuating level of consciousness, and presence of visual hallucinations favor a diagnosis of delirium over dementia. Additionally, sleep–wake cycle disturbance is a prominent feature of delirium. (D) Delirium is reversible, while dementia, by contrast, is often irreversible. Clinically, patients with dementia show gradual decline in cognition with preserved level of consciousness. Given the reversibility of the disease, the confused patient should be assumed to have delirium until proven otherwise. Reversible causes of delirium should be considered, including metabolic disorders, infections, medications, normal pressure hydrocephalus, vitamin deficiencies, or thyroid dysfunction, which may be potentially reversible causes of dementia-like symptoms. Delirium occurs in up to 20% of acute hospital inpatients and up to 60% of surgical patients in the perioperative period. Identifying and treating the cause of delirium is critical. (A) Anticholinergic medications will worsen delirium. (B) Neurofibrillary tangles and β-amyloid plaques seen on pathology are consistent with Alzheimer dementia, not delirium. (C) If long-term memory is intact, but short-term memory is affected, then this is more consistent with dementia.

34. **Answer:** B. Gallstone obstruction in the cystic duct. The patient in this question is presenting with acute cholecystitis. He is presenting with fever, right upper quadrant pain after a fatty meal that radiates to the right scapula, and positive Murphy sign (pain on palpation in the right upper quadrant with cessation of inspiration). Additional nonspecific findings include vomiting, leukocytosis, and mild elevation in transaminases. Acute cholecystitis usually arises from gallstone formation that obstructs the cystic duct. The symptoms occur after eating a fatty meal because the fat stimulates gallbladder contraction, and in the
presence of cystic duct obstruction, this leads to colicky pain. Infection results from stasis that contributes to bacterial growth in the gallbladder. (D) Importantly, alkaline phosphatase is not elevated in this patient with acute cholecystitis. Assume if laboratories are not shown, they are normal. If it were elevated (in addition to total bilirubin and direct bilirubin), this might indicate common bile duct obstruction in the setting of jaundice (choledocolithiasis). (A) Alcoholic liver disease does not present with this constellation of symptoms. (C) Similar to common bile duct obstruction, obstruction from a carcinoma of the head of the pancreas would cause severely elevated alkaline phosphatase levels and would normally present with weight loss and painless jaundice. (E) Pancreatitis should definitely be ruled out with a lipase check, but pain typically is only epigastric in nature and radiates to the back.

35. Answer: C. Amitriptyline. The patient in this question is presenting with signs and symptoms consistent with a diagnosis of fibromyalgia (FM). FM is more common in middle-aged women and is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure). Physical examination is typically normal except for point muscle tenderness in several areas including the mid trapezius, lateral epicondyle, and greater trochanter, among others. Of note, FM has no laboratory findings that are diagnostic of the condition. The first-line treatment for FM is patient education, aerobic exercise, and good sleep hygiene. This patient has clearly attempted those recommendations based on the history she provides, so the first-line medication is a tricyclic antidepressant (TCA) such as amitriptyline. Several other drugs (pregabalin and duloxetine) can be attempted if TCAs fail to alleviate the patient’s symptoms. (A, B, E) Corticosteroids and NSAIDs are useful in treating inflammatory conditions, but FM is not an inflammatory condition (not associated with elevated inflammatory markers such as ESR). (D) Colchicine is useful in treating gout, not FM.

36. Answer: B. Administration of fluids. This is a common question on the USMLE that emphasizes the importance of airway, breathing, and circulation (ABCs) in the management of patients (regardless of the underlying disorder). This patient presents with hypotension and delayed capillary refill, indicating that there is compromise of his circulation. The best next step in management of circulatory compromise (in this case from an upper GI bleed) is fluid resuscitation. After the patient is hemodynamically stable, treatment for the actual underlying condition can be initiated. (A, C, D) All these answer choices address the underlying cause of the upper GI bleeding (likely peptic ulcer bleeding); however, the patient must be stabilized before these modalities are pursued. (E) This is a life-threatening condition and reassurance is inappropriate.
37. **Answer: C. Abdominal x-ray.** The patient in this question is presenting with signs and symptoms concerning for a small bowel obstruction (SBO). The typical constellation of symptoms includes abdominal pain, vomiting, obstipation, abdominal distention, and diffuse tenderness. A mild leukocytosis and elevated amylase is often found in an SBO. The best initial test is an abdominal x-ray because it often reveals dilated bowel loops and several air–fluid levels. Treatment involves supportive care, bowel rest, and decompression with a nasogastric tube. Surgery is reserved for those patients who fail to improve with the aforementioned treatments and/or develop findings consistent with strangulation. *(A, B, D, E)* These options are not the best initial test in diagnosing an SBO.

38. **Answer: B. Nephrolithiasis.** This patient is presenting with the typical symptoms of a kidney stone. Patients with Crohn disease are at risk of developing calcium oxalate stones due to increased absorption of oxalate in the GI tract (and therefore increased oxaluria), which has two causes. First, malabsorption of bile salts and GI tract inflammation increase mucosal permeability. Second, fatty acids (also a result of malabsorption) bind intestinal calcium, and so less calcium is available to bind and trap intestinal oxalate. This causes an increase in free oxalate that can be absorbed, eventually making it back to the kidneys to be excreted. Calcium stones are the most common type of kidney stones, and patients with these stones are encouraged to increase their dietary intake of calcium (in order to decrease oxalate absorption in the GI tract). Ammonium magnesium phosphate (struvite) stones are caused by urinary tract infections with urease-positive organisms (e.g., *Proteus, Klebsiella*) and can form staghorn calculi. Uric acid stones are associated with hyperuricemia (e.g., leukemia, gout). Cystine stones are seen in the genetic disease cystinuria and are treated by alkalinizing the urine with acetazolamide. *(A) Pyelonephritis would also produce flank pain, but unlike nephrolithiasis it would also produce fever, leukocytosis, and a urine dipstick showing infection (e.g., positive nitrates, positive leukocyte esterase). (C) Appendicitis is important to consider in any young patient with abdominal pain, however it would be unusual for appendicitis to cause hematuria. (D) Ectopic pregnancies can mimic the pain of a kidney stone, however this diagnosis is unlikely given the negative pregnancy test. (E) This would be an unusual presentation of abdominal pain seen in pancreatitis, which is usually epigastric and radiating to the back.*

39. **Answer: C. Hyperventilation secondary to anxiety.** According to the ABG, this patient has an acute respiratory alkalosis (caused by loss of CO₂ which is balanced by increased excretion of HCO₃⁻). Respiratory alkalosis can only be caused by an increase in ventilation (commonly caused by high altitudes or sympathetic stimulation like anxiety or pain). *(A) Accumulation of unmeasured
anions due to hepatic metabolism of alcohol would cause an anion gap metabolic acidosis (low pH with low HCO₃ and low CO₂ and an increased gap, calculated by subtracting [Cl⁻ + HCO₃⁻] from Na⁺). (B) Vomiting causes a metabolic alkalosis from loss of acid and chloride. Metabolic alkalosis is characterized by high pH, high HCO₃, and high CO₂ (respiratory compensation by hypoventilating). (D) Diuretics are associated with a metabolic alkalosis from volume contraction. (E) Hypoventilation causes a low pH from CO₂ retention. This will cause a respiratory acidosis, not alkalosis as seen with this patient.

90. **Answer: C. Lactulose.** This patient is presenting with signs and symptoms of cirrhosis (ascites, spider angiomata) and hepatic encephalopathy (altered mental status and asterixis). In hepatic encephalopathy, the liver is unable to convert ammonia into urea and it therefore accumulates, in addition to other toxins the liver is unable to clear. It is often precipitated by illness or gastrointestinal bleed (as in this patient with hematemesis). Increased ammonia levels can assist in making the diagnosis, but the diagnosis is ultimately clinical and can cause confusion in the correct setting of end stage liver disease (ESLD). Treatment involves treating the precipitant and decreasing serum ammonia levels (however, even if one uses ammonia to help with diagnosis, it is not necessary to follow ammonia levels; rather, one should follow clinical improvement). Lactulose, a nonabsorbable disaccharide, is used because bacteria in the gut metabolize it into acidic compounds (lactic acid, acetic acid) that permit the absorbable ammonia to be converted into the nonabsorbable ammonium, thereby enabling excretion from the body. (A) Furosemide would improve the ascites and volume status in a cirrhotic patient, but is not helpful in the management of hepatic encephalopathy. (B) Thiamine is useful in the treatment of Wernicke encephalopathy, another form of encephalopathy characterized by altered mental status, ataxia, and nystagmus and is associated with thiamine deficiency. Of note, asterixis is not present in Wernicke encephalopathy. (D, E) Morphine and hydromorphone are narcotics that would be challenging for a cirrhotic patient to metabolize.

91. **Answer: B. Acetaminophen.** This patient is obese, greater than 40 years of age, and is presenting with bilateral knee and back pain. The fact that the pain is worsened with activity and relieved by rest suggests that it is most likely secondary to osteoarthritis (OA). If she reported morning stiffness lasting greater than 30 minutes and had systemic symptoms, rheumatoid arthritis would have been the likely diagnosis. OA is a noninflammmatory arthritis that results in eroding cartilage in the intra-articular joints. This causes joint crepitus (a “grating” or popping sound) that occurs when the surfaces of the joint grind against each other. Although the diagnosis is usually made clinically, the typical changes seen on x-ray include joint space narrowing, subchondral sclerosis (increased bone
formation around the joint), subchondral cyst formation, and osteophytes. Acetaminophen is the first-line treatment for mild to moderate OA. It is just as efficacious as NSAIDs in alleviating the pain in OA with considerably fewer side effects. (A) Intra-articular corticosteroid injections lead to short-term pain relief that lasts up to a few months. This should not be the initial treatment in OA. (C) Naproxen is an NSAID and although NSAIDs have been shown to be efficacious in the treatment of OA, their side-effect profile consists of gastrointestinal and renal consequences that make them second-line treatments. (D) Allopurinol is used in the prophylactic treatment of gout. It acts via inhibition of xanthine oxidase which decreases production of uric acid. It is not used in the treatment of OA. (E) This patient is clearly in pain and would benefit from medication, so observation is inappropriate.

92. **Answer: D. Vitamin B_{12} deficiency.** The patient in this question likely has cobalamin (vitamin B_{12}) deficiency. This results in a megaloblastic anemia. Long-term consequences of vitamin B_{12} deficiency include peripheral neuropathy and posterior column defects from abnormal myelin synthesis. Importantly, folic acid deficiency is another cause of macrocytic anemia and treatment with folic acid can improve the actual anemia of vitamin B_{12} deficiency since both folate and vitamin B_{12} are involved in the conversion of homocysteine to methionine. However, neurologic symptoms can be worsened in vitamin B_{12} deficiency with the treatment of folic acid since vitamin B_{12} is used in other biologic processes as well. As a result, it is critical to rule out vitamin B_{12} deficiency before initiating folic acid. Vitamin B_{12} deficiency results from inadequate vitamin B_{12} intake (diet lacking in animal products) and autoimmune gastritis. The loss of gastric parietal cells secondary to autoimmune gastritis causes intrinsic factor deficiency (which is necessary for vitamin B_{12} absorption in the terminal ileum). (A) The patient’s underlying disorder is vitamin B_{12} deficiency and no amount of folic acid supplementation will improve his neurologic symptoms. (B) Iron deficiency is a microcytic anemia (MCV < 80 fL) and is not associated with peripheral neuropathy. (C, E) Although glucose intolerance commonly causes peripheral neuropathy, this patient does not have a history that suggests diabetes.

93. **Answer: A. Amlodipine.** Amlodipine is a calcium channel blocker that is often used as an antihypertensive agent. It has a high incidence of peripheral edema as a side effect. (B) Metoprolol is a selective β_{1}-blocker used in hypertension, heart failure, and rate control for atrial fibrillation. It can cause bradycardia and hypotension, but avoids some of the adverse effects of nonselective β-blockers (e.g., bronchospasm). It rarely causes peripheral edema. (C) Hydrochlorothiazide blocks the Na-Cl channel in the distal convoluted tubule, leading to sodium and
water excretion. It is used as an antihypertensive agent, and can cause orthostatic hypotension, hypercalcemia, hypokalemia, hyperlipidemia, and hyperglycemia.  
(D) Metformin is a biguanide drug used in diabetes and acts by decreasing hepatic glucose secretion and increasing insulin sensitivity. It causes GI symptoms, vitamin B₁₂ deficiency, and lactic acidosis in patients with renal failure.  
(E) Glipizide is a sulfonylurea antidiabetic drug. It blocks potassium channels in islet cells of the pancreas, leading to increased insulin release that can result in hypoglycemia.

94. **Answer: A. Factitious hypoglycemia from surreptitious injection of insulin.**  
The patient in this question is presenting with clinical symptoms and laboratory findings consistent with surreptitious injection of insulin (elevated insulin, decreased glucose, and decreased C-peptide).  
(B) Since this patient presents with a decreased C-peptide level, this is not consistent with an ENDOGENOUS source of insulin since pancreatic β-cells produce proinsulin (which breaks down into insulin and C-peptide). Therefore, insulinoma is not the diagnosis since there are decreased levels of C-peptide in this patient.  
Note that surreptitious sulfonylurea use will also produce elevated insulin and C-peptide levels (similar to insulinoma) since this drug essentially stimulates proinsulin secretion. That is why it is critical to order a urine sulfonylurea level, which is undetectable in this patient.  
(C, D) Somatization disorder and glucagonoma do not produce hypoglycemia.  
(E) Dehydration cannot explain the severe hypoglycemia seen in this patient.

95. **Answer: D. Ciprofloxacin.** One reported adverse reaction of fluoroquinolone antibiotics is tendinopathy, and the Achilles tendon is most often affected.  
Fluoroquinolones can also cause GI upset, dizziness, rash, and a prolonged QT interval.  
(A) Trimethoprim-sulfamethoxazole may cause Stevens–Johnson syndrome, leukopenia, hyperkalemia, hypoglycemia, and hepatitis. The incidence of adverse reactions is much higher in HIV patients.  
(B) Metronidazole can cause a disulfiram-like reaction with alcohol.  
(C) Tobramycin and other aminoglycosides may cause renal failure and ototoxicity.  
(E) Azithromycin and other macrolides can cause a prolonged QT interval and hepatitis.

96. **Answer: B. Thyroid-stimulating hormone (TSH) levels.** The patient in this question is demonstrating clinical manifestations of hyperthyroidism. In approaching the diagnosis of thyroid disorders, the first step is to order a TSH level.  
TSH is the most sensitive test to detect primary hypothyroidism and hyperthyroidism. Based on the TSH level, additional tests can be performed.  
(A) Free T₄ is important in the diagnostic workup of thyroid disorders and should be the next test ordered if TSH comes back decreased. If free T₄ is increased with a decreased TSH level, this is diagnostic of primary hyperthyroidism. If free T₄ is decreased with a decreased TSH level, then central hypothyroidism is the
diagnosis and the etiology involves the pituitary gland or the hypothalamus. Finally, if free T4 is normal with a decreased TSH, then this is subclinical hypothyroidism. (C) Thyroglobulin is often increased in goiter and hyperthyroidism and is also a tumor marker for thyroid cancer. It is not the best first test in working up thyroid disorders. (D) Radioactive iodine uptake (RAIU) scan is the next best step once primary hyperthyroidism is diagnosed (increased free T4 with decreased TSH) as it can help differentiate causes of hyperthyroidism (Graves vs. multinodular goiter vs. silent thyroiditis). (E) A fine-needle aspiration (FNA) biopsy is far too invasive of a test without having basic laboratory values.

97. **Answer:** D. Reassurance. This patient demonstrates immunity to hepatitis B (positive for HBsAb) and therefore reassurance should be offered. Immunity to hepatitis B occurs when anti–hepatitis B surface antibodies (HBsAbs) develop against the recombinant hepatitis B surface antigen. Given the patient’s documented hepatitis B vaccination and positive titers for HBsAb, reassurance is appropriate. (A, C) If the patient had unknown vaccination history, he should receive both HBIG (passive immunity) and hepatitis B vaccine (active immunity). (B) The patient has documentation already revealing positivity for HBsAb. Therefore, a hepatitis B panel is unnecessary.

98. **Answer:** B. Tearing of the bridging veins. This patient is suffering from a subdural hematoma, which is caused by blunt trauma that tears the bridging veins, which connect the cortical superficial veins to the sagittal sinus in the dura. This blood will slowly extravasate into the subdural space, which is why this patient’s fall was recorded 4 days prior to admission. Epidural hematomas, on the other hand, become immediately symptomatic (although the classic description of epidural hematomas is that of a “lucid” phase followed by rapid decline). Subdural hematomas manifest symptomatically with headache and gradual confusion and loss of consciousness. Of note, subdural hematomas are much more common in elderly patients and alcoholic patients (brain atrophy and fragility of vasculature). Radiologic findings of a subdural hematoma include a white crescent on noncontrast CT of the head. Also, a midline shift is commonly appreciated. Treatment is neurosurgical hematoma evacuation. (A) Tearing of the middle meningeal artery is the underlying cause of most epidural hematomas. (C) Ruptured aneurysm is the underlying cause of a subarachnoid hemorrhage. (D) In addition to the radiologic evidence, this particular patient has an insignificant past medical history and therefore hypertensive hemorrhage is not the right answer. (E) Alzheimer disease would not present with this acute presentation. This patient clearly endorses trauma making a hematoma much more likely than underlying dementia.
99. **Answer:** D. Severe sepsis. This patient has severe sepsis secondary to pneumonia. It is important to know the definitions related to the topic of sepsis. Systemic inflammatory response syndrome (SIRS) is defined by 2 or more of the following: (1) temperature >38°C or <36°C; (2) a heart rate >90/min; (3) a respiratory rate >20/min or a PaCO₂ <32 mm Hg; and (4) a serum leukocyte count >12,000/mm³ or <4,000/mm³ or >10% bands. The 2016 Third International Consensus updated the definition of sepsis to be a qSOFA score of 2 or more (qSOFA includes respiratory rate of 22 or higher, altered mental status, or systolic blood pressure 100 mm Hg or less). Despite these guidelines, many providers still use the SIRS definition of sepsis and it is thus still important to know the previous definition. **(C)** When there is a suspected source of infection, the definition becomes sepsis. Severe sepsis is the definition for sepsis with end-organ dysfunction, signified by hypotension or hypoperfusion (e.g., oliguria, elevated serum lactate, etc.). Septic shock is severe sepsis that does not respond to adequate fluid resuscitation. This patient meets SIRS criteria with a suspected source of infection (pneumonia) and hypotension; **(E)** IV fluids have not been administered yet, so the definition of septic shock is not met. Septic shock is one type of distributive shock, which is characterized by hypotension with flat neck veins and warm extremities (low systemic vascular resistance). **(A, B)** Both cardiogenic shock and pulmonary embolism (a type of obstructive shock) are ruled out by the flat neck veins. Lastly, hypovolemic shock would present with flat neck veins and cool extremities, since systemic vascular resistance increases in an attempt to maintain blood pressure.

10. **Answer:** C. Administer oral chlorhexidine solution twice daily. Mechanical ventilation is the biggest risk factor for developing HAP, and the risk can be decreased with certain measures. **(A)** Patient should be placed in a semirecumbent position (head of the bed elevated 30 degrees to 45 degrees) to prevent aspiration events. **(B)** Daily attempts to wean a patient from the ventilator should be performed to minimize the duration of mechanical ventilation. **(D)** Omeprazole and other agents that increase the pH of gastric contents have been shown to increase the rate of HAP. They should be avoided if possible. **(E)** Endotracheal suctioning of subglottic secretions reduces the risk of VAP. Other important preventive measures include following proper hand hygiene protocols, avoiding gastric overdistention, and using orotracheal intubation rather than nasotracheal intubation.
Index

Note: Page numbers followed by b, f, and t indicates boxed material, figure, and table respectively.
A

- ABCD² score, 205b
- Abdominal aortic aneurysm (AAA), 54–56
  - causes, 55
  - clinical features, 55
  - diagnosis, 55
  - general characteristics, 54–55
  - treatment, 55–56
- Abdominal obesity, 178
- Abdominal pain
  - in acute mesenteric ischemia, 117
  - in colorectal cancer, 113
  - in CRC, 115
  - nontraumatic, approach to diagnosis of, 165f
- Abdominal radiograph, 494
  - acute pancreatitis, 140
  - in chronic pancreatitis, 142
- Abdominal ultrasound
  - in acute pancreatitis, 140
  - in cirrhosis, 121
- Acalculous cholecystitis, 134
- ACE inhibitors, 10, 21b
  - in angioedema, 421, 421f
- Achalasia, 149–150
  - causes, 149
  - clinical features, 149
  - diagnosis, 149, 149f
  - general characteristics, 149
  - treatment, 149–150
- Achlorhydria syndrome, 181
- Acid–base disorders, 319–322
  - metabolic acidosis, 319–320, 319b, 320b, 320f, 321f
  - metabolic alkalosis, 322–323
  - respiratory acidosis, 323–324
  - respiratory alkalosis, 324
- Acidosis, 276b
  - metabolic, 319–320
  - respiratory, 323–324
- Acid suppression therapy, 155, 155b
- Acne vulgaris, 415–416
Acromegaly, 191–192, 192b
ACTH level and Cushing syndrome, 198–199
ACTH test, 202
Actinic keratosis, 431, 431f
Acute AFib treatment, 23–24, 23f, 24b
Acute appendicitis, 138–139
- clinical features, 138–139
- diagnosis and treatment, 139
- incidence, 138
- pathogenesis, 138
Acute arterial occlusion, 57–58, 58t
Acute bacterial arthritis, 401t
Acute bacterial meningitis, 373b
Acute bronchitis, 447
Acute cholecystitis, 133–134
Acute coronary syndrome (ACS), 6b
Acute decompensated heart failure, 21
Acute gastritis, 156
Acute generalized exanthematous pustulosis (AGEP), 423
Acute hyponatremia, 194
Acute infectious arthritis, 399–401
Acute infectious diarrhea, pathogens, 456t
Acute interstitial nephritis (AIN), 285
  vs. chronic interstitial nephritis, 285b
Acute kidney injury (AKI), 266
  azotemia, 266
  causes of, 267f
  initiation, 276
  intrinsic renal failure, 268–269
  postrenal failure, 269
  prerenal failure, 267
  treatment, 272
  vs. chronic kidney disease, 273t
Acute leukemias, 360–361, 360b
Acute limb ischemia, 57–58
Acute liver failure, 119–120
  causes, 119
  diagnosis, 119–120
  general characteristics, 119
  management, 120
- signs, 120b
- Acute lymphoblastic leukemia (ALL), 360
- Acute mesenteric ischemia, 117–118
- Acute myelogenous leukemia (AML), 360
- Acute pancreatitis, 139–142
  - causes, 139–140, 140b
  - clinical features, 140
  - complications, 141
  - diagnosis, 140–141
  - general characteristics, 139
  - prognosis, 142
  - treatment, 141–142
- Acute pericarditis, 14, 35–36
  - causes, 35
  - clinical features, 35–36
  - complications, 35
  - diagnostic criteria, 36, 36b
  - general characteristics, 35
  - treatment, 36
- Acute promyelocytic leukemia (APL), 348
- Acute respiratory distress syndrome (ARDS), 97–100
  - causes, 98–99
  - clinical features, 99
  - complications, 100
  - definition, 98, 100b
  - diagnosis, 99–100, 99f
  - diffuse inflammatory process, 97
  - pathophysiology, 98
  - treatment, 100
- Acute respiratory failure, 94–97
  - causes, 94–95
  - classification, 95
  - clinical features, 96
  - diagnosis, 96
  - general criteria to define, 94
  - pathophysiology, 95–96
  - treatment, 96–97
- Acute rheumatic fever, 46
- Acute tubular necrosis (ATN), 269b
- Addison disease. See Primary adrenal insufficiency
\textbullet{} Adenocarcinoma, 148
\textbullet{} Adenomatous polyps, 114, 115–116
\textbullet{} Adenosine, side effects of, 28b
\textbullet{} Adrenal adenoma, 201
\textbullet{} Adrenal crisis, 202
\textbullet{} Adrenal glands, diseases of, 197–204
  \textbullet{} adrenal insufficiency, 201–203
  \textbullet{} congenital adrenal hyperplasia (CAH), 203–204
  \textbullet{} Cushing syndrome, 197–199
  \textbullet{} pheochromocytoma, 199–200
  \textbullet{} primary hyperaldosteronism, 200–201
\textbullet{} Adrenal hyperplasia, 201
\textbullet{} Adrenal incidentaloma, 201b
\textbullet{} Adrenal insufficiency, 201–203
  \textbullet{} causes, 201–202
  \textbullet{} clinical features, 202
  \textbullet{} diagnosis, 202, 202f
  \textbullet{} treatment, 202–203
\textbullet{} Age-related macular degeneration (ARMD), 472–473
\textbullet{} Albumin, 132
\textbullet{} Alcoholic liver disease-, 121
\textbullet{} Alcoholism, 484–485
\textbullet{} Alcohol withdrawal, 485b
\textbullet{} Aldosterone antagonists, 22b
\textbullet{} Alkaline phosphatase (ALK-P), 124b, 132
\textbullet{} Alkalosis, 320b
  \textbullet{} metabolic, 323–324
  \textbullet{} respiratory, 325
\textbullet{} Altered mental status, 219–221, 219b
  \textbullet{} coma, 220–221
  \textbullet{} delirium, 218
  \textbullet{} differential diagnosis of, 220b
\textbullet{} Alveolar filling disease, 93
\textbullet{} Alzheimer disease, 217–218
\textbullet{} Amaurosis fugax, 476
\textbullet{} Ambulatory venous HTN, 61
\textbullet{} Amebic liver abscess, 128
\textbullet{} Aminotransferases, 130–132
\textbullet{} Amyotrophic lateral sclerosis (ALS), 234–235
\textbullet{} Anaphylaxis, 422
Anaplastic carcinoma, 190
Anemias, 326–329
  • clinical features, 326
  • diagnosis, 326–328
  • evaluation, 328f, 329
  • hemolytic, 335–336
  • macrocytic, 333–334
  • microcytic, 329–330
  • normocytic, 332–333
  • symptoms of, 325
Androgen excess and masculinization, 198f
Angina pectoris, stable, 1–2
  • causes, 1
  • clinical features of, 1
  • prognostic indicators of, 1
  • risk factors for, 1
  • standard of care for, 4b
  • treatment of, 4–5
Angina pectoris, unstable, 5–7
  • diagnosis of, 6
  • NSTEMI vs., 6, 6b
  • pathophysiology of, 5, 6
  • treatment, 6–7
Angiodysplasia of colon, 117
Angioedema, 421, 421f
Angiotensin-converting enzyme (ACE), 91
Angiotensin II receptor blockers (ARBs), 21b
Ankle sprains, 465
Ankylosing spondylitis, 259–260, 259–260
  • complications of, 260b
Anogenital wart, 426
Anorectal disease, 163
Anoscopy, 147
Antacids, 155
Antibacterial antibiotic therapy
  • antituberculosis antibiotics, 506
  • cell wall inhibitors, 499–503
  • fluoroquinolones, 505–506
  • protein synthesis inhibitors, 503–505
Antibiotics
- in cholangitis, 135
- in COPD, 73, 74
  - Anticoagulation therapy
    - in acute AFib, 24
    - in DVT, 60
    - in pulmonary embolism, 108
  - Anti-GBM antibody disease, 93
  - Antimitochondrial antibodies (AMAs), 137
  - Antineutrophil cytoplasmic antibodies (ANCA), 92
  - Antiphospholipid antibody syndrome, 245b, 350
  - Antiretroviral therapy, 391t
  - Antisecretory drugs, 155, 156
  - Antithrombin (AT) III deficiency, 350
  - Antitopoisomerase I, 246
  - Aortic dissection, 53–54, 53b, 53f
  - Aortic insufficiency. See Aortic regurgitation
  - Aortic regurgitation, 42–43, 42b
  - Aortic stenosis, 41–42
    - causes, 41
    - clinical features, 41
    - diagnosis, 41
    - management, 41b
    - pathophysiology, 41
    - treatment, 42
  - Aortoenteric fistula, 144b
  - Aphasia, 235–236
    - causes of, 235b
    - treatment, 236
    - types of, 235
  - Aplastic anemia, 332–333
  - Appendix, diseases of, 138–139
    - acute appendicitis, 138–139
    - carcinoid syndrome, 139
    - carcinoid tumors, 139
  - Arrhythmias, 12, 21–22
    - premature atrial complexes, 21–22
    - premature ventricular complexes, 22
  - Arterial blood gas (ABG) analysis, 111t
    - in acute respiratory failure, 96
    - in ARDS, 100
• in asthma, 75
• in pulmonary embolism (PE), 105–106
• Arterial embolism, 117
• Arterial thrombosis, 117
• Arteriography
  • coronary, 3b
  • in GI bleeding, 147
• Arteriovenous malformations. See Angiodysplasia of colon
• Arthritis, causes of, 464b
• Asbestosis, 92
• Aspergillus, 406–407
• Aspirin
  • in MI, 10
  • in PAD, 57
  • Aspirin-sensitive asthma, 76b
• Asthma, 74–77
  • causes, 75
  • clinical features, 74, 74b
  • complications, 76b
  • diagnosis, 75
  • extrinsic vs. intrinsic, 74
  • treatment, 75–77, 76b, 76t
• Asymptomatic aneurysms, 55
• Asystole, 13
• Ataxia, 215
• Atheromatous occlusion, 55b
• Atherosclerosis, accelerated, 173
• Atherosclerotic occlusive disease, 118
• Atrial fibrillation, 22–25
  • annual stroke risk, 25t
  • causes, 22
  • clinical features, 23
  • diagnosis, 23
  • general characteristics, 22
  • treatment, 23–25, 23f
• Atrial flutter, 25–26, 26f
  • diagnosis, 26
  • general characteristics, 25
  • treatment, 26
• Atrial myxoma, 62
Atrial septal defect, 48–49
Atypical pneumonia syndrome, 365b
Auer rods, 361f
Austin flint murmur, 42
Autoimmune hemolytic anemia (AIHA), 341–342
  • cold, 341
  • warm, 341
Autonomic neuropathy, 175
Autosomal dominant polycystic kidney disease (ADPKD), 287–288
Autosomal recessive polycystic kidney disease (ARPKD), 288–289
AV block, 13, 32–33, 32f
AV nodal reentrant tachycardia, 26
Bariatric surgery, 179
Barium enema, 113, 119
Barium swallow
• in achalasia, 149
• in peptic ulcer disease, 154
Barrett esophagus, 148b
Bartter syndrome, 314
Basal cell carcinoma (BCC), 432–433, 432f
β-blockers, 4, 6
• in aortic dissection, 54
• in hyperthyroidism, 183
• in MI, 10
Becker muscular dystrophy, 225
Beck triad, 40
Bernard-Soulier syndrome, 345
Berylliosis, 93
Bile duct stricture, 138
Biliary colic, 132, 133b
Biliary dyskinesia, 138
Biliary tract obstruction, 133
Biliary tree, cystic dilatations of, 138
Bilirubin metabolism, 129b
Bite cells, 340
Bitemporal hemianopsia, 192
Bladder cancer, 299
Blood transfusion, 327b
Blowing holosystolic murmur, 44
Blumer shelf, 158b
Body fluid compartments, 302, 303f
Body mass index (BMI) classification, 178b
Boerhaave syndrome, 154
Botulism, 379
Bradyarrhythmias, 31–33
• AV block, 32–33, 32f
• sick sinus syndrome, 31
• sinus bradycardia, 31
Bradyarrhythmias sick sinus syndrome, 31
Breast cancer, 354–355
• risk factors, 354
- types of, 355
  - Breath sounds, 508
  - Broca aphasia, 235
  - Bronchiectasis, 77, 77b
  - Bronchodilators for COPD, 72, 74
  - Bronchoprovocation test, 75
  - Brown-Séquard syndrome, 227
  - Brown tumors, 196f
  - Budd–Chiari syndrome, 128–129
  - Budesonide, in Crohn disease, 163
  - Bullous pemphigoid, 425, 425f
  - BUN–creatinine ratio, 146
  - Bupropion (Zyban), 486
  - Bursitis
    - olecranon, 466
    - trochanteric, 466
C

- Cabergoline, 191
- Calcification of suprasellar region, 192b
- Calcium channel blockers (CCBs), 5
- Calcium metabolism
  - hormonal control of, 310–311
  - hypercalcemia, 312–313
  - hypocalcemia, 311
  - normal serum calcium, 310
- Candidiasis, 405–406, 406f
- Caplan syndrome, 252b
- CAPRICORN trial, 11b
- Carcinoembryonic antigen (CEA), 113
- Carcinoid syndrome, 139, 139b
- Carcinoid tumors, 139
- Carcinoma of gallbladder, 135
- Cardiac arrest, 30b
- Cardiac Arrhythmia Suppression Trial (CAST) I, 24b
- Cardiac catheterization, 6–7
  - aortic stenosis, 41
  - cardiac tamponade, 39
  - in CHF, 18
  - with coronary angiography, 3, 3b
- Cardiac disease, 90b
- Cardiac enzymes, 9, 9b
- Cardiac monitoring for patient with acute MI, 9b
- Cardiac neoplasms, 62
- Cardiac pacemakers, 31b
- Cardiac tamponade, 38–39
  - causes, 38
  - clinical features, 39
  - definition, 38
  - pathophysiology, 38
- Cardiogenic shock, 64–65
- Cardiometabolic risk, 178
- Cardiomyopathy, 191
- Cardiovascular diseases, 435–443
  - hyperlipidemias, 440–443
  - hypertension, 435–440
  - risk factors, 439b
• Cardioversion, 24–25
  • ventricular fibrillation, 31
  • vs. defibrillation, 24b
• CARE trial, 7b
• Carotid bruit, 207
• Carpal tunnel syndrome, 466
• Cataracts, 473, 474f
• Catheter-related sepsis, 412
• Cauda equina syndrome, 463b
• Cavernous hemangiomas, 126
• CBD stones
  • complications, 134
  • signs and symptoms, 134
• Cecal volvulus, 118
• Celiac sprue, 161
• Cellulitis, 62b, 396
• Central DI, 193–194
• Central pontine demyelination, 308
• Centrilobular emphysema, 69b
• Cerebrovascular accident (CVA), 24
• Cervical spine, disorders of, 463–464
  • cervical myelopathy, 464
  • cervical radiculopathy, 463
  • chronic axial neck pain, 463
  • spondylosis, 463
• Chancroid, 395, 396f
• Charcot triad, 135
• Chest pain, 1, 14–15, 512–513
  • in acute pericarditis, 35–36
  • differential diagnosis, 14
  • in myocardial infarction, 7
  • treatment approaches, 14–15
• Chest radiograph (CXR), 38, 491–494
  • in ARDS, 99–100, 99f
  • in asthma, 75
  • in CHF, 18, 18f
• COPD, 71, 72f
• in hemoptysis, 112
• in ILD, 88, 90f
• in lung cancer, 79, 79b
• in pleural effusion, 83
• in pulmonary embolism (PE), 106
  › Child–Pugh score, 120, 120t
  › Chlamydia, 385
  › Cholangiocarcinoma, 137–138
  › Cholangiography
    • in cholangiocarcinoma, 137
    • in cholangitis, 135
  › Cholangitis, 134, 135
  › Cholecystectomy, in acute cholecystitis, 133–134
  › Cholecystitis complications, 133b
  › Cholecystokinin (CCK), 138b
  › Choledochal cysts, 138
  › Choledocholithiasis, 134, 134t
  › Cholelithiasis, 132–133, 134t
  › Cholestasis, 129b, 132b
  › Cholesterol embolization syndrome, 58
  › Cholesterol stones, 132
  › Cholesterol treatment guidelines, 442t
  › CHOP therapy, 359b
  › Chronic AFib, 24
  › Chronic arterial insufficiency. See Peripheral arterial disease (PAD)
  › Chronic bronchitis, 69, 70t
  › Chronic cholecystitis, 133
  › Chronic gastritis, 157
  › Chronic hyponatremia, 194
  › Chronic hypoxemia, 103
  › Chronic lymphocytic leukemia, 361
  › Chronic lymphocytic thyroiditis, 185b, 186, 187
  › Chronic mesenteric ischemia, 118
  › Chronic myeloid leukemia, 362–363
  › Chronic obstructive pulmonary disease (COPD), 69–74, 69b, 71b, 74b
    • clinical features, 69–70
    • clinical monitoring of, 71b
    • complications, 74
    • diagnosis, 70–71
    • flow volume curves in patient with, 72f
    • general characteristics, 69
    • pathogenesis, 69
    • risk factors, 69
- taking history of patients with, 70b
  - types of, 69, 70t
- Chronic pancreatitis, 142–144
  - clinical features, 142
  - complications, 142–143
  - diagnosis, 142, 143f
  - general characteristics, 142
  - treatment, 143–144
- Chronic thromboembolic disease, 103
- Chronic thyroiditis, 185
- Chronic venous insufficiency, 61–62
- Churg–Strauss syndrome. See Eosinophilic granulomatosis with polyangiitis
- Chvostek sign, 311
- Cirrhosis, 120–124
  - causes, 121
  - Child–Pugh score, 120, 120t
  - clinical features, 121, 121b
  - complications, 121–124
    - ascites, 121–122, 122b
    - coagulopathy, 123
    - esophageal/gastric varices, 121, 122b
    - HCC, 124
    - hepatic encephalopathy, 122–123
    - hepatorenal syndrome, 123
    - hyperestrinism, 123
    - portal HTN, 121
    - SBP—infected ascitic fluid, 123
  - definition, 120
  - hepatic functional reserve assessment, 120–121
  - irreversible, 120
  - treatment, 124
- Coagulation, disorders of, 347–348
  - coagulopathy of liver disease, 349
  - disseminated intravascular coagulation, 347–348
  - hemophilia A, 346–347, 347t
  - hemophilia B, 347
  - hypercoagulable states, 350–351
  - laboratory findings for, 348t
  - vitamin K deficiency, 349
  - von Willebrand disease, 345–346, 346t
Coagulopathy of liver disease, 349
Clonidine, in Tourette syndrome, 216
Clubbing of finger, 89b, 89f
Cluster headaches, 444
Coal worker’s pneumoconiosis, 92
Coarctation of aorta, 50, 50b
Coexisting hypocalcemia, 317
“Coffee grounds” emesis, 145
“Cold” nodules, 189b
Colon, diseases of, 113–115
• acute mesenteric ischemia, 117–118
• angiodysplasia of colon, 116–117
• chronic mesenteric ischemia, 118
• colonic polyps, 115–116
• colonic volvulus, 118–119
• colorectal cancer, 113–115
• diverticulosis, 116–117
• ogilvie syndrome, 118
Colonic polyps, 115–116
Colonic volvulus, 118–119
Colonoscopy, 113, 147
Colorectal cancer (CRC), 113–115
• clinical features, 114–115
• general characteristics, 113
• risk factor, 114
• risk factors, 114
• screening, 113, 113b
• treatment, 115
Common cold, 447–448
Common wart, 426
Community-acquired pneumonia (CAP), 365
• atypical, 366b
• diagnosis of, 366, 367b
• sputum culture, 366b
• treatment, 368
• typical, 365
Compensatory mechanisms, 65b
Conduction aphasia, 235
Congenital adrenal hyperplasia (CAH), 203–204
Congenital heart diseases, 48–52, 48b
• atrial septal defect, 48–49
• coarctation of aorta, 50
• patent ductus arteriosus, 50–51
• tetralogy of fallot, 51–52
• ventricular septal defect, 49–50
• Congestive heart failure (CHF), 12, 15–21
  • cause of death from, 21b
  • definition, 15
  • diagnosis, 18
• heart failure with preserved ejection fraction, 17
• heart failure with reduced ejection fraction, 15–17
• left-sided, 17–18
• medications contraindicated in, 23b
• NYHA classification, 17b
• pathophysiology, 15, 16f
• right-sided, 18
• treatment, 19–20
  • general principles in, 20b
  • HFpEF therapy, 20–21
  • HFrEF therapy, 20b
• systolic dysfunction, 19
• Conjugated hyperbilirubinemia, 129–130
• Conjugated vs. unconjugated bilirubin, 129
• Conjunctivitis, 475
• Connective tissue diseases
  • mixed, 247
  • scleroderma, 244–246
  • Sjögren syndrome, 246–247
  • systemic lupus erythematosus, 241–244
• Constipation, 455–457
  • complications of, 457b
• Constrictive pericarditis, 36–37, 37b
  • causes, 36
  • clinical features, 37
  • diagnosis, 37
  • pathophysiology, 36
  • treatment, 37
• Contact dermatitis, 417–418, 418f
  • allergic, 417
  • irritant, 417
Corkscrew esophagus, 151
Coronary angiogram, 4f
Coronary angiography, cardiac catheterization with, 3, 3b
Coronary artery bypass grafting (CABG), 5b, 11b
Coronary ischemia, 1
Cor pulmonale, 104, 104b
Corrigan pulse, 42
Corticosteroids, in Crohn disease, 163
Cortisol, 197b
Cough, 446–447
  • acute, 447
  • cause, 446
  • chronic, 446
  • diagnosis, 446
  • treatment, 446–447
Cramping leg pain, 56
Craniopharyngioma, 192
Creatine kinase-MB (CK-MB), 9
CRH stimulation test, 199
Crigler–Najjar syndrome, 130
Crohn disease, 162–163, 162b, 164t
Cryptogenic organizing pneumonitis (COP), 94
Crystal-induced arthritides
  • gout, 252–255
  • pseudogout, 255, 256f
Cushing disease, 199b
Cushing syndrome, 197–199, 324
  • causes, 197–198
  • clinical features, 198
  • diagnosis, 198–199
  • general characteristics, 197
  • response to diagnostic tests in, 199t
  • treatment, 199
Cystic fibrosis, 77
Cytologic examination of sputum, 79
Cytoprotection, 156
Dawn phenomenon, 168b
D-dimer assay, 107
Decompression via sigmoidoscopy, 119
Deep venous thrombosis (DVT), 59–61, 61b
- clinical features, 59
- complications, 60
- diagnosis, 59–60
- general characteristics, 59
- treatment, 60–61
Defibrillation, 24b, 31b
Dementia
- causes of, 216b
- with Lewy bodies, 218
- vs. delirium, 219t
- vs. forgetfulness, 216b
Demyelinating disease
- Guillain-barré syndrome, 223–224
- multiple sclerosis, 222–223
Dermatitis herpetiformis, 161
Dermatomyositis, 256
Dermatophytes, 428–429, 429t
Desmopressin (DDAVP), 194
- in diabetes insipidus, 308
- in von Willebrand disease, 345
Diabetes insipidus (DI), 193–194
Diabetes mellitus (DM), 167–173
- acute complications of, 176–178
- diabetic ketoacidosis, 176–177
- hyperosmolar hyperglycemic nonketotic syndrome, 177–178, 177t
- chronic complications, 173–176, 173f
- macrovascular complications, 173
- microvascular complications, 174–175
- specific treatment of, 175–176
- chronic complications of, 173–175
- macrovascular, 173
- microvascular, 174–175
- classification, 167
- clinical presentation, 169–170, 169t
- diabetic ketoacidosis and, 176–177, 177t
- diabetic nephropathy and, 174
- diabetic neuropathy and, 175
- diabetic retinopathy and, 174
- diagnosis, 169, 169t
- monitoring glucose levels in, 172b
- outpatient management and monitoring, 168b
- pathogenesis, 167
- treatment, 170–173
  - diet and exercise, 170
  - insulin, 171–173, 171t
  - oral hypoglycemic drugs, 170–171, 171t
  - surgical, 173
  - Diabetic foot, 175
  - Diabetic ketoacidosis (DKA), 176–177, 177t
  - Diabetic nephropathy, 174, 175f
  - Diabetic retinopathy, 174
  - Dialysis, 275–278
    - hemodialysis, 276–277
    - limitations and complications of, 277–278
    - peritoneal, 277
  - Diarrhea, 452–455, 453b
    - acute, 452
    - causes, 453
    - chronic, 452
    - diagnosis, 453–455, 454f
    - laboratory tests for, 454b, 454f
    - pathogenic organisms for, 456t
    - treatment, 455
  - Diastolic dysfunction, 17
  - Diet and exercise, 170, 179
  - Diffuse esophageal spasm (DES), 150–151, 150f
  - Diffuse interstitial fibrosis, flow volume curves in patient with, 72f
  - Diffuse toxic goiter. See Graves disease
  - Digoxin, 22b, 23b
  - Dilated cardiomyopathy, 33
  - Direct oral anticoagulants (DOACs), for AFib, 24
  - Disseminated intravascular coagulation (DIC), 347–348
  - Distal esophageal webs. See Schatzki ring
  - Distal symmetric neuropathy, 175
  - Diuretics
• in acute decompensated heart failure, 20–21
• in hypertrophic cardiomyopathy, 34
• in systolic dysfunction, 20
  > Diverticulitis, 116
  > Diverticulosis, 116–117
• complications, 116–117, 116b
• vs. diverticulitis, 116b
• DLCO, 111t
• Dressler syndrome, 14
• Drug reactions, 422–424
  > overview, 422
  > Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), 423
• Dual antiplatelet therapy (DAPT), 6
• Duchenne muscular dystrophy, 225
• Duke clinical criteria, 47, 47t
• Duodenal vs. gastric ulcers, 155t
• Dyslipidemia syndromes, 440t
• Dyspepsia, 450–451
  > GERD and, 450
  > GI causes, 450
  > nonulcer, 450b
  > treatment, 450–451
• Dysphagia, 149, 153f
• Dyspnea, 110–112
E

- Eaton–Lambert syndrome, 79
- ECG, 37b, 41, 64
  - in acute pericarditis, 36
  - in aortic regurgitation, 43
  - in atrial flutter, 26, 26f
  - in cardiac tamponade, 39
  - in CHF, 18
  - in mitral stenosis, 40
  - in multifocal atrial tachycardia, 26, 27f
  - in myocardial infarction, 8–9, 8f, 9t
  - in pericardial effusion, 38
  - in premature atrial complexes, 21
  - in PSVT, 27f
  - in pulmonary hypertension, 103
  - resting, 2
  - in restrictive cardiomyopathy, 34
  - stress, 2
  - in tetralogy of fallot, 51
  - in tricuspid regurgitation, 45
  - in ventricular fibrillation, 30, 30f
  - in ventricular tachycardia, 29, 29f
- Ectopic ACTH production, 198
- Eisenmenger disease, 49
- Electrolytes, 276b
- Embolectomy, 118
- Embolic stroke, 207
- Emboli sources, 104b
- Embolization, 57
- Emphysema, 69, 70t
- Empyema, 84
- Encephalitis, 375–376
- Endocarditis, 46b, 47
- Endoluminal adenocarcinomas, 113
- Endoscopy, for dyspepsia, 450
- Endoscopy, in peptic ulcer disease, 154
- Environmental enteropathy. See Tropical sprue
- Environmental lung disease, 88, 92–93, 92b
- Eosinophilic granulomatosis with polyangiitis, 92
- Eosinophilic pneumonia, 93
- Epididymitis, 301
- Epigastric pain, 154, 156
- Epiphrenic diverticula, 153
- Erysipelas, 396–397
- Erythema multiforme (EM), 423, 423f
- Erythroderma, 424
- Esophageal cancer, 148–149
- Esophageal diverticula, 153–154
- Esophageal hiatal hernias, 151, 152f
- Esophageal perforation, 154
- Esophagectomy, 149
- Esophagomyotomy, 151
- Esophagus, diseases of, 148–154
  - achalasia, 149–150
  - diffuse esophageal spasm, 150–151
  - esophageal cancer, 148–149
  - esophageal diverticula, 153–154
  - esophageal hiatal hernias, 151
  - esophageal perforation, 154
  - Mallory–Weiss syndrome, 151
  - Plummer–Vinson syndrome, 151–152
  - Schatzki ring, 152–153
- Essential thrombocythemia, 364
- Estrogen replacement therapy, 441b
- Evidence-based medicine, 516–519
- Exercise-induced ischemia, 2
- Exercise stress ECG, 2b
- Exercise stress testing, 41
- Exophthalmos, 183f
- Expiratory reserve volume (ERV), 71f
- External compression stocking, 62
- Extracellular fluid (ECF), 302
- Extrinsic allergic alveolitis. See Hypersensitivity pneumonitis
- Extrinsic asthma, 74
- Exudative effusion, 82–83, 83b, 84
Facial Nerve Palsy, differential diagnosis for, 236b
Factor VIII coagulant protein, and von Willebrand disease, 346t
Familial adenomatous polyposis (FAP), CRC risk with, 114
Familial juvenile polyposis coli, CRC risk with, 114
Fatigue, 482–483
Fecal immunochemical tests (FIT), 113
Fecal occult blood testing (FOBT), 113
Felty syndrome, 252b
Fever of unknown origin (FUO), 408–411, 411b
Fiberoptic bronchoscopy, 79, 112
Fibromyalgia, 259
Fibrous thyroiditis, 187
Fine-needle aspiration (FNA) biopsy, 188, 188b
First-degree AV block, 32, 32f
Fistulae, 163
Flat war, 426
Flexible sigmoidoscopy, 113
Fluid replacement, 177, 178, 303
Focal nodular hyperplasia, 126
Fogarty balloon catheter, 59
Folate deficiency, 334–335
Follicular carcinoma, 189
Forceful dilatation, 150
Frank–Starling relationship, 16f
Free thyroxine index (FTI), 183
Free wall rupture, 13
G
gallbladder and biliary tract, diseases of, 132–138
  • acalculous cholecystitis, 134
  • acute cholecystitis, 133–134
  • bile duct stricture, 138
  • biliary dyskinesia, 138
  • carcinoma of gallbladder, 135
  • cholangiocarcinoma, 137–138
  • cholangitis, 135
  • choledochal cysts, 138
  • choledocholithiasis, 134
  • cholelithiasis, 132–133
  • primary biliary cirrhosis (PBC), 137
  • primary sclerosing cholangitis, 135–136
  • gallstone ileus, 133b
  • Gardner syndrome, 114
  • Gardner syndrome, CRC risk with, 114
  • gastric cancer, 158
  • gastric lymphoma, 158
  • gastric outlet obstruction, 157t
  • gastric ulcers, duodenal vs., 155t
  • gastrinoma. See Zollinger–Ellison syndrome (ZES)
  • Gastroenteritis, 458b
  • gastroesophageal reflux disease (GERD), 451–452
    • Barrett esophagus and, 451
    • erosive esophagitis and, 451
    • esophageal ulcer and, 451
    • heartburn in, 451
    • hiatal hernia in, 451
    • peptic stricture and, 451
    • pneumonia and, 452
    • treatment, 452
  • gastrointestinal bleeding, 144–148, 157t
    • causes, 145
    • clinical features, 145
    • diagnosis, 146–147, 146b, 146f
    • evaluation, 146f
    • factors increasing mortality in, 147b
    • general characteristics, 144
    • treatment, 147–148
Gastrointestinal disorders, 14b
Gastrointestinal system, diseases of, 113–166
  • appendix, diseases of, 138–139
  • colon, diseases of, 113–115
  • esophagus, diseases of, 148–154
  • gallbladder and biliary tract, diseases of, 132–138
  • gastrointestinal bleeding, 144–148
  • inflammatory bowel disease, 162–166
  • liver, diseases of, 119–132
  • pancreas, diseases of, 139–144
  • small intestine, diseases of, 158–161
  • stomach, diseases of, 154–158
Genital warts, 385
Gilbert syndrome, 130
Glanzmann thrombasthenia, 345
Glasgow coma scale, 221t
Glasgow Coma Scale, 221t
Glaucoma, 473–473
  • closed-angle, 472
  • diagnosis, 473
  • open-angle, 473
  • risk factors, 473
  • treatment, 473
Global aphasia, 235
Glucagonoma, 181
Gonococcal arthritis, 400b
Gonorrhea, 385–386
Goodpasture disease, 93
Granulomas, ILD associated with, 89–92
  • eosinophilic granulomatosis with polyangiitis, 92
  • granulomatosis with polyangiitis, 92
  • pulmonary langerhans cell histiocytosis, 91–92
  • sarcoidosis, 89–91
Granulomatosis with polyangiitis, 92
Graves disease, 182
Guillain-barré syndrome, 223–224
Haloperidol
- in delirium, 216
- in Tourette syndrome, 215
- Hartnup syndrome, 287
- Hashimoto disease, 185
- Hashimoto thyroiditis, 185b, 186
- Headache, 443–446
  - cluster, 444
  - differential diagnosis of, 443b
  - emergency evaluation of, 443b
  - migraine, 445–446
  - red flags, 444b
  - tension, 443
- Hearing impairment, 479b
- Hearing loss, 479–480
- Heart failure with preserved ejection fraction (HFpEF), 17, 20–21
- Heart failure with reduced ejection fraction (HFrEF), 15–17, 20b
- Heart muscle, diseases of, 33–35
  - dilated cardiomyopathy, 33
  - hypertrophic cardiomyopathy, 33–34
  - myocarditis, 35
  - restrictive cardiomyopathy, 34–35
- Heinz bodies, 340
- *Helicobacter pylori* eradication, 156t
- Helmet cells, 335
- Hematemesis, 145
- Hematochezia, 145
- Hematuria
  - causes, 280
  - diagnosis, 281–282
  - evaluation, 281f
  - gross, 282b
  - treatment, 281
- Hemobilia, 127
- Hemochromatosis, 125–126
- Hemodynamic monitoring, 64
- Hemoglobin/hematocrit level, 146
- Hemolytic anemias, 335–336
- Hemolytic transfusion reaction
• acute, 327b
• delayed, 327b
  ◦ Hemoptysis, 112, 112b
  ◦ Hemorrhagic pancreatitis, 141
  ◦ Hemorrhagic stroke
    • intracerebral hemorrhage, 210–211
    • subarachnoid hemorrhage, 211–212
  ◦ Hemorrhagic tamponade, 39
  ◦ Hemorrhoids, 459–460
  ◦ Heparin
    • administration, 351
    • contraindications to, 351
    • indications for use, 351
    • mechanism of action, 351
    • in MI, 11, 12b
    • reversing effects of, 351
  ◦ Heparin-induced thrombocytopenia, 345
  ◦ Hepatic abscess, 135b
  ◦ Hepatic functional reserve assessment, 120–121
  ◦ Hepatocellular adenoma, 126
  ◦ Hepatocellular carcinoma (HCC), 124, 126–127
    • clinical features, 127
    • diagnosis and treatment, 127
    • general characteristics, 126
    • prognosis, 127b
    • risk factors, 126–127
  ◦ Hereditary nonpolyposis CRC, 114
  ◦ Hereditary spherocytosis, 339
  ◦ Herpes simplex virus, 391f
  ◦ Herpes zoster, 428, 428f
  ◦ Herpetic whitlow, 393b
  ◦ Hidradenitis suppurativa, 417
  ◦ High-dose dexamethasone suppression test, 199
  ◦ High-output heart failure, 15b
  ◦ Hip osteoarthritis, 466b
  ◦ Hodgkin lymphoma, 356–358
  ◦ Horner syndrome, 78, 227
  ◦ “Hot” nodules, 189b
  ◦ Human parvovirus B19, 338
  ◦ Huntington chorea, 214
- Hürthle cell tumor, 189b
- Hydatid liver cysts, 128
- Hydralazine, 22b
- Hyperaldosteronism, 201b
- Hypercalcuiaria, 292b
- Hypercapnic (hypercarbic) respiratory failure, 95
- Hypercoagulable states, 350–351
- Hyperglycemia, 307
- Hyperinsulinemic hypoglycemia, laboratory values in, 181t
- Hyperlipidemia, 4
- Hyperlipidemias, 440–443, 443t
  - clinical features, 441
  - diagnosis, 441
  - drug therapy, 443t
  - HDL cholesterol, 441
  - LDL cholesterol, 441
  - treatment, 442
- Hypernatremia, 193
- Hyperosmolar hyperglycemic nonketotic syndrome, 177–178, 177t
- Hyperoxaluria, 292b
- Hyperphosphatemia, 319
- Hyperpigmentation, 199b, 202
- Hyperplastic (metaplastic) polyps, 115
- Hyperprolactinemia, 191
- Hypersensitivity, ILD associated with, 93
- Hypersensitivity pneumonitis, 93, 93b
- Hypertension (HTN), 50, 435–440
  - α blockers, 438
  - β blockers, 438
  - calcium channel blockers, 439
  - cotton wool spots, 436, 437f
  - definition, 435b
  - diagnosis, 437–438
  - essential, 435
  - pathophysiology, 435b
  - risk factors, 435
  - secondary, 435
  - target organ damage, 436
  - thiazide diuretics, 438
  - treatment, 438–440
- vasodilators, 439
- white coat, 439b
- Hypertensive emergency, 52–53, 53b
- Hypertensive nephrosclerosis, 291
- Hypertensive urgencies, 52, 53b
- Hyperthyroidism, 182–184, 184b
  - causes, 182
  - clinical features, 182
  - diagnosis, 183
  - Plummer disease and, 182
  - treatment
    - nonpregnant patients, 184
    - pharmacologic, 183–184
    - radioiodine, 184
    - surgical, 184
- Hypertonic hyponatremia, 307
- Hypertrophic cardiomyopathy, 33–34
  - clinical features, 33
  - diagnosis, 34
  - pathophysiology, 33
  - treatment, 34
- Hypertrophic pulmonary osteoarthropathy, 79
- Hypervolemia, 305
- Hypocalcemia, 311–312
  - ECG in, 311
- Hypoglycemia, 179–180, 514
  - causes, 179–180
  - clinical features, 180
  - diagnosis and treatment, 180
  - general characteristics, 179
  - hyperinsulinemnic, laboratory values in, 181t
  - insulinoma and, 180
  - physiologic responses to, 179b
- Hypoglycemic unawareness, 180b
- Hypokalemia, 181, 313–314, 315f
  - and arrhythmias, 314
  - causes, 313–314
  - clinical features, 314
  - treatment, 314
- Hyponatremia, 176, 194b, 306–308
- causes and classification, 306
- clinical features, 307
- diagnosis, 307, 308f
- treatment, 308
  - Hypoparathyroidism, 195–196
  - Hypopituitarism, 190, 192–193
  - Hypothyroidism, 185–186
  - Hypotonic hyponatremia, 306–307
  - Hypovolemia, 304–305
  - Hypovolemic shock, 65–66
    - diagnosis, 66
    - general characteristics, 65–66
    - hemodynamic changes in, 65t
    - obstructive, 66
    - treatment, 66
  - Hypoxemia, 95b, 96f
  - Hypoxemic respiratory failure, 95
I

- Iatrogenic Cushing syndrome, 197
- Idiopathic inflammatory myopathies, 256–258
- Idiopathic pulmonary fibrosis, 93–94
- Immune thrombocytopenic purpura, 344
- Impedance plethysmography, 59
- Inclusion body myositis, 258
- Infectious mononucleosis, 412–414, 413t
- Infective endocarditis (IE), 46–48
  - classifications, 46
  - complications, 47
  - definition, 46
  - diagnosis and treatment, 47, 47t
  - prophylaxis, 48
- Inferior vena cava filter placement, in DVT, 60
- Inferior vena cava interruption, 108–109
- Inflammatory bowel disease (IBD), 162–166
  - CRC risk with, 114
  - Crohn disease, 162–163
  - epidemiology, 163b
  - extraintestinal manifestations, 162b
  - ulcerative colitis (UC), 163–166
- Inflammatory polyps, 115
- Influenza, 372
- Inhaled anticholinergic drugs, in COPD, 71
- Inhaled b2-agonists, in asthma, 75, 76
- Inhaled corticosteroids
  - in asthma, 75–76, 76b
  - in COPD, 72
- Inotropy, 64
- Insomnia, 478
- Inspiratory capacity (IC), 71f
- Insulin, 171–173, 171t, 177, 178
- Insulinoma, 180–181
- Intensive insulin therapy, 172
- Internuclear ophthalmoplegia, 222
- Interstitial lung disease (ILD), 88–94, 88b
  - alveolar filling disease, 88, 93
  - associated with granulomas, 89–92
• associated with hypersensitivity, 93
• classification, 88
• clinical features, 88
• cryptogenic organizing pneumonitis (COP), 94
• diagnosis, 88–89, 90f
• environmental lung disease, 92–93
• general characteristics, 88
• hypersensitivity lung disease, 88
• idiopathic pulmonary fibrosis, 93–94
• radiation pneumonitis, 94
• Interstitial pulmonary inflammation, 94
• Interventricular septum, rupture of, 13
• Intoxications, 276b
• Intra-abdominal abscess, 379
• Intra-aortic balloon pump, 65b
• Intracellular fluid (ICF), 302
• Intracerebral hemorrhage (ICH), 210–211, 211f
• Intrinsic asthma, 74
• Iron deficiency anemia, 329
• Iron overload, 125–126
• Irritable bowel syndrome, 457–458
• Ischemia
  • detection methods, 3b
  • markers for, 8
  • Ischemic heart disease, 1–15
    • angina pectoris, stable, 1–2
    • angina pectoris, unstable, 5–7
    • chest pain, 14–15
    • diagnosis, 2
    • myocardial infarction, 7–14
  • Ischemic strokes, 205–210
    • causes of, 206–207, 206f
    • classes of, 205
    • complications, 208
    • deficits seen in, 207t
    • risk factors, 205
    • treatment, 208
  • Ischemic ulceration, 56
  • Isosorbide dinitrate, 22b
  • Isotonic hyponatremia (pseudohyponatremia), 307
J
- Jaundice, 129–130, 144
  - causes, 129–130, 129b
  - diagnosis and treatment, 130
  - general characteristics, 129
- Joint pain, causes of, 467
- Jugular venous pulse, 64b
K
   Kayexalate, 317
   Kayser–Fleischer ring, 124f
   Keratoacanthoma, 432
   Ketonemia, 176
   Klatskin tumors, 137b
   Knee pain, 464–465
     • causes, 464
     • diagnosis, 465
   Krukenberg tumor, 158b
\textbf{L}

- Lactated Ringer solution, 303
- Lacunar stroke, 207
- Lambert-Eaton myasthenic syndrome, 224b
- Large bowel obstruction, 159f
- Laryngitis, 449
- Left heart disease, 103
- Left-sided heart failure, 17–18
- Leg raise maneuvers, 33b
- Leriche syndrome, 55b
- Libman–Sacks endocarditis. See Nonbacterial verrucous endocarditis
- Lichen planus, 420
- Lipid-lowering therapy, 4
- Liver, diseases of, 119–132
  - acute liver failure, 119–120
  - Budd–Chiari syndrome, 128–129
  - cavernous hemangiomas, 126
  - cirrhosis, 120–124
  - focal nodular hyperplasia, 126
  - hemobilia, 127
  - hemochromatosis, 125–126
  - hepatocellular adenoma, 126
  - hepatocellular carcinoma, 126–127
  - jaundice, 129–130
  - liver abscess, 128
  - liver cysts, 127–128
  - liver function tests, 130–132
  - nonalcoholic steatohepatitis, 127
  - Wilson disease, 124–125
- Liver abscess, 128
- Liver cysts, 127–128
  - hydatid, 128
  - polycystic, 127–128
- Liver function tests, 130–132
  - albumin, 132
  - ALK-P, 132
  - ALT and AST, 130–132
  - GGT, 132
  - PT, 132
- Liver transplantation, in cirrhosis, 124
Locked in syndrome, 221b
Low back pain (LBP)
  • back examination, 462
  • causes, 460–462, 460b
  • chronic, 460
  • diagnostic tests, 460–463
  • management, 463
  • treatment, 463
Low back pain (LBP), 460–463
Lower GI bleeding, 144
  • causes, 145
  • treatment, 147
Low-molecular-weight heparin (LMWH), 6, 61b, 108
  • indications for use, 351
  • mechanism of action, 351
Luetic heart, 58–59
Lung abscess, 369–370
Lung cancer, 78–80
  • clinical features, 78–79, 78b
  • diagnosis, 78b
  • pathologic types, 78
  • prognosis, 80b
  • risk factors, 78
  • staging, 78
  • treatment, 79–80
  • types, 81t
Lung disease, 103
Lung neoplasms, 78–82
  • lung cancer, 78–80
  • mediastinal masses, 81–82
  • solitary pulmonary nodule, 80–81, 80f
Lung volumes, 71f
Lyme disease, 401–402, 402f
Lymphadenitis, 397
Lymphangitis, 62b
Lymphocytic thyroiditis. See Chronic lymphocytic thyroiditis
Lymphogranuloma venereum, 395
Lynch syndrome I and II, 114
Macroadenoma, 190
Macrovascular complications, 173
Magnesium metabolism, 317–318
  • absorption and balance, 317
  • hypermagnesemia, 318
  • hypomagnesemia, 317–318
Maintenance fluid, calculation of, 305, 310b
Malaria, 403–404
Malignant hepatoma. See Hepatocellular carcinoma
Malignant mesothelioma, 86–87, 86b
Mallory–Weiss syndrome, 151
Marantic endocarditis. See Nonbacterial thrombotic endocarditis
Marjolin ulcer, 433b
MDI and nebulizers, 76b
Mean corpuscular volume (MCV), 328
Mechanical ventilation, 100–102
  • complications, 102
  • general characteristics, 100–101
  • key parameters, 102
  • ventilator settings, 101–102, 101b
Mediastinal masses, 81–82
Mediastinoscopy, 79
Medullary carcinoma, 189
Medullary sponge kidney, 289, 289f
Melanoma, 433–434, 434f
Melena, 145
Meningitis, 373–375
  • acute, 373
  • aseptic, 373
  • bacterial, 373
  • chronic, 373
  • CSF findings in, 374t
  • treatment, 374–375, 375t
Metabolic acidosis, 176, 319–323, 320b
  • arterial blood gas interpretation, 322b
  • asthmatic child and, 323
  • causes, 321
  • clinical features, 322
  • diagnosis, 322–323
• pathophysiology, 320, 320f
• salicylate overdose and, 322
• treatment, 323
  • Metabolic alkalosis, 323–324
  • causes, 323–324
  • clinical features, 324
  • diagnosis, 324
  • treatment, 324
  • with volume contraction, 324
• Metabolic Syndrome X, 2b
• Metastases of gastric carcinoma, 158b
• Methacholine challenge, 111t
• Microadenoma, 190, 191b
• Microalbuminuria, 174
• Microvascular complications, 174–175
• Migraine, 445–446
  • clinical features, 445
  • treatment, 445–446
  • types, 445
  • visual aura, 445b
• Mineralocorticoids, 200
• Mitral regurgitation, 43–44
  • causes, 43
  • clinical features, 43–44
  • diagnosis and treatment, 44
  • pathophysiology, 43
• Mitral stenosis, 39–40
• Mitral valve prolapse, 45, 45b
• Model for End-Stage Liver Disease (MELD) score, 120–121
• Molluscum contagiosum, 427, 427f
• Mononeuropathies, 175
• Montelukast—leukotriene modifiers, 76
• Morphine, 11
• Movement disorders, 212–214
  • Huntington chorea, 214
  • Parkinson disease, 212–214
• Multifocal atrial tachycardia, 26
• Multinodular toxic goiter. See Plummer disease
• Multiple endocrine neoplasia (MEN) syndrome, 200b
• Multiple myeloma, 355–356
Multiple organ dysfunction syndrome (MODS), 67b
Multiple sclerosis (MS), 222–223
- clinical features, 222–223
- course, 222–223
- demyelination of CNS in, 222
- diagnosis, 223, 223b
- disease-modifying therapy, 223b
- high-dose IV corticosteroids in, 223
- relapses, 222b
- symptomatic therapy in, 223
- treatment, 223
Murmurs, 508
Myasthenia gravis, 224b
Mycotic aneurysm, 58
Myelodysplastic syndromes, 364
Myeloproliferative disorders
- myelodysplastic syndromes, 364
- polycythemia vera, 363
Myocardial infarction, 7–14
- anterior wall, 8f
- asymptomatic, 7
- cardiac monitoring for patient with acute, 9b
- causes of, 7
- chest pain in, 7
- complications, 12–14, 12f
- diagnosis, 8–9
- indications for, 11b
- symptoms, 7–8
- treatment, 10–11
Myocarditis, 35
Myxedema coma, 185b
Narcolepsy, 477
Narrow complex tachycardias, 30b
Nasogastric tube, 147
Native valve endocarditis, 46
Nausea and vomiting, 458–459
  • causes of, 458b
  • complications of, 459b
Nebulizers and MDI, 76b
Necrotizing fasciitis, 397
Nephrogenic DI, 193–194
Nephrolithiasis
  • diagnosis, 293
  • presentation, 293b
  • risk factors, 292
  • treatment, 294–295
  • types of stones, 292–293
Nephrotic syndrome, 278b, 307
Neurocutaneous syndromes
  • neurofibromatosis type I, 226
  • neurofibromatosis type II, 226
  • Sturge-Weber syndrome, 226
  • tuberous sclerosis, 226
  • Von Hippel-Lindau disease, 226
Neurogenic shock, 67
Neurologic lesion, 237–240
  • brainstem, 237
  • cerebellum, 237
  • cerebral cortex, 237, 238f
  • muscle, 239–240
  • neuromuscular junction, 239
  • peripheral nerve, 239
  • plexus, 237–238
  • roots, 238
  • spinal cord, 237
  • subcortical lesions, 237
Neuromuscular diseases
  • Becker muscular dystrophy, 225
  • Duchenne muscular dystrophy, 225
  • myasthenia gravis, 224–225
Neutropenic fever, 412
New York Heart Association (NYHA) classification, 17b
Nicotine chewing gum, 485
Nitrates, 4–5
  • in achalasia, 149
  • in acute decompensated heart failure, 21
  • in MI, 11
Nitroglycerin, sublingual, 14b, 149
Nonalcoholic steatohepatitis, 127
Nonbacterial thrombotic endocarditis, 48
Nonbacterial verrucous endocarditis, 48
Nonhemorrhagic tamponade, 39
Non-hodgkin lymphoma, 358–359, 359t
Noninsulin diabetes medications, 170–171, 171t
Noninvasive positive pressure ventilation (NPPV), 74, 98b
Nonneoplastic polyps, 115
Nonocclusive mesenteric ischemia, 117
Non–small cell lung cancer (NSCLC), 78, 79–80, 79b, 81t
Nontraumatic abdominal pain, approach to diagnosis of, 165f
Normal saline (NS), 303
NSTEMI vs. unstable angina pectoris, 6, 6b
Obesity, 178–179, 478–479
Obstructive lung diseases, 69–77
  • asthma, 74–77
  • bronchiectasis, 77
  • chronic obstructive pulmonary disease, 69–74
  • cystic fibrosis, 77
  • vs. restrictive lung disease, 71t
Obstructive shock, 67–68
Obstructive sleep apnea (OSA), 476–477
  • complications, 477b
Odynophagia, 148
Ogilvie syndrome, 118
Oliguria, 513–514
Optic neuritis, 222b
Oral glucocorticoids, 165
Oral hypoglycemic drugs, 170–171, 171t
Oral sodium loading, 201
Orlistat, 179
Orthodromic AV reentrant tachycardia, 26–27
Orthodromic reciprocating tachycardia, 28
Orthostatic syncope, 230b
Osmotic diuresis, 309
Osteitis fibrosa cystica, 196f
Osteoarthritis, 467–469, 469f
  • clinical features, 467–468
  • diagnosis, 468
  • risk factors, 467
  • treatment, 468–469
Osteomyelitis, 398–399
Osteoporosis, 469–472
  • bone mineral density T-score criteria for, 471b
  • diagnosis, 471
  • fracture risk in, 470b
  • treatment, 471
Oxygen delivery systems, 97t
Oxygen therapy for COPD, 73, 73b
Painless jaundice, 144b
Painless rectal bleeding, 116
Painless thyroiditis. See Subacute lymphocytic thyroiditis
Palpable gallbladder, 144
Pancoast tumor, 78–79
Pancreas, diseases of, 139–144, 167–181
- acute diabetic complications, 176–178
- acute pancreatitis, 139–142
- chronic diabetic complications, 173–176
- chronic pancreatitis, 142–144
- diabetes mellitus, 167–173
- glucagonoma, 181
- hypoglycemia, 179–180
- insulinoma, 180–181
- obesity, 178–179
- pancreatic cancer, 144
- somatostatinoma, 181
- VIPoma, 181
- Zollinger–Ellison syndrome (ZES), 181
Pancreatic cancer, 144
Pancreatic enzymes, 143
Pancreatic necrosis, 141
Pancreatic pseudocyst, 141
Panlobular emphysema, 69b
Papaverine, intra-arterial infusion of, 118
Papillary carcinoma, 189, 189b
Papillary muscle rupture, 13–14
Papilledema, 211b
Paraesophageal hiatal hernia (type 2), 151, 152f
Paralytic ileus, 161
Paraneoplastic syndromes, 79
Parapneumonic effusion, 84
Parathyroid glands, diseases of, 195–197
- hypoparathyroidism, 195–196
- primary hyperparathyroidism, 196–197
Parkinson disease, 212–214
Paroxysmal nocturnal hemoglobinuria (PNH), 342
Paroxysmal supraventricular tachycardia, 26–28
- causes, 27
- pathophysiology, 26–27, 28f
- treatment, 28
- Paroxysmal tachycardia, 28
- Partial seizure, 232
- Patellar tendinitis, 465
- Patellofemoral pain, 464
- Patent ductus arteriosus (PDA), 50–51, 51b
- Peak expiratory flow rate, 75
- Pediculosis pubis, 395–396
- Pemphigus vulgaris, 425, 426f
- Penile cancer, 300
- Peptic ulcer disease, 154–156, 157t
  - causes, 154
  - clinical features, 154
  - complications, 157t
  - diagnosis, 154–155
  - treatment, 155–156
- Percutaneous coronary intervention, 5b, 11b
- Perforation, 157f, 157t
- Pericardial diseases, 35–39
  - acute pericarditis, 35–36
  - cardiac tamponade, 38–39
  - constrictive pericarditis, 36–37
  - pericardial effusion, 37–38
- Pericardial effusion, 37–38, 37b
  - clinical features, 37
  - diagnosis, 38
  - general characteristics, 37
  - treatment, 38
- Pericardial fluid analysis, 38
- Pericardial friction rub, 36
- Pericardiocentesis, 39
- Periodic acid-Schiff stain (PAS)–positive macrophages, 161
- Peripheral arterial disease (PAD), 56–57, 58t
- Peripheral neuropathy, 175
- Peristalsis, 161
- Pernicious anemia, 333
- Phalen test, 467b
- Pharmacologic stress test, 3
- Phenoxybenzamine, 200
Phenytoin, 234
Pheochromocytoma, 199–200, 200b
Phlegmasia cerulea dolens, 60
Phosphate, 318–319
- excretion and balance, 318
- hyperphosphatemia, 319
- hypophosphatemia, 318
Phosphodiesterase-4 inhibitors, 73
Phrenic nerve palsy, 78
Physical examination pearls
- abdominal examination, 508–509
- neurologic examination, 509–510, 510f
Pigment stones, 132
Pimozide, in Tourette syndrome, 216
Pituitary adenomas, 190
Pituitary gland, diseases of, 190–195
- acromegaly, 191–192
- craniopharyngioma, 192
- diabetes insipidus (DI), 193–194
- hyperprolactinemia, 191
- hypopituitarism, 192–193
- pituitary adenomas, 190
- syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 194–195
Pityriasis rosea, 420, 420f
Plantar wart, 426
Plasma metanephrines, 200
Plasma osmolality, in DI, 193
Platelet disorders, 342–343, 343f
- Bernard–Soulier syndrome, 345
- Glanzmann thrombasthenia, 345
- heparin-induced thrombocytopenia, 345
- immune thrombocytopenic purpura, 344
- thrombocytopenia, 342–343, 344f
- thrombotic thrombocytopenic purpura, 344–345
Pleura, diseases of, 82–87
- empyema, 84
- malignant mesothelioma, 86–87
- pleural effusion, 82–84, 82f, 83f
- pneumothorax, 84–85
- tension pneumothorax, 85–86
Pleural effusion, 82–84
  • causes, 83
  • chest radiograph, 82f
  • clinical features, 83
  • diagnosis, 83–84
  • exudative, 82–83, 83b, 84
  • general characteristics, 82–83
  • transudative, 82, 83b, 84
  • treatment, 84
Pleural fluid pearls, 83b
Plica syndrome, 465
Plummer disease, 182
Plummer–Vinson syndrome, 151–152
Pneumoconiosis. See Environmental lung disease
Pneumonia, 365–369
  • community-acquired, 365
  • hospital-acquired, 369
  • nosocomial, 365
  • pleural effusion and, 369
  • ventilator-associated, 369
Pneumonia severity index, 368t
Pneumothorax, 84–85
Poliomyelitis, 227–228
Polycystic liver cysts, 127–128
Polycythemia vera, 363
Polymyalgia rheumatica, 258
Polymyositis, 256
  • diagnostic criteria for, 257b
Polyuria, 193
Porcelain gallbladder, 135b
Posterior reversible encephalopathy syndrome (PRES), 52
Postmyocardial infarction syndrome. See Dressler syndrome
Postnasal drip, 446b
Postphlebitic syndrome. See Chronic venous insufficiency
Postthrombotic syndrome, 60
Potassium metabolism, 313–314
  • excretion of potassium, 313
  • hyperkalemia, 314–315, 316f
  • hypokalemia, 313–314, 315f
  • normal serum level, 313
Prednisone, in Duchenne muscular dystrophy, 225
Predominant emphysema, 70t
Premature atrial complexes (PACs), 21–22
Premature ventricular complexes (PVCs), 21–22, 24b
Primary adrenal insufficiency, 201, 201b
Primary biliary cirrhosis (PBC)
  - clinical features, 137
  - diagnosis and treatment, 137
  - general characteristics, 137
  - vs. primary sclerosing cholangitis, 136t
Primary hyperaldosteronism, 200–201
Primary hyperparathyroidism, 196–197, 197b
Primary hypothyroidism, 185
Primary (simple) pneumothorax, 84–85
Primary sclerosing cholangitis (PSC), 135–136
  - clinical features, 136
  - diagnosis and treatment, 136
  - general characteristics, 135
  - vs. primary biliary cirrhosis, 136t
Prinzmetal angina, 7
Progressive supranuclear palsy (PSP), 213b
Prolactin, 191
Prolactinoma, 191
Prophylaxis after surgery, 60–61
Prostate cancer, 296–298
Prostatitis, 384–385
  - acute vs. chronic, 384b
Prosthetic valve endocarditis, 46–47
Protein C deficiency, 350
Protein S deficiency, 350
Proteinuria, 174
  - classification, 278
  - diagnosis, 279
  - treatment, 280
Prothrombin time (PT), 132
Pseudoanemia, 326
Pseudogout, 255–256, 256f
Pseudohypoparathyroidism, 195b
Pseudomembranous colitis, 379–380
Psoriasis, 418–419, 419f
Psoriatic arthritis, 261
PTH levels and primary hyperparathyroidism, 197
Pulmonary alveolar proteinosis, 93
Pulmonary angiography, 107
Pulmonary arterial hypertension (PAH), 103
Pulmonary artery catheter, 100
Pulmonary aspiration, 109–110
Pulmonary embolism (PE), 104–109
  • clinical features, 105
  • course and prognosis, 105
  • diagnosis, 105–106
  • general characteristics, 104–105
  • pathophysiology, 105
  • risk factors, 105b
  • sources of emboli, 104, 104b
  • treatment, 107–108
  • workup, 106b, 107f
Pulmonary embolus (PE), 60
Pulmonary function tests (PFTs), in asthma, 75, 75b
Pulmonary hypertension (HTN), 49, 51, 102–104
  • classification, 103
  • clinical features, 103
  • definition, 102
  • diagnosis, 103
  • pathophysiologic processes, 102–103, 102b
  • treatment, 103–104
Pulmonary langerhans cell histiocytosis, 91–92
Pulmonary rehabilitation, for COPD, 73
Pulmonary studies, 111t
Pulmonary tuberculosis, 153
Pulmonary vascular resistance (PVR), 49
Pulmonary vasculature, diseases of, 102–109
  • cor pulmonale, 104
  • pulmonary embolism (PE), 104–109
  • pulmonary hypertension (HTN), 102–104
Pulseless electrical activity (PEA), 31b
Pulse oximetry, 111t
Pulse volume recordings, 57
Pulsus paradoxus, 40
Pump failure, 12
- Pyelonephritis, 382–384
- P2Y12 inhibitors, 6, 10, 12
- Pyoderma gangrenosu, 425
- Pyogenic liver abscess, 128
Rabies, 404
Radiation pneumonitis, 94
Radiation therapy, in CRC, 115
Radioactive iodine, 183, 184, 188–189, 188f
Radioactive iodine ablation therapy, 184
Radioactive $T_3$ uptake, 183
Radiocontrast agents, in diabetic patients, 174b
Radiographic interpretation
- abdominal radiographs, 494
- chest radiograph, 491–494
Radionuclide scanning
- in acute cholecystitis, 133b
- in GI bleeding, 147
Ranson criteria, 140t
Raynaud phenomenon, 244
Reactive arthritis, 260–261
Recurrent infarction, 13
Recurrent knee effusion, 465b
Red eye, 474–475
Reed–Sternberg cells, 357f
Regional enteritis. See Crohn disease
Reiter syndrome, 260–261
Renal artery stenosis, 290
Renal cell carcinoma, 298
Renal cysts, simple, 290
Renal papillary necrosis, 285–286
Renal tubular acidosis (RTA), 286–287, 286t
- type 1, 286
- type 2, 287
- type 4, 287
Renal vein thrombosis, 290–291, 296
Respiratory acidosis, 94b, 324–325
Respiratory alkalosis, 325
Respiratory failure, 94–102
- acute, 94–97
- acute respiratory distress syndrome (ARDS), 97–100
- mechanical ventilation, 100–102
Restenosis, 5b
- Resting ECG, 2
- Restless leg syndrome, 215
- Rest pain, 56
- Restrictive cardiomyopathy, 34–35
  - causes, 34
  - clinical features, 34
  - diagnosis, 34
  - general characteristics, 34
  - treatment, 35
- Restrictive lung disease vs. obstructive lung diseases, 71t
- Reticulocyte index, 326
- Revascularization, 5
  - methods of, 11b
  - in MI, 11
- Reynolds pentad, 135
- Rhabdomyolysis, 269b
- Rheumatic heart disease, 45–46
- Rheumatoid arthritis (RA)
  - Boutonnière deformity, 249b
  - clinical features, 247–248, 248f
  - diagnosis, 248, 251b
  - extra-articular manifestations in, 250t
  - juvenile, 252
  - swan-neck deformity, 249f
  - treatment, 251–252
  - ulnar deviation of MCP joints in, 249f
- Riedel thyroiditis. See Fibrous thyroiditis
- Right-sided heart failure, 18
- Rinne test, 480
- Ristocetin assay, 345
- Rituximab, 358b
- Rocky mountain spotted fever, 403
- Rosacea, 416, 416f
- Rouleaux formation, 356f
Saline infusion test, 201
Sarcoidosis, 89–91, 91b
  • clinical features, 90
  • diagnosis, 90–91
  • general characteristics, 89
  • staging and treatment, 91
Scabies, 430–431, 430f
Schatzki ring, 152–153
Schistocytes, 335
Scleroderma, 291
  • diffuse, 246t
  • limited, 246t
Seborrheic dermatitis, 419, 420b
Seborrheic keratosis, 431, 432f
Secondary adrenal insufficiency, 202
Secondary biliary cirrhosis, 137b
Secondary hyperparathyroidism, 197b
Secondary hypothyroidism, 185
Secondary (complicated) pneumothorax, 85
Second-degree AV block, 32–33, 32b, 32f
Second sight, 474b
Seizures, 231–234
  • aspects of H & P, 232b
  • causes, 231
  • diagnosis, 233
  • epileptic, 232–233
  • generalized seizure, 232
  • partial seizure, 232
  • treatment, 234
Selegiline, in Parkinson disease, 213
Sepsis, 67b, 98b
Septic phlebitis, 62
Septic shock, 66–67, 66b, 67b
Seronegative spondyloarthropathies, 259, 260b
Serum biomarkers, evolution in acute MI, 10f
Severe hypercapnia, 94b
Severe hypoxemia, 94b
Shock
  • cardiogenic, 64–65
• categories of, 63
• definition, 62
• hemodynamic changes in, 63t
• hypovolemic, 65–66
• initial approach to patient with, 63
• neurogenic, 67
• obstructive, 67–68
• septic, 66–67
• signs and symptoms, 63
• treatment, 63–64
  ‣ Sickle cell crises, 337
  ‣ Sickle cell disease, 336–338, 338f
  ‣ Sickle cell nephropathy, 291
  ‣ Sideroblastic anemia, 332
  ‣ Sigmoidoscopy, 119
  ‣ Silent thyroiditis. See Subacute lymphocytic thyroiditis
  ‣ Silicosis, 92
  ‣ Sinus bradycardia, 13, 31
  ‣ Sinusitis, 448–449, 448b
    • acute, 448
    • chronic, 448
    • classifications, 448
    • complications, 448
    • diagnosis, 448
    • treatment, 449
  ‣ Sinus tachycardia, 13
  ‣ Sister Mary Joseph node, 158b
  ‣ Sites of metastases, 434b
  ‣ Sleep disorders
    • insomnia, 478
    • narcolepsy, 477
    • obstructive sleep apnea, 476–477
  ‣ Sliding hiatal hernias (type 1), 151, 152f
  ‣ Small bowel obstruction (SBO), 158–161, 158b
    • AP supine film, 160f
    • causes, 159
    • clinical features, 160, 161b
    • diagnosis, 160–161
    • general characteristics, 158–159
    • treatment, 161
\* Small cell lung cancer (SCLC), 81t
  \* prognosis, 79b
  \* treatment, 80
\* Small intestine, diseases of, 158–161
  \* celiac sprue, 161
  \* paralytic ileus, 161
  \* small bowel obstruction, 158–161
  \* tropical sprue, 161
  \* whipple disease, 161
\* Smoking, 485–486
  \* and cough, 446–447
\* Smoking cessation
  \* in COPD, 71, 72b, 73f
  \* in PAD, 57
\* Solitary pulmonary nodule, 80–81, 80f
  \* benign vs. malignant, 81t
  \* clinical features, 80
  \* diagnosis, 81
  \* evaluation, 80f
\* Somatostatinoma, 181
\* Somogyi effect, 168b
\* Sore throat, 449–450
\* Spinal cord diseases
  \* Brown-Séquard syndrome, 227
  \* Horner syndrome, 227
  \* poliomyelitis, 227–228
  \* syringomyelia, 226, 227f
  \* transverse myelitis, 227
\* Spirometry, 75, 111t
\* Spitz nevi, 433b
\* Splenic sequestration crisis, 337
\* Spontaneous pneumothorax, 84–85, 85b
\* Squamous cell carcinoma (SCC), 148, 433, 433f
\* Squatting, 33b, 45
\* Standing, 45
\* Statins, in MI, 10
\* Status epilepticus, 234b
\* Steatorrhea, 142
\* Stevens-Johnson syndrome, 423
\* Stomach, diseases of, 154–158
• acute gastritis, 156
• chronic gastritis, 157
• gastric cancer, 158
• gastric lymphoma, 158
• peptic ulcer disease, 154–156, 157t
• *Streptococcus pneumoniae*, community-acquired pneumonia, 365
• Stress echocardiography, 2
• Stress tests, 2, 2b, 6b
  • in CHF, 18
  • types, 3b
• Strokes, 205–212
  • hemorrhagic, 210–212
  • ischemic, 215–212
• Sturge-Weber syndrome, 226
• Subacute granulomatous thyroiditis. See Subacute (viral) thyroiditis
• Subacute lymphocytic thyroiditis, 186
• Subacute (viral) thyroiditis, 186
• Subarachnoid hemorrhage (SAH), 211–212
• Subclavian steal syndrome, 207b
• Subclinical hypothyroidism, 186b
• Sudden cardiac death, 30b
• Sulfasalazine, 163, 165
• Superficial thrombophlebitis, 62, 62b
• Superior vena cava (SVC) syndrome, 78
• Supplemental oxygen, 74
• Suppurative thrombophlebitis, 62
• Supraventricular tachycardias, 28
• Swelling of lower leg, 61
• Syncope, 229–232
  • causes, 229–230
  • diagnosis, 230–231
  • flowchart, 231f
  • vasovagal, 229, 230b
• Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 194–195, 194b
  • causes, 194
  • clinical features, 194, 195b
  • diagnosis, 194–195
  • pathophysiology, 194
  • treatment, 195
• Syndrome X, 2b
• Syphilis, 393–395, 394f
• Syringomyelia, 226, 227f
• Systemic corticosteroids, 74
• Systemic glucocorticoids, 73b
• Systemic inflammatory response syndrome (SIRS), 67b
• Systemic lupus erythematosus (SLE), 241–244
  • butterfly rash, 242f
  • clinical course of, 241–242
  • diagnosis, 242, 243f
  • drug-induced lupus, 241, 245b
  • epidemiology of, 241b
  • treatment, 243–244
• Systolic dysfunction, 15, 17
  • diuretics for, 20
  • lifestyle modification in, 18
• Systolic ejection murmur, 33
Tachyarrhythmias, 22–31
  • atrial fibrillation, 22–25
  • atrial flutter, 25–26
  • multifocal atrial tachycardia, 26
  • paroxysmal supraventricular tachycardia, 26–28
  • ventricular fibrillation, 30–31
  • ventricular tachycardia, 28–30
  • Wolff–Parkinson–White (WPW) Syndrome, 28
Tachycardias, 28b
Tendinitis, 466
Tension pneumothorax, 85–86
  • causes, 85
  • chest radiograph, 86f, 87f
  • clinical features, 85
  • general characteristics, 85
  • treatment, 85
Testicular cancer, 299–300
Testicular torsion, 301
Tetanus, 397–398
Tetralogy of fallot (TOF), 51–52
Theophylline, 72
Thionamides, 183
Third-degree AV block, 32f, 33
Thoracentesis, 84
Thrombocytopenia, 342–343, 344t
Thrombolytics, intra-arterial infusion of, 118
Thrombolytic therapy
  • in DVT, 60
  • in pulmonary embolism, 108
Thrombotic stroke, 207
Thrombotic thrombocytopenic purpura, 344
Thumbprinting, 118
Thyroid-associated ophthalmopathy (TAO), 187
Thyroid cancer, 189–190, 189b
Thyroid gland, diseases of, 182–190
  • cancer, 189–190
  • hyperthyroidism, 182–184
  • hypothyroidism, 185–186
  • nodules, 187–189
• storm, 184
• thyroiditis, 186–187
  • Thyroid hormones and TBG, 183b
  • Thyroiditis, 186–187
  • Thyroid nodules, 187–189
    • diagnosis, 188–189
    • general characteristics, 187
  • Thyroid scan, 188–189, 188f
  • Thyroid storm, 184, 184b
  • Thyrotoxicosis, 183f, 184b
  • Tinea versicolor, 429–430, 429f
  • Tissue biopsy, in ILD, 89
  • Tissue oxygenation, techniques to improve, 97b
  • Torsades de pointes, 29b
  • Tourette syndrome, 215–216
  • Toxic epidermal necrolysis (TEN), 423
  • Toxic shock syndrome, 411–412
  • Traction diverticula, 153
  • Transthoracic needle biopsy, 79
  • Transudative effusion, 82, 83b, 84
  • Transverse myelitis, 227
  • Tremor, 214–215, 214t
    • essential, 215
    • neurologic diseases and, 215
    • physiologic, 214
    • Tricuspid regurgitation (TR), 44–45
    • Trigeminal neuralgia, 236
    • Tropical sprue, 161
    • Troponins, 9
    • TSH level and hypothyroidism, 186b
  • Tuberculosis (TB), 370–372
    • clinical features, 371
    • diagnosis, 371
    • extrapulmonary, 371
    • medications, 372b
    • primary, 370
    • risk factors, 371
    • secondary, 371
    • treatment, 372
  • Tubulointerstitial diseases, 285–287
- acute interstitial nephritis, 285
- Fanconi syndrome, 287
- Hartnup syndrome, 287
- renal papillary necrosis, 285–286
- renal tubular acidosis, 286
- Tularemia, 405t
- Tumor lysis syndrome, 361b
- Tumor marker elevation, 127
- Tumor markers, 510
- Turcot syndrome, 114
- Tympanic membrane perforation, 479b
- Type I diabetes, 167–168, 168t
  - clinical presentation, 169–170, 169t
  - progression of, 170f
- Type II diabetes, 167–168, 168t
  - clinical presentation, 170
  - treatment, 170b
U

- Ulcerative colitis (UC), 163–166
  - clinical features, 164
  - complications, 164
  - diagnosis, 164
  - general characteristics, 163–164
  - treatment, 165
  - vs. Crohn disease, 164t
- Unconjugated bilirubin, 129
- Unconjugated hyperbilirubinemia, 130
- Upper endoscopy, 147
- Upper esophageal webs. See Plummer–Vinson syndrome
- Upper GI bleeding, 144
  - causes, 145
  - treatment, 147
- Urinalysis, 279b
- Urinary incontinence, 480–482
  - functional incontinence, 482
  - overflow incontinence, 481
  - stress incontinence, 481
  - urge incontinence, 481
- Urinary tract infections (UTIs)
  - clinical features, 381
  - complications, 382
  - diagnosis, 381
  - risk factors, 380–381
  - treatment, 382
- Urinary tract obstruction, 295–296
  - evaluation of, 295b
- Urine osmolality, 270b, 307
- Urine output monitoring, 66b
- Urticaria, 420, 421f
Vaccinations, 488, 488t–489t
Valsalva maneuver, 33b, 45
Valvular heart disease, 39–48
  • aortic regurgitation, 42–43
  • aortic stenosis, 41–42
  • infective endocarditis, 46–48
  • mitral regurgitation, 43–44
  • mitral stenosis, 39–40
  • mitral valve prolapse, 45
  • nonbacterial thrombotic endocarditis, 48
  • nonbacterial verrucous endocarditis, 48
  • rheumatic heart disease, 45–46
  • tricuspid regurgitation, 44–45
Variable-vessel vasculitis, 265
Variant angina. See Prinzmetal angina
Vascular ectasia. See Angiodysplasia of colon
Vasculation, diseases of, 52–62
  • abdominal aortic aneurysm (AAA), 54–56
  • acute arterial occlusion, 57–58, 58t
  • aortic dissection, 53–54, 53b, 53f
  • cholesterol embolization syndrome, 58
  • chronic venous insufficiency, 61–62
  • deep venous thrombosis, 59–61
  • hypertensive emergency, 52–53, 53b
  • luetic heart, 58–59
  • mycotic aneurysm, 58
  • peripheral arterial disease (PAD), 56–57
  • superficial thrombophlebitis, 62
Vasculitis, 261–262
  • Behçet syndrome, 265
  • Churg-Strauss syndrome, 264
  • cryoglobulinemic vasculitis, 264–265
  • overview, 261
  • polyarteritis nodosa, 263
  • Takayasu arteritis, 263
  • temporal/giant cell arteritis, 262
  • types, 262–265
Vasoactive agents, 103–104
Vaso-occlusive crises, 337
Vasovagal syncope, 229, 230b
Venography, 59
Venous duplex ultrasound of lower extremities, 106
Venous stasis disease. See Chronic venous insufficiency
Venous thrombosis, 117
Venous ulcers, 61
Ventilation–perfusion (V/Q) scan, 111t
Ventilator-associated pneumonia, 368–369
Ventricular aneurysm, 14
Ventricular assist device (VAD), 21b
Ventricular fibrillation, 30–31
  • causes, 30
  • clinical features, 30
  • diagnosis, 30, 30f
  • general characteristics, 30
  • recurrence, 30
  • treatment, 31
Ventricular pseudoaneurysm, 14
Ventricular septal defect, 49–50
Ventricular tachycardia, 28–30
  • causes, 28, 29b
  • clinical features, 29
  • diagnosis, 29, 29f
  • general characteristics, 28
  • monomorphic, 30b
  • nonsustained, 29, 30, 30b
  • sustained, 29, 30
  • treatment, 29–30
Ventricular tachycardia (VT), 12
Vertigo, 228, 228b, 229t
  • central, 228
  • peripheral, 228
VIPoma, 181
Viral conjunctivitis, 475b
Viral hepatitis
  • causes of, 376
  • clinical features, 377–378
  • diagnosis, 378–379
  • treatment, 378–379
Virchow node, 158b
Vitamin B<sub>12</sub> deficiency, 333–334, 334f
Vitamin K deficiency, 349
Volume disorders, 302–305
  • approach to, 302–304, 303f
  • hypervolemia, 305
  • hypovolemia, 304–305
Von Willebrand disease (vWD), 345–346, 346t
Waldenström macroglobulinemia, 356
Wandering atrial pacemaker, 26
Warfarin
  • administration, 352
  • adverse effects, 352
  • indications for use, 352
  • mechanism of action, 352
  • reversing effects of, 352
Warts
  • anogenital, 426
  • common, 426
  • flat, 426
  • HPV, 427, 427f
  • plantar, 426
Warts, 426–427
Water deprivation test, in DI, 193, 193t
Watery diarrhea, 181
Wegener granulomatosis. See Granulomatosis with polyangiitis
Wernicke aphasia, 235
Whipple disease, 161
White coat, 439b
Wide complex tachycardia, 30b
Wilson disease, 124–125
Wolff–Parkinson–White (WPW) Syndrome, 28
Z

- Zenker diverticulum, 153
- Zollinger-Ellison syndrome (ZES), 181